assays_ASI,assays_Desc,assays_CUB,assays_ASSTI,assays_SASI,assays_ASSTY,assays_ASSSTR,assays_BFOR,assays_DI,assays_ASSUBCFRAC,assays_CI,assays_SI,assays_CHEI,assays_ASSCT,assays_ASSCA,assays_ASORG,assays_RELTY,assays_CONFISCO,assays_TII,assays_VARII
1,The compound was tested for the in vitro inhibition of platelet 12-lipoxygenase at a concentration of 30 uM,Autocuration,,,B,,BAO_0000019,11087,,,1,CHEMBL615117,,,,H,8,,
2,Compound was evaluated for its ability to mobilize calcium in 1321NI cells,Autocuration,,,F,,BAO_0000219,684,,,1,CHEMBL615118,,,,U,0,,
3,,Autocuration,,,B,,BAO_0000019,15453,,,1,CHEMBL615119,,,,U,0,,
4,Binding affinity against A2 adenosine receptor in bovine striatal membranes using [3H]CGS-21680,Autocuration,9913.0,,B,,BAO_0000249,17841,,,1,CHEMBL615120,,,Bos taurus,H,4,,
5,In vitro cell cytotoxicity against 143-B cell lines (Human osteosarcoma cell line),Intermediate,9606.0,,F,,BAO_0000219,17430,,163.0,1,CHEMBL615121,143B,,Homo sapiens,N,1,,
6,In vitro cell cytotoxicity against 143-B cell lines (Human osteosarcoma cell line),Intermediate,9606.0,,F,,BAO_0000219,17430,,163.0,1,CHEMBL615122,143B,,Homo sapiens,N,1,,
7,Cytotoxic Activity was evaluated against 143B (TK-) tumor cells,Intermediate,10090.0,,F,,BAO_0000219,13799,,163.0,1,CHEMBL615123,143B,,Mus musculus,N,1,,
8,In vitro cell cytotoxicity was determined against 143B cell line,Expert,9606.0,,F,,BAO_0000219,17774,,163.0,1,CHEMBL615124,143B,,Homo sapiens,N,1,,
9,Inhibitory activity against tumor osteosarcoma cell line 143B after 72 hr continuous exposure to compound,Intermediate,9606.0,,F,,BAO_0000219,3801,,163.0,1,CHEMBL615125,143B,,Homo sapiens,N,1,,
10,In vitro cell cytotoxicity against 143B-LTK cell lines expressed in HSV-1 TK,Intermediate,9606.0,,F,,BAO_0000219,17430,,163.0,1,CHEMBL615126,143B,,Homo sapiens,N,1,,
11,In vitro cell cytotoxicity against 143B-LTK cell lines expressed in HSV-1 TK,Intermediate,9606.0,,F,,BAO_0000219,17430,,163.0,1,CHEMBL615127,143B,,Homo sapiens,N,1,,
12,In vitro cell cytotoxicity was determined against 143B-LTK cell line,Expert,9606.0,,F,,BAO_0000219,17774,,163.0,1,CHEMBL615128,143B,,Homo sapiens,N,1,,
13,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",Intermediate,1280.0,,F,,BAO_0000218,11324,,,1,CHEMBL857900,,,Staphylococcus aureus,N,1,,
14,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",Intermediate,1280.0,,F,,BAO_0000218,11324,,,1,CHEMBL615129,,,Staphylococcus aureus,N,1,,
15,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",Intermediate,1280.0,,F,,BAO_0000218,11324,,,1,CHEMBL615130,,,Staphylococcus aureus,N,1,,
16,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",Intermediate,1280.0,,F,,BAO_0000218,11324,,,1,CHEMBL615131,,,Staphylococcus aureus,N,1,,
17,Inhibition of cytochrome P450 progesterone 15-alpha hydroxylase,Expert,10116.0,,A,,BAO_0000357,11347,,,1,CHEMBL884521,,,Rattus norvegicus,D,9,,
18,Concentration that cause 50% activation of human reticulocyte 15-lipoxygenase (15-HLO),Autocuration,,,B,,BAO_0000357,16474,,,1,CHEMBL615132,,,,H,8,,
19,Inhibition of partially purified 15-lipoxygenase from human leukocytes,Autocuration,,,B,,BAO_0000019,10091,,,1,CHEMBL615133,,,,H,8,,
20,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO),Autocuration,,,B,,BAO_0000357,16474,,,1,CHEMBL615134,,,,H,8,,
21,Compound was evaluated for the percent increase in activation concentration of human reticulocyte 15-lipoxygenase (15-HLO),Autocuration,,,B,,BAO_0000357,16474,,,1,CHEMBL615135,,,,H,8,,
22,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO),Autocuration,,,B,,BAO_0000357,16474,,,1,CHEMBL615136,,,,H,8,,
23,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO); NI is no inhibition,Autocuration,,,B,,BAO_0000357,16474,,,1,CHEMBL615137,,,,H,8,,
24,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO); NI is no inhibition,Autocuration,,,B,,BAO_0000357,16474,,,1,CHEMBL615138,,,,H,8,,
25,"Inhibitory concentration against 15-lipoxygenase, by inhibiting 15-HETE production by human umbilical vein endothelial cells (HUVEC) stimulated by calcium ionophore A 23187 at concentration of 10e-5 M.",Autocuration,,,B,,BAO_0000219,14352,,,1,CHEMBL836324,,,,U,0,,
26,In vitro inhibitory activity of compound on rabbit reticulocyte 15-lipoxygenase,Autocuration,9986.0,,B,,BAO_0000357,5646,,,1,CHEMBL615139,,,Oryctolagus cuniculus,H,8,,
27,Inhibition of rabbit reticulocyte 15-lipoxygenase by compound (30 uM),Autocuration,9986.0,,B,,BAO_0000357,5646,,,1,CHEMBL615140,,,Oryctolagus cuniculus,H,8,,
28,Inhibitory activity against 15-lipoxygenase in rat polymorphonuclear leukocytes,Autocuration,,,B,,BAO_0000219,10997,,,1,CHEMBL615141,,,,H,8,,
29,Inhibitory activity against 15-lipoxygenase was determined obtained from soya bean,Autocuration,3847.0,,B,,BAO_0000357,6309,,,1,CHEMBL615142,,,soya bean,H,8,,
30,Inhibitory activity against soybean 15-lipoxygenase was evaluated,Autocuration,3847.0,,B,,BAO_0000357,167,,,1,CHEMBL615143,,,Glycine max,H,8,,
31,Inhibitory activity against soybean 15-lipoxygenase was evaluated at 100 uM,Autocuration,3847.0,,B,,BAO_0000357,167,,,1,CHEMBL615144,,,Glycine max,H,8,,
32,The compound was tested for the in vitro inhibition of 15-lipoxygenase of soybean at a concentration of 10 uM,Autocuration,3847.0,,B,,BAO_0000357,11087,,,1,CHEMBL872867,,,Glycine max,H,8,,
33,The compound was tested for the in vitro inhibition of 15-lipoxygenase of soybean at a concentration of 100 uM,Autocuration,3847.0,,B,,BAO_0000357,11087,,,1,CHEMBL615145,,,Glycine max,H,8,,
34,Compound was tested in vitro for inhibition of 15-lipoxygenase soybean,Autocuration,3847.0,,B,,BAO_0000357,13622,,,1,CHEMBL615146,,,Glycine max,H,8,,
35,Compound at 100 uM was tested in vitro for inhibition of 15-lipoxygenase soybean,Autocuration,3847.0,,B,,BAO_0000357,13622,,,1,CHEMBL615147,,,Glycine max,H,8,,
36,Inhibition of cytochrome P450 progesterone 16-alpha hydroxylase,Autocuration,10116.0,,A,,BAO_0000019,11347,,,1,CHEMBL615148,,,Rattus norvegicus,U,0,,
37,Binding affinity against bacterial 16S rRNA using mass spectrometry based assay,Autocuration,562.0,,B,,BAO_0000019,5926,,,1,CHEMBL615149,,,Escherichia coli,U,0,,
38,Dissociation constant with dimeric 16S rRNA RNA construct B,Autocuration,,,B,,BAO_0000019,4567,,,1,CHEMBL615150,,,,U,0,,
39,Dissociation constant towards 16S rRNA construct A,Intermediate,,,B,,BAO_0000225,3782,,,1,CHEMBL615151,,,,M,3,,
40,Dissociation constant towards 16S rRNA construct B,Intermediate,,,B,,BAO_0000225,3782,,,1,CHEMBL615152,,,,M,3,,
41,Binding affinity of aminoglycoside to 16S ribosomal RNA A-site in Escherichia coli,Expert,562.0,,B,,BAO_0000225,4466,,,1,CHEMBL615153,,,Escherichia coli,M,3,,
42,Binding affinity for the 16S ribosomal RNA A-site of Escherichia coli,Expert,562.0,,B,,BAO_0000225,6592,,,1,CHEMBL615154,,,Escherichia coli,M,3,,
43,Inhibitory activity against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),Autocuration,,,B,,BAO_0000019,898,,,1,CHEMBL615155,,,,H,8,,
44,Inhibitory constant against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),Autocuration,,,B,,BAO_0000019,898,,,1,CHEMBL615156,,,,H,8,,
45,The compound was tested at a concentration of 1 uM for inhibitory activity against 17 beta-hydroxysteroid dehydrogenase from human placental microsomes,Autocuration,9606.0,,B,,BAO_0000019,13163,,,1,CHEMBL615157,,,Homo sapiens,H,8,,
46,The compound was tested at a concentration of 1 uM for inhibitory activity against 17 beta-hydroxysteroid dehydrogenase from human placental microsomes,Autocuration,9606.0,,B,,BAO_0000019,13163,,,1,CHEMBL615158,,,Homo sapiens,H,8,,
47,"Inhibition of 17-alpha-hydroxylase/17,20 lyase from rat testes microsomal preparation",Expert,10116.0,,B,,BAO_0000019,10691,,,1,CHEMBL615159,,,Rattus norvegicus,D,9,,
48,"Inhibition of 17-alpha-hydroxylase/17,20 lyase from rat testes microsomal preparation",Expert,10116.0,,B,,BAO_0000019,10691,,,1,CHEMBL615172,,,Rattus norvegicus,D,9,,
49,"Percent inhibition of 17-alpha-hydroxylase/17,20 lyase of rat testes microsomes at 100 uM",Expert,10116.0,,B,,BAO_0000019,10691,,,1,CHEMBL615173,,,Rattus norvegicus,D,9,,
50,"Percent inhibition of Steroid 17-alpha-hydroxylase/17,20 lyase of rat testes microsomes at 100 uM",Expert,10116.0,,B,,BAO_0000019,10691,,,1,CHEMBL615174,,,Rattus norvegicus,D,9,,
51,Inhibitory activity against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),Autocuration,,,B,,BAO_0000019,898,,,1,CHEMBL884518,,,,H,8,,
52,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1),Autocuration,,,B,,BAO_0000357,912,,,1,CHEMBL615175,,,,H,8,,
53,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1) at 1 uM concentration,Autocuration,,,B,,BAO_0000357,912,,,1,CHEMBL615176,,,,H,8,,
54,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1) at 10 uM concentration,Autocuration,,,B,,BAO_0000357,912,,,1,CHEMBL615177,,,,H,8,,
55,Selectivity ratio of binding affinity towards mu to delta receptors of rat brain membranes,Autocuration,10116.0,,B,,BAO_0000249,15103,Membranes,,1,CHEMBL615178,,,Rattus norvegicus,D,5,,
56,Cytotoxicity against ovarian cancer cell line (1A-9) of humans was determined,Intermediate,9606.0,,F,,BAO_0000219,5116,,506.0,1,CHEMBL615179,1A9,,Homo sapiens,N,1,,
57,Functional antagonism by electrical assays in Xenopus oocytes expressing 1A/2A NMDA receptor subtype,Autocuration,10116.0,,F,,BAO_0000219,14578,,,1,CHEMBL615180,Oocytes,,Rattus norvegicus,D,7,,
58,Functional antagonism by electrical assays in Xenopus oocytes expressing the 1A/2B NMDA receptor,Autocuration,10116.0,,F,,BAO_0000219,14578,,,1,CHEMBL615181,Oocytes,,Rattus norvegicus,D,7,,
59,Functional antagonism by electrical assays in Xenopus oocytes expressing the 1A/2C NMDA receptor,Autocuration,10116.0,,F,,BAO_0000219,14578,,,1,CHEMBL615182,Oocytes,,Rattus norvegicus,D,7,,
60,In vitro effective concentration required to reduce the number of human ovarian cancer (1A9) after 3-day incubation,Expert,9606.0,,F,,BAO_0000219,4787,,506.0,1,CHEMBL615183,1A9,,Homo sapiens,N,1,,
61,In vitro effective concentration required to reduce the number of human ovarian cancer cells (1A9) after 3-day incubation,Intermediate,9606.0,,F,,BAO_0000219,4787,,506.0,1,CHEMBL615184,1A9,,Homo sapiens,N,1,,
62,Cytotoxic activity against human ovarian cancer (1A9) cell line,Intermediate,9606.0,,F,,BAO_0000219,3547,,506.0,1,CHEMBL615185,1A9,,Homo sapiens,N,1,,
63,Cytotoxic activity against human ovarian cancer (1A9) cell line; ND=Not determined,Intermediate,9606.0,,F,,BAO_0000219,3547,,506.0,1,CHEMBL615186,1A9,,Homo sapiens,N,1,,
64,Effective dose of compound against replication of 1A9 cell line was evaluated,Intermediate,9606.0,,F,,BAO_0000219,6726,,506.0,1,CHEMBL615187,1A9,,Homo sapiens,N,1,,
65,In vitro cytotoxic activity was determined against ovarian cancer (1A9) cell line,Expert,9606.0,,F,,BAO_0000219,3455,,506.0,1,CHEMBL885343,1A9,,Homo sapiens,N,1,,
66,In vitro cytotoxicity evaluated against human ovarian cancer (1A9 cell line),Intermediate,9606.0,,F,,BAO_0000219,5726,,506.0,1,CHEMBL615188,1A9,,Homo sapiens,N,1,,
67,In vitro cytotoxicity evaluated against human ovarian cancer (1A9 cell line); NA is not active,Intermediate,9606.0,,F,,BAO_0000219,5726,,506.0,1,CHEMBL615189,1A9,,Homo sapiens,N,1,,
68,In vitro percent inhibition evaluated against human ovarian cancer (1A9 cell line) at >20 ug/mL,Intermediate,9606.0,,F,,BAO_0000219,5726,,506.0,1,CHEMBL615190,1A9,,Homo sapiens,N,1,,
69,Inhibitory activity against Taxol resistant 1A9 cell lines,Intermediate,9606.0,,F,,BAO_0000219,3395,,506.0,1,CHEMBL615191,1A9,,Homo sapiens,N,1,,
70,Cytotoxicity against human ovarian cancer (1A9) cell lines.,Expert,9606.0,,F,,BAO_0000219,3415,,506.0,1,CHEMBL615192,1A9,,Homo sapiens,N,1,,
71,Percentage inhibition of human ovarian cancer (1A9) cell lines.,Expert,9606.0,,F,,BAO_0000219,3415,,506.0,1,CHEMBL827083,1A9,,Homo sapiens,N,1,,
72,Effective dose required for inhibitory activity against 1A9 human tumor cell line.,Expert,9606.0,,F,,BAO_0000219,17099,,506.0,1,CHEMBL615193,1A9,,Homo sapiens,N,1,,
73,Percent inhibition against 1A9 human tumor cell line at 0.10 ug/mL,Intermediate,9606.0,,F,,BAO_0000219,17099,,506.0,1,CHEMBL615194,1A9,,Homo sapiens,N,1,,
74,Percent inhibition against 1A9 human tumor cell line at <0.00008 ug/mL,Intermediate,9606.0,,F,,BAO_0000219,17099,,506.0,1,CHEMBL615195,1A9,,Homo sapiens,N,1,,
75,Percent inhibition against 1A9 human tumor cell line at >10 ug/mL,Intermediate,9606.0,,F,,BAO_0000219,17099,,506.0,1,CHEMBL615196,1A9,,Homo sapiens,N,1,,
76,Inhibitory concentration against Jurkat cells,Intermediate,9606.0,,F,,BAO_0000219,17721,,503.0,1,CHEMBL615197,Jurkat,,Homo sapiens,N,1,,
77,In vitro anticancer activity against 2 NCI SCLC cell lines; inactive,Intermediate,,,F,,BAO_0000019,1229,,,1,CHEMBL615198,,,,U,0,,
78,Inhibition of cytochrome P450 progesterone 2-alpha-hydroxylase,Expert,10116.0,,A,,BAO_0000357,11347,,,1,CHEMBL615199,,,Rattus norvegicus,D,9,,
79,"In vitro inhibition of human 2,3-oxidosqualene cyclase.",Expert,,,B,,BAO_0000357,17117,,,1,CHEMBL615200,,,,H,8,,
80,"In vitro inhibition of human 2,3-oxidosqualene cyclase.",Expert,,,B,,BAO_0000357,17117,,,1,CHEMBL615201,,,,H,8,,
81,"In vitro inhibition of human 2,3-oxidosqualene cyclase at 100 nM.",Expert,,,B,,BAO_0000357,17117,,,1,CHEMBL615202,,,,H,8,,
82,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in Candida albicans microsomes",Autocuration,5476.0,,B,,BAO_0000251,11375,Microsomes,,1,CHEMBL615203,,,Candida albicans,H,8,,
83,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in Candida albicans microsomes",Autocuration,5476.0,,B,,BAO_0000251,11375,Microsomes,,1,CHEMBL615204,,,Candida albicans,H,8,,
84,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in Saccharomyces cerevisiae microsomes",Autocuration,4932.0,,B,,BAO_0000251,11375,Microsomes,,1,CHEMBL615205,,,Saccharomyces cerevisiae,H,8,,
85,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in Saccharomyces cerevisiae microsomes",Autocuration,4932.0,,B,,BAO_0000251,11375,Microsomes,,1,CHEMBL615206,,,Saccharomyces cerevisiae,H,8,,
86,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in pig liver microsomes",Autocuration,9823.0,,B,,BAO_0000251,11375,Microsomes,,1,CHEMBL615207,,,Sus scrofa,H,8,2107.0,
87,"Concentration required to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase",Autocuration,10116.0,,B,,BAO_0000019,791,,,1,CHEMBL827084,,,Rattus norvegicus,H,8,,
88,"Concentration required to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase (OSC)",Autocuration,10116.0,,B,,BAO_0000019,791,,,1,CHEMBL615208,,,Rattus norvegicus,H,8,,
89,"Evaluated for its activity to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase, activity expressed as Ki",Autocuration,10116.0,,B,,BAO_0000019,791,,,1,CHEMBL615209,,,Rattus norvegicus,H,8,,
90,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in rat liver microsomes",Autocuration,10116.0,,B,,BAO_0000251,11375,Microsomes,,1,CHEMBL615210,,,Rattus norvegicus,D,9,2107.0,
91,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in rat liver microsomes",Autocuration,10116.0,,B,,BAO_0000251,11375,Microsomes,,1,CHEMBL615211,,,Rattus norvegicus,D,9,2107.0,
92,"Compound was evaluated for inhibitory activity against 2,3-oxidosqualene-lanosterol cyclase in rat liver microsomes",Autocuration,10116.0,,B,,BAO_0000251,153,Microsomes,,1,CHEMBL615212,,,Rattus norvegicus,D,9,2107.0,
93,Molar concentration needed to give 50% prevention of 2-5A (Adenosine dependent endoribonuclease),Expert,,,B,,BAO_0000357,8269,,,1,CHEMBL615213,,,,H,8,,
94,Molar concentration required to displace 50% of the radiolabeled probe from 2-5A (Adenosine dependent endoribonuclease) in endonuclease-nitrocellulose complex,Expert,,,B,,BAO_0000357,8269,,,1,CHEMBL615273,,,,H,8,,
95,In vitro cytotoxic concentration required to inhibit hepatitisB virus (HBV) replication in 2.2.15 cell line,Expert,9606.0,,F,,BAO_0000219,17653,,726.0,1,CHEMBL615274,HepG2,,Homo sapiens,N,1,,
96,50% Effective concentration of compound required for inhibiting intracellular viral replicative intermediate DNA in HBV-transfected 2.2.15 cell line.,Intermediate,9606.0,,F,,BAO_0000219,14277,,726.0,1,CHEMBL615275,HepG2,,Homo sapiens,N,1,,
97,Antiviral activity against Hepatitis B virus in 2.2.15 cell line,Intermediate,9606.0,,F,,BAO_0000219,1717,,726.0,1,CHEMBL615276,HepG2,,Homo sapiens,N,1,,
98,In vitro effective concentration against hepatitis B virus was determined in 2.2.15 cells,Intermediate,9606.0,,F,,BAO_0000219,14091,,726.0,1,CHEMBL615277,HepG2,,Homo sapiens,N,1,,
99,In vitro effective concentration against hepatitis B virus was determined in 2.2.15 cells; Not determined,Intermediate,9606.0,,F,,BAO_0000219,14091,,726.0,1,CHEMBL615326,HepG2,,Homo sapiens,N,1,,
100,In vitro effective concentration required to inhibit hepatitisB virus (HBV) replication in 2.2.15 cell line,Expert,10407.0,,F,,BAO_0000218,17653,,,1,CHEMBL883130,,,Hepatitis B virus,N,1,,
101,Ability to inhibit the episomal HBV-DNA in 2.2.15 cells.,Intermediate,9606.0,,F,,BAO_0000219,13105,,726.0,1,CHEMBL884519,HepG2,,Homo sapiens,N,1,,
102,Concentration required to inhibit 50% of 2.2.15 cell line,Intermediate,9606.0,,F,,BAO_0000219,1717,,726.0,1,CHEMBL615327,HepG2,,Homo sapiens,N,1,,
103,Anti viral activity against 2.2.15 cells (concentration required to reduce the log phase cell growth by 50%).,Intermediate,9606.0,,A,,BAO_0000219,13105,,726.0,1,CHEMBL615328,HepG2,,Homo sapiens,N,1,,
104,Cytotoxic activity of compound against uninfected 2.2.15 cells.,Intermediate,9606.0,,F,,BAO_0000218,13600,,,1,CHEMBL615329,2.2.15,,Homo sapiens,N,1,,
105,Anti hepatitis-B virus activity was evaluated in 2.2.15 cells.,Intermediate,9606.0,,F,,BAO_0000218,13467,,,1,CHEMBL615330,2.2.15,,Homo sapiens,N,1,,
106,"Inhibition of the replication of HBV in 2.2.15 cells, by DNA hybridization assay",Expert,10407.0,,F,,BAO_0000218,17477,,,1,CHEMBL615331,2.2.15,,Hepatitis B virus,N,1,,
107,In vitro anti-HBV activity in 2.2.15 cells,Intermediate,9606.0,,F,,BAO_0000218,1593,,,1,CHEMBL615332,2.2.15,,Homo sapiens,N,1,,
108,In vitro anti-HBV activity in 2.2.15 cells; Not determined,Intermediate,9606.0,,F,,BAO_0000218,1593,,,1,CHEMBL615333,2.2.15,,Homo sapiens,N,1,,
109,The compound was tested in vitro for the anti-HBV activity against 2.2.15 cells,Intermediate,9606.0,,F,,BAO_0000218,15089,,,1,CHEMBL615334,2.2.15,,Homo sapiens,N,1,,
110,The compound was tested in vitro for the anti-HBV activity in 2.2.15 cells,Intermediate,9606.0,,F,,BAO_0000218,15089,,,1,CHEMBL615335,2.2.15,,Homo sapiens,N,1,,
111,Cytotoxicity in 2.2.15 cells,Intermediate,9606.0,,F,,BAO_0000218,1593,,,1,CHEMBL615336,2.2.15,,Homo sapiens,N,1,,
112,Cytotoxicity in 2.2.15 cells; Not determined,Intermediate,9606.0,,F,,BAO_0000218,1593,,,1,CHEMBL615337,2.2.15,,Homo sapiens,N,1,,
113,Inhibitory activity of compound against hepatitis B virus (HBV) in growing cultures of 2.2.15 cells,Intermediate,9606.0,,F,,BAO_0000218,13600,,,1,CHEMBL615338,2.2.15,,Homo sapiens,N,1,,
114,The growth inhibition activity for the compound was evaluated in 2.2.15 cells.,Intermediate,9606.0,,F,,BAO_0000218,13467,,,1,CHEMBL615339,2.2.15,,Homo sapiens,N,1,,
115,Selectivity index was determined from the ratio of IC50 to the EC50 values evaluated in 2.2.15 cells.,Intermediate,9606.0,,F,,BAO_0000218,13467,,,1,CHEMBL615340,2.2.15,,Homo sapiens,N,1,,
116,Antiviral activity against HBV was determined in 2.215 cell line,Intermediate,9606.0,,F,,BAO_0000219,14764,,726.0,1,CHEMBL615341,HepG2,,Homo sapiens,N,1,,
117,Inhibition of 20-HETE synthesis in human renal microsomes,Autocuration,9606.0,,B,,BAO_0000251,6531,Microsomes,,1,CHEMBL615342,,,Homo sapiens,U,0,,
118,Inhibitory activity against 20-HETE production from arachidonic acid using human renal microsome 20-HETE synthase.,Autocuration,,,B,,BAO_0000019,17322,,,1,CHEMBL615343,,,,U,0,,
119,Inhibitory concentration against 2008 (ovarian) cells,Intermediate,9606.0,,F,,BAO_0000219,17072,,388.0,1,CHEMBL615344,2008,,Homo sapiens,N,1,,
120,50% Growth inhibitory concentration( GI 50 ) by using 2008 human ovarian carcinoma cell lines.,Intermediate,9606.0,,F,,BAO_0000219,16936,,388.0,1,CHEMBL615345,2008,,Homo sapiens,N,1,,
121,Compound was tested for 50% growth inhibitory concentration by using human ovarian carcinoma cell lines (2008),Intermediate,9606.0,,F,,BAO_0000219,16936,,388.0,1,CHEMBL615346,2008,,Homo sapiens,N,1,,
122,Direct cytotoxicity against the selected tumor cell line 2008 was determined especially on ovarian adenocarcinoma derived cells,Intermediate,9606.0,,F,,BAO_0000219,17146,,388.0,1,CHEMBL615347,2008,,Homo sapiens,N,1,,
123,Direct cytotoxicity against the selected tumor cell line 2008 was determined especially on ovarian adenocarcinoma derived cells; not detected,Intermediate,9606.0,,F,,BAO_0000219,17146,,388.0,1,CHEMBL615348,2008,,Homo sapiens,N,1,,
124,In vitro inhibition of 2008/R ovarian cancer cell line,Intermediate,9606.0,,F,,BAO_0000219,10797,,561.0,1,CHEMBL827085,2008/R,,Homo sapiens,N,1,,
125,In vitro inhibition of 2008/R ovarian cancer cell line; NA= Not achievable,Intermediate,9606.0,,F,,BAO_0000219,10797,,561.0,1,CHEMBL615349,2008/R,,Homo sapiens,N,1,,
126,In vitro inhibition of 2008/S ovarian cancer cell line,Intermediate,9606.0,,F,,BAO_0000219,10797,,389.0,1,CHEMBL615350,2008/S,,Homo sapiens,N,1,,
127,In vitro inhibition of 2008/S ovarian cancer cell line; NA= Not achievable,Intermediate,9606.0,,F,,BAO_0000219,10797,,389.0,1,CHEMBL615351,2008/S,,Homo sapiens,N,1,,
128,Tested in vitro for inhibition of chymotrypsin like activity of purified human 20S proteasome,Expert,9606.0,,B,,BAO_0000220,4823,,,1,CHEMBL615352,,,Homo sapiens,S,2,,
129,Compound was evaluated for inhibitory activity against 20S proteasome from human liver and brain,Intermediate,9606.0,,B,,BAO_0000220,12912,,,1,CHEMBL615353,,,Homo sapiens,S,2,,
130,Inhibition of chymotrypsin-like activity of 20S proteasome,Expert,,,B,,BAO_0000220,2957,,,1,CHEMBL615354,,,,S,2,,
131,Inhibition of chymotrypsin-like activity of 20S proteasome; value ranges from 10-20 uM,Expert,,,B,,BAO_0000220,2957,,,1,CHEMBL615355,,,,S,2,,
132,Inhibitory activity against 20S proteosome,Intermediate,,,B,,BAO_0000220,3260,,,1,CHEMBL615356,,,,S,2,,
133,Compound was tested for inhibitory activity against tryptase,Autocuration,9606.0,,B,,BAO_0000019,3451,,,1,CHEMBL615357,,,Homo sapiens,U,0,,
134,Concentration required to inhibit 50% of extracellular circular replication of HBV DNA using 2215 cell line,Intermediate,9606.0,,F,,BAO_0000219,13885,,726.0,1,CHEMBL615358,HepG2,,Homo sapiens,N,1,,
135,Concentration required to inhibit 50% of intracellular circular replication of HBV DNA using 2215 cell line,Intermediate,9606.0,,F,,BAO_0000219,13885,,726.0,1,CHEMBL827086,HepG2,,Homo sapiens,N,1,,
136,Compound was tested for the inhibition of Alpha-glucosidase,Autocuration,,,B,,BAO_0000019,3676,,,1,CHEMBL615359,,,,U,0,,
137,Inhibitory concentration against human neutrophil elastase (HNE),Autocuration,,,B,,BAO_0000357,6043,,,1,CHEMBL615360,,,,H,8,,
138,Change in heart rate was expressed in percent at at a dose 0.002 mg/kg iv in anesthetized rat,Autocuration,10116.0,,F,,BAO_0000218,11140,,,1,CHEMBL615361,,,Rattus norvegicus,U,0,948.0,
139,90% inhibition of the 20 Mycobacterium avium complex (MAC) clinical isolates,Autocuration,,,F,,BAO_0000019,10543,,,1,CHEMBL615362,,,,H,8,,
140,Minimum inhibitory concentration of compound against 20 Mycobacterium avium complex (MAC) clinical isolates,Expert,,,F,,BAO_0000019,10543,,,1,CHEMBL615363,,,,H,8,,
141,Minimum inhibitory concentration of compound against 20 Mycobacterium avium complex (MAC) clinical isolates,Autocuration,,,B,,BAO_0000357,10543,,,1,CHEMBL615364,,,,H,8,,
142,90% inhibition of the 20 Mycobacterium avium complex (MAC) clinical isolates,Expert,,,F,,BAO_0000019,10543,,,1,CHEMBL615365,,,,H,8,,
143,In Vitro evaluation for the growth inhibition of Subline (P388/AMSA) Leukemia cell lines,Intermediate,10090.0,,F,,BAO_0000219,11365,,524.0,1,CHEMBL615366,P338,,Mus musculus,N,1,,
144,In Vitro evaluation for the growth inhibition of Subline (P388/CP) Leukemia cell lines,Intermediate,10090.0,,F,,BAO_0000219,11365,,524.0,1,CHEMBL615367,P338,,Mus musculus,N,1,,
145,Compound was evaluated for the inhibition of cell replication human peripheral blood lymphocytes (PBL's).,Intermediate,9606.0,,F,,BAO_0000219,11803,,554.0,1,CHEMBL615368,PBL,,Homo sapiens,N,1,,
146,Compound was evaluated for the inhibition of cell replication sheep choroid plexus (SCP) cells,Autocuration,9940.0,,F,,BAO_0000019,11803,,,1,CHEMBL615369,,,Ovis aries,U,0,,
147,Compound was evaluated for the inhibition of cell replication sheep choroid plexus (SCP) cells.,Autocuration,9940.0,,F,,BAO_0000019,11803,,,1,CHEMBL615370,,,Ovis aries,U,0,,
148,Compound is evaluated in vitro for the inhibition single mutant of HIV-1 RT (Y181C),Autocuration,,,B,,BAO_0000357,12278,,,1,CHEMBL615673,,,,H,8,,
149,Compound was evaluated for its inhibitory effect on thymidine [3H]dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-5,Autocuration,9606.0,,F,,BAO_0000019,8249,,,1,CHEMBL615674,,,Homo sapiens,U,0,,
150,Compound was evaluated for its inhibitory effect on thymidine [3H]-dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-6,Autocuration,9606.0,,F,,BAO_0000019,8249,,,1,CHEMBL615675,,,Homo sapiens,U,0,,
151,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in at conc. 10e-7,Autocuration,9606.0,,F,,BAO_0000219,8249,,635.0,1,CHEMBL615676,CCRF-CEM,,Homo sapiens,U,0,,
152,Compound was evaluated for its inhibitory effect on thymidine ([3H]-dThd) incorporation into DNA of CEM cells in culture at conc. 10e-4,Autocuration,9606.0,,F,,BAO_0000219,8249,,635.0,1,CHEMBL615677,CCRF-CEM,,Homo sapiens,U,0,,
153,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in culture at conc. 10e-5,Autocuration,9606.0,,F,,BAO_0000219,8249,,635.0,1,CHEMBL615678,CCRF-CEM,,Homo sapiens,U,0,,
154,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in culture at conc. 10e-6,Autocuration,9606.0,,F,,BAO_0000219,8249,,635.0,1,CHEMBL615679,CCRF-CEM,,Homo sapiens,U,0,,
155,Compound was evaluated for its inhibitory effect on thymidine ([3H]-dThd) incorporation into DNA of CEM/MTX cells in at conc. 10e-7.,Autocuration,9606.0,,F,,BAO_0000019,8249,,,1,CHEMBL615680,,,Homo sapiens,U,0,,
156,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-4,Autocuration,9606.0,,F,,BAO_0000019,8249,,,1,CHEMBL615681,,,Homo sapiens,U,0,,
157,In vitro binding affinity towards (alpha-4)2(beta-2)3 neuronal nicotinic acetylcholine receptor in P2 membrane fractions of rat forebrain,Autocuration,,,B,,BAO_0000249,16992,,,1,CHEMBL857972,,,,H,6,,
158,Minimum inhibitory concentration of compound against Streptococcus pyogenus septicemia in the mouse,Intermediate,1314.0,,F,,BAO_0000218,10543,,,1,CHEMBL857899,,,Streptococcus pyogenes,N,1,,
159,Antiviral activity against 07/1 strain of thymidine kinase negative (TK-) Varicella-Zoster Virus (VZV),Intermediate,10335.0,,F,,BAO_0000218,17833,,,1,CHEMBL615371,,,Human herpesvirus 3,N,1,,
160,Antiviral activity against 07/1 strain of VZV in HEL (human erythroleukemia) cells.,Expert,10335.0,,F,,BAO_0000218,17290,,468.0,1,CHEMBL615372,HEL,,vericilla zoster virus,N,1,,
161,Antiviral activity against 07/1 strain of VZV; ND: No data,Intermediate,10335.0,,F,,BAO_0000218,17290,,,1,CHEMBL615373,,,vericilla zoster virus,N,1,,
162,Antiviral activity against 07/1 strain of VZV; ND=No data,Intermediate,10335.0,,F,,BAO_0000218,17290,,,1,CHEMBL615374,,,vericilla zoster virus,N,1,,
163,"Antibacterial activity was determined against gram negative organism, Enterobacter cloacae (MA2646)",Intermediate,561.0,,F,,BAO_0000218,10932,,,1,CHEMBL615375,,,escherichia cloac,N,1,,
164,Ratio of Ki at A2 to Ki at A1 receptors,Autocuration,,,B,,BAO_0000019,9707,,,1,CHEMBL615376,,,,U,0,,
165,"In vitro inhibition of 1,3-beta-glucan synthase in Candida albicans membrane assay.",Expert,5476.0,,B,,BAO_0000249,2346,,,1,CHEMBL615377,,,Candida albicans,H,8,,
166,"Inhibition of 1,3-beta-glucan synthase",Expert,284593.0,,B,,BAO_0000357,2205,,,1,CHEMBL615378,,,Candida glabrata CBS 138,H,8,,
167,Inhibition of growth of 1-87 human tumor cell line,Intermediate,9606.0,,F,,BAO_0000219,11900,,832.0,1,CHEMBL615379,1-87 tumor cell line,,Homo sapiens,N,1,,
168,Inhibition of 1-lipoxygenase (LOX)in RBL cells,Expert,10116.0,,B,,BAO_0000219,14864,,,1,CHEMBL615380,,,Rattus norvegicus,D,9,,
169,Inhibitory activity against soybean 1-lipoxygenase (SLO),Autocuration,3847.0,,B,,BAO_0000357,16474,,,1,CHEMBL615381,,,Glycine max,D,9,,
170,Inhibitory activity against soybean 1-lipoxygenase (SLO); no effect,Autocuration,3847.0,,B,,BAO_0000357,16474,,,1,CHEMBL615382,,,Glycine max,D,9,,
171,% inhibition against soybean 1-lipoxygenase (SLO),Autocuration,3847.0,,B,,BAO_0000357,16474,,,1,CHEMBL615383,,,Glycine max,D,9,,
172,percent inhibition against soybean 1-lipoxygenase (SLO);NI is no inhibition,Autocuration,3847.0,,B,,BAO_0000357,16474,,,1,CHEMBL615384,,,Glycine max,D,9,,
173,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 10:90,Autocuration,3847.0,,B,,BAO_0000357,3094,,,1,CHEMBL615385,,,Glycine max,D,9,,
174,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 1:99,Autocuration,3847.0,,B,,BAO_0000357,3094,,,1,CHEMBL615386,,,Glycine max,D,9,,
175,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 25:75,Autocuration,3847.0,,B,,BAO_0000357,3094,,,1,CHEMBL615387,,,Glycine max,D,9,,
176,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 35:65,Autocuration,3847.0,,B,,BAO_0000357,3094,,,1,CHEMBL615388,,,Glycine max,D,9,,
177,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 50:50,Autocuration,3847.0,,B,,BAO_0000357,3094,,,1,CHEMBL615214,,,Glycine max,D,9,,
178,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 76:24,Autocuration,3847.0,,B,,BAO_0000357,3094,,,1,CHEMBL827087,,,Glycine max,D,9,,
179,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 87:13,Autocuration,3847.0,,B,,BAO_0000357,3094,,,1,CHEMBL615215,,,Glycine max,D,9,,
180,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 89:11,Autocuration,3847.0,,B,,BAO_0000357,3094,,,1,CHEMBL615216,,,Glycine max,D,9,,
181,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 95:5,Autocuration,3847.0,,B,,BAO_0000357,3094,,,1,CHEMBL615217,,,Glycine max,D,9,,
182,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 97:3,Autocuration,3847.0,,B,,BAO_0000357,3094,,,1,CHEMBL615218,,,Glycine max,D,9,,
183,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 99:1,Autocuration,3847.0,,B,,BAO_0000357,3094,,,1,CHEMBL615219,,,Glycine max,D,9,,
184,Evaluated for inhibitory activity on 10-formyltetrahydrofolate synthetase(L cell) at folate substrate concentration of 100 uM,Autocuration,10090.0,,B,,BAO_0000019,10413,,,1,CHEMBL615220,,,Mus musculus,U,0,,
185,Cells were harvested and were assayed for luciferase and -galactosidase activities (Transcriptional activity),Intermediate,10090.0,,F,,BAO_0000219,16929,,294.0,1,CHEMBL615221,C3H 10T1/2,,Mus musculus,N,1,,
186,In vitro anticancer activity against 11 NCI NSCLC cell lines; inactive,Intermediate,,,F,,BAO_0000019,1229,,,1,CHEMBL615222,,,,U,0,,
187,In vitro inhibitory activity against human 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA),Autocuration,,,B,,BAO_0000357,16587,,,1,CHEMBL615223,,,,H,8,,
188,In vitro inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA),Autocuration,,,B,,BAO_0000357,16587,,,1,CHEMBL615224,,,,H,8,,
189,In vitro inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA).,Autocuration,,,B,,BAO_0000357,16587,,,1,CHEMBL615225,,,,H,8,,
190,Ability to convert [3H]cortisol to the tritium labeled cortisone in the presence of human 11 beta hydroxysteroid dehydrogenase type 2,Autocuration,,,B,,BAO_0000357,16587,,,1,CHEMBL615226,,,,H,8,,
191,Inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 2 at a concentration of 0.2 mM; NI means no inhibition,Autocuration,,,B,,BAO_0000357,16587,,,1,CHEMBL615227,,,,H,8,,
192,Evaluated for inhibition of bovine adrenal cortical mitochondrial 11 beta-hydroxylase,Expert,9913.0,,F,,BAO_0000019,8058,,,1,CHEMBL615228,,,Bos taurus,D,9,,
193,Effect on adrenal 11-beta-hydroxylase activity at 10e-4 M; No significant effect,Expert,10116.0,,B,,BAO_0000357,9065,,,1,CHEMBL615229,,,Rattus norvegicus,D,9,,
194,Inhibition of 11 beta-hydroxylase from rat adrenal gland,Expert,10116.0,,B,,BAO_0000357,8865,,,1,CHEMBL615230,,,Rattus norvegicus,D,9,2369.0,
195,Inhibition of rat adrenal 11-beta-hydroxylase,Expert,10116.0,,B,,BAO_0000357,9066,,,1,CHEMBL615231,,,Rattus norvegicus,D,9,,
196,Inhibition of rat adrenal 11-beta-hydroxylase,Expert,10116.0,,B,,BAO_0000357,8394,,,1,CHEMBL884520,,,Rattus norvegicus,D,9,,
197,Inhibition of rat adrenal 11-beta-hydroxylase at 10e-5 M,Expert,10116.0,,B,,BAO_0000357,8394,,,1,CHEMBL615232,,,Rattus norvegicus,D,9,,
198,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 1 of wistar rat liver cytosol at 10 uM was determined using [3H]cortisone,Autocuration,,,B,,BAO_0000019,6431,,,1,CHEMBL615233,,,,H,8,,
199,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 2 of wistar rat kidney at 10 uM was determined using [3H]cortisol,Autocuration,,,B,,BAO_0000357,6431,,,1,CHEMBL827088,,,,H,8,,
200,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 2 of wistar rat kidney at 10 uM was determined using [3H]cortisol,Autocuration,,,B,,BAO_0000357,6431,,,1,CHEMBL615234,,,,H,8,,
201,Compound was tested for the percent of inhibition against 12-LO at 10 uM,Autocuration,,,F,,BAO_0000019,9295,,,1,CHEMBL615235,,,,H,8,,
202,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,Autocuration,,,B,,BAO_0000019,10193,,,1,CHEMBL615236,,,,H,8,,
203,Compound was tested in vitro for inhibition of 12-LO human platelet,Autocuration,,,B,,BAO_0000019,13622,,,1,CHEMBL615237,,,,H,8,,
204,Inhibitory concentration against human platelet 12-lipoxygenase,Autocuration,,,F,,BAO_0000019,12079,,,1,CHEMBL615238,,,,H,8,,
205,Compound at 100 uM was tested in vitro for inhibition of 12-LO human platelet,Autocuration,,,B,,BAO_0000019,13622,,,1,CHEMBL615239,,,,H,8,,
206,Inhibitory concentration against human platelet 12-lipoxygenase,Autocuration,9606.0,,F,,BAO_0000019,12079,,,1,CHEMBL615240,,,Homo sapiens,D,9,,
207,Tested for inhibition of 12-LO (12-lipoxygenase) as an inhibitor of 12(S)-HETE biosynthesis in mouse epidermal homogenates,Expert,,,B,,BAO_0000019,13500,,,1,CHEMBL615241,,,,H,8,,
208,Inhibitory activity against conversion of [1-14C]arachidonic acid to 12-HPETE and its reduction product 12-HETE by porcine leukocyte type 12-lipoxygenase,Expert,,,B,,BAO_0000357,13723,,,1,CHEMBL615242,,,,H,8,,
209,Inhibitory activity against human platelet 12-lipoxygenase (12-HLO),Autocuration,,,B,,BAO_0000019,16474,,,1,CHEMBL615243,,,,H,8,,
210,Inhibitory activity against human platelet 12-lipoxygenase,Autocuration,,,B,,BAO_0000019,1630,,,1,CHEMBL615244,,,,H,8,,
211,Inhibitory activity against human platelet 12-lipoxygenase was evaluated,Autocuration,,,B,,BAO_0000019,167,,,1,CHEMBL615245,,,,H,8,,
212,% inhibition against human platelet 12-lipoxygenase (12-HLO),Autocuration,,,B,,BAO_0000019,16474,,,1,CHEMBL615246,,,,H,8,,
213,Inhibitory activity against human platelet 12-lipoxygenase was evaluated at 100 uM,Autocuration,,,B,,BAO_0000019,167,,,1,CHEMBL615247,,,,H,8,,
214,percent inhibition against human platelet 12-lipoxygenase (12-HLO); NI is no inhibition,Autocuration,,,B,,BAO_0000019,16474,,,1,CHEMBL615248,,,,H,8,,
215,Inhibitory activity towards porcine 12-lipoxygenase,Autocuration,,,B,,BAO_0000357,10091,,,1,CHEMBL615249,,,,H,8,,
216,Tested for inhibition against porcine 12-LO,Autocuration,,,B,,BAO_0000357,11966,,,1,CHEMBL615250,,,,H,8,,
217,Inhibition of 12-lipoxygenase was evaluated in rat platelets stimulated by thrombin up to a concentration of 10 uM; NE means No effect,Autocuration,,,B,,BAO_0000019,951,,,1,CHEMBL615251,,,,H,8,,
218,Inhibitory activity against 12-lipoxygenase in rat platelet rich plasma,Autocuration,,,B,,BAO_0000019,10997,,,1,CHEMBL615252,,,,H,8,,
219,In vitro inhibition of rat platelet 12-lipoxygenase,Expert,,,B,,BAO_0000019,10193,,,1,CHEMBL828340,,,,H,8,,
220,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,Autocuration,,,B,,BAO_0000019,10193,,,1,CHEMBL615253,,,,H,8,,
221,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 100 uM,Autocuration,,,B,,BAO_0000019,10193,,,1,CHEMBL615254,,,,H,8,,
222,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 30 uM,Autocuration,,,B,,BAO_0000019,10193,,,1,CHEMBL615255,,,,H,8,,
223,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,Autocuration,,,B,,BAO_0000019,10193,,,1,CHEMBL615256,,,,H,8,,
224,In vitro inhibitory activity against rat platelet 12-lipoxygenase,Autocuration,,,B,,BAO_0000019,10193,,,1,CHEMBL615257,,,,H,8,,
225,The compound was tested for the in vitro inhibition of platelet 12-lipoxygenase at a concentration of 100 uM,Autocuration,,,B,,BAO_0000019,11087,,,1,CHEMBL615258,,,,H,8,,
226,Cytotoxic activity in a panel of Human ovarian tumor 41M cell line after 96h of drug exposure,Intermediate,9606.0,,F,,BAO_0000219,15569,,621.0,1,CHEMBL615259,41M,,Homo sapiens,N,1,,
227,In vitro antitumor activity against 41M cell line.,Expert,9606.0,,F,,BAO_0000219,12989,,621.0,1,CHEMBL615260,41M,,Homo sapiens,N,1,,
228,cytotoxicity against 41M cells incubated for 24 hr in MTT assay.,Intermediate,9606.0,,F,,BAO_0000219,16745,,621.0,1,CHEMBL615261,41M,,Homo sapiens,N,1,,
229,Cytotoxic activity in a panel of Human ovarian tumor 41M/CDDP cell line after 96h of drug exposure,Intermediate,9606.0,,F,,BAO_0000219,15569,,621.0,1,CHEMBL615262,41M,,Homo sapiens,N,1,,
230,In vitro antitumor activity against 41McisR cell line.,Expert,9606.0,,F,,BAO_0000219,12989,,621.0,1,CHEMBL615263,41M,,Homo sapiens,N,1,,
231,Resistant factor was determined between IC50 of cisplatin-resistant human tumor cell lines to that of 41McisR cell line,Expert,9606.0,,F,,BAO_0000219,12989,,621.0,1,CHEMBL838393,41M,,Homo sapiens,N,1,,
232,cytotoxicity against 41McisR cells incubated for 24 hr in MTT assay,Intermediate,9606.0,,F,,BAO_0000219,16745,,621.0,1,CHEMBL615264,41M,,Homo sapiens,N,1,,
233,Inhibition of 5'-inosine monophosphate dehydrogenase type I (IMPDH I),Expert,9606.0,,B,,BAO_0000357,6210,,,1,CHEMBL615265,,,Homo sapiens,D,9,,
234,Inhibition of 5'-inosine monophosphate dehydrogenase type II (IMPDH II),Expert,9606.0,,B,,BAO_0000357,6210,,,1,CHEMBL615266,,,Homo sapiens,D,9,,
235,Inhibitory activity against inosine 5'-inosine monophosphate dehydrogenase type II (IMPDH II),Expert,,,B,,BAO_0000357,6226,,,1,CHEMBL615267,,,,H,8,,
236,Equilibrium dissociation constant towards human 5'-methylthioadenosine phosphorylase,Expert,,,B,,BAO_0000357,17855,,,1,CHEMBL615268,,,,H,8,,
237,Equilibrium dissociation constant towards human 5'-methylthioadenosine phosphorylase; nd = Not determined,Expert,,,B,,BAO_0000357,17855,,,1,CHEMBL615269,,,,H,8,,
238,Initial dissociation constant towards human 5'-methylthioadenosine phosphorylase,Expert,,,B,,BAO_0000357,17855,,,1,CHEMBL615270,,,,H,8,,
239,"Evaluated for inhibitory activity on 5,10-Methenyl Tetrahydrofolate Cyclohydrolase(L cell) at folate substrate concentration of 100 uM",Autocuration,,,B,,BAO_0000357,10413,,,1,CHEMBL615271,,,,H,8,,
240,"Inhibitory activity against 5,10-methylenetetrahydrofolate dehydrogenase from Escherichia coli at a concentration of 0.1 mM; NT=Not tested",Autocuration,562.0,,B,,BAO_0000357,10413,,,1,CHEMBL615272,,,Escherichia coli,H,8,,
241,"Inhibitory activity against 5,10-Methylene Tetrahydrofolate Cyclohydrolase from Escherichia coli at a concentration of 0.1 mM; NT=Not tested",Autocuration,562.0,,B,,BAO_0000357,10413,,,1,CHEMBL615103,,,Escherichia coli,H,8,,
242,"Inhibitory activity against 5,10-Methylene Tetrahydrofolate Cyclohydrolase from Escherichia coli at a concentration of 0.1 mM;NT=Not tested",Autocuration,562.0,,B,,BAO_0000357,10413,,,1,CHEMBL615104,,,Escherichia coli,H,8,,
243,"Evaluated for inhibitory activity on 5,10-Methylene Tetrahydrofolate Cyclohydrolase(L cell) at folate substrate concentration of 100 uM",Autocuration,,,B,,BAO_0000357,10413,,,1,CHEMBL615105,,,,H,8,,
244,"Evaluated for inhibitory activity on 5,10-methylenetetrahydrofolate dehydrogenase(L cell) at folate substrate concentration of 100 uM",Autocuration,,,B,,BAO_0000357,10413,,,1,CHEMBL872866,,,,H,8,,
245,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",Autocuration,9823.0,,B,,BAO_0000357,7587,,,1,CHEMBL615106,,,Sus scrofa,H,8,,
246,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (A,porcine liver) enzyme.",Autocuration,9823.0,,B,,BAO_0000019,7587,,,1,CHEMBL615107,,,Sus scrofa,H,8,,
247,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-4 M inhibitory concentration",Autocuration,9823.0,,B,,BAO_0000357,7587,,,1,CHEMBL615108,,,Sus scrofa,H,8,,
248,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-5 M inhibitory concentration",Autocuration,9823.0,,B,,BAO_0000357,7587,,,1,CHEMBL615109,,,Sus scrofa,H,8,,
249,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",Autocuration,9823.0,,B,,BAO_0000357,7587,,,1,CHEMBL615110,,,Sus scrofa,H,8,,
250,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-4 M inhibitory concentration",Autocuration,9823.0,,B,,BAO_0000019,7587,,,1,CHEMBL840105,,,Sus scrofa,H,8,,
251,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-5 M inhibitory concentration",Autocuration,9823.0,,B,,BAO_0000019,7587,,,1,CHEMBL615111,,,Sus scrofa,H,8,,
252,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-6 M inhibitory concentration",Autocuration,9823.0,,B,,BAO_0000019,7587,,,1,CHEMBL615112,,,Sus scrofa,H,8,,
253,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-7 M inhibitory concentration",Autocuration,9823.0,,B,,BAO_0000019,7587,,,1,CHEMBL615113,,,Sus scrofa,H,8,,
254,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme.",Autocuration,9823.0,,B,,BAO_0000019,7587,,,1,CHEMBL615114,,,Sus scrofa,H,8,,
255,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",Autocuration,9823.0,,B,,BAO_0000357,7587,,,1,CHEMBL615115,,,Sus scrofa,H,8,,
256,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-4 M inhibitory concentration",Autocuration,9823.0,,B,,BAO_0000019,7587,,,1,CHEMBL615116,,,Sus scrofa,H,8,,
257,"Compound was tested for in vitro inhibition of 5,10-Methylene Tetrahydrofolate Cyclohydrolase, competitive against (+)-L-5,10-methenyltetrahydrofolate",Autocuration,,,B,,BAO_0000357,7323,,,1,CHEMBL615698,,,,H,8,,
258,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Reductase (porcine kidney) enzyme at 10E-4 M inhibitory concentration",Autocuration,9823.0,,B,,BAO_0000019,7587,,,1,CHEMBL615699,,,Sus scrofa,U,0,,
259,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Reductase (porcine kidney) enzyme.",Autocuration,9823.0,,B,,BAO_0000019,7587,,,1,CHEMBL615700,,,Sus scrofa,U,0,,
260,Inhibition of 5-Desaturase involved in ergosterol biosynthesis,Expert,4932.0,,B,,BAO_0000357,13750,,,1,CHEMBL615701,,,Saccharomyces cerevisiae,H,8,,
261,Ability for reversible inhibition of Walker 256 5-Fluoro-2'-deoxyuridine Phosphorylase,Autocuration,10116.0,,B,,BAO_0000019,7662,,,1,CHEMBL615702,,,Rattus norvegicus,U,0,,
262,Ability for reversible inhibition of Walker 256 5-Fluoro-2'-deoxyuridine Phosphorylase,Autocuration,10116.0,,B,,BAO_0000019,7662,,,1,CHEMBL615703,,,Rattus norvegicus,U,0,,
263,"Irreversible inhibition of Walker 256 FUDR phosphorylase; expressed as Vo/Vi, velocity without inhibitor to that of velocity with inhibitor",Autocuration,10116.0,,B,,BAO_0000019,7662,,,1,CHEMBL615704,,,Rattus norvegicus,U,0,,
264,"Tested for 5-HT 3 receptor antagonist potency by ability to inhibit the reflex bradycardia, the Bezold-Jarisch reflex in the rat",Autocuration,,,F,,BAO_0000019,12211,,,1,CHEMBL615705,,,,H,6,,
265,"Compound was tested for its 5-HT 3 receptor antagonist potency by their ability to inhibit the reflex bradycardia, the Bezold-Jarisch reflex in the rat",Autocuration,,,F,,BAO_0000019,12211,,,1,CHEMBL615706,,,,H,6,,
266,Relative ability to increase cholinergically mediated contractions in isolated ileum of guinea pig,Intermediate,10141.0,,F,,BAO_0000221,12211,,,1,CHEMBL615707,,,Cavia porcellus,D,9,2116.0,
267,Stimulatory activity of intragastric pressure was tested in the rat,Expert,,,F,,BAO_0000019,12211,,,1,CHEMBL615708,,,,H,8,,
268,% Decrease of 5-HT carrier-receptor -bound radioactivity using paroxetine as a radioligand.,Autocuration,,,B,,BAO_0000357,15453,,,1,CHEMBL615709,,,,H,8,,
269,Dose to reduce neuronal firing against 5-HT cells in rats (iv),Autocuration,10116.0,,F,,BAO_0000218,11884,,,1,CHEMBL615710,,,Rattus norvegicus,U,0,,
270,Antagonistic activity of corresponding methoxy compound against serotonin 5-HT receptor,Autocuration,,,F,,BAO_0000019,7185,,,1,CHEMBL615711,,,,H,8,,
271,Binding affinity at 5-HT reuptake site labeled with [3H]paroxetine,Expert,9606.0,,B,,BAO_0000357,6876,,,1,CHEMBL615712,,,Homo sapiens,D,9,,
272,Binding affinity at 5-HT reuptake site labeled with [3H]paroxetine; No data,Expert,9606.0,,B,,BAO_0000357,6876,,,1,CHEMBL836325,,,Homo sapiens,D,9,,
273,Inhibition of high affinity 5-HT uptake at concentration of 1 uM,Autocuration,,,F,,BAO_0000019,11863,,,1,CHEMBL615713,,,,H,8,,
274,Inhibition constant of high-affinity 5-HT uptake,Autocuration,,,B,,BAO_0000357,11863,,,1,CHEMBL615714,,,,H,8,,
275,Michaelis-Menten constant was reported for high affinity transport of 5-HT,Autocuration,,,F,,BAO_0000019,11863,,,1,CHEMBL615715,,,,H,8,,
276,Maximum rate was determined for high affinity transport of 5-HT,Autocuration,,,F,,BAO_0000019,11863,,,1,CHEMBL615716,,,,H,8,,
277,Compound was tested for agonistic activity against 5-HT uptake,Autocuration,,,F,,BAO_0000019,4639,,,1,CHEMBL615717,,,,H,4,,
278,Inhibition affinity against 5-HT-1B receptor in rat frontal cortex using radio binding assay,Expert,,,B,,BAO_0000019,15796,,,1,CHEMBL881818,,,,H,8,,
279,Inhibition affinity against 5-HT-1D receptor in bovine caudate nucleus using radio binding assay,Expert,9913.0,,B,,BAO_0000357,15796,,,1,CHEMBL884540,,,Bos taurus,H,8,,
280,Binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand,Autocuration,10116.0,,B,,BAO_0000224,12801,,,1,CHEMBL615718,,,Rattus norvegicus,D,5,,
281,The compound was evaluated for the binding affinity towards 5-hydroxytryptamine 1 using [3H]5-HT as radioligand,Autocuration,,,B,,BAO_0000224,12801,,,1,CHEMBL615719,,,,H,4,,
282,Percent inhibition of binding of 3.0 nM [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat caudate membranes at 10 e -5 M,Autocuration,,,B,,BAO_0000249,12120,Membranes,,1,CHEMBL615720,,,,H,4,,
283,Percent inhibition of binding of 3.0 nM [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat caudate membranes at 10 e -5 M.,Autocuration,,,B,,BAO_0000249,12120,Membranes,,1,CHEMBL615721,,,,H,4,,
284,Displacement of binding of [3H]-5-HT to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,Autocuration,,,B,,BAO_0000019,11963,,,1,CHEMBL615722,,,,H,4,,
285,Dose required to reduce neuronal firing of 5-HT1A cells by 50%,Autocuration,,,F,,BAO_0000019,11701,,,1,CHEMBL615723,,,,H,8,,
286,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,Autocuration,,,B,,BAO_0000221,9995,,,1,CHEMBL615724,,,,H,8,10000000.0,
287,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,Autocuration,,,B,,BAO_0000221,9995,,,1,CHEMBL615725,,,,H,8,10000000.0,
288,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,Autocuration,,,B,,BAO_0000221,9995,,,1,CHEMBL615726,,,,H,8,10000000.0,
289,Antagonistic activity at postsynaptic 5-HT1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (.26-3.52),Autocuration,,,F,,BAO_0000218,16394,,,1,CHEMBL615727,,,,H,8,,
290,Effect on forskolin stimulated adenylate cyclase activity at 5-HT1D receptor of guinea pig substantia nigra.,Intermediate,10141.0,,F,,BAO_0000019,11574,,,1,CHEMBL615728,,,Cavia porcellus,D,9,,
291,Binding affinity towards 5-HT1F (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,Autocuration,,,B,,BAO_0000219,15779,,449.0,1,CHEMBL857971,CHO,,,H,8,,
292,Compound was tested for the displacement of [125I]DOI from clone human 5-hydroxytryptamine 2A receptor,Autocuration,,,B,,BAO_0000357,15363,,,1,CHEMBL615729,,,,H,8,,
293,Efficacy against 5-hydroxytryptamine 2A receptor,Expert,10116.0,,F,,BAO_0000019,15363,,,1,CHEMBL615730,,,Rattus norvegicus,D,9,,
294,Intrinsic activity towards 5-HT2A receptor of rat tail artery,Expert,,,F,,BAO_0000019,15329,,,1,CHEMBL615731,,,,H,8,,
295,Relative potency towards 5-HT2A receptor of rat tail artery,Expert,,,F,,BAO_0000019,15329,,,1,CHEMBL615732,,,,H,8,,
296,Blocking 5-HT2A receptor-mediated contractions of rat tail artery,Expert,,,F,,BAO_0000019,15329,,,1,CHEMBL615733,,,,H,8,,
297,Partial agonism at 5-HT2A receptor was evaluated in presence of ketanserin (3-10 nM) in isolated rat tail artery,Expert,,,F,,BAO_0000019,15329,,,1,CHEMBL615734,,,,H,8,,
298,Compound was tested for the intrinsic activity against 5-HT2A receptors of rat tail artery.,Autocuration,,,F,,BAO_0000019,15329,,,1,CHEMBL615735,,,,H,8,,
299,Effectiveness in blocking 5-HT2A receptor-mediated contractions of rat tail artery,Expert,,,F,,BAO_0000019,15329,,,1,CHEMBL615736,,,,H,8,,
300,Evaluated for the agonistic activity against 5-HT4 receptor in non-electrically stimulated guinea-pig ileum.,Intermediate,10141.0,,F,,BAO_0000221,273,,,1,CHEMBL615737,,,Cavia porcellus,D,9,2116.0,
301,Agonistic activity against Serotonin 5-HT4 receptor in low frequency field stimulation of guinea-pig ileum (FSGPI),Intermediate,10141.0,,F,,BAO_0000221,273,,,1,CHEMBL615738,,,Cavia porcellus,D,9,2116.0,
302,Evaluated for the agonistic activity against Serotonin 5-HT4 receptor in non-electrically stimulated guinea-pig ileum.,Intermediate,10141.0,,F,,BAO_0000221,273,,,1,CHEMBL615739,,,Cavia porcellus,D,9,2116.0,
303,The binding affinity was measured on 5-hydroxytryptamine 4 receptor using [3H]- GR-113808 as radioligand.,Autocuration,,,B,,BAO_0000357,12092,,,1,CHEMBL615278,,,,H,8,,
304,Antagonist activity against 5-HT4 receptor mediated relaxation of rat carbachol contracted esophageal muscularis mucosae,Expert,10116.0,,F,,BAO_0000019,1317,,,1,CHEMBL615279,,,Rattus norvegicus,D,9,,
305,Binding affinity against 5-hydroxytryptamine 4 receptor,Expert,,,B,,BAO_0000357,12409,,,1,CHEMBL615280,,,,H,8,,
306,Relative competitive index values for binding to 25-OH-D3-1-hydroxylase of chick intestine,Autocuration,9031.0,,B,,BAO_0000019,11126,,,1,CHEMBL615281,,,Gallus gallus,U,0,,
307,Inhibitory effect (10e-6 M) on the 25-OH-D3-1-hydroxylase activity,Autocuration,9606.0,,F,,BAO_0000019,11126,,,1,CHEMBL615282,,,Homo sapiens,U,0,,
308,25-OH-D3-1-hydroxylase activity (10e-6 M) was measured as %control,Autocuration,9606.0,,F,,BAO_0000019,11126,,,1,CHEMBL615283,,,Homo sapiens,U,0,,
309,Relative competitive index values for binding to 25-OH-D3-1-hydroxylase of human HL-60 cells,Autocuration,9606.0,,B,,BAO_0000219,11126,,649.0,1,CHEMBL615284,HL-60,,Homo sapiens,N,1,,
310,Inhibitory effect (10e-6 M) on the 25-hydroxyvitamin D3-1-hydroxylase activity,Autocuration,9606.0,,B,,BAO_0000019,11126,,,1,CHEMBL615285,,,Homo sapiens,U,0,,
311,25-hydroxyvitamin D3-1-hydroxylase activity (10e-6 M) was measured as %control,Autocuration,9606.0,,B,,BAO_0000019,11126,,,1,CHEMBL615286,,,Homo sapiens,U,0,,
312,Displacement of [3H]-Ro- 15-1788 from human GABA-A alpha-1-beta-3-gamma-2 receptor subunits expressed in Xenopus oocytes,Autocuration,9606.0,,B,,BAO_0000219,17807,,,1,CHEMBL615287,Oocytes,,Homo sapiens,D,7,,
313,Chymotryptic inhibitory activity against 26S proteasome,Intermediate,,,F,,BAO_0000220,16575,,,1,CHEMBL615288,,,,S,2,,
314,Inhibitory activity against 26S proteasome degradation of IkB,Intermediate,,,B,,BAO_0000220,15407,,,1,CHEMBL615289,,,,S,2,,
315,In vitro inhibition of 2780/DOX ovarian cancer cell line,Intermediate,9606.0,,F,,BAO_0000219,10797,,478.0,1,CHEMBL615290,A2780,,Homo sapiens,N,1,,
316,In vitro inhibition of 2780/S ovarian cancer cell line,Intermediate,9606.0,,F,,BAO_0000219,10797,,478.0,1,CHEMBL884522,A2780,,Homo sapiens,N,1,,
317,Relative activity on the cellular accumulation of vincristine in multidrug-resistant (MDR) human ovarian cancer 2780AD cells,Autocuration,9606.0,,F,,BAO_0000019,3469,,,1,CHEMBL615291,,,Homo sapiens,U,0,,
318,Association constant for binding to AATT 28-mer AATT hairpin,Intermediate,,,B,,BAO_0000225,16037,,,1,CHEMBL615292,,,,M,3,,
319,Kinetically Defined Association Constant for 28-mer AATT hairpin.,Intermediate,,,B,,BAO_0000225,16037,,,1,CHEMBL615293,,,,M,3,,
320,Reaction Rate Parameter for 28-mer AATT hairpin,Intermediate,,,B,,BAO_0000225,16037,,,1,CHEMBL615294,,,,M,3,,
321,Reaction Rate Parameter for 28-mer AATT hairpin,Intermediate,,,B,,BAO_0000225,16037,,,1,CHEMBL615295,,,,M,3,,
322,Antiviral activity against envelope deficient HIV-1 in a single cycle replication assay (experiment 1),Autocuration,9606.0,,F,,BAO_0000019,16524,,,1,CHEMBL825021,,,Homo sapiens,U,0,,
323,Antiviral activity against envelope deficient HIV-1 in a single cycle replication assay (experiment 2),Autocuration,9606.0,,F,,BAO_0000019,16524,,,1,CHEMBL615296,,,Homo sapiens,U,0,,
324,Inhibitory concentration by single cycle replication assay using envelope deficient HIV-1,Autocuration,9606.0,,F,,BAO_0000019,16524,,,1,CHEMBL615297,,,Homo sapiens,U,0,,
325,Cytotoxicity against cell line 2SC/20 determined by MTT test,Autocuration,10029.0,,F,,BAO_0000019,16758,,,1,CHEMBL615298,,,Cricetulus griseus,U,0,,
326,Cytotoxicity against cell line 2SC/20 of hamster determined by MTT test,Autocuration,10029.0,,F,,BAO_0000019,16758,,,1,CHEMBL615299,,,Cricetulus griseus,U,0,,
327,Inhibitory concentration against the growth of 2SC/20 cell line after 72 hr of drug exposure by MTT test,Autocuration,10029.0,,F,,BAO_0000019,16758,,,1,CHEMBL615300,,,Cricetulus griseus,U,0,,
328,Binding affinity on 3 beta-hydroxysteroid dehydrogenase,Autocuration,,,B,,BAO_0000357,14360,,,1,CHEMBL615301,,,,H,8,,
329,Binding affinity for 3-beta-hydroxysteroid dehydrogenase,Expert,9606.0,,B,,BAO_0000357,14360,,,1,CHEMBL615302,,,Homo sapiens,D,9,,
330,Selectivity ratio of ID50 in liver and heart,Autocuration,10116.0,,B,,BAO_0000019,9964,,,1,CHEMBL615303,,,Rattus norvegicus,U,0,,
331,"Selectivity, ratio of relative ID50 in liver and heart",Autocuration,,,B,,BAO_0000019,9964,,,1,CHEMBL615304,,,,H,8,,
332,Binding affinity to the receptor was determined in isolated nuclei of heart(In vitro) relative to T3,Autocuration,,,B,,BAO_0000019,9964,,,1,CHEMBL615305,,,,H,8,,
333,"Binding affinity to the receptor was determined in nuclei of heart In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",Autocuration,,,B,,BAO_0000218,9964,,,1,CHEMBL615306,,,,H,8,,
334,"Binding affinity to the receptor was determined in nuclei of liver In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",Autocuration,,,B,,BAO_0000218,9964,,,1,CHEMBL615307,,,,H,8,,
335,"Binding affinity to the receptor was determined in nuclei of liver in vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",Autocuration,,,B,,BAO_0000218,9964,,,1,CHEMBL615308,,,,H,8,,
336,"Binding affinity to the receptor was determined in nuclei of liver in vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",Autocuration,,,F,,BAO_0000218,9964,,,1,CHEMBL615309,,,,H,8,,
337,"Binding affinity to the thyroid hormone receptor was determined in vitro in isolated nuclei of rat liver relative to 3,5,3' triiodothyronine",Autocuration,,,B,,BAO_0000019,9964,,,1,CHEMBL615310,,,,U,0,,
338,Binding affinity to the receptor was determined in vitro in isolated nuclei of rat liver relative to T3,Autocuration,,,B,,BAO_0000019,9964,,,1,CHEMBL615311,,,,H,8,,
339,"Binding affinity to thyroid hormone receptor beta, relative to 3,5,3' triiodothyronine receptor, in isolated nuclei of heart",Autocuration,9606.0,,B,,BAO_0000019,9964,,,1,CHEMBL615312,,,Homo sapiens,U,0,,
340,In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to T3,Autocuration,,,B,,BAO_0000019,9964,,,1,CHEMBL615313,,,,H,8,,
341,In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to T3,Autocuration,,,F,,BAO_0000019,9964,,,1,CHEMBL615314,,,,H,8,,
342,"Binding affinity to the receptor was determined in isolated nuclei of heart(In vitro) relative to 3,5,3' triiodothyronine receptor",Autocuration,,,B,,BAO_0000019,9964,,,1,CHEMBL615315,,,,H,8,,
343,"In vivo binding affinity for 3,5,3'' triiodothyronine receptor of heart nuclei 1 hr after intravenous administration",Autocuration,10116.0,,B,,BAO_0000218,9964,,,1,CHEMBL615316,,,Rattus norvegicus,U,0,,
344,Binding affinity to the receptor was determined in nuclei of heart in vivo 1 hour after intravenous administration relative to T3,Autocuration,,,B,,BAO_0000218,9964,,,1,CHEMBL615317,,,,H,8,,
345,"Binding affinity to the receptor was determined in nuclei of liver In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",Autocuration,,,B,,BAO_0000218,9964,,,1,CHEMBL615318,,,,H,8,,
346,"In vivo binding affinity for 3,5,3' triiodothyronine receptor of liver nuclei 1 hour after intravenous administration",Autocuration,10116.0,,B,,BAO_0000218,9964,,,1,CHEMBL615319,,,Rattus norvegicus,U,0,,
347,"In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to 3,5,3' triiodothyronine receptor",Autocuration,,,B,,BAO_0000019,9964,,,1,CHEMBL615320,,,,H,8,,
348,"In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to 3,5,3' triiodothyronine receptor",Autocuration,,,F,,BAO_0000019,9964,,,1,CHEMBL615321,,,,H,8,,
349,"Inhibition of [125I]L-T3 binding to rat hepatic 3,5,3''-triiodo-L-thyronine receptor",Autocuration,10116.0,,B,,BAO_0000019,3796,,,1,CHEMBL615322,,,Rattus norvegicus,U,0,,
350,Inhibition constant for binding to Co2+ form of 3-dehydroquinate synthase (DHQ) purified from Escherichia coli,Autocuration,562.0,,B,,BAO_0000357,4251,,,1,CHEMBL615323,,,Escherichia coli,H,8,,
351,Inhibition constant for binding to Zn2+ form of 3-dehydroquinate synthase (DHQ) purified from Escherichia coli,Autocuration,562.0,,B,,BAO_0000357,4251,,,1,CHEMBL615407,,,Escherichia coli,H,8,,
352,Kinetics expressed as Michaelis-Menten constant against Co2+ form of 3-dehydroquinate synthase purified from Escherichia coli,Autocuration,562.0,,B,,BAO_0000357,4251,,,1,CHEMBL857267,,,Escherichia coli,H,8,,
353,Kinetics expressed as Michaelis-Menten constant against Zn2+ form of 3-dehydroquinate synthase purified from Escherichia coli,Autocuration,562.0,,B,,BAO_0000357,4251,,,1,CHEMBL615408,,,Escherichia coli,H,8,,
354,Type of inhibition of 3-dehydroquinate synthase was determined; R - Slowly reversible,Autocuration,,,B,,BAO_0000357,166,,,1,CHEMBL615409,,,,H,8,,
355,Compound was evaluated for its inhibitory constant against 3-dehydroquinate synthase,Autocuration,,,B,,BAO_0000357,17861,,,1,CHEMBL615410,,,,H,8,,
356,Inhibition constant against 3-dehydroquinate synthase,Autocuration,,,B,,BAO_0000357,166,,,1,CHEMBL615411,,,,H,8,,
357,Association rate constant against 3-dehydroquinate synthase,Autocuration,,,B,,BAO_0000357,166,,,1,CHEMBL615412,,,,H,8,,
358,Rate constant against 3-dehydroquinate synthase,Autocuration,,,B,,BAO_0000357,166,,,1,CHEMBL615413,,,,H,8,,
359,Inhibitory activity against fuc-TVII,Autocuration,,,B,,BAO_0000019,3548,,,1,CHEMBL615414,,,,U,0,,
360,Ability of compound (2.5 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,Autocuration,10116.0,,B,,BAO_0000251,9877,Microsomes,,1,CHEMBL615415,,,Rattus norvegicus,D,9,2107.0,
361,Ability of compound (2500 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,Autocuration,10116.0,,B,,BAO_0000251,9877,Microsomes,,1,CHEMBL615416,,,Rattus norvegicus,D,9,2107.0,
362,Ability of compound (250 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,Autocuration,10116.0,,B,,BAO_0000251,9877,Microsomes,,1,CHEMBL615417,,,Rattus norvegicus,D,9,2107.0,
363,Ability of compound (25 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,Autocuration,10116.0,,B,,BAO_0000251,9877,Microsomes,,1,CHEMBL615418,,,Rattus norvegicus,D,9,2107.0,
364,Ability of compound at 0 uM to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,Autocuration,10116.0,,B,,BAO_0000251,9877,Microsomes,,1,CHEMBL615419,,,Rattus norvegicus,D,9,2107.0,
365,Ability of compound to inhibit the activity of 3-hydroxy-3-methylglutarylcoenzyme A(HMGR) reductase in rat liver microsomes,Autocuration,10116.0,,B,,BAO_0000251,9877,Microsomes,,1,CHEMBL615420,,,Rattus norvegicus,D,9,2107.0,
366,Percentage inhibition of 3-hydroxy-3-methyl glutaryl coenzyme A reductase in rat liver microsomes at 250 uM,Autocuration,10116.0,,B,,BAO_0000251,9877,Microsomes,,1,CHEMBL615421,,,Rattus norvegicus,D,9,2107.0,
367,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 0 uM,Autocuration,10116.0,,B,,BAO_0000251,9877,Microsomes,,1,CHEMBL615422,,,Rattus norvegicus,D,9,2107.0,
368,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 2.5 uM,Autocuration,10116.0,,B,,BAO_0000251,9877,Microsomes,,1,CHEMBL615423,,,Rattus norvegicus,D,9,2107.0,
369,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 2500 uM,Autocuration,10116.0,,B,,BAO_0000251,9877,Microsomes,,1,CHEMBL872868,,,Rattus norvegicus,D,9,2107.0,
370,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 25 uM,Autocuration,10116.0,,B,,BAO_0000251,9877,Microsomes,,1,CHEMBL615424,,,Rattus norvegicus,D,9,2107.0,
371,Inhibitory activity against 3-phosphoglycerate kinase.,Autocuration,,,B,,BAO_0000224,3003,,,1,CHEMBL825022,,,,H,4,,
372,Binding affinity was evaluated towards 3-phosphoglycerate kinase at 37 degrees Celsius in 0.1 m NaCl pH 7.1,Autocuration,,,B,,BAO_0000224,3003,,,1,CHEMBL615425,,,,H,4,,
373,"Michaelis-Menten constant with 1,3-bisphosphoglyceric acid (1,3-BPG) against 3-phosphoglycerate kinase",Autocuration,,,B,,BAO_0000224,3003,,,1,CHEMBL615426,,,,H,4,,
374,Inhibition of human 3-phosphoinositide-dependent protein kinase 1 at 10 uM,Expert,9606.0,,B,,BAO_0000357,17185,,,1,CHEMBL615427,,,Homo sapiens,D,9,,
375,Cytotoxicity on 3677 melanoma cells,Intermediate,9606.0,,F,,BAO_0000219,6072,,844.0,1,CHEMBL615428,3677 melanoma cell line,,Homo sapiens,N,1,,
376,Cytotoxicity on 3677 melanoma cells in combination with L-49-sFv-bL,Intermediate,9606.0,,F,,BAO_0000219,6072,,844.0,1,CHEMBL615429,3677 melanoma cell line,,Homo sapiens,N,1,,
377,Antitumor activity against Mouse colon 38 at 500 ug/disk in disk diffusion assay,Intermediate,10090.0,,F,,BAO_0000219,5018,,700.0,1,CHEMBL615430,MC-38,,Mus musculus,N,1,,
378,Compound was evaluated for inhibition of tumor cell growth using sulforhodamine-B assay in 38 human cell lines,Intermediate,9606.0,,F,,BAO_0000019,2852,,,1,CHEMBL615431,,,Homo sapiens,U,0,,
379,In vivo antitumor activity against 3B131 intraperitoneally implanted B16 melanoma cells; NT= Not tested,Autocuration,,,F,,BAO_0000218,8663,,798.0,1,CHEMBL615432,B16,,,U,0,,
380,In vivo antitumor activity against 3B131 intraperitoneally implanted B16 melanoma cells; reproducible significant activity.,Autocuration,,,F,,BAO_0000218,8663,,798.0,1,CHEMBL615433,B16,,,U,0,,
381,Inhibitory activity against Human RhinoVirus serotype-14 3C Protease,Expert,12131.0,,F,,BAO_0000019,3245,,,1,CHEMBL615434,,,Human rhinovirus 14,D,9,,
382,Inhibitory activity against Human RhinoVirus serotype-14 3C Protease; NI means No inhibition to 50 uM,Intermediate,169066.0,,F,,BAO_0000218,3245,,,1,CHEMBL615435,,,Human rhinovirus sp.,N,1,,
383,Compound was evaluated for the inactivation of HRV 14 3C protease activity expressed as KI,Intermediate,169066.0,,F,,BAO_0000218,3877,,,1,CHEMBL615436,,,human rhinovirus type 14,N,1,,
384,Compound was evaluated for the inactivation of HRV 14 3C protease activity expressed as kinact,Intermediate,169066.0,,F,,BAO_0000218,3877,,,1,CHEMBL615437,,,human rhinovirus type 14,N,1,,
385,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,Expert,12131.0,,F,,BAO_0000019,5861,,,1,CHEMBL615438,,,Human rhinovirus 14,D,9,,
386,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,Expert,12131.0,,F,,BAO_0000019,5861,,,1,CHEMBL615439,,,Human rhinovirus 14,D,9,,
387,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,Expert,12131.0,,F,,BAO_0000019,5861,,,1,CHEMBL615440,,,Human rhinovirus 14,D,9,,
388,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay; inactive,Expert,12131.0,,F,,BAO_0000019,5861,,,1,CHEMBL615441,,,Human rhinovirus 14,D,9,,
389,Compound was tested for the inhibitory activity of compound towards human rhinovirus 3C protease,Intermediate,12059.0,,F,,BAO_0000218,13748,,,1,CHEMBL615641,,,Enterovirus,N,1,,
390,Compound was tested for the inhibitory activity of compound towards human rhinovirus-16 3C protease,Intermediate,12059.0,,F,,BAO_0000218,13748,,,1,CHEMBL872065,,,Enterovirus,N,1,,
391,Compound was tested for the inhibitory activity of compound towards human rhinovirus-2 3C protease,Intermediate,12059.0,,F,,BAO_0000218,13748,,,1,CHEMBL825023,,,Enterovirus,N,1,,
392,Compound was tested for the inhibitory activity of compound towards human rhinovirus-89 3C protease,Intermediate,12059.0,,F,,BAO_0000218,13748,,,1,CHEMBL615642,,,Enterovirus,N,1,,
393,Inhibition of human rhinovirus 3C protease,Expert,147712.0,,B,,BAO_0000357,13748,,,1,CHEMBL615643,,,Human rhinovirus B,H,8,,
394,Compound was tested for inhibition of a proteinase 3CL pro of human coronavirus; Inhibited,Autocuration,9606.0,,B,,BAO_0000019,17699,,,1,CHEMBL615644,,,Homo sapiens,U,0,,
395,Compound tested for activity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose of 100 mg/kg (Dose range 200-12.5),Intermediate,10090.0,,F,,BAO_0000218,7145,,833.0,1,CHEMBL615645,3EM 37,,Mus musculus,N,1,,
396,Compound tested for activity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose of 128 mg/kg (Dose range 256-16),Intermediate,10090.0,,F,,BAO_0000218,7145,,833.0,1,CHEMBL615646,3EM 37,,Mus musculus,N,1,,
397,Compound tested for toxicity against 3EM 37 Mouse Ependymoblastoma after single ip injection on day 1 at optimal dose (OD) of 100 mg/kg on the 5th day after the injection of the compound; (10/10),Intermediate,10090.0,,F,,BAO_0000218,7145,,833.0,1,CHEMBL615647,3EM 37,,Mus musculus,N,1,,
398,Compound tested for toxicity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose (OD) of 100 mg/kg on the 5th day after the injection of the compound; (6/6),Intermediate,10090.0,,F,,BAO_0000218,7145,,833.0,1,CHEMBL615648,3EM 37,,Mus musculus,N,1,,
399,Effect of compound on 3EM 37 mouse ependymoblastoma after single ip injection on day 1 recorded as animal weight difference of the treated and the control (T-C) at OD of 100 mg/kg,Intermediate,10090.0,,F,,BAO_0000218,7145,,833.0,1,CHEMBL615649,3EM 37,,Mus musculus,N,1,,
400,Effect of compound on 3EM 37 mouse ependymoblastoma after single ip injection on day 1 recorded as percentage of cured animals at OD of 100 mg/kg,Intermediate,10090.0,,F,,BAO_0000218,7145,,833.0,1,CHEMBL615650,3EM 37,,Mus musculus,N,1,,
401,In vivo anti-tumor and anti-metastatic activity was measured after oral dosing 15 mg/kg b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor,Intermediate,10090.0,,F,,BAO_0000218,5325,,847.0,1,CHEMBL615651,3LL cell line,,Mus musculus,N,1,,
402,In vivo anti-tumor and anti-metastatic activity was measured after oral dosing b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor,Intermediate,10090.0,,F,,BAO_0000218,5325,,847.0,1,CHEMBL615652,3LL cell line,,Mus musculus,N,1,,
403,In vivo anti-tumor and anti-metastatic activity following p.o. administration b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor; Not tested.,Expert,10090.0,,F,,BAO_0000218,5325,,847.0,1,CHEMBL615653,3LL cell line,,Mus musculus,N,1,,
404,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 1 uM dose,Intermediate,10090.0,,F,,BAO_0000219,16169,,847.0,1,CHEMBL615654,3LL cell line,,Mus musculus,N,1,,
405,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 10 uM dose,Intermediate,10090.0,,F,,BAO_0000219,16169,,847.0,1,CHEMBL615655,3LL cell line,,Mus musculus,N,1,,
406,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 250 uM dose,Intermediate,10090.0,,F,,BAO_0000219,16169,,847.0,1,CHEMBL825024,3LL cell line,,Mus musculus,N,1,,
407,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 50 uM dose,Intermediate,10090.0,,F,,BAO_0000219,16169,,847.0,1,CHEMBL615656,3LL cell line,,Mus musculus,N,1,,
408,accumulation of compound in 3LL cells was measured with DFMO by ICP-AES at 50 uM dose,Intermediate,10090.0,,F,,BAO_0000219,16169,,847.0,1,CHEMBL615657,3LL cell line,,Mus musculus,N,1,,
409,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 1 uM dose,Intermediate,10090.0,,F,,BAO_0000219,16169,,847.0,1,CHEMBL615658,3LL cell line,,Mus musculus,N,1,,
410,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 10 uM dose,Intermediate,10090.0,,F,,BAO_0000219,16169,,847.0,1,CHEMBL615659,3LL cell line,,Mus musculus,N,1,,
411,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 250 uM dose,Intermediate,10090.0,,F,,BAO_0000219,16169,,847.0,1,CHEMBL615660,3LL cell line,,Mus musculus,N,1,,
412,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 50 uM dose,Intermediate,10090.0,,F,,BAO_0000219,16169,,847.0,1,CHEMBL615661,3LL cell line,,Mus musculus,N,1,,
413,accumulation of compound in 3LL cells was measured without DFMO by ICP-AES at 50 uM dose,Intermediate,10090.0,,F,,BAO_0000219,16169,,847.0,1,CHEMBL615662,3LL cell line,,Mus musculus,N,1,,
414,Effect on the growth of 3LL cells by DFMO pretreatment at 48 hr incubation,Intermediate,10090.0,,F,,BAO_0000219,16169,,847.0,1,CHEMBL615663,3LL cell line,,Mus musculus,N,1,,
415,Effect on the growth of 3LL cells was evaluated using an MTT assay at 48 hour incubation,Intermediate,10090.0,,F,,BAO_0000219,16169,,847.0,1,CHEMBL615664,3LL cell line,,Mus musculus,N,1,,
416,Effect on the growth of 3LL cells was evaluated using an MTT assay at 72 hour incubation,Intermediate,10090.0,,F,,BAO_0000219,16169,,847.0,1,CHEMBL615665,3LL cell line,,Mus musculus,N,1,,
417,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 50 uM dose,Intermediate,10090.0,,F,,BAO_0000219,16169,,847.0,1,CHEMBL615666,3LL cell line,,Mus musculus,N,1,,
418,putrescine levels in 3LL cells after the treatment of 1 uM of Compound,Intermediate,10090.0,,F,,BAO_0000219,16169,,847.0,1,CHEMBL615667,3LL cell line,,Mus musculus,N,1,,
419,putrescine levels in 3LL cells after the treatment of 10 uM of Compound,Intermediate,10090.0,,F,,BAO_0000219,16169,,847.0,1,CHEMBL615668,3LL cell line,,Mus musculus,N,1,,
420,putrescine levels in 3LL cells after the treatment of 250 uM of Compound,Intermediate,10090.0,,F,,BAO_0000219,16169,,847.0,1,CHEMBL615669,3LL cell line,,Mus musculus,N,1,,
421,putrescine levels in 3LL cells after the treatment of 50 uM of Compound,Intermediate,10090.0,,F,,BAO_0000219,16169,,847.0,1,CHEMBL615670,3LL cell line,,Mus musculus,N,1,,
422,spermidine levels in 3LL cells after the treatment of 1 uM of Compound,Intermediate,10090.0,,F,,BAO_0000219,16169,,847.0,1,CHEMBL836739,3LL cell line,,Mus musculus,N,1,,
423,spermidine levels in 3LL cells after the treatment of 10 uM of Compound,Intermediate,10090.0,,F,,BAO_0000219,16169,,847.0,1,CHEMBL615671,3LL cell line,,Mus musculus,N,1,,
424,spermidine levels in 3LL cells after the treatment of 250 uM of Compound,Intermediate,10090.0,,F,,BAO_0000219,16169,,847.0,1,CHEMBL615672,3LL cell line,,Mus musculus,N,1,,
425,spermidine levels in 3LL cells after the treatment of 50 uM of Compound,Intermediate,10090.0,,F,,BAO_0000219,16169,,847.0,1,CHEMBL615791,3LL cell line,,Mus musculus,N,1,,
426,spermine levels in 3LL cells after the treatment of 1 uM of Compound,Intermediate,10090.0,,F,,BAO_0000219,16169,,847.0,1,CHEMBL615792,3LL cell line,,Mus musculus,N,1,,
427,spermine levels in 3LL cells after the treatment of 10 uM of Compound,Intermediate,10090.0,,F,,BAO_0000219,16169,,847.0,1,CHEMBL615793,3LL cell line,,Mus musculus,N,1,,
428,spermine levels in 3LL cells after the treatment of 250 uM of Compound,Intermediate,10090.0,,F,,BAO_0000219,16169,,847.0,1,CHEMBL615794,3LL cell line,,Mus musculus,N,1,,
429,spermine levels in 3LL cells after the treatment of 50 uM of Compound,Intermediate,10090.0,,F,,BAO_0000219,16169,,847.0,1,CHEMBL615795,3LL cell line,,Mus musculus,N,1,,
430,Concentration required to inhibit the colony formation of lung carcinoma (3LLD122) cell lines by 50%,Intermediate,9606.0,,F,,BAO_0000219,15547,,971.0,1,CHEMBL615590,3LLD122,,Homo sapiens,N,1,,
431,In vivo antitumor activity against 3M531 is the sarcoma M5076; reproducible minimal activity,Autocuration,,,F,,BAO_0000218,8663,,,1,CHEMBL615591,,,,U,0,,
432,In vivo antitumor activity against 3M531 is the sarcoma M5076; reproducible significant activity.,Autocuration,,,F,,BAO_0000218,8663,,,1,CHEMBL615592,,,,U,0,,
433,In vivo antitumor activity against 3MBG5 subrenal capsule mammary carcinoma MX-1 xenograft; NT= Not tested,Autocuration,,,F,,BAO_0000218,8663,,,1,CHEMBL615593,,,,U,0,,
434,In vivo antitumor activity against 3MBG5 subrenal capsule mammary carcinoma MX-1 xenograft; reproducible significant activity.,Autocuration,,,F,,BAO_0000218,8663,,,1,CHEMBL615594,,,,U,0,,
435,Effective dose required against Trypanosoma cruzi amastigotes in 3T3 Fibroblasts,Intermediate,10090.0,,F,,BAO_0000219,4504,,723.0,1,CHEMBL615595,NIH3T3,,Mus musculus,N,1,,
436,Effective dose required against Trypanosoma cruzi amastigotes in 3T3 Fibroblasts,Intermediate,10090.0,,F,,BAO_0000219,4504,,723.0,1,CHEMBL615596,NIH3T3,,Mus musculus,N,1,,
437,Inhibition of 6 nM bombesin induced [3H]thymidine incorporation measured in swiss 3T3 cells using a mitogenicity assay,Expert,,,F,,BAO_0000219,12695,,723.0,1,CHEMBL615597,NIH3T3,,,H,8,,
438,Ability of the peptide to inhibit 6 nM bombesin induced [3H]thymidine incorporation was measured in swiss 3T3 cells using mitogenicity assay; na=Not active,Intermediate,10090.0,,F,,BAO_0000219,12695,,723.0,1,CHEMBL615598,NIH3T3,,Mus musculus,N,1,,
439,Ability of the peptide to inhibit 6 nM bombesin induced [3H]thymidine incorporation was measured in swiss 3T3 cells using mitogenicity assay; nt=Not tested,Intermediate,10090.0,,F,,BAO_0000219,12695,,723.0,1,CHEMBL615599,NIH3T3,,Mus musculus,N,1,,
440,Effective dose against murine 3T3 fibroblasts cells,Expert,10090.0,,F,,BAO_0000219,17642,,723.0,1,CHEMBL615600,NIH3T3,,Mus musculus,N,1,,
441,Dose required against murine 3T3 fibroblasts cells; 1-10 uM,Expert,10090.0,,F,,BAO_0000219,17642,,723.0,1,CHEMBL615601,NIH3T3,,Mus musculus,N,1,,
442,Cytotoxic effect on 3T3 cells,Expert,10090.0,,F,,BAO_0000219,12340,,723.0,1,CHEMBL615602,NIH3T3,,Mus musculus,N,1,,
443,Cytotoxic effect on 3T3 cells,Expert,10090.0,,F,,BAO_0000219,12340,,723.0,1,CHEMBL615603,NIH3T3,,Mus musculus,N,1,,
444,Compound was tested for the concentration necessary to inhibit swiss 3T3 Mouse Fibroblast cell growth rate by 50%.,Intermediate,10090.0,,F,,BAO_0000219,12716,,723.0,1,CHEMBL615604,NIH3T3,,Mus musculus,N,1,,
445,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration,Intermediate,10090.0,,F,,BAO_0000219,6277,,723.0,1,CHEMBL615605,NIH3T3,,Mus musculus,N,1,,
446,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration; nd=No data,Intermediate,10090.0,,F,,BAO_0000219,6277,,723.0,1,CHEMBL615606,NIH3T3,,Mus musculus,N,1,,
447,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration,Expert,10090.0,,F,,BAO_0000219,6277,,723.0,1,CHEMBL884526,NIH3T3,,Mus musculus,N,1,,
448,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration; n.d.=no data,Expert,10090.0,,F,,BAO_0000219,6277,,723.0,1,CHEMBL615607,NIH3T3,,Mus musculus,N,1,,
449,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration; n.t.=not tested,Intermediate,10090.0,,F,,BAO_0000219,6277,,723.0,1,CHEMBL615608,NIH3T3,,Mus musculus,N,1,,
450,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration,Expert,10090.0,,F,,BAO_0000219,6277,,723.0,1,CHEMBL615609,NIH3T3,,Mus musculus,N,1,,
451,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration; n.d.=no data,Expert,10090.0,,F,,BAO_0000219,6277,,723.0,1,CHEMBL615682,NIH3T3,,Mus musculus,N,1,,
452,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration; n.t.=not tested,Intermediate,10090.0,,F,,BAO_0000219,6277,,723.0,1,CHEMBL615683,NIH3T3,,Mus musculus,N,1,,
453,In vivo inhibition of H-ras-transformed 3T3 fibroblasts in nude mouse tumor models,Expert,10090.0,,F,,BAO_0000218,17780,,723.0,1,CHEMBL615684,NIH3T3,,Mus musculus,N,1,,
454,Inhibition of PDGF-dependent autophosphorylation of PDGF-R in mouse BALB/c3T3 cells,Autocuration,10090.0,,F,,BAO_0000219,12751,,,1,CHEMBL615685,,,Mus musculus,D,7,,
455,Inhibition of Swiss 3T3 Mouse fibroblast proliferation,Expert,10090.0,,F,,BAO_0000219,12380,,723.0,1,CHEMBL615686,NIH3T3,,Mus musculus,N,1,,
456,Inhibitory activity against 3T3 cell line,Intermediate,10090.0,,F,,BAO_0000219,14892,,723.0,1,CHEMBL615687,NIH3T3,,Mus musculus,N,1,,
457,The ability of the peptide to inhibit the binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane was measured,Intermediate,10090.0,,F,,BAO_0000219,12695,,723.0,1,CHEMBL884523,NIH3T3,,Mus musculus,N,1,,
458,Ability of peptide to inhibit binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane.,Expert,,,F,,BAO_0000019,12695,,,1,CHEMBL615688,,,,H,8,,
459,The ability of the peptide to inhibit the binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane was measured; nt=Not tested,Intermediate,10090.0,,F,,BAO_0000219,12695,,723.0,1,CHEMBL615689,NIH3T3,,Mus musculus,N,1,,
460,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells was measured,Intermediate,10090.0,,F,,BAO_0000219,12695,,723.0,1,CHEMBL615690,NIH3T3,,Mus musculus,N,1,,
461,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells,Expert,,,F,,BAO_0000019,12695,,,1,CHEMBL615691,,,,H,8,,
462,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells; nt=Not tested,Expert,,,F,,BAO_0000019,12695,,,1,CHEMBL615692,,,,H,8,,
463,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration,Intermediate,10090.0,,F,,BAO_0000219,6277,,723.0,1,CHEMBL615693,NIH3T3,,Mus musculus,N,1,,
464,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line was determined using NR coloration; n.d.=no data,Expert,10090.0,,F,,BAO_0000219,6277,,723.0,1,CHEMBL615324,NIH3T3,,Mus musculus,N,1,,
465,Inhibition of ligand-induced proliferation in human EGF-R Kinase expressing 3T3 cells,Expert,9606.0,,F,,BAO_0000219,4959,,723.0,1,CHEMBL615325,NIH3T3,,Homo sapiens,D,9,,
466,Inhibition of ligand-induced proliferation in human EGF-R Kinase expressing 3T3 cells (Not tested),Expert,9606.0,,F,,BAO_0000219,4959,,723.0,1,CHEMBL615490,NIH3T3,,Homo sapiens,D,9,,
467,Inhibition of ligand induced proliferation in human Her-2 (p185erbB) tyrosine kinase expressing 3T3 cells,Expert,9606.0,,F,,BAO_0000219,4959,,723.0,1,CHEMBL615491,NIH3T3,,Homo sapiens,D,9,,
468,Inhibition of ligand-induced proliferation in human Her-2 (p185erbB) tyrosine kinase expressing 3T3 cells (Not tested),Expert,9606.0,,F,,BAO_0000219,4959,,723.0,1,CHEMBL615492,NIH3T3,,Homo sapiens,D,9,,
469,Inhibitory concentration of compound rwas calculated on 3T3 cells by [3H]Thd incorporation,Intermediate,10090.0,,F,,BAO_0000219,12082,,723.0,1,CHEMBL615493,NIH3T3,,Mus musculus,N,1,,
470,Inhibitory concentration of compound was calculated on 3T3 cells by [14C]Leu incorporation,Intermediate,10090.0,,F,,BAO_0000219,12082,,723.0,1,CHEMBL615494,NIH3T3,,Mus musculus,N,1,,
471,Inhibitory concentration of compound was calculated on 3T3 cells by using clonal assay,Intermediate,10090.0,,F,,BAO_0000219,12082,,723.0,1,CHEMBL615495,NIH3T3,,Mus musculus,N,1,,
472,Inhibitory concentration was calculated on 3T3 cells by using growth assay,Intermediate,10090.0,,F,,BAO_0000219,12082,,723.0,1,CHEMBL615496,NIH3T3,,Mus musculus,N,1,,
473,In vitro cytotoxicity was evaluated in mouse embryo BALB/c 3T3 cells,Intermediate,10090.0,,F,,BAO_0000219,2643,,723.0,1,CHEMBL615497,NIH3T3,,Mus musculus,N,1,,
474,Inhibition of Swiss 3T3 mouse fibroblast proliferation,Expert,10090.0,,F,,BAO_0000219,11926,,723.0,1,CHEMBL615498,NIH3T3,,Mus musculus,N,1,,
475,The compound was tested for cytotoxicity against 3T3 fibroblast murine cell line.,Intermediate,10090.0,,A,,BAO_0000219,15204,,723.0,1,CHEMBL615499,NIH3T3,,Mus musculus,N,1,,
476,Effective concentration required to inhibit the growth of murine 3T3 fibroblasts,Expert,10090.0,,F,,BAO_0000219,15992,,723.0,1,CHEMBL835522,NIH3T3,,Mus musculus,N,1,,
477,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014); Not tested,Intermediate,10090.0,,F,,BAO_0000219,16279,,723.0,1,CHEMBL615500,NIH3T3,,Mus musculus,N,1,,
478,Cytotoxicity against 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),Intermediate,10090.0,,F,,BAO_0000219,16279,,723.0,1,CHEMBL615501,NIH3T3,,Mus musculus,N,1,,
479,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),Intermediate,10090.0,,F,,BAO_0000219,16279,,723.0,1,CHEMBL615502,NIH3T3,,Mus musculus,N,1,,
480,cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),Intermediate,10090.0,,F,,BAO_0000219,16279,,723.0,1,CHEMBL615503,NIH3T3,,Mus musculus,N,1,,
481,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),Intermediate,10090.0,,F,,BAO_0000219,16279,,723.0,1,CHEMBL615504,NIH3T3,,Mus musculus,N,1,,
482,Cytotoxicity against 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),Intermediate,10090.0,,F,,BAO_0000219,16279,,723.0,1,CHEMBL615505,NIH3T3,,Mus musculus,N,1,,
483,Inhibition of swiss 3T3 mouse fibroblast proliferation,Expert,10090.0,,F,,BAO_0000219,12831,,723.0,1,CHEMBL615506,NIH3T3,,Mus musculus,N,1,,
484,Compound was tested for sublethal concentrations in 3T3 mouse fibroblast lysis.,Intermediate,10090.0,,F,,BAO_0000219,13497,,723.0,1,CHEMBL615507,NIH3T3,,Mus musculus,N,1,,
485,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,Intermediate,,,F,,BAO_0000218,13715,,620.0,1,CHEMBL615508,3T3-L1,,,N,1,,
486,Concentration required to stimulate glucose uptake in 3T3-L1 adipocytes after 48 hr incubation,Intermediate,10090.0,,F,,BAO_0000219,13618,,620.0,1,CHEMBL615509,3T3-L1,,Mus musculus,N,1,,
487,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 0.3 uM,Intermediate,10090.0,,F,,BAO_0000219,11902,,620.0,1,CHEMBL615510,3T3-L1,,Mus musculus,N,1,,
488,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 3 uM,Intermediate,10090.0,,F,,BAO_0000219,11902,,620.0,1,CHEMBL615511,3T3-L1,,Mus musculus,N,1,,
489,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 30 uM,Intermediate,10090.0,,F,,BAO_0000219,11902,,620.0,1,CHEMBL615512,3T3-L1,,Mus musculus,N,1,,
490,"In vitro ability to stimulate glucose transport in 3T3-L1 adipocytes, given at 100 mg/kg in mouse, after 24 hr",Intermediate,10090.0,,F,,BAO_0000218,14840,,620.0,1,CHEMBL615513,3T3-L1,,Mus musculus,N,1,,
491,"In vitro ability to stimulate glucose transport in 3T3-L1 adipocytes, given at 100 mg/kg in mouse, after 3 hr",Intermediate,10090.0,,F,,BAO_0000218,14840,,620.0,1,CHEMBL615514,3T3-L1,,Mus musculus,N,1,,
492,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes,Intermediate,,,F,,BAO_0000219,13715,,620.0,1,CHEMBL615515,3T3-L1,,,N,1,,
493,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 10 micro M,Intermediate,,,F,,BAO_0000219,13715,,620.0,1,CHEMBL615516,3T3-L1,,,N,1,,
494,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,Intermediate,,,F,,BAO_0000219,13715,,620.0,1,CHEMBL615517,3T3-L1,,,N,1,,
495,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 30 micro M,Intermediate,,,F,,BAO_0000219,13715,,620.0,1,CHEMBL615518,3T3-L1,,,N,1,,
496,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,Intermediate,,,F,,BAO_0000219,13715,,620.0,1,CHEMBL615519,3T3-L1,,,N,1,,
497,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 0.3 uM dose.,Intermediate,,,F,,BAO_0000218,13715,,620.0,1,CHEMBL615520,3T3-L1,,,N,1,,
498,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 0.5 uM dose.,Intermediate,,,F,,BAO_0000218,13715,,620.0,1,CHEMBL615521,3T3-L1,,,N,1,,
499,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 1 uM dose.,Intermediate,,,F,,BAO_0000218,13715,,620.0,1,CHEMBL615522,3T3-L1,,,N,1,,
500,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,Intermediate,,,F,,BAO_0000218,13715,,620.0,1,CHEMBL615523,3T3-L1,,,N,1,,
501,In vitro measurements 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 100 uM dose.,Expert,,,F,,BAO_0000218,13715,,620.0,1,CHEMBL615524,3T3-L1,,,N,1,,
502,Acute effects in vitro by measuring 2-deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,Expert,,,F,,BAO_0000218,13715,,620.0,1,CHEMBL615525,3T3-L1,,,N,1,,
503,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 1 uM dose.,Intermediate,,,F,,BAO_0000218,13715,,620.0,1,CHEMBL615526,3T3-L1,,,N,1,,
504,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,Intermediate,,,F,,BAO_0000218,13715,,620.0,1,CHEMBL615527,3T3-L1,,,N,1,,
505,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 300 uM dose.,Intermediate,,,F,,BAO_0000218,13715,,620.0,1,CHEMBL615528,3T3-L1,,,N,1,,
506,Acute effects in vitro by measuring 2-deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,Expert,,,F,,BAO_0000218,13715,,620.0,1,CHEMBL615529,3T3-L1,,,N,1,,
507,In vitro by measurements of 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,Expert,,,F,,BAO_0000218,13715,,620.0,1,CHEMBL615530,3T3-L1,,,N,1,,
508,In vitro measurements of 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 60 uM dose.,Expert,,,F,,BAO_0000218,13715,,620.0,1,CHEMBL615531,3T3-L1,,,N,1,,
509,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 10 micro M,Intermediate,,,F,,BAO_0000219,13715,,620.0,1,CHEMBL615532,3T3-L1,,,N,1,,
510,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,Intermediate,,,F,,BAO_0000219,13715,,620.0,1,CHEMBL615533,3T3-L1,,,N,1,,
511,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 30 micro M,Intermediate,,,F,,BAO_0000219,13715,,620.0,1,CHEMBL615534,3T3-L1,,,N,1,,
512,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 100 uM dose.,Intermediate,,,F,,BAO_0000218,13715,,620.0,1,CHEMBL615535,3T3-L1,,,N,1,,
513,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,Intermediate,,,F,,BAO_0000218,13715,,620.0,1,CHEMBL615536,3T3-L1,,,N,1,,
514,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,Intermediate,,,F,,BAO_0000218,13715,,620.0,1,CHEMBL615537,3T3-L1,,,N,1,,
515,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,Intermediate,,,F,,BAO_0000218,13715,,620.0,1,CHEMBL615538,3T3-L1,,,N,1,,
516,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 60 uM dose.,Intermediate,,,F,,BAO_0000218,13715,,620.0,1,CHEMBL836166,3T3-L1,,,N,1,,
517,Inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells,Expert,,,F,,BAO_0000219,6411,,620.0,1,CHEMBL615539,3T3-L1,,,H,8,,
518,Evaluated for the inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells; ND = No data,Intermediate,10090.0,,F,,BAO_0000219,6411,,620.0,1,CHEMBL615540,3T3-L1,,Mus musculus,N,1,,
519,Evaluated for the inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells; Na = Not active,Expert,,,F,,BAO_0000219,6411,,620.0,1,CHEMBL615541,3T3-L1,,,H,8,,
520,Insulin-sensitizing activity; triglyceride accumulation from insulin regulated differentiation of 3T3-L1 cells at 1 uM expressed as percent activity of pioglitazone,Expert,10090.0,,F,,BAO_0000219,3966,,620.0,1,CHEMBL615542,3T3-L1,,Mus musculus,N,1,,
521,Compound was tested for insulin-sensitizing activity by measuring triglyceride accumulation from insulin regulated differentiation of 3T3-L1 cells at 10 uM expressed as percent activity of pioglitazone,Intermediate,10090.0,,F,,BAO_0000219,3966,,620.0,1,CHEMBL615543,3T3-L1,,Mus musculus,N,1,,
522,Stimulation of adipogenesis in 3T3-L1 cells is expressed as concentration equivalent to the [ 1-14C] uptake counts after treatment with 0.2 ug/mL troglitazone,Expert,10090.0,,F,,BAO_0000219,15556,,620.0,1,CHEMBL615544,3T3-L1,,Mus musculus,N,1,,
523,Effective concentration for enhancement of insulin-induced triglyceride accumulation in 3T3-L1 cells,Expert,10090.0,,F,,BAO_0000219,5845,,620.0,1,CHEMBL615545,3T3-L1,,Mus musculus,N,1,,
524,Effective concentration for 50% enhancement of insulin-induced triglyceride accumulation in 3T3-L1 cells,Expert,10090.0,,F,,BAO_0000219,14422,,620.0,1,CHEMBL615546,3T3-L1,,Mus musculus,N,1,,
525,Percentage of rosiglitazone response for insulin-sensitizing activity at 1 uM concentration in 3T3-L1 cells,Expert,10090.0,,F,,BAO_0000219,5845,,620.0,1,CHEMBL615547,3T3-L1,,Mus musculus,N,1,,
526,In vitro glucose transport activity in 3T3-LI adipocytes at 10 uM concentration.,Expert,10090.0,,F,,BAO_0000219,14508,,620.0,1,CHEMBL615548,3T3-L1,,Mus musculus,N,1,,
527,In vitro glucose transport activity in 3T3-LI adipocytes at 3 uM concentration.,Expert,10090.0,,F,,BAO_0000219,14508,,620.0,1,CHEMBL615549,3T3-L1,,Mus musculus,N,1,,
528,In vitro glucose transport activity in 3T3-LI adipocytes at 30 uM concentration.,Expert,10090.0,,F,,BAO_0000219,14508,,620.0,1,CHEMBL615550,3T3-L1,,Mus musculus,N,1,,
529,Inhibitory activity against rat fibroblast (3Y1) cell line,Intermediate,10116.0,,F,,BAO_0000219,6349,,1118.0,1,CHEMBL615551,3Y1 cell line,,Rattus norvegicus,N,1,,
530,Mean concentration causing inhibition of cell growth in 3Y1 cells.,Expert,10116.0,,F,,BAO_0000219,15899,,1118.0,1,CHEMBL615552,3Y1 cell line,,Rattus norvegicus,N,1,,
531,Cytotoxicity in 3Y1 cells.,Expert,10116.0,,F,,BAO_0000219,15899,,1118.0,1,CHEMBL615553,3Y1 cell line,,Rattus norvegicus,N,1,,
532,Cytostatic effect in 3Y1 cells.,Expert,10116.0,,F,,BAO_0000219,15899,,1118.0,1,CHEMBL615554,3Y1 cell line,,Rattus norvegicus,N,1,,
533,"Mean averaged concentration for total growth inhibition, which signifies cytostatic effect",Intermediate,10116.0,,F,,BAO_0000219,15899,,1118.0,1,CHEMBL615555,3Y1 cell line,,Rattus norvegicus,N,1,,
534,Concentration to inhibit growth of normal rat fibroblast cells (3Y1-B cells) after 72 h exposure,Expert,10116.0,,F,,BAO_0000219,17038,,1118.0,1,CHEMBL615556,3Y1 cell line,,Rattus norvegicus,N,1,,
535,In vitro inhibitory activity against human adrenal 3-beta hydroxy-delta 5-teroid isomerase,Autocuration,,,B,,BAO_0000019,12421,,,1,CHEMBL615557,,,,U,0,,
536,Inhibition of recombinant human adrenal 3-beta-hydroxy-delta-5-steroid dehydrogenase,Autocuration,,,B,,BAO_0000019,12947,,,1,CHEMBL615558,,,,U,0,,
537,Inhibition of recombinant rat adrenal 3-beta-hydroxy-delta-5-steroid dehydrogenase,Autocuration,,,B,,BAO_0000019,12947,,,1,CHEMBL872066,,,,U,0,,
538,In vitro inhibition against of 4-Hydroxyphenylpyruvate dioxygenase (4-HPPD) from pig liver by the enol borate method,Expert,9823.0,,B,,BAO_0000019,4896,,,1,CHEMBL615559,,,Sus scrofa,D,9,,
539,In vitro inhibitory concentration required against 4-hydroxyphenylpyruvate dioxygenase (4-HPPD) taken from pig liver,Autocuration,,,B,,BAO_0000019,6148,,,1,CHEMBL615560,,,,H,8,,
540,Inhibition of pig liver 4-Hydroxyphenylpyruvate dioxygenase (4-HPPD) enzyme,Autocuration,,,B,,BAO_0000019,16432,,,1,CHEMBL615561,,,,H,8,,
541,Concentration required to achieve 50% inhibition against 4-Hydroxyphenylpyruvate dioxygenase (HPPD) from pig liver,Expert,,,B,,BAO_0000019,4978,,,1,CHEMBL857062,,,,H,8,,
542,Concentration required to achieve 50% inhibition against 4-Hydroxyphenylpyruvate dioxygenase (HPPD) from pig liver; (observed value),Expert,,,B,,BAO_0000019,4978,,,1,CHEMBL615562,,,,H,8,,
543,In vitro inhibitory activity against HPPD(4-hydroxyphenylpyruvate Dioxygenase) from pig liver using enol borate assay method,Autocuration,,,B,,BAO_0000019,3723,,,1,CHEMBL615563,,,,H,8,,
544,Compound was evaluated for complete competitive inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD),Autocuration,,,B,,BAO_0000357,3518,,,1,CHEMBL615564,,,,H,8,,
545,In vitro inhibition of 4-hydroxyphenylpyruvate dioxygenase obtained from purified pig liver by enol-borate method,Autocuration,,,B,,BAO_0000019,4164,,,1,CHEMBL615565,,,,H,8,,
546,Inhibitory activity on pig liver 4-hydroxyphenylpyruvate dioxygenase (HPPD) was evaluated,Autocuration,,,B,,BAO_0000019,3518,,,1,CHEMBL615566,,,,H,8,,
547,Inhibition of 4-hydroxyphenylpyruvate dioxygenase of purified pig liver by enol-borate method,Expert,9823.0,,B,,BAO_0000019,4164,,,1,CHEMBL615567,,,Sus scrofa,D,9,,
548,The inhibitory activity on pig liver 4-hydroxyphenylpyruvate dioxygenase (HPPD) was evaluated.,Autocuration,,,B,,BAO_0000019,3518,,,1,CHEMBL615568,,,,H,8,,
549,Compound was evaluated for competitive inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD) (complete inhibition was observed at a concentration of 0.5-1.0 mM),Autocuration,,,B,,BAO_0000357,3518,,,1,CHEMBL615569,,,,H,8,,
550,Concentration required to achieve 50% inhibition against 4-hydroxyphenylpyruvate dioxygenase from pig liver,Autocuration,,,B,,BAO_0000019,4978,,,1,CHEMBL615570,,,,H,8,,
551,Concentration required to achieve 50% inhibition against 4-hydroxyphenylpyruvate dioxygenase from pig liver; (observed value),Autocuration,,,B,,BAO_0000019,4978,,,1,CHEMBL615571,,,,H,8,,
552,Binding affinity against melatonin (MT1) receptor (pC1),Autocuration,,,B,,BAO_0000224,6455,,,1,CHEMBL615572,,,,H,4,,
553,Compound was tested for inhibitory activity against 5-hydroxytryptamine 1 receptor,Autocuration,,,B,,BAO_0000019,2222,,,1,CHEMBL615573,,,,U,0,,
554,Inhibition of [3H]- 5-HT binding to 5-hydroxytryptamine 1 receptor at 10e-5 M,Autocuration,,,B,,BAO_0000019,13020,,,1,CHEMBL615574,,,,U,0,,
555,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1 receptor of central nervous system,Autocuration,,,B,,BAO_0000019,13021,,,1,CHEMBL615575,,,,U,0,,
556,Inhibitory activity against 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand at 10e-5 M concentration,Autocuration,,,B,,BAO_0000357,14532,,,1,CHEMBL615576,,,,H,8,,
557,Binding affinity against 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand,Autocuration,,,B,,BAO_0000357,14118,,,1,CHEMBL615577,,,,H,8,,
558,Binding affinity at 5-hydroxytryptamine 1A receptor in bovine hippocampal preparation using [3H]8-OH-DPAT,Autocuration,,,B,,BAO_0000221,11884,,,1,CHEMBL615578,,,,H,8,10000000.0,
559,Binding affinity against 5-hydroxytryptamine 1A receptor was measured using [3H]8-OH-DPAT as radioligand,Expert,,,B,,BAO_0000357,13969,,,1,CHEMBL615579,,,,H,8,,
560,Binding affinity for 5-hydroxytryptamine 1A receptor,Expert,,,B,,BAO_0000357,13392,,,1,CHEMBL615580,,,,H,8,,
561,Affinity towards 5-hydroxytryptamine 1A receptor in membranes from bovine hippocampus using [3H]OH-DPAT,Expert,,,B,,BAO_0000019,14430,,,1,CHEMBL615581,,,,H,8,,
562,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,Autocuration,,,B,,BAO_0000221,12248,,,1,CHEMBL615582,,,,H,8,10000000.0,
563,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,Autocuration,,,B,,BAO_0000221,12249,,,1,CHEMBL615583,,,,H,8,10000000.0,
564,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-HT1A receptor from bovine hippocampus,Autocuration,,,B,,BAO_0000221,9995,,,1,CHEMBL615584,,,,H,8,10000000.0,
565,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,Autocuration,,,B,,BAO_0000221,9995,,,1,CHEMBL833691,,,,H,8,10000000.0,
566,In vitro inhibition of azido-[125I]-IPAPP (0.25 nM) binding to 5-HT1A receptor from bovine hippocampus,Autocuration,,,B,,BAO_0000221,9995,,,1,CHEMBL615585,,,,H,8,10000000.0,
567,In vitro inhibition of [125I]IPAPP (0.25 nM) binding to 5-HT1A receptor from bovine hippocampus,Autocuration,,,B,,BAO_0000221,9995,,,1,CHEMBL615586,,,,H,8,10000000.0,
568,In vitro inhibition of [125I]IPAPP (2.5 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,Autocuration,,,B,,BAO_0000221,9995,,,1,CHEMBL884524,,,,H,8,10000000.0,
569,Inhibitory concentration against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,Autocuration,,,B,,BAO_0000221,12249,,,1,CHEMBL615587,,,,H,8,10000000.0,
570,"Compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor from bovine hippocampus, used [3H]8-OH-DPAT as radioligand",Autocuration,,,B,,BAO_0000221,11799,,,1,CHEMBL615588,,,,H,8,10000000.0,
571,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampal membranes,Expert,10116.0,,B,,BAO_0000249,14331,Membranes,,1,CHEMBL615589,,,Rattus norvegicus,D,9,,
572,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of bovine hippocampus.,Expert,9913.0,,B,,BAO_0000221,11884,,,1,CHEMBL615442,,,Bos taurus,H,8,10000000.0,
573,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT (0.5 nM) ligand in hippocampus + frontal bovine was determined,Autocuration,,,B,,BAO_0000221,14331,,,1,CHEMBL615443,,,,H,8,10000000.0,
574,Compound was evaluated for its ability to displace [3H]DPAT from 5-HT1A receptor in homogenates of bovine hippocampus,Autocuration,,,B,,BAO_0000221,11701,,,1,CHEMBL615444,,,,H,8,10000000.0,
575,Ability to displace [3H]-DPAT from 5-hydroxytryptamine 1A receptor in homogenates of bovine hippocampus.,Expert,,,B,,BAO_0000221,11701,,,1,CHEMBL615445,,,,H,8,10000000.0,
576,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor in bovine hippocampus,Autocuration,,,B,,BAO_0000221,12248,,,1,CHEMBL615446,,,,H,8,10000000.0,
577,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in CHO cells,Autocuration,,,B,,BAO_0000219,12248,,449.0,1,CHEMBL615447,CHO,,,H,8,,
578,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,Expert,,,B,,BAO_0000221,12248,,,1,CHEMBL615448,,,,H,8,10000000.0,
579,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,Expert,,,B,,BAO_0000221,12249,,,1,CHEMBL615449,,,,H,8,10000000.0,
580,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,Autocuration,,,B,,BAO_0000219,12248,,449.0,1,CHEMBL615450,CHO,,,H,8,,
581,"Binding affinity against 5-hydroxytryptamine 1A receptor from bovine hippocampus, used [3H]8-OH-DPAT as radioligand",Expert,,,B,,BAO_0000221,11799,,,1,CHEMBL615451,,,,H,8,10000000.0,
582,Compound was tested for its binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand,Autocuration,,,B,,BAO_0000357,634,,,1,CHEMBL615452,,,,H,8,,
583,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-HT1A receptor from bovine hippocampus,Autocuration,,,B,,BAO_0000221,9995,,,1,CHEMBL615453,,,,H,8,10000000.0,
584,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,Autocuration,,,B,,BAO_0000221,9995,,,1,CHEMBL615454,,,,H,8,10000000.0,
585,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,Autocuration,,,B,,BAO_0000221,9995,,,1,CHEMBL615455,,,,H,8,10000000.0,
586,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,Autocuration,,,B,,BAO_0000221,9995,,,1,CHEMBL615456,,,,H,8,10000000.0,
587,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,Autocuration,,,B,,BAO_0000221,9995,,,1,CHEMBL615457,,,,H,8,10000000.0,
588,In vivo binding affinity towards [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus.,Expert,,,B,,BAO_0000218,12210,,,1,CHEMBL615458,,,,H,8,10000000.0,
589,Tested for activity against 5-hydroxytryptamine 1A receptor from bovine hippocampus,Expert,,,B,,BAO_0000221,13311,,,1,CHEMBL615459,,,,H,8,10000000.0,
590,"Tested in vitro for the inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor, expressed in cloned CHO cells.",Expert,9606.0,,B,,BAO_0000219,2331,,449.0,1,CHEMBL615460,CHO,,Homo sapiens,D,9,,
591,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor in guinea pig,Autocuration,10141.0,,F,,BAO_0000019,1375,,,1,CHEMBL615461,,,Cavia porcellus,H,8,,
592,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor in guinea pig; NT means not tested,Autocuration,10141.0,,F,,BAO_0000019,1375,,,1,CHEMBL615462,,,Cavia porcellus,H,8,,
593,Effect on forskolin stimulated adenylate cyclase activity at 5-hydroxytryptamine 1A receptor of guinea pig hippocampus.,Autocuration,10141.0,,F,,BAO_0000221,11574,,,1,CHEMBL615463,,,Cavia porcellus,H,8,10000000.0,
594,Ability to antagonize Acetylcholine induced contractile responses in Guinea pig ileum for 5-HT1A receptor.,Autocuration,10141.0,,B,,BAO_0000221,12867,,,1,CHEMBL615464,,,Cavia porcellus,H,8,2116.0,
595,Ability to antagonize Acetylcholine induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,Autocuration,10141.0,,B,,BAO_0000221,12867,,,1,CHEMBL615465,,,Cavia porcellus,H,8,2116.0,
596,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor.,Autocuration,10141.0,,B,,BAO_0000221,12867,,,1,CHEMBL615466,,,Cavia porcellus,H,8,2116.0,
597,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,Autocuration,10141.0,,B,,BAO_0000221,12867,,,1,CHEMBL615467,,,Cavia porcellus,H,8,2116.0,
598,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,Autocuration,10141.0,,B,,BAO_0000221,12867,,,1,CHEMBL615468,,,Cavia porcellus,H,8,2116.0,
599,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor; Inactive at dose level of 1.0 uM,Autocuration,10141.0,,B,,BAO_0000221,12867,,,1,CHEMBL615469,,,Cavia porcellus,H,8,2116.0,
600,Binding affinity against 5-hydroxytryptamine 1A receptor,Autocuration,10141.0,,B,,BAO_0000357,11574,,,1,CHEMBL615470,,,Cavia porcellus,H,8,,
601,Compound is evaluated for in vitro receptor binding affinity against 5-hydroxytryptamine 1A receptor,Autocuration,10141.0,,B,,BAO_0000357,13114,,,1,CHEMBL615471,,,Cavia porcellus,H,8,,
602,Binding affinity was determined against 5-hydroxytryptamine 1A receptor,Autocuration,10141.0,,B,,BAO_0000357,13181,,,1,CHEMBL615472,,,Cavia porcellus,H,8,,
603,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1A receptor of guinea pig hippocampus,Autocuration,10141.0,,B,,BAO_0000221,10639,,,1,CHEMBL883242,,,Cavia porcellus,H,8,10000000.0,
604,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1A receptor of guinea pig hippocampus,Autocuration,10141.0,,F,,BAO_0000221,10639,,,1,CHEMBL615473,,,Cavia porcellus,H,8,10000000.0,
605,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand in CHO cells (sc),Autocuration,10029.0,,B,,BAO_0000218,11883,,449.0,1,CHEMBL615474,CHO,,Cricetulus griseus,H,8,,
606,Fraction involved in salt bridge interactions with Asp3:11 part of the 5-hydroxytryptamine 1A receptor,Autocuration,,,B,,BAO_0000357,17785,,,1,CHEMBL615475,,,,H,8,,
607,Compound was tested for its ability to inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-HT 1A receptor in HeLa cells; value ranges from 85-370,Autocuration,,,F,,BAO_0000219,1558,,308.0,1,CHEMBL615476,HeLa,,,H,8,,
608,Compound was tested for its ability to inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1A receptor in HeLa cells; value ranges from 95-320,Autocuration,,,F,,BAO_0000219,1558,,308.0,1,CHEMBL615477,HeLa,,,H,8,,
609,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor,Autocuration,,,F,,BAO_0000019,15740,,,1,CHEMBL615478,,,,H,8,,
610,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor,Autocuration,,,F,,BAO_0000219,17624,,449.0,1,CHEMBL615160,CHO,,,H,8,,
611,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor,Expert,,,F,,BAO_0000219,17624,,449.0,1,CHEMBL615161,CHO,,,H,8,,
612,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor; nd=Not determined,Autocuration,,,F,,BAO_0000219,17624,,449.0,1,CHEMBL615162,CHO,,,H,8,,
613,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor; nd=not determined,Autocuration,,,F,,BAO_0000219,17624,,449.0,1,CHEMBL615163,CHO,,,H,8,,
614,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,Expert,,,B,,BAO_0000219,17624,,449.0,1,CHEMBL615164,CHO,,,H,8,,
615,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,Expert,,,B,,BAO_0000219,17624,,449.0,1,CHEMBL615165,CHO,,,H,8,,
616,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells; nd=not determined,Autocuration,,,B,,BAO_0000219,17624,,449.0,1,CHEMBL615166,CHO,,,H,8,,
617,In vitro potency at human 5-hydroxytryptamine 1A receptor in inhibiting forskolin-stimulated accumulation of intracellular cAMP,Autocuration,,,F,,BAO_0000219,14256,,,1,CHEMBL615167,,,,H,8,,
618,Stimulation of [35S]- GIPyS binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells,Expert,9606.0,,B,,BAO_0000219,3445,,308.0,1,CHEMBL615168,HeLa,,Homo sapiens,D,9,,
619,Stimulation of [35S]- GIPyS binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells; Inverse,Expert,9606.0,,B,,BAO_0000219,3445,,308.0,1,CHEMBL615169,HeLa,,Homo sapiens,D,9,,
620,Tested for functional response on CHO cells expressing cloned human 5-hydroxytryptamine 1A receptor,Expert,9606.0,,B,,BAO_0000219,17200,,449.0,1,CHEMBL615170,CHO,,Homo sapiens,D,9,,
621,Tested for functional response on CHO cells expressing cloned human 5-hydroxytryptamine 1A receptor; Not determined,Expert,9606.0,,B,,BAO_0000219,17200,,449.0,1,CHEMBL615171,CHO,,Homo sapiens,D,9,,
622,Eudisimic ratio(ER) is the antilog of the defference between the pKb and pD2 values against 5-hydroxytryptamine 1A receptor,Autocuration,,,F,,BAO_0000019,15180,,,1,CHEMBL615694,,,,H,8,,
623,Eudisimic ratio(ER) is the antilog of the difference between the pKb and pD2 values against 5-hydroxytryptamine 1A receptor,Autocuration,,,F,,BAO_0000019,15180,,,1,CHEMBL615695,,,,H,8,,
624,"Percent of maximum effect on binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",Autocuration,,,F,,BAO_0000019,16026,,,1,CHEMBL615696,,,,H,8,,
625,Agonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,Autocuration,,,F,,BAO_0000219,2759,,449.0,1,CHEMBL615697,CHO,,,H,8,,
626,Agonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 1),Expert,9606.0,,F,,BAO_0000219,2759,,449.0,1,CHEMBL859410,CHO,,Homo sapiens,D,9,,
627,Agonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 2),Autocuration,,,F,,BAO_0000219,2759,,449.0,1,CHEMBL615841,CHO,,,H,8,,
628,Agonistic efficacy in adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 2),Expert,9606.0,,F,,BAO_0000219,2759,,449.0,1,CHEMBL615842,CHO,,Homo sapiens,D,9,,
629,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,Autocuration,,,F,,BAO_0000219,2759,,449.0,1,CHEMBL835003,CHO,,,H,8,,
630,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 1),Autocuration,,,F,,BAO_0000219,2759,,449.0,1,CHEMBL615843,CHO,,,H,8,,
631,Antagonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 1),Expert,9606.0,,F,,BAO_0000219,2759,,449.0,1,CHEMBL615979,CHO,,Homo sapiens,D,9,,
632,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 2),Autocuration,,,F,,BAO_0000219,2759,,449.0,1,CHEMBL615980,CHO,,,H,8,,
633,Antagonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 2),Expert,9606.0,,F,,BAO_0000219,2759,,449.0,1,CHEMBL615981,CHO,,Homo sapiens,D,9,,
634,Percent efficacy against cloned human 5-hydroxytryptamine 1A receptor normalized to the maximal 5-HT response,Expert,9606.0,,F,,BAO_0000019,3445,,,1,CHEMBL615982,,,Homo sapiens,D,9,,
635,"Agonist activity at the 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",Expert,9606.0,,F,,BAO_0000019,5272,,,1,CHEMBL615983,,,Homo sapiens,D,9,,
636,"Agonist activity at the 5-hydroxytryptamine 1A receptor in vitro using a [35S]GTP-gamma-S, No data",Expert,9606.0,,F,,BAO_0000019,5272,,,1,CHEMBL615984,,,Homo sapiens,D,9,,
637,"Agonist activity at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S,",Expert,9606.0,,F,,BAO_0000019,5272,,,1,CHEMBL615985,,,Homo sapiens,D,9,,
638,Agonistic effect against 5-HT1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,Autocuration,,,F,,BAO_0000219,17624,,449.0,1,CHEMBL615986,CHO,,,H,8,,
639,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,Autocuration,,,F,,BAO_0000219,17624,,449.0,1,CHEMBL615987,CHO,,,H,8,,
640,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=Not determined,Autocuration,,,F,,BAO_0000219,17624,,449.0,1,CHEMBL615988,CHO,,,H,8,,
641,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,Expert,,,F,,BAO_0000219,17624,,449.0,1,CHEMBL615989,CHO,,,H,8,,
642,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=Not determined,Autocuration,,,F,,BAO_0000219,17624,,449.0,1,CHEMBL615990,CHO,,,H,8,,
643,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=not determined,Autocuration,,,F,,BAO_0000219,17624,,449.0,1,CHEMBL615991,CHO,,,H,8,,
644,Agonistic effect against 5-HT 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,Autocuration,,,F,,BAO_0000219,17624,,449.0,1,CHEMBL615992,CHO,,,H,8,,
645,Agonistic effect against 5-HT 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT; nd=Not determined,Autocuration,,,F,,BAO_0000219,17624,,449.0,1,CHEMBL615993,CHO,,,H,8,,
646,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,Expert,,,F,,BAO_0000219,17624,,449.0,1,CHEMBL615994,CHO,,,H,8,,
647,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT; nd=not determined,Autocuration,,,F,,BAO_0000219,17624,,449.0,1,CHEMBL615995,CHO,,,H,8,,
648,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,Autocuration,,,F,,BAO_0000219,17624,,449.0,1,CHEMBL615996,CHO,,,H,8,,
649,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35]GTPgammaS as radioligand in CHO cells relative to 5-HT; nd=Not determined,Autocuration,,,F,,BAO_0000219,17624,,449.0,1,CHEMBL615997,CHO,,,H,8,,
650,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",Autocuration,,,F,,BAO_0000019,6563,,,1,CHEMBL615998,,,,H,8,,
651,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",Autocuration,,,F,,BAO_0000019,6563,,,1,CHEMBL615999,,,,H,8,,
652,Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by forskolin stimulated cAMP assay,Autocuration,,,F,,BAO_0000019,6563,,,1,CHEMBL616000,,,,H,8,,
653,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,Autocuration,,,F,,BAO_0000219,17296,,722.0,1,CHEMBL616001,HEK293,,,H,8,,
654,"Evaluated for stimulation at 1 uM concentration expressed as percent of the maximal [35S]GTP-gamma-S, binding induced by 5-hydroxytryptamine",Expert,9606.0,,F,,BAO_0000019,6876,,,1,CHEMBL616002,,,Homo sapiens,D,9,,
655,"Stimulation of percent maximal [35S]GTP-gamma-S, binding induced by 5-hydroxytryptamine at 1 uM; nd = not determined",Expert,,,F,,BAO_0000019,6876,,,1,CHEMBL616003,,,,H,8,,
656,In vitro agonist activity at the 5-hydroxytryptamine 1A receptor,Expert,9606.0,,F,,BAO_0000019,5272,,,1,CHEMBL616004,,,Homo sapiens,D,9,,
657,In vitro agonist activity at the 5-hydroxytryptamine 1A receptor; No data,Expert,9606.0,,F,,BAO_0000019,5272,,,1,CHEMBL616005,,,Homo sapiens,D,9,,
658,"Maximal response as a result of 5-HT1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",Autocuration,,,F,,BAO_0000019,5548,,,1,CHEMBL616006,,,,H,8,,
659,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding",Expert,,,F,,BAO_0000019,5548,,,1,CHEMBL616007,,,,H,8,,
660,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",Autocuration,,,F,,BAO_0000019,5548,,,1,CHEMBL616008,,,,H,8,,
661,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",Autocuration,,,F,,BAO_0000019,5548,,,1,CHEMBL616009,,,,H,8,,
662,"Maximal stimulation of expressed human 5-hydroxytryptamine 1A receptor assayed by [35S]GTP-gamma-S, binding",Expert,,,F,,BAO_0000019,5929,,,1,CHEMBL616010,,,,H,8,,
663,"Maximal response towards 5-hydroxytryptamine 1A receptor in human using [35S]GTP-gamma-S, as radioligand; ND means not determined",Expert,9606.0,,F,,BAO_0000019,5929,,,1,CHEMBL616011,,,Homo sapiens,D,9,,
664,"Maximal response towards 5-hydroxytryptamine 1A receptor in human using [35S]GTP-gamma-S, as radioligand; ND=Not determined",Expert,9606.0,,F,,BAO_0000019,5929,,,1,CHEMBL615740,,,Homo sapiens,D,9,,
665,"Maximal stimulation was expressed as percentage of the maximal 5-HT response in the [35S]GTP-gamma-S, binding assay on 5-hydroxytryptamine 1A receptor",Autocuration,,,F,,BAO_0000019,16245,,,1,CHEMBL615741,,,,H,8,,
666,"Inhibition of 5-HT induced [35S]GTP-gamma-S, binding at human cloned 5-HT 1A receptors.",Expert,,,F,,BAO_0000019,5640,,,1,CHEMBL615742,,,,H,8,,
667,"5-hydroxytryptamine 1A receptor antagonism was evaluated by the ability to inhibit [35S]GTP-gamma-S, binding that was induced by 5-HT; Emin (%): not determined",Autocuration,,,F,,BAO_0000019,5640,,,1,CHEMBL615743,,,,H,8,,
668,Antagonist activity was measured against CHO cells expressing the human 5-hydroxytryptamine 1A receptor in a forskolin stimulated adenylate cyclase (FSC) assay,Autocuration,,,F,,BAO_0000219,14509,,449.0,1,CHEMBL615744,CHO,,,H,8,,
669,Antagonist activity against CHO cells expressing the human 5-hydroxytryptamine 1A receptor in a forskolin stimulated adenylate cyclase (FSC) assay.,Expert,,,F,,BAO_0000219,14509,,449.0,1,CHEMBL615745,CHO,,,H,8,,
670,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,Autocuration,,,B,,BAO_0000357,15331,,,1,CHEMBL615746,,,,H,8,,
671,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,Autocuration,,,B,,BAO_0000357,15331,,,1,CHEMBL615747,,,,H,8,,
672,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",Autocuration,,,F,,BAO_0000019,6563,,,1,CHEMBL615748,,,,H,8,,
673,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay; NA indicates not available",Autocuration,,,F,,BAO_0000019,6563,,,1,CHEMBL615749,,,,H,8,,
674,Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by forskolin stimulated cAMP assay,Autocuration,,,F,,BAO_0000019,6563,,,1,CHEMBL615750,,,,H,8,,
675,Forskolin stimulated cAMP assessment of agonist activity for 5-hydroxytryptamine 1A receptor,Expert,9606.0,,F,,BAO_0000019,6563,,,1,CHEMBL616259,,,Homo sapiens,D,9,,
676,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",Autocuration,,,F,,BAO_0000019,6563,,,1,CHEMBL616260,,,,H,8,,
677,Antagonism of 5-hydroxytryptamine 1A receptor determined in vitro,Expert,9606.0,,F,,BAO_0000019,5272,,,1,CHEMBL616261,,,Homo sapiens,D,9,,
678,"Antagonism of 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",Expert,9606.0,,F,,BAO_0000019,5272,,,1,CHEMBL616262,,,Homo sapiens,D,9,,
679,"Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S, No data",Expert,9606.0,,F,,BAO_0000019,5272,,,1,CHEMBL616263,,,Homo sapiens,D,9,,
680,Antagonism at the 5-hydroxytryptamine 1A receptor was determined in vitro; No data,Expert,9606.0,,F,,BAO_0000019,5272,,,1,CHEMBL616264,,,Homo sapiens,D,9,,
681,Antagonism at the 5-hydroxytryptamine 1A receptor in vitro,Expert,9606.0,,F,,BAO_0000019,5272,,,1,CHEMBL616265,,,Homo sapiens,D,9,,
682,"Antagonism at the 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",Expert,9606.0,,F,,BAO_0000019,5272,,,1,CHEMBL616266,,,Homo sapiens,D,9,,
683,"Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S, No data",Expert,9606.0,,F,,BAO_0000019,5272,,,1,CHEMBL616267,,,Homo sapiens,D,9,,
684,Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro; No data,Expert,9606.0,,F,,BAO_0000019,5272,,,1,CHEMBL616268,,,Homo sapiens,D,9,,
685,Inhibition of human 5-hydroxytryptamine 1A receptor,Expert,9606.0,,B,,BAO_0000357,16146,,,1,CHEMBL616269,,,Homo sapiens,D,9,,
686,Binding affinity against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,Autocuration,,,B,,BAO_0000219,17624,,449.0,1,CHEMBL884528,CHO,,,H,8,,
687,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor alpha expressed in HEK 293 cells,Expert,,,B,,BAO_0000219,13706,,722.0,1,CHEMBL616270,HEK293,,,D,9,,
688,Compound was tested for the displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1A receptor stably expressed in CHO cells,Autocuration,,,B,,BAO_0000219,15250,,449.0,1,CHEMBL616271,CHO,,,H,8,,
689,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,Autocuration,,,F,,BAO_0000219,17624,,449.0,1,CHEMBL616272,CHO,,,H,8,,
690,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in human CYP3A4 assay,Expert,,,B,,BAO_0000357,6861,,,1,CHEMBL616273,,,,H,8,,
691,In vitro inhibitory concentration required against [3H]8-OH-DPAT binding to cloned human 5-hydroxytryptamine 1A receptor,Expert,9606.0,,B,,BAO_0000357,17200,,,1,CHEMBL616274,,,Homo sapiens,D,9,,
692,Inhibition concentration against 5-HT 1A receptor using cAMP as radioligand in CHO cells,Autocuration,,,B,,BAO_0000219,17624,,449.0,1,CHEMBL616275,CHO,,,H,8,,
693,Inhibition concentration against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,Autocuration,,,B,,BAO_0000219,17624,,449.0,1,CHEMBL616276,CHO,,,H,8,,
694,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration,Autocuration,10116.0,,F,,BAO_0000218,12058,,,1,CHEMBL616277,,,Rattus norvegicus,U,0,,
695,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration; Inactive,Autocuration,10116.0,,F,,BAO_0000218,12058,,,1,CHEMBL616278,,,Rattus norvegicus,U,0,,
696,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration,Autocuration,10116.0,,F,,BAO_0000218,12058,,,1,CHEMBL616279,,,Rattus norvegicus,U,0,,
697,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Inactive,Autocuration,10116.0,,F,,BAO_0000218,12058,,,1,CHEMBL616280,,,Rattus norvegicus,U,0,,
698,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Partial response at the highest dose tested,Autocuration,10116.0,,F,,BAO_0000218,12058,,,1,CHEMBL616281,,,Rattus norvegicus,U,0,,
699,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Inactive,Autocuration,10116.0,,F,,BAO_0000218,12058,,,1,CHEMBL616282,,,Rattus norvegicus,U,0,,
700,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by po administration,Autocuration,10116.0,,F,,BAO_0000218,12058,,,1,CHEMBL616283,,,Rattus norvegicus,U,0,,
701,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by po administration; Inactive,Autocuration,10116.0,,F,,BAO_0000218,12058,,,1,CHEMBL616284,,,Rattus norvegicus,U,0,,
702,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration,Autocuration,10116.0,,F,,BAO_0000218,12058,,,1,CHEMBL616285,,,Rattus norvegicus,U,0,,
703,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration; Inactive,Autocuration,10116.0,,F,,BAO_0000218,12058,,,1,CHEMBL616286,,,Rattus norvegicus,U,0,,
704,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration; partial response at the highest dose tested,Autocuration,10116.0,,F,,BAO_0000218,12058,,,1,CHEMBL616287,,,Rattus norvegicus,U,0,,
705,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration,Autocuration,10116.0,,F,,BAO_0000218,12058,,,1,CHEMBL616288,,,Rattus norvegicus,U,0,,
706,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration; Inactive,Autocuration,10116.0,,F,,BAO_0000218,12058,,,1,CHEMBL616289,,,Rattus norvegicus,U,0,,
707,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration; Partial response at the highest dose tested,Autocuration,10116.0,,F,,BAO_0000218,12058,,,1,CHEMBL615610,,,Rattus norvegicus,U,0,,
708,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration,Autocuration,10116.0,,F,,BAO_0000218,12058,,,1,CHEMBL615611,,,Rattus norvegicus,U,0,,
709,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; Inactive,Autocuration,10116.0,,F,,BAO_0000218,12058,,,1,CHEMBL615612,,,Rattus norvegicus,U,0,,
710,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; Partial response at the highest dose tested,Autocuration,10116.0,,F,,BAO_0000218,12058,,,1,CHEMBL615613,,,Rattus norvegicus,U,0,,
711,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; partial response at the highest dose tested,Autocuration,10116.0,,F,,BAO_0000218,12058,,,1,CHEMBL615614,,,Rattus norvegicus,U,0,,
712,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration,Autocuration,10116.0,,F,,BAO_0000218,12058,,,1,CHEMBL615615,,,Rattus norvegicus,U,0,,
713,Affinity in displacing [125I](R)-DOI from rat cortical homogenate 5-HT2 receptor.,Autocuration,,,B,,BAO_0000019,11440,,,1,CHEMBL615616,,,,H,4,,
714,Binding affinity towards 5-HT 7 receptor in rat hypothalamus membranes using [3H]5-CT as radioligand,Autocuration,,,B,,BAO_0000249,6238,,,1,CHEMBL615617,,,,H,8,1898.0,
715,Inhibitory activity against 5-HT1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand; nd is No Data,Autocuration,,,B,,BAO_0000019,10046,,,1,CHEMBL615618,,,,H,8,,
716,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand; nd is No Data.,Autocuration,,,B,,BAO_0000019,10046,,,1,CHEMBL615619,,,,H,8,,
717,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand.,Expert,,,B,,BAO_0000019,10046,,,1,CHEMBL615620,,,,H,8,,
718,"Inhibitory activity against human whole blood, LTB4 5-lipoxygenase was evaluated",Autocuration,,,B,,BAO_0000357,167,,,1,CHEMBL615621,,,,H,8,,
719,"Inhibitory activity against intact human PMNL, LTB4 5-lipoxygenase was evaluated",Autocuration,,,B,,BAO_0000357,167,,,1,CHEMBL615622,,,,H,8,,
720,Compound was evaluated for the inhibition of 5-LO (lipoxygenase),Autocuration,,,F,,BAO_0000019,11520,,,1,CHEMBL615623,,,,H,8,,
721,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,Autocuration,,,F,,BAO_0000019,11520,,,1,CHEMBL615624,,,,H,8,,
722,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,Autocuration,,,F,,BAO_0000019,11520,,,1,CHEMBL615625,,,,H,8,,
723,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,Autocuration,,,F,,BAO_0000019,11520,,,1,CHEMBL767045,,,,H,8,,
724,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-LO isolated from guinea pig PMN,Autocuration,10141.0,,F,,BAO_0000019,135,,,1,CHEMBL615626,,,Cavia porcellus,H,8,,
725,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-LO isolated from guinea pig PMN; not active at the highest concentration (3 ug/mL) tested; No activity,Autocuration,10141.0,,F,,BAO_0000019,135,,,1,CHEMBL615627,,,Cavia porcellus,H,8,,
726,The compound was tested for inhibitory activity against 5-Lipoxygenase in guinea pig polymorphonuclear leukocytes,Autocuration,10141.0,,B,,BAO_0000019,11311,,,1,CHEMBL615628,,,Cavia porcellus,H,8,,
727,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant at 10 uM,Autocuration,10141.0,,B,,BAO_0000357,10193,,,1,CHEMBL615629,,,Cavia porcellus,H,8,,
728,Inhibitory concentration against 5-lipoxygenase from human whole blood,Expert,9606.0,,B,,BAO_0000357,12281,,,1,CHEMBL615630,,,Homo sapiens,D,9,,
729,The compound was tested for inhibitory activity against 5-Lipoxygenase in human polymorphonuclear leukocytes[PMNS],Autocuration,,,B,,BAO_0000219,11311,,,1,CHEMBL615631,,,,H,8,,
730,In vivo inhibition of 5-lipoxygenase (LTC4) in the mouse zymosan peritonitis assay at an oral dose of 30 mg/Kg,Autocuration,,,F,,BAO_0000218,12576,,,1,CHEMBL615632,,,,H,8,,
731,Inhibitory concentration against 5-lipoxygenase from mouse macrophage,Autocuration,,,B,,BAO_0000357,12281,,,1,CHEMBL615633,,,,H,8,,
732,In vivo inhibition of 5-lipoxygenase (LTC4) in the mouse zymosan peritonitis assay at an oral dose of 30 mg/Kg,Autocuration,,,F,,BAO_0000218,12576,,,1,CHEMBL615634,,,,H,8,,
733,Inhibition of arachidonate 5-lipoxygenase purified from porcine leukocytes.,Expert,9823.0,,B,,BAO_0000019,11089,,,1,CHEMBL615635,,,Sus scrofa,H,8,,
734,In vitro inhibition of rat 5-Lipoxygenase,Expert,,,B,,BAO_0000357,11006,,,1,CHEMBL615636,,,,H,8,,
735,Inhibitory activity against 5-Lipoxygenase,Expert,10116.0,,B,,BAO_0000357,11481,,,1,CHEMBL615637,,,Rattus norvegicus,D,9,,
736,Inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells,Expert,,,B,,BAO_0000219,10864,,702.0,1,CHEMBL615638,RBL-1,,,H,8,,
737,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),Autocuration,,,B,,BAO_0000219,3595,,702.0,1,CHEMBL615639,RBL-1,,,H,8,,
738,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat RBL-1,Autocuration,,,B,,BAO_0000219,11311,,702.0,1,CHEMBL615640,RBL-1,,,H,8,,
739,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat blood,Autocuration,,,B,,BAO_0000019,11311,,,1,CHEMBL615796,,,,H,8,,
740,The compound was tested for inhibitory activity against 5-Lipoxygenase receptor in rat polymorphonuclear leukocytes[PMNS],Autocuration,,,B,,BAO_0000219,11311,,,1,CHEMBL615845,,,,H,8,,
741,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM,Autocuration,,,B,,BAO_0000357,11006,,,1,CHEMBL615846,,,,H,8,,
742,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1)at 10 uM,Autocuration,,,B,,BAO_0000219,3595,,702.0,1,CHEMBL615847,RBL-1,,,H,8,,
743,The compound was tested for inhibition of isolated 5-Lipoxygenase,Autocuration,,,B,,BAO_0000357,11311,,,1,CHEMBL615848,,,,H,8,,
744,Ratio of IC50 against 5-LO and COX,Autocuration,10116.0,,B,,BAO_0000019,11481,,,1,CHEMBL615849,,,Rattus norvegicus,U,0,,
745,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM,Autocuration,,,B,,BAO_0000357,11006,,,1,CHEMBL615850,,,,H,8,,
746,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM; range is 20-35%,Autocuration,,,B,,BAO_0000357,11006,,,1,CHEMBL615851,,,,H,8,,
747,The compound was tested for inhibition against 5-Lipoxygenase in rat polymorphonuclear leukocytes at 10 uM concentration,Autocuration,,,B,,BAO_0000219,11311,,,1,CHEMBL615852,,,,H,8,,
748,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) ex vivo,Autocuration,,,F,,BAO_0000019,11006,,,1,CHEMBL615853,,,,H,8,,
749,Compound was tested for the inhibition of type 2 5-alpha-reductase of human prostates,Autocuration,,,B,,BAO_0000357,4288,,,1,CHEMBL884527,,,,H,8,2367.0,
750,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme at 10E-4 M inhibitory concentration,Autocuration,8932.0,,B,,BAO_0000019,7587,,,1,CHEMBL872871,,,Columba livia,U,0,,
751,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme at 10E-5 M inhibitory concentration,Autocuration,8932.0,,B,,BAO_0000019,7587,,,1,CHEMBL615854,,,Columba livia,U,0,,
752,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme.,Autocuration,8932.0,,B,,BAO_0000019,7587,,,1,CHEMBL767046,,,Columba livia,U,0,,
753,Compound was evaluated for the inhibition of 5-aminoimidazole-4-carboxamide ribonucleotide transformylase obtained from human at 100 uM,Autocuration,,,B,,BAO_0000357,11249,,,1,CHEMBL615855,,,,H,8,,
754,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT); NT = Not Tested,Expert,10116.0,,F,,BAO_0000019,8003,,,1,CHEMBL615856,,,Rattus norvegicus,D,9,,
755,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT),Expert,10116.0,,F,,BAO_0000019,8003,,,1,CHEMBL615857,,,Rattus norvegicus,D,9,,
756,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT),Expert,10116.0,,F,,BAO_0000019,8003,,,1,CHEMBL615858,,,Rattus norvegicus,D,9,,
757,In vitro affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in hippocampus,Expert,,,B,,BAO_0000221,12416,,,1,CHEMBL615859,,,,H,8,10000000.0,
758,Binding affinity towards human 5-hydroxytryptamine 1 receptor,Autocuration,,,B,,BAO_0000357,16293,,,1,CHEMBL615860,,,,H,8,,
759,Intrinsic activity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,Autocuration,9986.0,,B,,BAO_0000019,13047,,,1,CHEMBL615861,,,Oryctolagus cuniculus,U,0,,
760,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,Autocuration,9986.0,,B,,BAO_0000019,13047,,,1,CHEMBL615862,,,Oryctolagus cuniculus,U,0,,
761,Binding affinity against 5-hydroxytryptamine 1D receptor using rabbit saphenous vein assay.,Autocuration,9986.0,,B,,BAO_0000019,13047,,,1,CHEMBL615863,,,Oryctolagus cuniculus,U,0,,
762,Binding affinity against 5-hydroxytryptamine 4 receptor using rabbit saphenous vein assay.,Autocuration,9986.0,,B,,BAO_0000019,13047,,,1,CHEMBL615864,,,Oryctolagus cuniculus,U,0,,
763,Ability to bind at 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,Autocuration,,,B,,BAO_0000221,10085,,,1,CHEMBL615865,,,,H,4,10000000.0,
764,Ability to bind at 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,Autocuration,,,B,,BAO_0000221,10085,,,1,CHEMBL615866,,,,H,4,10000000.0,
765,Ability to bind at serotonin 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,Autocuration,,,B,,BAO_0000221,10085,,,1,CHEMBL615867,,,,H,4,10000000.0,
766,Ability to inhibit binding of titreated serotonin to the 5-hydroxytryptamine 1 receptor in rat brain frontal cortex membranes,Autocuration,,,B,,BAO_0000249,9841,Membranes,,1,CHEMBL615868,,,,H,4,,
767,Binding affinity towards 5-hydroxytryptamine 1 receptor in brain cortical membranes of rat,Autocuration,10116.0,,B,,BAO_0000249,8822,,,1,CHEMBL615869,,,Rattus norvegicus,D,5,,
768,Binding affinity towards 5-hydroxytryptamine 1 receptor in rat frontal cortex homogenates using [3H]5-HT as a radioligand,Autocuration,10116.0,,B,,BAO_0000019,9806,,,1,CHEMBL615870,,,Rattus norvegicus,D,5,,
769,Binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT as a radioligand from rat frontal cortex homogenates,Autocuration,10116.0,,B,,BAO_0000019,9806,,,1,CHEMBL615871,,,Rattus norvegicus,D,5,,
770,Binding affinity towards 5-hydroxytryptamine 1 receptor was measured using radioligand ([3H]5-HT) binding assay,Autocuration,,,B,,BAO_0000224,8868,,,1,CHEMBL615872,,,,H,4,,
771,Binding affinity towards hippocampus 5-hydroxytryptamine 1 receptor was measured using radioligand [3H]5-HT,Autocuration,,,B,,BAO_0000221,9036,,,1,CHEMBL833492,,,,H,4,10000000.0,
772,Compound was evaluated for the inhibition of [3H]5-HT (concentration of 12 nM) specific binding to rat hippocampus,Autocuration,,,B,,BAO_0000221,11374,,,1,CHEMBL615873,,,,H,4,10000000.0,
773,Inhibitory activity against 5-hydroxytryptamine 1 receptor by 3H ligand binding experiments.,Autocuration,,,B,,BAO_0000224,10881,,,1,CHEMBL615479,,,,H,4,,
774,Tested for its binding affinity towards 5-hydroxytryptamine 1 receptor in rat,Autocuration,,,B,,BAO_0000019,8822,,,1,CHEMBL615480,,,,H,4,,
775,Tested for its binding affinity towards 5-hydroxytryptamine 1 receptor in rat cortical membrane homogenates using radioligand ([3H]5-HT) binding assay.,Autocuration,10116.0,,B,,BAO_0000249,9806,,,1,CHEMBL615481,,,Rattus norvegicus,D,5,,
776,Compound at 1 uM was tested for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,Autocuration,,,B,,BAO_0000019,15463,,,1,CHEMBL872869,,,,H,4,,
777,Compound at 1 uM was tested for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,Autocuration,,,B,,BAO_0000019,15463,,,1,CHEMBL615482,,,,H,4,,
778,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,Autocuration,,,B,,BAO_0000221,14542,,,1,CHEMBL615483,,,,H,4,955.0,
779,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,Autocuration,,,B,,BAO_0000221,14542,,,1,CHEMBL615484,,,,H,4,955.0,
780,Percent inhibition of 5-hydroxytryptamine 1 receptor from rat cortex membrane using [3H]- serotonin as radioligand at 33 uM,Autocuration,,,B,,BAO_0000019,8569,,,1,CHEMBL615485,,,,H,4,,
781,Inhibition of [3H]5-HT radioligand binding against 5-hydroxytryptamine 1 receptor,Autocuration,10116.0,,B,,BAO_0000224,10062,,,1,CHEMBL615486,,,Rattus norvegicus,D,5,,
782,Ancillary Binding affinity towards rat 5-hydroxytryptamine 1 receptor,Autocuration,,,B,,BAO_0000224,4771,,,1,CHEMBL615487,,,,H,4,,
783,Binding affinity determined in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,Autocuration,,,B,,BAO_0000224,10062,,,1,CHEMBL615488,,,,H,4,,
784,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,Autocuration,,,B,,BAO_0000224,10062,,,1,CHEMBL615489,,,,H,4,,
785,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,Autocuration,,,B,,BAO_0000224,10062,,,1,CHEMBL615389,,,,H,4,,
786,Binding affinity towards 5-hydroxytryptamine 1 receptor was determined in rat cerebral cortex using [3H]5-HT as radioligand,Autocuration,,,B,,BAO_0000019,15463,,,1,CHEMBL615390,,,,H,4,,
787,Binding affinity towards central 5-hydroxytryptamine 1 receptor was determined in rat cerebral cortex using [3H]5-HT as radioligand,Autocuration,,,B,,BAO_0000019,15463,,,1,CHEMBL615391,,,,H,4,,
788,Binding affinity towards 5-hydroxytryptamine 1 receptor was determined,Autocuration,,,B,,BAO_0000224,9098,,,1,CHEMBL615392,,,,H,4,,
789,Affinity for 5-hydroxytryptamine 1 receptor,Autocuration,10116.0,,B,,BAO_0000019,3070,,,1,CHEMBL615393,,,Rattus norvegicus,U,0,,
790,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex,Autocuration,,,B,,BAO_0000221,14542,,,1,CHEMBL615394,,,,H,4,955.0,
791,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,Autocuration,,,B,,BAO_0000221,14542,,,1,CHEMBL615395,,,,H,4,955.0,
792,Compound was evaluated for 5-hydroxytryptamine 1 receptor binding,Autocuration,,,B,,BAO_0000224,6398,,,1,CHEMBL615396,,,,H,4,,
793,Compound was evaluated for its binding affinity to 5-hydroxytryptamine 1 receptor in rat brain using [3H]HT radioligand assay,Autocuration,,,B,,BAO_0000221,1344,,,1,CHEMBL615397,,,,H,4,955.0,
794,Displacement of binding of [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,Autocuration,,,B,,BAO_0000019,11963,,,1,CHEMBL615398,,,,H,4,,
795,Displacement of [3H]spiperone from 5-hydroxytryptamine 1 receptor of rat cortex,Autocuration,10116.0,,B,,BAO_0000019,8908,,,1,CHEMBL615399,,,Rattus norvegicus,U,0,,
796,Evaluated for binding affinity towards rat cortical membranes at 5-hydroxytryptamine 1 receptor binding site by using [3H]-5-HT as a radioligand.,Autocuration,,,B,,BAO_0000019,9098,,,1,CHEMBL615400,,,,H,4,,
797,Binding affinity for 5-hydroxytryptamine 1 receptor of rat prefrontal cortex,Autocuration,10116.0,,B,,BAO_0000019,8841,,,1,CHEMBL615401,,,Rattus norvegicus,D,5,,
798,Displacement of [3H]5-HT from 5-hydroxytryptamine 1 receptor of rat cortical membrane homogenates,Autocuration,10116.0,,B,,BAO_0000019,8814,,,1,CHEMBL615402,,,Rattus norvegicus,U,0,,
799,The ability to inhibit [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cortex,Autocuration,,,B,,BAO_0000019,11752,,,1,CHEMBL615403,,,,H,4,,
800,The binding affinity was measured on serotonin 5-hydroxytryptamine 1 receptor in rat brain tissue,Autocuration,,,B,,BAO_0000221,11642,,,1,CHEMBL615404,,,,H,4,955.0,
801,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1 receptor by displacing [3H]5-HT radioligand in rat cerebral cortex,Autocuration,,,B,,BAO_0000019,11642,,,1,CHEMBL615781,,,,H,4,,
802,Tested for 5-hydroxytryptamine 1 receptor binding ability by displacement of [3H]5-HT from rat brain synaptosomes,Autocuration,,,B,,BAO_0000220,9231,,,1,CHEMBL615782,,,,H,4,955.0,
803,Inhibition constant (1 uM) was measured on 5-hydroxytryptamine 1 receptor/uptake using [3H]- serotonin as radioligand in rat brain cortex.,Autocuration,,,B,,BAO_0000221,11351,,,1,CHEMBL615783,,,,H,4,955.0,
804,Compound was tested for binding affinity against 5-HT1 receptor,Autocuration,,,B,,BAO_0000019,4639,,,1,CHEMBL873481,,,,U,0,,
805,Inhibitory concentration against 5-hydroxytryptamine 1 receptor,Autocuration,,,B,,BAO_0000019,1205,,,1,CHEMBL615784,,,,U,0,,
806,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor at 1 uM,Expert,,,B,,BAO_0000357,10025,,,1,CHEMBL615785,,,,H,8,,
807,"Ability to inhibit 5-HT sensitive,forskolin-stimulated adenylyl cyclase(FSC) activity in rat hippocampal membranes mediated through 5-hydroxytryptamine 1A receptor",Autocuration,,,F,,BAO_0000249,13241,,,1,CHEMBL615786,,,,H,8,,
808,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while iv administration,Autocuration,,,F,,BAO_0000218,16245,,,1,CHEMBL615787,,,,H,8,,
809,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while subcutaneous administration,Autocuration,,,F,,BAO_0000218,16245,,,1,CHEMBL615788,,,,H,8,,
810,Inhibition of forskolin stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor,Autocuration,,,F,,BAO_0000019,12438,,,1,CHEMBL767044,,,,H,8,,
811,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while iv administration,Autocuration,,,F,,BAO_0000218,16245,,,1,CHEMBL615789,,,,H,8,,
812,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while subcutaneous administration,Autocuration,,,F,,BAO_0000218,16245,,,1,CHEMBL615790,,,,H,8,,
813,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats,Autocuration,,,F,,BAO_0000019,15740,,,1,CHEMBL615813,,,,H,8,,
814,Percent of maximum response by 5-HT when tested for inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation assessed in GH4ZD10 cells at 10 uM concentration,Autocuration,,,F,,BAO_0000219,15535,,,1,CHEMBL615814,,,,H,8,,
815,Percent inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation in GH4ZD10 cells expressing 5-HT1A receptor at 50 uM relative to 5-HT,Expert,,,F,,BAO_0000219,15535,,,1,CHEMBL615815,,,,H,8,,
816,Percent of maximum response by 5-HT when tested for inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation assessed in GH4ZD10 cells at 50 uM concentration; No effect,Autocuration,,,F,,BAO_0000219,15535,,,1,CHEMBL615816,,,,H,8,,
817,Binding affinity at [3H]8-OH-DPAT-Labeled 5-hydroxytryptamine 1A receptor sites in rat brain hippocampal membranes expressed as Hill values,Expert,,,B,,BAO_0000249,9888,,,1,CHEMBL615817,,,,H,8,,
818,Ability to bind at 5-hydroxytryptamine 1A receptor of rat hippocampus by displacing [3H]8-OH-DPAT,Autocuration,,,B,,BAO_0000221,10085,,,1,CHEMBL615818,,,,H,8,10000000.0,
819,Ability to bind at serotonin 5-hydroxytryptamine 1A receptors of rat hippocampus by displacing [3H]8-OH-DPAT,Autocuration,,,B,,BAO_0000221,10085,,,1,CHEMBL615819,,,,H,8,10000000.0,
820,Binding affinity against 5-hydroxytryptamine 1A receptor (5-HT1A) by displacement of [3H]8-OH-DPAT from rat hippocampus membranes,Expert,,,B,,BAO_0000249,17331,Membranes,,1,CHEMBL615820,,,,H,8,,
821,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]8-OH-DPAT,Expert,10116.0,,B,,BAO_0000221,10845,,,1,CHEMBL615821,,,Rattus norvegicus,D,9,10000000.0,
822,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]5-HT,Expert,10116.0,,B,,BAO_0000221,10845,,,1,CHEMBL615822,,,Rattus norvegicus,D,9,10000000.0,
823,Binding affinity against 5-hydroxytryptamine 1A receptor using in rat hippocampal tissue using [3H]8-OH-DPAT as radioligand,Expert,,,B,,BAO_0000221,10845,,,1,CHEMBL615823,,,,H,8,10000000.0,
824,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor; IA-Inactive,Expert,10116.0,,B,,BAO_0000221,10845,,,1,CHEMBL615824,,,Rattus norvegicus,D,9,10000000.0,
825,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]5-HT,Expert,10116.0,,B,,BAO_0000221,10845,,,1,CHEMBL615825,,,Rattus norvegicus,D,9,10000000.0,
826,Binding affinity towards rat 5-hydroxytryptamine 1A receptor was evaluated using [3H]8-OH-DPAT as radioligand,Expert,,,B,,BAO_0000357,13730,,,1,CHEMBL615826,,,,H,8,,
827,Binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampus membranes using [3H]8-OH-DPAT as radioligand,Expert,,,B,,BAO_0000249,13508,,,1,CHEMBL615827,,,,H,8,,
828,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus membrane using [3H]8-OH-DPAT as radioligand,Expert,,,B,,BAO_0000249,13508,,,1,CHEMBL615828,,,,H,8,10000000.0,
829,Binding affinity by measuring displacement of [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,Expert,,,B,,BAO_0000221,12073,,,1,CHEMBL615829,,,,H,8,10000000.0,
830,Binding affinity to 5-hydroxytryptamine 1A receptor of rat hippocampus with [3H]8-OH-DPAT as radioligand,Autocuration,,,B,,BAO_0000221,4671,,,1,CHEMBL615830,,,,H,8,10000000.0,
831,Binding affinity towards serotonin 5-HT1A receptor was determined in rat hippocampus using [3H]8-OH-DPAT as ligand,Expert,,,B,,BAO_0000221,13631,,,1,CHEMBL615831,,,,H,8,10000000.0,
832,Binding affinity was measured against serotonin 5-hydroxytryptamine 1A receptor,Autocuration,,,B,,BAO_0000357,12438,,,1,CHEMBL615832,,,,H,8,,
833,Binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]-8-OH- DPAT as radioligand,Autocuration,,,B,,BAO_0000019,10483,,,1,CHEMBL615833,,,,H,8,,
834,Binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]-8-OH- DPAT as radioligand,Autocuration,,,B,,BAO_0000221,10483,,,1,CHEMBL615834,,,,H,8,10000000.0,
835,Binding affinity against 5-hydroxytryptamine 1A (5-HT1A) receptor in rat hippocampus membranes,Intermediate,,,B,,BAO_0000249,12352,,,1,CHEMBL615835,,,,H,8,,
836,Binding affinity was measured at the serotonin 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat hippocampal membrane.,Autocuration,,,B,,BAO_0000249,14732,,,1,CHEMBL615836,,,,H,8,10000000.0,
837,Binding affinity to 5-hydroxytryptamine 1A receptor in the rat brain using [3H]8-hydroxy-2-(di-n-propylamine)tetralin as radioligand.,Expert,10116.0,,B,,BAO_0000019,11049,,,1,CHEMBL615837,,,Rattus norvegicus,D,9,,
838,Binding affinity to 5-hydroxytryptamine 1A receptor in the rat brain using [3H]8-hydroxy-2-(di-n-propylamine)tetralin as radioligand; ND-Not determined,Expert,10116.0,,B,,BAO_0000019,11049,,,1,CHEMBL615838,,,Rattus norvegicus,D,9,,
839,"Binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampus membranes,3H-8-OH-DPAT and buspirone for nonspecific binding (NSB)",Expert,,,B,,BAO_0000249,13657,,,1,CHEMBL615839,,,,H,8,,
840,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor in rat cortex using [3H]-8-OH-DPAT as radioligand,Autocuration,,,B,,BAO_0000019,11473,,,1,CHEMBL884525,,,,H,8,,
841,Compound was evaluated for its ability to displace [3H]8-OH-DPAT from serotonin 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes,Autocuration,,,B,,BAO_0000249,2014,,,1,CHEMBL615840,,,,H,8,,
842,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,Expert,,,B,,BAO_0000221,3086,,,1,CHEMBL615405,,,,H,8,10000000.0,
843,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,Expert,,,B,,BAO_0000019,15854,,,1,CHEMBL615406,,,,H,8,,
844,Affinity for 5-hydroxytryptamine 1A receptor labeled with [3H]8-OH-DPAT radioligand in hippocampus tissue,Expert,,,B,,BAO_0000221,10922,,,1,CHEMBL615900,,,,H,8,10000000.0,
845,Inhibition of [3H]8-OH-DPAT binding at serotonin 5-hydroxytryptamine 1A receptor from rat hippocampus tissue.,Expert,,,B,,BAO_0000221,13346,,,1,CHEMBL615901,,,,H,8,10000000.0,
846,In vitro inhibition of [3H]8-OH-DPAT binding to rat 5-HT 1a receptors.,Expert,,,B,,BAO_0000357,15311,,,1,CHEMBL615902,,,,H,8,,
847,Compound was measured for affinity at 5-hydroxytryptamine 1A receptor labeled with [3H]8-OH-DPAT radioligand in hippocampus tissue,Autocuration,,,B,,BAO_0000221,10922,,,1,CHEMBL615903,,,,H,8,10000000.0,
848,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor<br>at 1 uM,Autocuration,,,B,,BAO_0000357,10025,,,1,CHEMBL615904,,,,H,8,,
849,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor at 1 uM,Expert,,,B,,BAO_0000357,10025,,,1,CHEMBL615905,,,,H,8,,
850,In vitro Inhibitory activity tested at 5-hydroxytryptamine 1A receptor binding site in rat,Autocuration,,,B,,BAO_0000019,9742,,,1,CHEMBL615906,,,,H,8,,
851,In vitro Inhibitory activity tested at 5-hydroxytryptamine 1A receptor binding site in rat,Autocuration,,,F,,BAO_0000019,9742,,,1,CHEMBL615907,,,,H,8,,
852,In vitro ability to inhibit binding of radioligand [3H]8-OH-DPAT to 5-hydroxytryptamine 1A receptor in rat cerebral cortex,Expert,,,B,,BAO_0000019,12304,,,1,CHEMBL615908,,,,H,8,,
853,In vitro affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT in rat hippocampus,Autocuration,,,B,,BAO_0000221,15789,,,1,CHEMBL615909,,,,H,8,10000000.0,
854,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]-8-OH-DPAT as the radioligand",Autocuration,,,B,,BAO_0000019,9912,,,1,CHEMBL615910,,,,H,8,,
855,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]8-OH-DPAT as the radioligand.",Autocuration,,,B,,BAO_0000019,9912,,,1,CHEMBL615911,,,,H,8,,
856,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]8-OH-DPAT as the radioligand",Autocuration,,,B,,BAO_0000019,9912,,,1,CHEMBL615912,,,,H,8,,
857,In vitro binding affinity for serotonin 5-hydroxytryptamine 1A receptor fof rat cerebral cortex using [3H]8-OH-DPAT as radioligand,Expert,,,B,,BAO_0000019,16693,,,1,CHEMBL615913,,,,H,8,,
858,In vitro binding affinity measured on serotonin 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,Expert,,,B,,BAO_0000357,13276,,,1,CHEMBL615914,,,,H,8,,
859,In vitro binding affinity to 5-hydroxytryptamine 1A receptor using [125I](R)-(+)-trans-8-OH-PIPAT as radioligand in rat hippocampal homogenate,Autocuration,,,B,,BAO_0000221,12678,,,1,CHEMBL615915,,,,H,8,10000000.0,
860,In vitro binding affinity towards the 5-hydroxytryptamine 1A receptor was evaluated,Autocuration,,,B,,BAO_0000357,11825,,,1,CHEMBL615916,,,,H,8,,
861,In vitro binding affinity was measured on serotonergic 5-hydroxytryptamine 1A receptor by displacement of [3H]- tetralin,Expert,,,B,,BAO_0000357,12443,,,1,CHEMBL615917,,,,H,8,,
862,In vitro inhibitory activity against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,Expert,,,B,,BAO_0000357,13830,,,1,CHEMBL615918,,,,H,8,,
863,In vitro inhibitory concentration against radioligand [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membrane.,Expert,,,B,,BAO_0000249,14286,,,1,CHEMBL615919,,,,H,8,10000000.0,
864,In vitro radioligand binding assay on 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,Expert,10116.0,,B,,BAO_0000221,14356,,,1,CHEMBL615920,,,Rattus norvegicus,D,9,10000000.0,
865,Inhibition concentration against 5-hydroxytryptamine 1A receptor,Autocuration,,,B,,BAO_0000357,15306,,,1,CHEMBL615921,,,,H,8,,
866,Inhibitory concentration against 5-hydroxytryptamine 1A receptor (Inactive at >1000 nM concentration),Expert,,,B,,BAO_0000357,15306,,,1,CHEMBL615922,,,,H,8,,
867,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in hippocampal membranes",Expert,10116.0,,F,,BAO_0000249,16616,,,1,CHEMBL881290,,,Rattus norvegicus,D,9,,
868,"Inhibition of [3H]8-hydroxy-2-dipropylamino-1,2,3,4-tetrahydronaphthalene binding to 5-hydroxytryptamine 1A receptor in hippocampus region of rat brain; Residual radioligand binding higher than 50%",Autocuration,,,B,,BAO_0000221,3651,,,1,CHEMBL615923,,,,H,8,10000000.0,
869,Inhibition of forskolin-activated adenylate cyclase (cAMP) activity at 5-hydroxytryptamine 1A receptor in rat hippocampus,Autocuration,,,F,,BAO_0000221,14331,,,1,CHEMBL615924,,,,H,8,10000000.0,
870,Inhibition of forskolin-activated adenylate cyclase (cAMP) activity at 5-hydroxytryptamine 1A receptor in rat hippocampus,Autocuration,,,F,,BAO_0000221,14331,,,1,CHEMBL615925,,,,H,8,10000000.0,
871,Inhibition of radiolabeled [3H]-8-OH-DPAT ligand binding to 5-hydroxytryptamine 1A receptor,Expert,10116.0,,B,,BAO_0000357,14178,,,1,CHEMBL615926,,,Rattus norvegicus,D,9,,
872,Displacement of [3H]8-OH-DPAT from rat cortex 5-hydroxytryptamine 1A receptor,Expert,10116.0,,B,,BAO_0000019,10639,,,1,CHEMBL615927,,,Rattus norvegicus,D,9,,
873,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,Autocuration,,,B,,BAO_0000221,12306,,,1,CHEMBL615928,,,,H,8,10000000.0,
874,Inhibitory activity against 5-hydroxytryptamine 1A receptor subtype,Expert,10116.0,,B,,BAO_0000357,1348,,,1,CHEMBL615929,,,Rattus norvegicus,D,9,,
875,Inhibitory activity against [3H]DPAT binding to 5-HT1A receptor in rat hippocampus,Autocuration,,,B,,BAO_0000221,13605,,,1,CHEMBL615930,,,,H,8,10000000.0,
876,Inhibition concentration against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,Autocuration,,,B,,BAO_0000219,17624,,449.0,1,CHEMBL615931,CHO,,,H,8,,
877,Inhibition concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,Autocuration,,,F,,BAO_0000219,17624,,449.0,1,CHEMBL615932,CHO,,,H,8,,
878,Inhibition concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,Autocuration,,,F,,BAO_0000219,17624,,449.0,1,CHEMBL615933,CHO,,,H,8,,
879,Inhibition of [3H]- 8-OH-DAPT binding against human recombinant 5-hydroxytryptamine 1A receptor,Autocuration,,,B,,BAO_0000357,15267,,,1,CHEMBL615934,,,,H,8,,
880,The binding affinity at the 5-hydroxytryptamine 1A receptor determined using [3H]5-CT; Not tested,Autocuration,,,B,,BAO_0000357,16532,,,1,CHEMBL615935,,,,H,8,,
881,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",Autocuration,,,F,,BAO_0000019,6563,,,1,CHEMBL615936,,,,H,8,,
882,Ability to displace [3H]-8-OH-DPAT from CHO cells stably transfected with human 5-hydroxytryptamine 1A receptor at a concentration of 1 uM,Autocuration,,,B,,BAO_0000219,4751,,449.0,1,CHEMBL615937,CHO,,,H,8,,
883,Compound at 1 uM was tested for the inhibition of radioligand [3H]8-OH-DPAT binding to recombinant human 5-hydroxytryptamine 1A receptor,Autocuration,,,B,,BAO_0000357,15463,,,1,CHEMBL615938,,,,H,8,,
884,In vitro binding affinity against human 5-hydroxytryptamine 1A receptor at a concentration of 100 (nM),Autocuration,,,B,,BAO_0000357,3805,,,1,CHEMBL615797,,,,H,8,,
885,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,Autocuration,,,B,,BAO_0000357,5640,,,1,CHEMBL615798,,,,H,8,,
886,Inhibition of [3H]8-OH-DPAT binding to human 5-hydroxytryptamine 1A receptor at 1000 nM compound concentration,Autocuration,,,B,,BAO_0000357,6563,,,1,CHEMBL872870,,,,H,8,,
887,Inhibitory activity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand at 100 nM concentration,Autocuration,,,B,,BAO_0000357,5548,,,1,CHEMBL615799,,,,H,8,,
888,Percent binding affinity against 5-hydroxytryptamine 1A receptor,Autocuration,,,B,,BAO_0000357,6347,,,1,CHEMBL615800,,,,H,8,,
889,Intrinsic activity for human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,Autocuration,,,F,,BAO_0000219,17296,,722.0,1,CHEMBL615801,HEK293,,,H,8,,
890,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit jugular vein assay in the absence of endothelium,Autocuration,,,B,,BAO_0000019,13047,,,1,CHEMBL615802,,,,H,8,,
891,Dissociation constant against human 5-hydroxytryptamine 1A receptor receptor,Autocuration,,,B,,BAO_0000357,15740,,,1,CHEMBL615803,,,,H,8,,
892,"Inhibition of 5-HT induced [35S]GTP-gamma-S, binding at human cloned 5-HT 1A receptors.",Expert,,,F,,BAO_0000019,5640,,,1,CHEMBL835002,,,,H,8,,
893,"5-hydroxytryptamine 1A receptor antagonism was evaluated by the ability to inhibit [35S]GTP-gamma-S, binding that was induced by 5-HT; Ki (nM): not determined",Autocuration,,,F,,BAO_0000019,5640,,,1,CHEMBL615804,,,,H,8,,
894,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor,Expert,,,B,,BAO_0000219,17211,,308.0,1,CHEMBL615805,HeLa,,,H,8,,
895,Ability to displace [3H]8-OH-DPAT from CHO cells stably transfected with human 5-hydroxytryptamine 1A receptor,Autocuration,,,B,,BAO_0000219,4751,,449.0,1,CHEMBL615806,CHO,,,H,8,,
896,Affinity towards human 5-hydroxytryptamine 1A serotonin receptor,Expert,9606.0,,B,,BAO_0000357,6491,,,1,CHEMBL615807,,,Homo sapiens,D,9,,
897,Binding affinity towards human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT-as radioligand,Autocuration,,,B,,BAO_0000357,4707,,,1,CHEMBL615808,,,,H,8,,
898,Binding affinity against 5-hydroxytryptamine 1A receptor,Expert,9606.0,,B,,BAO_0000357,13910,,,1,CHEMBL615809,,,Homo sapiens,D,9,,
899,Binding affinity against 5-hydroxytryptamine 1A receptor in HeLa cells was determined using [3H]5-HT,Autocuration,,,B,,BAO_0000219,16190,,308.0,1,CHEMBL615810,HeLa,,,H,8,,
900,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,Autocuration,,,B,,BAO_0000357,16633,,,1,CHEMBL615811,,,,H,8,,
901,Binding affinity against [3H]- -8-OH-DPAT -labeled 5-hydroxytryptamine 1A sites in cloned CHO cells,Autocuration,,,B,,BAO_0000219,11898,,449.0,1,CHEMBL615812,CHO,,,H,8,,
902,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,Autocuration,,,B,,BAO_0000219,11898,,449.0,1,CHEMBL615751,CHO,,,H,8,,
903,Binding affinity against human 5-hydroxytryptamine 1A receptor,Autocuration,,,B,,BAO_0000357,14331,,,1,CHEMBL615752,,,,H,8,,
904,Binding affinity against human 5-hydroxytryptamine 1A receptor in CHO cells labeled with [3H]8-OH-DPAT radioligand,Expert,,,B,,BAO_0000219,17624,,449.0,1,CHEMBL615753,CHO,,,H,8,,
905,Binding affinity against human 5-hydroxytryptamine 1A receptor in CHO cells labeled with [3H]8-OH-DPAT radioligand; nd=not determined,Autocuration,,,B,,BAO_0000219,17624,,449.0,1,CHEMBL615754,CHO,,,H,8,,
906,Binding affinity of compound to human 5-hydroxytryptamine 1A receptor,Autocuration,,,B,,BAO_0000357,3307,,,1,CHEMBL615755,,,,H,8,,
907,Displacement of [3H]8-OH-DPAT from human 5-hydroxytryptamine 1A receptor expressed in CHO cells,Expert,9606.0,,B,,BAO_0000219,6563,,449.0,1,CHEMBL615756,CHO,,Homo sapiens,D,9,,
908,Binding affinity for 5-hydroxytryptamine 1A receptor in HeLa transfected cell type using [3H]8-OH-DPAT as radioligand,Autocuration,,,B,,BAO_0000019,14165,,,1,CHEMBL615757,,,,H,8,,
909,Binding affinity towards cloned human 5-hydroxytryptamine 1A receptor was determined,Autocuration,,,B,,BAO_0000357,5732,,,1,CHEMBL615758,,,,H,8,,
910,In vitro affinity at human cloned 5-hydroxytryptamine 1A receptor by [3H]8-OH-DPAT displacement.,Expert,,,B,,BAO_0000357,13366,,,1,CHEMBL615759,,,,H,8,,
911,Binding affinity towards human 5-hydroxytryptamine 1A receptor,Autocuration,,,B,,BAO_0000357,17626,,,1,CHEMBL615760,,,,H,8,,
912,Binding affinity towards human 5-hydroxytryptamine 1A receptor by the displacement of [3H]5-HT radioligand from the cloned receptor expressed in HeLa cells,Expert,,,B,,BAO_0000219,6588,,308.0,1,CHEMBL615761,HeLa,,,H,8,,
913,Binding affinity towards human 5-hydroxytryptamine 1A receptor was determined using [3H]-5-HT as radioligand,Autocuration,,,B,,BAO_0000357,16209,,,1,CHEMBL872104,,,,H,8,,
914,Binding affinity towards recombinant human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,Autocuration,,,B,,BAO_0000357,15463,,,1,CHEMBL615762,,,,H,8,,
915,Binding affinity towards recombinant human Compound at 1 uM was tested for the inhibition of radioligand [3H]8-OH-DPAT binding to recombinant human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,Autocuration,,,B,,BAO_0000357,15463,,,1,CHEMBL615763,,,,H,8,,
916,Binding affinity for recombinant human 5-hydroxytryptamine 1A receptor using [3H]5-HT as radioligand.,Autocuration,,,B,,BAO_0000357,14770,,,1,CHEMBL615764,,,,H,8,,
917,Binding affinity on human cloned 5-hydroxytryptamine 1A receptor transfected in human cell lines (He La),Autocuration,,,B,,BAO_0000219,16245,,1167.0,1,CHEMBL615765,Cell line,,,H,8,,
918,Binding affinity on human cloned 5-hydroxytryptamine 1A receptor transfected in human cell lines(He La),Autocuration,,,B,,BAO_0000019,16245,,,1,CHEMBL615766,,,,H,8,,
919,Binding affinity towards 5-HT1A receptor using [3H]8-OH-DPAT as radioligand,Autocuration,,,B,,BAO_0000357,5548,,,1,CHEMBL615767,,,,H,8,,
920,Binding affinity was determined towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,Expert,,,B,,BAO_0000357,5548,,,1,CHEMBL615768,,,,H,8,,
921,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,Autocuration,,,B,,BAO_0000357,5548,,,1,CHEMBL615769,,,,H,8,,
922,Binding affinity was evaluated at 5-hydroxytryptamine 1A receptor labeled with [3H]-8-OH-DPAT,Expert,,,B,,BAO_0000357,6876,,,1,CHEMBL615770,,,,H,8,,
923,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,Autocuration,,,B,,BAO_0000357,2598,,,1,CHEMBL615771,,,,H,8,,
924,Binding affinity to human 5-hydroxytryptamine 1A receptor was measured using [3H]-8-hydroxy-2-(di-n-propylamine) tetraline [3H]8-OH-DPAT) as radioligand,Expert,,,B,,BAO_0000357,17785,,,1,CHEMBL615772,,,,H,8,,
925,Binding affinity towards 5-hydroxytryptamine 1A receptor,Autocuration,,,B,,BAO_0000357,6013,,,1,CHEMBL615773,,,,H,8,,
926,Binding affinity towards 5-hydroxytryptamine 1A receptor in human using [3H]8-OH-DPAT as radioligand,Expert,,,B,,BAO_0000357,5929,,,1,CHEMBL615774,,,,H,8,,
927,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,Autocuration,,,B,,BAO_0000357,16633,,,1,CHEMBL615775,,,,H,8,,
928,Binding affinity towards cloned human 5-hydroxytryptamine 1A receptor was determined,Autocuration,,,B,,BAO_0000357,1558,,,1,CHEMBL615776,,,,H,8,,
929,Binding affinity towards human cloned 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,Expert,,,B,,BAO_0000357,16026,,,1,CHEMBL615777,,,,H,8,,
930,Binding affinity was measured on 5-hydroxytryptamine 1A receptor in AK cells transfected with human 5-HT1A gene labeled with [3H]-8-OH-DPAT,Autocuration,,,B,,BAO_0000219,12469,,,1,CHEMBL615778,,,,H,8,,
931,Binding affinity was measured on cloned Human 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,Expert,9606.0,,B,,BAO_0000357,15874,,,1,CHEMBL615779,,,Homo sapiens,D,9,,
932,Binding affinity was measured on cloned human 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,Autocuration,,,B,,BAO_0000357,15874,,,1,CHEMBL615780,,,,H,8,,
933,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1A receptor,Autocuration,,,B,,BAO_0000357,3935,,,1,CHEMBL616298,,,,H,8,,
934,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1A receptor,Autocuration,,,B,,BAO_0000357,15818,,,1,CHEMBL616299,,,,H,8,,
935,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells.,Autocuration,,,B,,BAO_0000219,13706,,485.0,1,CHEMBL616300,CHO-K1,,,H,8,,
936,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1A receptor in CHO-K1 cells,Expert,,,F,,BAO_0000219,13729,,485.0,1,CHEMBL616301,CHO-K1,,,H,8,,
937,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor,Autocuration,,,B,,BAO_0000019,15413,,,1,CHEMBL616302,,,,H,8,,
938,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor (Experiment 1),Autocuration,,,B,,BAO_0000019,15413,,,1,CHEMBL616117,,,,H,8,,
939,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor (Experiment 2),Autocuration,,,B,,BAO_0000019,15413,,,1,CHEMBL616118,,,,H,8,,
940,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor by Panlabs assay,Autocuration,,,B,,BAO_0000019,15413,,,1,CHEMBL616119,,,,H,8,,
941,Displacement of specific [3H]- 5-HT binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells,Expert,9606.0,,B,,BAO_0000219,3445,,308.0,1,CHEMBL616120,HeLa,,Homo sapiens,D,9,,
942,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor,Autocuration,,,B,,BAO_0000357,15740,,,1,CHEMBL616121,,,,H,8,,
943,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor receptor,Autocuration,,,B,,BAO_0000357,15740,,,1,CHEMBL616122,,,,H,8,,
944,In vitro binding affinity tested on human 5-hydroxytryptamine 1A receptor,Autocuration,,,B,,BAO_0000357,17626,,,1,CHEMBL616123,,,,H,8,,
945,In vitro binding affinity to human 5-hydroxytryptamine 1A receptor,Expert,9606.0,,B,,BAO_0000357,4234,,,1,CHEMBL616124,,,Homo sapiens,D,9,,
946,In vitro binding affinity at 5-hydroxytryptamine 1A receptor by [3H]8-OH-DPAT displacement.,Expert,,,B,,BAO_0000357,5640,,,1,CHEMBL616125,,,,H,8,,
947,In vitro binding affinity towards Human 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT,Expert,10116.0,,B,,BAO_0000357,5272,,,1,CHEMBL616126,,,Rattus norvegicus,H,8,,
948,In vitro binding affinity towards cloned human 5-hydroxytryptamine 1A receptor expressed in Chinese hamster ovary (CHO) cells using [3H]8-OH-DPAT as radioligand,Autocuration,,,B,,BAO_0000219,4622,,449.0,1,CHEMBL616127,CHO,,,H,8,,
949,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1A receptor,Expert,,,B,,BAO_0000019,17085,,,1,CHEMBL616128,,,,H,8,,
950,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand,Autocuration,,,B,,BAO_0000357,3025,,,1,CHEMBL616129,,,,H,8,,
951,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1A receptor,Expert,,,B,,BAO_0000357,15315,,,1,CHEMBL616130,,,,H,8,,
952,Inhibition of [3H]- OH-DPAT binding against 5-hydroxytryptamine 1A receptor from human recombinant,Autocuration,,,B,,BAO_0000357,15267,,,1,CHEMBL616131,,,,H,8,,
953,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor serotonergic receptor in human HeLa cells,Autocuration,,,B,,BAO_0000219,17158,,308.0,1,CHEMBL616132,HeLa,,,H,8,,
954,Receptor binding affinity for cloned human 5-hydroxytryptamine 1A receptor in HeLa cells,Expert,9606.0,,B,,BAO_0000219,14214,,308.0,1,CHEMBL616133,HeLa,,Homo sapiens,D,9,,
955,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,Autocuration,,,B,,BAO_0000357,17133,,,1,CHEMBL616134,,,,H,8,,
956,The binding affinity at the 5-hydroxytryptamine 1A receptor determined using [3H]5-CT,Autocuration,,,B,,BAO_0000357,16532,,,1,CHEMBL616135,,,,H,8,,
957,Affinity for 5-hydroxytryptamine 1A receptor subtype,Expert,9606.0,,B,,BAO_0000357,2391,,,1,CHEMBL616136,,,Homo sapiens,D,9,,
958,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1A receptor from cloned Human membranes,Autocuration,,,B,,BAO_0000019,14447,,,1,CHEMBL616137,,,,H,8,,
959,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1A receptor from cloned Human membranes.,Autocuration,,,B,,BAO_0000019,14447,,,1,CHEMBL872105,,,,H,8,,
960,The compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor receptor,Autocuration,,,B,,BAO_0000357,15086,,,1,CHEMBL616138,,,,H,8,,
961,Binding affinity for cloned human 5-hydroxytryptamine 1A receptor,Expert,9606.0,,B,,BAO_0000357,13051,,,1,CHEMBL616139,,,Homo sapiens,D,9,,
962,"Ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor; Not active",Autocuration,,,F,,BAO_0000019,16026,,,1,CHEMBL616140,,,,H,8,,
963,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1A receptor; ND means not determined,Expert,,,B,,BAO_0000019,17085,,,1,CHEMBL616141,,,,H,8,,
964,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,Autocuration,,,B,,BAO_0000357,17133,,,1,CHEMBL616142,,,,H,8,,
965,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand; ND means Not determined,Autocuration,,,B,,BAO_0000357,17133,,,1,CHEMBL616143,,,,H,8,,
966,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,Autocuration,,,B,,BAO_0000219,17211,,308.0,1,CHEMBL616144,HeLa,,,H,8,,
967,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT=not tested,Autocuration,,,B,,BAO_0000219,17211,,308.0,1,CHEMBL616145,HeLa,,,H,8,,
968,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,Autocuration,,,B,,BAO_0000219,17211,,308.0,1,CHEMBL616012,HeLa,,,H,8,,
969,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,Autocuration,,,B,,BAO_0000219,17211,,308.0,1,CHEMBL616013,HeLa,,,H,8,,
970,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",Autocuration,,,F,,BAO_0000019,16394,,,1,CHEMBL616014,,,,H,8,,
971,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",Autocuration,,,F,,BAO_0000019,16394,,,1,CHEMBL616015,,,,H,8,,
972,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",Autocuration,,,F,,BAO_0000019,16394,,,1,CHEMBL616016,,,,H,8,,
973,Antagonist induction of hypothermia by 8-OH-DPAT in 5-hydroxytryptamine 1A receptor after subcutaneous administration; NT is not tested,Autocuration,,,F,,BAO_0000218,16394,,,1,CHEMBL616017,,,,H,8,,
974,Binding affinity at human 5-hydroxytryptamine 1A receptor by inhibition of [3H]-8-OH-DPAT binding in Chinese hamster ovary cell line; NT is not tested,Autocuration,,,B,,BAO_0000019,16394,,,1,CHEMBL616018,,,,H,8,,
975,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor receptor; Not tested,Autocuration,,,F,,BAO_0000019,15740,,,1,CHEMBL616019,,,,H,8,,
976,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor; Not tested,Autocuration,,,F,,BAO_0000019,15740,,,1,CHEMBL616020,,,,H,8,,
977,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor,Autocuration,,,B,,BAO_0000357,15740,,,1,CHEMBL858018,,,,H,8,,
978,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,Autocuration,,,F,,BAO_0000219,17296,,722.0,1,CHEMBL616021,HEK293,,,H,8,,
979,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at 1 uM.",Expert,,,F,,BAO_0000019,5640,,,1,CHEMBL616022,,,,H,8,,
980,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; ND means Not determined",Autocuration,,,F,,BAO_0000019,5640,,,1,CHEMBL616023,,,,H,8,,
981,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; ND means not determined",Autocuration,,,F,,BAO_0000019,5640,,,1,CHEMBL616024,,,,H,8,,
982,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; Not determined",Autocuration,,,F,,BAO_0000019,5640,,,1,CHEMBL616025,,,,H,8,,
983,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,Autocuration,,,F,,BAO_0000219,2759,,449.0,1,CHEMBL616026,CHO,,,H,8,,
984,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT",Autocuration,,,F,,BAO_0000019,16394,,,1,CHEMBL616027,,,,H,8,,
985,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared to 5-HT",Expert,9606.0,,F,,BAO_0000019,16394,,,1,CHEMBL616028,,,Homo sapiens,D,9,,
986,Percent efficacy against human 5-hydroxytryptamine 1A receptor relative to maximal 5-HT response,Expert,9606.0,,F,,BAO_0000019,3445,,,1,CHEMBL616029,,,Homo sapiens,D,9,,
987,Binding affinity for 5-hydroxytryptamine 1A receptor was determined by incubating human 5-hydroxytryptamine 1A receptor transfected CHO cells with [3H]8-OH-DPAT,Expert,,,B,,BAO_0000219,4316,,449.0,1,CHEMBL616030,CHO,,,H,8,,
988,In vitro inhibition of [3H]8-OH-DPAT binding to human cloned 5-hydroxytryptamine 1A receptor on CHO cell membranes.,Expert,,,B,,BAO_0000019,4316,,,1,CHEMBL616031,,,,H,8,,
989,Agonist efficacy on 5-hydroxytryptamine 1A receptor subtype,Expert,9606.0,,F,,BAO_0000019,15180,,,1,CHEMBL616032,,,Homo sapiens,D,9,,
990,Agonist efficacy on 5-hydroxytryptamine 1A receptor subtype,Expert,9606.0,,F,,BAO_0000019,15180,,,1,CHEMBL616033,,,Homo sapiens,D,9,,
991,Maximum binding affinity was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,Autocuration,,,F,,BAO_0000019,15042,,,1,CHEMBL616034,,,,H,8,,
992,Maximum binding affinity was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,Autocuration,,,F,,BAO_0000019,15042,,,1,CHEMBL616035,,,,H,8,,
993,Maximum binding affinity was evaluated as ([35S]GTP binding on cloned human 5-hydroxytryptamine 1A receptor,Autocuration,,,F,,BAO_0000019,15042,,,1,CHEMBL616036,,,,H,8,,
994,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,Autocuration,,,F,,BAO_0000019,15042,,,1,CHEMBL616037,,,,H,8,,
995,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,Autocuration,,,F,,BAO_0000019,15042,,,1,CHEMBL616038,,,,H,8,,
996,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,Autocuration,,,F,,BAO_0000019,15042,,,1,CHEMBL616039,,,,H,8,,
997,Agonist efficacy was evaluated as [35S]GTP binding on cloned human 5-hydroxytryptamine 1A receptor,Autocuration,,,F,,BAO_0000019,15042,,,1,CHEMBL616040,,,,H,8,,
998,Concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,Expert,9606.0,,F,,BAO_0000219,15180,,308.0,1,CHEMBL616041,HeLa,,Homo sapiens,D,9,,
999,Negative logarithm of concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,Expert,9606.0,,F,,BAO_0000219,15180,,308.0,1,CHEMBL616042,HeLa,,Homo sapiens,D,9,,
1000,Negative logarithm of concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,Expert,9606.0,,F,,BAO_0000219,15180,,308.0,1,CHEMBL616043,HeLa,,Homo sapiens,D,9,,
1001,"Potency (pD2) for the stimulation of [35S]GTP-gamma-S, binding on 5-hydroxytryptamine 1A receptor",Autocuration,,,F,,BAO_0000019,16245,,,1,CHEMBL616044,,,,H,8,,
1002,"Ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",Autocuration,,,F,,BAO_0000019,16026,,,1,CHEMBL616045,,,,H,8,,
1003,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,Autocuration,,,F,,BAO_0000219,17296,,722.0,1,CHEMBL616046,HEK293,,,H,8,,
1004,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 2),Autocuration,,,F,,BAO_0000219,2759,,449.0,1,CHEMBL616047,CHO,,,H,8,,
1005,Compound was tested for its potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells,Autocuration,,,F,,BAO_0000219,2759,,449.0,1,CHEMBL616048,CHO,,,H,8,,
1006,Potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 1),Expert,9606.0,,F,,BAO_0000219,2759,,449.0,1,CHEMBL616049,CHO,,Homo sapiens,D,9,,
1007,Compound was tested for its potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 2),Autocuration,,,F,,BAO_0000219,2759,,449.0,1,CHEMBL616050,CHO,,,H,8,,
1008,In vitro effective concentration required to inhibit forskolin-stimulated cAMP levels in HA7 cells expressing human 5-HT1A receptor,Expert,,,F,,BAO_0000219,15419,,,1,CHEMBL616051,,,,H,8,,
1009,In vitro effective concentration required to inhibit forskolin-stimulated cAMP levels in HA7 cells expressing human 5-HT1A receptor; Not tested,Autocuration,,,F,,BAO_0000219,15419,,,1,CHEMBL616212,,,,H,8,,
1010,"ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",Autocuration,,,F,,BAO_0000019,16026,,,1,CHEMBL616213,,,,H,8,,
1011,Ability to bind to 5-hydroxytryptamine 1A receptor from cloned human expressed in Ha7 cells,Expert,,,B,,BAO_0000219,1414,,,1,CHEMBL616214,,,,H,8,,
1012,Ability to bind to 5-hydroxytryptamine 1A receptor subtype from cloned human expressed in Ha7 cells,Expert,,,B,,BAO_0000219,1414,,,1,CHEMBL616215,,,,H,8,,
1013,Binding activity radioligand.,Autocuration,,,B,,BAO_0000357,12861,,,1,CHEMBL616216,,,,H,8,,
1014,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,Autocuration,,,B,,BAO_0000019,12861,,,1,CHEMBL616217,,,,H,8,,
1015,Binding affinity for human cloned 5-hydroxytryptamine 1A receptor,Autocuration,,,B,,BAO_0000357,5104,,,1,CHEMBL616218,,,,H,8,,
1016,Binding affinity for human cloned 5-hydroxytryptamine 1A receptor,Autocuration,,,B,,BAO_0000357,5105,,,1,CHEMBL616219,,,,H,8,,
1017,binding affinity towards human recombinant 5-hydroxytryptamine 1A receptor,Autocuration,,,B,,BAO_0000357,16312,,,1,CHEMBL616220,,,,H,8,,
1018,Displacement of [3H]8-hydroxy-2-(di-n-propylamino)tetralin from human 5-hydroxytryptamine 1A receptor,Expert,9606.0,,B,,BAO_0000357,15180,,,1,CHEMBL833493,,,Homo sapiens,D,9,,
1019,Ability to displace the radioligand [3H]-8-OH-DPAT from human 5-hydroxytryptamine 1A receptor,Autocuration,,,B,,BAO_0000357,5033,,,1,CHEMBL616221,,,,H,8,,
1020,Affinity constant on CHO cells expressing Human recombinant 5-hydroxytryptamine receptor 1A,Expert,9606.0,,B,,BAO_0000219,16909,,449.0,1,CHEMBL616222,CHO,,Homo sapiens,D,9,,
1021,Antagonistic affinity against cloned human 5-hydroxytryptamine 1A receptor,Autocuration,,,F,,BAO_0000019,2590,,,1,CHEMBL616223,,,,H,8,,
1022,Antagonistic affinity against cloned human 5-hydroxytryptamine 1A receptor; Not determined,Autocuration,,,F,,BAO_0000019,2590,,,1,CHEMBL616224,,,,H,8,,
1023,Binding affinity at human 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding in Chinese hamster ovary cell line,Expert,,,B,,BAO_0000019,16394,,,1,CHEMBL616225,,,,H,8,,
1024,Binding affinity to human cloned 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]-8-OH- DPAT as radioligand,Expert,9606.0,,B,,BAO_0000219,4540,,722.0,1,CHEMBL616226,HEK293,,Homo sapiens,D,9,,
1025,Binding affinity against 5-hydroxytryptamine 1A human cloned receptors in HEK293 cells,Autocuration,,,B,,BAO_0000219,17296,,722.0,1,CHEMBL616227,HEK293,,,H,8,,
1026,Binding affinity against 5-hydroxytryptamine 1A human cloned receptors in HEK293 cells using [3H]8-OH-DPAT as radioligand,Autocuration,,,B,,BAO_0000219,17296,,722.0,1,CHEMBL616228,HEK293,,,H,8,,
1027,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;,Autocuration,,,B,,BAO_0000219,15779,,722.0,1,CHEMBL616229,HEK293,,,H,8,,
1028,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand; ND means no data,Autocuration,,,B,,BAO_0000219,15779,,722.0,1,CHEMBL616230,HEK293,,,H,8,,
1029,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;ND means no data.,Autocuration,,,B,,BAO_0000219,15779,,722.0,1,CHEMBL616231,HEK293,,,H,8,,
1030,Binding affinity towards 5-hydroxytryptamine 1A receptor in human using [3H]8-OH-DPAT as radioligand,Autocuration,,,B,,BAO_0000357,6166,,,1,CHEMBL616232,,,,H,8,,
1031,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;,Autocuration,,,B,,BAO_0000219,15779,,722.0,1,CHEMBL616233,HEK293,,,H,8,,
1032,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]8-OH-DPAT as the radioligand,Autocuration,,,B,,BAO_0000219,4199,,722.0,1,CHEMBL857973,HEK293,,,H,8,,
1033,Compound was evaluated for its ability to displace [3H]8-OH-DPAT binding from human 5-hydroxytryptamine 1A receptor in mammalian cells,Autocuration,,,B,,BAO_0000219,15316,,,1,CHEMBL616234,,,,H,8,,
1034,Compound was tested for binding affinity against human 5-hydroxytryptamine 1A receptor,Autocuration,,,B,,BAO_0000357,14875,,,1,CHEMBL616235,,,,H,8,,
1035,Binding affinity at human cloned 5-hydroxytryptamine 1A receptor expressed in HeLa cells by [3H]8-hydroxy-2-(di-n-propylamino)tetraline displacement.,Expert,,,B,,BAO_0000219,14727,,308.0,1,CHEMBL616236,HeLa,,,H,8,,
1036,Binding affinity at native 5-hydroxytryptamine 1A receptor in rat by [3H]8-hydroxy-2-(di-n-propylamino)tetraline displacement.,Expert,,,B,,BAO_0000019,14727,,,1,CHEMBL616237,,,,H,8,,
1037,Compound was tested for its binding affinity against 5-hydroxytryptamine 1A receptor in human cloned receptors in HEK 293 cells using [3H]8-OH-DPAT,Autocuration,,,B,,BAO_0000219,15146,,722.0,1,CHEMBL616238,HEK293,,,H,8,,
1038,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1A receptor in HEK 293 using [3H]5-CT as a radioligand,Autocuration,,,B,,BAO_0000219,5213,,722.0,1,CHEMBL616239,HEK293,,,H,8,,
1039,In vitro binding affinity at human recombinant 5-hydroxytryptamine 1A receptor in mammalian cells using 3[H]8-OH-DPAT as the radioligand,Autocuration,,,B,,BAO_0000219,16429,,,1,CHEMBL616240,,,,H,8,,
1040,The binding affinity was evaluated on cloned human 5-hydroxytryptamine 1A receptor expressed in HeLa cells by using DPAT as radioligand.,Expert,9606.0,,B,,BAO_0000219,15042,,308.0,1,CHEMBL616241,HeLa,,Homo sapiens,D,9,,
1041,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]8-OH-DPAT.,Autocuration,,,B,,BAO_0000219,14818,,722.0,1,CHEMBL616242,HEK293,,,H,8,,
1042,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1A receptor in HEK293 cells, using [3H]8-OH-DPAT as radioligand",Autocuration,,,B,,BAO_0000219,4829,,722.0,1,CHEMBL616243,HEK293,,,H,8,,
1043,In vitro inhibitory concentration required against [3H]8-OH-DPAT binding to cloned human 5-hydroxytryptamine 1A receptor,Expert,,,B,,BAO_0000357,17200,,,1,CHEMBL616244,,,,D,9,,
1044,The compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1A receptor,Autocuration,9606.0,,B,,BAO_0000357,13051,,,1,CHEMBL616245,,,Homo sapiens,D,9,,
1045,Binding affinity towards 5-HT1B receptor by the displacement of [3H]-5-CT] in human recombinant receptors in mammalian cell,Autocuration,,,B,,BAO_0000357,5486,,,1,CHEMBL616246,,,,H,8,,
1046,Binding affinity against 5-HT1D receptor,Autocuration,,,B,,BAO_0000357,5254,,,1,CHEMBL616247,,,,H,8,,
1047,Binding affinity against 5-hydroxytryptamine 1A receptor,Autocuration,,,B,,BAO_0000357,5254,,,1,CHEMBL616248,,,,H,8,,
1048,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,Autocuration,,,B,,BAO_0000357,15331,,,1,CHEMBL616249,,,,H,8,,
1049,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT binding assay,Autocuration,9606.0,,B,,BAO_0000357,13506,,,1,CHEMBL616250,,,Homo sapiens,H,8,,
1050,Inhibition of [3H]- 8-OH-DAPT binding against human recombinant 5-hydroxytryptamine 1A receptor,Autocuration,,,B,,BAO_0000357,15267,,,1,CHEMBL616251,,,,H,8,,
1051,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 15 min after administration of the compound,Autocuration,,,F,,BAO_0000218,16616,,,1,CHEMBL616252,,,,H,8,,
1052,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 30 min after administration of the compound,Autocuration,,,F,,BAO_0000218,16616,,,1,CHEMBL616253,,,,H,8,,
1053,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 60 min after administration of the compound,Autocuration,,,F,,BAO_0000218,16616,,,1,CHEMBL616254,,,,H,8,,
1054,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 15 min,Expert,10090.0,,F,,BAO_0000218,16616,,,1,CHEMBL616255,,,Mus musculus,D,9,,
1055,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 30 min,Expert,10090.0,,F,,BAO_0000218,16616,,,1,CHEMBL832872,,,Mus musculus,D,9,,
1056,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 60 min,Expert,10090.0,,F,,BAO_0000218,16616,,,1,CHEMBL616256,,,Mus musculus,D,9,,
1057,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 15 min,Expert,10090.0,,F,,BAO_0000218,16616,,,1,CHEMBL616257,,,Mus musculus,D,9,,
1058,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 30 min,Expert,10090.0,,F,,BAO_0000218,16616,,,1,CHEMBL616258,,,Mus musculus,D,9,,
1059,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 60 min,Expert,10090.0,,F,,BAO_0000218,16616,,,1,CHEMBL616384,,,Mus musculus,D,9,,
1060,Hill number was determined for inhibition of of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in mouse hippocampus,Autocuration,,,B,,BAO_0000221,10297,,,1,CHEMBL616385,,,,H,8,10000000.0,
1061,Inhibitory activity against serotonin 5-hydroxytryptamine 1A receptor from mice.,Expert,,,B,,BAO_0000357,13704,,,1,CHEMBL616386,,,,H,8,,
1062,Inhibitory activity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus,Expert,10090.0,,B,,BAO_0000221,10297,,,1,CHEMBL616387,,,Mus musculus,D,9,10000000.0,
1063,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus; Not determined,Autocuration,,,B,,BAO_0000221,10297,,,1,CHEMBL616388,,,,H,8,10000000.0,
1064,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus,Expert,10090.0,,B,,BAO_0000221,10297,,,1,CHEMBL616389,,,Mus musculus,D,9,10000000.0,
1065,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus; Not determined,Autocuration,,,B,,BAO_0000221,10297,,,1,CHEMBL616390,,,,H,8,10000000.0,
1066,Compound was tested for binding affinity to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as a radioligand,Autocuration,,,B,,BAO_0000357,217,,,1,CHEMBL616391,,,,H,8,,
1067,Hill number was determined for inhibition of of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in mouse hippocampus,Expert,10090.0,,B,,BAO_0000221,10297,,,1,CHEMBL616392,,,Mus musculus,D,9,10000000.0,
1068,Ability to displace [3H]8-OH-DPAT radioligand from porcine 5-hydroxytryptamine 1A receptor,Autocuration,9823.0,,B,,BAO_0000357,4921,,,1,CHEMBL616393,,,Sus scrofa,H,8,,
1069,Ability to displace [3H]8-OH-DPAT radioligand from porcine 5-hydroxytryptamine 1A receptor; ND denotes not determined,Autocuration,9823.0,,B,,BAO_0000357,4921,,,1,CHEMBL616394,,,Sus scrofa,H,8,,
1070,Binding affinity of compound measured for 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT-labeled porcine brain homogenates,Autocuration,9823.0,,B,,BAO_0000019,4996,,,1,CHEMBL616395,,,Sus scrofa,H,8,,
1071,Compound was evaluated for the binding affinity at 5- HT1A receptor,Autocuration,9823.0,,B,,BAO_0000357,12918,,,1,CHEMBL616396,,,Sus scrofa,H,8,,
1072,Compound was tested in vitro for its ability to compete with [3H]8-OH-DPAT at 5-hydroxytryptamine 1A receptor in porcine brain homogenate,Autocuration,9823.0,,B,,BAO_0000019,5333,,,1,CHEMBL872907,,,Sus scrofa,H,8,,
1073,In vitro for its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in porcine brain homogenate,Autocuration,9823.0,,B,,BAO_0000019,4437,,,1,CHEMBL616397,,,Sus scrofa,H,8,,
1074,Compound was tested for its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in pig cortex,Autocuration,9823.0,,B,,BAO_0000019,1742,,,1,CHEMBL616398,,,Sus scrofa,H,8,,
1075,Displacement of [3H]- 8-OH-DPAT from porcine 5-hydroxytryptamine 1A receptor,Expert,9823.0,,B,,BAO_0000357,16688,,,1,CHEMBL616399,,,Sus scrofa,H,8,,
1076,Binding activity radioligand.,Autocuration,9823.0,,B,,BAO_0000357,12861,,,1,CHEMBL857065,,,Sus scrofa,H,8,,
1077,Binding activity against 5-hydroxytryptamine 1A receptor from pig cortex membrane using [3H]8-OH-DPAT-HT as radioligand.,Expert,9823.0,,B,,BAO_0000019,12861,,,1,CHEMBL616400,,,Sus scrofa,H,8,,
1078,Binding activity against 5-hydroxytryptamine 1A receptor from pig cortex membrane using [3H]8-OH-DPAT-HT as radioligand.,Autocuration,9823.0,,B,,BAO_0000019,12861,,,1,CHEMBL616401,,,Sus scrofa,H,8,,
1079,Displacement of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor from pig cortex,Expert,,,B,,BAO_0000019,12490,,,1,CHEMBL616402,,,,H,8,,
1080,Displacement of [3H]8-OH-DPAT from pig cortex 5-hydroxytryptamine 1A receptor,Expert,9823.0,,B,,BAO_0000019,11828,,,1,CHEMBL616403,,,Sus scrofa,H,8,,
1081,Binding affinity for 5-hydroxytryptamine 1A receptor in piglet hippocampus using [3H]8-OH-DPAT,Autocuration,9823.0,,B,,BAO_0000221,11866,,,1,CHEMBL616404,,,Sus scrofa,H,8,10000000.0,
1082,Binding affinity towards 5-hydroxytryptamine 1A receptor in pig frontal cortex membranes using [8H]-OH-DPAT,Autocuration,9823.0,,B,,BAO_0000249,12827,,,1,CHEMBL616405,,,Sus scrofa,H,8,,
1083,Binding affinity was evaluated by 5-hydroxytryptamine 1A receptor agonism in the pig cortex by displacing 8-OH-DPAT,Autocuration,9823.0,,B,,BAO_0000019,12918,,,1,CHEMBL616406,,,Sus scrofa,H,8,,
1084,Agonistic activity against 5-hydroxytryptamine 1A receptor in pig cortex using [3H]8-OH-DPAT,Expert,9823.0,,F,,BAO_0000019,12919,,,1,CHEMBL616407,,,Sus scrofa,H,8,,
1085,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit jugular vein assay in the presence of endothelium,Autocuration,9986.0,,B,,BAO_0000019,13047,,,1,CHEMBL616408,,,Oryctolagus cuniculus,H,8,,
1086,Inhibition activity against 5-hydroxytryptamine 1A receptor in rat hippocampus membranes using radio binding assays,Expert,10116.0,,B,,BAO_0000249,15796,,,1,CHEMBL616409,,,Rattus norvegicus,D,9,,
1087,"Inhibition of [3H]8-hydroxy-2-dipropylamino-1,2,3,4-tetrahydronaphthalene binding to 5-hydroxytryptamine 1A receptor in hippocampus region of rat brain; Less active",Expert,10116.0,,B,,BAO_0000221,3651,,,1,CHEMBL616410,,,Rattus norvegicus,D,9,10000000.0,
1088,Tested for the effect on binding at 5-hydroxytryptamine 1A receptor; No activity,Autocuration,,,B,,BAO_0000357,188,,,1,CHEMBL616411,,,,H,8,,
1089,"Antagonist activity to stimulate binding of [35S]GTP-gamma-S, to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes",Expert,10116.0,,F,,BAO_0000249,16616,Membranes,,1,CHEMBL616412,,,Rattus norvegicus,D,9,,
1090,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding in rat hippocampal membranes",Expert,10116.0,,F,,BAO_0000249,16616,Membranes,,1,CHEMBL616413,,,Rattus norvegicus,D,9,10000000.0,
1091,The binding of [125I]MPPI ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,Autocuration,,,B,,BAO_0000221,12306,,,1,CHEMBL616414,,,,H,8,10000000.0,
1092,Binding affinity for rat hippocampus 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding,Expert,10116.0,,B,,BAO_0000221,17167,,,1,CHEMBL616415,,,Rattus norvegicus,D,9,10000000.0,
1093,Binding affinity measured at the 5-hydroxytryptamine 1A receptor by the inhibition of [3H]8-OH-DPAT binding to rat cortex using unlabeled buspirone for nonspecific binding.,Autocuration,,,B,,BAO_0000019,14776,,,1,CHEMBL616416,,,,H,8,,
1094,Binding affinity of 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand.,Expert,,,B,,BAO_0000357,12158,,,1,CHEMBL616417,,,,H,8,,
1095,Binding affinity of [3H]- -8-OH-DPAT labelled towards Rat Hippocampal 5-hydroxytryptamine 1A receptor using radioligand binding assay,Autocuration,,,B,,BAO_0000357,13481,,,1,CHEMBL616418,,,,H,8,,
1096,Binding affinity of [3H]-8-OH-DPAT towards 5-hydroxytryptamine 1A receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,Autocuration,,,B,,BAO_0000219,13427,,,1,CHEMBL616419,,,,H,8,,
1097,Binding affinity of compound against 5-hydroxytryptamine 1A receptor binding site using radioligand [3H]8-OH-DPAT,Autocuration,,,B,,BAO_0000357,10210,,,1,CHEMBL616420,,,,H,8,,
1098,Binding affinity of compound towards 5-HT 1A receptor by measuring ability to displace [3H]OH-DPAT from 5-hydroxytryptamine 1A receptor in rat striatal membranes,Autocuration,,,B,,BAO_0000249,10205,Membranes,,1,CHEMBL616421,,,,H,8,,
1099,Binding affinity of compound towards 5-HT 1A receptor by measuring ability to displace [3H]OH-DPAT from 5-hydroxytryptamine 1A receptor in rat striatal membranes,Autocuration,,,B,,BAO_0000249,10205,Membranes,,1,CHEMBL616422,,,,H,8,,
1100,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor in rat striatal membranes by [3H]OH-DPAT displacement.,Expert,,,B,,BAO_0000249,10205,Membranes,,1,CHEMBL616423,,,,H,8,,
1101,Binding affinity for 5-hydroxytryptamine 1A receptor with [3H]5-HT,Expert,10116.0,,B,,BAO_0000357,12280,,,1,CHEMBL616424,,,Rattus norvegicus,D,9,,
1102,Binding affinity to the rat 5-hydroxytryptamine 1A receptor,Expert,,,B,,BAO_0000357,17386,,,1,CHEMBL616425,,,,H,8,,
1103,Binding affinity was tested on 5-hydroxytryptamine 1A receptor using radioligand [3H]5-HT binding assay.,Expert,,,B,,BAO_0000357,13654,,,1,CHEMBL616426,,,,H,8,,
1104,Binding affinity against 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as the radioligand.,Autocuration,,,B,,BAO_0000221,14423,,,1,CHEMBL616427,,,,H,8,10000000.0,
1105,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampus tissue.,Autocuration,,,B,,BAO_0000221,15412,,,1,CHEMBL616428,,,,H,8,10000000.0,
1106,Binding affinity by measuring displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,Autocuration,,,B,,BAO_0000221,12073,,,1,CHEMBL616290,,,,H,8,10000000.0,
1107,Displacement of [3H]8-OH-DPAT from rat striata 5-hydroxytryptamine 1A receptor,Expert,10116.0,,B,,BAO_0000357,4101,,,1,CHEMBL616052,,,Rattus norvegicus,D,9,,
1108,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1A receptor,Autocuration,,,B,,BAO_0000357,10062,,,1,CHEMBL616053,,,,H,8,,
1109,Binding affinity towards 5-HT 1A receptor in rat cerebral cortex membranes using [3H]8-OH-DPAT as radioligand,Autocuration,,,B,,BAO_0000249,6238,,,1,CHEMBL616054,,,,H,8,,
1110,Binding affinity towards 5-hydroxytryptamine 1A receptor,Autocuration,,,B,,BAO_0000357,16273,,,1,CHEMBL616055,,,,H,8,,
1111,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in competitive binding assay,Autocuration,,,B,,BAO_0000357,11139,,,1,CHEMBL616056,,,,H,8,,
1112,Binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampal membranes,Expert,,,B,,BAO_0000019,16796,,,1,CHEMBL616057,,,,H,8,,
1113,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,Expert,10116.0,,B,,BAO_0000221,9548,,,1,CHEMBL616058,,,Rattus norvegicus,D,9,955.0,
1114,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,Autocuration,,,B,,BAO_0000221,10381,,,1,CHEMBL616059,,,,H,8,955.0,
1115,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hypocampus membrane using [3H]8-OH-DPAT as radioligand,Autocuration,,,B,,BAO_0000249,13408,,,1,CHEMBL616060,,,,H,8,,
1116,Binding affinity towards 5-hydroxytryptamine 1A receptor in the rat brain (hippocampus) using [3H]8-OH-DPAT,Expert,10116.0,,B,,BAO_0000221,13825,,,1,CHEMBL616061,,,Rattus norvegicus,D,9,10000000.0,
1117,Binding affinity towards 5-hydroxytryptamine 1A receptor of rat hippocampus using [3H]-8-hydroxy-2-(di-n-propylamine) tetralin (8-OH-DPAT) as a radioligand,Expert,,,B,,BAO_0000221,11147,,,1,CHEMBL616062,,,,H,8,10000000.0,
1118,Binding affinity towards 5-hydroxytryptamine 1A receptor sites in cortical membranes using [3H]8-OH-DPAT as radioligand,Autocuration,,,B,,BAO_0000249,10552,,,1,CHEMBL616063,,,,H,8,,
1119,"Binding affinity towards 5-hydroxytryptamine 1A receptor sites, in rat striatum membranes using [3H]- sandoz 205-501 as radioligand",Autocuration,,,B,,BAO_0000249,10552,,,1,CHEMBL616064,,,,H,8,2435.0,
1120,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat cortex membranes,Expert,10116.0,,B,,BAO_0000249,17136,Membranes,,1,CHEMBL616065,,,Rattus norvegicus,D,9,,
1121,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat cerebral cortex membranes,Expert,10116.0,,B,,BAO_0000249,5778,Membranes,,1,CHEMBL616066,,,Rattus norvegicus,D,9,,
1122,Binding affinity towards rat hippocampal 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,Autocuration,,,B,,BAO_0000221,13481,,,1,CHEMBL616067,,,,H,8,10000000.0,
1123,Binding affinity towards rat hippocampal 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand; Not tested,Autocuration,,,B,,BAO_0000221,13481,,,1,CHEMBL616068,,,,H,8,10000000.0,
1124,Binding affinity against rat hippocampal 5-hydroxytryptamine 1A (5-HT1A) receptor determined using [3H]8-OH-DPAT as radioligand,Intermediate,,,B,,BAO_0000221,13630,,,1,CHEMBL616069,,,,H,8,10000000.0,
1125,Binding was determined on 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,Expert,,,B,,BAO_0000249,16245,,,1,CHEMBL616070,,,,H,8,,
1126,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand,Autocuration,,,B,,BAO_0000221,14509,,,1,CHEMBL616071,,,,H,8,10000000.0,
1127,Binding affinity against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand.,Expert,,,B,,BAO_0000221,14509,,,1,CHEMBL616072,,,,H,8,10000000.0,
1128,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand.; ND = Not determined,Autocuration,,,B,,BAO_0000221,14509,,,1,CHEMBL616073,,,,H,8,10000000.0,
1129,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand; ND = Not determined,Autocuration,,,B,,BAO_0000221,14509,,,1,CHEMBL616074,,,,H,8,10000000.0,
1130,Binding affinity was evaluated by determining in vitro displacement of [3H]8-OH-DPAT from the central 5-hydroxytryptamine 1A receptor recognition site in rat frontal cortex homogenate.,Expert,,,B,,BAO_0000019,14256,,,1,CHEMBL616075,,,,H,8,,
1131,Binding affinity was evaluated by using [3H]8-OH-DPAT radioligand by using competitive binding assay on 5-hydroxytryptamine 1A receptor,Autocuration,,,B,,BAO_0000357,11139,,,1,CHEMBL616076,,,,H,8,,
1132,Binding affinity for 5-HT1A measured by displacing [3H]8-OH-DPAT from rat cortical membranes; Not determined,Expert,10116.0,,B,,BAO_0000019,11047,,,1,CHEMBL616077,,,Rattus norvegicus,D,9,,
1133,Binding affinity for 5-hydroxytryptamine 1A receptor measured by displacing [3H]8-OH-DPAT from rat cortical membranes,Expert,10116.0,,B,,BAO_0000019,11047,,,1,CHEMBL616078,,,Rattus norvegicus,D,9,,
1134,Binding affinity for 5-hydroxytryptamine 1A receptor measured by displacing [3H]8-OH-DPAT from rat cortical membranes;ND-Not determined,Expert,10116.0,,B,,BAO_0000019,11047,,,1,CHEMBL616079,,,Rattus norvegicus,D,9,,
1135,Binding affinity against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells,Expert,10116.0,,B,,BAO_0000219,2395,,485.0,1,CHEMBL616080,CHO-K1,,Rattus norvegicus,D,9,,
1136,Binding affinity towards 5-hydroxytryptamine 1A receptor,Autocuration,,,B,,BAO_0000357,9699,,,1,CHEMBL616081,,,,H,8,,
1137,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [125I]trans-8-OH-PIPAT in membrane homogenates of hippocampal tissue of rat brain,Expert,10116.0,,B,,BAO_0000221,12028,,,1,CHEMBL616082,,,Rattus norvegicus,D,9,10000000.0,
1138,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in membrane homogenates of hippocampal tissue of rat brain,Autocuration,,,B,,BAO_0000221,12028,,,1,CHEMBL616083,,,,H,8,10000000.0,
1139,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex,Autocuration,,,B,,BAO_0000019,5815,,,1,CHEMBL616084,,,,H,8,,
1140,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenates,Expert,,,B,,BAO_0000019,16616,,,1,CHEMBL616085,,,,H,8,,
1141,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]-8-OH-DPAT,Autocuration,,,B,,BAO_0000019,5815,,,1,CHEMBL616086,,,,H,8,,
1142,"Binding affinity towards 5-hydroxytryptamine 1A receptor using 0.1 nM [3H]-8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tet-ralin), from rat hippocampal homogenate",Autocuration,,,B,,BAO_0000221,2761,,,1,CHEMBL616087,,,,H,8,10000000.0,
1143,Binding affinity was determined against 5-hydroxytryptamine 1A receptor using [3H]WB-4101,Expert,,,B,,BAO_0000357,13133,,,1,CHEMBL616088,,,,H,8,,
1144,Binding affinity was determined against 5-hydroxytryptamine 1A receptor was determined in male Sprague-Dawley rat brain.,Autocuration,,,B,,BAO_0000019,10444,,,1,CHEMBL616089,,,,H,8,,
1145,Binding affinity was measured against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT by lysergic acid amides,Expert,10116.0,,B,,BAO_0000357,13278,,,1,CHEMBL616090,,,Rattus norvegicus,D,9,,
1146,Binding affinity was measured on cloned rat 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,Autocuration,,,B,,BAO_0000357,15874,,,1,CHEMBL616091,,,,H,8,,
1147,"Binding affinity of the compound towards 5-hydroxytryptamine 1A receptor sites, in rat striatum membranes using [3H]- sandoz 205-501 as radioligand",Autocuration,,,B,,BAO_0000249,10552,Membranes,,1,CHEMBL616092,,,,H,8,2435.0,
1148,Binding constant against 5-hydroxytryptamine 1A receptor (in vitro),Autocuration,,,B,,BAO_0000357,11130,,,1,CHEMBL616093,,,,H,8,,
1149,Binding constant against 5-hydroxytryptamine 1A receptor (in vivo),Autocuration,,,B,,BAO_0000218,11130,,,1,CHEMBL616094,,,,H,8,,
1150,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]-8-OH- -DPAT in rat brain cortex,Autocuration,,,B,,BAO_0000221,14542,,,1,CHEMBL616095,,,,H,8,955.0,
1151,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,Expert,10116.0,,B,,BAO_0000357,13670,,,1,CHEMBL616096,,,Rattus norvegicus,D,9,,
1152,Binding affinity at [3H]8-OH-DPAT-Labeled 5-hydroxytryptamine 1A receptor sites in rat brain hippocampal membranes,Expert,,,B,,BAO_0000249,9888,,,1,CHEMBL616097,,,,H,8,,
1153,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus membranes,Expert,10116.0,,B,,BAO_0000249,3678,Membranes,,1,CHEMBL616098,,,Rattus norvegicus,D,9,,
1154,Compound was evaluated for in vitro binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]8-OH-DPAT as radioligand,Autocuration,,,B,,BAO_0000221,11332,,,1,CHEMBL616099,,,,H,8,10000000.0,
1155,Compound was evaluated for in vitro binding affinity towards serotonin 5-hydroxytryptamine 1A receptor receptor in rat hippocampus using [3H]8-OH-DPAT as radioligand,Autocuration,,,B,,BAO_0000221,11332,,,1,CHEMBL616100,,,,H,8,10000000.0,
1156,Ability to displace [3H]-8-OH-DPAT from serotonergic 5-hydroxytryptamine 1A receptor,Expert,,,B,,BAO_0000357,1185,,,1,CHEMBL616101,,,,H,8,,
1157,Binding affinity at 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes by [3H]8-OH-DPAT displacement.,Expert,,,B,,BAO_0000249,2014,,,1,CHEMBL616102,,,,H,8,,
1158,Compound was evaluated for its ability to displace [3H]8-OH-DPAT from serotonergic 5-hydroxytryptamine 1A receptor,Autocuration,,,B,,BAO_0000357,1185,,,1,CHEMBL616103,,,,H,8,,
1159,Compound was evaluated for its binding affinity against 5-hydroxytryptamine 1A receptor from rat cerebral cortex,Expert,,,B,,BAO_0000019,14429,,,1,CHEMBL616104,,,,H,8,,
1160,"Binding affinity to 5-hydroxytryptamine 1A receptor (5-HT 1A receptor, serotonin receptor) from rat cortex using [3H]8-OH-DPAT as radioligand",Expert,,,B,,BAO_0000019,16288,,,1,CHEMBL616105,,,,H,8,,
1161,Displacement of [3H]prazosin from rat cortex membrane 5-hydroxytryptamine 1A receptor,Expert,10116.0,,B,,BAO_0000019,5432,,,1,CHEMBL616106,,,Rattus norvegicus,D,9,,
1162,Compound was evaluated for its binding affinity with 5-hydroxytryptamine 1A receptor using membranes prepared from rat cerebral cortex,Autocuration,,,B,,BAO_0000019,14429,,,1,CHEMBL616107,,,,H,8,,
1163,Binding affinity towards rat 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand.,Expert,,,B,,BAO_0000357,13672,,,1,CHEMBL616108,,,,H,8,,
1164,In vitro ability to displace [3H]8-hydroxy-2-(di-n-propylamino) tetralin binding from 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,Expert,,,B,,BAO_0000221,11296,,,1,CHEMBL616109,,,,H,8,10000000.0,
1165,In vitro ability to displace [3H]8-hydroxy-2-(di-n-propylamino) tetralin binding from 5-hydroxytryptamine 1A receptor site.,Autocuration,,,B,,BAO_0000357,11296,,,1,CHEMBL616110,,,,H,8,,
1166,Binding affinity against rat 5-hydroxytryptamine 1A receptor in CHO cells.,Expert,,,B,,BAO_0000219,14749,,449.0,1,CHEMBL616111,CHO,,,H,8,,
1167,Binding affinity towards 5-hydroxytryptamine 1A receptor from rat brain using [3H]-8-OH-DPAT as radioligand,Expert,,,B,,BAO_0000019,15086,,,1,CHEMBL616112,,,,H,8,,
1168,Compound was tested for the Binding affinity against rat hippocampal 5-hydroxytryptamine 1A receptor by Radio ligand [3H]8-OH-DPAT binding assay.,Autocuration,,,B,,BAO_0000221,13462,,,1,CHEMBL616113,,,,H,8,10000000.0,
1169,Compound was tested for the displacement of [3H]-8-OH- DPAT from rat brain 5-hydroxytryptamine 1A receptor,Autocuration,,,B,,BAO_0000019,15363,,,1,CHEMBL616114,,,,H,8,,
1170,Compound was tested for the displacement of [3H]-8-OH- DPAT from rat brain 5-hydroxytryptamine 1A receptor,Autocuration,,,B,,BAO_0000019,15363,,,1,CHEMBL616115,,,,H,8,,
1171,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 1A receptor,Autocuration,,,B,,BAO_0000357,10796,,,1,CHEMBL616116,,,,H,8,,
1172,Binding affinity for 5-hydroxytryptamine 1A receptor in rat brain tissue using [3H]8-OH-DPAT as radioligand,Expert,,,B,,BAO_0000221,12816,,,1,CHEMBL615844,,,,H,8,955.0,
1173,In vitro displacement of [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,Expert,,,B,,BAO_0000221,13542,,,1,CHEMBL615939,,,,H,8,10000000.0,
1174,In vitro ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor sites of rat brain cortex.,Expert,,,B,,BAO_0000019,13308,,,1,CHEMBL615940,,,,H,8,,
1175,In vitro affinity at 5-hydroxytryptamine 1A receptor of rat hippocampus by [3H]8-OH-DPAT displacement.,Expert,,,B,,BAO_0000221,13541,,,1,CHEMBL615941,,,,H,8,10000000.0,
1176,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-HT1A receptor of rat hippocampus and the value ranges from 9 - 12,Autocuration,,,B,,BAO_0000221,10058,,,1,CHEMBL615942,,,,H,8,10000000.0,
1177,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus,Autocuration,,,B,,BAO_0000221,10058,,,1,CHEMBL615943,,,,H,8,10000000.0,
1178,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus (94%CI) from 12 to 17,Autocuration,,,B,,BAO_0000221,10058,,,1,CHEMBL615944,,,,H,8,10000000.0,
1179,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus (94%CI) from 391-841,Autocuration,,,B,,BAO_0000221,10058,,,1,CHEMBL615945,,,,H,8,10000000.0,
1180,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 12 to 17.,Autocuration,,,B,,BAO_0000221,10058,,,1,CHEMBL615946,,,,H,8,10000000.0,
1181,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 12 to 20.,Autocuration,,,B,,BAO_0000221,10058,,,1,CHEMBL615947,,,,H,8,10000000.0,
1182,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 245 to 736,Autocuration,,,B,,BAO_0000221,10058,,,1,CHEMBL615948,,,,H,8,10000000.0,
1183,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 25 - 84,Autocuration,,,B,,BAO_0000221,10058,,,1,CHEMBL615949,,,,H,8,10000000.0,
1184,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 48 to 59,Autocuration,,,B,,BAO_0000221,10058,,,1,CHEMBL615950,,,,H,8,10000000.0,
1185,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 3 -5,Autocuration,,,B,,BAO_0000221,10058,,,1,CHEMBL615951,,,,H,8,10000000.0,
1186,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 15 - 31,Autocuration,,,B,,BAO_0000221,10058,,,1,CHEMBL615952,,,,H,8,10000000.0,
1187,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 27 - 42,Autocuration,,,B,,BAO_0000221,10058,,,1,CHEMBL615953,,,,H,8,10000000.0,
1188,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 6 - 13,Autocuration,,,B,,BAO_0000221,10058,,,1,CHEMBL615954,,,,H,8,10000000.0,
1189,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus,Expert,10116.0,,B,,BAO_0000221,10058,,,1,CHEMBL615955,,,Rattus norvegicus,D,9,10000000.0,
1190,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus.; ND is No Data.,Autocuration,,,B,,BAO_0000221,10058,,,1,CHEMBL615956,,,,H,8,10000000.0,
1191,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus. and the value ranges from 16 - 27,Autocuration,,,B,,BAO_0000221,10058,,,1,CHEMBL615957,,,,H,8,10000000.0,
1192,Displacement of [3H]2-(di-N-propylamino)-8-hydroxytetralin from central 5-hydroxytryptamine 1A receptor recognition sites in rat frontal cortex homogenates.,Expert,,,B,,BAO_0000019,12879,,,1,CHEMBL615958,,,,H,8,,
1193,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate,Expert,,,B,,BAO_0000019,11964,,,1,CHEMBL615959,,,,H,8,,
1194,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate (experiment 1),Autocuration,,,B,,BAO_0000019,11964,,,1,CHEMBL615960,,,,H,8,,
1195,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate (experiment 2),Autocuration,,,B,,BAO_0000019,11964,,,1,CHEMBL615961,,,,H,8,,
1196,Evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,Expert,,,B,,BAO_0000221,9548,,,1,CHEMBL615962,,,,H,8,955.0,
1197,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand.,Expert,,,B,,BAO_0000019,9098,,,1,CHEMBL615963,,,,H,8,,
1198,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand; ND is no data.,Autocuration,,,B,,BAO_0000019,9098,,,1,CHEMBL615964,,,,H,8,,
1199,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand;ND means no data,Autocuration,,,B,,BAO_0000019,9098,,,1,CHEMBL615965,,,,H,8,,
1200,In vitro displacement of radioactively labeled ligand [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor site in CHO cells,Expert,,,B,,BAO_0000219,13248,,449.0,1,CHEMBL615966,CHO,,,H,8,,
1201,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat cortical membranes,Expert,,,B,,BAO_0000249,3147,,,1,CHEMBL615967,,,,H,8,,
1202,In vitro binding affinity against 5-hydroxytryptamine 1A receptor of rat cerebral cortex using [3H]8-OH-DPAT as radioligand.,Expert,,,B,,BAO_0000019,13949,,,1,CHEMBL615968,,,,H,8,,
1203,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand in CHO cells (sc),Autocuration,,,B,,BAO_0000218,11883,,449.0,1,CHEMBL615969,CHO,,,H,8,,
1204,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT (agonist) as radioligand (sc),Autocuration,,,B,,BAO_0000218,11883,,,1,CHEMBL615970,,,,H,8,,
1205,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT,Expert,10116.0,,B,,BAO_0000357,11883,,,1,CHEMBL615971,,,Rattus norvegicus,D,9,,
1206,In vitro binding affinity at 5-HT1A receptors assayed by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,Expert,,,B,,BAO_0000249,15535,Membranes,,1,CHEMBL615972,,,,H,8,,
1207,In vitro binding affinity at 5-HT1A receptor by measuring its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes + cortex,Autocuration,,,B,,BAO_0000249,15535,,,1,CHEMBL615973,,,,H,8,,
1208,In vitro binding affinity at 5-HT1A receptor by measuring its ability to displace [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes+cortex,Autocuration,,,B,,BAO_0000249,15535,,,1,CHEMBL615974,,,,H,8,,
1209,Displacement of [3H]8-OH-DPAT from human 5-hydroxytryptamine 1A receptor expressed in CHO cells,Expert,9606.0,,B,,BAO_0000219,16372,,449.0,1,CHEMBL615975,CHO,,Homo sapiens,D,9,,
1210,In vitro binding affinity for 5-hydroxytryptamine 1A receptor in rat hippocampal membranes by [125I]-labeled agonist displacement.,Expert,,,B,,BAO_0000249,14608,,,1,CHEMBL615976,,,,H,8,,
1211,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus,Expert,10116.0,,B,,BAO_0000221,4795,,,1,CHEMBL872106,,,Rattus norvegicus,D,9,10000000.0,
1212,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,Autocuration,,,B,,BAO_0000357,13863,,,1,CHEMBL615977,,,,H,8,,
1213,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=100-230,Autocuration,,,B,,BAO_0000357,13863,,,1,CHEMBL615978,,,,H,8,,
1214,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=12-14,Autocuration,,,B,,BAO_0000357,13863,,,1,CHEMBL616166,,,,H,8,,
1215,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=16-20,Autocuration,,,B,,BAO_0000357,13863,,,1,CHEMBL616167,,,,H,8,,
1216,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=160-430,Autocuration,,,B,,BAO_0000357,13863,,,1,CHEMBL616168,,,,H,8,,
1217,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=174-224,Autocuration,,,B,,BAO_0000357,13863,,,1,CHEMBL616169,,,,H,8,,
1218,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=184-503,Autocuration,,,B,,BAO_0000357,13863,,,1,CHEMBL616170,,,,H,8,,
1219,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=19-23,Autocuration,,,B,,BAO_0000357,13863,,,1,CHEMBL616171,,,,H,8,,
1220,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=2.2-3.2,Autocuration,,,B,,BAO_0000357,13863,,,1,CHEMBL616172,,,,H,8,,
1221,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=2.7-3.6,Autocuration,,,B,,BAO_0000357,13863,,,1,CHEMBL616173,,,,H,8,,
1222,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=20-23,Autocuration,,,B,,BAO_0000357,13863,,,1,CHEMBL616174,,,,H,8,,
1223,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=21-28,Autocuration,,,B,,BAO_0000357,13863,,,1,CHEMBL616175,,,,H,8,,
1224,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=240-760,Autocuration,,,B,,BAO_0000357,13863,,,1,CHEMBL616176,,,,H,8,,
1225,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=39-87,Autocuration,,,B,,BAO_0000357,13863,,,1,CHEMBL616177,,,,H,8,,
1226,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=4.6-5.2,Autocuration,,,B,,BAO_0000357,13863,,,1,CHEMBL616178,,,,H,8,,
1227,Inhibitory activity tested in vitro at 5-hydroxytryptamine 1A receptor binding site in rat,Autocuration,,,B,,BAO_0000019,9742,,,1,CHEMBL616179,,,,H,8,,
1228,Inhibitory concentration against 5-hydroxytryptamine 1A receptor,Autocuration,,,B,,BAO_0000357,12073,,,1,CHEMBL616180,,,,H,8,,
1229,Inhibitory concentration against binding of 5-hydroxytryptamine 1A receptor from striata of male Wistar rats by displacement of [3H]8-OH-DPAT,Autocuration,,,B,,BAO_0000357,4101,,,1,CHEMBL616181,,,,H,8,,
1230,Inhibitory concentration against radioligand [3H]hydroxy-2-(di-n-propylamino)-tetralin binding to 5-hydroxytryptamine 1A receptor in rat,Autocuration,,,B,,BAO_0000019,15360,,,1,CHEMBL616182,,,,H,8,,
1231,Inhibitory concentration against radioligand [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,Autocuration,,,B,,BAO_0000221,11576,,,1,CHEMBL616183,,,,H,8,10000000.0,
1232,Inhibition of the 5-hydroxytryptamine 1A receptor in rat dorsal raphe,Expert,,,B,,BAO_0000019,5834,,,1,CHEMBL615874,,,,H,8,,
1233,Inhibitory concentration against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells,Expert,10116.0,,B,,BAO_0000219,2395,,485.0,1,CHEMBL615875,CHO-K1,,Rattus norvegicus,D,9,,
1234,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]OH-DPAT radioligand,Autocuration,,,B,,BAO_0000019,1375,,,1,CHEMBL615876,,,,H,8,,
1235,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]OH-DPAT radioligand; NT means not tested,Autocuration,,,B,,BAO_0000019,1375,,,1,CHEMBL615877,,,,H,8,,
1236,The compound was evaluated for the ability to displace [3H]- 8-OH -DPAT from 5-hydroxytryptamine 1A receptor ( striata of male wistar rats),Autocuration,,,B,,BAO_0000357,3967,,,1,CHEMBL615878,,,,H,8,,
1237,Binding affinity towards 5-hydroxytryptamine 1A receptor binding site using [3H]8-OH-DPAT. ,Expert,,,B,,BAO_0000357,12884,,,1,CHEMBL615879,,,,H,8,,
1238,Binding affinity towards 5-hydroxytryptamine 1A receptor using receptor binding assay,Expert,,,B,,BAO_0000357,2343,,,1,CHEMBL615880,,,,H,8,,
1239,"The compound was tested in vitro for inhibitory activity against 5-HT1A receptor in rats, using [3H]8-OH-DPAT as radioligand",Autocuration,,,B,,BAO_0000019,11511,,,1,CHEMBL615881,,,,H,8,,
1240,"Inhibitory activity against 5-hydroxytryptamine 1A receptor in rats, using [3H]8-OH-DPAT as radioligand",Expert,10116.0,,B,,BAO_0000019,11511,,,1,CHEMBL615882,,,Rattus norvegicus,D,9,,
1241,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat,Autocuration,,,F,,BAO_0000218,16394,,,1,CHEMBL615883,,,,H,8,,
1242,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.10-6.20),Autocuration,,,F,,BAO_0000218,16394,,,1,CHEMBL615884,,,,H,8,,
1243,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.20-1.60),Autocuration,,,F,,BAO_0000218,16394,,,1,CHEMBL615885,,,,H,8,,
1244,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.20-1.80),Autocuration,,,F,,BAO_0000218,16394,,,1,CHEMBL615886,,,,H,8,,
1245,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.37-4.27),Autocuration,,,F,,BAO_0000218,16394,,,1,CHEMBL615887,,,,H,8,,
1246,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.40-2.70),Autocuration,,,F,,BAO_0000218,16394,,,1,CHEMBL615888,,,,H,8,,
1247,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.40-4),Autocuration,,,F,,BAO_0000218,16394,,,1,CHEMBL615889,,,,H,8,,
1248,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.45-4.51),Autocuration,,,F,,BAO_0000218,16394,,,1,CHEMBL615890,,,,H,8,,
1249,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.50-5.30),Autocuration,,,F,,BAO_0000218,16394,,,1,CHEMBL615891,,,,H,8,,
1250,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.60-1.60),Autocuration,,,F,,BAO_0000218,16394,,,1,CHEMBL615892,,,,H,8,,
1251,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.72-2.87),Autocuration,,,F,,BAO_0000218,16394,,,1,CHEMBL615893,,,,H,8,,
1252,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.80-5.80),Autocuration,,,F,,BAO_0000218,16394,,,1,CHEMBL615894,,,,H,8,,
1253,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (1.50-16.5),Autocuration,,,F,,BAO_0000218,16394,,,1,CHEMBL615895,,,,H,8,,
1254,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (2.20-30.5),Autocuration,,,F,,BAO_0000218,16394,,,1,CHEMBL615896,,,,H,8,,
1255,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges is not computable,Autocuration,,,F,,BAO_0000218,16394,,,1,CHEMBL615897,,,,H,8,,
1256,"Percent increase of R(+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes",Expert,10116.0,,F,,BAO_0000249,16616,Membranes,,1,CHEMBL615898,,,Rattus norvegicus,D,9,,
1257,% inhibition towards 5-HT1A receptor from rat hippocampal membranes,Autocuration,,,B,,BAO_0000019,16796,,,1,CHEMBL615899,,,,H,8,,
1258,% inhibition towards 5-hydroxytryptamine 1A receptor from rat hippocampal membranes,Autocuration,,,B,,BAO_0000019,16796,,,1,CHEMBL616291,,,,H,8,,
1259,Tested in vitro for % inhibition against (serotonin)5-HT 1A receptor.,Autocuration,,,B,,BAO_0000357,15629,,,1,CHEMBL616292,,,,H,8,,
1260,"Ability to inhibit 5-HT sensitive,forskolin-stimulated adenylyl cyclase(FSC) activity in rat hippocampal membranes mediated through 5-hydroxytryptamine 1A receptor",Autocuration,,,F,,BAO_0000249,13241,,,1,CHEMBL616293,,,,H,8,,
1261,Measurement of binding affinity by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,Expert,,,B,,BAO_0000221,12073,,,1,CHEMBL616294,,,,H,8,10000000.0,
1262,Compound at 10E-5 M was tested in vitro for the inhibition of radioligand [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membrane,Autocuration,,,B,,BAO_0000249,14286,,,1,CHEMBL616295,,,,H,8,10000000.0,
1263,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]-8-OH- -DPAT in rat brain cortex at 10 uM,Autocuration,,,B,,BAO_0000221,14542,,,1,CHEMBL616296,,,,H,8,955.0,
1264,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 10 uM 5-HT.,Autocuration,,,F,,BAO_0000019,13630,,,1,CHEMBL616297,,,,H,8,,
1265,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0+ 1 uM 5-HT.,Autocuration,,,F,,BAO_0000019,13630,,,1,CHEMBL616605,,,,H,8,,
1266,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.01 uM+ 1 uM 5-HT.,Autocuration,,,F,,BAO_0000019,13630,,,1,CHEMBL616606,,,,H,8,,
1267,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM,Autocuration,,,F,,BAO_0000019,13630,,,1,CHEMBL616607,,,,H,8,,
1268,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM,Expert,,,F,,BAO_0000019,13630,,,1,CHEMBL616608,,,,H,8,,
1269,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM+ 1 uM 5-HT.,Autocuration,,,F,,BAO_0000019,13630,,,1,CHEMBL616609,,,,H,8,,
1270,Effect against 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at 0.1 uM dose,Expert,10116.0,,F,,BAO_0000019,13630,,,1,CHEMBL616610,,,Rattus norvegicus,D,9,,
1271,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 10 uM 5-HT.,Autocuration,,,F,,BAO_0000019,13630,,,1,CHEMBL616611,,,,H,8,,
1272,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 1 uM 5-HT.,Expert,,,F,,BAO_0000019,13630,,,1,CHEMBL616612,,,,H,8,,
1273,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 0.1 uM 5-HT.,Autocuration,,,F,,BAO_0000019,13630,,,1,CHEMBL616613,,,,H,8,,
1274,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 10 uM,Expert,,,F,,BAO_0000019,13630,,,1,CHEMBL616614,,,,H,8,,
1275,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 10 uM+ 10 uM 5-HT.,Autocuration,,,F,,BAO_0000019,13630,,,1,CHEMBL616615,,,,H,8,,
1276,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM,Expert,,,F,,BAO_0000019,13630,,,1,CHEMBL616616,,,,H,8,,
1277,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 0.1 uM 5-HT.,Autocuration,,,F,,BAO_0000019,13630,,,1,CHEMBL616617,,,,H,8,,
1278,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 10 uM 5-HT.,Autocuration,,,F,,BAO_0000019,13630,,,1,CHEMBL616618,,,,H,8,,
1279,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 1 uM 5-HT.,Autocuration,,,F,,BAO_0000019,13630,,,1,CHEMBL616619,,,,H,8,,
1280,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 3 uM 5-HT.,Expert,,,F,,BAO_0000019,13630,,,1,CHEMBL616620,,,,H,8,,
1281,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 50 uM 5-HT.,Expert,,,F,,BAO_0000019,13630,,,1,CHEMBL616621,,,,H,8,,
1282,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 30 uM,Autocuration,,,F,,BAO_0000019,13630,,,1,CHEMBL616622,,,,H,8,,
1283,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 50 uM,Expert,,,F,,BAO_0000019,13630,,,1,CHEMBL616146,,,,H,8,,
1284,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 50 uM+ 50 uM 5-HT.,Autocuration,,,F,,BAO_0000019,13630,,,1,CHEMBL832873,,,,H,8,,
1285,Effect on 5-hydroxytryptamine 1A receptor-mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM,Autocuration,,,F,,BAO_0000019,13630,,,1,CHEMBL616147,,,,H,8,,
1286,Effect on 5-hydroxytryptamine 1A receptor-mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 10 uM 5-HT.,Autocuration,,,F,,BAO_0000019,13630,,,1,CHEMBL872872,,,,H,8,,
1287,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM,Autocuration,,,F,,BAO_0000019,13630,,,1,CHEMBL616148,,,,H,8,,
1288,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue,Autocuration,,,B,,BAO_0000221,9783,,,1,CHEMBL616149,,,,H,8,10000000.0,
1289,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue at 1 uM,Expert,,,B,,BAO_0000221,9783,,,1,CHEMBL616150,,,,H,8,10000000.0,
1290,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membranes at 10e-7 M,Expert,10116.0,,B,,BAO_0000249,14331,Membranes,,1,CHEMBL616151,,,Rattus norvegicus,D,9,,
1291,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue at 1 uM,Expert,,,B,,BAO_0000221,15260,,,1,CHEMBL872873,,,,H,8,10000000.0,
1292,Inhibitory activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor at 0.1 uM concentration,Autocuration,,,B,,BAO_0000221,15260,,,1,CHEMBL616670,,,,H,8,10000000.0,
1293,Inhibitory activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor at 1 uM concentration,Autocuration,,,B,,BAO_0000221,15260,,,1,CHEMBL616671,,,,H,8,10000000.0,
1294,"Percent inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in hippocampal membranes",Expert,10116.0,,F,,BAO_0000249,16616,,,1,CHEMBL884861,,,Rattus norvegicus,D,9,,
1295,Tested in vitro for % inhibition against (serotonin)5-HT 1A receptor,Autocuration,,,B,,BAO_0000357,15629,,,1,CHEMBL616672,,,,H,8,,
1296,The compound was tested binding affinity against 5-hydroxytryptamine 1A receptor from rat brain using [3H]8-OH-DPAT as radioligand at 10e-6 M.,Autocuration,,,B,,BAO_0000019,15086,,,1,CHEMBL616673,,,,H,8,,
1297,Antagonistic activity against 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]8-OH-DPAT as radioligand.,Expert,,,F,,BAO_0000019,5717,,,1,CHEMBL616674,,,,H,8,,
1298,Binding affinity against the site labelled by the 5-hydroxytryptamine 1A receptor agonist [3H]- 8-OH-DPAT,Autocuration,,,B,,BAO_0000357,12652,,,1,CHEMBL616675,,,,H,8,,
1299,In vitro binding affinity for 5-hydroxytryptamine 1A receptor was determined by measuring specific inhibition of [125I]-binding to rat hippocampal membrane preparations,Autocuration,,,B,,BAO_0000221,14608,,,1,CHEMBL616676,,,,H,8,10000000.0,
1300,Inhibition of binding of [125I]-8-OH-PIPAT ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,Autocuration,,,B,,BAO_0000221,12306,,,1,CHEMBL616677,,,,H,8,10000000.0,
1301,The binding of [125I]MPPI ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,Autocuration,,,B,,BAO_0000221,12306,,,1,CHEMBL616678,,,,H,8,10000000.0,
1302,Ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,Expert,10116.0,,B,,BAO_0000357,15247,,,1,CHEMBL616679,,,Rattus norvegicus,D,9,,
1303,Ability to bind to central serotonin 5-hydroxytryptamine 1A receptor in vitro in hippocampus of the rat brain using [3H]8-OH-DPAT radioligand,Expert,,,B,,BAO_0000221,17529,,,1,CHEMBL616680,,,,H,8,10000000.0,
1304,Ability to displace [3H]- -OH-DPAT bound to 5-hydroxytryptamine 1A receptor in rat hippocampus,Autocuration,,,B,,BAO_0000221,14826,,,1,CHEMBL616681,,,,H,8,10000000.0,
1305,Ability to displace [3H]- -(OH)-DPAT bound to 5-hydroxytryptamine 1A receptor in rat hippocampus,Autocuration,,,B,,BAO_0000221,14826,,,1,CHEMBL616682,,,,H,8,10000000.0,
1306,Ability to displace [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,Autocuration,,,B,,BAO_0000221,13241,,,1,CHEMBL616683,,,,H,8,10000000.0,
1307,Ability to displace [3H]-8-OH-DPAT from rat hippocampal homogenate 5-hydroxytryptamine 1A receptor,Autocuration,,,B,,BAO_0000221,14093,,,1,CHEMBL616684,,,,H,8,10000000.0,
1308,Ability to displace [3H]-8-OH-DPAT from rat hippocampal homogenate 5-hydroxytryptamine 1A receptor; Not tested,Autocuration,,,B,,BAO_0000221,14093,,,1,CHEMBL616685,,,,H,8,10000000.0,
1309,Affinity at [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor in rat brain homogenate was determined,Autocuration,,,B,,BAO_0000221,14442,,,1,CHEMBL616686,,,,H,8,955.0,
1310,Affinity for 5-hydroxytryptamine 1A receptor site,Autocuration,,,B,,BAO_0000357,9919,,,1,CHEMBL616687,,,,H,8,,
1311,Affinity for 5-hydroxytryptamine 1A receptor site,Autocuration,,,B,,BAO_0000357,9919,,,1,CHEMBL616688,,,,H,8,,
1312,Affinity in displacing [3H]8-OH-DPAT from rat hippocampal 5-HT1A receptor.,Autocuration,,,B,,BAO_0000221,11440,,,1,CHEMBL616689,,,,H,8,10000000.0,
1313,Affinity on 5-hydroxytryptamine 1A receptor labeled by [3H]8-OH-DPAT,Autocuration,,,B,,BAO_0000357,11257,,,1,CHEMBL616690,,,,H,8,,
1314,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand,Expert,,,B,,BAO_0000357,10330,,,1,CHEMBL616691,,,,H,8,,
1315,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus mambranes,Expert,10116.0,,B,,BAO_0000221,17331,,,1,CHEMBL616692,,,Rattus norvegicus,D,9,10000000.0,
1316,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane,Expert,,,B,,BAO_0000249,16567,,,1,CHEMBL616693,,,,H,8,,
1317,"Binding affinity against 5-hydroxytryptamine 1A receptor in homogenated rat brain tissue, using by [3H]8-OH-DPAT as radioligand",Expert,10116.0,,B,,BAO_0000019,12058,,,1,CHEMBL616694,,,Rattus norvegicus,D,9,,
1318,Binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal tissue,Autocuration,,,B,,BAO_0000221,9699,,,1,CHEMBL616695,,,,H,8,10000000.0,
1319,Binding affinity against 5-hydroxytryptamine 1A receptor of rat was determined using [3H]8-OH-DPAT in binding assay,Autocuration,,,B,,BAO_0000357,9547,,,1,CHEMBL616696,,,,H,8,,
1320,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]DOB as radioligand,Autocuration,,,B,,BAO_0000357,10330,,,1,CHEMBL616697,,,,H,8,,
1321,Binding affinity against rat 5-hydroxytryptamine 1A receptor,Autocuration,,,B,,BAO_0000357,14331,,,1,CHEMBL616698,,,,H,8,,
1322,Binding affinity against rat brain 5-hydroxytryptamine 1A receptor,Expert,10116.0,,B,,BAO_0000019,14060,,,1,CHEMBL616949,,,Rattus norvegicus,D,9,,
1323,Binding affinity against the 5-hydroxytryptamine 1A receptor labelled with [3H]8-OH-DPAT in rat hippocampal homogenates,Autocuration,,,B,,BAO_0000221,14744,,,1,CHEMBL616950,,,,H,8,10000000.0,
1324,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT binding assay,Autocuration,,,B,,BAO_0000357,13506,,,1,CHEMBL832875,,,,H,8,,
1325,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,Expert,,,B,,BAO_0000221,10862,,,1,CHEMBL616951,,,,H,8,955.0,
1326,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,Expert,,,B,,BAO_0000221,10862,,,1,CHEMBL616952,,,,H,8,955.0,
1327,Binding affinity at rat 5-hydroxytryptamine 1A receptor by [3H]WB-4101 displacement.,Expert,,,B,,BAO_0000357,10062,,,1,CHEMBL616953,,,,H,8,,
1328,Binding affinity for 5-hydroxytryptamine 1A receptor by use of [3H]8-OH-DPAT in male rat,Autocuration,,,B,,BAO_0000357,12073,,,1,CHEMBL616954,,,,H,8,,
1329,GTPgammaS radioligand binding assay,Autocuration,,,B,,BAO_0000357,14875,,,1,CHEMBL616955,,,,H,8,,
1330,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Not determined,Autocuration,,,B,,BAO_0000357,2391,,,1,CHEMBL616956,,,,H,8,,
1331,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Partial agonist,Autocuration,,,F,,BAO_0000019,2391,,,1,CHEMBL616957,,,,H,8,,
1332,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Slient antagonist,Autocuration,,,F,,BAO_0000019,2391,,,1,CHEMBL616958,,,,H,8,,
1333,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor,Autocuration,,,B,,BAO_0000357,2391,,,1,CHEMBL616959,,,,H,8,,
1334,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Not determined,Autocuration,,,B,,BAO_0000357,2391,,,1,CHEMBL616960,,,,H,8,,
1335,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; silent antagonist,Autocuration,,,F,,BAO_0000019,2391,,,1,CHEMBL616961,,,,H,8,,
1336,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor,Expert,,,B,,BAO_0000219,17211,,308.0,1,CHEMBL616962,HeLa,,,H,8,,
1337,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor receptor,Autocuration,,,B,,BAO_0000219,17211,,308.0,1,CHEMBL616963,HeLa,,,H,8,,
1338,Affinity towards human 5-hydroxytryptamine 1B serotonin receptor,Expert,9606.0,,B,,BAO_0000357,6491,,,1,CHEMBL616524,,,Homo sapiens,D,9,,
1339,Binding affinity against 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as radioligand,Autocuration,,,B,,BAO_0000219,16190,,449.0,1,CHEMBL616525,CHO,,,H,8,,
1340,Binding affinity for 5-hydroxytryptamine 1B receptor in C6-glial transfected cell type using [3H]5-CT as radioligand,Autocuration,,,B,,BAO_0000019,14165,,,1,CHEMBL872908,,,,H,8,,
1341,Binding affinity for 5-hydroxytryptamine 1B receptor in C6-glial transfected cell type using [3H]GR-125743 as radioligand,Autocuration,,,B,,BAO_0000019,14165,,,1,CHEMBL616526,,,,H,8,,
1342,Binding affinity to cloned human 5-hydroxytryptamine 1B receptor,Expert,9606.0,,B,,BAO_0000357,4234,,,1,CHEMBL616527,,,Homo sapiens,D,9,,
1343,Binding affinity towards human 5-hydroxytryptamine 1B receptor in L-M(tk-) cells using [3H]GR-125743 as radioligand,Expert,,,B,,BAO_0000219,6328,,,1,CHEMBL616528,,,,H,8,,
1344,Binding affinity for recombinant human 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,Autocuration,,,B,,BAO_0000357,14770,,,1,CHEMBL616529,,,,H,8,,
1345,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1B receptor using [3H]5-CT as radioligand,Autocuration,,,B,,BAO_0000357,2598,,,1,CHEMBL616530,,,,H,8,,
1346,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1B receptor,Expert,,,B,,BAO_0000357,6897,,,1,CHEMBL616531,,,,H,8,,
1347,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1B receptor,Autocuration,,,B,,BAO_0000357,6897,,,1,CHEMBL616532,,,,H,8,,
1348,Binding affinity towards 5-hydroxytryptamine 1B receptor,Autocuration,,,B,,BAO_0000357,6013,,,1,CHEMBL616533,,,,H,8,,
1349,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor,Expert,,,B,,BAO_0000357,5843,,,1,CHEMBL616534,,,,H,8,,
1350,Binding affinity towards human 5-hydroxytryptamine 1B receptor using [3H]5-HT trifluoroacetate as radioligand,Expert,,,B,,BAO_0000357,14454,,,1,CHEMBL616535,,,,H,8,,
1351,Binding affinity towards human 5-hydroxytryptamine 1B receptor using [3H]5-HT radioligand,Autocuration,,,B,,BAO_0000357,16209,,,1,CHEMBL616536,,,,H,8,,
1352,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1B receptor,Autocuration,,,B,,BAO_0000357,3935,,,1,CHEMBL616537,,,,H,8,,
1353,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1B receptor in CHO-K1 cells,Expert,,,F,,BAO_0000219,13729,,485.0,1,CHEMBL616538,CHO-K1,,,H,8,,
1354,Agonist activity to the human recombinant 5-hydroxytryptamine 1B receptor,Expert,,,F,,BAO_0000019,14251,,,1,CHEMBL616539,,,,H,8,,
1355,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1B receptor,Expert,,,B,,BAO_0000019,17085,,,1,CHEMBL616540,,,,H,8,,
1356,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1B receptor using [3H]5-CT radioligand,Autocuration,,,B,,BAO_0000357,3025,,,1,CHEMBL616429,,,,H,8,,
1357,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1B receptor,Expert,,,B,,BAO_0000357,15315,,,1,CHEMBL616430,,,,H,8,,
1358,Receptor binding affinity for cloned human 5-hydroxytryptamine 1B receptor in Cos-7 cells,Expert,9606.0,,B,,BAO_0000219,14214,,,1,CHEMBL616431,,,Homo sapiens,D,9,,
1359,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor,Expert,9606.0,,B,,BAO_0000357,3804,,,1,CHEMBL616432,,,Homo sapiens,D,9,,
1360,Affinity for 5-hydroxytryptamine 1B receptor subtype,Expert,9606.0,,B,,BAO_0000357,2391,,,1,CHEMBL616433,,,Homo sapiens,D,9,,
1361,Binding affinity for human 5-hydroxytryptamine 1B receptor,Expert,9606.0,,B,,BAO_0000357,4175,,,1,CHEMBL616434,,,Homo sapiens,D,9,,
1362,Binding affinity against cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-CT as radioligand; Not determined,Autocuration,,,B,,BAO_0000219,17296,,449.0,1,CHEMBL616435,CHO,,,H,8,,
1363,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1B receptor; ND means not determined,Expert,,,B,,BAO_0000019,17085,,,1,CHEMBL616436,,,,H,8,,
1364,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT denotes not tested,Autocuration,,,B,,BAO_0000219,17211,,308.0,1,CHEMBL616437,HeLa,,,H,8,,
1365,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT=not tested,Autocuration,,,B,,BAO_0000219,17211,,308.0,1,CHEMBL616438,HeLa,,,H,8,,
1366,Ability to displace [3H]-5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT denotes not tested,Autocuration,,,B,,BAO_0000219,17211,,308.0,1,CHEMBL616439,HeLa,,,H,8,,
1367,Binding activity against human 5-hydroxytryptamine 1B receptor; NT means not tested,Expert,9606.0,,B,,BAO_0000357,15926,,,1,CHEMBL616440,,,Homo sapiens,D,9,,
1368,Binding affinity in CHO-K1 cells transfected with human recombinant 5-hydroxytryptamine 1B receptor; not tested,Autocuration,,,B,,BAO_0000219,16312,,485.0,1,CHEMBL616441,CHO-K1,,,H,8,,
1369,Selectivity ratio against cloned human 5-HT1B receptor to that of h5-HT1D receptor,Expert,,,B,,BAO_0000357,5843,,,1,CHEMBL616442,,,,H,8,,
1370,Selectivity ratio against cloned human 5-hydroxytryptamine 1B receptor to that of human 5-hydroxytryptamine 1D receptor,Autocuration,,,B,,BAO_0000357,5843,,,1,CHEMBL616443,,,,H,8,,
1371,Binding affinity in CHO-K1 cells transfected with human recombinant 5-hydroxytryptamine 1B receptor,Expert,,,B,,BAO_0000219,16312,,485.0,1,CHEMBL616444,CHO-K1,,,H,8,,
1372,Binding activity against human 5-hydroxytryptamine 1B receptor,Expert,9606.0,,B,,BAO_0000357,15926,,,1,CHEMBL616445,,,Homo sapiens,D,9,,
1373,Binding activity against human 5-hydroxytryptamine 1B receptor,Expert,9606.0,,B,,BAO_0000357,15926,,,1,CHEMBL616446,,,Homo sapiens,D,9,,
1374,Binding affinity to human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as radioligand,Expert,9606.0,,B,,BAO_0000219,4540,,449.0,1,CHEMBL616447,CHO,,Homo sapiens,D,9,,
1375,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor was determined,Autocuration,,,B,,BAO_0000357,6166,,,1,CHEMBL616448,,,,H,8,,
1376,Binding affinity against cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-CT as radioligand,Autocuration,,,B,,BAO_0000219,17296,,449.0,1,CHEMBL616449,CHO,,,H,8,,
1377,Binding affinity against human 5-hydroxytryptamine 1B receptor cloned receptors in CHO cells,Autocuration,,,B,,BAO_0000219,17296,,449.0,1,CHEMBL616450,CHO,,,H,8,,
1378,Binding affinity against human 5-hydroxytryptamine 1B receptor cloned receptors in CHO cells using [3H]5-CT as radioligand,Autocuration,,,B,,BAO_0000219,17296,,449.0,1,CHEMBL857974,CHO,,,H,8,,
1379,Binding affinity towards 5-hydroxytryptamine 1B (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,Autocuration,,,B,,BAO_0000219,15779,,449.0,1,CHEMBL616451,CHO,,,H,8,,
1380,Binding affinity towards 5-hydroxytryptamine 1B receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,Autocuration,,,B,,BAO_0000219,15779,,449.0,1,CHEMBL616452,CHO,,,H,8,,
1381,Binding affinity towards 5-hydroxytryptamine 1B receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand;ND means no data.,Autocuration,,,B,,BAO_0000219,15779,,449.0,1,CHEMBL616453,CHO,,,H,8,,
1382,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as the radioligand,Autocuration,,,B,,BAO_0000219,4199,,449.0,1,CHEMBL616454,CHO,,,H,8,,
1383,Binding affinity for human 5-hydroxytryptamine 1B receptor,Expert,9606.0,,B,,BAO_0000357,14875,,,1,CHEMBL616455,,,Homo sapiens,D,9,,
1384,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT,Autocuration,,,B,,BAO_0000219,15146,,449.0,1,CHEMBL616456,CHO,,,H,8,,
1385,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1B receptor in CHO using [3H]5-HT as a radioligand,Autocuration,,,B,,BAO_0000357,5213,,,1,CHEMBL616457,,,,H,8,,
1386,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT,Autocuration,,,B,,BAO_0000219,14818,,449.0,1,CHEMBL616458,CHO,,,H,8,,
1387,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1B receptor in CHO cells, using [3H]5-HT as radioligand",Autocuration,,,B,,BAO_0000219,4829,,449.0,1,CHEMBL616459,CHO,,,H,8,,
1388,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1B receptor at concentration 1 uM,Expert,,,F,,BAO_0000019,14454,,,1,CHEMBL616460,,,,H,8,,
1389,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1B receptor at concentration 10 uM,Expert,,,F,,BAO_0000019,14454,,,1,CHEMBL616461,,,,H,8,,
1390,"Effect of compound on [35S]GTP-gamma-S, radioligand binding CHO cells expressing human 5-hydroxytryptamine 1B receptor",Autocuration,,,F,,BAO_0000219,14875,,449.0,1,CHEMBL616462,CHO,,,H,8,,
1391,"Effect of compound on [35S]GTP-gamma-S, radioligand binding in CHO cells expressing human 5-hydroxytryptamine 1B receptor",Autocuration,,,F,,BAO_0000219,14875,,449.0,1,CHEMBL616463,CHO,,,H,8,,
1392,"Compound was tested for maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by 5-HT.",Autocuration,,,F,,BAO_0000019,15250,,,1,CHEMBL616464,,,,H,8,,
1393,Compound was tested for the displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1D receptor stably expressed in CHO cells.,Autocuration,,,B,,BAO_0000219,15250,,449.0,1,CHEMBL616465,CHO,,,H,8,,
1394,The compound was tested for binding affinity against 5-hydroxytryptamine 1B receptor,Autocuration,,,B,,BAO_0000357,15086,,,1,CHEMBL832874,,,,H,8,,
1395,5-hydroxytryptamine 1B receptor agonist potency determined in rabbit saphenous vein contraction model,Autocuration,9986.0,,F,,BAO_0000019,3025,,,1,CHEMBL616184,,,Oryctolagus cuniculus,H,8,,
1396,The vascular 5-hydroxytryptamine 1B receptor affinity was assessed using ring preparations of rabbit saphenous vein (RbSV).,Autocuration,9986.0,,B,,BAO_0000019,14998,,,1,CHEMBL616185,,,Oryctolagus cuniculus,H,8,,
1397,"Binding affinity against vascular 5-hydroxytryptamine 1B receptor, measured using ring preparations of rabbit saphenous vein (RbSV)",Intermediate,9986.0,,B,,BAO_0000019,14998,,,1,CHEMBL616186,,,Oryctolagus cuniculus,H,8,,
1398,The vascular 5-hydroxytryptamine 1B receptor affinity was assessed using ring preparations of rabbit saphenous vein(RbSV).,Autocuration,9986.0,,B,,BAO_0000019,14998,,,1,CHEMBL616187,,,Oryctolagus cuniculus,H,8,,
1399,Binding affinity towards 5-hydroxytryptamine 1B receptor was measured using [3H]5-HT as radioligand,Expert,,,B,,BAO_0000357,13969,,,1,CHEMBL616188,,,,H,8,,
1400,Binding affinity for 5-hydroxytryptamine 1B receptor,Intermediate,,,B,,BAO_0000357,13392,,,1,CHEMBL873475,,,,D,9,,
1401,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatum; Less active,Expert,10116.0,,B,,BAO_0000019,3651,,,1,CHEMBL616189,,,Rattus norvegicus,D,9,2435.0,
1402,Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol binding to 5-hydroxytryptamine 1B receptor at 1 uM,Expert,,,B,,BAO_0000357,10025,,,1,CHEMBL616190,,,,H,8,,
1403,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=48-77,Autocuration,,,B,,BAO_0000357,13863,,,1,CHEMBL616191,,,,H,8,,
1404,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=63-95,Autocuration,,,B,,BAO_0000357,13863,,,1,CHEMBL616192,,,,H,8,,
1405,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=710-980,Autocuration,,,B,,BAO_0000357,13863,,,1,CHEMBL616193,,,,H,8,,
1406,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=78-140,Autocuration,,,B,,BAO_0000357,13863,,,1,CHEMBL616194,,,,H,8,,
1407,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=85-130,Autocuration,,,B,,BAO_0000357,13863,,,1,CHEMBL616195,,,,H,8,,
1408,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=89-280,Autocuration,,,B,,BAO_0000357,13863,,,1,CHEMBL616196,,,,H,8,,
1409,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat hippocampus membrane.,Autocuration,,,B,,BAO_0000249,4622,,,1,CHEMBL616197,,,,H,8,10000000.0,
1410,Binding affinity at 5-hydroxytryptamine 1A (5-HT1A) receptor in rat cerebral cortex using [3H]8-OH-DPAT as radioligand,Intermediate,,,B,,BAO_0000019,14911,,,1,CHEMBL616198,,,,H,8,,
1411,In vitro binding affinity to 5-hydroxytryptamine 1A receptor using [125I](R)-(+)-trans-8-OH-PIPAT as radioligand in rat hippocampal homogenate,Autocuration,,,B,,BAO_0000221,12678,,,1,CHEMBL616199,,,,H,8,10000000.0,
1412,In vitro binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampal homogenate by [125I](R)-(+)-trans-8-OH-PIPAT displacement.,Expert,,,B,,BAO_0000221,12678,,,1,CHEMBL616200,,,,H,8,10000000.0,
1413,In vitro binding affinity to rat hippocampal 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,Expert,,,B,,BAO_0000221,14235,,,1,CHEMBL616201,,,,H,8,10000000.0,
1414,In vitro binding affinity towards 5-hydroxytryptamine 1A r receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates,Expert,,,B,,BAO_0000221,14949,,,1,CHEMBL616202,,,,H,8,10000000.0,
1415,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates,Expert,,,B,,BAO_0000221,14949,,,1,CHEMBL616203,,,,H,8,10000000.0,
1416,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; ND=not determined,Expert,,,B,,BAO_0000221,14949,,,1,CHEMBL616204,,,,H,8,10000000.0,
1417,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; Not determined,Expert,,,B,,BAO_0000221,14949,,,1,CHEMBL616205,,,,H,8,10000000.0,
1418,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; not determined,Expert,,,B,,BAO_0000221,14949,,,1,CHEMBL616206,,,,H,8,10000000.0,
1419,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes,Expert,,,B,,BAO_0000249,16118,,,1,CHEMBL616207,,,,H,8,,
1420,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membranes,Autocuration,,,B,,BAO_0000249,3268,,,1,CHEMBL616208,,,,H,8,,
1421,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membranes; Inactive,Autocuration,,,B,,BAO_0000249,3268,,,1,CHEMBL616209,,,,H,8,,
1422,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using radioligand [3H]-8-OH-DPAT,Expert,,,B,,BAO_0000357,16117,,,1,CHEMBL616210,,,,H,8,,
1423,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue.,Expert,,,B,,BAO_0000221,9783,,,1,CHEMBL616211,,,,H,8,10000000.0,
1424,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue; NT=Not tested,Autocuration,,,B,,BAO_0000221,9783,,,1,CHEMBL616504,,,,H,8,10000000.0,
1425,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor,Expert,10116.0,,B,,BAO_0000221,14356,,,1,CHEMBL616505,,,Rattus norvegicus,D,9,10000000.0,
1426,Inhibition constant of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor,Autocuration,,,F,,BAO_0000019,15740,,,1,CHEMBL616506,,,,H,8,,
1427,Inhibition of binding of [125I]8-OH-PIPAT ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,Autocuration,,,B,,BAO_0000221,12306,,,1,CHEMBL872107,,,,H,8,10000000.0,
1428,Displacement of [3H]5-HT from rat hippocampal 5-hydroxytryptamine 1A receptor with 10e-6 M ketanserin,Expert,10116.0,,B,,BAO_0000221,13348,,,1,CHEMBL616507,,,Rattus norvegicus,D,9,10000000.0,
1429,Inhibitory activity against 5-hydroxytryptamine 1A receptor in rat cortical membranes using [3H]8-OH-DPAT as a radioligand,Autocuration,,,B,,BAO_0000249,10394,,,1,CHEMBL616303,,,,H,8,,
1430,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue,Autocuration,,,B,,BAO_0000221,15260,,,1,CHEMBL616304,,,,H,8,10000000.0,
1431,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,Expert,,,B,,BAO_0000221,10046,,,1,CHEMBL616305,,,,H,8,10000000.0,
1432,Antagonist activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor,Intermediate,,,F,,BAO_0000221,15260,,,1,CHEMBL616306,,,,H,8,10000000.0,
1433,Inhibitory affinity constant against 5-hydroxytryptamine 1A receptor,Autocuration,,,B,,BAO_0000357,12851,,,1,CHEMBL616307,,,,H,8,,
1434,Displacement of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat brain hippocampus,Expert,10116.0,,B,,BAO_0000221,2148,,,1,CHEMBL881829,,,Rattus norvegicus,D,9,10000000.0,
1435,Affinity against the 5-hydroxytryptamine receptor 1A using [3H]WB-4101.,Expert,,,B,,BAO_0000357,13134,,,1,CHEMBL616308,,,,H,8,,
1436,Tested for affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in homogenized rat brain,Autocuration,,,B,,BAO_0000019,12462,,,1,CHEMBL616309,,,,H,8,,
1437,Tested for affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in homogenized rat brain tissue,Expert,,,B,,BAO_0000019,12462,,,1,CHEMBL616310,,,,H,8,,
1438,Tested for affinity against 5-hydroxytryptamine 1A receptors using [3H]8-OH-DPAT in homogenized rat cloned CHO cells,Autocuration,,,B,,BAO_0000219,12462,,449.0,1,CHEMBL616311,CHO,,,H,8,,
1439,Tested for binding affinity against 5-hydroxytryptamine 1A receptor from rat frontal cortical regions using [3H]8-OH-DPAT as radioligand,Expert,,,B,,BAO_0000357,11933,,,1,CHEMBL616312,,,,H,8,,
1440,Tested for binding affinity against 5-hydroxytryptamine 1A receptor from rat frontal cortical regions using [3H]8-OH-DPAT as radioligand; ND is Not Determined,Autocuration,,,B,,BAO_0000357,11933,,,1,CHEMBL616313,,,,H,8,,
1441,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor,Expert,10116.0,,B,,BAO_0000221,403,,,1,CHEMBL616314,,,Rattus norvegicus,D,9,10000000.0,
1442,Tested for binding affinity by measuring displacement of [3H]8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus,Autocuration,,,B,,BAO_0000221,15538,,,1,CHEMBL616315,,,,H,8,10000000.0,
1443,Tested for binding affinity by measuring displacement of [3H]8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus; NA means Not Active,Autocuration,,,B,,BAO_0000221,15538,,,1,CHEMBL616567,,,,H,8,10000000.0,
1444,Tested for binding affinity by measuring displacement of [3H]-8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus; ND means Not Determined,Autocuration,,,B,,BAO_0000221,15538,,,1,CHEMBL616568,,,,H,8,10000000.0,
1445,Binding affinity to displace [3H]2-(di-N-propylamino)-8-hydroxy-tetralin from 5-hydroxytryptamine 1A (5-HT1A) receptor in rat frontal cortex homogenates,Intermediate,,,B,,BAO_0000019,12464,,,1,CHEMBL616569,,,,H,8,,
1446,Binding affinity to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand assay.,Expert,,,B,,BAO_0000357,1455,,,1,CHEMBL616570,,,,H,8,,
1447,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 1A receptor agonist [3H]- 8-OH-DPAT,Autocuration,,,B,,BAO_0000357,12652,,,1,CHEMBL616571,,,,H,8,,
1448,Tested for the inhibitory activity against 5-hydroxytryptamine 1A receptor in rat hippocampal,Autocuration,,,B,,BAO_0000221,12639,,,1,CHEMBL616572,,,,H,8,10000000.0,
1449,Tested in vitro for binding affinity by measuring its ability to inhibit [3H]8-OH-DPAT binding at 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes.,Expert,,,B,,BAO_0000249,13949,,,1,CHEMBL616573,,,,H,8,,
1450,Tested in vitro for receptor binding affinity against 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT,Expert,10116.0,,B,,BAO_0000357,12463,,,1,CHEMBL616574,,,Rattus norvegicus,D,9,,
1451,The binding affinity by measuring its ability to displace [3H]8-OH-DPAT radioligand in 5-hydroxytryptamine 1A receptor on rat hippocampal preparation,Expert,,,B,,BAO_0000221,14829,,,1,CHEMBL616575,,,,H,8,10000000.0,
1452,The binding affinity by measuring its ability to displace [3H]8-OH-DPAT radioligand in 5-hydroxytryptamine 1A receptor on rat hippocampal preparation; ND=not determined,Autocuration,,,B,,BAO_0000221,14829,,,1,CHEMBL872108,,,,H,8,10000000.0,
1453,The binding affinity was measured on 5-hydroxytryptamine 1A receptor using [3H]- 8-OH-DPAT as radioligand.,Autocuration,,,B,,BAO_0000357,12092,,,1,CHEMBL616576,,,,H,8,,
1454,The compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal membranes using [3H]8-OH-DPAT as radioligand in the presence of 1 mM of MnCl2,Autocuration,,,B,,BAO_0000249,403,,,1,CHEMBL616577,,,,H,8,,
1455,The compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal membranes using [3H]8-OH-DPAT as radioligand in the presence of 3*10e-5 M GTP gamma S,Autocuration,,,B,,BAO_0000249,403,,,1,CHEMBL616578,,,,H,8,,
1456,Binding affinity at 5-hydroxytryptamine 1A receptor from striata of wistar rats by [3H]- 8-OH -DPAT displacement.,Expert,,,B,,BAO_0000357,3967,,,1,CHEMBL616579,,,,H,8,,
1457,Binding affinity towards 5-hydroxytryptamine 1A receptor of rat brain synaptosomal preparations,Expert,10116.0,,B,,BAO_0000019,12771,,,1,CHEMBL616580,,,Rattus norvegicus,D,9,,
1458,The compound was tested binding affinity against 5-hydroxytryptamine 1A receptor from rat brain using [3H]8-OH-DPAT as radioligand at 10e-6 M.,Autocuration,,,B,,BAO_0000019,15086,,,1,CHEMBL616581,,,,H,8,,
1459,The compound was tested for binding affinity on [3H]8-OH-DPAT as specific ligand on 5-hydroxytryptamine 1A receptor in rat hippocampus,Autocuration,,,B,,BAO_0000221,14909,,,1,CHEMBL616582,,,,H,8,10000000.0,
1460,The compound was tested for binding affinity on [3H]8-OH-DPAT as specific ligand on 5-hydroxytryptamine 1A receptor in rat hippocampus,Expert,,,B,,BAO_0000221,14949,,,1,CHEMBL616583,,,,H,8,10000000.0,
1461,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampus using [3H]8-OH-DPAT,Expert,10116.0,,B,,BAO_0000221,2309,,,1,CHEMBL616584,,,Rattus norvegicus,D,9,10000000.0,
1462,Binding affinity towards 5-hydroxytryptamine 1A receptor,Expert,,,B,,BAO_0000357,4170,,,1,CHEMBL616585,,,,H,8,,
1463,Binding affinity towards 5-hydroxytryptamine 1A receptor by displacing [3H]WB-4101 from rat hippocampus,Expert,10116.0,,B,,BAO_0000221,11642,,,1,CHEMBL616586,,,Rattus norvegicus,D,9,10000000.0,
1464,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1A receptor by displacing [3H]WB-4101 radioligand in rat hippocampus,Autocuration,,,B,,BAO_0000221,11642,,,1,CHEMBL616587,,,,H,8,10000000.0,
1465,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]-8-OH-DPAT as radioligand,Autocuration,,,B,,BAO_0000221,12953,,,1,CHEMBL616588,,,,H,8,10000000.0,
1466,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as radioligand.,Autocuration,,,B,,BAO_0000221,12953,,,1,CHEMBL616589,,,,H,8,10000000.0,
1467,Binding affinity for 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as radioligand,Expert,,,B,,BAO_0000221,12953,,,1,CHEMBL616590,,,,H,8,10000000.0,
1468,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1A receptor expressed in CHO cells, by using [3H]8-OH-DPAT as radioligand.",Expert,,,B,,BAO_0000219,12903,,449.0,1,CHEMBL616591,CHO,,,H,8,,
1469,Displacement of the radioligand [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,Expert,,,B,,BAO_0000357,12536,,,1,CHEMBL616592,,,,H,8,,
1470,The inhibition activity of 5-HT1A at 1 uM,Autocuration,,,B,,BAO_0000357,10058,,,1,CHEMBL616593,,,,H,8,,
1471,"Binding affinity against 5-hydroxytryptamine 1A receptor from CHO-K1 cells, using [3H]8-OH-DPAT as the radioligand.",Expert,,,B,,BAO_0000219,12902,,485.0,1,CHEMBL616594,CHO-K1,,,H,8,,
1472,Binding affinities against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membrane,Expert,,,B,,BAO_0000249,14057,,,1,CHEMBL616595,,,,H,8,,
1473,Compound was evaluated for its ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-HT 1A receptor site.,Autocuration,,,B,,BAO_0000357,11296,,,1,CHEMBL616596,,,,H,8,,
1474,Compound was evaluated for its ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,Autocuration,,,B,,BAO_0000221,11296,,,1,CHEMBL616597,,,,H,8,10000000.0,
1475,Ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,Expert,,,B,,BAO_0000221,11296,,,1,CHEMBL616598,,,,H,8,10000000.0,
1476,Antagonist activity to stimulate binding of [35S]-GTP-gamma S binding to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes,Expert,10116.0,,F,,BAO_0000249,16616,Membranes,,1,CHEMBL616599,,,Rattus norvegicus,D,9,,
1477,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding in rat hippocampal membranes",Expert,10116.0,,F,,BAO_0000249,16616,Membranes,,1,CHEMBL616600,,,Rattus norvegicus,D,9,10000000.0,
1478,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not -determined.,Autocuration,,,B,,BAO_0000019,16567,,,1,CHEMBL616601,,,,H,8,,
1479,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not defined.,Autocuration,,,B,,BAO_0000019,16567,,,1,CHEMBL616602,,,,H,8,,
1480,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not determined.,Autocuration,,,B,,BAO_0000019,16567,,,1,CHEMBL616603,,,,H,8,,
1481,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND means not determined.,Autocuration,,,B,,BAO_0000019,16567,,,1,CHEMBL616604,,,,H,8,,
1482,Binding affinity towards 5-hydroxytryptamine 1A receptor was determined in rat cortex membranes using [3H]8-OH-DPAT as radioligand; No data,Autocuration,,,B,,BAO_0000249,17136,,,1,CHEMBL616316,,,,H,8,,
1483,Binding affinity towards 5-hydroxytryptamine 1A receptor was determined in rat cortex membranes using [3H]8-OH-DPAT as radioligand; Not determined,Autocuration,,,B,,BAO_0000249,17136,,,1,CHEMBL616317,,,,H,8,,
1484,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenates; ND means No data,Expert,10116.0,,B,,BAO_0000019,16616,,,1,CHEMBL616318,,,Rattus norvegicus,D,9,,
1485,Binding affinity against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT from rat hippocampus mambranes,Autocuration,,,B,,BAO_0000221,17331,,,1,CHEMBL616319,,,,H,8,10000000.0,
1486,Binding affinity against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT from rat hippocampus mambranes; Not tested,Autocuration,,,B,,BAO_0000221,17331,,,1,CHEMBL616320,,,,H,8,10000000.0,
1487,Binding affinity for rat hippocampus 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding; Not tested,Expert,10116.0,,B,,BAO_0000221,17167,,,1,CHEMBL616321,,,Rattus norvegicus,D,9,10000000.0,
1488,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; Not tested,Autocuration,,,F,,BAO_0000019,15740,,,1,CHEMBL616322,,,,H,8,,
1489,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; not tested,Autocuration,,,F,,BAO_0000019,15740,,,1,CHEMBL616323,,,,H,8,,
1490,Ratio of binding affinity to 5-HT 1A and D2 receptor,Autocuration,,,B,,BAO_0000357,4671,,,1,CHEMBL616324,,,,H,8,,
1491,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus at 1 uM,Autocuration,,,B,,BAO_0000221,10058,,,1,CHEMBL616325,,,,H,8,10000000.0,
1492,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus at 1 uM,Autocuration,,,B,,BAO_0000221,10058,,,1,CHEMBL616326,,,,H,8,10000000.0,
1493,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus.,Autocuration,,,B,,BAO_0000221,10058,,,1,CHEMBL616327,,,,H,8,10000000.0,
1494,Percentage inhibition against 5-hydroxytryptamine 1A receptor,Autocuration,,,B,,BAO_0000357,12073,,,1,CHEMBL616328,,,,H,8,,
1495,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 1),Autocuration,,,B,,BAO_0000249,2759,,,1,CHEMBL858110,,,,H,8,,
1496,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 1),Autocuration,,,F,,BAO_0000249,2759,,,1,CHEMBL616329,,,,H,8,,
1497,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 2),Autocuration,,,B,,BAO_0000249,2759,,,1,CHEMBL616330,,,,H,8,,
1498,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 2),Autocuration,,,F,,BAO_0000249,2759,,,1,CHEMBL616331,,,,H,8,,
1499,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes.,Autocuration,,,F,,BAO_0000249,2759,,,1,CHEMBL616332,,,,H,8,,
1500,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,Autocuration,,,B,,BAO_0000249,9737,,,1,CHEMBL857063,,,,H,8,955.0,
1501,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex using [3H]8-OH-DPAT as a radioligand,Autocuration,,,B,,BAO_0000019,9737,,,1,CHEMBL616333,,,,H,8,,
1502,Antagonistic activity against 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]-8-OH-DPAT as radioligand.,Expert,,,F,,BAO_0000019,5717,,,1,CHEMBL616334,,,,H,8,,
1503,Binding affinity of 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,Autocuration,,,B,,BAO_0000221,12253,,,1,CHEMBL616335,,,,H,8,10000000.0,
1504,Affinity pKi for 5-hydroxytryptamine 1A receptor was measured in rat cortex homogenates.,Autocuration,,,B,,BAO_0000019,14025,,,1,CHEMBL616336,,,,H,8,,
1505,Binding affinity against 5-hydroxytryptamine 1A receptor in rat cerebral cortical membrane using [3H]-8-OH-DPAT as radioligand.,Expert,,,B,,BAO_0000249,10425,,,1,CHEMBL616337,,,,H,8,,
1506,Binding affinity against 5-hydroxytryptamine 1A receptor in rat cortex homogenates.,Autocuration,,,B,,BAO_0000019,14998,,,1,CHEMBL616338,,,,H,8,,
1507,Binding affinity against native 5-HT1A-receptors from rat hippocampus using radioligand ([3H]- 8-hydri\oxy-2-(di-n-propylamino)tetraline) binding assay,Autocuration,,,B,,BAO_0000221,13694,,,1,CHEMBL616339,,,,H,8,10000000.0,
1508,Binding affinity against native 5-HT1A-receptors from rat hippocampus using radioligand ([3H]8-hydroxy-2-(di-n-propylamino)-tetraline) binding assay,Autocuration,,,B,,BAO_0000221,13694,,,1,CHEMBL616340,,,,H,8,10000000.0,
1509,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined,Autocuration,,,B,,BAO_0000357,4342,,,1,CHEMBL616341,,,,H,8,,
1510,Binding affinity against rat 5-hydroxytryptamine 1A receptor,Expert,10116.0,,B,,BAO_0000357,12936,,,1,CHEMBL616342,,,Rattus norvegicus,D,9,,
1511,Inhibition of [3H]2-(di-N-propylamino)-8-hydroxytetralin binding to 5-HT1A receptor of rat frontal cortex homogenates,Expert,10116.0,,B,,BAO_0000019,13144,,,1,CHEMBL616343,,,Rattus norvegicus,D,9,,
1512,Binding affinity of a compound to rat brain 5-hydroxytryptamine 1A (serotonin) receptor assayed by radiolabeled [3H]-8-OH-DPAT ligand displacement,Expert,,,B,,BAO_0000019,13343,,,1,CHEMBL616344,,,,H,8,,
1513,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,Expert,,,B,,BAO_0000357,12132,,,1,CHEMBL616345,,,,H,8,,
1514,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cortex using [3H]8-OH-DPAT as a radioligand,Expert,,,B,,BAO_0000019,15419,,,1,CHEMBL616346,,,,H,8,,
1515,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,Autocuration,,,B,,BAO_0000221,1479,,,1,CHEMBL616347,,,,H,8,10000000.0,
1516,In vitro by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor on rat cortical membrane,Expert,,,B,,BAO_0000019,14287,,,1,CHEMBL616348,,,,H,8,,
1517,Binding affinity at 5-hydroxytryptamine 1A receptor,Expert,,,B,,BAO_0000357,13116,,,1,CHEMBL616349,,,,H,8,,
1518,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat frontal cortex membranes,Expert,10116.0,,B,,BAO_0000249,2759,Membranes,,1,CHEMBL616152,,,Rattus norvegicus,D,9,,
1519,Compound was tested for inhibition constant against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes.,Autocuration,,,B,,BAO_0000249,2759,,,1,CHEMBL616153,,,,H,8,,
1520,"Binding affinity for rat cortex 5-hydroxytryptamine 1A receptor, by displacement of 0.2 nM [3H]8-OH-DPAT radioligand",Expert,,,B,,BAO_0000019,14748,,,1,CHEMBL616154,,,,H,8,,
1521,In vitro ability to inhibit binding of radioligand [3H]8-OH-DPAT to 5-hydroxytryptamine 1A receptor in rat cerebral cortex,Autocuration,,,B,,BAO_0000019,12304,,,1,CHEMBL616155,,,,H,8,,
1522,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]8-OH-DPAT,Expert,10116.0,,B,,BAO_0000221,12409,,,1,CHEMBL616156,,,Rattus norvegicus,D,9,10000000.0,
1523,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus with [3H]8-OH-DPAT,Expert,10116.0,,B,,BAO_0000221,12409,,,1,CHEMBL616157,,,Rattus norvegicus,D,9,10000000.0,
1524,The binding affinity (pKi) was measured against 5-hydroxytryptamine 4 receptor of piglet hippocampus using [125I]-SB 207710 as radioligand,Autocuration,,,B,,BAO_0000221,13267,,,1,CHEMBL616158,,,,H,8,10000000.0,
1525,The compound was tested for the binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,Autocuration,,,B,,BAO_0000357,15194,,,1,CHEMBL616159,,,,H,8,,
1526,pKi value against rat 5-hydroxytryptamine 1A receptor.,Expert,,,B,,BAO_0000357,14256,,,1,CHEMBL616160,,,,H,8,,
1527,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is define as non-determined.,Autocuration,,,B,,BAO_0000019,16567,,,1,CHEMBL616161,,,,H,8,,
1528,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; Not tested,Autocuration,,,F,,BAO_0000019,15740,,,1,CHEMBL616162,,,,H,8,,
1529,Binding affinity was measured against 5-hydroxytryptamine 2A receptor by displacement of [3H]- ketanserin by lysergic acid amides,Expert,10116.0,,B,,BAO_0000357,13278,,,1,CHEMBL616163,,,Rattus norvegicus,D,9,,
1530,Inhibition of specific [3H]OH-DPAT binding at 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,Expert,,,B,,BAO_0000249,1970,Membranes,,1,CHEMBL616164,,,,H,8,,
1531,Concentration of compound required to inhibit cortical 5-hydroxytryptamine 1A receptor binding sites in rat brain was evaluated,Autocuration,,,B,,BAO_0000221,10034,,,1,CHEMBL616165,,,,H,8,955.0,
1532,Inhibitory activity against 5-hydroxytryptamine 1A receptor isolated from rat hippocampus membranes membrane using [3H]5-HT as radioligand in the presence of 10e-6 M ketanserin as 5-HT2 blocker,Autocuration,10116.0,,B,,BAO_0000019,13348,,,1,CHEMBL616355,,,Rattus norvegicus,H,8,,
1533,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 50 uM 5-HT.,Autocuration,,,F,,BAO_0000019,13630,,,1,CHEMBL616356,,,,H,8,,
1534,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,Autocuration,,,B,,BAO_0000221,10862,,,1,CHEMBL616357,,,,H,8,955.0,
1535,"Binding affinity against 5-hydroxytryptamine 1A receptor in homogenated rat brain tissue, using by [3H]8-OH-DPAT as radioligand",Autocuration,,,B,,BAO_0000019,12058,,,1,CHEMBL616358,,,,H,8,,
1536,Compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor,Autocuration,,,B,,BAO_0000357,4639,,,1,CHEMBL616359,,,,H,8,,
1537,Percent decrease in 5-hydroxytryptamine 1A receptor binding using 8-OH-DPAT,Expert,,,B,,BAO_0000357,15453,,,1,CHEMBL616360,,,,H,8,,
1538,Binding affinity towards 5-hydroxytryptamine 1A receptor,Expert,,,B,,BAO_0000357,4820,,,1,CHEMBL616361,,,,H,8,,
1539,Tested for binding affinity for 5-hydroxytryptamine 1A receptor,Autocuration,,,B,,BAO_0000357,1089,,,1,CHEMBL616362,,,,H,8,,
1540,The compound was evaluated for its ability to displace [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in cellular brain membranes,Autocuration,,,B,,BAO_0000249,386,Brain membranes,,1,CHEMBL616363,,,,H,8,,
1541,Inhibition of binding towards 5-hydroxytryptamine 1A receptor at 100 nM concentration,Autocuration,,,B,,BAO_0000357,6011,,,1,CHEMBL616364,,,,H,8,,
1542,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1A receptor,Autocuration,,,B,,BAO_0000357,5014,,,1,CHEMBL616365,,,,H,8,,
1543,Binding affinity for 5-hydroxytryptamine 1A receptor determined using [3H]8-OH-DPAT as radioligand,Expert,,,B,,BAO_0000357,4402,,,1,CHEMBL616366,,,,H,8,,
1544,Binding affinity towards 5-hydroxytryptamine 1A receptor,Expert,,,B,,BAO_0000357,17066,,,1,CHEMBL872906,,,,H,8,,
1545,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1A receptor; inactive at 10 uM,Autocuration,,,B,,BAO_0000357,17515,,,1,CHEMBL616367,,,,H,8,,
1546,Binding affinity against 5-hydroxytryptamine 1A receptor,Autocuration,,,B,,BAO_0000357,2474,,,1,CHEMBL616368,,,,H,8,,
1547,Binding affinity to 5-hydroxytryptamine 1A receptor was determined,Autocuration,,,B,,BAO_0000357,4775,,,1,CHEMBL616369,,,,H,8,,
1548,Binding affinity towards Serotonin 5-hydroxytryptamine 1A receptor by displacement of [3H]-(+)-8-OH-DPAT.,Expert,9606.0,,B,,BAO_0000357,14294,,,1,CHEMBL616370,,,Homo sapiens,D,9,,
1549,Binding affinity towards Serotonin 5-hydroxytryptamine 1A receptor by displacement of [3H](+)-8-OH-DPAT; inactive,Expert,9606.0,,B,,BAO_0000357,14294,,,1,CHEMBL616371,,,Homo sapiens,D,9,,
1550,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,Autocuration,,,B,,BAO_0000219,12249,,449.0,1,CHEMBL616372,CHO,,,H,8,,
1551,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor expressed in CHO cell membranes,Expert,,,B,,BAO_0000219,11376,,,1,CHEMBL616373,,,,H,8,,
1552,Compound was measured in vivo for its binding affinity at 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,Autocuration,,,B,,BAO_0000218,2474,,,1,CHEMBL616374,,,,H,8,,
1553,Tested for activity against 5-hydroxytryptamine 1A receptor from bovine hippocampus,Autocuration,,,B,,BAO_0000221,13311,,,1,CHEMBL616375,,,,H,8,10000000.0,
1554,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1A receptor was determined,Autocuration,,,B,,BAO_0000357,4373,,,1,CHEMBL616376,,,,H,8,,
1555,Binding affinity towards 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT.,Expert,,,B,,BAO_0000357,1633,,,1,CHEMBL857064,,,,H,8,,
1556,Binding affinity for 5-hydroxytryptamine 1A receptor was determined,Autocuration,,,B,,BAO_0000357,11866,,,1,CHEMBL616377,,,,H,8,,
1557,Binding affinity for 5-hydroxytryptamine 1A receptor was determined,Autocuration,,,B,,BAO_0000357,4373,,,1,CHEMBL616378,,,,H,8,,
1558,Evaluated for the binding affinity to 5-hydroxytryptamine 1A receptor,Autocuration,,,B,,BAO_0000357,4687,,,1,CHEMBL616379,,,,H,8,,
1559,Ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,Autocuration,,,B,,BAO_0000357,16946,,,1,CHEMBL616380,,,,H,8,,
1560,Binding affinity against 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT radioligand,Autocuration,,,B,,BAO_0000357,13291,,,1,CHEMBL616381,,,,H,8,,
1561,Compound was evaluated for the affinity at 5-hydroxytryptamine 1A receptor,Autocuration,,,B,,BAO_0000357,14159,,,1,CHEMBL616382,,,,H,8,,
1562,Compound was tested for the binding affinity against 5-hydroxytryptamine 1A receptor by using [3H]DPAT as radioligand,Autocuration,,,B,,BAO_0000357,10812,,,1,CHEMBL616383,,,,H,8,,
1563,In vitro binding affinity against 5-hydroxytryptamine 1A receptor in CHO cells,Expert,10090.0,,B,,BAO_0000219,3032,,449.0,1,CHEMBL616350,CHO,,Mus musculus,D,9,,
1564,Inhibition of 5-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,Autocuration,,,B,,BAO_0000357,16655,,,1,CHEMBL616351,,,,H,8,,
1565,Inhibitory activity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand at 10e-5 M concentration,Autocuration,,,B,,BAO_0000357,14532,,,1,CHEMBL616352,,,,H,8,,
1566,Binding affinity against 5-hydroxytryptamine 1A receptor,Autocuration,,,B,,BAO_0000357,13944,,,1,CHEMBL616353,,,,H,8,,
1567,Binding affinity against serotonergic 5-HT1a receptor,Autocuration,,,B,,BAO_0000357,13033,,,1,CHEMBL616354,,,,H,8,,
1568,Binding affinity for 5-hydroxytryptamine 1A receptor was determined by using [3H]8-OH-DPAT as radioligand,Autocuration,,,B,,BAO_0000357,10321,,,1,CHEMBL616508,,,,H,8,,
1569,Binding affinity for 5-hydroxytryptamine 1A receptor,Expert,10090.0,,B,,BAO_0000357,2968,,,1,CHEMBL616559,,,Mus musculus,D,9,,
1570,Binding affinity at 5-hydroxytryptamine 1A receptor,Autocuration,,,B,,BAO_0000357,13964,,,1,CHEMBL616560,,,,H,8,,
1571,"Binding affinity towards 5-hydroxytryptamine 1A receptor receptor, using [3H]5-HT as radioligand.",Autocuration,,,B,,BAO_0000357,15527,,,1,CHEMBL616561,,,,H,8,,
1572,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,Autocuration,,,B,,BAO_0000219,12248,,449.0,1,CHEMBL616562,CHO,,,H,8,,
1573,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,Autocuration,,,B,,BAO_0000219,12249,,449.0,1,CHEMBL616563,CHO,,,H,8,,
1574,Compound was tested for binding affinity using [3H]8-OH-DPAT against 5-hydroxytryptamine 1A receptor,Autocuration,,,B,,BAO_0000357,15120,,,1,CHEMBL616564,,,,H,8,,
1575,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by using [3H]-8-OH-DPAT as radioligand,Autocuration,,,B,,BAO_0000357,13313,,,1,CHEMBL616565,,,,H,8,,
1576,In vivo binding affinity was evaluated against 5-hydroxytryptamine 1A receptor,Autocuration,,,B,,BAO_0000218,2613,,,1,CHEMBL616566,,,,H,8,,
1577,The binding affinity towards 5-hydroxytryptamine 1A receptor; No affinity,Autocuration,,,B,,BAO_0000357,16700,,,1,CHEMBL616989,,,,H,8,,
1578,Ability to displace [125I]iodosulpiride from 5-hydroxytryptamine 1A receptor,Autocuration,,,B,,BAO_0000357,2201,,,1,CHEMBL857975,,,,H,8,,
1579,Binding affinity against 5-hydroxytryptamine 1A receptor,Expert,10090.0,,B,,BAO_0000357,1274,,,1,CHEMBL616990,,,Mus musculus,D,9,,
1580,Compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor using radioligand binding assay,Autocuration,,,B,,BAO_0000357,1317,,,1,CHEMBL616991,,,,H,8,,
1581,Tested against 5-hydroxytryptamine 1A receptor,Autocuration,,,B,,BAO_0000357,12146,,,1,CHEMBL616992,,,,H,8,,
1582,The compound's binding affinity against 5-hydroxytryptamine 1A receptor,Autocuration,,,B,,BAO_0000357,14059,,,1,CHEMBL616993,,,,H,8,,
1583,Dissociation equilibrium constant against the vascular 5-hydroxytryptamine 1B like receptor in the rabbit saphenous vein,Expert,9986.0,,B,,BAO_0000019,14025,,,1,CHEMBL616994,,,Oryctolagus cuniculus,H,8,,
1584,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 1B like receptor in the rabbit saphenous vein(RbSV); NS=non surmountable,Autocuration,9986.0,,B,,BAO_0000019,14025,,,1,CHEMBL616995,,,Oryctolagus cuniculus,H,8,,
1585,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1B receptor from cloned gorilla membranes expressed in cultured HEK 293 cells,Intermediate,9593.0,,B,,BAO_0000219,14447,,722.0,1,CHEMBL616996,HEK293,,Gorilla gorilla,D,9,,
1586,5-HT1B agonist potency was evaluated as effective dose that induced hypothermia in the guinea-pig upon intraperitoneal administration,Autocuration,10141.0,,F,,BAO_0000218,3025,,,1,CHEMBL616997,,,Cavia porcellus,H,8,,
1587,5-hydroxytryptamine 1B receptor agonist potency was evaluated as effective dose that induced hypothermia in the guinea-pig upon intraperitoneal administration,Autocuration,10141.0,,F,,BAO_0000218,3025,,,1,CHEMBL616998,,,Cavia porcellus,H,8,,
1588,Affinity of compound towards 5-hydroxytryptamine 1B receptor in isolated guinea-pig iliac artery,Autocuration,10141.0,,F,,BAO_0000019,15329,,,1,CHEMBL616999,,,Cavia porcellus,H,8,,
1589,Affinity of compound towards 5-hydroxytryptamine 1B receptor in isolated guinea-pig iliac artery; n.d. indicates Not determined,Autocuration,10141.0,,F,,BAO_0000019,15329,,,1,CHEMBL617000,,,Cavia porcellus,H,8,,
1590,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 1B receptor of guinea pig,Autocuration,10141.0,,F,,BAO_0000019,15847,,,1,CHEMBL617001,,,Cavia porcellus,H,8,,
1591,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 1B receptor of guinea pig; ND means not done,Autocuration,10141.0,,F,,BAO_0000019,15847,,,1,CHEMBL858111,,,Cavia porcellus,H,8,,
1592,Intrinsic activity for Antagonism of 5-hydroxytryptamine 1B receptor-mediated stimulation of [35S]GTP gamma S binding,Autocuration,,,F,,BAO_0000019,14165,,,1,CHEMBL617002,,,,H,8,,
1593,Antagonism tested at 1 uM against the agonist-induced inhibitory effect of 10 nM 5-carbamoyltryptamine (5-CT),Autocuration,,,F,,BAO_0000019,14214,,,1,CHEMBL617003,,,,H,8,,
1594,Antagonism tested at 1 uM against the agonist-induced inhibitory effect of 10 nM 5-carbamoyltryptamine(5-CT),Autocuration,,,F,,BAO_0000019,14214,,,1,CHEMBL617004,,,,H,8,,
1595,Agonist activity at 5-hydroxytryptamine 1B receptor by measuring the inhibition of forskolin-stimulated cAMP formation,Expert,9606.0,,F,,BAO_0000019,14214,,,1,CHEMBL617005,,,Homo sapiens,D,9,,
1596,Inhibition of forskolin-stimulated c-AMP formation by human 5-hydroxytryptamine 1B receptor expressed in CHO-K1 cells,Expert,9606.0,,F,,BAO_0000219,13729,,485.0,1,CHEMBL616623,CHO-K1,,Homo sapiens,D,9,,
1597,Effective concentration determined by measuring inhibition of forskolin-stimulated c-AMP formation at 5-hydroxytryptamine 1B receptor stably transfected in CHO cell lines,Autocuration,,,F,,BAO_0000219,3025,,449.0,1,CHEMBL616624,CHO,,,H,8,,
1598,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor,Autocuration,,,B,,BAO_0000357,2391,,,1,CHEMBL883243,,,,H,8,,
1599,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; full agonist,Autocuration,,,F,,BAO_0000019,2391,,,1,CHEMBL616625,,,,H,8,,
1600,"Agonist-induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with human 5-hydroxytryptamine 1B receptor",Expert,,,F,,BAO_0000219,14956,,449.0,1,CHEMBL616626,CHO,,,H,8,,
1601,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line,Autocuration,,,F,,BAO_0000219,2598,,449.0,1,CHEMBL616627,CHO,,,H,8,,
1602,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Antagonist,Autocuration,,,F,,BAO_0000219,2598,,449.0,1,CHEMBL616628,CHO,,,H,8,,
1603,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Full Agonist,Autocuration,,,F,,BAO_0000219,2598,,449.0,1,CHEMBL616629,CHO,,,H,8,,
1604,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Partial Agonist,Autocuration,,,F,,BAO_0000219,2598,,449.0,1,CHEMBL616630,CHO,,,H,8,,
1605,"Efficacy was evaluated relative to human 5-HT1B receptor using [35S]GTP-gamma-S, as radioligand",Expert,,,F,,BAO_0000019,14956,,,1,CHEMBL616631,,,,H,8,,
1606,"Efficacy of compound was evaluated relative to human 5-hydroxytryptamine 1B receptor using [35S]GTP-gamma-S, as radioligand",Autocuration,,,F,,BAO_0000019,14956,,,1,CHEMBL616632,,,,H,8,,
1607,Percentage Maximal inhibition obtained with 1 uM 5-HT against 5-hydroxytryptamine 1B receptor,Expert,9606.0,,B,,BAO_0000357,14214,,,1,CHEMBL616633,,,Homo sapiens,D,9,,
1608,Ability to displace [3H]5-HT from recombinant human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells determined in vitro,Expert,,,B,,BAO_0000219,3463,,449.0,1,CHEMBL616634,CHO,,,H,8,,
1609,Affinity of compound towards 5-hydroxytryptamine 1B receptor was evaluated using radioligand binding technique,Autocuration,,,B,,BAO_0000357,15331,,,1,CHEMBL616635,,,,H,8,,
1610,Binding affinity against 5-hydroxytryptamine 1B receptor,Expert,9606.0,,B,,BAO_0000357,16146,,,1,CHEMBL885358,,,Homo sapiens,D,9,,
1611,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1B receptor expressed in CHO cells,Expert,9606.0,,B,,BAO_0000219,14159,,449.0,1,CHEMBL616636,CHO,,Homo sapiens,D,9,,
1612,Binding affinity to human cloned 5-hydroxytryptamine 1B receptor in CHO cells by [3H]5-HT binding displacement.,Expert,,,B,,BAO_0000219,14158,,449.0,1,CHEMBL616637,CHO,,,H,8,,
1613,Compound was evaluated for the affinity at 5-hydroxytryptamine 1B receptor,Autocuration,,,B,,BAO_0000357,14159,,,1,CHEMBL616638,,,,H,8,,
1614,Displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1B receptor stably expressed in CHO cells,Expert,,,B,,BAO_0000219,15250,,449.0,1,CHEMBL616639,CHO,,,H,8,,
1615,Binding affinity at cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells by [3H]5-HT displacement.,Expert,,,B,,BAO_0000219,15250,,449.0,1,CHEMBL616640,CHO,,,H,8,,
1616,Displacement of [3H]5-HT binding from the cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells,Expert,,,B,,BAO_0000219,15331,,449.0,1,CHEMBL616641,CHO,,,H,8,,
1617,Displacement of [3H]5-HT binding from cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells.,Expert,,,B,,BAO_0000219,15332,,449.0,1,CHEMBL616642,CHO,,,H,8,,
1618,Displacement of specific [3H]5-HT binding to cloned human 5-hydroxytryptamine 1B receptor expressed in CHO cells,Expert,,,B,,BAO_0000219,14956,,449.0,1,CHEMBL616643,CHO,,,H,8,,
1619,In vitro binding affinity against human 5-hydroxytryptamine 1B receptor at a concentration of 100 (nM),Autocuration,,,B,,BAO_0000357,3805,,,1,CHEMBL616644,,,,H,8,,
1620,Intrinsic activity for each compound is calculated as a percentage of the 5-hydroxytryptamine 1B receptor response,Autocuration,,,B,,BAO_0000357,14875,,,1,CHEMBL616645,,,,H,8,,
1621,Compound was tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),Autocuration,9986.0,,F,,BAO_0000019,14454,,,1,CHEMBL616646,,,Oryctolagus cuniculus,H,8,,
1622,Tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),Expert,9986.0,,F,,BAO_0000019,14454,,,1,CHEMBL616647,,,Oryctolagus cuniculus,H,8,,
1623,Affinity at 5-hydroxytryptamine 1D receptor (For sumatriptan = Ki (nM)-12+/-1.9),Autocuration,,,B,,BAO_0000357,16288,,,1,CHEMBL616509,,,,H,8,,
1624,Affinity at 5-hydroxytryptamine 1D receptor from calf caudate using [3H]5-HT as radioligand (For sumatriptan = Ki(nM)-12+/-1.9),Autocuration,,,B,,BAO_0000357,16288,,,1,CHEMBL616510,,,,H,8,,
1625,Binding affinity against calf caudate 5-hydroxytryptamine 1D receptor,Autocuration,,,B,,BAO_0000357,16312,,,1,CHEMBL616511,,,,H,8,,
1626,Inhibitory activity against 5-hydroxytryptamine 1D receptor subtype,Expert,9913.0,,B,,BAO_0000357,1348,,,1,CHEMBL616512,,,Bos taurus,H,8,,
1627,Inhibitory concentration required against 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT,Autocuration,9913.0,,B,,BAO_0000357,5834,,,1,CHEMBL616513,,,Bos taurus,H,8,,
1628,Binding affinity towards 5-hydroxytryptamine 1D receptor was determined in calf striatum homogenate,Autocuration,9913.0,,B,,BAO_0000019,13366,,,1,CHEMBL616514,,,Bos taurus,H,8,2435.0,
1629,Ability to bind to 5-hydroxytryptamine 1D receptor of calf substantia nigra,Expert,9913.0,,B,,BAO_0000357,1414,,,1,CHEMBL616515,,,Bos taurus,H,8,,
1630,Binding affinity against 5-hydroxytryptamine 1D receptor in calf caudate homogenates.,Autocuration,9913.0,,B,,BAO_0000019,14998,,,1,CHEMBL616516,,,Bos taurus,H,8,,
1631,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]- serotonin as radioligand,Autocuration,9913.0,,B,,BAO_0000357,11473,,,1,CHEMBL616517,,,Bos taurus,H,8,,
1632,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]- serotonin as radioligand,Autocuration,9913.0,,B,,BAO_0000357,11473,,,1,CHEMBL616518,,,Bos taurus,H,8,,
1633,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 1D receptor of bovine caudate using [3H]5-HT as the radioligand,Autocuration,9913.0,,B,,BAO_0000357,10639,,,1,CHEMBL616519,,,Bos taurus,H,8,,
1634,Inhibitory activity against 5-hydroxytryptamine 1D receptor of bovine caudate using [3H]5-HT as the radioligand,Autocuration,9913.0,,B,,BAO_0000357,10639,,,1,CHEMBL616520,,,Bos taurus,H,8,,
1635,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT radioligand,Autocuration,9913.0,,B,,BAO_0000357,1375,,,1,CHEMBL616521,,,Bos taurus,H,8,,
1636,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT radioligand; NT means not tested,Autocuration,9913.0,,B,,BAO_0000357,1375,,,1,CHEMBL616522,,,Bos taurus,H,8,,
1637,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT; Not tested,Autocuration,9913.0,,B,,BAO_0000357,16532,,,1,CHEMBL884531,,,Bos taurus,H,8,,
1638,Binding affinity towards 5-hydroxytryptamine 1D receptor using [3H]5-HT as radioligand,Autocuration,9913.0,,B,,BAO_0000357,11147,,,1,CHEMBL616523,,,Bos taurus,H,8,,
1639,Binding affinity towards 5-hydroxytryptamine 1D receptor was determined in calf striatum homogenate,Autocuration,9913.0,,B,,BAO_0000019,13366,,,1,CHEMBL616731,,,Bos taurus,H,8,2435.0,
1640,Binding affinity was determined against 5-hydroxytryptamine 1D receptor in bovine caudate homogenate,Autocuration,9913.0,,B,,BAO_0000019,10444,,,1,CHEMBL616732,,,Bos taurus,H,8,,
1641,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT,Autocuration,9913.0,,B,,BAO_0000357,16532,,,1,CHEMBL616733,,,Bos taurus,H,8,,
1642,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT; Not tested,Autocuration,9913.0,,B,,BAO_0000357,16532,,,1,CHEMBL616734,,,Bos taurus,H,8,,
1643,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex membranes using [125]ICYP,Autocuration,9913.0,,B,,BAO_0000249,12827,,,1,CHEMBL616735,,,Bos taurus,H,8,,
1644,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex membranes using [125]ICYP; Not determined,Autocuration,9913.0,,B,,BAO_0000249,12827,,,1,CHEMBL616736,,,Bos taurus,H,8,,
1645,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,Expert,9913.0,,F,,BAO_0000019,12919,,,1,CHEMBL616737,,,Bos taurus,H,8,,
1646,Affinity pKi for 5-hydroxytryptamine 1D receptor was measured in calf caudate homogenate,Autocuration,9913.0,,B,,BAO_0000019,14025,,,1,CHEMBL616738,,,Bos taurus,H,8,,
1647,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,Expert,9913.0,,F,,BAO_0000019,12919,,,1,CHEMBL616739,,,Bos taurus,H,8,,
1648,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,Expert,9913.0,,F,,BAO_0000019,12919,,,1,CHEMBL616740,,,Bos taurus,H,8,,
1649,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,Expert,9913.0,,F,,BAO_0000019,12919,,,1,CHEMBL616741,,,Bos taurus,H,8,,
1650,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1D receptor from cloned gorilla membranes expressed in cultured HEK 293 cells,Autocuration,9593.0,,B,,BAO_0000219,14447,,722.0,1,CHEMBL616742,HEK293,,Gorilla gorilla,H,8,,
1651,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor in guinea pig substantia nigra,Intermediate,10141.0,,B,,BAO_0000019,1375,,,1,CHEMBL616743,,,Cavia porcellus,D,9,,
1652,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor in guinea pig substantia nigra; NT means not tested,Intermediate,10141.0,,B,,BAO_0000019,1375,,,1,CHEMBL616744,,,Cavia porcellus,D,9,,
1653,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptor by the agonist GR-46611,Intermediate,10141.0,,F,,BAO_0000019,12409,,,1,CHEMBL616745,,,Cavia porcellus,D,9,,
1654,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,Intermediate,10141.0,,F,,BAO_0000019,12409,,,1,CHEMBL616746,,,Cavia porcellus,D,9,,
1655,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611; range is 2-9,Intermediate,10141.0,,F,,BAO_0000019,12409,,,1,CHEMBL616747,,,Cavia porcellus,D,9,,
1656,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611;range is 0.2-0.4,Intermediate,10141.0,,F,,BAO_0000019,12409,,,1,CHEMBL616748,,,Cavia porcellus,D,9,,
1657,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611;range is 0.2-1.2,Intermediate,10141.0,,F,,BAO_0000019,12409,,,1,CHEMBL616648,,,Cavia porcellus,D,9,,
1658,Binding affinity against 5-hydroxytryptamine 1D receptor,Intermediate,10141.0,,B,,BAO_0000357,11574,,,1,CHEMBL616649,,,Cavia porcellus,D,9,,
1659,Binding affinity towards guinea pig 5-hydroxytryptamine 1D receptor was determined,Intermediate,10141.0,,B,,BAO_0000357,1558,,,1,CHEMBL616650,,,Cavia porcellus,D,9,,
1660,Compound at 3 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,Intermediate,10141.0,,F,,BAO_0000218,12409,,,1,CHEMBL616651,,,Cavia porcellus,D,9,,
1661,Compound at 45 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,Intermediate,10141.0,,F,,BAO_0000218,12409,,,1,CHEMBL616652,,,Cavia porcellus,D,9,,
1662,Compound at 50 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,Intermediate,10141.0,,F,,BAO_0000218,12409,,,1,CHEMBL616653,,,Cavia porcellus,D,9,,
1663,Compound at oral dose of 45 mg/kg was tested for percent inhibition against 5-hydroxytryptamine 1D receptor causes hypothermia in guinea pig,Intermediate,10141.0,,F,,BAO_0000218,12409,,,1,CHEMBL616654,,,Cavia porcellus,D,9,,
1664,Binding affinity of 5-hydroxytryptamine 1D receptor using [3H]-8-HT in guinea pig cortex,Intermediate,10141.0,,B,,BAO_0000019,12253,,,1,CHEMBL616655,,,Cavia porcellus,D,9,,
1665,Binding affinity against guinea pig 5-hydroxytryptamine 1D receptor,Intermediate,10141.0,,B,,BAO_0000357,12936,,,1,CHEMBL616656,,,Cavia porcellus,D,9,,
1666,Binding affinity was determined against 5-hydroxytryptamine 4 receptor using [125I]SB 207710 as radioligand from piglet hippocampal membranes,Autocuration,10141.0,,B,,BAO_0000019,13181,,,1,CHEMBL616657,,,Cavia porcellus,H,8,,
1667,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor in guinea-pig striatum in presence of BMY-7378 and mesulergine,Intermediate,10141.0,,B,,BAO_0000357,12409,,,1,CHEMBL616658,,,Cavia porcellus,D,9,2435.0,
1668,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1D receptor of guinea pig substantia nigra,Intermediate,10141.0,,B,,BAO_0000357,10639,,,1,CHEMBL616659,,,Cavia porcellus,D,9,,
1669,Binding affinity against 5-hydroxytryptamine 1D receptor,Autocuration,,,B,,BAO_0000357,5254,,,1,CHEMBL616660,,,,H,8,,
1670,The compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor beta,Autocuration,,,B,,BAO_0000357,13051,,,1,CHEMBL616661,,,,H,8,,
1671,Maximum stimulation of [35S]GTP gamma-S binding expressed relative to the maximal effect produced by 5-hydroxytryptamine 1D receptor,Expert,,,F,,BAO_0000019,3463,,,1,CHEMBL616662,,,,H,8,,
1672,Ability to inhibit forskolin-stimulated adenylate cyclase in a cell line expressing human 5-hydroxytryptamine 1D receptor,Autocuration,,,F,,BAO_0000019,15315,,,1,CHEMBL616663,,,,H,8,,
1673,Ability to inhibit forskolin-stimulated adenylate cyclase activity in Chinese hamster ovary (CHO) stable cell lines expressing human 5-hydroxytryptamine 1D receptor,Autocuration,,,F,,BAO_0000019,6011,,,1,CHEMBL616664,,,,H,8,,
1674,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing 5-hydroxytryptamine 1D receptor",Expert,9606.0,,F,,BAO_0000219,14159,,449.0,1,CHEMBL881820,CHO,,Homo sapiens,D,9,,
1675,"Compound was evaluated for the stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor.",Autocuration,,,F,,BAO_0000219,14159,,449.0,1,CHEMBL616665,CHO,,,H,8,,
1676,Agonist-induced [35S]- GTPgammaS binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor,Expert,,,B,,BAO_0000219,15250,,449.0,1,CHEMBL616666,CHO,,,H,8,,
1677,Compound was tested for measuring agonist-induced [35S]- GTPgammaS binding in CHO cells stably transfected with human 5-hydroxytryptamine 1D receptor,Autocuration,,,B,,BAO_0000219,15250,,449.0,1,CHEMBL616667,CHO,,,H,8,,
1678,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor",Expert,,,F,,BAO_0000219,15331,,449.0,1,CHEMBL616668,CHO,,,H,8,,
1679,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor",Expert,9606.0,,F,,BAO_0000219,15332,,449.0,1,CHEMBL616669,CHO,,Homo sapiens,D,9,,
1680,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the human 5-hydroxytryptamine 1D receptor.",Expert,,,F,,BAO_0000219,15332,,449.0,1,CHEMBL617040,CHO,,,H,8,,
1681,"Measurement of agonist induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor",Autocuration,,,F,,BAO_0000219,3294,,449.0,1,CHEMBL617041,CHO,,,H,8,,
1682,"Measurement of agonist induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor.",Expert,,,F,,BAO_0000219,14158,,449.0,1,CHEMBL617042,CHO,,,H,8,,
1683,"Agonist-induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with human 5-hydroxytryptamine 1D receptor",Expert,,,F,,BAO_0000219,14956,,449.0,1,CHEMBL617043,CHO,,,H,8,,
1684,Compound was evaluated for its agonistic activity on 5-hydroxytryptamine 1D receptor,Autocuration,,,F,,BAO_0000019,12469,,,1,CHEMBL617044,,,,H,8,,
1685,Measurement of agonist-induced [35S]-GTP gamma-S binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor,Expert,,,F,,BAO_0000219,3463,,449.0,1,CHEMBL617045,CHO,,,H,8,,
1686,"Maximum stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing human 5-HT-1d relative to 5-HT",Expert,9606.0,,F,,BAO_0000219,15250,,449.0,1,CHEMBL617046,CHO,,Homo sapiens,D,9,,
1687,"Maximum stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing human 5-HT-1d relative to 5-HT",Expert,9606.0,,F,,BAO_0000219,15250,,449.0,1,CHEMBL617047,CHO,,Homo sapiens,D,9,,
1688,"Efficacy was evaluated relative to human 5-hydroxytryptamine 1D receptor using [35S]GTP-gamma-S, as radioligand",Expert,,,F,,BAO_0000019,14956,,,1,CHEMBL617048,,,,H,8,,
1689,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by 5-hydroxytryptamine 1D receptor.",Autocuration,,,F,,BAO_0000019,14159,,,1,CHEMBL616897,,,,H,8,,
1690,"Maximum stimulation of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1D receptor relative to 5-HT",Expert,9606.0,,F,,BAO_0000019,14159,,,1,CHEMBL616898,,,Homo sapiens,D,9,,
1691,Percent efficacy relative to 5-HT treatment of CHO cells expressing 5-HT 1d receptor,Expert,9606.0,,F,,BAO_0000219,14499,,449.0,1,CHEMBL858201,CHO,,Homo sapiens,D,9,,
1692,Intrinsic activity for 5-hydroxytryptamine 1D receptor,Autocuration,,,F,,BAO_0000019,15315,,,1,CHEMBL616899,,,,H,8,,
1693,Ability to displace [3H]- -5-HT binding to cloned 5-hydroxytryptamine 1D receptor stably expressed in chinese hamster cells (CHO cells),Autocuration,,,B,,BAO_0000219,3294,,,1,CHEMBL616900,,,,H,8,,
1694,Ability to displace [3H]-5-HT from recombinant human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells determined in vitro,Expert,,,B,,BAO_0000219,3463,,449.0,1,CHEMBL616901,CHO,,,H,8,,
1695,Affinity of compound towards 5-hydroxytryptamine 1D receptor was evaluated using radioligand binding technique,Autocuration,,,B,,BAO_0000357,15331,,,1,CHEMBL616902,,,,H,8,,
1696,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,Expert,9606.0,,B,,BAO_0000219,14159,,449.0,1,CHEMBL616903,CHO,,Homo sapiens,D,9,,
1697,Binding affinity by displacement to human cloned 5-hydroxytryptamine 1D receptor in CHO cells by [3H]5-HT displacement.,Expert,,,B,,BAO_0000219,14158,,449.0,1,CHEMBL616904,CHO,,,H,8,,
1698,Compound was evaluated for the affinity at 5-hydroxytryptamine 1D receptor,Autocuration,,,B,,BAO_0000357,14159,,,1,CHEMBL616905,,,,H,8,,
1699,Binding affinity at human cloned 5-hydroxytryptamine 1D receptor stably expressed in CHO cells by [3H]5-HT displacement.,Expert,,,B,,BAO_0000219,15250,,449.0,1,CHEMBL616906,CHO,,,H,8,,
1700,Displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,Expert,,,B,,BAO_0000219,15250,,449.0,1,CHEMBL616907,CHO,,,H,8,,
1701,Displacement of [3H]5-HT binding from the cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,Expert,,,B,,BAO_0000219,15331,,449.0,1,CHEMBL616908,CHO,,,H,8,,
1702,Displacement of [3H]5-HT binding from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,Expert,9606.0,,B,,BAO_0000219,15332,,449.0,1,CHEMBL616909,CHO,,Homo sapiens,D,9,,
1703,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,Expert,9606.0,,B,,BAO_0000219,14499,,449.0,1,CHEMBL616910,CHO,,Homo sapiens,D,9,,
1704,Displacement of [3H]5-HT binding to the cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,Expert,,,B,,BAO_0000219,15332,,449.0,1,CHEMBL616911,CHO,,,H,8,,
1705,Displacement of specific [3H]5-HT binding to cloned human 5-hydroxytryptamine 1D receptor expressed in CHO cells,Expert,,,B,,BAO_0000219,14956,,449.0,1,CHEMBL616912,CHO,,,H,8,,
1706,In vitro binding affinity against human 5-hydroxytryptamine 1D receptor at a concentration of 100 (nM),Autocuration,,,B,,BAO_0000357,3805,,,1,CHEMBL616913,,,,H,8,,
1707,Inhibition of [3H]5-HT binding to human 5-hydroxytryptamine 1D receptor expressed in CHO cells at 1 uM,Expert,9606.0,,B,,BAO_0000219,6011,,449.0,1,CHEMBL616914,CHO,,Homo sapiens,D,9,,
1708,Binding affinity against 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand,Autocuration,,,B,,BAO_0000219,16190,,449.0,1,CHEMBL616915,CHO,,,H,8,,
1709,Binding affinity for 5-hydroxytryptamine 1D receptor in Cos-7 transfected cell type using [3H]5-CT as radioligand,Autocuration,,,B,,BAO_0000019,14165,,,1,CHEMBL616916,,,,H,8,,
1710,Binding affinity to cloned human 5-hydroxytryptamine 1D receptor,Expert,9606.0,,B,,BAO_0000357,4234,,,1,CHEMBL616917,,,Homo sapiens,D,9,,
1711,"Binding affinity towards 5-HT1D receptor, using [3H]5-HT as radioligand.",Autocuration,,,B,,BAO_0000357,15527,,,1,CHEMBL616918,,,,H,8,,
1712,Binding affinity towards human 5-hydroxytryptamine 1D receptor in L-M(tk-) cells using [3H]GR-125743 as radioligand,Expert,,,B,,BAO_0000219,6328,,,1,CHEMBL616919,,,,H,8,,
1713,Binding affinity towards human 5-hydroxytryptamine 1D receptor was determined using [3H]5-HT as radioligand,Autocuration,,,B,,BAO_0000357,16209,,,1,CHEMBL616920,,,,H,8,,
1714,Binding affinity for recombinant human 5-hydroxytryptamine 1D receptor using [3H]5-HT as radioligand.,Autocuration,,,B,,BAO_0000357,14770,,,1,CHEMBL872914,,,,H,8,,
1715,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1D receptor using [3H]-5-CT as radioligand,Autocuration,,,B,,BAO_0000357,2598,,,1,CHEMBL616921,,,,H,8,,
1716,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1D receptor,Expert,,,B,,BAO_0000357,6897,,,1,CHEMBL616922,,,,H,8,,
1717,Binding affinity towards 5-hydroxytryptamine 1D receptor,Autocuration,,,B,,BAO_0000357,6013,,,1,CHEMBL616923,,,,H,8,,
1718,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor,Expert,,,B,,BAO_0000357,5843,,,1,CHEMBL616924,,,,H,8,,
1719,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand,Expert,,,B,,BAO_0000357,14454,,,1,CHEMBL875909,,,,H,8,,
1720,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand; Not determined,Autocuration,,,B,,BAO_0000357,14454,,,1,CHEMBL616925,,,,H,8,,
1721,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand; not determined,Autocuration,,,B,,BAO_0000357,14454,,,1,CHEMBL616926,,,,H,8,,
1722,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1D receptor,Autocuration,,,B,,BAO_0000357,15818,,,1,CHEMBL616927,,,,H,8,,
1723,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1D receptor in CHO-K1 cells,Expert,,,F,,BAO_0000219,13729,,485.0,1,CHEMBL616928,CHO-K1,,,H,8,,
1724,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in Chinese hamster ovary cells (CHO cells),Expert,9606.0,,B,,BAO_0000219,6011,,,1,CHEMBL616929,,,Homo sapiens,D,9,,
1725,In vitro binding affinity to human 5-hydroxytryptamine 1D receptor,Expert,9606.0,,B,,BAO_0000357,4234,,,1,CHEMBL616930,,,Homo sapiens,D,9,,
1726,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor,Expert,,,B,,BAO_0000019,17085,,,1,CHEMBL616931,,,,H,8,,
1727,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1D receptor using [3H]5-CT radioligand,Autocuration,,,B,,BAO_0000357,3025,,,1,CHEMBL616932,,,,H,8,,
1728,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1D receptor,Expert,,,B,,BAO_0000357,15315,,,1,CHEMBL616933,,,,H,8,,
1729,Receptor binding affinity for cloned human 5-hydroxytryptamine 1D receptor in Cos-7 cells,Expert,9606.0,,B,,BAO_0000219,14214,,,1,CHEMBL616934,,,Homo sapiens,D,9,,
1730,Binding affinity for human 5-hydroxytryptamine 1D receptor,Expert,9606.0,,B,,BAO_0000357,3804,,,1,CHEMBL616935,,,Homo sapiens,D,9,,
1731,The binding affinity towards the 5-hydroxytryptamine 1D receptor; No affinity,Autocuration,,,B,,BAO_0000357,16700,,,1,CHEMBL616936,,,,H,8,,
1732,Affinity for 5-hydroxytryptamine 1D receptor subtype,Expert,9606.0,,B,,BAO_0000357,2391,,,1,CHEMBL616937,,,Homo sapiens,D,9,,
1733,Binding affinity for human 5-hydroxytryptamine 1D receptor,Expert,9606.0,,B,,BAO_0000357,4175,,,1,CHEMBL616938,,,Homo sapiens,D,9,,
1734,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor,Autocuration,,,B,,BAO_0000019,17085,,,1,CHEMBL616939,,,,H,8,,
1735,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor; ND means not determined,Expert,,,B,,BAO_0000019,17085,,,1,CHEMBL616940,,,,H,8,,
1736,Binding activity against human 5-hydroxytryptamine 1D receptor; NT means not tested,Expert,9606.0,,B,,BAO_0000357,15926,,,1,CHEMBL616941,,,Homo sapiens,D,9,,
1737,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor; Not tested,Autocuration,,,B,,BAO_0000219,16312,,485.0,1,CHEMBL616942,CHO-K1,,,H,8,,
1738,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor; not tested,Autocuration,,,B,,BAO_0000219,16312,,485.0,1,CHEMBL616943,CHO-K1,,,H,8,,
1739,Selectivity towards 5-HT1D and to that of 5-HT1B in CHO cells,Autocuration,,,B,,BAO_0000219,14956,,449.0,1,CHEMBL616944,CHO,,,H,4,,
1740,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by the 5-HT",Autocuration,,,F,,BAO_0000019,3294,,,1,CHEMBL616945,,,,H,8,,
1741,Binding activity radioligand.,Autocuration,,,B,,BAO_0000357,12861,,,1,CHEMBL616946,,,,H,8,,
1742,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,Autocuration,,,B,,BAO_0000019,12861,,,1,CHEMBL616947,,,,H,8,,
1743,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor,Expert,,,B,,BAO_0000219,16312,,485.0,1,CHEMBL616948,CHO-K1,,,H,8,,
1744,Binding affinity for human cloned 5-hydroxytryptamine 1D receptor,Autocuration,,,B,,BAO_0000357,5104,,,1,CHEMBL616851,,,,H,8,,
1745,Binding affinity for human cloned 5-hydroxytryptamine 1D receptor,Autocuration,,,B,,BAO_0000357,5105,,,1,CHEMBL616852,,,,H,8,,
1746,Measured as -log Ka on 5-hydroxytryptamine 1D receptor,Autocuration,,,B,,BAO_0000357,14499,,,1,CHEMBL616853,,,,H,8,,
1747,Binding activity against human 5-hydroxytryptamine 1D receptor,Expert,9606.0,,B,,BAO_0000357,15926,,,1,CHEMBL616854,,,Homo sapiens,D,9,,
1748,Binding affinity to human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand,Expert,9606.0,,B,,BAO_0000219,4540,,449.0,1,CHEMBL616855,CHO,,Homo sapiens,D,9,,
1749,Binding affinity towards 5-hydroxytryptamine 1D (human cloned receptor) in CHO cells using [3H]-5-HT as radioligand.,Autocuration,,,B,,BAO_0000219,15779,,449.0,1,CHEMBL616856,CHO,,,H,8,,
1750,Binding affinity towards 5-hydroxytryptamine 1D (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,Autocuration,,,B,,BAO_0000219,15779,,449.0,1,CHEMBL616857,CHO,,,H,8,,
1751,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor,Autocuration,,,B,,BAO_0000357,6166,,,1,CHEMBL616858,,,,H,8,,
1752,Binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand.,Autocuration,,,B,,BAO_0000219,15779,,449.0,1,CHEMBL616859,CHO,,,H,8,,
1753,Binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]-5-HT as radioligand.;ND means no data.,Autocuration,,,B,,BAO_0000219,15779,,449.0,1,CHEMBL616860,CHO,,,H,8,,
1754,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand,Autocuration,,,B,,BAO_0000219,17451,,722.0,1,CHEMBL616861,HEK293,,,H,8,,
1755,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand,Autocuration,,,B,,BAO_0000219,17451,,722.0,1,CHEMBL616541,HEK293,,,H,8,,
1756,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand; Not determined,Autocuration,,,B,,BAO_0000219,17451,,722.0,1,CHEMBL616542,HEK293,,,H,8,,
1757,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as the radioligand,Autocuration,,,B,,BAO_0000219,4199,,449.0,1,CHEMBL616543,CHO,,,H,8,,
1758,Binding affinity for human 5-hydroxytryptamine 1D receptor,Expert,9606.0,,B,,BAO_0000357,14875,,,1,CHEMBL616544,,,Homo sapiens,D,9,,
1759,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT,Autocuration,,,B,,BAO_0000219,15146,,449.0,1,CHEMBL616545,CHO,,,H,8,,
1760,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1D receptor in CHO using [3H]5-HT as a radioligand,Autocuration,,,B,,BAO_0000357,5213,,,1,CHEMBL616546,,,,H,8,,
1761,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT.,Autocuration,,,B,,BAO_0000219,14818,,449.0,1,CHEMBL616547,CHO,,,H,8,,
1762,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells, using [3H]5-HT as radioligand",Autocuration,,,B,,BAO_0000219,4829,,449.0,1,CHEMBL616548,CHO,,,H,8,,
1763,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1D receptor at concentration 1 uM,Expert,,,F,,BAO_0000019,14454,,,1,CHEMBL616549,,,,H,8,,
1764,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1D receptor at concentration 10 uM,Expert,,,F,,BAO_0000019,14454,,,1,CHEMBL616550,,,,H,8,,
1765,Binding affinity against 5-HT2C receptor,Autocuration,,,B,,BAO_0000357,5254,,,1,CHEMBL857066,,,,H,8,,
1766,Binding affinity against 5-hydroxytryptamine 1D receptor,Autocuration,,,B,,BAO_0000357,5254,,,1,CHEMBL616551,,,,H,8,,
1767,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1B receptor of rat substantia nigra,Autocuration,,,B,,BAO_0000357,10639,,,1,CHEMBL616552,,,,H,8,,
1768,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1B receptor of rat substantia nigra,Autocuration,,,F,,BAO_0000019,10639,,,1,CHEMBL832876,,,,H,8,,
1769,"Binding affinity for 5-hydroxytryptamine 1B receptor in rat cortex, striatum and globus pallidus",Expert,,,B,,BAO_0000019,12352,,,1,CHEMBL616553,,,,H,8,,
1770,Binding affinity towards 5-HT1B was determined,Autocuration,,,B,,BAO_0000357,9098,,,1,CHEMBL616554,,,,H,8,,
1771,Affinity towards 5-hydroxytryptamine 1B receptor in membranes from rat frontal cortex using [3H]5-HT,Expert,,,B,,BAO_0000019,14430,,,1,CHEMBL616555,,,,H,8,,
1772,"Binding affinity to 5-HT1B receptors using rat cortex+striatum + globus pallidus,[3H]-5-OH-tryptamine, and serotonin for NSB",Expert,,,B,,BAO_0000019,13657,,,1,CHEMBL616556,,,,H,8,,
1773,"Compound was evaluated for binding affinity on 5-HT1B receptors using rat cortex+striatum+ globus pallidus,[ 3H]-5-OH-tryptamine, and serotonin for NSB.",Autocuration,,,B,,BAO_0000019,13657,,,1,CHEMBL616557,,,,H,8,,
1774,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,Expert,,,B,,BAO_0000019,15854,,,1,CHEMBL616558,,,,H,8,,
1775,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat cortex using [3H]5-HT,Expert,10116.0,,B,,BAO_0000019,10639,,,1,CHEMBL616749,,,Rattus norvegicus,D,9,,
1776,Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol binding to 5-hydroxytryptamine 1B receptor at 1 uM,Autocuration,,,B,,BAO_0000357,10025,,,1,CHEMBL616750,,,,H,8,,
1777,"Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol, binds to 5-hydroxytryptamine 1B receptor at 1 uM",Autocuration,,,B,,BAO_0000357,10025,,,1,CHEMBL616751,,,,H,8,,
1778,In vitro inhibitory concentration against radioligand [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatal membrane,Autocuration,,,B,,BAO_0000249,14286,,,1,CHEMBL616752,,,,H,8,,
1779,Inhibition of [3H]-5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatum; Residual radioligand binding higher than 50%,Autocuration,,,B,,BAO_0000019,3651,,,1,CHEMBL616753,,,,H,8,2435.0,
1780,Inhibition of radiolabeled [3H]-5-HT ligand binding to 5-hydroxytryptamine 1B receptor,Expert,10116.0,,B,,BAO_0000357,14178,,,1,CHEMBL616754,,,Rattus norvegicus,D,9,,
1781,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat cortex using [3H]5-HT as the radioligand.,Autocuration,,,B,,BAO_0000019,10639,,,1,CHEMBL616755,,,,H,8,,
1782,Inhibitory activity against [3H]5-HT binding to 5-HT1B receptor in rat striatum,Autocuration,,,B,,BAO_0000019,13605,,,1,CHEMBL616756,,,,H,8,2435.0,
1783,Inhibitory concentration required against 5-hydroxytryptamine 1B receptor in rat striatum using [3H]5-HT,Autocuration,,,B,,BAO_0000019,5834,,,1,CHEMBL616757,,,,H,8,2435.0,
1784,compound was measured for affinity against 5-hydroxytryptamine 1B receptor labelled with [3H]5-HT radioligand in striatum tissue,Autocuration,,,B,,BAO_0000357,10922,,,1,CHEMBL616758,,,,H,8,2435.0,
1785,Compound at 10E-5 M was tested in vitro for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatal membrane,Autocuration,,,B,,BAO_0000249,14286,,,1,CHEMBL616759,,,,H,8,,
1786,In vitro binding affinity towards the 5-hydroxytryptamine 1B receptor at 10 e-6 M,Autocuration,,,B,,BAO_0000357,11825,,,1,CHEMBL616760,,,,H,8,,
1787,Ability to displace [3H]5-HT bound to 5-hydroxytryptamine 1B receptor in rat striatum,Autocuration,,,B,,BAO_0000019,14826,,,1,CHEMBL616761,,,,H,8,2435.0,
1788,Binding affinity against 5-HT1B serotonin receptor in rat striatum,Autocuration,,,B,,BAO_0000019,9699,,,1,CHEMBL616762,,,,H,8,2435.0,
1789,Binding affinity against 5-hydroxytryptamine 1B receptor in membranes of Rat cerebral cortex,Autocuration,,,B,,BAO_0000019,14423,,,1,CHEMBL616763,,,,H,8,,
1790,Binding affinity at rat 5-hydroxytryptamine 1B receptor by [3H]5-HT displacement.,Expert,,,B,,BAO_0000357,10062,,,1,CHEMBL872909,,,,H,8,,
1791,Binding affinity determined in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1B receptor,Autocuration,,,B,,BAO_0000357,10062,,,1,CHEMBL616764,,,,H,8,,
1792,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1B receptor,Expert,10116.0,,B,,BAO_0000357,12280,,,1,CHEMBL616765,,,Rattus norvegicus,D,9,,
1793,Binding affinity against 5-hydroxytryptamine 1B receptor of rat striatum,Autocuration,,,B,,BAO_0000357,15412,,,1,CHEMBL616766,,,,H,8,2435.0,
1794,Binding affinity against 5-hydroxytryptamine 1B receptor of rat striatum.,Autocuration,,,B,,BAO_0000357,15412,,,1,CHEMBL616767,,,,H,8,2435.0,
1795,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1B receptor,Autocuration,,,B,,BAO_0000357,10062,,,1,CHEMBL616768,,,,H,8,,
1796,Binding affinity towards 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand,Autocuration,,,B,,BAO_0000357,11147,,,1,CHEMBL616769,,,,H,8,,
1797,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat was determined using 50 uL of [125I]ICYP in binding assay,Autocuration,,,B,,BAO_0000019,9547,,,1,CHEMBL616770,,,,H,8,,
1798,Binding affinity was determined against 5-hydroxytryptamine 1B receptor was determined in male Sprague-Dawley rat brain.,Autocuration,,,B,,BAO_0000019,10444,,,1,CHEMBL616771,,,,H,8,,
1799,Binding affinity was measured on 5-hydroxytryptamine 1B receptor in rat striatum labeled with [3H]5-HT,Autocuration,,,B,,BAO_0000019,12469,,,1,CHEMBL616772,,,,H,8,2435.0,
1800,Binding affinity (Ki) to rat cortical membranes at 5-HT1B binding site by using [125 I] ICYP as a radioligand.,Expert,,,B,,BAO_0000019,9098,,,1,CHEMBL616773,,,,H,8,,
1801,Compound was evaluated for the binding affinity (Ki) to rat cortical membranes at 5-HT1B binding site by using [125 I] ICYP as a radioligand; ND is no data.,Autocuration,,,B,,BAO_0000019,9098,,,1,CHEMBL616774,,,,H,8,,
1802,Evaluated for binding affinity towards 5-hydroxytryptamine 1B receptor,Autocuration,,,B,,BAO_0000357,9699,,,1,CHEMBL616775,,,,H,8,,
1803,Inhibitory activity against 5-hydroxytryptamine 1B receptor in rat cortical membranes using [3H]5-HT as a radioligand,Autocuration,,,B,,BAO_0000249,10394,,,1,CHEMBL616776,,,,H,8,,
1804,The binding affinity was measured on 5-hydroxytryptamine 1B receptor using [3H]- serotonin as radioligand.,Autocuration,,,B,,BAO_0000357,12092,,,1,CHEMBL616777,,,,H,8,,
1805,The binding affinity towards the receptor rat 5-hydroxytryptamine 1B receptor; No affinity,Autocuration,,,B,,BAO_0000357,16700,,,1,CHEMBL616778,,,,H,8,,
1806,Binding affinity against 5-hydroxytryptamine 1B receptor in rat striatal membranes using [3H]5-HT as radioligand,Expert,10116.0,,B,,BAO_0000249,403,,,1,CHEMBL616779,,,Rattus norvegicus,D,9,,
1807,Binding affinity towards 5-hydroxytryptamine 1B receptor,Expert,10116.0,,B,,BAO_0000357,12771,,,1,CHEMBL616780,,,Rattus norvegicus,D,9,,
1808,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1B receptor by displacing [3H]serotonin radioligand in rat cerebral cortex,Autocuration,,,B,,BAO_0000019,11642,,,1,CHEMBL616781,,,,H,8,,
1809,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand,Autocuration,,,B,,BAO_0000357,12953,,,1,CHEMBL616782,,,,H,8,,
1810,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand.,Autocuration,,,B,,BAO_0000357,12953,,,1,CHEMBL616783,,,,H,8,,
1811,Binding affinity for 5-hydroxytryptamine 1B receptor in rat striatum using [3H]5-HT as radioligand,Expert,,,B,,BAO_0000019,12953,,,1,CHEMBL616784,,,,H,8,2435.0,
1812,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand; Nonactive at 10 uM,Autocuration,,,B,,BAO_0000357,12953,,,1,CHEMBL616785,,,,H,8,,
1813,Binding affinity against 5-HT1B receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,Autocuration,,,B,,BAO_0000249,9737,,,1,CHEMBL857067,,,,H,8,955.0,
1814,Binding affinity against 5-HT1B receptor in rat frontal cortex using [3H]-5-HT in presence of 0.1 uM [3H]-8-OH-DPAT as a radioligand,Autocuration,,,B,,BAO_0000019,9737,,,1,CHEMBL616786,,,,H,8,,
1815,Binding affinity towards 5-HT1B receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,Autocuration,,,B,,BAO_0000249,9737,,,1,CHEMBL616787,,,,H,8,955.0,
1816,Binding affinity towards 5-hydroxytryptamine 2C receptor of porcine choroid plexus using [3H]mesulergine,Autocuration,,,B,,BAO_0000357,12827,,,1,CHEMBL616788,,,,H,8,,
1817,Ability to displace the radioligand [125I](-)-iodocyanopindolol from rat striatal 5-hydroxytryptamine 1B receptor,Autocuration,,,B,,BAO_0000357,5033,,,1,CHEMBL616789,,,,H,8,,
1818,Displacement of [3H]5-HT from 5-HT1B receptor of rat frontal cortex homogenate,Expert,10116.0,,B,,BAO_0000019,9786,,,1,CHEMBL616790,,,Rattus norvegicus,D,9,,
1819,Binding affinity at 5-hydroxytryptamine 1B receptor,Expert,,,B,,BAO_0000357,13116,,,1,CHEMBL616791,,,,H,8,,
1820,In vitro binding affinity at 5-hydroxytryptamine 1B receptor in rat striatal muscles using [125I](-)-iodocyanopindolol as the radioligand,Autocuration,,,B,,BAO_0000019,16429,,,1,CHEMBL616792,,,,H,8,,
1821,In vitro binding affinity towards 5-hydroxytryptamine 1B receptor in rat striatal membrane with [125I]- iodocyanopindolol,Expert,10116.0,,B,,BAO_0000249,12409,,,1,CHEMBL616793,,,Rattus norvegicus,D,9,,
1822,The compound was tested for the binding affinity against 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand,Autocuration,,,B,,BAO_0000357,15194,,,1,CHEMBL616794,,,,H,8,,
1823,The compound was tested for the binding affinity against 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,Autocuration,,,B,,BAO_0000357,15194,,,1,CHEMBL616795,,,,H,8,,
1824,Binding affinity towards 5-HT2 receptor by the displacement of [3H]-ketanserin] in rat cerebral cortex,Autocuration,,,B,,BAO_0000019,5486,,,1,CHEMBL616796,,,,H,4,,
1825,Compound was tested for binding affinity against 5-hydroxytryptamine 1B receptor,Autocuration,,,B,,BAO_0000357,4639,,,1,CHEMBL616797,,,,H,8,,
1826,The compound was evaluated for its ability to displace [3H]5-HT from 5-hydroxytryptamine 1B receptor in cellular brain membranes,Autocuration,,,B,,BAO_0000249,386,Brain membranes,,1,CHEMBL616798,,,,H,8,,
1827,Compound was measured for its binding affinity at 5-hydroxytryptamine 1B receptor at a concentration of 100 nM using [125I]CYP as radioligand,Autocuration,,,B,,BAO_0000357,2474,,,1,CHEMBL616799,,,,H,8,,
1828,Inhibition of binding towards 5-hydroxytryptamine 1B receptor at 100 nM concentration,Autocuration,,,B,,BAO_0000357,6011,,,1,CHEMBL616800,,,,H,8,,
1829,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1B receptor,Autocuration,,,B,,BAO_0000357,5014,,,1,CHEMBL616801,,,,H,8,,
1830,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1B receptor; inactive at 10 uM,Autocuration,,,B,,BAO_0000357,17515,,,1,CHEMBL616802,,,,H,8,,
1831,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1B receptor was determined,Autocuration,,,B,,BAO_0000357,4373,,,1,CHEMBL616803,,,,H,8,,
1832,Binding affinity towards 5-hydroxytryptamine 1B receptor by displacement of [3H]5-HT.,Expert,,,B,,BAO_0000357,1633,,,1,CHEMBL857068,,,,H,8,,
1833,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 1B receptor by displacement of [3H]ketanserin.,Autocuration,,,B,,BAO_0000357,1633,,,1,CHEMBL616804,,,,H,8,,
1834,Binding affinity for 5-hydroxytryptamine 1B receptor was determined,Autocuration,,,B,,BAO_0000357,4373,,,1,CHEMBL616805,,,,H,8,,
1835,Evaluated for the binding affinity to 5-hydroxytryptamine 1B receptor,Autocuration,,,B,,BAO_0000357,4687,,,1,CHEMBL616806,,,,H,8,,
1836,Binding affinity against 5-hydroxytryptamine 1B receptor,Autocuration,,,B,,BAO_0000357,11574,,,1,CHEMBL616807,,,,H,8,,
1837,Binding affinity for 5-hydroxytryptamine 1B receptor was determined by using [3H]5-HT as radioligand,Autocuration,,,B,,BAO_0000357,10321,,,1,CHEMBL616808,,,,H,8,,
1838,Binding affinity towards 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,Autocuration,,,B,,BAO_0000357,15527,,,1,CHEMBL616809,,,,H,8,,
1839,Inhibitory constant against 5-hydroxytryptamine 1B receptor using with [125I]- cyanopindolol radioligand,Autocuration,,,B,,BAO_0000357,17200,,,1,CHEMBL616810,,,,H,8,,
1840,Binding affinity against 5-hydroxytryptamine 1B receptor - 5-hydroxytryptamine 1D receptor using [3H]5-HT as the radioligand.,Autocuration,,,B,,BAO_0000224,14423,,,1,CHEMBL616811,,,,H,4,,
1841,Inhibitory concentration required against 5-hydroxytryptamine 1C receptor in bovine choroid plexus using [3H]mesulergine,Autocuration,9913.0,,B,,BAO_0000357,5834,,,1,CHEMBL616812,,,Bos taurus,H,8,,
1842,Binding affinity towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand,Autocuration,9823.0,,B,,BAO_0000357,11473,,,1,CHEMBL616813,,,Sus scrofa,H,8,,
1843,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1C receptor in pig choroid plexus using [3H]mesulergine as radioligand,Autocuration,9823.0,,B,,BAO_0000357,11473,,,1,CHEMBL616814,,,Sus scrofa,H,8,,
1844,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 1C receptor of pig choroid plexus using [3H]mesulergine as the radioligand,Autocuration,9823.0,,B,,BAO_0000357,10639,,,1,CHEMBL616815,,,Sus scrofa,H,8,,
1845,inhibitory activity against 5-hydroxytryptamine 1C receptor of pig choroid plexus using [3H]mesulergine as the radioligand,Autocuration,9823.0,,B,,BAO_0000357,10639,,,1,CHEMBL616816,,,Sus scrofa,H,8,,
1846,Binding affinity of compound towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine (1.2 nM) ligand in choroid Plexus pig was determined,Autocuration,9823.0,,B,,BAO_0000357,14331,,,1,CHEMBL616817,,,Sus scrofa,H,8,,
1847,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 1C receptor,Autocuration,9823.0,,B,,BAO_0000357,10796,,,1,CHEMBL616818,,,Sus scrofa,H,8,,
1848,Evaluated for the binding affinity to porcine choroid plexus at 5-hydroxytryptamine 2C receptor binding site by using [3H]-MES as a radioligand.,Expert,9823.0,,B,,BAO_0000357,9098,,,1,CHEMBL616819,,,Sus scrofa,H,8,,
1849,Inhibition of [3H]mesulergine binding to 5-hydroxytryptamine 1C receptor of pig choroid Plexus,Expert,9823.0,,B,,BAO_0000357,14331,,,1,CHEMBL616820,,,Sus scrofa,H,8,,
1850,Displacement of [3H]mesulergine from pig cortex 5-hydroxytryptamine 1C receptor,Expert,9823.0,,B,,BAO_0000019,11828,,,1,CHEMBL616821,,,Sus scrofa,H,8,,
1851,Binding affinity for 5-hydroxytryptamine 1C receptor in piglet choroid plexus using [3H]5-HT,Autocuration,9823.0,,B,,BAO_0000357,11866,,,1,CHEMBL616822,,,Sus scrofa,H,8,,
1852,Binding affinity against 5-hydroxytryptamine 1D receptor alpha using rabbit saphenous vein assay.,Autocuration,9986.0,,B,,BAO_0000019,13047,,,1,CHEMBL616823,,,Oryctolagus cuniculus,H,8,,
1853,Tested for the effect on binding at 5-hydroxytryptamine 1C receptor; No activity,Autocuration,10116.0,,B,,BAO_0000357,188,,,1,CHEMBL616824,,,Rattus norvegicus,D,9,,
1854,In vitro binding affinity towards the 5-hydroxytryptamine 1C receptor at 10 e-6 M,Autocuration,10116.0,,B,,BAO_0000357,11825,,,1,CHEMBL616825,,,Rattus norvegicus,D,9,,
1855,In vitro binding affinity towards the 5-hydroxytryptamine 1C receptor at 10 e-6 M,Autocuration,10116.0,,B,,BAO_0000357,11825,,,1,CHEMBL616826,,,Rattus norvegicus,D,9,,
1856,Binding affinity against 5-hydroxytryptamine 1C receptor in rat using [3H]mesulergine as radioligand,Expert,10116.0,,B,,BAO_0000019,11624,,,1,CHEMBL616827,,,Rattus norvegicus,D,9,,
1857,Binding affinity towards 5-hydroxytryptamine 1C receptor using [125 I]-SCH23982 as radioligand in competitive binding assay,Autocuration,10116.0,,B,,BAO_0000357,11139,,,1,CHEMBL616828,,,Rattus norvegicus,D,9,,
1858,Binding affinity towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand,Autocuration,10116.0,,B,,BAO_0000357,11147,,,1,CHEMBL616829,,,Rattus norvegicus,D,9,,
1859,Binding affinity was determined against 5-hydroxytryptamine 1C receptor was determined in male Sprague-Dawley rat brain.,Autocuration,10116.0,,B,,BAO_0000019,10444,,,1,CHEMBL616830,,,Rattus norvegicus,D,9,,
1860,Binding affinity against 5-hydroxytryptamine 1C receptor,Expert,10116.0,,B,,BAO_0000357,11624,,,1,CHEMBL616831,,,Rattus norvegicus,D,9,,
1861,"Compound was tested for binding affinity towards 5-HT1C (5-HT1C) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",Autocuration,10116.0,,B,,BAO_0000019,11662,,,1,CHEMBL616832,,,Rattus norvegicus,D,9,,
1862,"Compound was tested for binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",Autocuration,10116.0,,B,,BAO_0000019,11662,,,1,CHEMBL616833,,,Rattus norvegicus,D,9,,
1863,"Binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",Expert,10116.0,,B,,BAO_0000019,11662,,,1,CHEMBL616834,,,Rattus norvegicus,D,9,,
1864,"Compound was tested for binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",Autocuration,10116.0,,B,,BAO_0000019,11662,,,1,CHEMBL829595,,,Rattus norvegicus,D,9,,
1865,Evaluated for the binding affinity to porcine choroid plexus at 5-hydroxytryptamine 1C receptor binding site by using [3H]- MES as a radioligand.,Autocuration,10116.0,,B,,BAO_0000357,9098,,,1,CHEMBL616835,,,Rattus norvegicus,D,9,,
1866,Inhibitory activity against 5-hydroxytryptamine 1C receptor in rat cortical membranes using [3H]mesulergine as a radioligand,Autocuration,10116.0,,B,,BAO_0000249,10394,,,1,CHEMBL872910,,,Rattus norvegicus,D,9,,
1867,Tested for binding affinity against 5-hydroxytryptamine 1C receptor from rat frontal cortical regions using [3H]mesulergine as radioligand,Expert,,,B,,BAO_0000357,11933,,,1,CHEMBL616836,,,,H,8,,
1868,The binding affinity was measured on 5-hydroxytryptamine 1C receptor using [3H]- serotonin as radioligand.,Autocuration,10116.0,,B,,BAO_0000357,12092,,,1,CHEMBL616837,,,Rattus norvegicus,D,9,,
1869,Binding affinity of 5-hydroxytryptamine 1C receptor using [3H]- ketanserin in rat frontal cortex,Autocuration,10116.0,,B,,BAO_0000019,12253,,,1,CHEMBL616466,,,Rattus norvegicus,D,9,,
1870,Binding affinity towards rat 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand expressed in 293 cells,Autocuration,10116.0,,B,,BAO_0000219,12253,,722.0,1,CHEMBL616467,HEK293,,Rattus norvegicus,D,9,,
1871,Compound was tested for its affinity towards 5-hydroxytryptamine 1C receptor,Autocuration,,,B,,BAO_0000357,1558,,,1,CHEMBL616468,,,,H,8,,
1872,Compound was measured for its binding affinity at 5-hydroxytryptamine 1C receptor at a concentration of 100 nM using [3H]mesulergine as radioligand,Autocuration,,,B,,BAO_0000357,2474,,,1,CHEMBL616469,,,,H,8,,
1873,Compound was measured for its binding affinity at 5-hydroxytryptamine 1C receptor at a concentration of 100 nM using [3H]mesulergine as radioligand,Autocuration,,,B,,BAO_0000357,2474,,,1,CHEMBL616470,,,,H,8,,
1874,Binding affinity against 5-hydroxytryptamine 1C receptor,Autocuration,,,B,,BAO_0000357,11574,,,1,CHEMBL616471,,,,H,8,,
1875,Compound was tested for its affinity towards 5-hydroxytryptamine 1C receptor,Autocuration,,,B,,BAO_0000357,1558,,,1,CHEMBL616472,,,,H,8,,
1876,Binding affinity against 5-hydroxytryptamine 1C receptor,Autocuration,,,B,,BAO_0000357,13944,,,1,CHEMBL616473,,,,H,8,,
1877,Binding affinity against serotonergic 5-HT1c receptor,Autocuration,,,B,,BAO_0000357,13033,,,1,CHEMBL616474,,,,H,8,,
1878,Binding affinity for 5-hydroxytryptamine 1C receptor was determined by using [3H]- mesulergine as radioligand,Autocuration,,,B,,BAO_0000357,10321,,,1,CHEMBL616475,,,,H,8,,
1879,Binding affinity for 5-hydroxytryptamine 1C receptor was determined,Autocuration,,,B,,BAO_0000357,11866,,,1,CHEMBL616476,,,,H,8,,
1880,Compound was tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),Autocuration,9986.0,,B,,BAO_0000019,14454,,,1,CHEMBL616477,,,Oryctolagus cuniculus,H,8,,
1881,Binding affinity against 5-hydroxytryptamine 2 receptor using [125I]DOI as radioligand.,Autocuration,,,B,,BAO_0000224,11574,,,1,CHEMBL616478,,,,H,4,,
1882,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ket as radioligand.,Autocuration,,,B,,BAO_0000224,11574,,,1,CHEMBL616479,,,,H,4,,
1883,Binding affinity towards serotonin 5-HT2 receptor was determined in rat cortex using [3H]spiperone as ligand,Autocuration,,,B,,BAO_0000019,13631,,,1,CHEMBL616480,,,,H,4,,
1884,Binding affinity towards 5-hydroxytryptamine 2 receptor as antagonism of serotonin-induced contractions in rat jugular vein,Autocuration,10116.0,,B,,BAO_0000019,9630,,,1,CHEMBL616481,,,Rattus norvegicus,D,5,,
1885,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain cortical membranes,Autocuration,10116.0,,B,,BAO_0000249,8822,,,1,CHEMBL616482,,,Rattus norvegicus,D,5,,
1886,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain using [3H]spiroperidol,Autocuration,10116.0,,B,,BAO_0000221,9064,,,1,CHEMBL884713,,,Rattus norvegicus,D,5,955.0,
1887,Binding affinity towards 5-hydroxytryptamine 2 receptor measured using radioligand ([3H]spiperone) binding assay,Autocuration,,,B,,BAO_0000224,8868,,,1,CHEMBL616483,,,,H,4,,
1888,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- spiroperidol,Autocuration,,,B,,BAO_0000224,9064,,,1,CHEMBL616484,,,,H,4,,
1889,Binding affinity at 5-hydroxytryptamine 2 receptor from rat frontal cortex homogenates by [3H]-spiperone displacement.,Autocuration,,,B,,BAO_0000019,9806,,,1,CHEMBL616485,,,,H,4,,
1890,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,Autocuration,,,B,,BAO_0000224,9098,,,1,CHEMBL616486,,,,H,4,,
1891,Binding affinity towards 5-hydroxytryptamine 2 receptor was measured using radioligand ([3H]spiperone) binding assay,Autocuration,,,B,,BAO_0000224,8868,,,1,CHEMBL616487,,,,H,4,,
1892,Binding affinity at serotonin 5-hydroxytryptamine 2 receptor by [3H]ketanserin displacement.,Autocuration,,,B,,BAO_0000224,12765,,,1,CHEMBL616488,,,,H,4,,
1893,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,Autocuration,,,B,,BAO_0000019,11049,,,1,CHEMBL616489,,,,H,4,,
1894,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,Autocuration,,,B,,BAO_0000019,11049,,,1,CHEMBL616490,,,,H,4,,
1895,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]-Ketanserin as radioligand; not determined,Autocuration,,,B,,BAO_0000019,11049,,,1,CHEMBL616491,,,,H,4,,
1896,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand; ND-Not determined,Autocuration,,,B,,BAO_0000019,11049,,,1,CHEMBL616492,,,,H,4,,
1897,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,Autocuration,,,B,,BAO_0000019,11049,,,1,CHEMBL616493,,,,H,4,,
1898,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor in rat anterior cortex using [125I]DOI as radioligand,Autocuration,,,B,,BAO_0000019,11473,,,1,CHEMBL616494,,,,H,4,,
1899,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor in rat anterior cortex using [3H]ketanserin as radioligand,Autocuration,,,B,,BAO_0000019,11473,,,1,CHEMBL616495,,,,H,4,,
1900,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat pre frontal cortex,Autocuration,,,B,,BAO_0000019,3086,,,1,CHEMBL616496,,,,H,4,,
1901,Compound was evaluated for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,Autocuration,,,B,,BAO_0000019,11049,,,1,CHEMBL616497,,,,H,4,,
1902,Compound was evaluated for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,Autocuration,,,B,,BAO_0000019,11049,,,1,CHEMBL616498,,,,H,4,,
1903,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 2 receptor of rat anterior cortex using [3H]ketanserin as the radioligand,Autocuration,,,B,,BAO_0000019,10639,,,1,CHEMBL616499,,,,H,4,,
1904,Compound was measured for affinity at 5-hydroxytryptamine 2 receptor in rat cortical by [3H]spiroperidol displacement.,Autocuration,,,B,,BAO_0000019,10922,,,1,CHEMBL616500,,,,H,4,,
1905,Binding affinity against serotonin-2 receptor in rat brain using [3H]spiroperidol,Autocuration,10116.0,,B,,BAO_0000221,9064,,,1,CHEMBL616501,,,Rattus norvegicus,D,5,955.0,
1906,Compound was tested for its inhibitory effect on the binding profile in 5-hydroxytryptamine 2 receptor using [3H]spiroperidol in rat brain.,Autocuration,,,B,,BAO_0000221,10748,,,1,CHEMBL616502,,,,H,4,955.0,
1907,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor from rat cortical membranes.,Autocuration,,,B,,BAO_0000249,11614,Membranes,,1,CHEMBL884529,,,,H,4,,
1908,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat cortical membranes,Autocuration,,,B,,BAO_0000249,11615,Membranes,,1,CHEMBL616503,,,,H,4,,
1909,Compound was tested for the displacement of [3H]ketanserin from serotonin 5-hydroxytryptamine 2 receptor,Autocuration,,,B,,BAO_0000224,11615,,,1,CHEMBL616964,,,,H,4,,
1910,Compound was tested for the displacement of [3H]ketanserin from serotonin 5-hydroxytryptamine 2 receptor from rat cortical membranes.,Autocuration,,,B,,BAO_0000249,11614,Membranes,,1,CHEMBL616965,,,,H,4,,
1911,Inhibition of [3H]ketanserin binding to rat 5-hydroxytryptamine 2 receptors.,Autocuration,,,B,,BAO_0000224,11702,,,1,CHEMBL616966,,,,H,4,,
1912,Compound was tested for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor; NT=Not tested,Autocuration,,,B,,BAO_0000224,11702,,,1,CHEMBL616967,,,,H,4,,
1913,Inhibition of [3H]ketanserin binding to dopamine 5-hydroxytryptamine 2 receptor,Autocuration,10116.0,,B,,BAO_0000224,11702,,,1,CHEMBL616968,,,Rattus norvegicus,D,5,,
1914,Compound was tested for the inhibition of [3H]ketanserin binding to dopamine 5-hydroxytryptamine 2 receptor; NT=Not tested,Autocuration,,,B,,BAO_0000224,11702,,,1,CHEMBL616969,,,,H,4,,
1915,Inhibition of [3H]ketanserin binding at 5-hydroxytryptamine 2 receptor from rat frontal cortex.,Autocuration,,,B,,BAO_0000019,13346,,,1,CHEMBL884530,,,,H,4,,
1916,Concentration necessary to achieve half maximal inhibition of [3H]-ketanserin binding to 5-hydroxytryptamine 2 receptor,Autocuration,,,B,,BAO_0000224,10025,,,1,CHEMBL616970,,,,H,4,,
1917,Concentration necessary to achieve half maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 1 uM,Autocuration,,,B,,BAO_0000224,10025,,,1,CHEMBL616971,,,,H,4,,
1918,"Concentration necessary to achieve half maximal inhibition of [3H]ketanserin, binds to 5-hydroxytryptamine 2 receptor at 1 uM",Autocuration,,,B,,BAO_0000224,10025,,,1,CHEMBL616972,,,,H,4,,
1919,Evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using radioligand [3H]-spiperone,Autocuration,,,B,,BAO_0000224,9036,,,1,CHEMBL616973,,,,H,4,,
1920,Evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using radioligand [3H]spiperone; IA=Inactive,Autocuration,,,B,,BAO_0000224,9036,,,1,CHEMBL616974,,,,H,4,,
1921,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.,Autocuration,,,B,,BAO_0000019,9161,,,1,CHEMBL616975,,,,H,4,,
1922,Inhibition of binding of radioligand [3H]ketanserin to 5-hydroxytryptamine 2 receptor in rat cerebral cortex,Autocuration,,,B,,BAO_0000019,12304,,,1,CHEMBL616976,,,,H,4,,
1923,In vitro binding affinity measured on serotonin 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand.,Autocuration,,,B,,BAO_0000224,13276,,,1,CHEMBL616977,,,,H,4,,
1924,In vitro binding affinity towards the 5-hydroxytryptamine 2 receptor at 10 e-6 M,Autocuration,,,B,,BAO_0000224,11825,,,1,CHEMBL616978,,,,H,4,,
1925,In vitro binding affinity was measured on serotonergic 5-hydroxytryptamine 2 receptor by displacement of [3H]- ketanserin,Autocuration,,,B,,BAO_0000224,12443,,,1,CHEMBL616979,,,,H,4,,
1926,In vitro inhibitory activity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor,Autocuration,,,B,,BAO_0000224,13830,,,1,CHEMBL616980,,,,H,4,,
1927,Inhibition of [3H]spiperone binding to 5-hydroxytryptamine 2 receptor from rat cortical membranes,Autocuration,,,B,,BAO_0000249,9592,Membranes,,1,CHEMBL616981,,,,H,4,,
1928,Inhibition of [3H]spiperone binding to 5-hydroxytryptamine 2 receptor from rat cortical membranes; Not tested,Autocuration,,,B,,BAO_0000249,9592,Membranes,,1,CHEMBL616982,,,,H,4,,
1929,Inhibitory activity against 5-hydroxytryptamine 2 receptor by 3H ligand binding experiments.,Autocuration,,,B,,BAO_0000224,10881,,,1,CHEMBL616983,,,,H,4,,
1930,Inhibitory activity against [3H]spiroperidol binding to 5-HT2 receptor in rat cortex,Autocuration,,,B,,BAO_0000019,13605,,,1,CHEMBL616984,,,,H,4,,
1931,Inhibitory activity against 5-hydroxytryptamine 2 receptor,Autocuration,10116.0,,B,,BAO_0000224,11624,,,1,CHEMBL616985,,,Rattus norvegicus,D,5,,
1932,Inhibitory concentration against 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]-ketanserin,Autocuration,,,B,,BAO_0000224,4101,,,1,CHEMBL616986,,,,H,4,,
1933,Inhibitory concentration against binding of 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]-ketanserin,Autocuration,,,B,,BAO_0000224,4101,,,1,CHEMBL616987,,,,H,4,,
1934,Inhibitory concentration against radioligand [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat,Autocuration,,,B,,BAO_0000019,15360,,,1,CHEMBL616988,,,,H,4,,
1935,Inhibitory concentration against radioligand [3H]spiperone binding to 5-hydroxytryptamine 2 receptor in rat cortex,Autocuration,,,B,,BAO_0000019,11576,,,1,CHEMBL617243,,,,H,4,,
1936,Inhibitory concentration required against 5-hydroxytryptamine 2 receptor in rat cortex using [3H]spiperone,Autocuration,,,B,,BAO_0000019,5834,,,1,CHEMBL617244,,,,H,4,,
1937,Inhibitory concentration against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,Autocuration,10116.0,,B,,BAO_0000219,2395,,485.0,1,CHEMBL617245,CHO-K1,,Rattus norvegicus,D,5,,
1938,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat cortical membranes,Autocuration,,,B,,BAO_0000249,11965,Membranes,,1,CHEMBL617246,,,,H,4,,
1939,The compound was evaluated for the ability to displace [3H]ketanserin from 5-hydroxytryptamine 2 receptor ( striata of male wistar rats),Autocuration,,,B,,BAO_0000224,3967,,,1,CHEMBL617546,,,,H,4,,
1940,The concentration required to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat brain membranes (in vitro),Autocuration,,,B,,BAO_0000249,11130,Brain membranes,,1,CHEMBL617547,,,,H,4,,
1941,Binding affinity of [3H]ketanserin towards 5-hydroxytryptamine 2 receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,Autocuration,,,B,,BAO_0000219,13427,,,1,CHEMBL617548,,,,H,4,,
1942,Binding affinity towards 5-hydroxytryptamine 2 receptor,Autocuration,,,B,,BAO_0000224,9443,,,1,CHEMBL617549,,,,H,4,,
1943,Binding affinity towards 5-hydroxytryptamine 2 receptor at 1.0 uM concentration,Autocuration,,,B,,BAO_0000224,9443,,,1,CHEMBL617550,,,,H,4,,
1944,In vitro binding affinity towards the 5-hydroxytryptamine 2 receptor at 10 e-6 M,Autocuration,,,B,,BAO_0000224,11825,,,1,CHEMBL617551,,,,H,4,,
1945,Percent inhibition of binding of 1.0 nM [3H]ketanserin to 5-hydroxytryptamine 2 receptor in rat cortical membranes at 10 e -5 M,Autocuration,,,B,,BAO_0000249,12120,Membranes,,1,CHEMBL617552,,,,H,4,,
1946,Percent inhibition of binding of 1.0 nM [3H]-ketanserin to 5-hydroxytryptamine 2 receptor in rat cortical membranes at 10 e-5 M.,Autocuration,,,B,,BAO_0000249,12120,Membranes,,1,CHEMBL617553,,,,H,4,,
1947,Tested for antagonistic activity against 5-hydroxytryptamine 2 receptor from rat thoracic aorta,Autocuration,,,F,,BAO_0000019,11963,,,1,CHEMBL617554,,,,H,4,1515.0,
1948,Binding affinity for membrane-bound 5-hydroxytryptamine 2 receptor,Autocuration,,,B,,BAO_0000019,9069,,,1,CHEMBL617555,,,,H,4,,
1949,Compound was tested for its effect on 5-hydroxytryptamine 2 receptor saturation analysis,Autocuration,,,B,,BAO_0000224,8868,,,1,CHEMBL617556,,,,H,4,,
1950,Inhibitory constant against human 5-hydroxytryptamine 1B receptor using [3H]5-CT radioligand,Autocuration,,,B,,BAO_0000357,17200,,,1,CHEMBL617557,,,,H,8,,
1951,Inhibitory constant against human 5-hydroxytryptamine 1D receptor using [3H]5-CT radioligand,Autocuration,,,B,,BAO_0000357,17200,,,1,CHEMBL617558,,,,H,8,,
1952,Binding affinity against 5-hydroxytryptamine 1D receptor was measured using [3H]5-HT as radioligand,Expert,,,B,,BAO_0000357,13969,,,1,CHEMBL617559,,,,H,8,,
1953,Binding affinity for 5-hydroxytryptamine 1D receptor,Expert,,,B,,BAO_0000357,13392,,,1,CHEMBL617560,,,,D,9,,
1954,Compound was tested for its ability to displace [125I]GTI binding to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,Autocuration,,,B,,BAO_0000249,1742,,,1,CHEMBL617561,,,,H,8,,
1955,Compound was tested for its ability to displace [3H]-5-HT binding to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,Autocuration,,,B,,BAO_0000249,1742,,,1,CHEMBL617562,,,,H,8,,
1956,Binding affinity against 5-hydroxytryptamine 1D receptor using [3H]5-HT in pig striatum + frontalCortex,Autocuration,,,B,,BAO_0000357,14331,,,1,CHEMBL617563,,,,H,8,2435.0,
1957,Relative agonist efficacy against 1 uM 5-hydroxytryptamine 1D receptor,Autocuration,,,F,,BAO_0000019,12861,,,1,CHEMBL617564,,,,H,8,,
1958,Binding activity against 5-hydroxytryptamine 1D receptor from pig caudate membrane using [3H]5-HT as radioligand,Expert,,,B,,BAO_0000019,12861,,,1,CHEMBL617565,,,,H,8,,
1959,Binding activity radioligand.,Autocuration,,,B,,BAO_0000357,12861,,,1,CHEMBL856076,,,,H,8,,
1960,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,Autocuration,,,B,,BAO_0000019,12861,,,1,CHEMBL617566,,,,H,8,,
1961,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,Expert,,,B,,BAO_0000019,12861,,,1,CHEMBL875911,,,,H,8,,
1962,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand; NA Not Available,Autocuration,,,B,,BAO_0000019,12861,,,1,CHEMBL617567,,,,H,8,,
1963,Compound was tested for the displacement of [3H]-5-HT to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,Autocuration,,,B,,BAO_0000249,675,,,1,CHEMBL617568,,,,H,8,,
1964,Displacement of [3H]5-HT binding to 5-hydroxytryptamine 1D receptor from pig caudate membrane,Expert,,,B,,BAO_0000019,12490,,,1,CHEMBL617569,,,,H,8,,
1965,Displacement of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1D receptor in pig caudate membrane,Expert,,,B,,BAO_0000249,11828,,,1,CHEMBL617570,,,,H,8,,
1966,Binding affinity for 5-hydroxytryptamine 1D receptor in piglet caudate using [3H]5-HT,Autocuration,,,B,,BAO_0000357,11866,,,1,CHEMBL617571,,,,H,8,,
1967,In Vitro Binding affinity againist 5-hydroxytryptamine 1D receptor by displacing [125I]GTI from pig caudate,Autocuration,9823.0,,B,,BAO_0000357,773,,,1,CHEMBL617572,,,Sus scrofa,H,8,,
1968,The compound was tested for intrinsic activity against 5-HT1D receptor,Expert,9986.0,,B,,BAO_0000357,13047,,,1,CHEMBL617573,,,Oryctolagus cuniculus,H,8,,
1969,Intrinsic activity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,Autocuration,9986.0,,B,,BAO_0000019,13047,,,1,CHEMBL617574,,,Oryctolagus cuniculus,H,8,,
1970,The compound was tested for binding affinity against 5-HT1D receptor,Expert,9986.0,,B,,BAO_0000357,13047,,,1,CHEMBL617575,,,Oryctolagus cuniculus,H,8,,
1971,Tested for the effect on binding at 5-hydroxytryptamine 1D receptor; No activity,Autocuration,,,B,,BAO_0000357,188,,,1,CHEMBL617576,,,,H,8,,
1972,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1D receptor of rat substantia nigra,Autocuration,,,F,,BAO_0000019,10639,,,1,CHEMBL617577,,,,H,8,,
1973,Inhibition of forskolin stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor,Autocuration,,,F,,BAO_0000019,12438,,,1,CHEMBL617578,,,,H,8,,
1974,Binding affinity was measured against serotonin 5-hydroxytryptamine 1D receptor,Autocuration,,,B,,BAO_0000357,12438,,,1,CHEMBL617579,,,,H,8,,
1975,Binding affinity towards 5-hydroxytryptamine 1D receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,Expert,,,B,,BAO_0000019,15854,,,1,CHEMBL617580,,,,H,8,,
1976,Inhibitory activity against 5-hydroxytryptamine 1D receptor in rat cortical membranes using [3H]5-HT as a radioligand,Autocuration,,,B,,BAO_0000249,10394,,,1,CHEMBL617581,,,,H,8,,
1977,The binding affinity was measured on 5-hydroxytryptamine 1D receptor using [3H]- serotonin as radioligand.,Autocuration,,,B,,BAO_0000357,12092,,,1,CHEMBL617582,,,,H,8,,
1978,Binding affinity to 5-hydroxytryptamine 1D receptor in the rat forebrain by [3H]- SB-204269 displacement.,Expert,,,B,,BAO_0000019,3389,,,1,CHEMBL617583,,,,H,8,,
1979,Inhibition of binding towards 5-hydroxytryptamine 1D receptor at 100 nM concentration,Autocuration,,,B,,BAO_0000357,6011,,,1,CHEMBL617584,,,,H,8,,
1980,Compound was tested for binding affinity against 5-hydroxytryptamine 1D receptor,Autocuration,,,B,,BAO_0000357,4639,,,1,CHEMBL617585,,,,H,8,,
1981,Compound was measured for its binding affinity at 5-hydroxytryptamine 1D receptor at a concentration of 10 uM using [3H]5-HT as radioligand,Autocuration,,,B,,BAO_0000357,2474,,,1,CHEMBL875912,,,,H,8,,
1982,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1D receptor,Autocuration,,,B,,BAO_0000357,5014,,,1,CHEMBL617586,,,,H,8,,
1983,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1D receptor; inactive at 10 uM,Autocuration,,,B,,BAO_0000357,17515,,,1,CHEMBL617587,,,,H,8,,
1984,Binding affinity for 5-hydroxytryptamine 1D receptor was determined,Autocuration,,,B,,BAO_0000357,11866,,,1,CHEMBL617588,,,,H,8,,
1985,Evaluated for the binding affinity against 5-hydroxytryptamine 1D receptor,Autocuration,,,B,,BAO_0000357,4687,,,1,CHEMBL857980,,,,H,8,,
1986,Tested against 5-hydroxytryptamine 1D receptor,Autocuration,,,B,,BAO_0000357,12146,,,1,CHEMBL617589,,,,H,8,,
1987,Binding affinity for 5-hydroxytryptamine 1D receptor was determined by using [3H]5-HT as radioligand,Autocuration,,,B,,BAO_0000357,10321,,,1,CHEMBL617590,,,,H,8,,
1988,Antagonistic binding affinity measured against 5-hydroxytryptamine 2A receptor (human clone expressed in 293 cells) using [3H]ketanserin as radioligand,Autocuration,,,B,,BAO_0000219,13267,,722.0,1,CHEMBL617591,HEK293,,,H,8,,
1989,Binding affinity against 5-Hydroxytryptamine 1D receptor,Expert,9606.0,,B,,BAO_0000357,1274,,,1,CHEMBL617592,,,Homo sapiens,D,9,,
1990,,Autocuration,,,B,,BAO_0000357,15250,,,1,CHEMBL617593,,,,H,8,,
1991,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,Autocuration,,,B,,BAO_0000219,13706,,485.0,1,CHEMBL617594,CHO-K1,,,H,8,,
1992,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,Autocuration,,,B,,BAO_0000219,13706,,485.0,1,CHEMBL617595,CHO-K1,,,H,8,,
1993,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor alpha clones expressed in human embryonic kidney (HEK 293) cells line.,Autocuration,,,B,,BAO_0000219,13706,,722.0,1,CHEMBL617596,HEK293,,,H,8,,
1994,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor alpha clones expressed in human embryonic kidney (HEK 293) cells line; NT= not tested,Autocuration,,,B,,BAO_0000219,13706,,722.0,1,CHEMBL617597,HEK293,,,H,8,,
1995,Binding affinity against 5-hydroxytryptamine 1D receptor beta using rabbit saphenous vein assay.,Autocuration,,,B,,BAO_0000019,13047,,,1,CHEMBL617598,,,,H,8,,
1996,Binding affinity of compound against 5-HT1Dalpha Binding affinity of compound against 5-HT1D alpha receptors in human,Autocuration,,,B,,BAO_0000357,13366,,,1,CHEMBL872916,,,,H,8,,
1997,In vitro affinity human cloned 5-hydroxytryptamine 1D receptor alpha by [3H]5-HT displacement.,Expert,,,B,,BAO_0000357,13366,,,1,CHEMBL617599,,,,H,8,,
1998,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor alpha was determined,Autocuration,,,B,,BAO_0000357,1558,,,1,CHEMBL617091,,,,H,8,,
1999,"Binding affinity against 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells, using [3H]-5-HT as the radioligand.",Expert,,,B,,BAO_0000219,12902,,485.0,1,CHEMBL617092,CHO-K1,,,H,8,,
2000,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,Autocuration,,,B,,BAO_0000219,13706,,485.0,1,CHEMBL617093,CHO-K1,,,H,8,,
2001,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor alpha measured as the reduction of forskolin-stimulated cAMP.,Autocuration,,,F,,BAO_0000019,13706,,,1,CHEMBL617094,,,,H,8,,
2002,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,Autocuration,,,F,,BAO_0000019,13706,,,1,CHEMBL617095,,,,H,8,,
2003,Compound was tested for its agonist activity against human 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,Autocuration,,,F,,BAO_0000019,14251,,,1,CHEMBL617096,,,,H,8,,
2004,Compound was tested for its agonist activity against human recombinant 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,Autocuration,,,F,,BAO_0000019,14251,,,1,CHEMBL617097,,,,H,8,,
2005,Compound was tested for its agonist activity against human recombinant 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,Autocuration,,,F,,BAO_0000019,14251,,,1,CHEMBL617098,,,,H,8,,
2006,In vitro binding affinity towards 5-HT1D alpha receptor by using [3H]5-HT as radioligand,Autocuration,,,B,,BAO_0000357,13313,,,1,CHEMBL617301,,,,H,8,,
2007,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor alpha by using [3H]5-HT as radioligand,Autocuration,,,B,,BAO_0000357,13313,,,1,CHEMBL617302,,,,H,8,,
2008,Selectivity towards 5-hydroxytryptamine 1D receptor beta to that of 5-hydroxytryptamine 1D receptor alpha,Autocuration,,,B,,BAO_0000357,13366,,,1,CHEMBL617303,,,,H,8,,
2009,Binding affinity to recombinant human 5-hydroxytryptamine 1D receptor alpha,Expert,,,B,,BAO_0000357,13051,,,1,CHEMBL617304,,,,H,8,,
2010,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor alpha expressed in CHO cells, by using [3H]5-HT as radioligand",Expert,,,B,,BAO_0000219,12903,,449.0,1,CHEMBL617305,CHO,,,H,8,,
2011,Binding affinity was measured on 5-hydroxytryptamine 1D receptor alpha in COS cells transfected with human 5-HT1D alpha gene labeled with [3H]5-HT,Autocuration,9606.0,,B,,BAO_0000219,12469,,,1,CHEMBL617306,,,Homo sapiens,D,9,,
2012,Binding affinity (in vitro) against 5-hydroxytryptamine 1D receptor alpha using radio-ligand binding assay,Autocuration,,,B,,BAO_0000357,5619,,,1,CHEMBL617307,,,,H,8,,
2013,Binding affinity against 5-hydroxytryptamine 4 receptor using rabbit saphenous vein assay.,Autocuration,9986.0,,B,,BAO_0000019,13047,,,1,CHEMBL617308,,,Oryctolagus cuniculus,H,8,,
2014,Binding affinities against 5-hydroxytryptamine 1D receptor alpha,Autocuration,,,B,,BAO_0000357,16633,,,1,CHEMBL617309,,,,H,8,,
2015,Binding affinities towards 5-hydroxytryptamine 1D receptor alpha,Autocuration,,,B,,BAO_0000357,16633,,,1,CHEMBL617310,,,,H,8,,
2016,Binding affinities towards 5-hydroxytryptamine 1D receptor alpha,Autocuration,,,B,,BAO_0000357,16633,,,1,CHEMBL617311,,,,H,8,,
2017,Binding affinity towards 5-hydroxytryptamine 1D receptor alpha using [3H]8-OH-DPAT as radioligand,Autocuration,,,B,,BAO_0000357,16633,,,1,CHEMBL617312,,,,H,8,,
2018,Affinity against 5-hydroxytryptamine 1D receptor alpha,Autocuration,,,B,,BAO_0000357,3269,,,1,CHEMBL617313,,,,H,8,,
2019,Binding affinity against 5-hydroxytryptamine 1D receptor alpha,Expert,,,B,,BAO_0000357,12409,,,1,CHEMBL617314,,,,H,8,,
2020,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,Autocuration,,,F,,BAO_0000019,13706,,,1,CHEMBL617315,,,,H,8,,
2021,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor beta clones expressed in human embryonic kidney (HEK 293) cells line.,Autocuration,,,B,,BAO_0000219,13706,,722.0,1,CHEMBL617316,HEK293,,,H,8,,
2022,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor beta clones expressed in human embryonic kidney (HEK 293) cells line; NT= not tested,Autocuration,,,B,,BAO_0000219,13706,,722.0,1,CHEMBL617317,HEK293,,,H,8,,
2023,"The compound was tested in vitro for binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor beta expressed in CHO cells, by using [3H]5-HT as radioligand",Autocuration,,,B,,BAO_0000219,12903,,449.0,1,CHEMBL617318,CHO,,,H,8,,
2024,Binding affinity against 5-hydroxytryptamine 1D receptor beta using rabbit saphenous vein assay.,Autocuration,,,B,,BAO_0000019,13047,,,1,CHEMBL617319,,,,H,8,,
2025,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,Expert,,,B,,BAO_0000357,13366,,,1,CHEMBL617320,,,,D,9,,
2026,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,Expert,,,B,,BAO_0000357,13366,,,1,CHEMBL617321,,,,D,9,,
2027,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,Expert,,,B,,BAO_0000357,13366,,,1,CHEMBL617322,,,,D,9,,
2028,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor beta was determined using [3H]8-OH-DPAT as radioligand,Autocuration,,,B,,BAO_0000357,13366,,,1,CHEMBL616862,,,,H,8,,
2029,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor was determined using [3H]8-OH-DPAT as radioligand,Autocuration,,,B,,BAO_0000357,13366,,,1,CHEMBL616863,,,,H,8,,
2030,Binding affinity was measured on 5-hydroxytryptamine 1D receptor beta in CHO cells transfected with human 5-HT1D beta gene labeled with [3H]5-HT,Autocuration,,,B,,BAO_0000219,12469,,449.0,1,CHEMBL616864,CHO,,,H,8,,
2031,Compound was tested for binding affinity against cloned human 5-HT1D beta receptor expressed in CHO-K1 cells.,Autocuration,,,B,,BAO_0000219,13706,,485.0,1,CHEMBL616865,CHO-K1,,,H,8,,
2032,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor beta expressed in CHO-K1 cells.,Autocuration,,,B,,BAO_0000219,13706,,485.0,1,CHEMBL616866,CHO-K1,,,H,8,,
2033,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,Autocuration,,,F,,BAO_0000019,13706,,,1,CHEMBL616867,,,,H,8,,
2034,"Binding affinity against 5-hydroxytryptamine 1D receptor beta expressed in CHO-K1 cells, using [3H]5-HT as the radioligand.",Expert,,,B,,BAO_0000219,12902,,485.0,1,CHEMBL616868,CHO-K1,,,H,8,,
2035,Binding affinity for cloned human 5-hydroxytryptamine 1D receptor beta,Expert,,,B,,BAO_0000357,13051,,,1,CHEMBL616869,,,,H,8,,
2036,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor beta expressed in CHO cells, by using [3H]5-HT as radioligand",Expert,,,B,,BAO_0000219,12903,,449.0,1,CHEMBL616870,CHO,,,H,8,,
2037,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 0.24-0.55,Autocuration,,,F,,BAO_0000219,1558,,485.0,1,CHEMBL616871,CHO-K1,,,H,8,,
2038,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 0.6-2.0,Autocuration,,,F,,BAO_0000219,1558,,485.0,1,CHEMBL616872,CHO-K1,,,H,8,,
2039,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 2.8-6.5,Autocuration,,,F,,BAO_0000219,1558,,485.0,1,CHEMBL616873,CHO-K1,,,H,8,,
2040,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 30-70,Autocuration,,,F,,BAO_0000219,1558,,485.0,1,CHEMBL616838,CHO-K1,,,H,8,,
2041,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor beta was determined,Autocuration,,,B,,BAO_0000357,1558,,,1,CHEMBL616839,,,,H,8,,
2042,Binding affinity against 5-hydroxytryptamine 3 receptor using rabbit saphenous vein assay.,Autocuration,9986.0,,B,,BAO_0000019,13047,,,1,CHEMBL616840,,,Oryctolagus cuniculus,H,8,,
2043,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor alpha by using [3H]-5-HT as radioligand,Autocuration,,,B,,BAO_0000357,13313,,,1,CHEMBL616841,,,,H,8,,
2044,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor beta by using [3H]5-HT as radioligand,Autocuration,,,B,,BAO_0000357,13313,,,1,CHEMBL616842,,,,H,8,,
2045,Binding affinity against 5-hydroxytryptamine 1D receptor beta,Expert,,,B,,BAO_0000357,12409,,,1,CHEMBL857976,,,,H,8,,
2046,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1E receptor stably expressed in CHO cells,Autocuration,,,B,,BAO_0000219,15250,,449.0,1,CHEMBL616843,CHO,,,H,8,,
2047,Inhibitory activity against 5-hydroxytryptamine 1E receptor subtype,Expert,9606.0,,B,,BAO_0000357,1348,,,1,CHEMBL616844,,,Homo sapiens,D,9,,
2048,Inhibitory activity against 5-hydroxytryptamine 1E receptor subtype; NA denotes data not available,Autocuration,,,B,,BAO_0000357,1348,,,1,CHEMBL616845,,,,H,8,,
2049,Binding affinity to cloned human 5-hydroxytryptamine 1E receptor,Expert,9606.0,,B,,BAO_0000357,4234,,,1,CHEMBL616846,,,Homo sapiens,D,9,,
2050,Binding affinity towards human 5-hydroxytryptamine 1E receptor was determined using [3H]5-HT as radioligand,Autocuration,,,B,,BAO_0000357,16209,,,1,CHEMBL616847,,,,H,8,,
2051,Binding affinity was determined against 5-hydroxytryptamine 1E receptor in human cortical homogenate,Autocuration,,,B,,BAO_0000019,10444,,,1,CHEMBL616848,,,,H,8,,
2052,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1E receptor,Autocuration,,,B,,BAO_0000357,3935,,,1,CHEMBL616849,,,,H,8,,
2053,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1E receptor,Autocuration,,,B,,BAO_0000357,15818,,,1,CHEMBL872911,,,,H,8,,
2054,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1E receptor,Autocuration,,,B,,BAO_0000019,17085,,,1,CHEMBL616850,,,,H,8,,
2055,Binding affinity against human 5-hydroxytryptamine 1E receptor expressed in CHO cells,Expert,9606.0,,B,,BAO_0000219,12936,,449.0,1,CHEMBL616699,CHO,,Homo sapiens,D,9,,
2056,Binding affinity towards cloned human 5-hydroxytryptamine 1E receptor was determined,Autocuration,,,B,,BAO_0000357,6166,,,1,CHEMBL616700,,,,H,8,,
2057,Binding affinity towards 5-hydroxytryptamine 1E receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,Autocuration,,,B,,BAO_0000219,15779,,449.0,1,CHEMBL616701,CHO,,,H,8,,
2058,Binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as radioligand.,Autocuration,,,B,,BAO_0000219,15779,,449.0,1,CHEMBL616702,CHO,,,H,8,,
2059,Binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as radioligand;ND means no data.,Autocuration,,,B,,BAO_0000219,15779,,449.0,1,CHEMBL616703,CHO,,,H,8,,
2060,Binding affinity was determined against 5-hydroxytryptamine 1D receptor,Autocuration,,,B,,BAO_0000357,13181,,,1,CHEMBL616704,,,,H,8,,
2061,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as the radioligand,Autocuration,,,B,,BAO_0000219,4199,,449.0,1,CHEMBL616705,CHO,,,H,8,,
2062,Compound was tested for binding affinity against human 5-hydroxytryptamine 1E receptor,Autocuration,,,B,,BAO_0000357,14875,,,1,CHEMBL616706,,,,H,8,,
2063,Compound was tested for its binding affinity against cloned human 5-hydroxytryptamine 1E receptor in CHO cells using [3H]-5-HT,Autocuration,,,B,,BAO_0000219,15146,,449.0,1,CHEMBL616707,CHO,,,H,8,,
2064,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1E receptor in CHO using [3H]5-HT as a radioligand,Autocuration,,,B,,BAO_0000357,5213,,,1,CHEMBL616708,,,,H,8,,
2065,Tested for binding affinity towards cloned human 5-hydroxytryptamine 1E receptor using [3H]5-HT as radioligand,Autocuration,,,B,,BAO_0000357,12146,,,1,CHEMBL616709,,,,H,8,,
2066,The binding affinity (pKi) measured against 5-hydroxytryptamine 1E receptor (cloned human receptors in CHO cells) using [3H]5-HT1E as radioligand,Autocuration,,,B,,BAO_0000219,13267,,449.0,1,CHEMBL616710,CHO,,,H,8,,
2067,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT.,Autocuration,,,B,,BAO_0000219,14818,,449.0,1,CHEMBL616711,CHO,,,H,8,,
2068,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells, using [3H]5-HT as radioligand",Autocuration,,,B,,BAO_0000219,4829,,449.0,1,CHEMBL616712,CHO,,,H,8,,
2069,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1E receptor was determined,Autocuration,,,B,,BAO_0000357,4373,,,1,CHEMBL616713,,,,H,8,,
2070,Binding affinity for 5-hydroxytryptamine 1E receptor was determined,Autocuration,,,B,,BAO_0000357,4373,,,1,CHEMBL616714,,,,H,8,,
2071,Compound was evaluated for the affinity at 5-hydroxytryptamine 1E receptor,Autocuration,,,B,,BAO_0000357,14159,,,1,CHEMBL616715,,,,H,8,,
2072,Binding affinity towards 5-hydroxytryptamine 1E receptor,Autocuration,,,B,,BAO_0000357,16633,,,1,CHEMBL616716,,,,H,8,,
2073,"In vitro effective concentration for stimulation of [35S]GTP-gamma-S, binding in mouse LM(tk-)cells expressing the human 5-HT1F receptor",Autocuration,,,F,,BAO_0000019,17085,,,1,CHEMBL616717,,,,H,8,,
2074,"In vitro effective concentration for stimulation of [35S]GTP-gamma-S, binding in mouse LM(tk-)cells expressing the human 5-hydroxytryptamine 1F receptor",Expert,,,F,,BAO_0000019,17085,,,1,CHEMBL616718,,,,H,8,,
2075,In vitro effective concentration for inhibition of skolin-stimulated adenylate cyclase in cell line expressing human 5-hydroxytryptamine 1F receptor,Autocuration,,,F,,BAO_0000019,16209,,,1,CHEMBL875905,,,,H,8,,
2076,In vitro agonist potency against human 5-hydroxytryptamine 1F receptor,Autocuration,,,F,,BAO_0000019,16209,,,1,CHEMBL616719,,,,H,8,,
2077,"Maximum stimulation of of [35S]GTP-gamma-S, binding expressed relative to the maximal effect of 5-hydroxytryptamine 1F receptor",Expert,,,F,,BAO_0000019,17085,,,1,CHEMBL616720,,,,H,8,,
2078,Compound was evaluated for the affinity at 5-hydroxytryptamine 1F receptor,Autocuration,,,B,,BAO_0000357,14159,,,1,CHEMBL616721,,,,H,8,,
2079,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1F receptor stably expressed in CHO cells,Autocuration,,,B,,BAO_0000219,15250,,449.0,1,CHEMBL616722,CHO,,,H,8,,
2080,In vitro binding affinity against human 5-hydroxytryptamine 1F receptor at a concentration of 100 (nM),Autocuration,,,B,,BAO_0000357,3805,,,1,CHEMBL616723,,,,H,8,,
2081,Binding affinity against 5-hydroxytryptamine 1F receptor in CHO cells using [3H]5-HT radioligand,Autocuration,,,B,,BAO_0000219,16190,,449.0,1,CHEMBL616724,CHO,,,H,8,,
2082,Binding affinity against 5-hydroxytryptamine 1F receptor in CHO using [3H]5-HT radioligand,Autocuration,,,B,,BAO_0000357,16190,,,1,CHEMBL616725,,,,H,8,,
2083,Binding affinity towards human 5-hydroxytryptamine 1F receptor,Autocuration,,,B,,BAO_0000357,16209,,,1,CHEMBL616726,,,,H,8,,
2084,Binding affinity towards human 5-hydroxytryptamine 1F receptor was determined,Autocuration,,,B,,BAO_0000357,16209,,,1,CHEMBL616727,,,,H,8,,
2085,Binding affinity towards human 5-hydroxytryptamine 1F receptor using [3H]-5-HT radioligand,Autocuration,,,B,,BAO_0000357,16209,,,1,CHEMBL616728,,,,H,8,,
2086,In vitro binding affinity for human 5-hydroxytryptamine 1F receptor,Autocuration,,,B,,BAO_0000357,6866,,,1,CHEMBL616729,,,,H,8,,
2087,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1F receptor,Expert,,,B,,BAO_0000019,17085,,,1,CHEMBL616730,,,,H,8,,
2088,Binding affinity towards human recombinant 5-hydroxytryptamine 1F receptor,Autocuration,,,B,,BAO_0000357,16312,,,1,CHEMBL617125,,,,H,8,,
2089,Binding affinity towards cloned human 5-hydroxytryptamine 1F receptor was determined,Autocuration,,,B,,BAO_0000357,6166,,,1,CHEMBL857977,,,,H,8,,
2090,Binding affinity towards 5-hydroxytryptamine 1F receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,Autocuration,,,B,,BAO_0000219,15779,,449.0,1,CHEMBL617126,CHO,,,H,8,,
2091,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1F receptor in CHO cells using [3H]-5-HT as the radioligand,Autocuration,,,B,,BAO_0000219,4199,,449.0,1,CHEMBL617127,CHO,,,H,8,,
2092,Compound was tested for binding affinity against human 5-hydroxytryptamine 1F receptor,Autocuration,,,B,,BAO_0000357,14875,,,1,CHEMBL617128,,,,H,8,,
2093,Compound was tested for its binding affinity against 5-hydroxytryptamine 1F receptor in human cloned receptors in CHO cells using [3H]5-HT,Autocuration,,,B,,BAO_0000219,15146,,449.0,1,CHEMBL617129,CHO,,,H,8,,
2094,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1F receptor in CHO using [3H]5-HT as a radioligand,Autocuration,,,B,,BAO_0000357,5213,,,1,CHEMBL617130,,,,H,8,,
2095,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1F receptor in CHO cells using [3H]5-HT.,Autocuration,,,B,,BAO_0000219,14818,,449.0,1,CHEMBL617131,CHO,,,H,8,,
2096,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1F receptor in CHO cells, using [3H]5-HT as radioligand",Autocuration,,,B,,BAO_0000219,4829,,449.0,1,CHEMBL617132,CHO,,,H,8,,
2097,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1F receptor in CHO cells, using [3H]5-HT as radioligand",Autocuration,,,B,,BAO_0000219,4829,,449.0,1,CHEMBL617133,CHO,,,H,8,,
2098,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1F receptor was determined,Autocuration,,,B,,BAO_0000357,4373,,,1,CHEMBL617134,,,,H,8,,
2099,Binding affinity for 5-hydroxytryptamine 1F receptor was determined,Autocuration,,,B,,BAO_0000357,4373,,,1,CHEMBL617135,,,,H,8,,
2100,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1F receptor,Autocuration,,,B,,BAO_0000357,5014,,,1,CHEMBL617136,,,,H,8,,
2101,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 (5-hydroxytryptamine-2) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]-ketanserin as radioligand",Autocuration,,,B,,BAO_0000019,11662,,,1,CHEMBL617137,,,,H,4,,
2102,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand",Autocuration,,,B,,BAO_0000019,11662,,,1,CHEMBL617138,,,,H,4,,
2103,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 (5-hydroxytryptamine-2) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",Autocuration,,,B,,BAO_0000019,11662,,,1,CHEMBL617139,,,,H,4,,
2104,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor,Autocuration,,,B,,BAO_0000019,14093,,,1,CHEMBL617140,,,,H,8,,
2105,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-HT2 receptor 1 hr after oral administration",Autocuration,,,F,,BAO_0000218,11200,,,1,CHEMBL617141,,,,H,4,,
2106,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,Autocuration,,,F,,BAO_0000019,11200,,,1,CHEMBL858112,,,,H,4,,
2107,Binding affinity towards 5-hydroxytryptamine 2 receptor in calf frontal cortex,Intermediate,,,B,,BAO_0000019,12352,,,1,CHEMBL617142,,,,H,8,,
2108,"Binding affinity to 5-hydroxytryptamine 2 receptor using calf frontal cortex, [3H]- ketanserin, and spiperone for NSB",Autocuration,9913.0,,B,,BAO_0000019,13657,,,1,CHEMBL617143,,,Bos taurus,U,0,,
2109,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of bovine frontal cortex at 10e-7 M,Autocuration,9913.0,,B,,BAO_0000019,14331,,,1,CHEMBL617144,,,Bos taurus,U,0,,
2110,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of bovine frontal cortex,Autocuration,9913.0,,B,,BAO_0000019,14331,,,1,CHEMBL617145,,,Bos taurus,U,0,,
2111,Binding affinity of compound towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin (0.8 nM) ligand in frontal cortex bovine was determined,Autocuration,,,B,,BAO_0000019,14331,,,1,CHEMBL617146,,,,U,0,,
2112,Binding affinity for serotonin 5-hydroxytryptamine 2 receptor using [3H]ketanserin in guinea pig frontal cortex,Autocuration,10141.0,,B,,BAO_0000019,12685,,,1,CHEMBL617147,,,Cavia porcellus,H,4,,
2113,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of guinea pig frontal cortex membranes,Autocuration,10141.0,,B,,BAO_0000019,14389,,,1,CHEMBL617148,,,Cavia porcellus,H,4,,
2114,Compound was tested for its binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin from guinea pig frontal cortex,Autocuration,10141.0,,B,,BAO_0000019,14386,,,1,CHEMBL617149,,,Cavia porcellus,H,4,,
2115,Binding affinity towards cloned human 5-hydroxytryptamine 2 receptor was determined,Autocuration,,,B,,BAO_0000224,5732,,,1,CHEMBL617150,,,,H,4,,
2116,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,Autocuration,,,B,,BAO_0000224,16293,,,1,CHEMBL617151,,,,H,4,,
2117,In vitro binding affinity of compound against neuronal 5-hydroxytryptamine 2 receptor,Autocuration,,,B,,BAO_0000224,2078,,,1,CHEMBL617201,,,,H,4,,
2118,Binding affinity towards 5-HT7 receptor by the displacement of [3H]-5-CT] in human recombinant receptors in mammalian cell,Autocuration,,,B,,BAO_0000357,5486,,,1,CHEMBL617202,,,,H,8,,
2119,Effective dose through peroral route for in vivo inhibition against 5-hydroxytryptamine 2 receptor in male CF-1 mice by using radioligand [3H]ketanserin,Autocuration,,,B,,BAO_0000218,11820,,,1,CHEMBL617203,,,,H,4,,
2120,Hill number was determined for inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in mouse cerebral cortex,Autocuration,,,B,,BAO_0000019,10297,,,1,CHEMBL617204,,,,H,4,,
2121,Inhibitory activity against serotonin 5-hydroxytryptamine 2 receptor from mice.,Autocuration,,,B,,BAO_0000224,13704,,,1,CHEMBL617205,,,,H,4,,
2122,Inhibitory activity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]ketanserin in mouse cerebral cortex,Autocuration,10090.0,,B,,BAO_0000019,10297,,,1,CHEMBL617206,,,Mus musculus,D,5,,
2123,Effective dose through peroral route for in vivo inhibition against 5-hydroxytryptamine 2 receptor in male CF-1 mice by using radioligand [3H]ketanserin,Autocuration,,,B,,BAO_0000218,11820,,,1,CHEMBL617207,,,,H,4,,
2124,Binding affinity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]-ketanserin in mouse cerebral cortex,Autocuration,10090.0,,B,,BAO_0000019,10297,,,1,CHEMBL617208,,,Mus musculus,D,5,,
2125,The compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2 receptor,Autocuration,,,B,,BAO_0000224,11555,,,1,CHEMBL617209,,,,H,4,,
2126,In vitro binding affinity for serotonin 5-hydroxytryptamine (5-HT) 2 receptors,Autocuration,,,B,,BAO_0000224,11555,,,1,CHEMBL617210,,,,H,4,,
2127,The compound was tested in vitro for its binding affinity towards serotonin 5-hydroxytryptamine 2 receptor; nd = no data,Autocuration,,,B,,BAO_0000224,11555,,,1,CHEMBL617211,,,,H,4,,
2128,Hill number was determined for inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in mouse cerebral cortex,Autocuration,10090.0,,B,,BAO_0000019,10297,,,1,CHEMBL617212,,,Mus musculus,D,5,,
2129,Binding affinity for porcine 5-hydroxytryptamine 2 receptor using [3H]- ketanserin,Autocuration,9823.0,,B,,BAO_0000224,16688,,,1,CHEMBL617213,,,Sus scrofa,H,4,,
2130,Binding affinity for porcine 5-hydroxytryptamine 2 receptor using [3H]- ketanserin with 10 uM prazosin,Autocuration,9823.0,,B,,BAO_0000224,16688,,,1,CHEMBL617214,,,Sus scrofa,H,4,,
2131,Compound was tested in vitro for its ability to compete with [3H]-ketanserin at 5-hydroxytryptamine 2 receptor in porcine brain homogenate,Autocuration,,,B,,BAO_0000221,5333,,,1,CHEMBL617215,,,,U,0,,
2132,In vitro for its ability to displace [3H]- ketanserin from 5-hydroxytryptamine 2 receptor in porcine brain homogenate,Autocuration,,,B,,BAO_0000221,4437,,,1,CHEMBL617216,,,,U,0,,
2133,Ability to displace the radioligand [3H]mesulergine from pig choroid plexus 5-hydroxytryptamine 2 receptor,Autocuration,9823.0,,B,,BAO_0000357,5033,,,1,CHEMBL617217,,,Sus scrofa,H,8,,
2134,Inhibition of [3H]- Ketanserin binding against rat brain 5-hydroxytryptamine 2 receptor,Autocuration,,,B,,BAO_0000019,15267,,,1,CHEMBL617218,,,,H,4,,
2135,Inhibition of [3H]- Ketanserin binding against rat brain 5-hydroxytryptamine 2 receptor,Autocuration,,,B,,BAO_0000019,15267,,,1,CHEMBL872913,,,,H,4,,
2136,Binding affinity against 5-hydroxytryptamine 2 receptor from rat cortical synaptosomal membrane using radioligand [3H]ketanserin.,Autocuration,,,B,,BAO_0000019,11820,,,1,CHEMBL617219,,,,H,4,,
2137,Evaluated for binding activity against [3H]ketanserin as radioligand for 5-hydroxytryptamine 2 receptor,Autocuration,,,B,,BAO_0000224,9069,,,1,CHEMBL873482,,,,H,4,,
2138,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein; ND means no data,Autocuration,10116.0,,B,,BAO_0000019,9162,,,1,CHEMBL617220,,,Rattus norvegicus,D,5,,
2139,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein.,Autocuration,,,B,,BAO_0000019,9162,,,1,CHEMBL617221,,,,H,4,,
2140,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein; no appreciable 5-HT2 receptor affinity,Autocuration,,,B,,BAO_0000019,9162,,,1,CHEMBL617222,,,,H,4,,
2141,Antagonistic activity against (5-hydroxytryptamine 2 receptor) serotonin-induced contractions in the rat jugular vein,Autocuration,,,F,,BAO_0000019,10428,,,1,CHEMBL875906,,,,H,4,,
2142,Binding affinity to the 5-hydroxytryptamine 2 receptor assayed by antagonism of serotonin-induced contractions in the rat jugular vein,Autocuration,,,B,,BAO_0000019,9628,,,1,CHEMBL617223,,,,H,4,,
2143,Binding affinity against serotonin 5-hydroxytryptamine 2 receptor,Autocuration,,,B,,BAO_0000224,12704,,,1,CHEMBL617224,,,,H,4,,
2144,Percent decrease in 5-hydroxytryptamine 2 receptor binding using ketanserin,Autocuration,10116.0,,B,,BAO_0000224,15453,,,1,CHEMBL617225,,,Rattus norvegicus,D,5,,
2145,Tested for the effect on binding at 5-hydroxytryptamine 2 receptor; No activity,Autocuration,,,B,,BAO_0000224,188,,,1,CHEMBL617226,,,,H,4,,
2146,Effect of 2 week administration of compound on 5-hydroxytryptamine 2 receptor binding by using 0.4 nM dose of [3H]- spiperone as a radioligand.,Autocuration,,,B,,BAO_0000224,10349,,,1,CHEMBL617227,,,,H,4,,
2147,Effect of 2 week administration of compound on 5-hydroxytryptamine 2 receptor binding by using 0.6 nM dose of [3H]- spiperone as a radioligand.,Autocuration,,,B,,BAO_0000224,10349,,,1,CHEMBL617228,,,,H,4,,
2148,Compound was tested for its effect on 5-hydroxytryptamine 2 receptor saturation analysis,Autocuration,,,B,,BAO_0000224,8868,,,1,CHEMBL617229,,,,H,4,,
2149,Concentration necessary to achieve half maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 1 uM,Autocuration,,,B,,BAO_0000224,10025,,,1,CHEMBL617230,,,,H,4,,
2150,"Concentration necessary to achieve half maximal inhibition of [3H]ketanserin, binds to 5-hydroxytryptamine 2 receptor at 1 uM",Autocuration,,,B,,BAO_0000224,10025,,,1,CHEMBL617231,,,,H,4,,
2151,Compound was tested for the inhibition of quipazine binding at 5-HT2 receptor,Autocuration,,,B,,BAO_0000224,11702,,,1,CHEMBL617232,,,,H,4,,
2152,Compound was tested for the inhibition of quipazine binding at 5-hydroxytryptamine 2 receptor,Autocuration,,,B,,BAO_0000224,11702,,,1,CHEMBL617233,,,,H,4,,
2153,Compound was tested for the inhibition of quipazine binding at 5-hydroxytryptamine 2 receptor; NT=Not tested,Autocuration,,,B,,BAO_0000224,11702,,,1,CHEMBL617234,,,,H,4,,
2154,Compound was tested for the inhibition of quipazine induced head twitches in rats,Autocuration,,,F,,BAO_0000019,11702,,,1,CHEMBL617235,,,,H,4,,
2155,Compound was tested for the inhibition of quipazine induced head twitches in rats; NT=Not tested,Autocuration,,,F,,BAO_0000019,11702,,,1,CHEMBL617236,,,,H,4,,
2156,Ability to bind at 5-hydroxytryptamine 2 receptor of rat hippocampus by displacing [3H]spiperone,Autocuration,,,B,,BAO_0000221,10085,,,1,CHEMBL617237,,,,H,4,10000000.0,
2157,Ability to bind at serotonin 5-hydroxytryptamine 2 receptors of rat hippocampus by displacing [3H]spiperone,Autocuration,,,B,,BAO_0000221,10085,,,1,CHEMBL617238,,,,H,4,10000000.0,
2158,Displacement of [3H]spiroperidol from 5-hydroxytryptamine 2 receptor in rat brain,Autocuration,10116.0,,B,,BAO_0000221,9630,,,1,CHEMBL617239,,,Rattus norvegicus,D,5,955.0,
2159,Ability to inhibit binding of [3H]KET to 5-hydroxytryptamine 2 receptor in rat cortex,Autocuration,,,B,,BAO_0000019,11070,,,1,CHEMBL617240,,,,H,4,,
2160,Ability to inhibit binding of titreated spiperone to 5-hydroxytryptamine 2 receptor in rat brain frontal cortex membranes,Autocuration,,,B,,BAO_0000249,9841,Membranes,,1,CHEMBL617241,,,,H,4,,
2161,Ability to inhibit binding of titreated spiperone to the 5-hydroxytryptamine 2 receptor in rat brain frontal cortex membranes,Autocuration,,,B,,BAO_0000249,9841,Membranes,,1,CHEMBL875907,,,,H,4,,
2162,Affinity for 5-hydroxytryptamine 2 receptor binding sites by its ability to displace [3H]spiperone from rat frontal cortex.,Autocuration,,,B,,BAO_0000019,13291,,,1,CHEMBL617242,,,,H,4,,
2163,Antagonistic activity against 5-hydroxytryptamine 2 receptor on rat frontal cortex membrane.,Autocuration,,,F,,BAO_0000019,10590,,,1,CHEMBL617152,,,,H,4,,
2164,Binding affinity against serotonin-2 receptor in rat brain using [3H]spiroperidol,Autocuration,10116.0,,B,,BAO_0000221,9064,,,1,CHEMBL617153,,,Rattus norvegicus,D,5,955.0,
2165,Binding affinity at 5-hydroxytryptamine 2 receptor by the inhibition of binding to [3H]ketanserin in rat cortical membranes,Autocuration,10116.0,,B,,BAO_0000249,12268,Membranes,,1,CHEMBL617154,,,Rattus norvegicus,D,5,,
2166,Binding affinity against 5-hydroxytryptamine 2 receptor in rat brain using [3H]ketanserin as radioligand,Autocuration,,,B,,BAO_0000221,13508,,,1,CHEMBL617155,,,,H,4,955.0,
2167,5-hydroxytryptamine 2 receptor antagonistic activity on the rat tail artery determined by Schild plot.,Autocuration,,,F,,BAO_0000019,11279,,,1,CHEMBL617156,,,,H,4,,
2168,In vitro antagonistic activity against the contraction induced by 5-HT through 5-HT2 receptor in rat thoracic aortic strips,Autocuration,,,F,,BAO_0000019,11200,,,1,CHEMBL617157,,,,H,4,,
2169,In vitro antagonistic activity tested against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,Autocuration,,,F,,BAO_0000019,11200,,,1,CHEMBL617158,,,,H,4,,
2170,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips; NC=non competitive antagonism,Autocuration,,,F,,BAO_0000019,11200,,,1,CHEMBL617159,,,,H,4,,
2171,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips; NC=non competitive antagonism,Autocuration,,,F,,BAO_0000019,11200,,,1,CHEMBL617160,,,,H,4,,
2172,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,Autocuration,,,F,,BAO_0000019,11200,,,1,CHEMBL858113,,,,H,4,,
2173,Tested for 5-hydroxytryptamine 2 receptor binding ability by displacement of [3H]spiperone from rat brain frontal cortex synaptosomes,Autocuration,,,B,,BAO_0000220,9231,,,1,CHEMBL617247,,,,H,4,955.0,
2174,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex using [3H]ketanserin as radioligand,Autocuration,,,B,,BAO_0000019,9737,,,1,CHEMBL617248,,,,H,4,,
2175,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,Autocuration,,,B,,BAO_0000249,9737,,,1,CHEMBL617249,,,,H,4,955.0,
2176,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex,Autocuration,,,B,,BAO_0000019,9737,,,1,CHEMBL617250,,,,H,4,,
2177,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex using [3H]ketanserin as radioligand,Autocuration,,,B,,BAO_0000019,9737,,,1,CHEMBL617251,,,,H,4,,
2178,isplacement of [3H]DOB from rat cortex homogenate 5-hydroxytryptamine 2 receptor,Autocuration,10116.0,,B,,BAO_0000019,11828,,,1,CHEMBL617252,,,Rattus norvegicus,D,5,,
2179,Binding affinity of 5-hydroxytryptamine 2 receptor using [3H]- ketanserin in rat frontal cortex,Autocuration,,,B,,BAO_0000019,12253,,,1,CHEMBL617006,,,,H,4,,
2180,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin in rat frontal cortex,Autocuration,,,B,,BAO_0000019,12253,,,1,CHEMBL617007,,,,H,4,,
2181,"5-hydroxytryptamine 2 receptor antagonistic activity at concentrations of<br>3,10 and 30 uM on the rat tail artery.",Autocuration,,,F,,BAO_0000019,11279,,,1,CHEMBL617008,,,,H,4,,
2182,Binding affinity for 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- ketanserin,Autocuration,,,B,,BAO_0000019,11866,,,1,CHEMBL617009,,,,H,4,,
2183,Binding affinity against 5-hydroxytryptamine 2 receptor in serotonin-induced contraction of the rat aorta,Autocuration,10116.0,,B,,BAO_0000224,14424,,,1,CHEMBL617010,,,Rattus norvegicus,D,5,,
2184,Displacement of [3H]ketanserin from rat brain 5-hydroxytryptamine 2 receptor,Autocuration,10116.0,,B,,BAO_0000019,15180,,,1,CHEMBL857978,,,Rattus norvegicus,D,5,,
2185,Displacement of [3H]ketanserin from rat brain 5-hydroxytryptamine 2 receptor,Autocuration,10116.0,,B,,BAO_0000019,15180,,,1,CHEMBL617011,,,Rattus norvegicus,D,5,,
2186,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat frontal cortex homogenate,Autocuration,10116.0,,B,,BAO_0000019,9786,,,1,CHEMBL617012,,,Rattus norvegicus,D,5,,
2187,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]-ketanserin as radioligand.,Autocuration,,,B,,BAO_0000224,12132,,,1,CHEMBL617013,,,,H,4,,
2188,Binding affinity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]ketanserin in rat cerebral cortex membrane,Autocuration,,,B,,BAO_0000249,5486,,,1,CHEMBL617014,,,,H,4,,
2189,Compound was evaluated for its ability to displace [3H]ketanserin binding from cloned rat cerebral cortex membranes 5-hydroxytryptamine 2 receptor,Autocuration,,,B,,BAO_0000019,15316,,,1,CHEMBL617015,,,,H,4,,
2190,In vitro binding affinity to 5-hydroxytryptamine 2 receptor of rat cerebral cortex membranes using [3H]ketanserin as the radioligand,Autocuration,,,B,,BAO_0000019,16429,,,1,CHEMBL617016,,,,H,4,,
2191,pKi value for 5-hydroxytryptamine 2 receptor binding site,Autocuration,,,B,,BAO_0000224,14617,,,1,CHEMBL617017,,,,H,4,,
2192,Inhibitory constant (1 uM) was measured on 5-hydroxytryptamine 2 receptor/uptake using [3H]- ketanserin as radioligand in rat brain cortex.,Autocuration,,,B,,BAO_0000221,11351,,,1,CHEMBL617018,,,,H,4,955.0,
2193,5-hydroxytryptamine 2 receptor antagonistic activity on the rat tail artery determined by Schild plot.,Autocuration,,,F,,BAO_0000019,11279,,,1,CHEMBL617019,,,,H,4,,
2194,Binding affinity at 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,Autocuration,,,B,,BAO_0000019,9523,,,1,CHEMBL617020,,,,H,4,,
2195,Binding affinity at 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,Autocuration,,,B,,BAO_0000019,9523,,,1,CHEMBL617021,,,,H,4,,
2196,Binding affinity at [3H]DOB labeled sites of 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,Autocuration,,,B,,BAO_0000019,9523,,,1,CHEMBL617022,,,,H,4,,
2197,Binding affinity at [3H]DOB labeled sites of 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,Autocuration,,,B,,BAO_0000019,9523,,,1,CHEMBL617023,,,,H,4,,
2198,Binding affinity at [3H]KET labeled sites of 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,Autocuration,,,B,,BAO_0000019,9523,,,1,CHEMBL617024,,,,H,4,,
2199,Binding affinity at [3H]KET labeled sites of 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,Autocuration,,,B,,BAO_0000019,9523,,,1,CHEMBL617025,,,,H,4,,
2200,Hill coefficient of compound was determined,Autocuration,,,B,,BAO_0000224,9523,,,1,CHEMBL617026,,,,H,4,,
2201,Ancillary Binding affinity towards rat 5-hydroxytryptamine 2 receptor,Autocuration,,,B,,BAO_0000019,4771,,,1,CHEMBL617027,,,,U,0,,
2202,Ability to displace the radioligand [3H]5-carboximidotryptamine ([3H]-ketanserin) from 5-hydroxytryptamine 2 receptor of rat cerebral cortex membrane,Autocuration,10116.0,,B,,BAO_0000019,5033,,,1,CHEMBL617028,,,Rattus norvegicus,D,5,,
2203,Binding affinity against rat 5-hydroxytryptamine 2 receptor in rat cerebral cortex tissue using [3H]spiperone as radioligand,Expert,,,B,,BAO_0000019,10845,,,1,CHEMBL617029,,,,H,8,,
2204,Binding affinity against rat 5-hydroxytryptamine 2 receptor in rat cerebral cortex tissue using [3H]spiperone as radioligand; IA-Inactive,Expert,,,B,,BAO_0000019,10845,,,1,CHEMBL875908,,,,H,8,,
2205,Affinity at 5-hydroxytryptamine 2 receptor (For ketanserin = Ki(nM)= 0.7+/-0.09),Autocuration,,,B,,BAO_0000357,16288,,,1,CHEMBL617030,,,,H,8,,
2206,Affinity at 5-hydroxytryptamine 2 receptor from rat frontal cortex using [3H]ketanserin as radioligand (For ketanserin = Ki(nM)=0.7+/-0.09),Autocuration,,,B,,BAO_0000019,16288,,,1,CHEMBL617031,,,,H,8,,
2207,Binding affinity for 5-hydroxytryptamine 2 receptor of rat cortical membrane using [3H]DOB radioligand,Autocuration,,,B,,BAO_0000019,16190,,,1,CHEMBL617032,,,,H,8,,
2208,Tested in vitro for receptor binding affinity against 5-hydroxytryptamine 2 receptor using radioligand [3H]ketanserin,Autocuration,10116.0,,B,,BAO_0000224,12463,,,1,CHEMBL617033,,,Rattus norvegicus,D,5,,
2209,"Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- 1-(4-bromo-2,5-dimethoxy-phenyl)-2-aminopropane (D) as radioligand",Autocuration,,,B,,BAO_0000224,9699,,,1,CHEMBL617034,,,,H,4,,
2210,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- ketanserin as radioligand,Autocuration,,,B,,BAO_0000224,9699,,,1,CHEMBL617035,,,,H,4,,
2211,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",Autocuration,,,B,,BAO_0000019,11662,,,1,CHEMBL617036,,,,H,4,,
2212,Inhibitory concentration against 5-hydroxytryptamine 2 receptor,Autocuration,,,B,,BAO_0000224,1205,,,1,CHEMBL617037,,,,H,4,,
2213,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2 receptor from mammalian clones expressed in CHO cell membranes using [3H]-ketanserin as radioligand,Autocuration,,,B,,BAO_0000219,11376,,,1,CHEMBL617038,,,,U,0,,
2214,"Binding affinity towards 5-hydroxytryptamine 2 receptor expressed in CHO cell membranes using [3H]ketanserin (60 Ci/mmol, 1 nM)",Autocuration,,,B,,BAO_0000219,11376,,,1,CHEMBL617039,,,,H,4,,
2215,Compound was tested for binding affinity against 5-hydroxytryptamine 2 receptor,Autocuration,,,B,,BAO_0000224,4639,,,1,CHEMBL617161,,,,H,4,,
2216,Compound was tested for inhibitory activity against 5-hydroxytryptamine 2 receptor,Autocuration,,,B,,BAO_0000224,2222,,,1,CHEMBL617162,,,,H,4,,
2217,Compound was tested for its affinity towards 5-hydroxytryptamine 2 receptor,Autocuration,,,B,,BAO_0000224,1558,,,1,CHEMBL617163,,,,H,4,,
2218,Tested for binding affinity for 5-hydroxytryptamine 2 receptor,Autocuration,,,B,,BAO_0000224,1089,,,1,CHEMBL617164,,,,H,4,,
2219,The compound was evaluated for its ability to displace [3H]ketanserin from 5-hydroxytryptamine 2 receptor in cellular brain membranes,Autocuration,,,B,,BAO_0000249,386,Brain membranes,,1,CHEMBL617165,,,,H,4,,
2220,Compound was measured for its binding affinity at 5-hydroxytryptamine 2 receptor at a concentration of 10 uM using [3H]ketanserin as radioligand,Autocuration,,,B,,BAO_0000224,2474,,,1,CHEMBL617166,,,,H,4,,
2221,Binding affinity towards 5-HT2 receptor,Autocuration,,,B,,BAO_0000224,17066,,,1,CHEMBL617167,,,,H,4,,
2222,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor,Autocuration,,,B,,BAO_0000224,959,,,1,CHEMBL872912,,,,H,4,,
2223,Compound was evaluated for 5-hydroxytryptamine 2 receptor binding,Autocuration,,,B,,BAO_0000224,6398,,,1,CHEMBL617168,,,,H,4,,
2224,In vitro binding affinity against rat 5-hydroxytryptamine 2 receptor.,Autocuration,,,B,,BAO_0000224,11889,,,1,CHEMBL617169,,,,H,4,,
2225,In vitro binding affinity for 5-hydroxytryptamine 2 receptor,Autocuration,,,B,,BAO_0000224,4221,,,1,CHEMBL617170,,,,H,4,,
2226,The compound was tested for binding affinity against 5-hydroxytryptamine 2 receptor using ketanserin as radioligand,Autocuration,,,B,,BAO_0000224,11026,,,1,CHEMBL617171,,,,H,4,,
2227,Binding affinity for 5-hydroxytryptamine 2 receptor was determined,Autocuration,,,B,,BAO_0000224,11866,,,1,CHEMBL617172,,,,H,4,,
2228,In vitro binding affinity for 5-hydroxytryptamine 2 receptor,Autocuration,,,B,,BAO_0000224,4221,,,1,CHEMBL617173,,,,H,4,,
2229,In Vitro binding affinity for 5-hydroxytryptamine 2 receptor,Autocuration,,,B,,BAO_0000019,13950,,,1,CHEMBL617174,,,,U,0,,
2230,5-hydroxytryptamine 2 receptor binding affinity,Autocuration,,,B,,BAO_0000224,1263,,,1,CHEMBL617175,,,,H,4,,
2231,Binding affinity against 5-hydroxytryptamine 2 receptor was determined using [ [3H]spiperone radioligand,Autocuration,,,B,,BAO_0000357,13291,,,1,CHEMBL617176,,,,H,8,,
2232,Compound was tested for the binding affinity against 5-hydroxytryptamine 2 receptor by using [3H]ketanserin as radioligand,Autocuration,,,B,,BAO_0000357,10812,,,1,CHEMBL617177,,,,H,8,,
2233,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 10e-5 M,Autocuration,,,B,,BAO_0000224,13020,,,1,CHEMBL617178,,,,H,4,,
2234,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of central nervous system,Autocuration,,,B,,BAO_0000224,13021,,,1,CHEMBL617179,,,,H,4,,
2235,Ketanserin binding to 5-hydroxytryptamine 2 receptor at 10e-5 M,Autocuration,,,B,,BAO_0000224,13020,,,1,CHEMBL617180,,,,H,4,,
2236,Inhibitory activity against 5-hydroxytryptamine 2 receptor using [3H]-ketanserin as radioligand at 10e-5 M concentration,Autocuration,,,B,,BAO_0000357,14532,,,1,CHEMBL617181,,,,H,8,,
2237,Binding affinity against 5-hydroxytryptamine 2 receptor,Autocuration,,,B,,BAO_0000357,13944,,,1,CHEMBL617182,,,,H,8,,
2238,Binding affinity against 5-hydroxytryptamine 2 receptor,Autocuration,,,B,,BAO_0000357,14331,,,1,CHEMBL617183,,,,H,8,,
2239,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand,Autocuration,,,B,,BAO_0000357,14118,,,1,CHEMBL617184,,,,H,8,,
2240,Binding affinity against serotonergic 5-HT2 receptor,Autocuration,,,B,,BAO_0000357,13033,,,1,CHEMBL617185,,,,H,8,,
2241,Binding affinity for 5-hydroxytryptamine 2 receptor was determined by using [3H]ketanserin as radioligand,Autocuration,,,B,,BAO_0000357,10321,,,1,CHEMBL617186,,,,H,8,,
2242,Compound was evaluated for the binding affinity at 5- HT2 receptor,Autocuration,,,B,,BAO_0000357,12918,,,1,CHEMBL617187,,,,H,8,,
2243,Compound was tested for binding affinity using [3H]ketanserin against 5-hydroxytryptamine 2 receptor,Autocuration,,,B,,BAO_0000357,15120,,,1,CHEMBL617188,,,,H,8,,
2244,In vivo binding affinity was evaluated against 5-hydroxytryptamine 2 receptor,Autocuration,,,B,,BAO_0000218,2613,,,1,CHEMBL617189,,,,H,8,,
2245,Inhibitory activity against cloned human 5-HT2 receptor,Autocuration,9606.0,,B,,BAO_0000224,13378,,,1,CHEMBL617190,,,Homo sapiens,D,5,,
2246,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells",Autocuration,9606.0,,B,,BAO_0000219,2331,,449.0,1,CHEMBL617191,CHO,,Homo sapiens,D,5,,
2247,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells.",Autocuration,9606.0,,B,,BAO_0000219,2331,,449.0,1,CHEMBL617192,CHO,,Homo sapiens,D,5,,
2248,"Tested in vitro for the inhibition of [3H]-ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells; Inactive",Autocuration,9606.0,,B,,BAO_0000219,2331,,449.0,1,CHEMBL617193,CHO,,Homo sapiens,D,5,,
2249,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells; not tested",Autocuration,9606.0,,B,,BAO_0000219,2331,,449.0,1,CHEMBL617194,CHO,,Homo sapiens,D,5,,
2250,Binding affinity towards 5-hydroxytryptamine 2 receptor,Autocuration,,,B,,BAO_0000224,4170,,,1,CHEMBL617195,,,,H,4,,
2251,Percent decrease in 5-hydroxytryptamine 2 receptor binding using ketanserin,Autocuration,,,B,,BAO_0000224,15453,,,1,CHEMBL881830,,,,H,4,,
2252,Binding affinity towards 5-hydroxytryptamine 2 receptor,Autocuration,,,B,,BAO_0000357,1479,,,1,CHEMBL617196,,,,H,8,,
2253,Binding affinity towards 5-hydroxytryptamine 2- receptor using [3H]ketanserin as radioligand in competitive binding assay,Autocuration,,,B,,BAO_0000224,11139,,,1,CHEMBL617197,,,,H,4,,
2254,Binding affinity against 5-hydroxytryptamine 2A receptor was measured using [3H]ketanserin as radioligand,Expert,,,B,,BAO_0000357,13969,,,1,CHEMBL617198,,,,H,8,,
2255,Binding affinity towards 5-hydroxytryptamine 2A receptor,Expert,,,B,,BAO_0000357,13392,,,1,CHEMBL873476,,,,H,8,,
2256,Affinity towards 5-hydroxytryptamine 2A receptor in membranes from bovine frontal cortex using [3H]ketanserin,Expert,,,B,,BAO_0000019,14430,,,1,CHEMBL617199,,,,H,8,,
2257,Binding affinity was determined against 5-hydroxytryptamine 2A receptor,Autocuration,10141.0,,B,,BAO_0000357,13181,,,1,CHEMBL617200,,,Cavia porcellus,H,8,,
2258,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,Autocuration,,,B,,BAO_0000357,17200,,,1,CHEMBL617484,,,,H,8,,
2259,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,Autocuration,,,B,,BAO_0000357,17200,,,1,CHEMBL617485,,,,H,8,,
2260,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,Autocuration,,,B,,BAO_0000357,17200,,,1,CHEMBL617486,,,,H,8,,
2261,Binding affinity analysed on 5-HT 2A human clone using [3H]ketanserin as radioligand,Autocuration,,,B,,BAO_0000357,13463,,,1,CHEMBL858022,,,,H,8,,
2262,Effective concentration against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand,Autocuration,,,B,,BAO_0000219,6347,,449.0,1,CHEMBL617049,CHO,,,H,8,,
2263,Functional activity against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader,Expert,9606.0,,F,,BAO_0000219,6857,,449.0,1,CHEMBL617050,CHO,,Homo sapiens,D,9,,
2264,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line,Autocuration,,,F,,BAO_0000219,4176,,,1,CHEMBL617051,,,,H,8,,
2265,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line; no data,Autocuration,,,F,,BAO_0000219,4176,,,1,CHEMBL617052,,,,H,8,,
2266,Functional antagonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line,Autocuration,,,F,,BAO_0000219,4176,,,1,CHEMBL617053,,,,H,8,,
2267,"Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand, expressed as Emax",Autocuration,,,B,,BAO_0000219,6347,,449.0,1,CHEMBL617054,CHO,,,H,8,,
2268,"Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells, expressed as Emax",Autocuration,,,B,,BAO_0000219,6347,,449.0,1,CHEMBL617055,CHO,,,H,8,,
2269,Affinity of compound towards human 5-hydroxytryptamine 2A receptor was evaluated using radioligand binding technique,Autocuration,,,B,,BAO_0000357,15331,,,1,CHEMBL882924,,,,H,8,,
2270,Inhibition of human 5-hydroxytryptamine 2A receptor,Expert,9606.0,,B,,BAO_0000357,16146,,,1,CHEMBL617056,,,Homo sapiens,D,9,,
2271,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,Autocuration,,,B,,BAO_0000219,15250,,449.0,1,CHEMBL617057,CHO,,,H,8,,
2272,Inhibitory concentration against human 5-HT2A receptor in BEK cells,Expert,,,B,,BAO_0000219,13631,,,1,CHEMBL617058,,,,H,8,,
2273,In vitro binding affinity against human 5-hydroxytryptamine 2A receptor at a concentration of 100 (nM),Autocuration,,,B,,BAO_0000357,3805,,,1,CHEMBL617059,,,,H,8,,
2274,Ability to displace [3H]ketanserin from CHO cells expressing human 5-hydroxytryptamine 2A receptor was determined,Autocuration,,,B,,BAO_0000219,4011,,449.0,1,CHEMBL617060,CHO,,,H,8,,
2275,Displacement of [3H]ketanserin from CHO cells expressing human 5-hydroxytryptamine 2A receptor.,Expert,,,B,,BAO_0000219,4012,,449.0,1,CHEMBL617061,CHO,,,H,8,,
2276,Ability to displace [125I]R91150 from human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells,Expert,,,B,,BAO_0000219,6366,,307.0,1,CHEMBL617062,L929,,,H,8,,
2277,Ability to displace [3H]ketanserin binding to human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,Expert,,,B,,BAO_0000219,15949,,449.0,1,CHEMBL617063,CHO,,,H,8,,
2278,Agonist activity at cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI radioligand,Autocuration,,,F,,BAO_0000019,14093,,,1,CHEMBL617064,,,,H,8,,
2279,Agonistic activity at cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,Autocuration,,,F,,BAO_0000019,13481,,,1,CHEMBL617065,,,,H,8,,
2280,Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand,Autocuration,,,B,,BAO_0000219,6347,,449.0,1,CHEMBL617066,CHO,,,H,8,,
2281,Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand; Nd means not done,Autocuration,,,B,,BAO_0000219,6347,,449.0,1,CHEMBL617067,CHO,,,H,8,,
2282,Antagonist activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]-Ketanserin radioligand,Autocuration,,,F,,BAO_0000019,14093,,,1,CHEMBL617068,,,,H,8,,
2283,Antagonist activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin radioligand; Not tested,Autocuration,,,F,,BAO_0000019,14093,,,1,CHEMBL617069,,,,H,8,,
2284,Antagonistic activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,Autocuration,,,F,,BAO_0000019,13481,,,1,CHEMBL617070,,,,H,8,,
2285,Binding ability of compound at cloned human 5-hydroxytryptamine 2A receptor using [125 I]DOI as radioligand,Autocuration,,,B,,BAO_0000357,14442,,,1,CHEMBL617071,,,,H,8,,
2286,Binding ability of compound at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,Autocuration,,,B,,BAO_0000357,14442,,,1,CHEMBL872915,,,,H,8,,
2287,Binding activity against cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as the radioligand.,Autocuration,,,B,,BAO_0000357,14755,,,1,CHEMBL617072,,,,H,8,,
2288,Binding affinity against 5-hydroxytryptamine 2A receptor in humans,Autocuration,,,B,,BAO_0000357,16441,,,1,CHEMBL617073,,,,H,8,,
2289,Binding affinity against the cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as the radioligand,Autocuration,,,B,,BAO_0000357,14744,,,1,CHEMBL617074,,,,H,8,,
2290,Binding affinity for displacement of [3H]ketanserin to human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,Expert,,,B,,BAO_0000219,16659,,449.0,1,CHEMBL617075,CHO,,,H,8,,
2291,Binding affinity of compound to human 5-hydroxytryptamine 2A receptor,Autocuration,,,B,,BAO_0000357,3307,,,1,CHEMBL617076,,,,H,8,,
2292,Affinity for human 5-hydroxytryptamine 2A receptor expressed in mammalian cell line,Expert,9606.0,,B,,BAO_0000019,6857,,,1,CHEMBL617077,,,Homo sapiens,D,9,,
2293,Binding affinity against 5-hydroxytryptamine 2A receptor using [125I]DOI radioligand.,Expert,,,B,,BAO_0000357,5635,,,1,CHEMBL617078,,,,H,8,,
2294,Binding affinity to cloned human 5-hydroxytryptamine 2A receptor,Expert,9606.0,,B,,BAO_0000357,4234,,,1,CHEMBL617079,,,Homo sapiens,D,9,,
2295,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand.,Autocuration,,,B,,BAO_0000357,15527,,,1,CHEMBL617080,,,,H,8,,
2296,Binding affinity towards human 5-hydroxytryptamine 2A receptor by the displacement of [3H]ketanserin radioligand from the cloned receptor expressed in CHO cells,Expert,,,B,,BAO_0000219,6588,,449.0,1,CHEMBL617081,CHO,,,H,8,,
2297,Binding affinity towards human 5-HT2A receptor in BEK cells,Expert,,,B,,BAO_0000219,13631,,,1,CHEMBL617082,,,,H,8,,
2298,Binding affinity towards human serotonin 5-hydroxytryptamine 2A receptor,Autocuration,,,B,,BAO_0000357,17723,,,1,CHEMBL617083,,,,H,8,,
2299,Binding affinity for recombinant human 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand.,Autocuration,,,B,,BAO_0000357,14770,,,1,CHEMBL617084,,,,H,8,,
2300,Binding affinity for human 5-hydroxytryptamine 2A receptor,Expert,9606.0,,B,,BAO_0000357,16293,,,1,CHEMBL617085,,,Homo sapiens,D,9,,
2301,Binding affinity towards human 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,Autocuration,,,B,,BAO_0000357,16209,,,1,CHEMBL617086,,,,H,8,,
2302,Binding affinity was measured on 5-hydroxytryptamine 2A receptor in GF6 cells transfected with human 5-HT2A gene labeled with [3H]ketanserin,Autocuration,,,B,,BAO_0000219,12469,,,1,CHEMBL617087,,,,H,8,,
2303,Compound was tested for the displacement of [125I]-DOI from clone human 5-hydroxytryptamine 2A receptor,Autocuration,,,B,,BAO_0000357,15363,,,1,CHEMBL617088,,,,H,8,,
2304,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2A receptor,Autocuration,,,B,,BAO_0000357,15363,,,1,CHEMBL617089,,,,H,8,,
2305,"Tested on genetically transfected COS7 cell membranes selectively expressing human 5-hydroxytryptamine 2A receptor, using [3H]ketanserin as radioligand",Expert,,,B,,BAO_0000019,16441,,,1,CHEMBL617090,,,,H,8,,
2306,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in human using [3H]ketanserin as radioligand,Autocuration,,,B,,BAO_0000357,8,,,1,CHEMBL617513,,,,H,8,,
2307,In vitro binding affinity towards human 5-hydroxytryptamine 2A receptor expressed in HEK293 cells was determined using [3H]ketanserin as radioligand,Autocuration,,,B,,BAO_0000219,4176,,722.0,1,CHEMBL617514,HEK293,,,H,8,,
2308,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2A receptor,Autocuration,,,B,,BAO_0000019,17085,,,1,CHEMBL617515,,,,H,8,,
2309,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,Autocuration,,,B,,BAO_0000357,17200,,,1,CHEMBL617516,,,,H,8,,
2310,Inhibitory constant determined against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,Expert,9606.0,,B,,BAO_0000357,17200,,,1,CHEMBL617517,,,Homo sapiens,D,9,,
2311,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor expressed in CHO cells,Expert,9606.0,,B,,BAO_0000219,4013,,449.0,1,CHEMBL617518,CHO,,Homo sapiens,D,9,,
2312,Tested for binding affinity towards 5-hydroxytryptamine 2A receptor,Autocuration,,,B,,BAO_0000357,5088,,,1,CHEMBL617519,,,,H,8,,
2313,Displacement of [3H]DOB from human 5-hydroxytryptamine 2A receptor,Expert,9606.0,,B,,BAO_0000357,5088,,,1,CHEMBL617520,,,Homo sapiens,D,9,,
2314,Tested for binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]DOB as labeled ligand; binding data not obtained,Autocuration,,,B,,BAO_0000357,5088,,,1,CHEMBL617521,,,,H,8,,
2315,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor,Expert,9606.0,,B,,BAO_0000357,5088,,,1,CHEMBL617522,,,Homo sapiens,D,9,,
2316,Tested for binding affinity towards human 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand,Autocuration,,,B,,BAO_0000357,5088,,,1,CHEMBL617523,,,,H,8,,
2317,Tested for binding affinity towards human 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,Autocuration,,,B,,BAO_0000357,5088,,,1,CHEMBL617524,,,,H,8,,
2318,Ability to displace 0.75 nM [3H]ketanserin in 5-hydroxytryptamine 2 receptor from rat frontal cortex homogenate,Autocuration,,,B,,BAO_0000019,9786,,,1,CHEMBL617525,,,,H,4,,
2319,Ability to inhibit [3H]spiperone binding to 5-hydroxytryptamine 2 receptor determined in rat,Autocuration,10116.0,,B,,BAO_0000019,9205,,,1,CHEMBL617526,,,Rattus norvegicus,D,5,,
2320,Affinity on 5-hydroxytryptamine 2 receptor labeled by [125I]DOI,Autocuration,,,B,,BAO_0000224,11257,,,1,CHEMBL617527,,,,H,4,,
2321,Affinity towards [3H]- DOB -labeled 5-hydroxytryptamine 2 receptor sites in rat cortical homogenates,Autocuration,,,B,,BAO_0000019,9362,,,1,CHEMBL617528,,,,H,4,,
2322,Affinity towards [3H]- ketanserin-labeled 5-hydroxytryptamine 2 receptor sites in rat cortical homogenates,Autocuration,,,B,,BAO_0000019,9362,,,1,CHEMBL617529,,,,H,4,,
2323,Inhibition of 5-hydroxytryptamine 2 induced vasoconstriction of rat caudal artery.,Autocuration,,,B,,BAO_0000224,10590,,,1,CHEMBL617530,,,,H,4,,
2324,Binding affinity against 5-hydroxytryptamine 2 receptor of rat frontal cortex using [3H]ketanserin radioligand,Autocuration,,,B,,BAO_0000019,10468,,,1,CHEMBL617531,,,,H,4,,
2325,Binding affinity against 5-hydroxytryptamine 2 receptor from rat frontal cortex using [125]-(R)-DOI as radioligand,Autocuration,,,B,,BAO_0000019,13050,,,1,CHEMBL617532,,,,H,4,,
2326,Binding affinity against 5-hydroxytryptamine 2 receptor in rat using [3H]ketanserin as radioligand,Autocuration,,,B,,BAO_0000019,11624,,,1,CHEMBL617533,,,,H,4,,
2327,Binding affinity against 5-hydroxytryptamine 2 receptor of rat frontal cortex using [3H]ketanserin radioligand,Autocuration,,,B,,BAO_0000019,10468,,,1,CHEMBL617534,,,,H,4,,
2328,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand,Autocuration,,,B,,BAO_0000224,10330,,,1,CHEMBL617535,,,,H,4,,
2329,Binding affinity at rat 5-hydroxytryptamine 2 receptor by [3H]ketanserin displacement.,Autocuration,,,B,,BAO_0000224,10062,,,1,CHEMBL617536,,,,H,4,,
2330,Binding affinity determined in radioreceptor binding assay by using [3H]ketanserin radioligand against 5-hydroxytryptamine 2 receptor,Autocuration,,,B,,BAO_0000224,11642,,,1,CHEMBL617537,,,,H,4,,
2331,Binding affinity determined in radioreceptor binding assay by using [3H]ketanserin radioligand against 5-hydroxytryptamine 2 receptor,Autocuration,,,B,,BAO_0000224,10062,,,1,CHEMBL617538,,,,H,4,,
2332,Binding affinity of [3H]ketanserin towards 5-hydroxytryptamine 2 receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,Autocuration,,,B,,BAO_0000219,13427,,,1,CHEMBL617539,,,,H,4,,
2333,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor,Autocuration,10116.0,,B,,BAO_0000224,12280,,,1,CHEMBL617540,,,Rattus norvegicus,D,5,,
2334,Binding affinity for 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]ketanserin,Autocuration,10116.0,,B,,BAO_0000224,4101,,,1,CHEMBL617541,,,Rattus norvegicus,D,5,,
2335,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 2 receptor,Autocuration,,,B,,BAO_0000224,10062,,,1,CHEMBL617542,,,,H,4,,
2336,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]DOB as,Autocuration,,,B,,BAO_0000224,11147,,,1,CHEMBL617543,,,,H,4,,
2337,Binding affinity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,Autocuration,10116.0,,B,,BAO_0000219,2395,,485.0,1,CHEMBL617544,CHO-K1,,Rattus norvegicus,D,5,,
2338,Binding affinity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,Autocuration,10116.0,,B,,BAO_0000219,2395,,485.0,1,CHEMBL617545,CHO-K1,,Rattus norvegicus,D,5,,
2339,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- DOB as a radioligand,Autocuration,10116.0,,B,,BAO_0000019,9098,,,1,CHEMBL617413,,,Rattus norvegicus,D,5,,
2340,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- DOB as a radioligand.,Autocuration,,,B,,BAO_0000019,9098,,,1,CHEMBL617414,,,,H,4,,
2341,Binding affinity to 5-hydroxytryptamine 2 receptor of rat cortical membranes using [3H]- DOB; ND means no data.,Autocuration,10116.0,,B,,BAO_0000019,9098,,,1,CHEMBL617415,,,Rattus norvegicus,D,5,,
2342,Binding affinity towards 5-hydroxytryptamine 2 receptor,Autocuration,,,B,,BAO_0000224,9443,,,1,CHEMBL617416,,,,H,4,,
2343,Binding affinity towards 5-hydroxytryptamine 2 receptor at 1.0 uM concentration,Autocuration,,,B,,BAO_0000224,9443,,,1,CHEMBL617417,,,,H,4,,
2344,"Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- 1-(4-bromo-2,5-dimethoxy-phenyl)-2-aminopropane (D) as radioligand in rat frontal cortex",Autocuration,,,B,,BAO_0000019,9699,,,1,CHEMBL617418,,,,H,4,,
2345,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- ketanserin as radioligand in rat frontal cortex,Autocuration,,,B,,BAO_0000019,9699,,,1,CHEMBL617419,,,,H,4,,
2346,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,Autocuration,,,B,,BAO_0000224,9098,,,1,CHEMBL617420,,,,H,4,,
2347,Affinity for 5-hydroxytryptamine 2 receptor,Autocuration,10116.0,,B,,BAO_0000224,3070,,,1,CHEMBL617421,,,Rattus norvegicus,D,5,,
2348,Binding affinity towards serotonin 5-hydroxytryptamine 2 receptor of rat determined using 0.5 nM of [3H]ketanserin in binding assay,Autocuration,,,B,,BAO_0000224,9547,,,1,CHEMBL617422,,,,H,4,,
2349,Binding affinity was determined against 5-hydroxytryptamine 2 receptor from male Sprague-Dawley rat brain.,Autocuration,,,B,,BAO_0000019,10444,,,1,CHEMBL617423,,,,H,4,,
2350,Binding affinity which represents concentration giving half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor from rat tissue homogenate,Autocuration,,,B,,BAO_0000019,14617,,,1,CHEMBL617424,,,,H,4,,
2351,Binding affinity which represents concentration giving half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor rat tissue homogenate,Autocuration,,,B,,BAO_0000019,14617,,,1,CHEMBL617425,,,,H,4,,
2352,Binding constant against 5-hydroxytryptamine 2 receptor (in vitro),Autocuration,,,B,,BAO_0000224,11130,,,1,CHEMBL617426,,,,H,4,,
2353,Binding constant against 5-hydroxytryptamine 2 receptor (in vivo),Autocuration,,,B,,BAO_0000218,11130,,,1,CHEMBL617427,,,,H,4,,
2354,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin in rat brain,Autocuration,,,B,,BAO_0000221,14542,,,1,CHEMBL617428,,,,H,4,955.0,
2355,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2 receptor from rat,Autocuration,,,B,,BAO_0000224,2797,,,1,CHEMBL617429,,,,H,4,,
2356,Compound was evaluated for in vitro binding affinity towards 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- spiperone as radioligand,Autocuration,,,B,,BAO_0000019,11332,,,1,CHEMBL617430,,,,H,4,,
2357,Compound was evaluated for in vitro binding affinity towards serotonin 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- spiperone as radioligand,Autocuration,,,B,,BAO_0000019,11332,,,1,CHEMBL617431,,,,H,4,,
2358,Compound was evaluated for its ability to displace 0.25 nM [125I](R)-DOI from binding sites in rat frontal cortex.,Autocuration,,,B,,BAO_0000019,10752,,,1,CHEMBL617432,,,,H,4,1870.0,
2359,Ability to displace [3H]ketanserin from serotonergic 5-hydroxytryptamine 2 receptor,Autocuration,,,B,,BAO_0000224,1185,,,1,CHEMBL617433,,,,H,4,,
2360,Compound was evaluated for its ability to displace [3H]ketanserin from serotonergic 5-hydroxytryptamine 2 receptor,Autocuration,,,B,,BAO_0000224,1185,,,1,CHEMBL617434,,,,H,4,,
2361,Binding affinity against 5-Hydroxy tryptamine 2 (5-hydroxytryptamine 2)receptor,Autocuration,10116.0,,B,,BAO_0000224,11624,,,1,CHEMBL617435,,,Rattus norvegicus,D,5,,
2362,Compound was evaluated for its binding affinity to 5-hydroxytryptamine 2 receptor in rat cortex using [3H]ketanserin radioligand assay,Autocuration,,,B,,BAO_0000019,1344,,,1,CHEMBL617436,,,,H,4,,
2363,Binding affinity against 5-hydroxytryptamine 2 receptor in rat striatum using [3H]-RP62203,Autocuration,10116.0,,B,,BAO_0000019,15453,,,1,CHEMBL617437,,,Rattus norvegicus,D,5,2435.0,
2364,"Binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand",Autocuration,,,B,,BAO_0000019,11662,,,1,CHEMBL617438,,,,H,4,,
2365,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",Autocuration,,,B,,BAO_0000019,11662,,,1,CHEMBL617439,,,,H,4,,
2366,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 2 receptor,Autocuration,,,B,,BAO_0000224,10796,,,1,CHEMBL617440,,,,H,4,,
2367,Evaluated for binding activity against [3H]ketanserin as radioligand for 5-hydroxytryptamine 2 receptor,Autocuration,,,B,,BAO_0000224,9069,,,1,CHEMBL617441,,,,H,4,,
2368,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat cortical membrane homogenates,Autocuration,10116.0,,B,,BAO_0000019,8814,,,1,CHEMBL872918,,,Rattus norvegicus,D,5,,
2369,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat cortex,Autocuration,10116.0,,B,,BAO_0000019,8908,,,1,CHEMBL617442,,,Rattus norvegicus,D,5,,
2370,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand; ND means no data.,Autocuration,,,B,,BAO_0000019,9098,,,1,CHEMBL617443,,,,H,4,,
2371,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 (5-HT2) receptor using [3H]KET as a radioligand,Autocuration,,,B,,BAO_0000019,9098,,,1,CHEMBL617444,,,,H,4,,
2372,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand; ND means no data.,Autocuration,,,B,,BAO_0000019,9098,,,1,CHEMBL617445,,,,H,4,,
2373,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand.,Autocuration,,,B,,BAO_0000019,9098,,,1,CHEMBL617446,,,,H,4,,
2374,Binding affinity to 5-hydroxytryptamine 2 receptor in rat frontal cortical membranes by [3H]- KET displacement.,Autocuration,,,B,,BAO_0000249,9098,,,1,CHEMBL617447,,,,H,4,,
2375,Evaluated for the binding affinity to rat frontal cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand.;ND is not determined,Autocuration,,,B,,BAO_0000019,9098,,,1,CHEMBL617448,,,,H,4,,
2376,Evaluated for the binding affinity to rat frontal cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand;ND means no data,Autocuration,,,B,,BAO_0000019,9098,,,1,CHEMBL617449,,,,H,4,,
2377,In vitro binding affinity at 5-hydroxytryptamine 2 receptor in rat cortical tissue by [3H]spiperone displacement; No data.,Autocuration,,,B,,BAO_0000019,9161,,,1,CHEMBL617450,,,,H,4,,
2378,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 165 to 263,Autocuration,,,B,,BAO_0000019,9161,,,1,CHEMBL617451,,,,H,4,,
2379,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 2.4 to 5.3,Autocuration,,,B,,BAO_0000019,9161,,,1,CHEMBL617452,,,,H,4,,
2380,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]-Spiperone as the radioligand in rat cortical tissue.,Autocuration,,,B,,BAO_0000019,9161,,,1,CHEMBL617453,,,,H,4,,
2381,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.; value may range from 140 to 980,Autocuration,,,B,,BAO_0000019,9161,,,1,CHEMBL617660,,,,H,4,,
2382,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.; value may range from 76 to 299,Autocuration,,,B,,BAO_0000019,9161,,,1,CHEMBL617661,,,,H,4,,
2383,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]-Spiperone as the radioligand in rat cortical tissue; value may range from 12 to 66,Autocuration,,,B,,BAO_0000019,9161,,,1,CHEMBL617662,,,,H,4,,
2384,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 136 to 220,Autocuration,,,B,,BAO_0000019,9161,,,1,CHEMBL872919,,,,H,4,,
2385,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 197 to 341,Autocuration,,,B,,BAO_0000019,9161,,,1,CHEMBL617663,,,,H,4,,
2386,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 23 to 187,Autocuration,,,B,,BAO_0000019,9161,,,1,CHEMBL617664,,,,H,4,,
2387,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 29 to 132,Autocuration,,,B,,BAO_0000019,9161,,,1,CHEMBL617665,,,,H,4,,
2388,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 6 to 75,Autocuration,,,B,,BAO_0000019,9161,,,1,CHEMBL617666,,,,H,4,,
2389,In vitro binding affinity on 5-hydroxytryptamine 2 receptor is inhibition of binding of [125I]- I-LSD to P11 cells,Autocuration,,,B,,BAO_0000019,12094,,,1,CHEMBL617667,,,,H,4,,
2390,In vitro binding affinity towards 5-hydroxytryptamine 2 receptor in rat striatal membranes by [3H]ketanserin displacement.,Autocuration,,,B,,BAO_0000249,12018,,,1,CHEMBL617668,,,,H,4,,
2391,Inhibitory activity against 5-hydroxytryptamine 2 receptor in rat cortical membranes using [3H]ketanserin as a radioligand,Autocuration,,,B,,BAO_0000249,10394,,,1,CHEMBL617669,,,,H,4,,
2392,Inhibitory activity against rat cortical 5-hydroxytryptamine 2 receptor,Autocuration,,,B,,BAO_0000224,15260,,,1,CHEMBL617670,,,,H,4,,
2393,Inhibitory constant against 5-hydroxytryptamine 2 receptor,Autocuration,10116.0,,B,,BAO_0000224,11624,,,1,CHEMBL617671,,,Rattus norvegicus,D,5,,
2394,Percentage specific displacement of radioligand [3H]-ketanserin from 5-hydroxytryptamine 2 receptor,Autocuration,,,B,,BAO_0000224,13654,,,1,CHEMBL617672,,,,H,4,,
2395,Potency to displace [3H]- Spiperone from 5-hydroxytryptamine 2 receptor in rat striatum,Autocuration,,,B,,BAO_0000019,9541,,,1,CHEMBL617673,,,,H,4,,
2396,Tested for binding affinity against 5-hydroxytryptamine 2 receptor from rat frontal cortical regions using [3H]ketanserin as radioligand,Autocuration,,,B,,BAO_0000224,11933,,,1,CHEMBL617674,,,,H,4,,
2397,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex,Autocuration,,,B,,BAO_0000019,15538,,,1,CHEMBL617675,,,,H,4,,
2398,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex; NA means Not Active,Autocuration,,,B,,BAO_0000019,15538,,,1,CHEMBL617676,,,,H,4,,
2399,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex; not determined,Autocuration,,,B,,BAO_0000019,15538,,,1,CHEMBL617677,,,,H,4,,
2400,Displacement of [3H]ketanserin from rat prefrontal cortex 5-hydroxytryptamine 2 receptor,Autocuration,,,B,,BAO_0000019,8841,,,1,CHEMBL617678,,,,D,5,,
2401,Binding affinity to 5-hydroxytryptamine 2 receptor using [3H]ketanserin radioligand assay.,Autocuration,,,B,,BAO_0000224,1455,,,1,CHEMBL617679,,,,H,4,,
2402,Tested for its binding affinity to Tested for its binding affinity to 5-hydroxytryptamine 2 receptor using [3H]-ketanserin radioligand assay using [3H]-ketanserin radioligand assay,Autocuration,,,B,,BAO_0000224,1455,,,1,CHEMBL617680,,,,H,4,,
2403,The ability to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat whole brain,Autocuration,,,B,,BAO_0000019,11752,,,1,CHEMBL617681,,,,H,4,,
2404,The binding affinity was measured on 5-hydroxytryptamine 2 receptor in rat brain tissue,Autocuration,,,B,,BAO_0000221,11642,,,1,CHEMBL617682,,,,H,4,955.0,
2405,The binding affinity was measured on 5-hydroxytryptamine 2 receptor using [3H]- spiperone as radioligand.,Autocuration,,,B,,BAO_0000224,12092,,,1,CHEMBL617683,,,,H,4,,
2406,Binding affinity at 5-hydroxytryptamine 2 receptor from striata wistar rats by [3H]ketanserin displacement.,Autocuration,,,B,,BAO_0000224,3967,,,1,CHEMBL617684,,,,H,4,,
2407,Binding affinity towards 5-hydroxytryptamine 2 receptor,Autocuration,10116.0,,B,,BAO_0000224,12771,,,1,CHEMBL617685,,,Rattus norvegicus,D,5,,
2408,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2 receptor by displacing [3H]ketanserin radioligand in rat cerebral cortex,Autocuration,,,B,,BAO_0000019,11642,,,1,CHEMBL617686,,,,H,4,,
2409,The compound was tested in vitro for binding affinity towards 5-hydroxytryptamine 2 receptor by displacing [125]I-LSD radioligand,Autocuration,,,B,,BAO_0000224,11628,,,1,CHEMBL617687,,,,H,4,,
2410,Percentage specific displacement of radioligand [3H]ketanserin from 5-hydroxytryptamine 2 receptor,Autocuration,,,B,,BAO_0000224,13654,,,1,CHEMBL617688,,,,H,4,,
2411,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,Autocuration,,,F,,BAO_0000019,11200,,,1,CHEMBL617689,,,,H,4,,
2412,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,Autocuration,,,F,,BAO_0000019,11200,,,1,CHEMBL617690,,,,H,4,,
2413,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 1 hr after oral administration",Autocuration,,,F,,BAO_0000218,11200,,,1,CHEMBL617691,,,,H,4,,
2414,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 3h after oral administration",Autocuration,,,F,,BAO_0000218,11200,,,1,CHEMBL617692,,,,H,4,,
2415,"In vivo inhibitory activity of 3 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 1 hr after oral administration",Autocuration,,,F,,BAO_0000218,11200,,,1,CHEMBL617693,,,,H,4,,
2416,"In vivo inhibitory activity of 3 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 3h after oral administration",Autocuration,,,F,,BAO_0000218,11200,,,1,CHEMBL617694,,,,H,4,,
2417,Affinity for 5-hydroxytryptamine 2A receptor in rat brain cortex by ability to displace [3H]ketanserin,Expert,,,B,,BAO_0000221,15436,,,1,CHEMBL857985,,,,H,8,955.0,
2418,Affinity at 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,Expert,10116.0,,B,,BAO_0000019,15436,,,1,CHEMBL617695,,,Rattus norvegicus,D,9,,
2419,Affinity pKi for 5-hydroxytryptamine 2A receptor was measured in rat cortex homogenates,Autocuration,,,B,,BAO_0000019,14025,,,1,CHEMBL617696,,,,H,8,,
2420,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2A receptor was determined,Autocuration,,,B,,BAO_0000357,4342,,,1,CHEMBL617697,,,,H,8,,
2421,Displacement of [3H]ketanserin from 5-HT2A receptor of rat frontal cortex,Expert,10116.0,,B,,BAO_0000019,13735,,,1,CHEMBL617257,,,Rattus norvegicus,D,9,,
2422,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin,Expert,10116.0,,B,,BAO_0000357,5816,,,1,CHEMBL617258,,,Rattus norvegicus,D,9,,
2423,Binding affinity was evaluated in vitro by displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor on rat cortical membrane,Expert,,,B,,BAO_0000019,14287,,,1,CHEMBL617259,,,,H,8,,
2424,In vitro affinity against serotonin ( 5-hydroxytryptamine 2A receptor ) receptor,Autocuration,,,B,,BAO_0000357,15738,,,1,CHEMBL617260,,,,H,8,,
2425,In vitro affinity against serotonin 5-hydroxytryptamine 2A receptor,Expert,10116.0,,B,,BAO_0000357,15738,,,1,CHEMBL617261,,,Rattus norvegicus,D,9,,
2426,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat frontal cortex using [3H]-ketanserin as radioligand,Autocuration,,,B,,BAO_0000019,15026,,,1,CHEMBL617262,,,,H,8,,
2427,Half-maximal inhibition of [3H]- Ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex homogenate,Expert,,,B,,BAO_0000019,16647,,,1,CHEMBL617263,,,,H,8,,
2428,Half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat tissue homogenate,Autocuration,,,B,,BAO_0000019,16647,,,1,CHEMBL617264,,,,H,8,,
2429,Displacement of [3H]-ketanserin from rat brain 5-hydroxytryptamine 2A receptor,Expert,10116.0,,B,,BAO_0000019,13345,,,1,CHEMBL617265,,,Rattus norvegicus,D,9,,
2430,Inhibition constant for in vitro inhibition of [3H]ketanserin binding to rat frontal cortex membranes 5-hydroxytryptamine 2A receptor,Autocuration,,,B,,BAO_0000249,1543,Membranes,,1,CHEMBL617266,,,,H,8,,
2431,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor rat frontal cortex membrane,Autocuration,,,B,,BAO_0000019,12444,,,1,CHEMBL617267,,,,H,8,,
2432,Inhibitory constant on 5-hydroxytryptamine 2A receptor of Rat frontal cortex,Expert,,,B,,BAO_0000019,16404,,,1,CHEMBL617268,,,,H,8,,
2433,Inhibitory constant on human 5-hydroxytryptamine 2A receptor transfected in to CHO cells,Autocuration,,,B,,BAO_0000219,16404,,449.0,1,CHEMBL617269,CHO,,,H,8,,
2434,Kinetic inhibition constant evaluated by measuring serotonergic activity,Expert,,,B,,BAO_0000357,15577,,,1,CHEMBL617323,,,,H,8,,
2435,Serotonergic activity of the compound.,Autocuration,,,B,,BAO_0000357,15577,,,1,CHEMBL617324,,,,H,8,,
2436,Tested in vitro for its ability to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat frontal cortex membranes,Autocuration,,,B,,BAO_0000249,2495,,,1,CHEMBL617325,,,,H,8,,
2437,The binding affinity was evaluated on 5-hydroxytryptamine 2A receptor expressed in rat cortex by using [3H]ketanserin as radioligand.,Expert,10116.0,,B,,BAO_0000019,15042,,,1,CHEMBL617326,,,Rattus norvegicus,D,9,,
2438,In vitro ability to displace [3H]ketanserin binding from 5-hydroxytryptamine 2A receptor in rat striatal membrane.,Expert,,,B,,BAO_0000249,15026,,,1,CHEMBL617327,,,,H,8,,
2439,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,Expert,10116.0,,F,,BAO_0000019,12919,,,1,CHEMBL617328,,,Rattus norvegicus,D,9,,
2440,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,Expert,10116.0,,F,,BAO_0000019,12919,,,1,CHEMBL617329,,,Rattus norvegicus,D,9,,
2441,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,Expert,10116.0,,F,,BAO_0000019,12919,,,1,CHEMBL617330,,,Rattus norvegicus,D,9,,
2442,The compound was tested for the binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,Autocuration,,,B,,BAO_0000357,15194,,,1,CHEMBL617331,,,,H,8,,
2443,The compound was tested for the binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand.,Autocuration,,,B,,BAO_0000357,15194,,,1,CHEMBL617332,,,,H,8,,
2444,Binding affinity towards 5-hydroxytryptamine 2A receptor,Expert,,,B,,BAO_0000357,4820,,,1,CHEMBL617333,,,,H,8,,
2445,Binding affinity against serotonin 5-hydroxytryptamine 2A receptor was determined using human [125I]-eotaxin,Autocuration,,,B,,BAO_0000357,6736,,,1,CHEMBL617334,,,,H,8,,
2446,Binding affinity towards 5-hydroxytryptamine 2A receptor was determined at a concentration of 0.000001 mol/L,Autocuration,,,B,,BAO_0000357,5163,,,1,CHEMBL617335,,,,H,8,,
2447,Binding affinity towards 5-hydroxytryptamine 2A receptor was determined at a concentration of 0.00001 mol/L,Autocuration,,,B,,BAO_0000357,5163,,,1,CHEMBL617336,,,,H,8,,
2448,Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration,Autocuration,,,B,,BAO_0000357,6011,,,1,CHEMBL617337,,,,H,8,,
2449,Percent inhibition against 5-hydroxytryptamine 2A receptor using [3H]ketanserin at 1 uM,Expert,9606.0,,B,,BAO_0000357,14294,,,1,CHEMBL617338,,,Homo sapiens,D,9,,
2450,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 2A receptor,Autocuration,,,B,,BAO_0000357,5014,,,1,CHEMBL617339,,,,H,8,,
2451,Binding affinity towards 5-hydroxytryptamine 2A receptor,Expert,,,B,,BAO_0000357,17066,,,1,CHEMBL617340,,,,H,8,,
2452,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2A receptor; inactive at 10 uM,Autocuration,,,B,,BAO_0000357,17515,,,1,CHEMBL617341,,,,H,8,,
2453,Inhibition of [125I]-eotaxin binding to serotonin 5-hydroxytryptamine 2A receptor,Expert,,,B,,BAO_0000357,6736,,,1,CHEMBL617342,,,,H,8,,
2454,Affinity for 5-hydroxytryptamine 2A receptor,Expert,,,B,,BAO_0000357,5163,,,1,CHEMBL617343,,,,H,8,,
2455,Binding affinity was performed using [3H]ketanserin as the radioligand and stably transfected NIH3T3 cells expressing the 5-hydroxytryptamine 2A receptor (GF-62 cells).,Expert,,,B,,BAO_0000219,16911,,723.0,1,CHEMBL617344,NIH3T3,,,H,8,,
2456,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin,Expert,,,B,,BAO_0000357,6841,,,1,CHEMBL617345,,,,H,8,,
2457,Binding affinity towards 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand.,Expert,,,B,,BAO_0000357,6119,,,1,CHEMBL617346,,,,H,8,,
2458,Compound was evaluated for its binding against 5-hydroxytryptamine 2A receptor,Autocuration,,,B,,BAO_0000357,3962,,,1,CHEMBL617347,,,,H,8,,
2459,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2A receptor was determined,Autocuration,,,B,,BAO_0000357,4373,,,1,CHEMBL617348,,,,H,8,,
2460,Binding affinity relative to indolopiperidine (compound 1)for 5-hydroxytryptamine 2A receptor was determined,Autocuration,,,B,,BAO_0000357,4373,,,1,CHEMBL617349,,,,H,8,,
2461,Compound was evaluated for its inverse agonist activity against 5-hydroxytryptamine 2A receptor,Autocuration,,,F,,BAO_0000019,3962,,,1,CHEMBL617350,,,,H,8,,
2462,Binding affinity towards 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin,Expert,,,B,,BAO_0000357,1633,,,1,CHEMBL872339,,,,H,8,,
2463,Binding affinity for 5-hydroxytryptamine 2A receptor was determined,Autocuration,,,B,,BAO_0000357,4373,,,1,CHEMBL617351,,,,H,8,,
2464,Binding affinity towards serotonin 5-hydroxytryptamine 2A receptor,Expert,,,B,,BAO_0000357,6576,,,1,CHEMBL617352,,,,H,8,,
2465,Evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor,Autocuration,,,B,,BAO_0000357,4687,,,1,CHEMBL617353,,,,H,8,,
2466,Ability to displace [3H]-ketanserin from 5-hydroxytryptamine 2A receptor,Autocuration,,,B,,BAO_0000357,16946,,,1,CHEMBL617354,,,,H,8,,
2467,Compound was evaluated for the affinity at 5-hydroxytryptamine 2A receptor,Autocuration,,,B,,BAO_0000357,14159,,,1,CHEMBL617355,,,,H,8,,
2468,In vitro binding affinity against 5-hydroxytryptamine 2A receptor in CHO cells,Expert,10090.0,,B,,BAO_0000219,3032,,449.0,1,CHEMBL617356,CHO,,Mus musculus,H,8,,
2469,Inhibition of ketanserin binding to 5-hydroxytryptamine 2A receptor,Autocuration,,,B,,BAO_0000357,16655,,,1,CHEMBL617357,,,,H,8,,
2470,Binding affinity at 5-hydroxytryptamine 2A receptor,Autocuration,,,B,,BAO_0000357,13964,,,1,CHEMBL617358,,,,H,8,,
2471,Binding affinity towards Serotonin 5-hydroxytryptamine 2A receptor,Expert,,,B,,BAO_0000357,16989,,,1,CHEMBL617359,,,,H,8,,
2472,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor was determined,Autocuration,,,B,,BAO_0000357,16117,,,1,CHEMBL617360,,,,H,8,,
2473,The binding affinity towards 5-hydroxytryptamine 2A receptor; No affinity,Autocuration,,,B,,BAO_0000357,16700,,,1,CHEMBL875913,,,,H,8,,
2474,Affinity against 5-hydroxytryptamine 2A receptor,Autocuration,,,B,,BAO_0000357,3269,,,1,CHEMBL617361,,,,H,8,,
2475,Binding affinity against 5-Hydroxytryptamine 2A receptor,Expert,9606.0,,B,,BAO_0000357,1274,,,1,CHEMBL617362,,,Homo sapiens,D,9,,
2476,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using radioligand binding assay,Autocuration,,,B,,BAO_0000357,1317,,,1,CHEMBL617363,,,,H,8,,
2477,Tested against 5-hydroxytryptamine 2A receptor,Autocuration,,,B,,BAO_0000357,12146,,,1,CHEMBL617364,,,,H,8,,
2478,Binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H]- ketanserin,Autocuration,,,B,,BAO_0000224,12652,,,1,CHEMBL617365,,,,H,4,,
2479,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H] ketanserin,Autocuration,,,B,,BAO_0000224,12652,,,1,CHEMBL617366,,,,H,4,,
2480,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor agonist [125I]- - (+/-)DOI,Autocuration,,,B,,BAO_0000224,12652,,,1,CHEMBL617367,,,,H,4,,
2481,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H]- ketanserin,Autocuration,,,B,,BAO_0000224,12652,,,1,CHEMBL617368,,,,H,4,,
2482,Selectivity ratio towards 5-hydroxytryptamine 2A receptor to Dopamine receptor D2 (5-HT2A/D2 ),Autocuration,,,B,,BAO_0000357,16647,,,1,CHEMBL617369,,,,H,8,,
2483,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND means no data,Expert,9606.0,,B,,BAO_0000219,15851,,722.0,1,CHEMBL617370,HEK293,,Homo sapiens,D,9,,
2484,Functional activity against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader,Expert,9606.0,,F,,BAO_0000219,6857,,449.0,1,CHEMBL617371,CHO,,Homo sapiens,D,9,,
2485,In vitro binding affinity against human 5-HT2B receptor at a concentration of 100 (nM),Autocuration,,,B,,BAO_0000357,3805,,,1,CHEMBL617372,,,,H,8,,
2486,Affinity towards human 5-hydroxytryptamine 2B serotonin receptor,Expert,9606.0,,B,,BAO_0000357,6491,,,1,CHEMBL617373,,,Homo sapiens,D,9,,
2487,Agonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT radioligand,Autocuration,,,F,,BAO_0000019,14093,,,1,CHEMBL617374,,,,H,8,,
2488,Agonistic activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]-5-HT as radioligand,Autocuration,,,F,,BAO_0000019,13481,,,1,CHEMBL617375,,,,H,8,,
2489,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine radioligand,Autocuration,,,F,,BAO_0000019,14093,,,1,CHEMBL617376,,,,H,8,,
2490,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine radioligand; Not tested,Autocuration,,,F,,BAO_0000019,14093,,,1,CHEMBL617377,,,,H,8,,
2491,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine radioligand,Autocuration,,,F,,BAO_0000019,14093,,,1,CHEMBL617378,,,,H,8,,
2492,Antagonistic activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand,Autocuration,,,F,,BAO_0000019,13481,,,1,CHEMBL617379,,,,H,8,,
2493,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine as radioligand,Autocuration,,,B,,BAO_0000357,14442,,,1,CHEMBL617380,,,,H,8,,
2494,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT 2B as radioligand,Autocuration,,,B,,BAO_0000357,14442,,,1,CHEMBL617381,,,,H,8,,
2495,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand,Autocuration,,,B,,BAO_0000357,14442,,,1,CHEMBL617382,,,,H,8,,
2496,The compound evaluated for its affinity against 5-hydroxytryptamine 2A receptor,Autocuration,,,B,,BAO_0000357,12369,,,1,CHEMBL617383,,,,H,8,,
2497,Affinity against 5-hydroxytryptamine 2A receptor (D) labeled with [125I]DOI.,Expert,,,B,,BAO_0000357,12369,,,1,CHEMBL617384,,,,H,8,,
2498,Affinity against 5-hydroxytryptamine 2A receptor (K) labeled with [3H]ketanserin.,Expert,,,B,,BAO_0000357,12369,,,1,CHEMBL617385,,,,H,8,,
2499,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 2A receptor from cloned Human membranes,Autocuration,,,B,,BAO_0000019,14447,,,1,CHEMBL617386,,,,H,8,,
2500,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 2A receptor from cloned Human membranes.,Autocuration,,,B,,BAO_0000019,14447,,,1,CHEMBL617387,,,,H,8,,
2501,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,Autocuration,,,B,,BAO_0000219,17451,,723.0,1,CHEMBL617388,NIH3T3,,,H,8,,
2502,Relative efficacy against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,Autocuration,,,F,,BAO_0000219,6857,,449.0,1,CHEMBL617389,CHO,,,H,8,,
2503,Relative efficacy against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,Expert,9606.0,,F,,BAO_0000219,6857,,449.0,1,CHEMBL617390,CHO,,Homo sapiens,D,9,,
2504,Selectivity ratio of binding affinity of 5-hydroxytryptamine 2A receptor to that of 5-hydroxytryptamine 2C receptor.,Autocuration,,,B,,BAO_0000224,5635,,,1,CHEMBL617391,,,,H,4,,
2505,Binding activity radioligand.,Autocuration,,,B,,BAO_0000357,12861,,,1,CHEMBL617392,,,,H,8,,
2506,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,Autocuration,,,B,,BAO_0000019,12861,,,1,CHEMBL617393,,,,H,8,,
2507,Binding affinity for human cloned 5-HT2A receptor expressed in L929 cells using [125I]R91150 as radioligand,Autocuration,,,B,,BAO_0000219,5105,,307.0,1,CHEMBL617394,L929,,,H,8,,
2508,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand,Expert,,,B,,BAO_0000219,5104,,307.0,1,CHEMBL617395,L929,,,H,8,,
2509,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells by [125I]R91150 displacement.,Expert,,,B,,BAO_0000219,5105,,307.0,1,CHEMBL617396,L929,,,H,8,,
2510,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand; Not tested,Autocuration,,,B,,BAO_0000219,5105,,307.0,1,CHEMBL617397,L929,,,H,8,,
2511,Binding affinity against 5-HT2A receptor,Autocuration,,,B,,BAO_0000357,5254,,,1,CHEMBL617398,,,,H,8,,
2512,Binding affinity against 5-hydroxytryptamine 2A receptor,Autocuration,,,B,,BAO_0000357,5254,,,1,CHEMBL617399,,,,H,8,,
2513,Antagonistic binding affinity measured against 5-hydroxytryptamine 2A receptor (human clone expressed in 293 cells) using [3H]ketanserin as radioligand,Autocuration,,,B,,BAO_0000219,13267,,722.0,1,CHEMBL617400,HEK293,,,H,8,,
2514,Antagonistic binding affinity measured against 5-hydroxytryptamine 2C receptor (human clone expressed in 293 cells) using [3H]mesulergine as radioligand,Autocuration,,,B,,BAO_0000219,13267,,722.0,1,CHEMBL617401,HEK293,,,H,8,,
2515,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor expressed in HEK 293 cells,Expert,9606.0,,B,,BAO_0000219,14157,,722.0,1,CHEMBL617402,HEK293,,Homo sapiens,D,9,,
2516,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,Expert,9606.0,,B,,BAO_0000219,12936,,722.0,1,CHEMBL617403,HEK293,,Homo sapiens,D,9,,
2517,Binding affinity against human 5-hydroxytryptamine 2A receptor using displacement of [3H]5-HT,Expert,,,B,,BAO_0000357,14068,,,1,CHEMBL617404,,,,H,8,,
2518,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,Expert,9606.0,,B,,BAO_0000219,12936,,722.0,1,CHEMBL857981,HEK293,,Homo sapiens,D,9,,
2519,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,Expert,9606.0,,B,,BAO_0000219,12936,,722.0,1,CHEMBL617405,HEK293,,Homo sapiens,D,9,,
2520,Binding affinity to human cloned 5-hydroxytryptamine 2A receptor in HEK 293 cells using [3H]- ketanserin as radioligand,Expert,9606.0,,B,,BAO_0000219,4540,,722.0,1,CHEMBL617253,HEK293,,Homo sapiens,D,9,,
2521,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor.,Expert,,,B,,BAO_0000357,6166,,,1,CHEMBL617254,,,,H,8,,
2522,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptors in HEK 293 cells using [3H]ketanserin as radioligand,Autocuration,,,B,,BAO_0000219,17296,,722.0,1,CHEMBL617255,HEK293,,,H,8,,
2523,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptors in HEK 293 cells using [3H]ketanserin as radioligand,Autocuration,,,B,,BAO_0000219,17296,,722.0,1,CHEMBL617256,HEK293,,,H,8,,
2524,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptorswithouteffect in HEK 293 cells using [3H]ketanserin as radioligand,Autocuration,,,B,,BAO_0000219,17296,,722.0,1,CHEMBL616874,HEK293,,,H,8,,
2525,Binding affinity towards 5-hydroxytryptamine 2A receptor (human cloned receptor) in HEK 293 cells using [3H]ketanserin as radioligand.,Expert,9606.0,,B,,BAO_0000219,15779,,722.0,1,CHEMBL616875,HEK293,,Homo sapiens,D,9,,
2526,Binding affinity towards human 5-hydroxytryptamine 2A receptor expressed in HEK 293 cells using [3H]ketanserin as radioligand,Expert,,,B,,BAO_0000219,14391,,722.0,1,CHEMBL616876,HEK293,,,H,8,,
2527,"Binding affinity towards human cloned 5-hydroxytryptamine receptor 2A in HEK293 cells, using [3H]ketanserin as radioligand.",Expert,,,B,,BAO_0000219,15851,,722.0,1,CHEMBL616877,HEK293,,,H,8,,
2528,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor expressed in HEK293 cells; compound is insoluble,Expert,9606.0,,B,,BAO_0000219,15851,,722.0,1,CHEMBL616878,HEK293,,Homo sapiens,D,9,,
2529,Binding affinity towards human cloned 5-hydroxytryptamine 2A receptor of HEK293 cells by displacement of [3H]ketanserin,Expert,,,B,,BAO_0000219,3832,,722.0,1,CHEMBL616879,HEK293,,,H,8,,
2530,In vitro binding affinity at human cloned 5-hydroxytryptamine 2A receptor of HEK293 cells by [3H]ketanserin displacement.,Expert,,,B,,BAO_0000219,3833,,722.0,1,CHEMBL616880,HEK293,,,H,8,,
2531,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,Expert,9606.0,,B,,BAO_0000219,12936,,722.0,1,CHEMBL616881,HEK293,,Homo sapiens,D,9,,
2532,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand,Autocuration,,,B,,BAO_0000219,17451,,723.0,1,CHEMBL616882,NIH3T3,,,H,8,,
2533,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,Autocuration,,,B,,BAO_0000219,17451,,723.0,1,CHEMBL616883,NIH3T3,,,H,8,,
2534,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,Autocuration,,,B,,BAO_0000219,17451,,723.0,1,CHEMBL616884,NIH3T3,,,H,8,,
2535,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 2A receptor in HEK 293 cells using [3H]ketanserin as the radioligand,Autocuration,,,B,,BAO_0000219,4199,,722.0,1,CHEMBL616885,HEK293,,,H,8,,
2536,Compound was evaluated for displacement of [3H]ketanserin from human cloned 5-hydroxytryptamine 2A receptor in transfected CHO-K1 cells,Autocuration,,,B,,BAO_0000219,1883,,485.0,1,CHEMBL616886,CHO-K1,,,H,8,,
2537,Displacement of [3H]-ketanserin from human cloned 5-hydroxytryptamine 2A receptor expressed in CHO-K1 cells.,Expert,,,B,,BAO_0000219,1883,,485.0,1,CHEMBL616887,CHO-K1,,,H,8,,
2538,Binding affinity for human 5-hydroxytryptamine 2A receptor,Expert,9606.0,,B,,BAO_0000357,14875,,,1,CHEMBL616888,,,Homo sapiens,D,9,,
2539,Compound was tested for its binding affinity against 5-hydroxytryptamine 2A receptor in human cloned receptors in HEK 293 cells using [3H]ketanserin,Autocuration,,,B,,BAO_0000219,15146,,722.0,1,CHEMBL616889,HEK293,,,H,8,,
2540,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2A receptor in HEK 293 using [3H]ketanserin as a radioligand,Autocuration,,,B,,BAO_0000219,5213,,722.0,1,CHEMBL616890,HEK293,,,H,8,,
2541,Inhibitory constant for human 5-hydroxytryptamine 2A receptor transfected in to CHO cells,Expert,9606.0,,B,,BAO_0000219,16404,,449.0,1,CHEMBL616891,CHO,,Homo sapiens,D,9,,
2542,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2A receptor in HEK293 cells using [3H]-ketanserin.,Autocuration,,,B,,BAO_0000219,14818,,722.0,1,CHEMBL616892,HEK293,,,H,8,,
2543,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2A receptor in HEK293 cells, using [3H]ketanserin as radioligand",Autocuration,,,B,,BAO_0000219,4829,,722.0,1,CHEMBL616893,HEK293,,,H,8,,
2544,Percent of maximum stimulation of phosphatidylinositol turnover at cloned 5-hydroxytryptamine 2A receptor in 3T3 cells,Autocuration,,,F,,BAO_0000219,12652,,723.0,1,CHEMBL616894,NIH3T3,,,H,8,,
2545,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor expressed NIH3T3 cells,Expert,,,B,,BAO_0000219,4682,,723.0,1,CHEMBL616895,NIH3T3,,,H,8,,
2546,The maximum responses of [3H]- inositol monophosphate accumulation in cells expressing the 5-hydroxytryptamine 2A receptor,Autocuration,,,F,,BAO_0000019,12652,,,1,CHEMBL616896,,,,H,8,,
2547,Ability to displace [3H]-Ketanserin radioligand from porcine 5-hydroxytryptamine 2A receptor,Autocuration,,,B,,BAO_0000357,4921,,,1,CHEMBL617099,,,,H,8,,
2548,Ability to displace [3H]ketanserin radioligand from porcine 5-hydroxytryptamine 2A receptor; ND denotes not determined,Autocuration,,,B,,BAO_0000357,4921,,,1,CHEMBL617100,,,,H,8,,
2549,Binding affinity against rabbit aorta 5-HT2A receptor,Autocuration,9986.0,,B,,BAO_0000357,16312,,,1,CHEMBL884532,,,Oryctolagus cuniculus,H,8,,
2550,Binding affinity for 5-hydroxytryptamine 2A receptor of rabbit aorta ring preparations,Expert,9986.0,,B,,BAO_0000357,14998,,,1,CHEMBL617101,,,Oryctolagus cuniculus,H,8,,
2551,Dissociation equilibrium constant against the vascular 5-hydroxytryptamine 2A receptor in the rabbit saphenous aorta,Expert,9986.0,,B,,BAO_0000357,14025,,,1,CHEMBL617102,,,Oryctolagus cuniculus,H,8,,
2552,Binding affinity against 5-hydroxytryptamine 1D receptor alpha using rabbit saphenous vein assay.,Autocuration,9986.0,,B,,BAO_0000019,13047,,,1,CHEMBL617103,,,Oryctolagus cuniculus,H,8,,
2553,The compound was tested for binding affinity against 5-HT2A receptor,Expert,9986.0,,B,,BAO_0000357,13047,,,1,CHEMBL617104,,,Oryctolagus cuniculus,H,8,,
2554,Compound was evaluated for displacement of [3H]ketanserin from cloned rat 5-hydroxytryptamine 2A receptor in transfected CHO-K1 cells.,Autocuration,,,B,,BAO_0000219,1883,,485.0,1,CHEMBL857979,CHO-K1,,,H,8,,
2555,Binding affinity analysed towards 5-HT 2A in rat jugular vein,Autocuration,,,B,,BAO_0000019,13463,,,1,CHEMBL857502,,,,H,8,,
2556,Binding affinity analysed towards 5-HT 2A in rat jugular vein.,Autocuration,,,B,,BAO_0000019,13463,,,1,CHEMBL617105,,,,H,8,,
2557,Binding affinity analysed on 5-HT 2A in rat stomach fundus.,Autocuration,,,B,,BAO_0000019,13463,,,1,CHEMBL858021,,,,H,8,945.0,
2558,Binding affinity for 5-HT 2A in rat stomach fundus,Expert,10116.0,,B,,BAO_0000019,13463,,,1,CHEMBL875910,,,Rattus norvegicus,D,9,945.0,
2559,Binding affinity analysed towards 5-HT 2A in rat jugular vein.,Autocuration,,,B,,BAO_0000019,13463,,,1,CHEMBL617106,,,,H,8,,
2560,Ability to stimulate phosphoinositide hydrolysis in NIH3T3 cells expressing the 5-hydroxytryptamine 2A receptor,Expert,,,B,,BAO_0000219,16326,,723.0,1,CHEMBL617107,NIH3T3,,,H,8,,
2561,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast 5-hydroxytryptamine 2A receptor,Autocuration,,,F,,BAO_0000019,14093,,,1,CHEMBL617108,,,,H,8,,
2562,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast expressing 5-hydroxytryptamine 2A receptor,Autocuration,,,F,,BAO_0000019,14093,,,1,CHEMBL617109,,,,H,8,,
2563,Evaluated for the effective concentration at [125I]-DOI-labeled rat 5-hydroxytryptamine 2A receptor,Autocuration,,,B,,BAO_0000357,15740,,,1,CHEMBL617110,,,,H,8,,
2564,Functional potency at the rat 5-hydroxytryptamine 2A receptor as effective concentration EC50 for stimulating Phosphoinositide accumulation,Autocuration,,,B,,BAO_0000357,16633,,,1,CHEMBL617111,,,,H,8,,
2565,In vitro relative agonist activity against 5-hydroxytryptamine 2A using PI assay in rat vascular smooth muscle cells,Expert,10116.0,,F,,BAO_0000019,17200,,,1,CHEMBL617112,,,Rattus norvegicus,D,9,,
2566,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,Autocuration,,,B,,BAO_0000357,17133,,,1,CHEMBL617113,,,,H,8,,
2567,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,Autocuration,,,B,,BAO_0000357,17133,,,1,CHEMBL617114,,,,H,8,,
2568,Tested for its ability to activate phospholipase c by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,Autocuration,,,B,,BAO_0000357,17133,,,1,CHEMBL617115,,,,H,8,,
2569,The receptor (5-hydroxytryptamine 2A ) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,Autocuration,,,F,,BAO_0000219,17200,,,1,CHEMBL617116,,,,H,8,,
2570,Efficacy at 5-hydroxytryptamine 2A receptor,Autocuration,,,F,,BAO_0000019,15363,,,1,CHEMBL617117,,,,H,8,,
2571,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor was determined by using CA+ assay (Emax),Autocuration,,,B,,BAO_0000357,17200,,,1,CHEMBL617118,,,,H,8,,
2572,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor was determined by using CA+ assay (Emax),Expert,10116.0,,B,,BAO_0000357,17200,,,1,CHEMBL617119,,,Rattus norvegicus,D,9,,
2573,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor determined by using PI assay (Emax),Expert,10116.0,,B,,BAO_0000357,17200,,,1,CHEMBL617120,,,Rattus norvegicus,D,9,,
2574,The receptor (5-hydroxytryptamine 2A ) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,Expert,10116.0,,F,,BAO_0000219,17200,,,1,CHEMBL617121,,,Rattus norvegicus,D,9,,
2575,The receptor (5-hydroxytryptamine 2A) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,Autocuration,,,F,,BAO_0000219,17200,,,1,CHEMBL617122,,,,H,8,,
2576,Ability to displace [3H]ketanserin (0.5 nM) from cerebral cortex of rat 5-hydroxytryptamine 2A receptor,Autocuration,,,B,,BAO_0000019,17211,,,1,CHEMBL617123,,,,H,8,,
2577,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]-ketanserin from rat prefrontal cerebral cortex mambranes,Expert,,,B,,BAO_0000019,17331,,,1,CHEMBL617124,,,,H,8,,
2578,Binding affinity to serotonin 5-hydroxytryptamine 2A receptors using a radioligand [3H]ketanserin binding assay in rat cortical membranes,Expert,,,B,,BAO_0000249,13565,,,1,CHEMBL617600,,,,H,8,,
2579,Binding affinity towards rat 5-hydroxytryptamine 2A receptor was evaluated using [3H]- ketanserin as radioligand,Expert,,,B,,BAO_0000357,13730,,,1,CHEMBL617601,,,,H,8,,
2580,In vitro affinity towards 5-hydroxytryptamine 2A receptor using [3H]spiroperidol as radioligand in cortex,Expert,,,B,,BAO_0000019,12416,,,1,CHEMBL882923,,,,H,8,,
2581,Compound was tested for it's binding affinity towards 5-hydroxytryptamine 2A receptor,Autocuration,,,B,,BAO_0000357,15295,,,1,CHEMBL617602,,,,H,8,,
2582,Compound was tested for its ability to displace [3H]DOB from 5-hydroxytryptamine 2A receptor in rat cortex homogenates,Autocuration,,,B,,BAO_0000019,1742,,,1,CHEMBL617603,,,,H,8,,
2583,Compound was tested for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor,Autocuration,,,B,,BAO_0000357,15295,,,1,CHEMBL617604,,,,H,8,,
2584,Binding affinity towards 5-hydroxytryptamine 2A receptor from rat frontal cortex using [3H]ketanserin as radioligand,Expert,,,B,,BAO_0000019,14970,,,1,CHEMBL617605,,,,H,8,,
2585,In vitro binding affinity for serotonin 5-hydroxytryptamine 2A receptor of rat cerebral cortex using [3H]ketanserin as radioligand,Expert,,,B,,BAO_0000019,16693,,,1,CHEMBL617606,,,,H,8,,
2586,Inhibition of [3H]ketanserin binding to rat frontal cortex membrane 5-hydroxytryptamine 2A receptor,Expert,10116.0,,B,,BAO_0000019,14776,,,1,CHEMBL617607,,,Rattus norvegicus,D,9,,
2587,In vitro inhibitory concentration against radioligand [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cortical membrane,Autocuration,,,B,,BAO_0000249,14286,,,1,CHEMBL617455,,,,H,8,,
2588,In vitro inhibition of [125I]DOI binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex,Expert,10116.0,,B,,BAO_0000019,17200,,,1,CHEMBL617456,,,Rattus norvegicus,D,9,,
2589,Inhibitory concentration against 5-hydroxytryptamine 2A receptor (Inactive at >1000 nM concentration),Expert,,,B,,BAO_0000357,15306,,,1,CHEMBL617457,,,,H,8,,
2590,Inhibition of radiolabeled [3H]-Ketanserin ligand binding to 5-hydroxytryptamine 2A receptor,Expert,10116.0,,B,,BAO_0000357,14178,,,1,CHEMBL617458,,,Rattus norvegicus,D,9,,
2591,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor from rat brain,Expert,10116.0,,B,,BAO_0000019,14229,,,1,CHEMBL617459,,,Rattus norvegicus,D,9,,
2592,Binding affinity towards 5-hydroxytryptamine 2A receptor binding site using [3H]ketanserin. ,Expert,,,B,,BAO_0000357,12884,,,1,CHEMBL617460,,,,H,8,,
2593,"Binding affinity for 5-hydroxytryptamine 2A receptor, activity is expressed as IC50 values.",Expert,,,B,,BAO_0000357,13149,,,1,CHEMBL617461,,,,H,8,,
2594,Displacement of [3H]ketanserin from rat cortical membrane 5-hydroxytryptamine 2A receptor at 10e-7 M,Expert,10116.0,,B,,BAO_0000019,15295,,,1,CHEMBL617462,,,Rattus norvegicus,D,9,,
2595,Intrinsic activity was determined at 5-hydroxytryptamine 2A receptor which is percentage response given compared with the response produced by 10 uM serotonin.,Autocuration,,,B,,BAO_0000357,15740,,,1,CHEMBL617463,,,,H,8,,
2596,"Compound was tested for binding affinity at 5-hydroxytryptamine 2A receptor sites in rat cortical homogenate using [125I]-2,5-Dimethoxy -4-iodoamphetamine (DOI).",Autocuration,,,B,,BAO_0000019,15185,,,1,CHEMBL617464,,,,H,8,,
2597,"Compound was tested for binding affinity using [3H]MDL-100,907 at 5-hydroxytryptamine 2A receptor sites in rat cortical homogenate.",Autocuration,,,B,,BAO_0000019,15185,,,1,CHEMBL617465,,,,H,8,,
2598,Ability to bind to central serotonin 5-hydroxytryptamine 2A receptor in vitro in cortex of the rat brain using [3H]ketanserin radioligand,Expert,,,B,,BAO_0000019,17529,,,1,CHEMBL617466,,,,H,8,,
2599,Ability to displace [3H]- ketanserin bound to 5-hydroxytryptamine 2A receptor in rat pre-frontal cortex,Autocuration,,,B,,BAO_0000019,14826,,,1,CHEMBL617467,,,,H,8,,
2600,Displacement of [3H]ketanserin (0.5 nM) from rat cerebral cortex 5-hydroxytryptamine 2A receptors,Expert,,,B,,BAO_0000019,17211,,,1,CHEMBL617468,,,,H,8,,
2601,Ability to displace [3H]ketanserin bound to 5-hydroxytryptamine 2A receptor in rat pre-frontal cortex,Autocuration,,,B,,BAO_0000019,14826,,,1,CHEMBL617469,,,,H,8,,
2602,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor,Autocuration,,,B,,BAO_0000019,14093,,,1,CHEMBL617470,,,,H,8,,
2603,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor; Not tested,Autocuration,,,B,,BAO_0000019,14093,,,1,CHEMBL617471,,,,H,8,,
2604,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2A serotonin receptor in NIH3T3 cell line membranes,Expert,,,B,,BAO_0000219,13246,,723.0,1,CHEMBL617472,NIH3T3,,,H,8,,
2605,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2A serotonin receptor.,Expert,,,B,,BAO_0000357,13246,,,1,CHEMBL617473,,,,H,8,,
2606,Affinity 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,Expert,10116.0,,B,,BAO_0000019,15436,,,1,CHEMBL617474,,,Rattus norvegicus,D,9,,
2607,Affinity at 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,Expert,10116.0,,B,,BAO_0000019,15436,,,1,CHEMBL617475,,,Rattus norvegicus,D,9,,
2608,Affinity at [3H]ketanserin-labeled 5-hydroxytryptamine 2A receptor in rat brain homogenate was determined,Autocuration,,,B,,BAO_0000221,14442,,,1,CHEMBL617476,,,,H,8,955.0,
2609,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 2A receptor,Expert,,,B,,BAO_0000357,12457,,,1,CHEMBL617477,,,,H,8,,
2610,Affinity was evaluated by inhibition of [125I]LSD binding to NIH 3T3 cells transfected with cloned rat 5-hydroxytryptamine 2A receptor,Expert,,,B,,BAO_0000219,12457,,723.0,1,CHEMBL617478,NIH3T3,,,H,8,,
2611,"Antagonistic activity measured for 5-hydroxytryptamine 2A receptor using [3H]-MDL- 100,907 as radioligand in rat cortical homogenates.",Autocuration,,,F,,BAO_0000221,14755,,,1,CHEMBL617479,,,,H,8,,
2612,Binding affinity towards rat 5-hydroxytryptamine 2A receptor was determined using [125I]- DOI as radioligand,Autocuration,,,B,,BAO_0000357,4707,,,1,CHEMBL617480,,,,H,8,,
2613,Binding affinity against 5-hydroxytryptamine 2A receptor,Expert,,,B,,BAO_0000357,13297,,,1,CHEMBL617481,,,,H,8,,
2614,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin from rat prefrontal cerebral cortex mambranes,Expert,,,B,,BAO_0000019,17331,,,1,CHEMBL617482,,,,H,8,,
2615,Binding affinity against 5-hydroxytryptamine 2A receptor from rat forebrain using [3H]ketanserin as radioligand,Autocuration,,,B,,BAO_0000019,4664,,,1,CHEMBL617483,,,,H,8,,
2616,Binding affinity against 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,Autocuration,,,B,,BAO_0000357,16633,,,1,CHEMBL621528,,,,H,8,,
2617,Binding affinity against 5-hydroxytryptamine 2A receptor expressed NIH3T3 cells using [3H]ketanserin,Expert,10116.0,,B,,BAO_0000219,4664,,723.0,1,CHEMBL621529,NIH3T3,,Rattus norvegicus,D,9,,
2618,Binding affinity against rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,Expert,,,B,,BAO_0000357,16133,,,1,CHEMBL621530,,,,H,8,,
2619,Binding affinity against rat 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,Expert,,,B,,BAO_0000357,16133,,,1,CHEMBL621531,,,,H,8,,
2620,Binding affinity against rat brain 5-hydroxytryptamine 2A receptor,Expert,10116.0,,B,,BAO_0000019,14060,,,1,CHEMBL621532,,,Rattus norvegicus,D,9,,
2621,Binding affinity at cloned rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,Expert,,,B,,BAO_0000357,16326,,,1,CHEMBL621533,,,,H,8,,
2622,Binding affinity for displacement of [3H]ketanserin to rat 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,Expert,,,B,,BAO_0000219,16659,,449.0,1,CHEMBL621534,CHO,,,H,8,,
2623,Binding affinity measured at the 5-hydroxytryptamine 2A receptor by the inhibition of [3H]ketanserin binding to rat cortex using unlabeled mianserin for nonspecific binding.,Autocuration,,,B,,BAO_0000019,14776,,,1,CHEMBL621535,,,,H,8,,
2624,Binding affinity of [3H]- ketanserin labelled towards Rat cortical 5-hydroxytryptamine 2A receptor using radioligand binding assay,Autocuration,,,B,,BAO_0000357,13481,,,1,CHEMBL621536,,,,H,8,,
2625,Binding affinity of compound was tested for 5-hydroxytryptamine 2A receptor,Autocuration,,,B,,BAO_0000357,17386,,,1,CHEMBL621537,,,,H,8,,
2626,Binding affinity for 5-hydroxytryptamine 2A receptor,Expert,10116.0,,B,,BAO_0000357,6611,,,1,CHEMBL621538,,,Rattus norvegicus,D,9,,
2627,Binding affinity against 5-hydroxytryptamine 2A receptor from rat cortex using [3H]ketanserin as the radioligand.,Autocuration,,,B,,BAO_0000019,14423,,,1,CHEMBL621539,,,,H,8,,
2628,Binding affinity against 5-hydroxytryptamine 2A receptor of rat pre-frontal cortex,Autocuration,,,B,,BAO_0000019,15412,,,1,CHEMBL621540,,,,H,8,,
2629,Binding affinity against 5-hydroxytryptamine 2A receptor of rat pre-frontal cortex.,Autocuration,,,B,,BAO_0000019,15412,,,1,CHEMBL621541,,,,H,8,,
2630,Binding affinity towards 5-HT 2A receptor in rat cerebral frontal cortex membranes using [3H]ketanserin as radioligand,Autocuration,,,B,,BAO_0000019,6238,,,1,CHEMBL621542,,,,H,8,,
2631,Binding affinity at 5-hydroxytryptamine 2A receptor of rat.,Expert,,,B,,BAO_0000357,6648,,,1,CHEMBL621543,,,,H,8,,
2632,Binding affinity towards 5-hydroxytryptamine 2A receptor sites by using [3H]ketanserin as radioligand,Expert,,,B,,BAO_0000357,5667,,,1,CHEMBL621544,,,,H,8,,
2633,Binding affinity for 5-hydroxytryptamine 2A serotonin receptor,Expert,10116.0,,B,,BAO_0000357,6611,,,1,CHEMBL621545,,,Rattus norvegicus,D,9,,
2634,Binding affinity towards rat cortical 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,Autocuration,,,B,,BAO_0000357,13481,,,1,CHEMBL621546,,,,H,8,,
2635,Binding affinity towards rat cortical 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand; Not tested,Autocuration,,,B,,BAO_0000357,13481,,,1,CHEMBL621547,,,,H,8,,
2636,Displacement of [3H]ketanserin from NIH3T3 cells stably expressing rat 5-hydroxytryptamine 2A receptor,Expert,,,B,,BAO_0000219,15558,,723.0,1,CHEMBL618692,NIH3T3,,,H,8,,
2637,Binding affinity towards 5-hydroxytryptamine 2A receptor,Autocuration,,,B,,BAO_0000357,6013,,,1,CHEMBL618693,,,,H,8,,
2638,Binding affinity towards 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,Autocuration,,,B,,BAO_0000357,16633,,,1,CHEMBL872922,,,,H,8,,
2639,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor from fundus tissue was determined using [3H]mesulergine as radioligand,Autocuration,,,B,,BAO_0000357,6013,,,1,CHEMBL618694,,,,H,8,,
2640,Binding affinity for rat 5-hydroxytryptamine 2A receptor using [3H]DOB,Expert,10116.0,,B,,BAO_0000357,6013,,,1,CHEMBL618695,,,Rattus norvegicus,D,9,,
2641,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor was determined using [3H]DOB as radioligand; ND=No data,Autocuration,,,B,,BAO_0000357,6013,,,1,CHEMBL618696,,,,H,8,,
2642,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor by [3H]ketanserin displacement.,Expert,,,B,,BAO_0000357,6013,,,1,CHEMBL618697,,,,H,8,,
2643,Binding affinity towards cloned rat Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration was determined using [3H]DOB as radioligand,Autocuration,,,B,,BAO_0000357,6013,,,1,CHEMBL618892,,,,H,8,,
2644,Binding affinity towards cloned rat Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration was determined using [3H]ketanserin as radioligand,Autocuration,,,B,,BAO_0000357,6013,,,1,CHEMBL618893,,,,H,8,,
2645,Binding affinity towards rat 5-hydroxytryptamine 2A receptor,Autocuration,,,B,,BAO_0000357,16293,,,1,CHEMBL618894,,,,H,8,,
2646,Binding affinity towards rat 5-hydroxytryptamine 2A receptor expressed in NIH3T3 cells using [3H]ketanserin as radioligand,Expert,,,B,,BAO_0000219,17175,,723.0,1,CHEMBL618895,NIH3T3,,,H,8,,
2647,Binding affinity was measured against 5-hydroxytryptamine 2A receptor by displacement of [3H]- ketanserin by lysergic acid amides,Expert,10116.0,,B,,BAO_0000357,13278,,,1,CHEMBL618896,,,Rattus norvegicus,D,9,,
2648,Compound was evaluated for affinity towards cerebral 5-hydroxytryptamine 2A receptor in homogenate of caudate putamen tissue from rat brain,Autocuration,,,B,,BAO_0000019,3682,,,1,CHEMBL618897,,,,H,8,5383.0,
2649,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as a radioligand,Autocuration,,,B,,BAO_0000357,2014,,,1,CHEMBL618898,,,,H,8,,
2650,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as a radioligand; Not determined,Autocuration,,,B,,BAO_0000357,2014,,,1,CHEMBL618899,,,,H,8,,
2651,Compound was evaluated for its ability to displace (+/-)[125I]-DOI from 5-hydroxytryptamine 2A receptor in cloned rat cell culture,Autocuration,,,B,,BAO_0000357,4932,,,1,CHEMBL618900,,,,H,8,,
2652,Compound was evaluated for its ability to displace [125I](R)-DOI from 5-hydroxytryptamine 2A receptor in cloned rat prefrontal cortex homogenate,Autocuration,,,B,,BAO_0000019,4932,,,1,CHEMBL618901,,,,H,8,,
2653,Compound was evaluated for its binding affinity for rat 5-hydroxytryptamine 2A receptor,Autocuration,,,B,,BAO_0000357,3935,,,1,CHEMBL618902,,,,H,8,,
2654,Displacement of [3H]8-OH-DPAT from rat hippocampus membrane 5-hydroxytryptamine 2A receptor,Expert,10116.0,,B,,BAO_0000221,5432,,,1,CHEMBL618903,,,Rattus norvegicus,D,9,10000000.0,
2655,Compound was evaluated for its binding affinity towards rat 5-hydroxytryptamine 2A receptor,Autocuration,,,B,,BAO_0000357,15818,,,1,CHEMBL618904,,,,H,8,,
2656,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin radioligand.,Autocuration,,,B,,BAO_0000357,13672,,,1,CHEMBL618905,,,,H,8,,
2657,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]-ketanserin radioligand.,Autocuration,,,B,,BAO_0000357,13672,,,1,CHEMBL618906,,,,H,8,,
2658,Binding affinity against rat 5-hydroxytryptamine 2A receptor in NIH3T3 cells.,Expert,,,B,,BAO_0000219,14749,,723.0,1,CHEMBL618907,NIH3T3,,,H,8,,
2659,Compound was tested for the Binding affinity against rat frontal cortex 5-hydroxytryptamine 2A receptor by Radio ligand [3H]ketanserin binding assay.,Autocuration,,,B,,BAO_0000019,13462,,,1,CHEMBL618908,,,,H,8,,
2660,Evaluated for the binding constant at [125I]-DOI-labeled rat 5-hydroxytryptamine 2A receptor,Autocuration,,,B,,BAO_0000357,15740,,,1,CHEMBL617909,,,,H,8,,
2661,Half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex homogenate,Expert,,,B,,BAO_0000019,16647,,,1,CHEMBL617910,,,,H,8,,
2662,In vitro ability to displace [3H]ketanserin from 5-hydroxytryptamine 2A receptor in rat brain.,Autocuration,,,B,,BAO_0000221,13345,,,1,CHEMBL617911,,,,H,8,955.0,
2663,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,Autocuration,,,B,,BAO_0000249,16740,,,1,CHEMBL872923,,,,H,8,,
2664,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,Autocuration,,,B,,BAO_0000249,16740,,,1,CHEMBL617912,,,,H,8,,
2665,In vitro binding affinity at 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin from rat cortex,Expert,10116.0,,B,,BAO_0000019,15535,,,1,CHEMBL617913,,,Rattus norvegicus,D,9,,
2666,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,Expert,,,B,,BAO_0000249,16740,,,1,CHEMBL617914,,,,H,8,,
2667,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,Autocuration,,,B,,BAO_0000249,16740,,,1,CHEMBL617915,,,,H,8,,
2668,In vitro binding affinity at serotonin 5-hydroxytryptamine 2A receptor in rat cortical membrane,Autocuration,,,B,,BAO_0000249,16740,,,1,CHEMBL617916,,,,H,8,,
2669,Displacement of [3H]- Ketanserin from rat cortex 5-hydroxytryptamine 2A receptor,Expert,10116.0,,B,,BAO_0000019,4795,,,1,CHEMBL617917,,,Rattus norvegicus,D,9,,
2670,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in rat tissue homogenate using [3H]ketanserin as radioligand,Expert,,,B,,BAO_0000019,8,,,1,CHEMBL617918,,,,H,8,,
2671,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in rat tissue homogenate using [3H]ketanserin as radioligand; Not active at 10-5 M,Autocuration,,,B,,BAO_0000019,8,,,1,CHEMBL617919,,,,H,8,,
2672,In vitro inhibitory constant against [125I]DOI binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex,Expert,10116.0,,B,,BAO_0000019,17200,,,1,CHEMBL617920,,,Rattus norvegicus,D,9,,
2673,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor of rat brain cortex,Expert,10116.0,,B,,BAO_0000019,2148,,,1,CHEMBL617921,,,Rattus norvegicus,D,9,,
2674,"Relative binding affinity for D2 receptor and 5-hydroxytryptamine 2A receptor, ratio of Ki",Expert,10116.0,,B,,BAO_0000224,13345,,,1,CHEMBL617922,,,Rattus norvegicus,D,5,,
2675,Tested for binding affinity towards rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,Autocuration,,,B,,BAO_0000357,5088,,,1,CHEMBL617923,,,,H,8,,
2676,Tested for binding affinity towards rat 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,Autocuration,,,B,,BAO_0000357,5088,,,1,CHEMBL617924,,,,H,8,,
2677,Tested in vitro for its ability to bind to 5-hydroxytryptamine 2A receptor using [125 I]-DOI as radioligand,Autocuration,,,B,,BAO_0000357,17133,,,1,CHEMBL617925,,,,H,8,,
2678,In vitro binding to 5-hydroxytryptamine 2A receptor using [125 I]-DOI,Expert,10116.0,,B,,BAO_0000357,17133,,,1,CHEMBL617926,,,Rattus norvegicus,D,9,,
2679,The binding affinity at 5-hydroxytryptamine 2A receptor was determined using [3H]ketanserin,Autocuration,,,B,,BAO_0000357,16532,,,1,CHEMBL617927,,,,H,8,,
2680,The compound was tested for binding affinity against 5-hydroxytryptamine 2A receptor,Autocuration,,,B,,BAO_0000357,15086,,,1,CHEMBL617928,,,,H,8,,
2681,Binding affinity for 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,Expert,10116.0,,B,,BAO_0000019,2309,,,1,CHEMBL617929,,,Rattus norvegicus,D,9,,
2682,Binding affinity to 5-hydroxytryptamine 2A receptor from rat cortex assayed using [3H]ketanserin as radioligand.,Expert,,,B,,BAO_0000019,12953,,,1,CHEMBL617930,,,,H,8,,
2683,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat cortex using [3H]ketanserin as radioligand.; Nonactive at 10 uM,Autocuration,,,B,,BAO_0000019,12953,,,1,CHEMBL617931,,,,H,8,,
2684,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat cortex using [3H]-ketanserin as radioligand; Nonactive at 10 uM,Autocuration,,,B,,BAO_0000019,12953,,,1,CHEMBL617932,,,,H,8,,
2685,Binding affinity for displacement of [3H]ketanserin to rat 5-hydroxytryptamine 2A receptor stably expressed in CHO cells; ND is No Data,Autocuration,,,B,,BAO_0000219,16659,,449.0,1,CHEMBL617933,CHO,,,H,8,,
2686,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane; ND means no data,Autocuration,,,B,,BAO_0000019,16740,,,1,CHEMBL617934,,,,H,8,,
2687,In vitro binding affinity at serotonin 5-hydroxytryptamine 2A receptor in rat cortical membrane; ND means no data,Autocuration,,,B,,BAO_0000019,16740,,,1,CHEMBL617935,,,,H,8,,
2688,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor; Not determined,Autocuration,,,B,,BAO_0000357,17133,,,1,CHEMBL617936,,,,H,8,,
2689,Ability to displace [3H]ketanserin (0.5 nM) from cerebral cortex of rat 5-hydroxytryptamine 2A receptor; NT=not tested,Autocuration,,,B,,BAO_0000019,17211,,,1,CHEMBL617937,,,,H,8,,
2690,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]-ketanserin from rat prefrontal cerebral cortex mambranes; Not tested,Autocuration,,,B,,BAO_0000019,17331,,,1,CHEMBL617938,,,,H,8,,
2691,Compound was evaluated for effective dose measured in nmol/kg following a dose of 0.04 mg/kg and 0.093 uM/kg (95%CI); range 32-63,Autocuration,,,B,,BAO_0000218,16633,,,1,CHEMBL617939,,,,H,8,,
2692,Compound was evaluated for the percentage of rats disrupted following a dose of 0.04 mg/kg and 0.097 uM/kg,Autocuration,,,B,,BAO_0000218,16633,,,1,CHEMBL617940,,,,H,8,,
2693,Compound was evaluated for the percentage of rats disrupted following a dose of 0.08 mg/kg and 0.194 uM/kg,Autocuration,,,B,,BAO_0000218,16633,,,1,CHEMBL617941,,,,H,8,,
2694,Ratio of pKi of 5-HT2A to that of 5-HT2C receptor,Expert,,,B,,BAO_0000357,15026,,,1,CHEMBL617942,,,,H,8,,
2695,Ratio of pKi of 5-HT2A to that of D2 receptor,Expert,,,B,,BAO_0000357,15026,,,1,CHEMBL617943,,,,H,8,,
2696,Selectivity ratio towards KB of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2B receptor,Expert,,,B,,BAO_0000224,16404,,,1,CHEMBL617944,,,,H,4,,
2697,Selectivity ratio towards KB of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2B receptor,Expert,,,B,,BAO_0000224,16404,,,1,CHEMBL617945,,,,H,4,,
2698,Selectivity ratio towards Ki of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2C receptor,Expert,,,B,,BAO_0000224,16404,,,1,CHEMBL617946,,,,H,4,,
2699,Selectivity ratio towards Ki of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2C receptor; ND is no data,Autocuration,,,B,,BAO_0000357,16404,,,1,CHEMBL617947,,,,H,8,,
2700,Percent maximal 5-HT stimulation at cloned rat 5-hydroxytryptamine 2A receptor (phosphoinositide hydrolysis study) at a conc of 100 uM,Expert,,,B,,BAO_0000357,16326,,,1,CHEMBL617948,,,,H,8,,
2701,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 2A receptor of rat,Autocuration,,,F,,BAO_0000019,15847,,,1,CHEMBL858116,,,,H,8,,
2702,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 2A receptor of rat; ND means not done,Autocuration,,,F,,BAO_0000019,15847,,,1,CHEMBL617949,,,,H,8,,
2703,Effectiveness of compound in blocking 5-hydroxytryptamine 2A receptor-mediated contractions of rat tail artery,Autocuration,,,F,,BAO_0000019,15329,,,1,CHEMBL617950,,,,H,8,,
2704,Negative log concentration of antagonist on 5-hydroxytryptamine 2A receptor in rat thoracic aorta,Expert,,,F,,BAO_0000019,16404,,,1,CHEMBL617951,,,,H,8,1515.0,
2705,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2A receptor of Rat thoracic aorta,Expert,,,F,,BAO_0000019,16404,,,1,CHEMBL617952,,,,H,8,1515.0,
2706,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2A receptor of Rat thoracic aorta; ND is not determined.,Autocuration,,,F,,BAO_0000019,16404,,,1,CHEMBL617953,,,,H,8,1515.0,
2707,Binding activity radioligand.,Autocuration,,,B,,BAO_0000357,12861,,,1,CHEMBL617954,,,,H,8,,
2708,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,Expert,,,B,,BAO_0000019,12861,,,1,CHEMBL617955,,,,H,8,,
2709,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand; NA Not Available,Autocuration,,,B,,BAO_0000019,12861,,,1,CHEMBL857071,,,,H,8,,
2710,Displacement of [3H]DOB binding to 5-hydroxytryptamine 2A receptor from rat cortex homogenate,Expert,,,B,,BAO_0000019,12490,,,1,CHEMBL617270,,,,H,8,,
2711,Binding affinity towards 5-hydroxytryptamine 3 receptor in membranes of N1E-115 neuroblastoma cells using [3H]-ICS 205-930,Autocuration,,,B,,BAO_0000219,12827,,339.0,1,CHEMBL617271,N1E-115,,,H,8,,
2712,Binding affinity towards 5-hydroxytryptamine 3 receptor in membranes of N1E-115 neuroblastoma cells using [3H]-ICS 205-930; Not determined,Autocuration,,,B,,BAO_0000219,12827,,339.0,1,CHEMBL617272,N1E-115,,,H,8,,
2713,Binding affinity was evaluated by 5-hydroxytryptamine 2A receptor agonism in the rat cortex by displacing ketanserin,Autocuration,,,B,,BAO_0000019,12918,,,1,CHEMBL617273,,,,H,8,,
2714,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]-ketanserin,Expert,10116.0,,F,,BAO_0000019,12919,,,1,CHEMBL617274,,,Rattus norvegicus,D,9,,
2715,Binding affinity towards human serotonin 5-hydroxytryptamine 2C receptor,Autocuration,,,B,,BAO_0000357,17723,,,1,CHEMBL617275,,,,H,8,,
2716,Binding affinity towards 5-hydroxytryptamine 2C receptor,Autocuration,,,B,,BAO_0000357,6013,,,1,CHEMBL617276,,,,H,8,,
2717,Binding affinity towards human 5-hydroxytryptamine 2C receptor,Autocuration,,,B,,BAO_0000357,16293,,,1,CHEMBL617277,,,,H,8,,
2718,Binding affinity using [125I]DOI as radioligand with membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor,Expert,,,B,,BAO_0000019,3857,,,1,CHEMBL617278,,,,H,8,,
2719,Binding affinity using [125I]DOI as radioligand with membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor; Not determined,Expert,,,B,,BAO_0000019,3857,,,1,CHEMBL617279,,,,H,8,,
2720,Binding affinity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor,Expert,,,B,,BAO_0000019,3857,,,1,CHEMBL617280,,,,H,8,,
2721,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2C receptor,Autocuration,,,B,,BAO_0000357,15363,,,1,CHEMBL617281,,,,H,8,,
2722,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2C receptor,Autocuration,,,B,,BAO_0000357,15363,,,1,CHEMBL617282,,,,H,8,,
2723,Tested on transfected cell membranes selectively expressing human 5-hydroxytryptamine 2C receptor using [3H]mesulergine,Expert,,,B,,BAO_0000019,16441,,,1,CHEMBL617283,,,,H,8,,
2724,Tested on transfected cell membranes selectively expressing human 5-hydroxytryptamine 2C receptor using [3H]-mesulergine; ND is No Data.,Expert,,,B,,BAO_0000019,16441,,,1,CHEMBL617284,,,,H,8,,
2725,In vitro binding affinity towards human 5-hydroxytryptamine 2C receptor expressed in HEK293 cells was determined using [3H]mesulergine as radioligand,Autocuration,,,B,,BAO_0000219,4176,,722.0,1,CHEMBL617285,HEK293,,,H,8,,
2726,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2C receptor,Autocuration,,,B,,BAO_0000019,17085,,,1,CHEMBL617286,,,,H,8,,
2727,Inhibitory constant against cloned human 5-hydroxytryptamine 2C receptor using with [125I]- DOI radioligand,Expert,9606.0,,B,,BAO_0000357,17200,,,1,CHEMBL617287,,,Homo sapiens,D,9,,
2728,Binding affinity towards human 5-hydroxytryptamine 2C receptor.,Expert,,,B,,BAO_0000357,5088,,,1,CHEMBL617288,,,,H,8,,
2729,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]DOB as radioligand,Autocuration,,,B,,BAO_0000357,5088,,,1,CHEMBL617289,,,,H,8,,
2730,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,Autocuration,,,B,,BAO_0000357,5088,,,1,CHEMBL872917,,,,H,8,,
2731,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]5-HT as radioligand,Autocuration,,,B,,BAO_0000357,5088,,,1,CHEMBL617290,,,,H,8,,
2732,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,Autocuration,,,B,,BAO_0000219,16659,,449.0,1,CHEMBL617291,CHO,,,H,8,,
2733,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells; ND is no data,Autocuration,,,B,,BAO_0000219,16659,,449.0,1,CHEMBL617292,CHO,,,H,8,,
2734,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2C receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,Autocuration,,,B,,BAO_0000219,17451,,723.0,1,CHEMBL617293,NIH3T3,,,H,8,,
2735,Relative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,Expert,9606.0,,F,,BAO_0000219,6857,,449.0,1,CHEMBL617294,CHO,,Homo sapiens,D,9,,
2736,Inhibitory activity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor at a concentration of 1 uM,Expert,,,B,,BAO_0000019,3857,,,1,CHEMBL617295,,,,H,8,,
2737,Binding activity radioligand.,Autocuration,,,B,,BAO_0000357,12861,,,1,CHEMBL617296,,,,H,8,,
2738,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,Autocuration,,,B,,BAO_0000019,12861,,,1,CHEMBL617297,,,,H,8,,
2739,Binding affinity for human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells using [3H]mesulergine as radioligand,Expert,,,B,,BAO_0000219,5104,,449.0,1,CHEMBL617298,CHO,,,H,8,,
2740,Binding affinity at human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells by [3H]mesulergine displacement.,Expert,,,B,,BAO_0000219,5105,,449.0,1,CHEMBL617299,CHO,,,H,8,,
2741,Binding affinity for human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells using [3H]mesulergine as radioligand; NT means not tested,Autocuration,,,B,,BAO_0000219,5105,,449.0,1,CHEMBL617300,CHO,,,H,8,,
2742,Binding affinity against 5-HT2C receptor,Autocuration,,,B,,BAO_0000357,5254,,,1,CHEMBL617454,,,,H,8,,
2743,Antagonistic binding affinity measured against 5-hydroxytryptamine 2C receptor (human clone expressed in 293 cells) using [3H]mesulergine as radioligand,Autocuration,,,B,,BAO_0000219,13267,,722.0,1,CHEMBL617505,HEK293,,,H,8,,
2744,Displacement of [3H]mesulergine from 5-hydroxytryptamine 2C receptor expressed in HEK 293 cells,Expert,9606.0,,B,,BAO_0000219,14157,,722.0,1,CHEMBL617506,HEK293,,Homo sapiens,D,9,,
2745,Binding affinity against human 5-hydroxytryptamine 2C receptor expressed in 293 cells using [3H]mesulergine,Expert,9606.0,,B,,BAO_0000219,12936,,722.0,1,CHEMBL617507,HEK293,,Homo sapiens,D,9,,
2746,Binding affinity against human 5-hydroxytryptamine 2C receptor using displacement of [3H]DOB,Expert,,,B,,BAO_0000357,14068,,,1,CHEMBL617508,,,,H,8,,
2747,Binding affinity against human 5-hydroxytryptamine 2C receptor expressed in 293 cells using [3H]mesulergine,Expert,9606.0,,B,,BAO_0000219,12936,,722.0,1,CHEMBL857982,HEK293,,Homo sapiens,D,9,,
2748,Binding affinity to human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]- mesulergine as radioligand,Expert,9606.0,,B,,BAO_0000219,4540,,722.0,1,CHEMBL617509,HEK293,,Homo sapiens,D,9,,
2749,Binding affinity to human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]- mesulergine as radioligand; Nd means not determined,Expert,9606.0,,B,,BAO_0000219,4540,,722.0,1,CHEMBL617510,HEK293,,Homo sapiens,D,9,,
2750,Binding affinity towards cloned human 5-hydroxytryptamine 2C receptor was determined,Autocuration,,,B,,BAO_0000357,6166,,,1,CHEMBL617511,,,,H,8,,
2751,Binding affinity against 5-hydroxytryptamine 2C receptor human cloned receptors in HEK 293 cells using [3H]mesulergine as radioligand,Autocuration,,,B,,BAO_0000219,17296,,722.0,1,CHEMBL617512,HEK293,,,H,8,,
2752,Binding affinity against 5-hydroxytryptamine 2C receptor human cloned receptorswithouteffect in HEK 293 cells using [3H]mesulergine as radioligand,Autocuration,,,B,,BAO_0000219,17296,,722.0,1,CHEMBL617749,HEK293,,,H,8,,
2753,Binding affinity towards 5-HT2C (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,Autocuration,,,B,,BAO_0000219,15779,,722.0,1,CHEMBL617750,HEK293,,,H,8,,
2754,Binding affinity towards 5-hydroxytryptamine 2C receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,Autocuration,,,B,,BAO_0000219,15779,,722.0,1,CHEMBL617751,HEK293,,,H,8,,
2755,Binding affinity towards cloned human 5-hydroxytryptamine 2C receptor expressed in HEK 293 cells using [3H]mesulergine as radioligand,Expert,,,B,,BAO_0000219,14391,,722.0,1,CHEMBL617752,HEK293,,,H,8,,
2756,"Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]mesulergine as radioligand",Autocuration,,,B,,BAO_0000219,15779,,722.0,1,CHEMBL617753,HEK293,,,H,8,,
2757,"Binding affinity towards human cloned 5-hydroxytryptamine receptor 2C in HEK293 cells, using [3H]mesulergine as radioligand.",Expert,,,B,,BAO_0000219,15851,,722.0,1,CHEMBL617754,HEK293,,,H,8,,
2758,Displacement of [3H]mesulergine from human 5-hydroxytryptamine 2C receptor expressed in HEK293 cells; compound insoluble,Expert,9606.0,,B,,BAO_0000219,15851,,722.0,1,CHEMBL617755,HEK293,,Homo sapiens,D,9,,
2759,"Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]mesulergine as radioligand; no data",Autocuration,,,B,,BAO_0000219,15779,,722.0,1,CHEMBL617756,HEK293,,,H,8,,
2760,Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor of HEK293 cells by displacement of [3H]mesulergine,Expert,,,B,,BAO_0000219,3832,,722.0,1,CHEMBL617757,HEK293,,,H,8,,
2761,In vitro binding affinity at human cloned 5-hydroxytryptamine 2C receptor of HEK293 cells by [3H]mesulergine displacement.,Expert,,,B,,BAO_0000219,3833,,722.0,1,CHEMBL617758,HEK293,,,H,8,,
2762,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2C receptor expressed in 3T3 cells using [3H]5-HT as radioligand,Autocuration,,,B,,BAO_0000219,17451,,723.0,1,CHEMBL617759,NIH3T3,,,H,8,,
2763,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]mesulergine as the radioligand,Autocuration,,,B,,BAO_0000219,4199,,722.0,1,CHEMBL617760,HEK293,,,H,8,,
2764,Displacement of [3H]mesulergine from human cloned 5-hydroxytryptamine 2C receptor expressed in CHO-K1 cells,Expert,,,B,,BAO_0000219,1883,,485.0,1,CHEMBL617761,CHO-K1,,,H,8,,
2765,Binding affinity against 5-hydroxytryptamine 2C receptor,Expert,9606.0,,B,,BAO_0000357,4321,,,1,CHEMBL617762,,,Homo sapiens,D,9,,
2766,Compound was tested for binding affinity against human 5-hydroxytryptamine 2C receptor,Autocuration,,,B,,BAO_0000357,14875,,,1,CHEMBL617763,,,,H,8,,
2767,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]mesulergine,Autocuration,,,B,,BAO_0000219,15146,,722.0,1,CHEMBL857983,HEK293,,,H,8,,
2768,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2C receptor in HEK 293 using [3H]mesulergine as a radioligand,Autocuration,,,B,,BAO_0000219,5213,,722.0,1,CHEMBL617764,HEK293,,,H,8,,
2769,Inhibitory constant on human 5-hydroxytryptamine 2C receptor transfected in to HeLa cells,Autocuration,,,B,,BAO_0000219,16404,,308.0,1,CHEMBL617765,HeLa,,,H,8,,
2770,Selectivity as the ratio of Ki value towards 5-hydroxytryptamine 2C receptor to that of pA2 value towards 5-hydroxytryptamine 2B receptor,Autocuration,,,F,,BAO_0000019,13267,,,1,CHEMBL617766,,,,H,8,,
2771,The binding affinity (pKi) measured against 5-hydroxytryptamine 3 receptor of rat hippocampus and entorhinal cortex using [3H]granisetron as radioligand,Autocuration,,,F,,BAO_0000221,13267,,,1,CHEMBL617767,,,,H,8,10000000.0,
2772,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2C receptor in HEK293 cells using [3H]mesulergine.,Autocuration,,,B,,BAO_0000219,14818,,722.0,1,CHEMBL617768,HEK293,,,H,8,,
2773,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]5-mesulergine as radioligand",Autocuration,,,B,,BAO_0000219,4829,,722.0,1,CHEMBL617769,HEK293,,,H,8,,
2774,Binding affinity analysed on 5-HT 2C in human clone using [3H]mesulergine as radioligand,Autocuration,,,B,,BAO_0000357,13463,,,1,CHEMBL858023,,,,H,8,,
2775,Binding affinity analysed on 5-HT 2C in rat stomach fundus,Autocuration,,,B,,BAO_0000019,13463,,,1,CHEMBL617770,,,,H,8,945.0,
2776,Binding affinity analysed towards 5-HT 2C in rat stomach fundus,Autocuration,,,B,,BAO_0000019,13463,,,1,CHEMBL617771,,,,H,8,945.0,
2777,Percent of maximum stimulation of phosphatidylinositol turnover at cloned 5-hydroxytryptamine 2C receptor in A9 cells,Autocuration,,,F,,BAO_0000219,12652,,625.0,1,CHEMBL617772,A9,,,H,8,,
2778,Binding affinity to 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand in stably transfected NIH3T3 cells,Autocuration,,,B,,BAO_0000219,4682,,723.0,1,CHEMBL617773,NIH3T3,,,H,8,,
2779,Binding affinity to 5-hydroxytryptamine 2C receptor measured using radioligand [3H]Mesulergine in stably transfected NIH3T3 cells,Autocuration,,,B,,BAO_0000219,4682,,723.0,1,CHEMBL617850,NIH3T3,,,H,8,,
2780,Binding affinity to 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand in stably transfected NIH3T3 cells,Autocuration,,,B,,BAO_0000219,4682,,723.0,1,CHEMBL617851,NIH3T3,,,H,8,,
2781,The maximum responses of [3H]- inositol monophosphate accumulation in cells expressing the 5-hydroxytryptamine 2C receptor,Autocuration,,,F,,BAO_0000019,12652,,,1,CHEMBL617852,,,,H,8,,
2782,Binding affinity analysed on 5-HT 2C in rat stomach fundus.,Autocuration,10090.0,,B,,BAO_0000019,13463,,,1,CHEMBL858024,,,Mus musculus,H,8,945.0,
2783,Binding affinity towards 5-HT 2C receptor in rat stomach fundus,Expert,10116.0,,B,,BAO_0000019,13463,,,1,CHEMBL617853,,,Rattus norvegicus,D,9,945.0,
2784,Binding affinity against 5-Hydroxytryptamine 2C Receptor was measured using [3H]N-methyl-mesulergine as radioligand,Expert,,,B,,BAO_0000357,13969,,,1,CHEMBL617854,,,,H,8,,
2785,Binding affinity for 5-hydroxytryptamine 2C receptor,Expert,9823.0,,B,,BAO_0000357,13392,,,1,CHEMBL873477,,,Sus scrofa,H,8,,
2786,Binding affinity towards 5-hydroxytryptamine 2C receptor,Expert,,,B,,BAO_0000357,13392,,,1,CHEMBL617855,,,,H,8,,
2787,Affinity towards 5-hydroxytryptamine 2C receptor in membranes from pig choroid plexus using [3H]N-methyl-mesulergine,Expert,,,B,,BAO_0000019,14430,,,1,CHEMBL617856,,,,H,8,,
2788,Compound was tested for its ability to displace [3H]mesulergine from 5-hydroxytryptamine 2C receptor in pig cortex,Autocuration,,,B,,BAO_0000019,1742,,,1,CHEMBL617857,,,,H,8,,
2789,In vitro inhibitory concentration against radioligand [3H]mesulergine binding to 5-hydroxytryptamine 2C receptor in pig cortical membrane,Autocuration,,,B,,BAO_0000249,14286,,,1,CHEMBL617858,,,,H,8,,
2790,Binding affinity towards pig 5-hydroxytryptamine 2C receptor,Autocuration,,,B,,BAO_0000357,5619,,,1,CHEMBL617859,,,,H,8,,
2791,The compound was tested for binding affinity against 5-hydroxytryptamine 2C receptor,Autocuration,,,B,,BAO_0000357,15086,,,1,CHEMBL617860,,,,H,8,,
2792,Binding activity radioligand.,Autocuration,,,B,,BAO_0000357,12861,,,1,CHEMBL617861,,,,H,8,,
2793,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,Expert,,,B,,BAO_0000019,12861,,,1,CHEMBL617862,,,,H,8,,
2794,Binding activity against 5-hydroxytryptamine 3 receptor from pig cortex membrane using [3H]mesulergine as radioligand; NA Not Available,Autocuration,,,B,,BAO_0000019,12861,,,1,CHEMBL617863,,,,H,8,,
2795,Binding affinity towards 5-hydroxytryptamine 1D receptor in calf caudate membranes using [3H]5-HT,Autocuration,,,B,,BAO_0000249,12827,,,1,CHEMBL617864,,,,H,8,,
2796,Binding affinity towards 5-hydroxytryptamine 1D receptor in calf caudate membranes using [3H]5-HT; Not determined,Autocuration,,,B,,BAO_0000249,12827,,,1,CHEMBL617649,,,,H,8,,
2797,Agonistic activity against 5-hydroxytryptamine 2C receptor in pig choroid plexus using [3H]mesulergine,Expert,9823.0,,F,,BAO_0000019,12919,,,1,CHEMBL617650,,,Sus scrofa,H,8,,
2798,Agonistic activity against 5-hydroxytryptamine 2C receptor in pig choroid plexus using [3H]mesulergine,Expert,9823.0,,F,,BAO_0000019,12919,,,1,CHEMBL617651,,,Sus scrofa,H,8,,
2799,In vitro binding affinity at 5-hydroxytryptamine 2C receptor in pig choroid plexus using 3[H]mesulergine as the radioligand,Autocuration,9823.0,,B,,BAO_0000357,16429,,,1,CHEMBL617652,,,Sus scrofa,H,8,,
2800,In Vitro Binding affinity againist 5-hydroxytryptamine 2C receptor by displacing [3H]mesulergine from pig cortex,Autocuration,9823.0,,B,,BAO_0000019,773,,,1,CHEMBL857072,,,Sus scrofa,H,8,,
2801,Ability to displace the radioligand [3H]mesulergine from pig choroid plexus 5-hydroxytryptamine 2C receptor,Autocuration,9823.0,,B,,BAO_0000357,5033,,,1,CHEMBL617653,,,Sus scrofa,H,8,,
2802,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,Autocuration,,,B,,BAO_0000019,12861,,,1,CHEMBL617654,,,,H,8,,
2803,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast 5-hydroxytryptamine 2C receptor,Autocuration,,,F,,BAO_0000019,14093,,,1,CHEMBL617655,,,,H,8,,
2804,Binding affinity towards 5-HT2C receptor from rat using [3H]mesulergine as radioligand,Expert,,,B,,BAO_0000357,14970,,,1,CHEMBL617656,,,,H,8,,
2805,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2C receptor from rat using [3H]mesulergine as radioligand,Autocuration,,,B,,BAO_0000357,14970,,,1,CHEMBL617657,,,,H,8,,
2806,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2C receptor from rat using [3H]mesulergine as radioligand; Not tested,Autocuration,,,B,,BAO_0000357,14970,,,1,CHEMBL617658,,,,H,8,,
2807,Inhibition of radiolabeled [3H]-Ketanserin ligand binding to 5-hydroxytryptamine 2C receptor,Expert,10116.0,,B,,BAO_0000357,14178,,,1,CHEMBL617659,,,Rattus norvegicus,D,9,,
2808,Inhibition of radiolabeled [3H]mesulergine ligand binding to 5-hydroxytryptamine 2C receptor,Expert,10116.0,,B,,BAO_0000357,14178,,,1,CHEMBL617838,,,Rattus norvegicus,D,9,,
2809,Inhibition of [3H]mesulergine binding to 5-hydroxytryptamine 2C receptor in rat brain membranes,Expert,10116.0,,B,,BAO_0000249,14229,Brain membranes,,1,CHEMBL617839,,,Rattus norvegicus,D,9,,
2810,The binding affinity at 5-hydroxytryptamine 2C receptor was determined using [3H]mesulergine; Not tested,Autocuration,,,B,,BAO_0000357,16532,,,1,CHEMBL617840,,,,H,8,,
2811,Ability to displace [3H]mesulergine bound to 5-hydroxytryptamine 2C receptor in rat cortex,Autocuration,,,B,,BAO_0000019,14826,,,1,CHEMBL617841,,,,H,8,,
2812,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-HT2C receptor,Autocuration,,,B,,BAO_0000019,17211,,,1,CHEMBL875915,,,,H,8,,
2813,Displacement of [3H]mesulergine (0.5 nM) from rat 5-hydroxytryptamine 2C receptor expressed in SR-3T3 cells,Expert,,,B,,BAO_0000219,17211,,,1,CHEMBL617842,,,,H,8,,
2814,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2C serotonin receptor in NIH3T3 cell line membranes,Expert,,,B,,BAO_0000219,13246,,723.0,1,CHEMBL617843,NIH3T3,,,H,8,,
2815,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2C serotonin receptor.,Expert,,,B,,BAO_0000357,13246,,,1,CHEMBL617844,,,,H,8,,
2816,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 2C receptor,Expert,,,B,,BAO_0000357,12457,,,1,CHEMBL617845,,,,H,8,,
2817,Affinity was evaluated by inhibition of [125I]LSD binding to NIH 3T3 cells transfected with cloned rat 5-hydroxytryptamine 2C receptor,Expert,,,B,,BAO_0000219,12457,,723.0,1,CHEMBL617846,NIH3T3,,,H,8,,
2818,Binding affinity towards rat 5-hydroxytryptamine 2C receptor was determined using [125I]- DOI as radioligand,Autocuration,,,B,,BAO_0000357,4707,,,1,CHEMBL617847,,,,H,8,,
2819,Binding affinity against 5-hydroxytryptamine 2C receptor,Expert,,,B,,BAO_0000357,13297,,,1,CHEMBL617848,,,,H,8,,
2820,Binding affinity against 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,Autocuration,,,B,,BAO_0000357,16633,,,1,CHEMBL617849,,,,H,8,,
2821,Binding affinity against rat 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,Expert,,,B,,BAO_0000357,16133,,,1,CHEMBL621507,,,,H,8,,
2822,Binding affinity at cloned rat 5-hydroxytryptamine 2C receptor using [3H]DOI as radioligand,Expert,,,B,,BAO_0000357,16326,,,1,CHEMBL621508,,,,H,8,,
2823,Binding affinity against 5-hydroxytryptamine 2C receptor from rat cortex using [3H]mesulergine as the radioligand.,Autocuration,,,B,,BAO_0000019,14423,,,1,CHEMBL621509,,,,H,8,,
2824,Binding affinity against 5-hydroxytryptamine 2C receptor of rat cortex,Autocuration,,,B,,BAO_0000019,15412,,,1,CHEMBL621510,,,,H,8,,
2825,Binding affinity against 5-hydroxytryptamine 2C receptor of rat cortex.,Autocuration,,,B,,BAO_0000019,15412,,,1,CHEMBL621511,,,,H,8,,
2826,Displacement of [3H]mesulergine from A9 cells stably expressing rat 5-hydroxytryptamine 2C receptor,Expert,,,B,,BAO_0000219,15558,,625.0,1,CHEMBL621512,A9,,,H,8,,
2827,Binding affinity towards 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,Autocuration,,,B,,BAO_0000357,16633,,,1,CHEMBL621513,,,,H,8,,
2828,Binding affinity towards cloned rat 5-hydroxytryptamine 2C receptor from fundus tissue by [3H]mesulergine displacement.,Expert,,,B,,BAO_0000357,6013,,,1,CHEMBL621514,,,,H,8,,
2829,Binding affinity towards rat 5-hydroxytryptamine 2C receptor expressed in A-9 cells using [3H]mesulergine as radioligand,Expert,,,B,,BAO_0000219,17175,,,1,CHEMBL621515,,,,H,8,,
2830,Binding affinity was measured on 5-hydroxytryptamine 2C receptor in J1 cells transfected with rat 5-HT2C gene labeled with [3H]mesulergine,Autocuration,,,B,,BAO_0000219,12469,,,1,CHEMBL621516,,,,H,8,,
2831,Compound was evaluated for affinity towards cerebral 5-hydroxytryptamine 2C receptor in homogenate of caudate putamen tissue from rat brain,Autocuration,,,B,,BAO_0000019,3682,,,1,CHEMBL621517,,,,H,8,5383.0,
2832,Compound was evaluated for its ability to displace (+/-)[125I]-DOI from 5-hydroxytryptamine 2C receptor in cloned rat cell culture,Autocuration,,,B,,BAO_0000357,4932,,,1,CHEMBL621518,,,,H,8,,
2833,Compound was evaluated for its ability to displace [125I](R)-DOI from 5-hydroxytryptamine 2C receptor in cloned rat prefrontal cortex homogenate; ND denotes no data,Autocuration,,,B,,BAO_0000019,4932,,,1,CHEMBL621519,,,,H,8,,
2834,Compound was evaluated for its binding affinity for rat 5-hydroxytryptamine 2C receptor,Autocuration,,,B,,BAO_0000357,3935,,,1,CHEMBL621520,,,,H,8,,
2835,Compound was evaluated for its binding affinity towards rat 5-hydroxytryptamine 2C receptor,Autocuration,,,B,,BAO_0000357,15818,,,1,CHEMBL621521,,,,H,8,,
2836,Compound was evaluated for its binding affinity towards rat r5-hydroxytryptamine 2C receptor,Autocuration,,,B,,BAO_0000357,15818,,,1,CHEMBL621522,,,,H,8,,
2837,Binding affinity against rat 5-hydroxytryptamine 2C receptor in A-9 cells.,Expert,,,B,,BAO_0000219,14749,,,1,CHEMBL621523,,,,H,8,,
2838,Evaluated for the binding constant at [125I]-DOI-labeled rat 5-hydroxytryptamine 2C receptor,Autocuration,,,B,,BAO_0000357,15740,,,1,CHEMBL621524,,,,H,8,,
2839,In vitro binding to 5-hydroxytryptamine 2C receptor using [125 I]-DOI,Expert,10116.0,,B,,BAO_0000357,17133,,,1,CHEMBL621525,,,Rattus norvegicus,D,9,,
2840,The binding affinity at 5-hydroxytryptamine 2C receptor was determined using [3H]mesulergine,Autocuration,,,B,,BAO_0000357,16532,,,1,CHEMBL872921,,,,H,8,,
2841,The compound evaluated for its affinity against 5-hydroxytryptamine 2C receptor,Autocuration,,,B,,BAO_0000357,12369,,,1,CHEMBL621526,,,,H,8,,
2842,Affinity against 5-hydroxytryptamine 2C receptor in J1 cells transfected with the rat 5-HT2C gene labeled with [3H]mesulergine.,Expert,,,B,,BAO_0000219,12369,,,1,CHEMBL621527,,,,H,8,,
2843,Binding affinity against 5-hydroxytryptamine 2C receptor in rat choroid plexus using [3H]N-methyl-mesulergine,Expert,10116.0,,B,,BAO_0000019,2309,,,1,CHEMBL617865,,,Rattus norvegicus,D,9,,
2844,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor,Autocuration,,,B,,BAO_0000357,12953,,,1,CHEMBL617866,,,,H,8,,
2845,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor from rat cortex using [3H]-citalopram as radioligand; Nonactive at 10 uM,Autocuration,,,B,,BAO_0000019,12953,,,1,CHEMBL617867,,,,H,8,,
2846,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand; Nonactive at 10 uM,Autocuration,,,B,,BAO_0000357,12953,,,1,CHEMBL617487,,,,H,8,,
2847,Binding affinity for 5-hydroxytryptamine 2C receptor,Expert,,,B,,BAO_0000357,12953,,,1,CHEMBL617488,,,,H,8,,
2848,Tested in vitro for its ability to bind to 5-hydroxytryptamine 2C receptor using [125 I]-DOI as radioligand; Not determined,Autocuration,,,B,,BAO_0000357,17133,,,1,CHEMBL617489,,,,H,8,,
2849,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-hydroxytryptamine 2C receptor; NT denotes not tested,Autocuration,,,B,,BAO_0000019,17211,,,1,CHEMBL617490,,,,H,8,,
2850,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-hydroxytryptamine 2C receptor; NT=not tested,Autocuration,,,B,,BAO_0000019,17211,,,1,CHEMBL617491,,,,H,8,,
2851,Affinity pKi for 5-hydroxytryptamine 2C receptor was measured in rat cortex homogenates.,Autocuration,,,B,,BAO_0000019,14025,,,1,CHEMBL617492,,,,H,8,,
2852,Binding affinity against 5-hydroxytryptamine 2C receptor in rat cortex homogenates.,Autocuration,,,B,,BAO_0000019,14998,,,1,CHEMBL617493,,,,H,8,,
2853,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2C receptor was determined,Autocuration,,,B,,BAO_0000357,4342,,,1,CHEMBL617494,,,,H,8,,
2854,Displacement of [3H]mesulergine from rat 5-HT2C receptor expressed in HEK293,Expert,10116.0,,B,,BAO_0000019,13735,,,1,CHEMBL617495,,,Rattus norvegicus,D,9,,
2855,Binding affinity was determined against cloned human 5-hydroxytryptamine 2C receptor using [3H]5-HT as radioligand,Autocuration,,,B,,BAO_0000357,13181,,,1,CHEMBL617496,,,,H,8,,
2856,Compound was evaluated for displacement of [3H]mesulergine from cloned rat 5-hydroxytryptamine 2C receptor in transfected CHO-K1 cells.,Autocuration,,,B,,BAO_0000219,1883,,485.0,1,CHEMBL617497,CHO-K1,,,H,8,,
2857,The compound was tested for the binding affinity against 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,Autocuration,,,B,,BAO_0000357,15194,,,1,CHEMBL617498,,,,H,8,,
2858,The compound was tested for the binding affinity against 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand.,Autocuration,,,B,,BAO_0000357,15194,,,1,CHEMBL617499,,,,H,8,,
2859,Compound tested for relative response using 0.1 uM 5-HT as agonist against 5-hydroxytryptamine 2C receptor,Autocuration,,,F,,BAO_0000019,14579,,,1,CHEMBL617500,,,,H,8,,
2860,Compound was tested for binding affinity against 5-hydroxytryptamine 2C receptor,Autocuration,,,B,,BAO_0000357,4639,,,1,CHEMBL617501,,,,H,8,,
2861,Binding affinity towards 5-hydroxytryptamine 2C receptor,Expert,,,B,,BAO_0000357,4820,,,1,CHEMBL617502,,,,H,8,,
2862,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand; Not Tested,Autocuration,,,B,,BAO_0000357,14442,,,1,CHEMBL617503,,,,H,8,,
2863,Binding activity against cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT as the radioligand.,Autocuration,,,B,,BAO_0000357,14755,,,1,CHEMBL617504,,,,H,8,,
2864,Binding affinity against the cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT as the radioligand,Autocuration,,,B,,BAO_0000357,14744,,,1,CHEMBL617406,,,,H,8,,
2865,Affinity for human 5-hydroxytryptamine 2B receptor expressed in mammalian cell line,Expert,9606.0,,B,,BAO_0000019,6857,,,1,CHEMBL617407,,,Homo sapiens,D,9,,
2866,Binding affinity towards human 5-hydroxytryptamine 2B receptor using [3H]5-HT as radioligand,Autocuration,,,B,,BAO_0000357,16209,,,1,CHEMBL617408,,,,H,8,,
2867,Compound was tested for the displacement of [3H]5-HT from clone human 5-hydroxytryptamine 2B receptor,Autocuration,,,B,,BAO_0000357,15363,,,1,CHEMBL617409,,,,H,8,,
2868,Compound was tested for the displacement of [3H]5-HT from clone human 5-hydroxytryptamine 2B receptor,Autocuration,,,B,,BAO_0000357,15363,,,1,CHEMBL617410,,,,H,8,,
2869,Compound was tested for the displacement of [3H]5-HT from cloned human 5-hydroxytryptamine 2B receptor,Autocuration,,,B,,BAO_0000357,15363,,,1,CHEMBL617411,,,,H,8,,
2870,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2B receptor,Autocuration,,,B,,BAO_0000019,17085,,,1,CHEMBL617412,,,,H,8,,
2871,Inhibitory constant against cloned human 5-hydroxytryptamine 2B receptor using with [125I]- DOI radioligand,Expert,9606.0,,B,,BAO_0000357,17200,,,1,CHEMBL617774,,,Homo sapiens,D,9,,
2872,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND = no data,Expert,9606.0,,B,,BAO_0000219,15851,,722.0,1,CHEMBL617775,HEK293,,Homo sapiens,D,9,,
2873,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND = no data,Expert,9606.0,,B,,BAO_0000219,15851,,722.0,1,CHEMBL617776,HEK293,,Homo sapiens,D,9,,
2874,Relative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,Expert,9606.0,,F,,BAO_0000219,6857,,449.0,1,CHEMBL617777,CHO,,Homo sapiens,D,9,,
2875,Rleative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,Expert,9606.0,,F,,BAO_0000219,6857,,449.0,1,CHEMBL617778,CHO,,Homo sapiens,D,9,,
2876,"Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",Autocuration,,,B,,BAO_0000219,15779,,722.0,1,CHEMBL617779,HEK293,,,H,8,,
2877,Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells using [3H]5-HT as radioligand.,Expert,,,B,,BAO_0000219,15851,,722.0,1,CHEMBL617780,HEK293,,,H,8,,
2878,"Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand; no data",Autocuration,,,B,,BAO_0000219,15779,,722.0,1,CHEMBL617781,HEK293,,,H,8,,
2879,Displacement of [3H]5-HT from 5-hydroxytryptamine 2B receptor expressed in HEK 293 cells,Expert,9606.0,,B,,BAO_0000219,14157,,722.0,1,CHEMBL617782,HEK293,,Homo sapiens,D,9,,
2880,Binding affinity to human cloned 5-HT2B receptor in HEK 293 cells using [3H]- -5-HT as radioligand,Expert,9606.0,,B,,BAO_0000219,4540,,722.0,1,CHEMBL617783,HEK293,,Homo sapiens,D,9,,
2881,Binding affinity towards cloned human 5-hydroxytryptamine 2B receptor was determined,Autocuration,,,B,,BAO_0000357,6166,,,1,CHEMBL617784,,,,H,8,,
2882,Binding affinity towards 5-hydroxytryptamine 2B receptor (human cloned receptor) in HEK 293 cells using [3H]5-HT as radioligand.,Autocuration,,,B,,BAO_0000219,15779,,722.0,1,CHEMBL617785,HEK293,,,H,8,,
2883,Binding affinity towards cloned human 5-hydroxytryptamine 2B receptor expressed in HEK 293 cells using [3H]5-HT as radioligand,Expert,,,B,,BAO_0000219,14391,,722.0,1,CHEMBL857984,HEK293,,,H,8,,
2884,Binding affinity towards human cloned 5-HT2B receptor of HEK293 cells by displacement of [3H]5-HT,Expert,,,B,,BAO_0000219,3832,,722.0,1,CHEMBL617786,HEK293,,,H,8,,
2885,In vitro binding affinity at human cloned 5-hydroxytryptamine 2B receptor of HEK293 cells by [3H]5-HT displacement.,Expert,,,B,,BAO_0000219,3833,,722.0,1,CHEMBL617787,HEK293,,,H,8,,
2886,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells,Expert,9606.0,,B,,BAO_0000219,15851,,722.0,1,CHEMBL617788,HEK293,,Homo sapiens,D,9,,
2887,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; compound is insoluble,Expert,9606.0,,B,,BAO_0000219,15851,,722.0,1,CHEMBL617789,HEK293,,Homo sapiens,D,9,,
2888,Compound was evaluated for binding affinity against human cloned 5-HT2B receptor in HEK 293 cells using [3H]5-HT as the radioligand,Autocuration,,,B,,BAO_0000219,4199,,722.0,1,CHEMBL617790,HEK293,,,H,8,,
2889,Displacement of [3H]-5-5HT from human cloned 5-hydroxytryptamine 2B receptor expressed in CHO-K1 cells,Expert,,,B,,BAO_0000219,1883,,485.0,1,CHEMBL617791,CHO-K1,,,H,8,,
2890,Binding affinity against 5-hydroxytryptamine 2B receptor,Expert,,,B,,BAO_0000357,4321,,,1,CHEMBL617608,,,,H,8,,
2891,Compound was tested for its binding affinity against cloned human 5-hydroxytryptamine 2B receptor in HEK 293 cells using [3H]5-HT,Autocuration,,,B,,BAO_0000219,15146,,722.0,1,CHEMBL617609,HEK293,,,H,8,,
2892,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2B receptor in HEK 293 using [3H]ketanserin as a radioligand,Autocuration,,,B,,BAO_0000219,5213,,722.0,1,CHEMBL617610,HEK293,,,H,8,,
2893,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2B receptors in HEK293 cells using [3H]5-HT.,Autocuration,,,B,,BAO_0000219,14818,,722.0,1,CHEMBL617611,HEK293,,,H,8,,
2894,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",Autocuration,,,B,,BAO_0000219,4829,,722.0,1,CHEMBL617612,HEK293,,,H,8,,
2895,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",Autocuration,,,B,,BAO_0000219,4829,,722.0,1,CHEMBL617613,HEK293,,,H,8,,
2896,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 2B receptor in the endothelium intact rabbit jugular vein.,Autocuration,9986.0,,B,,BAO_0000019,14025,,,1,CHEMBL617614,,,Oryctolagus cuniculus,H,8,,
2897,Binding affinity analysed for 5-HT 2B receptor in rat stomach fundus,Expert,,,B,,BAO_0000019,13463,,,1,CHEMBL617615,,,,H,8,945.0,
2898,Affinity against 5-hydroxytryptamine 2B receptor in the isolated rat stomach fundus,Expert,,,B,,BAO_0000357,7259,,,1,CHEMBL858114,,,,H,8,945.0,
2899,Affinity against serotonergic receptor in the isolated rat stomach fundus,Autocuration,,,B,,BAO_0000357,7259,,,1,CHEMBL617616,,,,H,8,945.0,
2900,Antagonistic activity against 5-hydroxytryptamine 2B receptor obtained from rat stomach fundus preparation,Expert,10116.0,,F,,BAO_0000019,7185,,,1,CHEMBL617617,,,Rattus norvegicus,D,9,945.0,
2901,Antagonistic against 5-hydroxytryptamine 2B receptor,Expert,10116.0,,F,,BAO_0000019,7185,,,1,CHEMBL875914,,,Rattus norvegicus,D,9,,
2902,Antagonistic affinity measured as pA2 value on 5-hydroxytryptamine 2B receptor of the rat stomach fundus,Autocuration,,,F,,BAO_0000019,13267,,,1,CHEMBL617618,,,,H,8,945.0,
2903,Inhibition of 5-HT binding to 5-HT2B receptor of Rat stomach fundus,Expert,10116.0,,B,,BAO_0000357,13735,,,1,CHEMBL617619,,,Rattus norvegicus,D,9,945.0,
2904,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B receptor ) receptor,Autocuration,,,F,,BAO_0000019,15738,,,1,CHEMBL617620,,,,H,8,,
2905,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B receptor ) receptor; No data,Autocuration,,,F,,BAO_0000019,15738,,,1,CHEMBL617621,,,,H,8,,
2906,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B) receptor,Autocuration,,,F,,BAO_0000019,15738,,,1,CHEMBL617622,,,,H,8,,
2907,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,Expert,10116.0,,B,,BAO_0000357,12936,,,1,CHEMBL617623,,,Rattus norvegicus,D,9,945.0,
2908,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,Expert,10116.0,,B,,BAO_0000357,12936,,,1,CHEMBL617624,,,Rattus norvegicus,D,9,945.0,
2909,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,Expert,10116.0,,B,,BAO_0000357,12936,,,1,CHEMBL617625,,,Rattus norvegicus,D,9,945.0,
2910,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,Expert,10116.0,,B,,BAO_0000357,12936,,,1,CHEMBL617626,,,Rattus norvegicus,D,9,945.0,
2911,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,Autocuration,,,F,,BAO_0000019,16404,,,1,CHEMBL617627,,,,H,8,945.0,
2912,Negative log concentration of antagonist was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,Expert,,,F,,BAO_0000019,16404,,,1,CHEMBL617628,,,,H,8,945.0,
2913,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus; ND is No Data.,Autocuration,,,F,,BAO_0000019,16404,,,1,CHEMBL617629,,,,H,8,945.0,
2914,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus; ND is not determined.,Autocuration,,,F,,BAO_0000019,16404,,,1,CHEMBL858115,,,,H,8,945.0,
2915,Antagonistic activity on 5-hydroxytryptamine 2B receptor of Rat stomach fundus;ND is not determined,Expert,10116.0,,F,,BAO_0000019,16404,,,1,CHEMBL617630,,,Rattus norvegicus,D,9,945.0,
2916,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat thoracic aorta; ND is not determined,Autocuration,,,F,,BAO_0000019,16404,,,1,CHEMBL617631,,,,H,8,1515.0,
2917,The binding affinity of compound to 5-HT receptor of rat fundus was expressed as pA2 value; Unable to determine valid PA2 value due to slope of Schild plot,Autocuration,,,B,,BAO_0000357,7483,,,1,CHEMBL617632,,,,H,8,,
2918,The binding affinity to 5-hydroxytryptamine 2B receptor of rat fundus,Expert,,,B,,BAO_0000357,7483,,,1,CHEMBL617633,,,,H,8,,
2919,The binding affinity of compound to 5-hydroxytryptamine 2B receptor of rat fundus was expressed as pA2 value; Unable to determine valid PA2 value due to slope of Schild plot,Autocuration,,,B,,BAO_0000357,7483,,,1,CHEMBL617634,,,,H,8,,
2920,The binding affinity of compound to 5-hydroxytryptamine 2B receptor of rat fundus; Unable to determine valid PA2 value due to slope of Schild plot,Autocuration,,,B,,BAO_0000357,7483,,,1,CHEMBL617635,,,,H,8,,
2922,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,Autocuration,10116.0,,F,,BAO_0000019,16404,,,1,CHEMBL617637,,,Rattus norvegicus,D,9,945.0,
2923,Binding affinity against 5-hydroxytryptamine 1A receptor,Autocuration,,,B,,BAO_0000357,6347,,,1,CHEMBL617638,,,,H,8,,
2924,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2B receptor was determined,Autocuration,,,B,,BAO_0000357,4373,,,1,CHEMBL617639,,,,H,8,,
2925,Binding affinity for 5-hydroxytryptamine 2B receptor was determined,Autocuration,,,B,,BAO_0000357,4373,,,1,CHEMBL617640,,,,H,8,,
2926,Evaluated for the binding affinity to 5-HT 2B receptor,Autocuration,,,B,,BAO_0000357,4687,,,1,CHEMBL617641,,,,H,8,,
2927,Ability to displace [3H]5-HT from 5-hydroxytryptamine 2B receptor,Autocuration,,,B,,BAO_0000357,16946,,,1,CHEMBL617642,,,,H,8,,
2928,Binding affinities against 5-hydroxytryptamine 2B receptor,Autocuration,,,B,,BAO_0000357,16633,,,1,CHEMBL617643,,,,H,8,,
2929,Binding affinities towards 5-hydroxytryptamine 2B receptor,Autocuration,,,B,,BAO_0000357,16633,,,1,CHEMBL617644,,,,H,8,,
2930,Binding affinity towards 5-hydroxytryptamine 2B receptor using [125I]DOI as radioligand,Autocuration,,,B,,BAO_0000357,16633,,,1,CHEMBL617645,,,,H,8,,
2931,In vitro ability to displace [3H]mesulergine binding from 5-hydroxytryptamine 2C receptor from bovine choroid plexus.,Expert,,,B,,BAO_0000357,15026,,,1,CHEMBL617646,,,,H,8,,
2932,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor,Autocuration,9913.0,,B,,BAO_0000357,15738,,,1,CHEMBL617647,,,Bos taurus,H,8,,
2933,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at a concentration of 10E-6 M,Autocuration,9913.0,,B,,BAO_0000357,15738,,,1,CHEMBL617648,,,Bos taurus,H,8,,
2934,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at a concentration of 10e-6 M,Autocuration,9913.0,,B,,BAO_0000357,15738,,,1,CHEMBL617875,,,Bos taurus,H,8,,
2935,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at concentration of 10e-6 M,Autocuration,9913.0,,B,,BAO_0000357,15738,,,1,CHEMBL617876,,,Bos taurus,H,8,,
2936,Inhibitory constant was determined on 5-hydroxytryptamine 2C receptor of Bovine choroid plexus,Expert,9913.0,,B,,BAO_0000357,16404,,,1,CHEMBL617877,,,Bos taurus,H,8,,
2937,In vitro ability to displace [3H]mesulergine binding from 5-hydroxytryptamine 2C receptor from bovine choroid plexus.,Expert,9913.0,,B,,BAO_0000357,15026,,,1,CHEMBL617878,,,Bos taurus,H,8,,
2938,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor,Autocuration,9913.0,,B,,BAO_0000357,15738,,,1,CHEMBL617879,,,Bos taurus,H,8,,
2939,Binding affinity against guinea pig cortex 5-HT2C receptor in the presence of [3H]mesulergine,Autocuration,10141.0,,B,,BAO_0000019,16312,,,1,CHEMBL617880,,,Cavia porcellus,H,8,,
2940,Binding affinity towards 5-HT4 receptor by the displacement of [3H]GR-113808 in guinea-pig striatum,Intermediate,10141.0,,B,,BAO_0000357,5486,,,1,CHEMBL617881,,,Cavia porcellus,D,9,2435.0,
2941,Binding affinity against 5-HT1A receptor,Autocuration,,,B,,BAO_0000357,5254,,,1,CHEMBL857073,,,,H,8,,
2942,Agonistic activity for 5-HT2c (5-HT2C) by measuring [3H]inositol monophosphate fromation in CHO cells in which the human 5-HT2C receptor subtype was stably expressed,Expert,,,F,,BAO_0000219,3857,,449.0,1,CHEMBL617882,CHO,,,H,8,,
2943,Functional activity against human 5-hydroxytryptamine 2C receptor expressed in CHO cells using fluorometric imaging plate reader,Expert,9606.0,,F,,BAO_0000219,6857,,449.0,1,CHEMBL617883,CHO,,Homo sapiens,D,9,,
2944,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2c receptor cell line,Autocuration,,,F,,BAO_0000219,4176,,,1,CHEMBL617884,,,,H,8,,
2945,Agonistic binding efficacy against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI radioligand,Autocuration,,,B,,BAO_0000219,6347,,449.0,1,CHEMBL617885,CHO,,,H,8,,
2946,"Agonistic binding affinity against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI radioligand, expressed as Emax",Autocuration,,,B,,BAO_0000219,6347,,449.0,1,CHEMBL617886,CHO,,,H,8,,
2947,Inhibition of human 5-hydroxytryptamine 2C receptor,Expert,9606.0,,B,,BAO_0000357,16146,,,1,CHEMBL617887,,,Homo sapiens,D,9,,
2948,In vitro binding affinity against human 5-hydroxytryptamine 2C receptor at a concentration of 100 (nM),Autocuration,,,B,,BAO_0000357,3805,,,1,CHEMBL617888,,,,H,8,,
2949,Inhibitory activity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor at a concentration of 1 uM,Autocuration,,,B,,BAO_0000019,3857,,,1,CHEMBL617889,,,,H,8,,
2950,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor,Autocuration,,,B,,BAO_0000357,5635,,,1,CHEMBL617890,,,,H,8,,
2951,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor Intrinsic efficacy against 5-hydroxytryptamine 2C receptor; Intrinsic efficacy (%) not determined,Autocuration,,,B,,BAO_0000357,5635,,,1,CHEMBL617891,,,,H,8,,
2952,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor; Intrinsic efficacy (%) not determined,Autocuration,,,B,,BAO_0000357,5635,,,1,CHEMBL617892,,,,H,8,,
2953,Displacement of [H]-mesulergine from CHO cells expressing human 5-hydroxytryptamine 2C receptor.,Expert,,,B,,BAO_0000219,4012,,449.0,1,CHEMBL617893,CHO,,,H,8,,
2954,Ability to displace [3H]- mesulergine from human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells,Expert,,,B,,BAO_0000219,6366,,449.0,1,CHEMBL617894,CHO,,,H,8,,
2955,Ability to displace [3H]mesulergine binding to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,Expert,,,B,,BAO_0000219,15949,,449.0,1,CHEMBL617895,CHO,,,H,8,,
2956,Ability to displace [3H]mesulergine (0.5 nM) from CHO cells of human 5-hydroxytryptamine 2C receptor,Autocuration,,,B,,BAO_0000219,17211,,449.0,1,CHEMBL617896,CHO,,,H,8,,
2957,Affinity towards human 5-hydroxytryptamine 2C serotonin receptor,Expert,9606.0,,B,,BAO_0000357,6491,,,1,CHEMBL617897,,,Homo sapiens,D,9,,
2958,Agonist activity at cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI radioligand,Autocuration,,,F,,BAO_0000019,14093,,,1,CHEMBL617898,,,,H,8,,
2959,Agonistic activity at cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,Autocuration,,,F,,BAO_0000019,13481,,,1,CHEMBL617899,,,,H,8,,
2960,Agonistic binding affinity against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI ,Expert,10116.0,,B,,BAO_0000219,6347,,449.0,1,CHEMBL617900,CHO,,Rattus norvegicus,H,8,,
2961,Antagonist activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine radioligand,Autocuration,,,F,,BAO_0000019,14093,,,1,CHEMBL617901,,,,H,8,,
2962,Antagonist activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine radioligand; Not tested,Autocuration,,,F,,BAO_0000019,14093,,,1,CHEMBL617902,,,,H,8,,
2963,Antagonistic activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,Autocuration,,,F,,BAO_0000019,13481,,,1,CHEMBL617903,,,,H,8,,
2964,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [125 I]DOI as radioligand,Autocuration,,,B,,BAO_0000357,14442,,,1,CHEMBL617904,,,,H,8,,
2965,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [3H]- mesulergine as radioligand,Autocuration,,,B,,BAO_0000357,14442,,,1,CHEMBL617905,,,,H,8,,
2966,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [3H]- mesulergine as radioligand;not tested,Autocuration,,,B,,BAO_0000357,14442,,,1,CHEMBL617906,,,,H,8,,
2967,Binding activity against cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as the radioligand.,Autocuration,,,B,,BAO_0000357,14755,,,1,CHEMBL617907,,,,H,8,,
2968,Binding affinity against the cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as the radioligand,Autocuration,,,B,,BAO_0000357,14744,,,1,CHEMBL617908,,,,H,8,,
2969,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,Expert,,,B,,BAO_0000219,16659,,449.0,1,CHEMBL620617,CHO,,,H,8,,
2970,Affinity for human 5-hydroxytryptamine 2C receptor expressed in mammalian cell line,Expert,9606.0,,B,,BAO_0000019,6857,,,1,CHEMBL620618,,,Homo sapiens,D,9,,
2971,Binding affinity against 5-hydroxytryptamine 2C receptor using [125I]DOI radioligand.,Expert,,,B,,BAO_0000357,5635,,,1,CHEMBL620619,,,,H,8,,
2972,Binding affinity to cloned human 5-hydroxytryptamine 2C receptor,Expert,9606.0,,B,,BAO_0000357,4234,,,1,CHEMBL620620,,,Homo sapiens,D,9,,
2973,Binding affinity towards human 5-HT2C receptor was determined using [125I]- DOI as radioligand,Autocuration,,,B,,BAO_0000357,16209,,,1,CHEMBL620621,,,,H,8,,
2974,Binding affinity for 5-HT3 receptor by displacement of [3H]-LY 278584 in rat cerebral cortex membranes,Autocuration,10116.0,,B,,BAO_0000249,5778,Membranes,,1,CHEMBL872920,,,Rattus norvegicus,D,7,,
2975,Binding affinity towards rat 5-hydroxytryptamine 3 receptor was evaluated,Autocuration,,,B,,BAO_0000223,5094,,,1,CHEMBL620622,,,,H,6,,
2976,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 in rat posterior cortex,Autocuration,10116.0,,B,,BAO_0000019,809,,,1,CHEMBL620623,,,Rattus norvegicus,D,7,,
2977,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 as radioligand in rat posterior cortex,Autocuration,,,B,,BAO_0000019,1578,,,1,CHEMBL620624,,,,H,6,,
2978,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 as radioligand in rat posterior cortex; Not tested,Autocuration,,,B,,BAO_0000019,809,,,1,CHEMBL620625,,,,H,6,,
2979,Binding affinity was measured on 5-hydroxytryptamine 3 receptor in NG-108 cells labeled with [3H]GR-65630,Autocuration,,,B,,BAO_0000219,12469,,,1,CHEMBL620626,,,,H,6,,
2980,Binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]-BRL 43694 as radioligand in rat posterior cortex,Autocuration,,,B,,BAO_0000019,14290,,,1,CHEMBL621307,,,,H,6,,
2981,Binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]-BRL 43694 as radioligand in rat posterior cortex.,Autocuration,,,B,,BAO_0000019,14290,,,1,CHEMBL621308,,,,H,6,,
2982,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]-5-HT,Autocuration,,,B,,BAO_0000223,10609,,,1,CHEMBL621309,,,,H,6,,
2983,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]GR-65630,Autocuration,,,B,,BAO_0000223,10609,,,1,CHEMBL621310,,,,H,6,,
2984,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]-ketanserin,Autocuration,,,B,,BAO_0000223,10609,,,1,CHEMBL621311,,,,H,6,,
2985,"Compound was evaluated for its in vitro affinity at serotonergic 5-hydroxytryptamine 3 receptor by radioligand binding assay, using [3H]-LY 278584 in rat cerebral cortex membranes.",Autocuration,,,B,,BAO_0000249,15253,,,1,CHEMBL621502,,,,H,6,,
2986,"In vitro affinity at serotonergic 5-hydroxytryptamine 3 receptor by radioligand binding assay, using [3H]-LY 278584 in rat cerebral cortex membranes.",Autocuration,,,B,,BAO_0000249,15253,,,1,CHEMBL621503,,,,H,6,,
2987,Displacement of the 5-hydroxytryptamine 3 receptor ligand [3H]GR-65630 from rat brain cortical membranes.,Autocuration,,,B,,BAO_0000249,11683,Membranes,,1,CHEMBL621504,,,,H,6,,
2988,Compound was evaluated for binding affinity against 5-hydroxytryptamine 3 receptor,Autocuration,,,B,,BAO_0000223,12092,,,1,CHEMBL621505,,,,H,6,,
2989,Binding affinity at 5-hydroxytryptamine 3 receptor in rat entorhinal cortex by [3H]BRL-43694 displacement.,Autocuration,,,B,,BAO_0000019,1946,,,1,CHEMBL621506,,,,H,6,,
2990,Ability to displace [3H]quipazine binding to 5-hydroxytryptamine 3 receptor sites in NG 108-15.,Autocuration,,,B,,BAO_0000223,11623,,,1,CHEMBL619781,,,,H,6,,
2991,Compound was evaluated for its ability to displace [3H]quipazine binding to 5-hydroxytryptamine 3 receptor sites in NG 108-15. ,Autocuration,,,B,,BAO_0000223,11623,,,1,CHEMBL619782,,,,H,6,,
2992,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement [3H]GR-65630 in rat cerebral cortex,Autocuration,,,B,,BAO_0000019,14788,,,1,CHEMBL619783,,,,H,6,,
2993,Displacement of [3H]ketanserin from rat cortex 5-HT3 receptor,Autocuration,10116.0,,B,,BAO_0000019,5432,,,1,CHEMBL619784,,,Rattus norvegicus,D,7,,
2994,Ability to displace [3H]granisetron specifically bound to 5-hydroxytryptamine 3 receptor in rat cortical membrane,Autocuration,,,B,,BAO_0000249,14826,,,1,CHEMBL619785,,,,H,6,,
2995,Compound was tested for its binding affinity for the 5-hydroxytryptamine 3 receptor,Autocuration,,,B,,BAO_0000223,2222,,,1,CHEMBL619786,,,,H,6,,
2996,Displacement of binding of [3H]-BRL 43694 to 5-hydroxytryptamine 3 receptor in rat cerebral cortex,Autocuration,,,B,,BAO_0000019,11963,,,1,CHEMBL619787,,,,H,6,,
2997,In vitro affinity for 5-hydroxytryptamine 3 (5-HT3) receptor by displacement of [3H]BRL-43694 from rat entorhinal cortex,Autocuration,,,B,,BAO_0000019,14145,,,1,CHEMBL872925,,,,H,6,,
2998,In vitro binding affinity at serotonin 5-hydroxytryptamine 3 receptor in rat cortex by [3H]granisetron displacement.,Autocuration,,,B,,BAO_0000019,17819,,,1,CHEMBL619788,,,,H,6,,
2999,Inhibitory activity against 5-hydroxytryptamine 3 receptor in rat cortical membranes using [3H]- 1-Methyl-1H-indazole-3-carboxylic acid (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amide as a radioligand,Autocuration,,,B,,BAO_0000249,10394,,,1,CHEMBL619789,,,,H,6,,
3000,Inhibitory activity against 5-hydroxytryptamine 3 receptor in rat cortical membranes using [3H]-1-Methyl-1H-indazole-3-carboxylic acid (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amide as a radioligand,Autocuration,,,B,,BAO_0000249,10394,,,1,CHEMBL619790,,,,H,6,,
3001,Inhibitory concentration against 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-LY 278584 as radioligand,Autocuration,,,B,,BAO_0000019,15034,,,1,CHEMBL619791,,,,H,6,,
3002,Binding affinity at 5-hydroxytryptamine 3 receptor in rat entorhinal cortex by [3H]BRL-43694 displacement.,Autocuration,,,B,,BAO_0000019,691,,,1,CHEMBL619792,,,,H,6,,
3003,Displacement of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor in rat brain cortical membranes,Autocuration,,,B,,BAO_0000249,12092,Membranes,,1,CHEMBL619793,,,,H,6,,
3004,Inhibition of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor,Autocuration,10116.0,,B,,BAO_0000223,11752,,,1,CHEMBL619794,,,Rattus norvegicus,D,7,,
3005,The ability to inhibit [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor in rat brain cortices,Autocuration,,,B,,BAO_0000221,11752,,,1,CHEMBL619795,,,,H,6,955.0,
3006,Binding affinity at 5-hydroxytryptamine 3 receptor in rat posterior cortex by [3H]-BRL 43694 displacement.,Autocuration,,,B,,BAO_0000019,301,,,1,CHEMBL619796,,,,H,6,,
3007,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584,Autocuration,,,B,,BAO_0000223,16532,,,1,CHEMBL620448,,,,H,6,,
3008,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584; Not tested,Autocuration,,,B,,BAO_0000223,16532,,,1,CHEMBL620449,,,,H,6,,
3009,The binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand.,Autocuration,,,B,,BAO_0000223,12092,,,1,CHEMBL620450,,,,H,6,,
3010,The compound was evaluated for the binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of radioligand [3H]GR-65630,Autocuration,,,B,,BAO_0000223,11684,,,1,CHEMBL620451,,,,H,6,,
3011,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of radioligand [3H]GR-65630.,Autocuration,,,B,,BAO_0000223,11684,,,1,CHEMBL620631,,,,H,6,,
3012,Binding affinity for 5-hydroxytryptamine 3 receptor from rat cortex using [3H]BRL-43694 as radioligand,Autocuration,,,B,,BAO_0000019,12953,,,1,CHEMBL620632,,,,H,6,,
3013,The compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor from rat cortex using [3H]BRL-43694 as radioligand; NA means Not active,Autocuration,,,B,,BAO_0000019,12953,,,1,CHEMBL620633,,,,H,6,,
3014,The compound was tested for their binding affinity towards 5-hydroxytryptamine 3 receptor; Nonactive at 10 uM,Autocuration,,,B,,BAO_0000223,12953,,,1,CHEMBL620634,,,,H,6,,
3015,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand; NA Not Available,Autocuration,,,B,,BAO_0000019,12861,,,1,CHEMBL620635,,,,H,6,,
3016,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 0.5 hours in urethane-anesthetized rats,Autocuration,,,F,,BAO_0000218,11454,,,1,CHEMBL620636,,,,H,6,,
3017,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 1 hour in urethane-anesthetized rats,Autocuration,,,F,,BAO_0000218,11454,,,1,CHEMBL620637,,,,H,6,,
3018,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 3 hours in urethane-anesthetized rats,Autocuration,,,F,,BAO_0000218,11454,,,1,CHEMBL620638,,,,H,6,,
3019,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 6 hours in urethane-anesthetized rats,Autocuration,,,F,,BAO_0000218,11454,,,1,CHEMBL620639,,,,H,6,,
3020,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 0.5 hours in urethane-anesthetized rats,Autocuration,,,F,,BAO_0000218,11454,,,1,CHEMBL620640,,,,H,6,,
3021,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 1 hour in urethane-anesthetized rats,Autocuration,,,F,,BAO_0000218,11454,,,1,CHEMBL620641,,,,H,6,,
3022,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 16 hours in urethane-anesthetized rats,Autocuration,,,F,,BAO_0000218,11454,,,1,CHEMBL620642,,,,H,6,,
3023,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 3 hours in urethane-anesthetized rats,Autocuration,,,F,,BAO_0000218,11454,,,1,CHEMBL620643,,,,H,6,,
3024,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 6 hours in urethane-anesthetized rats,Autocuration,,,F,,BAO_0000218,11454,,,1,CHEMBL620644,,,,H,6,,
3025,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 0.5 hours in urethane-anesthetized rats,Autocuration,,,F,,BAO_0000218,11454,,,1,CHEMBL620645,,,,H,6,,
3026,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 1 hour in urethane-anesthetized rats,Autocuration,,,F,,BAO_0000218,11454,,,1,CHEMBL620646,,,,H,6,,
3027,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 3 hours in urethane-anesthetized rats,Autocuration,,,F,,BAO_0000218,11454,,,1,CHEMBL620647,,,,H,6,,
3028,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 6 hours in urethane-anesthetized rats,Autocuration,,,F,,BAO_0000218,11454,,,1,CHEMBL620648,,,,H,6,,
3029,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 0.5 hours in urethane-anesthetized rats,Autocuration,,,F,,BAO_0000218,11454,,,1,CHEMBL620649,,,,H,6,,
3030,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 3 hours in urethane-anesthetized rats,Autocuration,,,F,,BAO_0000218,11454,,,1,CHEMBL620650,,,,H,6,,
3031,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 mg/kg at 1 hour in urethane-anesthetized rats,Autocuration,,,F,,BAO_0000218,11454,,,1,CHEMBL620651,,,,H,6,,
3032,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 mg/kg at 3 hours in urethane-anesthetized rats,Autocuration,,,F,,BAO_0000218,11454,,,1,CHEMBL872875,,,,H,6,,
3033,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 1 hour in urethane-anesthetized rats,Autocuration,,,F,,BAO_0000218,11454,,,1,CHEMBL620652,,,,H,6,,
3034,5-hydroxytryptamine 3 receptor antagonist activity was confirmed by its ability to antagonize 5-HT evoked tachycardia of rabbit isolated heart,Autocuration,,,F,,BAO_0000019,10609,,,1,CHEMBL620653,,,,H,6,,
3035,Binding activity against 5-hydroxytryptamine 2A receptor from rat cortex homogenates using [3H]DOB as radioligand.,Autocuration,,,B,,BAO_0000019,12861,,,1,CHEMBL857076,,,,H,6,,
3036,Inhibition of [3H]-Q-ICS 205-930 binding to rat cortex homogenate 5-hydroxytryptamine 3 receptor,Autocuration,10116.0,,B,,BAO_0000019,12861,,,1,CHEMBL620654,,,Rattus norvegicus,D,7,,
3037,Binding activity radioligand.,Autocuration,,,B,,BAO_0000223,12861,,,1,CHEMBL620655,,,,H,6,,
3038,Compound was evaluated for the displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor in rat brain membranes,Autocuration,,,B,,BAO_0000249,10728,Brain membranes,,1,CHEMBL620656,,,,H,6,,
3039,Displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor recognition sites in rat brain membranes.,Autocuration,,,B,,BAO_0000249,10728,Brain membranes,,1,CHEMBL620657,,,,H,6,,
3040,Binding affinity towards 5-hydroxytryptamine 2C receptor was determined at a concentration of 0.000001 mol/L,Autocuration,,,B,,BAO_0000357,5163,,,1,CHEMBL620658,,,,H,8,,
3041,Binding affinity towards 5-hydroxytryptamine 2C receptor was determined at a concentration of 0.00001 mol/L,Autocuration,,,B,,BAO_0000357,5163,,,1,CHEMBL620659,,,,H,8,,
3042,Inhibition of binding towards 5-hydroxytryptamine 2C receptor at 100 nM concentration,Autocuration,,,B,,BAO_0000357,6011,,,1,CHEMBL620660,,,,H,8,,
3043,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 2C receptor,Autocuration,,,B,,BAO_0000357,5014,,,1,CHEMBL620661,,,,H,8,,
3044,Binding affinity of compound towards 5-hydroxytryptamine 2C receptor,Autocuration,,,B,,BAO_0000357,5635,,,1,CHEMBL620662,,,,H,8,,
3045,Affinity for 5-hydroxytryptamine 2C receptor,Expert,,,B,,BAO_0000357,5163,,,1,CHEMBL620663,,,,H,8,,
3046,Binding affinity towards 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,Autocuration,,,B,,BAO_0000357,6841,,,1,CHEMBL620664,,,,H,8,,
3047,Binding affinity towards 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand.,Expert,,,B,,BAO_0000357,6119,,,1,CHEMBL620665,,,,H,8,,
3048,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2C receptor was determined,Autocuration,,,B,,BAO_0000357,4373,,,1,CHEMBL620666,,,,H,8,,
3049,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2C receptor by displacement of [3H]-Ketanserin,Autocuration,,,B,,BAO_0000357,1633,,,1,CHEMBL620667,,,,H,8,,
3050,Binding affinity towards 5-hydroxytryptamine 2C receptor by displacement of [3H]N-methyl-mesulergine,Expert,,,B,,BAO_0000357,1633,,,1,CHEMBL620668,,,,H,8,,
3051,Binding affinity for 5-hydroxytryptamine 2C receptor was determined,Autocuration,,,B,,BAO_0000357,4373,,,1,CHEMBL620669,,,,H,8,,
3052,Binding affinity towards serotonin 5-hydroxytryptamine 2C receptor,Expert,,,B,,BAO_0000357,6576,,,1,CHEMBL620670,,,,H,8,,
3053,Evaluated for the binding affinity to 5-hydroxytryptamine 2C receptor,Autocuration,,,B,,BAO_0000357,4687,,,1,CHEMBL620671,,,,H,8,,
3054,Tested agains t5-hydroxytryptamine 2C receptor in experiment 1,Autocuration,,,B,,BAO_0000357,12146,,,1,CHEMBL620672,,,,H,8,,
3055,Tested against 5-hydroxytryptamine 2C receptor in experiment 2,Autocuration,,,B,,BAO_0000357,12146,,,1,CHEMBL620673,,,,H,8,,
3056,Ability to displace [3H]mesulergine from 5-hydroxytryptamine 2C receptor,Autocuration,,,B,,BAO_0000357,16946,,,1,CHEMBL620674,,,,H,8,,
3057,Compound was evaluated for the affinity at 5-hydroxytryptamine 2C receptor,Autocuration,,,B,,BAO_0000357,14159,,,1,CHEMBL620675,,,,H,8,,
3058,The binding affinity towards 5-hydroxytryptamine 2C receptor; No affinity,Autocuration,,,B,,BAO_0000357,16700,,,1,CHEMBL620676,,,,H,8,,
3059,Affinity against 5-hydroxytryptamine 2C receptor,Autocuration,,,B,,BAO_0000357,3269,,,1,CHEMBL621382,,,,H,8,,
3060,Binding affinity against 5-hydroxytryptamine 2C receptor,Expert,9606.0,,B,,BAO_0000357,1274,,,1,CHEMBL621383,,,Homo sapiens,D,9,,
3061,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2C receptor using radioligand binding assay,Autocuration,,,B,,BAO_0000357,1317,,,1,CHEMBL621384,,,,H,8,,
3062,Inhibitory concentration required against 5-HT3 receptor in bovine area postrema using [3H]GR-65630,Autocuration,9913.0,,B,,BAO_0000357,5834,,,1,CHEMBL621385,,,Bos taurus,H,8,,
3063,Binding affinity towards 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand,Autocuration,9913.0,,B,,BAO_0000357,11147,,,1,CHEMBL617989,,,Bos taurus,H,8,,
3064,Antagonistic potency against serotonin 5-hydroxytryptamine 3 receptor in GPI assay,Expert,10141.0,,F,,BAO_0000019,14145,,,1,CHEMBL617990,,,Cavia porcellus,H,4,,
3065,Binding affinity to 5-hydroxytryptamine 3 receptor entirely in guinea pig ileum,Autocuration,10141.0,,B,,BAO_0000221,10561,,,1,CHEMBL875085,,,Cavia porcellus,H,4,2116.0,
3066,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 3 receptor of guinea pig,Autocuration,10141.0,,F,,BAO_0000019,15847,,,1,CHEMBL617991,,,Cavia porcellus,H,4,,
3067,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 3 receptor of guinea pig; ND means not done,Autocuration,10141.0,,F,,BAO_0000019,15847,,,1,CHEMBL617992,,,Cavia porcellus,H,4,,
3068,Potency to 5-hydroxytryptamine 3 receptor entirely in guinea pig ileum,Autocuration,10141.0,,B,,BAO_0000221,10561,,,1,CHEMBL617993,,,Cavia porcellus,H,4,2116.0,
3069,In vitro binding affinity was measured for 5-hydroxytryptamine 3 receptor in the guinea pig ileum.,Autocuration,10141.0,,B,,BAO_0000221,11454,,,1,CHEMBL617994,,,Cavia porcellus,H,4,2116.0,
3070,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea colon at a concentration 0.01 uM,Autocuration,10141.0,,F,,BAO_0000019,4639,,,1,CHEMBL617995,,,Cavia porcellus,H,4,,
3071,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 0.1 uM,Autocuration,10141.0,,F,,BAO_0000019,4639,,,1,CHEMBL617996,,,Cavia porcellus,H,4,,
3072,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 1 uM,Autocuration,10141.0,,F,,BAO_0000019,4639,,,1,CHEMBL617997,,,Cavia porcellus,H,4,,
3073,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 1 uM in the presence of 30 uM MDL 72222,Autocuration,10141.0,,F,,BAO_0000019,4639,,,1,CHEMBL617998,,,Cavia porcellus,H,4,,
3074,Percent of control response to 5-HT3 antagonistic activity on guinea colon at a concentration 0.01 uM,Autocuration,10141.0,,F,,BAO_0000019,4639,,,1,CHEMBL617999,,,Cavia porcellus,H,4,,
3075,Percent of control response to 5-HT3 antagonistic activity on guinea colon at a concentration 1 uM,Autocuration,10141.0,,F,,BAO_0000019,4639,,,1,CHEMBL618000,,,Cavia porcellus,H,4,,
3076,"Concentration required to produce 50% of maximal contraction induced by 5-HT through 5-HT3 receptors in the presence of the compound, in isolated guinea pig ileum",Autocuration,10141.0,,F,,BAO_0000221,15253,,,1,CHEMBL617815,,,Cavia porcellus,H,4,2116.0,
3077,"Concentration required to produce 50% of maximal contraction induced by 5-HT through 5-HT3 receptors in the presence of the compound, in isolated guinea pig ileum.",Autocuration,10141.0,,F,,BAO_0000221,15253,,,1,CHEMBL617816,,,Cavia porcellus,H,4,2116.0,
3078,Tested for the antagonistic activity against 5-hydroxytryptamine 3 receptor from guinea pig ileum,Autocuration,10141.0,,F,,BAO_0000221,11963,,,1,CHEMBL617817,,,Cavia porcellus,H,4,2116.0,
3079,In vitro 5-hydroxytryptamine 3 receptor activity in guinea pig ileum,Autocuration,10141.0,,B,,BAO_0000221,1946,,,1,CHEMBL617818,,,Cavia porcellus,H,4,2116.0,
3080,In vitro 5-hydroxytryptamine 3 receptor activity in guinea pig ileum; Not tested,Autocuration,10141.0,,B,,BAO_0000221,1946,,,1,CHEMBL617819,,,Cavia porcellus,H,4,2116.0,
3081,Binding affinity towards [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in HG108-15,Autocuration,10141.0,,B,,BAO_0000223,12045,,,1,CHEMBL617820,,,Cavia porcellus,H,4,,
3082,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,Autocuration,10141.0,,B,,BAO_0000221,1559,,,1,CHEMBL617821,,,Cavia porcellus,H,4,2116.0,
3083,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),Autocuration,10141.0,,F,,BAO_0000221,273,,,1,CHEMBL617822,,,Cavia porcellus,H,4,2116.0,
3084,Antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor of isolated guinea pig ileum (GPI),Autocuration,10141.0,,F,,BAO_0000221,273,,,1,CHEMBL617823,,,Cavia porcellus,H,4,2116.0,
3085,Tested for antagonistic activity on 5-hydroxytryptamine 3 receptor mediated effects of 5-HT in guinea pig isolated ileum,Autocuration,10141.0,,F,,BAO_0000221,188,,,1,CHEMBL617824,,,Cavia porcellus,H,4,2116.0,
3086,Agonistic activity against 5-hydroxytryptamine 3 receptor in guinea pig ileum assay,Autocuration,10141.0,,F,,BAO_0000221,12919,,,1,CHEMBL617825,,,Cavia porcellus,H,4,2116.0,
3087,5-hydroxytryptamine 3 receptor agonism in the guinea pig ileum by functional 5-HT3 receptor assay,Autocuration,10141.0,,F,,BAO_0000221,12918,,,1,CHEMBL617826,,,Cavia porcellus,H,4,2116.0,
3088,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,Autocuration,10141.0,,B,,BAO_0000221,1559,,,1,CHEMBL617827,,,Cavia porcellus,H,4,2116.0,
3089,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),Autocuration,10141.0,,F,,BAO_0000221,273,,,1,CHEMBL617828,,,Cavia porcellus,H,4,2116.0,
3090,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,Autocuration,10141.0,,B,,BAO_0000221,1559,,,1,CHEMBL617829,,,Cavia porcellus,H,4,2116.0,
3091,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum; Not determined,Autocuration,10141.0,,B,,BAO_0000221,1559,,,1,CHEMBL617830,,,Cavia porcellus,H,4,2116.0,
3092,Binding affinity towards 5-hydroxytryptamine 3 receptor of guinea pig ileum; not determined,Autocuration,10141.0,,B,,BAO_0000221,1559,,,1,CHEMBL617831,,,Cavia porcellus,H,4,2116.0,
3093,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor in guinea pig ileum.,Autocuration,10141.0,,B,,BAO_0000221,14424,,,1,CHEMBL617832,,,Cavia porcellus,H,4,2116.0,
3094,Binding affinity was determined against 5-hydroxytryptamine 2A receptor,Autocuration,10141.0,,B,,BAO_0000019,13181,,,1,CHEMBL617833,,,Cavia porcellus,U,0,,
3095,Binding affinity towards 5-HT1A receptor by the displacement of [3H]-8-OH-DPAT] in human recombinant receptors in mammalian cell,Autocuration,,,B,,BAO_0000357,5486,,,1,CHEMBL617834,,,,H,8,,
3096,Affinity towards human 5-hydroxytryptamine 3 serotonin receptor,Expert,9606.0,,B,,BAO_0000223,6491,,,1,CHEMBL617835,,,Homo sapiens,D,5,,
3097,Binding affinity towards 5-HT3 receptor,Autocuration,,,B,,BAO_0000223,6013,,,1,CHEMBL617836,,,,H,4,,
3098,Binding activity radioligand.,Autocuration,,,B,,BAO_0000223,12861,,,1,CHEMBL617837,,,,H,4,,
3099,Binding activity against 5-hydroxytryptamine 1A receptor from human brain cortex using [3H]8-OH-DPAT-HT as radioligand.,Autocuration,,,B,,BAO_0000019,12861,,,1,CHEMBL620392,,,,H,4,,
3100,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor,Autocuration,,,B,,BAO_0000223,5104,,,1,CHEMBL620393,,,,H,4,,
3101,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor,Autocuration,,,B,,BAO_0000223,5105,,,1,CHEMBL620394,,,,H,4,,
3102,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor; NT means Not tested,Autocuration,,,B,,BAO_0000223,5104,,,1,CHEMBL620395,,,,H,4,,
3103,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 3 receptor,Autocuration,,,B,,BAO_0000019,3935,,,1,CHEMBL620396,,,,U,0,,
3104,Displacement of [3H]-BRC 36694 from 5-hydroxytryptamine 3 receptor in NG108-15 cells,Expert,,,B,,BAO_0000219,13657,,433.0,1,CHEMBL620582,NG108-15,,,H,4,,
3105,"Percent inhibition of [3H]5 binding to 5-hydroxytryptamine 3 receptor was evaluated by injection of compound (75 microCi/kg, 1.32 ug/kg) into the tail vein of mice (in vivo)",Autocuration,,,B,,BAO_0000218,10369,,,1,CHEMBL620583,,,,H,4,,
3106,The binding affinity was measured for 5-hydroxytryptamine 3 receptor on NG 108-15 cell line of mouse neuroblastoma-glioma cells in presence of [3H]5 radioligand (in vitro),Autocuration,,,B,,BAO_0000019,10369,,,1,CHEMBL620584,,,,H,4,,
3107,Compound was evaluated for the binding affinity at 5- HT3 receptor subtype,Autocuration,,,B,,BAO_0000224,12918,,,1,CHEMBL620585,,,,H,4,,
3108,Compound was evaluated for the binding affinity at 5- HT3 receptor,Autocuration,,,B,,BAO_0000224,12918,,,1,CHEMBL620586,,,,H,4,,
3109,The binding affinity was measured for 5-hydroxytryptamine 3 receptor on NG 108-15 cell line of mouse neuroblastoma-glioma cells in presence of [3H]5 radioligand (in vitro),Autocuration,,,B,,BAO_0000019,10369,,,1,CHEMBL620587,,,,H,4,,
3110,In Vitro Binding affinity againist 5-hydroxytryptamine 3 receptor by displacing [3H]-Q-ICS 205-930 from rat cortex homogenates,Autocuration,,,B,,BAO_0000019,773,,,1,CHEMBL620588,,,,H,4,,
3111,5-hydroxytryptamine 3 receptor agonism in mouse,Autocuration,,,F,,BAO_0000218,12918,,,1,CHEMBL620589,,,,H,4,,
3112,Binding affinity towards 5-hydroxytryptamine 3 receptor was determined by using [3H]-ICS 205-930 as radioligand in mouse N1E 115 cells,Autocuration,,,B,,BAO_0000219,10561,,,1,CHEMBL620590,,,,H,4,,
3113,Binding affinity towards 5-hydroxytryptamine 2A receptor in rat cortex preparations using [3H]ketanserin,Autocuration,,,B,,BAO_0000019,12827,,,1,CHEMBL617956,,,,H,4,,
3114,Binding affinity towards 5-hydroxytryptamine 2A receptor in rat cortex preparations using [3H]ketanserin,Autocuration,,,B,,BAO_0000019,12827,,,1,CHEMBL617957,,,,H,4,,
3115,Binding affinity was evaluated by 5-hydroxytryptamine 3 receptor agonism in the mouse NIE-115 by displacing tropisetron,Autocuration,,,B,,BAO_0000224,12918,,,1,CHEMBL617958,,,,H,4,,
3116,Compound was evaluated for binding to 5-hydroxytryptamine 3 receptor in N1E cells using [3H]- -Tropisetron as radioligand,Autocuration,,,B,,BAO_0000219,273,,,1,CHEMBL617959,,,,H,4,,
3117,Compound was evaluated for binding to Serotonin 5-hydroxytryptamine 3 receptor in N1E cells using [3H]- -Tropisetron as radioligand,Autocuration,,,B,,BAO_0000219,273,,,1,CHEMBL617960,,,,H,4,,
3118,Potency at neuronal 5-hydroxytryptamine 3 receptor in the rabbit heart,Autocuration,,,B,,BAO_0000224,10561,,,1,CHEMBL617961,,,,H,4,,
3119,Ability to displace the radioligand [3H]GR-65630 from 5-hydroxytryptamine 3 receptor expressed in NIE-115 cells,Autocuration,,,B,,BAO_0000219,5033,,,1,CHEMBL617962,,,,H,4,,
3120,In vitro binding affinity at 5-hydroxytryptamine 3 receptor in N1E-115 cells using 3[H]GR-65630 as the radioligand,Autocuration,,,B,,BAO_0000219,16429,,339.0,1,CHEMBL617963,N1E-115,,,H,4,,
3121,In vitro binding affinity for the 5-hydroxytryptamine 3 receptor was determined with NG-108-15 mouse neuroblastoma-glioma cells,Autocuration,,,B,,BAO_0000019,10322,,,1,CHEMBL617964,,,,H,8,,
3122,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor in NG cells 108-15,Autocuration,,,B,,BAO_0000219,14331,,,1,CHEMBL617965,,,,H,8,,
3123,Compound was tested for the Binding affinity against N1e-115 neuroblastoma 5-hydroxytryptamine 3 receptor by Radio ligand [3H]GR-65630 binding assay.,Autocuration,10090.0,,B,,BAO_0000357,13462,,,1,CHEMBL617966,,,Mus musculus,D,9,,
3124,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,Autocuration,,,B,,BAO_0000019,12861,,,1,CHEMBL857074,,,,H,8,,
3125,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor,Autocuration,9823.0,,B,,BAO_0000357,15086,,,1,CHEMBL617967,,,Sus scrofa,H,8,,
3126,Binding activity radioligand.,Autocuration,9823.0,,B,,BAO_0000357,12861,,,1,CHEMBL617968,,,Sus scrofa,H,8,,
3127,Binding affinity to 5-hydroxytryptamine 3 receptor of neuronal in the afferent rabbit vagus,Autocuration,9986.0,,B,,BAO_0000223,10561,,,1,CHEMBL617969,,,Oryctolagus cuniculus,H,4,,
3128,Potency at neuronal 5-hydroxytryptamine 3 receptor in the rabbit heart,Autocuration,9986.0,,B,,BAO_0000223,10561,,,1,CHEMBL617970,,,Oryctolagus cuniculus,H,4,,
3129,Potency at neuronal 5-hydroxytryptamine 3 receptors in the rabbit heart,Autocuration,9986.0,,B,,BAO_0000223,10561,,,1,CHEMBL617971,,,Oryctolagus cuniculus,H,4,,
3130,Potency to 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand in rat cortex,Autocuration,9986.0,,B,,BAO_0000019,10561,,,1,CHEMBL617972,,,Oryctolagus cuniculus,H,4,,
3131,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),Autocuration,9986.0,,F,,BAO_0000019,273,,,1,CHEMBL617973,,,Oryctolagus cuniculus,H,4,,
3132,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),Autocuration,9986.0,,F,,BAO_0000019,273,,,1,CHEMBL617974,,,Oryctolagus cuniculus,H,4,,
3133,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),Autocuration,9986.0,,F,,BAO_0000221,273,,,1,CHEMBL617975,,,Oryctolagus cuniculus,H,4,2116.0,
3134,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),Autocuration,9986.0,,F,,BAO_0000019,273,,,1,CHEMBL617976,,,Oryctolagus cuniculus,H,4,,
3135,Antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),Autocuration,9986.0,,F,,BAO_0000019,273,,,1,CHEMBL617977,,,Oryctolagus cuniculus,H,4,,
3136,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),Autocuration,9986.0,,F,,BAO_0000019,273,,,1,CHEMBL617978,,,Oryctolagus cuniculus,H,4,,
3137,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),Autocuration,9986.0,,F,,BAO_0000019,273,,,1,CHEMBL617979,,,Oryctolagus cuniculus,H,4,,
3138,Binding affinity against 5-hydroxytryptamine 3 receptor in CHO cells using [3H]5-HT as radioligand,Autocuration,9986.0,,B,,BAO_0000219,13047,,449.0,1,CHEMBL617980,CHO,,Oryctolagus cuniculus,H,4,,
3139,In vitro displacement of [3H]-LY 278584 from rat cerebral cortex 5-hydroxytryptamine 3 receptor,Autocuration,10116.0,,B,,BAO_0000019,1650,,,1,CHEMBL617981,,,Rattus norvegicus,D,7,,
3140,Affinity at 5-hydroxytryptamine 3 receptor from rat frontal cortex using [3H]granisetron as radioligand (For granisetron = Ki(nM)=0.3+/-0.01),Autocuration,,,B,,BAO_0000019,16288,,,1,CHEMBL617982,,,,H,8,,
3141,Affinity at 5-hydroxytryptamine 3 receptor (For granisetron = Ki (nM)=0.3+/-0.01),Autocuration,,,B,,BAO_0000357,16288,,,1,CHEMBL617983,,,,H,8,,
3142,In vitro displacement of [3H]ICS-205-930 from 5-hydroxytryptamine 3 receptor in cultured NG-108-15 rat glioma cells,Autocuration,10116.0,,B,,BAO_0000019,10254,,,1,CHEMBL617984,,,Rattus norvegicus,D,7,,
3143,"Binding affinity for 5-hydroxytryptamine 3 receptor in rat cerebral cortex, determined by displacement of [3H]GR-65630",Autocuration,,,B,,BAO_0000019,14532,,,1,CHEMBL617985,,,,H,6,,
3144,"5-Hydroxy tryptamine 3 receptor showing agonist activity (in vivo) in Von Bezold-Jarisch Reflex in rats at 120 (ug/kg), evaluated as change in heart rate",Autocuration,,,F,,BAO_0000218,13392,,,1,CHEMBL617986,,,,H,6,948.0,
3145,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 100 (ug/kg), evaluated as change in heart rate",Autocuration,,,F,,BAO_0000019,13392,,,1,CHEMBL617987,,,,H,6,948.0,
3146,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 120 (ug/kg), evaluated as change in heart rate",Autocuration,,,F,,BAO_0000019,13392,,,1,CHEMBL617988,,,,H,6,948.0,
3147,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 60 (ug/kg), evaluated as change in heart rate",Autocuration,,,F,,BAO_0000019,13392,,,1,CHEMBL617792,,,,H,6,948.0,
3148,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptorr in Von Bezold-Jarisch Reflex in rats at 100 (ug/kg), evaluated as change in heart rate",Autocuration,,,F,,BAO_0000019,13392,,,1,CHEMBL617793,,,,H,6,948.0,
3149,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 100(ug/kg), evaluated as percent inhibition of bradycardia",Autocuration,,,F,,BAO_0000019,13392,,,1,CHEMBL617794,,,,H,6,,
3150,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 60 (ug/kg), evaluated as percent inhibition of bradycardia",Autocuration,,,F,,BAO_0000019,13392,,,1,CHEMBL617795,,,,H,6,,
3151,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch reflex in rats at 60 (ug/kg), evaluated as percent inhibition of bradycardia",Autocuration,,,F,,BAO_0000019,13392,,,1,CHEMBL617796,,,,H,6,,
3152,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch reflex in rats at 60(ug/kg), evaluated as percent inhibition of bradycardia",Autocuration,,,F,,BAO_0000019,13392,,,1,CHEMBL617797,,,,H,6,,
3153,Antagonism of 5-HT-induced Von Bezold-Jarisch reflex in rat after intravenous administration of 30 ug/kg of HT (5-hydroxytryptamine 3 receptor antagonism),Autocuration,10116.0,,F,,BAO_0000218,1089,,,1,CHEMBL617798,,,Rattus norvegicus,D,7,,
3154,Ability to antagonise the 5-HT- induced Von Bezold-Jarisch reflex in the rat after intravenous administration of 30 ug/kg of HT (5-hydroxytryptamine 3 receptor),Autocuration,,,F,,BAO_0000218,1089,,,1,CHEMBL617799,,,,H,6,,
3155,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1000 ug/kg dose in urethane-anesthetized rats,Autocuration,10116.0,,F,,BAO_0000218,11454,,,1,CHEMBL617800,,,Rattus norvegicus,D,7,,
3156,Inhibition of 5-HT-induced bradycardia by 5-hydroxytryptamine 3+,Autocuration,10116.0,,F,,BAO_0000019,11454,,,1,CHEMBL617801,,,Rattus norvegicus,D,7,,
3157,In vivo inhibitory concentration after 5 minutes against 5-hydroxytryptamine 3 receptor induced bradycardia [bezold-jarisch (B-J) reflex test] in rat by intravenous administration,Autocuration,10116.0,,F,,BAO_0000218,12205,,,1,CHEMBL617802,,,Rattus norvegicus,D,7,,
3158,Inhibition of 5-HT (1 ug/mL) induced depolarization in rat vagus nerve (5-hydroxytryptamine 3 receptor antagonism),Autocuration,10116.0,,F,,BAO_0000019,1089,,,1,CHEMBL617803,,,Rattus norvegicus,D,7,,
3159,Binding affinity towards 5-HT3 receptor in rat was evaluated,Autocuration,,,B,,BAO_0000019,5094,,,1,CHEMBL617804,,,,H,6,,
3160,Inhibition of [3H]GR-65630 binding to rat cortical membrane 5-hydroxytryptamine 3 receptor,Autocuration,10116.0,,B,,BAO_0000019,2622,,,1,CHEMBL617805,,,Rattus norvegicus,D,7,,
3161,Binding affinity was evaluated in vitro by displacement of [3H]zacopride radioligand from 5-hydroxytryptamine 3 receptor,Autocuration,,,B,,BAO_0000223,245,,,1,CHEMBL617806,,,,H,6,,
3162,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement [3H]GR-65630 in rat cerebral cortex.,Autocuration,,,B,,BAO_0000019,14788,,,1,CHEMBL617807,,,,H,6,,
3163,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement of [3H]granisetron from rat cerebral cortex,Autocuration,,,B,,BAO_0000019,14788,,,1,CHEMBL617808,,,,H,6,,
3164,Binding affinity against 5-hydroxytryptamine 3 receptor in rat cortical membrane using [3H]GR-65630 as radioligand,Autocuration,,,B,,BAO_0000249,3020,,,1,CHEMBL617809,,,,H,6,,
3165,Compound was tested for its ability to displace [3H]-Q-ICS 205-930 from 5-hydroxytryptamine 3 receptor in rat cortex homogenates,Autocuration,,,B,,BAO_0000019,1742,,,1,CHEMBL617810,,,,H,6,,
3166,Concentration of compound required to inhibit the binding of radioligand [3H]GR-65630 to 5-hydroxytryptamine 3 receptor in rat brain cortical membrane,Autocuration,,,B,,BAO_0000249,17394,,,1,CHEMBL617811,,,,H,6,955.0,
3167,Concentration required to inhibit the binding of radioligand [3H]GR-65630 to serotonin 5-hydroxytryptamine-3 receptor (5-HT 3 receptor)in rat brain cortical membrane,Autocuration,,,B,,BAO_0000221,17394,,,1,CHEMBL617812,,,,H,6,955.0,
3168,Concentration of compound required to inhibit the binding of radioligand [3H]GR-65630 to serotonin 5-hydroxytryptamine 3 receptor in rat cortical membrane,Autocuration,,,B,,BAO_0000249,17394,,,1,CHEMBL617813,,,,H,6,,
3169,In vitro inhibitory concentration against radioligand [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor in rat cortical membrane,Autocuration,,,B,,BAO_0000249,14286,,,1,CHEMBL617814,,,,H,6,,
3170,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate.,Autocuration,,,B,,BAO_0000019,14178,,,1,CHEMBL617698,,,,H,6,,
3171,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate; Not active at 10000 nm,Autocuration,10116.0,,B,,BAO_0000019,14178,,,1,CHEMBL617699,,,Rattus norvegicus,D,7,,
3172,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate; not active at 10000 nM,Autocuration,10116.0,,B,,BAO_0000019,14178,,,1,CHEMBL617700,,,Rattus norvegicus,D,7,,
3173,Inhibition of radiolabeled [3H]-Zacopride ligand binding to 5-hydroxytryptamine 3 receptor,Autocuration,10116.0,,B,,BAO_0000223,14178,,,1,CHEMBL617701,,,Rattus norvegicus,D,7,,
3174,Inhibitory concentration against 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-LY 278584 as radioligand,Autocuration,,,B,,BAO_0000019,15034,,,1,CHEMBL617702,,,,H,6,,
3175,"Tested for inhibition of binding of [3H]GR-65630 to rat cortical membranes, expressed as IC50",Autocuration,,,B,,BAO_0000249,1089,Membranes,,1,CHEMBL617703,,,,H,6,,
3176,Inhibition of [3H]GR-65630 binding to rat cortical membrane serotonin 3 receptor,Autocuration,10116.0,,B,,BAO_0000019,1089,,,1,CHEMBL617704,,,Rattus norvegicus,D,7,,
3177,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584; Not tested,Autocuration,,,B,,BAO_0000223,16532,,,1,CHEMBL617705,,,,H,6,,
3178,Inhibition of [3H]BRL-43694 binding to rat 5-hydroxytryptamine 3 receptor,Autocuration,10116.0,,B,,BAO_0000223,12801,,,1,CHEMBL617706,,,Rattus norvegicus,D,7,,
3179,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from NG108-15 cells (using [3H]zacopride as radioligand),Autocuration,,,B,,BAO_0000219,15194,,433.0,1,CHEMBL617707,NG108-15,,,H,6,,
3180,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from NG108-15 cells using [3H]zacopride as radioligand,Autocuration,,,B,,BAO_0000219,15194,,433.0,1,CHEMBL617708,NG108-15,,,H,6,,
3181,Binding affinity against 5-hydroxytryptamine 3 (5-HT3) receptor from rat cortical homogenate using [3H]zacopride as radioligand,Autocuration,,,B,,BAO_0000019,15194,,,1,CHEMBL617709,,,,H,6,,
3182,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; NA= Not active,Autocuration,,,B,,BAO_0000019,15194,,,1,CHEMBL617710,,,,H,6,,
3183,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; NA=Not active,Autocuration,,,B,,BAO_0000019,15194,,,1,CHEMBL882925,,,,H,6,,
3184,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; not active,Autocuration,,,B,,BAO_0000019,15194,,,1,CHEMBL617711,,,,H,6,,
3185,Antagonist potency to 5-hydroxytryptamine 3 receptor was assayed by antagonism of the 5-HT-evoked reflex bradycardia [Bezold-Jarisch(BJ) reflex] in rats,Autocuration,,,F,,BAO_0000019,10610,,,1,CHEMBL617712,,,,H,6,,
3186,Antagonistic activity against 5-hydroxytryptamine 3 receptor as inhibition of 5-HT-induced bradycardia (von Bezold-jarisch reflex) in anesthetized rat,Autocuration,10116.0,,F,,BAO_0000019,10355,,,1,CHEMBL617713,,,Rattus norvegicus,D,7,,
3187,"Compound was tested as a 5-hydroxytryptamine 3 receptor antagonist in the rat by assessment of the inhibition of the Bezold-Jarisch effect, when administered intravenously",Autocuration,,,F,,BAO_0000019,691,,,1,CHEMBL617714,,,,H,6,,
3188,In vivo 5-hydroxytryptamine 3 receptor (5-HT 3 receptor) antagonistic activity expressed as ability to inhibit Bezold-Jarich reflex evoked by 5-HT in rats,Autocuration,,,F,,BAO_0000218,10611,,,1,CHEMBL617715,,,,H,6,,
3189,Inhibition dose for 50 percent antagonism for 5-hydroxytryptamine 3 receptor in vivo in rats,Autocuration,,,F,,BAO_0000218,12801,,,1,CHEMBL617716,,,,H,6,,
3190,Inhibition of 5-HT evoked reflex bradycardia in rat.,Autocuration,,,F,,BAO_0000218,10609,,,1,CHEMBL617717,,,,H,6,,
3191,5-HT3 receptor antagonistic activity was measured by the inhibition of 5-HT-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,Autocuration,,,F,,BAO_0000218,11454,,,1,CHEMBL617718,,,,H,6,,
3192,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1 ug/kg dose in urethane-anesthetized rats,Autocuration,,,F,,BAO_0000218,11454,,,1,CHEMBL617719,,,,H,6,,
3193,5-hydroxytryptamine 3 receptor antagonistic activity measured by inhibition of 5-HT-induced bradycardia (iv administration 10 ug/kg dose in urethane-anesthetized rats),Autocuration,,,F,,BAO_0000218,11454,,,1,CHEMBL617720,,,,H,6,,
3194,5-hydroxytryptamine 3 receptor antagonistic activity as inhibition of 5-HT-induced bradycardia after iv administration of 100 ug/kg dose in urethane-anesthetized rats,Autocuration,10116.0,,F,,BAO_0000218,11454,,,1,CHEMBL617721,,,Rattus norvegicus,D,7,,
3195,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,Autocuration,,,F,,BAO_0000218,11454,,,1,CHEMBL617722,,,,H,6,,
3196,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1000 ug/kgetized rats,Autocuration,,,F,,BAO_0000218,11454,,,1,CHEMBL617723,,,,H,6,,
3197,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 3 ug/kg dose in urethane-anesthetized rats,Autocuration,,,F,,BAO_0000218,11454,,,1,CHEMBL617724,,,,H,6,,
3198,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 10 ug/kg dose in urethane-anesthetized rats,Autocuration,,,F,,BAO_0000218,11454,,,1,CHEMBL617725,,,,H,6,,
3199,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 100 ug/kg dose in urethane-anesthetized rats,Autocuration,,,F,,BAO_0000218,11454,,,1,CHEMBL617726,,,,H,6,,
3200,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 1000 ug/kg dose in urethane-anesthetized rats,Autocuration,,,F,,BAO_0000218,11454,,,1,CHEMBL617727,,,,H,6,,
3201,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 30 ug/kg dose in urethane-anesthetized rats,Autocuration,,,F,,BAO_0000218,11454,,,1,CHEMBL617728,,,,H,6,,
3202,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 300 ug/kg dose in urethane-anesthetized rats,Autocuration,,,F,,BAO_0000218,11454,,,1,CHEMBL617729,,,,H,6,,
3203,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 3ug/kg dose in urethane-anesthetized rats,Autocuration,,,F,,BAO_0000218,11454,,,1,CHEMBL617730,,,,H,6,,
3204,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5-HT-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,Autocuration,,,F,,BAO_0000218,11454,,,1,CHEMBL617731,,,,H,6,,
3205,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 0.3 ug/kg dose in urethane-anesthetized rats,Autocuration,,,F,,BAO_0000218,11454,,,1,CHEMBL617732,,,,H,6,,
3206,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 1 ug/kg dose in urethane-anesthetized rats,Autocuration,,,F,,BAO_0000218,11454,,,1,CHEMBL617733,,,,H,6,,
3207,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 30 ug/kg dose in urethane-anesthetized rats,Autocuration,,,F,,BAO_0000218,11454,,,1,CHEMBL617734,,,,H,6,,
3208,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 0.05 hour,Autocuration,,,F,,BAO_0000218,11454,,,1,CHEMBL872874,,,,H,6,,
3209,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 1 hour,Autocuration,,,F,,BAO_0000218,11454,,,1,CHEMBL617735,,,,H,6,,
3210,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 16 hour,Autocuration,,,F,,BAO_0000218,11454,,,1,CHEMBL617736,,,,H,6,,
3211,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 3 hour,Autocuration,,,F,,BAO_0000218,11454,,,1,CHEMBL617737,,,,H,6,,
3212,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 6 hour,Autocuration,,,F,,BAO_0000218,11454,,,1,CHEMBL617738,,,,H,6,,
3213,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 ug/kg dose in urethane-anesthetized rats,Autocuration,,,F,,BAO_0000218,11454,,,1,CHEMBL617739,,,,H,6,,
3214,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 100 ug/kg dose in urethane-anesthetized rats,Autocuration,,,F,,BAO_0000218,11454,,,1,CHEMBL617740,,,,H,6,,
3215,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1000 ug/kg dose in urethane-anesthetized rats,Autocuration,,,F,,BAO_0000218,11454,,,1,CHEMBL617741,,,,H,6,,
3216,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 ug/kg dose in urethane-anesthetized rats,Autocuration,,,F,,BAO_0000218,11454,,,1,CHEMBL617742,,,,H,6,,
3217,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 3 ug/kg dose in urethane-anesthetized rats,Autocuration,,,F,,BAO_0000218,11454,,,1,CHEMBL617743,,,,H,6,,
3218,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 30 ug/kg dose in urethane-anesthetized rats,Autocuration,,,F,,BAO_0000218,11454,,,1,CHEMBL617744,,,,H,6,,
3219,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 300 ug/kg dose in urethane-anesthetized rats,Autocuration,,,F,,BAO_0000218,11454,,,1,CHEMBL617745,,,,H,6,,
3220,"In vivo 5-hydroxytryptamine 3 receptor antagonist activity by antagonism of the von Bezold-Jarisch (B-J) reflex in anesthetized rats, (i.v.)",Autocuration,,,F,,BAO_0000218,670,,,1,CHEMBL617746,,,,H,6,,
3221,"In vivo 5-hydroxytryptamine 3 receptor antagonist activity by antagonism of the von Bezold-Jarisch (B-J) reflex in anesthetized rats, (i.v.); Not tested",Autocuration,,,F,,BAO_0000218,670,,,1,CHEMBL617747,,,,H,6,,
3222,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 10 ug/Kg,Autocuration,,,F,,BAO_0000218,10321,,,1,CHEMBL617748,,,,H,6,,
3223,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 100 ug/Kg,Autocuration,,,F,,BAO_0000218,10321,,,1,CHEMBL618909,,,,H,6,,
3224,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 2 ug/Kg,Autocuration,,,F,,BAO_0000218,10321,,,1,CHEMBL618910,,,,H,6,,
3225,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 20 ug/Kg,Autocuration,,,F,,BAO_0000218,10321,,,1,CHEMBL618911,,,,H,6,,
3226,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 5 ug/Kg,Autocuration,,,F,,BAO_0000218,10321,,,1,CHEMBL618912,,,,H,6,,
3227,Tested for inhibition of Bezold-Jarisch (B-J) reflex mediated by 5-hydroxytryptamine 3 receptor in rats after intravenous administration (2.0 ug/kg),Autocuration,,,F,,BAO_0000218,10322,,,1,CHEMBL618913,,,,H,6,,
3228,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; A means pure agonist,Autocuration,,,F,,BAO_0000019,15412,,,1,CHEMBL618914,,,,H,6,,
3229,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; A means pure agonist,Autocuration,,,F,,BAO_0000019,15412,,,1,CHEMBL618915,,,,H,6,,
3230,Intrinsic efficacy for rat 5-hydroxytryptamine 3 receptor,Autocuration,10116.0,,B,,BAO_0000223,15412,,,1,CHEMBL618916,,,Rattus norvegicus,D,7,,
3231,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; PA means partial agonist,Autocuration,,,F,,BAO_0000019,15412,,,1,CHEMBL618917,,,,H,6,,
3232,Inhibition of [3H]granisetron binding to 5-hydroxytryptamine 3 receptor (5-HT 3 receptor) of rat cortex and hippocampus tissue,Intermediate,,,B,,BAO_0000221,15412,,,1,CHEMBL618918,,,,D,7,10000000.0,
3233,Inhibition of [3H]granisetron binding to 5-hydroxytryptamine 3 receptor of rat cortical membrane,Autocuration,10116.0,,B,,BAO_0000019,15412,,,1,CHEMBL618919,,,Rattus norvegicus,D,7,,
3234,Inhibition of [3H]GR-65630 binding to rat cortical membrane serotonin 5-hydroxytryptamine 3 receptor,Autocuration,10116.0,,B,,BAO_0000019,17394,,,1,CHEMBL618920,,,Rattus norvegicus,D,7,,
3235,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 3 receptor,Autocuration,,,B,,BAO_0000223,12457,,,1,CHEMBL618921,,,,H,6,,
3236,Affinity was evaluated by inhibition of [3H]GR-65630 binding to NG108-15 cell transfected with cloned rat 5-hydroxytryptamine 3 receptor,Autocuration,,,B,,BAO_0000019,12457,,,1,CHEMBL618922,,,,H,6,,
3237,Binding affinity against radioligand [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in neuroblastoma-glioma (NG108-15) cells.,Autocuration,,,B,,BAO_0000019,12205,,,1,CHEMBL618923,,,,H,6,,
3238,Binding affinity for 5-hydroxytryptamine 3 receptor was determined by measuring displacement of [3H]GR-65630 from rat brain cortices,Autocuration,,,B,,BAO_0000019,14532,,,1,CHEMBL618924,,,,H,6,,
3239,Binding affinity to 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-BRL 43694 as radioligand,Autocuration,,,B,,BAO_0000019,1122,,,1,CHEMBL618925,,,,H,6,,
3240,Binding affinity towards 5-HT3 receptor in rat was evaluated,Autocuration,,,B,,BAO_0000019,5094,,,1,CHEMBL618926,,,,H,6,,
3241,5-hydroxytryptamine 4 receptor agonist activity as increased response to electrical stimulation in guinea pig ileum,Intermediate,10141.0,,F,,BAO_0000221,809,,,1,CHEMBL618927,,,Cavia porcellus,D,9,2116.0,
3242,5-hydroxytryptamine 4 receptor agonist activity expressed as the concentration which gave a 50% increase in the response to the electrical stimulation in male guinea pig ileum; Not tested,Intermediate,10141.0,,F,,BAO_0000221,809,,,1,CHEMBL618928,,,Cavia porcellus,D,9,2116.0,
3243,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum",Intermediate,10141.0,,F,,BAO_0000221,14290,,,1,CHEMBL618929,,,Cavia porcellus,D,9,2116.0,
3244,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Inactive up to 10E-5 M",Intermediate,10141.0,,F,,BAO_0000221,14290,,,1,CHEMBL618930,,,Cavia porcellus,D,9,2116.0,
3245,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Not tested",Intermediate,10141.0,,F,,BAO_0000221,14290,,,1,CHEMBL618931,,,Cavia porcellus,D,9,2116.0,
3246,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Not tested",Intermediate,10141.0,,F,,BAO_0000221,14290,,,1,CHEMBL619594,,,Cavia porcellus,D,9,2116.0,
3247,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not capable of evaluation",Intermediate,10141.0,,F,,BAO_0000221,14290,,,1,CHEMBL619595,,,Cavia porcellus,D,9,2116.0,
3248,concentration which gave a 50% increase in the response to electrical stimulation against 5-hydroxytryptamine 4 receptor in the guinea pig ileum.,Intermediate,10141.0,,F,,BAO_0000221,13961,,,1,CHEMBL619596,,,Cavia porcellus,D,9,2116.0,
3249,concentration which gave a 50% increase in the response to electrical stimulation against 5-hydroxytryptamine 4 receptor in the guinea pig ileum. Activity expressed as percent of the maximum 5-HT response given in brackets.,Intermediate,10141.0,,F,,BAO_0000221,13961,,,1,CHEMBL619755,,,Cavia porcellus,D,9,2116.0,
3250,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum,Intermediate,10141.0,,F,,BAO_0000221,809,,,1,CHEMBL619756,,,Cavia porcellus,D,9,2116.0,
3251,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum; Not evaluable,Intermediate,10141.0,,F,,BAO_0000221,809,,,1,CHEMBL619757,,,Cavia porcellus,D,9,2116.0,
3252,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum; Not tested,Intermediate,10141.0,,F,,BAO_0000221,809,,,1,CHEMBL619758,,,Cavia porcellus,D,9,2116.0,
3253,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum",Intermediate,10141.0,,F,,BAO_0000221,14290,,,1,CHEMBL619759,,,Cavia porcellus,D,9,2116.0,
3254,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Inactive up to 10-5 M",Intermediate,10141.0,,F,,BAO_0000221,14290,,,1,CHEMBL619760,,,Cavia porcellus,D,9,2116.0,
3255,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Inactive up to 10E-5 M",Intermediate,10141.0,,F,,BAO_0000221,14290,,,1,CHEMBL619761,,,Cavia porcellus,D,9,2116.0,
3256,5-hydroxytryptamine 4 receptor antagonist activity as inhibition of 5-HT-induced contractions in guinea pig ileum; Not capable of evaluation.,Intermediate,10141.0,,F,,BAO_0000221,14290,,,1,CHEMBL619762,,,Cavia porcellus,D,9,2116.0,
3257,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not tested",Intermediate,10141.0,,F,,BAO_0000221,14290,,,1,CHEMBL619763,,,Cavia porcellus,D,9,2116.0,
3258,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not tested",Intermediate,10141.0,,F,,BAO_0000221,14290,,,1,CHEMBL617868,,,Cavia porcellus,D,9,2116.0,
3259,Displacement of [3H]GR-113808 from 5-hydroxytryptamine 4 receptor in guinea pig striatum,Intermediate,10141.0,,B,,BAO_0000357,15034,,,1,CHEMBL617869,,,Cavia porcellus,D,9,,
3260,Binding affinity towards 5-HT4 receptor in striatum membranes of guinea-pig brain was evaluated,Intermediate,10141.0,,B,,BAO_0000249,5094,,,1,CHEMBL882926,,,Cavia porcellus,D,9,2435.0,
3261,Binding affinity towards 5-hydroxytryptamine 4 receptor in striatum membranes of guinea-pig brain was evaluated,Intermediate,10141.0,,B,,BAO_0000249,5094,,,1,CHEMBL617870,,,Cavia porcellus,D,9,2435.0,
3262,Inhibitory activity against 5-hydroxytryptamine 4 receptor of guinea pig striatum using [3H]GR-113808 as radioligand,Intermediate,10141.0,,B,,BAO_0000357,5399,,,1,CHEMBL617871,,,Cavia porcellus,D,9,2435.0,
3263,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to 5-hydroxytryptamine 4 receptor in guinea pig striatum,Intermediate,10141.0,,B,,BAO_0000357,17394,,,1,CHEMBL617872,,,Cavia porcellus,D,9,2435.0,
3264,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to 5-hydroxytryptamine 4 receptor in guinea-pig striatum,Intermediate,10141.0,,B,,BAO_0000357,17394,,,1,CHEMBL617873,,,Cavia porcellus,D,9,2435.0,
3265,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to serotonin 5-hydroxytryptamine 4 receptor in guinea-pig striatum,Intermediate,10141.0,,B,,BAO_0000357,17394,,,1,CHEMBL617874,,,Cavia porcellus,D,9,2435.0,
3266,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum.,Intermediate,10141.0,,F,,BAO_0000221,13961,,,1,CHEMBL619067,,,Cavia porcellus,D,9,2116.0,
3267,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum. 95% confidence limits are in brackets.,Intermediate,10141.0,,F,,BAO_0000221,13961,,,1,CHEMBL619068,,,Cavia porcellus,D,9,2116.0,
3268,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum;ne=not capable of evaluation.,Intermediate,10141.0,,F,,BAO_0000221,13961,,,1,CHEMBL619069,,,Cavia porcellus,D,9,2116.0,
3269,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor at concentration of 10e-6 M in guinea pig,Intermediate,10141.0,,B,,BAO_0000357,16946,,,1,CHEMBL619070,,,Cavia porcellus,D,9,,
3270,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor at concentration of 10e-8 M in guinea pig,Intermediate,10141.0,,B,,BAO_0000357,16946,,,1,CHEMBL619071,,,Cavia porcellus,D,9,,
3271,Agonistic activity against 5-hydroxytryptamine 4 receptor,Intermediate,10141.0,,F,,BAO_0000019,15034,,,1,CHEMBL619072,,,Cavia porcellus,D,9,,
3272,Agonistic activity against 5-hydroxytryptamine 4 receptor; not tested,Intermediate,10141.0,,F,,BAO_0000019,15034,,,1,CHEMBL619073,,,Cavia porcellus,D,9,,
3273,Compound was evaluated for the relative potency with respect to serotonin against 5-hydroxytryptamine 4 receptor,Intermediate,10141.0,,F,,BAO_0000019,12918,,,1,CHEMBL619074,,,Cavia porcellus,D,9,,
3274,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor,Intermediate,10141.0,,B,,BAO_0000357,16946,,,1,CHEMBL619075,,,Cavia porcellus,D,9,,
3275,Inhibition of [3H]GR-113808 binding to guinea pig striatum 5-hydroxytryptamine 4 receptor,Intermediate,10141.0,,B,,BAO_0000357,17394,,,1,CHEMBL619076,,,Cavia porcellus,D,9,2435.0,
3276,Binding affinity against 5-hydroxytryptamine 4 receptor in guinea pig striatum using [3H]GR-113808 as radioligand,Intermediate,10141.0,,B,,BAO_0000357,15034,,,1,CHEMBL619077,,,Cavia porcellus,D,9,2435.0,
3277,Binding affinity towards 5-HT4 receptor in striatum membranes of guinea-pig brain was evaluated,Intermediate,10141.0,,B,,BAO_0000249,5094,,,1,CHEMBL619078,,,Cavia porcellus,D,9,2435.0,
3278,Binding affinity towards 5-hydroxytryptamine 4 receptor in striatum membranes of guinea-pig brain was evaluated,Intermediate,10141.0,,B,,BAO_0000249,5094,,,1,CHEMBL619079,,,Cavia porcellus,D,9,2435.0,
3279,Tested for affinity against 5-hydroxytryptamine 4 receptor in the myenteric plexus of the guinea pig ileum.,Intermediate,10141.0,,B,,BAO_0000221,17358,,,1,CHEMBL619080,,,Cavia porcellus,D,9,2116.0,
3280,Displacement of [3H]-GR113808 from 5-HT4 receptor of guinea pig striatum,Expert,10141.0,,B,,BAO_0000357,12953,,,1,CHEMBL619081,,,Cavia porcellus,D,9,,
3281,The compound was tested for their binding affinity towards 5-HT4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand; Nonactive at 10 uM,Intermediate,10141.0,,B,,BAO_0000357,12953,,,1,CHEMBL619082,,,Cavia porcellus,D,9,,
3282,The compound was tested for their binding affinity towards 5-hydroxytryptamine 4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand.,Intermediate,10141.0,,B,,BAO_0000357,12953,,,1,CHEMBL619083,,,Cavia porcellus,D,9,,
3283,The compound was tested for their binding affinity towards 5-hydroxytryptamine 4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand; Nonactive at 10 uM,Intermediate,10141.0,,B,,BAO_0000357,12953,,,1,CHEMBL619084,,,Cavia porcellus,D,9,,
3284,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in non-electrically stimulated guinea-pig ileum.,Intermediate,10141.0,,F,,BAO_0000221,273,,,1,CHEMBL859397,,,Cavia porcellus,D,9,2116.0,
3285,5-hydroxytryptamine 4 receptor agonist activity in the guinea pig ileum assay,Intermediate,10141.0,,F,,BAO_0000221,12918,,,1,CHEMBL619085,,,Cavia porcellus,D,9,2116.0,
3286,5-hydroxytryptamine 4 receptor agonistic activity was measured by twitch response enhancing activity in electrically stimulated guinea pig ileum preparation,Intermediate,10141.0,,F,,BAO_0000221,12919,,,1,CHEMBL619086,,,Cavia porcellus,D,9,2116.0,
3287,Agonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in low frequency field stimulation of guinea-pig ileum (FSGPI).,Intermediate,10141.0,,F,,BAO_0000221,273,,,1,CHEMBL619087,,,Cavia porcellus,D,9,2116.0,
3288,Agonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in non-electrically stimulated guinea-pig ileum.,Intermediate,10141.0,,F,,BAO_0000221,273,,,1,CHEMBL619088,,,Cavia porcellus,D,9,2116.0,
3289,Ability to antagonize 5-HT-evoked contractions mediated through 5-hydroxytryptamine 4 receptor activation in the guinea pig distal colon LMMP,Intermediate,10141.0,,B,,BAO_0000357,13181,,,1,CHEMBL619089,,,Cavia porcellus,D,9,,
3290,Binding affinity was determined against 5-hydroxytryptamine 3 receptor,Autocuration,10141.0,,B,,BAO_0000357,13181,,,1,CHEMBL619090,,,Cavia porcellus,H,8,,
3291,Antagonistic activity against 5-hydroxytryptamine 4 receptor,Intermediate,10141.0,,F,,BAO_0000019,15034,,,1,CHEMBL619091,,,Cavia porcellus,D,9,,
3292,Ability to displace the radioligand [3H]GR-113808 from guinea pig striatum 5-hydroxytryptamine 4 receptor,Intermediate,10141.0,,B,,BAO_0000357,5033,,,1,CHEMBL619092,,,Cavia porcellus,D,9,,
3293,Binding affinity for 5-hydroxytryptamine 4 receptor by displacement of [3H]GR-113808 from guinea pig brain striatum.,Intermediate,10141.0,,B,,BAO_0000019,1980,,,1,CHEMBL619093,,,Cavia porcellus,D,9,,
3294,Binding affinity was determined against 5-hydroxytryptamine 2C receptor using cloned rat receptors expressed in 293 cells radiolabeled with [3H]mesulergine,Autocuration,10141.0,,B,,BAO_0000219,13181,,722.0,1,CHEMBL619094,HEK293,,Cavia porcellus,H,8,,
3295,In vitro by displacement of [3H]GR-113808 from 5-hydroxytryptamine 4 receptor on guinea pig striatal membrane,Intermediate,10141.0,,B,,BAO_0000019,14287,,,1,CHEMBL619095,,,Cavia porcellus,D,9,,
3296,Compound was evaluated for binding affinity against 5-hydroxytryptamine 4 receptor using radioligand binding assay using [3H]GR as radioligand,Intermediate,10141.0,,B,,BAO_0000357,1317,,,1,CHEMBL857988,,,Cavia porcellus,D,9,,
3297,Compound was evaluated for its ability to displace [3H]GR-113808 binding from 5-hydroxytryptamine 4 receptor in guinea pig striatum.,Intermediate,10141.0,,B,,BAO_0000357,15316,,,1,CHEMBL619096,,,Cavia porcellus,D,9,,
3298,In vitro binding affinity at 5-hydroxytryptamine 4 receptor in guinea pig striatum using 3[H]GR-113808 as the radioligand,Intermediate,10141.0,,B,,BAO_0000357,16429,,,1,CHEMBL619097,,,Cavia porcellus,D,9,2435.0,
3299,The compound was tested for its binding affinity towards 5-hydroxytryptamine 4 receptor in guinea pig hippocampus using [125I]SB-207710.,Intermediate,10141.0,,B,,BAO_0000221,14818,,,1,CHEMBL619098,,,Cavia porcellus,D,9,10000000.0,
3300,The compound was tested for the binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand,Intermediate,10141.0,,B,,BAO_0000357,15194,,,1,CHEMBL619751,,,Cavia porcellus,D,9,,
3301,The compound was tested for the binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand.,Intermediate,10141.0,,B,,BAO_0000357,15194,,,1,CHEMBL619752,,,Cavia porcellus,D,9,,
3302,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum;ne=not capable of evaluation.,Intermediate,10141.0,,F,,BAO_0000221,13961,,,1,CHEMBL875096,,,Cavia porcellus,D,9,2116.0,
3303,Binding affinity towards 5-HT2C receptor by the displacement of [3H]mesulergine] in human recombinant receptors in mammalian cell,Autocuration,,,B,,BAO_0000357,5486,,,1,CHEMBL619004,,,,H,8,,
3304,Binding affinity towards human 5-hydroxytryptamine 4 receptor using [3H]5-HT as radioligand,Autocuration,,,B,,BAO_0000357,16209,,,1,CHEMBL619005,,,,H,8,,
3305,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 4 receptor,Autocuration,,,B,,BAO_0000019,17085,,,1,CHEMBL619006,,,,H,8,,
3306,Compound was evaluated for the binding affinity against human cloned 5-hydroxytryptamine 4 receptor in HeLa cells using [3H]-LSD as the radioligand,Autocuration,,,B,,BAO_0000219,4199,,308.0,1,CHEMBL619007,HeLa,,,H,8,,
3307,Compound was tested for its binding affinity against 5-hydroxytryptamine 4 receptor,Autocuration,,,B,,BAO_0000357,15146,,,1,CHEMBL619008,,,,H,8,,
3308,Compound was tested for its binding affinity for 5-hydroxytryptamine 4 receptor,Autocuration,,,B,,BAO_0000357,5213,,,1,CHEMBL619009,,,,H,8,,
3309,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 4 receptor in HeLa cells, using [3H]LSD as radioligand",Autocuration,,,B,,BAO_0000219,4829,,308.0,1,CHEMBL619010,HeLa,,,H,8,,
3310,Tested for ability to stimulate production of cAMP mediated by 5-hydroxytryptamine 4 receptor in mouse Coliculi neurons,Autocuration,,,B,,BAO_0000357,17358,,,1,CHEMBL619011,,,,H,8,,
3311,Tested for ability to stimulate production of cAMP mediated by 5-hydroxytryptamine 4 receptor in mouse Coliculi neurons; IA means inactive,Autocuration,,,B,,BAO_0000357,17358,,,1,CHEMBL619012,,,,H,8,,
3312,Ability to displace [3H]GR-113808 from mouse 5-hydroxytryptamine 4 receptor in COS7 cells,Autocuration,,,B,,BAO_0000219,16946,,,1,CHEMBL619013,,,,H,8,,
3313,Tested for ability to stimulate 5-hydroxytryptamine 4 receptors in mouse Coliculi neurons,Autocuration,,,B,,BAO_0000357,17358,,,1,CHEMBL619014,,,,H,8,,
3314,Evaluated for the 5-hydroxytryptamine 4 receptor antagonistic activity in piglet atrium model,Autocuration,,,F,,BAO_0000019,268,,,1,CHEMBL857503,,,,H,8,2081.0,
3315,Evaluated for the 5-hydroxytryptamine 4 receptor antagonistic activity in piglet atrium model; compound found inactive at 1 uM,Autocuration,,,F,,BAO_0000019,268,,,1,CHEMBL619015,,,,H,8,2081.0,
3316,The compound was tested for binding affinity against 5-hydroxytryptamine 4 receptor,Autocuration,,,B,,BAO_0000357,15086,,,1,CHEMBL619016,,,,H,8,,
3317,Compound was tested for binding affinity against piglet hippocampus 5-hydroxytryptamine 4 receptor,Autocuration,,,B,,BAO_0000221,14875,,,1,CHEMBL619017,,,,H,8,10000000.0,
3318,The binding affinity (pKi) was measured against 5-hydroxytryptamine 4 receptor of piglet hippocampus using [125I]SB 207710 as radioligand,Autocuration,9823.0,,B,,BAO_0000221,13267,,,1,CHEMBL619018,,,Sus scrofa,H,8,10000000.0,
3319,Binding affinity against 5-hydroxytryptamine 2A receptor using rabbit saphenous vein assay.,Autocuration,9986.0,,B,,BAO_0000019,13047,,,1,CHEMBL619019,,,Oryctolagus cuniculus,H,8,,
3320,Displacement of [3H]GR-113808 from rat striatum 5-hydroxytryptamine 4 receptor,Expert,10116.0,,B,,BAO_0000357,1650,,,1,CHEMBL619020,,,Rattus norvegicus,D,9,,
3321,Tested for its agonist potency against the 5-hydroxytryptamine 4 receptor located in the rat esophageal tunica muscularis mucosae,Autocuration,,,F,,BAO_0000019,567,,,1,CHEMBL619021,,,,H,8,,
3322,Tested for affinity towards 5-hydroxytryptamine 4 receptor in relaxation of rat oesophagus,Autocuration,,,B,,BAO_0000357,17358,,,1,CHEMBL619022,,,,H,8,,
3323,Tested for the effect on binding at 5-hydroxytryptamine 4 receptor; No activity,Autocuration,,,B,,BAO_0000357,188,,,1,CHEMBL619023,,,,H,8,,
3324,lntrinsic activity relative to 5-HT receptor,Autocuration,,,F,,BAO_0000019,670,,,1,CHEMBL619024,,,,H,8,,
3325,Compound was evaluated for the agonistic activity towards 5-hydroxytryptamine 4 receptor using the rat tunica muscularis mucosae (TMM) esophagus strip assay,Autocuration,,,F,,BAO_0000019,204,,,1,CHEMBL619025,,,,H,8,,
3326,In vitro relaxation of carbachol pre-contracted rat oesophageal TMM.,Expert,,,F,,BAO_0000019,1946,,,1,CHEMBL619026,,,,H,8,,
3327,Compound was tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay,Autocuration,,,F,,BAO_0000019,6398,,,1,CHEMBL619027,,,,H,8,,
3328,Compound was tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay; IN = Inactive,Autocuration,,,F,,BAO_0000019,6398,,,1,CHEMBL619028,,,,H,8,,
3329,Efficient 5-hydroxytryptamine 4 agonist in the rat tunica muscularis mucosae,Autocuration,,,F,,BAO_0000019,17358,,,1,CHEMBL619029,,,,H,8,,
3330,Tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay of racemate mixture,Autocuration,,,F,,BAO_0000019,6398,,,1,CHEMBL619030,,,,H,8,,
3331,Relaxation of carbachol induced contractions of rat tunica muscularis mucosae,Expert,,,B,,BAO_0000357,11752,,,1,CHEMBL619031,,,,H,8,,
3332,5-hydroxytryptamine 4 receptor agonist activity was determined by the relaxation of the carbachol-contracted rat esophageal tunica muscularis mucosae,Autocuration,,,F,,BAO_0000019,809,,,1,CHEMBL619032,,,,H,8,,
3333,Inhibition of radiolabeled [3H]GR-113808 ligand binding to 5-hydroxytryptamine 4 receptor,Expert,10116.0,,B,,BAO_0000357,14178,,,1,CHEMBL619033,,,Rattus norvegicus,D,9,,
3334,Tested for its efficacy against the 5-hydroxytryptamine 4 receptor located in the rat esophageal tunica muscularis mucosae,Autocuration,,,B,,BAO_0000357,567,,,1,CHEMBL619034,,,,H,8,,
3335,In vitro 5-hydroxytryptamine 4 receptor activity by using carbachol-precontracted esophageal tunica muscularis mucosae.,Autocuration,,,B,,BAO_0000357,1946,,,1,CHEMBL619035,,,,H,8,,
3336,In vitro 5-hydroxytryptamine 4 receptor activity by using carbachol-precontracted esophageal tunica muscularis mucosae; No activity up to 104M concentration,Autocuration,,,B,,BAO_0000357,1946,,,1,CHEMBL619036,,,,H,8,,
3337,Binding affinity (Ki+/-SEM) against 5-hydroxytryptamine 4 receptor from cheng Prusoff equation by using [3H]GR-113808 in rat striatum,Expert,10116.0,,B,,BAO_0000019,13961,,,1,CHEMBL619037,,,Rattus norvegicus,D,9,,
3338,Binding affinity towards 5-HT 4 receptor in rat striatum membranes using [3H]GR-113808 as radioligand,Autocuration,,,B,,BAO_0000249,6238,,,1,CHEMBL619038,,,,H,8,2435.0,
3339,Binding affinity towards 5-HT4 receptor was determined in rat striatal membranes using [3H]GR-113808 as radioligand; Not tested,Autocuration,,,B,,BAO_0000249,14290,,,1,CHEMBL619039,,,,H,8,,
3340,Binding affinity towards 5-hydroxytryptamine 4 receptor was determined in rat striatal membranes using [3H]GR-113808 as radioligand,Expert,,,B,,BAO_0000249,14290,,,1,CHEMBL619040,,,,H,8,,
3341,Binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum,Expert,10116.0,,B,,BAO_0000019,809,,,1,CHEMBL619041,,,Rattus norvegicus,D,9,2435.0,
3342,Binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum,Autocuration,,,B,,BAO_0000019,1578,,,1,CHEMBL619042,,,,H,8,2435.0,
3343,Binding affinity to 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum membrane,Expert,,,B,,BAO_0000249,16709,,,1,CHEMBL619043,,,,H,8,2435.0,
3344,Binding affinity at 5-hydroxytryptamine 4 receptor in rat striatum by [3H]GR-113808 displacement.,Expert,,,B,,BAO_0000019,1946,,,1,CHEMBL619044,,,,H,8,2435.0,
3345,In vitro affinity at serotonergic 5-hydroxytryptamine 4 receptor by radioligand binding assay using [3H]GR-113808 in rat striatum membranes.,Expert,,,B,,BAO_0000249,15253,,,1,CHEMBL619045,,,,H,8,2435.0,
3346,In vitro binding affinity to 5-hydroxytryptamine 4 receptor in rat striatum membrane,Expert,,,B,,BAO_0000249,4535,,,1,CHEMBL619046,,,,H,8,2435.0,
3347,Binding affinity at 5-hydroxytryptamine 4 receptor in rat striatal membranes by [3H]GR-113808 displacement.,Expert,,,B,,BAO_0000249,13961,,,1,CHEMBL619047,,,,H,8,,
3348,Tested for potency against 5-hydroxytryptamine 4 receptor agonist in rat brain,Autocuration,,,F,,BAO_0000221,17358,,,1,CHEMBL619048,,,,H,8,955.0,
3349,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 4 receptor of rat,Autocuration,,,F,,BAO_0000019,15847,,,1,CHEMBL859398,,,,H,8,,
3350,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 4 receptor of rat; ND means not done,Autocuration,,,F,,BAO_0000019,15847,,,1,CHEMBL619049,,,,H,8,,
3351,5-hydroxytryptamine 4 receptor agonist activity in the rat esophageal muscularis mucosae,Autocuration,,,F,,BAO_0000019,670,,,1,CHEMBL857886,,,,H,8,,
3352,5-hydroxytryptamine 4 receptor agonist activity in the rat esophageal muscularis mucosae; Not tested,Autocuration,,,F,,BAO_0000019,670,,,1,CHEMBL619050,,,,H,8,,
3353,Antagonist activity against 5-hydroxytryptamine 4 receptor mediated relaxation of rat carbachol contracted esophageal muscularis mucosae,Autocuration,,,F,,BAO_0000019,1317,,,1,CHEMBL620591,,,,H,8,,
3354,Binding affinity against rat 5-hydroxytryptamine 4 receptor,Expert,10116.0,,B,,BAO_0000357,12936,,,1,CHEMBL620592,,,Rattus norvegicus,D,9,,
3355,pKi against 5-hydroxytryptamine 4 receptor in rat striatum membrane,Expert,,,B,,BAO_0000249,4535,,,1,CHEMBL620593,,,,H,8,2435.0,
3356,Antagonistic activity evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-5 M.,Expert,10116.0,,F,,BAO_0000019,14424,,,1,CHEMBL620594,,,Rattus norvegicus,D,9,,
3357,Antagonistic activity by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-6 M.,Expert,,,F,,BAO_0000019,14424,,,1,CHEMBL875079,,,,H,8,,
3358,Antagonistic activity by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-7 M.,Expert,,,F,,BAO_0000019,14424,,,1,CHEMBL620595,,,,H,8,,
3359,Antagonistic activity evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-8 M.,Expert,10116.0,,F,,BAO_0000019,14424,,,1,CHEMBL620596,,,Rattus norvegicus,D,9,,
3360,Antagonistic activity of compound was evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 3*10e-7 M.,Autocuration,,,F,,BAO_0000019,14424,,,1,CHEMBL620597,,,,H,8,,
3361,Antagonistic activity evaluated by ability to block serotonin induced relaxation (via 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 3*10e-8 M.,Expert,,,F,,BAO_0000019,14424,,,1,CHEMBL620598,,,,H,8,,
3362,Antagonistic activity evaluated by ability to block serotonin induced relaxation via 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 0.1 mg/kg (p.o.),Expert,,,F,,BAO_0000218,14424,,,1,CHEMBL620599,,,,H,8,,
3363,Antagonistic activity of compound was evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-7 M.,Autocuration,,,F,,BAO_0000019,14424,,,1,CHEMBL620600,,,,H,8,,
3364,Estimate from relaxation of carbachol-contracted rat esophageal muscularis mucosae,Autocuration,10116.0,,F,,BAO_0000019,1980,,,1,CHEMBL620601,,,Rattus norvegicus,H,8,,
3365,Compound was tested for agonistic activity against 5-hydroxytryptamine 4 receptor on guinea colon at a concentration 0.1 uM,Autocuration,,,F,,BAO_0000019,4639,,,1,CHEMBL620602,,,,H,8,,
3366,Tested for affinity towards 5-hydroxytryptamine 4 receptor,Autocuration,,,B,,BAO_0000357,17358,,,1,CHEMBL620603,,,,H,8,,
3367,Tested for affinity towards 5-hydroxytryptamine 4 receptor.,Autocuration,,,B,,BAO_0000357,17358,,,1,CHEMBL620604,,,,H,8,,
3368,Compound was tested for 5-hydroxytryptamine 4 binding affinity,Autocuration,,,B,,BAO_0000357,17358,,,1,CHEMBL620605,,,,H,8,,
3369,Compound was tested for its affinity towards 5-hydroxytryptamine 4 receptor,Autocuration,,,B,,BAO_0000357,1558,,,1,CHEMBL620606,,,,H,8,,
3370,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,Autocuration,,,F,,BAO_0000019,17358,,,1,CHEMBL620607,,,,H,8,,
3371,In vitro binding affinity towards 5-HT4 receptor was determined,Autocuration,,,B,,BAO_0000357,16117,,,1,CHEMBL620608,,,,H,8,,
3372,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,Autocuration,,,F,,BAO_0000019,17358,,,1,CHEMBL620609,,,,H,8,,
3373,Tested for agonist activity against 5-hydroxytryptamine 4 receptor,Autocuration,,,F,,BAO_0000019,17358,,,1,CHEMBL620610,,,,H,8,,
3374,Tested for selectivity for 5-hydroxytryptamine 4 receptor,Autocuration,,,B,,BAO_0000357,17358,,,1,CHEMBL620611,,,,H,8,,
3375,Tested for 5-hydroxytryptamine 4 binding affinity against cisapride,Autocuration,,,B,,BAO_0000357,17358,,,1,CHEMBL620612,,,,H,8,,
3376,Tested for 5-hydroxytryptamine 4 binding affinity against renzapride,Autocuration,,,B,,BAO_0000357,17358,,,1,CHEMBL620613,,,,H,8,,
3377,Tested for 5-hydroxytryptamine 4 binding affinity against zacopride,Autocuration,,,B,,BAO_0000357,17358,,,1,CHEMBL620614,,,,H,8,,
3378,Binding affinity against 5-Hydroxytryptamine 4 receptor,Expert,,,B,,BAO_0000357,1274,,,1,CHEMBL620615,,,,H,8,,
3379,Compound was evaluated for the displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 recognition sites in rat brain membranes,Autocuration,,,B,,BAO_0000249,10728,Brain membranes,,1,CHEMBL857075,,,,H,6,,
3380,Compound was evaluated for the displacement of [3H]Q-ICS-205-930 from 5-HT3 recognition sites in rat brain membranes,Autocuration,,,B,,BAO_0000249,11695,Brain membranes,,1,CHEMBL620616,,,,H,6,,
3381,Displacement of [3H]Q-ICS-205-930 from 5-hydroxytryptamine 3 receptor recognition sites in rat brain membranes,Autocuration,,,B,,BAO_0000249,11695,Brain membranes,,1,CHEMBL619411,,,,H,6,,
3382,Displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor from rat cortex homogenate,Autocuration,,,B,,BAO_0000019,12490,,,1,CHEMBL619412,,,,H,6,,
3383,Displacement of [3H]-Q-ICS 205-930 from rat cortex homogenate 5-hydroxytryptamine 3 receptor,Autocuration,10116.0,,B,,BAO_0000019,11828,,,1,CHEMBL619413,,,Rattus norvegicus,D,7,,
3384,Binding affinity of 5-hydroxytryptamine 3 receptor using [3H]granisetron in rat hippocampus and entorhinal cortex,Autocuration,,,B,,BAO_0000221,12253,,,1,CHEMBL619414,,,,H,6,10000000.0,
3385,Binding affinity to 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand in rat cortex,Autocuration,,,B,,BAO_0000019,10561,,,1,CHEMBL619415,,,,H,6,,
3386,Binding affinity to 5-hydroxytryptamine 3 receptor using [3H]quipazine as radioligand in rat cortex,Autocuration,,,B,,BAO_0000019,10561,,,1,CHEMBL619416,,,,H,6,,
3387,Rat 5-hydroxytryptamine 3 receptor (5-HT3) antagonist,Autocuration,,,F,,BAO_0000019,14432,,,1,CHEMBL619417,,,,H,6,,
3388,Binding affinity against rat 5-hydroxytryptamine 3 receptor,Autocuration,10116.0,,B,,BAO_0000223,12936,,,1,CHEMBL619418,,,Rattus norvegicus,D,7,,
3389,Binding affinity against 5-Hydroxytryptamine 3 receptor,Autocuration,10116.0,,B,,BAO_0000223,1274,,,1,CHEMBL619419,,,Rattus norvegicus,D,7,,
3390,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of racemic [3H]zacopride from rat cortex,Autocuration,,,B,,BAO_0000019,1980,,,1,CHEMBL619420,,,,H,6,,
3391,Binding affinity to 5-hydroxytryptamine 3 receptor was determined in rat cerebro cortical membranes using [3H]quipazine.,Autocuration,,,B,,BAO_0000249,670,,,1,CHEMBL619421,,,,H,6,,
3392,Displacement of [3H]granisetron from 5-hydroxytryptamine 3 receptor of rat cortex,Autocuration,10116.0,,B,,BAO_0000019,968,,,1,CHEMBL619422,,,Rattus norvegicus,D,7,,
3393,In vitro by displacement of [3H]LY-278584 from 5-hydroxytryptamine 3 receptor on rat entorhinal cortex,Autocuration,,,B,,BAO_0000019,14287,,,1,CHEMBL619423,,,,H,6,,
3394,Tested for its binding affinity by measuring its ability to displace [3H]granisetron from 5-hydroxytryptamine 3 receptor in rat cortex,Autocuration,,,B,,BAO_0000019,567,,,1,CHEMBL875080,,,,H,6,,
3395,The binding affinity (pKi) measured against 5-hydroxytryptamine 1A receptor of rat cortex using [3H]8-OH-DPAT as radioligand,Autocuration,,,B,,BAO_0000019,13267,,,1,CHEMBL619424,,,,H,6,,
3396,Binding affinity at 5-hydroxytryptamine 3 receptor in rat cortical membrane by [3H]graniestron displacement.,Autocuration,,,B,,BAO_0000249,14826,,,1,CHEMBL619425,,,,H,6,,
3397,The compound was tested for the binding affinity against 5-hydroxytryptamine 3 receptor using [3H]zacopride as radioligand,Autocuration,,,B,,BAO_0000223,15194,,,1,CHEMBL619426,,,,H,6,,
3398,The compound was tested for the binding affinity against 5-hydroxytryptamine 3 receptor using [3H]zacopride as radioligand.,Autocuration,,,B,,BAO_0000223,15194,,,1,CHEMBL619427,,,,H,6,,
3399,pKi value for inhibition of [3H]LY-278584 binding to 5-hydroxytryptamine 3 receptor,Autocuration,10116.0,,B,,BAO_0000223,10394,,,1,CHEMBL619645,,,Rattus norvegicus,D,7,,
3400,"Compound was evaluated for binding affinity on 5-hydroxytryptamine 1A receptor in rat hippocampus membranes,3H-8-OH-DPAT and buspirone for nonspecific binding",Expert,,,B,,BAO_0000249,13657,,,1,CHEMBL619646,,,,D,9,,
3401,Compound was tested for its antagonistic activity against 5-hydroxytryptamine 3 receptor in rat brain using [3H]zacopride as the radioligand.,Autocuration,,,F,,BAO_0000221,1879,,,1,CHEMBL619647,,,,H,8,955.0,
3402,Compound was tested in vitro for its antagonistic activity against 5-hydroxytryptamine 3 receptor,Autocuration,,,F,,BAO_0000019,1879,,,1,CHEMBL619648,,,,H,8,,
3403,Compound was tested in vitro for its antagonistic activity against 5-hydroxytryptamine 3 receptor in rat CNS.,Autocuration,,,F,,BAO_0000019,1879,,,1,CHEMBL619165,,,,H,8,,
3404,Compound was evaluated in vivo for the antagonistic activity towards 5-hydroxytryptamine 3 receptor,Autocuration,,,F,,BAO_0000218,204,,,1,CHEMBL620719,,,,H,8,,
3405,Compound was tested for its binding affinity towards 5-HT-3 receptor in whole rat brain using (S)-[125I]-zacopride as the radioligand.,Autocuration,,,B,,BAO_0000019,1879,,,1,CHEMBL872924,,,,H,8,,
3406,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor,Autocuration,,,B,,BAO_0000357,1879,,,1,CHEMBL620720,,,,H,8,,
3407,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor in whole rat brain using (S)-[125I]-zacopride as the radioligand.,Autocuration,,,B,,BAO_0000019,1879,,,1,CHEMBL620721,,,,H,8,,
3408,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor in whole rat brain using [125I]DAIZAC as the radioligand.,Autocuration,,,B,,BAO_0000019,1879,,,1,CHEMBL620722,,,,H,8,,
3409,"Concentration that inhibits the binding of radioligand, [3H]-ICS 205930, to 5-hydroxytryptamine 3 receptor from rat cortex",Autocuration,,,B,,BAO_0000019,10641,,,1,CHEMBL620723,,,,H,6,,
3410,In Vitro Binding affinity againist 5-hydroxytryptamine 3 receptor by displacing [3H]-Q-ICS 205-930 from rat cortex homogenates,Autocuration,,,B,,BAO_0000019,773,,,1,CHEMBL620724,,,,H,8,,
3411,Binding affinity against 5-hydroxytryptamine 3 (5-HT3) receptor in rat brain cortical membranes using radioligand [3H]quipazine,Autocuration,,,B,,BAO_0000249,11952,,,1,CHEMBL620725,,,,H,6,,
3412,Antagonist activity (100 ug/kg) for the Bezold Jarisch reflex evoked by 30 (ug/Kg) of 5-hydroxytryptamine 3 receptor in ethylurethane anesthetized rats i.v.,Autocuration,10116.0,,F,,BAO_0000019,14145,,,1,CHEMBL620726,,,Rattus norvegicus,D,9,,
3413,Binding affinity towards 5-hydroxytryptamine 3 receptor,Expert,,,B,,BAO_0000357,17066,,,1,CHEMBL620727,,,,H,8,,
3414,Compound was evaluated for 5-hydroxytryptamine 3 receptor binding,Autocuration,,,B,,BAO_0000223,6398,,,1,CHEMBL620728,,,,H,4,,
3415,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of [3H]2 in Neuroblastoma-Glioma NG-108-15 cells,Autocuration,,,B,,BAO_0000019,10321,,,1,CHEMBL620729,,,,U,0,,
3416,Tested for 5-hydroxytryptamine 3 receptor antagonist activity by inhibiting the 5-HT evoked Bezold-Jarisch reflex,Autocuration,,,F,,BAO_0000019,511,,,1,CHEMBL858288,,,,H,4,,
3417,Compound was tested for binding affinity towards 5-hydroxytryptamine 3 receptor,Autocuration,,,B,,BAO_0000223,4639,,,1,CHEMBL620730,,,,H,4,,
3418,Binding affinity towards 5-hydroxytryptamine 3 receptor,Autocuration,,,B,,BAO_0000223,4639,,,1,CHEMBL620731,,,,H,4,,
3419,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 0.3 uM,Autocuration,10141.0,,F,,BAO_0000019,4639,,,1,CHEMBL620732,,,Cavia porcellus,H,4,,
3420,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 3 uM,Autocuration,10141.0,,F,,BAO_0000019,4639,,,1,CHEMBL618042,,,Cavia porcellus,H,4,,
3421,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 30 uM,Autocuration,10141.0,,F,,BAO_0000019,4639,,,1,CHEMBL618043,,,Cavia porcellus,H,4,,
3422,Compound was tested for its affinity towards 5-hydroxytryptamine 3 receptor,Autocuration,,,B,,BAO_0000223,1558,,,1,CHEMBL618044,,,,H,4,,
3423,Evaluated for the 5-hydroxytryptamine 3 receptor antagonistic activity in Bezold-Jarisch model expressed as inhibition of the reflex bradycardia induced by an intravenous injection,Autocuration,,,F,,BAO_0000019,268,,,1,CHEMBL618045,,,,H,4,,
3424,Compound was measured for its binding affinity at 5-hydroxytryptamine 3 receptor at a concentration of 10 uM using [3H]BRL-43694 as radioligand,Autocuration,,,B,,BAO_0000223,2474,,,1,CHEMBL618046,,,,H,4,,
3425,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); A: agonist,Autocuration,,,F,,BAO_0000019,5067,,,1,CHEMBL618047,,,,H,4,,
3426,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); ANT: agonist,Autocuration,,,F,,BAO_0000019,5067,,,1,CHEMBL875084,,,,H,4,,
3427,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); ANT: antagonist,Autocuration,,,F,,BAO_0000019,5067,,,1,CHEMBL618048,,,,H,4,,
3428,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); NA means data not available,Autocuration,,,B,,BAO_0000223,5067,,,1,CHEMBL618049,,,,H,4,,
3429,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); PA: Partial agonist,Autocuration,,,F,,BAO_0000019,5067,,,1,CHEMBL619764,,,,H,4,,
3430,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; A: agonist,Autocuration,,,F,,BAO_0000019,5067,,,1,CHEMBL619765,,,,H,4,,
3431,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; ANT: Antagonist,Autocuration,,,F,,BAO_0000019,5067,,,1,CHEMBL619766,,,,H,4,,
3432,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; NA: not active,Autocuration,,,B,,BAO_0000223,5067,,,1,CHEMBL619767,,,,H,4,,
3433,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; NA means data not available,Autocuration,,,B,,BAO_0000223,5067,,,1,CHEMBL619768,,,,H,4,,
3434,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; PA: Partial agonist,Autocuration,,,F,,BAO_0000019,5067,,,1,CHEMBL619769,,,,H,4,,
3435,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; na means data not available,Autocuration,,,B,,BAO_0000223,5067,,,1,CHEMBL619770,,,,H,4,,
3436,Binding affinity towards 5-hydroxytryptamine 3 receptor,Autocuration,,,B,,BAO_0000223,5067,,,1,CHEMBL619771,,,,H,4,,
3437,Binding affinity of compound towards 5-hydroxytryptamine 3 receptor using [3H]-BRL-43694 (1 nM) ligand in NG cells 108-15 was determined,Autocuration,,,B,,BAO_0000219,14331,,,1,CHEMBL619772,,,,H,4,,
3438,Binding affinity of compound towards 5-hydroxytryptamine 3 receptor; NA: not active,Autocuration,,,B,,BAO_0000223,5067,,,1,CHEMBL619773,,,,H,4,,
3439,Binding affinity for 5-HT3 receptor of NG108-15 cells using [3H]GR-65630,Autocuration,,,B,,BAO_0000219,6179,,433.0,1,CHEMBL619774,NG108-15,,,H,4,,
3440,Binding affinity to 5-HT3 serotonin receptor in NG 108-15 neuroblastoma glioma cells using [3H]GR-65630 radioligand.,Autocuration,,,B,,BAO_0000019,4265,,,1,CHEMBL875083,,,,H,4,,
3441,Binding affinity to 5-HT3 serotonin receptor in NG108-15 neuroblastoma glioma cells using [3H]GR-65630 radioligand,Autocuration,,,B,,BAO_0000219,4265,,433.0,1,CHEMBL620718,NG108-15,,,H,4,,
3442,Compound was tested for 5-hydroxytryptamine 3 receptor binding affinity,Autocuration,,,B,,BAO_0000223,17358,,,1,CHEMBL618127,,,,H,4,,
3443,Compound was tested for selectivity against 5-hydroxytryptamine 3 receptor binding affinity,Autocuration,,,B,,BAO_0000223,17358,,,1,CHEMBL618128,,,,H,4,,
3444,Compound was tested for the inhibition of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor expressed in NG 108-15 cells,Autocuration,,,B,,BAO_0000219,13628,,,1,CHEMBL618129,,,,H,4,,
3445,In vitro Binding affinity towards 5-hydroxytryptamine 3 receptor was determined,Autocuration,,,B,,BAO_0000223,4612,,,1,CHEMBL618130,,,,H,4,,
3446,Tested for 5-hydroxytryptamine 3 receptor antagonist activity,Autocuration,,,F,,BAO_0000019,17358,,,1,CHEMBL618131,,,,H,4,,
3447,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 1 uM,Autocuration,10141.0,,F,,BAO_0000019,4639,,,1,CHEMBL618132,,,Cavia porcellus,H,4,,
3448,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 10 uM,Autocuration,10141.0,,F,,BAO_0000019,4639,,,1,CHEMBL618133,,,Cavia porcellus,H,4,,
3449,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 10 uM in the presence of 30 uM MDL 72222,Autocuration,10141.0,,F,,BAO_0000019,4639,,,1,CHEMBL618134,,,Cavia porcellus,H,4,,
3450,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 3 uM,Autocuration,10141.0,,F,,BAO_0000019,4639,,,1,CHEMBL618135,,,Cavia porcellus,H,4,,
3451,Binding affinity for the 5-hydroxytryptamine 3 receptor was evaluated in vitro by examining its ability to displace [3H]-BRL 43694.,Autocuration,,,B,,BAO_0000223,511,,,1,CHEMBL618136,,,,H,4,,
3452,Binding affinity towards 5-hydroxytryptamine 3 receptor,Autocuration,,,B,,BAO_0000223,1479,,,1,CHEMBL618137,,,,H,4,,
3453,Compound was evaluated for binding affinity against 5-hydroxytryptamine 3 receptor using radioligand binding assay,Autocuration,,,B,,BAO_0000223,1317,,,1,CHEMBL618138,,,,H,4,,
3454,Tested against 5-hydroxytryptamine 3 receptor in experiment 1,Autocuration,,,B,,BAO_0000223,12146,,,1,CHEMBL618139,,,,H,4,,
3455,Tested against 5-hydroxytryptamine 3 receptor in experiment 2,Autocuration,,,B,,BAO_0000223,12146,,,1,CHEMBL618140,,,,H,4,,
3456,Binding affinity against 5-hydroxytryptamine 3 receptor was measured using [3H]granisetron as radioligand,Autocuration,,,B,,BAO_0000223,13969,,,1,CHEMBL618141,,,,H,4,,
3457,Binding affinity for 5-hydroxytryptamine 2C receptor,Expert,,,B,,BAO_0000357,13392,,,1,CHEMBL873478,,,,H,8,,
3458,Binding affinity towards 5-hydroxytryptamine 3 receptor,Autocuration,,,B,,BAO_0000223,13392,,,1,CHEMBL618142,,,,H,6,,
3459,Compound was evaluated for the affinity at 5-hydroxytryptamine 3 receptor,Autocuration,,,B,,BAO_0000357,14159,,,1,CHEMBL618143,,,,H,8,,
3460,Compound was tested for its affinity towards 5-hydroxytryptamine 3 receptor,Autocuration,,,B,,BAO_0000357,1558,,,1,CHEMBL618144,,,,H,8,,
3461,Inhibition of GR-65630 binding to 5-hydroxytryptamine 3 receptor,Autocuration,,,B,,BAO_0000357,16655,,,1,CHEMBL618145,,,,H,8,,
3462,Inhibition of [3H]- BRL 43 694 binding to 5-hydroxytryptamine 3 receptor at 10e-5 M,Autocuration,,,B,,BAO_0000223,13020,,,1,CHEMBL618146,,,,H,4,,
3463,Inhibition of [3H]-BRL 43 694 binding to 5-hydroxytryptamine 3 receptor of central nervous system,Autocuration,,,B,,BAO_0000223,13021,,,1,CHEMBL618147,,,,H,4,,
3464,Inhibition of [3H]- BRL 43 694 binding to 5-hydroxytryptamine 3 receptor at 10e-5 M,Autocuration,,,B,,BAO_0000223,13020,,,1,CHEMBL618148,,,,H,4,,
3465,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of [3H]2 in Neuroblastoma-Glioma NG-108-15 cells,Autocuration,,,B,,BAO_0000019,10321,,,1,CHEMBL618149,,,,H,8,,
3466,Compound was evaluated for its binding affinity towards 5-hydroxytryptamine 3 receptor,Autocuration,,,B,,BAO_0000357,15818,,,1,CHEMBL872927,,,,H,8,,
3467,Compound was evaluated for its binding affinity towards 5-hydroxytryptamine 3 receptor,Autocuration,,,B,,BAO_0000357,15818,,,1,CHEMBL618150,,,,H,8,,
3468,Compound was tested for 5-hydroxytryptamine 3 receptor binding affinity,Autocuration,,,B,,BAO_0000357,17358,,,1,CHEMBL618151,,,,H,8,,
3469,Compound was tested for its binding affinity for the 5-hydroxytryptamine 3 receptor,Autocuration,,,B,,BAO_0000357,2222,,,1,CHEMBL875094,,,,H,8,,
3470,In vitro binding affinity for the 5-hydroxytryptamine 3 receptor was determined with NG-108-15 mouse neuroblastoma-glioma cells,Autocuration,,,B,,BAO_0000019,10322,,,1,CHEMBL618152,,,,H,8,,
3471,In vitro binding affinity towards 5-hydroxytryptamine 3 receptor was determined,Autocuration,,,B,,BAO_0000357,16117,,,1,CHEMBL618153,,,,H,8,,
3472,Inhibitory constant against 5-hydroxytryptamine 3 receptor using [3H]GR-65630 radioligand,Autocuration,,,B,,BAO_0000357,17200,,,1,CHEMBL618888,,,,H,8,,
3473,Tested for 5-hydroxytryptamine 3 receptor agonist activity,Autocuration,,,F,,BAO_0000019,17358,,,1,CHEMBL618889,,,,H,8,,
3474,The binding affinity towards 5-hydroxytryptamine 3 receptor; No affinity,Autocuration,,,B,,BAO_0000357,16700,,,1,CHEMBL618890,,,,H,8,,
3475,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of [3H](R)-zacopride from ondansetron-treated NG-108-15 cell membranes,Autocuration,,,B,,BAO_0000019,1980,,,1,CHEMBL618891,,,,H,8,,
3476,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of [3H]-BRL 43694 from NG-108-15 cell membranes,Autocuration,,,B,,BAO_0000019,1980,,,1,CHEMBL619054,,,,H,8,,
3477,Binding affinity against the 5-hydroxytryptamine 3 receptor,Autocuration,,,B,,BAO_0000223,12409,,,1,CHEMBL619055,,,,H,4,,
3478,Binding affinity against human 5-hydroxytryptamine 3A receptor,Autocuration,,,B,,BAO_0000357,4365,,,1,CHEMBL619056,,,,H,8,,
3479,Percent efficacy against 5-hydroxytryptamine 3A receptor,Autocuration,,,F,,BAO_0000019,4365,,,1,CHEMBL619057,,,,H,8,,
3480,Binding affinity against human 5-hydroxytryptamine 3A receptor,Autocuration,,,B,,BAO_0000357,4365,,,1,CHEMBL619058,,,,H,8,,
3481,Response at rat 5-hydroxytryptamine 3a receptor expressed in xenopus oocytes,Expert,10116.0,,F,,BAO_0000219,6769,,,1,CHEMBL619059,Oocytes,,Rattus norvegicus,D,9,,
3482,Ability to block serotonin (30 uM)-evoked responses at rat 5HT3-alpha receptor expressed in xenopus oocytes,Expert,10116.0,,F,,BAO_0000219,6769,,,1,CHEMBL619060,Oocytes,,Rattus norvegicus,D,9,,
3483,Effect on rat 5-hydroxytryptamine 3a receptor expressed in xenopus oocytes at concentration up to 100 uM,Expert,10116.0,,F,,BAO_0000219,6769,,,1,CHEMBL875095,Oocytes,,Rattus norvegicus,D,9,,
3484,5-hydroxytryptamine 4 receptor agonist activity as percent maximum 5-HT effect in response to electrical stimulation in male guinea pig ileum,Intermediate,10141.0,,F,,BAO_0000221,809,,,1,CHEMBL619061,,,Cavia porcellus,D,9,2116.0,
3485,5-hydroxytryptamine 4 receptor agonist activity expressed as the concentration which gave a 50% increase in the response to the electrical stimulation in male guinea pig ileum,Intermediate,10141.0,,F,,BAO_0000221,809,,,1,CHEMBL619062,,,Cavia porcellus,D,9,2116.0,
3486,5-hydroxytryptamine 4 receptor agonist activity is expressed as percent of the maximum 5-HT response,Intermediate,10141.0,,F,,BAO_0000019,14290,,,1,CHEMBL619063,,,Cavia porcellus,D,9,,
3487,Tested for affinity towards 5-hydroxytryptamine 4 receptor in electrically stimulated longitudinal muscle preparation of guinea pig ileum,Intermediate,10141.0,,B,,BAO_0000221,17358,,,1,CHEMBL619064,,,Cavia porcellus,D,9,2116.0,
3488,Tested for affinity towards 5-hydroxytryptamine 4 receptor in guinea pig distal colon preparation,Intermediate,10141.0,,B,,BAO_0000357,17358,,,1,CHEMBL619065,,,Cavia porcellus,D,9,,
3489,Tested for affinity towards 5-hydroxytryptamine 4 receptor in isolated guinea pig ileum longitudinal muscle preparation,Intermediate,10141.0,,B,,BAO_0000221,17358,,,1,CHEMBL619066,,,Cavia porcellus,D,9,2116.0,
3490,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor nondesensitization,Autocuration,,,B,,BAO_0000221,17386,,,1,CHEMBL619775,,,,H,8,2116.0,
3491,Affinity against 5-hydroxytryptamine 7 receptor,Autocuration,,,B,,BAO_0000357,3269,,,1,CHEMBL619776,,,,H,8,,
3492,Ability to displace [3H]5-HT binding from 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand,Autocuration,10141.0,,B,,BAO_0000224,7721,,,1,CHEMBL619777,,,Cavia porcellus,H,4,,
3493,Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand,Autocuration,10141.0,,B,,BAO_0000224,7721,,,1,CHEMBL619778,,,Cavia porcellus,H,4,,
3494,Evaluated for inhibition of 5-hydroxytryptamine receptor on guinea pig ileum at 10 uM; No effect,Autocuration,10141.0,,B,,BAO_0000221,9117,,,1,CHEMBL619779,,,Cavia porcellus,H,4,2116.0,
3495,"Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand, activity is expressed as Kd.",Autocuration,10141.0,,B,,BAO_0000224,7721,,,1,CHEMBL619780,,,Cavia porcellus,H,4,,
3496,"Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor using 1 uM LSD as masking ligand, activity is expressed as Kd.",Autocuration,10141.0,,B,,BAO_0000224,7721,,,1,CHEMBL619166,,,Cavia porcellus,H,4,,
3497,5-HT level in K+ induced 5-hydroxytryptamine release in guinea pig cortex.,Autocuration,10141.0,,F,,BAO_0000019,15796,,,1,CHEMBL619167,,,Cavia porcellus,H,4,,
3498,5-hydroxytryptamine level in K+ induced 5-hydroxytryptamine release in guinea pig cortex.,Autocuration,10141.0,,F,,BAO_0000019,15796,,,1,CHEMBL619168,,,Cavia porcellus,H,4,,
3499,Concentration required to produce half-maximal response against 5-hydroxytryptamine receptor in the presence of 10 nM compound in isolated human atrial myocytes,Expert,9606.0,,B,,BAO_0000219,15650,,,1,CHEMBL619169,,,Homo sapiens,D,9,2081.0,
3500,Concentration required to produce half-maximal response against 5-hydroxytryptamine receptor on the L-type calcium current (I Ca) in isolated human atrial myocytes,Expert,9606.0,,B,,BAO_0000219,15650,,,1,CHEMBL619170,,,Homo sapiens,D,9,2081.0,
3501,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect of 5-hydroxytryptamine",Autocuration,9606.0,,F,,BAO_0000019,6866,,,1,CHEMBL619171,,,Homo sapiens,D,5,,
3502,",Antagonism of stimulation of 5-hydroxytryptamine receptor on the L-type calcium current (I Ca) in isolated human atrial myocytes",Expert,9606.0,,F,,BAO_0000219,15650,,,1,CHEMBL619172,,,Homo sapiens,D,9,2081.0,
3503,Ability (10 ug/kg) to inhibit binding of [125I]iododexetimide to 5-hydroxytryptamine receptor in mice,Autocuration,10090.0,,B,,BAO_0000019,10063,,,1,CHEMBL619173,,,Mus musculus,U,0,,
3504,Percent inhibition of radioligand [3H]-LSD binding to 5-HT receptor at 10 uM concentration,Autocuration,10090.0,,B,,BAO_0000019,12665,,,1,CHEMBL619174,,,Mus musculus,U,0,,
3505,5-hydroxytryptamine receptor binding affinity was determined in rats,Autocuration,,,B,,BAO_0000019,7504,,,1,CHEMBL619175,,,,H,4,,
3506,Binding affinity at rat 5-hydroxytryptamine receptor.,Autocuration,,,B,,BAO_0000224,7504,,,1,CHEMBL619176,,,,H,4,,
3507,Affinity against 5-hydroxytryptamine receptors in rat fundus model,Autocuration,,,B,,BAO_0000019,7038,,,1,CHEMBL619177,,,,H,4,,
3508,Affinity for 5-hydroxytryptamine receptor was determined using male Dawley rat fundus preparation,Autocuration,,,B,,BAO_0000224,7626,,,1,CHEMBL619178,,,,H,4,,
3509,Affinity for 5-hydroxytryptamine receptor was determined using male Dawley rat fundus preparation; Not determined,Autocuration,,,B,,BAO_0000224,7626,,,1,CHEMBL619179,,,,H,4,,
3510,Antagonistic activity against serotonin 5-HT receptor obtained from rat stomach fundus preparation,Autocuration,,,F,,BAO_0000019,7185,,,1,CHEMBL619180,,,,H,4,945.0,
3511,Antagonistic activity against serotonin 5-HT receptor obtained from rat stomach fundus preparation (resulted in discoloration in the oxygenated muscle bath to give varying results).,Autocuration,,,F,,BAO_0000019,7185,,,1,CHEMBL619181,,,,H,4,945.0,
3512,Antagonistic activity of corresponding methoxy compound against serotonin 5-HT receptor,Autocuration,,,F,,BAO_0000019,7185,,,1,CHEMBL619182,,,,H,4,,
3513,Compound was evaluated for binding affinity towards 5-hydroxytryptamine receptor in isolated rat fundus preparation measured as pA2,Autocuration,,,B,,BAO_0000224,6960,,,1,CHEMBL619183,,,,H,4,,
3514,"Compound was evaluated for binding affinity towards 5-hydroxytryptamine receptor in isolated rat fundus preparation measured as pA2; Valid pA2, can not be determined because of slope of Schild plot.",Autocuration,,,B,,BAO_0000224,6960,,,1,CHEMBL619184,,,,H,4,,
3515,In vitro affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in hippocampus,Autocuration,,,B,,BAO_0000221,12416,,,1,CHEMBL619185,,,,H,8,10000000.0,
3516,Binding affinity for rat 5-hydroxytryptamine transporter.,Expert,,,B,,BAO_0000357,15753,,,1,CHEMBL619186,,,,H,8,,
3517,Evaluated for inhibition of specific [3H]5-HT receptor binding in rat cortex.,Autocuration,,,B,,BAO_0000019,8062,,,1,CHEMBL619187,,,,H,4,,
3518,Binding affinity at serotonin 5-HT1-type site receptor in rat cortex by displacing [3H]5-HT,Autocuration,10116.0,,B,,BAO_0000019,9036,,,1,CHEMBL619188,,,Rattus norvegicus,D,5,,
3519,Compound was tested for its inhibitory activity against 5-hydroxytryptamine receptor,Autocuration,10116.0,,B,,BAO_0000224,15067,,,1,CHEMBL619189,,,Rattus norvegicus,D,5,,
3520,Inhibitory activity against [3H]- 5-hydroxytryptamine reuptake in whole rat brain minus cerebellum,Expert,10116.0,,F,,BAO_0000019,15753,,,1,CHEMBL619190,,,Rattus norvegicus,D,9,955.0,
3521,Inhibition of [3H]5-HT reuptake in whole rat brain (minus cerebellum) homogenate.,Expert,10116.0,,F,,BAO_0000221,15753,,,1,CHEMBL619191,,,Rattus norvegicus,D,9,2037.0,
3522,Displacement of [3H]-citalopram from rat forebrain membrane 5-hydroxytryptamine receptor at 10e-7 M,Autocuration,10116.0,,B,,BAO_0000019,15295,,,1,CHEMBL619192,,,Rattus norvegicus,D,5,,
3523,Percent binding affinity against 5-hydroxytryptamine receptor,Autocuration,10116.0,,B,,BAO_0000224,6347,,,1,CHEMBL619193,,,Rattus norvegicus,D,5,,
3524,Ability to displace 0.4 nM [3H]paroxetine binding to 5-hydroxytryptamine receptor in rat frontal cortex,Autocuration,,,B,,BAO_0000019,6763,,,1,CHEMBL619194,,,,U,0,,
3525,The binding affinity was measured on 5-hydroxytryptamine receptor uptake receptor using [3H]- paroxetine as radioligand.,Autocuration,10116.0,,B,,BAO_0000224,12092,,,1,CHEMBL619195,,,Rattus norvegicus,D,5,,
3526,Affinity against 5-hydroxytryptamine receptor was determined,Autocuration,10116.0,,B,,BAO_0000224,1579,,,1,CHEMBL619196,,,Rattus norvegicus,D,5,,
3527,Affinity against 5-hydroxytryptamine receptor was determined in rat stomach fundus strip,Autocuration,10116.0,,B,,BAO_0000019,1579,,,1,CHEMBL619197,,,Rattus norvegicus,D,5,945.0,
3528,Inhibition of [3H]5-HT uptake in HEK cells expressing human SERT,Expert,9606.0,,B,,BAO_0000219,5963,,,1,CHEMBL619198,,,Homo sapiens,D,9,,
3529,Inhibition of [3H]5-HT uptake in HEK cells expressing human SERT,Expert,9606.0,,B,,BAO_0000219,5963,,,1,CHEMBL875081,,,Homo sapiens,D,9,,
3530,Ability to compete with radioactive ligands specific to the Serotonergic 5-HT receptor at 10 uM; NA means compound failed to compete,Autocuration,,,B,,BAO_0000357,5030,,,1,CHEMBL884712,,,,H,8,,
3531,Inhibition of 5-hydroxytryptamine reuptake,Expert,,,B,,BAO_0000357,15796,,,1,CHEMBL884710,,,,H,8,,
3532,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding",Autocuration,,,F,,BAO_0000019,15413,,,1,CHEMBL619199,,,,H,8,,
3533,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding (Experiment 1)",Autocuration,,,F,,BAO_0000019,15413,,,1,CHEMBL619200,,,,H,8,,
3534,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding (Experiment 2)",Autocuration,,,F,,BAO_0000019,15413,,,1,CHEMBL619201,,,,H,8,,
3535,Tested for 5-hydroxytryptamine receptor uptake,Autocuration,,,F,,BAO_0000019,12409,,,1,CHEMBL619202,,,,H,8,,
3536,Affinity constant on CHO cells expressing Human recombinant 5-hydroxytryptamine receptor 1A,Expert,9606.0,,B,,BAO_0000219,16909,,449.0,1,CHEMBL619203,CHO,,Homo sapiens,D,9,,
3537,Antagonistic affinity tested against isolated human cloned alpha-1d adrenoceptor subtype,Expert,9606.0,,F,,BAO_0000019,16909,,,1,CHEMBL619204,,,Homo sapiens,D,9,,
3538,In vitro binding affinity towards 5-hydroxytryptamine receptor 1A receptor by using [3H]8-OH-DPAT in rat hippocampal membranes.,Autocuration,9606.0,,B,,BAO_0000249,15629,,,1,CHEMBL619205,,,Homo sapiens,H,8,,
3539,Tested in vitro for % inhibition against 5-hydroxytryptamine receptor 1A,Autocuration,,,B,,BAO_0000357,15629,,,1,CHEMBL619206,,,,H,8,,
3540,In vitro binding affinity at 5-hydroxytryptamine receptor 1A receptor in rat hippocampal membranes by [3H]8-OH-DPAT displacement.,Expert,,,B,,BAO_0000249,15629,,,1,CHEMBL619207,,,,H,8,,
3541,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats corpus striatum at a dosage of 0.10 umol/kg,Autocuration,,,F,,BAO_0000019,10034,,,1,CHEMBL619208,,,,H,8,2435.0,
3542,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats corpus striatum at a dosage of 10 umol/kg,Autocuration,,,F,,BAO_0000019,10034,,,1,CHEMBL619209,,,,H,8,2435.0,
3543,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 0.32 umol/kg,Autocuration,,,F,,BAO_0000019,10034,,,1,CHEMBL619210,,,,H,8,2435.0,
3544,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 3.2 umol/kg,Autocuration,,,F,,BAO_0000019,10034,,,1,CHEMBL619211,,,,H,8,2435.0,
3545,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 32 umol/kg,Autocuration,,,F,,BAO_0000019,10034,,,1,CHEMBL619212,,,,H,8,2435.0,
3546,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 0.032 umol/kg,Autocuration,,,F,,BAO_0000019,10034,,,1,CHEMBL620681,,,,H,8,2435.0,
3547,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 1.0 umol/kg,Autocuration,,,F,,BAO_0000019,10034,,,1,CHEMBL620682,,,,H,8,2435.0,
3548,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 10 umol/kg,Autocuration,,,F,,BAO_0000019,10034,,,1,CHEMBL620683,,,,H,8,2435.0,
3549,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 100 umol/kg,Autocuration,,,F,,BAO_0000019,10034,,,1,CHEMBL620684,,,,H,8,2435.0,
3550,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 3.2 umol/kg,Autocuration,,,F,,BAO_0000019,10034,,,1,CHEMBL620685,,,,H,8,2435.0,
3551,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 32 umol/kg,Autocuration,,,F,,BAO_0000019,10034,,,1,CHEMBL620686,,,,H,8,2435.0,
3552,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.032 umol/kg,Autocuration,,,F,,BAO_0000019,10034,,,1,CHEMBL620687,,,,H,8,349.0,
3553,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.10 umol/kg,Autocuration,,,F,,BAO_0000019,10034,,,1,CHEMBL620688,,,,H,8,349.0,
3554,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.32 umol/kg,Autocuration,,,F,,BAO_0000019,10034,,,1,CHEMBL620689,,,,H,8,349.0,
3555,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 1.0 umol/kg,Autocuration,,,F,,BAO_0000019,10034,,,1,CHEMBL620690,,,,H,8,349.0,
3556,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 10 umol/kg,Autocuration,,,F,,BAO_0000019,10034,,,1,CHEMBL620691,,,,H,8,349.0,
3557,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 100 umol/kg,Autocuration,,,F,,BAO_0000019,10034,,,1,CHEMBL620692,,,,H,8,349.0,
3558,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 3.2 umol/kg,Autocuration,,,F,,BAO_0000019,10034,,,1,CHEMBL620693,,,,H,8,349.0,
3559,Binding affinity against 5-hydroxytryptamine 4 receptor,Expert,,,B,,BAO_0000357,1274,,,1,CHEMBL620694,,,,H,8,,
3560,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,Autocuration,,,F,,BAO_0000019,17358,,,1,CHEMBL857986,,,,H,8,,
3561,Inhibitory activity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand at 10e-5 M concentration,Autocuration,,,B,,BAO_0000357,14532,,,1,CHEMBL620695,,,,H,8,,
3562,Binding affinity towards Serotonin 5-hydroxytryptamine 4 receptor,Expert,,,B,,BAO_0000357,16989,,,1,CHEMBL620696,,,,H,8,,
3563,Inhibitory constant against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 radioligand,Autocuration,,,B,,BAO_0000357,17200,,,1,CHEMBL620697,,,,H,8,,
3564,Binding affinity towards 5-hydroxytryptamine 4 receptor,Autocuration,,,B,,BAO_0000357,15779,,,1,CHEMBL620698,,,,H,8,,
3565,Binding affinity towards 5-hydroxytryptamine 4 receptor; ND means no data.,Autocuration,,,B,,BAO_0000357,15779,,,1,CHEMBL620699,,,,H,8,,
3566,Binding affinity towards 5-hydroxytryptamine 4 receptor; ND means no data.,Autocuration,,,B,,BAO_0000357,15779,,,1,CHEMBL620700,,,,H,8,,
3567,Binding affinity was determined against cloned 5-hydroxytryptamine 4A receptor isoform expressed in COS-7 cells,Autocuration,,,B,,BAO_0000219,15650,,643.0,1,CHEMBL620701,COS-7,,,H,8,,
3568,Binding affinity was determined against cloned 5-hydroxytryptamine 4B receptor isoform expressed in COS-7 cells,Autocuration,,,B,,BAO_0000219,15650,,643.0,1,CHEMBL875082,COS-7,,,H,8,,
3569,Binding affinity was determined against cloned 5-hydroxytryptamine 4C receptor isoform expressed in COS-7 cells,Autocuration,,,B,,BAO_0000219,15650,,643.0,1,CHEMBL620702,COS-7,,,H,8,,
3570,Binding affinity was determined against cloned 5-hydroxytryptamine 4D receptor isoform expressed in COS-7 cells,Autocuration,,,B,,BAO_0000219,15650,,643.0,1,CHEMBL620703,COS-7,,,H,8,,
3571,Binding affinity of compound towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand,Autocuration,,,B,,BAO_0000219,17046,,673.0,1,CHEMBL620704,C6,,,H,8,,
3572,Binding affinity towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand,Expert,,,B,,BAO_0000219,17046,,673.0,1,CHEMBL620705,C6,,,H,8,,
3573,Binding affinity was determined against cloned 5-hydroxytryptamine 4E receptor isoform expressed in C6 glial cells incubated with 0.2 nM [3H]GR-113808,Expert,,,B,,BAO_0000219,15650,,673.0,1,CHEMBL620706,C6,,,H,8,,
3574,Binding affinity towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand; Not determined,Expert,,,B,,BAO_0000219,17046,,673.0,1,CHEMBL620707,C6,,,H,8,,
3575,Binding affinity towards 5-hydroxytryptamine 5 receptor,Expert,,,B,,BAO_0000357,17066,,,1,CHEMBL620708,,,,H,8,,
3576,Inhibitory constant against human 5-hydroxytryptamine 5A receptor using [3H]LSD radioligand,Autocuration,,,B,,BAO_0000357,17200,,,1,CHEMBL620709,,,,H,8,,
3577,Binding affinity against 5-hydroxytryptamine 5A receptor,Expert,9606.0,,B,,BAO_0000357,16146,,,1,CHEMBL620710,,,Homo sapiens,D,9,,
3578,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 5A receptor stably expressed in CHO cells,Autocuration,,,B,,BAO_0000219,15250,,449.0,1,CHEMBL620711,CHO,,,H,8,,
3579,Affinity towards human 5-hydroxytryptamine 5A serotonin receptor,Expert,9606.0,,B,,BAO_0000357,6491,,,1,CHEMBL620712,,,Homo sapiens,D,9,,
3580,Binding affinity towards human 5-hydroxytryptamine 5A receptor,Expert,9606.0,,B,,BAO_0000357,17066,,,1,CHEMBL620713,,,Homo sapiens,D,9,,
3581,Binding affinity towards human 5-hydroxytryptamine 5A receptor was evaluated using [3H]-5-CT as radioligand,Expert,9606.0,,B,,BAO_0000357,17066,,,1,CHEMBL620714,,,Homo sapiens,D,9,,
3582,Binding affinity to cloned human 5-hydroxytryptamine 5A receptor,Expert,9606.0,,B,,BAO_0000357,4234,,,1,CHEMBL620715,,,Homo sapiens,D,9,,
3583,Binding affinity towards 5-HT5A receptor,Autocuration,,,B,,BAO_0000357,6013,,,1,CHEMBL620716,,,,H,8,,
3584,Binding affinity towards human 5-hydroxytryptamine 5A receptor using LSD as radioligand,Expert,,,B,,BAO_0000357,17175,,,1,CHEMBL620717,,,,H,8,,
3585,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 5A receptor,Autocuration,,,B,,BAO_0000357,15818,,,1,CHEMBL618072,,,,H,8,,
3586,Binding affinity towards cloned human 5-HT5A receptor was determined,Autocuration,,,B,,BAO_0000357,6166,,,1,CHEMBL857987,,,,H,8,,
3587,Binding affinity towards 5-hydroxytryptamine 5A receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,Autocuration,,,B,,BAO_0000219,15779,,722.0,1,CHEMBL618073,HEK293,,,H,8,,
3588,Binding affinity towards 5-hydroxytryptamine 5A receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand;ND means no data.,Autocuration,,,B,,BAO_0000219,15779,,722.0,1,CHEMBL618074,HEK293,,,H,8,,
3589,Compound was tested for its binding affinity in 5-hydroxytryptamine 5A receptor (using human cloned receptors in HEK 293 and [3H]5-CTas a radioligand ),Autocuration,,,B,,BAO_0000219,5213,,722.0,1,CHEMBL618075,HEK293,,,H,8,,
3590,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor,Expert,10090.0,,B,,BAO_0000357,17066,,,1,CHEMBL618076,,,Mus musculus,D,9,,
3591,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [125I]-2-iodo LSD as radioligand,Expert,10090.0,,B,,BAO_0000357,17066,,,1,CHEMBL618077,,,Mus musculus,D,9,,
3592,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [3H]- LSD as radioligand,Expert,10090.0,,B,,BAO_0000357,17066,,,1,CHEMBL618078,,,Mus musculus,D,9,,
3593,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [3H]LSD as radioligand,Expert,10090.0,,B,,BAO_0000357,17066,,,1,CHEMBL881821,,,Mus musculus,D,9,,
3594,Binding affinity towards murine 5-hydroxytryptamine 5A receptor,Expert,10090.0,,B,,BAO_0000357,17066,,,1,CHEMBL618079,,,Mus musculus,D,9,,
3595,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor using LSD as radioligand,Expert,,,B,,BAO_0000357,17175,,,1,CHEMBL618080,,,,H,8,,
3596,Binding affinity against 5-hydroxytryptamine 5A receptor in HEK 293 cells was determined using [3H]LSD as radioligand,Autocuration,,,B,,BAO_0000219,16190,,722.0,1,CHEMBL618081,HEK293,,,H,8,,
3597,Binding affinity against 5-hydroxytryptamine 5A receptor in HEK 293 cells was determined using [3H]LSD as radioligand,Autocuration,,,B,,BAO_0000219,16190,,722.0,1,CHEMBL618082,HEK293,,,H,8,,
3598,Binding affinity towards 5-HT5a receptor,Expert,,,B,,BAO_0000357,4820,,,1,CHEMBL618083,,,,H,8,,
3599,Binding affinity towards 5-hydroxytryptamine 5A receptor,Expert,9606.0,,B,,BAO_0000357,17066,,,1,CHEMBL618084,,,Homo sapiens,D,9,,
3600,Binding affinity for rodent 5-hydroxytryptamine 5A receptor,Expert,,,B,,BAO_0000357,17066,,,1,CHEMBL618085,,,,H,8,,
3601,Binding affinity towards 5-hydroxytryptamine 5A receptor using lysergic acid diethylamide (LSD) as radioligand,Expert,,,B,,BAO_0000357,17175,,,1,CHEMBL618086,,,,H,8,,
3602,Binding affinities against 5-hydroxytryptamine 5A receptor,Autocuration,,,B,,BAO_0000357,16633,,,1,CHEMBL875092,,,,H,8,,
3603,Binding affinities towards 5-hydroxytryptamine 5A receptor,Autocuration,,,B,,BAO_0000357,16633,,,1,CHEMBL618087,,,,H,8,,
3604,The binding affinity towards 5-hydroxytryptamine 5A receptor; No affinity,Autocuration,,,B,,BAO_0000357,16700,,,1,CHEMBL872926,,,,H,8,,
3605,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 0.01 uM,Autocuration,10141.0,,F,,BAO_0000019,4639,,,1,CHEMBL618088,,,Cavia porcellus,H,4,,
3606,Binding affinity towards 5-HT3 receptor by the displacement of [3H]GR-65630] in human recombinant receptors in mammalian cell,Autocuration,,,B,,BAO_0000223,5486,,,1,CHEMBL618089,,,,H,4,,
3607,Inhibition of human 5-hydroxytryptamine 6 receptor,Expert,9606.0,,B,,BAO_0000357,16146,,,1,CHEMBL618090,,,Homo sapiens,D,9,,
3608,Binding affinity towards 5-hydroxytryptamine 6 receptor using [3H]- LSD as radioligand,Expert,9606.0,,B,,BAO_0000357,17273,,,1,CHEMBL618091,,,Homo sapiens,D,9,,
3609,Inhibition against human 5-hydroxytryptamine 6 receptor,Autocuration,,,B,,BAO_0000357,17687,,,1,CHEMBL618092,,,,H,8,,
3610,Affinity towards human 5-hydroxytryptamine 6 serotonin receptor,Expert,9606.0,,B,,BAO_0000357,6491,,,1,CHEMBL618093,,,Homo sapiens,D,9,,
3611,Binding affinity as displacement of [3H]5-HT binding to 5-hydroxytryptamine 6 receptor in HeLa cells.,Expert,,,B,,BAO_0000219,16190,,308.0,1,CHEMBL618094,HeLa,,,H,8,,
3612,Binding affinity towards [3H]LSD-labeled human 5-hydroxytryptamine 6 receptor,Expert,9606.0,,B,,BAO_0000357,17066,,,1,CHEMBL618095,,,Homo sapiens,D,9,,
3613,Binding affinity towards human 5-hydroxytryptamine 6 receptor,Expert,9606.0,,B,,BAO_0000357,17066,,,1,CHEMBL875093,,,Homo sapiens,D,9,,
3614,Binding affinity towards human 5-hydroxytryptamine 6 receptor was evaluated using [125I]-2-iodo LSD as radioligand,Expert,9606.0,,B,,BAO_0000357,17066,,,1,CHEMBL618096,,,Homo sapiens,D,9,,
3615,Binding affinity towards human 5-hydroxytryptamine 6 receptor was evaluated using [3H]-LSD as radioligand,Expert,9606.0,,B,,BAO_0000357,17066,,,1,CHEMBL618118,,,Homo sapiens,D,9,,
3616,Binding affinity against 5-hydroxytryptamine 6 receptor,Expert,9606.0,,B,,BAO_0000357,3555,,,1,CHEMBL618119,,,Homo sapiens,D,9,,
3617,Binding affinity towards human 5-hydroxytryptamine 6 receptor,Expert,,,B,,BAO_0000357,5808,,,1,CHEMBL618120,,,,H,8,,
3618,Binding affinity towards human 5-hydroxytryptamine 6 receptor,Autocuration,,,B,,BAO_0000357,6013,,,1,CHEMBL618121,,,,H,8,,
3619,"Binding affinity for human 5-hydroxytryptamine 6 receptor expressed in HEK 293 human embryonic kidney cells, [3H]-lysergic acid diethylamide as radioligand",Expert,,,B,,BAO_0000219,15818,,722.0,1,CHEMBL618122,HEK293,,,H,8,,
3620,Binding affinity towards human 5-hydroxytryptamine 6 receptor using [3H]LSD as radioligand,Autocuration,,,B,,BAO_0000357,16209,,,1,CHEMBL618123,,,,H,8,,
3621,Binding affinity against human 5-hydroxytryptamine 6 receptor stably transfected to HEK 293 human embryonic kidney cells using [3H]-lysergic acid diethylamide as radioligand,Expert,,,B,,BAO_0000219,3935,,722.0,1,CHEMBL618124,HEK293,,,H,8,,
3622,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 6 receptor,Autocuration,,,B,,BAO_0000357,15818,,,1,CHEMBL618125,,,,H,8,,
3623,Displacement of [3H]LSD from human 5-hydroxytryptamine 6 receptor expressed in HEK 293 cells,Expert,9606.0,,B,,BAO_0000219,3805,,722.0,1,CHEMBL618126,HEK293,,Homo sapiens,D,9,,
3624,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 6 receptor incubated with 1 nM [3H]LSD,Expert,,,B,,BAO_0000019,16441,,,1,CHEMBL618236,,,,H,8,,
3625,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 6 receptor incubated with 1 nM [3H]LSD; ND is No Data.,Expert,,,B,,BAO_0000019,16441,,,1,CHEMBL618237,,,,H,8,,
3626,Ability to displace [3H]LSD from human 5-hydroxytryptamine 6 receptor transiently expressed in COS-7 cells,Expert,,,B,,BAO_0000219,6786,,643.0,1,CHEMBL618238,COS-7,,,H,8,,
3627,In vitro binding affinity to human 5-hydroxytryptamine 6 receptor,Expert,9606.0,,B,,BAO_0000357,4234,,,1,CHEMBL618239,,,Homo sapiens,D,9,,
3628,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 6 receptor,Autocuration,,,B,,BAO_0000019,17085,,,1,CHEMBL618240,,,,H,8,,
3629,Inhibitory constant against human 5-hydroxytryptamine 6 receptor using [3H]LSD radioligand,Autocuration,,,B,,BAO_0000357,17200,,,1,CHEMBL618241,,,,H,8,,
3630,Antagonism assessed in a functional cAMP binding assay using 5-CT to stimulate human 5-hydroxytryptamine 6 receptor expressed in HEK 293 cells,Autocuration,,,B,,BAO_0000219,17451,,722.0,1,CHEMBL859399,HEK293,,,H,8,,
3631,The compound was tested for antagonist activity by inhibition of human 5-HT6 stimulated adenylate cyclase,Autocuration,,,F,,BAO_0000019,3935,,,1,CHEMBL618242,,,,H,8,,
3632,Ability to displace the radioligand [3H]LSD from human 5-hydroxytryptamine 6 receptor,Autocuration,,,B,,BAO_0000357,5033,,,1,CHEMBL857991,,,,H,8,,
3633,Binding affinity against human 5-hydroxytryptamine 6 receptor,Expert,,,B,,BAO_0000357,4540,,,1,CHEMBL619951,,,,H,8,,
3634,Binding affinity to human cloned 5-HT6 receptor in HeLa cells using [3H]- LSD as radioligand,Expert,9606.0,,B,,BAO_0000219,4540,,308.0,1,CHEMBL619952,HeLa,,Homo sapiens,D,9,,
3635,Binding affinity to human cloned 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]- LSD as radioligand,Expert,9606.0,,B,,BAO_0000219,4540,,308.0,1,CHEMBL619953,HeLa,,Homo sapiens,D,9,,
3636,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells,Autocuration,,,B,,BAO_0000219,17296,,308.0,1,CHEMBL619954,HeLa,,,H,8,,
3637,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells using [3H]LSD as radioligand,Autocuration,,,B,,BAO_0000219,17296,,308.0,1,CHEMBL619955,HeLa,,,H,8,,
3638,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells using [3H]LSD as radioligand,Autocuration,,,B,,BAO_0000219,17296,,308.0,1,CHEMBL619956,HeLa,,,H,8,,
3639,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,Autocuration,,,B,,BAO_0000219,15779,,449.0,1,CHEMBL619957,CHO,,,H,8,,
3640,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,Autocuration,,,B,,BAO_0000219,15779,,722.0,1,CHEMBL619958,HEK293,,,H,8,,
3641,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand; ND means no data.,Autocuration,,,B,,BAO_0000219,15779,,722.0,1,CHEMBL620627,HEK293,,,H,8,,
3642,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand;ND means no data.,Autocuration,,,B,,BAO_0000219,15779,,722.0,1,CHEMBL620628,HEK293,,,H,8,,
3643,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HeLa cells using [3H]LSD as radioligand;ND means no data.,Autocuration,,,B,,BAO_0000219,15779,,308.0,1,CHEMBL620629,HeLa,,,H,8,,
3644,Binding affinity towards human 5-hydroxytryptamine 6 receptor,Autocuration,,,B,,BAO_0000357,6166,,,1,CHEMBL620630,,,,H,8,,
3645,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 6 receptor expressed in HeLa cells using [3H]LSD as radioligand,Autocuration,,,B,,BAO_0000219,17451,,308.0,1,CHEMBL620782,HeLa,,,H,8,,
3646,Compound was evaluated for its ability to displace [3H]LSD binding from human recombinant 5-hydroxytryptamine 6 receptor,Autocuration,,,B,,BAO_0000357,15316,,,1,CHEMBL620783,,,,H,8,,
3647,Binding affinity against human 5-hydroxytryptamine 6 receptor,Expert,,,B,,BAO_0000357,4199,,,1,CHEMBL620784,,,,H,8,,
3648,Binding affinity against human cloned 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]LSD,Expert,,,B,,BAO_0000219,15146,,308.0,1,CHEMBL620785,HeLa,,,H,8,,
3649,Compound was tested for its binding affinity in 5-hydroxytryptamine 6 receptor (using human cloned receptors in HeLa and [3H]LSD as a radioligand ),Autocuration,,,B,,BAO_0000357,5213,,,1,CHEMBL857992,,,,H,8,,
3650,In vitro binding affinity at human recombinant 5-hydroxytryptamine 6 receptor in mammalian cells using 3[H]LSD as the radioligand,Autocuration,,,B,,BAO_0000219,16429,,,1,CHEMBL620786,,,,H,8,,
3651,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]5-LSD.,Autocuration,,,B,,BAO_0000219,14818,,308.0,1,CHEMBL620787,HeLa,,,H,8,,
3652,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]5-LSD as radioligand; n=3",Autocuration,,,B,,BAO_0000219,4829,,308.0,1,CHEMBL620788,HeLa,,,H,8,,
3653,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]5-LSD as radioligand; n=9",Autocuration,,,B,,BAO_0000219,4829,,308.0,1,CHEMBL620789,HeLa,,,H,8,,
3654,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]LSD as radioligand; n=3",Autocuration,,,B,,BAO_0000219,4829,,308.0,1,CHEMBL620790,HeLa,,,H,8,,
3655,Compound was tested for the displacement of [3H]5-HT binding to cloned rat 5-hydroxytryptamine 6 receptor stably expressed in CHO cells,Autocuration,,,B,,BAO_0000219,15250,,449.0,1,CHEMBL620791,CHO,,,H,8,,
3656,Binding affinity against 5-hydroxytryptamine 6 receptor from CHO cell membranes using [3H]5-HT as the radioligand.,Autocuration,,,B,,BAO_0000019,14423,,,1,CHEMBL620792,,,,H,8,,
3657,The compound was tested for binding affinity against 5-hydroxytryptamine 6 receptor,Autocuration,,,B,,BAO_0000357,15086,,,1,CHEMBL620793,,,,H,8,,
3658,Binding affinity of compound towards serotonin 5-hydroxytryptamine 6 receptor was determined,Autocuration,,,B,,BAO_0000357,4342,,,1,CHEMBL620794,,,,H,8,,
3659,Binding affinity as displacement of [3H]5-HT binding to 5-hydroxytryptamine 6 receptor in HeLa cells,Autocuration,9606.0,,B,,BAO_0000219,16190,,308.0,1,CHEMBL620795,HeLa,,Homo sapiens,D,9,,
3660,Binding affinity towards human 5-hydroxytryptamine 6 receptor,Expert,,,B,,BAO_0000357,4820,,,1,CHEMBL620796,,,,H,8,,
3661,Percentage of displacement at 5-hydroxytryptamine 6 receptor at 10e-8 M,Autocuration,,,B,,BAO_0000357,4639,,,1,CHEMBL620797,,,,H,8,,
3662,Antagonistic activity towards 5-hydroxytryptamine 6 receptor was evaluated in cAMP assay,Expert,9606.0,,F,,BAO_0000019,17066,,,1,CHEMBL620798,,,Homo sapiens,D,9,,
3663,Inhibition of binding towards 5-hydroxytryptamine 6 receptor at 100 nM concentration,Autocuration,,,B,,BAO_0000357,6011,,,1,CHEMBL620799,,,,H,8,,
3664,Binding affinity towards human 5-hydroxytryptamine 6 receptor,Expert,,,B,,BAO_0000357,17066,,,1,CHEMBL620800,,,,H,8,,
3665,Binding affinity of compound towards serotonin 5-hydroxytryptamine 6 receptor; inactive at 10 uM,Autocuration,,,B,,BAO_0000357,17515,,,1,CHEMBL620801,,,,H,8,,
3666,Compound was tested for its binding affinity towards 5-hydroxytryptamine 6 receptor,Autocuration,,,B,,BAO_0000357,5014,,,1,CHEMBL875100,,,,H,8,,
3667,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 6 receptor was determined,Autocuration,,,B,,BAO_0000357,4373,,,1,CHEMBL620802,,,,H,8,,
3668,Antagonistic activity towards 5-hydroxytryptamine 6 receptor,Expert,,,F,,BAO_0000019,17066,,,1,CHEMBL620803,,,,H,8,,
3669,Antagonistic activity towards 5-hydroxytryptamine 6 receptor was evaluated in cAMP assay,Expert,,,F,,BAO_0000019,17066,,,1,CHEMBL620804,,,,H,8,,
3670,Binding affinity for 5-hydroxytryptamine 6 receptor was determined,Autocuration,,,B,,BAO_0000357,4373,,,1,CHEMBL620805,,,,H,8,,
3671,Evaluated for the binding affinity towards 5-hydroxytryptamine 6 receptor,Autocuration,,,B,,BAO_0000357,4687,,,1,CHEMBL620806,,,,H,8,,
3672,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 6 receptor at concentration of 10e-6 M,Autocuration,,,B,,BAO_0000357,16946,,,1,CHEMBL620807,,,,H,8,,
3673,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 6 receptor at concentration of 10e-8 M,Autocuration,,,B,,BAO_0000357,16946,,,1,CHEMBL620808,,,,H,8,,
3674,Binding affinities against 5-hydroxytryptamine 6 receptor,Autocuration,,,B,,BAO_0000357,16633,,,1,CHEMBL620809,,,,H,8,,
3675,Binding affinities towards 5-hydroxytryptamine 6 receptor,Autocuration,,,B,,BAO_0000357,16633,,,1,CHEMBL620810,,,,H,8,,
3676,Binding affinity towards 5-hydroxytryptamine 6 receptor,Expert,9606.0,,B,,BAO_0000357,17066,,,1,CHEMBL620811,,,Homo sapiens,D,9,,
3677,The binding affinity towards 5-hydroxytryptamine 6 receptor; No affinity,Autocuration,,,B,,BAO_0000357,16700,,,1,CHEMBL620812,,,,H,8,,
3678,Affinity against 5-hydroxytryptamine 6 receptor,Autocuration,,,B,,BAO_0000357,3269,,,1,CHEMBL620813,,,,H,8,,
3679,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor by the displacement of [3H]-5-CT],Autocuration,,,B,,BAO_0000357,5486,,,1,CHEMBL620814,,,,H,8,,
3680,Inhibition of human 5-hydroxytryptamine 7 receptor,Expert,9606.0,,B,,BAO_0000357,16146,,,1,CHEMBL620815,,,Homo sapiens,D,9,,
3681,Compound was tested for its binding affinity towards human 5-hydroxytryptamine 7 receptor from HEK293 cells using radioligand [3H]LSD,Autocuration,,,B,,BAO_0000219,5014,,722.0,1,CHEMBL620816,HEK293,,,H,8,,
3682,Compound at 1 uM was tested for the inhibition of radioligand [3H]LSD binding to recombinant human 5-hydroxytryptamine 7 receptor,Autocuration,,,B,,BAO_0000357,15463,,,1,CHEMBL620817,,,,H,8,,
3683,In vitro binding affinity against human 5-hydroxytryptamine 7 receptor at a concentration of 100 (nM),Autocuration,,,B,,BAO_0000357,3805,,,1,CHEMBL620818,,,,H,8,,
3684,Inhibition (at 1 uM) of radioligand [3H]LSD binding to human 5-hydroxytryptamine 7 receptor on HEK293 cells,Expert,,,B,,BAO_0000219,5014,,722.0,1,CHEMBL620819,HEK293,,,H,8,,
3685,Affinity towards human 5-hydroxytryptamine 7 serotonin receptor,Expert,9606.0,,B,,BAO_0000357,6491,,,1,CHEMBL620820,,,Homo sapiens,D,9,,
3686,Binding affinity for 5-hydroxytryptamine 7 receptor human cloned receptors in CHO cells using [3H]5-HT,Autocuration,,,B,,BAO_0000219,16190,,449.0,1,CHEMBL620821,CHO,,,H,8,,
3687,Binding affinity towards human 5-hydroxytryptamine 7 receptor,Expert,9606.0,,B,,BAO_0000357,17066,,,1,CHEMBL620822,,,Homo sapiens,D,9,,
3688,Displacement of [3H]5-HT from human 5-hydroxytryptamine 7 receptor,Expert,9606.0,,B,,BAO_0000357,17066,,,1,CHEMBL620823,,,Homo sapiens,D,9,,
3689,Binding affinity against 5-hydroxytryptamine 7 receptor,Expert,9606.0,,B,,BAO_0000357,3555,,,1,CHEMBL620824,,,Homo sapiens,D,9,,
3690,Binding affinity towards human 5-hydroxytryptamine 7 receptor by the displacement of [3H]-5-HT radioligand from the cloned receptor expressed in CHO cells,Expert,,,B,,BAO_0000219,6588,,449.0,1,CHEMBL620825,CHO,,,H,8,,
3691,Binding affinity towards recombinant human 5-hydroxytryptamine 7 receptor was determined using [3H]LSD as radioligand,Autocuration,,,B,,BAO_0000357,15463,,,1,CHEMBL872930,,,,H,8,,
3692,Binding affinity towards 5-hydroxytryptamine 7 receptor,Autocuration,,,B,,BAO_0000357,6013,,,1,CHEMBL620826,,,,H,8,,
3693,Binding affinity towards human 5-hydroxytryptamine 7 receptor using [3H]5-HT as radioligand,Autocuration,,,B,,BAO_0000357,16209,,,1,CHEMBL620827,,,,H,8,,
3694,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 7 receptor,Autocuration,,,B,,BAO_0000357,3935,,,1,CHEMBL620828,,,,H,8,,
3695,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 7 receptor,Autocuration,,,B,,BAO_0000357,15818,,,1,CHEMBL620829,,,,H,8,,
3696,Binding affinity towards human 5-hydroxytryptamine 7 receptor on HEK293 cells using radioligand [3H]LSD,Expert,,,B,,BAO_0000219,5014,,722.0,1,CHEMBL620830,HEK293,,,H,8,,
3697,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 7 receptor incubated with 1 nM [3H]LSD,Expert,,,B,,BAO_0000019,16441,,,1,CHEMBL620831,,,,H,8,,
3698,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 7 receptor incubated with 1 nM [3H]LSD; ND is No Data.,Expert,,,B,,BAO_0000019,16441,,,1,CHEMBL620832,,,,H,8,,
3699,In vitro binding affinity to human 5-hydroxytryptamine 7 receptor,Expert,9606.0,,B,,BAO_0000357,4234,,,1,CHEMBL621548,,,Homo sapiens,D,9,,
3700,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 7 receptor,Autocuration,,,B,,BAO_0000019,17085,,,1,CHEMBL621549,,,,H,8,,
3701,Inhibitory constant against human 5-hydroxytryptamine 7 receptor using [3H]LSD radioligand,Autocuration,,,B,,BAO_0000357,17200,,,1,CHEMBL621550,,,,H,8,,
3702,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 7 receptor expressed in CHO cells using [3H]-LSD as radioligand; Not determined,Autocuration,,,B,,BAO_0000219,17451,,449.0,1,CHEMBL621551,CHO,,,H,8,,
3703,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 7 receptor; ND means not determined,Autocuration,,,B,,BAO_0000019,17085,,,1,CHEMBL621552,,,,H,8,,
3704,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor,Autocuration,,,B,,BAO_0000357,5104,,,1,CHEMBL857077,,,,H,8,,
3705,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor; Not tested,Autocuration,,,B,,BAO_0000357,5104,,,1,CHEMBL618158,,,,H,8,,
3706,Ability to displace the radioligand [3H]5-carboxyamidotryptamine ([3H]5-CT) from human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells,Expert,9606.0,,B,,BAO_0000219,5033,,643.0,1,CHEMBL618159,COS-7,,Homo sapiens,D,9,,
3707,Ability to displace the radioligand [3H]5-carboximidotryptamine ([3H]-5-CT) from cloned human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells,Autocuration,,,B,,BAO_0000219,5486,,643.0,1,CHEMBL875101,COS-7,,,H,8,,
3708,Binding affinity to human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]-5-CT as radioligand,Expert,9606.0,,B,,BAO_0000219,4540,,722.0,1,CHEMBL618160,HEK293,,Homo sapiens,D,9,,
3709,Binding affinity at human cloned 5-hydroxytryptamine 7 receptor.,Expert,,,B,,BAO_0000357,6166,,,1,CHEMBL618161,,,,H,8,,
3710,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor was determined in HEK293 cells using [3H]5-CT as radioligand,Expert,,,B,,BAO_0000219,17342,,722.0,1,CHEMBL618162,HEK293,,,H,8,,
3711,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor was determined using [3H]5-CT as radioligand,Expert,,,B,,BAO_0000357,17342,,,1,CHEMBL618163,,,,H,8,,
3712,Binding affinity against 5-hydroxytryptamine 7 human receptors,Autocuration,,,B,,BAO_0000357,17296,,,1,CHEMBL618164,,,,H,8,,
3713,Binding affinity to human recombinant 5-hydroxytryptamine 7 receptor in mammalian cells using [3H]5-CT as radioligand,Expert,,,B,,BAO_0000219,16429,,,1,CHEMBL618165,,,,H,8,,
3714,Binding affinity toward 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]-5-CT as radioligand.,Autocuration,,,B,,BAO_0000219,15779,,722.0,1,CHEMBL618166,HEK293,,,H,8,,
3715,Binding affinity towards 5-hydroxytryptamine 7 receptor (a) (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,Autocuration,,,B,,BAO_0000219,15779,,722.0,1,CHEMBL857989,HEK293,,,H,8,,
3716,Binding affinity towards 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,Autocuration,,,B,,BAO_0000219,15779,,722.0,1,CHEMBL619888,HEK293,,,H,8,,
3717,Binding affinity towards 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,Autocuration,,,B,,BAO_0000219,15779,,722.0,1,CHEMBL619889,HEK293,,,H,8,,
3718,Binding affinity towards 5-hydroxytryptamine 7 receptor 7(a) (human cloned receptor in HEK 293 cells using [3H]5-CT as radioligand.,Autocuration,,,B,,BAO_0000219,15779,,722.0,1,CHEMBL619890,HEK293,,,H,8,,
3719,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 7 receptor expressed in CHO cells using [3H]LSD as radioligand,Autocuration,,,B,,BAO_0000219,17451,,449.0,1,CHEMBL619891,CHO,,,H,8,,
3720,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT as the radioligand (n=3),Autocuration,,,B,,BAO_0000219,4199,,722.0,1,CHEMBL619892,HEK293,,,H,8,,
3721,Displacement of [3H]-5-CT from human 5-hydroxytryptamine 7 receptor expressed in HEK-293 cells,Expert,,,B,,BAO_0000219,4199,,722.0,1,CHEMBL619893,HEK293,,,D,9,,
3722,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT as the radioligand(n=6),Autocuration,,,B,,BAO_0000219,4199,,722.0,1,CHEMBL619894,HEK293,,,H,8,,
3723,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor in HEK 293 cells,Intermediate,,,B,,BAO_0000219,3680,,722.0,1,CHEMBL619895,HEK293,,,D,9,,
3724,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor using [3H]5-CT as radioligand,Intermediate,,,B,,BAO_0000357,3680,,,1,CHEMBL619896,,,,D,9,,
3725,Compound was evaluated for its ability to displace [3H]5-CT binding from cloned human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells.,Autocuration,,,B,,BAO_0000219,15316,,643.0,1,CHEMBL619897,COS-7,,,H,8,,
3726,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT,Autocuration,,,B,,BAO_0000219,15146,,722.0,1,CHEMBL619898,HEK293,,,H,8,,
3727,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor in HEK 293 using [3H]5-CT as a radioligand,Expert,,,B,,BAO_0000219,5213,,722.0,1,CHEMBL619899,HEK293,,,H,8,,
3728,Compound was tested for its binding affinity in 5-hydroxytryptamine 7 receptor (using human cloned receptors in HEK 293 and [3H]5-CT as a radioligand ),Autocuration,,,B,,BAO_0000219,5213,,722.0,1,CHEMBL619900,HEK293,,,H,8,,
3729,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor expressed in HEK 293 cells using [3H]5-CT,Expert,9606.0,,B,,BAO_0000219,14818,,722.0,1,CHEMBL619901,HEK293,,Homo sapiens,D,9,,
3730,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 7 receptor expressed in HEK 293 cells using [3H]5-CT. ,Autocuration,,,B,,BAO_0000219,14818,,722.0,1,CHEMBL620580,HEK293,,,H,8,,
3731,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT.,Autocuration,,,B,,BAO_0000219,14818,,722.0,1,CHEMBL620581,HEK293,,,H,8,,
3732,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 7 receptor in HEK293 cells, using [3H]5-CT as radioligand",Autocuration,,,B,,BAO_0000219,4829,,722.0,1,CHEMBL620733,HEK293,,,H,8,,
3733,Inhibitory constant against human 5-hydroxytryptamine 7 receptor using [3H]-LSD radioligand; Not determined,Autocuration,9606.0,,B,,BAO_0000357,17200,,,1,CHEMBL620734,,,Homo sapiens,D,9,,
3734,Binding affinity towards mouse 5-hydroxytryptamine 7 receptor was evaluated using [3H]5-HT as radioligand,Expert,10090.0,,B,,BAO_0000357,17066,,,1,CHEMBL620735,,,Mus musculus,D,9,,
3735,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 7 receptor in the endothelium denuded rabbit jugular vein.,Autocuration,9986.0,,B,,BAO_0000019,14025,,,1,CHEMBL620736,,,Oryctolagus cuniculus,H,8,,
3736,Compound was tested for the displacement of [3H]5-HT binding to cloned rat 5-hydroxytryptamine 7 receptor stably expressed in CHO cells,Autocuration,,,B,,BAO_0000219,15250,,449.0,1,CHEMBL620737,CHO,,,H,8,,
3737,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 10000 nM,Autocuration,,,B,,BAO_0000219,16372,,449.0,1,CHEMBL620738,CHO,,,H,8,,
3738,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 100 nM,Autocuration,,,B,,BAO_0000219,16372,,449.0,1,CHEMBL620739,CHO,,,H,8,,
3739,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 1 nM,Autocuration,,,B,,BAO_0000219,16372,,449.0,1,CHEMBL620740,CHO,,,H,8,,
3740,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 10000 nM 5-HT.,Autocuration,,,B,,BAO_0000219,16372,,449.0,1,CHEMBL620741,CHO,,,H,8,,
3741,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 100 nM 5-HT.,Autocuration,,,B,,BAO_0000219,16372,,449.0,1,CHEMBL620742,CHO,,,H,8,,
3742,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 1 nM 5-HT,Autocuration,,,B,,BAO_0000219,16372,,449.0,1,CHEMBL620743,CHO,,,H,8,,
3743,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 10000 nM,Autocuration,,,B,,BAO_0000219,16372,,449.0,1,CHEMBL620744,CHO,,,H,8,,
3744,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 100 nM,Autocuration,,,B,,BAO_0000219,16372,,449.0,1,CHEMBL620745,CHO,,,H,8,,
3745,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 1 nM,Autocuration,,,B,,BAO_0000219,16372,,449.0,1,CHEMBL620746,CHO,,,H,8,,
3746,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 10000 nM 5-HT.,Autocuration,,,B,,BAO_0000219,16372,,449.0,1,CHEMBL620747,CHO,,,H,8,,
3747,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 100 nM 5-HT.,Autocuration,,,B,,BAO_0000219,16372,,449.0,1,CHEMBL620748,CHO,,,H,8,,
3748,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 1 nM 5-HT.,Autocuration,,,B,,BAO_0000219,16372,,449.0,1,CHEMBL620749,CHO,,,H,8,,
3749,Binding affinity towards rat 5-hydroxytryptamine 7 receptor,Expert,,,B,,BAO_0000357,17066,,,1,CHEMBL620750,,,,H,8,,
3750,Binding affinity towards rat 5-hydroxytryptamine 7 receptor was evaluated using [3H]5-HT as radioligand,Expert,10116.0,,B,,BAO_0000357,17066,,,1,CHEMBL620751,,,Rattus norvegicus,D,9,,
3751,Binding affinity to the rat 5-hydroxytryptamine 7 receptor,Expert,,,B,,BAO_0000357,17386,,,1,CHEMBL620752,,,,H,8,,
3752,Binding affinity against 5-hydroxytryptamine 7 receptor using from CHO cell membranes [3H]5-HT as the radioligand.,Autocuration,,,B,,BAO_0000019,14423,,,1,CHEMBL872929,,,,H,8,,
3753,Binding affinity against Rat 5-hydroxytryptamine 7 receptor using [3H]5-HT,Expert,10116.0,,B,,BAO_0000357,15874,,,1,CHEMBL620753,,,Rattus norvegicus,D,9,,
3754,Displacement of [3H]5-HT from over-expressed rat 5-hydroxytryptamine 7 receptor,Expert,10116.0,,B,,BAO_0000357,15874,,,1,CHEMBL620754,,,Rattus norvegicus,D,9,,
3755,Displacement of [3H]5-HT from rat 5-hydroxytryptamine 7 receptor expressed in CHO cells,Expert,10116.0,,B,,BAO_0000219,16372,,449.0,1,CHEMBL620755,CHO,,Rattus norvegicus,D,9,,
3756,In vitro binding affinity towards cloned rat 5-hydroxytryptamine 7 receptor using [3H]5-HT as radioligand,Autocuration,,,B,,BAO_0000357,4622,,,1,CHEMBL620756,,,,H,8,,
3757,The compound was tested for binding affinity against 5-hydroxytryptamine 7 receptor,Autocuration,,,B,,BAO_0000357,15086,,,1,CHEMBL620757,,,,H,8,,
3758,"Effect of compound on stimulation of cAMP production in CHO cells expressing rat 5-HT7 receptors at 1, 10, 100 1000 and 10000 nM conc; Not tested",Autocuration,,,B,,BAO_0000219,16372,,449.0,1,CHEMBL620758,CHO,,,H,8,,
3759,"Effect of compound on stimulation of cAMP production in CHO cells expressing rat 5-HT7 receptors at 1, 10, 100 1000 and 10000 nM conc; not tested",Autocuration,,,B,,BAO_0000219,16372,,449.0,1,CHEMBL620759,CHO,,,H,8,,
3760,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 1 nM; not tested,Autocuration,,,B,,BAO_0000219,16372,,449.0,1,CHEMBL620760,CHO,,,H,8,,
3761,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 1 nM 5-HT; Not tested,Autocuration,,,B,,BAO_0000219,16372,,449.0,1,CHEMBL620761,CHO,,,H,8,,
3762,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor desensitization,Autocuration,,,F,,BAO_0000221,17386,,,1,CHEMBL620762,,,,H,8,2116.0,
3763,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor nondesensitization,Autocuration,,,F,,BAO_0000221,17386,,,1,CHEMBL620763,,,,H,8,2116.0,
3764,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine receptor desensitization,Autocuration,,,F,,BAO_0000221,17386,,,1,CHEMBL620764,,,,H,8,2116.0,
3765,Inhibition of [3H]-5-CT binding to 5-hydroxytryptamine 7 receptor of rat cortical membranes,Expert,10116.0,,B,,BAO_0000249,5831,Membranes,,1,CHEMBL857990,,,Rattus norvegicus,D,9,,
3766,Binding affinity of compound towards serotonin 5-hydroxytryptamine 7 receptor was determined,Autocuration,,,B,,BAO_0000357,4342,,,1,CHEMBL620765,,,,H,8,,
3767,Binding affinity at rat 5-hydroxytryptamine 7 receptor.,Expert,,,B,,BAO_0000357,17319,,,1,CHEMBL620766,,,,H,8,,
3768,Binding affinity towards 5-hydroxytryptamine receptor 7 on rat hypothalamus membranes using [3H]5-CT as radioligand.,Expert,,,B,,BAO_0000019,17342,,,1,CHEMBL620767,,,,H,8,1898.0,
3769,Binding affinity towards cloned rat 5-hydroxytryptamine 7 receptor was determined using [3H]5-HT as radioligand,Autocuration,,,B,,BAO_0000357,17342,,,1,CHEMBL620768,,,,H,8,,
3770,Binding affinity against 5-hydroxytryptamine 7 receptor using [3H]-5-CT in rat hypothalamus membranes,Expert,,,B,,BAO_0000249,3680,,,1,CHEMBL619051,,,,H,8,1898.0,
3771,Binding affinity towards 5-hydroxytryptamine 7 receptor,Expert,,,B,,BAO_0000357,3680,,,1,CHEMBL619052,,,,H,8,,
3772,Agonistic activity against rat 5-HT7 adenyl cyclase expressed by HEK293 cells,Expert,10116.0,,F,,BAO_0000219,17319,,722.0,1,CHEMBL619053,HEK293,,Rattus norvegicus,D,9,,
3773,Agonistic activity against rat 5-HT7 adenyl cyclase expressed in HEK293 cells; Active,Expert,10116.0,,F,,BAO_0000219,17319,,722.0,1,CHEMBL619703,HEK293,,Rattus norvegicus,D,9,,
3774,Agonistic activity against rat 5-HT7-adenyl cyclase expressed by HEK293 cells; Active,Autocuration,10116.0,,F,,BAO_0000219,17319,,722.0,1,CHEMBL619704,HEK293,,Rattus norvegicus,D,9,,
3775,Binding affinity towards 5-hydroxytryptamine 7 receptor,Expert,,,B,,BAO_0000357,4820,,,1,CHEMBL619851,,,,H,8,,
3776,Percentage of displacement at 5-hydroxytryptamine 7 receptor at 10e-8 M,Autocuration,,,B,,BAO_0000357,4639,,,1,CHEMBL619852,,,,H,8,,
3777,Inhibition of binding towards 5-hydroxytryptamine 7 receptor at 100 nM concentration,Autocuration,,,B,,BAO_0000357,6011,,,1,CHEMBL619853,,,,H,8,,
3778,Binding affinity towards human 5-hydroxytryptamine 7 receptor,Expert,9606.0,,B,,BAO_0000357,17066,,,1,CHEMBL619854,,,Homo sapiens,D,9,,
3779,Binding affinity of compound towards rodent 5-hydroxytryptamine 7 receptor,Expert,,,B,,BAO_0000357,17066,,,1,CHEMBL619855,,,,H,8,,
3780,Binding affinity of compound towards serotonin 5-hydroxytryptamine 7 receptor; inactive at 10 uM,Autocuration,,,B,,BAO_0000357,17515,,,1,CHEMBL619856,,,,H,8,,
3781,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 7 receptor was determined,Autocuration,,,B,,BAO_0000357,4373,,,1,CHEMBL619857,,,,H,8,,
3782,Antagonistic activity towards 5-hydroxytryptamine 7 receptor was evaluated by cAMP assay,Expert,,,F,,BAO_0000019,17066,,,1,CHEMBL619858,,,,H,8,,
3783,Binding affinity for 5-hydroxytryptamine 7 receptor was determined,Autocuration,,,B,,BAO_0000357,4373,,,1,CHEMBL619859,,,,H,8,,
3784,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 7 receptor was determined,Autocuration,,,B,,BAO_0000357,4373,,,1,CHEMBL619860,,,,H,8,,
3785,Evaluated for the binding affinity to 5-hydroxytryptamine 7 receptor,Autocuration,,,B,,BAO_0000357,4687,,,1,CHEMBL619861,,,,H,8,,
3786,Non-selective inhibitory activity was determined against 5-hydroxytryptamine 7 receptor,Expert,,,B,,BAO_0000357,17342,,,1,CHEMBL619862,,,,H,8,,
3787,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 7 receptor at concentration of 10e-6 M,Autocuration,,,B,,BAO_0000357,16946,,,1,CHEMBL619863,,,,H,8,,
3788,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 7 receptor at concentration of 10e-8 M,Autocuration,,,B,,BAO_0000357,16946,,,1,CHEMBL619864,,,,H,8,,
3789,Binding affinities against 5-hydroxytryptamine 7 receptor,Autocuration,,,B,,BAO_0000357,16633,,,1,CHEMBL872928,,,,H,8,,
3790,Binding affinities towards 5-hydroxytryptamine 7 receptor,Autocuration,,,B,,BAO_0000357,16633,,,1,CHEMBL619865,,,,H,8,,
3791,Binding affinity towards rodent 5-hydroxytryptamine 7 receptor,Expert,,,B,,BAO_0000357,17066,,,1,CHEMBL619866,,,,H,8,,
3792,The binding affinity towards 5-hydroxytryptamine 7 receptor; No affinity,Autocuration,,,B,,BAO_0000357,16700,,,1,CHEMBL619867,,,,H,8,,
3793,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor desensitization,Autocuration,,,B,,BAO_0000221,17386,,,1,CHEMBL619868,,,,H,8,2116.0,
3794,Compound was evaluated for the potency to inhibit oxidation of arachidonic acid by human recombinant 5-Lipoxygenase using a spectrophotometric assay,Autocuration,,,F,,BAO_0000019,14080,,,1,CHEMBL619869,,,,H,8,,
3795,Inhibition of oxidation of arachidonic acid by human 5-Lipoxygenase using spectrophotometric assay,Expert,9606.0,,F,,BAO_0000019,14080,,,1,CHEMBL619870,,,Homo sapiens,D,9,,
3796,In vitro inhibition of human recombinant 5-lipoxygenase enzyme,Autocuration,,,B,,BAO_0000357,409,,,1,CHEMBL619871,,,,H,8,,
3797,In vitro inhibition of human recombinant lipoxygenase enzyme,Autocuration,,,B,,BAO_0000357,409,,,1,CHEMBL619872,,,,H,8,,
3798,In vitro inhibition of human recombinant lipoxygenase enzyme; No inhibition,Autocuration,,,B,,BAO_0000357,409,,,1,CHEMBL619873,,,,H,8,,
3799,Inhibition of 5-lipoxygenase in human whole blood.,Expert,,,B,,BAO_0000357,11090,,,1,CHEMBL619874,,,,H,8,178.0,
3800,Inhibition of 5-lipoxygenase in human whole blood.,Expert,,,B,,BAO_0000357,11090,,,1,CHEMBL619875,,,,H,8,178.0,
3801,Compound was tested for the inhibition of 5-lipoxygenase of human PMN stimulated by calcium ionophore A-23187 for the formation of 5-HETE,Autocuration,,,B,,BAO_0000357,948,,,1,CHEMBL619876,,,,H,8,,
3802,Compound was tested for the inhibition of 5-lipoxygenase of human PMN stimulated by calcium ionophore A-23187 for the formation of leukotriene B4 (LTB4),Autocuration,,,B,,BAO_0000357,948,,,1,CHEMBL619877,,,,H,8,,
3803,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in human polymorphonuclear leukocytes.,Expert,,,F,,BAO_0000219,13622,,,1,CHEMBL619878,,,,H,8,,
3804,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in human whole blood,Autocuration,,,F,,BAO_0000019,13622,,,1,CHEMBL619879,,,,H,8,178.0,
3805,In vitro inhibition of 5-lipoxygenase from human polymorphs,Autocuration,,,B,,BAO_0000357,9637,,,1,CHEMBL619880,,,,H,8,,
3806,In vitro inhibition of leukotriene B4 synthesis in human whole blood by inhibiting 5-LPO (5-lipoxygenase),Autocuration,,,B,,BAO_0000357,11320,,,1,CHEMBL619881,,,,H,8,,
3807,In vitro inhibition of leukotriene B4 synthesis in human whole blood by inhibiting 5-lipoxygenase,Expert,,,B,,BAO_0000357,11320,,,1,CHEMBL619882,,,,H,8,,
3808,In vitro inhibitory activity against 5-lipoxygenase in a human whole blood assay,Autocuration,,,B,,BAO_0000357,6838,,,1,CHEMBL619883,,,,H,8,,
3809,Inhibition of 5-Lipoxygenase (5-LO) of human whole blood (HWB),Expert,9606.0,,B,,BAO_0000357,17667,,,1,CHEMBL619884,,,Homo sapiens,D,9,178.0,
3810,In vitro potency against human 5-Lipoxygenase,Autocuration,,,B,,BAO_0000357,12703,,,1,CHEMBL619885,,,,H,8,,
3811,Inhibitory activity against 5-lipoxygenase in Human whole blood (HWBL) stimulated with calcium ionophore (A23187) and LTB4 measured by enzyme immunoassay,Expert,9606.0,,F,,BAO_0000019,14312,,,1,CHEMBL619886,,,Homo sapiens,D,9,,
3812,Inhibition activity against 5-lipoxygenase in Human whole blood (HWBL) stimulated with calcium ionophore (A23187) and LTB4 measured by enzyme immunoassay; No data,Autocuration,,,F,,BAO_0000019,14312,,,1,CHEMBL619887,,,,H,8,178.0,
3813,Inhibition of 5-lipoxygenase activity of compound evaluated as determined by the inhibition of calcium ionophore-induced leukotriene B4 production in human blood.,Autocuration,,,F,,BAO_0000019,5364,,,1,CHEMBL875097,,,,H,8,,
3814,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE,Autocuration,,,B,,BAO_0000219,951,,,1,CHEMBL618001,,,,H,8,,
3815,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE; NA means Not active,Autocuration,,,B,,BAO_0000219,951,,,1,CHEMBL618002,,,,H,8,,
3816,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4,Autocuration,,,B,,BAO_0000219,951,,,1,CHEMBL618003,,,,H,8,,
3817,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4; NA means Not active,Autocuration,,,B,,BAO_0000219,951,,,1,CHEMBL618004,,,,H,8,,
3818,Inhibition of human 5-lipoxygenase in human cells,Autocuration,,,B,,BAO_0000219,12365,,,1,CHEMBL618005,,,,H,8,,
3819,Inhibition of human neutrophil 5-lipoxygenase,Expert,,,B,,BAO_0000357,10603,,,1,CHEMBL618006,,,,H,8,,
3820,Inhibitory activity against 5-lipoxygenase expressed from human polymorphonuclear cells,Autocuration,,,B,,BAO_0000019,10501,,,1,CHEMBL875086,,,,H,8,,
3821,Inhibition of 5-lipoxygenase from human whole blood,Expert,,,B,,BAO_0000357,12281,,,1,CHEMBL618007,,,,H,8,178.0,
3822,Inhibitory concentration required against 5-lipoxygenase activity in cytosolic fractions of human neutrophils,Autocuration,,,B,,BAO_0000357,2567,,,1,CHEMBL618008,,,,H,8,,
3823,Inhibitory concentration required against 5-lipoxygenase activity in intact cells of human neutrophils,Autocuration,,,B,,BAO_0000219,2567,,,1,CHEMBL618009,,,,H,8,,
3824,In vitro inhibition of polymorphonuclear leukocyte derived human 5-lipoxygenase,Expert,,,B,,BAO_0000357,10193,,,1,CHEMBL618010,,,,H,8,,
3825,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,Autocuration,,,B,,BAO_0000357,10193,,,1,CHEMBL618011,,,,H,8,,
3826,Potency to inhibit oxidation of arachidonic acid by recombinant human 5-lipoxygenase,Expert,,,B,,BAO_0000357,13623,,,1,CHEMBL618012,,,,H,8,,
3827,Tested against 5-lipoxygenase,Autocuration,,,B,,BAO_0000357,12780,,,1,CHEMBL882927,,,,H,8,,
3828,Tested for activity against 5-Lipoxygenase (5-LO),Autocuration,,,B,,BAO_0000357,12780,,,1,CHEMBL618013,,,,H,8,,
3829,Tested for activity against 5-lipoxygenase,Autocuration,,,B,,BAO_0000357,12780,,,1,CHEMBL618014,,,,H,8,,
3830,Tested for inhibition of 5-HPETE production by human 5-LO,Autocuration,,,B,,BAO_0000357,11966,,,1,CHEMBL618015,,,,H,8,,
3831,The 5-lipoxygenase activity by the inhibition of calcium ionophore-induced leukotriene B4 production in human blood.,Autocuration,,,F,,BAO_0000019,5364,,,1,CHEMBL618016,,,,H,8,,
3832,Inhibition of Human 5-lipoxygenase,Expert,,,B,,BAO_0000357,13165,,,1,CHEMBL618017,,,,H,8,,
3833,The compound was evaluated for its inhibitory activity against 5-lipoxygenase using granulocytes-type cells,Autocuration,,,B,,BAO_0000019,5364,,,1,CHEMBL618018,,,,H,8,,
3834,The compound was tested for inhibitory activity against 5-lipoxygenase in human polymorphonuclear leukocytes[PMNS],Autocuration,,,B,,BAO_0000219,11311,,,1,CHEMBL875087,,,,H,8,,
3835,The compound was tested for inhibitory activity against LT synthesis in human polymorphonuclear leukocytes[PMNS],Autocuration,,,B,,BAO_0000219,11311,,,1,CHEMBL618019,,,,H,8,,
3836,The compound was tested for the concentration (in uM) to inhibit 50% of 5-Lipoxygenase (5-LOX) and is expressed in IC50.,Autocuration,,,B,,BAO_0000019,14863,,,1,CHEMBL618020,,,,H,8,,
3837,The compound was tested for the concentration (in uM) to inhibit 50% of 5-Lipoxygenase (5-LOX) and is expressed in IC50; Not tested,Autocuration,,,B,,BAO_0000019,14863,,,1,CHEMBL618021,,,,H,8,,
3838,The compound was tested for the inhibition of 5-lipoxygenase (5-lo) in human whole blood (HWBL),Autocuration,,,B,,BAO_0000357,11087,,,1,CHEMBL618022,,,,H,8,178.0,
3839,The compound was tested in vitro for inhibition against 5-lipoxygenase in intact human neutrophils,Autocuration,,,B,,BAO_0000357,455,,,1,CHEMBL618023,,,,H,8,,
3840,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),Autocuration,,,B,,BAO_0000357,13183,,,1,CHEMBL618024,,,,H,8,,
3841,In vitro inhibitory activity against 5-lipoxygenase in human polymorphonuclear (PMN) cells,Expert,,,B,,BAO_0000019,10319,,,1,CHEMBL873950,,,,H,8,,
3842,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,Autocuration,,,B,,BAO_0000357,10193,,,1,CHEMBL618025,,,,H,8,,
3843,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE at 10 uM,Autocuration,,,B,,BAO_0000219,951,,,1,CHEMBL618026,,,,H,8,,
3844,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE at 10 uM; NA means Inactive,Autocuration,,,B,,BAO_0000219,951,,,1,CHEMBL618027,,,,H,8,,
3845,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4 at 10 uM,Autocuration,,,B,,BAO_0000219,951,,,1,CHEMBL618028,,,,H,8,,
3846,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4 at 10 uM; NA means Inactive,Autocuration,,,B,,BAO_0000219,951,,,1,CHEMBL618029,,,,H,8,,
3847,Inhibitory activity against 5-lipoxygenase at 10 uM concentration,Expert,,,B,,BAO_0000357,9859,,,1,CHEMBL618030,,,,H,8,,
3848,Inhibitory activity against 5-lipoxygenase at 1 uM concentration,Expert,,,B,,BAO_0000357,9859,,,1,CHEMBL618031,,,,H,8,,
3849,Inhibitory activity against lipoxygenase (LO) at 10 uM concentration,Autocuration,,,B,,BAO_0000357,9859,,,1,CHEMBL618032,,,,H,8,,
3850,Inhibitory concentration required against 5-lipoxygenase activity in cytosolic fractions of human neutrophils,Autocuration,,,B,,BAO_0000357,2567,,,1,CHEMBL618033,,,,H,8,,
3851,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 1 uM,Autocuration,,,B,,BAO_0000357,10193,,,1,CHEMBL618034,,,,H,8,,
3852,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,Autocuration,,,B,,BAO_0000357,10193,,,1,CHEMBL875088,,,,H,8,,
3853,Tested for the inhibition of 5-lipoxygenase from human polymorphonuclear leukocytes(PMN) at 10 uM concentration of the compound; IA= Inactive,Autocuration,,,B,,BAO_0000019,949,,,1,CHEMBL618035,,,,H,8,,
3854,Tested for the inhibition of 5-lipoxygenase from human polymorphonuclear leukocytes(PMN) at 10 uM concentration of the compound; value ranges from 70-90,Autocuration,,,B,,BAO_0000019,949,,,1,CHEMBL618036,,,,H,8,,
3855,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 0.1 uM,Expert,,,B,,BAO_0000357,10603,,,1,CHEMBL618037,,,,H,8,,
3856,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 1 uM,Expert,,,B,,BAO_0000357,10603,,,1,CHEMBL618038,,,,H,8,,
3857,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 1 uM,Autocuration,,,F,,BAO_0000019,10603,,,1,CHEMBL618761,,,,H,8,,
3858,Inhibition of lipoxygenase at the concentration of 0.1 uM,Expert,,,B,,BAO_0000357,10603,,,1,CHEMBL618762,,,,H,8,,
3859,Inhibition of lipoxygenase at the concentration of 1 uM,Expert,,,B,,BAO_0000357,10603,,,1,CHEMBL618763,,,,H,8,,
3860,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell,Autocuration,,,B,,BAO_0000357,10193,,,1,CHEMBL618764,,,,H,8,,
3861,Inhibition of 5-Lipoxygenase (5-LOX),Expert,9606.0,,B,,BAO_0000357,14580,,,1,CHEMBL618765,,,Homo sapiens,D,9,,
3862,Inhibition of 5-lipoxygenase in mouse macrophages.,Expert,,,B,,BAO_0000357,11090,,,1,CHEMBL618766,,,,H,8,,
3863,Inhibition of 5-lipoxygenase in mouse macrophages.,Expert,,,B,,BAO_0000357,11090,,,1,CHEMBL618767,,,,H,8,,
3864,Inhibitory activity against lipoxygenase-2 in mice,Autocuration,,,B,,BAO_0000357,6339,,,1,CHEMBL619380,,,,H,8,,
3865,Inhibitory activity against murine lipoxygenase-2.,Expert,,,B,,BAO_0000357,6339,,,1,CHEMBL619381,,,,H,8,,
3866,Inhibition of 5-lipoxygenase from mouse macrophage,Expert,10090.0,,B,,BAO_0000357,12281,,,1,CHEMBL619382,,,Mus musculus,D,9,,
3867,The compound was tested for inhibitory activity against 5-lipoxygenase in mouse macrophages,Autocuration,,,B,,BAO_0000357,11311,,,1,CHEMBL619383,,,,H,8,,
3868,The compound was tested for the inhibition of Arachidonate 5-lipoxygenase purified from porcine leukocytes.,Autocuration,9823.0,,B,,BAO_0000019,11089,,,1,CHEMBL619384,,,Sus scrofa,H,8,,
3869,Inhibition of 5-lipoxygenase reaction catalyzed by purified enzyme from porcine leukocytes,Autocuration,9823.0,,B,,BAO_0000019,10091,,,1,CHEMBL619385,,,Sus scrofa,H,8,,
3870,Inhibitory concentration against 5-lipoxygenase from isolated rabbit granulocytes,Autocuration,9986.0,,B,,BAO_0000019,14352,,,1,CHEMBL882928,,,Oryctolagus cuniculus,H,8,,
3871,5-lipoxygenase Inhibitory activity against rat polymorphonuclear leucocytes using 5-HETE,Expert,10116.0,,B,,BAO_0000019,13329,,,1,CHEMBL619386,,,Rattus norvegicus,D,9,,
3872,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE. ",Autocuration,,,B,,BAO_0000019,13329,,,1,CHEMBL619387,,,,H,8,,
3873,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE.",Autocuration,,,B,,BAO_0000019,13329,,,1,CHEMBL619388,,,,H,8,,
3874,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using LTB4.",Autocuration,,,B,,BAO_0000019,13329,,,1,CHEMBL619389,,,,H,8,,
3875,Inhibition of 5-lipoxygenase pathway in rat polymorphonuclear assay (inhibition of 5-HETE formation),Expert,,,B,,BAO_0000019,13329,,,1,CHEMBL619390,,,,H,8,,
3876,"Inhibition of 5-lipoxygenase pathway in rat polymorphonuclear assay, by ability to inhibit formation of LTB4 AT 10 uM",Expert,,,B,,BAO_0000019,13329,,,1,CHEMBL619391,,,,H,8,,
3877,Inhibition of 5-lipoxygenase pathway was evaluated in rat polymorphonuclear assay by compound (50 uM) ability to inhibit formation of 5-HETE,Autocuration,,,B,,BAO_0000019,13329,,,1,CHEMBL619392,,,,H,8,,
3878,The effective dose for inhibition of 5-lipoxygenase in rat blood leukocyte (ex vivo),Autocuration,,,B,,BAO_0000019,11311,,,1,CHEMBL619393,,,,H,8,,
3879,The effective dose for inhibition of 5-lipoxygenase in rat passive Arthus model after oral administration,Autocuration,,,B,,BAO_0000019,11311,,,1,CHEMBL619394,,,,H,8,,
3880,"In vitro inhibition of 5-lipoxygenase HETE (5-hydroperoxyeicosatetraenoic acid) in RBL-1 macrophage, a cell-free enzyme assay",Autocuration,,,B,,BAO_0000219,105,,702.0,1,CHEMBL619395,RBL-1,,,H,8,,
3881,"In vitro inhibition of 5-lipoxygenase HETE (5-hydroperoxyeicosatetraenoic acid) in RBL-1 macrophage, a cell-free enzyme assay",Autocuration,,,B,,BAO_0000219,105,,702.0,1,CHEMBL619396,RBL-1,,,H,8,,
3882,Inhibition of rat neutrophil 5- Lipoxygenase (5-LO),Autocuration,,,B,,BAO_0000357,9138,,,1,CHEMBL619397,,,,H,8,,
3883,"Inhibition of rat neutrophil 5- Lipoxygenase (5-LO),",Autocuration,,,B,,BAO_0000357,9138,,,1,CHEMBL619398,,,,H,8,,
3884,"Inhibition of rat neutrophil 5- Lipoxygenase (5-LO), (at a concentration of 0.2 nM ),",Autocuration,,,B,,BAO_0000357,9138,,,1,CHEMBL619399,,,,H,8,,
3885,5-LO inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography; Not determined,Autocuration,,,B,,BAO_0000357,14427,,,1,CHEMBL619400,,,,H,8,,
3886,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE.",Autocuration,,,B,,BAO_0000019,13329,,,1,CHEMBL619401,,,,H,8,,
3887,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using LTB4. ",Autocuration,,,B,,BAO_0000019,13329,,,1,CHEMBL619402,,,,H,8,,
3888,Inhibition of 5-lipoxygenase mediated conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cells,Expert,10116.0,,B,,BAO_0000219,14427,,663.0,1,CHEMBL619403,RBL-2H3,,Rattus norvegicus,D,9,,
3889,5-lipoxygenase inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography; Not determined,Autocuration,,,B,,BAO_0000357,14427,,,1,CHEMBL619404,,,,H,8,,
3890,5-lipoxygenase inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography.,Autocuration,,,B,,BAO_0000357,14427,,,1,CHEMBL619405,,,,H,8,,
3891,Ability to inhibit 5-lipoxygenase by using a crude preparation of the cytosolic enzyme from the rat basophilic leukemia (RBL-1) cell line,Expert,,,B,,BAO_0000219,10293,,702.0,1,CHEMBL619406,RBL-1,,,H,8,,
3892,Inhibition of 5-Lipoxygenase of rat basophilic leukemia cells,Expert,10116.0,,B,,BAO_0000219,338,,702.0,1,CHEMBL619407,RBL-1,,Rattus norvegicus,D,9,,
3893,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase),Autocuration,,,B,,BAO_0000357,303,,,1,CHEMBL619408,,,,H,8,,
3894,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) in intact RBL-1 cell line assay,Autocuration,,,B,,BAO_0000219,303,,702.0,1,CHEMBL619409,RBL-1,,,H,8,,
3895,Inhibition of rat basophilic leukemia-1 (RBL-1) 5-lipoxygenase,Expert,,,B,,BAO_0000219,9247,,702.0,1,CHEMBL619410,RBL-1,,,H,8,,
3896,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM; NS = no significant activity,Autocuration,,,B,,BAO_0000219,9247,,702.0,1,CHEMBL619753,RBL-1,,,H,8,,
3897,Compound was evaluated in an intact RBL-1 cell line for inhibition of 5-lipoxygenase,Autocuration,,,B,,BAO_0000219,137,,702.0,1,CHEMBL619754,RBL-1,,,H,8,,
3898,Evaluated in vitro for its inhibitory activity against 5-lipoxygenase,Expert,,,B,,BAO_0000357,11481,,,1,CHEMBL619903,,,,H,8,,
3899,"Evaluated in vitro for its inhibitory activity against 5-lipoxygenase; N=Inactive, <50% inhibition at 10 uM concentration",Expert,,,B,,BAO_0000357,11481,,,1,CHEMBL619904,,,,H,8,,
3900,Inhibition of rat polymorphonuclear leukocyte (PMN) 5-Lipoxygenase in vitro,Expert,,,B,,BAO_0000357,9029,,,1,CHEMBL619905,,,,H,8,,
3901,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells,Autocuration,,,B,,BAO_0000019,1701,,,1,CHEMBL619906,,,,H,8,,
3902,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells at concentration of 32 uM; Not active,Autocuration,,,B,,BAO_0000019,1701,,,1,CHEMBL619907,,,,H,8,,
3903,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells at concentration of 50 uM; Not active,Autocuration,,,B,,BAO_0000019,1701,,,1,CHEMBL619908,,,,H,8,,
3904,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells; No data,Autocuration,,,B,,BAO_0000019,1701,,,1,CHEMBL619909,,,,H,8,,
3905,Inhibition of 5-lipoxygenase by measuring 5-HETE levels in RBL-1 cell-free supernatant,Expert,,,F,,BAO_0000219,13358,,702.0,1,CHEMBL619910,RBL-1,,,H,8,,
3906,Inhibitory activity against 5-lipoxygenase enzyme from RBL-1 cells,Expert,,,B,,BAO_0000219,1175,,702.0,1,CHEMBL882929,RBL-1,,,H,8,,
3907,Ability to inhibit 5-lipoxygenase in rat basophilic leukemia cells.,Expert,,,B,,BAO_0000219,8797,,702.0,1,CHEMBL619911,RBL-1,,,H,8,,
3908,Compound was tested for its ability to inhibit 5-lipoxygenase in rat basophilic leukemia cells; No data,Autocuration,,,B,,BAO_0000019,8797,,,1,CHEMBL619912,,,,H,8,,
3909,Inhibition of rat basophilic leukemia cell 5-lipoxygenase,Expert,10116.0,,B,,BAO_0000357,577,,,1,CHEMBL619913,,,Rattus norvegicus,D,9,,
3910,In vitro inhibitory activity against RBL-1 5-LO,Expert,,,B,,BAO_0000219,9295,,702.0,1,CHEMBL619914,RBL-1,,,H,8,,
3911,Compound was tested for its in vitro inhibitory activity against RBL-1 5-LO (insoluble above 45 uM),Autocuration,,,B,,BAO_0000219,9295,,702.0,1,CHEMBL619915,RBL-1,,,H,8,,
3912,Compound was tested for its in vitro inhibitory activity against RBL-1 5-LO (time dependent),Autocuration,,,B,,BAO_0000219,9295,,702.0,1,CHEMBL619916,RBL-1,,,H,8,,
3913,Compound was tested for its inhibition activity against 5-LO of the whole cell in vitro in rat.,Autocuration,,,B,,BAO_0000218,9295,,,1,CHEMBL619917,,,,H,8,,
3914,Compound was tested for its inhibition activity against the 5-LO in isolated enzyme,Autocuration,,,B,,BAO_0000357,9295,,,1,CHEMBL619918,,,,H,8,,
3915,Compound was tested for its inhibitory activity against 5-lipoxygenase in rat.,Autocuration,,,B,,BAO_0000218,216,,,1,CHEMBL619919,,,,H,8,,
3916,Compound was tested for the inhibition of 5-lipoxygenase (5-LPO) in rat basophilic leukemia (RBL) cells.,Autocuration,,,B,,BAO_0000219,11090,,702.0,1,CHEMBL883710,RBL-1,,,H,8,,
3917,Compound was tested for the inhibition of 5-lipoxygenase (5-Lpo) in rat whole blood.,Autocuration,,,B,,BAO_0000019,11090,,,1,CHEMBL619920,,,,H,8,178.0,
3918,Concentration required for 50 % inhibition of arachidonic acid oxidation by rat 5-lipoxygenase,Expert,,,B,,BAO_0000357,10091,,,1,CHEMBL619921,,,,H,8,,
3919,Concentration that produces 50% inhibition of A-23187-stimulated radiolabeled 5-HETE and TXB2 synthesis by PMN 5-lipoxygenase.,Autocuration,,,F,,BAO_0000019,10274,,,1,CHEMBL619922,,,,H,8,,
3920,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in rat polymorphonuclear leukocytes,Autocuration,,,F,,BAO_0000219,13622,,,1,CHEMBL619923,,,,H,8,,
3921,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined,Expert,,,B,,BAO_0000219,12118,,702.0,1,CHEMBL619924,RBL-1,,,H,8,,
3922,In vitro inhibition of 5-lipoxygenase (5-HETE) derived from the 9000xg supernatant of RBL broken cell assay,Expert,,,B,,BAO_0000357,12576,,,1,CHEMBL619925,,,,H,8,,
3923,In vitro inhibition of 5-lipoxygenase from RBL-1 cells,Expert,,,B,,BAO_0000219,9546,,702.0,1,CHEMBL619926,RBL-1,,,H,8,,
3924,In vitro inhibition of 5-lipoxygenase in RBL-1 cells,Autocuration,,,B,,BAO_0000219,9521,,702.0,1,CHEMBL619927,RBL-1,,,H,8,,
3925,In vitro inhibition of 5-lipoxygenase pathway in rat basophilic leukemia (RBL-1) cells,Expert,,,B,,BAO_0000219,10626,,702.0,1,CHEMBL619928,RBL-1,,,H,8,,
3926,In vitro inhibition of RBL-1 5-lipoxygenase,Autocuration,,,B,,BAO_0000219,9225,,702.0,1,CHEMBL619929,RBL-1,,,H,8,,
3927,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.18-0.31,Autocuration,,,B,,BAO_0000219,9225,,702.0,1,CHEMBL875089,RBL-1,,,H,8,,
3928,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.3-1.6,Autocuration,,,B,,BAO_0000219,9225,,702.0,1,CHEMBL619930,RBL-1,,,H,8,,
3929,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.4-2.2,Autocuration,,,B,,BAO_0000219,9225,,702.0,1,CHEMBL619931,RBL-1,,,H,8,,
3930,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.72-1.07,Autocuration,,,B,,BAO_0000219,9225,,702.0,1,CHEMBL619932,RBL-1,,,H,8,,
3931,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.9-4.0,Autocuration,,,B,,BAO_0000219,9225,,702.0,1,CHEMBL619933,RBL-1,,,H,8,,
3932,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-1.5,Autocuration,,,B,,BAO_0000219,9225,,702.0,1,CHEMBL619934,RBL-1,,,H,8,,
3933,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-1.7,Autocuration,,,B,,BAO_0000219,9225,,702.0,1,CHEMBL619935,RBL-1,,,H,8,,
3934,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-2.4,Autocuration,,,B,,BAO_0000219,9225,,702.0,1,CHEMBL619936,RBL-1,,,H,8,,
3935,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.07-5.54,Autocuration,,,B,,BAO_0000219,9225,,702.0,1,CHEMBL619937,RBL-1,,,H,8,,
3936,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.1-1.6,Autocuration,,,B,,BAO_0000219,9225,,702.0,1,CHEMBL619938,RBL-1,,,H,8,,
3937,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.3-2.8,Autocuration,,,B,,BAO_0000219,9225,,702.0,1,CHEMBL619939,RBL-1,,,H,8,,
3938,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.4-3.2,Autocuration,,,B,,BAO_0000219,9225,,702.0,1,CHEMBL619940,RBL-1,,,H,8,,
3939,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.7-2.6,Autocuration,,,B,,BAO_0000219,9225,,702.0,1,CHEMBL875090,RBL-1,,,H,8,,
3940,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.8-2.8,Autocuration,,,B,,BAO_0000219,9225,,702.0,1,CHEMBL619941,RBL-1,,,H,8,,
3941,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.8-5.7,Autocuration,,,B,,BAO_0000219,9225,,702.0,1,CHEMBL619942,RBL-1,,,H,8,,
3942,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.9-2.4,Autocuration,,,B,,BAO_0000219,9225,,702.0,1,CHEMBL883711,RBL-1,,,H,8,,
3943,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 2.3-.8,Autocuration,,,B,,BAO_0000219,9225,,702.0,1,CHEMBL619943,RBL-1,,,H,8,,
3944,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 2.46-2.63,Autocuration,,,B,,BAO_0000219,9225,,702.0,1,CHEMBL619944,RBL-1,,,H,8,,
3945,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 3.3-3.5,Autocuration,,,B,,BAO_0000219,9225,,702.0,1,CHEMBL619945,RBL-1,,,H,8,,
3946,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 3.8-7.1,Autocuration,,,B,,BAO_0000219,9225,,702.0,1,CHEMBL619946,RBL-1,,,H,8,,
3947,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 4.0-6.4,Autocuration,,,B,,BAO_0000219,9225,,702.0,1,CHEMBL619947,RBL-1,,,H,8,,
3948,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 4.9-11.6,Autocuration,,,B,,BAO_0000219,9225,,702.0,1,CHEMBL619948,RBL-1,,,H,8,,
3949,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 7.5-11.8,Autocuration,,,B,,BAO_0000219,9225,,702.0,1,CHEMBL619949,RBL-1,,,H,8,,
3950,In vitro inhibitory activity against 5-lipoxygenase from rat basophilic leukemia cells.,Expert,,,B,,BAO_0000019,9401,,,1,CHEMBL619950,,,,H,8,,
3951,In vitro inhibitory activity against 5-Lipoxygenase in rat by Peritoneal 5-lipoxygenase assay,Autocuration,,,B,,BAO_0000019,10325,,,1,CHEMBL618050,,,,H,8,,
3952,In vitro inhibition of 5-lipoxygenase in RBL-2H3 (Rat basophilic leukemia) cells.,Expert,,,F,,BAO_0000219,1556,,663.0,1,CHEMBL875091,RBL-2H3,,,H,8,,
3953,In vitro inhibition of 5-lipoxygenase in RBL-2H3 (Rat basophilic leukemia) cells; Not tested,Expert,,,F,,BAO_0000219,1556,,663.0,1,CHEMBL618051,RBL-2H3,,,H,8,,
3954,Inhibition of 5-lipoxygenase from rat basophilic leukemia(RBL-1) cells,Expert,10116.0,,B,,BAO_0000219,961,,702.0,1,CHEMBL618052,RBL-1,,Rattus norvegicus,D,9,,
3955,In vitro inhibitory activity against 5-lipoxygenase in an RBL-2H3 cell lysate,Autocuration,,,B,,BAO_0000019,6838,,,1,CHEMBL618053,,,,H,8,,
3956,In vitro inhibition of 5-lipoxygenase in rat (peritoneal assay),Expert,,,B,,BAO_0000019,10325,,,1,CHEMBL618054,,,,H,8,,
3957,In vitro inhibitory activity against 5-lipoxygenase in rat RBL-1 cells,Expert,10116.0,,B,,BAO_0000219,9209,,702.0,1,CHEMBL618055,RBL-1,,Rattus norvegicus,D,9,,
3958,inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cell line.,Expert,,,B,,BAO_0000219,11520,,702.0,1,CHEMBL618056,RBL-1,,,H,8,,
3959,In vitro inhibitory activity against 5-lipoxygenase was determined,Autocuration,,,B,,BAO_0000357,137,,,1,CHEMBL618057,,,,H,8,,
3960,In vitro inhibitory concentration against 5-lipoxygenase in RBL-1 cells,Autocuration,,,B,,BAO_0000219,4717,,702.0,1,CHEMBL618058,RBL-1,,,H,8,,
3961,Inhibition of 5-lipoxygenase in intact RBL-1 cell line,Expert,,,B,,BAO_0000219,10636,,702.0,1,CHEMBL618059,RBL-1,,,H,8,,
3962,Inhibitory activity against 5-lipoxygenase catalysis (5-LO) in sonicated rat basophilic leukemia cell lysate,Expert,10116.0,,F,,BAO_0000019,14312,,,1,CHEMBL618060,,,Rattus norvegicus,D,9,,
3963,Inhibition of 5-Lipoxygenase (5-LO) in rat basophilic leukemia cells,Autocuration,,,B,,BAO_0000219,1203,,702.0,1,CHEMBL618061,RBL-1,,,H,8,,
3964,Inhibition of 5-Lipoxygenase (5-LO) in rat basophilic leukemic cells,Autocuration,,,B,,BAO_0000019,1203,,,1,CHEMBL618062,,,,H,8,,
3965,Inhibition of 5-lipoxygenase catalysis in rat basophilic leukemia (RBL) cells by measuring 5-HETE product formation,Expert,,,B,,BAO_0000219,13622,,702.0,1,CHEMBL618063,RBL-1,,,H,8,,
3966,Inhibition of 5-lipoxygenase from rat peritoneal neutrophils after oral administration,Autocuration,,,B,,BAO_0000357,9793,,,1,CHEMBL618064,,,,H,8,,
3967,Inhibition of 5-lipoxygenase of rat basophilic leukemia (RBL) cell cytosolic enzymes,Expert,10116.0,,B,,BAO_0000219,1143,,702.0,1,CHEMBL618065,RBL-1,,Rattus norvegicus,D,9,,
3968,Inhibition 5-lipoxygenase mediated LTB4 formation in rat basophilic leukemia (RBL-1) cells,Expert,10116.0,,B,,BAO_0000219,11854,,702.0,1,CHEMBL618066,RBL-1,,Rattus norvegicus,D,9,,
3969,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),Autocuration,,,B,,BAO_0000219,3595,,702.0,1,CHEMBL618067,RBL-1,,,H,8,,
3970,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1),Autocuration,,,B,,BAO_0000219,3595,,702.0,1,CHEMBL618068,RBL-1,,,H,8,,
3971,Inhibition of 5-lipoxygenase in rat RBL-1 cells,Expert,10116.0,,B,,BAO_0000219,10501,,702.0,1,CHEMBL618069,RBL-1,,Rattus norvegicus,D,9,,
3972,Inhibition of 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,Expert,,,B,,BAO_0000219,12526,,702.0,1,CHEMBL618070,RBL-1,,,H,8,,
3973,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 32 umol/kg,Autocuration,,,F,,BAO_0000019,10034,,,1,CHEMBL618071,,,,H,8,349.0,
3974,Compound was tested for its effects on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.10 umol/kg,Autocuration,,,F,,BAO_0000019,10034,,,1,CHEMBL619247,,,,H,8,349.0,
3975,Approximate dose levels for a half maximal reduction of 5-HTP levels,Autocuration,,,F,,BAO_0000019,10034,,,1,CHEMBL619248,,,,H,8,,
3976,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,Autocuration,,,B,,BAO_0000221,10046,,,1,CHEMBL619249,,,,H,8,10000000.0,
3977,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,Autocuration,,,B,,BAO_0000221,10046,,,1,CHEMBL619250,,,,H,8,10000000.0,
3978,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand.,Autocuration,,,B,,BAO_0000019,10046,,,1,CHEMBL619251,,,,H,8,,
3979,Inhibitory concentration against human platelet 5-lipoxygenase in dog whole blood,Autocuration,9615.0,,F,,BAO_0000019,12079,,,1,CHEMBL619252,,,Canis lupus familiaris,H,8,178.0,
3980,Inhibitory concentration against human platelet 5-lipoxygenase in human whole blood,Autocuration,,,F,,BAO_0000019,12079,,,1,CHEMBL619253,,,,H,8,178.0,
3981,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat polymorphonuclear leukocytes[PMNS],Autocuration,,,B,,BAO_0000219,11311,,,1,CHEMBL619254,,,,H,8,,
3982,Inhibition of 5-lipoxygenase in bovine polymorphonuclear leukocytes,Expert,,,B,,BAO_0000219,12338,,,1,CHEMBL619255,,,,H,8,,
3983,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL).,Expert,,,B,,BAO_0000219,12143,,,1,CHEMBL619256,,,,H,8,,
3984,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL),Autocuration,,,B,,BAO_0000219,12143,,,1,CHEMBL875418,,,,H,8,,
3985,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL) at 30 uM,Expert,,,B,,BAO_0000219,12143,,,1,CHEMBL619257,,,,H,8,,
3986,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL) at 30 uM,Autocuration,,,B,,BAO_0000219,12143,,,1,CHEMBL619258,,,,H,8,,
3987,Inhibition of 5-lipoxygenase in bovine PMNL cell assay.,Expert,,,B,,BAO_0000357,12365,,,1,CHEMBL619259,,,,H,8,,
3988,Tested for inhibition of 5-lipoxygenase as inhibition of 5-HETE and LTB4 biosynthesis in bovine PMNL,Expert,,,B,,BAO_0000357,13500,,,1,CHEMBL619260,,,,H,8,,
3989,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",Autocuration,9615.0,,F,,BAO_0000218,12832,,,1,CHEMBL619261,,,Canis lupus familiaris,H,8,178.0,
3990,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",Autocuration,9615.0,,F,,BAO_0000218,12832,,,1,CHEMBL619263,,,Canis lupus familiaris,H,8,178.0,
3991,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",Autocuration,9615.0,,F,,BAO_0000218,12832,,,1,CHEMBL619264,,,Canis lupus familiaris,H,8,178.0,
3992,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",Autocuration,9615.0,,F,,BAO_0000218,12832,,,1,CHEMBL619265,,,Canis lupus familiaris,H,8,178.0,
3993,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",Autocuration,9615.0,,F,,BAO_0000218,12832,,,1,CHEMBL619266,,,Canis lupus familiaris,H,8,178.0,
3994,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",Autocuration,9615.0,,F,,BAO_0000218,12832,,,1,CHEMBL619902,,,Canis lupus familiaris,H,8,178.0,
3995,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",Autocuration,9615.0,,F,,BAO_0000218,12832,,,1,CHEMBL620058,,,Canis lupus familiaris,H,8,178.0,
3996,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",Autocuration,9615.0,,F,,BAO_0000218,12832,,,1,CHEMBL620059,,,Canis lupus familiaris,H,8,178.0,
3997,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",Autocuration,9615.0,,F,,BAO_0000218,12832,,,1,CHEMBL620060,,,Canis lupus familiaris,H,8,178.0,
3998,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",Autocuration,9615.0,,F,,BAO_0000218,12832,,,1,CHEMBL620061,,,Canis lupus familiaris,H,8,178.0,
3999,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 0.3 mg/kg",Autocuration,9615.0,,F,,BAO_0000218,12832,,,1,CHEMBL620062,,,Canis lupus familiaris,H,8,178.0,
4000,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 1.0 mg/kg",Autocuration,9615.0,,F,,BAO_0000218,12832,,,1,CHEMBL620063,,,Canis lupus familiaris,H,8,178.0,
4001,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 3.0 mg/kg",Autocuration,9615.0,,F,,BAO_0000218,12832,,,1,CHEMBL620064,,,Canis lupus familiaris,H,8,178.0,
4002,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",Autocuration,9615.0,,F,,BAO_0000218,12832,,,1,CHEMBL620065,,,Canis lupus familiaris,H,8,178.0,
4003,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 0.3 mg/kg",Autocuration,9615.0,,F,,BAO_0000218,12832,,,1,CHEMBL620066,,,Canis lupus familiaris,H,8,178.0,
4004,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 1.0 mg/kg",Autocuration,9615.0,,F,,BAO_0000218,12832,,,1,CHEMBL620067,,,Canis lupus familiaris,H,8,178.0,
4005,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 3.0 mg/kg",Autocuration,9615.0,,F,,BAO_0000218,12832,,,1,CHEMBL620068,,,Canis lupus familiaris,H,8,178.0,
4006,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",Autocuration,9615.0,,F,,BAO_0000218,12832,,,1,CHEMBL620069,,,Canis lupus familiaris,H,8,178.0,
4007,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 0.3 mg/kg",Autocuration,9615.0,,F,,BAO_0000218,12832,,,1,CHEMBL620070,,,Canis lupus familiaris,H,8,178.0,
4008,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 1.0 mg/kg",Autocuration,9615.0,,F,,BAO_0000218,12832,,,1,CHEMBL620071,,,Canis lupus familiaris,H,8,178.0,
4009,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 3.0 mg/kg",Autocuration,9615.0,,F,,BAO_0000218,12832,,,1,CHEMBL620072,,,Canis lupus familiaris,H,8,178.0,
4010,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",Autocuration,9615.0,,F,,BAO_0000218,12832,,,1,CHEMBL620036,,,Canis lupus familiaris,H,8,178.0,
4011,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 0.3 mg/kg",Autocuration,9615.0,,F,,BAO_0000218,12832,,,1,CHEMBL857702,,,Canis lupus familiaris,H,8,178.0,
4012,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 1.0 mg/kg",Autocuration,9615.0,,F,,BAO_0000218,12832,,,1,CHEMBL620037,,,Canis lupus familiaris,H,8,178.0,
4013,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 3.0 mg/kg",Autocuration,9615.0,,F,,BAO_0000218,12832,,,1,CHEMBL620038,,,Canis lupus familiaris,H,8,178.0,
4014,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",Autocuration,9615.0,,F,,BAO_0000218,12832,,,1,CHEMBL620039,,,Canis lupus familiaris,H,8,178.0,
4015,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 0.3 mg/kg",Autocuration,9615.0,,F,,BAO_0000218,12832,,,1,CHEMBL620040,,,Canis lupus familiaris,H,8,178.0,
4016,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 1.0 mg/kg",Autocuration,9615.0,,F,,BAO_0000218,12832,,,1,CHEMBL620041,,,Canis lupus familiaris,H,8,178.0,
4017,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 3.0 mg/kg",Autocuration,9615.0,,F,,BAO_0000218,12832,,,1,CHEMBL620042,,,Canis lupus familiaris,H,8,178.0,
4018,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",Autocuration,9615.0,,F,,BAO_0000218,12832,,,1,CHEMBL620043,,,Canis lupus familiaris,H,8,178.0,
4019,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 0.3 mg/kg",Autocuration,9615.0,,F,,BAO_0000218,12832,,,1,CHEMBL620044,,,Canis lupus familiaris,H,8,178.0,
4020,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 1.0 mg/kg",Autocuration,9615.0,,F,,BAO_0000218,12832,,,1,CHEMBL620045,,,Canis lupus familiaris,H,8,178.0,
4021,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 3.0 mg/kg",Autocuration,9615.0,,F,,BAO_0000218,12832,,,1,CHEMBL620046,,,Canis lupus familiaris,H,8,178.0,
4022,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",Autocuration,9615.0,,F,,BAO_0000218,12832,,,1,CHEMBL620047,,,Canis lupus familiaris,H,8,178.0,
4023,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 0.3 mg/kg",Autocuration,9615.0,,F,,BAO_0000218,12832,,,1,CHEMBL620048,,,Canis lupus familiaris,H,8,178.0,
4024,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 1.0 mg/kg",Autocuration,9615.0,,F,,BAO_0000218,12832,,,1,CHEMBL857703,,,Canis lupus familiaris,H,8,178.0,
4025,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 3.0 mg/kg",Autocuration,9615.0,,F,,BAO_0000218,12832,,,1,CHEMBL620049,,,Canis lupus familiaris,H,8,178.0,
4026,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",Autocuration,9615.0,,F,,BAO_0000218,12832,,,1,CHEMBL620050,,,Canis lupus familiaris,H,8,178.0,
4027,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",Autocuration,9615.0,,F,,BAO_0000218,12832,,,1,CHEMBL620051,,,Canis lupus familiaris,H,8,178.0,
4028,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",Autocuration,9615.0,,F,,BAO_0000218,12832,,,1,CHEMBL619213,,,Canis lupus familiaris,H,8,178.0,
4029,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",Autocuration,9615.0,,F,,BAO_0000218,12832,,,1,CHEMBL619214,,,Canis lupus familiaris,H,8,178.0,
4030,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",Autocuration,9615.0,,F,,BAO_0000218,12832,,,1,CHEMBL619804,,,Canis lupus familiaris,H,8,178.0,
4031,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 1.0 mg/kg",Autocuration,9615.0,,F,,BAO_0000218,12832,,,1,CHEMBL619805,,,Canis lupus familiaris,H,8,178.0,
4032,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",Autocuration,9615.0,,F,,BAO_0000218,12832,,,1,CHEMBL619806,,,Canis lupus familiaris,H,8,178.0,
4033,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",Autocuration,9615.0,,F,,BAO_0000218,12832,,,1,CHEMBL619807,,,Canis lupus familiaris,H,8,178.0,
4034,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",Autocuration,9615.0,,F,,BAO_0000218,12832,,,1,CHEMBL619808,,,Canis lupus familiaris,H,8,178.0,
4035,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 24 hr r,Autocuration,9615.0,,B,,BAO_0000218,3595,,,1,CHEMBL619809,,,Canis lupus familiaris,H,8,,
4036,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 24 hr r to canine,Autocuration,9615.0,,B,,BAO_0000218,3595,,,1,CHEMBL619810,,,Canis lupus familiaris,H,8,,
4037,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 2 hr,Autocuration,9615.0,,B,,BAO_0000218,3595,,,1,CHEMBL619811,,,Canis lupus familiaris,H,8,,
4038,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 2 hr to canine,Autocuration,9615.0,,B,,BAO_0000218,3595,,,1,CHEMBL620769,,,Canis lupus familiaris,H,8,,
4039,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 4 hr,Autocuration,9615.0,,B,,BAO_0000218,3595,,,1,CHEMBL620770,,,Canis lupus familiaris,H,8,,
4040,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 4 hr to canine,Autocuration,9615.0,,B,,BAO_0000218,3595,,,1,CHEMBL620771,,,Canis lupus familiaris,H,8,,
4041,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 8 hr,Autocuration,9615.0,,B,,BAO_0000218,3595,,,1,CHEMBL620772,,,Canis lupus familiaris,H,8,,
4042,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 8 hr to canine,Autocuration,9615.0,,B,,BAO_0000218,3595,,,1,CHEMBL620773,,,Canis lupus familiaris,H,8,,
4043,Ability to inhibit 5-lipoxygenase in guinea pig,Autocuration,10141.0,,B,,BAO_0000357,9203,,,1,CHEMBL620774,,,Cavia porcellus,H,8,,
4044,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-lipoxygenase in vitro (guinea pig PMN),Expert,10141.0,,B,,BAO_0000357,82,,,1,CHEMBL620775,,,Cavia porcellus,H,8,,
4045,Compound was tested for the inhibition of 5-lipoxygenase (5-Lpo) in guinea pig.,Autocuration,10141.0,,B,,BAO_0000357,11090,,,1,CHEMBL620776,,,Cavia porcellus,H,8,,
4046,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 12 h, following intravenous administration at the dose of 1.0 mg/kg",Autocuration,10141.0,,B,,BAO_0000218,12832,,,1,CHEMBL620777,,,Cavia porcellus,H,8,178.0,
4047,In vitro 5-lipoxygenase inhibition in guinea pig PMNs was determined based on 5-hydroxyeicosapentaenoic acid (5-HETE) production,Autocuration,10141.0,,B,,BAO_0000357,1065,,,1,CHEMBL620778,,,Cavia porcellus,H,8,,
4048,In vitro 5-lipoxygenase inhibition in guinea pig PMNs was determined based on LTB4 production,Autocuration,10141.0,,B,,BAO_0000357,1065,,,1,CHEMBL620779,,,Cavia porcellus,H,8,,
4049,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]-AA to 5-HETE in guinea pig peritoneal polymorphonuclear leukocytes,Expert,10141.0,,B,,BAO_0000019,12832,,,1,CHEMBL621500,,,Cavia porcellus,H,8,,
4050,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]AA to LTB4 in guinea pig peritoneal polymorphonuclear leukocytes,Expert,10141.0,,B,,BAO_0000019,12832,,,1,CHEMBL621501,,,Cavia porcellus,H,8,,
4051,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]AA to LTB4 in guinea pig peritoneal polymorphonuclear leukocytes,Autocuration,10141.0,,B,,BAO_0000019,12832,,,1,CHEMBL618098,,,Cavia porcellus,H,8,,
4052,Inhibition against 5-lipoxygenase from guinea pig polymorphonuclear lymphocytes,Autocuration,10141.0,,B,,BAO_0000019,10504,,,1,CHEMBL618099,,,Cavia porcellus,H,8,,
4053,Inhibitory activity against 5-lipoxygenase,Autocuration,10141.0,,B,,BAO_0000357,7788,,,1,CHEMBL618100,,,Cavia porcellus,H,8,,
4054,Inhibitory activity against 5-lipoxygenase in guinea pig leukocyte,Autocuration,10141.0,,B,,BAO_0000357,10001,,,1,CHEMBL618101,,,Cavia porcellus,H,8,,
4055,Inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant,Autocuration,10141.0,,B,,BAO_0000357,10193,,,1,CHEMBL618102,,,Cavia porcellus,H,8,,
4056,Inhibitory activity against partially-purified Guinea pig PMN 5-lipoxygenase,Autocuration,10141.0,,B,,BAO_0000357,13243,,,1,CHEMBL618103,,,Cavia porcellus,H,8,,
4057,Inhibitory activity uM,Autocuration,10141.0,,B,,BAO_0000357,13243,,,1,CHEMBL618104,,,Cavia porcellus,H,8,,
4058,Inhibitory activity against 5-lipoxygenase in guinea pig leukocytes was determined,Autocuration,10141.0,,B,,BAO_0000219,969,,,1,CHEMBL883712,,,Cavia porcellus,H,8,,
4059,Inhibitory activity against 5-lipoxygenase at 10 uM,Autocuration,10141.0,,B,,BAO_0000357,10001,,,1,CHEMBL618105,,,Cavia porcellus,H,8,,
4060,Inhibitory activity against 5-lipoxygenase at a dose of 0.1 mM,Autocuration,10141.0,,B,,BAO_0000357,7788,,,1,CHEMBL618106,,,Cavia porcellus,H,8,,
4061,Inhibitory activity against 5-lipoxygenase in guinea pig leukocyte at 30 uM,Autocuration,10141.0,,B,,BAO_0000357,10001,,,1,CHEMBL618107,,,Cavia porcellus,H,8,,
4062,Inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant at 10 uM,Autocuration,10141.0,,B,,BAO_0000357,10193,,,1,CHEMBL618108,,,Cavia porcellus,H,8,,
4063,Inhibitory activity uM,Autocuration,10141.0,,B,,BAO_0000357,13243,,,1,CHEMBL618109,,,Cavia porcellus,H,8,,
4064,Inhibitory activity against partially-purified Guinea pig PMN 5-lipoxygenase at 10 uM,Autocuration,10141.0,,B,,BAO_0000357,13243,,,1,CHEMBL618110,,,Cavia porcellus,H,8,,
4065,Inhibitory activity uM,Expert,10141.0,,B,,BAO_0000357,13243,,,1,CHEMBL618111,,,Cavia porcellus,H,8,,
4066,Inhibitory activity uM,Autocuration,10141.0,,F,,BAO_0000019,13243,,,1,CHEMBL618112,,,Cavia porcellus,H,8,,
4067,Percent inhibition against 5-lipoxygenase from guinea pig polymorphonuclear lymphocytes,Autocuration,10141.0,,B,,BAO_0000019,10504,,,1,CHEMBL618113,,,Cavia porcellus,H,8,,
4068,Inhibitory activity against 5-lipoxygenase at a dose of 0.1 mM,Autocuration,10141.0,,B,,BAO_0000357,7788,,,1,CHEMBL618114,,,Cavia porcellus,H,8,,
4069,Evaluated for inhibition of the formation and release of 5-lipoxygenase in isolated guinea pig ileum,Expert,10141.0,,F,,BAO_0000221,10546,,,1,CHEMBL620871,,,Cavia porcellus,H,8,2116.0,
4070,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),Autocuration,,,B,,BAO_0000357,13183,,,1,CHEMBL620872,,,,H,8,,
4071,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),Autocuration,,,B,,BAO_0000357,13183,,,1,CHEMBL620873,,,,H,8,,
4072,Compound was evaluated for in vitro inhibition of recombinant human 5-lipoxygenase (5-LO),Autocuration,,,B,,BAO_0000357,2578,,,1,CHEMBL620874,,,,H,8,,
4073,In vitro inhibition of human 5-Lipoxygenase.,Expert,,,B,,BAO_0000357,12780,,,1,CHEMBL620875,,,,H,8,,
4074,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 75 uM,Autocuration,10116.0,,B,,BAO_0000251,7411,Microsomes,,1,CHEMBL620876,,,Rattus norvegicus,U,0,2107.0,
4075,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1 uM,Autocuration,10116.0,,B,,BAO_0000251,7411,Microsomes,,1,CHEMBL620877,,,Rattus norvegicus,U,0,2107.0,
4076,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM,Autocuration,10116.0,,B,,BAO_0000251,7411,Microsomes,,1,CHEMBL857854,,,Rattus norvegicus,U,0,2107.0,
4077,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM exposed 100 uM,Autocuration,10116.0,,B,,BAO_0000251,7411,Microsomes,,1,CHEMBL620878,,,Rattus norvegicus,U,0,2107.0,
4078,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 100 uM,Autocuration,10116.0,,B,,BAO_0000251,7411,Microsomes,,1,CHEMBL620879,,,Rattus norvegicus,U,0,2107.0,
4079,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,Autocuration,10116.0,,B,,BAO_0000251,7411,Microsomes,,1,CHEMBL620880,,,Rattus norvegicus,U,0,2107.0,
4080,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,Autocuration,10116.0,,B,,BAO_0000251,7411,Microsomes,,1,CHEMBL620881,,,Rattus norvegicus,U,0,2107.0,
4081,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 150 uM,Autocuration,10116.0,,B,,BAO_0000251,7411,Microsomes,,1,CHEMBL620882,,,Rattus norvegicus,U,0,2107.0,
4082,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1500 uM,Autocuration,10116.0,,B,,BAO_0000251,7411,Microsomes,,1,CHEMBL620883,,,Rattus norvegicus,U,0,2107.0,
4083,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 2.5 uM,Autocuration,10116.0,,B,,BAO_0000251,7411,Microsomes,,1,CHEMBL620884,,,Rattus norvegicus,U,0,2107.0,
4084,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 200 uM,Autocuration,10116.0,,B,,BAO_0000251,7411,Microsomes,,1,CHEMBL620885,,,Rattus norvegicus,U,0,2107.0,
4085,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 27.5 uM,Autocuration,10116.0,,B,,BAO_0000251,7411,Microsomes,,1,CHEMBL620886,,,Rattus norvegicus,U,0,2107.0,
4086,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 5 uM,Autocuration,10116.0,,B,,BAO_0000251,7411,Microsomes,,1,CHEMBL620887,,,Rattus norvegicus,U,0,2107.0,
4087,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,Autocuration,10116.0,,B,,BAO_0000251,7411,Microsomes,,1,CHEMBL618039,,,Rattus norvegicus,U,0,2107.0,
4088,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 500 uM,Autocuration,10116.0,,B,,BAO_0000251,7411,Microsomes,,1,CHEMBL618040,,,Rattus norvegicus,U,0,2107.0,
4089,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to exposed to 3-methylcholanthrene at concentration of 200 uM,Autocuration,10116.0,,B,,BAO_0000251,7411,Microsomes,,1,CHEMBL618041,,,Rattus norvegicus,U,0,2107.0,
4090,"Compound was evaluated for inhibition constant, in liver microsomes from 3-methylcholanthrene-exposed rats",Autocuration,10116.0,,B,,BAO_0000251,7411,Microsomes,,1,CHEMBL618216,,,Rattus norvegicus,U,0,2107.0,
4091,"Compound was evaluated for inhibition constant, in liver microsomes from beta-naphthoflavone-exposed rats",Autocuration,10116.0,,B,,BAO_0000251,7411,Microsomes,,1,CHEMBL618217,,,Rattus norvegicus,U,0,2107.0,
4092,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 100 uM,Autocuration,10116.0,,B,,BAO_0000251,7411,Microsomes,,1,CHEMBL618218,,,Rattus norvegicus,U,0,2107.0,
4093,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 200 uM,Autocuration,10116.0,,B,,BAO_0000251,7411,Microsomes,,1,CHEMBL618219,,,Rattus norvegicus,U,0,2107.0,
4094,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 50 uM,Autocuration,10116.0,,B,,BAO_0000251,7411,Microsomes,,1,CHEMBL618220,,,Rattus norvegicus,U,0,2107.0,
4095,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at 5 uM,Autocuration,10116.0,,B,,BAO_0000251,7411,Microsomes,,1,CHEMBL618221,,,Rattus norvegicus,U,0,2107.0,
4096,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at 50 uM,Autocuration,10116.0,,B,,BAO_0000251,7411,Microsomes,,1,CHEMBL618222,,,Rattus norvegicus,U,0,2107.0,
4097,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 10 uM,Autocuration,10116.0,,B,,BAO_0000251,7411,Microsomes,,1,CHEMBL618223,,,Rattus norvegicus,U,0,2107.0,
4098,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 100 uM,Autocuration,10116.0,,B,,BAO_0000251,7411,Microsomes,,1,CHEMBL618224,,,Rattus norvegicus,U,0,2107.0,
4099,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 1 uM,Autocuration,10116.0,,B,,BAO_0000251,7411,Microsomes,,1,CHEMBL618225,,,Rattus norvegicus,U,0,2107.0,
4100,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 20 uM,Autocuration,10116.0,,B,,BAO_0000251,7411,Microsomes,,1,CHEMBL618226,,,Rattus norvegicus,U,0,2107.0,
4101,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 200 uM,Autocuration,10116.0,,B,,BAO_0000251,7411,Microsomes,,1,CHEMBL618227,,,Rattus norvegicus,U,0,2107.0,
4102,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 25 uM,Autocuration,10116.0,,B,,BAO_0000251,7411,Microsomes,,1,CHEMBL618228,,,Rattus norvegicus,U,0,2107.0,
4103,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 50 uM,Autocuration,10116.0,,B,,BAO_0000251,7411,Microsomes,,1,CHEMBL618229,,,Rattus norvegicus,U,0,2107.0,
4104,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 75 uM,Autocuration,10116.0,,B,,BAO_0000251,7411,Microsomes,,1,CHEMBL618230,,,Rattus norvegicus,U,0,2107.0,
4105,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1 uM,Autocuration,10116.0,,B,,BAO_0000251,7411,Microsomes,,1,CHEMBL618231,,,Rattus norvegicus,U,0,2107.0,
4106,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM,Autocuration,10116.0,,B,,BAO_0000251,7411,Microsomes,,1,CHEMBL618232,,,Rattus norvegicus,U,0,2107.0,
4107,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 100 uM,Autocuration,10116.0,,B,,BAO_0000251,7411,Microsomes,,1,CHEMBL618233,,,Rattus norvegicus,U,0,2107.0,
4108,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,Autocuration,10116.0,,B,,BAO_0000251,7411,Microsomes,,1,CHEMBL618234,,,Rattus norvegicus,U,0,2107.0,
4109,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 150 uM,Autocuration,10116.0,,B,,BAO_0000251,7411,Microsomes,,1,CHEMBL618235,,,Rattus norvegicus,U,0,2107.0,
4110,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1500 uM,Autocuration,10116.0,,B,,BAO_0000251,7411,Microsomes,,1,CHEMBL618115,,,Rattus norvegicus,U,0,2107.0,
4111,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 2.5 uM,Autocuration,10116.0,,B,,BAO_0000251,7411,Microsomes,,1,CHEMBL618116,,,Rattus norvegicus,U,0,2107.0,
4112,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 200 uM,Autocuration,10116.0,,B,,BAO_0000251,7411,Microsomes,,1,CHEMBL618117,,,Rattus norvegicus,U,0,2107.0,
4113,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 5 uM,Autocuration,10116.0,,B,,BAO_0000251,7411,Microsomes,,1,CHEMBL619968,,,Rattus norvegicus,U,0,2107.0,
4114,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,Autocuration,10116.0,,B,,BAO_0000251,7411,Microsomes,,1,CHEMBL619969,,,Rattus norvegicus,U,0,2107.0,
4115,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 500 uM,Autocuration,10116.0,,B,,BAO_0000251,7411,Microsomes,,1,CHEMBL619970,,,Rattus norvegicus,U,0,2107.0,
4116,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 1000 uM,Autocuration,10116.0,,B,,BAO_0000251,7411,Microsomes,,1,CHEMBL619971,,,Rattus norvegicus,U,0,2107.0,
4117,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 1500 uM,Autocuration,10116.0,,B,,BAO_0000251,7411,Microsomes,,1,CHEMBL619972,,,Rattus norvegicus,U,0,2107.0,
4118,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 27.5 uM,Autocuration,10116.0,,B,,BAO_0000251,7411,Microsomes,,1,CHEMBL619973,,,Rattus norvegicus,U,0,2107.0,
4119,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 500 uM,Autocuration,10116.0,,B,,BAO_0000251,7411,Microsomes,,1,CHEMBL619974,,,Rattus norvegicus,U,0,2107.0,
4120,Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,Autocuration,10116.0,,B,,BAO_0000251,7411,Microsomes,,1,CHEMBL619975,,,Rattus norvegicus,U,0,2107.0,
4121,Vmax determined by 7-ethoxycoumarin deethylation in the presence by liver microsomes from rats exposed to 3-methylcholanthrene at concentration of 10 uM,Autocuration,10116.0,,B,,BAO_0000251,7411,Microsomes,,1,CHEMBL619976,,,Rattus norvegicus,U,0,,
4122,"Compound was evaluated for alpha -rate constant, in liver microsomes from 3-methylcholanthrene-exposed rats",Autocuration,10116.0,,B,,BAO_0000251,7411,Microsomes,,1,CHEMBL619977,,,Rattus norvegicus,U,0,2107.0,
4123,"Compound was evaluated for alpha -rate constant, in liver microsomes from beta-naphthoflavone-exposed rats",Autocuration,10116.0,,B,,BAO_0000251,7411,Microsomes,,1,CHEMBL619978,,,Rattus norvegicus,U,0,2107.0,
4124,"Compound was evaluated for alpha -rate constant, in liver microsomes from beta-naphthoflavone-exposed rats; competitive inhibition",Autocuration,10116.0,,B,,BAO_0000251,7411,Microsomes,,1,CHEMBL619979,,,Rattus norvegicus,U,0,2107.0,
4125,"Compound was evaluated for alpha inhibition constant, in liver microsomes from 3-methylcholanthrene-exposed rats",Autocuration,10116.0,,B,,BAO_0000251,7411,Microsomes,,1,CHEMBL619980,,,Rattus norvegicus,U,0,2107.0,
4126,"Compound was evaluated for alpha inhibition constant, in liver microsomes from beta-naphthoflavone-exposed rats",Autocuration,10116.0,,B,,BAO_0000251,7411,Microsomes,,1,CHEMBL619981,,,Rattus norvegicus,U,0,2107.0,
4127,In vitro inhibition of 7226/S myeloma cancer cell line,Intermediate,9606.0,,F,,BAO_0000219,10797,,741.0,1,CHEMBL619982,RPMI-8226,,Homo sapiens,N,1,,
4128,In vitro antitumor activity of compound against 7404 cell line (human liver carcinoma cells),Intermediate,9606.0,,F,,BAO_0000219,6881,,993.0,1,CHEMBL619983,BEL-7404 tumor cell line,,Homo sapiens,N,1,,
4129,In vitro growth inhibition of compound was determined against 768-0 cell lines of Renal cancer,Intermediate,9606.0,,F,,BAO_0000219,3838,,391.0,1,CHEMBL620031,786-0,,Homo sapiens,N,1,,
4130,In vitro growth inhibition of compound was determined against 768-0 cell lines of Renal cancer,Intermediate,9606.0,,F,,BAO_0000219,3838,,391.0,1,CHEMBL620032,786-0,,Homo sapiens,N,1,,
4131,Net accumulation of the [99mTc]Isonitrile complex was measured in 77A cell lines in the presence of Verapamil.,Expert,10029.0,,F,,BAO_0000219,12981,,505.0,1,CHEMBL620033,V79,,Cricetulus griseus,N,1,,
4132,Verapamil index represents the ratio of net uptake in the presense of verapamil over control in 77A cell lines.,Expert,10029.0,,F,,BAO_0000219,12981,,505.0,1,CHEMBL620034,V79,,Cricetulus griseus,N,1,,
4133,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 10 ug/mL dose,Intermediate,10116.0,,F,,BAO_0000219,7653,,1119.0,1,CHEMBL620035,7800C1 cell line,,Rattus norvegicus,N,1,,
4134,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 2 ug/mL dose,Intermediate,10116.0,,F,,BAO_0000219,7653,,1119.0,1,CHEMBL618318,7800C1 cell line,,Rattus norvegicus,N,1,,
4135,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 20 ug/mL dose,Intermediate,10116.0,,F,,BAO_0000219,7653,,1119.0,1,CHEMBL618319,7800C1 cell line,,Rattus norvegicus,N,1,,
4136,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 5 ug/mL dose,Intermediate,10116.0,,F,,BAO_0000219,7653,,1119.0,1,CHEMBL618320,7800C1 cell line,,Rattus norvegicus,N,1,,
4137,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 50 ug/mL dose,Intermediate,10116.0,,F,,BAO_0000219,7653,,1119.0,1,CHEMBL618321,7800C1 cell line,,Rattus norvegicus,N,1,,
4138,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 75 ug/mL dose,Intermediate,10116.0,,F,,BAO_0000219,7653,,1119.0,1,CHEMBL883118,7800C1 cell line,,Rattus norvegicus,N,1,,
4139,In vitro antitumor activity against renal 786-0 tumor cell lines,Intermediate,9606.0,,F,,BAO_0000219,17229,,391.0,1,CHEMBL883795,786-0,,Homo sapiens,N,1,,
4140,Cytotoxic activity against 786-0 Renal cancer cell line,Intermediate,9606.0,,F,,BAO_0000219,12858,,391.0,1,CHEMBL618322,786-0,,Homo sapiens,N,1,,
4141,Growth inhibitory activity was determined against 786-0 cancer cell line of Renal cancer,Intermediate,9606.0,,F,,BAO_0000219,16325,,391.0,1,CHEMBL618323,786-0,,Homo sapiens,N,1,,
4142,Growth inhibitory activity was determined against 786-0 cancer cell line of renal cancer,Intermediate,9606.0,,F,,BAO_0000219,16325,,391.0,1,CHEMBL618324,786-0,,Homo sapiens,N,1,,
4143,In vitro antitumor activity against human renal 786-0 cell line,Intermediate,9606.0,,F,,BAO_0000219,5858,,391.0,1,CHEMBL618325,786-0,,Homo sapiens,N,1,,
4144,Inhibition of Renal cancer in 786-0 cancer cell lines,Intermediate,9606.0,,F,,BAO_0000219,16325,,391.0,1,CHEMBL875416,786-0,,Homo sapiens,N,1,,
4145,Inhibition of the growth of renal cancer(786-0) cell line. value in parentheses is percent inhibition at 0.01 uM,Intermediate,9606.0,,F,,BAO_0000219,14696,,391.0,1,CHEMBL618326,786-0,,Homo sapiens,N,1,,
4146,The compound was tested for its cytotoxic activity against the following renal cancer cell lines 786-0,Intermediate,9606.0,,F,,BAO_0000219,3786,,391.0,1,CHEMBL618327,786-0,,Homo sapiens,N,1,,
4147,inhibition of the growth of renal cancer(786-0) cell line,Intermediate,9606.0,,F,,BAO_0000219,14696,,391.0,1,CHEMBL619215,786-0,,Homo sapiens,N,1,,
4148,Compound was evaluated for in vitro activity against 786-0 kidney cell lines (Human tumor cells ),Intermediate,9606.0,,F,,BAO_0000219,14769,,391.0,1,CHEMBL619216,786-0,,Homo sapiens,N,1,,
4149,Compound was tested for the growth inhibition of 786-0 renal tumor cell line,Intermediate,9606.0,,F,,BAO_0000219,15354,,391.0,1,CHEMBL619217,786-0,,Homo sapiens,N,1,,
4150,The IC50 value was measured on 786-0 cell line in ovarian tumor,Intermediate,9606.0,,F,,BAO_0000219,14255,,391.0,1,CHEMBL619218,786-0,,Homo sapiens,N,1,,
4151,The IC50 value was measured on 786-0 cell line in ovarian tumor t,Intermediate,9606.0,,F,,BAO_0000219,14255,,391.0,1,CHEMBL619219,786-0,,Homo sapiens,N,1,,
4152,The IC50 value was measured on 786-0 cell line in renal tumor type.,Intermediate,9606.0,,F,,BAO_0000219,14255,,391.0,1,CHEMBL619220,786-0,,Homo sapiens,N,1,,
4153,Inhibition of the growth of renal cancer(786-0) cell line at 0.01 uM,Intermediate,9606.0,,F,,BAO_0000219,14696,,391.0,1,CHEMBL619221,786-0,,Homo sapiens,N,1,,
4154,Tested for cytotoxic activity against renal cancer 786-0 cell line,Intermediate,9606.0,,F,,BAO_0000219,12016,,391.0,1,CHEMBL619222,786-0,,Homo sapiens,N,1,,
4155,Compound was tested for growth inhibitory activity against 786-0 cell line,Intermediate,9606.0,,F,,BAO_0000219,2597,,391.0,1,CHEMBL857454,786-0,,Homo sapiens,N,1,,
4156,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187; Inactive(N)= <50% inhibition at 10 uM,Autocuration,,,B,,BAO_0000219,12526,,702.0,1,CHEMBL619223,RBL-1,,,H,8,,
4157,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187; N=Inactive,Autocuration,,,B,,BAO_0000219,12526,,702.0,1,CHEMBL619224,RBL-1,,,H,8,,
4158,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells,Autocuration,,,B,,BAO_0000019,14799,,,1,CHEMBL619225,,,,H,8,,
4159,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),Expert,,,B,,BAO_0000219,3595,,702.0,1,CHEMBL619226,RBL-1,,,H,8,,
4160,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1),Expert,,,B,,BAO_0000219,3595,,702.0,1,CHEMBL619227,RBL-1,,,H,8,,
4161,Inhibitory activity against rat basophilic leukemia 5-lipoxygenase,Autocuration,,,B,,BAO_0000357,12767,,,1,CHEMBL619228,,,,H,8,,
4162,Inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes,Autocuration,,,B,,BAO_0000219,10997,,,1,CHEMBL619229,,,,H,8,,
4163,Inhibitory activity against 5-lipoxygenase of RBL-1 cell line,Autocuration,,,B,,BAO_0000219,11388,,702.0,1,CHEMBL619230,RBL-1,,,H,8,,
4164,Inhibitory activity against RBL broken cell-supematant 5-lipoxygenase was evaluated,Autocuration,,,B,,BAO_0000357,167,,,1,CHEMBL619231,,,,H,8,,
4165,"Inhibitory activity against intact rat PMNL, LTB4 5-lipoxygenase was evaluated",Autocuration,,,B,,BAO_0000357,167,,,1,CHEMBL619232,,,,H,8,,
4166,Inhibitory activity against rat 5-lipoxygenase by using continuous oxygen consumption assay.,Expert,,,B,,BAO_0000357,13744,,,1,CHEMBL619233,,,,H,8,,
4167,Inhibitory activity against rat basophilic leukemia cell 5-lipoxygenase,Autocuration,,,B,,BAO_0000357,1630,,,1,CHEMBL619234,,,,H,8,,
4168,Inhibitory activity against rat basophilic leukemia cell 5-lipoxygenase (5-LO),Autocuration,,,B,,BAO_0000357,1630,,,1,CHEMBL619235,,,,H,8,,
4169,"Inhibitory activity against 5-lipoxygenase in rat neutrophils as inhibition of A 23,187-induced LTB4 production",Expert,10116.0,,B,,BAO_0000019,969,,,1,CHEMBL619236,,,Rattus norvegicus,D,9,,
4170,Inhibitory concentration against 5-lipoxygenase in rat RBL-1 cells,Autocuration,,,B,,BAO_0000219,13621,,702.0,1,CHEMBL619237,RBL-1,,,H,8,,
4171,Inhibitory concentration to inhibit 5-lipoxygenase in the rat,Autocuration,,,B,,BAO_0000357,10089,,,1,CHEMBL619238,,,,H,8,,
4172,In vitro inhibition of rat polymorphonuclear leukocyte 5-lipoxygenase,Expert,,,B,,BAO_0000357,10193,,,1,CHEMBL619239,,,,H,8,,
4173,Tested for inhibition of 5-HPETE production by rat 5-LO; value ranges from 16-36 nM,Autocuration,,,B,,BAO_0000357,11966,,,1,CHEMBL619240,,,,H,8,,
4174,Tested for inhibition of 5-LO by measuring the reduction of leukotriene B4 (LTB4) in intact basophilic rat leukemia cells,Autocuration,,,B,,BAO_0000019,12251,,,1,CHEMBL875417,,,,H,8,,
4175,Tested for inhibition of 5-Lipoxygenase (ARBL) in calcium-stimulated rat basophilic leukemia cells(RBL-1),Autocuration,,,B,,BAO_0000219,211,,702.0,1,CHEMBL619241,RBL-1,,,H,8,,
4176,Inhibition of 5-lipoxygenase measured by the reduction of leukotriene B4 (LTB4) in intact basophilic rat leukemia cells,Expert,,,F,,BAO_0000019,12251,,,1,CHEMBL619242,,,,H,8,,
4177,Tested for inhibitory activity against 5-lipoxygenase in microsome of RBL-1 cells,Autocuration,,,B,,BAO_0000219,12495,,702.0,1,CHEMBL883796,RBL-1,,,H,8,,
4178,Tested for its inhibitory activity against 5-lipoxygenase,Autocuration,,,B,,BAO_0000357,414,,,1,CHEMBL619243,,,,H,8,,
4179,Tested for its inhibitory activity against 5-lipoxygenase; Not determined,Autocuration,,,B,,BAO_0000357,414,,,1,CHEMBL619244,,,,H,8,,
4180,"Iin vitro inhibition of 5-lipoxygenase activity in rat basophil leukemia type 1(RBL1) cell homogenates, (reduction of [14C]-5-HETE formation)",Expert,,,B,,BAO_0000019,10325,,,1,CHEMBL619245,,,,H,8,,
4181,In vitro test for inhibition of 5-lipoxygenase in cell-free preparations from rat PMN leukocytes,Expert,,,B,,BAO_0000019,11966,,,1,CHEMBL619246,,,,H,8,,
4182,In vitro inhibition of 5-lipoxygenase activity in RBL-1 cells.,Expert,,,B,,BAO_0000219,165,,702.0,1,CHEMBL619984,RBL-1,,,H,8,,
4183,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells; No significant inhibitory activity up to 30 uM,Autocuration,,,B,,BAO_0000219,165,,702.0,1,CHEMBL619985,RBL-1,,,H,8,,
4184,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells.,Autocuration,,,B,,BAO_0000219,165,,702.0,1,CHEMBL619986,RBL-1,,,H,8,,
4185,In vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells.,Expert,,,B,,BAO_0000219,165,,702.0,1,CHEMBL619987,RBL-1,,,H,8,,
4186,The compound was tested for inhibitory activity against 5-lipoxygenase in mouse,Autocuration,,,B,,BAO_0000218,11311,,,1,CHEMBL619988,,,,H,8,,
4187,The compound was tested for inhibitory activity against 5-lipoxygenase in rat RBL-1,Autocuration,,,B,,BAO_0000219,11311,,702.0,1,CHEMBL619989,RBL-1,,,H,8,,
4188,The compound was tested for inhibitory activity against 5-lipoxygenase in rat RBL-1 cells,Autocuration,,,B,,BAO_0000219,11311,,702.0,1,CHEMBL619990,RBL-1,,,H,8,,
4189,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS],Autocuration,,,B,,BAO_0000219,11311,,,1,CHEMBL619991,,,,H,8,,
4190,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] (in vitro),Autocuration,,,B,,BAO_0000219,11311,,,1,CHEMBL619992,,,,H,8,,
4191,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] (in vivo),Autocuration,,,B,,BAO_0000218,11311,,,1,CHEMBL619993,,,,H,8,,
4192,The compound was tested for inhibitory activity against 5-lipoxygenase translocation inhibitor in RBL-2H3 cells,Autocuration,,,F,,BAO_0000219,11311,,663.0,1,CHEMBL619994,RBL-2H3,,,H,8,,
4193,The compound was tested for inhibitory activity against 5-lipoxygenase translocation inhibitor in rat RBL-2H3 cells,Autocuration,,,F,,BAO_0000219,11311,,663.0,1,CHEMBL619995,RBL-2H3,,,H,8,,
4194,The compound was tested for inhibitory activity against 5-lipoxygenase using rat polymorphonuclear leukocytes[PMNS],Autocuration,,,B,,BAO_0000019,11311,,,1,CHEMBL619996,,,,H,8,,
4195,The compound was tested for its inhibitory activity against arachidonic acid in rat 5-lipoxygenase,Autocuration,,,B,,BAO_0000019,11732,,,1,CHEMBL619997,,,,H,8,,
4196,Tested for its inhibitory activity against arachidonic acid in rat 5-lipoxygenase.,Expert,,,B,,BAO_0000019,11732,,,1,CHEMBL619998,,,,H,8,,
4197,In vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells,Expert,,,B,,BAO_0000019,11087,,,1,CHEMBL619999,,,,H,8,,
4198,The compound was tested for the in vitro inhibition of 5-lipoxygenase from the 20000 g supernatant of RBI-1 cells,Autocuration,,,B,,BAO_0000019,11087,,,1,CHEMBL620000,,,,H,8,,
4199,The compound was tested for the inhibition of 5-lipoxygenase (5-lo) in homogenized rat basophilic leukemia (RBL-1) cells,Autocuration,,,B,,BAO_0000219,11087,,702.0,1,CHEMBL620001,RBL-1,,,H,8,,
4200,Inhibition of 5-lipoxygenase (5-lo) in intact rat polymorphonuclear leukocyte RPMNL,Expert,10116.0,,B,,BAO_0000357,11087,,,1,CHEMBL620002,,,Rattus norvegicus,D,9,,
4201,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells,Autocuration,,,B,,BAO_0000219,496,,702.0,1,CHEMBL620003,RBL-1,,,H,8,,
4202,Inhibition of 5-lipoxygenase on rat basophil leukemia cell line lysate (RBL-1 2H3 subline) by measuring 5-HETE production,Expert,,,F,,BAO_0000219,13986,,702.0,1,CHEMBL620004,RBL-1,,,H,8,,
4203,Compound was evaluated for the inhibition of 5-lipoxygenase,Autocuration,,,B,,BAO_0000357,11520,,,1,CHEMBL874063,,,,H,8,,
4204,Ability to inhibit 5-lipoxygenase by using a crude preparation of the cytosolic enzyme from the rat basophilic leukemia (RBL-1) cell line at a concentration of 25 uM,Autocuration,,,B,,BAO_0000219,10293,,702.0,1,CHEMBL620005,RBL-1,,,H,8,,
4205,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) at 10 uM concentration in intact RBL-1 cell line assay,Autocuration,,,B,,BAO_0000219,303,,702.0,1,CHEMBL620006,RBL-1,,,H,8,,
4206,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) at 10 uM concentration in intact RBL-1 cell line assay; Less than 5% inhibition at 10 uM reported as not active,Autocuration,,,B,,BAO_0000219,303,,702.0,1,CHEMBL620007,RBL-1,,,H,8,,
4207,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 10 uM,Autocuration,,,B,,BAO_0000219,9247,,702.0,1,CHEMBL620008,RBL-1,,,H,8,,
4208,Inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM,Expert,10116.0,,B,,BAO_0000219,9247,,702.0,1,CHEMBL620009,RBL-1,,Rattus norvegicus,D,9,,
4209,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM; NS = no significant activity,Autocuration,,,B,,BAO_0000219,9247,,702.0,1,CHEMBL620010,RBL-1,,,H,8,,
4210,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 30 uM,Autocuration,,,B,,BAO_0000219,9247,,702.0,1,CHEMBL620011,RBL-1,,,H,8,,
4211,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 300 uM,Autocuration,,,B,,BAO_0000219,9247,,702.0,1,CHEMBL620677,RBL-1,,,H,8,,
4212,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 33 uM,Autocuration,,,B,,BAO_0000219,9247,,702.0,1,CHEMBL620678,RBL-1,,,H,8,,
4213,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 40 uM,Autocuration,,,B,,BAO_0000219,9247,,702.0,1,CHEMBL620679,RBL-1,,,H,8,,
4214,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 75 uM,Autocuration,,,B,,BAO_0000219,9247,,702.0,1,CHEMBL620680,RBL-1,,,H,8,,
4215,Inhibitory activity against 5-lipoxygenase at 10 uM,Expert,10116.0,,B,,BAO_0000357,11481,,,1,CHEMBL620838,,,Rattus norvegicus,D,9,,
4216,In vitro inhibition of 5-lipoxygenase; NS means no significant inhibition,Autocuration,,,B,,BAO_0000357,105,,,1,CHEMBL620839,,,,H,8,,
4217,In vitro inhibition of rat polymorphonuclear leukocyte (PMN) 5-Lipoxygenase at 10 uM,Expert,,,B,,BAO_0000357,9029,,,1,CHEMBL620840,,,,H,8,,
4218,Inhibitory activity against 5-lipoxygenase enzyme from RBL-1 cells at 20 uM,Expert,,,B,,BAO_0000219,1175,,702.0,1,CHEMBL620841,RBL-1,,,H,8,,
4219,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined at 100 uM,Autocuration,,,B,,BAO_0000219,12118,,702.0,1,CHEMBL620842,RBL-1,,,H,8,,
4220,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined at 10e-4 M,Autocuration,,,B,,BAO_0000219,12118,,702.0,1,CHEMBL620843,RBL-1,,,H,8,,
4221,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determinedb at 100 uM,Autocuration,,,B,,BAO_0000219,12118,,702.0,1,CHEMBL620844,RBL-1,,,H,8,,
4222,In vitro inhibition of RBL-1 5-lipoxygenase at 20 uM,Autocuration,,,B,,BAO_0000219,9225,,702.0,1,CHEMBL620845,RBL-1,,,H,8,,
4223,In vitro inhibitory activity against 5-Lipoxygenase from rat basophilic leukemia cells at 30 uM concentration,Autocuration,,,B,,BAO_0000019,9401,,,1,CHEMBL620846,,,,H,8,,
4224,In vitro inhibitory activity against 5-lipoxygenase was determined at 16 uM,Autocuration,,,B,,BAO_0000357,137,,,1,CHEMBL873951,,,,H,8,,
4225,In vitro inhibitory activity against 5-lipoxygenase was determined at 16 uM,Autocuration,,,B,,BAO_0000357,137,,,1,CHEMBL620847,,,,H,8,,
4226,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 10 uM concentration,Autocuration,,,B,,BAO_0000219,4717,,702.0,1,CHEMBL620848,RBL-1,,,H,8,,
4227,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1) at 10 uM,Autocuration,,,B,,BAO_0000219,3595,,702.0,1,CHEMBL620849,RBL-1,,,H,8,,
4228,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at 40 uM concentration,Autocuration,,,B,,BAO_0000219,10501,,702.0,1,CHEMBL620850,RBL-1,,,H,8,,
4229,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at a concentration 40 uM,Autocuration,,,B,,BAO_0000219,10501,,702.0,1,CHEMBL620851,RBL-1,,,H,8,,
4230,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at a concentration 40 uM.,Autocuration,,,B,,BAO_0000219,10501,,702.0,1,CHEMBL620852,RBL-1,,,H,8,,
4231,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,Autocuration,,,B,,BAO_0000219,12526,,702.0,1,CHEMBL875098,RBL-1,,,H,8,,
4232,Inhibition of 5-lipoxygenase of rat basophilic leukemia cells at 30 uM,Expert,10116.0,,B,,BAO_0000219,14799,,702.0,1,CHEMBL620853,RBL-1,,Rattus norvegicus,D,9,,
4233,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells at 30 uM concentration; NT=Not tested,Autocuration,,,B,,BAO_0000019,14799,,,1,CHEMBL620854,,,,H,8,,
4234,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1) at 10 uM,Autocuration,,,B,,BAO_0000219,3595,,702.0,1,CHEMBL620855,RBL-1,,,H,8,,
4235,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1)at 10 uM,Expert,,,B,,BAO_0000219,3595,,702.0,1,CHEMBL839884,RBL-1,,,H,8,,
4236,Inhibitory activity at 10 uM against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,Autocuration,,,B,,BAO_0000219,12526,,702.0,1,CHEMBL620856,RBL-1,,,H,8,,
4237,Inhibitory activity at 1 uM against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,Autocuration,,,B,,BAO_0000219,12526,,702.0,1,CHEMBL620857,RBL-1,,,H,8,,
4238,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 1 uM,Autocuration,,,B,,BAO_0000019,10193,,,1,CHEMBL620858,,,,H,8,,
4239,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 10 uM,Autocuration,,,B,,BAO_0000019,10193,,,1,CHEMBL620859,,,,H,8,,
4240,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 1 uM,Autocuration,,,B,,BAO_0000019,10193,,,1,CHEMBL620860,,,,H,8,,
4241,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 3 uM,Autocuration,,,B,,BAO_0000019,10193,,,1,CHEMBL620861,,,,H,8,,
4242,Percent inhibition of rat neutrophil 5-lipoxygenase (5-LO),Expert,,,B,,BAO_0000357,9138,,,1,CHEMBL620862,,,,H,8,,
4243,Percent inhibition of rat neutrophil 5- Lipoxygenase (5-LO) at 100 uM,Autocuration,,,B,,BAO_0000357,9138,,,1,CHEMBL620863,,,,H,8,,
4244,Tested in vitro for the inhibition of 5-lipoxygenase in cell-free preparations from rat PMN leukocytes,Autocuration,,,B,,BAO_0000019,11966,,,1,CHEMBL620864,,,,H,8,,
4245,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 100 uM,Autocuration,,,B,,BAO_0000219,165,,702.0,1,CHEMBL620865,RBL-1,,,H,8,,
4246,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 30 uM,Autocuration,,,B,,BAO_0000219,165,,702.0,1,CHEMBL620866,RBL-1,,,H,8,,
4247,The compound was tested for inhibition of 5-lipoxygenase in rat RBL-2H3 cells,Autocuration,,,B,,BAO_0000219,11311,,663.0,1,CHEMBL620867,RBL-2H3,,,H,8,,
4248,The compound was tested for inhibition of 5-lipoxygenase translocation in SAR in rat RBL-2H3 cells,Autocuration,,,B,,BAO_0000219,11311,,663.0,1,CHEMBL620868,RBL-2H3,,,H,8,,
4249,The compound was tested for inhibition of 5-lipoxygenase translocation in SAR in rat RBL-2H3 cells,Autocuration,,,F,,BAO_0000219,11311,,663.0,1,CHEMBL620869,RBL-2H3,,,H,8,,
4250,The compound was tested for inhibition of LTB4 synthesis on isolated 5-lipoxygenase,Autocuration,,,F,,BAO_0000019,11311,,,1,CHEMBL873952,,,,H,8,,
4251,The compound was tested for inhibition of isolated 5-lipoxygenase,Autocuration,,,B,,BAO_0000357,11311,,,1,CHEMBL875099,,,,H,8,,
4252,The compound was tested for inhibition of isolated 5-lipoxygenase translocation into rat RBL-2H3 cells,Autocuration,,,F,,BAO_0000219,11311,,663.0,1,CHEMBL620870,RBL-2H3,,,H,8,,
4253,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells at a concentration of 30 uM,Autocuration,,,B,,BAO_0000019,11087,,,1,CHEMBL618261,,,,H,8,,
4254,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells at a concentration of 32 uM,Autocuration,,,B,,BAO_0000019,11087,,,1,CHEMBL618262,,,,H,8,,
4255,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells measured at a concentration of 30 uM,Autocuration,,,B,,BAO_0000019,11087,,,1,CHEMBL619428,,,,H,8,,
4256,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells; NS indicates nonsignificant inhibition at 32 uM concentration,Autocuration,,,B,,BAO_0000019,11087,,,1,CHEMBL619429,,,,H,8,,
4257,The compound was tested for the in vitro inhibition of 5-lipoxygenase from the 20000 g supernatant of RBI-1 cells; NS indicates nonsignificant inhibition at 32 uM concentration,Autocuration,,,B,,BAO_0000019,11087,,,1,CHEMBL619430,,,,H,8,,
4258,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells at 1.0 uM,Autocuration,,,B,,BAO_0000219,496,,702.0,1,CHEMBL620017,RBL-1,,,H,8,,
4259,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells at 10 uM,Autocuration,,,B,,BAO_0000219,496,,702.0,1,CHEMBL620018,RBL-1,,,H,8,,
4260,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.1 uM,Autocuration,,,F,,BAO_0000219,13986,,702.0,1,CHEMBL620019,RBL-1,,,H,8,,
4261,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.195 uM,Autocuration,,,F,,BAO_0000219,13986,,702.0,1,CHEMBL620020,RBL-1,,,H,8,,
4262,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.2 at uM,Autocuration,,,F,,BAO_0000219,13986,,702.0,1,CHEMBL620021,RBL-1,,,H,8,,
4263,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.25 uM,Autocuration,,,F,,BAO_0000219,13986,,702.0,1,CHEMBL620022,RBL-1,,,H,8,,
4264,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.39,Autocuration,,,F,,BAO_0000219,13986,,702.0,1,CHEMBL620023,RBL-1,,,H,8,,
4265,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.39 uM,Autocuration,,,F,,BAO_0000219,13986,,702.0,1,CHEMBL620024,RBL-1,,,H,8,,
4266,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.195 uM,Autocuration,,,F,,BAO_0000219,13986,,702.0,1,CHEMBL620025,RBL-1,,,H,8,,
4267,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.2 uM,Autocuration,,,F,,BAO_0000219,13986,,702.0,1,CHEMBL620026,RBL-1,,,H,8,,
4268,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.39 uM,Autocuration,,,F,,BAO_0000219,13986,,702.0,1,CHEMBL620027,RBL-1,,,H,8,,
4269,Inhibition of 5-lipoxygenase on rat basophil leukemia cell (RBL-2H3) lysate as 5-HETE production at 32 uM,Expert,10116.0,,F,,BAO_0000019,13986,,,1,CHEMBL620028,,,Rattus norvegicus,D,9,,
4270,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase,Autocuration,,,B,,BAO_0000357,10193,,,1,CHEMBL620029,,,,H,8,,
4271,Compound was tested for the percent of inhibition against 5-LO at 10 uM,Autocuration,,,B,,BAO_0000357,9295,,,1,CHEMBL620030,,,,H,8,,
4272,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 1 uM concentration,Autocuration,,,B,,BAO_0000219,4717,,702.0,1,CHEMBL875415,RBL-1,,,H,8,,
4273,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 10 uM concentration,Autocuration,,,B,,BAO_0000219,4717,,702.0,1,CHEMBL618256,RBL-1,,,H,8,,
4274,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line,Autocuration,,,B,,BAO_0000219,11854,,702.0,1,CHEMBL618257,RBL-1,,,H,8,,
4275,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line at 10 uM,Autocuration,,,B,,BAO_0000219,11854,,702.0,1,CHEMBL618258,RBL-1,,,H,8,,
4276,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line at 16 uM,Autocuration,,,B,,BAO_0000219,11854,,702.0,1,CHEMBL618259,RBL-1,,,H,8,,
4277,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 10 uM,Autocuration,,,B,,BAO_0000019,10193,,,1,CHEMBL618260,,,,H,8,,
4278,Percent inhibition against RBL-1 5-LO in vitro at 10 uM,Autocuration,,,B,,BAO_0000219,9295,,702.0,1,CHEMBL618215,RBL-1,,,H,8,,
4279,Percent inhibition against RBL-1 5-LO in vitro at 100 uM,Autocuration,,,B,,BAO_0000219,9295,,702.0,1,CHEMBL618390,RBL-1,,,H,8,,
4280,Percent inhibition against RBL-1 5-LO in vitro at 30 uM,Autocuration,,,B,,BAO_0000219,9295,,702.0,1,CHEMBL618391,RBL-1,,,H,8,,
4281,Percent inhibition against RBL-1 5-LO in vitro at 300 uM,Autocuration,,,B,,BAO_0000219,9295,,702.0,1,CHEMBL618392,RBL-1,,,H,8,,
4282,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 20 uM,Autocuration,,,B,,BAO_0000219,165,,702.0,1,CHEMBL618393,RBL-1,,,H,8,,
4283,The compound was tested for inhibition against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] at 10 uM concentration,Autocuration,,,B,,BAO_0000219,11311,,,1,CHEMBL618394,,,,H,8,,
4284,In vitro inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells(RBL-1),Expert,9606.0,,B,,BAO_0000219,10489,,702.0,1,CHEMBL618395,RBL-1,,Homo sapiens,H,8,,
4285,In vitro inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells(RBL-1),Expert,10116.0,,B,,BAO_0000219,10489,,702.0,1,CHEMBL618396,RBL-1,,Rattus norvegicus,D,9,,
4286,Logarithmic value of inhibitory concentration against 5-lipoxygenase in rat basophilic leukemia cells (RBL-1),Expert,10116.0,,B,,BAO_0000219,10489,,702.0,1,CHEMBL858253,RBL-1,,Rattus norvegicus,D,9,,
4287,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells,Autocuration,10116.0,,B,,BAO_0000019,14799,,,1,CHEMBL618397,,,Rattus norvegicus,D,9,,
4288,Compound was tested for the percent of inhibition against soybean 15-LO (at 100 uM),Autocuration,3847.0,,B,,BAO_0000357,9295,,,1,CHEMBL618398,,,Glycine max,H,8,,
4289,"Inhibitory activity against 5-lipoxygenase, by using soybean lipoxygenase spectrophotometric assay",Autocuration,,,B,,BAO_0000019,16811,,,1,CHEMBL618399,,,,U,0,,
4290,In vitro inhibition of 5-Lipoxygenase; Inactive.,Expert,,,B,,BAO_0000357,168,,,1,CHEMBL618400,,,,H,8,,
4291,Inhibitory concentration against 5-lipoxygenase was determined; No inhibition,Autocuration,,,B,,BAO_0000357,6309,,,1,CHEMBL618401,,,,H,8,,
4292,Inhibitory concentration against 5-lipoxygenase; No inhibition,Autocuration,,,B,,BAO_0000357,6309,,,1,CHEMBL618402,,,,H,8,,
4293,Evaluated for inhibitory activity against RBL-1 cell 5-lipoxygenase in guinea pig,Autocuration,,,B,,BAO_0000219,3092,,702.0,1,CHEMBL876400,RBL-1,,,H,8,,
4294,Inhibitory activity against 5-lipoxygenase.,Expert,,,B,,BAO_0000357,168,,,1,CHEMBL618403,,,,H,8,,
4295,Inhibitory Activity against 5-Lipoxygenase was determined; IA=Inactive,Autocuration,,,B,,BAO_0000357,168,,,1,CHEMBL618404,,,,H,8,,
4296,Inhibitory Activity against 5-Lipoxygenase was determined; IA=Inactive at concentrations less than 32 uM,Autocuration,,,B,,BAO_0000357,168,,,1,CHEMBL618405,,,,H,8,,
4297,Inhibitory Activity against 5-Lipoxygenase was determined; NA=No significant inhibitory activity up to 300 uM,Autocuration,,,B,,BAO_0000357,168,,,1,CHEMBL618406,,,,H,8,,
4298,Inhibitory concentration against arachidonic acid 5-lipoxygenation,Expert,,,F,,BAO_0000019,12338,,,1,CHEMBL618407,,,,H,8,,
4299,Tested for the inhibitory activity against 5-lipoxygenase,Autocuration,,,B,,BAO_0000357,4501,,,1,CHEMBL618408,,,,H,8,,
4300,Compound was tested for its inhibitory activity against 5-lipoxygenase,Autocuration,,,B,,BAO_0000357,1132,,,1,CHEMBL618409,,,,H,8,,
4301,Compound was tested for inhibition of 5-lipoxygenase at 50 uM; NI means no inhibition was observed,Autocuration,,,B,,BAO_0000357,2117,,,1,CHEMBL618410,,,,H,8,,
4302,Inhibitory Activity against 5-Lipoxygenase at 30 uM was determined; Weakly active,Autocuration,,,B,,BAO_0000357,168,,,1,CHEMBL618411,,,,H,8,,
4303,Inhibitory Activity against 5-Lipoxygenase at concentration 32 uM was determined,Autocuration,,,B,,BAO_0000357,168,,,1,CHEMBL618412,,,,H,8,,
4304,Concentration required to inhibit RBL-1 supernatant 5-lipoxygenase,Autocuration,,,B,,BAO_0000219,13575,,702.0,1,CHEMBL618413,RBL-1,,,H,8,,
4305,,Autocuration,,,B,,BAO_0000357,11089,,,1,CHEMBL618414,,,,H,8,,
4306,Compound was tested for its binding activity towards 5-lipoxygenase activating protein (FLAP),Autocuration,,,B,,BAO_0000357,216,,,1,CHEMBL618415,,,,H,8,,
4307,Inhibition of 5-lipoxygenase activating protein using human leukocyte membrane preparations,Autocuration,,,B,,BAO_0000019,13165,,,1,CHEMBL618416,,,,H,8,,
4308,Measuring the affinity of leukotriene synthesis inhibitor for 5-Lipoxygenase activating protein (FLAP) by using [125I]L-691831 as radioligand.,Autocuration,,,B,,BAO_0000357,3278,,,1,CHEMBL876401,,,,H,8,,
4309,Measuring the affinity of leukotriene synthesis inhibitor for 5-lipoxygenase activating protein by using [125I]L-691831 as radioligand.,Expert,,,B,,BAO_0000357,3278,,,1,CHEMBL618417,,,,H,8,,
4310,Tested for inhibition of leukotriene biosynthesis by binding to 5-lipoxygenase activating protein,Autocuration,,,B,,BAO_0000357,11966,,,1,CHEMBL618418,,,,H,8,,
4311,"The compound was tested for the inhibition of binding of [125I]- L- 691,831 binding to 5-lipoxygenase activating protein",Autocuration,,,B,,BAO_0000357,175,,,1,CHEMBL618419,,,,H,8,,
4312,"The compound was tested for the inhibition of binding of [125I]- L- 691,831 binding to 5-lipoxygenase activating protein (FLAP)",Autocuration,,,B,,BAO_0000357,175,,,1,CHEMBL618420,,,,H,8,,
4313,Binding affinity of compound for 5-lipoxygenase activating protein protein by FLAP binding assay,Autocuration,,,B,,BAO_0000357,13449,,,1,CHEMBL618421,,,,H,8,,
4314,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane,Autocuration,,,B,,BAO_0000019,12014,,,1,CHEMBL618422,,,,H,8,,
4315,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane (R metabolically resistant),Autocuration,,,B,,BAO_0000019,12014,,,1,CHEMBL618423,,,,H,8,,
4316,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane (S substrate),Autocuration,,,B,,BAO_0000019,12014,,,1,CHEMBL618424,,,,H,8,,
4317,Inhibition of protein biosynthesis at the level of the peptidyl transferase center of the 50 s ribosomal subunit,Intermediate,,,B,,BAO_0000220,99,,,1,CHEMBL618425,,,,S,2,,
4318,The dark toxicity against 543 human galactophore carcinoma cells,Autocuration,9606.0,,F,,BAO_0000019,4349,,,1,CHEMBL618426,,,Homo sapiens,U,0,,
4319,Tested in vitro for cytotoxicity against 56 human tumor cell lines,Expert,9606.0,,F,,BAO_0000219,4071,,390.0,1,CHEMBL618427,Panel (56 tumour cell lines),,Homo sapiens,N,1,,
4320,Cytotoxic activity against human 5637 cell line at 20 uM expressed as percent growth value,Expert,9606.0,,F,,BAO_0000219,17589,,345.0,1,CHEMBL618428,5637,,Homo sapiens,N,1,,
4321,Antitumor activity was evaluated against human bladder carcinoma cell line 5637.,Intermediate,9606.0,,F,,BAO_0000219,15002,,345.0,1,CHEMBL618429,5637,,Homo sapiens,N,1,,
4322,"Compound was tested for antiproliferative activity against 5637, human bladder carcinoma cell line",Intermediate,9606.0,,F,,BAO_0000219,13958,,345.0,1,CHEMBL618430,5637,,Homo sapiens,N,1,,
4323,Growth inhibition against human 5637 cell lines,Expert,9606.0,,F,,BAO_0000219,17589,,345.0,1,CHEMBL618431,5637,,Homo sapiens,N,1,,
4324,Antitumor activity against human bladder carcinoma 5637 cells.,Expert,9606.0,,F,,BAO_0000219,16748,,345.0,1,CHEMBL883799,5637,,Homo sapiens,N,1,,
4325,Antitumor activity against human bladder carcinoma 5637 cells,Intermediate,9606.0,,F,,BAO_0000219,16747,,345.0,1,CHEMBL618432,5637,,Homo sapiens,N,1,,
4326,Antitumor activity against human bladder carcinoma 5637 cells,Intermediate,9606.0,,F,,BAO_0000219,16747,,345.0,1,CHEMBL618433,5637,,Homo sapiens,N,1,,
4327,In vitro inhibition of bovine trypsin(Trp).,Expert,9913.0,,B,,BAO_0000357,15285,,,1,CHEMBL618434,,,Bos taurus,D,9,,
4328,Transcriptional activation in CV-1 cells expressing retinoic acid gamma receptor,Expert,9527.0,,B,,BAO_0000219,3726,,407.0,1,CHEMBL618435,CV-1,,Cercopithecidae,H,8,,
4329,Ability to displace the radioligand [125I](-)-iodocyanopindolol from rat striatal 5-HT1B receptor,Autocuration,,,B,,BAO_0000357,5033,,,1,CHEMBL876402,,,,H,8,,
4330,In vitro antagonism of the 5-HT-3 receptor determined by inhibition of 5-HT-induced depolarization of the isolated rat vagus nerve.,Autocuration,,,F,,BAO_0000019,11756,,,1,CHEMBL618436,,,,H,6,,
4331,Concentration required to inhibit pressor response to serotonin after 15 min i.v. administration of compound mediated via activation of vascular 5-HT2 receptors in rat,Autocuration,,,F,,BAO_0000218,11953,,,1,CHEMBL618437,,,,U,0,,
4332,Ability to displace the radioligand [3H]GR-113808 from guinea pig striatum 5-HT4 receptor,Intermediate,10141.0,,B,,BAO_0000357,5033,,,1,CHEMBL618438,,,Cavia porcellus,D,9,,
4333,Inhibition of progesterone 6-beta-hydroxylase in rat hepatic microsomes,Expert,10116.0,,A,,BAO_0000251,11347,Microsomes,,1,CHEMBL883800,,,Rattus norvegicus,H,8,,
4334,Inhibition of progesterone 6-beta-hydroxylase in rat hepatic microsomes,Expert,10116.0,,A,,BAO_0000251,11347,Microsomes,,1,CHEMBL618439,,,Rattus norvegicus,H,8,,
4335,In vitro anticancer activity against 6 NCI ovarian cancer cell lines; inactive,Intermediate,,,F,,BAO_0000019,1229,,,1,CHEMBL618440,,,,U,0,,
4336,In vitro anticancer activity against 6 NCI ovarian cancer cell lines; inactive,Intermediate,,,F,,BAO_0000019,1229,,,1,CHEMBL618441,,,,U,0,,
4337,Inhibition constant against 6-phosphogluconate dehydrogenase of Trypanosoma brucei expressed in Escherichia coli,Expert,5691.0,,B,,BAO_0000019,17588,,,1,CHEMBL618442,,,Trypanosoma brucei,H,8,,
4338,Inhibition constant against 6-phosphogluconate dehydrogenase of Trypanosoma brucei expressed in Escherichia coli; NI denotes no inhibition,Autocuration,5691.0,,B,,BAO_0000019,17588,,,1,CHEMBL618443,,,Trypanosoma brucei,H,8,,
4339,Inhibition constant against 6-phosphogluconate dehydrogenase of sheep liver,Expert,9940.0,,B,,BAO_0000019,17588,,,1,CHEMBL619158,,,Ovis aries,H,8,,
4340,Inhibition constant against 6-phosphogluconate dehydrogenase of sheep liver; NI denotes no inhibition,Autocuration,9940.0,,B,,BAO_0000019,17588,,,1,CHEMBL620974,,,Ovis aries,H,8,,
4341,log Kd which is the binding affinity against 6-phosphogluconate dehydrogenase,Autocuration,,,B,,BAO_0000357,16485,,,1,CHEMBL620975,,,,H,8,,
4342,Average inhibitory concentration against 60 human cell lines was reported,Intermediate,9606.0,,F,,BAO_0000019,4337,,,1,CHEMBL620976,,,Homo sapiens,U,0,,
4343,Inhibition of proliferation in NCI panel of 60 human tumor cell lines,Expert,9606.0,,F,,BAO_0000019,4112,,,1,CHEMBL620977,,,Homo sapiens,U,0,,
4344,Cancer specificity was measured from the +/- value under average log LC50 60-cell line,Intermediate,9606.0,,F,,BAO_0000219,16160,,542.0,1,CHEMBL620978,Panel NCI-60 (60 carcinoma cell lines),,Homo sapiens,N,1,,
4345,Cancer specificity was measured from the +/- value under average log LC50 60-cell line. ,Intermediate,9606.0,,F,,BAO_0000219,16160,,542.0,1,CHEMBL620979,Panel NCI-60 (60 carcinoma cell lines),,Homo sapiens,N,1,,
4346,In vitro mean growth inhibitory activity against 60-cell panel,Expert,,,F,,BAO_0000219,17376,,542.0,1,CHEMBL620980,Panel NCI-60 (60 carcinoma cell lines),,,N,1,,
4347,In vitro mean growth lethal concentration against 60-cell panel,Expert,,,F,,BAO_0000219,17376,,542.0,1,CHEMBL620981,Panel NCI-60 (60 carcinoma cell lines),,,N,1,,
4348,In vitro mean growth lethal concentration in colon subpanel against 60-cell panel,Expert,,,F,,BAO_0000219,17376,,542.0,1,CHEMBL620982,Panel NCI-60 (60 carcinoma cell lines),,,N,1,,
4349,In vitro mean growth lethal concentration in renal subpanel against 60-cell panel,Expert,,,F,,BAO_0000219,17376,,542.0,1,CHEMBL620983,Panel NCI-60 (60 carcinoma cell lines),,,N,1,,
4350,Inhibition of CK-II-mediated 60S acidic ribosomal P protein activity at 10 uM,Autocuration,,,F,,BAO_0000019,3241,,,1,CHEMBL620984,,,,H,4,,
4351,Inhibition of CK-II-mediated 60S acidic ribosomal P protein activity at 10 uM,Autocuration,,,F,,BAO_0000019,3241,,,1,CHEMBL620985,,,,H,4,,
4352,Transcriptional activation in CV-1 expressing retinoid X receptor RXR alpha,Expert,,,B,,BAO_0000357,3725,,,1,CHEMBL620986,,,,H,8,,
4353,Inhibitory activity against Plasmodium falciparum 68 neutral proteinase,Expert,5833.0,,F,,BAO_0000218,10805,,,1,CHEMBL620987,,,Plasmodium falciparum,N,1,,
4354,In vitro inhibition of Plasmodium falciparum 68 neutral proteinase activity by reinvasion of red blood cells,Expert,5833.0,,F,,BAO_0000218,10805,,,1,CHEMBL620988,,,Plasmodium falciparum,N,1,,
4355,Inhibitory activity against Plasmodium falciparum 68 neutral proteinase.,Expert,5833.0,,F,,BAO_0000218,10805,,,1,CHEMBL620989,,,Plasmodium falciparum,N,1,,
4356,Substrate affinity for Plasmodium falciparum 68 neutral proteinase.,Expert,5833.0,,F,,BAO_0000218,10805,,,1,CHEMBL620990,,,Plasmodium falciparum,N,1,,
4357,Reaction velocity for Plasmodium falciparum 68 neutral proteinase.,Intermediate,5833.0,,F,,BAO_0000218,10805,,,1,CHEMBL620991,,,Plasmodium falciparum,N,1,,
4358,Percent inhibition against 6C3HED lymphosarcoma at dose 100 mg/kg in C3H mice,Intermediate,10090.0,,F,,BAO_0000218,10144,,850.0,1,CHEMBL620992,6C3HED,,Mus musculus,N,1,,
4359,Percent inhibition against 6C3HED lymphosarcoma at dose 12.5 mg/kg in C3H mice,Intermediate,10090.0,,F,,BAO_0000218,10144,,850.0,1,CHEMBL620993,6C3HED,,Mus musculus,N,1,,
4360,Percent inhibition against 6C3HED lymphosarcoma at dose 200 mg/kg in C3H mice,Intermediate,10090.0,,F,,BAO_0000218,10144,,850.0,1,CHEMBL620994,6C3HED,,Mus musculus,N,1,,
4361,Percent inhibition against 6C3HED lymphosarcoma at dose 25 mg/kg in C3H mice,Intermediate,10090.0,,F,,BAO_0000218,10144,,850.0,1,CHEMBL620995,6C3HED,,Mus musculus,N,1,,
4362,Percent inhibition against 6C3HED lymphosarcoma at dose 50 mg/kg in C3H mice,Intermediate,10090.0,,F,,BAO_0000218,10144,,850.0,1,CHEMBL620996,6C3HED,,Mus musculus,N,1,,
4363,Percent inhibition against 6C3HED lymphosarcoma at dose 6 mg/kg in C3H mice,Intermediate,10090.0,,F,,BAO_0000218,10144,,850.0,1,CHEMBL875581,6C3HED,,Mus musculus,N,1,,
4364,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 100 mg/kg,Autocuration,10090.0,,F,,BAO_0000218,10685,,,1,CHEMBL620997,,,Mus musculus,U,0,,
4365,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 150 mg/kg,Autocuration,10090.0,,F,,BAO_0000218,10685,,,1,CHEMBL620998,,,Mus musculus,U,0,,
4366,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 1600 mg/kg (intraperitoneal dosing for 8 days),Autocuration,10090.0,,F,,BAO_0000218,10685,,,1,CHEMBL620999,,,Mus musculus,U,0,,
4367,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 200 mg/kg,Autocuration,10090.0,,F,,BAO_0000218,10685,,,1,CHEMBL621000,,,Mus musculus,U,0,,
4368,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 225 mg/kg,Autocuration,10090.0,,F,,BAO_0000218,10685,,,1,CHEMBL621001,,,Mus musculus,U,0,,
4369,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 270 mg/kg,Autocuration,10090.0,,F,,BAO_0000218,10685,,,1,CHEMBL621002,,,Mus musculus,U,0,,
4370,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 275 mg/kg,Autocuration,10090.0,,F,,BAO_0000218,10685,,,1,CHEMBL621003,,,Mus musculus,U,0,,
4371,"Antitumor activity in vivo against the 6C3HED lymphosarcoma, dosed for 10 days at 300 mg/kg",Autocuration,10090.0,,F,,BAO_0000218,10685,,,1,CHEMBL621004,,,Mus musculus,U,0,,
4372,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 300 mg/kg (intraperitoneal dosing for 8 days),Autocuration,10090.0,,F,,BAO_0000218,10685,,,1,CHEMBL621005,,,Mus musculus,U,0,,
4373,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 300 mg/kg (ip dosing daily for 8 days),Autocuration,10090.0,,F,,BAO_0000218,10685,,,1,CHEMBL621006,,,Mus musculus,U,0,,
4374,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 600 mg/kg,Autocuration,10090.0,,F,,BAO_0000218,10685,,,1,CHEMBL621007,,,Mus musculus,U,0,,
4375,Percent inhibition against 6C3HED lymphosarcoma at dose 100 mg/kg in C3H mice,Autocuration,10090.0,,F,,BAO_0000218,10144,,,1,CHEMBL621008,,,Mus musculus,U,0,,
4376,Percent inhibition against 6C3HED lymphosarcoma at dose 12.5 mg/kg in C3H mice,Autocuration,10090.0,,F,,BAO_0000218,10144,,,1,CHEMBL621009,,,Mus musculus,U,0,,
4377,Percent inhibition against 6C3HED lymphosarcoma at dose 25 mg/kg in C3H mice,Autocuration,10090.0,,F,,BAO_0000218,10144,,,1,CHEMBL857705,,,Mus musculus,U,0,,
4378,Percent inhibition against 6C3HED lymphosarcoma at dose 50 mg/kg in C3H mice,Autocuration,10090.0,,F,,BAO_0000218,10144,,,1,CHEMBL619828,,,Mus musculus,U,0,,
4379,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 100 mg/kg dosage administered for 8 days intraperitoneally,Autocuration,10090.0,,F,,BAO_0000218,10685,,,1,CHEMBL619829,,,Mus musculus,U,0,,
4380,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 200 mg/kg dosage administered for 10 days intraperitoneally,Autocuration,10090.0,,F,,BAO_0000218,10685,,,1,CHEMBL619830,,,Mus musculus,U,0,,
4381,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 200 mg/kg dosage administered for 8 days intraperitoneally,Autocuration,10090.0,,F,,BAO_0000218,10685,,,1,CHEMBL619831,,,Mus musculus,U,0,,
4382,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 50 mg/kg dosage administered for 8 days intraperitoneally,Autocuration,10090.0,,F,,BAO_0000218,10685,,,1,CHEMBL619832,,,Mus musculus,U,0,,
4383,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 100 mg/kg dosage administered for 8 days intraperitoneally; 0/10,Autocuration,10090.0,,A,,BAO_0000218,10685,,,1,CHEMBL619833,,,Mus musculus,U,0,,
4384,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 200 mg/kg dosage administered for 8 days perorally; 1/10,Autocuration,10090.0,,A,,BAO_0000218,10685,,,1,CHEMBL619834,,,Mus musculus,U,0,,
4385,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 200 mg/kg dosage administered for 10 days intraperitoneally; 1/10,Autocuration,10090.0,,A,,BAO_0000218,10685,,,1,CHEMBL619835,,,Mus musculus,U,0,,
4386,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 50 mg/kg dosage administered for 8 days perorally; 3/10,Autocuration,10090.0,,A,,BAO_0000218,10685,,,1,CHEMBL619836,,,Mus musculus,U,0,,
4387,"Compound was evaluated for the antitumor activity against 6C3HED lymphosarcoma for ip administration and daily x 8 schedule; Number of toxic deaths over total number of mice per group (T/C), 0/10 at dose of 35 mg/kg",Intermediate,10090.0,,F,,BAO_0000218,8831,,850.0,1,CHEMBL619837,6C3HED,,Mus musculus,N,1,,
4388,In vivo antitumor activity against 6C3HED tumor type after intraperitoneal administration of 400 mg/kg,Autocuration,,,F,,BAO_0000218,11704,,,1,CHEMBL619838,,,,U,0,,
4389,In vivo antitumor activity against 6C3HED tumor type was expressed as toxic deaths/total treated mice at 400 mg/kg dose; 2/10,Intermediate,10090.0,,A,,BAO_0000218,11704,,,1,CHEMBL619839,,,Mus musculus,N,1,,
4390,Antitumor activity in vivo expressed as percent of inhibition in 6C3HED-lymphosarcoma tumor cell line,Intermediate,10090.0,,F,,BAO_0000218,10685,,850.0,1,CHEMBL619840,6C3HED,,Mus musculus,N,1,,
4391,Antitumor activity in vivo expressed as percent of inhibition in 6C3HED-lymphosarcoma tumor cell line; 95-100% inhibition,Intermediate,10090.0,,F,,BAO_0000218,10685,,850.0,1,CHEMBL619841,6C3HED,,Mus musculus,N,1,,
4392,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 150 mg/kg given orally(daily x 8),Expert,10090.0,,F,,BAO_0000218,11368,,850.0,1,CHEMBL857704,6C3HED,,Mus musculus,N,1,,
4393,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 200 mg/kg given orally(daily x 8),Intermediate,10090.0,,F,,BAO_0000218,11368,,850.0,1,CHEMBL619842,6C3HED,,Mus musculus,N,1,,
4394,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 300 mg/kg given orally (daily x 8),Expert,10090.0,,F,,BAO_0000218,11368,,850.0,1,CHEMBL619843,6C3HED,,Mus musculus,N,1,,
4395,"Inhibition of Staphylococcus aureus 7,8-dihydroneopterin aldolase",Autocuration,1280.0,,B,,BAO_0000019,17763,,,1,CHEMBL619844,,,Staphylococcus aureus,U,0,,
4396,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at a concentration of 5 uM,Autocuration,10116.0,,B,,BAO_0000251,7411,Microsomes,,1,CHEMBL857855,,,Rattus norvegicus,U,0,2107.0,
4397,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 10 uM,Autocuration,10116.0,,B,,BAO_0000251,7411,Microsomes,,1,CHEMBL619845,,,Rattus norvegicus,U,0,2107.0,
4398,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 1 uM,Autocuration,10116.0,,B,,BAO_0000251,7411,Microsomes,,1,CHEMBL619846,,,Rattus norvegicus,U,0,2107.0,
4399,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 20 uM,Autocuration,10116.0,,B,,BAO_0000251,7411,Microsomes,,1,CHEMBL619847,,,Rattus norvegicus,U,0,2107.0,
4400,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 25 uM,Autocuration,10116.0,,B,,BAO_0000251,7411,Microsomes,,1,CHEMBL619848,,,Rattus norvegicus,U,0,2107.0,
4401,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 50 uM,Autocuration,10116.0,,B,,BAO_0000251,7411,Microsomes,,1,CHEMBL620893,,,Rattus norvegicus,U,0,2107.0,
4402,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 5 uM,Autocuration,10116.0,,B,,BAO_0000251,7411,Microsomes,,1,CHEMBL620894,,,Rattus norvegicus,U,0,2107.0,
4403,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 10 uM,Autocuration,10116.0,,B,,BAO_0000251,7411,Microsomes,,1,CHEMBL620895,,,Rattus norvegicus,U,0,2107.0,
4404,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 100 uM,Autocuration,10116.0,,B,,BAO_0000251,7411,Microsomes,,1,CHEMBL620896,,,Rattus norvegicus,U,0,2107.0,
4405,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 200 uM,Autocuration,10116.0,,B,,BAO_0000251,7411,Microsomes,,1,CHEMBL620897,,,Rattus norvegicus,U,0,2107.0,
4406,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 25 uM,Autocuration,10116.0,,B,,BAO_0000251,7411,Microsomes,,1,CHEMBL620898,,,Rattus norvegicus,U,0,2107.0,
4407,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 50 uM,Autocuration,10116.0,,B,,BAO_0000251,7411,Microsomes,,1,CHEMBL620899,,,Rattus norvegicus,U,0,2107.0,
4408,The apparent total plasma clearance in monkey,Autocuration,9527.0,,A,,BAO_0000218,347,,,1,CHEMBL620900,,,Cercopithecidae,U,0,1969.0,
4409,Compound was evaluated for Hepatic clearance in monkey,Autocuration,9527.0,,A,,BAO_0000218,3341,,,1,CHEMBL620901,,,Cercopithecidae,U,0,,
4410,Lower clearance in monkey (i.v.) at 0.5 mpk,Autocuration,9527.0,,A,,BAO_0000218,17853,,,1,CHEMBL620902,,,Cercopithecidae,U,0,,
4411,Plasma clearance in rhesus monkey,Autocuration,9527.0,,A,,BAO_0000218,4514,,,1,CHEMBL620903,,,Cercopithecidae,U,0,,
4412,Plasma clearance for the compound was measured in monkey after an iv dose of 1 mg/kg,Autocuration,9527.0,,A,,BAO_0000218,6062,,,1,CHEMBL620904,,,Cercopithecidae,U,0,,
4413,Plasma clearance of compound was determined in monkey,Autocuration,9527.0,,A,,BAO_0000218,6821,,,1,CHEMBL620905,,,Cercopithecidae,U,0,,
4414,Plasma clearance was calculated in rhesus monkey,Autocuration,9527.0,,A,,BAO_0000218,6057,,,1,CHEMBL620906,,,Cercopithecidae,U,0,,
4415,Plasma clearance in rhesus monkey,Autocuration,9527.0,,A,,BAO_0000218,5145,,,1,CHEMBL875420,,,Cercopithecidae,U,0,,
4416,Plasma clearance in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),Autocuration,9527.0,,A,,BAO_0000218,6641,,,1,CHEMBL620907,,,Cercopithecidae,U,0,,
4417,Plasma clearance was evaluated in rhesus,Autocuration,9527.0,,A,,BAO_0000218,5472,,,1,CHEMBL620908,,,Cercopithecidae,U,0,,
4418,Plasma clearance value was determined in monkey after a 3 mg/kg of iv dose,Autocuration,9527.0,,A,,BAO_0000218,4257,,,1,CHEMBL620909,,,Cercopithecidae,U,0,,
4419,Plasma clearance was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,Autocuration,9527.0,,A,,BAO_0000218,5546,,,1,CHEMBL620910,,,Cercopithecidae,U,0,,
4420,Plasma clearance was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),Autocuration,9527.0,,A,,BAO_0000218,5334,,,1,CHEMBL620911,,,Cercopithecidae,U,0,,
4421,Plasma clearance was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),Autocuration,9527.0,,A,,BAO_0000218,5334,,,1,CHEMBL620912,,,Cercopithecidae,U,0,,
4422,Cmax 24 hr after 2 mg/kg oral administration in monkeys,Autocuration,9527.0,,A,,BAO_0000218,17509,,,1,CHEMBL620913,,,Cercopithecidae,U,0,,
4423,Cmax in monkey after administration of 1 mg/kg iv,Autocuration,9527.0,,A,,BAO_0000218,6535,,,1,CHEMBL620914,,,Cercopithecidae,U,0,,
4424,Cmax was determine after peroral administration at 10 mpk in Rhesus,Autocuration,9527.0,,A,,BAO_0000218,5668,,,1,CHEMBL620915,,,Cercopithecidae,U,0,,
4425,Cmax in cynomolgus monkey by iv administration,Autocuration,9527.0,,A,,BAO_0000218,5922,,,1,CHEMBL620916,,,Cercopithecidae,U,0,,
4426,Cmax in cynomolgus monkey by po administration,Autocuration,9527.0,,A,,BAO_0000218,5922,,,1,CHEMBL620917,,,Cercopithecidae,U,0,,
4427,Cmax value evaluated in monkey,Autocuration,9527.0,,A,,BAO_0000218,6078,,,1,CHEMBL620918,,,Cercopithecidae,U,0,,
4428,Compound was evaluated for maximum concentration after treatment with oral dose of 2 mgkg to female cynomolgus monkey,Autocuration,9527.0,,A,,BAO_0000218,2661,,,1,CHEMBL620919,,,Cercopithecidae,U,0,,
4429,Maximal concentration (Cmax) in rhesus monkey plasma at a dose of 5 mg/kg,Autocuration,9527.0,,A,,BAO_0000218,3249,,,1,CHEMBL620920,,,Cercopithecidae,U,0,1969.0,
4430,Maximal concentration (Cmax) in squirrel monkey plasma at a dose of 5 mg/kg,Autocuration,9527.0,,A,,BAO_0000218,3249,,,1,CHEMBL620921,,,Cercopithecidae,U,0,1969.0,
4431,Maximal plasma concentration in squirrel monkeys,Autocuration,9527.0,,A,,BAO_0000218,5553,,,1,CHEMBL620922,,,Cercopithecidae,U,0,1969.0,
4432,Maximum concentration was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,Autocuration,9527.0,,A,,BAO_0000218,1916,,,1,CHEMBL620923,,,Cercopithecidae,U,0,,
4433,Maximum plasma concentration (Cmax) in rhesus monkey(in vivo) at a dose of 5 mg/kg,Autocuration,9527.0,,A,,BAO_0000218,6227,,,1,CHEMBL620924,,,Cercopithecidae,U,0,1969.0,
4434,Pharmacokinetic parameter Cmax was determined in monkey after (po) administration of a dose of 50 (uM/kg),Autocuration,9527.0,,A,,BAO_0000218,4809,,,1,CHEMBL620925,,,Cercopithecidae,U,0,,
4435,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys; NA means Not applicable,Autocuration,9527.0,,A,,BAO_0000218,5355,,,1,CHEMBL620926,,,Cercopithecidae,U,0,,
4436,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys; NA means not applicable,Autocuration,9527.0,,A,,BAO_0000218,5355,,,1,CHEMBL620927,,,Cercopithecidae,U,0,,
4437,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys;NA means not applicable,Autocuration,9527.0,,A,,BAO_0000218,5355,,,1,CHEMBL620928,,,Cercopithecidae,U,0,,
4438,The peak concentration (Cmax) value after oral administration in cynomolgus monkeys,Autocuration,9527.0,,A,,BAO_0000218,5355,,,1,CHEMBL620929,,,Cercopithecidae,U,0,,
4439,The peak plasma concentration after 5 hr administration (2.5 mg/kg) in monkey was determined,Autocuration,9527.0,,A,,BAO_0000218,6221,,,1,CHEMBL620930,,,Cercopithecidae,U,0,1969.0,
4440,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Monkey at maximum of 0.4 hours,Autocuration,9527.0,,A,,BAO_0000218,167,,,1,CHEMBL620931,,,Cercopithecidae,U,0,,
4441,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Monkey at maximum of 1.0 hours,Autocuration,9527.0,,A,,BAO_0000218,167,,,1,CHEMBL620932,,,Cercopithecidae,U,0,,
4442,Absolute bioavailability was evaluated in monkey,Autocuration,9443.0,,A,,BAO_0000218,4257,,,1,CHEMBL620933,,,monkey,U,0,,
4443,Bioavailability after oral administration (2.5 mg/kg) in monkey was determined,Autocuration,9443.0,,A,,BAO_0000218,6221,,,1,CHEMBL620934,,,monkey,U,0,,
4444,Bioavailability of compound at 3 mg/kg in monkey after i.v. administration,Autocuration,9443.0,,A,,BAO_0000218,17667,,,1,CHEMBL620935,,,monkey,U,0,,
4445,Bioavailability of compound was determined in rhesus monkey,Autocuration,9544.0,,A,,BAO_0000218,17267,,,1,CHEMBL620936,,,Macaca mulatta,U,0,,
4446,Bioavailability determined after oral administration in marmoset,Autocuration,38020.0,,A,,BAO_0000218,4256,,,1,CHEMBL620937,,,marmosets,U,0,,
4447,Oral bioavailability in cynomolgus monkey,Autocuration,9541.0,,A,,BAO_0000218,4256,,,1,CHEMBL620938,,,Macaca fascicularis,U,0,,
4448,Bioavailability in monkey (p.o.) at 2.0 mpk,Autocuration,9443.0,,A,,BAO_0000218,17853,,,1,CHEMBL620939,,,monkey,U,0,,
4449,Bioavailability was evaluated after oral administration in monkey,Autocuration,9443.0,,A,,BAO_0000218,16365,,,1,CHEMBL620940,,,monkey,U,0,,
4450,Bioavailability was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,Autocuration,9541.0,,A,,BAO_0000218,1916,,,1,CHEMBL620941,,,Macaca fascicularis,U,0,,
4451,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),Autocuration,9544.0,,A,,BAO_0000218,5334,,,1,CHEMBL620942,,,Macaca mulatta,U,0,,
4452,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),Autocuration,9544.0,,A,,BAO_0000218,5334,,,1,CHEMBL620943,,,Macaca mulatta,U,0,,
4453,Bioavailability of the compound was determined in monkey,Autocuration,9443.0,,A,,BAO_0000218,17592,,,1,CHEMBL620944,,,monkey,U,0,,
4454,Bioavailability in squirrel monkey (dose 5 mg/kg),Autocuration,9521.0,,A,,BAO_0000218,1399,,,1,CHEMBL620945,,,Saimiri sciureus,U,0,,
4455,Bioavailability was determined in monkey after (po) administration of a dose of 50 (uM/kg),Autocuration,9443.0,,A,,BAO_0000218,4809,,,1,CHEMBL620946,,,monkey,U,0,,
4456,Oral bioavailability in monkey,Autocuration,9443.0,,A,,BAO_0000218,3341,,,1,CHEMBL620947,,,monkey,U,0,,
4457,Compound was tested for bioavailability in squirrel monkey,Autocuration,9521.0,,A,,BAO_0000218,64,,,1,CHEMBL620948,,,Saimiri sciureus,U,0,,
4458,Oral bioavailability in Rhesus monkey,Autocuration,9544.0,,A,,BAO_0000218,5005,,,1,CHEMBL620949,,,Macaca mulatta,U,0,,
4459,Oral bioavailability in Rhesus monkey (dose of 0.75 mg/kg i.v. and 1.5 mg/kg p.o.),Autocuration,9544.0,,A,,BAO_0000218,5005,,,1,CHEMBL620950,,,Macaca mulatta,U,0,,
4460,Oral bioavailability in cynomolgus monkeys for the compound was determined; Acceptable,Autocuration,9541.0,,A,,BAO_0000218,5237,,,1,CHEMBL620951,,,Macaca fascicularis,U,0,,
4461,Oral bioavailability in cynomolgus monkeys was determined; Acceptable,Autocuration,9541.0,,A,,BAO_0000218,5237,,,1,CHEMBL620952,,,Macaca fascicularis,U,0,,
4462,Oral bioavailability in monkey (dose 5 mg/kg),Autocuration,9443.0,,A,,BAO_0000218,5302,,,1,CHEMBL875421,,,monkey,U,0,,
4463,Oral bioavailability of compound at 5 mg/kg in monkey,Autocuration,9443.0,,A,,BAO_0000218,17667,,,1,CHEMBL620953,,,monkey,U,0,,
4464,Pharmacokinetic profile in terms of half life was determined at a dose of 0.5 mg/kg administered intravenously in dog,Intermediate,9615.0,,A,,BAO_0000218,6161,,,1,CHEMBL873491,,,Canis lupus familiaris,N,1,,
4465,Pharmacokinetic profile in terms of half life was determined at a dose of 5 mg/kg administered intravenously in dog,Intermediate,9615.0,,A,,BAO_0000218,6161,,,1,CHEMBL620954,,,Canis lupus familiaris,N,1,,
4466,Plasma half life determined,Intermediate,9615.0,,A,,BAO_0000218,3854,,,1,CHEMBL620955,,,Canis lupus familiaris,N,1,1969.0,
4467,Plasma half life in dog,Intermediate,9615.0,,A,,BAO_0000218,993,,,1,CHEMBL618097,,,Canis lupus familiaris,N,1,1969.0,
4468,Plasma half-life in Beagle dogs,Intermediate,9615.0,,A,,BAO_0000218,4514,,,1,CHEMBL618268,,,Canis lupus familiaris,N,1,1969.0,
4469,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),Intermediate,9615.0,,A,,BAO_0000218,5334,,,1,CHEMBL618269,,,Canis lupus familiaris,N,1,1969.0,
4470,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg respectively in Beagle dog (male),Intermediate,9615.0,,A,,BAO_0000218,5334,,,1,CHEMBL618270,,,Canis lupus familiaris,N,1,1969.0,
4471,Tested for t1/2 upon intravenous administration of 5.0 mg/Kg dose in dog,Intermediate,9615.0,,A,,BAO_0000218,1466,,,1,CHEMBL618271,,,Canis lupus familiaris,N,1,,
4472,Tested for t1/2 upon peroral administration of 10.0 mg/Kg dose in dog,Intermediate,9615.0,,A,,BAO_0000218,1466,,,1,CHEMBL873493,,,Canis lupus familiaris,N,1,,
4473,Tested for the half life period in dog,Intermediate,9615.0,,A,,BAO_0000218,5313,,,1,CHEMBL621031,,,Canis lupus familiaris,N,1,,
4474,Tested for the half life period in dog at dosage of 10 mpk,Intermediate,9615.0,,A,,BAO_0000218,5313,,,1,CHEMBL621032,,,Canis lupus familiaris,N,1,,
4475,The compound was tested for half life in dog,Intermediate,9615.0,,A,,BAO_0000218,3880,,,1,CHEMBL621033,,,Canis lupus familiaris,N,1,,
4476,"The compound was tested for time taken to decrease, half of its initial concentration in dog plasma.",Intermediate,9615.0,,A,,BAO_0000218,3639,,,1,CHEMBL621034,,,Canis lupus familiaris,N,1,1969.0,
4477,The half life was determined,Intermediate,9615.0,,A,,BAO_0000218,3880,,,1,CHEMBL621035,,,Canis lupus familiaris,N,1,,
4478,The plasma half-life in dogs,Intermediate,9615.0,,A,,BAO_0000218,3918,,,1,CHEMBL621036,,,Canis lupus familiaris,N,1,1969.0,
4479,suboptimal plasma half-life caused a10% prolongation of QTc interval in dogs at a plasma level of 2.5 M,Intermediate,9615.0,,A,,BAO_0000218,16452,,,1,CHEMBL621037,,,Canis lupus familiaris,N,1,1969.0,
4480,Half life in dog,Intermediate,9615.0,,A,,BAO_0000218,17796,,,1,CHEMBL619812,,,Canis lupus familiaris,N,1,,
4481,Pharmacokinetic property (t1/2beta) was measured in dog at the dose of 0.032 mg/kg i.v.,Intermediate,9615.0,,A,,BAO_0000218,5983,,,1,CHEMBL619813,,,Canis lupus familiaris,N,1,,
4482,tmax upon peroral administration of 10.0 mg/Kg dose in dog,Intermediate,9615.0,,A,,BAO_0000218,1466,,,1,CHEMBL873335,,,Canis lupus familiaris,N,1,,
4483,Volume of distribution in Beagle dogs after intravenous administration at a dose of 10 mg/kg,Intermediate,9615.0,,A,,BAO_0000218,16456,,,1,CHEMBL619814,,,Canis lupus familiaris,N,1,,
4484,Cmax in ferrets after 30 mg/kg oral dose,Expert,9669.0,,A,,BAO_0000218,6113,,,1,CHEMBL619815,,,Mustela putorius furo,N,1,,
4485,Emesis in ferrets at 30 mg/kg oral dose,Expert,9669.0,,F,,BAO_0000218,6113,,,1,CHEMBL619816,,,Mustela putorius furo,N,1,,
4486,Bioavailability in cynomolgus monkey,Autocuration,9541.0,,A,,BAO_0000218,17796,,,1,CHEMBL619817,,,Macaca fascicularis,U,0,,
4487,Volume of distribution in cynomolgus,Intermediate,9541.0,,A,,BAO_0000218,17796,,,1,CHEMBL619818,,,Macaca fascicularis,N,1,,
4488,AUC tested in guinea pig when 3 mg/kg dose was given perorally,Autocuration,10141.0,,A,,BAO_0000218,5308,,,1,CHEMBL619819,,,Cavia porcellus,U,0,1969.0,
4489,Tested for concentration as Area Under Curve against PDE4 in guinea pig lung eosinophilia orally at 5 mg/kg,Autocuration,10141.0,,A,,BAO_0000218,4877,,,1,CHEMBL619820,,,Cavia porcellus,U,0,,
4490,"Tested for the pharmacokinetic parameter in guinea pig, administered orally at 5 mg/kg",Autocuration,10141.0,,A,,BAO_0000218,4876,,,1,CHEMBL875419,,,Cavia porcellus,U,0,,
4491,AUC in guinea pig after 3mg/kg oral dose,Autocuration,10141.0,,A,,BAO_0000218,4878,,,1,CHEMBL619821,,,Cavia porcellus,U,0,1969.0,
4492,Bioavailability in guinea pig was tested,Autocuration,10141.0,,A,,BAO_0000218,5308,,,1,CHEMBL619822,,,Cavia porcellus,U,0,,
4493,Tested for oral bioavailability in guinea pig at 5 mg/kg,Autocuration,10141.0,,A,,BAO_0000218,4877,,,1,CHEMBL619823,,,Cavia porcellus,U,0,,
4494,Tested for the oral bioavailability of the compound,Autocuration,10141.0,,A,,BAO_0000218,4876,,,1,CHEMBL619824,,,Cavia porcellus,U,0,,
4495,Compound at a dose 5 mg/kg was administered orally to guinea pig and the pharmacokinetic parameter (Cmax) was reported,Autocuration,10141.0,,A,,BAO_0000218,4876,,,1,CHEMBL619825,,,Cavia porcellus,U,0,,
4496,Maximum plsma drug concentration in guinea pig when 3 mg/kg dose was given perorally,Autocuration,10141.0,,A,,BAO_0000218,5308,,,1,CHEMBL619826,,,Cavia porcellus,U,0,,
4497,Tested for maximum concentration against PDE4 in guinea pig lung eosinophilia orally at 5 mg/kg,Autocuration,10141.0,,A,,BAO_0000218,4877,,,1,CHEMBL619827,,,Cavia porcellus,U,0,2048.0,
4498,Cmax in guinea pig after 3mg/kg oral dose,Autocuration,10141.0,,A,,BAO_0000218,4878,,,1,CHEMBL618167,,,Cavia porcellus,U,0,,
4499,Distribution in blood expressed as [18F]- organ uptake in % of injected activity/gram,Autocuration,10141.0,,A,,BAO_0000019,5689,,,1,CHEMBL618168,,,Cavia porcellus,U,0,178.0,
4500,Distribution in brain expressed as [18F]- organ uptake in % of injected activity/gram,Autocuration,10141.0,,A,,BAO_0000019,5689,,,1,CHEMBL618169,,,Cavia porcellus,U,0,955.0,
4501,Distribution in heart expressed as [18F]- organ uptake in % of injected activity/gram,Autocuration,10141.0,,A,,BAO_0000019,5689,,,1,CHEMBL618170,,,Cavia porcellus,U,0,,
4502,Distribution in intestine expressed as [18F]- organ uptake in % of injected activity/gram,Autocuration,10141.0,,A,,BAO_0000019,5689,,,1,CHEMBL618171,,,Cavia porcellus,U,0,160.0,
4503,Distribution in kidney expressed as [18F]- organ uptake in % of injected activity/gram,Autocuration,10141.0,,A,,BAO_0000019,5689,,,1,CHEMBL618172,,,Cavia porcellus,U,0,2113.0,
4504,Distribution in liver expressed as [18F]- organ uptake in % of injected activity/gram,Autocuration,10141.0,,A,,BAO_0000019,5689,,,1,CHEMBL618173,,,Cavia porcellus,U,0,2107.0,
4505,Distribution in lung expressed as [18F]- organ uptake in % of injected activity/gram,Autocuration,10141.0,,A,,BAO_0000019,5689,,,1,CHEMBL618174,,,Cavia porcellus,U,0,,
4506,Distribution in spleen expressed as [18F]- organ uptake in % of injected activity/gram,Autocuration,10141.0,,A,,BAO_0000019,5689,,,1,CHEMBL875408,,,Cavia porcellus,U,0,2106.0,
4507,Elimination T1/2 in Guinea pig (PO dose),Autocuration,10141.0,,A,,BAO_0000218,14465,,,1,CHEMBL839827,,,Cavia porcellus,U,0,,
4508,Partition coefficient was measured as -log (counts per min ),Autocuration,10141.0,,A,,BAO_0000019,5689,,,1,CHEMBL618175,,,Cavia porcellus,U,0,,
4509,Biological half life when administered at 0.1 umol/kg intravenously to guinea pig in GR-64349 antagonism,Autocuration,10141.0,,A,,BAO_0000218,611,,,1,CHEMBL618176,,,Cavia porcellus,U,0,,
4510,Biological half life when administered at 5 umol/kg intravenously to guinea pig in GR-64349 antagonism,Autocuration,10141.0,,A,,BAO_0000218,611,,,1,CHEMBL618177,,,Cavia porcellus,U,0,,
4511,Elimination T1/2 in Guinea pig (PO dose),Autocuration,10141.0,,A,,BAO_0000218,14465,,,1,CHEMBL618178,,,Cavia porcellus,U,0,,
4512,"Tested for the half life period of the compound, intravenously",Autocuration,10141.0,,A,,BAO_0000218,4876,,,1,CHEMBL618179,,,Cavia porcellus,U,0,,
4513,Half-life was measured,Autocuration,10141.0,,A,,BAO_0000019,5689,,,1,CHEMBL873489,,,Cavia porcellus,U,0,,
4514,The time required for onset of inotropy after addition of a single dose of delta F75,Autocuration,10141.0,,A,,BAO_0000019,7515,,,1,CHEMBL618180,,,Cavia porcellus,U,0,,
4515,Bioavailability of compound at 10 mg/kg in guinea pig after i.v. administration,Autocuration,10141.0,,A,,BAO_0000218,17667,,,1,CHEMBL618181,,,Cavia porcellus,U,0,,
4516,Bioavailability of compound at 3 mg/kg in guinea pig after i.v. administration,Autocuration,10141.0,,A,,BAO_0000218,17667,,,1,CHEMBL618182,,,Cavia porcellus,U,0,,
4517,Plasma clearance was measured in hamster at the dose of 10 mg/kg by peroral administration,Autocuration,10029.0,,A,,BAO_0000218,4727,,,1,CHEMBL618183,,,Cricetulus griseus,U,0,,
4518,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,Intermediate,10090.0,,A,,BAO_0000218,10107,,,1,CHEMBL618184,,,Mus musculus,N,1,,
4519,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,Intermediate,10090.0,,A,,BAO_0000218,10107,,,1,CHEMBL618185,,,Mus musculus,N,1,,
4520,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,Intermediate,10090.0,,A,,BAO_0000218,10107,,,1,CHEMBL618186,,,Mus musculus,N,1,,
4521,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,Intermediate,10090.0,,A,,BAO_0000218,10107,,,1,CHEMBL618187,,,Mus musculus,N,1,,
4522,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hr,Intermediate,10090.0,,A,,BAO_0000218,10107,,,1,CHEMBL618188,,,Mus musculus,N,1,,
4523,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,Intermediate,10090.0,,A,,BAO_0000218,10107,,,1,CHEMBL875409,,,Mus musculus,N,1,,
4524,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,Intermediate,10090.0,,A,,BAO_0000218,10107,,,1,CHEMBL618189,,,Mus musculus,N,1,,
4525,Biodistribution of the injected compound in blood of female BALB/C mice for 0.5 hours,Intermediate,10090.0,,A,,BAO_0000218,3655,,,1,CHEMBL618190,,,Mus musculus,N,1,178.0,
4526,Biodistribution of the injected compound in blood of female BALB/C mice for 2.5 hours,Intermediate,10090.0,,A,,BAO_0000218,3655,,,1,CHEMBL618191,,,Mus musculus,N,1,178.0,
4527,Biodistribution of the injected compound in blood of female BALB/C mice for 5 hours,Intermediate,10090.0,,A,,BAO_0000218,3655,,,1,CHEMBL618192,,,Mus musculus,N,1,178.0,
4528,Biodistribution of the injected compound in bone of female BALB/C mice for 0.5 hours,Intermediate,10090.0,,A,,BAO_0000218,3655,,,1,CHEMBL618193,,,Mus musculus,N,1,10000001.0,
4529,Biodistribution of the injected compound in bone of female BALB/C mice for 2.5 hours,Intermediate,10090.0,,A,,BAO_0000218,3655,,,1,CHEMBL618194,,,Mus musculus,N,1,10000001.0,
4530,Biodistribution of the injected compound in bone of female BALB/C mice for 5 hours,Intermediate,10090.0,,A,,BAO_0000218,3655,,,1,CHEMBL618195,,,Mus musculus,N,1,10000001.0,
4531,Biodistribution of the injected compound in brain of female BALB/C mice for 0.5 hours,Intermediate,10090.0,,A,,BAO_0000218,3655,,,1,CHEMBL618196,,,Mus musculus,N,1,955.0,
4532,Biodistribution of the injected compound in brain of female BALB/C mice for 2.5 hours,Intermediate,10090.0,,A,,BAO_0000218,3655,,,1,CHEMBL618197,,,Mus musculus,N,1,955.0,
4533,Biodistribution of the injected compound in brain of female BALB/C mice for 5 hours,Intermediate,10090.0,,A,,BAO_0000218,3655,,,1,CHEMBL618198,,,Mus musculus,N,1,955.0,
4534,Biodistribution of the injected compound in heart of female BALB/C mice for 0.5 hours,Intermediate,10090.0,,A,,BAO_0000218,3655,,,1,CHEMBL618199,,,Mus musculus,N,1,948.0,
4535,Biodistribution of the injected compound in heart of female BALB/C mice for 2.5 hours,Intermediate,10090.0,,A,,BAO_0000218,3655,,,1,CHEMBL618200,,,Mus musculus,N,1,948.0,
4536,Biodistribution of the injected compound in heart of female BALB/C mice for 5 hours,Intermediate,10090.0,,A,,BAO_0000218,3655,,,1,CHEMBL618201,,,Mus musculus,N,1,948.0,
4537,Biodistribution of the injected compound in intestines of female BALB/C mice for 0.5 hours,Intermediate,10090.0,,A,,BAO_0000218,3655,,,1,CHEMBL618202,,,Mus musculus,N,1,160.0,
4538,Biodistribution of the injected compound in intestines of female BALB/C mice for 2.5 hours,Intermediate,10090.0,,A,,BAO_0000218,3655,,,1,CHEMBL618203,,,Mus musculus,N,1,160.0,
4539,Biodistribution of the injected compound in intestines of female BALB/C mice for 5 hours,Intermediate,10090.0,,A,,BAO_0000218,3655,,,1,CHEMBL618204,,,Mus musculus,N,1,160.0,
4540,Biodistribution of the injected compound in kidneys of female BALB/C mice for 0.5 hours,Intermediate,10090.0,,A,,BAO_0000218,3655,,,1,CHEMBL618205,,,Mus musculus,N,1,2113.0,
4541,Biodistribution of the injected compound in kidneys of female BALB/C mice for 2.5 hours,Intermediate,10090.0,,A,,BAO_0000218,3655,,,1,CHEMBL618206,,,Mus musculus,N,1,2113.0,
4542,Biodistribution of the injected compound in kidneys of female BALB/C mice for 5 hours,Intermediate,10090.0,,A,,BAO_0000218,3655,,,1,CHEMBL618207,,,Mus musculus,N,1,2113.0,
4543,Biodistribution of the injected compound in liver of female BALB/C mice for 0.5 hours,Intermediate,10090.0,,A,,BAO_0000218,3655,,,1,CHEMBL618208,,,Mus musculus,N,1,2107.0,
4544,Biodistribution of the injected compound in liver of female BALB/C mice for 2.5 hours,Intermediate,10090.0,,A,,BAO_0000218,3655,,,1,CHEMBL618932,,,Mus musculus,N,1,2107.0,
4545,Biodistribution of the injected compound in liver of female BALB/C mice for 5 hours,Intermediate,10090.0,,A,,BAO_0000218,3655,,,1,CHEMBL618933,,,Mus musculus,N,1,2107.0,
4546,Biodistribution of the injected compound in lung of female BALB/C mice for 0.5 hours,Intermediate,10090.0,,A,,BAO_0000218,3655,,,1,CHEMBL618934,,,Mus musculus,N,1,2048.0,
4547,Biodistribution of the injected compound in lung of female BALB/C mice for 2.5 hours,Intermediate,10090.0,,A,,BAO_0000218,3655,,,1,CHEMBL618935,,,Mus musculus,N,1,2048.0,
4548,Biodistribution of the injected compound in lung of female BALB/C mice for 5 hours,Intermediate,10090.0,,A,,BAO_0000218,3655,,,1,CHEMBL618936,,,Mus musculus,N,1,2048.0,
4549,Biodistribution of the injected compound in muscle of female BALB/C mice for 0.5 hours,Intermediate,10090.0,,A,,BAO_0000218,3655,,,1,CHEMBL618937,,,Mus musculus,N,1,2385.0,
4550,Biodistribution of the injected compound in muscle of female BALB/C mice for 2.5 hours,Intermediate,10090.0,,A,,BAO_0000218,3655,,,1,CHEMBL618938,,,Mus musculus,N,1,2385.0,
4551,Biodistribution of the injected compound in muscle of female BALB/C mice for 5 hours,Intermediate,10090.0,,A,,BAO_0000218,3655,,,1,CHEMBL619104,,,Mus musculus,N,1,2385.0,
4552,Biodistribution of the injected compound in spleen of female BALB/C mice for 0.5 hours,Intermediate,10090.0,,A,,BAO_0000218,3655,,,1,CHEMBL619105,,,Mus musculus,N,1,2106.0,
4553,Biodistribution of the injected compound in spleen of female BALB/C mice for 2.5 hours,Intermediate,10090.0,,A,,BAO_0000218,3655,,,1,CHEMBL619106,,,Mus musculus,N,1,2106.0,
4554,Biodistribution of the injected compound in spleen of female BALB/C mice for 5 hours,Intermediate,10090.0,,A,,BAO_0000218,3655,,,1,CHEMBL619107,,,Mus musculus,N,1,2106.0,
4555,Biodistribution of the injected compound in stomach of female BALB/C mice for 0.5 hours,Intermediate,10090.0,,A,,BAO_0000218,3655,,,1,CHEMBL875410,,,Mus musculus,N,1,945.0,
4556,Biodistribution of the injected compound in stomach of female BALB/C mice for 2.5 hours,Intermediate,10090.0,,A,,BAO_0000218,3655,,,1,CHEMBL619108,,,Mus musculus,N,1,945.0,
4557,Biodistribution of the injected compound in stomach of female BALB/C mice for 5 hours,Intermediate,10090.0,,A,,BAO_0000218,3655,,,1,CHEMBL619109,,,Mus musculus,N,1,945.0,
4558,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for MRT,Intermediate,10090.0,,A,,BAO_0000218,16597,,,1,CHEMBL619110,,,Mus musculus,N,1,,
4559,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for MRT,Intermediate,10090.0,,F,,BAO_0000218,16597,,,1,CHEMBL619111,,,Mus musculus,N,1,,
4560,MRT value at a dose of 10 mg/kg intravenous administration in mice.,Intermediate,10090.0,,A,,BAO_0000218,16597,,,1,CHEMBL619112,,,Mus musculus,N,1,,
4561,MRT value at a dose of 10 mg/kg peroral administration in mice.,Intermediate,10090.0,,A,,BAO_0000218,16597,,,1,CHEMBL619113,,,Mus musculus,N,1,,
4562,Mean-residence time of compound after intravenous administration in mice at 24 uM/kg,Intermediate,10090.0,,A,,BAO_0000218,17764,,,1,CHEMBL619114,,,Mus musculus,N,1,,
4563,Mean-residence time was determined for compound after intraperitoneal administration in mice at 18 uM/kg,Intermediate,10090.0,,F,,BAO_0000218,17764,,,1,CHEMBL619115,,,Mus musculus,N,1,,
4564,In vitro cytotoxicity of compound was determined against A2780 cell lines (cisplatin resistant) at 37 degree C after 96 hr,Intermediate,9606.0,,F,,BAO_0000219,3830,,478.0,1,CHEMBL619116,A2780,,Homo sapiens,N,1,,
4565,In vitro cytotoxicity of compound was determined against A2780 cell lines (cisplatin resistant) at 37 degree C for 96 hr,Intermediate,9606.0,,F,,BAO_0000219,3829,,478.0,1,CHEMBL619117,A2780,,Homo sapiens,N,1,,
4566,Compound was evaluated for cytotoxicity against A2780 cell lines.,Intermediate,9606.0,,F,,BAO_0000219,2040,,478.0,1,CHEMBL619118,A2780,,Homo sapiens,N,1,,
4567,Potentiation of growth inhibition of A2780 by compound alone in experiment 1,Intermediate,9606.0,,F,,BAO_0000219,15684,,478.0,1,CHEMBL619119,A2780,,Homo sapiens,N,1,,
4568,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 2,Intermediate,9606.0,,F,,BAO_0000219,15684,,478.0,1,CHEMBL619120,A2780,,Homo sapiens,N,1,,
4569,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 1,Intermediate,9606.0,,F,,BAO_0000219,15684,,478.0,1,CHEMBL619121,A2780,,Homo sapiens,N,1,,
4570,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 2,Intermediate,9606.0,,F,,BAO_0000219,15684,,478.0,1,CHEMBL619122,A2780,,Homo sapiens,N,1,,
4571,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 1,Intermediate,9606.0,,F,,BAO_0000219,15684,,478.0,1,CHEMBL619123,A2780,,Homo sapiens,N,1,,
4572,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 2,Intermediate,9606.0,,F,,BAO_0000219,15684,,478.0,1,CHEMBL619124,A2780,,Homo sapiens,N,1,,
4573,Compound was evaluated for cytotoxicity against A2780 cell line,Intermediate,9606.0,,F,,BAO_0000219,2859,,478.0,1,CHEMBL619125,A2780,,Homo sapiens,N,1,,
4574,In vitro inhibitory activity against human tumor cell line A2780,Intermediate,9606.0,,F,,BAO_0000219,5618,,478.0,1,CHEMBL875411,A2780,,Homo sapiens,N,1,,
4575,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 1,Intermediate,9606.0,,F,,BAO_0000219,15684,,478.0,1,CHEMBL619126,A2780,,Homo sapiens,N,1,,
4576,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 2,Intermediate,9606.0,,F,,BAO_0000219,15684,,478.0,1,CHEMBL619127,A2780,,Homo sapiens,N,1,,
4577,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 1,Intermediate,9606.0,,F,,BAO_0000219,15684,,478.0,1,CHEMBL619128,A2780,,Homo sapiens,N,1,,
4578,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 2,Intermediate,9606.0,,F,,BAO_0000219,15684,,478.0,1,CHEMBL619129,A2780,,Homo sapiens,N,1,,
4579,The compound was tested for cytotoxic potency against A2780 human tumor cell lines,Intermediate,9606.0,,F,,BAO_0000219,2113,,478.0,1,CHEMBL619130,A2780,,Homo sapiens,N,1,,
4580,The compound was tested for cytotoxic potency against A2780 human tumor cell lines.,Intermediate,9606.0,,F,,BAO_0000219,2113,,478.0,1,CHEMBL619131,A2780,,Homo sapiens,N,1,,
4581,cytotoxicity against A2780 cells incubated for 24 hr in MTT assay.,Intermediate,9606.0,,F,,BAO_0000219,16745,,478.0,1,CHEMBL619132,A2780,,Homo sapiens,N,1,,
4582,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,Expert,9606.0,,F,,BAO_0000218,16597,,478.0,1,CHEMBL619133,A2780,,Homo sapiens,N,1,,
4583,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 1,Intermediate,9606.0,,F,,BAO_0000219,15684,,478.0,1,CHEMBL619134,A2780,,Homo sapiens,N,1,,
4584,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 2,Intermediate,9606.0,,F,,BAO_0000219,15684,,478.0,1,CHEMBL619135,A2780,,Homo sapiens,N,1,,
4585,Compound was evaluated for cytotoxicity against A2780 cis cell lines.,Intermediate,9606.0,,F,,BAO_0000219,2040,,478.0,1,CHEMBL619136,A2780,,Homo sapiens,N,1,,
4586,Relative resistance factor in A2780 cisplatin-resistant line,Intermediate,9606.0,,F,,BAO_0000219,2040,,478.0,1,CHEMBL619137,A2780,,Homo sapiens,N,1,,
4587,Concentration required to inhibit 50% growth of A2780 human ovarian cancer cells,Intermediate,9606.0,,F,,BAO_0000219,16165,,478.0,1,CHEMBL883713,A2780,,Homo sapiens,N,1,,
4588,Concentration required to inhibit 50% growth of A2780 human ovarian cancer cells.,Intermediate,9606.0,,F,,BAO_0000219,16165,,478.0,1,CHEMBL875412,A2780,,Homo sapiens,N,1,,
4589,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,Expert,9606.0,,F,,BAO_0000218,16597,,478.0,1,CHEMBL619138,A2780,,Homo sapiens,N,1,,
4590,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,Expert,9606.0,,F,,BAO_0000218,16597,,478.0,1,CHEMBL619262,A2780,,Homo sapiens,N,1,,
4591,Cytotoxicity against A2780 ovarian carcinoma cells was evaluated using standard sulforhodamine 96h assay test,Intermediate,9606.0,,F,,BAO_0000219,3992,,478.0,1,CHEMBL619139,A2780,,Homo sapiens,N,1,,
4592,In vitro cytotoxicity was determined against A2780 human ovarian cell line using NCI screen,Intermediate,9606.0,,F,,BAO_0000219,10553,,478.0,1,CHEMBL619140,A2780,,Homo sapiens,N,1,,
4593,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin,Intermediate,9606.0,,F,,BAO_0000219,15608,,478.0,1,CHEMBL619141,A2780,,Homo sapiens,N,1,,
4594,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 1,Intermediate,9606.0,,F,,BAO_0000219,15608,,478.0,1,CHEMBL619142,A2780,,Homo sapiens,N,1,,
4595,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 2,Intermediate,9606.0,,F,,BAO_0000219,15608,,478.0,1,CHEMBL619143,A2780,,Homo sapiens,N,1,,
4596,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 3,Intermediate,9606.0,,F,,BAO_0000219,15608,,478.0,1,CHEMBL619144,A2780,,Homo sapiens,N,1,,
4597,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 5,Intermediate,9606.0,,F,,BAO_0000219,15608,,478.0,1,CHEMBL619145,A2780,,Homo sapiens,N,1,,
4598,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 8,Intermediate,9606.0,,F,,BAO_0000219,15608,,478.0,1,CHEMBL619146,A2780,,Homo sapiens,N,1,,
4599,Cytotoxic activity in a panel of Human ovarian tumor A2780/CDDP cell line after 96h of drug exposure,Intermediate,9606.0,,F,,BAO_0000219,15569,,478.0,1,CHEMBL619147,A2780,,Homo sapiens,N,1,,
4600,Antiproliferative effect of compound on A2780/DX cell line,Intermediate,9606.0,,F,,BAO_0000219,17420,,478.0,1,CHEMBL619148,A2780,,Homo sapiens,N,1,,
4601,Antiproliferative effect of compound on A2780/DX cell line; n.d. indicates not determined,Intermediate,9606.0,,F,,BAO_0000219,17420,,478.0,1,CHEMBL619149,A2780,,Homo sapiens,N,1,,
4602,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780/DX(RI),Intermediate,9606.0,,F,,BAO_0000219,15099,,478.0,1,CHEMBL619150,A2780,,Homo sapiens,N,1,,
4603,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780/Dx(RI),Intermediate,9606.0,,F,,BAO_0000219,15099,,478.0,1,CHEMBL619151,A2780,,Homo sapiens,N,1,,
4604,Cytotoxicity against ovarian carcinoma A2780/cis tumor cell lines,Intermediate,9606.0,,F,,BAO_0000219,17672,,478.0,1,CHEMBL883794,A2780,,Homo sapiens,N,1,,
4605,Cytotoxicity against ovarian carcinoma A2780/cis90 tumor cell lines,Intermediate,9606.0,,F,,BAO_0000219,17672,,478.0,1,CHEMBL619152,A2780,,Homo sapiens,N,1,,
4606,In vitro cytotoxicity against A2780ADR cell line,Intermediate,9606.0,,F,,BAO_0000219,17270,,478.0,1,CHEMBL619153,A2780,,Homo sapiens,N,1,,
4607,In vitro cytotoxicity against A2780CIS cell line,Intermediate,9606.0,,F,,BAO_0000219,17270,,478.0,1,CHEMBL619154,A2780,,Homo sapiens,N,1,,
4608,In vitro cytotoxic activity against human tumor cell line A2780CisR after incubation for 96 hours,Intermediate,9606.0,,F,,BAO_0000219,5574,,478.0,1,CHEMBL619155,A2780,,Homo sapiens,N,1,,
4609,The compound was tested for cytotoxic potency against A2780R human tumor cell lines.,Intermediate,9606.0,,F,,BAO_0000219,2113,,478.0,1,CHEMBL619156,A2780,,Homo sapiens,N,1,,
4610,"Inhibitory effect of Gold(III) complex, 2,2' bipy on growth of cisplatin-resistant A2780/R human tumor cell lines",Intermediate,9606.0,,F,,BAO_0000219,16913,,478.0,1,CHEMBL619157,A2780,,Homo sapiens,N,1,,
4611,"Inhibitory effect of Gold(III) complex, CDDP on growth of cisplatin-resistant A2780/R human tumor cell lines",Intermediate,9606.0,,F,,BAO_0000219,16913,,478.0,1,CHEMBL619797,A2780,,Homo sapiens,N,1,,
4612,Oral bioavailability of compound in rhesus macaques,Autocuration,9544.0,,A,,BAO_0000218,17839,,,1,CHEMBL619798,,,Macaca mulatta,U,0,,
4613,Oral bioavailability in monkey,Autocuration,9443.0,,A,,BAO_0000218,6821,,,1,CHEMBL619799,,,monkey,U,0,,
4614,Oral bioavailability evaluated in monkey,Autocuration,9443.0,,A,,BAO_0000218,6078,,,1,CHEMBL619800,,,monkey,U,0,,
4615,Oral bioavailability in monkey (dose 1 mg/kg p.o.),Autocuration,9443.0,,A,,BAO_0000218,6535,,,1,CHEMBL619801,,,monkey,U,0,,
4616,Oral bioavailability in Rhesus monkey,Autocuration,9544.0,,A,,BAO_0000218,4449,,,1,CHEMBL619802,,,Macaca mulatta,U,0,,
4617,Oral bioavailability was calculated in rhesus monkey,Autocuration,9544.0,,A,,BAO_0000218,6057,,,1,CHEMBL619803,,,Macaca mulatta,U,0,,
4618,Oral bioavailability in cynomolgus monkey,Autocuration,9541.0,,A,,BAO_0000218,5922,,,1,CHEMBL619965,,,Macaca fascicularis,U,0,,
4619,Oral bioavailability in monkey,Autocuration,9443.0,,A,,BAO_0000218,5940,,,1,CHEMBL619966,,,monkey,U,0,,
4620,Oral bioavailability in monkey,Autocuration,9443.0,,A,,BAO_0000218,6265,,,1,CHEMBL619967,,,monkey,U,0,,
4621,Oral bioavailability in monkey (dose 1 mg/kg),Autocuration,9443.0,,A,,BAO_0000218,6265,,,1,CHEMBL620073,,,monkey,U,0,,
4622,Oral bioavailability in monkey (dose 5 mg/kg),Autocuration,9443.0,,A,,BAO_0000218,6265,,,1,CHEMBL620074,,,monkey,U,0,,
4623,Oral bioavailability in monkey,Autocuration,9443.0,,A,,BAO_0000218,5940,,,1,CHEMBL620075,,,monkey,U,0,,
4624,Oral bioavailability in monkey,Autocuration,9443.0,,A,,BAO_0000218,5940,,,1,CHEMBL620076,,,monkey,U,0,,
4625,Oral bioavailability in rhesus monkey,Autocuration,9544.0,,A,,BAO_0000218,4514,,,1,CHEMBL620077,,,Macaca mulatta,U,0,,
4626,Oral bioavailability in rhesus monkey at a dose of 2 mg/kg by po administration,Autocuration,9544.0,,A,,BAO_0000218,5546,,,1,CHEMBL620078,,,Macaca mulatta,U,0,,
4627,Oral bioavailability in squirrel monkey at a dose of 10 mg/kg,Autocuration,9521.0,,A,,BAO_0000218,5553,,,1,CHEMBL620079,,,Saimiri sciureus,U,0,,
4628,Oral bioavailability in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),Autocuration,9443.0,,A,,BAO_0000218,6641,,,1,CHEMBL620080,,,monkey,U,0,,
4629,Oral bioavailability in Rhesus monkey,Autocuration,9544.0,,A,,BAO_0000218,5472,,,1,CHEMBL620081,,,Macaca mulatta,U,0,,
4630,Oral bioavailability in Rhesus monkey (dose 10 mg/kg p.o.),Autocuration,9544.0,,A,,BAO_0000218,5668,,,1,CHEMBL620082,,,Macaca mulatta,U,0,,
4631,Oral bioavailability in monkey at 10 mg/kg of the compound,Autocuration,9443.0,,A,,BAO_0000218,5711,,,1,CHEMBL620083,,,monkey,U,0,,
4632,Bioavailability in Rhesus monkey,Autocuration,9544.0,,A,,BAO_0000218,5145,,,1,CHEMBL620084,,,Macaca mulatta,U,0,,
4633,Glomerular Filtration Rate(GFR) evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,Autocuration,9527.0,,A,,BAO_0000218,3443,,,1,CHEMBL620085,,,Cercopithecidae,U,0,,
4634,Glomerular Filtration Rate(GFR)of the compound compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,Autocuration,9527.0,,A,,BAO_0000218,3443,,,1,CHEMBL874595,,,Cercopithecidae,U,0,,
4635,Half life by ''Cr'' assay in rhesus monkey at a dose of 5 mg/kg,Autocuration,9527.0,,A,,BAO_0000218,3249,,,1,CHEMBL873352,,,Cercopithecidae,U,0,,
4636,Half life the of compound was determined by ''Cr'' assay in squirrel monkey at a dose of 5 mg/kg,Autocuration,9527.0,,A,,BAO_0000218,3249,,,1,CHEMBL620086,,,Cercopithecidae,U,0,,
4637,Mean residence time was determined after intravenous administration in cynomolgus monkeys,Autocuration,9527.0,,A,,BAO_0000218,5355,,,1,CHEMBL620087,,,Cercopithecidae,U,0,,
4638,Mean residence time was determined after oral administration in cynomolgus monkeys; NA means Not applicable,Autocuration,9527.0,,A,,BAO_0000218,5355,,,1,CHEMBL620088,,,Cercopithecidae,U,0,,
4639,Mean residence time was determined after oral administration in cynomolgus monkeys; NA means not applicable,Autocuration,9527.0,,A,,BAO_0000218,5355,,,1,CHEMBL620089,,,Cercopithecidae,U,0,,
4640,Pharmacokinetic parameter MRT was determined in monkey after (iv) administration of a dose of 13 (uM/kg),Autocuration,9527.0,,A,,BAO_0000218,4809,,,1,CHEMBL620090,,,Cercopithecidae,U,0,,
4641,Pharmacokinetic parameter MRT was determined in monkey after (po) administration of a dose of 50 (uM/kg),Autocuration,9527.0,,A,,BAO_0000218,4809,,,1,CHEMBL620091,,,Cercopithecidae,U,0,,
4642,Metabolism of compound in monkey S9 microsomes ('+''indicates <20% largest observed peak),Autocuration,9527.0,,A,,BAO_0000251,14294,Microsomes,,1,CHEMBL620092,,,Cercopithecidae,U,0,,
4643,Metabolism of compound in monkey S9 microsomes ('++''indicates 20-50% largest observed peak),Autocuration,9527.0,,A,,BAO_0000251,14294,Microsomes,,1,CHEMBL620093,,,Cercopithecidae,U,0,,
4644,Metabolism of compound in monkey S9 microsomes ('+++'indicates 50-80% largest observed peak),Autocuration,9527.0,,A,,BAO_0000251,14294,Microsomes,,1,CHEMBL620094,,,Cercopithecidae,U,0,,
4645,Metabolism of compound in monkey S9 microsomes ('++++' indicates largest observed peak),Autocuration,9527.0,,A,,BAO_0000251,14294,Microsomes,,1,CHEMBL620095,,,Cercopithecidae,U,0,,
4646,Plasma clearance evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,Autocuration,9527.0,,A,,BAO_0000218,3443,,,1,CHEMBL620096,,,Cercopithecidae,U,0,,
4647,Plasma clearance compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,Autocuration,9527.0,,A,,BAO_0000218,3443,,,1,CHEMBL620097,,,Cercopithecidae,U,0,,
4648,Clearance from plasma(with matabolite-corrected plasma radioactivity-time integral) at 30 min after administration.,Autocuration,9527.0,,A,,BAO_0000019,11271,,,1,CHEMBL620098,,,Cercopithecidae,U,0,,
4649,Renal clearance evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,Autocuration,9527.0,,A,,BAO_0000218,3443,,,1,CHEMBL620099,,,Cercopithecidae,U,0,,
4650,Renal clearance compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,Autocuration,9527.0,,A,,BAO_0000218,3443,,,1,CHEMBL620100,,,Cercopithecidae,U,0,,
4651,Elimination Half-life of compound was determined in monkey,Autocuration,9527.0,,A,,BAO_0000019,6821,,,1,CHEMBL620101,,,Cercopithecidae,U,0,,
4652,Half life of compound was determined in rhesus monkey,Autocuration,9527.0,,A,,BAO_0000019,17267,,,1,CHEMBL620102,,,Cercopithecidae,U,0,,
4653,Half life in monkey plasma,Autocuration,9527.0,,A,,BAO_0000366,5819,,,1,CHEMBL620103,,,Cercopithecidae,U,0,1969.0,
4654,Half life in monkey plasma; Not detected,Autocuration,9527.0,,A,,BAO_0000366,5819,,,1,CHEMBL620104,,,Cercopithecidae,U,0,1969.0,
4655,Half life period was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,Autocuration,9527.0,,A,,BAO_0000218,1916,,,1,CHEMBL874596,,,Cercopithecidae,U,0,,
4656,Half-life 24 hr after 2 mg/kg iv administration in monkeys,Autocuration,9527.0,,A,,BAO_0000218,17509,,,1,CHEMBL873490,,,Cercopithecidae,U,0,,
4657,Terminal half life of the compound.,Autocuration,9527.0,,A,,BAO_0000019,1399,,,1,CHEMBL620105,,,Cercopithecidae,U,0,,
4658,Maximum time was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,Autocuration,9527.0,,A,,BAO_0000218,1916,,,1,CHEMBL620780,,,Cercopithecidae,U,0,,
4659,Pharmacokinetic parameter Tmax was determined in monkey after (po) administration of a dose of 50 (uM/kg),Autocuration,9527.0,,A,,BAO_0000218,4809,,,1,CHEMBL620781,,,Cercopithecidae,U,0,,
4660,Unbound plasma was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,Autocuration,9527.0,,A,,BAO_0000218,5546,,,1,CHEMBL620956,,,Cercopithecidae,U,0,,
4661,Urinary recovery evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,Autocuration,9527.0,,A,,BAO_0000218,3443,,,1,CHEMBL620957,,,Cercopithecidae,U,0,1088.0,
4662,Urinary recovery compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,Autocuration,9527.0,,A,,BAO_0000218,3443,,,1,CHEMBL620958,,,Cercopithecidae,U,0,1088.0,
4663,Volume of distribution was determined in monkey after a 3 mg/kg of iv dose,Autocuration,9527.0,,A,,BAO_0000218,4257,,,1,CHEMBL620959,,,Cercopithecidae,U,0,,
4664,Volume distribution after oral administration (2.5 mg/kg) in monkey was determined,Autocuration,9527.0,,A,,BAO_0000218,6221,,,1,CHEMBL620960,,,Cercopithecidae,U,0,,
4665,Volume of distribution was evaluated in rhesus,Autocuration,9527.0,,A,,BAO_0000218,5472,,,1,CHEMBL620961,,,Cercopithecidae,U,0,,
4666,Plasma clearance was measured in hamster at the dose of 10 mg/kg by peroral administration,Autocuration,10029.0,,A,,BAO_0000218,4727,,,1,CHEMBL620962,,,Cricetulus griseus,U,0,,
4667,Plasma clearance was measured in hamster at the dose of 3 mg/kg by intravenous administration,Autocuration,10029.0,,A,,BAO_0000218,4727,,,1,CHEMBL620963,,,Cricetulus griseus,U,0,,
4668,Bioavailability in hamster was determined,Autocuration,10029.0,,A,,BAO_0000218,4727,,,1,CHEMBL620964,,,Cricetulus griseus,U,0,,
4669,Bioavailability in hamster at a dose of 3 mg/kg by intravenous administration,Autocuration,10029.0,,A,,BAO_0000218,4727,,,1,CHEMBL620965,,,Cricetulus griseus,U,0,,
4670,Bioavailability in hamster at a dose of 3 mg/kg by oral administration,Autocuration,10029.0,,A,,BAO_0000218,4727,,,1,CHEMBL620966,,,Cricetulus griseus,U,0,,
4671,Half life of compound was determined in hamster blood,Autocuration,10029.0,,A,,BAO_0000221,4727,,,1,CHEMBL620967,,,Cricetulus griseus,U,0,178.0,
4672,Michaelis-Menten constant of the compound.,Autocuration,9823.0,,A,,BAO_0000019,1452,,,1,CHEMBL620968,,,Sus scrofa,U,0,,
4673,Vmax value was measured at 0 uM concentration of silyl ether.,Autocuration,9823.0,,A,,BAO_0000019,1452,,,1,CHEMBL874597,,,Sus scrofa,U,0,,
4674,Vmax value was measured at 10 uM concentration of silyl ether.,Autocuration,9823.0,,A,,BAO_0000019,1452,,,1,CHEMBL620969,,,Sus scrofa,U,0,,
4675,Vmax value was measured at 5 uM concentration of silyl ether.,Autocuration,9823.0,,A,,BAO_0000019,1452,,,1,CHEMBL620970,,,Sus scrofa,U,0,,
4676,Inactivation of human leukocyte (neutrophil) elastase(HLE)(HNE) as rate constant,Expert,9606.0,,B,,BAO_0000357,11706,,,1,CHEMBL620971,,,Homo sapiens,D,9,,
4677,Area under curve was evaluated against man at a dose of 10 mg/kg after po administration,Autocuration,9606.0,,A,,BAO_0000218,1916,,,1,CHEMBL620972,,,Homo sapiens,U,0,,
4678,Compound was evaluated for area under the curve expressed as (h*ug/ml),Autocuration,9606.0,,A,,BAO_0000019,17791,,,1,CHEMBL620973,,,Homo sapiens,U,0,,
4679,Active metabolite of ifosfamide determined in humans; A-Active,Autocuration,9606.0,,A,,BAO_0000019,7766,,,1,CHEMBL618243,,,Homo sapiens,U,0,,
4680,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis,Autocuration,9606.0,,A,,BAO_0000019,6567,,,1,CHEMBL618244,,,Homo sapiens,U,0,,
4681,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; -0.5 to 1,Autocuration,9606.0,,A,,BAO_0000019,6567,,,1,CHEMBL618245,,,Homo sapiens,U,0,,
4682,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; 1-2,Autocuration,9606.0,,A,,BAO_0000019,6567,,,1,CHEMBL618246,,,Homo sapiens,U,0,,
4683,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; trace,Autocuration,9606.0,,A,,BAO_0000019,6567,,,1,CHEMBL618247,,,Homo sapiens,U,0,,
4684,Compound was evaluated for oral bioavailability in human,Autocuration,9606.0,,A,,BAO_0000218,17791,,,1,CHEMBL618248,,,Homo sapiens,U,0,,
4685,Metabolite of ifosfamide determined in urine; NF-Not found,Autocuration,9606.0,,A,,BAO_0000019,7766,,,1,CHEMBL618249,,,Homo sapiens,U,0,1088.0,
4686,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection (Group A and B),Autocuration,9606.0,,A,,BAO_0000019,6852,,,1,CHEMBL618250,,,Homo sapiens,U,0,,
4687,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection after dosing with normal antibiotics,Autocuration,9606.0,,A,,BAO_0000019,6852,,,1,CHEMBL874598,,,Homo sapiens,U,0,,
4688,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection after dosing with normal antibiotics and lactose,Autocuration,9606.0,,A,,BAO_0000019,6852,,,1,CHEMBL618251,,,Homo sapiens,U,0,,
4689,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection before dosing with normal antibiotics,Autocuration,9606.0,,A,,BAO_0000019,6852,,,1,CHEMBL618252,,,Homo sapiens,U,0,,
4690,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection before dosing with normal antibiotics and lactose,Autocuration,9606.0,,A,,BAO_0000019,6852,,,1,CHEMBL618253,,,Homo sapiens,U,0,,
4691,Percent of compound in cirrhotic patients of sterile ascitic fluid (Group C),Autocuration,9606.0,,A,,BAO_0000019,6852,,,1,CHEMBL618254,,,Homo sapiens,U,0,,
4692,Percent of compound in healthy individuals (Group D),Autocuration,9606.0,,A,,BAO_0000019,6852,,,1,CHEMBL618255,,,Homo sapiens,U,0,,
4693,Percent of the parent compound remaining after 20 mins incubation with human liver microsomes,Autocuration,9606.0,,A,,BAO_0000251,4397,Microsomes,,1,CHEMBL618983,,,Homo sapiens,U,0,2107.0,
4694,Binding towards human plasma protein at 10 uM,Autocuration,9606.0,,A,,BAO_0000019,17409,,,1,CHEMBL618984,,,Homo sapiens,U,0,,
4695,Binding towards human plasma protein at 100 uM,Autocuration,9606.0,,A,,BAO_0000019,17409,,,1,CHEMBL618985,,,Homo sapiens,U,0,,
4696,Human plasma protein binding activity was determined,Autocuration,9606.0,,A,,BAO_0000019,17176,,,1,CHEMBL618986,,,Homo sapiens,U,0,,
4697,The ability binding to plasma (Binding classified based on injection of compound at 80 concentration.),Autocuration,9606.0,,A,,BAO_0000019,15444,,,1,CHEMBL618987,,,Homo sapiens,U,0,,
4698,Percent binding of compound towards human plasma protein was determined,Autocuration,9606.0,,A,,BAO_0000019,17267,,,1,CHEMBL618988,,,Homo sapiens,U,0,,
4699,Plasma clearance in human liver microsomes,Autocuration,9606.0,,A,,BAO_0000251,5944,Microsomes,,1,CHEMBL618989,,,Homo sapiens,U,0,2107.0,
4700,In vitro intrinsic clearance in human liver microsome,Autocuration,9606.0,,A,,BAO_0000251,5668,Microsomes,,1,CHEMBL618990,,,Homo sapiens,U,0,2107.0,
4701,In vitro intrinsic clearance in human liver microsome,Autocuration,9606.0,,A,,BAO_0000251,5669,Microsomes,,1,CHEMBL618991,,,Homo sapiens,U,0,2107.0,
4702,In vitro microsome metabolism clearance in human was determined,Autocuration,9606.0,,A,,BAO_0000251,5041,Microsomes,,1,CHEMBL876725,,,Homo sapiens,U,0,,
4703,In vitro microsome metabolism clearance in human was determined; High,Autocuration,9606.0,,A,,BAO_0000251,5041,Microsomes,,1,CHEMBL618992,,,Homo sapiens,U,0,,
4704,In vitro microsome metabolism clearance in human was determined; ND denotes no data,Autocuration,9606.0,,A,,BAO_0000251,5041,Microsomes,,1,CHEMBL618993,,,Homo sapiens,U,0,,
4705,Pharmacokinetic property (clearance) in human liver microsome,Autocuration,9606.0,,A,,BAO_0000251,5676,Microsomes,,1,CHEMBL618994,,,Homo sapiens,U,0,2107.0,
4706,Plasma clearance in human liver microsomes,Autocuration,9606.0,,A,,BAO_0000251,5944,Microsomes,,1,CHEMBL618995,,,Homo sapiens,U,0,2107.0,
4707,In vitro clearance in human liver microsomes,Autocuration,9606.0,,A,,BAO_0000251,17538,Microsomes,,1,CHEMBL618996,,,Homo sapiens,U,0,2107.0,
4708,Intrinsic clearance in human liver microsomes was determined,Autocuration,9606.0,,A,,BAO_0000251,6331,Microsomes,,1,CHEMBL618997,,,Homo sapiens,U,0,2107.0,
4709,Intrinsic clearance in human liver microsomes was determined,Autocuration,9606.0,,A,,BAO_0000251,5948,Microsomes,,1,CHEMBL618998,,,Homo sapiens,U,0,2107.0,
4710,Cmax (Tissue distribution) of compound was determined at a dose of 5 mg/kg in human,Autocuration,9606.0,,A,,BAO_0000218,5965,,,1,CHEMBL618999,,,Homo sapiens,U,0,,
4711,Maximum concentration was evaluated against man at a dose of 10 mg/kg after po administration,Autocuration,9606.0,,A,,BAO_0000218,1916,,,1,CHEMBL620223,,,Homo sapiens,U,0,,
4712,Cmin (Clearance) of compound was determined at a dose of 5 mg/kg in human,Autocuration,9606.0,,A,,BAO_0000218,5965,,,1,CHEMBL620224,,,Homo sapiens,U,0,,
4713,Stability in human plasma 2 hr after incubation expressed as percent concentration,Autocuration,9606.0,,A,,BAO_0000019,1299,,,1,CHEMBL620225,,,Homo sapiens,U,0,,
4714,Stability in human plasma 4 hr after incubation expressed as percent concentration,Autocuration,9606.0,,A,,BAO_0000019,1299,,,1,CHEMBL620226,,,Homo sapiens,U,0,,
4715,Portion of holoxan excreted in the form of the metabolite from 1200 mL of urine on day 3 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,Autocuration,9606.0,,A,,BAO_0000019,7766,,,1,CHEMBL620227,,,Homo sapiens,U,0,1088.0,
4716,Portion of holoxan excreted in the form of the metabolite from 1200 mL of urine on day 7 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,Autocuration,9606.0,,A,,BAO_0000019,7766,,,1,CHEMBL876726,,,Homo sapiens,U,0,1088.0,
4717,Portion of holoxan excreted in the form of the metabolite from 1300 mL of urine on day 6 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,Autocuration,9606.0,,A,,BAO_0000019,7766,,,1,CHEMBL620228,,,Homo sapiens,U,0,1088.0,
4718,Portion of holoxan excreted in the form of the metabolite from 1300 mL of urine on day 8 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,Autocuration,9606.0,,A,,BAO_0000019,7766,,,1,CHEMBL620229,,,Homo sapiens,U,0,1088.0,
4719,Mean-residence time was determined for compound after intraperitoneal administration in mice at 23 uM/kg,Intermediate,10090.0,,F,,BAO_0000218,17764,,,1,CHEMBL620230,,,Mus musculus,N,1,,
4720,Mean-residence time was determined for compound after intraperitoneal administration in mice at 25 uM/kg,Intermediate,10090.0,,F,,BAO_0000218,17764,,,1,CHEMBL620231,,,Mus musculus,N,1,,
4721,Mean-residence time was determined for compound after intraperitoneal administration in mice at 26 uM/kg,Intermediate,10090.0,,F,,BAO_0000218,17764,,,1,CHEMBL620232,,,Mus musculus,N,1,,
4722,Mean-residence time was determined for compound intravenous administration in mice at 23 uM/kg,Intermediate,10090.0,,F,,BAO_0000218,17764,,,1,CHEMBL620233,,,Mus musculus,N,1,,
4723,Metabolism of compound in Mouse S9 microsomes ('++++'indicates largest observed peak),Intermediate,10090.0,,A,,BAO_0000218,14294,,,1,CHEMBL620234,,,Mus musculus,N,1,,
4724,Metabolism of compound in mouse S9 microsomes ('+''indicates <20% largest observed peak),Intermediate,10090.0,,A,,BAO_0000218,14294,,,1,CHEMBL620235,,,Mus musculus,N,1,,
4725,Metabolism of compound in mouse S9 microsomes ('++++' indicates largest observed peak),Intermediate,10090.0,,A,,BAO_0000218,14294,,,1,CHEMBL620236,,,Mus musculus,N,1,,
4726,In vitro metabolic potential in mouse liver microsomes,Intermediate,10090.0,,A,,BAO_0000218,6251,,,1,CHEMBL620237,,,Mus musculus,N,1,2107.0,
4727,Ability of compound to bind to plasma protein was evaluated in HSA cells,Intermediate,10090.0,,A,,BAO_0000218,17582,,,1,CHEMBL620238,,,Mus musculus,N,1,,
4728,Compound was tested for radioactivity level in mice adrenal glands (Compound is radiolabeled),Intermediate,10090.0,,A,,BAO_0000218,17811,,,1,CHEMBL620239,,,Mus musculus,N,1,2369.0,
4729,Compound was tested for radioactivity level in mice brain (Compound is radiolabeled); 2.2-4.9% ID/g,Intermediate,10090.0,,A,,BAO_0000218,17811,,,1,CHEMBL620240,,,Mus musculus,N,1,955.0,
4730,Compound was tested for radioactivity level in mice brain (Compound is radiolabeled); 2.6-4.4% ID/g,Intermediate,10090.0,,A,,BAO_0000218,17811,,,1,CHEMBL620241,,,Mus musculus,N,1,955.0,
4731,Compound was tested for radioactivity level in mice heart (Compound is radiolabeled),Intermediate,10090.0,,A,,BAO_0000218,17811,,,1,CHEMBL876727,,,Mus musculus,N,1,,
4732,Compound was tested for radioactivity level in mice kidney (Compound is radiolabeled),Intermediate,10090.0,,A,,BAO_0000218,17811,,,1,CHEMBL620242,,,Mus musculus,N,1,2113.0,
4733,Compound was tested for radioactivity level in mice lungs (Compound is radiolabeled),Intermediate,10090.0,,A,,BAO_0000218,17811,,,1,CHEMBL620243,,,Mus musculus,N,1,,
4734,Tested for urinary recovery in mice after subcutaneous administration of 20 mg/Kg,Intermediate,10090.0,,A,,BAO_0000218,5288,,,1,CHEMBL620244,,,Mus musculus,N,1,,
4735,Compound was evaluated for its potency in CDF1 mice and the serum cholesterol levels were determined,Intermediate,10090.0,,A,,BAO_0000218,2717,,,1,CHEMBL620245,,,Mus musculus,N,1,1977.0,
4736,Compound was evaluated for its potency in CDF1 mice and the serum metabolite levels were determined,Intermediate,10090.0,,A,,BAO_0000218,2717,,,1,CHEMBL620246,,,Mus musculus,N,1,1977.0,
4737,Compound was evaluated for its potency in CDF1 mice and the serum triglyceride levels were determined,Intermediate,10090.0,,A,,BAO_0000218,2717,,,1,CHEMBL620247,,,Mus musculus,N,1,1977.0,
4738,Half life of compound was determined in plasma of mice at 24 mg/Kg,Intermediate,10090.0,,A,,BAO_0000218,17753,,,1,CHEMBL620248,,,Mus musculus,N,1,1969.0,
4739,Half life of compound was determined in plasma of mice at 40 mg/Kg,Intermediate,10090.0,,A,,BAO_0000218,17753,,,1,CHEMBL873497,,,Mus musculus,N,1,1969.0,
4740,Half life of compound was determined in plasma of mice at 5 mg/Kg,Intermediate,10090.0,,A,,BAO_0000218,17753,,,1,CHEMBL620249,,,Mus musculus,N,1,1969.0,
4741,Half life after intraperitoneal administration in mice at 18 uM/kg,Intermediate,10090.0,,F,,BAO_0000218,17764,,,1,CHEMBL620250,,,Mus musculus,N,1,,
4742,Half life after intraperitoneal administration in mice at 23 uM/kg,Intermediate,10090.0,,F,,BAO_0000218,17764,,,1,CHEMBL620251,,,Mus musculus,N,1,,
4743,Half life after intraperitoneal administration in mice at 25 uM/kg,Intermediate,10090.0,,F,,BAO_0000218,17764,,,1,CHEMBL620252,,,Mus musculus,N,1,,
4744,Half life after intraperitoneal administration in mice at 26 uM/kg,Intermediate,10090.0,,F,,BAO_0000218,17764,,,1,CHEMBL620253,,,Mus musculus,N,1,,
4745,Half life after intravenous administration in mice at 23 uM/kg,Intermediate,10090.0,,F,,BAO_0000218,17764,,,1,CHEMBL620254,,,Mus musculus,N,1,,
4746,Half life after intravenous administration in mice at 24 uM/kg,Intermediate,10090.0,,A,,BAO_0000218,17764,,,1,CHEMBL620255,,,Mus musculus,N,1,,
4747,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for T max,Intermediate,10090.0,,A,,BAO_0000218,16597,,,1,CHEMBL620256,,,Mus musculus,N,1,,
4748,Maximum time required to reach Cp max was evaluated in mice after intravenous administration; T max Not determined,Intermediate,10090.0,,A,,BAO_0000218,2675,,,1,CHEMBL876728,,,Mus musculus,N,1,,
4749,Maximum time required to reach Cp max was evaluated in mice after oral administration,Intermediate,10090.0,,A,,BAO_0000218,2675,,,1,CHEMBL620257,,,Mus musculus,N,1,,
4750,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for half life (T1/2),Intermediate,10090.0,,A,,BAO_0000218,16597,,,1,CHEMBL620258,,,Mus musculus,N,1,,
4751,"Compound was evaluated for the pharmacokinetic parameter, Terminal half life period",Intermediate,10090.0,,A,,BAO_0000218,4890,,,1,CHEMBL620259,,,Mus musculus,N,1,,
4752,Evaluated for pharmacokinetic parameter half-life in mouse at the dose 20 mg/kg,Intermediate,10090.0,,A,,BAO_0000218,429,,,1,CHEMBL620260,,,Mus musculus,N,1,,
4753,Half life of compound in mouse blood following i.v. administration of 10 mg/kg,Intermediate,10090.0,,A,,BAO_0000218,17837,,,1,CHEMBL620261,,,Mus musculus,N,1,178.0,
4754,Half life at a dose of 10 mg/kg intravenous administration in mice.,Intermediate,10090.0,,A,,BAO_0000218,16597,,,1,CHEMBL620262,,,Mus musculus,N,1,,
4755,Half life at a dose of 10 mg/kg peroral administration in mice.,Intermediate,10090.0,,A,,BAO_0000218,16597,,,1,CHEMBL620263,,,Mus musculus,N,1,,
4756,Half life in ob/ob mice,Intermediate,10090.0,,A,,BAO_0000218,6619,,,1,CHEMBL620264,,,Mus musculus,N,1,,
4757,Half-life at a single subcutaneous administration of 40 mg/kg in mice,Intermediate,10090.0,,A,,BAO_0000218,4066,,,1,CHEMBL620265,,,Mus musculus,N,1,,
4758,Half-life was measured in mouse,Intermediate,10090.0,,A,,BAO_0000218,4239,,,1,CHEMBL620266,,,Mus musculus,N,1,,
4759,In vivo half life period was determined in murine septicemia at dose of 50 mg/kg,Intermediate,10090.0,,A,,BAO_0000218,5969,,,1,CHEMBL620267,,,Mus musculus,N,1,,
4760,Time for esterases in unfractionated mouse serum to reduce the concentration due to thio ester deacylation,Intermediate,10090.0,,A,,BAO_0000218,8999,,,1,CHEMBL619364,,,Mus musculus,N,1,,
4761,Time for esterases in unfractionated mouse serum to reduce the concentration due to thio ester deacylation; 10 % hydrolysis at 60 mins,Intermediate,10090.0,,A,,BAO_0000218,8999,,,1,CHEMBL619365,,,Mus musculus,N,1,,
4762,T2 in brain of mice at the oral dose of 50 mg/kg,Intermediate,10090.0,,A,,BAO_0000218,17641,,,1,CHEMBL619366,,,Mus musculus,N,1,955.0,
4763,T2 in kidney of mice at the oral dose of 50 mg/kg,Intermediate,10090.0,,A,,BAO_0000218,17641,,,1,CHEMBL619367,,,Mus musculus,N,1,2113.0,
4764,T2 in liver of mice at the oral dose of 50 mg/kg,Intermediate,10090.0,,A,,BAO_0000218,17641,,,1,CHEMBL619368,,,Mus musculus,N,1,2107.0,
4765,T2 in lungs of mice at the oral dose of 50 mg/kg,Intermediate,10090.0,,A,,BAO_0000218,17641,,,1,CHEMBL619369,,,Mus musculus,N,1,2048.0,
4766,T2 in spleen of mice at the oral dose of 50 mg/kg,Intermediate,10090.0,,A,,BAO_0000218,17641,,,1,CHEMBL876729,,,Mus musculus,N,1,2106.0,
4767,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for T max,Intermediate,10090.0,,A,,BAO_0000218,16597,,,1,CHEMBL619370,,,Mus musculus,N,1,,
4768,"Compound was evaluated for the pharmacokinetic parameter, maximum time constant",Intermediate,10090.0,,A,,BAO_0000218,4890,,,1,CHEMBL619371,,,Mus musculus,N,1,,
4769,Evaluated for pharmacokinetic parameter tmax in mouse at the dose 20 mg/kg,Intermediate,10090.0,,A,,BAO_0000218,429,,,1,CHEMBL619372,,,Mus musculus,N,1,,
4770,Evaluated for pharmacokinetic parameter tmax in mouse at the dose 20 mg/kg was determined,Intermediate,10090.0,,A,,BAO_0000218,429,,,1,CHEMBL620012,,,Mus musculus,N,1,,
4771,In vivo Tmax was determined in murine septicemia at dose of 100 mg/kg,Intermediate,10090.0,,A,,BAO_0000218,5969,,,1,CHEMBL620013,,,Mus musculus,N,1,,
4772,"Inhibitory effect of Gold(III) complex, [Au(bipy)-(OH)2]-[PF6] on growth of cisplatin-resistant A2780/R human tumor cell lines",Intermediate,9606.0,,F,,BAO_0000219,16913,,478.0,1,CHEMBL620014,A2780,,Homo sapiens,N,1,,
4773,"Inhibitory effect of Gold(III) complex, [Au(bipy-H)(OH)]-[PF6] on growth of cisplatin-resistant A2780/R human tumor cell lines",Intermediate,9606.0,,F,,BAO_0000219,16913,,478.0,1,CHEMBL620015,A2780,,Homo sapiens,N,1,,
4774,"Inhibitory effect of Gold(III) complex, 2,2' bipy on growth of cisplatin-sensitive A2780/S human tumor cell lines",Intermediate,9606.0,,F,,BAO_0000219,16913,,478.0,1,CHEMBL621010,A2780,,Homo sapiens,N,1,,
4775,"Inhibitory effect of Gold(III) complex, CDDP on growth of cisplatin-sensitive A2780/S human tumor cell lines",Intermediate,9606.0,,F,,BAO_0000219,16913,,478.0,1,CHEMBL621011,A2780,,Homo sapiens,N,1,,
4776,"Inhibitory effect of Gold(III) complex, [Au(bipy)-(OH)2]-[PF6] on growth of cisplatin-sensitive A2780/S human tumor cell lines",Intermediate,9606.0,,F,,BAO_0000219,16913,,478.0,1,CHEMBL621012,A2780,,Homo sapiens,N,1,,
4777,"Inhibitory effect of Gold(III) complex, [Au(bipy-H)(OH)]-[PF6] on growth of cisplatin-sensitive A2780/S human tumor cell lines",Intermediate,9606.0,,F,,BAO_0000219,16913,,478.0,1,CHEMBL621013,A2780,,Homo sapiens,N,1,,
4778,In vitro cytotoxicity against A2780TAX cell line,Intermediate,9606.0,,F,,BAO_0000219,17270,,478.0,1,CHEMBL621014,A2780,,Homo sapiens,N,1,,
4779,In vitro inhibitory activity against human tumor cell line A2780cis,Intermediate,9606.0,,F,,BAO_0000219,5618,,481.0,1,CHEMBL618154,A2780cisR,,Homo sapiens,N,1,,
4780,Growth inhibition against A2780 cisplatin resistant wild-type ovarian cell lines,Expert,9606.0,,F,,BAO_0000219,17777,,478.0,1,CHEMBL618155,A2780,,Homo sapiens,N,1,,
4781,Antitumor activity of compound for 96-h exposure in A2780cisR (acquired resistance to cisplatin) human ovarian cell line,Intermediate,9606.0,,F,,BAO_0000219,16112,,481.0,1,CHEMBL618156,A2780cisR,,Homo sapiens,N,1,,
4782,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ),Intermediate,9606.0,,F,,BAO_0000219,15748,,481.0,1,CHEMBL618157,A2780cisR,,Homo sapiens,N,1,,
4783,Concentration required to inhibit A2780cisR cell growth when compared with control after incubation for 96 h at 37 C,Intermediate,9606.0,,F,,BAO_0000219,6633,,478.0,1,CHEMBL618328,A2780,,Homo sapiens,N,1,,
4784,Compound was evaluated against human Ovarian carcinoma cell line A2780cisR,Intermediate,9606.0,,F,,BAO_0000219,16930,,478.0,1,CHEMBL618329,A2780,,Homo sapiens,N,1,,
4785,Cytotoxicity against human ovarian carcinoma A2780cisR cell line,Intermediate,9606.0,,F,,BAO_0000219,17496,,478.0,1,CHEMBL618330,A2780,,Homo sapiens,N,1,,
4786,In vitro antitumor activity against A2780cisR cell line.,Expert,9606.0,,F,,BAO_0000219,12989,,478.0,1,CHEMBL618331,A2780,,Homo sapiens,N,1,,
4787,Tested for the cytotoxicity in A2780cisR ovarian cell line (cisR denotes resistance to cisplatin),Intermediate,9606.0,,F,,BAO_0000219,4840,,478.0,1,CHEMBL618332,A2780,,Homo sapiens,N,1,,
4788,Resistant factor determined between IC50 of resistant line to that of A2780cisR cell line,Expert,9606.0,,F,,BAO_0000219,12989,,478.0,1,CHEMBL618333,A2780,,Homo sapiens,N,1,,
4789,cytotoxicity against A2780cisR cells incubated for 24 hr in MTT assay,Intermediate,9606.0,,F,,BAO_0000219,16745,,481.0,1,CHEMBL618334,A2780cisR,,Homo sapiens,N,1,,
4790,Inhibition of A2780 / DDP-S human ovarian carcinoma cell proliferation,Expert,9606.0,,F,,BAO_0000219,16597,,478.0,1,CHEMBL618335,A2780,,Homo sapiens,N,1,,
4791,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes,Expert,10116.0,,B,,BAO_0000019,16547,,,1,CHEMBL618336,,,Rattus norvegicus,D,9,,
4792,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes (functional antagonist activity),Expert,,,F,,BAO_0000019,16547,,,1,CHEMBL618337,,,,H,8,,
4793,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes (functional antagonist activity),Expert,10116.0,,F,,BAO_0000019,16547,,,1,CHEMBL618338,,,Rattus norvegicus,D,9,,
4794,Antagonist activity against human A2B adenosine receptor expressed in HEK293 cells uisng [3H]ZM-241385 or [125I]-IABOPX,Expert,9606.0,,F,,BAO_0000219,15856,,722.0,1,CHEMBL618339,HEK293,,Homo sapiens,D,9,,
4795,Antagonist activity against human A2B adenosine receptor expressed in HEK293 cells using [3H]ZM-241385 (or) [125 I]IABOPX at 10e-5 M,Expert,9606.0,,F,,BAO_0000219,15856,,722.0,1,CHEMBL618340,HEK293,,Homo sapiens,D,9,,
4796,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes,Expert,10090.0,,B,,BAO_0000019,16547,,,1,CHEMBL618341,,,Mus musculus,D,9,,
4797,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes (functional antagonist activity),Expert,,,F,,BAO_0000019,16547,,,1,CHEMBL618342,,,,H,8,,
4798,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes (functional antagonist activity),Expert,10090.0,,F,,BAO_0000019,16547,,,1,CHEMBL618343,,,Mus musculus,D,9,,
4799,Ability to displace the binding of [3H]-MRE 3008-F20 to the ligand binding site of CHO:hA3 (human Adenosine receptor) at concentration of 10 uM,Expert,,,B,,BAO_0000357,17402,,,1,CHEMBL621038,,,,H,8,,
4800,Compound was tested in vitro for inhibition of cytopathogenicity of LAV(IIIB) in CD4+ T-cells (A3.01),Autocuration,9606.0,,F,,BAO_0000219,11746,,574.0,1,CHEMBL621039,T-cells,,Homo sapiens,U,0,,
4801,Compound was tested in vitro for inhibition of cytopathogenicity of LAV(IIIB) in CD4+ T-cells (A3.01); Not active,Autocuration,9606.0,,F,,BAO_0000219,11746,,574.0,1,CHEMBL621040,T-cells,,Homo sapiens,U,0,,
4802,Compound was evaluated for cytotoxic activity against human melanoma cell line A375,Intermediate,9606.0,,F,,BAO_0000219,5455,,455.0,1,CHEMBL621041,A-375,,Homo sapiens,N,1,,
4803,In vitro antitumor activity against A375 (melanoma) human tumor cell lines.,Intermediate,9606.0,,F,,BAO_0000219,2068,,455.0,1,CHEMBL621042,A-375,,Homo sapiens,N,1,,
4804,In vitro antitumor activity against A375cell line extracted form melanoma,Intermediate,9606.0,,F,,BAO_0000219,2683,,455.0,1,CHEMBL621043,A-375,,Homo sapiens,N,1,,
4805,Inhibition of cell growth in (A375) melan cell line,Expert,9606.0,,F,,BAO_0000219,15313,,455.0,1,CHEMBL621044,A-375,,Homo sapiens,N,1,,
4806,In vitro tumor cell growth inhibitory activity against Human melanoma cell lines A375,Intermediate,9606.0,,F,,BAO_0000219,13739,,455.0,1,CHEMBL621045,A-375,,Homo sapiens,N,1,,
4807,In vitro tumor cell growth inhibitory activity against Human melanoma cell lines. A375,Intermediate,9606.0,,F,,BAO_0000219,13739,,455.0,1,CHEMBL621046,A-375,,Homo sapiens,N,1,,
4808,Compound was tested in vitro for cytotoxicity against A375 cell lines from melanoma.,Intermediate,9606.0,,F,,BAO_0000219,14750,,455.0,1,CHEMBL621047,A-375,,Homo sapiens,N,1,,
4809,Antiproliferative activity measured against A427 human lung carcinoma,Intermediate,9606.0,,F,,BAO_0000219,14777,,797.0,1,CHEMBL621048,A-427,,Homo sapiens,N,1,,
4810,Antiproliferative activity measured against A427 human lung carcinoma,Intermediate,9606.0,,F,,BAO_0000219,14777,,797.0,1,CHEMBL883798,A-427,,Homo sapiens,N,1,,
4811,Cytotoxicity against lung carcinoma A427 tumor cell lines,Intermediate,9606.0,,F,,BAO_0000219,17672,,797.0,1,CHEMBL621049,A-427,,Homo sapiens,N,1,,
4812,Inhibition of large cell lung carcinoma (A427),Intermediate,9606.0,,F,,BAO_0000219,14368,,797.0,1,CHEMBL621050,A-427,,Homo sapiens,N,1,,
4813,Inhibition of large cell lung carcinoma (A427) after 48-h treatment,Intermediate,9606.0,,F,,BAO_0000219,14368,,797.0,1,CHEMBL621051,A-427,,Homo sapiens,N,1,,
4814,Inhibitory activity against A427 epithelial Cancer cell line at the concentration 0-30 uM for 48 hr,Intermediate,9606.0,,F,,BAO_0000219,13866,,797.0,1,CHEMBL621052,A-427,,Homo sapiens,N,1,,
4815,Inhibitory concentration in human lung carcinoma A427 cell line,Intermediate,9606.0,,F,,BAO_0000219,2545,,797.0,1,CHEMBL621053,A-427,,Homo sapiens,N,1,,
4816,Inhibitory concentration in human lung carcinoma A427/VCR cell line,Intermediate,9606.0,,F,,BAO_0000219,2545,,797.0,1,CHEMBL621054,A-427,,Homo sapiens,N,1,,
4817,Terminal phase volume of distribution was measured in monkey after an iv dose of 1 mg/kg,Autocuration,9527.0,,A,,BAO_0000218,6062,,,1,CHEMBL621055,,,Cercopithecidae,U,0,,
4818,Tested for volume of distribution upon iv administration to african green monkey,Autocuration,9527.0,,A,,BAO_0000218,4578,,,1,CHEMBL876398,,,Cercopithecidae,U,0,,
4819,Volume of distribution in monkey,Autocuration,9527.0,,A,,BAO_0000218,17592,,,1,CHEMBL621056,,,Cercopithecidae,U,0,,
4820,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,Autocuration,9544.0,,A,,BAO_0000218,5005,,,1,CHEMBL621057,,,Macaca mulatta,U,0,,
4821,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po; ND is not determined.,Autocuration,9544.0,,A,,BAO_0000218,5005,,,1,CHEMBL621058,,,Macaca mulatta,U,0,,
4822,Pharmacokinetic property(Vdss) in cynomolgus monkey,Autocuration,9527.0,,A,,BAO_0000218,5922,,,1,CHEMBL621059,,,Cercopithecidae,U,0,,
4823,The distribution volume after intravenous administration in cynomolgus monkeys,Autocuration,9527.0,,A,,BAO_0000218,5355,,,1,CHEMBL621060,,,Cercopithecidae,U,0,,
4824,The distribution volume after oral administration in cynomolgus monkeys; NA means Not applicable,Autocuration,9527.0,,A,,BAO_0000218,5355,,,1,CHEMBL621061,,,Cercopithecidae,U,0,,
4825,The distribution volume after oral administration in cynomolgus monkeys; NA means not applicable,Autocuration,9527.0,,A,,BAO_0000218,5355,,,1,CHEMBL621062,,,Cercopithecidae,U,0,,
4826,Volume displacement was calculated in rhesus monkey,Autocuration,9527.0,,A,,BAO_0000218,6057,,,1,CHEMBL621063,,,Cercopithecidae,U,0,,
4827,Volume of distribution in steady state was determined in rhesus monkey,Autocuration,9527.0,,A,,BAO_0000218,5145,,,1,CHEMBL621064,,,Cercopithecidae,U,0,,
4828,Volume of distribution of compound was determined in monkey,Autocuration,9527.0,,A,,BAO_0000218,6821,,,1,CHEMBL621065,,,Cercopithecidae,U,0,,
4829,Volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),Autocuration,9527.0,,A,,BAO_0000218,5334,,,1,CHEMBL621066,,,Cercopithecidae,U,0,,
4830,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),Autocuration,9527.0,,A,,BAO_0000218,5334,,,1,CHEMBL621067,,,Cercopithecidae,U,0,,
4831,Volumes of distribution in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),Autocuration,9527.0,,A,,BAO_0000218,6641,,,1,CHEMBL621068,,,Cercopithecidae,U,0,,
4832,Compound was evaluated for volume of distribution (steady state) after treatment with iv dose of 1 mgkg to female cynomolgus monkey,Autocuration,9527.0,,A,,BAO_0000218,2661,,,1,CHEMBL876399,,,Cercopithecidae,U,0,,
4833,Volume distribution in monkey after administration of 1 mg/kg iv,Autocuration,9527.0,,A,,BAO_0000218,6535,,,1,CHEMBL621069,,,Cercopithecidae,U,0,,
4834,Volume distribution was determined in monkey after (iv) administration of a dose of 13 (uM/kg),Autocuration,9527.0,,A,,BAO_0000218,4809,,,1,CHEMBL621070,,,Cercopithecidae,U,0,,
4835,Volume of distribution was measured in monkey after an iv dose of 1 mg/kg,Autocuration,9527.0,,A,,BAO_0000218,6062,,,1,CHEMBL621071,,,Cercopithecidae,U,0,,
4836,Half life evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,Autocuration,9527.0,,A,,BAO_0000218,3443,,,1,CHEMBL621072,,,Cercopithecidae,U,0,,
4837,Oral systemic bioavailability upon iv administration to african green monkey,Autocuration,9527.0,,A,,BAO_0000218,4578,,,1,CHEMBL618209,,,Cercopithecidae,U,0,,
4838,Plasma clearance was determined in monkey after (iv) administration of a dose of 13 (uM/kg),Autocuration,9527.0,,A,,BAO_0000218,4809,,,1,CHEMBL618210,,,Cercopithecidae,U,0,,
4839,Baboon plasma free fraction. ,Autocuration,9527.0,,A,,BAO_0000019,11271,,,1,CHEMBL618211,,,Cercopithecidae,U,0,,
4840,Area under the curve was calculated in rhesus monkey after iv administration,Autocuration,9527.0,,A,,BAO_0000218,6057,,,1,CHEMBL618212,,,Cercopithecidae,U,0,,
4841,Area under the curve was calculated in rhesus monkey after peroral administration,Autocuration,9527.0,,A,,BAO_0000019,6057,,,1,CHEMBL618213,,,Cercopithecidae,U,0,,
4842,Dose-normalized area under curve in monkey (p.o.) at 2.0 mpk,Autocuration,9527.0,,A,,BAO_0000019,17853,,,1,CHEMBL618214,,,Cercopithecidae,U,0,,
4843,Half life period in monkey after 5 mg/kg dose,Autocuration,9527.0,,A,,BAO_0000218,5302,,,1,CHEMBL873492,,,Cercopithecidae,U,0,,
4844,Half-life was determined in monkey after 3 mg/kg of i.v. dose,Autocuration,9527.0,,A,,BAO_0000218,4257,,,1,CHEMBL618272,,,Cercopithecidae,U,0,,
4845,Half-life was determined in monkey after 3 mg/kg of i.v. dose; Not determined,Autocuration,9527.0,,A,,BAO_0000218,4257,,,1,CHEMBL618273,,,Cercopithecidae,U,0,,
4846,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 1 mg/kg to rhesus monkey,Autocuration,9527.0,,A,,BAO_0000218,13501,,,1,CHEMBL618274,,,Cercopithecidae,U,0,1969.0,
4847,Compound at a dose 3 mg/kg was administered to monkey and was evaluated for half life after administration into monkey at 3 mg/kg,Autocuration,9527.0,,A,,BAO_0000218,5394,,,1,CHEMBL618275,,,Cercopithecidae,U,0,,
4848,Compound was evaluated for half-life after treatment with iv dose of 1 mgkg to female cynomolgus monkey,Autocuration,9527.0,,A,,BAO_0000218,2661,,,1,CHEMBL618276,,,Cercopithecidae,U,0,,
4849,Compound was evaluated for terminal half life in monkey,Autocuration,9527.0,,A,,BAO_0000019,3341,,,1,CHEMBL618277,,,Cercopithecidae,U,0,,
4850,Compound was evaluated for the half life period after iv administration in cynomolgus monkey,Autocuration,9527.0,,A,,BAO_0000218,3045,,,1,CHEMBL618278,,,Cercopithecidae,U,0,,
4851,Compound was tested for its plasma half life in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,Autocuration,9544.0,,A,,BAO_0000218,5005,,,1,CHEMBL618279,,,Macaca mulatta,U,0,1969.0,
4852,Half life of compound was determined in squirrel monkey,Autocuration,9527.0,,A,,BAO_0000019,4847,,,1,CHEMBL618280,,,Cercopithecidae,U,0,,
4853,Half life after iv administration in cynomolgus monkey,Autocuration,9541.0,,A,,BAO_0000218,4256,,,1,CHEMBL618281,,,Macaca fascicularis,U,0,,
4854,Half life in monkey plasma after administration of 1 mg/kg iv,Autocuration,9527.0,,A,,BAO_0000218,6535,,,1,CHEMBL618282,,,Cercopithecidae,U,0,1969.0,
4855,Half life was calculated in rhesus monkey,Autocuration,9527.0,,A,,BAO_0000019,6057,,,1,CHEMBL618283,,,Cercopithecidae,U,0,,
4856,Half life in monkey,Autocuration,9527.0,,A,,BAO_0000019,17592,,,1,CHEMBL618284,,,Cercopithecidae,U,0,,
4857,Half life in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),Autocuration,9527.0,,A,,BAO_0000218,6641,,,1,CHEMBL618285,,,Cercopithecidae,U,0,,
4858,Half life was evaluated in rhesus,Autocuration,9527.0,,A,,BAO_0000019,5472,,,1,CHEMBL618286,,,Cercopithecidae,U,0,,
4859,Half life period after oral administration (2.5 mg/kg) in monkey was determined,Autocuration,9527.0,,A,,BAO_0000218,6221,,,1,CHEMBL618287,,,Cercopithecidae,U,0,,
4860,Half life period was determine after peroral administration at 10 mpk in Rhesus,Autocuration,9527.0,,A,,BAO_0000218,5668,,,1,CHEMBL618288,,,Cercopithecidae,U,0,,
4861,Half life period was determined in monkey after (iv) administration of a dose of 13 (uM/kg),Autocuration,9527.0,,A,,BAO_0000218,4809,,,1,CHEMBL876393,,,Cercopithecidae,U,0,,
4862,Half life period was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,Autocuration,9527.0,,A,,BAO_0000218,5546,,,1,CHEMBL618289,,,Cercopithecidae,U,0,,
4863,Half life period was determined in squirrel monkey after iv administration at a dose of 5 mg/kg,Autocuration,9527.0,,A,,BAO_0000218,5553,,,1,CHEMBL618290,,,Cercopithecidae,U,0,,
4864,Half-life was calculated in monkey,Autocuration,9527.0,,A,,BAO_0000019,6078,,,1,CHEMBL618291,,,Cercopithecidae,U,0,,
4865,Half-life in Squirrel monkey,Autocuration,9527.0,,A,,BAO_0000019,5147,,,1,CHEMBL618292,,,Cercopithecidae,U,0,,
4866,Half-life in rhesus monkey,Autocuration,9527.0,,A,,BAO_0000019,5145,,,1,CHEMBL618293,,,Cercopithecidae,U,0,,
4867,Half-life was measured in monkey after an iv dose of 1 mg/kg,Autocuration,9527.0,,A,,BAO_0000218,6062,,,1,CHEMBL618294,,,Cercopithecidae,U,0,,
4868,Half-life period after intravenous administration in cynomolgus monkeys,Autocuration,9527.0,,A,,BAO_0000218,5355,,,1,CHEMBL618295,,,Cercopithecidae,U,0,,
4869,Half-life period after oral administration in cynomolgus monkeys,Autocuration,9527.0,,A,,BAO_0000218,5355,,,1,CHEMBL618296,,,Cercopithecidae,U,0,,
4870,Half-life period after oral administration in cynomolgus monkeys; ND meansn Not determined,Autocuration,9527.0,,A,,BAO_0000218,5355,,,1,CHEMBL618297,,,Cercopithecidae,U,0,,
4871,Portion of holoxan excreted in the form of the metabolite from 1500 mL of urine on day 9 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,Autocuration,9606.0,,A,,BAO_0000019,7766,,,1,CHEMBL618298,,,Homo sapiens,U,0,1088.0,
4872,Portion of holoxan excreted in the form of the metabolite from 1600 mL of urine on day 10 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,Autocuration,9606.0,,A,,BAO_0000019,7766,,,1,CHEMBL618299,,,Homo sapiens,U,0,1088.0,
4873,Portion of holoxan excreted in the form of the metabolite from 1700 mL of urine on day 5 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,Autocuration,9606.0,,A,,BAO_0000019,7766,,,1,CHEMBL618300,,,Homo sapiens,U,0,1088.0,
4874,Portion of holoxan excreted in the form of the metabolite from 2310 mL of urine on day 4 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,Autocuration,9606.0,,A,,BAO_0000019,7766,,,1,CHEMBL618301,,,Homo sapiens,U,0,1088.0,
4875,Percent ratio of the enantiomeric form (+)R extracted from the urine of alveolar rhabdomyosarcoma patients was determined,Autocuration,9606.0,,A,,BAO_0000019,7766,,,1,CHEMBL618302,,,Homo sapiens,U,0,1088.0,
4876,Percent ratio of the enantiomeric form (+)R extracted from the urine of embryonal rhabdomyosarcoma patients was determined,Autocuration,9606.0,,A,,BAO_0000019,7766,,,1,CHEMBL876394,,,Homo sapiens,U,0,1088.0,
4877,Percent ratio of the enantiomeric form (-)S extracted from the urine of alveolar rhabdomyosarcoma patients was determined,Autocuration,9606.0,,A,,BAO_0000019,7766,,,1,CHEMBL618303,,,Homo sapiens,U,0,1088.0,
4878,Percent ratio of the enantiomeric form (-)S extracted from the urine of embryonal rhabdomyosarcoma patients was determined,Autocuration,9606.0,,A,,BAO_0000019,7766,,,1,CHEMBL618304,,,Homo sapiens,U,0,1088.0,
4879,Bioavailability was evaluated in man at a dose of 10 mg/kg after po administration; not determined,Autocuration,9606.0,,A,,BAO_0000218,1916,,,1,CHEMBL618305,,,Homo sapiens,U,0,,
4880,Oral bioavailability in human,Autocuration,9606.0,,A,,BAO_0000218,16643,,,1,CHEMBL618306,,,Homo sapiens,U,0,,
4881,Compound was tested for human plasma protein binding,Autocuration,9606.0,,A,,BAO_0000019,17248,,,1,CHEMBL618307,,,Homo sapiens,U,0,,
4882,Compound was tested for human plasma protein binding; Not determined,Autocuration,9606.0,,A,,BAO_0000019,17248,,,1,CHEMBL618308,,,Homo sapiens,U,0,,
4883,Protein binding activity of compound in human plasma; % Free,Autocuration,9606.0,,A,,BAO_0000019,6241,,,1,CHEMBL618309,,,Homo sapiens,U,0,,
4884,Unbound fraction (plasma),Autocuration,9606.0,,A,,BAO_0000019,17716,,,1,CHEMBL618310,,,Homo sapiens,U,0,,
4885,Half life for the hydrolysis of compound in human blood serum,Autocuration,9606.0,,A,,BAO_0000366,17605,,,1,CHEMBL873353,,,Homo sapiens,U,0,1969.0,
4886,Half life period in human plasma using phosphate buffer (0.08 M),Autocuration,9606.0,,A,,BAO_0000366,17625,,,1,CHEMBL618311,,,Homo sapiens,U,0,1969.0,
4887,Half life period in human plasma using phosphate buffer (0.1 M),Autocuration,9606.0,,A,,BAO_0000366,17625,,,1,CHEMBL618312,,,Homo sapiens,U,0,1969.0,
4888,Half-life in human plasma was determined,Autocuration,9606.0,,A,,BAO_0000366,17747,,,1,CHEMBL618313,,,Homo sapiens,U,0,1969.0,
4889,Concentration required for 50% toxicity in metastatic lung carcinoma (MV522) cells.,Autocuration,9606.0,,A,,BAO_0000019,15613,,,1,CHEMBL618314,,,Homo sapiens,U,0,,
4890,Effect of compound on gelation time of human serum induced by dithiothreitol (DTT),Autocuration,9606.0,,A,,BAO_0000019,354,,,1,CHEMBL618315,,,Homo sapiens,U,0,,
4891,"Rate constant in chemical and enzymatic hydrolysis to form L-DOPA, in 80% human plasma",Autocuration,9606.0,,A,,BAO_0000019,3741,,,1,CHEMBL618316,,,Homo sapiens,U,0,,
4892,"Rate constant in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 1)",Autocuration,9606.0,,A,,BAO_0000019,3741,,,1,CHEMBL618317,,,Homo sapiens,U,0,,
4893,"Rate constant in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 2)",Autocuration,9606.0,,A,,BAO_0000019,3741,,,1,CHEMBL620138,,,Homo sapiens,U,0,,
4894,Partition coefficient (logP),Autocuration,9606.0,,A,,BAO_0000019,17599,,,1,CHEMBL858280,,,Homo sapiens,U,0,,
4895,In vitro metabolic stability in human was measured as pmol/min/mg/protein,Autocuration,9606.0,,A,,BAO_0000019,5486,,,1,CHEMBL620139,,,Homo sapiens,U,0,,
4896,In vitro metabolic stability determined after 30 min of incubation in human hepatic microsomes,Autocuration,9606.0,,A,,BAO_0000251,5600,Microsomes,,1,CHEMBL620140,,,Homo sapiens,U,0,,
4897,Metabolism of compound in human liver slices (male) ('+''indicates <20% largest observed peak),Autocuration,9606.0,,A,,BAO_0000019,14294,,,1,CHEMBL620141,,,Homo sapiens,U,0,,
4898,Metabolism of compound in human liver slices (male) ('++''indicates 20-50% largest observed peak),Autocuration,9606.0,,A,,BAO_0000019,14294,,,1,CHEMBL620142,,,Homo sapiens,U,0,,
4899,Metabolism of compound in human liver slices (male) ('++++' indicates largest observed peak),Autocuration,9606.0,,A,,BAO_0000019,14294,,,1,CHEMBL620143,,,Homo sapiens,U,0,,
4900,Metabolism of compound in human microsomes ('+''indicates <20% largest observed peak),Autocuration,9606.0,,A,,BAO_0000251,14294,Microsomes,,1,CHEMBL620144,,,Homo sapiens,U,0,,
4901,Metabolism of compound in human microsomes ('++++' indicates largest observed peak),Autocuration,9606.0,,A,,BAO_0000251,14294,Microsomes,,1,CHEMBL620145,,,Homo sapiens,U,0,,
4902,Metabolism of compound in human microsomes; Trace,Autocuration,9606.0,,A,,BAO_0000251,14294,Microsomes,,1,CHEMBL620146,,,Homo sapiens,U,0,,
4903,Percent of compound remaining after 120 min of Metabolization upon incubation with human liver microsomes,Autocuration,9606.0,,A,,BAO_0000251,6260,Microsomes,,1,CHEMBL620147,,,Homo sapiens,U,0,2107.0,
4904,Percent metabolized in an in vitro human liver microsomal incubation assay after 60 min,Autocuration,9606.0,,A,,BAO_0000251,6187,Microsomes,,1,CHEMBL620148,,,Homo sapiens,U,0,,
4905,In vitro metabolic potential in human liver microsomes,Autocuration,9606.0,,A,,BAO_0000251,6251,Microsomes,,1,CHEMBL620149,,,Homo sapiens,U,0,2107.0,
4906,Metabolism by recombinant human NAD(P)H:quinone oxidoreductase (NQO1) was evaluated,Autocuration,9606.0,,A,,BAO_0000019,3246,,,1,CHEMBL876412,,,Homo sapiens,U,0,,
4907,Tested for human plasma protein binding of the compound; Not tested,Autocuration,9606.0,,A,,BAO_0000019,17313,,,1,CHEMBL619352,,,Homo sapiens,U,0,,
4908,Compound was tested for percent protein binding (PB) in human,Autocuration,9606.0,,A,,BAO_0000019,6227,,,1,CHEMBL619353,,,Homo sapiens,U,0,,
4909,Protein binding in human plasma,Autocuration,9606.0,,A,,BAO_0000019,5530,,,1,CHEMBL619354,,,Homo sapiens,U,0,1969.0,
4910,Permeability coefficient (B to A) in Caco-2 cell,Autocuration,9606.0,,A,,BAO_0000019,6108,,,1,CHEMBL619355,,,Homo sapiens,U,0,,
4911,Permeability directional ratio (PB-A/PA-B) in Caco-2 cell,Autocuration,9606.0,,A,,BAO_0000019,6108,,,1,CHEMBL619356,,,Homo sapiens,U,0,,
4912,Apparent permeability coefficient (Papp) was determined in human Caco-2 cell monolayer (n = 3),Autocuration,9606.0,,A,,BAO_0000019,2774,,,1,CHEMBL619357,,,Homo sapiens,U,0,,
4913,In vitro rate of absorption observed as Caco-2 permeability in humans,Autocuration,9606.0,,A,,BAO_0000019,16643,,,1,CHEMBL619358,,,Homo sapiens,U,0,,
4914,Cellular permeability of compound was determined in Caco-2 cells; High,Autocuration,9606.0,,A,,BAO_0000219,17582,,495.0,1,CHEMBL619359,Caco-2,,Homo sapiens,U,0,,
4915,Permeability in Caco-2 cells of compound,Autocuration,9606.0,,A,,BAO_0000219,6838,,495.0,1,CHEMBL619360,Caco-2,,Homo sapiens,U,0,,
4916,Permeability coefficient (A to B) in Caco-2 cell,Autocuration,9606.0,,A,,BAO_0000019,6108,,,1,CHEMBL619361,,,Homo sapiens,U,0,,
4917,Permeability coefficient (B to A) in Caco-2 cell,Autocuration,9606.0,,A,,BAO_0000019,6108,,,1,CHEMBL619362,,,Homo sapiens,U,0,,
4918,Permeability coefficient (Papp) (Caco-2 cell monolayer),Autocuration,9606.0,,A,,BAO_0000019,6108,,,1,CHEMBL619363,,,Homo sapiens,U,0,,
4919,Compound was measured for binding rate for human serum at a carbapenem concentration of 10 ug/mL,Autocuration,9606.0,,A,,BAO_0000019,2146,,,1,CHEMBL618942,,,Homo sapiens,U,0,,
4920,Compound was tested for protein binding in human plasma,Autocuration,9606.0,,A,,BAO_0000019,4514,,,1,CHEMBL618943,,,Homo sapiens,U,0,,
4921,Transcellular permeability of the [(PA-B+PB-A)/2)] compound was determined in Caco-2 cell,Autocuration,9606.0,,A,,BAO_0000019,6108,,,1,CHEMBL618944,,,Homo sapiens,U,0,,
4922,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1200 mL of urine tested on day 3,Autocuration,9606.0,,A,,BAO_0000019,7766,,,1,CHEMBL618945,,,Homo sapiens,U,0,1088.0,
4923,In vivo Tmax was determined in murine septicemia at dose of 50 mg/kg,Intermediate,10090.0,,A,,BAO_0000218,5969,,,1,CHEMBL618946,,,Mus musculus,N,1,,
4924,Maximum time was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),Intermediate,10090.0,,A,,BAO_0000218,3277,,,1,CHEMBL876413,,,Mus musculus,N,1,,
4925,Tested for Tmax value at the dose of 10 mg/kg when administered perorally in mouse,Intermediate,10090.0,,A,,BAO_0000218,3802,,,1,CHEMBL618947,,,Mus musculus,N,1,,
4926,Time taken to reach maximum concentration in plasma upon oral administration in mouse,Intermediate,10090.0,,A,,BAO_0000218,2862,,,1,CHEMBL618948,,,Mus musculus,N,1,1969.0,
4927,Time to reach maximum plasma concentration was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,Intermediate,10090.0,,A,,BAO_0000218,6348,,,1,CHEMBL618949,,,Mus musculus,N,1,1969.0,
4928,Tmax after intraperitoneal administration in mice at 23 uM/kg,Intermediate,10090.0,,F,,BAO_0000218,17764,,,1,CHEMBL618950,,,Mus musculus,N,1,,
4929,Tmax after oral administration at 30 mg/kg in ICR mouse,Intermediate,10090.0,,A,,BAO_0000218,5781,,,1,CHEMBL618951,,,Mus musculus,N,1,,
4930,Tmax after peroral administration in mice at 2.4 uM/kg,Intermediate,10090.0,,A,,BAO_0000218,17764,,,1,CHEMBL618952,,,Mus musculus,N,1,,
4931,Tmax at a single subcutaneous administration of 40 mg/kg in mice,Intermediate,10090.0,,A,,BAO_0000218,4066,,,1,CHEMBL618953,,,Mus musculus,N,1,,
4932,Tmax in brain of mice at the oral dose of 50 mg/kg,Intermediate,10090.0,,A,,BAO_0000218,17641,,,1,CHEMBL618954,,,Mus musculus,N,1,955.0,
4933,Tmax in kidney of mice at the oral dose of 50 mg/kg,Intermediate,10090.0,,A,,BAO_0000218,17641,,,1,CHEMBL618955,,,Mus musculus,N,1,2113.0,
4934,Tmax in liver of mice at the oral dose of 50 mg/kg,Intermediate,10090.0,,A,,BAO_0000218,17641,,,1,CHEMBL618956,,,Mus musculus,N,1,2107.0,
4935,Tmax in lungs of mice at the oral dose of 50 mg/kg,Intermediate,10090.0,,A,,BAO_0000218,17641,,,1,CHEMBL618957,,,Mus musculus,N,1,2048.0,
4936,Tmax in mice at 18 uM/kg i.p. administration,Intermediate,10090.0,,F,,BAO_0000218,17764,,,1,CHEMBL618958,,,Mus musculus,N,1,,
4937,Tmax in mice at 23 uM/kg i.v. administration,Intermediate,10090.0,,F,,BAO_0000218,17764,,,1,CHEMBL618959,,,Mus musculus,N,1,,
4938,Tmax in mice at 25 uM/kg i.p. administration,Intermediate,10090.0,,F,,BAO_0000218,17764,,,1,CHEMBL618960,,,Mus musculus,N,1,,
4939,Tmax in mice at 26 uM/kg i.p. administration,Intermediate,10090.0,,F,,BAO_0000218,17764,,,1,CHEMBL876723,,,Mus musculus,N,1,,
4940,Tmax in spleen of mice at the oral dose of 50 mg/kg,Intermediate,10090.0,,A,,BAO_0000218,17641,,,1,CHEMBL618961,,,Mus musculus,N,1,2106.0,
4941,Tmax value at a dose of 10 mg/kg intravenous administration in mice.,Intermediate,10090.0,,A,,BAO_0000218,16597,,,1,CHEMBL618962,,,Mus musculus,N,1,,
4942,Tmax value at a dose of 10 mg/kg peroral administration in mice.,Intermediate,10090.0,,A,,BAO_0000218,16597,,,1,CHEMBL618963,,,Mus musculus,N,1,,
4943,Tmax value in IRC mice,Intermediate,10090.0,,A,,BAO_0000218,5951,,,1,CHEMBL618964,,,Mus musculus,N,1,,
4944,Tmax value was determined at a dose of 100 mg/kg (i.p.) in Mice,Intermediate,10090.0,,A,,BAO_0000218,5506,,,1,CHEMBL618965,,,Mus musculus,N,1,,
4945,Tmax value was determined at a dose of 200 mg/kg (i.p.) in Mice,Intermediate,10090.0,,A,,BAO_0000218,5506,,,1,CHEMBL618966,,,Mus musculus,N,1,,
4946,Evaluated for pharmacokinetic parameter urine recovery in mouse at the dose 20 mg/kg ( 0-24 hr ),Intermediate,10090.0,,A,,BAO_0000218,429,,,1,CHEMBL618967,,,Mus musculus,N,1,1088.0,
4947,Evaluated for pharmacokinetic parameter urine recovery in mouse at the dose 20 mg/kg (0-24 hr),Intermediate,10090.0,,A,,BAO_0000218,429,,,1,CHEMBL618968,,,Mus musculus,N,1,1088.0,
4948,Urinary recovery by disk method using Streptococcus pyogenes (0-24 h),Intermediate,10090.0,,A,,BAO_0000218,4066,,,1,CHEMBL618969,,,Mus musculus,N,1,1088.0,
4949,The first compartment constitutes the majority of the volume of distribution after intraperitoneal administration of 100 mg/kg in mice,Intermediate,10090.0,,A,,BAO_0000218,17734,,,1,CHEMBL618970,,,Mus musculus,N,1,,
4950,The second majority of the volume of distribution after intraperitoneal administration of 100 mg/kg in mice,Intermediate,10090.0,,A,,BAO_0000218,17734,,,1,CHEMBL618971,,,Mus musculus,N,1,,
4951,Terminal phase volume of distribution was measured in mouse after an iv dose of 1 mg/kg,Intermediate,10090.0,,A,,BAO_0000218,6062,,,1,CHEMBL618972,,,Mus musculus,N,1,,
4952,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 100 mg/kg,Intermediate,10090.0,,A,,BAO_0000218,5969,,,1,CHEMBL618973,,,Mus musculus,N,1,,
4953,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 50 mg/kg,Intermediate,10090.0,,A,,BAO_0000218,5969,,,1,CHEMBL618974,,,Mus musculus,N,1,,
4954,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,Intermediate,10090.0,,A,,BAO_0000218,5969,,,1,CHEMBL618975,,,Mus musculus,N,1,,
4955,Vd in mice,Intermediate,10090.0,,A,,BAO_0000218,5980,,,1,CHEMBL618976,,,Mus musculus,N,1,,
4956,Volume of distribution in mouse,Intermediate,10090.0,,A,,BAO_0000218,17592,,,1,CHEMBL618977,,,Mus musculus,N,1,,
4957,Volume of distribution was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,Intermediate,10090.0,,A,,BAO_0000218,6348,,,1,CHEMBL876724,,,Mus musculus,N,1,,
4958,Volume of distribution of compound in plasma was determined at 24 mg/Kg,Intermediate,10090.0,,A,,BAO_0000218,17753,,,1,CHEMBL618978,,,Mus musculus,N,1,,
4959,Volume of distribution of compound in plasma was determined at 40 mg/Kg,Intermediate,10090.0,,A,,BAO_0000218,17753,,,1,CHEMBL618979,,,Mus musculus,N,1,,
4960,Volume of distribution of compound in plasma was determined at 5 mg/Kg,Intermediate,10090.0,,A,,BAO_0000218,17753,,,1,CHEMBL618980,,,Mus musculus,N,1,,
4961,Pharmacokinetic property (vdss) was measured in mouse,Intermediate,10090.0,,A,,BAO_0000218,4239,,,1,CHEMBL618981,,,Mus musculus,N,1,,
4962,Value distribution upon iv administration in mouse,Intermediate,10090.0,,A,,BAO_0000218,2862,,,1,CHEMBL618982,,,Mus musculus,N,1,,
4963,Volume of distribution after intraperitoneal administration of 100 mg/kg in mice,Intermediate,10090.0,,A,,BAO_0000218,17734,,,1,CHEMBL620150,,,Mus musculus,N,1,,
4964,Volume of distribution was evaluated in mice after intravenous administration,Intermediate,10090.0,,A,,BAO_0000218,2675,,,1,CHEMBL620151,,,Mus musculus,N,1,,
4965,Volume of distribution was evaluated in mice after oral administration,Intermediate,10090.0,,A,,BAO_0000218,2675,,,1,CHEMBL620152,,,Mus musculus,N,1,,
4966,Steady state volume of distribution of compound in mouse blood following i.v. administration of 10 mg/kg,Intermediate,10090.0,,A,,BAO_0000218,17837,,,1,CHEMBL620153,,,Mus musculus,N,1,,
4967,Steady state volume of distribution was determined in mice,Intermediate,10090.0,,A,,BAO_0000218,5727,,,1,CHEMBL876395,,,Mus musculus,N,1,,
4968,Volume distribution (steady state) of compound was determined in mouse,Intermediate,10090.0,,A,,BAO_0000218,17852,,,1,CHEMBL620154,,,Mus musculus,N,1,,
4969,Volume of solubility in solution after intravenous administration in mice at 24 uM/kg,Intermediate,10090.0,,A,,BAO_0000218,17764,,,1,CHEMBL620155,,,Mus musculus,N,1,,
4970,Vss value at a dose of 10 mg/kg intravenous administration in mice.,Intermediate,10090.0,,A,,BAO_0000218,16597,,,1,CHEMBL620156,,,Mus musculus,N,1,,
4971,Volume of distribution was measured in mouse after an iv dose of 1 mg/kg,Intermediate,10090.0,,A,,BAO_0000218,6062,,,1,CHEMBL620157,,,Mus musculus,N,1,,
4972,Biodistribution of compound (oxidized form) in in kidney tissue,Intermediate,10090.0,,A,,BAO_0000218,16438,,,1,CHEMBL620158,,,Mus musculus,N,1,2113.0,
4973,Biodistribution in mice as total concentration of both oxidized and reduced forms in blood and animals were sacrificed 10 minutes after ip administration in DMSO solution,Intermediate,10090.0,,A,,BAO_0000218,16438,,,1,CHEMBL620159,,,Mus musculus,N,1,178.0,
4974,"Biodistribution in mice as total concentration of both oxidized and reduced forms in blood and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",Intermediate,10090.0,,A,,BAO_0000218,16438,,,1,CHEMBL620160,,,Mus musculus,N,1,178.0,
4975,"Biodistribution in mice as total concentration of both oxidized and reduced forms in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",Intermediate,10090.0,,A,,BAO_0000218,16438,,,1,CHEMBL620161,,,Mus musculus,N,1,178.0,
4976,Evaluated for the inhibitory concentration required to cause growth inhibition of A427Mer- cell line of lung using the MTT Cytotoxicity Assay,Intermediate,9606.0,,F,,BAO_0000219,10708,,797.0,1,CHEMBL620162,A-427,,Homo sapiens,N,1,,
4977,Inhibition of A431 human squamous cell carcinoma cell proliferation,Expert,9606.0,,F,,BAO_0000219,16597,,500.0,1,CHEMBL620163,A-431,,Homo sapiens,N,1,,
4978,Inhibition of cell growth of human epidermoid carcinoma xenograft (A431) model using cell based assay,Expert,9606.0,,F,,BAO_0000219,16062,,500.0,1,CHEMBL620833,A-431,,Homo sapiens,N,1,,
4979,Inhibition of human epidermoid carcinoma xenograft (A431) tumor growth,Expert,9606.0,,F,,BAO_0000219,16062,,500.0,1,CHEMBL876396,A-431,,Homo sapiens,N,1,,
4980,Concentration required to inhibit growth of human carcinoma epidermoid (A431) cell line,Expert,9606.0,,F,,BAO_0000219,16958,,500.0,1,CHEMBL620834,A-431,,Homo sapiens,N,1,,
4981,Inhibition of A431 human carcinoma cell proliferation,Expert,9606.0,,F,,BAO_0000219,6700,,500.0,1,CHEMBL620835,A-431,,Homo sapiens,N,1,,
4982,In vitro inhibition of A431 (human carcinoma) cell basal growth.,Expert,9606.0,,F,,BAO_0000219,17226,,500.0,1,CHEMBL620836,A-431,,Homo sapiens,N,1,,
4983,Inhibitory concentration of compound against growth of human A431 cell line; Resistant,Intermediate,9606.0,,F,,BAO_0000219,6828,,500.0,1,CHEMBL620837,A-431,,Homo sapiens,N,1,,
4984,In vitro cytotoxicity against epidermoid carcinoma cell line,Intermediate,9606.0,,F,,BAO_0000219,12314,,500.0,1,CHEMBL621017,A-431,,Homo sapiens,N,1,,
4985,"In vivo efficacy following oral administration in nude mouse tumor model, xenograft A431 cells expressing EGF-R",Expert,9606.0,,F,,BAO_0000218,13412,,500.0,1,CHEMBL621018,A-431,,Homo sapiens,D,9,,
4986,Antiproliferative activity of compound was measured on human tumor cell line A431.,Intermediate,9606.0,,F,,BAO_0000219,13299,,500.0,1,CHEMBL621019,A-431,,Homo sapiens,N,1,,
4987,Antiproliferative effect of compound on A431 cell line expressing mutant p53,Intermediate,9606.0,,F,,BAO_0000219,17420,,500.0,1,CHEMBL621020,A-431,,Homo sapiens,N,1,,
4988,Compound was evaluated for cell growth inhibition against A 431 cell line by irradiation in the presence of examined compound,Intermediate,9606.0,,F,,BAO_0000219,13678,,500.0,1,CHEMBL621021,A-431,,Homo sapiens,N,1,,
4989,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells.,Expert,,,F,,BAO_0000219,14171,,500.0,1,CHEMBL621022,A-431,,,H,8,,
4990,Tested for antiproliferative activity against human A431 cells,Expert,9606.0,,F,,BAO_0000219,6333,,500.0,1,CHEMBL621023,A-431,,Homo sapiens,N,1,,
4991,Inhibition of epidermal growth factor receptor (EGF-R) autophosphorylation in A431 cells,Expert,9606.0,,F,,BAO_0000219,2356,,500.0,1,CHEMBL621024,A-431,,Homo sapiens,D,9,,
4992,Concentration needed to inhibit 50% growth of the human A431 (epidermoid carcinoma) cell lines,Expert,9606.0,,F,,BAO_0000219,15578,,500.0,1,CHEMBL621025,A-431,,Homo sapiens,N,1,,
4993,Inhibition of A431 cell proliferation,Expert,9606.0,,F,,BAO_0000219,5126,,500.0,1,CHEMBL621026,A-431,,Homo sapiens,N,1,,
4994,Cytotoxic effect on A431 human epidermoid carcinoma cells,Expert,9606.0,,F,,BAO_0000219,6844,,500.0,1,CHEMBL621027,A-431,,Homo sapiens,N,1,,
4995,Cytotoxic effect on A431 human epidermoid carcinoma cells (No response to 1 mM),Expert,9606.0,,F,,BAO_0000219,6844,,500.0,1,CHEMBL876397,A-431,,Homo sapiens,N,1,,
4996,Cytotoxicity expressed as inhibitory concentration required to reduce the cell growth of A431 human epidermal carcinoma cell line,Intermediate,9606.0,,F,,BAO_0000219,4925,,500.0,1,CHEMBL883797,A-431,,Homo sapiens,N,1,,
4997,Cytotoxicity expressed as inhibitory concentration required to reduce the cell growth of A431 human epidermal carcinoma cell line; NT=Not tested,Intermediate,9606.0,,F,,BAO_0000219,4925,,500.0,1,CHEMBL621028,A-431,,Homo sapiens,N,1,,
4998,In vitro Growth Inhibitory activity against A431 Human vulva cancer cell line,Intermediate,9606.0,,F,,BAO_0000219,13978,,500.0,1,CHEMBL621029,A-431,,Homo sapiens,N,1,,
4999,In vitro cytotoxicity of compound against human A431 (epidermoid) cancer cell line after 72 hr of drug exposure,Intermediate,9606.0,,F,,BAO_0000219,16786,,500.0,1,CHEMBL621030,A-431,,Homo sapiens,N,1,,
5000,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells expressing EGF-R,Expert,,,F,,BAO_0000219,13412,,500.0,1,CHEMBL621147,A-431,,,H,8,,
5001,In vivo antiproliferative activity against A431 cell line,Intermediate,9606.0,,F,,BAO_0000218,17824,,500.0,1,CHEMBL621148,A-431,,Homo sapiens,N,1,,
5002,Inhibition of EGF-dependent autophosphorylation of EGF-R in human A431 cells,Expert,9606.0,,F,,BAO_0000219,12751,,500.0,1,CHEMBL621149,A-431,,Homo sapiens,D,9,,
5003,Inhibition of A431 human epidermoid carcinoma cell proliferation,Expert,9606.0,,F,,BAO_0000219,12380,,500.0,1,CHEMBL621150,A-431,,Homo sapiens,N,1,,
5004,Inhibition of autophosphorylation of human epidermal growth factor-receptor (EGF-R) expressed in A431 cells,Expert,9606.0,,F,,BAO_0000219,4959,,500.0,1,CHEMBL621151,A-431,,Homo sapiens,D,9,,
5005,Inhibitory effect on nonphospho-Src after EGF (100 uM) stimulation of A431 cells (control=178),Intermediate,9606.0,,F,,BAO_0000219,6333,,500.0,1,CHEMBL621152,A-431,,Homo sapiens,N,1,,
5006,Inhibitory effect on phospho-Src (Tyr416) after EGF (100 uM) stimulation of A431 cells (38),Intermediate,9606.0,,F,,BAO_0000219,6333,,500.0,1,CHEMBL621153,A-431,,Homo sapiens,N,1,,
5007,Inhibitory effect on phospho-Src/nonphospho after EGF (100 uM) stimulation of A431 cells (21),Intermediate,9606.0,,F,,BAO_0000219,6333,,500.0,1,CHEMBL884000,A-431,,Homo sapiens,N,1,,
5008,Inhibition of EGFR overexpressing A431 cell proliferation,Expert,9606.0,,F,,BAO_0000019,5296,,,1,CHEMBL621154,,,Homo sapiens,D,9,,
5009,Inhibition of A431 cell proliferation,Expert,9606.0,,F,,BAO_0000219,12624,,500.0,1,CHEMBL621155,A-431,,Homo sapiens,N,1,,
5010,No inhibition of EGFR phosphorylation in A431 cells 8 hour after washing cells free of the inhibitor,Expert,9606.0,,F,,BAO_0000219,14926,,500.0,1,CHEMBL621156,A-431,,Homo sapiens,D,9,,
5011,"Partial inhibition of EGFR phosphorylation in A431 cells, 8 hour after washing cells free of the inhibitor",Expert,9606.0,,F,,BAO_0000219,14926,,500.0,1,CHEMBL621157,A-431,,Homo sapiens,D,9,,
5012,Irreversible inhibition of ATP binding site of EGFR (lack of phosphorylated EGFR) in A431 cells 8 hour after washing cells free of the inhibitor),Expert,,,F,,BAO_0000219,14926,,500.0,1,CHEMBL621158,A-431,,,H,8,,
5013,The compound was tested in vitro for antiproliferative activity against A431 tumor cell lines,Intermediate,9606.0,,F,,BAO_0000219,15144,,500.0,1,CHEMBL621159,A-431,,Homo sapiens,N,1,,
5014,The compound was tested in vitro for antiproliferative activity against A431 tumor cell lines,Intermediate,9606.0,,F,,BAO_0000219,15144,,500.0,1,CHEMBL621160,A-431,,Homo sapiens,N,1,,
5015,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration at 2 uM after 48 h; Did not affect the viability,Intermediate,9606.0,,F,,BAO_0000219,5245,,500.0,1,CHEMBL621161,A-431,,Homo sapiens,N,1,,
5016,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration in the range of 1-10 uM after 48 h; Did not affect the viability,Intermediate,9606.0,,F,,BAO_0000219,5245,,500.0,1,CHEMBL621162,A-431,,Homo sapiens,N,1,,
5017,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration up to 10 uM after 48 h; Did not affect the viability,Intermediate,9606.0,,F,,BAO_0000219,5245,,500.0,1,CHEMBL621163,A-431,,Homo sapiens,N,1,,
5018,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration 0.01 uM after 48 h; Cell death,Intermediate,9606.0,,F,,BAO_0000219,5245,,500.0,1,CHEMBL621164,A-431,,Homo sapiens,N,1,,
5019,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration 2 uM after 48 h; Cell death,Intermediate,9606.0,,F,,BAO_0000219,5245,,500.0,1,CHEMBL621165,A-431,,Homo sapiens,N,1,,
5020,Half-life period in cynomolgus monkey,Autocuration,9527.0,,A,,BAO_0000019,5922,,,1,CHEMBL619159,,,Cercopithecidae,U,0,,
5021,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in monkey plasma",Autocuration,9527.0,,A,,BAO_0000366,1116,,,1,CHEMBL619160,,,Cercopithecidae,U,0,1969.0,
5022,Longer half-life in monkey (i.v.) at 0.5 mpk,Autocuration,9527.0,,A,,BAO_0000218,17853,,,1,CHEMBL619161,,,Cercopithecidae,U,0,,
5023,Plasma half life in monkey,Autocuration,9527.0,,A,,BAO_0000366,993,,,1,CHEMBL619162,,,Cercopithecidae,U,0,1969.0,
5024,Plasma half-life in rhesus monkey,Autocuration,9527.0,,A,,BAO_0000366,4514,,,1,CHEMBL619163,,,Cercopithecidae,U,0,1969.0,
5025,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),Autocuration,9527.0,,A,,BAO_0000218,5334,,,1,CHEMBL619164,,,Cercopithecidae,U,0,1969.0,
5026,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),Autocuration,9527.0,,A,,BAO_0000218,5334,,,1,CHEMBL619320,,,Cercopithecidae,U,0,1969.0,
5027,Tested for half life upon iv administration to african green monkey,Autocuration,9527.0,,A,,BAO_0000218,4578,,,1,CHEMBL619321,,,Cercopithecidae,U,0,,
5028,Compound was evaluated for maximum time to reach Cmax after treatment with oral dose of 2 mgkg to female cynomolgus monkey,Autocuration,9527.0,,A,,BAO_0000218,2661,,,1,CHEMBL873336,,,Cercopithecidae,U,0,,
5029,The time for peak concentration value after intravenous administration in cynomolgus monkeys; NA means Not applicable,Autocuration,9527.0,,A,,BAO_0000218,5355,,,1,CHEMBL619322,,,Cercopithecidae,U,0,,
5030,The time for peak concentration value after intravenous administration in cynomolgus monkeys; NA means not applicable,Autocuration,9527.0,,A,,BAO_0000218,5355,,,1,CHEMBL619323,,,Cercopithecidae,U,0,,
5031,The time for peak concentration value after oral administration in cynomolgus monkeys,Autocuration,9527.0,,A,,BAO_0000218,5355,,,1,CHEMBL619324,,,Cercopithecidae,U,0,,
5032,Percentage of tracer or metabolite (CO2) in baboon plasma at 10 min after injection of the compound,Autocuration,9527.0,,A,,BAO_0000019,11271,,,1,CHEMBL619325,,,Cercopithecidae,U,0,,
5033,Percentage of tracer or metabolite (CO2) in baboon plasma at 1 min after injection of the compound,Autocuration,9527.0,,A,,BAO_0000019,11271,,,1,CHEMBL876411,,,Cercopithecidae,U,0,,
5034,Percentage of tracer or metabolite (CO2) in baboon plasma at 30 min after injection of the compound,Autocuration,9527.0,,A,,BAO_0000019,11271,,,1,CHEMBL619326,,,Cercopithecidae,U,0,,
5035,Percentage of tracer or metabolite (CO2) in baboon plasma at 5 min after injection of the compound,Autocuration,9527.0,,A,,BAO_0000019,11271,,,1,CHEMBL619327,,,Cercopithecidae,U,0,,
5036,Percentage of tracer or metabolite(EME) in baboon plasma at 10 min after injection of the compound,Autocuration,9527.0,,A,,BAO_0000019,11271,,,1,CHEMBL619328,,,Cercopithecidae,U,0,,
5037,Percentage of tracer or metabolite(EME) in baboon plasma at 1 min after injection of the compound,Autocuration,9527.0,,A,,BAO_0000019,11271,,,1,CHEMBL619329,,,Cercopithecidae,U,0,,
5038,Percentage of tracer or metabolite(EME) in baboon plasma at 30 min after injection of the compound,Autocuration,9527.0,,A,,BAO_0000019,11271,,,1,CHEMBL619330,,,Cercopithecidae,U,0,,
5039,Percentage of tracer or metabolite(EME) in baboon plasma at 5 min after injection of the compound,Autocuration,9527.0,,A,,BAO_0000019,11271,,,1,CHEMBL619331,,,Cercopithecidae,U,0,,
5040,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 10 min after injection of the compound,Autocuration,9527.0,,A,,BAO_0000019,11271,,,1,CHEMBL619332,,,Cercopithecidae,U,0,,
5041,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 1 min after injection of the compound,Autocuration,9527.0,,A,,BAO_0000019,11271,,,1,CHEMBL619333,,,Cercopithecidae,U,0,,
5042,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 30 min after injection of the compound,Autocuration,9527.0,,A,,BAO_0000019,11271,,,1,CHEMBL619334,,,Cercopithecidae,U,0,,
5043,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 5 min after injection of the compound,Autocuration,9527.0,,A,,BAO_0000019,11271,,,1,CHEMBL619335,,,Cercopithecidae,U,0,,
5044,Percentage of tracer or metabolite (unchanged) in baboon plasma at 10 min after injection of the compound,Autocuration,9527.0,,A,,BAO_0000019,11271,,,1,CHEMBL619336,,,Cercopithecidae,U,0,,
5045,Percentage of tracer or metabolite (unchanged) in baboon plasma at 1 min after injection of the compound,Autocuration,9527.0,,A,,BAO_0000019,11271,,,1,CHEMBL619337,,,Cercopithecidae,U,0,,
5046,Percentage of tracer or metabolite (unchanged) in baboon plasma at 30 min after injection of the compound,Autocuration,9527.0,,A,,BAO_0000019,11271,,,1,CHEMBL619338,,,Cercopithecidae,U,0,,
5047,Percentage of tracer or metabolite (unchanged) in baboon plasma at 5 min after injection of the compound,Autocuration,9527.0,,A,,BAO_0000019,11271,,,1,CHEMBL619339,,,Cercopithecidae,U,0,,
5048,Bioavailability in rat (cannulated) (dose 2 mg/kg),Intermediate,10116.0,,A,,BAO_0000218,5809,,,1,CHEMBL619340,,,Rattus norvegicus,N,1,,
5049,Half life at a dose of 4 mg/kg in Rat Plasma after iv administration,Intermediate,10116.0,,A,,BAO_0000218,17720,,,1,CHEMBL873496,,,Rattus norvegicus,N,1,1969.0,
5050,AUC value in rat after IV administration at a dose of 10 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,3546,,,1,CHEMBL619341,,,Rattus norvegicus,N,1,1969.0,
5051,AUC value in rat after oral administration at a dose of 10 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,3546,,,1,CHEMBL619342,,,Rattus norvegicus,N,1,1969.0,
5052,Cmax value in rat after oral administration at a dose of 10 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,3546,,,1,CHEMBL619343,,,Rattus norvegicus,N,1,,
5053,Bioavailability in rat after oral administration at a dose of 10 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,3546,,,1,CHEMBL619344,,,Rattus norvegicus,N,1,,
5054,Tmax value in rat after oral administration at a dose of 10 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,3546,,,1,CHEMBL619345,,,Rattus norvegicus,N,1,,
5055,Vc value in rat after IV administration at a dose of 10 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,3546,,,1,CHEMBL619346,,,Rattus norvegicus,N,1,,
5056,Half life period in rat after IV administration at a dose of 10 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,3546,,,1,CHEMBL619347,,,Rattus norvegicus,N,1,,
5057,The absolute striatal uptake of the carbon-11 labeled compound at 60 min was determined in baboon,Autocuration,9557.0,,A,,BAO_0000019,10625,,,1,CHEMBL619348,,,Papio hamadryas,U,0,,
5058,Peak plasma radioactivity for the carbon-11 labeled compound was determined at 0.5 min after injection in baboon; (Range = 0.08-0.11),Autocuration,9557.0,,A,,BAO_0000019,10625,,,1,CHEMBL619349,,,Papio hamadryas,U,0,,
5059,Peak plasma radioactivity for the carbon-11 labeled compound was determined at 1.5 min after injection in baboon; (Range = 0.08-0.11),Autocuration,9557.0,,A,,BAO_0000019,10625,,,1,CHEMBL619350,,,Papio hamadryas,U,0,,
5060,The amount of unchanged tracer in baboon plasma was determined 1 min after injection of the carbon-11 labeled compound,Autocuration,9557.0,,A,,BAO_0000019,10625,,,1,CHEMBL619351,,,Papio hamadryas,U,0,,
5061,The amount of unchanged tracer in baboon plasma was determined 10 min after injection of the carbon-11 labeled compound,Autocuration,9557.0,,A,,BAO_0000019,10625,,,1,CHEMBL875953,,,Papio hamadryas,U,0,,
5062,The amount of unchanged tracer in baboon plasma was determined 30 min after injection of the carbon-11 labeled compound,Autocuration,9557.0,,A,,BAO_0000019,10625,,,1,CHEMBL621716,,,Papio hamadryas,U,0,,
5063,The amount of unchanged tracer in baboon plasma was determined 60 min after injection of the carbon-11 labeled compound,Autocuration,9557.0,,A,,BAO_0000019,10625,,,1,CHEMBL621717,,,Papio hamadryas,U,0,,
5064,The absolute striatal uptake of the carbon-11 labeled compound at 60 min was determined in baboon,Autocuration,9557.0,,A,,BAO_0000019,10625,,,1,CHEMBL621718,,,Papio hamadryas,U,0,,
5065,Area under curve after 1 mpk peroral administration to beagles,Autocuration,9615.0,,A,,BAO_0000019,3510,,,1,CHEMBL621719,,,beagle,U,0,,
5066,Area under curve after 2 mpk peroral administration to beagles,Autocuration,9615.0,,A,,BAO_0000019,3510,,,1,CHEMBL621720,,,beagle,U,0,,
5067,Cmax value after 1 mpk peroral administration to beagles,Autocuration,9615.0,,A,,BAO_0000218,3510,,,1,CHEMBL621721,,,beagle,U,0,,
5068,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1200 mL of urine tested on day 7,Autocuration,9606.0,,A,,BAO_0000019,7766,,,1,CHEMBL621722,,,Homo sapiens,U,0,1088.0,
5069,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1300 mL of urine tested on day 6,Autocuration,9606.0,,A,,BAO_0000019,7766,,,1,CHEMBL621723,,,Homo sapiens,U,0,1088.0,
5070,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1300 mL of urine tested on day 8,Autocuration,9606.0,,A,,BAO_0000019,7766,,,1,CHEMBL621724,,,Homo sapiens,U,0,1088.0,
5071,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1500 mL of urine tested on day 9,Autocuration,9606.0,,A,,BAO_0000019,7766,,,1,CHEMBL623443,,,Homo sapiens,U,0,1088.0,
5072,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1600 mL of urine tested on day 10,Autocuration,9606.0,,A,,BAO_0000019,7766,,,1,CHEMBL623444,,,Homo sapiens,U,0,1088.0,
5073,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1700 mL of urine tested on day 5,Autocuration,9606.0,,A,,BAO_0000019,7766,,,1,CHEMBL623445,,,Homo sapiens,U,0,1088.0,
5074,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 2310 mL of urine tested on day 4,Autocuration,9606.0,,A,,BAO_0000019,7766,,,1,CHEMBL623446,,,Homo sapiens,U,0,1088.0,
5075,Metabolic stability observed at 30 min after administration in human liver microsomes,Autocuration,9606.0,,A,,BAO_0000251,16643,Microsomes,,1,CHEMBL623447,,,Homo sapiens,U,0,2107.0,
5076,Percent recovery of 100 ug/mL compound after administration in cirrhotic patients,Autocuration,9606.0,,A,,BAO_0000019,6852,,,1,CHEMBL623448,,,Homo sapiens,U,0,,
5077,Percent recovery of 10 ug/mL compound after administration in cirrhotic patients,Autocuration,9606.0,,A,,BAO_0000019,6852,,,1,CHEMBL623449,,,Homo sapiens,U,0,,
5078,Percent recovery of 500 ug/mL compound after administration in cirrhotic patients,Autocuration,9606.0,,A,,BAO_0000019,6852,,,1,CHEMBL623450,,,Homo sapiens,U,0,,
5079,"Compound remaining after incubation with 2 mg/mL of human liver microsomes at 37 degrees C for 30 min in a pH 7.4, 0.05 M phosphate buffer",Autocuration,9606.0,,A,,BAO_0000251,6567,Microsomes,,1,CHEMBL623451,,,Homo sapiens,U,0,2107.0,
5080,Metabolic stability (% remaining at 30 mins) in human S9.,Autocuration,9606.0,,A,,BAO_0000019,6570,,,1,CHEMBL623452,,,Homo sapiens,U,0,,
5081,Metabolic stability determined as remaining percent after 30 min of incubation in human isolated liver S9 preparations; N/D= Not determined,Autocuration,9606.0,,A,,BAO_0000019,6570,,,1,CHEMBL623453,,,Homo sapiens,U,0,,
5082,Percent parent compound remaining after 20 min incubation with human liver microsomes,Autocuration,9606.0,,A,,BAO_0000251,5237,Microsomes,,1,CHEMBL623454,,,Homo sapiens,U,0,2107.0,
5083,Percent parent compound remaining after 20 min incubation with human liver microsomes; ND=No data,Autocuration,9606.0,,A,,BAO_0000251,5237,Microsomes,,1,CHEMBL623455,,,Homo sapiens,U,0,2107.0,
5084,Percent parent compound remaining after 20 min incubation with human liver microsomes; No data,Autocuration,9606.0,,A,,BAO_0000251,5237,Microsomes,,1,CHEMBL624371,,,Homo sapiens,U,0,2107.0,
5085,First pass metabolism and metabolic bioavailability using human hepatic microsomes,Autocuration,9606.0,,A,,BAO_0000218,5202,,,1,CHEMBL624372,,,Homo sapiens,U,0,,
5086,Percent compound remaining in human plasma after incubation for 60 min at 37 C.,Autocuration,9606.0,,A,,BAO_0000019,5481,,,1,CHEMBL624373,,,Homo sapiens,U,0,,
5087,Percent remaining in human plasma after incubation for 60 min at 37 C.,Autocuration,9606.0,,A,,BAO_0000019,5481,,,1,CHEMBL624374,,,Homo sapiens,U,0,,
5088,The percent remaining in human plasma after 30 min was determined,Autocuration,9606.0,,A,,BAO_0000019,3956,,,1,CHEMBL624556,,,Homo sapiens,U,0,,
5089,Conversion rate of the prodrug in human plasma,Autocuration,9606.0,,A,,BAO_0000366,5074,,,1,CHEMBL624557,,,Homo sapiens,U,0,1969.0,
5090,Conversion rate of the prodrug in human plasma; ND means no data,Autocuration,9606.0,,A,,BAO_0000366,5074,,,1,CHEMBL624558,,,Homo sapiens,U,0,1969.0,
5091,Half life of compound was determined in human blood,Autocuration,9606.0,,A,,BAO_0000221,4727,,,1,CHEMBL624559,,,Homo sapiens,U,0,178.0,
5092,Half life of compound was determined in man with once daily dosing,Autocuration,9606.0,,A,,BAO_0000019,5965,,,1,CHEMBL624560,,,Homo sapiens,U,0,,
5093,Half life in human microsomes,Autocuration,9606.0,,A,,BAO_0000251,5732,Microsomes,,1,CHEMBL624561,,,Homo sapiens,U,0,,
5094,Half life in human plasma,Autocuration,9606.0,,A,,BAO_0000366,5819,,,1,CHEMBL624562,,,Homo sapiens,U,0,1969.0,
5095,Half life in human plasma; Not detected,Autocuration,9606.0,,A,,BAO_0000366,5819,,,1,CHEMBL624563,,,Homo sapiens,U,0,1969.0,
5096,Half life period was evaluated against man at a dose of 10 mg/kg after po administration,Autocuration,9606.0,,A,,BAO_0000218,1916,,,1,CHEMBL624564,,,Homo sapiens,U,0,,
5097,Half-life for oxidative metabolic stability was determined using rat liver microsomes,Autocuration,9606.0,,A,,BAO_0000251,6597,Microsomes,,1,CHEMBL624565,,,Homo sapiens,U,0,2107.0,
5098,Half-life in human plasma,Autocuration,9606.0,,A,,BAO_0000366,5229,,,1,CHEMBL875152,,,Homo sapiens,U,0,1969.0,
5099,Half-life of the parent prodrug in plasma,Autocuration,9606.0,,A,,BAO_0000366,5229,,,1,CHEMBL624566,,,Homo sapiens,U,0,1969.0,
5100,In vitro half life in human plasma was determined,Autocuration,9606.0,,A,,BAO_0000366,2192,,,1,CHEMBL873805,,,Homo sapiens,U,0,1969.0,
5101,The compound was tested In Vitro for half life in human liver microsomes.,Autocuration,9606.0,,A,,BAO_0000251,3032,Microsomes,,1,CHEMBL624567,,,Homo sapiens,U,0,2107.0,
5102,Maximum time was evaluated against man at a dose of 10 mg/kg after po administration,Autocuration,9606.0,,A,,BAO_0000218,1916,,,1,CHEMBL624568,,,Homo sapiens,U,0,,
5103,Observed volume of distribution,Autocuration,9606.0,,A,,BAO_0000218,17716,,,1,CHEMBL624569,,,Homo sapiens,U,0,,
5104,Oral bioavailability in human,Autocuration,9606.0,,A,,BAO_0000218,15778,,,1,CHEMBL624570,,,Homo sapiens,U,0,,
5105,Tested for human plasma protein binding of the compound,Autocuration,9606.0,,A,,BAO_0000019,17313,,,1,CHEMBL624571,,,Homo sapiens,U,0,,
5106,"First order rate constant, k was determined in human plasma",Autocuration,9606.0,,A,,BAO_0000019,4231,,,1,CHEMBL624572,,,Homo sapiens,U,0,,
5107,Observed rate constant in 80% human plasma at 37 degree Centigrade,Autocuration,9606.0,,A,,BAO_0000019,4755,,,1,CHEMBL624573,,,Homo sapiens,U,0,,
5108,Observed rate constant in 80% human plasma at 37 degree Centigrade,Autocuration,9606.0,,A,,BAO_0000019,4755,,,1,CHEMBL875153,,,Homo sapiens,U,0,,
5109,Loss of compound (%metabolized) after 30 min exposure to human liver microsomes,Autocuration,9606.0,,A,,BAO_0000251,16907,Microsomes,,1,CHEMBL624574,,,Homo sapiens,U,0,2107.0,
5110,The compound was tested for the plasma binding in human,Autocuration,9606.0,,A,,BAO_0000019,10839,,,1,CHEMBL624575,,,Homo sapiens,U,0,,
5111,Plasma protein binding (human),Autocuration,9606.0,,A,,BAO_0000019,10839,,,1,CHEMBL624576,,,Homo sapiens,U,0,,
5112,Compound was evaluated for half-life in human liver microsomes,Autocuration,9606.0,,A,,BAO_0000251,3199,Microsomes,,1,CHEMBL624577,,,Homo sapiens,U,0,2107.0,
5113,Half life measured in vitro for its stability in human blood,Autocuration,9606.0,,A,,BAO_0000221,1345,,,1,CHEMBL624578,,,Homo sapiens,U,0,178.0,
5114,Half life in human serum,Autocuration,9606.0,,A,,BAO_0000019,4297,,,1,CHEMBL622796,,,Homo sapiens,U,0,1977.0,
5115,Half life in human serum; ND=not determined,Autocuration,9606.0,,A,,BAO_0000019,4297,,,1,CHEMBL622797,,,Homo sapiens,U,0,1977.0,
5116,Half life were determined in CEM-SS cell extract in decomposition step 1,Autocuration,9606.0,,A,,BAO_0000019,4297,,,1,CHEMBL622798,,,Homo sapiens,U,0,,
5117,Half life were determined in CEM-SS cell extract in decomposition step 2,Autocuration,9606.0,,A,,BAO_0000019,4297,,,1,CHEMBL622799,,,Homo sapiens,U,0,,
5118,Half life of the in human plasma,Autocuration,9606.0,,A,,BAO_0000366,4231,,,1,CHEMBL622800,,,Homo sapiens,U,0,1969.0,
5119,Half life period in human hepatic S9 fraction was determined,Autocuration,9606.0,,A,,BAO_0000220,5633,S9,,1,CHEMBL622801,,,Homo sapiens,U,0,,
5120,Half life period in human liver microsome was determined,Autocuration,9606.0,,A,,BAO_0000251,5633,Microsomes,,1,CHEMBL622802,,,Homo sapiens,U,0,2107.0,
5121,Half life period was determined; 6-7,Autocuration,9606.0,,A,,BAO_0000019,17791,,,1,CHEMBL622803,,,Homo sapiens,U,0,,
5122,Half life period was evaluated in human,Autocuration,9606.0,,A,,BAO_0000019,17791,,,1,CHEMBL875154,,,Homo sapiens,U,0,,
5123,Half life time in human plasma,Autocuration,9606.0,,A,,BAO_0000366,3160,,,1,CHEMBL622804,,,Homo sapiens,U,0,1969.0,
5124,"Biodistribution in mice as total concentration of both oxidized and reduced forms in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",Intermediate,10090.0,,A,,BAO_0000218,16438,,,1,CHEMBL622805,,,Mus musculus,N,1,955.0,
5125,"Biodistribution in mice as total concentration of both oxidized and reduced forms in heart tissues, animals were sacrificed 10 minutes after dosing, in DMSO sol.",Intermediate,10090.0,,A,,BAO_0000218,16438,,,1,CHEMBL622611,,,Mus musculus,N,1,948.0,
5126,"Biodistribution in mice as total concentration of both oxidized and reduced forms in heart tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",Intermediate,10090.0,,A,,BAO_0000218,16438,,,1,CHEMBL622612,,,Mus musculus,N,1,948.0,
5127,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney and animals were sacrificed 10 minutes after dosing, in DMSO sol.",Intermediate,10090.0,,A,,BAO_0000218,16438,,,1,CHEMBL875160,,,Mus musculus,N,1,2113.0,
5128,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",Intermediate,10090.0,,A,,BAO_0000218,16438,,,1,CHEMBL622613,,,Mus musculus,N,1,2113.0,
5129,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",Intermediate,10090.0,,A,,BAO_0000218,16438,,,1,CHEMBL622614,,,Mus musculus,N,1,2113.0,
5130,"Biodistribution in mice as total concentration of both oxidized and reduced forms in liver and animals were sacrificed 10 minutes after dosing, in DMSO sol.",Intermediate,10090.0,,A,,BAO_0000218,16438,,,1,CHEMBL622615,,,Mus musculus,N,1,2107.0,
5131,Biodistribution in mice as total concentration of both oxidized and reduced forms in liver and animals were sacrificed 10 minutes after ip administration in DMSO solution,Intermediate,10090.0,,A,,BAO_0000218,16438,,,1,CHEMBL622616,,,Mus musculus,N,1,2107.0,
5132,"Biodistribution in mice as total concentration of both oxidized and reduced forms in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",Intermediate,10090.0,,A,,BAO_0000218,16438,,,1,CHEMBL622617,,,Mus musculus,N,1,2107.0,
5133,Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen and animals were sacrificed 10 minutes after ip administration in DMSO solution,Intermediate,10090.0,,A,,BAO_0000218,16438,,,1,CHEMBL622618,,,Mus musculus,N,1,2106.0,
5134,"Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",Intermediate,10090.0,,A,,BAO_0000218,16438,,,1,CHEMBL622619,,,Mus musculus,N,1,2106.0,
5135,"Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",Intermediate,10090.0,,A,,BAO_0000218,16438,,,1,CHEMBL622620,,,Mus musculus,N,1,2106.0,
5136,"Biodistribution in mice, total concentration of both oxidized and reduced forms in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO",Intermediate,10090.0,,A,,BAO_0000218,16438,,,1,CHEMBL622621,,,Mus musculus,N,1,955.0,
5137,Biodistribution of compound (oxidized form) in blood tissue,Intermediate,10090.0,,A,,BAO_0000218,16438,,,1,CHEMBL622622,,,Mus musculus,N,1,178.0,
5138,"Biodistribution of compound (oxidized form) in blood tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",Intermediate,10090.0,,A,,BAO_0000218,16438,,,1,CHEMBL622623,,,Mus musculus,N,1,178.0,
5139,"Biodistribution of compound (oxidized form) in blood tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",Intermediate,10090.0,,A,,BAO_0000218,16438,,,1,CHEMBL622624,,,Mus musculus,N,1,178.0,
5140,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO",Intermediate,10090.0,,A,,BAO_0000218,16438,,,1,CHEMBL622625,,,Mus musculus,N,1,178.0,
5141,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",Intermediate,10090.0,,A,,BAO_0000218,16438,,,1,CHEMBL622626,,,Mus musculus,N,1,178.0,
5142,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO solution",Intermediate,10090.0,,A,,BAO_0000218,16438,,,1,CHEMBL622627,,,Mus musculus,N,1,178.0,
5143,Biodistribution of compound (oxidized form) in brain tissue of mice,Intermediate,10090.0,,A,,BAO_0000218,16438,,,1,CHEMBL622628,,,Mus musculus,N,1,955.0,
5144,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",Intermediate,10090.0,,A,,BAO_0000218,16438,,,1,CHEMBL622629,,,Mus musculus,N,1,955.0,
5145,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO",Intermediate,10090.0,,A,,BAO_0000218,16438,,,1,CHEMBL622630,,,Mus musculus,N,1,955.0,
5146,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",Intermediate,10090.0,,A,,BAO_0000218,16438,,,1,CHEMBL622631,,,Mus musculus,N,1,955.0,
5147,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",Intermediate,10090.0,,A,,BAO_0000218,16438,,,1,CHEMBL622632,,,Mus musculus,N,1,955.0,
5148,"Biodistribution of compound (oxidized form) in brain tissues, animals were sacrificed 10 minutes after dosing, in DMSO solution",Intermediate,10090.0,,A,,BAO_0000218,16438,,,1,CHEMBL622633,,,Mus musculus,N,1,955.0,
5149,Biodistribution of compound (oxidized form) in heart tissue of mice,Intermediate,10090.0,,A,,BAO_0000218,16438,,,1,CHEMBL622634,,,Mus musculus,N,1,948.0,
5150,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",Intermediate,10090.0,,A,,BAO_0000218,16438,,,1,CHEMBL622635,,,Mus musculus,N,1,948.0,
5151,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",Intermediate,10090.0,,A,,BAO_0000218,16438,,,1,CHEMBL875161,,,Mus musculus,N,1,948.0,
5152,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO",Intermediate,10090.0,,A,,BAO_0000218,16438,,,1,CHEMBL622636,,,Mus musculus,N,1,948.0,
5153,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",Intermediate,10090.0,,A,,BAO_0000218,16438,,,1,CHEMBL623335,,,Mus musculus,N,1,948.0,
5154,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",Intermediate,10090.0,,A,,BAO_0000218,16438,,,1,CHEMBL623336,,,Mus musculus,N,1,948.0,
5155,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",Intermediate,10090.0,,A,,BAO_0000218,16438,,,1,CHEMBL623337,,,Mus musculus,N,1,2113.0,
5156,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",Intermediate,10090.0,,A,,BAO_0000218,16438,,,1,CHEMBL623338,,,Mus musculus,N,1,2113.0,
5157,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO",Intermediate,10090.0,,A,,BAO_0000218,16438,,,1,CHEMBL623339,,,Mus musculus,N,1,2113.0,
5158,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",Intermediate,10090.0,,A,,BAO_0000218,16438,,,1,CHEMBL623524,,,Mus musculus,N,1,2113.0,
5159,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",Intermediate,10090.0,,A,,BAO_0000218,16438,,,1,CHEMBL623525,,,Mus musculus,N,1,2113.0,
5160,Biodistribution of compound (oxidized form) in liver tissue,Intermediate,10090.0,,A,,BAO_0000218,16438,,,1,CHEMBL623526,,,Mus musculus,N,1,2107.0,
5161,"Biodistribution of compound (oxidized form) in liver tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",Intermediate,10090.0,,A,,BAO_0000218,16438,,,1,CHEMBL623527,,,Mus musculus,N,1,2107.0,
5162,"Biodistribution of compound (oxidized form) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO",Intermediate,10090.0,,A,,BAO_0000218,16438,,,1,CHEMBL623528,,,Mus musculus,N,1,2107.0,
5163,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration in the range of 1-10 uM of the compound after 48 h; Cell death,Intermediate,9606.0,,F,,BAO_0000219,5245,,500.0,1,CHEMBL624615,A-431,,Homo sapiens,N,1,,
5164,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration up to 10 uM after 48 h; Did not affect the viability,Intermediate,9606.0,,F,,BAO_0000219,5245,,500.0,1,CHEMBL621672,A-431,,Homo sapiens,N,1,,
5165,"In vivo activity in A431 tumor bearing mice, maximum dose (schedule 10-24 days)",Expert,,,F,,BAO_0000218,16289,,500.0,1,CHEMBL621673,A-431,,,N,1,,
5166,"In vivo activity in A431 tumor bearing mice, maximum dose (schedule 12-26 days)",Expert,,,F,,BAO_0000218,16289,,500.0,1,CHEMBL621674,A-431,,,N,1,,
5167,Inhibition of EGF-induced Tyrosine phosphorylation in A431 cells expressing EGF-R,Expert,9606.0,,F,,BAO_0000219,16093,,500.0,1,CHEMBL884002,A-431,,Homo sapiens,D,9,,
5168,"Concentration required to inhibit the epidermoid A431 cell growth by 50%, P53 status of cell line used was wild-type. ",Intermediate,9606.0,,F,,BAO_0000219,16825,,500.0,1,CHEMBL621850,A-431,,Homo sapiens,N,1,,
5169,Inhibitory activity against proliferation of human epidermoid carcinoma (A431) cells,Intermediate,9606.0,,F,,BAO_0000219,4848,,500.0,1,CHEMBL621851,A-431,,Homo sapiens,N,1,,
5170,Inhibition of EGF-dependent autophosphorylation of EGF-R in A431 cells,Expert,9606.0,,F,,BAO_0000219,14827,,500.0,1,CHEMBL621852,A-431,,Homo sapiens,D,9,,
5171,Inhibition of autophosphorylation of epidermal growth factor receptor in A431 cells in culture,Expert,9606.0,,F,,BAO_0000219,14827,,500.0,1,CHEMBL621853,A-431,,Homo sapiens,D,9,,
5172,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 10-24 days)",Expert,,,F,,BAO_0000218,16289,,500.0,1,CHEMBL621854,A-431,,,N,1,,
5173,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 12-26 days)",Expert,,,F,,BAO_0000218,16289,,500.0,1,CHEMBL621855,A-431,,,N,1,,
5174,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 12-26 days)",Expert,,,F,,BAO_0000218,16289,,500.0,1,CHEMBL623724,A-431,,,N,1,,
5175,"In vivo activity in A431 tumor bearing mice, ratio of treated and control tumor mass day 24",Expert,,,F,,BAO_0000218,16289,,500.0,1,CHEMBL623725,A-431,,,N,1,,
5176,"In vivo activity in A431 tumor bearing mice, ratio of treated and control tumor mass day 26",Expert,,,F,,BAO_0000218,16289,,500.0,1,CHEMBL623726,A-431,,,N,1,,
5177,"Irreversible inhibition of EGF-R phosphorylation in A431 cells, 8 hr after washing cells free of compound",Expert,9606.0,,F,,BAO_0000219,16289,,500.0,1,CHEMBL623727,A-431,,Homo sapiens,D,9,,
5178,Irreversible inhibition of formation of phosphorylated EGFR in A431 cells 8 hr after washing cells free of compound,Expert,,,F,,BAO_0000219,16289,,500.0,1,CHEMBL623728,A-431,,,H,8,,
5179,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 10-24",Expert,,,F,,BAO_0000218,16289,,500.0,1,CHEMBL623729,A-431,,,N,1,,
5180,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 12-26",Expert,,,F,,BAO_0000218,16289,,500.0,1,CHEMBL623730,A-431,,,N,1,,
5181,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 12-26",Expert,,,F,,BAO_0000218,16289,,500.0,1,CHEMBL623731,A-431,,,N,1,,
5182,"Ratio of treated and control A431 cell tumor mass in mice at 5 mg/kg peroral dose, days 7-21 administration",Expert,10090.0,,F,,BAO_0000218,14555,,500.0,1,CHEMBL623732,A-431,,Mus musculus,N,1,,
5183,"Difference in days for treated (T) and control (C) A431 cell tumors to reach 750 mg in mice at 5 mg/kg peroral dose, days 7-21 administration",Expert,10090.0,,F,,BAO_0000218,14555,,500.0,1,CHEMBL623733,A-431,,Mus musculus,N,1,,
5184,"Net reduction in tumor burden between first and last treatments of A431 cell tumors in mice at 5 mg/kg peroral dose, days 7-21 administration",Expert,10090.0,,F,,BAO_0000218,14555,,500.0,1,CHEMBL623734,A-431,,Mus musculus,N,1,,
5185,"Weight change of A431 cell tumors in mice at 5 mg/kg peroral dose, days 7-21 administration",Expert,10090.0,,F,,BAO_0000218,14555,,500.0,1,CHEMBL623735,A-431,,Mus musculus,N,1,,
5186,In vitro antiproliferative effect against A431 human epidermoid carcinoma cells,Expert,9606.0,,F,,BAO_0000219,1937,,500.0,1,CHEMBL623736,A-431,,Homo sapiens,N,1,,
5187,In vitro tumor cell growth inhibitory activity against Human leiomyosarcoma A431 cell lines,Intermediate,9606.0,,F,,BAO_0000219,13739,,500.0,1,CHEMBL623737,A-431,,Homo sapiens,N,1,,
5188,Cytotoxicity against A437 cells is the dose giving 50% decrease in the formation of formazan dye,Intermediate,9606.0,,F,,BAO_0000219,3558,,500.0,1,CHEMBL623738,A-431,,Homo sapiens,N,1,,
5189,Dose giving a 50% decrease in the living cell number (A437 cells),Intermediate,9606.0,,F,,BAO_0000219,3558,,500.0,1,CHEMBL875168,A-431,,Homo sapiens,N,1,,
5190,In vitro inhibitory concentration against proliferation of A459 cell line.,Expert,9606.0,,F,,BAO_0000219,17686,,646.0,1,CHEMBL623739,A549,,Homo sapiens,N,1,,
5191,Inhibitory concentration of compound for cytotoxicity against A459 human lung cells was determined,Intermediate,9606.0,,F,,BAO_0000219,5305,,646.0,1,CHEMBL623740,A549,,Homo sapiens,N,1,,
5192,Inhibition of growth of human NSCL non small cell lung carcinoma cell line (A459) after 72 hr of drug exposure,Intermediate,9606.0,,F,,BAO_0000219,3614,,646.0,1,CHEMBL624424,A549,,Homo sapiens,N,1,,
5193,In vitro antitumor activity against renal A498 tumor cell lines,Intermediate,9606.0,,F,,BAO_0000219,17229,,624.0,1,CHEMBL624425,A498,,Homo sapiens,N,1,,
5194,"In vitro growth inhibition of human kidney carcinoma cell line, A498 with low levels of folate receptors",Intermediate,9606.0,,F,,BAO_0000219,15935,,624.0,1,CHEMBL624426,A498,,Homo sapiens,N,1,,
5195,"In vitro growth inhibition of human kidney carcinoma cell line, A498 with low levels of folate receptors in folate deficient medium",Intermediate,9606.0,,F,,BAO_0000219,15935,,624.0,1,CHEMBL624427,A498,,Homo sapiens,N,1,,
5196,Cytotoxicity against A498 Tumor cell line in SRB Cell viability test,Intermediate,9606.0,,F,,BAO_0000219,15560,,624.0,1,CHEMBL624428,A498,,Homo sapiens,N,1,,
5197,Cytotoxicity concentration against human kidney carcinoma A-498 cell line,Intermediate,9606.0,,F,,BAO_0000219,13891,,624.0,1,CHEMBL624429,A498,,Homo sapiens,N,1,,
5198,Cytotoxicity concentration against human kidney carcinoma A-498 cell line; NT =Not tested,Intermediate,9606.0,,F,,BAO_0000219,13891,,624.0,1,CHEMBL624620,A498,,Homo sapiens,N,1,,
5199,Cytotoxicity on kidney carcinoma (A-498) cell line,Intermediate,9606.0,,F,,BAO_0000219,13788,,624.0,1,CHEMBL624621,A498,,Homo sapiens,N,1,,
5200,Compound was evaluated against Human cell line renal A498,Intermediate,9606.0,,F,,BAO_0000219,15403,,624.0,1,CHEMBL624622,A498,,Homo sapiens,N,1,,
5201,Compound was tested for inhibition of A498 human renal cancer cell line,Intermediate,9606.0,,F,,BAO_0000219,1009,,624.0,1,CHEMBL624623,A498,,Homo sapiens,N,1,,
5202,Growth inhibitory activity against A498 human cancer cell line,Intermediate,9606.0,,F,,BAO_0000219,1043,,624.0,1,CHEMBL874365,A498,,Homo sapiens,N,1,,
5203,In vitro antitumor activity against human renal A498 cell line,Intermediate,9606.0,,F,,BAO_0000219,5858,,624.0,1,CHEMBL624624,A498,,Homo sapiens,N,1,,
5204,In vitro cytotoxic activity against renal (A498) cell line,Intermediate,9606.0,,F,,BAO_0000219,5958,,624.0,1,CHEMBL624625,A498,,Homo sapiens,N,1,,
5205,In vitro cytotoxic activity against human renal cancer (A498) cell line,Intermediate,9606.0,,F,,BAO_0000219,5506,,624.0,1,CHEMBL624626,A498,,Homo sapiens,N,1,,
5206,Tested for cytostatic activity against renal A498 cell line,Intermediate,9606.0,,F,,BAO_0000219,12781,,624.0,1,CHEMBL624627,A498,,Homo sapiens,N,1,,
5207,The compound was tested for the concentration to inhibit 50% of renal A498 cell lines.,Intermediate,9606.0,,F,,BAO_0000219,14399,,624.0,1,CHEMBL883157,A498,,Homo sapiens,N,1,,
5208,In vitro cytotoxic activity against renal (A498) cell line at a concentration of 10e-5 M,Expert,9606.0,,F,,BAO_0000219,5958,,624.0,1,CHEMBL624628,A498,,Homo sapiens,N,1,,
5209,Cmax value after 2 mpk peroral administration to beagles,Autocuration,9615.0,,A,,BAO_0000218,3510,,,1,CHEMBL624629,,,beagle,U,0,,
5210,Bioavailability,Autocuration,9615.0,,A,beagle,BAO_0000218,3510,,,1,CHEMBL623551,,,Canis lupus familiaris,U,0,,
5211,Bioavailability after 1 mpk peroral administration to beagles,Autocuration,9615.0,,A,beagle,BAO_0000218,3510,,,1,CHEMBL623552,,,Canis lupus familiaris,U,0,,
5212,Bioavailability after 2 mpk peroral administration to beagles,Autocuration,9615.0,,A,beagle,BAO_0000218,3510,,,1,CHEMBL623553,,,Canis lupus familiaris,U,0,,
5213,Specificity constant of the BSA-catalyzed deprotonation of compound at pH 9,Autocuration,9913.0,,A,,BAO_0000019,3085,,,1,CHEMBL623554,,,Bos taurus,U,0,,
5214,Specificity constant of the bovine serum albumin catalyzed reaction expressed as (kcat/KM)/kuncat,Autocuration,9913.0,,A,,BAO_0000019,3085,,,1,CHEMBL623555,,,Bos taurus,U,0,,
5215,Michaelis-Menten kinetics of the bovine serum albumin catalyzed reaction of the compound,Autocuration,9913.0,,A,,BAO_0000019,3085,,,1,CHEMBL623556,,,Bos taurus,U,0,,
5216,Solubility against bovine alpha-chymotrypsin,Autocuration,9913.0,,A,,BAO_0000019,9372,,,1,CHEMBL623557,,,Bos taurus,U,0,,
5217,Rate constant of the bovine serum albumin catalyzed reaction of the compound,Autocuration,9913.0,,A,,BAO_0000019,3085,,,1,CHEMBL623558,,,Bos taurus,U,0,,
5218,Rate constant of the bovine serum albumin catalyzed reaction of the compound,Autocuration,9913.0,,A,,BAO_0000019,3085,,,1,CHEMBL623559,,,Bos taurus,U,0,,
5219,Half life (t) of enzymatic phosphodiester hydrolysis of compound towards calf spleen (CS-PDE) at a concentration of 20 microg,Autocuration,9913.0,,A,,BAO_0000221,1469,,,1,CHEMBL623560,,,Bos taurus,U,0,2106.0,
5220,Half life in culture medium containing 10% of heat inactivated foetal calf serum,Autocuration,9913.0,,A,,BAO_0000019,4297,,,1,CHEMBL623561,,,Bos taurus,U,0,,
5221,Half life in culture medium containing 10% of heat inactivated foetal calf serum; ND=not determined,Autocuration,9913.0,,A,,BAO_0000019,4297,,,1,CHEMBL623562,,,Bos taurus,U,0,,
5222,Ability to get deaminated by adenosine deaminase (ADA); Expressed as t1/2,Autocuration,9913.0,,A,,BAO_0000019,17585,,,1,CHEMBL623563,,,Bos taurus,U,0,,
5223,Enzymatic stability was assessed with bovine spleen phosphodiesterase (BS PDE) exonuclase,Autocuration,9913.0,,A,,BAO_0000221,1336,,,1,CHEMBL623564,,,Bos taurus,U,0,2106.0,
5224,Half life in presence of 2 mg/mL BSA at pH 8.8,Autocuration,9913.0,,A,,BAO_0000019,3085,,,1,CHEMBL873806,,,Bos taurus,U,0,,
5225,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 1,Autocuration,9913.0,,A,,BAO_0000019,2857,,,1,CHEMBL623565,,,Bos taurus,U,0,,
5226,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 2,Autocuration,9913.0,,A,,BAO_0000019,2857,,,1,CHEMBL623566,,,Bos taurus,U,0,,
5227,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 2; Not determined,Autocuration,9913.0,,A,,BAO_0000019,2857,,,1,CHEMBL623567,,,Bos taurus,U,0,,
5228,Half-life in the culture medium (RPMI 1640+10% fetal calf serum FCS),Autocuration,9913.0,,A,,BAO_0000019,1540,,,1,CHEMBL623568,,,Bos taurus,U,0,,
5229,AUC (Area Under Plasma concentration-time curve) was after oral administration at 5 mg/kg,Intermediate,9615.0,,A,,BAO_0000218,6316,,,1,CHEMBL623569,,,Canis lupus familiaris,N,1,1969.0,
5230,AUC after administration at 100 mg/kg/day in dogs,Intermediate,9615.0,,A,,BAO_0000218,17594,,,1,CHEMBL623570,,,Canis lupus familiaris,N,1,1969.0,
5231,AUC in dog at 0-24 hr by peroral administration at 3 mpk,Intermediate,9615.0,,A,,BAO_0000218,4953,,,1,CHEMBL624254,,,Canis lupus familiaris,N,1,1969.0,
5232,AUC value after 15 mg/kg iv dose in Dogs,Intermediate,9615.0,,A,,BAO_0000218,16907,,,1,CHEMBL624255,,,Canis lupus familiaris,N,1,1969.0,
5233,AUC value after 30 mg/kg po dose in Dogs,Intermediate,9615.0,,A,,BAO_0000218,16907,,,1,CHEMBL624256,,,Canis lupus familiaris,N,1,1969.0,
5234,AUC value after administration of 4 mg/Kg oral dose in dog,Intermediate,9615.0,,A,,BAO_0000218,2959,,,1,CHEMBL624257,,,Canis lupus familiaris,N,1,1969.0,
5235,AUC0-infinity after single intravenous bolus of 1 mg/kg in dogs,Intermediate,9615.0,,A,,BAO_0000218,17594,,,1,CHEMBL624258,,,Canis lupus familiaris,N,1,1969.0,
5236,Area Under Curve for the compound was determined in dogs at 1 mg/kg oral dosing; 25-50 ug min/mL,Intermediate,9615.0,,A,,BAO_0000218,5356,,,1,CHEMBL875277,,,Canis lupus familiaris,N,1,,
5237,Area under curve (AUC) value in dogs after an intravenous dose of 0.2 mg/Kg in 0.025 M aqueous methanesulfonic acid solution with 5% mannitol at a concentration of 0.2,Intermediate,9615.0,,A,,BAO_0000218,16807,,,1,CHEMBL622667,,,Canis lupus familiaris,N,1,,
5238,Area under curve by intravenous administration at a dose of 1 uM/kg in dog was determined,Intermediate,9615.0,,A,,BAO_0000218,4527,,,1,CHEMBL622668,,,Canis lupus familiaris,N,1,,
5239,Area under curve by oral administration at a dose of 10 uM/kg in dog was determined,Intermediate,9615.0,,A,,BAO_0000218,4527,,,1,CHEMBL622669,,,Canis lupus familiaris,N,1,,
5240,Area under curve determined in dogs after intravenous administration of 3 mg/kg,Intermediate,9615.0,,A,,BAO_0000218,15660,,,1,CHEMBL622670,,,Canis lupus familiaris,N,1,,
5241,Area under curve determined in dogs after oral administration of 10 mg/kg,Intermediate,9615.0,,A,,BAO_0000218,15660,,,1,CHEMBL622671,,,Canis lupus familiaris,N,1,,
5242,Area under curve of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,Intermediate,9615.0,,A,,BAO_0000218,5802,,,1,CHEMBL622672,,,Canis lupus familiaris,N,1,,
5243,Area under curve of compound determined in dog after iv administration at a dose of 10 mg/kg,Expert,9615.0,,A,,BAO_0000218,3598,,,1,CHEMBL622673,,,Canis lupus familiaris,N,1,,
5244,Area under curve of compound from zero time to infinity determined in dog after iv administration at a dose of 10 mg/kg,Expert,9615.0,,A,,BAO_0000218,3598,,,1,CHEMBL622674,,,Canis lupus familiaris,N,1,,
5245,Area under curve determined in dog at a dose of 0 mg/kg by oral administration along with indavir (10 mg/kg),Intermediate,9615.0,,A,,BAO_0000218,5944,,,1,CHEMBL622675,,,Canis lupus familiaris,N,1,,
5246,Area under curve determined in dog at a dose of 10 mg/kg by oral administration,Intermediate,9615.0,,A,,BAO_0000218,5944,,,1,CHEMBL622676,,,Canis lupus familiaris,N,1,,
5247,Area under curve determined in dog at a dose of 10 mg/kg by oral administration along with indavir (10 mg/kg),Intermediate,9615.0,,A,,BAO_0000218,5944,,,1,CHEMBL622677,,,Canis lupus familiaris,N,1,,
5248,Area under curve determined in dog at a dose of 5 mg/kg by oral administration,Intermediate,9615.0,,A,,BAO_0000218,5944,,,1,CHEMBL622678,,,Canis lupus familiaris,N,1,,
5249,Area under curve in dog after administration of 20 mg/kg dose through peroral route,Intermediate,9615.0,,A,,BAO_0000218,4186,,,1,CHEMBL622679,,,Canis lupus familiaris,N,1,,
5250,Area under curve in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),Intermediate,9615.0,,A,,BAO_0000218,5007,,,1,CHEMBL622680,,,Canis lupus familiaris,N,1,,
5251,Area under curve was determine after peroral administration at 10 mpk in dog,Intermediate,9615.0,,A,,BAO_0000218,5668,,,1,CHEMBL622681,,,Canis lupus familiaris,N,1,,
5252,Area under curve was determine after peroral administration at 5 mpk in dog,Intermediate,9615.0,,A,,BAO_0000218,5668,,,1,CHEMBL875278,,,Canis lupus familiaris,N,1,,
5253,Area under curve was determined,Intermediate,9615.0,,A,,BAO_0000218,5006,,,1,CHEMBL622682,,,Canis lupus familiaris,N,1,,
5254,Area under curve in dogs,Intermediate,9615.0,,A,,BAO_0000218,5006,,,1,CHEMBL622683,,,Canis lupus familiaris,N,1,,
5255,Area under curve in dogs at 10 mg/kg dose fo oral administration,Intermediate,9615.0,,A,,BAO_0000218,3771,,,1,CHEMBL622684,,,Canis lupus familiaris,N,1,,
5256,Area under curve in dogs at 10 mg/kg dose fo oral administration (Evokes hyperglycerolemia),Intermediate,9615.0,,A,,BAO_0000218,3771,,,1,CHEMBL622685,,,Canis lupus familiaris,N,1,,
5257,Area under curve in dogs at 3 mg/kg dose fo intravenous administration,Intermediate,9615.0,,A,,BAO_0000218,3771,,,1,CHEMBL622686,,,Canis lupus familiaris,N,1,,
5258,Area under curve was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,Intermediate,9615.0,,A,,BAO_0000218,1916,,,1,CHEMBL618344,,,Canis lupus familiaris,N,1,,
5259,Area under curve value in dog at a dose of 5 mg/kg,Intermediate,9615.0,,A,,BAO_0000218,5302,,,1,CHEMBL875582,,,Canis lupus familiaris,N,1,,
5260,Area under curve was determined after 0.1 mg/kg iv administration in dog,Intermediate,9615.0,,A,,BAO_0000218,5600,,,1,CHEMBL618345,,,Canis lupus familiaris,N,1,,
5261,Area under curve was determined after 0.3 mg/kg po administration in dog,Intermediate,9615.0,,A,,BAO_0000218,5600,,,1,CHEMBL618346,,,Canis lupus familiaris,N,1,,
5262,Area under curve was determined for compound after intravenous administration in dogs at 1.2 uM/kg,Intermediate,9615.0,,A,,BAO_0000218,17764,,,1,CHEMBL618347,,,Canis lupus familiaris,N,1,,
5263,Area under curve was determined for the compound by intravenous administration of 1.2 mg/kg in dog,Intermediate,9615.0,,A,,BAO_0000218,4368,,,1,CHEMBL618348,,,Canis lupus familiaris,N,1,,
5264,Tested for half life period at 37 degree Celsius in PBS buffer at 10.5 pH containing human serum esterase,Autocuration,9606.0,,A,,BAO_0000019,5318,,,1,CHEMBL618349,,,Homo sapiens,U,0,,
5265,Tested for half life period at 37 degree Centigrade in PBS buffer at 7.3 pH containing human serum esterase,Autocuration,9606.0,,A,,BAO_0000019,5318,,,1,CHEMBL618350,,,Homo sapiens,U,0,,
5266,Tested for half life period at 37 degree Celsius in PBS buffer at 8.0 pH containing human serum esterase,Autocuration,9606.0,,A,,BAO_0000019,5318,,,1,CHEMBL618351,,,Homo sapiens,U,0,,
5267,Tested for half life period at 37 degree Celsius in PBS buffer at 8.8 pH containing human serum esterase,Autocuration,9606.0,,A,,BAO_0000019,5318,,,1,CHEMBL618352,,,Homo sapiens,U,0,,
5268,Time taken to reduce 50% of the concentration of compound in blood plasma,Autocuration,9606.0,,A,,BAO_0000221,14518,,,1,CHEMBL873494,,,Homo sapiens,U,0,178.0,
5269,"Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I).",Autocuration,9606.0,,A,,BAO_0000366,2209,,,1,CHEMBL618353,,,Homo sapiens,U,0,1969.0,
5270,Half life in human plasma,Autocuration,9606.0,,A,,BAO_0000366,6787,,,1,CHEMBL618354,,,Homo sapiens,U,0,1969.0,
5271,Half life in human plasma was reported,Autocuration,9606.0,,A,,BAO_0000366,4898,,,1,CHEMBL875583,,,Homo sapiens,U,0,1969.0,
5272,Half life in human serum,Autocuration,9606.0,,A,,BAO_0000019,6072,,,1,CHEMBL618355,,,Homo sapiens,U,0,1977.0,
5273,Half life upon exposure to human plasma,Autocuration,9606.0,,A,,BAO_0000366,16907,,,1,CHEMBL618356,,,Homo sapiens,U,0,1969.0,
5274,t1/2 in human microsomes,Autocuration,9606.0,,A,,BAO_0000251,5656,Microsomes,,1,CHEMBL618357,,,Homo sapiens,U,0,,
5275,Half life period in 80% human plasma at 37 degree Centigrade,Autocuration,9606.0,,A,,BAO_0000366,4755,,,1,CHEMBL618358,,,Homo sapiens,U,0,1969.0,
5276,Half-life for rate of hydrolysis was determined in in human skin homogenate (pH 7.4),Autocuration,9606.0,,A,,BAO_0000221,17503,,,1,CHEMBL618359,,,Homo sapiens,U,0,14.0,
5277,Half-life measured in in vitro Cathepsin B assay in human plasma,Autocuration,9606.0,,A,,BAO_0000366,12357,,,1,CHEMBL618360,,,Homo sapiens,U,0,1969.0,
5278,Half-life at initial concentration of 5*10e-5 M in CEM cell extract,Autocuration,9606.0,,A,,BAO_0000019,3076,,,1,CHEMBL618361,,,Homo sapiens,U,0,,
5279,Half-life determined by human liver microsome stability assay at a concentration of 5 uM,Autocuration,9606.0,,A,,BAO_0000251,6410,Microsomes,,1,CHEMBL618362,,,Homo sapiens,U,0,2107.0,
5280,"Half-life in chemical and enzymatic hydrolysis to form L-DOPA, in 80% human plasma",Autocuration,9606.0,,A,,BAO_0000366,3741,,,1,CHEMBL618363,,,Homo sapiens,U,0,1969.0,
5281,"Half-life in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 1)",Autocuration,9606.0,,A,,BAO_0000366,3741,,,1,CHEMBL618364,,,Homo sapiens,U,0,1969.0,
5282,"Half-life in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 2)",Autocuration,9606.0,,A,,BAO_0000366,3741,,,1,CHEMBL875584,,,Homo sapiens,U,0,1969.0,
5283,Half-life in the CEM cell extracts,Autocuration,9606.0,,A,,BAO_0000019,1540,,,1,CHEMBL618365,,,Homo sapiens,U,0,,
5284,Half-life was calculated by Human plasma stability assay at 37 degree Centigrade,Autocuration,9606.0,,A,,BAO_0000366,2905,,,1,CHEMBL873495,,,Homo sapiens,U,0,1969.0,
5285,Half-life was calculated by Human plasma stability assay at 37 degree centigrade; Not hydrolyzed,Autocuration,9606.0,,A,,BAO_0000366,2905,,,1,CHEMBL618366,,,Homo sapiens,U,0,1969.0,
5286,Half-life was determined,Autocuration,9606.0,,A,,BAO_0000019,5523,,,1,CHEMBL618367,,,Homo sapiens,U,0,,
5287,Half-life (human blood stability),Autocuration,9606.0,,A,,BAO_0000221,1499,,,1,CHEMBL618368,,,Homo sapiens,U,0,178.0,
5288,Half-life (human blood stability); no data,Autocuration,9606.0,,A,,BAO_0000221,1499,,,1,CHEMBL618369,,,Homo sapiens,U,0,178.0,
5289,Half-life in human plasma,Autocuration,9606.0,,A,,BAO_0000366,17065,,,1,CHEMBL618370,,,Homo sapiens,U,0,1969.0,
5290,CYP3A4 metabolism half-life (t1/2),Autocuration,9606.0,,A,,BAO_0000019,6861,,,1,CHEMBL618371,,,Homo sapiens,U,0,,
5291,Half-life was determined; 88% of parent remained after incubation for 120 min (human blood stability),Autocuration,9606.0,,A,,BAO_0000221,1499,,,1,CHEMBL618372,,,Homo sapiens,U,0,178.0,
5292,In vitro half life in human plasma,Autocuration,9606.0,,A,,BAO_0000366,530,,,1,CHEMBL618373,,,Homo sapiens,U,0,1969.0,
5293,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in human plasma",Autocuration,9606.0,,A,,BAO_0000366,1116,,,1,CHEMBL618374,,,Homo sapiens,U,0,1969.0,
5294,In vitro hydrolysis in human plasma,Autocuration,9606.0,,A,,BAO_0000366,6695,,,1,CHEMBL618375,,,Homo sapiens,U,0,1969.0,
5295,In vitro hydrolysis in human plasma; no data,Autocuration,9606.0,,A,,BAO_0000366,6695,,,1,CHEMBL618376,,,Homo sapiens,U,0,1969.0,
5296,In vitro metabolic stability at 5 uM was determined by incubating with human liver microsomes at 37 degree C,Autocuration,9606.0,,A,,BAO_0000251,10,Microsomes,,1,CHEMBL618377,,,Homo sapiens,U,0,2107.0,
5297,Plasma half life in human,Autocuration,9606.0,,A,,BAO_0000366,993,,,1,CHEMBL618378,,,Homo sapiens,U,0,1969.0,
5298,Stability after incubation with human plasma (at 37 degree C),Autocuration,9606.0,,A,,BAO_0000366,15429,,,1,CHEMBL618379,,,Homo sapiens,U,0,1969.0,
5299,T1/2 was evaluated in human plasma,Autocuration,9606.0,,A,,BAO_0000366,1675,,,1,CHEMBL618380,,,Homo sapiens,U,0,1969.0,
5300,"Tested for Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I).",Autocuration,9606.0,,A,,BAO_0000366,2209,,,1,CHEMBL618381,,,Homo sapiens,U,0,1969.0,
5301,"Tested for Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I); Not determined",Autocuration,9606.0,,A,,BAO_0000366,2209,,,1,CHEMBL618382,,,Homo sapiens,U,0,1969.0,
5302,Tested for half life period at 37 degree Centigrade in PBS buffer at 7.3 pH containing human serum esterase,Autocuration,9606.0,,A,,BAO_0000019,5318,,,1,CHEMBL618383,,,Homo sapiens,U,0,,
5303,Tested in vitro for the time for half reactivation against human lysosomal alpha-glucosidase,Autocuration,9606.0,,A,,BAO_0000019,2412,,,1,CHEMBL618384,,,Homo sapiens,U,0,,
5304,Tested in vitro for the time for half reactivation against human lysosomal alpha-glucosidase; ND=Not determined,Autocuration,9606.0,,A,,BAO_0000019,2412,,,1,CHEMBL618385,,,Homo sapiens,U,0,,
5305,The release rate of the free drug from the substrate in human plasma by human plasma stability assay,Autocuration,9606.0,,A,,BAO_0000366,2906,,,1,CHEMBL619099,,,Homo sapiens,U,0,1969.0,
5306,The release rate of the free drug from the substrate in human plasma by human plasma stability assay; Not hydrolyzed,Autocuration,9606.0,,A,,BAO_0000366,2906,,,1,CHEMBL619100,,,Homo sapiens,U,0,1969.0,
5307,Time taken for 50% to be consumed by serum PON1 was determined,Autocuration,9606.0,,A,,BAO_0000019,5495,,,1,CHEMBL619101,,,Homo sapiens,U,0,,
5308,Time taken for 50% to be consumed by serum PON1; NH is Not hydrolysed,Autocuration,9606.0,,A,,BAO_0000019,5495,,,1,CHEMBL619102,,,Homo sapiens,U,0,,
5309,Percent of the parent compound remaining after 20 mins incubation with human liver microsomes,Autocuration,9606.0,,A,,BAO_0000251,4397,Microsomes,,1,CHEMBL619103,,,Homo sapiens,U,0,2107.0,
5310,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice blood upon intraveneous administration at 2.6 gmol/mice after 1 hour,Autocuration,10095.0,,A,,BAO_0000218,2413,,,1,CHEMBL619268,,,Mus sp.,U,0,,
5311,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice blood upon intraveneous administration at 2.6 gmol/mice after 3 hour,Autocuration,10095.0,,A,,BAO_0000218,2413,,,1,CHEMBL619269,,,Mus sp.,U,0,,
5312,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice brain upon intraveneous administration at 2.6 gmol/mice after 1 hour,Autocuration,10095.0,,A,,BAO_0000218,2413,,,1,CHEMBL619270,,,Mus sp.,U,0,,
5313,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice brain upon intraveneous administration at 2.6 gmol/mice after 3 hour,Autocuration,10095.0,,A,,BAO_0000218,2413,,,1,CHEMBL619271,,,Mus sp.,U,0,,
5314,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 1 hour,Autocuration,10095.0,,A,,BAO_0000218,2413,,,1,CHEMBL875585,,,Mus sp.,U,0,,
5315,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 24 hour,Autocuration,10095.0,,A,,BAO_0000218,2413,,,1,CHEMBL619272,,,Mus sp.,U,0,,
5316,Compound tested for growth inhibition of renal cancer cell line 786-0,Intermediate,9606.0,,F,,BAO_0000219,6058,,391.0,1,CHEMBL619273,786-0,,Homo sapiens,N,1,,
5317,Compound was tested for 50% growth inhibition against human renal cancer 786-0 cell line,Intermediate,9606.0,,F,,BAO_0000219,17708,,391.0,1,CHEMBL619274,786-0,,Homo sapiens,N,1,,
5318,Concentration which reduced cell growth to 50 % of level against 786-0 renal cancer line,Expert,9606.0,,F,,BAO_0000219,14017,,391.0,1,CHEMBL619275,786-0,,Homo sapiens,N,1,,
5319,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-4 concentration",Intermediate,9606.0,,F,,BAO_0000219,16818,,391.0,1,CHEMBL619276,786-0,,Homo sapiens,N,1,,
5320,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-6 concentration",Intermediate,9606.0,,F,,BAO_0000219,16818,,391.0,1,CHEMBL619277,786-0,,Homo sapiens,N,1,,
5321,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-8 concentration",Intermediate,9606.0,,F,,BAO_0000219,16818,,391.0,1,CHEMBL619278,786-0,,Homo sapiens,N,1,,
5322,Tested for cytotoxicity against 786-0 cell lines in renal cancer,Intermediate,9606.0,,F,,BAO_0000219,11970,,391.0,1,CHEMBL619279,786-0,,Homo sapiens,N,1,,
5323,Tested in vitro for cytotoxicity in 786-0 cell line of Renal cancer,Intermediate,9606.0,,F,,BAO_0000219,12400,,391.0,1,CHEMBL858458,786-0,,Homo sapiens,N,1,,
5324,Cytotoxic effect on renal cancer line 786-0,Expert,9606.0,,F,,BAO_0000219,12888,,391.0,1,CHEMBL619280,786-0,,Homo sapiens,N,1,,
5325,In vitro antitumor activity against Renal cancer 786-0 cell lines by 6-day assay,Intermediate,9606.0,,F,,BAO_0000219,15300,,391.0,1,CHEMBL619281,786-0,,Homo sapiens,N,1,,
5326,Compound was evaluated for in vitro activity against 786-0 kidney cell lines (Human tumor cells ),Intermediate,9606.0,,F,,BAO_0000219,14769,,391.0,1,CHEMBL619282,786-0,,Homo sapiens,N,1,,
5327,"Cytotoxicity against NCI tumor panel, 786-0 renal cancer cell line",Intermediate,9606.0,,F,,BAO_0000219,15895,,391.0,1,CHEMBL619283,786-0,,Homo sapiens,N,1,,
5328,Concentration of compound that cause 50% cytotoxicity of 786-0 renal cancer cell line,Intermediate,9606.0,,F,,BAO_0000219,17376,,391.0,1,CHEMBL619284,786-0,,Homo sapiens,N,1,,
5329,Compound was tested for antitumor activity against 786-0 renal cancer cell line(molar concentration that inhibits 50% net cell growth).,Intermediate,9606.0,,F,,BAO_0000219,14882,,391.0,1,CHEMBL619285,786-0,,Homo sapiens,N,1,,
5330,Compound was tested for antitumor activity against 786-0 renal cancer cell line(molar concentration leading to 50% net cell death),Intermediate,9606.0,,F,,BAO_0000219,14882,,391.0,1,CHEMBL619286,786-0,,Homo sapiens,N,1,,
5331,Growth inhibition of the 786-O Renal cancer cell line for 2-day in vitro assay.,Intermediate,9606.0,,F,,BAO_0000219,15176,,391.0,1,CHEMBL619287,786-0,,Homo sapiens,N,1,,
5332,In vitro anti tumor activity against human tumor Renal cancer cell lines was determined,Intermediate,9606.0,,F,,BAO_0000219,12696,,391.0,1,CHEMBL857455,786-0,,Homo sapiens,N,1,,
5333,The compound was tested in vitro for cytotoxic activity against 786-O cell line (human perirenal carcinoma),Intermediate,9606.0,,F,,BAO_0000219,2496,,391.0,1,CHEMBL883801,786-0,,Homo sapiens,N,1,,
5334,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression,Intermediate,9606.0,,F,,BAO_0000219,11831,,972.0,1,CHEMBL619288,791T cell line,,Homo sapiens,N,1,,
5335,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression (49% inhibition achieved at 100 micro g/mL),Intermediate,9606.0,,F,,BAO_0000219,11831,,972.0,1,CHEMBL619289,791T cell line,,Homo sapiens,N,1,,
5336,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression; <20% inhibition achieved,Intermediate,9606.0,,F,,BAO_0000219,11831,,972.0,1,CHEMBL619290,791T cell line,,Homo sapiens,N,1,,
5337,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H1: MSR-33),Intermediate,9606.0,,F,,BAO_0000219,11831,,972.0,1,CHEMBL619291,791T cell line,,Homo sapiens,N,1,,
5338,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H2: MSR-26),Intermediate,9606.0,,F,,BAO_0000219,11831,,972.0,1,CHEMBL619292,791T cell line,,Homo sapiens,N,1,,
5339,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H3: MSR-28); <20% inhibition achieved,Intermediate,9606.0,,F,,BAO_0000219,11831,,972.0,1,CHEMBL619293,791T cell line,,Homo sapiens,N,1,,
5340,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H1: MSR-33),Intermediate,9606.0,,F,,BAO_0000219,11831,,972.0,1,CHEMBL619294,791T cell line,,Homo sapiens,N,1,,
5341,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H2: MSR-26),Intermediate,9606.0,,F,,BAO_0000219,11831,,972.0,1,CHEMBL619295,791T cell line,,Homo sapiens,N,1,,
5342,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H2: MSR-26) (less than 20% inhibition achieved),Intermediate,9606.0,,F,,BAO_0000219,11831,,972.0,1,CHEMBL619296,791T cell line,,Homo sapiens,N,1,,
5343,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H3: MSR-28); <20% inhibition achieved,Intermediate,9606.0,,F,,BAO_0000219,11831,,972.0,1,CHEMBL619297,791T cell line,,Homo sapiens,N,1,,
5344,Growth inhibitory concentration against tumor cells in culture renal cancer 796-0 cell line,Intermediate,9606.0,,F,,BAO_0000219,12782,,391.0,1,CHEMBL619298,786-0,,Homo sapiens,N,1,,
5345,In vitro anticancer activity against 8 NCI CNS cancer cell lines; inactive,Intermediate,,,F,,BAO_0000019,1229,,,1,CHEMBL619299,,,,U,0,,
5346,Inhibition of cell growth in drug resistant 8226 myeloma cell line,Expert,9606.0,,F,,BAO_0000219,15313,,741.0,1,CHEMBL619300,RPMI-8226,,Homo sapiens,N,1,,
5347,Inhibition of cell growth in drug sensitive 8226 myeloma cell line,Expert,9606.0,,F,,BAO_0000219,15313,,741.0,1,CHEMBL619301,RPMI-8226,,Homo sapiens,N,1,,
5348,In vitro inhibition of tumor cell growth in the human myeloma 8226 system.,Intermediate,9606.0,,F,,BAO_0000219,11544,,741.0,1,CHEMBL619302,RPMI-8226,,Homo sapiens,N,1,,
5349,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,Intermediate,9606.0,,F,,BAO_0000219,9424,,741.0,1,CHEMBL619303,RPMI-8226,,Homo sapiens,N,1,,
5350,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,Intermediate,9606.0,,F,,BAO_0000219,9424,,741.0,1,CHEMBL619304,RPMI-8226,,Homo sapiens,N,1,,
5351,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),Intermediate,9606.0,,F,,BAO_0000219,9424,,741.0,1,CHEMBL857706,RPMI-8226,,Homo sapiens,N,1,,
5352,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),Intermediate,9606.0,,F,,BAO_0000219,9424,,741.0,1,CHEMBL619305,RPMI-8226,,Homo sapiens,N,1,,
5353,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),Intermediate,9606.0,,F,,BAO_0000219,9424,,741.0,1,CHEMBL619306,RPMI-8226,,Homo sapiens,N,1,,
5354,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),Intermediate,9606.0,,F,,BAO_0000219,9424,,741.0,1,CHEMBL619307,RPMI-8226,,Homo sapiens,N,1,,
5355,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),Intermediate,9606.0,,F,,BAO_0000219,9424,,741.0,1,CHEMBL619308,RPMI-8226,,Homo sapiens,N,1,,
5356,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),Intermediate,9606.0,,F,,BAO_0000219,9424,,741.0,1,CHEMBL619309,RPMI-8226,,Homo sapiens,N,1,,
5357,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),Intermediate,9606.0,,F,,BAO_0000219,9424,,741.0,1,CHEMBL619310,RPMI-8226,,Homo sapiens,N,1,,
5358,Compound was evaluated for in vitro activity against A498 kidney cell lines (Human tumor cells ),Intermediate,9606.0,,F,,BAO_0000219,14769,,624.0,1,CHEMBL619311,A498,,Homo sapiens,N,1,,
5359,Compound was tested for the growth inhibition of A498 renal tumor cell line,Intermediate,9606.0,,F,,BAO_0000219,15354,,624.0,1,CHEMBL619312,A498,,Homo sapiens,N,1,,
5360,In vitro cytotoxicity against human tumor A498 cell line (renal cancer),Intermediate,9606.0,,F,,BAO_0000219,17445,,624.0,1,CHEMBL619313,A498,,Homo sapiens,N,1,,
5361,In vitro inhibitory concentration against renal cancer cell line A498,Intermediate,9606.0,,F,,BAO_0000219,4337,,624.0,1,CHEMBL619314,A498,,Homo sapiens,N,1,,
5362,Cytotoxicity against A 498 tumor cell line,Intermediate,9606.0,,F,,BAO_0000219,15277,,624.0,1,CHEMBL619959,A498,,Homo sapiens,N,1,,
5363,In vitro antitumor activity against A498 human cancer cell line,Intermediate,9606.0,,F,,BAO_0000219,4812,,624.0,1,CHEMBL619960,A498,,Homo sapiens,N,1,,
5364,In vitro antitumor activity against A498 human cancer cell line (Data from NCI-screening),Intermediate,9606.0,,F,,BAO_0000219,4812,,624.0,1,CHEMBL619961,A498,,Homo sapiens,N,1,,
5365,Inhibitory dose required against A498 human tumor cell lines,Intermediate,9606.0,,F,,BAO_0000219,4995,,624.0,1,CHEMBL619962,A498,,Homo sapiens,N,1,,
5366,Anticancer activity against one renal cancer (A498 cell line),Intermediate,9606.0,,F,,BAO_0000219,5847,,624.0,1,CHEMBL875586,A498,,Homo sapiens,N,1,,
5367,In vitro cytotoxicity against melanoma A498 cell line,Intermediate,9606.0,,F,,BAO_0000219,6557,,624.0,1,CHEMBL619963,A498,,Homo sapiens,N,1,,
5368,Compound was tested for growth inhibitory activity against A498 cell line,Intermediate,9606.0,,F,,BAO_0000219,2597,,624.0,1,CHEMBL619964,A498,,Homo sapiens,N,1,,
5369,Compound tested for growth inhibition of renal cancer cell line A498,Intermediate,9606.0,,F,,BAO_0000219,6058,,624.0,1,CHEMBL620108,A498,,Homo sapiens,N,1,,
5370,Compound was tested for 50% growth inhibition against human renal cancer A498 cell line,Intermediate,9606.0,,F,,BAO_0000219,17708,,624.0,1,CHEMBL620109,A498,,Homo sapiens,N,1,,
5371,Growth inhibition of the A498 Renal cancer cell line for 2-day in vitro assay.,Intermediate,9606.0,,F,,BAO_0000219,15176,,624.0,1,CHEMBL620110,A498,,Homo sapiens,N,1,,
5372,In vitro antitumor activity against Renal cancer A498 cell lines by 6-day assay,Intermediate,9606.0,,F,,BAO_0000219,15300,,624.0,1,CHEMBL620111,A498,,Homo sapiens,N,1,,
5373,Tested for cytotoxicity against A498 cell lines in renal cancer,Intermediate,9606.0,,F,,BAO_0000219,11970,,624.0,1,CHEMBL620112,A498,,Homo sapiens,N,1,,
5374,Tested in vitro for cytotoxicity in A498 cell line of Renal cancer,Intermediate,9606.0,,F,,BAO_0000219,12400,,624.0,1,CHEMBL620113,A498,,Homo sapiens,N,1,,
5375,Cytotoxic effect on renal cancer lines A498,Expert,9606.0,,F,,BAO_0000219,12888,,624.0,1,CHEMBL620114,A498,,Homo sapiens,N,1,,
5376,Antitumor activity was evaluated for reduction of growth of renal cancer (A498) cells at a concentration of 100 uM,Intermediate,9606.0,,F,,BAO_0000219,3030,,624.0,1,CHEMBL620115,A498,,Homo sapiens,N,1,,
5377,Compound was evaluated for in vitro activity against A498 kidney cell lines (Human tumor cells ),Intermediate,9606.0,,F,,BAO_0000219,14769,,624.0,1,CHEMBL620116,A498,,Homo sapiens,N,1,,
5378,Concentration of compound that cause 50% cytotoxicity of A498 renal cancer cell line,Intermediate,9606.0,,F,,BAO_0000219,17376,,624.0,1,CHEMBL620117,A498,,Homo sapiens,N,1,,
5379,Growth inhibitory activity against A498-2LM human solid tumor cell line using MTT assay,Intermediate,9606.0,,F,,BAO_0000219,16558,,624.0,1,CHEMBL620118,A498,,Homo sapiens,N,1,,
5380,Cytotoxicity against human kidney carcinoma cell lines A4982LM,Intermediate,9606.0,,F,,BAO_0000219,5194,,624.0,1,CHEMBL620119,A498,,Homo sapiens,N,1,,
5381,Evaluated for the inhibitory concentration required to cause growth inhibition of A498Rem- renal cell line using the MTT Cytotoxicity Assay,Intermediate,9606.0,,F,,BAO_0000219,10708,,624.0,1,CHEMBL620120,A498,,Homo sapiens,N,1,,
5382,Antiproliferative activity in vitro against A549 (human non-small lung carcinoma) cell line.,Expert,9606.0,,F,,BAO_0000219,16880,,646.0,1,CHEMBL620121,A549,,Homo sapiens,N,1,,
5383,Antitumor activity against A549 human lung carcinoma cell line,Intermediate,9606.0,,F,,BAO_0000219,10196,,646.0,1,CHEMBL620122,A549,,Homo sapiens,N,1,,
5384,Antitumor activity against A549 human lung carcinoma cell line in experiment 1,Intermediate,9606.0,,F,,BAO_0000219,10196,,646.0,1,CHEMBL620123,A549,,Homo sapiens,N,1,,
5385,Antitumor activity against A549 human lung carcinoma cell line in experiment 2,Intermediate,9606.0,,F,,BAO_0000219,10196,,646.0,1,CHEMBL620124,A549,,Homo sapiens,N,1,,
5386,"Concentration required to inhibit tumor growth in A549, human lung carcinoma (NSCLC) cell line",Intermediate,9606.0,,F,,BAO_0000219,12083,,646.0,1,CHEMBL620125,A549,,Homo sapiens,N,1,,
5387,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay,Expert,9606.0,,F,,BAO_0000219,16464,,646.0,1,CHEMBL620126,A549,,Homo sapiens,N,1,,
5388,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,Intermediate,9606.0,,F,,BAO_0000219,16464,,646.0,1,CHEMBL883027,A549,,Homo sapiens,N,1,,
5389,In vitro cytotoxic activity against human lung A549 cell line,Expert,9606.0,,F,,BAO_0000219,16470,,646.0,1,CHEMBL620127,A549,,Homo sapiens,N,1,,
5390,In vitro cytotoxic activity against human lung A549 cell line ( standard deviation in parenthesis),Intermediate,9606.0,,F,,BAO_0000219,16470,,646.0,1,CHEMBL620128,A549,,Homo sapiens,N,1,,
5391,In vitro cytotoxic activity against human lung A549 cell line),Intermediate,9606.0,,F,,BAO_0000219,16470,,646.0,1,CHEMBL620129,A549,,Homo sapiens,N,1,,
5392,In vitro cytotoxic activity against human lung A549 cell line;NT is not tested,Intermediate,9606.0,,F,,BAO_0000219,16470,,646.0,1,CHEMBL620130,A549,,Homo sapiens,N,1,,
5393,In vitro cytotoxicity against human non small-cell-lung cell line A549.,Expert,9606.0,,F,,BAO_0000219,16582,,646.0,1,CHEMBL620131,A549,,Homo sapiens,N,1,,
5394,"In vitro growth inhibition of human lung carcinoma cell line, A549 with low levels of folate receptors",Intermediate,9606.0,,F,,BAO_0000219,15935,,646.0,1,CHEMBL620132,A549,,Homo sapiens,N,1,,
5395,"In vitro growth inhibition of human lung carcinoma cell line, A549 with low levels of folate receptors in folate deficient medium",Intermediate,9606.0,,F,,BAO_0000219,15935,,646.0,1,CHEMBL620133,A549,,Homo sapiens,N,1,,
5396,Inhibition of A549 human lung carcinoma cell proliferation,Expert,9606.0,,F,,BAO_0000219,16597,,646.0,1,CHEMBL620134,A549,,Homo sapiens,N,1,,
5397,Inhibitory activity against A549 lung adenocarcinoma cell line,Intermediate,9606.0,,F,,BAO_0000219,17376,,646.0,1,CHEMBL620135,A549,,Homo sapiens,N,1,,
5398,Inhibitory concentration required to reduce A549 tumor cell growth by 50% in MTT assay,Intermediate,9606.0,,F,,BAO_0000219,16496,,646.0,1,CHEMBL620136,A549,,Homo sapiens,N,1,,
5399,in vitro anticancer activity against cultured A549 human tumor(lung) cell line,Intermediate,9606.0,,F,,BAO_0000219,16152,,646.0,1,CHEMBL620137,A549,,Homo sapiens,N,1,,
5400,in vitro inhibition of tumor cell growth in cultured A549 human tumor cell line,Intermediate,9606.0,,F,,BAO_0000219,16152,,646.0,1,CHEMBL620268,A549,,Homo sapiens,N,1,,
5401,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,Intermediate,9606.0,,F,,BAO_0000219,16464,,646.0,1,CHEMBL620269,A549,,Homo sapiens,N,1,,
5402,Cytotoxicity was evaluated against A549 non-small cell lung carcinoma human cancer cell line,Intermediate,9606.0,,F,,BAO_0000219,2288,,646.0,1,CHEMBL620270,A549,,Homo sapiens,N,1,,
5403,Compound was tested for antiproliferative activity against human A549 cancer cell lines using MTT assay,Intermediate,9606.0,,F,,BAO_0000219,17350,,646.0,1,CHEMBL620271,A549,,Homo sapiens,N,1,,
5404,Inhibition of A549 cancer cell proliferation,Expert,9606.0,,F,,BAO_0000219,4090,,646.0,1,CHEMBL620272,A549,,Homo sapiens,N,1,,
5405,Inhibition of A549 cancer cell proliferation (Not tested),Expert,9606.0,,F,,BAO_0000219,4090,,646.0,1,CHEMBL620273,A549,,Homo sapiens,N,1,,
5406,Compound was tested for antiproliferative activity against human A549 cancer cell lines using MTT assay,Intermediate,9606.0,,F,,BAO_0000219,17350,,646.0,1,CHEMBL620274,A549,,Homo sapiens,N,1,,
5407,In vitro inhibitory concentration required against human lung A549 carcinoma cells proliferation,Intermediate,9606.0,,F,,BAO_0000219,4197,,646.0,1,CHEMBL620275,A549,,Homo sapiens,N,1,,
5408,Antiproliferative potency determined as inhibitory concentration against A549 cells,Intermediate,9606.0,,F,,BAO_0000219,17072,,646.0,1,CHEMBL620276,A549,,Homo sapiens,N,1,,
5409,Percent assembly of bovine brain tubulin induced by compound at 10 uM versus that caused by 10 uM paclitaxel,Intermediate,9606.0,,F,,BAO_0000219,17072,,646.0,1,CHEMBL620277,A549,,Homo sapiens,N,1,,
5410,Cytotoxicity against Renal cell lines A549 was determined,Intermediate,9606.0,,F,,BAO_0000219,5194,,646.0,1,CHEMBL620278,A549,,Homo sapiens,N,1,,
5411,Area under curve was determined in dog after a 3 mg/kg of oral dose,Intermediate,9615.0,,A,,BAO_0000218,4257,,,1,CHEMBL620279,,,Canis lupus familiaris,N,1,,
5412,Area under curve was determined in dog after oral administration at 1 mg/kg,Intermediate,9615.0,,A,,BAO_0000218,6123,,,1,CHEMBL620280,,,Canis lupus familiaris,N,1,,
5413,Area under curve was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,Intermediate,9615.0,,A,,BAO_0000218,1337,,,1,CHEMBL620281,,,Canis lupus familiaris,N,1,,
5414,Area under curve was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,Intermediate,9615.0,,A,,BAO_0000218,1337,,,1,CHEMBL620282,,,Canis lupus familiaris,N,1,,
5415,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of ( 0-2 mins),Intermediate,9615.0,,A,,BAO_0000218,8833,,,1,CHEMBL621134,,,Canis lupus familiaris,N,1,,
5416,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of ( 0-5 mins),Intermediate,9615.0,,A,,BAO_0000218,8833,,,1,CHEMBL621135,,,Canis lupus familiaris,N,1,,
5417,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of (0-15 mins),Intermediate,9615.0,,A,,BAO_0000218,8833,,,1,CHEMBL621136,,,Canis lupus familiaris,N,1,,
5418,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of( 0-120 mins),Intermediate,9615.0,,A,,BAO_0000218,8833,,,1,CHEMBL621137,,,Canis lupus familiaris,N,1,,
5419,Area under plasma concentration time curve in dog upon oral administration,Intermediate,9615.0,,A,,BAO_0000218,17657,,,1,CHEMBL621138,,,Canis lupus familiaris,N,1,1969.0,
5420,Area under plasma concentration time curve was measured in dogs after an oral dose of 10 uM/kg,Intermediate,9615.0,,A,,BAO_0000218,17650,,,1,CHEMBL875587,,,Canis lupus familiaris,N,1,1969.0,
5421,Area under the curve for compound was evaluated in dog at a dose of 10 mg/kg.,Intermediate,9615.0,,A,,BAO_0000218,1977,,,1,CHEMBL621139,,,Canis lupus familiaris,N,1,,
5422,Area under the curve for compound was evaluated in dog at a dose of 20 mg/kg.,Intermediate,9615.0,,A,,BAO_0000218,1977,,,1,CHEMBL621140,,,Canis lupus familiaris,N,1,,
5423,Area under the curve for the compound was obtained when tested in dog,Intermediate,9615.0,,A,,BAO_0000218,3132,,,1,CHEMBL621141,,,Canis lupus familiaris,N,1,,
5424,Area under the curve at a dose of 1 mg/kg,Intermediate,9615.0,,A,,BAO_0000218,5473,,,1,CHEMBL621142,,,Canis lupus familiaris,N,1,,
5425,Area under the curve at a dose of 1 mg/kg (oral),Intermediate,9615.0,,A,,BAO_0000218,5474,,,1,CHEMBL621143,,,Canis lupus familiaris,N,1,,
5426,Area under the curve at i.v. dose of 0.2 mg/kg,Intermediate,9615.0,,A,,BAO_0000218,5474,,,1,CHEMBL621144,,,Canis lupus familiaris,N,1,,
5427,Area under the curve was measured in dog after an iv dose of 1 mg/kg,Intermediate,9615.0,,A,,BAO_0000218,6062,,,1,CHEMBL621145,,,Canis lupus familiaris,N,1,,
5428,Bioavailability from area under the curve at time 0 to infinity after intravenous administration of 1 mg/kg in dog,Intermediate,9615.0,,A,,BAO_0000218,4709,,,1,CHEMBL621146,,,Canis lupus familiaris,N,1,,
5429,Compound was evaluated for area under curve (total concentration) in dogs at a dose of 1 mpk perorally,Intermediate,9615.0,,A,,BAO_0000218,2652,,,1,CHEMBL622567,,,Canis lupus familiaris,N,1,,
5430,Compound was evaluated for area under curve (total concentration) in dogs at a dose of 5 mpk perorally,Intermediate,9615.0,,A,,BAO_0000218,2652,,,1,CHEMBL622568,,,Canis lupus familiaris,N,1,,
5431,Compound was evaluated for area under the curve in dog blood.,Intermediate,9615.0,,A,,BAO_0000218,2877,,,1,CHEMBL622569,,,Canis lupus familiaris,N,1,,
5432,In vivo area under curve was calculated by peroral administration at 1 mg/kg in fasted dog,Intermediate,9615.0,,A,,BAO_0000218,5444,,,1,CHEMBL622570,,,Canis lupus familiaris,N,1,,
5433,AUC in dog after oral dose (1 mg/kg),Intermediate,9615.0,,A,,BAO_0000218,5130,,,1,CHEMBL622571,,,Canis lupus familiaris,N,1,1969.0,
5434,Pharmacokinetic (PK) property (AUC) was determined in dog at the single oral dose of 1 mg/kg,Intermediate,9615.0,,A,,BAO_0000218,6265,,,1,CHEMBL622572,,,Canis lupus familiaris,N,1,,
5435,"Pharmacokinetic data in dogs at dose of 1 mg/kg perorally, and the area under curve (AUC) was reported.",Intermediate,9615.0,,A,,BAO_0000218,4657,,,1,CHEMBL622573,,,Canis lupus familiaris,N,1,,
5436,Pharmacokinetic parameter AUC after intravenous administration to dogs,Intermediate,9615.0,,A,,BAO_0000218,16367,,,1,CHEMBL622574,,,Canis lupus familiaris,N,1,,
5437,Pharmacokinetic parameter AUC after oral administration to dogs,Intermediate,9615.0,,A,,BAO_0000218,16367,,,1,CHEMBL622575,,,Canis lupus familiaris,N,1,,
5438,Pharmacokinetic parameter AUC was determined in dog after oral administration of 17b,Intermediate,9615.0,,A,,BAO_0000218,9579,,,1,CHEMBL622576,,,Canis lupus familiaris,N,1,,
5439,Pharmacokinetic parameter AUC was determined in dog after oral administration of 2b,Intermediate,9615.0,,A,,BAO_0000218,9579,,,1,CHEMBL622577,,,Canis lupus familiaris,N,1,,
5440,Pharmacokinetic property (AUC) was measured in dog at the dose of 0.032 mg/kg p.o.,Intermediate,9615.0,,A,,BAO_0000218,5983,,,1,CHEMBL622578,,,Canis lupus familiaris,N,1,,
5441,Pharmacokinetic property in dogs after oral administration at 1 mg/kg,Intermediate,9615.0,,A,,BAO_0000218,6241,,,1,CHEMBL622579,,,Canis lupus familiaris,N,1,,
5442,"Tested for the pharmacokinetic data, area under the curve of concentration versus time in dog",Intermediate,9615.0,,A,,BAO_0000218,5313,,,1,CHEMBL622580,,,Canis lupus familiaris,N,1,,
5443,"Tested for the pharmacokinetic data, area under the curve of concentration versus time in dog at dosage of 10 mpk",Intermediate,9615.0,,A,,BAO_0000218,5313,,,1,CHEMBL622581,,,Canis lupus familiaris,N,1,,
5444,Oral AUCN in dog ( (dosed as a mixture of five compounds at 0.5 mpk each via iv only),Intermediate,9615.0,,A,,BAO_0000218,6642,,,1,CHEMBL622582,,,Canis lupus familiaris,N,1,,
5445,Oral AUCN in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),Intermediate,9615.0,,A,,BAO_0000218,6642,,,1,CHEMBL622583,,,Canis lupus familiaris,N,1,,
5446,Oral AUCN in dog (dosed at 0.5 mpk iv ),Intermediate,9615.0,,A,,BAO_0000218,6641,,,1,CHEMBL622584,,,Canis lupus familiaris,N,1,,
5447,Oral AUCN in dog (dosed at 0.5 mpk iv ),Intermediate,9615.0,,A,,BAO_0000218,6642,,,1,CHEMBL622585,,,Canis lupus familiaris,N,1,,
5448,Compound was evaluated for oral bioavailability in dog; 90-100,Intermediate,9615.0,,A,,BAO_0000218,17791,,,1,CHEMBL622586,,,Canis lupus familiaris,N,1,,
5449,Compound was tested for its cell permeability in the Madin-Darby canine kidney cell monolayer transport assay,Intermediate,9615.0,,A,,BAO_0000218,17655,,,1,CHEMBL623281,,,Canis lupus familiaris,N,1,,
5450,Compound was tested for its cell permeability in the Madin-Darby canine kidney cell monolayer transport assay; Not determined,Intermediate,9615.0,,A,,BAO_0000218,17655,,,1,CHEMBL623282,,,Canis lupus familiaris,N,1,,
5451,PAPP (membrane permeability) in dog kidney cell monolayer assay,Intermediate,9615.0,,A,,BAO_0000218,6596,,,1,CHEMBL623283,,,Canis lupus familiaris,N,1,,
5452,Oral bioavailability in dog,Intermediate,9615.0,,A,,BAO_0000218,3880,,,1,CHEMBL623284,,,Canis lupus familiaris,N,1,,
5453,Bioavailability administered orally at a dose of 10 mg/kg to dogs,Intermediate,9615.0,,A,,BAO_0000218,16367,,,1,CHEMBL623285,,,Canis lupus familiaris,N,1,,
5454,Plasma protein binding towards dog plasma at 10 uM,Intermediate,9615.0,,A,,BAO_0000218,17409,,,1,CHEMBL623463,,,Canis lupus familiaris,N,1,1969.0,
5455,Plasma protein binding towards dog plasma at 100 uM,Intermediate,9615.0,,A,,BAO_0000218,17409,,,1,CHEMBL875952,,,Canis lupus familiaris,N,1,1969.0,
5456,Bioavailability in dog (dose 4 mg/kg p.o.),Intermediate,9615.0,,A,,BAO_0000218,2959,,,1,CHEMBL621705,,,Canis lupus familiaris,N,1,,
5457,Bioavailability was determined after oral administration of compound 18 at a dose of 2 mg/kg to dog,Intermediate,9615.0,,A,,BAO_0000218,13501,,,1,CHEMBL621706,,,Canis lupus familiaris,N,1,,
5458,Bioavailability by oral administration at a dose of 10 uM/kg in dog was determined,Intermediate,9615.0,,A,,BAO_0000218,4527,,,1,CHEMBL621707,,,Canis lupus familiaris,N,1,,
5459,Bioavailability in dogs,Intermediate,9615.0,,A,,BAO_0000218,15145,,,1,CHEMBL621708,,,Canis lupus familiaris,N,1,,
5460,Bioavailability,Intermediate,9615.0,,A,,BAO_0000218,4219,,,1,CHEMBL621709,,,Canis lupus familiaris,N,1,,
5461,Oral bioavailability in dog (dose 10 mg/kg),Intermediate,9615.0,,A,,BAO_0000218,17538,,,1,CHEMBL621710,,,Canis lupus familiaris,N,1,,
5462,Bioavailability in dog after po administration at a dose of 10 mg/kg; nd is not determined,Intermediate,9615.0,,A,,BAO_0000218,17538,,,1,CHEMBL621711,,,Canis lupus familiaris,N,1,,
5463,Bioavailability in dog (dose 10.0 mg/kg p.o.),Intermediate,9615.0,,A,,BAO_0000218,1466,,,1,CHEMBL621712,,,Canis lupus familiaris,N,1,,
5464,Bioavailability was measured in dogs after an oral dose of 10 uM/kg,Intermediate,9615.0,,A,,BAO_0000218,17650,,,1,CHEMBL621713,,,Canis lupus familiaris,N,1,,
5465,Bioavailability was obtained by the comparison of AUC of intravenous dosing and AUC of oral dosing in dog,Intermediate,9615.0,,A,,BAO_0000218,3132,,,1,CHEMBL621714,,,Canis lupus familiaris,N,1,,
5466,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 3 hour,Autocuration,10095.0,,A,,BAO_0000218,2413,,,1,CHEMBL621715,,,Mus sp.,U,0,,
5467,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 1 hour,Autocuration,10095.0,,A,,BAO_0000218,2413,,,1,CHEMBL623717,,,Mus sp.,U,0,2107.0,
5468,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 24 hour,Autocuration,10095.0,,A,,BAO_0000218,2413,,,1,CHEMBL623718,,,Mus sp.,U,0,2107.0,
5469,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 3 hour,Autocuration,10095.0,,A,,BAO_0000218,2413,,,1,CHEMBL623719,,,Mus sp.,U,0,2107.0,
5470,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice lungs upon intraveneous administration at 2.6 gmol/mice after 1 hour,Autocuration,10095.0,,A,,BAO_0000218,2413,,,1,CHEMBL623720,,,Mus sp.,U,0,,
5471,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice lungs upon intraveneous administration at 2.6 gmol/mice after 3 hour,Autocuration,10095.0,,A,,BAO_0000218,2413,,,1,CHEMBL623721,,,Mus sp.,U,0,,
5472,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 1 hour,Autocuration,10095.0,,A,,BAO_0000218,2413,,,1,CHEMBL623722,,,Mus sp.,U,0,2385.0,
5473,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 24 hour,Autocuration,10095.0,,A,,BAO_0000218,2413,,,1,CHEMBL623723,,,Mus sp.,U,0,2385.0,
5474,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 3 hour,Autocuration,10095.0,,A,,BAO_0000218,2413,,,1,CHEMBL618543,,,Mus sp.,U,0,2385.0,
5475,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice spleen upon intraveneous administration at 2.6 gmol/mice after 1 hour,Autocuration,10095.0,,A,,BAO_0000218,2413,,,1,CHEMBL618544,,,Mus sp.,U,0,2106.0,
5476,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice spleen upon intraveneous administration at 2.6 gmol/mice after 3 hour,Autocuration,10095.0,,A,,BAO_0000218,2413,,,1,CHEMBL875155,,,Mus sp.,U,0,2106.0,
5477,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 1 hour,Autocuration,10095.0,,A,,BAO_0000218,2413,,,1,CHEMBL618545,,,Mus sp.,U,0,,
5478,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 24 hour,Autocuration,10095.0,,A,,BAO_0000218,2413,,,1,CHEMBL618546,,,Mus sp.,U,0,,
5479,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 3 hour,Autocuration,10095.0,,A,,BAO_0000218,2413,,,1,CHEMBL623529,,,Mus sp.,U,0,,
5480,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice uvea upon intraveneous administration at 2.6 gmol/mice after 24 hour,Autocuration,10095.0,,A,,BAO_0000218,2413,,,1,CHEMBL623530,,,Mus sp.,U,0,,
5481,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice uvea upon intraveneous administration at 2.6 gmol/mice after 3 hour,Autocuration,10095.0,,A,,BAO_0000218,2413,,,1,CHEMBL621764,,,Mus sp.,U,0,,
5482,Compound (i.v.) was evaluated for elimination rate constants in brainstem of rhesus monkeys (Radiolabeled compound),Autocuration,9527.0,,A,,BAO_0000019,17827,,,1,CHEMBL621765,,,Cercopithecidae,U,0,,
5483,Compound (i.v.) was evaluated for elimination rate constants in cerebellum of rhesus monkeys (Radiolabeled compound),Autocuration,9527.0,,A,,BAO_0000019,17827,,,1,CHEMBL621766,,,Cercopithecidae,U,0,2037.0,
5484,Compound (i.v.) was evaluated for elimination rate constants in frontal cortex of rhesus monkey (Radiolabeled compound),Autocuration,9527.0,,A,,BAO_0000019,17827,,,1,CHEMBL621767,,,Cercopithecidae,U,0,1870.0,
5485,Compound (i.v.) was evaluated for elimination rate constants in jaw bone of rhesus monkeys; NA = not active (Radiolabeled compound),Autocuration,9527.0,,A,,BAO_0000019,17827,,,1,CHEMBL621768,,,Cercopithecidae,U,0,,
5486,Compound (i.v.) was evaluated for elimination rate constants in striatum of rhesus monkey (Radiolabeled compound),Autocuration,9527.0,,A,,BAO_0000019,17827,,,1,CHEMBL621769,,,Cercopithecidae,U,0,2435.0,
5487,Compound (i.v.) was evaluated for uptake rate constants in brainstem of rhesus monkeys (Radiolabeled compound),Autocuration,9527.0,,A,,BAO_0000019,17827,,,1,CHEMBL621770,,,Cercopithecidae,U,0,,
5488,Compound (i.v.) was evaluated for uptake rate constants in cerebellum of rhesus monkeys (Radiolabeled compound),Autocuration,9527.0,,A,,BAO_0000019,17827,,,1,CHEMBL621771,,,Cercopithecidae,U,0,2037.0,
5489,Compound (i.v.) was evaluated for uptake rate constants in frontal cortex of rhesus monkey (Radiolabeled compound),Autocuration,9527.0,,A,,BAO_0000019,17827,,,1,CHEMBL621772,,,Cercopithecidae,U,0,1870.0,
5490,Compound (i.v.) was evaluated for uptake rate constants in jaw bone of rhesus monkey (Radiolabeled compound),Autocuration,9527.0,,A,,BAO_0000019,17827,,,1,CHEMBL621773,,,Cercopithecidae,U,0,,
5491,Compound (i.v.) was evaluated for uptake rate constants in striatum of rhesus monkeys (Radiolabeled compound),Autocuration,9527.0,,A,,BAO_0000019,17827,,,1,CHEMBL621774,,,Cercopithecidae,U,0,2435.0,
5492,Compound was evaluated for oral bioavailability in rats,Autocuration,9527.0,,A,,BAO_0000218,17791,,,1,CHEMBL621775,,,Cercopithecidae,U,0,,
5493,Maximum concentration of compound found in plasma at 5 mg/kg after oral administration,Autocuration,9527.0,,A,,BAO_0000218,17667,,,1,CHEMBL621776,,,Cercopithecidae,U,0,1969.0,
5494,Half life period was evaluated in monkey,Autocuration,9527.0,,A,,BAO_0000019,17791,,,1,CHEMBL621777,,,Cercopithecidae,U,0,,
5495,Half-life in rhesus monkeys by intravenous administration of dose,Autocuration,9527.0,,A,,BAO_0000218,110,,,1,CHEMBL875162,,,Cercopithecidae,U,0,,
5496,AUC (0-6 hr) after oral administration at 30 mg/kg in ICR mouse,Intermediate,10090.0,,A,,BAO_0000218,5781,,,1,CHEMBL621778,,,Mus musculus,N,1,1969.0,
5497,AUC after intraperitoneal administration of 100 mg/kg in mice,Intermediate,10090.0,,A,,BAO_0000218,17734,,,1,CHEMBL621779,,,Mus musculus,N,1,1969.0,
5498,AUC value was determined after oral administration,Intermediate,10090.0,,A,,BAO_0000218,17718,,,1,CHEMBL622479,,,Mus musculus,N,1,1969.0,
5499,Area under curve (AUC) determined at a dose 10 mg/kg administered intraperitoneally to mice,Intermediate,10090.0,,A,,BAO_0000218,4573,,,1,CHEMBL622480,,,Mus musculus,N,1,,
5500,Area under curve (AUC) was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),Intermediate,10090.0,,A,,BAO_0000218,3277,,,1,CHEMBL622481,,,Mus musculus,N,1,,
5501,Area under curve by ioral administration in mouse,Intermediate,10090.0,,A,,BAO_0000218,2862,,,1,CHEMBL622482,,,Mus musculus,N,1,,
5502,Area under curve by iv administration in mouse,Intermediate,10090.0,,A,,BAO_0000218,2862,,,1,CHEMBL622483,,,Mus musculus,N,1,,
5503,Area under curve at 0-8 hr in IRC mice after peroral administration,Intermediate,10090.0,,A,,BAO_0000218,5951,,,1,CHEMBL622484,,,Mus musculus,N,1,,
5504,Area under curve when injected i.p. in mice at a dose of 50 mg/kg,Intermediate,10090.0,,A,,BAO_0000218,17729,,,1,CHEMBL622641,,,Mus musculus,N,1,,
5505,Area under curve when injected intraperitoneally in BALB/C mice at a dose of 20 mg/kg,Intermediate,10090.0,,A,,BAO_0000218,17728,,,1,CHEMBL622642,,,Mus musculus,N,1,,
5506,Area under curve when injected intravenously in BALB/C mice at a dose of 20 mg/kg,Intermediate,10090.0,,A,,BAO_0000218,17728,,,1,CHEMBL622643,,,Mus musculus,N,1,,
5507,Area under curve when injected intravenously in mice at a dose of 20 mg/kg,Intermediate,10090.0,,A,,BAO_0000218,17729,,,1,CHEMBL622644,,,Mus musculus,N,1,,
5508,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,Intermediate,9606.0,,F,,BAO_0000219,9424,,741.0,1,CHEMBL622645,RPMI-8226,,Homo sapiens,N,1,,
5509,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,Intermediate,9606.0,,F,,BAO_0000219,9424,,741.0,1,CHEMBL622646,RPMI-8226,,Homo sapiens,N,1,,
5510,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),Intermediate,9606.0,,F,,BAO_0000219,9424,,741.0,1,CHEMBL621238,RPMI-8226,,Homo sapiens,N,1,,
5511,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),Intermediate,9606.0,,F,,BAO_0000219,9424,,741.0,1,CHEMBL621239,RPMI-8226,,Homo sapiens,N,1,,
5512,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),Intermediate,9606.0,,F,,BAO_0000219,9424,,741.0,1,CHEMBL621240,RPMI-8226,,Homo sapiens,N,1,,
5513,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),Intermediate,9606.0,,F,,BAO_0000219,9424,,741.0,1,CHEMBL621241,RPMI-8226,,Homo sapiens,N,1,,
5514,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),Intermediate,9606.0,,F,,BAO_0000219,9424,,741.0,1,CHEMBL621242,RPMI-8226,,Homo sapiens,N,1,,
5515,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),Intermediate,9606.0,,F,,BAO_0000219,9424,,741.0,1,CHEMBL620350,RPMI-8226,,Homo sapiens,N,1,,
5516,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,Intermediate,9606.0,,F,,BAO_0000219,9424,,741.0,1,CHEMBL620351,RPMI-8226,,Homo sapiens,N,1,,
5517,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,Intermediate,9606.0,,F,,BAO_0000219,9424,,741.0,1,CHEMBL620352,RPMI-8226,,Homo sapiens,N,1,,
5518,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),Intermediate,9606.0,,F,,BAO_0000219,9424,,741.0,1,CHEMBL620353,RPMI-8226,,Homo sapiens,N,1,,
5519,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),Intermediate,9606.0,,F,,BAO_0000219,9424,,741.0,1,CHEMBL620354,RPMI-8226,,Homo sapiens,N,1,,
5520,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),Intermediate,9606.0,,F,,BAO_0000219,9424,,741.0,1,CHEMBL620355,RPMI-8226,,Homo sapiens,N,1,,
5521,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),Intermediate,9606.0,,F,,BAO_0000219,9424,,741.0,1,CHEMBL620356,RPMI-8226,,Homo sapiens,N,1,,
5522,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),Intermediate,9606.0,,F,,BAO_0000219,9424,,741.0,1,CHEMBL620357,RPMI-8226,,Homo sapiens,N,1,,
5523,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),Intermediate,9606.0,,F,,BAO_0000219,9424,,741.0,1,CHEMBL620358,RPMI-8226,,Homo sapiens,N,1,,
5524,In vitro inhibition of human 8226 myeloma tumor cell line growth.,Expert,9606.0,,F,,BAO_0000219,9424,,741.0,1,CHEMBL620359,RPMI-8226,,Homo sapiens,N,1,,
5525,In vitro inhibition of tumor cell growth in the human myeloma 8226/ADR system.,Intermediate,9606.0,,F,,BAO_0000219,11544,,741.0,1,CHEMBL620360,RPMI-8226,,Homo sapiens,N,1,,
5526,Cytotoxicity of compound against 8226/DOX1V cells,Intermediate,9606.0,,F,,BAO_0000219,17378,,741.0,1,CHEMBL620361,RPMI-8226,,Homo sapiens,N,1,,
5527,Cytotoxicity of compound against 8226/S cells,Intermediate,9606.0,,F,,BAO_0000219,17378,,741.0,1,CHEMBL620362,RPMI-8226,,Homo sapiens,N,1,,
5528,Inhibitory concentration against 8226 myeloma cancer cell line,Intermediate,9606.0,,F,,BAO_0000219,17079,,741.0,1,CHEMBL620363,RPMI-8226,,Homo sapiens,N,1,,
5529,Inhibitory concentration against 8226/Dox40 (Dox-Re) cancer cell line,Intermediate,9606.0,,F,,BAO_0000219,17079,,741.0,1,CHEMBL620364,RPMI-8226,,Homo sapiens,N,1,,
5530,Inhibition of cell growth was studied in human teratocarcinoma (833K).,Intermediate,9606.0,,F,,BAO_0000219,13466,,854.0,1,CHEMBL620365,833K,,Homo sapiens,N,1,,
5531,Inhibition of cell growth was studied in human teratocarcinoma (833K); ND ='not determined',Intermediate,9606.0,,F,,BAO_0000219,13466,,854.0,1,CHEMBL620366,833K,,Homo sapiens,N,1,,
5532,Tested in vitro for growth inhibitory activity against 833K (human teratorcarcinoma) cells,Expert,9606.0,,F,,BAO_0000219,2392,,854.0,1,CHEMBL620367,833K,,Homo sapiens,N,1,,
5533,The compound was tested in vitro for growth inhibitory activity against 833K (human teratorcarcinoma) cells; No data,Intermediate,9606.0,,F,,BAO_0000219,2392,,854.0,1,CHEMBL620368,833K,,Homo sapiens,N,1,,
5534,Inhibitory activity against caspase-1,Autocuration,,,B,,BAO_0000019,6608,,,1,CHEMBL620369,,,,U,0,,
5535,Percent inhibition of DAla-DAla Ligase at 10e -3 M of the compound,Autocuration,1351.0,,B,,BAO_0000357,10199,,,1,CHEMBL620370,,,Enterococcus faecalis,H,8,,
5536,In vitro antiproliferative activity against 8701-BC human breast cancer cells at a concentration of (0-100 uM) for 72 hr using MTT assay,Intermediate,9606.0,,F,,BAO_0000219,17749,,705.0,1,CHEMBL620371,8701-BC,,Homo sapiens,N,1,,
5537,In vitro antiproliferative activity against 8701-BC human breast cancer cells at a concentration of (0-100 uM,Intermediate,9606.0,,F,,BAO_0000219,17749,,705.0,1,CHEMBL620372,8701-BC,,Homo sapiens,N,1,,
5538,In vitro anticancer activity against 9 NCI colon cancer cell lines; inactive,Intermediate,,,F,,BAO_0000019,1229,,,1,CHEMBL876492,,,,U,0,,
5539,In vitro anticancer activity against 9 NCI melanoma cell lines; inactive,Intermediate,,,F,,BAO_0000019,1229,,,1,CHEMBL620373,,,,U,0,,
5540,In vitro anticancer activity against 9 NCI renal cancer cell lines; inactive,Intermediate,,,F,,BAO_0000019,1229,,,1,CHEMBL620374,,,,U,0,,
5541,Inhibitory activity was determined against 9-cis-epoxycarotenoid dioxygenase (NCED) expressed in Escherichia coli in presence of 9''-cis-neo-xanthin,Autocuration,,,B,,BAO_0000019,6390,,,1,CHEMBL620375,,,,U,0,,
5542,Minimum inhibitory concentration against Streptococcus pyogenes 930MLSB,Autocuration,1314.0,,F,,BAO_0000019,16219,,,1,CHEMBL857902,,,Streptococcus pyogenes,U,0,,
5543,Minimum inhibitory concentration against Streptococcus pyogenes 930MLSB,Autocuration,1314.0,,F,,BAO_0000019,16219,,,1,CHEMBL620376,,,Streptococcus pyogenes,U,0,,
5544,Percent inhibition against Cdc25C phosphatase at 50 uM of compound,Autocuration,,,B,,BAO_0000357,17043,,,1,CHEMBL620377,,,,H,8,,
5545,Tested for in vitro cytotoxic potency of compound in 9KB assay,Intermediate,9606.0,,F,,BAO_0000219,6929,,324.0,1,CHEMBL620378,KB ,,Homo sapiens,N,1,,
5546,Tested for in vitro cytotoxic potency of compound in 9KB assay,Intermediate,9606.0,,A,,BAO_0000219,6929,,324.0,1,CHEMBL620379,KB ,,Homo sapiens,N,1,,
5547,In vitro cytotoxicity of compound was tested against 9KB cells.,Autocuration,9606.0,,F,,BAO_0000219,7083,,,1,CHEMBL620380,,,Homo sapiens,U,0,,
5548,Cytotoxic concentration against 9L cells was determined on day 3,Intermediate,10116.0,,F,,BAO_0000219,12446,,392.0,1,CHEMBL884006,9L,,Rattus norvegicus,N,1,,
5549,Tested in vitro for anticancer activity against 9L cells,Expert,10116.0,,F,,BAO_0000219,15345,,392.0,1,CHEMBL620381,9L,,Rattus norvegicus,N,1,,
5550,Tested in vitro for anticancer activity against 9L cells; Not determined,Expert,10116.0,,F,,BAO_0000219,15345,,392.0,1,CHEMBL620382,9L,,Rattus norvegicus,N,1,,
5551,In vitro inhibitory activity against human A549 non-small cell lung tumor; Active,Intermediate,9606.0,,F,,BAO_0000219,6301,,646.0,1,CHEMBL620383,A549,,Homo sapiens,N,1,,
5552,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; No inhibition,Intermediate,9606.0,,F,,BAO_0000219,4833,,646.0,1,CHEMBL876493,A549,,Homo sapiens,N,1,,
5553,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; Significant inhibition,Intermediate,9606.0,,F,,BAO_0000219,4833,,646.0,1,CHEMBL620384,A549,,Homo sapiens,N,1,,
5554,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; Slight inhibition,Intermediate,9606.0,,F,,BAO_0000219,4833,,646.0,1,CHEMBL620385,A549,,Homo sapiens,N,1,,
5555,Cytotoxicity against human lung carcinoma A549 cell line,Expert,9606.0,,F,,BAO_0000219,13330,,646.0,1,CHEMBL620386,A549,,Homo sapiens,N,1,,
5556,Ability to induce human IL-6 assay in A549 lung carcinoma cell line.,Expert,9606.0,,F,,BAO_0000219,17517,,646.0,1,CHEMBL620387,A549,,Homo sapiens,D,9,,
5557,"Ability to induce human IL-6 assay in A549 lung carcinoma cell line; n.r.: not reported, EC50 values not reported in cases were %dex e 35%.",Expert,9606.0,,F,,BAO_0000219,17517,,646.0,1,CHEMBL621404,A549,,Homo sapiens,D,9,,
5558,"In vitro growth inhibition of A549, lung carcinoma",Intermediate,9606.0,,F,,BAO_0000219,14425,,646.0,1,CHEMBL621405,A549,,Homo sapiens,N,1,,
5559,"In vitro growth inhibition of A549, lung carcinoma.",Intermediate,9606.0,,F,,BAO_0000219,14425,,646.0,1,CHEMBL621406,A549,,Homo sapiens,N,1,,
5560,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,Expert,9606.0,,F,,BAO_0000219,5228,,646.0,1,CHEMBL621407,A549,,Homo sapiens,N,1,,
5561,Cytotoxic activity against human lung cancer A549 cell line was determined,Intermediate,9606.0,,F,,BAO_0000219,5351,,646.0,1,CHEMBL621408,A549,,Homo sapiens,N,1,,
5562,Cytotoxicity against human solid tumor lung carcinoma A549 cell line,Expert,9606.0,,F,,BAO_0000219,12198,,646.0,1,CHEMBL885345,A549,,Homo sapiens,N,1,,
5563,Cytotoxicity concentration against human lung carcinoma A-549 cell line,Intermediate,9606.0,,F,,BAO_0000219,13891,,646.0,1,CHEMBL621409,A549,,Homo sapiens,N,1,,
5564,Cytotoxicity in A549 (human carcinoma) cell line.,Expert,9606.0,,F,,BAO_0000219,5677,,646.0,1,CHEMBL876034,A549,,Homo sapiens,N,1,,
5565,Cytotoxicity on lung carcinoma (A-549) cell line,Intermediate,9606.0,,F,,BAO_0000219,13788,,646.0,1,CHEMBL621410,A549,,Homo sapiens,N,1,,
5566,Effective dose against 50% reduction in Human lung carcinoma (A-549) cell number after 3-day incubation.,Expert,9606.0,,F,,BAO_0000219,13384,,646.0,1,CHEMBL621411,A549,,Homo sapiens,N,1,,
5567,Effective dose of compound against replication of A549 cell line was evaluated,Intermediate,9606.0,,F,,BAO_0000219,6726,,646.0,1,CHEMBL621412,A549,,Homo sapiens,N,1,,
5568,In vitro cytotoxic activity was determined against lung carcinoma (A549) cell line,Expert,9606.0,,F,,BAO_0000219,3455,,646.0,1,CHEMBL621413,A549,,Homo sapiens,N,1,,
5569,In vitro cytotoxicity evaluated against human lung cancer (A549 cell line),Intermediate,9606.0,,F,,BAO_0000219,5726,,646.0,1,CHEMBL621414,A549,,Homo sapiens,N,1,,
5570,In vitro cytotoxicity evaluated against human lung cancer (A549 cell line); NA is not active,Intermediate,9606.0,,F,,BAO_0000219,5726,,646.0,1,CHEMBL621415,A549,,Homo sapiens,N,1,,
5571,The compound was evaluated for antiproliferative activity against A549 cell line,Intermediate,9606.0,,F,,BAO_0000219,3936,,646.0,1,CHEMBL621416,A549,,Homo sapiens,N,1,,
5572,The compound was tested for tumor cell growth inhibitory activity against human lung carcinoma (A549) cell line.,Intermediate,9606.0,,F,,BAO_0000219,14991,,646.0,1,CHEMBL621417,A549,,Homo sapiens,N,1,,
5573,Concentration required for growth inhibition of human lung carcinoma cell line A549,Intermediate,9606.0,,F,,BAO_0000219,5243,,646.0,1,CHEMBL621418,A549,,Homo sapiens,N,1,,
5574,Cytotoxic activity against A549/ATCC non-small cell-lung cancer cell line,Intermediate,9606.0,,F,,BAO_0000219,12858,,646.0,1,CHEMBL621419,A549,,Homo sapiens,N,1,,
5575,Growth inhibition against A549 cell line was evaluated,Intermediate,9606.0,,F,,BAO_0000219,6776,,646.0,1,CHEMBL621420,A549,,Homo sapiens,N,1,,
5576,Growth inhibitory activity against A549 human solid tumor cell line using MTT assay,Intermediate,9606.0,,F,,BAO_0000219,16558,,646.0,1,CHEMBL875823,A549,,Homo sapiens,N,1,,
5577,Inhibition of anchorage independent growth of human tumor cell line A549 K-ras-transformed in soft agar,Expert,9606.0,,F,,BAO_0000219,4583,,646.0,1,CHEMBL621421,A549,,Homo sapiens,N,1,,
5578,Inhibitor activity against A549 (Human lung carcinoma)cell line with varying concentration of the drug for 72 hrs,Intermediate,9606.0,,F,,BAO_0000219,13514,,646.0,1,CHEMBL621422,A549,,Homo sapiens,N,1,,
5579,Chemosensitivity against DT-diaphorase rich A549 cell lines,Expert,9606.0,,F,,BAO_0000219,15166,,646.0,1,CHEMBL884014,A549,,Homo sapiens,N,1,,
5580,Compound tested against A549 lung carcinoma in the sulforhodamine B assay.,Intermediate,9606.0,,F,,BAO_0000219,13873,,646.0,1,CHEMBL621423,A549,,Homo sapiens,N,1,,
5581,In vitro cytotoxicity against human A549 (lung cancer) cell line.,Expert,9606.0,,F,,BAO_0000219,6447,,646.0,1,CHEMBL621424,A549,,Homo sapiens,N,1,,
5582,In vitro antitumor activity against A549 (lung) human tumor cell lines.,Intermediate,9606.0,,F,,BAO_0000219,2068,,646.0,1,CHEMBL621425,A549,,Homo sapiens,N,1,,
5583,In vitro cytotoxic activity against human lung carcinoma A549 cell line,Expert,9606.0,,F,,BAO_0000219,1863,,646.0,1,CHEMBL621426,A549,,Homo sapiens,N,1,,
5584,Compound was tested against A549 lung cancer cell line in the sulforhodamine B assay.,Intermediate,9606.0,,F,,BAO_0000219,13873,,646.0,1,CHEMBL621427,A549,,Homo sapiens,N,1,,
5585,Compound was tested against A549 lung carcinoma cell line in the sulforhodamine B assay.,Intermediate,9606.0,,F,,BAO_0000219,13873,,646.0,1,CHEMBL621428,A549,,Homo sapiens,N,1,,
5586,Tested against A549 lung carcinoma in the sulforhodamine B assay.,Expert,9606.0,,F,,BAO_0000219,13873,,646.0,1,CHEMBL621429,A549,,Homo sapiens,N,1,,
5587,Compound was tested for cytotoxicity on A549 lung adenocarcinoma cell line using a proliferation assay (MTT reduction),Intermediate,9606.0,,F,,BAO_0000219,579,,646.0,1,CHEMBL621430,A549,,Homo sapiens,N,1,,
5588,Compound was tested for cytotoxicity on A549 lung adenocarcinoma cell line using a proliferation assay (MTT reduction).,Intermediate,9606.0,,F,,BAO_0000219,579,,646.0,1,CHEMBL621431,A549,,Homo sapiens,N,1,,
5589,Compound was tested for inhibition of growth of human lung carcinoma cell line A549 up to a conc of 10 uM; NI means no inhibition,Intermediate,9606.0,,F,,BAO_0000219,4584,,646.0,1,CHEMBL621432,A549,,Homo sapiens,N,1,,
5590,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line,Expert,9606.0,,F,,BAO_0000219,5421,,646.0,1,CHEMBL621433,A549,,Homo sapiens,N,1,,
5591,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line,Intermediate,9606.0,,F,,BAO_0000219,5421,,646.0,1,CHEMBL875824,A549,,Homo sapiens,N,1,,
5592,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line at 20 uM concentration,Intermediate,9606.0,,F,,BAO_0000219,5421,,646.0,1,CHEMBL621434,A549,,Homo sapiens,N,1,,
5593,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line; NA=Not assayed,Intermediate,9606.0,,F,,BAO_0000219,5421,,646.0,1,CHEMBL621435,A549,,Homo sapiens,N,1,,
5594,Compound was tested for potency against human lung A549 cells using sulforhodamine B assay.,Intermediate,9606.0,,F,,BAO_0000219,14188,,646.0,1,CHEMBL621436,A549,,Homo sapiens,N,1,,
5595,Compound was tested for potency against human lung A549 cells using sulforhodamine B assay; UA=Potency was so low that the IC50 was unachievable.,Intermediate,9606.0,,F,,BAO_0000219,14188,,646.0,1,CHEMBL621437,A549,,Homo sapiens,N,1,,
5596,Compound was tested for the growth inhibition of A549 lung tumor cell line,Intermediate,9606.0,,F,,BAO_0000219,15354,,646.0,1,CHEMBL621438,A549,,Homo sapiens,N,1,,
5597,Growth inhibition of human non-small-lung carcinoma (A549) cell line,Expert,9606.0,,F,,BAO_0000219,14253,,646.0,1,CHEMBL621439,A549,,Homo sapiens,N,1,,
5598,Compound was tested against A549 lung carcinoma cell line in the sulforhodamine B assay.,Intermediate,9606.0,,F,,BAO_0000219,13873,,646.0,1,CHEMBL621440,A549,,Homo sapiens,N,1,,
5599,Oral bioavailability in dog (conscious),Intermediate,9615.0,,A,,BAO_0000218,3043,,,1,CHEMBL621441,,,Canis lupus familiaris,N,1,,
5600,Compound was evaluated for the oral bioavailability after oral administration in dog.,Intermediate,9615.0,,A,,BAO_0000218,3045,,,1,CHEMBL621442,,,Canis lupus familiaris,N,1,,
5601,Compound was tested for percent of oral bioavailability at 10 mg/ml dose in dogs,Intermediate,9615.0,,A,,BAO_0000218,3022,,,1,CHEMBL621443,,,Canis lupus familiaris,N,1,,
5602,Oral bioavailability in dog,Intermediate,9615.0,,A,,BAO_0000218,4453,,,1,CHEMBL621444,,,Canis lupus familiaris,N,1,,
5603,Oral bioavailability in dog,Intermediate,9615.0,,A,,BAO_0000218,1696,,,1,CHEMBL625133,,,Canis lupus familiaris,N,1,,
5604,Oral bioavailability in dog,Intermediate,9615.0,,A,,BAO_0000218,5045,,,1,CHEMBL625134,,,Canis lupus familiaris,N,1,,
5605,Oral bioavailability in dog (fasted),Intermediate,9615.0,,A,,BAO_0000218,5356,,,1,CHEMBL625135,,,Canis lupus familiaris,N,1,,
5606,Oral bioavailability after intravenous administration in dogs at 1.2 uM/kg,Intermediate,9615.0,,A,,BAO_0000218,17764,,,1,CHEMBL625136,,,Canis lupus familiaris,N,1,,
5607,Oral bioavailability in dog,Intermediate,9615.0,,A,,BAO_0000218,6448,,,1,CHEMBL625137,,,Canis lupus familiaris,N,1,,
5608,Oral bioavailability in dog,Intermediate,9615.0,,A,,BAO_0000218,1475,,,1,CHEMBL625138,,,Canis lupus familiaris,N,1,,
5609,Percent bioavailability in dog,Intermediate,9615.0,,A,,BAO_0000218,3788,,,1,CHEMBL625139,,,Canis lupus familiaris,N,1,,
5610,Percent oral bioavailability of intravenously administered compound (6 mg/kg) was tested in dog,Intermediate,9615.0,,A,,BAO_0000218,3639,,,1,CHEMBL872264,,,Canis lupus familiaris,N,1,,
5611,Oral bioavailability in dog,Intermediate,9615.0,,A,,BAO_0000218,13397,,,1,CHEMBL625140,,,Canis lupus familiaris,N,1,,
5612,The compound was evaluated for bioavailability in dogs; 34-44,Intermediate,9615.0,,A,,BAO_0000218,2137,,,1,CHEMBL624436,,,Canis lupus familiaris,N,1,,
5613,Bioavailability in dog (dose 4 mg/kg p.o.),Intermediate,9615.0,,A,,BAO_0000218,2959,,,1,CHEMBL624437,,,Canis lupus familiaris,N,1,,
5614,Oral bioavailability in dog,Intermediate,9615.0,,A,,BAO_0000218,6448,,,1,CHEMBL872261,,,Canis lupus familiaris,N,1,,
5615,8 hour trough Blood level in dog was measured after administration of compound,Intermediate,9615.0,,A,,BAO_0000218,6084,,,1,CHEMBL624438,,,Canis lupus familiaris,N,1,,
5616,The compound was tested for maximum concentration ( Cmax ) in dog plasma.,Intermediate,9615.0,,A,,BAO_0000218,3639,,,1,CHEMBL624439,,,Canis lupus familiaris,N,1,1969.0,
5617,C24 after oral administration at 5 mg/kg,Intermediate,9615.0,,A,,BAO_0000218,6316,,,1,CHEMBL624440,,,Canis lupus familiaris,N,1,,
5618,Clearance after oral and iv dosing in dogs,Intermediate,9615.0,,A,,BAO_0000218,5238,,,1,CHEMBL624441,,,Canis lupus familiaris,N,1,,
5619,Clearance of the drug was measured in the plasma of dog,Intermediate,9615.0,,A,,BAO_0000218,17796,,,1,CHEMBL624442,,,Canis lupus familiaris,N,1,1969.0,
5620,Compound was evaluated for Clearance in dogs at a dose of 1 mpk intravenously,Intermediate,9615.0,,A,,BAO_0000218,2652,,,1,CHEMBL624443,,,Canis lupus familiaris,N,1,,
5621,CL (clearance) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,Intermediate,9615.0,,A,,BAO_0000218,5654,,,1,CHEMBL624444,,,Canis lupus familiaris,N,1,,
5622,Clearance of compound was determined in dogs,Intermediate,9615.0,,A,,BAO_0000218,6621,,,1,CHEMBL624445,,,Canis lupus familiaris,N,1,,
5623,Clearance on i.v. administration of 2 mg/kg was measured in dog,Intermediate,9615.0,,A,,BAO_0000218,6505,,,1,CHEMBL624446,,,Canis lupus familiaris,N,1,,
5624,Clearance of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,Intermediate,9615.0,,A,,BAO_0000218,5802,,,1,CHEMBL624447,,,Canis lupus familiaris,N,1,,
5625,Plasma clearance in dog was determined,Intermediate,9615.0,,A,,BAO_0000218,17267,,,1,CHEMBL624448,,,Canis lupus familiaris,N,1,,
5626,Plasma clearance in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,Intermediate,9615.0,,A,,BAO_0000218,4521,,,1,CHEMBL624449,,,Canis lupus familiaris,N,1,,
5627,Plasma clearance in dog after administration of 0.25 mg/kg iv,Intermediate,9615.0,,A,,BAO_0000218,6535,,,1,CHEMBL624450,,,Canis lupus familiaris,N,1,,
5628,Plasma clearance in dog after administration of 1 mg/kg iv,Intermediate,9615.0,,A,,BAO_0000218,6535,,,1,CHEMBL875942,,,Canis lupus familiaris,N,1,,
5629,Plasma clearance in dogs,Intermediate,9615.0,,A,,BAO_0000218,6535,,,1,CHEMBL624451,,,Canis lupus familiaris,N,1,,
5630,Plasma clearance by iv administration in dog at a dose of 0.3 mg/kg,Intermediate,9615.0,,A,,BAO_0000218,5542,,,1,CHEMBL624452,,,Canis lupus familiaris,N,1,,
5631,Plasma clearance was determined in canine following intravenous (iv) administration of drug (1 mg/kg).,Intermediate,9615.0,,A,,BAO_0000218,5199,,,1,CHEMBL624453,,,Canis lupus familiaris,N,1,,
5632,Plasma clearance after 15 mg/kg iv dose in Dogs,Intermediate,9615.0,,A,,BAO_0000218,16907,,,1,CHEMBL624454,,,Canis lupus familiaris,N,1,,
5633,Plasma clearance after 30 mg/kg po dose in Dogs,Intermediate,9615.0,,A,,BAO_0000218,16907,,,1,CHEMBL624455,,,Canis lupus familiaris,N,1,,
5634,Plasma administration to dogs,Intermediate,9615.0,,A,,BAO_0000218,16367,,,1,CHEMBL624456,,,Canis lupus familiaris,N,1,,
5635,Plasma clearance was determined,Intermediate,9615.0,,A,,BAO_0000218,5505,,,1,CHEMBL624457,,,Canis lupus familiaris,N,1,,
5636,Systemic clearance after intravenous administration (0.5 mg/kg) was determined in dog,Intermediate,9615.0,,A,,BAO_0000218,6215,,,1,CHEMBL624458,,,Canis lupus familiaris,N,1,,
5637,Tested for systemic clearance upon intravenous administration of 5.0 mg/Kg dose in dog,Intermediate,9615.0,,A,,BAO_0000218,1466,,,1,CHEMBL624459,,,Canis lupus familiaris,N,1,,
5638,Intrinsic clearance in human liver microsomes,Intermediate,9606.0,,A,,BAO_0000251,5007,Microsomes,,1,CHEMBL624460,,,Homo sapiens,S,2,2107.0,
5639,Intrinsic clearance in human liver microsomes,Intermediate,9606.0,,A,,BAO_0000251,5007,Microsomes,,1,CHEMBL624461,,,Homo sapiens,S,2,2107.0,
5640,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,Intermediate,9615.0,,A,,BAO_0000218,16452,,,1,CHEMBL875943,,,Canis lupus familiaris,N,1,,
5641,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,Intermediate,9615.0,,A,,BAO_0000218,16452,,,1,CHEMBL624462,,,Canis lupus familiaris,N,1,,
5642,Clearance in dog (dose 1 mg/kg i.v.),Intermediate,9615.0,,A,,BAO_0000218,16452,,,1,CHEMBL624463,,,Canis lupus familiaris,N,1,,
5643,Plasma clearance after oral administration (2.5 mg/kg) in dog was determined,Intermediate,9615.0,,A,,BAO_0000218,6221,,,1,CHEMBL624464,,,Canis lupus familiaris,N,1,,
5644,Plasma clearance in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),Intermediate,9615.0,,A,,BAO_0000218,5007,,,1,CHEMBL624465,,,Canis lupus familiaris,N,1,,
5645,Plasma clearance after peroral administration at 10 mpk in dog,Intermediate,9615.0,,A,,BAO_0000218,5668,,,1,CHEMBL624466,,,Canis lupus familiaris,N,1,,
5646,Plasma clearance after peroral administration at 5 mpk in dog,Intermediate,9615.0,,A,,BAO_0000218,5668,,,1,CHEMBL624467,,,Canis lupus familiaris,N,1,,
5647,Plasma clearance after peroral administration at 5 mg/kg in dog,Intermediate,9615.0,,A,,BAO_0000218,5668,,,1,CHEMBL624468,,,Canis lupus familiaris,N,1,,
5648,Plasma clearance was measured in dog,Intermediate,9615.0,,A,,BAO_0000218,15660,,,1,CHEMBL624469,,,Canis lupus familiaris,N,1,,
5649,Plasma clearance was measured in dog,Intermediate,9615.0,,A,,BAO_0000218,15660,,,1,CHEMBL624470,,,Canis lupus familiaris,N,1,,
5650,Pharmacokinetic property (CLtot) was measured in dog at the dose of 0.032 mg/kg i.v.,Intermediate,9615.0,,A,,BAO_0000218,5983,,,1,CHEMBL624471,,,Canis lupus familiaris,N,1,,
5651,Total clearance was determined after 0.1 mg/kg iv administration in dog,Intermediate,9615.0,,A,,BAO_0000218,5600,,,1,CHEMBL624472,,,Canis lupus familiaris,N,1,,
5652,Clearance of compound after intravenous administration in dogs at 1.2 uM/kg,Intermediate,9615.0,,A,,BAO_0000218,17764,,,1,CHEMBL622775,,,Canis lupus familiaris,N,1,,
5653,Clearance after intravenous administration of 0.5 mg/kg in dog was determined,Intermediate,9615.0,,A,,BAO_0000218,6039,,,1,CHEMBL622776,,,Canis lupus familiaris,N,1,,
5654,Clearance after intravenous administration of 1.0 mg/kg in dog was determined,Intermediate,9615.0,,A,,BAO_0000218,6039,,,1,CHEMBL622777,,,Canis lupus familiaris,N,1,,
5655,Clearance after peroral administration of 0.2 mg/kg in dog was determined,Intermediate,9615.0,,A,,BAO_0000218,6039,,,1,CHEMBL622778,,,Canis lupus familiaris,N,1,,
5656,Clearance by intravenous administration of 1.2 mg/kg in dog,Intermediate,9615.0,,A,,BAO_0000218,4368,,,1,CHEMBL622779,,,Canis lupus familiaris,N,1,,
5657,Clearance by iv administration in dogs at a dose of 1 mg/kg,Intermediate,9615.0,,A,,BAO_0000218,4305,,,1,CHEMBL622780,,,Canis lupus familiaris,N,1,,
5658,Clearance value was evaluated in dog plasma,Intermediate,9615.0,,A,,BAO_0000218,1918,,,1,CHEMBL622781,,,Canis lupus familiaris,N,1,1969.0,
5659,Clearance was evaluated after i.v. administration in dog at a dose of 1 mg/kg,Intermediate,9615.0,,A,,BAO_0000218,6005,,,1,CHEMBL622782,,,Canis lupus familiaris,N,1,,
5660,Compound was tested for plasma clearance in dog,Intermediate,9615.0,,A,,BAO_0000218,4839,,,1,CHEMBL622783,,,Canis lupus familiaris,N,1,1969.0,
5661,Pharmacokinetic property (Plasma clearance) was measured in dog,Intermediate,9615.0,,A,,BAO_0000218,4239,,,1,CHEMBL622784,,,Canis lupus familiaris,N,1,,
5662,Area under curve when injected perorally in mice at a dose of 50 mg/kg,Intermediate,10090.0,,A,,BAO_0000218,17729,,,1,CHEMBL622785,,,Mus musculus,N,1,,
5663,Area under curve when injected perorally in BALB/C mice at a dose of 50 mg/kg,Intermediate,10090.0,,A,,BAO_0000218,17728,,,1,CHEMBL622786,,,Mus musculus,N,1,,
5664,Area under curve value in mouse at a dose of 10 mg/kg,Intermediate,10090.0,,A,,BAO_0000218,5302,,,1,CHEMBL622787,,,Mus musculus,N,1,,
5665,Area under curve was determined at a dose of 100 mg/kg (i.p.) in Mice,Intermediate,10090.0,,A,,BAO_0000218,5506,,,1,CHEMBL875949,,,Mus musculus,N,1,,
5666,Area under curve was determined at a dose of 200 mg/kg (i.p.) in Mice,Intermediate,10090.0,,A,,BAO_0000218,5506,,,1,CHEMBL622788,,,Mus musculus,N,1,,
5667,Area under curve was determined for compound after intraperitoneal administration in mice at 18 uM/kg,Intermediate,10090.0,,F,,BAO_0000218,17764,,,1,CHEMBL622789,,,Mus musculus,N,1,,
5668,Area under curve was determined for compound after intraperitoneal administration in mice at 23 uM/kg,Intermediate,10090.0,,F,,BAO_0000218,17764,,,1,CHEMBL622790,,,Mus musculus,N,1,,
5669,Area under curve was determined for compound after intraperitoneal administration in mice at 25 uM/kg,Intermediate,10090.0,,F,,BAO_0000218,17764,,,1,CHEMBL622791,,,Mus musculus,N,1,,
5670,Area under curve was determined for compound after intraperitoneal administration in mice at 26 uM/kg,Intermediate,10090.0,,F,,BAO_0000218,17764,,,1,CHEMBL622792,,,Mus musculus,N,1,,
5671,Area under curve was determined for compound after intravenous administration in mice at 24 uM/kg,Intermediate,10090.0,,A,,BAO_0000218,17764,,,1,CHEMBL622793,,,Mus musculus,N,1,,
5672,Area under curve was determined for the compound at 24 mg/Kg,Intermediate,10090.0,,A,,BAO_0000218,17753,,,1,CHEMBL622794,,,Mus musculus,N,1,,
5673,Area under curve was determined for the compound at 40 mg/Kg,Intermediate,10090.0,,A,,BAO_0000218,17753,,,1,CHEMBL622795,,,Mus musculus,N,1,,
5674,Area under curve was determined for the compound at 5 mg/Kg,Intermediate,10090.0,,A,,BAO_0000218,17753,,,1,CHEMBL621803,,,Mus musculus,N,1,,
5675,Area under the curve for the compound is obtained at dose 25 mg/kg,Intermediate,10090.0,,A,,BAO_0000218,3132,,,1,CHEMBL621804,,,Mus musculus,N,1,,
5676,Area under the curve for the compound was obtained when tested in mouse,Intermediate,10090.0,,A,,BAO_0000218,3132,,,1,CHEMBL621805,,,Mus musculus,N,1,,
5677,Area under the curve of compound in mouse blood following i.v. administration of 10 mg/kg,Intermediate,10090.0,,A,,BAO_0000218,17837,,,1,CHEMBL621806,,,Mus musculus,N,1,,
5678,Area under the curve of compound in mouse blood following p.o. administration of 30 mg/kg,Intermediate,10090.0,,A,,BAO_0000218,17837,,,1,CHEMBL621807,,,Mus musculus,N,1,,
5679,Area under the curve was measured in mouse after an iv dose of 1 mg/kg,Intermediate,10090.0,,A,,BAO_0000218,6062,,,1,CHEMBL621808,,,Mus musculus,N,1,,
5680,Area under the curve was determined for the compound at a single subcutaneous administration of 40 mg/kg in mice,Intermediate,10090.0,,A,,BAO_0000218,4066,,,1,CHEMBL621809,,,Mus musculus,N,1,,
5681,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for area under curve (AUCtot),Intermediate,10090.0,,A,,BAO_0000218,16597,,,1,CHEMBL621810,,,Mus musculus,N,1,,
5682,Compound was evaluated for the area under the concentration - time curve by administering intravenously at 25 mg/kg in mice,Intermediate,10090.0,,A,,BAO_0000218,14239,,,1,CHEMBL875164,,,Mus musculus,N,1,,
5683,Compound was evaluated for the area under the concentration - time curve by administering orally at 25 mg/kg in mice,Intermediate,10090.0,,A,,BAO_0000218,14239,,,1,CHEMBL621811,,,Mus musculus,N,1,,
5684,"Compound was evaluated for the pharmacokinetic parameter, area under curve",Intermediate,10090.0,,A,,BAO_0000218,4890,,,1,CHEMBL621812,,,Mus musculus,N,1,,
5685,Evaluated for pharmacokinetic parameter area under curve in mouse at the dose 20 mg/kg (0-4 hr ),Intermediate,10090.0,,A,,BAO_0000218,429,,,1,CHEMBL621813,,,Mus musculus,N,1,,
5686,Evaluated for pharmacokinetic parameter area under curve in mouse at the dose 20 mg/kg (0-4 hr),Intermediate,10090.0,,A,,BAO_0000218,429,,,1,CHEMBL621814,,,Mus musculus,N,1,,
5687,In vivo area under curve (AUC) was determined in murine septicemia at dose of 100 mg/kg,Intermediate,10090.0,,A,,BAO_0000218,5969,,,1,CHEMBL621815,,,Mus musculus,N,1,,
5688,In vivo area under curve (AUC) was determined in murine septicemia at dose of 50 mg/kg,Intermediate,10090.0,,A,,BAO_0000218,5969,,,1,CHEMBL621816,,,Mus musculus,N,1,,
5689,In vivo area under curve (AUC) was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,Intermediate,10090.0,,A,,BAO_0000218,5969,,,1,CHEMBL621817,,,Mus musculus,N,1,,
5690,Pharmacokinetic activity (AUC) in vivo after intravenous administration of 10 mg/kg in mouse,Intermediate,10090.0,,A,,BAO_0000218,6091,,,1,CHEMBL621818,,,Mus musculus,N,1,,
5691,Pharmacokinetic activity (AUC) in vivo after intravenous administration of 10 mg/kg in mouse;ND=Not determined,Intermediate,10090.0,,A,,BAO_0000218,6091,,,1,CHEMBL621819,,,Mus musculus,N,1,,
5692,Pharmacokinetic activity (AUC) in vivo after peroral administration of 10 mg/kg in mice,Intermediate,10090.0,,A,,BAO_0000218,6091,,,1,CHEMBL621820,,,Mus musculus,N,1,,
5693,Pharmacokinetic activity (AUC) in vivo after peroral administration of 10 mg/kg in mice;ND=Not determined,Intermediate,10090.0,,A,,BAO_0000218,6091,,,1,CHEMBL621821,,,Mus musculus,N,1,,
5694,Pharmacokinetic property (AUC) was determined after ip administration of 32 mg/kg in mice,Intermediate,10090.0,,A,,BAO_0000218,6178,,,1,CHEMBL621822,,,Mus musculus,N,1,,
5695,Pharmacokinetic property (AUC) was determined after po administration of 32 mg/kg in mice,Intermediate,10090.0,,A,,BAO_0000218,6178,,,1,CHEMBL619474,,,Mus musculus,N,1,,
5696,"Reduction in area under curve was determined in DIO mice by oral glucose tolerance test following a single i.p. dose (10 mg/kg, 30 min pre-treatment)",Intermediate,10090.0,,A,,BAO_0000218,6619,,,1,CHEMBL619475,,,Mus musculus,N,1,,
5697,"Reduction in area under curve was determined in ob/ob mice by oral glucose tolerance test following a single i.p. dose (10 mg/kg, 30 min pre-treatment)",Intermediate,10090.0,,A,,BAO_0000218,6619,,,1,CHEMBL619476,,,Mus musculus,N,1,,
5698,"The area under concentration-time curve(AUC) was determined at 5 mg/kg of compound dose, administered intravenously in mice",Intermediate,10090.0,,A,,BAO_0000218,3760,,,1,CHEMBL619477,,,Mus musculus,N,1,,
5699,"The area under concentration-time curve(AUC) was determined at 5 mg/kg of compound dose, administered perorally in mice",Intermediate,10090.0,,A,,BAO_0000218,3760,,,1,CHEMBL619478,,,Mus musculus,N,1,,
5700,"The area under concentration-time curve(AUC) was determined at 50 mg/kg of compound dose, administered intravenously in mice",Intermediate,10090.0,,A,,BAO_0000218,3760,,,1,CHEMBL619479,,,Mus musculus,N,1,,
5701,"The area under concentration-time curve(AUC) was determined at 50 mg/kg of compound dose, administered perorally in mice",Intermediate,10090.0,,A,,BAO_0000218,3760,,,1,CHEMBL619480,,,Mus musculus,N,1,,
5702,The area under curve in vivo in mouse blood level after oral administration at dose 50 mk/kg e-1,Intermediate,10090.0,,A,,BAO_0000218,3192,,,1,CHEMBL619481,,,Mus musculus,N,1,,
5703,The area under curve in vivo in mouse blood level after subcutaneous administration at dose 50 mk/kg e-1,Intermediate,10090.0,,A,,BAO_0000218,3192,,,1,CHEMBL619482,,,Mus musculus,N,1,,
5704,Area under the curve was evaluated in mice after intravenous administration,Intermediate,10090.0,,A,,BAO_0000218,2675,,,1,CHEMBL619483,,,Mus musculus,N,1,,
5705,Area under the curve was evaluated in mice after oral administration,Intermediate,10090.0,,A,,BAO_0000218,2675,,,1,CHEMBL619484,,,Mus musculus,N,1,,
5706,AUC total value at a dose of 10 mg/kg intravenous administration in mice.,Intermediate,10090.0,,A,,BAO_0000218,16597,,,1,CHEMBL619485,,,Mus musculus,N,1,1969.0,
5707,AUC total value at a dose of 10 mg/kg peroral administration in mice.,Intermediate,10090.0,,A,,BAO_0000218,16597,,,1,CHEMBL619486,,,Mus musculus,N,1,1969.0,
5708,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for area under curve (AUCtot),Intermediate,10090.0,,A,,BAO_0000218,16597,,,1,CHEMBL619487,,,Mus musculus,N,1,,
5709,AUMC after intraperitoneal administration of 100 mg/kg in mice,Intermediate,10090.0,,A,,BAO_0000218,17734,,,1,CHEMBL619488,,,Mus musculus,N,1,,
5710,Biodistribution in blood was determined in mice after iv administration at 15 min Value expressed as percent injected dose per gram,Intermediate,10090.0,,A,,BAO_0000218,7767,,,1,CHEMBL620106,,,Mus musculus,N,1,178.0,
5711,The compound was tested in vitro for anticancer activity against 9L cells,Intermediate,,,F,,BAO_0000219,15345,,392.0,1,CHEMBL620107,9L,,,N,1,,
5712,Anti proliferation activity determined; Weak effect,Autocuration,10116.0,,F,,BAO_0000019,2181,,,1,CHEMBL620283,,,Rattus norvegicus,U,0,,
5713,Inhibition of cell growth by compound at a concentration of 100 uM in 9Ltk+ cells; Completely stopped the process,Autocuration,10116.0,,F,,BAO_0000219,2181,,,1,CHEMBL875176,,,Rattus norvegicus,U,0,,
5714,Inhibition of cell growth by compound at a concentration of 10 uM in 9Ltk+ cells,Autocuration,10116.0,,F,,BAO_0000219,2181,,,1,CHEMBL620284,,,Rattus norvegicus,U,0,,
5715,Inhibition of cell growth by compound at a concentration of 10 uM in 9Ltk+ cells; Completely stopped the process,Autocuration,10116.0,,F,,BAO_0000219,2181,,,1,CHEMBL623515,,,Rattus norvegicus,U,0,,
5716,The cytotoxic activity was in vitro tested by 9PS assay method,Autocuration,10090.0,,F,,BAO_0000019,10486,,,1,CHEMBL623516,,,Mus musculus,U,0,,
5717,The cytotoxic activity was in vitro tested by 9PS assay method.,Autocuration,10090.0,,F,,BAO_0000019,10486,,,1,CHEMBL623517,,,Mus musculus,U,0,,
5718,Partition coefficient (logD6.5),Autocuration,,,A,,BAO_0000019,15508,,,1,CHEMBL857878,,,,U,0,,
5719,Inhibitory concentration in vitro for cytotoxic activity against A 2780 human ovarian carcinoma cells,Expert,9606.0,,F,,BAO_0000219,5242,,478.0,1,CHEMBL623518,A2780,,Homo sapiens,N,1,,
5720,Effective concentration against A 375 cell line growth (DFMO concentration is 5.0 mM),Intermediate,9606.0,,F,,BAO_0000219,16167,,455.0,1,CHEMBL624195,A-375,,Homo sapiens,N,1,,
5721,Inhibitory concentration required against A 431 human epidermoid carcinoma cell line,Expert,9606.0,,F,,BAO_0000219,4782,,500.0,1,CHEMBL624196,A-431,,Homo sapiens,N,1,,
5722,Inhibition of EGF-induced Tyrosine phosphorylation in A431 cells expressing EGF-R,Expert,9606.0,,F,,BAO_0000219,16093,,500.0,1,CHEMBL624197,A-431,,Homo sapiens,D,9,,
5723,Compound was evaluated for in vitro cytotoxicity against A 498 cancer cell line,Intermediate,9606.0,,F,,BAO_0000219,2596,,624.0,1,CHEMBL624198,A498,,Homo sapiens,N,1,,
5724,in vitro cytotoxicity against A 498 cancer cell line,Intermediate,9606.0,,F,,BAO_0000219,2596,,624.0,1,CHEMBL621287,A498,,Homo sapiens,N,1,,
5725,In vitro cytotoxic activity against renal (A 498) cancer cell line.,Intermediate,9606.0,,F,,BAO_0000219,3239,,624.0,1,CHEMBL621288,A498,,Homo sapiens,N,1,,
5726,Cytotoxic activity against A 498 renal cancer cell lines.,Intermediate,9606.0,,F,,BAO_0000219,1847,,624.0,1,CHEMBL876496,A498,,Homo sapiens,N,1,,
5727,In vitro cytotoxicity was determined against A 498 human renal tumor cell line using NCI screen,Intermediate,9606.0,,F,,BAO_0000219,10553,,624.0,1,CHEMBL621289,A498,,Homo sapiens,N,1,,
5728,Minimum inhibitory concentration against Staphylococcus aureus A 5177 MLSB-i,Autocuration,1280.0,,F,,BAO_0000019,16219,,,1,CHEMBL621290,,,Staphylococcus aureus,U,0,,
5729,Minimum inhibitory concentration against Staphylococcus aureus A 5177 MLSB-i,Autocuration,1280.0,,F,,BAO_0000019,16219,,,1,CHEMBL621291,,,Staphylococcus aureus,U,0,,
5730,Minimum inhibitory concentration against Staphylococcus aureus A 5278 MLSB-c,Autocuration,1280.0,,F,,BAO_0000019,16219,,,1,CHEMBL621292,,,Staphylococcus aureus,U,0,,
5731,Minimum inhibitory concentration against Staphylococcus aureus A 5278 MLSB-c,Autocuration,1280.0,,F,,BAO_0000019,16219,,,1,CHEMBL621293,,,Staphylococcus aureus,U,0,,
5732,Inhibitory concentration required against A 549 lung cancer cell line,Intermediate,9606.0,,F,,BAO_0000219,4782,,646.0,1,CHEMBL621294,A549,,Homo sapiens,N,1,,
5733,Growth inhibition of A 549 cell line by MTT reduction for 3 days of incubation time,Intermediate,9606.0,,F,,BAO_0000219,11805,,646.0,1,CHEMBL621295,A549,,Homo sapiens,N,1,,
5734,Growth inhibition of A 549 cell line by MTT reduction for 7 days of incubation time,Intermediate,9606.0,,F,,BAO_0000219,11805,,646.0,1,CHEMBL884007,A549,,Homo sapiens,N,1,,
5735,In vitro cytotoxicity against lung cancer A 549 cell lines,Intermediate,9606.0,,F,,BAO_0000219,2007,,646.0,1,CHEMBL621296,A549,,Homo sapiens,N,1,,
5736,Compound was tested for its cytotoxicity against A 549 cell line,Intermediate,9606.0,,F,,BAO_0000219,4594,,646.0,1,CHEMBL621297,A549,,Homo sapiens,N,1,,
5737,"Cytotoxic activity against A 549 human lung tumor cell line, using sulforhodamine B (SRB) assay.",Expert,9606.0,,F,,BAO_0000219,6018,,646.0,1,CHEMBL839828,A549,,Homo sapiens,N,1,,
5738,"Cytotoxic activity against A 549 human lung tumor cell line, using sulforhodamine B (SRB) assay.; No data",Intermediate,9606.0,,F,,BAO_0000219,6018,,646.0,1,CHEMBL620397,A549,,Homo sapiens,N,1,,
5739,In vitro cytotoxic activity against A 549 (non-small cell lung) using SRB (sulforhodamine B) assay,Expert,9606.0,,F,,BAO_0000219,3599,,646.0,1,CHEMBL620398,A549,,Homo sapiens,N,1,,
5740,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay,Intermediate,9606.0,,F,,BAO_0000219,2551,,646.0,1,CHEMBL620399,A549,,Homo sapiens,N,1,,
5741,In vitro inhibition of A549 (human lung cancer) cell growth.,Expert,9606.0,,F,,BAO_0000219,16132,,646.0,1,CHEMBL620400,A549,,Homo sapiens,N,1,,
5742,Cytotoxic related antitumor activity against human cancer cell lines A 549; No data available,Intermediate,9606.0,,F,,BAO_0000219,16132,,646.0,1,CHEMBL620401,A549,,Homo sapiens,N,1,,
5743,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay,Expert,9606.0,,F,,BAO_0000219,2551,,646.0,1,CHEMBL620402,A549,,Homo sapiens,N,1,,
5744,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay; not active (> 100 uM),Expert,9606.0,,F,,BAO_0000219,2551,,646.0,1,CHEMBL620403,A549,,Homo sapiens,N,1,,
5745,Tested against A II at (100 ng/kg iv) in Dawley rats (n=2). 24 h,Autocuration,,,F,,BAO_0000218,11913,,,1,CHEMBL620404,,,,U,0,,
5746,The duration of action for the % peak inhibition of A II pressor response for dose of 0.1 mg/kg intravenous administration in conscious dogs.,Autocuration,,,F,,BAO_0000218,12621,,,1,CHEMBL620405,,,,H,4,,
5747,The duration of action for the % peak inhibition of A II pressor response for dose of 1.0 mg/kg peroral administration in rhesus monkeys.,Autocuration,,,F,,BAO_0000218,12621,,,1,CHEMBL620406,,,,H,4,,
5748,The duration of action for the % peak inhibition of angiotensin II pressor response for dose of 0.1 mg/kg peroral administration in conscious rats.,Autocuration,,,F,,BAO_0000218,12621,,,1,CHEMBL620407,,,,H,4,,
5749,The compound was evaluated for the % peak inhibition of A II pressor response for dose of 0.3 mg/kg peroral administration in rhesus monkeys.,Autocuration,,,F,,BAO_0000218,12621,,,1,CHEMBL620408,,,,H,4,,
5750,The compound was evaluated for the percentage of inhibition of A II pressor response in rats for peroral administration.,Autocuration,,,F,,BAO_0000218,12621,,,1,CHEMBL620409,,,,H,4,,
5751,Inhibition of A-498 human Renal cell proliferation,Expert,9606.0,,F,,BAO_0000219,3600,,624.0,1,CHEMBL620410,A498,,Homo sapiens,N,1,,
5752,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 0.1 uM",Autocuration,10116.0,,F,,BAO_0000019,1796,,,1,CHEMBL620411,,,Rattus norvegicus,U,0,,
5753,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 1 uM",Autocuration,10116.0,,F,,BAO_0000019,1796,,,1,CHEMBL620412,,,Rattus norvegicus,U,0,,
5754,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 10 uM",Autocuration,10116.0,,F,,BAO_0000019,1796,,,1,CHEMBL876596,,,Rattus norvegicus,U,0,,
5755,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay,Expert,9606.0,,F,,BAO_0000219,16464,,622.0,1,CHEMBL620413,A 172,,Homo sapiens,N,1,,
5756,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay; NE is no effect at 1x 10 E-5,Intermediate,9606.0,,F,,BAO_0000219,16464,,622.0,1,CHEMBL620414,A 172,,Homo sapiens,N,1,,
5757,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay; NE is no effect at 1x 10 E-5,Intermediate,9606.0,,F,,BAO_0000219,16464,,622.0,1,CHEMBL620415,A 172,,Homo sapiens,N,1,,
5758,Concentration required to inhibit growth of human tumor A549 (NSCL) cell line.,Expert,9606.0,,F,,BAO_0000219,13617,,646.0,1,CHEMBL620416,A549,,Homo sapiens,N,1,,
5759,Concentration which produces 50% inhibition of growth of human lung carcinoma cell line A549,Intermediate,9606.0,,F,,BAO_0000219,4584,,646.0,1,CHEMBL620417,A549,,Homo sapiens,N,1,,
5760,Cytotoxic activity evaluated against A549 tumor cells,Expert,9606.0,,F,,BAO_0000219,13799,,646.0,1,CHEMBL620418,A549,,Homo sapiens,N,1,,
5761,Cytotoxic potentiation of Topotecan (TP) by the compound in human lung carcinoma A549 cell line,Intermediate,9606.0,,F,,BAO_0000219,16726,,646.0,1,CHEMBL620419,A549,,Homo sapiens,N,1,,
5762,Cytotoxicity against A549 cells when the drug is exposed for a time of 1 hr,Intermediate,9606.0,,F,,BAO_0000219,16109,,646.0,1,CHEMBL620420,A549,,Homo sapiens,N,1,,
5763,Cytotoxicity against A549 cells when the drug is exposed for a time of 96 hrs,Intermediate,9606.0,,F,,BAO_0000219,16109,,646.0,1,CHEMBL620421,A549,,Homo sapiens,N,1,,
5764,Cytotoxicity against A549 tumor cell line determined by WST-1 assay,Intermediate,9606.0,,F,,BAO_0000219,15474,,646.0,1,CHEMBL620422,A549,,Homo sapiens,N,1,,
5765,Cytotoxicity of compound against A549 cell line,Intermediate,9606.0,,F,,BAO_0000219,6851,,646.0,1,CHEMBL620423,A549,,Homo sapiens,N,1,,
5766,Cytotoxicity against human lung cell carcinoma A549 cell line,Expert,9606.0,,F,,BAO_0000219,17534,,646.0,1,CHEMBL620424,A549,,Homo sapiens,N,1,,
5767,Cytotoxicity against human lung carcinoma A549 cell line using MTT assay,Intermediate,9606.0,,F,,BAO_0000219,2621,,646.0,1,CHEMBL620425,A549,,Homo sapiens,N,1,,
5768,Cytotoxicity was evaluated in vitro against A549 (non-small cell lung carcinoma) human tumor cell lines,Intermediate,9606.0,,F,,BAO_0000219,830,,646.0,1,CHEMBL620426,A549,,Homo sapiens,N,1,,
5769,In vitro antitumor activity against A549 human non-small lung carcinoma cells containing 10% fetal bovine serum,Intermediate,9606.0,,F,,BAO_0000219,14255,,646.0,1,CHEMBL620427,A549,,Homo sapiens,N,1,,
5770,In vitro antitumor activity against A549 human non-small lung carcinoma cells containing 10% fetal bovine serum; Not determined,Intermediate,9606.0,,F,,BAO_0000219,14255,,646.0,1,CHEMBL620428,A549,,Homo sapiens,N,1,,
5771,In vitro antitumor activity against A549 human NSCLC lung carcinoma cells,Intermediate,9606.0,,F,,BAO_0000219,1590,,646.0,1,CHEMBL620429,A549,,Homo sapiens,N,1,,
5772,In vitro concentration required to inhibit the TNF-alpha-induced RANTES production in A549 human lung epithelium cell line,Expert,9606.0,,F,,BAO_0000219,6146,,646.0,1,CHEMBL620430,A549,,Homo sapiens,N,1,,
5773,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,Expert,9606.0,,F,,BAO_0000219,17427,,646.0,1,CHEMBL839887,A549,,Homo sapiens,N,1,,
5774,In vitro cytotoxicity against parental and drug resistant lung human tumor cell line A549,Intermediate,9606.0,,F,,BAO_0000219,5280,,646.0,1,CHEMBL620431,A549,,Homo sapiens,N,1,,
5775,In vitro cytotoxicity of compound against human A549 (non small cell lung) cancer cell line after 72 hr of drug exposure,Intermediate,9606.0,,F,,BAO_0000219,16786,,646.0,1,CHEMBL884010,A549,,Homo sapiens,N,1,,
5776,In vitro cytotoxicity against A549 (human lung cancer),Intermediate,9606.0,,F,,BAO_0000219,5895,,646.0,1,CHEMBL620538,A549,,Homo sapiens,N,1,,
5777,In vitro cytotoxicity against A-549 (human lung carcinoma) cell line.,Expert,9606.0,,F,,BAO_0000219,14297,,646.0,1,CHEMBL620539,A549,,Homo sapiens,N,1,,
5778,In vivo antiproliferative activity against A549 cell line,Intermediate,9606.0,,F,,BAO_0000218,17824,,646.0,1,CHEMBL623373,A549,,Homo sapiens,N,1,,
5779,Inhibition of non-small-cell lung adenocarcinoma (A549),Intermediate,9606.0,,F,,BAO_0000219,14368,,646.0,1,CHEMBL623374,A549,,Homo sapiens,N,1,,
5780,Inhibition of non-small-cell lung adenocarcinoma (A549) after 48-h treatment,Intermediate,9606.0,,F,,BAO_0000219,14368,,646.0,1,CHEMBL623375,A549,,Homo sapiens,N,1,,
5781,Inhibition of the growth against human non-small-lung carcinoma (A549) cell line after 72 hr exposure,Intermediate,9606.0,,F,,BAO_0000219,14254,,646.0,1,CHEMBL623376,A549,,Homo sapiens,N,1,,
5782,Inhibitory activity against A549 cell line using MTT assay(Wild type p53),Intermediate,9606.0,,F,,BAO_0000219,15897,,646.0,1,CHEMBL623377,A549,,Homo sapiens,N,1,,
5783,Inhibitory activity against A549 epithelial Cancer cell line at the concentration 0-30 uM for 48 hr,Intermediate,9606.0,,F,,BAO_0000219,13866,,646.0,1,CHEMBL623378,A549,,Homo sapiens,N,1,,
5784,Inhibitory activity of compound against human A549 lung carcinoma cell line.,Intermediate,9606.0,,F,,BAO_0000219,13370,,646.0,1,CHEMBL623379,A549,,Homo sapiens,N,1,,
5785,Inhibitory activity against A549 lung cancer cell line,Intermediate,9606.0,,F,,BAO_0000219,4862,,646.0,1,CHEMBL623380,A549,,Homo sapiens,N,1,,
5786,Inhibitory activity against Taxol-resistant A549 lung cancer cell line,Intermediate,9606.0,,F,,BAO_0000219,4862,,646.0,1,CHEMBL623381,A549,,Homo sapiens,N,1,,
5787,Inhibitory activity against Taxol-resistant A549 lung cancer cell line; not determined,Intermediate,9606.0,,F,,BAO_0000219,4862,,646.0,1,CHEMBL623382,A549,,Homo sapiens,N,1,,
5788,Inhibitory concentration against A549 (lung cancer) cell line,Intermediate,9606.0,,F,,BAO_0000219,15970,,646.0,1,CHEMBL623383,A549,,Homo sapiens,N,1,,
5789,In vitro cytotoxicity against A-549 (human lung carcinoma) cell line.,Expert,9606.0,,F,,BAO_0000219,17713,,646.0,1,CHEMBL623384,A549,,Homo sapiens,N,1,,
5790,Tested in vitro for inhibitory effect on the growth of human A-549 cancer cell line,Intermediate,9606.0,,F,,BAO_0000219,4833,,646.0,1,CHEMBL623385,A549,,Homo sapiens,N,1,,
5791,Activity against A549 cancer cell line.,Expert,9606.0,,F,,BAO_0000219,13736,,646.0,1,CHEMBL623386,A549,,Homo sapiens,N,1,,
5792,The compound was evaluated for cytotoxicity against A549 cell line,Intermediate,9606.0,,F,,BAO_0000219,4312,,646.0,1,CHEMBL884105,A549,,Homo sapiens,N,1,,
5793,The compound was examined for its ability to block tumor necrosis factor alpha (TNF alpha) induced IL-8 production in A549 human lung carcinoma cell line using an ELISA,Intermediate,9606.0,,F,,BAO_0000219,5421,,646.0,1,CHEMBL623387,A549,,Homo sapiens,N,1,,
5794,The compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line,Intermediate,9606.0,,F,,BAO_0000219,5421,,646.0,1,CHEMBL621568,A549,,Homo sapiens,N,1,,
5795,Growth inhibitory activity was measured for human A549 tumor cell line.,Intermediate,9606.0,,F,,BAO_0000219,14717,,646.0,1,CHEMBL621569,A549,,Homo sapiens,N,1,,
5796,Inhibitory activity against A549 lung cancer cell line,Intermediate,9606.0,,F,,BAO_0000219,4634,,646.0,1,CHEMBL621570,A549,,Homo sapiens,N,1,,
5797,Inhibitory activity against A549 cell line; inactive,Intermediate,9606.0,,F,,BAO_0000219,1149,,646.0,1,CHEMBL621571,A549,,Homo sapiens,N,1,,
5798,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line at 20 uM,Expert,9606.0,,F,,BAO_0000219,5421,,646.0,1,CHEMBL621572,A549,,Homo sapiens,N,1,,
5799,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line at 20 uM,Expert,9606.0,,F,,BAO_0000219,5421,,646.0,1,CHEMBL621573,A549,,Homo sapiens,N,1,,
5800,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line at 20 uM concentration,Intermediate,9606.0,,F,,BAO_0000219,5421,,646.0,1,CHEMBL621574,A549,,Homo sapiens,N,1,,
5801,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-4 (M/L),Intermediate,9606.0,,F,,BAO_0000219,3320,,646.0,1,CHEMBL621575,A549,,Homo sapiens,N,1,,
5802,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-5 (M/L),Intermediate,9606.0,,F,,BAO_0000219,3320,,646.0,1,CHEMBL621576,A549,,Homo sapiens,N,1,,
5803,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-6 (M/L),Intermediate,9606.0,,F,,BAO_0000219,3320,,646.0,1,CHEMBL621577,A549,,Homo sapiens,N,1,,
5804,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-7 (M/L),Intermediate,9606.0,,F,,BAO_0000219,3320,,646.0,1,CHEMBL621578,A549,,Homo sapiens,N,1,,
5805,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-8 (M/L),Intermediate,9606.0,,F,,BAO_0000219,3320,,646.0,1,CHEMBL621579,A549,,Homo sapiens,N,1,,
5806,In vitro percent inhibition evaluated against human lung cancer (A549 cell line) at >20 ug/mL,Intermediate,9606.0,,F,,BAO_0000219,5726,,646.0,1,CHEMBL621580,A549,,Homo sapiens,N,1,,
5807,Plasma clearance (in vivo) in mongrel dogs was determined,Intermediate,9615.0,,A,,BAO_0000218,17800,,,1,CHEMBL621581,,,Canis lupus familiaris,N,1,,
5808,Plasma clearance was measured in dog,Intermediate,9615.0,,A,,BAO_0000218,5985,,,1,CHEMBL621582,,,Canis lupus familiaris,N,1,,
5809,Plasma clearance in vivo in dog by intravenous administration at a dose of 0.2 mg/kg,Intermediate,9615.0,,A,,BAO_0000218,5530,,,1,CHEMBL621583,,,Canis lupus familiaris,N,1,,
5810,Plasma clearance in vivo in dog by intravenous administration at a dose of 1 mg/kg,Intermediate,9615.0,,A,,BAO_0000218,5530,,,1,CHEMBL621584,,,Canis lupus familiaris,N,1,,
5811,Tested for plasma clearance in dog,Intermediate,9615.0,,A,,BAO_0000218,4839,,,1,CHEMBL621585,,,Canis lupus familiaris,N,1,1969.0,
5812,The compound was tested for clearance in dog plasma.,Intermediate,9615.0,,A,,BAO_0000218,3639,,,1,CHEMBL621586,,,Canis lupus familiaris,N,1,,
5813,"The pharmacokinetic parameter, clearance was reported in dog after intravenous administration",Intermediate,9615.0,,A,,BAO_0000218,4838,,,1,CHEMBL875835,,,Canis lupus familiaris,N,1,,
5814,Clearance value of compound was determined after intravenous administration of 1 mg/kg/h in dog,Intermediate,9615.0,,A,,BAO_0000218,4137,,,1,CHEMBL621587,,,Canis lupus familiaris,N,1,,
5815,Compound was tested for its ability of plasma clearance when administered in dog perorally (1 mg/kg) and intravenously (0.2 mg/kg),Intermediate,9615.0,,A,,BAO_0000218,5017,,,1,CHEMBL621588,,,Canis lupus familiaris,N,1,1969.0,
5816,In vitro clearance in dog liver microsomes,Intermediate,9615.0,,A,,BAO_0000218,17538,Microsomes,,1,CHEMBL621589,,,Canis lupus familiaris,N,1,2107.0,
5817,Pharmacokinetic profile in terms of clearance was determined at a dose of 0.5 mg/kg administered intravenously in dog,Intermediate,9615.0,,A,,BAO_0000218,6161,,,1,CHEMBL621590,,,Canis lupus familiaris,N,1,,
5818,Pharmacokinetic profile in terms of clearance was determined at a dose of 5 mg/kg administered intravenously in dog,Intermediate,9615.0,,A,,BAO_0000218,6161,,,1,CHEMBL621591,,,Canis lupus familiaris,N,1,,
5819,Plasma clearance in dog,Intermediate,9615.0,,A,,BAO_0000218,1696,,,1,CHEMBL621592,,,Canis lupus familiaris,N,1,,
5820,Clearance rate in dog,Intermediate,9615.0,,A,,BAO_0000218,6762,,,1,CHEMBL621593,,,Canis lupus familiaris,N,1,,
5821,Plasma concentration in dogs after 2 hr at 30mg/kg oral dose,Intermediate,9615.0,,A,,BAO_0000218,5932,,,1,CHEMBL621594,,,Canis lupus familiaris,N,1,1969.0,
5822,Clearance in dogs,Intermediate,9615.0,,A,,BAO_0000218,6305,,,1,CHEMBL621595,,,Canis lupus familiaris,N,1,,
5823,Plasma clearance in dogs,Intermediate,9615.0,,A,,BAO_0000218,4942,,,1,CHEMBL621596,,,Canis lupus familiaris,N,1,,
5824,Plasma clearance was determined,Intermediate,9615.0,,A,,BAO_0000218,4219,,,1,CHEMBL621597,,,Canis lupus familiaris,N,1,,
5825,Lower clearance in dog (i.v.) at 0.5 mpk,Intermediate,9615.0,,A,,BAO_0000218,17853,,,1,CHEMBL621598,,,Canis lupus familiaris,N,1,,
5826,Plasma clearance in Beagle dogs,Intermediate,9615.0,,A,,BAO_0000218,4514,,,1,CHEMBL621599,,,Canis lupus familiaris,N,1,,
5827,Plasma clearance (Clp) in dog,Intermediate,9615.0,,A,,BAO_0000218,6448,,,1,CHEMBL875836,,,Canis lupus familiaris,N,1,,
5828,Plasma clearance (pharmacokinetic parameter) in dog (in vivo) at a dose of 1 mg/kg,Intermediate,9615.0,,A,,BAO_0000218,6227,,,1,CHEMBL621600,,,Canis lupus familiaris,N,1,,
5829,Plasma clearance (pharmacokinetic parameter) in dog was determined,Intermediate,9615.0,,A,,BAO_0000218,6227,,,1,CHEMBL621601,,,Canis lupus familiaris,N,1,,
5830,Plasma clearance for the compound was measured in dog after an iv dose of 1 mg/kg,Intermediate,9615.0,,A,,BAO_0000218,6062,,,1,CHEMBL618474,,,Canis lupus familiaris,N,1,,
5831,Plasma clearance of compound was determined in dog,Intermediate,9615.0,,A,,BAO_0000218,6821,,,1,CHEMBL618475,,,Canis lupus familiaris,N,1,,
5832,Plasma clearance after intravenous administration of 1 mg/kg in dog,Intermediate,9615.0,,A,,BAO_0000218,4709,,,1,CHEMBL624524,,,Canis lupus familiaris,N,1,,
5833,Plasma clearance in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,Intermediate,9615.0,,A,,BAO_0000218,4521,,,1,CHEMBL624525,,,Canis lupus familiaris,N,1,,
5834,Plasma clearance in dog was determined,Intermediate,9615.0,,A,,BAO_0000218,5374,,,1,CHEMBL624526,,,Canis lupus familiaris,N,1,,
5835,Plasma clearance was calculated in dog,Intermediate,9615.0,,A,,BAO_0000218,6057,,,1,CHEMBL624527,,,Canis lupus familiaris,N,1,,
5836,Plasma clearance at the dose of 2 mg/kg in dog,Intermediate,9615.0,,A,,BAO_0000218,4727,,,1,CHEMBL624528,,,Canis lupus familiaris,N,1,,
5837,Plasma clearance in dog,Intermediate,9615.0,,A,,BAO_0000218,5145,,,1,CHEMBL624529,,,Canis lupus familiaris,N,1,,
5838,Plasma clearance in dog,Intermediate,9615.0,,A,,BAO_0000218,17657,,,1,CHEMBL624530,,,Canis lupus familiaris,N,1,,
5839,Plasma clearance in dog; Unable to calculate,Intermediate,9615.0,,A,,BAO_0000218,17657,,,1,CHEMBL624531,,,Canis lupus familiaris,N,1,,
5840,Plasma clearance in rhesus monkey,Intermediate,9615.0,,A,,BAO_0000218,5145,,,1,CHEMBL624532,,,Canis lupus familiaris,N,1,,
5841,Plasma clearance in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),Intermediate,9615.0,,A,,BAO_0000218,6642,,,1,CHEMBL624533,,,Canis lupus familiaris,N,1,,
5842,Plasma clearance in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),Intermediate,9615.0,,A,,BAO_0000218,6641,,,1,CHEMBL624534,,,Canis lupus familiaris,N,1,,
5843,Plasma clearance in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),Intermediate,9615.0,,A,,BAO_0000218,6642,,,1,CHEMBL624535,,,Canis lupus familiaris,N,1,,
5844,Plasma clearance was evaluated in dog,Intermediate,9615.0,,A,,BAO_0000218,5472,,,1,CHEMBL624536,,,Canis lupus familiaris,N,1,,
5845,Plasma clearance was evaluated in dog; Not tested,Intermediate,9615.0,,A,,BAO_0000218,5472,,,1,CHEMBL624537,,,Canis lupus familiaris,N,1,,
5846,Plasma clearance was evaluated in rhesus,Intermediate,9615.0,,A,,BAO_0000218,5472,,,1,CHEMBL624538,,,Canis lupus familiaris,N,1,,
5847,Plasma clearance was evaluated in rhesus; Not tested,Intermediate,9615.0,,A,,BAO_0000218,5472,,,1,CHEMBL624539,,,Canis lupus familiaris,N,1,,
5848,Plasma clearance value was determined in dog after a 3 mg/kg of iv dose,Intermediate,9615.0,,A,,BAO_0000218,4257,,,1,CHEMBL624540,,,Canis lupus familiaris,N,1,,
5849,Plasma clearance was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,Intermediate,9615.0,,A,,BAO_0000218,6679,,,1,CHEMBL624541,,,Canis lupus familiaris,N,1,,
5850,Plasma clearance was determined in Beagle dog at a dose of 1 mg/kg by iv administration,Intermediate,9615.0,,A,,BAO_0000218,5546,,,1,CHEMBL624542,,,Canis lupus familiaris,N,1,,
5851,Plasma clearance was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,Intermediate,9615.0,,A,,BAO_0000218,6348,,,1,CHEMBL624543,,,Canis lupus familiaris,N,1,,
5852,Clearance value at a dose of 0.2 mg/kg i.v.,Intermediate,9615.0,,A,,BAO_0000218,5474,,,1,CHEMBL624544,,,Canis lupus familiaris,N,1,,
5853,Cmax (Maximum (Peak) plasma drug concentration) was after oral administration at 5 mg/kg,Intermediate,9615.0,,A,,BAO_0000218,6316,,,1,CHEMBL624545,,,Canis lupus familiaris,N,1,1969.0,
5854,Cmax after oral dose of compound at 3 mg/kg in dogs,Intermediate,9615.0,,A,,BAO_0000218,17594,,,1,CHEMBL624546,,,Canis lupus familiaris,N,1,,
5855,Cmax after single intravenous bolus of 1 mg/kg in dogs,Intermediate,9615.0,,A,,BAO_0000218,17594,,,1,CHEMBL875957,,,Canis lupus familiaris,N,1,,
5856,Cmax of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,Intermediate,9615.0,,A,,BAO_0000218,5802,,,1,CHEMBL624547,,,Canis lupus familiaris,N,1,,
5857,Cmax in dog after administration of 0.25 mg/kg iv; ND = not determined,Intermediate,9615.0,,A,,BAO_0000218,6535,,,1,CHEMBL624548,,,Canis lupus familiaris,N,1,,
5858,Cmax in dog after administration of 1 mg/kg iv,Intermediate,9615.0,,A,,BAO_0000218,6535,,,1,CHEMBL624549,,,Canis lupus familiaris,N,1,,
5859,Cmax in plasma was determined upon peroral administration of 10.0 mg/Kg dose in dog,Intermediate,9615.0,,A,,BAO_0000218,1466,,,1,CHEMBL624550,,,Canis lupus familiaris,N,1,1969.0,
5860,Cmax on p.o. administration of 10 mg/kg was measured in dog,Intermediate,9615.0,,A,,BAO_0000218,6505,,,1,CHEMBL621613,,,Canis lupus familiaris,N,1,,
5861,Cmax was determine after peroral administration at 10 mpk in dog,Intermediate,9615.0,,A,,BAO_0000218,5668,,,1,CHEMBL621614,,,Canis lupus familiaris,N,1,,
5862,Cmax was determine after peroral administration at 5 mpk in dog,Intermediate,9615.0,,A,,BAO_0000218,5668,,,1,CHEMBL623431,,,Canis lupus familiaris,N,1,,
5863,Cmax was determine after peroral administration at 5 mg/kg in dog,Intermediate,9615.0,,A,,BAO_0000218,5668,,,1,CHEMBL623432,,,Canis lupus familiaris,N,1,,
5864,Cmax after 0.3 mg/kg po administration in dog,Intermediate,9615.0,,A,,BAO_0000218,5600,,,1,CHEMBL623433,,,Canis lupus familiaris,N,1,,
5865,Cmax after peroral administration in dogs at 2.4 uM/kg,Intermediate,9615.0,,A,,BAO_0000218,17764,,,1,CHEMBL623434,,,Canis lupus familiaris,N,1,,
5866,Cmax in dog after oral administration at 1 mg/kg,Intermediate,9615.0,,A,,BAO_0000218,6123,,,1,CHEMBL623435,,,Canis lupus familiaris,N,1,,
5867,Cmax in dog after oral administration at 1 mg/kg; Below the level of quantitation,Intermediate,9615.0,,A,,BAO_0000218,6123,,,1,CHEMBL623436,,,Canis lupus familiaris,N,1,,
5868,Cmax upon oral administration in male Beagle dog at 10 mg/kg,Intermediate,9615.0,,A,,BAO_0000218,6757,,,1,CHEMBL875958,,,Canis lupus familiaris,N,1,,
5869,Cmax value after 15 mg/kg iv dose in Dogs,Intermediate,9615.0,,A,,BAO_0000218,16907,,,1,CHEMBL623437,,,Canis lupus familiaris,N,1,,
5870,Biodistribution in blood was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,Intermediate,10090.0,,A,,BAO_0000218,7767,,,1,CHEMBL623438,,,Mus musculus,N,1,178.0,
5871,Biodistribution in blood was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,Intermediate,10090.0,,A,,BAO_0000218,7767,,,1,CHEMBL623439,,,Mus musculus,N,1,178.0,
5872,Biodistribution in bone was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,Intermediate,10090.0,,A,,BAO_0000218,7767,,,1,CHEMBL623440,,,Mus musculus,N,1,10000001.0,
5873,Biodistribution in bone was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,Intermediate,10090.0,,A,,BAO_0000218,7767,,,1,CHEMBL623441,,,Mus musculus,N,1,10000001.0,
5874,Biodistribution in bone was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,Intermediate,10090.0,,A,,BAO_0000218,7767,,,1,CHEMBL623442,,,Mus musculus,N,1,10000001.0,
5875,Biodistribution in fat and fur was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,Intermediate,10090.0,,A,,BAO_0000218,7767,,,1,CHEMBL623469,,,Mus musculus,N,1,,
5876,Biodistribution in fat and fur was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,Intermediate,10090.0,,A,,BAO_0000218,7767,,,1,CHEMBL623470,,,Mus musculus,N,1,,
5877,Biodistribution in fat and fur was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,Intermediate,10090.0,,A,,BAO_0000218,7767,,,1,CHEMBL623471,,,Mus musculus,N,1,,
5878,Biodistribution in heart was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,Intermediate,10090.0,,A,,BAO_0000218,7767,,,1,CHEMBL623472,,,Mus musculus,N,1,948.0,
5879,Biodistribution in heart was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,Intermediate,10090.0,,A,,BAO_0000218,7767,,,1,CHEMBL623473,,,Mus musculus,N,1,948.0,
5880,Biodistribution in heart was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,Intermediate,10090.0,,A,,BAO_0000218,7767,,,1,CHEMBL623474,,,Mus musculus,N,1,948.0,
5881,Biodistribution in kidney was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,Intermediate,10090.0,,A,,BAO_0000218,7767,,,1,CHEMBL623475,,,Mus musculus,N,1,2113.0,
5882,Biodistribution in kidney was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,Intermediate,10090.0,,A,,BAO_0000218,7767,,,1,CHEMBL623476,,,Mus musculus,N,1,2113.0,
5883,Biodistribution in kidney was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,Intermediate,10090.0,,A,,BAO_0000218,7767,,,1,CHEMBL623477,,,Mus musculus,N,1,2113.0,
5884,Biodistribution in large intestine after iv administration at 1 hr; Value expressed as percent injected dose per gram,Intermediate,10090.0,,A,,BAO_0000218,7767,,,1,CHEMBL621896,,,Mus musculus,N,1,160.0,
5885,Biodistribution in large intestine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,Intermediate,10090.0,,A,,BAO_0000218,7767,,,1,CHEMBL621897,,,Mus musculus,N,1,160.0,
5886,Biodistribution in large intestine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,Intermediate,10090.0,,A,,BAO_0000218,7767,,,1,CHEMBL621898,,,Mus musculus,N,1,160.0,
5887,Biodistribution in liver was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,Intermediate,10090.0,,A,,BAO_0000218,7767,,,1,CHEMBL621899,,,Mus musculus,N,1,2107.0,
5888,Biodistribution in liver was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,Intermediate,10090.0,,A,,BAO_0000218,7767,,,1,CHEMBL621900,,,Mus musculus,N,1,2107.0,
5889,Biodistribution in liver was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,Intermediate,10090.0,,A,,BAO_0000218,7767,,,1,CHEMBL621901,,,Mus musculus,N,1,2107.0,
5890,Biodistribution in lung was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,Intermediate,10090.0,,A,,BAO_0000218,7767,,,1,CHEMBL621902,,,Mus musculus,N,1,2048.0,
5891,Biodistribution in lung was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,Intermediate,10090.0,,A,,BAO_0000218,7767,,,1,CHEMBL621903,,,Mus musculus,N,1,2048.0,
5892,Biodistribution in lung was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,Intermediate,10090.0,,A,,BAO_0000218,7767,,,1,CHEMBL622587,,,Mus musculus,N,1,2048.0,
5893,Biodistribution in muscle was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,Intermediate,10090.0,,A,,BAO_0000218,7767,,,1,CHEMBL620285,,,Mus musculus,N,1,2385.0,
5894,Biodistribution in muscle was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,Intermediate,10090.0,,A,,BAO_0000218,7767,,,1,CHEMBL875285,,,Mus musculus,N,1,2385.0,
5895,Biodistribution in muscle was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,Intermediate,10090.0,,A,,BAO_0000218,7767,,,1,CHEMBL620286,,,Mus musculus,N,1,2385.0,
5896,Biodistribution in pancreatic tissue was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,Intermediate,10090.0,,A,,BAO_0000218,7767,,,1,CHEMBL620287,,,Mus musculus,N,1,,
5897,Biodistribution in pancreatic tissue was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,Intermediate,10090.0,,A,,BAO_0000218,7767,,,1,CHEMBL620288,,,Mus musculus,N,1,,
5898,Biodistribution in pancreatic tissue was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,Intermediate,10090.0,,A,,BAO_0000218,7767,,,1,CHEMBL620289,,,Mus musculus,N,1,,
5899,Biodistribution in small intestine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,Intermediate,10090.0,,A,,BAO_0000218,7767,,,1,CHEMBL620290,,,Mus musculus,N,1,160.0,
5900,Biodistribution in small intestine was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,Intermediate,10090.0,,A,,BAO_0000218,7767,,,1,CHEMBL620291,,,Mus musculus,N,1,160.0,
5901,Biodistribution in small intestine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,Intermediate,10090.0,,A,,BAO_0000218,7767,,,1,CHEMBL620292,,,Mus musculus,N,1,160.0,
5902,Biodistribution in spleen was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,Intermediate,10090.0,,A,,BAO_0000218,7767,,,1,CHEMBL620293,,,Mus musculus,N,1,2106.0,
5903,Biodistribution in spleen was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,Intermediate,10090.0,,A,,BAO_0000218,7767,,,1,CHEMBL620294,,,Mus musculus,N,1,2106.0,
5904,Biodistribution in spleen was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,Intermediate,10090.0,,A,,BAO_0000218,7767,,,1,CHEMBL618614,,,Mus musculus,N,1,2106.0,
5905,Biodistribution in stomach was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,Intermediate,10090.0,,A,,BAO_0000218,7767,,,1,CHEMBL618615,,,Mus musculus,N,1,945.0,
5906,Biodistribution in stomach was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,Intermediate,10090.0,,A,,BAO_0000218,7767,,,1,CHEMBL618616,,,Mus musculus,N,1,945.0,
5907,Cytotoxicity against A-172 human tumor cell lines,Expert,9606.0,,F,,BAO_0000219,2036,,622.0,1,CHEMBL618617,A 172,,Homo sapiens,N,1,,
5908,Compound was evaluated for the in vitro cytotoxicity against A-172 human glioblastoma cell line,Intermediate,9606.0,,F,,BAO_0000219,2357,,622.0,1,CHEMBL618618,A 172,,Homo sapiens,N,1,,
5909,Antiproliferative activity of compound was tested against rhabdomyosarcoma (A-204) human tumor cells,Intermediate,9606.0,,F,,BAO_0000219,1457,,623.0,1,CHEMBL618619,A204,,Homo sapiens,N,1,,
5910,Tested for antiproliferative activity against A-2780 tumoral cell line,Intermediate,9606.0,,F,,BAO_0000219,4379,,478.0,1,CHEMBL618620,A2780,,Homo sapiens,N,1,,
5911,Inhibitory concentration against melanoma A-375 cell line for cytotoxicity was determined,Intermediate,9606.0,,F,,BAO_0000219,1093,,455.0,1,CHEMBL618621,A-375,,Homo sapiens,N,1,,
5912,Tested in vitro against A-375 cell line human melanoma,Intermediate,9606.0,,F,,BAO_0000219,12152,,455.0,1,CHEMBL618622,A-375,,Homo sapiens,N,1,,
5913,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay,Expert,9606.0,,F,,BAO_0000219,16464,,797.0,1,CHEMBL618623,A-427,,Homo sapiens,N,1,,
5914,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,Intermediate,9606.0,,F,,BAO_0000219,16464,,797.0,1,CHEMBL618624,A-427,,Homo sapiens,N,1,,
5915,In vitro cytotoxicity against human non small-cell-lung cell line A-427.,Expert,9606.0,,F,,BAO_0000219,16582,,797.0,1,CHEMBL618625,A-427,,Homo sapiens,N,1,,
5916,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,Intermediate,9606.0,,F,,BAO_0000219,16464,,797.0,1,CHEMBL618626,A-427,,Homo sapiens,N,1,,
5917,Antitumor activity on A-427 lung carcinoma cell lines,Intermediate,9606.0,,F,,BAO_0000219,10413,,797.0,1,CHEMBL618627,A-427,,Homo sapiens,N,1,,
5918,Cytotoxic activity against human A-427 lung tumor cell line,Intermediate,9606.0,,F,,BAO_0000219,6418,,797.0,1,CHEMBL618628,A-427,,Homo sapiens,N,1,,
5919,In vitro antitumor effects against human A-427 cell lines.,Expert,9606.0,,F,,BAO_0000219,17134,,797.0,1,CHEMBL618629,A-427,,Homo sapiens,N,1,,
5920,In vitro inhibition of A-427 (human lung cancer) cell growth.,Expert,9606.0,,F,,BAO_0000219,16132,,797.0,1,CHEMBL618630,A-427,,Homo sapiens,N,1,,
5921,Cytotoxic related antitumor activity against human cancer cell lines A-427; No data available,Intermediate,9606.0,,F,,BAO_0000219,16132,,797.0,1,CHEMBL618631,A-427,,Homo sapiens,N,1,,
5922,Cytotoxic activity of compound against A-427 lung human tumor cell line,Intermediate,9606.0,,F,,BAO_0000219,16780,,797.0,1,CHEMBL618632,A-427,,Homo sapiens,N,1,,
5923,Cytotoxicity measured for the growth inhibition of A-431 Human epidermoid carcinoma cell line,Expert,9606.0,,F,,BAO_0000219,4085,,500.0,1,CHEMBL618633,A-431,,Homo sapiens,N,1,,
5924,Cytotoxic activity was tested against human A-498 (Kidney carcinoma) cell line,Intermediate,9606.0,,F,,BAO_0000219,1276,,624.0,1,CHEMBL619315,A498,,Homo sapiens,N,1,,
5925,Cytotoxicity against A-498 cell line in the purdue cell culture screen was determined,Expert,9606.0,,F,,BAO_0000219,3498,,624.0,1,CHEMBL619316,A498,,Homo sapiens,N,1,,
5926,Cytotoxicity against human kidney carcinoma A-498cell lines,Intermediate,9606.0,,F,,BAO_0000219,1169,,624.0,1,CHEMBL619317,A498,,Homo sapiens,N,1,,
5927,In vitro cytotoxic activity against A-498 (human kidney carcinoma) cell line,Intermediate,9606.0,,F,,BAO_0000219,4450,,624.0,1,CHEMBL619318,A498,,Homo sapiens,N,1,,
5928,In vitro cytotoxicity against Renal A-498 human tumors following a 6 day exposure.,Intermediate,9606.0,,F,,BAO_0000219,3311,,624.0,1,CHEMBL619319,A498,,Homo sapiens,N,1,,
5929,Antitumor cytotoxic activity against A-498 cell line was determined,Intermediate,9606.0,,F,,BAO_0000219,4461,,624.0,1,CHEMBL619739,A498,,Homo sapiens,N,1,,
5930,In vitro cytotoxicity against Renal A-498 human tumors following a 2 day exposure.,Intermediate,9606.0,,F,,BAO_0000219,3311,,624.0,1,CHEMBL619740,A498,,Homo sapiens,N,1,,
5931,In vitro cytotoxicity against Renal A-498 human tumors following a 2 day exposure; ND is no data,Intermediate,9606.0,,F,,BAO_0000219,3311,,624.0,1,CHEMBL883158,A498,,Homo sapiens,N,1,,
5932,Antiproliferative activity of compound was tested against renal cancer (A-498) human tumor cells,Intermediate,9606.0,,F,,BAO_0000219,1457,,624.0,1,CHEMBL884012,A498,,Homo sapiens,N,1,,
5933,In vitro inhibitory activity against A-498 ovarian cancer cell lines,Intermediate,9606.0,,F,,BAO_0000219,3664,,624.0,1,CHEMBL619741,A498,,Homo sapiens,N,1,,
5934,"Cytotoxicity against NCI tumor panel, A-498 renal cancer cell line",Intermediate,9606.0,,F,,BAO_0000219,15895,,624.0,1,CHEMBL619742,A498,,Homo sapiens,N,1,,
5935,Inhibition of growth lung non-small cell carcinoma A-549 cell line,Intermediate,9606.0,,F,,BAO_0000219,11843,,646.0,1,CHEMBL876610,A549,,Homo sapiens,N,1,,
5936,Inhibition of growth of lung non-small cell carcinoma A-549 cell line,Intermediate,9606.0,,F,,BAO_0000219,11843,,646.0,1,CHEMBL619743,A549,,Homo sapiens,N,1,,
5937,In vitro antiproliferative activity against human A-549 NSCL cell line,Intermediate,9606.0,,F,,BAO_0000219,17705,,646.0,1,CHEMBL619744,A549,,Homo sapiens,N,1,,
5938,In vitro antiproliferative activity against human A-549 NSCL cell line; NS = Not significant,Intermediate,9606.0,,F,,BAO_0000219,17705,,646.0,1,CHEMBL619745,A549,,Homo sapiens,N,1,,
5939,Growth inhibition of A-549 human lung adenocarcinoma at 0.01 uM compound concentration in standard MTT assay,Intermediate,9606.0,,F,,BAO_0000219,4369,,646.0,1,CHEMBL619746,A549,,Homo sapiens,N,1,,
5940,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-6 M compound concentration in standard MTT assay,Intermediate,9606.0,,F,,BAO_0000219,4369,,646.0,1,CHEMBL619747,A549,,Homo sapiens,N,1,,
5941,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-6 M compound concentration in standard MTT assay; ND means No data,Intermediate,9606.0,,F,,BAO_0000219,4369,,646.0,1,CHEMBL619748,A549,,Homo sapiens,N,1,,
5942,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-7 M compound concentration in standard MTT assay,Intermediate,9606.0,,F,,BAO_0000219,4369,,646.0,1,CHEMBL619749,A549,,Homo sapiens,N,1,,
5943,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-7 M compound concentration in standard MTT assay; ND means No data,Intermediate,9606.0,,F,,BAO_0000219,4369,,646.0,1,CHEMBL619750,A549,,Homo sapiens,N,1,,
5944,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-8 M compound concentration in standard MTT assay,Intermediate,9606.0,,F,,BAO_0000219,4369,,646.0,1,CHEMBL624014,A549,,Homo sapiens,N,1,,
5945,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-8 M compound concentration in standard MTT assay; ND means No data,Intermediate,9606.0,,F,,BAO_0000219,4369,,646.0,1,CHEMBL624015,A549,,Homo sapiens,N,1,,
5946,In vitro effective concentration required to reduce the number of human lung carcinoma (A-549) after 3-day incubation,Expert,9606.0,,F,,BAO_0000219,4787,,646.0,1,CHEMBL885344,A549,,Homo sapiens,N,1,,
5947,In vitro effective concentration required to reduce the number of human lung carcinoma cells (A-549) after 3-day incubation,Intermediate,9606.0,,F,,BAO_0000219,4787,,646.0,1,CHEMBL623224,A549,,Homo sapiens,N,1,,
5948,Cytotoxic activity against A-549 cell line,Intermediate,9606.0,,F,,BAO_0000219,6513,,646.0,1,CHEMBL623225,A549,,Homo sapiens,N,1,,
5949,Antitumor cytotoxicity was determined against the A-549(human lung carcinoma) cell line; Range: 0.01 to 0.03,Intermediate,9606.0,,F,,BAO_0000219,6690,,646.0,1,CHEMBL622698,A549,,Homo sapiens,N,1,,
5950,Antitumor cytotoxicity was determined against the A-549(human lung carcinoma) cell line; Range: 10.4 to 118.1,Intermediate,9606.0,,F,,BAO_0000219,6690,,646.0,1,CHEMBL622699,A549,,Homo sapiens,N,1,,
5951,"Cytotoxicity in vitro expressed as 50% reduction in cell number after a 3-day incubation, in human lung carcinoma A-549 cell line",Expert,9606.0,,F,,BAO_0000219,12263,,646.0,1,CHEMBL622700,A549,,Homo sapiens,N,1,,
5952,Compound was tested for cytotoxic activity against human lung carcinoma (A-549),Intermediate,9606.0,,F,,BAO_0000219,1054,,646.0,1,CHEMBL622701,A549,,Homo sapiens,N,1,,
5953,Compound was tested for its cytotoxic activity in MTT assay against A-549 cell line (human lung carcinoma),Intermediate,9606.0,,F,,BAO_0000219,1359,,646.0,1,CHEMBL622702,A549,,Homo sapiens,N,1,,
5954,Cytotoxic activity against human lung carcinoma (A-549) cell line,Intermediate,9606.0,,F,,BAO_0000219,3547,,646.0,1,CHEMBL622703,A549,,Homo sapiens,N,1,,
5955,Cytotoxic activity towards A-549 cells,Expert,9606.0,,F,,BAO_0000219,5771,,646.0,1,CHEMBL622704,A549,,Homo sapiens,N,1,,
5956,"In vitro percent inhibition of A549, lung carcinoma.",Intermediate,9606.0,,F,,BAO_0000219,14425,,646.0,1,CHEMBL622705,A549,,Homo sapiens,N,1,,
5957,"In vitro percent inhibition of A549, lung carcinoma",Intermediate,9606.0,,F,,BAO_0000219,14425,,646.0,1,CHEMBL622706,A549,,Homo sapiens,N,1,,
5958,"In vitro percent inhibition of A549, lung carcinoma.",Intermediate,9606.0,,F,,BAO_0000219,14425,,646.0,1,CHEMBL622707,A549,,Homo sapiens,N,1,,
5959,"In vitro percent inhibition of A549, lung carcinoma.; Range 18-23",Intermediate,9606.0,,F,,BAO_0000219,14425,,646.0,1,CHEMBL622708,A549,,Homo sapiens,N,1,,
5960,Percentage inhibition against parental and drug resistant lung human tumor cell line A549 at 10 uM,Intermediate,9606.0,,F,,BAO_0000219,5280,,646.0,1,CHEMBL622709,A549,,Homo sapiens,N,1,,
5961,Growth inhibition of the A549/ATCC non-small cell lung cancer cell line for 2-day in vitro assay.,Intermediate,9606.0,,F,,BAO_0000219,15176,,646.0,1,CHEMBL622710,A549,,Homo sapiens,N,1,,
5962,In vitro antitumor activity against Non-small cell lung cancer A549/ATCC cell lines by 6-day assay,Intermediate,9606.0,,F,,BAO_0000219,15300,,646.0,1,CHEMBL622711,A549,,Homo sapiens,N,1,,
5963,"Antitumor activity against A549 non small cell carcinoma at dose range of 1.56-6.25 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",Intermediate,9606.0,,F,,BAO_0000218,17824,,646.0,1,CHEMBL622712,A549,,Homo sapiens,N,1,,
5964,"Antitumor activity against A549 non small cell carcinoma at dose range of 25-100 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",Intermediate,9606.0,,F,,BAO_0000218,17824,,646.0,1,CHEMBL622713,A549,,Homo sapiens,N,1,,
5965,"Antitumor activity against A549 non small cell carcinoma at dose range of 3.12-12.5 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",Intermediate,9606.0,,F,,BAO_0000218,17824,,646.0,1,CHEMBL622714,A549,,Homo sapiens,N,1,,
5966,"Antitumor activity against A549 non small cell carcinoma at dose range of 6.25-25 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",Intermediate,9606.0,,F,,BAO_0000218,17824,,646.0,1,CHEMBL622715,A549,,Homo sapiens,N,1,,
5967,"Antitumor activity against A549 non small cell carcinoma at dose range of 70-100 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",Intermediate,9606.0,,F,,BAO_0000218,17824,,646.0,1,CHEMBL622716,A549,,Homo sapiens,N,1,,
5968,"Antitumor activity against A549 non small cell carcinoma on day 14, 21, 28; activity expressed as maximum tolerated dose; NT = Not tested",Intermediate,9606.0,,F,,BAO_0000219,17824,,646.0,1,CHEMBL622717,A549,,Homo sapiens,N,1,,
5969,Optimal dose required to inhibit human non small cell lung A549 tumor growth after subcutaneous transplantation on athymic mice at 10 mg/kg (treatment schedule: q7dX3),Intermediate,9606.0,,F,,BAO_0000218,17528,,646.0,1,CHEMBL622718,A549,,Homo sapiens,N,1,,
5970,Cytotoxic potentiation factor of temoxolomide in human A549 tumor cell line at 0.4 uM concentration,Expert,9606.0,,F,,BAO_0000219,6870,,646.0,1,CHEMBL622719,A549,,Homo sapiens,N,1,,
5971,Compound was evaluated for cytotoxic potentiation factor of temoxolomide in human A549 tumor cell line at 0.4 uM concentration; ND - not determined,Intermediate,9606.0,,F,,BAO_0000219,6870,,646.0,1,CHEMBL622720,A549,,Homo sapiens,N,1,,
5972,Compound was evaluated for cytotoxic potentiation factor of topotecan in human A549 tumor cell line at 0.4 uM concentration,Intermediate,9606.0,,F,,BAO_0000219,6870,,646.0,1,CHEMBL622721,A549,,Homo sapiens,N,1,,
5973,Compound was evaluated for cytotoxic potentiation factor of topotecan in human A549 tumor cell line at 0.4 uM concentration; ND - not determined,Intermediate,9606.0,,F,,BAO_0000219,6870,,646.0,1,CHEMBL622722,A549,,Homo sapiens,N,1,,
5974,Cytotoxicity potentiation of Topotecan in human lung carcinoma A549 cells by the compound as potentiation factor at 50% growth inhibition,Intermediate,9606.0,,F,,BAO_0000219,16726,,646.0,1,CHEMBL876030,A549,,Homo sapiens,N,1,,
5975,"Concentration required for 50% inhibition of proliferation of lung cancer cell line, A549 with respect to paclitaxel was tested in vitro after 72 hr of incubation",Intermediate,9606.0,,F,,BAO_0000219,6170,,646.0,1,CHEMBL620206,A549,,Homo sapiens,N,1,,
5976,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-4 mol/L,Expert,9606.0,,F,,BAO_0000219,6583,,646.0,1,CHEMBL620207,A549,,Homo sapiens,N,1,,
5977,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-5 mol/L,Expert,9606.0,,F,,BAO_0000219,6583,,646.0,1,CHEMBL620208,A549,,Homo sapiens,N,1,,
5978,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-6 mol/L,Expert,9606.0,,F,,BAO_0000219,6583,,646.0,1,CHEMBL620209,A549,,Homo sapiens,N,1,,
5979,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-7 mol/L,Expert,9606.0,,F,,BAO_0000219,6583,,646.0,1,CHEMBL620210,A549,,Homo sapiens,N,1,,
5980,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-8 mol/L,Expert,9606.0,,F,,BAO_0000219,6583,,646.0,1,CHEMBL621639,A549,,Homo sapiens,N,1,,
5981,Tested for cytotoxicity against human lung adenocarcinoma A549 cell line,Intermediate,9606.0,,F,,BAO_0000219,17321,,646.0,1,CHEMBL621640,A549,,Homo sapiens,N,1,,
5982,Percentage tumor growth inhibition was calculated in respect to controls one week after the end of the treatment,Expert,9606.0,,F,,BAO_0000219,17528,,646.0,1,CHEMBL621641,A549,,Homo sapiens,N,1,,
5983,Cytotoxic effect on non-small-cell lung cancer cell line A549/ATCC,Expert,9606.0,,F,,BAO_0000219,12888,,646.0,1,CHEMBL621642,A549,,Homo sapiens,N,1,,
5984,Cytotoxicity of compound in synergy in 94% BCNU (10 uM) against A549 cell line,Intermediate,9606.0,,F,,BAO_0000219,4312,,646.0,1,CHEMBL621643,A549,,Homo sapiens,N,1,,
5985,Cytotoxicity of compound in synergy in BCNU (10 uM) against A549 cell line,Intermediate,9606.0,,F,,BAO_0000219,4312,,646.0,1,CHEMBL621644,A549,,Homo sapiens,N,1,,
5986,Cytotoxicity of compound in synergy in BCNU (10 uM) against A549 cell line; No data,Intermediate,9606.0,,F,,BAO_0000219,4312,,646.0,1,CHEMBL621645,A549,,Homo sapiens,N,1,,
5987,In vitro antiproliferative activity against A549 cell line,Intermediate,10090.0,,F,,BAO_0000219,17737,,646.0,1,CHEMBL621646,A549,,Mus musculus,N,1,,
5988,Synergism with indomethacin in A549 cells,Intermediate,,,F,,BAO_0000219,6630,,646.0,1,CHEMBL621647,A549,,,N,1,,
5989,Synergism with tolmetin in A549 cells,Intermediate,,,F,,BAO_0000219,6630,,646.0,1,CHEMBL621648,A549,,,N,1,,
5990,Synergism with sulindac in A549 cells,Intermediate,,,F,,BAO_0000219,6630,,646.0,1,CHEMBL621649,A549,,,N,1,,
5991,Antagonism of indomethacin in A549 cells,Intermediate,,,F,,BAO_0000219,6630,,646.0,1,CHEMBL621650,A549,,,N,1,,
5992,Antagonism of sulindac in A549 cells,Intermediate,,,F,,BAO_0000219,6630,,646.0,1,CHEMBL621651,A549,,,N,1,,
5993,Antagonism of tolmetin in A549 cells,Intermediate,,,F,,BAO_0000219,6630,,646.0,1,CHEMBL621652,A549,,,N,1,,
5994,Synergism with indomethacin in A549 cells,Intermediate,,,F,,BAO_0000219,6630,,646.0,1,CHEMBL621653,A549,,,N,1,,
5995,Synergism with sulindac in A549 cells,Intermediate,,,F,,BAO_0000219,6630,,646.0,1,CHEMBL621654,A549,,,N,1,,
5996,Drug interaction towards A549 cell line was determined in terms of combination index in presence of Tolmetin; Not available,Intermediate,,,F,,BAO_0000219,6630,,646.0,1,CHEMBL621655,A549,,,N,1,,
5997,Cmax value after 30 mg/kg po dose in Dogs,Intermediate,9615.0,,A,,BAO_0000218,16907,,,1,CHEMBL621656,,,Canis lupus familiaris,N,1,,
5998,Cmax value determined in dog at a dose of 0 mg/kg by oral administration along with indavir (10 mg/kg),Intermediate,9615.0,,A,,BAO_0000218,5944,,,1,CHEMBL621657,,,Canis lupus familiaris,N,1,,
5999,Cmax value determined in dog at a dose of 10 mg/kg by oral administration,Intermediate,9615.0,,A,,BAO_0000218,5944,,,1,CHEMBL621658,,,Canis lupus familiaris,N,1,,
6000,Cmax value determined in dog at a dose of 10 mg/kg by oral administration along with indavir (10 mg/kg),Intermediate,9615.0,,A,,BAO_0000218,5944,,,1,CHEMBL621659,,,Canis lupus familiaris,N,1,,
6001,Cmax value determined in dog at a dose of 5 mg/kg by oral administration,Intermediate,9615.0,,A,,BAO_0000218,5944,,,1,CHEMBL621660,,,Canis lupus familiaris,N,1,,
6002,Cmax value after administration of 4 mg/Kg oral dose in dog,Intermediate,9615.0,,A,,BAO_0000218,2959,,,1,CHEMBL621661,,,Canis lupus familiaris,N,1,,
6003,Cmax value in dog,Intermediate,9615.0,,A,,BAO_0000218,6241,,,1,CHEMBL621662,,,Canis lupus familiaris,N,1,,
6004,Cmax value in dogs after oral administration at 1 mg/kg,Intermediate,9615.0,,A,,BAO_0000218,6241,,,1,CHEMBL621663,,,Canis lupus familiaris,N,1,,
6005,Bioavailability as Cmax in dogs at 5 mg/kg oral dose,Intermediate,9615.0,,A,,BAO_0000218,2652,,,1,CHEMBL621664,,,Canis lupus familiaris,N,1,,
6006,Compound was evaluated for maximum observed plasma concentration at dose 27.5 mg/kg DMP323 equiv in dogs,Intermediate,9615.0,,A,,BAO_0000218,1806,,,1,CHEMBL621665,,,Canis lupus familiaris,N,1,1969.0,
6007,Compound was evaluated for maximum observed plasma concentration at dose 7.7 mg/kg DMP323 equiv in dogs,Intermediate,9615.0,,A,,BAO_0000218,1806,,,1,CHEMBL621666,,,Canis lupus familiaris,N,1,1969.0,
6008,Concentration maxima after oral dosing in dogs,Intermediate,9615.0,,A,,BAO_0000218,1021,,,1,CHEMBL621667,,,Canis lupus familiaris,N,1,,
6009,Concentration maxima after oral dosing in dogs; not available,Intermediate,9615.0,,A,,BAO_0000218,1021,,,1,CHEMBL876738,,,Canis lupus familiaris,N,1,,
6010,Concentration maxima after oral dosing in dogs; not available,Intermediate,9615.0,,A,,BAO_0000218,1021,,,1,CHEMBL621668,,,Canis lupus familiaris,N,1,,
6011,In vivo maximal concentration was calculated at 0.4 mg/kg in dog; Not absorbed,Intermediate,9615.0,,A,,BAO_0000218,5444,,,1,CHEMBL621669,,,Canis lupus familiaris,N,1,,
6012,In vivo maximal concentration was calculated at 0.6 mg/kg in dog; Not absorbed,Intermediate,9615.0,,A,,BAO_0000218,5444,,,1,CHEMBL621670,,,Canis lupus familiaris,N,1,,
6013,In vivo maximal concentration was calculated at 1 mg/kg in dog,Intermediate,9615.0,,A,,BAO_0000218,5444,,,1,CHEMBL621671,,,Canis lupus familiaris,N,1,,
6014,In vivo maximal concentration was calculated at 1 mg/kg in dog; Not absorbed,Intermediate,9615.0,,A,,BAO_0000218,5444,,,1,CHEMBL622360,,,Canis lupus familiaris,N,1,,
6015,In vivo maximal concentration was calculated at 1 mg/kg in dog; Poor absorption,Intermediate,9615.0,,A,,BAO_0000218,5444,,,1,CHEMBL622361,,,Canis lupus familiaris,N,1,,
6016,Cmax in dog plasma after oral dose (1 mg/kg),Intermediate,9615.0,,A,,BAO_0000218,5130,,,1,CHEMBL622362,,,Canis lupus familiaris,N,1,1969.0,
6017,Maximal concentration (Cmax) in dog plasma at a dose of 5 mg/kg,Intermediate,9615.0,,A,,BAO_0000218,3249,,,1,CHEMBL622363,,,Canis lupus familiaris,N,1,1969.0,
6018,Maximal plasma concentration at a dose of 1 mg/kg,Intermediate,9615.0,,A,,BAO_0000218,5473,,,1,CHEMBL622364,,,Canis lupus familiaris,N,1,1969.0,
6019,Maximal plasma concentration at a dose of 1 mg/kg (oral),Intermediate,9615.0,,A,,BAO_0000218,5474,,,1,CHEMBL622365,,,Canis lupus familiaris,N,1,1969.0,
6020,Maximal plasma concentration required for pharmacokinetic data in dogs at dose of 1 mg/kg perorally,Intermediate,9615.0,,A,,BAO_0000218,4657,,,1,CHEMBL622533,,,Canis lupus familiaris,N,1,1969.0,
6021,Maximum concentration of compound in dog was evaluated.,Intermediate,9615.0,,A,,BAO_0000218,3031,,,1,CHEMBL622534,,,Canis lupus familiaris,N,1,,
6022,Maximum concentration by oral administration at a dose of 10 uM/kg in dog was determined,Intermediate,9615.0,,A,,BAO_0000218,4527,,,1,CHEMBL622535,,,Canis lupus familiaris,N,1,,
6023,Maximum concentration in dog after administration of 20 mg/kg dose through peroral route,Intermediate,9615.0,,A,,BAO_0000218,4186,,,1,CHEMBL876739,,,Canis lupus familiaris,N,1,,
6024,Maximum concentration in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),Intermediate,9615.0,,A,,BAO_0000218,5007,,,1,CHEMBL622536,,,Canis lupus familiaris,N,1,,
6025,Maximum concentration obtained in dog plasma was determined,Intermediate,9615.0,,A,,BAO_0000218,3132,,,1,CHEMBL622537,,,Canis lupus familiaris,N,1,1969.0,
6026,Maximum concentration was determined,Intermediate,9615.0,,A,,BAO_0000218,5006,,,1,CHEMBL622538,,,Canis lupus familiaris,N,1,,
6027,Maximum concentration at the dose of 2 mg/kg in dog,Intermediate,9615.0,,A,,BAO_0000218,4727,,,1,CHEMBL627867,,,Canis lupus familiaris,N,1,,
6028,Maximum concentration was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,Intermediate,9615.0,,A,,BAO_0000218,1916,,,1,CHEMBL627868,,,Canis lupus familiaris,N,1,,
6029,Maximum concentration was evaluated in dog plasma,Intermediate,9615.0,,A,,BAO_0000218,1918,,,1,CHEMBL627869,,,Canis lupus familiaris,N,1,1969.0,
6030,Maximum concentration was evaluated after 75 min after administration in dog,Intermediate,9615.0,,A,,BAO_0000218,3045,,,1,CHEMBL627870,,,Canis lupus familiaris,N,1,,
6031,Maximum plasma concentration determined in dog after oral administration of 17b,Intermediate,9615.0,,A,,BAO_0000218,9579,,,1,CHEMBL627871,,,Canis lupus familiaris,N,1,1969.0,
6032,Maximum plasma concentration determined in dog after oral administration of 2b,Intermediate,9615.0,,A,,BAO_0000218,9579,,,1,CHEMBL627872,,,Canis lupus familiaris,N,1,1969.0,
6033,Maximum plasma concentration in dog,Intermediate,9615.0,,A,,BAO_0000218,933,,,1,CHEMBL627873,,,Canis lupus familiaris,N,1,1969.0,
6034,Maximum plasma concentration of compound in dog following p.o. administration of 0.5 mg/kg,Intermediate,9615.0,,A,,BAO_0000218,17839,,,1,CHEMBL627874,,,Canis lupus familiaris,N,1,1969.0,
6035,Maximum plasma concentration of compound in dog following p.o. administration of 0.9 mg/kg,Intermediate,9615.0,,A,,BAO_0000218,17839,,,1,CHEMBL627875,,,Canis lupus familiaris,N,1,1969.0,
6036,Maximum plasma concentration of compound in dog following p.o. administration of 0.95 mg/kg,Intermediate,9615.0,,A,,BAO_0000218,17839,,,1,CHEMBL627876,,,Canis lupus familiaris,N,1,1969.0,
6037,Maximum plasma concentration of compound in dog following p.o. administration of 1 mg/kg,Intermediate,9615.0,,A,,BAO_0000218,17839,,,1,CHEMBL627877,,,Canis lupus familiaris,N,1,1969.0,
6038,Maximum plasma concentration of compound was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,Intermediate,9615.0,,A,,BAO_0000218,6348,,,1,CHEMBL627878,,,Canis lupus familiaris,N,1,1969.0,
6039,Maximum plasma concentration after oral administration to dogs at a dose of 10 mg/kg,Intermediate,9615.0,,A,,BAO_0000218,16367,,,1,CHEMBL627879,,,Canis lupus familiaris,N,1,1969.0,
6040,Maximum plasma concentration in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,Intermediate,9615.0,,A,,BAO_0000218,1337,,,1,CHEMBL875355,,,Canis lupus familiaris,N,1,1969.0,
6041,Maximum plasma concentration in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,Intermediate,9615.0,,A,,BAO_0000218,1337,,,1,CHEMBL627880,,,Canis lupus familiaris,N,1,1969.0,
6042,Maximum plasma concentration at a 1 mg/kg oral dose in male and female Beagle dogs.,Intermediate,9615.0,,A,,BAO_0000218,5199,,,1,CHEMBL627881,,,Canis lupus familiaris,N,1,1969.0,
6043,Maximum plasma concentration was measured in dogs after an oral dose of 10 uM/kg,Intermediate,9615.0,,A,,BAO_0000218,17650,,,1,CHEMBL627882,,,Canis lupus familiaris,N,1,1969.0,
6044,Maximum plasma concentration reached by compound was determined after 2 mg/kg (p.o.) administration,Intermediate,9615.0,,A,,BAO_0000218,6679,,,1,CHEMBL627883,,,Canis lupus familiaris,N,1,1969.0,
6045,Maximum plasma concentration was determined as in dogs at 1 mg/kg oral dosing Cmax; 0.05-0.2 ug/mL,Intermediate,9615.0,,A,,BAO_0000218,5356,,,1,CHEMBL628526,,,Canis lupus familiaris,N,1,1969.0,
6046,Maximum plasma concentration was determined in dogs at 1 mg/kg oral dosing; 0.05-0.2 ug/mL,Intermediate,9615.0,,A,,BAO_0000218,5356,,,1,CHEMBL628527,,,Canis lupus familiaris,N,1,1969.0,
6047,Maximum plasma concentration (Cmax) in dog (in vivo) at a dose of 1 mg/kg,Intermediate,9615.0,,A,,BAO_0000218,6227,,,1,CHEMBL628528,,,Canis lupus familiaris,N,1,1969.0,
6048,Maximum plasma concentration (Cmax) in dog at a dose of 0.5 mg/kg,Intermediate,9615.0,,A,,BAO_0000218,6227,,,1,CHEMBL628529,,,Canis lupus familiaris,N,1,1969.0,
6049,Maximum plasma concentration (Cmax) in dog at a dose of 0.7 mg/kg,Intermediate,9615.0,,A,,BAO_0000218,6227,,,1,CHEMBL628530,,,Canis lupus familiaris,N,1,1969.0,
6050,Maximum plasma concentration (Cmax) in dog at a dose of 1 mg/kg,Intermediate,9615.0,,A,,BAO_0000218,6227,,,1,CHEMBL625243,,,Canis lupus familiaris,N,1,1969.0,
6051,Maximum plasma drug concentration of compound determined in dog after iv administration at a dose of 10 mg/kg,Expert,9615.0,,A,,BAO_0000218,3598,,,1,CHEMBL625244,,,Canis lupus familiaris,N,1,1969.0,
6052,Maximum concentration by intravenous administration of 1.2 mg/kg in dog,Intermediate,9615.0,,A,,BAO_0000218,4368,,,1,CHEMBL625245,,,Canis lupus familiaris,N,1,,
6053,Pharmacokinetic (PK) property (Cmax) was determined in dog at the single dose of 1 mg/kg,Intermediate,9615.0,,A,,BAO_0000218,6265,,,1,CHEMBL625246,,,Canis lupus familiaris,N,1,,
6054,Biodistribution in stomach was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,Intermediate,10090.0,,A,,BAO_0000218,7767,,,1,CHEMBL625247,,,Mus musculus,N,1,945.0,
6055,Biodistribution in urine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,Intermediate,10090.0,,A,,BAO_0000218,7767,,,1,CHEMBL625248,,,Mus musculus,N,1,1088.0,
6056,Biodistribution in urine was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram; ND- No data,Intermediate,10090.0,,A,,BAO_0000218,7767,,,1,CHEMBL625249,,,Mus musculus,N,1,1088.0,
6057,Biodistribution in urine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram; ND- No data,Intermediate,10090.0,,A,,BAO_0000218,7767,,,1,CHEMBL625250,,,Mus musculus,N,1,1088.0,
6058,Compound (0.09% dose/g) was tested for accumulation in mice bone (Compound is radiolabeled) after 120 min; No increase,Intermediate,10090.0,,A,,BAO_0000218,17811,,,1,CHEMBL625251,,,Mus musculus,N,1,,
6059,Compound (0.31% dose/g) was tested for accumulation in mice bone (Compound is radiolabeled) after 30 min; Low increase,Intermediate,10090.0,,A,,BAO_0000218,17811,,,1,CHEMBL875356,,,Mus musculus,N,1,,
6060,Compound (i.v.) was tested for maximum activity in mice (Radiolabeled compound),Intermediate,10090.0,,A,,BAO_0000218,17827,,,1,CHEMBL625252,,,Mus musculus,N,1,,
6061,Compound was evaluated for elimination rate constants in vivo in whole blood of normal mice (Radiolabeled compound),Intermediate,10090.0,,A,,BAO_0000218,17827,,,1,CHEMBL625253,,,Mus musculus,N,1,178.0,
6062,Compound was evaluated for rate of bone uptake after administration of radiolabeled in mice (Radiolabeled compound),Intermediate,10090.0,,A,,BAO_0000218,17827,,,1,CHEMBL625254,,,Mus musculus,N,1,,
6063,Compound was evaluated for rate of bone uptake in mice (Radiolabeled compound),Intermediate,10090.0,,A,,BAO_0000218,17827,,,1,CHEMBL625255,,,Mus musculus,N,1,,
6064,Compound was evaluated for rate of bone uptake in mice; NA - not active (Radiolabeled compound),Intermediate,10090.0,,A,,BAO_0000218,17827,,,1,CHEMBL625256,,,Mus musculus,N,1,,
6065,Compound was evaluated for uptake rate constants in vivo in whole blood of normal mice (Radiolabeled compound),Intermediate,10090.0,,A,,BAO_0000218,17827,,,1,CHEMBL625257,,,Mus musculus,N,1,178.0,
6066,Compound was evaluated for uptake rate constants in vivo in whole blood of normal mice; NA = not active (Radiolabeled compound),Intermediate,10090.0,,A,,BAO_0000218,17827,,,1,CHEMBL625258,,,Mus musculus,N,1,178.0,
6067,Compound was evaluated for washout rate in mice (Radiolabeled compound),Intermediate,10090.0,,A,,BAO_0000218,17827,,,1,CHEMBL625259,,,Mus musculus,N,1,,
6068,Compound was evaluated for washout rate in mice after radiolabeled ligand injected,Intermediate,10090.0,,A,,BAO_0000218,17827,,,1,CHEMBL625260,,,Mus musculus,N,1,,
6069,"Maximum activity (i.v.) after in mice, expressed as [(ID%-kg)/g] (Radiolabeled compound)",Intermediate,10090.0,,A,,BAO_0000218,17827,,,1,CHEMBL625261,,,Mus musculus,N,1,,
6070,"Maximum activity in mice, expressed as [(ID%-kg)/g] (Radiolabeled compound)",Intermediate,10090.0,,A,,BAO_0000218,17827,,,1,CHEMBL625262,,,Mus musculus,N,1,,
6071,"Residual activity in mice at 120 minutes, expressed as [(ID%-kg)/g] (Radiolabeled compound)",Intermediate,10090.0,,A,,BAO_0000218,17827,,,1,CHEMBL622639,,,Mus musculus,N,1,,
6072,Tested for plasma level after 90 min of 10 mg/kg dose administered in mice,Intermediate,10090.0,,A,,BAO_0000218,17257,,,1,CHEMBL622640,,,Mus musculus,N,1,,
6073,Tested for plasma level after 90 min of 10 mg/kg dose administered in mice; Not detected.,Intermediate,10090.0,,A,,BAO_0000218,17257,,,1,CHEMBL622812,,,Mus musculus,N,1,,
6074,Tested for plasma level after 90 min of 30 mg/kg dose administered in mice,Intermediate,10090.0,,A,,BAO_0000218,17257,,,1,CHEMBL622813,,,Mus musculus,N,1,,
6075,Tested for plasma level after 90 min of 30 mg/kg dose administered in mice; Not determined,Intermediate,10090.0,,A,,BAO_0000218,17257,,,1,CHEMBL622814,,,Mus musculus,N,1,,
6076,Time at maximum activity in mice (Radiolabeled compound),Intermediate,10090.0,,A,,BAO_0000218,17827,,,1,CHEMBL622815,,,Mus musculus,N,1,,
6077,Percent oral bioavailability was determined after administration of compound at 5 mg/kg perorally in mice,Intermediate,10090.0,,A,,BAO_0000218,3760,,,1,CHEMBL625342,,,Mus musculus,N,1,,
6078,Percent oral bioavailability was determined after administration of compound at 50 mg/kg perorally in mice,Intermediate,10090.0,,A,,BAO_0000218,3760,,,1,CHEMBL625343,,,Mus musculus,N,1,,
6079,Binding towards mouse plasma protein at 10 uM,Intermediate,10090.0,,A,,BAO_0000218,17409,,,1,CHEMBL877591,,,Mus musculus,N,1,,
6080,Binding towards mouse plasma protein at 100 uM,Intermediate,10090.0,,A,,BAO_0000218,17409,,,1,CHEMBL625344,,,Mus musculus,N,1,,
6081,Bioavailability was evaluated in mice after intravenous administration,Intermediate,10090.0,,A,,BAO_0000218,2675,,,1,CHEMBL625345,,,Mus musculus,N,1,,
6082,Bioavailability was evaluated in mice after oral administration,Intermediate,10090.0,,A,,BAO_0000218,2675,,,1,CHEMBL625346,,,Mus musculus,N,1,,
6083,Bioavailability was obtained by the comparison of AUC of subcutaneous dosing and AUC of oral dosing in mouse,Intermediate,10090.0,,A,,BAO_0000218,3132,,,1,CHEMBL625347,,,Mus musculus,N,1,,
6084,Bioavailability was obtained by the comparison of AUC of subcutaneous dosing and AUC of oral dosing in mouse at dose 25 mg/kg,Intermediate,10090.0,,A,,BAO_0000218,3132,,,1,CHEMBL625348,,,Mus musculus,N,1,,
6085,Bioavailability at a dose of 10 mg/kg peroral administration in mice.,Intermediate,10090.0,,A,,BAO_0000218,16597,,,1,CHEMBL625349,,,Mus musculus,N,1,,
6086,Oral bioavailability in mouse,Intermediate,10090.0,,A,,BAO_0000218,2862,,,1,CHEMBL625350,,,Mus musculus,N,1,,
6087,Oral bioavailability after intravenous administration in mice at 24 uM/kg,Intermediate,10090.0,,A,,BAO_0000218,17764,,,1,CHEMBL882952,,,Mus musculus,N,1,,
6088,Biodistribution of [123I]- labeled compound in mice brain was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,Intermediate,10090.0,,A,,BAO_0000218,846,,,1,CHEMBL625351,,,Mus musculus,N,1,955.0,
6089,Biodistribution of [123I]- labeled compound in mice brain was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,Intermediate,10090.0,,A,,BAO_0000218,846,,,1,CHEMBL625352,,,Mus musculus,N,1,955.0,
6090,Biodistribution of [123I]- labeled compound in mice brain was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,Intermediate,10090.0,,A,,BAO_0000218,846,,,1,CHEMBL877592,,,Mus musculus,N,1,955.0,
6091,Biodistribution of [123I]- labeled compound in mice brain was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,Intermediate,10090.0,,A,,BAO_0000218,846,,,1,CHEMBL625353,,,Mus musculus,N,1,955.0,
6092,Biodistribution of [123I]- labeled compound in mice brain was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,Intermediate,10090.0,,A,,BAO_0000218,846,,,1,CHEMBL625354,,,Mus musculus,N,1,955.0,
6093,Biodistribution of [123I]- labeled compound in mice brain was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,Intermediate,10090.0,,A,,BAO_0000218,846,,,1,CHEMBL626019,,,Mus musculus,N,1,955.0,
6094,Biodistribution of [123I]- labeled compound in mice heart was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,Intermediate,10090.0,,A,,BAO_0000218,846,,,1,CHEMBL626020,,,Mus musculus,N,1,948.0,
6095,Biodistribution of [123I]- labeled compound in mice heart was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,Intermediate,10090.0,,A,,BAO_0000218,846,,,1,CHEMBL626021,,,Mus musculus,N,1,948.0,
6096,Biodistribution of [123I]- labeled compound in mice heart was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,Intermediate,10090.0,,A,,BAO_0000218,846,,,1,CHEMBL626022,,,Mus musculus,N,1,948.0,
6097,Biodistribution of [123I]- labeled compound in mice heart was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,Intermediate,10090.0,,A,,BAO_0000218,846,,,1,CHEMBL626192,,,Mus musculus,N,1,948.0,
6098,Cytotoxic activity was tested against human prostate cell line A-549 (lung carcinoma),Intermediate,9606.0,,F,,BAO_0000219,1276,,646.0,1,CHEMBL626193,A549,,Homo sapiens,N,1,,
6099,Cytotoxicity against A-549 cell line in the purdue cell culture screen was determined,Expert,9606.0,,F,,BAO_0000219,3498,,646.0,1,CHEMBL626194,A549,,Homo sapiens,N,1,,
6100,Cytotoxicity against human lung carcinoma A-549 cell lines,Intermediate,9606.0,,F,,BAO_0000219,1169,,646.0,1,CHEMBL626195,A549,,Homo sapiens,N,1,,
6101,In vitro cytotoxic activity against A-549 (human lung carcinoma) cell line,Intermediate,9606.0,,F,,BAO_0000219,4450,,646.0,1,CHEMBL626196,A549,,Homo sapiens,N,1,,
6102,In vitro cytotoxicity against human lung carcinoma cell line A-549,Intermediate,9606.0,,F,,BAO_0000219,358,,646.0,1,CHEMBL626197,A549,,Homo sapiens,N,1,,
6103,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 3.6*10e-5 M,Intermediate,9606.0,,F,,BAO_0000219,358,,646.0,1,CHEMBL626198,A549,,Homo sapiens,N,1,,
6104,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 4.2*10e-5M,Intermediate,9606.0,,F,,BAO_0000219,358,,646.0,1,CHEMBL626199,A549,,Homo sapiens,N,1,,
6105,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 4.3*10e-5M,Intermediate,9606.0,,F,,BAO_0000219,358,,646.0,1,CHEMBL626200,A549,,Homo sapiens,N,1,,
6106,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 5.0*10e-5M,Intermediate,9606.0,,F,,BAO_0000219,358,,646.0,1,CHEMBL626201,A549,,Homo sapiens,N,1,,
6107,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 6.1*10e-5 M,Intermediate,9606.0,,F,,BAO_0000219,358,,646.0,1,CHEMBL626202,A549,,Homo sapiens,N,1,,
6108,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 7.4*10e-5 M,Intermediate,9606.0,,F,,BAO_0000219,358,,646.0,1,CHEMBL626203,A549,,Homo sapiens,N,1,,
6109,In vitro cytotoxicity against A-549 human lung cancer cells,Intermediate,9606.0,,F,,BAO_0000219,15167,,646.0,1,CHEMBL626204,A549,,Homo sapiens,N,1,,
6110,In vitro cytotoxicity against human lung carcinoma (A-549) cell line,Intermediate,9606.0,,F,,BAO_0000219,4139,,646.0,1,CHEMBL624701,A549,,Homo sapiens,N,1,,
6111,In vitro cytotoxicity in human tumor lung carcinoma A-549 cell lines,Intermediate,9606.0,,F,,BAO_0000219,833,,646.0,1,CHEMBL624702,A549,,Homo sapiens,N,1,,
6112,Tested in vitro for cytotoxic activity against lung carcinoma (A-549) cell line,Expert,9606.0,,F,,BAO_0000219,15718,,646.0,1,CHEMBL624703,A549,,Homo sapiens,N,1,,
6113,Tested in vitro for cytotoxicity against A-549 lung cancer cells,Intermediate,9606.0,,F,,BAO_0000219,12373,,646.0,1,CHEMBL624704,A549,,Homo sapiens,N,1,,
6114,The compound was tested for cytotoxicity against A-549 cell in human lung carcinoma,Intermediate,9606.0,,F,,BAO_0000219,637,,646.0,1,CHEMBL624705,A549,,Homo sapiens,N,1,,
6115,Cytotoxicity against human lung carcinoma cells (A-549) using SRB assay.,Expert,9606.0,,F,,BAO_0000219,14867,,646.0,1,CHEMBL624706,A549,,Homo sapiens,N,1,,
6116,Antitumor cytotoxic activity against A-549 cell line was determined,Intermediate,9606.0,,F,,BAO_0000219,4461,,646.0,1,CHEMBL624707,A549,,Homo sapiens,N,1,,
6117,"Tested for the cytotoxicity against the Non-small cell lung cancer cell line A-549, growth inhibition by 50% is reported",Intermediate,9606.0,,F,,BAO_0000219,5406,,646.0,1,CHEMBL624708,A549,,Homo sapiens,N,1,,
6118,Compound was tested for cytotoxicity against A-549 human solid tumor cell line,Intermediate,9606.0,,F,,BAO_0000219,4457,,646.0,1,CHEMBL624709,A549,,Homo sapiens,N,1,,
6119,Antineoplastic activity against A-549 (human lung carcinoma) cell line.,Expert,9606.0,,F,,BAO_0000219,1386,,646.0,1,CHEMBL884107,A549,,Homo sapiens,N,1,,
6120,Antitumoral activity was assayed against A-549 cell line,Intermediate,9606.0,,F,,BAO_0000219,3265,,646.0,1,CHEMBL624710,A549,,Homo sapiens,N,1,,
6121,Compound was evaluated for the cytotoxicity against A-549 tumor cell line after 3 days of incubation,Intermediate,9606.0,,F,,BAO_0000219,2359,,646.0,1,CHEMBL624711,A549,,Homo sapiens,N,1,,
6122,Compound was tested for cytotoxicity against A-549 human solid tumor cell line,Intermediate,9606.0,,F,,BAO_0000219,4457,,646.0,1,CHEMBL624712,A549,,Homo sapiens,N,1,,
6123,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,Expert,9606.0,,F,,BAO_0000219,12454,,646.0,1,CHEMBL624713,A549,,Homo sapiens,N,1,,
6124,Compound was tested for inhibition of cell growth of A-549 cells,Intermediate,9606.0,,F,,BAO_0000219,1481,,646.0,1,CHEMBL624714,A549,,Homo sapiens,N,1,,
6125,Compound was tested for its inhibitory effect on the growth of A-549 tumor cell line from lung.,Intermediate,9606.0,,F,,BAO_0000219,1750,,646.0,1,CHEMBL624715,A549,,Homo sapiens,N,1,,
6126,Concentration required for 50% inhibition of growth in human lung carcinoma cell line was determined,Intermediate,9606.0,,F,,BAO_0000219,5065,,646.0,1,CHEMBL624716,A549,,Homo sapiens,N,1,,
6127,In vitro cytotoxicity against A549-human lung carcinoma cells.,Expert,9606.0,,F,,BAO_0000219,808,,646.0,1,CHEMBL619505,A549,,Homo sapiens,N,1,,
6128,Cytotoxic activity against cultured cells of A-549 human lung carcinoma.,Expert,9606.0,,F,,BAO_0000219,16364,,646.0,1,CHEMBL619506,A549,,Homo sapiens,N,1,,
6129,Cytotoxic activity against A-549 cell lines.,Intermediate,9606.0,,F,,BAO_0000219,1847,,646.0,1,CHEMBL619507,A549,,Homo sapiens,N,1,,
6130,Cytotoxicity was measured against neoplastic cultured A-549 cells of human lung carcinoma.,Expert,9606.0,,F,,BAO_0000219,1747,,646.0,1,CHEMBL619508,A549,,Homo sapiens,N,1,,
6131,Cytotoxicity against human A549 non small cell lung cell lines,Intermediate,9606.0,,F,,BAO_0000219,1003,,646.0,1,CHEMBL619509,A549,,Homo sapiens,N,1,,
6132,Inhibition of cell growth in (A-549) lung cell line,Expert,9606.0,,F,,BAO_0000219,15313,,646.0,1,CHEMBL619510,A549,,Homo sapiens,N,1,,
6133,Growth inhibitory effect of compound was measured on A-549 human lung adenocarcinoma cancer cell line,Intermediate,9606.0,,F,,BAO_0000219,3122,,646.0,1,CHEMBL619511,A549,,Homo sapiens,N,1,,
6134,In vitro antitumor activity against A-549 tumor cells.,Intermediate,9606.0,,F,,BAO_0000219,16049,,646.0,1,CHEMBL619512,A549,,Homo sapiens,N,1,,
6135,In vitro antitumor effects against human A-549 cell lines.,Expert,9606.0,,F,,BAO_0000219,17134,,646.0,1,CHEMBL619513,A549,,Homo sapiens,N,1,,
6136,In vitro cytotoxic activity of compound against A-549 cell line,Intermediate,9606.0,,F,,BAO_0000219,6406,,646.0,1,CHEMBL619514,A549,,Homo sapiens,N,1,,
6137,In vitro cytotoxicity against human lung carcinoma A-549 cell line,Intermediate,9606.0,,F,,BAO_0000219,627,,646.0,1,CHEMBL619515,A549,,Homo sapiens,N,1,,
6138,In vitro cytotoxicity against human non-small cell lung carcinoma A549,Intermediate,9606.0,,F,,BAO_0000219,12307,,646.0,1,CHEMBL619516,A549,,Homo sapiens,N,1,,
6139,In vitro cytotoxicity against human A-549 cancer cell line was evaluated,Intermediate,9606.0,,F,,BAO_0000219,17861,,646.0,1,CHEMBL884005,A549,,Homo sapiens,N,1,,
6140,In vitro cytotoxicity against the A-549 (human lung carcinoma) neoplastic cell line,Expert,9606.0,,F,,BAO_0000219,6682,,646.0,1,CHEMBL619517,A549,,Homo sapiens,N,1,,
6141,Inhibitory concentration of compound against A-549 cell line,Intermediate,9606.0,,F,,BAO_0000219,6663,,646.0,1,CHEMBL619518,A549,,Homo sapiens,N,1,,
6142,Tested for the cytostatic activity as inhibitory concentration against A-549 human pulmonary adenocarcinoma cells,Intermediate,9606.0,,F,,BAO_0000219,2454,,646.0,1,CHEMBL619519,A549,,Homo sapiens,N,1,,
6143,cytotoxic activity against leukemia (A-549) cancer cell line,Intermediate,9606.0,,F,,BAO_0000219,14709,,646.0,1,CHEMBL876489,A549,,Homo sapiens,N,1,,
6144,Tested in vitro for cytotoxic activity against lung carcinoma (A-549) cell line,Expert,9606.0,,F,,BAO_0000219,15718,,646.0,1,CHEMBL619520,A549,,Homo sapiens,N,1,,
6145,Percent inhibition for cytotoxic activity against lung carcinoma (A-549) cell line,Intermediate,9606.0,,F,,BAO_0000219,15718,,646.0,1,CHEMBL619521,A549,,Homo sapiens,N,1,,
6146,Cytotoxic activity of compound against A-549 cell lines at concentration of 0.1(ug/ml),Intermediate,9606.0,,F,,BAO_0000219,17130,,646.0,1,CHEMBL619522,A549,,Homo sapiens,N,1,,
6147,Cytotoxic activity of compound against A-549 cell lines at concentration of 0.4(ug/ml),Intermediate,9606.0,,F,,BAO_0000219,17130,,646.0,1,CHEMBL619523,A549,,Homo sapiens,N,1,,
6148,Cytotoxic activity of compound against A-549 cell lines at concentration of 1.1 (ug/ml),Intermediate,9606.0,,F,,BAO_0000219,17130,,646.0,1,CHEMBL619524,A549,,Homo sapiens,N,1,,
6149,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml),Intermediate,9606.0,,F,,BAO_0000219,17130,,646.0,1,CHEMBL619525,A549,,Homo sapiens,N,1,,
6150,Drug interaction towards A549 cell line was determined in terms of combination index in presence of Tometin; Not available,Intermediate,,,F,,BAO_0000219,6630,,646.0,1,CHEMBL619526,A549,,,N,1,,
6151,Influence of PARP-1 cellular activity in human lung carcinoma A549 cells on %ADP Polymer formation at a concentration of 25 uM of the compound,Intermediate,9606.0,,F,,BAO_0000219,16726,,646.0,1,CHEMBL619527,A549,,Homo sapiens,N,1,,
6152,Cytotoxicity against A549 cells; No cytotoxicity,Intermediate,9606.0,,F,,BAO_0000219,17846,,646.0,1,CHEMBL619528,A549,,Homo sapiens,N,1,,
6153,Cytotoxicity against human lung carcinoma (A549) cell lines,Expert,9606.0,,F,,BAO_0000219,3415,,646.0,1,CHEMBL619529,A549,,Homo sapiens,N,1,,
6154,Cytotoxicity against human lung carcinoma (A549) cell lines; Not active,Expert,9606.0,,F,,BAO_0000219,3415,,646.0,1,CHEMBL619530,A549,,Homo sapiens,N,1,,
6155,In vitro anticancer activity against human lung (A549) cell line,Intermediate,9606.0,,F,,BAO_0000219,5609,,646.0,1,CHEMBL876490,A549,,Homo sapiens,N,1,,
6156,Percent growth inhibition at 200 uM PARP inhibitor in A549 cells,Intermediate,9606.0,,F,,BAO_0000219,17206,,646.0,1,CHEMBL619531,A549,,Homo sapiens,N,1,,
6157,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..006 uM compound concentration in A549 cells,Intermediate,9606.0,,F,,BAO_0000219,17206,,646.0,1,CHEMBL619532,A549,,Homo sapiens,N,1,,
6158,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..03 uM compound concentration in A549 cells,Intermediate,9606.0,,F,,BAO_0000219,17206,,646.0,1,CHEMBL619533,A549,,Homo sapiens,N,1,,
6159,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..15 uM compound concentration in A549 cells,Intermediate,9606.0,,F,,BAO_0000219,17206,,646.0,1,CHEMBL619534,A549,,Homo sapiens,N,1,,
6160,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..4 uM compound concentration in A549 cells,Intermediate,9606.0,,F,,BAO_0000219,17206,,646.0,1,CHEMBL620164,A549,,Homo sapiens,N,1,,
6161,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 11 uM compound concentration in A549 cells,Intermediate,9606.0,,F,,BAO_0000219,17206,,646.0,1,CHEMBL620165,A549,,Homo sapiens,N,1,,
6162,Inhibition of A549 human lung tumor cell proliferation,Expert,9606.0,,F,,BAO_0000219,16295,,646.0,1,CHEMBL620166,A549,,Homo sapiens,N,1,,
6163,"Concentration required to inhibit the lung A549 cell growth by 50%,P53 status of cell line used was wild-type. ",Intermediate,9606.0,,F,,BAO_0000219,16825,,646.0,1,CHEMBL620167,A549,,Homo sapiens,N,1,,
6164,In vitro cytotoxicity against human tumor cell line A549,Expert,9606.0,,F,,BAO_0000219,3439,,646.0,1,CHEMBL620168,A549,,Homo sapiens,N,1,,
6165,In vitro growth inhibitory activity against A549 human nonsmall cell lung carcinoma cells. ,Intermediate,9606.0,,F,,BAO_0000219,10870,,646.0,1,CHEMBL620338,A549,,Homo sapiens,N,1,,
6166,Inhibitory concentration of compound against proliferation of lung carcinoma A549 cell line,Intermediate,9606.0,,F,,BAO_0000219,4845,,646.0,1,CHEMBL620339,A549,,Homo sapiens,N,1,,
6167,Inhibitory concentration (resynthesized pure material) against TNF-alpha induced apoptosis of A549 cells,Intermediate,9606.0,,F,,BAO_0000219,5822,,646.0,1,CHEMBL620340,A549,,Homo sapiens,N,1,,
6168,Inhibitory concentration (solid phase) against TNF-alpha induced apoptosis of A549 cells,Intermediate,9606.0,,F,,BAO_0000219,5822,,646.0,1,CHEMBL620341,A549,,Homo sapiens,N,1,,
6169,Inhibitory concentration (solid phase) against TNF-alpha induced apoptosis of A549 cells: Not tested,Intermediate,9606.0,,F,,BAO_0000219,5822,,646.0,1,CHEMBL876491,A549,,Homo sapiens,N,1,,
6170,% inhibition against A549 cells (lung cancer) at 0.04 ug/mL,Intermediate,9606.0,,F,,BAO_0000219,16381,,646.0,1,CHEMBL620342,A549,,Homo sapiens,N,1,,
6171,% inhibition against A549 cells (lung cancer) at 0.4 ug/mL,Intermediate,9606.0,,F,,BAO_0000219,16381,,646.0,1,CHEMBL620343,A549,,Homo sapiens,N,1,,
6172,% inhibition against A549 cells (lung cancer) at 4 ug/mL,Intermediate,9606.0,,F,,BAO_0000219,16381,,646.0,1,CHEMBL620344,A549,,Homo sapiens,N,1,,
6173,In vitro anticancer activity against human lung (A549) cell line,Intermediate,9606.0,,F,,BAO_0000219,5609,,646.0,1,CHEMBL620345,A549,,Homo sapiens,N,1,,
6174,Inhibition of proliferation of A549 cells at concentration of 0.1 uM was determined,Intermediate,9606.0,,F,,BAO_0000219,4644,,646.0,1,CHEMBL620346,A549,,Homo sapiens,N,1,,
6175,Inhibition of proliferation of A549 cells at concentration of 100 uM was determined,Intermediate,9606.0,,F,,BAO_0000219,4644,,646.0,1,CHEMBL620347,A549,,Homo sapiens,N,1,,
6176,Inhibition of proliferation of A549 cells at concentration of 10 uM was determined,Intermediate,9606.0,,F,,BAO_0000219,4644,,646.0,1,CHEMBL620348,A549,,Homo sapiens,N,1,,
6177,Inhibition of proliferation of A549 cells at concentration of 1 uM was determined,Intermediate,9606.0,,F,,BAO_0000219,4644,,646.0,1,CHEMBL620349,A549,,Homo sapiens,N,1,,
6178,Inhibitory concentration (resynthesized pure material) against TNF-alpha induced apoptosis of A549 cells at 20 uM,Intermediate,9606.0,,F,,BAO_0000219,5822,,646.0,1,CHEMBL618667,A549,,Homo sapiens,N,1,,
6179,Percentage inhibition of human lung carcinoma (A549) cell lines,Expert,9606.0,,F,,BAO_0000219,3415,,646.0,1,CHEMBL618668,A549,,Homo sapiens,N,1,,
6180,Influence of PARP-1 cellular activity on NAD+ levels at a concentration of 25 uM of the compound,Intermediate,9606.0,,F,,BAO_0000219,16726,,646.0,1,CHEMBL876031,A549,,Homo sapiens,N,1,,
6181,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TM); ND denotes not determined",Intermediate,9606.0,,F,,BAO_0000219,17206,,646.0,1,CHEMBL618759,A549,,Homo sapiens,N,1,,
6182,Concentration that gives 50% growth inhibition (temozolomide alone/ (temozolomide + 0.4 uM of compound)) in A549 cells; ND denotes not determined,Intermediate,9606.0,,F,,BAO_0000219,17206,,646.0,1,CHEMBL618760,A549,,Homo sapiens,N,1,,
6183,Concentration that gives 50% growth inhibition (topotecan alone/ (topotecan + 0.4 uM of compound)) in A549 cells; ND denotes not determined,Intermediate,9606.0,,F,,BAO_0000219,17206,,646.0,1,CHEMBL619000,A549,,Homo sapiens,N,1,,
6184,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TM)",Intermediate,9606.0,,F,,BAO_0000219,17206,,646.0,1,CHEMBL619001,A549,,Homo sapiens,N,1,,
6185,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.006 uM",Intermediate,9606.0,,F,,BAO_0000219,17206,,646.0,1,CHEMBL619002,A549,,Homo sapiens,N,1,,
6186,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.03 uM",Intermediate,9606.0,,F,,BAO_0000219,17206,,646.0,1,CHEMBL619003,A549,,Homo sapiens,N,1,,
6187,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.15 uM",Intermediate,9606.0,,F,,BAO_0000219,17206,,646.0,1,CHEMBL619597,A549,,Homo sapiens,N,1,,
6188,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.4 uM",Intermediate,9606.0,,F,,BAO_0000219,17206,,646.0,1,CHEMBL619598,A549,,Homo sapiens,N,1,,
6189,Concentration that gives 50% growth inhibition (temozolomide alone/ (temozolomide + 0.4 uM of compound)) in A549 cells,Intermediate,9606.0,,F,,BAO_0000219,17206,,646.0,1,CHEMBL619599,A549,,Homo sapiens,N,1,,
6190,Concentration that gives 50% growth inhibition (topotecan alone/ (topotecan + 0.4 uM of compound)) in A549 cells,Intermediate,9606.0,,F,,BAO_0000219,17206,,646.0,1,CHEMBL619600,A549,,Homo sapiens,N,1,,
6191,Cytotoxicity potentiation of Topotecan in human lung carcinoma A549 cells by the compound as potentiation factor at 50% growth inhibition,Intermediate,9606.0,,F,,BAO_0000219,16726,,646.0,1,CHEMBL619601,A549,,Homo sapiens,N,1,,
6192,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.006 uM compound concentration in A549 cells,Intermediate,9606.0,,F,,BAO_0000219,17206,,646.0,1,CHEMBL619602,A549,,Homo sapiens,N,1,,
6193,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.03 uM compound concentration in A549 cells,Intermediate,9606.0,,F,,BAO_0000219,17206,,646.0,1,CHEMBL619603,A549,,Homo sapiens,N,1,,
6194,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.15 uM compound concentration in A549 cells,Intermediate,9606.0,,F,,BAO_0000219,17206,,646.0,1,CHEMBL619604,A549,,Homo sapiens,N,1,,
6195,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.4 uM compound concentration in A549 cells,Intermediate,9606.0,,F,,BAO_0000219,17206,,646.0,1,CHEMBL619605,A549,,Homo sapiens,N,1,,
6196,Pharmacokinetic activity (Cmax) (10 mg/kg) was determined in dog,Intermediate,9615.0,,A,,BAO_0000218,6084,,,1,CHEMBL619606,,,Canis lupus familiaris,N,1,,
6197,Pharmacokinetic activity (Cmax) in dog,Intermediate,9615.0,,A,,BAO_0000218,6084,,,1,CHEMBL876032,,,Canis lupus familiaris,N,1,,
6198,Pharmacokinetic parameter Cmax was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),Intermediate,9615.0,,A,,BAO_0000218,4809,,,1,CHEMBL619607,,,Canis lupus familiaris,N,1,,
6199,Pharmacokinetic property (Cmax) was measured in dog at the dose of 0.032 mg/kg,Intermediate,9615.0,,A,,BAO_0000218,5983,,,1,CHEMBL619608,,,Canis lupus familiaris,N,1,,
6200,Plasma clearance rate by iv administration in dog at a dose of 6 mg/kg,Intermediate,9615.0,,A,,BAO_0000218,6251,,,1,CHEMBL619609,,,Canis lupus familiaris,N,1,,
6201,Cmax in dog plasma after 30mg/kg oral dose,Intermediate,9615.0,,A,,BAO_0000218,5932,,,1,CHEMBL619610,,,Canis lupus familiaris,N,1,1969.0,
6202,Tested for the peak blood level in dog,Intermediate,9615.0,,A,,BAO_0000218,4273,,,1,CHEMBL619611,,,Canis lupus familiaris,N,1,178.0,
6203,"Tested for the pharmacokinetic data, maximum concentration (Cmax) in dog",Intermediate,9615.0,,A,,BAO_0000218,5313,,,1,CHEMBL619612,,,Canis lupus familiaris,N,1,,
6204,"Tested for the pharmacokinetic data, maximum concentration (Cmax) in dog at dosage of 10 mpk",Intermediate,9615.0,,A,,BAO_0000218,5313,,,1,CHEMBL619613,,,Canis lupus familiaris,N,1,,
6205,The peak blood concentration after 5 hr administration (2.5 mg/kg) in dog was determined,Intermediate,9615.0,,A,,BAO_0000218,6221,,,1,CHEMBL619614,,,Canis lupus familiaris,N,1,178.0,
6206,Concentration in the plasma after intravenous administration of 1 mg/kg in dog,Intermediate,9615.0,,A,,BAO_0000218,4709,,,1,CHEMBL619615,,,Canis lupus familiaris,N,1,,
6207,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Dog at maximum of 0.3 hours,Intermediate,9615.0,,A,,BAO_0000218,167,,,1,CHEMBL619616,,,Canis lupus familiaris,N,1,,
6208,Final plasma concentration in dogs after oral administration at 1 mg/kg,Intermediate,9615.0,,A,,BAO_0000218,6241,,,1,CHEMBL619617,,,Canis lupus familiaris,N,1,1969.0,
6209,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 300 min,Intermediate,9615.0,,A,,BAO_0000218,344,,,1,CHEMBL619618,,,Canis lupus familiaris,N,1,,
6210,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 30 min,Intermediate,9615.0,,A,,BAO_0000218,344,,,1,CHEMBL876033,,,Canis lupus familiaris,N,1,,
6211,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 60 min,Intermediate,9615.0,,A,,BAO_0000218,344,,,1,CHEMBL619619,,,Canis lupus familiaris,N,1,,
6212,Percent of radioactive dose in urine and faeces excreted in 0-24 hr by dogs,Intermediate,9615.0,,A,,BAO_0000218,2189,,,1,CHEMBL619620,,,Canis lupus familiaris,N,1,,
6213,Percent of radioactive dose in urine and feces excreted by 0-24 hr in dogs,Intermediate,9615.0,,A,,BAO_0000218,2189,,,1,CHEMBL619621,,,Canis lupus familiaris,N,1,1088.0,
6214,Percent of radioactive dose in urine and feces excreted by 0-24 hr in dogs; NA is <10% inhibition at 1 uM for binding data,Intermediate,9615.0,,A,,BAO_0000218,2189,,,1,CHEMBL619622,,,Canis lupus familiaris,N,1,1088.0,
6215,Percent of radioactive dose in urine and feces excreted in 0-24 hr by dogs; NA is <10% inhibition at 1 uM for binding data,Intermediate,9615.0,,A,,BAO_0000218,2189,,,1,CHEMBL618874,,,Canis lupus familiaris,N,1,1088.0,
6216,Absolute bioavailability was evaluated in dog,Intermediate,9615.0,,A,,BAO_0000218,4257,,,1,CHEMBL618875,,,Canis lupus familiaris,N,1,,
6217,Bioavailability after oral administration (2.5 mg/kg) in dog was determined,Intermediate,9615.0,,A,,BAO_0000218,6221,,,1,CHEMBL618876,,,Canis lupus familiaris,N,1,,
6218,Bioavailability after peroral administration (1 mg/kg) was determined in dog,Intermediate,9615.0,,A,,BAO_0000218,6215,,,1,CHEMBL618877,,,Canis lupus familiaris,N,1,,
6219,Bioavailability in dog,Intermediate,9615.0,,A,,BAO_0000218,17267,,,1,CHEMBL618878,,,Canis lupus familiaris,N,1,,
6220,Bioavailability in dog,Intermediate,9615.0,,A,,BAO_0000218,6621,,,1,CHEMBL618879,,,Canis lupus familiaris,N,1,,
6221,Bioavailability after intravenous administration in dogs,Intermediate,9615.0,,A,,BAO_0000218,3854,,,1,CHEMBL618880,,,Canis lupus familiaris,N,1,,
6222,Bioavailability after peroral administration in dogs,Intermediate,9615.0,,A,,BAO_0000218,3854,,,1,CHEMBL618881,,,Canis lupus familiaris,N,1,,
6223,Bioavailability in dog (dose 5 mg/kg p.o. and 2 mg/kg i.v.),Intermediate,9615.0,,A,,BAO_0000218,5007,,,1,CHEMBL618882,,,Canis lupus familiaris,N,1,,
6224,Bioavailability in dog (Beagle) (male) (dose 3 mg/kg i.v. and 10 mg/kg p.o.) measured from 1 to 24 hr,Intermediate,9615.0,,A,,BAO_0000218,4333,,,1,CHEMBL624226,,,Canis lupus familiaris,N,1,,
6225,Bioavailability in plasma of male Beagle dogs treated with 3 mg/kg (i.v.) and 10 mg/kg (p.o.) measured from 1 to 24 hr; ND indicates not determined,Intermediate,9615.0,,A,,BAO_0000218,4333,,,1,CHEMBL624227,,,Canis lupus familiaris,N,1,1969.0,
6226,Bioavailability,Intermediate,9615.0,,A,,BAO_0000218,5006,,,1,CHEMBL624228,,,Canis lupus familiaris,N,1,,
6227,Bioavailability,Intermediate,9615.0,,A,,BAO_0000218,5199,,,1,CHEMBL624229,,,Canis lupus familiaris,N,1,,
6228,Bioavailability by intravenous administration of 1.2 mg/kg in dog,Intermediate,9615.0,,A,,BAO_0000218,4368,,,1,CHEMBL624230,,,Canis lupus familiaris,N,1,,
6229,Bioavailability in dog,Intermediate,9615.0,,A,,BAO_0000218,3771,,,1,CHEMBL624231,,,Canis lupus familiaris,N,1,,
6230,Bioavailability in dog,Intermediate,9615.0,,A,,BAO_0000218,4953,,,1,CHEMBL624232,,,Canis lupus familiaris,N,1,,
6231,Bioavailability in dog,Intermediate,9615.0,,A,,BAO_0000218,5064,,,1,CHEMBL625127,,,Canis lupus familiaris,N,1,,
6232,Bioavailability in dog,Intermediate,9615.0,,A,,BAO_0000218,17657,,,1,CHEMBL625128,,,Canis lupus familiaris,N,1,,
6233,Bioavailability in dog,Intermediate,9615.0,,A,,BAO_0000218,17796,,,1,CHEMBL621675,,,Canis lupus familiaris,N,1,,
6234,Bioavailability in dog (p.o.) at 2.0 mpk,Intermediate,9615.0,,A,,BAO_0000218,17853,,,1,CHEMBL621676,,,Canis lupus familiaris,N,1,,
6235,Bioavailability in dog (dose 2 mg/kg p.o. and 0.5 mg/kg i.v.),Intermediate,9615.0,,A,,BAO_0000218,4521,,,1,CHEMBL621677,,,Canis lupus familiaris,N,1,,
6236,Bioavailability in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,Intermediate,9615.0,,A,,BAO_0000218,4521,,,1,CHEMBL621678,,,Canis lupus familiaris,N,1,,
6237,Bioavailability in dog,Intermediate,9615.0,,A,,BAO_0000218,5006,,,1,CHEMBL621679,,,Canis lupus familiaris,N,1,,
6238,Bioavailability was evaluated after oral administration in dog,Intermediate,9615.0,,A,,BAO_0000218,16365,,,1,CHEMBL621680,,,Canis lupus familiaris,N,1,,
6239,Bioavailability was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,Intermediate,9615.0,,A,,BAO_0000218,1916,,,1,CHEMBL621681,,,Canis lupus familiaris,N,1,,
6240,Bioavailability was evaluated in dog,Intermediate,9615.0,,A,,BAO_0000218,1918,,,1,CHEMBL876740,,,Canis lupus familiaris,N,1,,
6241,Bioavailability in dog,Intermediate,9615.0,,A,,BAO_0000218,4239,,,1,CHEMBL621682,,,Canis lupus familiaris,N,1,,
6242,Bioavailability in dog,Intermediate,9615.0,,A,,BAO_0000218,6505,,,1,CHEMBL621683,,,Canis lupus familiaris,N,1,,
6243,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),Intermediate,9615.0,,A,,BAO_0000218,5334,,,1,CHEMBL621684,,,Canis lupus familiaris,N,1,,
6244,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Beagle dog (male),Intermediate,9615.0,,A,,BAO_0000218,5334,,,1,CHEMBL621685,,,Canis lupus familiaris,N,1,,
6245,Bioavailability was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),Intermediate,9615.0,,A,,BAO_0000218,4809,,,1,CHEMBL621686,,,Canis lupus familiaris,N,1,,
6246,Bioavailability was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,Intermediate,9615.0,,A,,BAO_0000218,6348,,,1,CHEMBL621687,,,Canis lupus familiaris,N,1,,
6247,Bioavailability was evaluated in dog after peroral administration at a dose of 1 mg/kg,Intermediate,9615.0,,A,,BAO_0000218,6005,,,1,CHEMBL621688,,,Canis lupus familiaris,N,1,,
6248,Bioavailability of compound in dog was determined after peroral administration,Intermediate,9615.0,,A,,BAO_0000218,17804,,,1,CHEMBL621689,,,Canis lupus familiaris,N,1,,
6249,Oral bioavailability in dog,Intermediate,9615.0,,A,,BAO_0000218,3184,,,1,CHEMBL621690,,,Canis lupus familiaris,N,1,,
6250,Compound was evaluated for oral bioavailability at different dose 27.5 mg/kg DMP323 equiv in dogs,Intermediate,9615.0,,A,,BAO_0000218,1806,,,1,CHEMBL621691,,,Canis lupus familiaris,N,1,,
6251,Compound was evaluated for oral bioavailability at different dose 7.7 mg/kg DMP323 equiv in dogs,Intermediate,9615.0,,A,,BAO_0000218,1806,,,1,CHEMBL875941,,,Canis lupus familiaris,N,1,,
6252,Compound was evaluated for oral bioavailability in dogs; 37-38 %,Intermediate,9615.0,,A,,BAO_0000218,1806,,,1,CHEMBL621692,,,Canis lupus familiaris,N,1,,
6253,Bioavailability in dog,Intermediate,9615.0,,A,,BAO_0000218,4839,,,1,CHEMBL621693,,,Canis lupus familiaris,N,1,,
6254,Oral bioavailability in dog (1 mg/kg p.o. and 0.2 mg/kg i.v.),Intermediate,9615.0,,A,,BAO_0000218,5017,,,1,CHEMBL621694,,,Canis lupus familiaris,N,1,,
6255,Biodistribution of [123I]- labeled compound in mice heart was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,Intermediate,10090.0,,A,,BAO_0000218,846,,,1,CHEMBL621695,,,Mus musculus,N,1,948.0,
6256,Biodistribution of [123I]- labeled compound in mice heart was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,Intermediate,10090.0,,A,,BAO_0000218,846,,,1,CHEMBL621696,,,Mus musculus,N,1,948.0,
6257,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,Intermediate,10090.0,,A,,BAO_0000218,846,,,1,CHEMBL621697,,,Mus musculus,N,1,2113.0,
6258,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,Intermediate,10090.0,,A,,BAO_0000218,846,,,1,CHEMBL621698,,,Mus musculus,N,1,2113.0,
6259,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,Intermediate,10090.0,,A,,BAO_0000218,846,,,1,CHEMBL623420,,,Mus musculus,N,1,2113.0,
6260,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,Intermediate,10090.0,,A,,BAO_0000218,846,,,1,CHEMBL623421,,,Mus musculus,N,1,2113.0,
6261,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,Intermediate,10090.0,,A,,BAO_0000218,846,,,1,CHEMBL623422,,,Mus musculus,N,1,2113.0,
6262,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,Intermediate,10090.0,,A,,BAO_0000218,846,,,1,CHEMBL623423,,,Mus musculus,N,1,2113.0,
6263,Biodistribution of [123I]- labeled compound in mice liver was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,Intermediate,10090.0,,A,,BAO_0000218,846,,,1,CHEMBL623424,,,Mus musculus,N,1,2107.0,
6264,Biodistribution of [123I]- labeled compound in mice liver was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,Intermediate,10090.0,,A,,BAO_0000218,846,,,1,CHEMBL623425,,,Mus musculus,N,1,2107.0,
6265,Biodistribution of [123I]- labeled compound in mice liver was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,Intermediate,10090.0,,A,,BAO_0000218,846,,,1,CHEMBL623426,,,Mus musculus,N,1,2107.0,
6266,Biodistribution of [123I]- labeled compound in mice liver was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,Intermediate,10090.0,,A,,BAO_0000218,846,,,1,CHEMBL623427,,,Mus musculus,N,1,2107.0,
6267,Biodistribution of [123I]- labeled compound in mice liver was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,Intermediate,10090.0,,A,,BAO_0000218,846,,,1,CHEMBL623428,,,Mus musculus,N,1,2107.0,
6268,Biodistribution of [123I]- labeled compound in mice liver was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,Intermediate,10090.0,,A,,BAO_0000218,846,,,1,CHEMBL875947,,,Mus musculus,N,1,2107.0,
6269,Biodistribution of [123I]- labeled compound in mice lungs was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,Intermediate,10090.0,,A,,BAO_0000218,846,,,1,CHEMBL623429,,,Mus musculus,N,1,2048.0,
6270,Biodistribution of [123I]- labeled compound in mice lungs was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,Intermediate,10090.0,,A,,BAO_0000218,846,,,1,CHEMBL623430,,,Mus musculus,N,1,2048.0,
6271,Biodistribution of [123I]- labeled compound in mice lungs was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,Intermediate,10090.0,,A,,BAO_0000218,846,,,1,CHEMBL622588,,,Mus musculus,N,1,2048.0,
6272,Biodistribution of [123I]- labeled compound in mice lungs was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,Intermediate,10090.0,,A,,BAO_0000218,846,,,1,CHEMBL622589,,,Mus musculus,N,1,2048.0,
6273,Biodistribution of [123I]- labeled compound in mice lungs was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,Intermediate,10090.0,,A,,BAO_0000218,846,,,1,CHEMBL622751,,,Mus musculus,N,1,2048.0,
6274,Biodistribution of [123I]- labeled compound in mice lungs was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,Intermediate,10090.0,,A,,BAO_0000218,846,,,1,CHEMBL622752,,,Mus musculus,N,1,2048.0,
6275,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 1 hour,Intermediate,10090.0,,A,,BAO_0000218,6599,,42.0,1,CHEMBL622753,CCRF S-180,,Mus musculus,N,1,,
6276,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 2 hours,Intermediate,10090.0,,A,,BAO_0000218,6599,,42.0,1,CHEMBL622647,CCRF S-180,,Mus musculus,N,1,,
6277,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 30 minutes,Intermediate,10090.0,,A,,BAO_0000218,6599,,42.0,1,CHEMBL875163,CCRF S-180,,Mus musculus,N,1,,
6278,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 4 hours,Intermediate,10090.0,,A,,BAO_0000218,6599,,42.0,1,CHEMBL622648,CCRF S-180,,Mus musculus,N,1,,
6279,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 8 hours,Intermediate,10090.0,,A,,BAO_0000218,6599,,42.0,1,CHEMBL622649,CCRF S-180,,Mus musculus,N,1,,
6280,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice brain bearing S180 tumor cell line for 1 hour,Intermediate,10090.0,,A,,BAO_0000218,6599,,42.0,1,CHEMBL622650,CCRF S-180,,Mus musculus,N,1,955.0,
6281,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 2 hours,Intermediate,10090.0,,A,,BAO_0000218,6599,,42.0,1,CHEMBL622651,CCRF S-180,,Mus musculus,N,1,955.0,
6282,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 30 minutes,Intermediate,10090.0,,A,,BAO_0000218,6599,,42.0,1,CHEMBL622652,CCRF S-180,,Mus musculus,N,1,955.0,
6283,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 4 hours,Intermediate,10090.0,,A,,BAO_0000218,6599,,42.0,1,CHEMBL622653,CCRF S-180,,Mus musculus,N,1,955.0,
6284,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 8 hours,Intermediate,10090.0,,A,,BAO_0000218,6599,,42.0,1,CHEMBL622654,CCRF S-180,,Mus musculus,N,1,955.0,
6285,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice heart bearing S180 tumor cell line for 1 hour,Intermediate,10090.0,,A,,BAO_0000218,6599,,42.0,1,CHEMBL622655,CCRF S-180,,Mus musculus,N,1,948.0,
6286,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 2 hours,Intermediate,10090.0,,A,,BAO_0000218,6599,,42.0,1,CHEMBL622656,CCRF S-180,,Mus musculus,N,1,948.0,
6287,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice heart bearing S180 tumor cell line for 30 minutes,Intermediate,10090.0,,A,,BAO_0000218,6599,,42.0,1,CHEMBL622657,CCRF S-180,,Mus musculus,N,1,948.0,
6288,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 4 hours,Intermediate,10090.0,,A,,BAO_0000218,6599,,42.0,1,CHEMBL622658,CCRF S-180,,Mus musculus,N,1,948.0,
6289,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 8 hours,Intermediate,10090.0,,A,,BAO_0000218,6599,,42.0,1,CHEMBL622659,CCRF S-180,,Mus musculus,N,1,948.0,
6290,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice kidney bearing S180 tumor cell line for 1 hour,Intermediate,10090.0,,A,,BAO_0000218,6599,,42.0,1,CHEMBL624630,CCRF S-180,,Mus musculus,N,1,2113.0,
6291,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice kidney bearing S180 tumor cell line for 2 hours,Intermediate,10090.0,,A,,BAO_0000218,6599,,42.0,1,CHEMBL624631,CCRF S-180,,Mus musculus,N,1,2113.0,
6292,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 30 minutes,Intermediate,10090.0,,A,,BAO_0000218,6599,,42.0,1,CHEMBL624632,CCRF S-180,,Mus musculus,N,1,2113.0,
6293,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml) on,Intermediate,9606.0,,F,,BAO_0000219,17130,,646.0,1,CHEMBL624633,A549,,Homo sapiens,N,1,,
6294,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml)on,Intermediate,9606.0,,F,,BAO_0000219,17130,,646.0,1,CHEMBL624634,A549,,Homo sapiens,N,1,,
6295,Cytotoxic activity of compound against A-549 cell lines at concentration of 3.3 (ug/ml),Intermediate,9606.0,,F,,BAO_0000219,17130,,646.0,1,CHEMBL624635,A549,,Homo sapiens,N,1,,
6296,Cytotoxic activity of compound against A-549 cell lines at concentration of 3.3 (ug/ml)),Intermediate,9606.0,,F,,BAO_0000219,17130,,646.0,1,CHEMBL624636,A549,,Homo sapiens,N,1,,
6297,Antineoplastic activity against A-549 (human lung carcinoma) cell line.,Expert,9606.0,,F,,BAO_0000219,3263,,646.0,1,CHEMBL857055,A549,,Homo sapiens,N,1,,
6298,In vitro rate of inhibition of A-549 tumor cell growth at 10E-4 mol/L,Expert,9606.0,,F,,BAO_0000219,6663,,646.0,1,CHEMBL624637,A549,,Homo sapiens,N,1,,
6299,In vitro rate of inhibition of A-549 tumor cell growth at 10E-5 mol/L,Expert,9606.0,,F,,BAO_0000219,6663,,646.0,1,CHEMBL624638,A549,,Homo sapiens,N,1,,
6300,In vitro rate of inhibition of A-549 tumor cell growth at 10E-6 mol/L,Expert,9606.0,,F,,BAO_0000219,6663,,646.0,1,CHEMBL874366,A549,,Homo sapiens,N,1,,
6301,In vitro rate of inhibition of A-549 tumor cell growth at 10E-7 mol/L,Expert,9606.0,,F,,BAO_0000219,6663,,646.0,1,CHEMBL624639,A549,,Homo sapiens,N,1,,
6302,In vitro rate of inhibition of A-549 tumor cell growth at 10E-8 mol/L,Expert,9606.0,,F,,BAO_0000219,6663,,646.0,1,CHEMBL624640,A549,,Homo sapiens,N,1,,
6303,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.0625 uM,Intermediate,9606.0,,F,,BAO_0000219,6663,,646.0,1,CHEMBL624641,A549,,Homo sapiens,N,1,,
6304,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.125 uM,Intermediate,9606.0,,F,,BAO_0000219,6663,,646.0,1,CHEMBL624642,A549,,Homo sapiens,N,1,,
6305,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.25 uM,Intermediate,9606.0,,F,,BAO_0000219,6663,,646.0,1,CHEMBL624643,A549,,Homo sapiens,N,1,,
6306,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.5 uM,Intermediate,9606.0,,F,,BAO_0000219,6663,,646.0,1,CHEMBL624644,A549,,Homo sapiens,N,1,,
6307,Rate of inhibition of A-549 tumor cell growth at a concentration of 1 uM,Intermediate,9606.0,,F,,BAO_0000219,6663,,646.0,1,CHEMBL624645,A549,,Homo sapiens,N,1,,
6308,The compound was evaluated for its cytotoxic potency against A-549 cell line,Intermediate,9606.0,,F,,BAO_0000219,3983,,646.0,1,CHEMBL619445,A549,,Homo sapiens,N,1,,
6309,Cytotoxic concentration required to inhibit 50% cell growth in A-549 lung carcinoma cell lines,Expert,9606.0,,F,,BAO_0000219,11141,,646.0,1,CHEMBL839886,A549,,Homo sapiens,N,1,,
6310,Cytotoxic activity of compound against A-549 tumor cell line.,Intermediate,9606.0,,F,,BAO_0000219,5076,,646.0,1,CHEMBL619446,A549,,Homo sapiens,N,1,,
6311,In vitro cytotoxicity against Lung A-549 human tumors following a 6 day exposure.,Intermediate,9606.0,,F,,BAO_0000219,3311,,646.0,1,CHEMBL619447,A549,,Homo sapiens,N,1,,
6312,In vitro cytotoxicity against Lung A-549 human tumors following a 2 day exposure.,Intermediate,9606.0,,F,,BAO_0000219,3311,,646.0,1,CHEMBL619448,A549,,Homo sapiens,N,1,,
6313,In vitro cytotoxicity against Lung A-549 human tumors following a 2 day exposure; ND is no data,Intermediate,9606.0,,F,,BAO_0000219,3311,,646.0,1,CHEMBL619449,A549,,Homo sapiens,N,1,,
6314,Cytotoxic activity of compound against A-549 tumor cell line at conc. of 20 ug/mL,Intermediate,9606.0,,F,,BAO_0000219,5076,,646.0,1,CHEMBL619450,A549,,Homo sapiens,N,1,,
6315,Compound was tested for cytotoxic activity against A-549 human lung carcinoma (ATCC:CCL-185),Intermediate,9606.0,,F,,BAO_0000219,4150,,646.0,1,CHEMBL619451,A549,,Homo sapiens,N,1,,
6316,In vitro inhibitory concentration against cell culture of A-549 human lung carcinoma,Expert,9606.0,,F,,BAO_0000219,2150,,646.0,1,CHEMBL619452,A549,,Homo sapiens,N,1,,
6317,Concentration for in vitro cytotoxicity against A-549 human lung tumor cells,Intermediate,9606.0,,F,,BAO_0000219,4644,,646.0,1,CHEMBL619453,A549,,Homo sapiens,N,1,,
6318,Dose required for in vitro cytotoxic activity against A-549 lung carcinoma cells at concentration of 10 ug/ml; NA is no cytotoxicity,Intermediate,9606.0,,F,,BAO_0000219,263,,646.0,1,CHEMBL874367,A549,,Homo sapiens,N,1,,
6319,Cytotoxic concentration against A-549 tumor cells.,Intermediate,9606.0,,F,,BAO_0000219,11333,,646.0,1,CHEMBL619454,A549,,Homo sapiens,N,1,,
6320,Cytotoxic concentration against A-549 tumor cells; Inactive at 10 ug/mL.,Intermediate,9606.0,,F,,BAO_0000219,11333,,646.0,1,CHEMBL619455,A549,,Homo sapiens,N,1,,
6321,"Cytotoxicity against NCI tumor panel, A-549/ATCC non small-cell lung cancer cell line",Intermediate,9606.0,,F,,BAO_0000219,15895,,646.0,1,CHEMBL619456,A549,,Homo sapiens,N,1,,
6322,Minimum inhibitory concentration (lowest peptide concentration) required to prevent visible bacterial growth after 18 hr of incubation at 37 C in Mueller-Hinton broth against Acinetobacter baumannii 118A,Expert,470.0,,F,,BAO_0000218,16677,,,1,CHEMBL619457,,,Acinetobacter baumannii,N,1,,
6323,Activity against Acinetobacter calcoaceticus (AC54),Intermediate,471.0,,F,,BAO_0000218,10624,,,1,CHEMBL619458,,,Acinetobacter calcoaceticus,N,1,,
6324,In vitro antifungal activity against Aspergillus flavus CM74,Expert,5059.0,,F,,BAO_0000218,16717,,,1,CHEMBL619459,,,Aspergillus flavus,N,1,,
6325,In vitro antifungal activity against Aspergillus flavus CM74,Expert,5059.0,,F,,BAO_0000218,16717,,,1,CHEMBL619460,,,Aspergillus flavus,N,1,,
6326,Inhibitory activity tested against Aspergillus fumigatus at 256 ug/mL concentration,Intermediate,746128.0,,F,,BAO_0000218,5513,,,1,CHEMBL619461,,,Aspergillus fumigatus,N,1,,
6327,In vitro minimum fungicidal concentration required to inhibit Aspergillus fumigatus(MFC),Intermediate,746128.0,,F,,BAO_0000218,15962,,,1,CHEMBL619462,,,Aspergillus fumigatus,N,1,,
6328,Antimicrobial activity against Aspergillus fumigatus (MIC),Intermediate,746128.0,,F,,BAO_0000218,15962,,,1,CHEMBL620388,,,Aspergillus fumigatus,N,1,,
6329,Antimicrobial activity against Aspergillus fumigatus (MIC),Intermediate,746128.0,,F,,BAO_0000218,15962,,,1,CHEMBL620389,,,Aspergillus fumigatus,N,1,,
6330,In vitro antimicrobial activity against Aspergillus fumigatus (MIC),Intermediate,746128.0,,F,,BAO_0000218,15962,,,1,CHEMBL620390,,,Aspergillus fumigatus,N,1,,
6331,In vitro antifungal activity against Aspergillus fumigatus 48238E,Expert,746128.0,,F,,BAO_0000218,16717,,,1,CHEMBL620391,,,Aspergillus fumigatus,N,1,,
6332,In vitro antifungal activity against Aspergillus fumigatus 48238E,Expert,746128.0,,F,,BAO_0000218,16717,,,1,CHEMBL621073,,,Aspergillus fumigatus,N,1,,
6333,Compound is evaluated for plaque-bactericidal index (PBI) against Actinomyces naeslundii 631,Intermediate,1655.0,,F,,BAO_0000218,8117,,,1,CHEMBL621074,,,Actinomyces naeslundii,N,1,,
6334,Compound is evaluated for plaque-bactericidal index (PBI) against Actinomyces viscosus M-100,Intermediate,1656.0,,F,,BAO_0000218,8117,,,1,CHEMBL621075,,,Actinomyces viscosus,N,1,,
6335,Tested in vivo for Acanthocheilonema viteae at 200 mg/kg X 5 days(perorally),Intermediate,6277.0,,F,,BAO_0000218,15472,,,1,CHEMBL619554,,,Acanthocheilonema viteae,N,1,,
6336,Tested in vivo for Acanthocheilonema viteae at 200 mg/kg X 5 days(perorally),Intermediate,6277.0,,F,,BAO_0000218,15472,,,1,CHEMBL619555,,,Acanthocheilonema viteae,N,1,,
6337,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527,Intermediate,714.0,,F,,BAO_0000218,16443,,,1,CHEMBL619556,,,Aggregatibacter actinomycetemcomitans,N,1,,
6338,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527; value ranges from 1-2,Intermediate,714.0,,F,,BAO_0000218,16443,,,1,CHEMBL619557,,,Aggregatibacter actinomycetemcomitans,N,1,,
6339,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527; value ranges from 1-2; ND is Not Determined,Intermediate,714.0,,F,,BAO_0000218,16443,,,1,CHEMBL619558,,,Aggregatibacter actinomycetemcomitans,N,1,,
6340,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 11 uM compound concentration in A549 cells,Intermediate,9606.0,,F,,BAO_0000219,17206,,646.0,1,CHEMBL619559,A549,,Homo sapiens,N,1,,
6341,Percent ADP-ribose polymer formation at 25 uM compound concentration in A549 cells,Intermediate,9606.0,,F,,BAO_0000219,17206,,646.0,1,CHEMBL619560,A549,,Homo sapiens,N,1,,
6342,% inhibition against A549 cells (lung cancer) at 0.04 ug/mL,Intermediate,9606.0,,F,,BAO_0000219,16381,,646.0,1,CHEMBL619561,A549,,Homo sapiens,N,1,,
6343,% inhibition against A549 cells (lung cancer) at 0.4 ug/mL,Intermediate,9606.0,,F,,BAO_0000219,16381,,646.0,1,CHEMBL619562,A549,,Homo sapiens,N,1,,
6344,% inhibition against A549 cells (lung cancer) at 4 ug/mL,Intermediate,9606.0,,F,,BAO_0000219,16381,,646.0,1,CHEMBL619563,A549,,Homo sapiens,N,1,,
6345,GI values against A549 cells (lung cancer),Intermediate,9606.0,,F,,BAO_0000219,16381,,646.0,1,CHEMBL857457,A549,,Homo sapiens,N,1,,
6346,Effect on NAD+ depletion (% remaining versus vehicle control) 25 uM compound concentration in A549 cells,Intermediate,9606.0,,F,,BAO_0000219,17206,,646.0,1,CHEMBL619564,A549,,Homo sapiens,N,1,,
6347,Inhibitory activity against A549 human adenocarcinoma,Intermediate,9606.0,,F,,BAO_0000219,16325,,646.0,1,CHEMBL619565,A549,,Homo sapiens,N,1,,
6348,Evaluated for the antineoplastic activity against A549 lung (nonsmall cell) tumor xenograft in nude mice after administering 3 injections (intra peritoneally) at a dose of 200 mg/kg,Intermediate,9606.0,,F,,BAO_0000218,10708,,646.0,1,CHEMBL619566,A549,,Homo sapiens,N,1,,
6349,Evaluated for the antineoplastic activity against A549 lung (nonsmall cell) tumor xenograft in nude mice after administering 3 injections (intra peritoneally) at a dose of 100 mg/kg,Intermediate,9606.0,,F,,BAO_0000218,10708,,646.0,1,CHEMBL619567,A549,,Homo sapiens,N,1,,
6350,Inhibitory activity against A549 lung adenocarcinoma cell line,Intermediate,9606.0,,F,,BAO_0000219,17376,,646.0,1,CHEMBL619568,A549,,Homo sapiens,N,1,,
6351,Inhibitory activity against A549 lung adenocarcinoma cell line; not determined,Intermediate,9606.0,,F,,BAO_0000219,17376,,646.0,1,CHEMBL619569,A549,,Homo sapiens,N,1,,
6352,Cytotoxicity against human A549 lung cells,Intermediate,9606.0,,F,,BAO_0000219,17488,,646.0,1,CHEMBL619570,A549,,Homo sapiens,N,1,,
6353,In vivo percent inhibitory activity of intraperitoneally administered compound (50 mg/kg/day) against mice infected with A549 tumor,Intermediate,9606.0,,F,,BAO_0000218,17404,,646.0,1,CHEMBL619571,A549,,Homo sapiens,N,1,,
6354,Growth inhibition of A549 (human lung carcinoma) cell line.,Expert,9606.0,,F,,BAO_0000219,10958,,646.0,1,CHEMBL619572,A549,,Homo sapiens,N,1,,
6355,Effective dose required for inhibitory activity against A549 human tumor cell line.,Expert,9606.0,,F,,BAO_0000219,17099,,646.0,1,CHEMBL619573,A549,,Homo sapiens,N,1,,
6356,Effective dose required for inhibitory activity against A549 human tumor cell line; Not active,Intermediate,9606.0,,F,,BAO_0000219,17099,,646.0,1,CHEMBL619574,A549,,Homo sapiens,N,1,,
6357,Cytotoxicity was evaluated against A549 tumor cell lines; Inactive,Intermediate,9606.0,,F,,BAO_0000219,4096,,646.0,1,CHEMBL619575,A549,,Homo sapiens,N,1,,
6358,Cytotoxicity evaluated against A549 tumor cell lines; significant activity,Expert,9606.0,,F,,BAO_0000219,4096,,646.0,1,CHEMBL619576,A549,,Homo sapiens,N,1,,
6359,Cytotoxicity was evaluated against A549 tumor cell lines; Slightly active,Intermediate,9606.0,,F,,BAO_0000219,4096,,646.0,1,CHEMBL619577,A549,,Homo sapiens,N,1,,
6360,In vitro inhibitory activity against A549 tumor cell culture,Intermediate,9606.0,,F,,BAO_0000219,2525,,646.0,1,CHEMBL619578,A549,,Homo sapiens,N,1,,
6361,In vitro inhibitory activity against A549 tumor cell culture; IA= Inactive,Intermediate,9606.0,,F,,BAO_0000219,2525,,646.0,1,CHEMBL884009,A549,,Homo sapiens,N,1,,
6362,Activity against human lung cancer with mutated beta-tubulin (A549-T2415),Intermediate,9606.0,,F,,BAO_0000219,5302,,646.0,1,CHEMBL619579,A549,,Homo sapiens,N,1,,
6363,Growth inhibitory activity was determined against A549/ATCC cancer cell line of non-small cell lung cancer,Intermediate,9606.0,,F,,BAO_0000219,16325,,646.0,1,CHEMBL619580,A549,,Homo sapiens,N,1,,
6364,Inhibition of growth of A549/ATCC nonsmall cell lung cancer cell line,Intermediate,9606.0,,F,,BAO_0000219,16939,,646.0,1,CHEMBL619581,A549,,Homo sapiens,N,1,,
6365,In vitro antitumor activity against NSCL A549/ATCC tumor cell lines,Intermediate,9606.0,,F,,BAO_0000219,17229,,646.0,1,CHEMBL619582,A549,,Homo sapiens,N,1,,
6366,Cytotoxicity evaluation against A549/ATCC non-small-cell lung cancer cells,Intermediate,9606.0,,F,,BAO_0000219,17380,,646.0,1,CHEMBL619583,A549,,Homo sapiens,N,1,,
6367,Cytotoxicity evaluation against A549/ATCC non-small-cell lung cancer cells; No data,Intermediate,9606.0,,F,,BAO_0000219,17380,,646.0,1,CHEMBL876502,A549,,Homo sapiens,N,1,,
6368,In vitro cytotoxicity against human Non-small cell lung cancer A549/ATCC cell line.,Intermediate,9606.0,,F,,BAO_0000219,1903,,646.0,1,CHEMBL619584,A549,,Homo sapiens,N,1,,
6369,In vitro growth inhibition of compound was determined against A549/ATCC cell lines of non-small cell lung cancer,Intermediate,9606.0,,F,,BAO_0000219,3838,,646.0,1,CHEMBL619585,A549,,Homo sapiens,N,1,,
6370,Inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line,Intermediate,9606.0,,F,,BAO_0000219,14696,,646.0,1,CHEMBL619586,A549,,Homo sapiens,N,1,,
6371,In vitro growth inhibition of compound was determined against A549/ATCC cell lines of non-small cell lung cancer,Intermediate,9606.0,,F,,BAO_0000219,3838,,646.0,1,CHEMBL619587,A549,,Homo sapiens,N,1,,
6372,Tested for in vitro cytotoxicity against non-small cell lung cancer cell line A549/ATCC,Intermediate,9606.0,,F,,BAO_0000219,1522,,646.0,1,CHEMBL619588,A549,,Homo sapiens,N,1,,
6373,Tested in vitro for cytotoxicity in A549/ATCC cell lines,Intermediate,9606.0,,F,,BAO_0000219,12400,,646.0,1,CHEMBL619589,A549,,Homo sapiens,N,1,,
6374,inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line,Intermediate,9606.0,,F,,BAO_0000219,14696,,646.0,1,CHEMBL619590,A549,,Homo sapiens,N,1,,
6375,Compound was evaluated for in vitro activity against A549/ATCC lung cancer cell lines (Human tumor cells ),Intermediate,9606.0,,F,,BAO_0000219,14769,,646.0,1,CHEMBL619591,A549,,Homo sapiens,N,1,,
6376,Inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line at 0.01 uM,Intermediate,9606.0,,F,,BAO_0000219,14696,,646.0,1,CHEMBL619592,A549,,Homo sapiens,N,1,,
6377,Compound was evaluated for cytotoxic activity against non-small lung cancer A549/ATCC cell lines.,Intermediate,9606.0,,F,,BAO_0000219,1888,,646.0,1,CHEMBL619593,A549,,Homo sapiens,N,1,,
6378,Tested for cytotoxic activity against non-small cell lung cancer A549/ATCC cell line,Intermediate,9606.0,,F,,BAO_0000219,12016,,646.0,1,CHEMBL620217,A549,,Homo sapiens,N,1,,
6379,Compound tested for growth inhibition of non-small cell lung cancer cell line A549/ATCC,Intermediate,9606.0,,F,,BAO_0000219,6058,,646.0,1,CHEMBL620218,A549,,Homo sapiens,N,1,,
6380,Compound was tested for 50% growth inhibition against human non-small cell lung cancer A549/ATCC cell line,Intermediate,9606.0,,F,,BAO_0000219,17708,,646.0,1,CHEMBL620219,A549,,Homo sapiens,N,1,,
6381,Antitumor activity against A549/ATCC cell line,Intermediate,9606.0,,F,,BAO_0000219,12301,,646.0,1,CHEMBL620220,A549,,Homo sapiens,N,1,,
6382,Tested for cytotoxicity against A549/ATCC cell lines in non-small-cell lung cancer,Intermediate,9606.0,,F,,BAO_0000219,11970,,646.0,1,CHEMBL625141,A549,,Homo sapiens,N,1,,
6383,In vitro cytotoxicity against A549/ATCC cell line.,Expert,9606.0,,F,,BAO_0000219,11818,,646.0,1,CHEMBL625142,A549,,Homo sapiens,N,1,,
6384,Tested in vitro for cytotoxicity in A549/ATCC cell line of Non-Small Cell Lung Cancer,Intermediate,9606.0,,F,,BAO_0000219,12400,,646.0,1,CHEMBL625143,A549,,Homo sapiens,N,1,,
6385,In vitro inhibition of Non-Small Cell Lung Cancer A549/ATCC cell lines,Intermediate,9606.0,,F,,BAO_0000219,3381,,646.0,1,CHEMBL625144,A549,,Homo sapiens,N,1,,
6386,Concentration of compound that cause 50% cytotoxicity of A549/ATCC non small cell lung cancer cell line,Intermediate,9606.0,,F,,BAO_0000219,17376,,646.0,1,CHEMBL622474,A549,,Homo sapiens,N,1,,
6387,Evaluated for the inhibitory concentration required to cause growth inhibition of A549Rem- cell line of lung using the MTT Cytotoxicity Assay,Intermediate,9606.0,,F,,BAO_0000219,10708,,646.0,1,CHEMBL884104,A549,,Homo sapiens,N,1,,
6388,Cytotoxicity was evaluated against A649 human mammary carcinoma cells,Autocuration,9606.0,,F,,BAO_0000219,2964,,,1,CHEMBL622475,,,Homo sapiens,U,0,,
6389,Compound was tested for oral bioavailability in dogs,Intermediate,9615.0,,A,,BAO_0000218,5005,,,1,CHEMBL622476,,,Canis lupus familiaris,U,0,,
6390,Compound was tested for orally bioavailable in dogs with a half life of 0.7 hr,Intermediate,9615.0,,A,,BAO_0000218,6229,,,1,CHEMBL875831,,,Canis lupus familiaris,N,1,,
6391,Compound was tested for orally bioavailable in dogs with a half life of 1.2h,Intermediate,9615.0,,A,,BAO_0000218,6229,,,1,CHEMBL622477,,,Canis lupus familiaris,N,1,,
6392,Oral bioavailability in dog,Intermediate,9615.0,,A,,BAO_0000218,5374,,,1,CHEMBL622478,,,Canis lupus familiaris,N,1,,
6393,Compound was tested for the oral bioavailability in dog; No availability,Intermediate,9615.0,,A,,BAO_0000218,5374,,,1,CHEMBL623172,,,Canis lupus familiaris,N,1,,
6394,Oral bioavailability in dog (dose 5 mg/kg),Intermediate,9615.0,,A,,BAO_0000218,6265,,,1,CHEMBL623173,,,Canis lupus familiaris,N,1,,
6395,Oral bioavailability (F%) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg; ND=not determined,Intermediate,9615.0,,A,,BAO_0000218,5654,,,1,CHEMBL623174,,,Canis lupus familiaris,N,1,,
6396,Oral bioavailability (F%) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg; ND=not determined,Intermediate,9615.0,,A,,BAO_0000218,5654,,,1,CHEMBL623175,,,Canis lupus familiaris,N,1,,
6397,Oral bioavailability in Beagle dogs after Per oral administration at dose of 50(mg/kg),Intermediate,9615.0,,A,,BAO_0000218,16456,,,1,CHEMBL623340,,,Canis lupus familiaris,N,1,,
6398,Oral bioavailability in dog (dose 5 mg/kg),Intermediate,9615.0,,A,,BAO_0000218,5302,,,1,CHEMBL623341,,,Canis lupus familiaris,N,1,,
6399,Oral bioavailability in dog (p.o. dosing of 0.05 M citric acid/0.05 M hydrochloric acid solution),Intermediate,9615.0,,A,,BAO_0000218,3624,,,1,CHEMBL623342,,,Canis lupus familiaris,N,1,,
6400,Oral bioavailability of active FTIs in dogs,Intermediate,9615.0,,A,,BAO_0000218,16452,,,1,CHEMBL623343,,,Canis lupus familiaris,N,1,,
6401,Oral bioavailability in dog (dose 5 mg/kg p.o. and 2 mg/kg i.v.),Intermediate,9615.0,,A,,BAO_0000218,5802,,,1,CHEMBL623344,,,Canis lupus familiaris,N,1,,
6402,Oral bioavailability of compound determined in dog after iv administration at a dose of 10 mg/kg,Expert,9615.0,,A,,BAO_0000218,3598,,,1,CHEMBL623345,,,Canis lupus familiaris,N,1,,
6403,Oral bioavailability in dog,Intermediate,9615.0,,A,,BAO_0000218,17839,,,1,CHEMBL875832,,,Canis lupus familiaris,N,1,,
6404,Oral bioavailability in dog,Intermediate,9615.0,,A,,BAO_0000218,6762,,,1,CHEMBL623346,,,Canis lupus familiaris,N,1,,
6405,Oral bioavailability in dog,Intermediate,9615.0,,A,,BAO_0000218,6821,,,1,CHEMBL623347,,,Canis lupus familiaris,N,1,,
6406,Oral bioavailability of compound was determined in dog; Not tested,Intermediate,9615.0,,A,,BAO_0000218,6821,,,1,CHEMBL623348,,,Canis lupus familiaris,N,1,,
6407,Oral bioavailability in dog,Intermediate,9615.0,,A,,BAO_0000218,5210,,,1,CHEMBL623349,,,Canis lupus familiaris,N,1,,
6408,Oral bioavailability (10 mg/kg) was determined in dog,Intermediate,9615.0,,A,,BAO_0000218,6227,,,1,CHEMBL623350,,,Canis lupus familiaris,N,1,,
6409,Oral bioavailability,Intermediate,9615.0,,A,,BAO_0000218,761,,,1,CHEMBL623351,,,Canis lupus familiaris,N,1,,
6410,Oral bioavailability in dog (dosed as neat powder in hard gelatin capsule),Intermediate,9615.0,,A,,BAO_0000218,761,,,1,CHEMBL623352,,,Canis lupus familiaris,N,1,,
6411,Oral bioavailability administered in solution in rats,Intermediate,9615.0,,A,,BAO_0000218,761,,,1,CHEMBL623353,,,Canis lupus familiaris,N,1,,
6412,Oral bioavailability after 30 mg/kg po dose in Dogs,Intermediate,9615.0,,A,,BAO_0000218,16907,,,1,CHEMBL875833,,,Canis lupus familiaris,N,1,,
6413,Oral bioavailability at a dose of 1 mg/kg in dogs,Intermediate,9615.0,,A,,BAO_0000218,5474,,,1,CHEMBL623354,,,Canis lupus familiaris,N,1,,
6414,Oral bioavailability in dog (dose 1 mg/kg p.o.),Intermediate,9615.0,,A,,BAO_0000218,6535,,,1,CHEMBL623355,,,Canis lupus familiaris,N,1,,
6415,Oral bioavailability in Dog; ND = not determined,Intermediate,9615.0,,A,,BAO_0000218,6535,,,1,CHEMBL623356,,,Canis lupus familiaris,N,1,,
6416,Oral bioavailability in dog,Intermediate,9615.0,,A,,BAO_0000218,3352,,,1,CHEMBL623357,,,Canis lupus familiaris,N,1,,
6417,Oral bioavailability in dog,Intermediate,9615.0,,A,,BAO_0000218,6168,,,1,CHEMBL623358,,,Canis lupus familiaris,N,1,,
6418,Oral bioavailability in dog,Intermediate,9615.0,,A,,BAO_0000218,5988,,,1,CHEMBL623359,,,Canis lupus familiaris,N,1,,
6419,Oral bioavailability in dog,Intermediate,9615.0,,A,,BAO_0000218,4942,,,1,CHEMBL623360,,,Canis lupus familiaris,N,1,,
6420,Oral bioavailability in dogs; No data,Intermediate,9615.0,,A,,BAO_0000218,4942,,,1,CHEMBL623361,,,Canis lupus familiaris,N,1,,
6421,Oral bioavailability measured in dogs,Intermediate,9615.0,,A,,BAO_0000218,14541,,,1,CHEMBL623362,,,Canis lupus familiaris,N,1,,
6422,Oral bioavailability in dog,Intermediate,9615.0,,A,,BAO_0000218,4449,,,1,CHEMBL623363,,,Canis lupus familiaris,N,1,,
6423,Oral bioavailability was calculated in dog,Intermediate,9615.0,,A,,BAO_0000218,6057,,,1,CHEMBL623364,,,Canis lupus familiaris,N,1,,
6424,Oral bioavailability after 0.3 mg/kg po administration in dog,Intermediate,9615.0,,A,,BAO_0000218,5600,,,1,CHEMBL875834,,,Canis lupus familiaris,N,1,,
6425,Oral bioavailability in dog (i.v. dosing),Intermediate,9615.0,,A,,BAO_0000218,5542,,,1,CHEMBL623365,,,Canis lupus familiaris,N,1,,
6426,Oral bioavailability in dog,Intermediate,9615.0,,A,,BAO_0000218,5542,,,1,CHEMBL623366,,,Canis lupus familiaris,N,1,,
6427,Oral bioavailability in Beagle dog at a dose of 2 mg/kg by po administration,Intermediate,9615.0,,A,,BAO_0000218,5546,,,1,CHEMBL623367,,,Canis lupus familiaris,N,1,,
6428,Oral bioavailability in Beagle dogs,Intermediate,9615.0,,A,,BAO_0000218,4514,,,1,CHEMBL623368,,,Canis lupus familiaris,N,1,,
6429,Oral bioavailability in dog,Intermediate,9615.0,,A,,BAO_0000218,3624,,,1,CHEMBL623369,,,Canis lupus familiaris,N,1,,
6430,Oral bioavailability in dog,Intermediate,9615.0,,A,,BAO_0000218,3854,,,1,CHEMBL623370,,,Canis lupus familiaris,N,1,,
6431,Oral bioavailability in dog,Intermediate,9615.0,,A,,BAO_0000218,5836,,,1,CHEMBL623371,,,Canis lupus familiaris,N,1,,
6432,Oral bioavailability in dog,Intermediate,9615.0,,A,,BAO_0000218,5940,,,1,CHEMBL623372,,,Canis lupus familiaris,N,1,,
6433,Oral bioavailability in dog,Intermediate,9615.0,,A,,BAO_0000218,6168,,,1,CHEMBL621351,,,Canis lupus familiaris,N,1,,
6434,Oral bioavailability in dog,Intermediate,9615.0,,A,,BAO_0000218,6227,,,1,CHEMBL621352,,,Canis lupus familiaris,N,1,,
6435,Oral bioavailability in dog,Intermediate,9615.0,,A,,BAO_0000218,6251,,,1,CHEMBL621353,,,Canis lupus familiaris,N,1,,
6436,Oral bioavailability in dog,Intermediate,9615.0,,A,,BAO_0000218,6448,,,1,CHEMBL621354,,,Canis lupus familiaris,N,1,,
6437,Oral bioavailability in dog,Intermediate,9615.0,,A,,BAO_0000218,6647,,,1,CHEMBL621355,,,Canis lupus familiaris,N,1,,
6438,Oral bioavailability in dog,Intermediate,9615.0,,A,,BAO_0000218,5940,,,1,CHEMBL621356,,,Canis lupus familiaris,N,1,,
6439,Oral bioavailability in dog,Intermediate,9615.0,,A,,BAO_0000218,933,,,1,CHEMBL621357,,,Canis lupus familiaris,N,1,,
6440,Oral bioavailability in dog,Intermediate,9615.0,,A,,BAO_0000218,5210,,,1,CHEMBL621358,,,Canis lupus familiaris,N,1,,
6441,Oral bioavailability in dog (dosed as a mixture of five compounds at 0.5 mg/kg each via i.v. only),Intermediate,9615.0,,A,,BAO_0000218,6642,,,1,CHEMBL621359,,,Canis lupus familiaris,N,1,,
6442,Oral bioavailability in dog (dose 0.5 mg/kg i.v. and 2.0 mg/kg p.o.),Intermediate,9615.0,,A,,BAO_0000218,6641,,,1,CHEMBL621360,,,Canis lupus familiaris,N,1,,
6443,Oral bioavailability in dog (dose 0.5 mg/kg i.v. and 2.0 mg/kg p.o.),Intermediate,9615.0,,A,,BAO_0000218,6642,,,1,CHEMBL621361,,,Canis lupus familiaris,N,1,,
6444,Oral bioavailability in dog,Intermediate,9615.0,,A,,BAO_0000218,5472,,,1,CHEMBL621362,,,Canis lupus familiaris,N,1,,
6445,Oral bioavailability in dog,Intermediate,9615.0,,A,,BAO_0000218,5985,,,1,CHEMBL621363,,,Canis lupus familiaris,N,1,,
6446,Oral bioavailability in dog,Intermediate,9615.0,,A,,BAO_0000218,15660,,,1,CHEMBL621364,,,Canis lupus familiaris,N,1,,
6447,Oral bioavailability in dog (dose 0.2 mg/kg i.v.),Intermediate,9615.0,,A,,BAO_0000218,5530,,,1,CHEMBL621166,,,Canis lupus familiaris,N,1,,
6448,Oral bioavailability in dog (dose 1 mg/kg i.v.),Intermediate,9615.0,,A,,BAO_0000218,5530,,,1,CHEMBL621167,,,Canis lupus familiaris,N,1,,
6449,Oral bioavailability (F) in dogs,Intermediate,9615.0,,A,,BAO_0000218,6305,,,1,CHEMBL621168,,,Canis lupus familiaris,N,1,,
6450,Oral bioavailability in dog,Intermediate,9615.0,,A,,BAO_0000218,5210,,,1,CHEMBL621169,,,Canis lupus familiaris,N,1,,
6451,Bioavailability in dog,Intermediate,9615.0,,A,,BAO_0000218,5238,,,1,CHEMBL875950,,,Canis lupus familiaris,N,1,,
6452,Oral bioavailability in dog (dose 10 mg/kg),Intermediate,9615.0,,A,,BAO_0000218,5668,,,1,CHEMBL621170,,,Canis lupus familiaris,N,1,,
6453,Oral bioavailability after peroral administration at 5 mpk in Dog,Intermediate,9615.0,,A,,BAO_0000218,5668,,,1,CHEMBL621171,,,Canis lupus familiaris,N,1,,
6454,Oral bioavailability in dog (dose 5 mg/kg),Intermediate,9615.0,,A,,BAO_0000218,5668,,,1,CHEMBL621172,,,Canis lupus familiaris,N,1,,
6455,Oral bioavailability in dog (dose 10 mg/kg),Intermediate,9615.0,,A,,BAO_0000218,6084,,,1,CHEMBL621173,,,Canis lupus familiaris,N,1,,
6456,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 4 hours,Intermediate,10090.0,,A,,BAO_0000218,6599,,42.0,1,CHEMBL621174,CCRF S-180,,Mus musculus,N,1,2113.0,
6457,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 8 hours,Intermediate,10090.0,,A,,BAO_0000218,6599,,42.0,1,CHEMBL621175,CCRF S-180,,Mus musculus,N,1,2113.0,
6458,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 1 hour,Intermediate,10090.0,,A,,BAO_0000218,6599,,42.0,1,CHEMBL621176,CCRF S-180,,Mus musculus,N,1,2107.0,
6459,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 2 hours,Intermediate,10090.0,,A,,BAO_0000218,6599,,42.0,1,CHEMBL621177,CCRF S-180,,Mus musculus,N,1,2107.0,
6460,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice liver bearing S180 tumor cell line for 30 minutes,Intermediate,10090.0,,A,,BAO_0000218,6599,,42.0,1,CHEMBL621178,CCRF S-180,,Mus musculus,N,1,2107.0,
6461,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice liver bearing S180 tumor cell line for 4 hours,Intermediate,10090.0,,A,,BAO_0000218,6599,,42.0,1,CHEMBL621179,CCRF S-180,,Mus musculus,N,1,2107.0,
6462,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 8 hours,Intermediate,10090.0,,A,,BAO_0000218,6599,,42.0,1,CHEMBL621180,CCRF S-180,,Mus musculus,N,1,2107.0,
6463,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 1 hour,Intermediate,10090.0,,A,,BAO_0000218,6599,,42.0,1,CHEMBL875951,CCRF S-180,,Mus musculus,N,1,2048.0,
6464,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 2 hours,Intermediate,10090.0,,A,,BAO_0000218,6599,,42.0,1,CHEMBL621181,CCRF S-180,,Mus musculus,N,1,2048.0,
6465,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice lung bearing S180 tumor cell line for 30 minutes,Intermediate,10090.0,,A,,BAO_0000218,6599,,42.0,1,CHEMBL621182,CCRF S-180,,Mus musculus,N,1,2048.0,
6466,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 4 hours,Intermediate,10090.0,,A,,BAO_0000218,6599,,42.0,1,CHEMBL621183,CCRF S-180,,Mus musculus,N,1,2048.0,
6467,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice lung bearing S180 tumor cell line for 8 hours,Intermediate,10090.0,,A,,BAO_0000218,6599,,42.0,1,CHEMBL621184,CCRF S-180,,Mus musculus,N,1,2048.0,
6468,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 1 hour,Intermediate,10090.0,,A,,BAO_0000218,6599,,42.0,1,CHEMBL621185,CCRF S-180,,Mus musculus,N,1,,
6469,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice muscle bearing S180 tumor cell line for 2 hours,Intermediate,10090.0,,A,,BAO_0000218,6599,,42.0,1,CHEMBL621186,CCRF S-180,,Mus musculus,N,1,,
6470,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 30 minutes,Intermediate,10090.0,,A,,BAO_0000218,6599,,42.0,1,CHEMBL621187,CCRF S-180,,Mus musculus,N,1,,
6471,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 4 hours,Intermediate,10090.0,,A,,BAO_0000218,6599,,42.0,1,CHEMBL621188,CCRF S-180,,Mus musculus,N,1,,
6472,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 8 hours,Intermediate,10090.0,,A,,BAO_0000218,6599,,42.0,1,CHEMBL621189,CCRF S-180,,Mus musculus,N,1,,
6473,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice spleen bearing S180 tumor cell line for 1 hour,Intermediate,10090.0,,A,,BAO_0000218,6599,,42.0,1,CHEMBL621190,CCRF S-180,,Mus musculus,N,1,2106.0,
6474,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 2 hours,Intermediate,10090.0,,A,,BAO_0000218,6599,,42.0,1,CHEMBL618520,CCRF S-180,,Mus musculus,N,1,2106.0,
6475,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 30 minutes,Intermediate,10090.0,,A,,BAO_0000218,6599,,42.0,1,CHEMBL621739,CCRF S-180,,Mus musculus,N,1,2106.0,
6476,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 4 hours,Intermediate,10090.0,,A,,BAO_0000218,6599,,42.0,1,CHEMBL621740,CCRF S-180,,Mus musculus,N,1,2106.0,
6477,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 8 hours,Intermediate,10090.0,,A,,BAO_0000218,6599,,42.0,1,CHEMBL621741,CCRF S-180,,Mus musculus,N,1,2106.0,
6478,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 1 hour,Intermediate,10090.0,,A,,BAO_0000218,6599,,42.0,1,CHEMBL621742,CCRF S-180,,Mus musculus,N,1,,
6479,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor bearing S180 tumor cell line for 2 hours,Intermediate,10090.0,,A,,BAO_0000218,6599,,42.0,1,CHEMBL621743,CCRF S-180,,Mus musculus,N,1,,
6480,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 30 minutes,Intermediate,10090.0,,A,,BAO_0000218,6599,,42.0,1,CHEMBL621744,CCRF S-180,,Mus musculus,N,1,,
6481,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 4 hours,Intermediate,10090.0,,A,,BAO_0000218,6599,,42.0,1,CHEMBL621745,CCRF S-180,,Mus musculus,N,1,,
6482,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor bearing S180 tumor cell line for 8 hours,Intermediate,10090.0,,A,,BAO_0000218,6599,,42.0,1,CHEMBL621746,CCRF S-180,,Mus musculus,N,1,,
6483,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 1 hour,Intermediate,10090.0,,A,,BAO_0000218,6599,,42.0,1,CHEMBL621747,CCRF S-180,,Mus musculus,N,1,,
6484,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 2 hours,Intermediate,10090.0,,A,,BAO_0000218,6599,,42.0,1,CHEMBL621748,CCRF S-180,,Mus musculus,N,1,,
6485,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 30 minutes,Intermediate,10090.0,,A,,BAO_0000218,6599,,42.0,1,CHEMBL621749,CCRF S-180,,Mus musculus,N,1,,
6486,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 4 hours,Intermediate,10090.0,,A,,BAO_0000218,6599,,42.0,1,CHEMBL621750,CCRF S-180,,Mus musculus,N,1,,
6487,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 8 hours,Intermediate,10090.0,,A,,BAO_0000218,6599,,42.0,1,CHEMBL621751,CCRF S-180,,Mus musculus,N,1,,
6488,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/heart bearing S180 tumor cell line for 1 hour,Intermediate,10090.0,,A,,BAO_0000218,6599,,42.0,1,CHEMBL621752,CCRF S-180,,Mus musculus,N,1,948.0,
6489,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/heart bearing S180 tumor cell line for 2 hours,Intermediate,10090.0,,A,,BAO_0000218,6599,,42.0,1,CHEMBL621753,CCRF S-180,,Mus musculus,N,1,948.0,
6490,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 30 minutes,Intermediate,10090.0,,A,,BAO_0000218,6599,,42.0,1,CHEMBL875955,CCRF S-180,,Mus musculus,N,1,948.0,
6491,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 4 hours,Intermediate,10090.0,,A,,BAO_0000218,6599,,42.0,1,CHEMBL621754,CCRF S-180,,Mus musculus,N,1,948.0,
6492,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 8 hours,Intermediate,10090.0,,A,,BAO_0000218,6599,,42.0,1,CHEMBL621755,CCRF S-180,,Mus musculus,N,1,948.0,
6493,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 1 hour,Intermediate,10090.0,,A,,BAO_0000218,6599,,42.0,1,CHEMBL621756,CCRF S-180,,Mus musculus,N,1,2107.0,
6494,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/liver bearing S180 tumor cell line for 2 hours,Intermediate,10090.0,,A,,BAO_0000218,6599,,42.0,1,CHEMBL624199,CCRF S-180,,Mus musculus,N,1,2107.0,
6495,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/liver bearing S180 tumor cell line for 30 minutes,Intermediate,10090.0,,A,,BAO_0000218,6599,,42.0,1,CHEMBL624200,CCRF S-180,,Mus musculus,N,1,2107.0,
6496,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 4 hours,Intermediate,10090.0,,A,,BAO_0000218,6599,,42.0,1,CHEMBL624375,CCRF S-180,,Mus musculus,N,1,2107.0,
6497,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 8 hours,Intermediate,10090.0,,A,,BAO_0000218,6599,,42.0,1,CHEMBL624376,CCRF S-180,,Mus musculus,N,1,2107.0,
6498,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 1 hour,Intermediate,10090.0,,A,,BAO_0000218,6599,,42.0,1,CHEMBL624377,CCRF S-180,,Mus musculus,N,1,2048.0,
6499,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/lung bearing S180 tumor cell line for 2 hours,Intermediate,10090.0,,A,,BAO_0000218,6599,,42.0,1,CHEMBL624378,CCRF S-180,,Mus musculus,N,1,2048.0,
6500,Compound tested for the antimicrobial activity against Acinetobacter anitratus,Intermediate,107673.0,,F,,BAO_0000218,12269,,,1,CHEMBL857901,,,aeinetobacter anitrotap,N,1,,
6501,Compound tested for the antimicrobial activity against Acinetobacter anitratus,Intermediate,107673.0,,F,,BAO_0000218,12269,,,1,CHEMBL875274,,,Acinetobacter calcoaceticus subsp. anitratus,N,1,,
6502,Compound tested for the antimicrobial activity against Acinetobacter anitratus,Intermediate,107673.0,,F,,BAO_0000218,12269,,,1,CHEMBL624379,,,Acinetobacter calcoaceticus subsp. anitratus,N,1,,
6503,Compound tested for the antimicrobial activity against Acinetobacter anitratus,Intermediate,107673.0,,F,,BAO_0000218,12269,,,1,CHEMBL624380,,,aeinetobacter anitrotap,N,1,,
6504,Activity against Acinetobacter calcoaceticus (AC54),Intermediate,471.0,,F,,BAO_0000218,10624,,,1,CHEMBL624381,,,Acinetobacter calcoaceticus,N,1,,
6505,Biological activity using the lizard skin (Anolis carolinensis) assay. The value indicates no prolonged biological activity,Intermediate,28377.0,,F,,BAO_0000218,17216,,,1,CHEMBL624382,,,Anolis carolinensis,N,1,,
6506,Biological activity using the lizard skin (Anolis carolinensis) assay. The value indicates prolonged biological activity,Intermediate,28377.0,,F,,BAO_0000218,17216,,,1,CHEMBL624383,,,Anolis carolinensis,N,1,,
6507,Chlorohexidine coefficient for Actinomyces naeslundii 631,Intermediate,1655.0,,F,,BAO_0000218,9560,,,1,CHEMBL624384,,,Actinomyces naeslundii,N,1,,
6508,Chlorohexidine coefficient for Actinomyces naeslundii B74,Intermediate,1655.0,,F,,BAO_0000218,9560,,,1,CHEMBL624385,,,Actinomyces naeslundii,N,1,,
6509,Chlorohexidine coefficient for Actinomyces naeslundii N/3,Intermediate,1655.0,,F,,BAO_0000218,9560,,,1,CHEMBL624386,,,Actinomyces naeslundii,N,1,,
6510,Chlorohexidine coefficient for Actinomyces naeslundii N/9,Intermediate,1655.0,,F,,BAO_0000218,9560,,,1,CHEMBL624387,,,Actinomyces naeslundii,N,1,,
6511,Plaque bactericidal index against Actinomyces naeslundii 631,Intermediate,1655.0,,F,,BAO_0000218,9560,,,1,CHEMBL624388,,,Actinomyces naeslundii,N,1,,
6512,Plaque bactericidal index against Actinomyces naeslundii N/9,Intermediate,1655.0,,F,,BAO_0000218,9560,,,1,CHEMBL624389,,,Actinomyces naeslundii,N,1,,
6513,Plaque bactericidal index against Actinomyces naeslundii B74,Intermediate,1655.0,,F,,BAO_0000218,9560,,,1,CHEMBL624390,,,Actinomyces naeslundii,N,1,,
6514,Plaque bactericidal index against Actinomyces naeslundii N/3,Intermediate,1655.0,,F,,BAO_0000218,9560,,,1,CHEMBL875275,,,Actinomyces naeslundii,N,1,,
6515,Compound was tested for its inhibitory activity using brine shrimp (Artemia salina) immobilization assay,Intermediate,85549.0,,F,,BAO_0000218,114,,,1,CHEMBL624391,,,Artemia salina,N,1,,
6516,"Compound was tested for its inhibitory activity using brine shrimp (Artemia salina) immobilization assay; highest level tested, showed <100% activity",Intermediate,85549.0,,F,,BAO_0000218,114,,,1,CHEMBL623636,,,Artemia salina,N,1,,
6517,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 0 uM,Intermediate,6253.0,,F,,BAO_0000218,10841,,,1,CHEMBL623637,,,Ascaris suum,N,1,,
6518,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 10 uM,Intermediate,6253.0,,F,,BAO_0000218,10841,,,1,CHEMBL623638,,,Ascaris suum,N,1,,
6519,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 200 uM,Intermediate,6253.0,,F,,BAO_0000218,10841,,,1,CHEMBL623639,,,Ascaris suum,N,1,,
6520,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 25 uM,Intermediate,6253.0,,F,,BAO_0000218,10841,,,1,CHEMBL623640,,,Ascaris suum,N,1,,
6521,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 3 uM,Intermediate,6253.0,,F,,BAO_0000218,10841,,,1,CHEMBL623641,,,Ascaris suum,N,1,,
6522,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 50 uM.,Intermediate,6253.0,,F,,BAO_0000218,10841,,,1,CHEMBL623642,,,Ascaris suum,N,1,,
6523,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 0 uM,Intermediate,6253.0,,F,,BAO_0000218,10841,,,1,CHEMBL623643,,,Ascaris suum,N,1,,
6524,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 10 uM,Intermediate,6253.0,,F,,BAO_0000218,10841,,,1,CHEMBL623644,,,Ascaris suum,N,1,,
6525,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 200 uM,Intermediate,6253.0,,F,,BAO_0000218,10841,,,1,CHEMBL623645,,,Ascaris suum,N,1,,
6526,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 25 uM,Intermediate,6253.0,,F,,BAO_0000218,10841,,,1,CHEMBL623646,,,Ascaris suum,N,1,,
6527,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 3 uM,Intermediate,6253.0,,F,,BAO_0000218,10841,,,1,CHEMBL623647,,,Ascaris suum,N,1,,
6528,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 50 uM,Intermediate,6253.0,,F,,BAO_0000218,10841,,,1,CHEMBL623648,,,Ascaris suum,N,1,,
6529,Compound is evaluated for minimal bactericidal concentration against plaque formation for Actinomyces viscosus,Intermediate,1656.0,,F,,BAO_0000218,8117,,,1,CHEMBL623649,,,Actinomyces viscosus,N,1,,
6530,Compound is evaluated for minimal bactericidal concentration against plaque formation for Actinomyces viscosus,Intermediate,1656.0,,F,,BAO_0000218,8117,,,1,CHEMBL623650,,,Actinomyces viscosus,N,1,,
6531,Chlorohexidine coefficient for Actinomyces viscosus 8A06,Intermediate,1656.0,,F,,BAO_0000218,9560,,,1,CHEMBL623651,,,Actinomyces viscosus,N,1,,
6532,Chlorohexidine coefficient for Actinomyces viscosus M-100,Expert,1656.0,,F,,BAO_0000218,9560,,,1,CHEMBL623652,,,Actinomyces viscosus,N,1,,
6533,Chlorohexidine coefficient for Actinomyces viscosus M-626,Intermediate,1656.0,,F,,BAO_0000218,9560,,,1,CHEMBL623653,,,Actinomyces viscosus,N,1,,
6534,Chlorohexidine coefficient for Actinomyces viscosus T14V,Intermediate,1656.0,,F,,BAO_0000218,9560,,,1,CHEMBL623654,,,Actinomyces viscosus,N,1,,
6535,Plaque bactericidal index against Actinomyces viscosus 8A06,Intermediate,1656.0,,F,,BAO_0000218,9560,,,1,CHEMBL623655,,,Actinomyces viscosus,N,1,,
6536,Plaque bactericidal index against Actinomyces viscosus M-100,Intermediate,1656.0,,F,,BAO_0000218,9560,,,1,CHEMBL623656,,,Actinomyces viscosus,N,1,,
6537,Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient,Expert,1656.0,,F,,BAO_0000218,9560,,,1,CHEMBL623657,,,Actinomyces viscosus,N,1,,
6538,"Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient; d=Not bactericidal at highest concentration tested (0.2% w/v, 2min, 5 days)",Intermediate,1656.0,,F,,BAO_0000218,9560,,,1,CHEMBL623658,,,Actinomyces viscosus,N,1,,
6539,"Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient; not bactericidal at highest concentration tested (0.2% w/v, 2min, 5 days)",Intermediate,1656.0,,F,,BAO_0000218,9560,,,1,CHEMBL623659,,,Actinomyces viscosus,N,1,,
6540,Plaque bactericidal index against Actinomyces viscosus 626,Intermediate,1656.0,,F,,BAO_0000218,9560,,,1,CHEMBL623660,,,Actinomyces viscosus,N,1,,
6541,Plaque bactericidal index against Actinomyces viscosus T14V,Intermediate,1656.0,,F,,BAO_0000218,9560,,,1,CHEMBL623661,,,Actinomyces viscosus,N,1,,
6542,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 1.56 mg/kg/day(5 days) dose,Intermediate,6277.0,,F,,BAO_0000218,10986,,,1,CHEMBL875281,,,Acanthocheilonema viteae,N,1,,
6543,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 100 mg/kg/day(5 days) dose,Intermediate,6277.0,,F,,BAO_0000218,10986,,,1,CHEMBL623662,,,Acanthocheilonema viteae,N,1,,
6544,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 12.5 mg/kg/day(5 days) dose,Intermediate,6277.0,,F,,BAO_0000218,10986,,,1,CHEMBL623663,,,Acanthocheilonema viteae,N,1,,
6545,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 200 mg/kg/day(5 days) dose,Intermediate,6277.0,,F,,BAO_0000218,10986,,,1,CHEMBL623664,,,Acanthocheilonema viteae,N,1,,
6546,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 25 mg/kg/day(5 days) dose,Intermediate,6277.0,,F,,BAO_0000218,10986,,,1,CHEMBL623665,,,Acanthocheilonema viteae,N,1,,
6547,Evaluated for the inhibitory concentration required to cause growth inhibition of A673Mer+ sarcoma cell line using the MTT Cytotoxicity Assay,Intermediate,9606.0,,F,,BAO_0000219,10708,,165.0,1,CHEMBL621856,A673,,Homo sapiens,N,1,,
6548,Evaluated for the inhibitory concentration required to cause growth inhibition of A704Rem- renal cell line using the MTT Cytotoxicity Assay,Intermediate,9606.0,,F,,BAO_0000219,10708,,645.0,1,CHEMBL620432,A704,,Homo sapiens,N,1,,
6549,Tested for inhibition of ET-1 induced phosphoinositide (PI) turnover in A7r5 smooth muscle cells,Autocuration,10116.0,,F,,BAO_0000219,416,,,1,CHEMBL620433,,,Rattus norvegicus,U,0,,
6550,Inhibition of Forskolin-Induced cAMP production in A9 L cells expressing m2 receptors,Intermediate,10090.0,,F,,BAO_0000219,14354,,625.0,1,CHEMBL620434,A9,,Mus musculus,N,1,,
6551,Percent inhibition of Forskolin-Induced cAMP production in A9 L cells expressing m2 receptors,Intermediate,10090.0,,F,,BAO_0000219,14354,,625.0,1,CHEMBL620435,A9,,Mus musculus,N,1,,
6552,Cytotoxicity against Beta- tubulin mutant expressing A9-PTX10 cell line of humans was tested,Intermediate,9606.0,,F,,BAO_0000219,5116,,625.0,1,CHEMBL620436,A9,,Homo sapiens,N,1,,
6553,Percentage inhibition at higher concentration (100 nM) against Beta- tubulin mutant expressing A9-PTX10 cell line,Intermediate,9606.0,,F,,BAO_0000219,5116,,625.0,1,CHEMBL876597,A9,,Homo sapiens,N,1,,
6554,Inhibition of human ovarian carcinoma (A90) FGF-R overexpressing cell proliferation,Expert,9606.0,,F,,BAO_0000219,15694,,874.0,1,CHEMBL620437,Human ovarian carcinoma cell line,,Homo sapiens,N,1,,
6555,"Tested for stimulating PI (phosphoinositol) hydrolysis in A9L-m1 cells, activity expressed as EC50 mM.",Expert,10090.0,,F,,BAO_0000219,13038,,625.0,1,CHEMBL620438,A9,,Mus musculus,N,1,,
6556,Stimulating PI (phosphoinositol) hydrolysis in A9L-m1 cells.,Expert,10090.0,,F,,BAO_0000219,13038,,625.0,1,CHEMBL620439,A9,,Mus musculus,N,1,,
6557,Increase in phosphoinositide (PI) metabolism in A9L-m1 cells at 100 uM.,Expert,10090.0,,F,,BAO_0000219,10923,,625.0,1,CHEMBL619657,A9,,Mus musculus,N,1,,
6558,The increase in phosphoinositide (PI) metabolism in A9L-m1 cells was measured at 100 uM; - = Not determined,Intermediate,10090.0,,F,,BAO_0000219,10923,,625.0,1,CHEMBL619658,A9,,Mus musculus,N,1,,
6559,The increase in phosphoinositide (PI) metabolism in A9L-m1 cells was measured at 100 uM; i = inactive,Intermediate,10090.0,,F,,BAO_0000219,10923,,625.0,1,CHEMBL619659,A9,,Mus musculus,N,1,,
6560,"Increase in phosphoinositide (PI) metabolism in A9L-cholinergic receptor, muscarinic 3 expressing cells was measured at 100 uMolar",Expert,,,F,,BAO_0000019,10923,,,1,CHEMBL619660,,,,H,8,,
6561,The increase in phosphoinositide (PI) metabolism in A9L-m3 cells was measured at 100 uM; - = Not determined,Intermediate,10090.0,,F,,BAO_0000219,10923,,625.0,1,CHEMBL619661,A9,,Mus musculus,N,1,,
6562,The increase in phosphoinositide (PI) metabolism in A9L-m3 cells was measured at 100 uM; i = inactive,Intermediate,10090.0,,F,,BAO_0000219,10923,,625.0,1,CHEMBL619662,A9,,Mus musculus,N,1,,
6563,Ability to inhibit growth of AA-6 cells (a mutant cell line resistant to 8-azaadenine and lacks adenine phosphoryltransferase) was determined,Intermediate,10029.0,,F,,BAO_0000219,8158,,975.0,1,CHEMBL619663,AA6,,Cricetulus griseus,N,1,,
6564,Intracellular phosphorylation (100 uM) in uninfected AA2 cells was studied after 5 hrs of Incubation.,Autocuration,9606.0,,F,,BAO_0000219,15494,,,1,CHEMBL619664,,,Homo sapiens,U,0,,
6565,"Intracellular phosphorylation (100 uM) in uninfected AA2 cells was studied, after 5 hrs of Incubation.",Autocuration,9606.0,,F,,BAO_0000219,15494,,,1,CHEMBL619665,,,Homo sapiens,U,0,,
6566,Anti -HIV activity was measured against AA5/HIV-1(IIIB),Intermediate,9606.0,,F,,BAO_0000219,12348,,974.0,1,CHEMBL883244,AA5,,Homo sapiens,N,1,,
6567,Cytotoxicity was measured against AA5/HIV-1(IIIB),Intermediate,9606.0,,F,,BAO_0000219,12348,,974.0,1,CHEMBL884011,AA5,,Homo sapiens,N,1,,
6568,Compound was evaluated for the anti-HIV activity against HIV strain IIIB in AA5 EBV-infected B-cell,Intermediate,9606.0,,F,,BAO_0000219,2726,,974.0,1,CHEMBL619666,AA5,,Homo sapiens,N,1,,
6569,Compound was evaluated for the anti-HIV activity against HIV strain IIIB in U937 monocytic cell,Intermediate,9606.0,,F,,BAO_0000219,2726,,379.0,1,CHEMBL619667,U-937,,Homo sapiens,N,1,,
6570,Hypersensitivity factor obtained from in vitro cytotoxicities against Chinese hamster ovary derived AA8 / UV4 cell lines,Intermediate,10029.0,,F,,BAO_0000219,10747,,274.0,1,CHEMBL619668,UV4,,Cricetulus griseus,N,1,,
6571,"Inhibition of cell growth in culture against Chinese hamster ovary derived cell line, AA8",Expert,10029.0,,F,,BAO_0000219,11005,,185.0,1,CHEMBL619669,CHO-AA8,,Cricetulus griseus,N,1,,
6572,Average intracellular compound concentration when the hypoxic SER=1.6,Intermediate,10029.0,,F,,BAO_0000219,12687,,185.0,1,CHEMBL876608,CHO-AA8,,Cricetulus griseus,N,1,,
6573,Average intracellular compound concentration when the hypoxic SER=1.6.,Intermediate,10029.0,,F,,BAO_0000219,12687,,185.0,1,CHEMBL619670,CHO-AA8,,Cricetulus griseus,N,1,,
6574,Average intracellular compound concentration where the hypoxia sensitizer enhancement ratio (SER)=1.6,Intermediate,10029.0,,F,,BAO_0000219,12687,,185.0,1,CHEMBL619671,CHO-AA8,,Cricetulus griseus,N,1,,
6575,Average intracellular compound concentration where the sensitizer enhancement ratio (SER)=1.6 under hypoxia,Intermediate,10029.0,,F,,BAO_0000219,12687,,185.0,1,CHEMBL619672,CHO-AA8,,Cricetulus griseus,N,1,,
6576,Compound concentration at which sensitizer enhancement ratio =1.6 under hypoxia.,Intermediate,10029.0,,F,,BAO_0000219,12687,,185.0,1,CHEMBL619673,CHO-AA8,,Cricetulus griseus,N,1,,
6577,"Compound was tested for the concentration required to reduce cell survival under hypoxic conditions, using the cell line AA8 in the clonogenic assay.",Intermediate,10029.0,,F,,BAO_0000219,13436,,185.0,1,CHEMBL619674,CHO-AA8,,Cricetulus griseus,N,1,,
6578,"Concentration needed to reduce cell survival to 10% of control values, using 1 hour exposure of plateau phase AA8 cells at 10e6 cells/ml",Intermediate,10029.0,,F,,BAO_0000219,13435,,185.0,1,CHEMBL619675,CHO-AA8,,Cricetulus griseus,N,1,,
6579,Activity to reduce the surviving fraction to 10% (CT10) was used as an inverse measure of cytotoxic potency in aerobic conditions,Intermediate,10029.0,,F,,BAO_0000219,13302,,185.0,1,CHEMBL619676,CHO-AA8,,Cricetulus griseus,N,1,,
6580,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition,Intermediate,10029.0,,F,,BAO_0000219,12687,,185.0,1,CHEMBL619677,CHO-AA8,,Cricetulus griseus,N,1,,
6581,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition,Intermediate,10029.0,,A,,BAO_0000219,12687,,185.0,1,CHEMBL619678,CHO-AA8,,Cricetulus griseus,N,1,,
6582,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition.,Intermediate,10029.0,,A,,BAO_0000219,12687,,185.0,1,CHEMBL619679,CHO-AA8,,Cricetulus griseus,N,1,,
6583,Concentration x time (uM h) to reduce cell survival to 10% of control values under hypoxic conditions by clonogenic assay,Expert,10029.0,,A,,BAO_0000219,12878,,185.0,1,CHEMBL619680,CHO-AA8,,Cricetulus griseus,N,1,,
6584,Concentration x time (uM h) to reduce cell survival to 10% of control values under hypoxic conditions by clonogenic assay. Inactive at the solubility limit,Intermediate,10029.0,,A,,BAO_0000219,12878,,185.0,1,CHEMBL621457,CHO-AA8,,Cricetulus griseus,N,1,,
6585,Cytotoxicity under aerobic conditions determined to reduce the AA8 cell survival to 10% controls in clonogenic assay,Expert,10029.0,,F,,BAO_0000219,14367,,185.0,1,CHEMBL876609,CHO-AA8,,Cricetulus griseus,N,1,,
6586,Cytotoxicity under aerobic conditions determined to reduce the AA8 cell survival to 10% of controls in clonogenic assay,Intermediate,10029.0,,F,,BAO_0000219,14367,,185.0,1,CHEMBL621458,CHO-AA8,,Cricetulus griseus,N,1,,
6587,Aerobic cytotoxicity was assessed in a growth inhibition assay using log phase cultures of the chinese hamster ovary fibroblast line AA8,Expert,36483.0,,F,,BAO_0000219,12398,,185.0,1,CHEMBL621459,CHO-AA8,,hampster,N,1,,
6588,Aerobic growth inhibition in Chinese hamster cell line AA8,Expert,10029.0,,F,,BAO_0000219,12878,,185.0,1,CHEMBL621460,CHO-AA8,,Cricetulus griseus,N,1,,
6589,Cytotoxicity against AA8 cell and IC50 values were determined as drug concentration required to inhibit cell protein to 50%.,Expert,10029.0,,F,,BAO_0000219,13820,,185.0,1,CHEMBL621461,CHO-AA8,,Cricetulus griseus,N,1,,
6590,Inhibition of growth under aerobic conditions in AA8 cells,Expert,10029.0,,F,,BAO_0000219,13436,,185.0,1,CHEMBL621462,CHO-AA8,,Cricetulus griseus,N,1,,
6591,Oral bioavailability in dog (dose 10 mg/kg),Intermediate,9615.0,,A,,BAO_0000218,6084,,,1,CHEMBL621463,,,Canis lupus familiaris,N,1,,
6592,Oral bioavailability in dog at 10 mg/kg of the compound,Intermediate,9615.0,,A,,BAO_0000218,5711,,,1,CHEMBL621464,,,Canis lupus familiaris,N,1,,
6593,Oral bioavailability in dog (dose 5 uM/kg),Intermediate,9615.0,,A,,BAO_0000218,4353,,,1,CHEMBL621465,,,Canis lupus familiaris,N,1,,
6594,Oral bioavailability in dog (dose 5 uM/kg),Intermediate,9615.0,,A,,BAO_0000218,4353,,,1,CHEMBL621466,,,Canis lupus familiaris,N,1,,
6595,Oral bioavailability in dog (mongrel),Intermediate,9615.0,,A,,BAO_0000218,17800,,,1,CHEMBL621467,,,Canis lupus familiaris,N,1,,
6596,Oral bioavailability in dog (dose 10 mg/kg),Intermediate,9615.0,,A,,BAO_0000218,3994,,,1,CHEMBL621468,,,Canis lupus familiaris,N,1,,
6597,Oral bioavailability in dog (dose 10 mg/kg),Intermediate,9615.0,,F,,BAO_0000218,3994,,,1,CHEMBL876734,,,Canis lupus familiaris,N,1,,
6598,Bioavailability in dog,Intermediate,9615.0,,A,,BAO_0000218,5145,,,1,CHEMBL618476,,,Canis lupus familiaris,N,1,,
6599,Bioavailability in dog (dose 1 mg/kg i.v.),Intermediate,9615.0,,A,,BAO_0000218,16452,,,1,CHEMBL618477,,,Canis lupus familiaris,N,1,,
6600,Pharmacokinetic data for dose given to dogs intravenously (oral PK study in parentheses),Intermediate,9615.0,,A,,BAO_0000218,16452,,,1,CHEMBL618478,,,Canis lupus familiaris,N,1,,
6601,Pharmacokinetic property (F) was measured in dog at the dose of 0.032 mg/kg,Intermediate,9615.0,,A,,BAO_0000218,5983,,,1,CHEMBL618479,,,Canis lupus familiaris,N,1,,
6602,Bioavailability in dog,Intermediate,9615.0,,A,,BAO_0000218,4273,,,1,CHEMBL618480,,,Canis lupus familiaris,N,1,,
6603,Bioavailability in dog (dose 3-10 mg/kg),Intermediate,9615.0,,A,,BAO_0000218,12500,,,1,CHEMBL618481,,,Canis lupus familiaris,N,1,,
6604,The compound was tested for bioavailability of compound in plasma of dog; Complete,Intermediate,9615.0,,A,,BAO_0000218,12500,,,1,CHEMBL618482,,,Canis lupus familiaris,N,1,1969.0,
6605,Oral bioavailability in dog,Intermediate,9615.0,,A,,BAO_0000218,3639,,,1,CHEMBL618483,,,Canis lupus familiaris,N,1,,
6606,Oral bioavailability in dog,Intermediate,9615.0,,A,,BAO_0000218,3880,,,1,CHEMBL618484,,,Canis lupus familiaris,N,1,,
6607,Bioavailability in dog,Intermediate,9615.0,,A,,BAO_0000218,4838,,,1,CHEMBL618485,,,Canis lupus familiaris,N,1,,
6608,oral bioavailability was measured in dogs,Intermediate,9615.0,,A,,BAO_0000218,15600,,,1,CHEMBL618486,,,Canis lupus familiaris,N,1,,
6609,Compound was tested for plasma protein binding in dog; Not determined,Intermediate,9615.0,,A,,BAO_0000218,17248,,,1,CHEMBL618487,,,Canis lupus familiaris,N,1,,
6610,Compound was tested for plasma protein binding of dog,Intermediate,9615.0,,A,,BAO_0000218,17248,,,1,CHEMBL618488,,,Canis lupus familiaris,N,1,,
6611,Compound was tested for plasma protein binding of dog; Not determined,Intermediate,9615.0,,A,,BAO_0000218,17248,,,1,CHEMBL876735,,,Canis lupus familiaris,N,1,,
6612,Concentration in dogs after oral administration at dose of 1 mg/kg after 180 min.,Intermediate,9615.0,,A,,BAO_0000218,17443,,,1,CHEMBL618489,,,Canis lupus familiaris,N,1,,
6613,Apparent terminal elimination half-life in dog after administration of 20 mg/kg dose through peroral route,Intermediate,9615.0,,A,,BAO_0000218,4186,,,1,CHEMBL618490,,,Canis lupus familiaris,N,1,,
6614,Half life was determined,Intermediate,9615.0,,A,,BAO_0000218,3749,,,1,CHEMBL618491,,,Canis lupus familiaris,N,1,,
6615,Half life by ''Cr'' assay in dog at a dose of 5 mg/kg,Intermediate,9615.0,,A,,BAO_0000218,3249,,,1,CHEMBL618492,,,Canis lupus familiaris,N,1,,
6616,Half life was evaluated in dog,Intermediate,9615.0,,A,,BAO_0000218,3022,,,1,CHEMBL873354,,,Canis lupus familiaris,N,1,,
6617,Half life was determined,Intermediate,9615.0,,A,,BAO_0000218,3749,,,1,CHEMBL618493,,,Canis lupus familiaris,N,1,,
6618,Biodistribution of compound was measured in bile at 2 hr post-injection in canine deep vein thrombosis model (DVT),Intermediate,9615.0,,A,,BAO_0000218,2517,,,1,CHEMBL618494,,,Canis lupus familiaris,N,1,,
6619,Biodistribution of compound was measured in heart at 2 hr post-injection in canine deep vein thrombosis model (DVT),Intermediate,9615.0,,A,,BAO_0000218,2517,,,1,CHEMBL618495,,,Canis lupus familiaris,N,1,948.0,
6620,Biodistribution of compound was measured in kidney at 2 hr post-injection in canine deep vein thrombosis model (DVT),Intermediate,9615.0,,A,,BAO_0000218,2517,,,1,CHEMBL618496,,,Canis lupus familiaris,N,1,2113.0,
6621,Biodistribution of compound was measured in liver at 2 hr post-injection in canine deep vein thrombosis model (DVT),Intermediate,9615.0,,A,,BAO_0000218,2517,,,1,CHEMBL618497,,,Canis lupus familiaris,N,1,2107.0,
6622,Biodistribution of compound was measured in lung at 2 hr post-injection in canine deep vein thrombosis model (DVT),Intermediate,9615.0,,A,,BAO_0000218,2517,,,1,CHEMBL618498,,,Canis lupus familiaris,N,1,2048.0,
6623,Biodistribution of compound was measured in spleen at 2 hr post-injection in canine deep vein thrombosis model (DVT),Intermediate,9615.0,,A,,BAO_0000218,2517,,,1,CHEMBL618499,,,Canis lupus familiaris,N,1,2106.0,
6624,LogP in dog,Intermediate,9615.0,,A,,BAO_0000218,3639,,,1,CHEMBL876736,,,Canis lupus familiaris,N,1,,
6625,Partition coefficient (logP),Intermediate,9615.0,,A,,BAO_0000218,6227,,,1,CHEMBL618500,,,Canis lupus familiaris,N,1,,
6626,Partition coefficient in dog,Intermediate,9615.0,,A,,BAO_0000218,6227,,,1,CHEMBL857831,,,Canis lupus familiaris,N,1,,
6627,Mean-residence time of compound after intravenous administration in dogs at 1.2 uM/kg,Intermediate,9615.0,,A,,BAO_0000218,17764,,,1,CHEMBL618501,,,Canis lupus familiaris,N,1,,
6628,Pharmacokinetic parameter MRT was determined in Beagle dogs after (po) administration of a dose of 28 (uM/kg),Intermediate,9615.0,,A,,BAO_0000218,4809,,,1,CHEMBL618502,,,Canis lupus familiaris,N,1,,
6629,In vitro metabolic stability determined after 30 min of incubation in dog hepatic microsomes,Intermediate,9615.0,,A,,BAO_0000218,5600,,,1,CHEMBL618503,,,Canis lupus familiaris,N,1,,
6630,Metabolism of compound in dog S9 microsomes ('++''indicates 20-50% largest observed peak),Intermediate,9615.0,,A,,BAO_0000218,14294,,,1,CHEMBL618504,,,Canis lupus familiaris,N,1,,
6631,Metabolism of compound in dog S9 microsomes ('++++' indicates largest observed peak),Intermediate,9615.0,,A,,BAO_0000218,14294,,,1,CHEMBL618505,,,Canis lupus familiaris,N,1,,
6632,Metabolism of compound in dog S9 microsomes; Trace,Intermediate,9615.0,,A,,BAO_0000218,14294,,,1,CHEMBL618506,,,Canis lupus familiaris,N,1,,
6633,In vitro metabolic potential in dog liver microsomes,Intermediate,9615.0,,A,,BAO_0000218,6251,,,1,CHEMBL618507,,,Canis lupus familiaris,N,1,2107.0,
6634,Oral bioavailability of perorally administered compound (10 mg/kg) was tested in dogs,Intermediate,9615.0,,A,,BAO_0000218,3748,,,1,CHEMBL876737,,,Canis lupus familiaris,N,1,,
6635,Oral bioavailability in dog,Intermediate,9615.0,,A,,BAO_0000218,2713,,,1,CHEMBL618508,,,Canis lupus familiaris,N,1,,
6636,Oral bioavailability in dog,Intermediate,9615.0,,A,,BAO_0000218,6512,,,1,CHEMBL618509,,,Canis lupus familiaris,N,1,,
6637,Oral bioavailability was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,Intermediate,9615.0,,A,,BAO_0000218,6679,,,1,CHEMBL618510,,,Canis lupus familiaris,N,1,,
6638,The compound was tested for bioavailability in dogs,Intermediate,9615.0,,A,,BAO_0000218,3749,,,1,CHEMBL618511,,,Canis lupus familiaris,N,1,,
6639,The compound was tested for oral bioavailability in dogs,Intermediate,9615.0,,A,,BAO_0000218,3749,,,1,CHEMBL618512,,,Canis lupus familiaris,N,1,,
6640,Oral bioavailability in dog,Intermediate,9615.0,,A,,BAO_0000218,6742,,,1,CHEMBL618513,,,Canis lupus familiaris,N,1,,
6641,Compound was tested for percent protein binding (PB) in dog,Intermediate,9615.0,,A,,BAO_0000218,6227,,,1,CHEMBL618514,,,Canis lupus familiaris,N,1,,
6642,Apparent permeability coefficient (Papp) for apical to basolateral flux was determined in MadinDarby Canine Kidney cells,Intermediate,9615.0,,A,,BAO_0000218,6874,,,1,CHEMBL620052,,,Canis lupus familiaris,N,1,,
6643,Compound was evaluated for plasma clearance.,Intermediate,9615.0,,A,,BAO_0000218,2877,,,1,CHEMBL620053,,,Canis lupus familiaris,N,1,1969.0,
6644,The compound was tested for plasma clearance in dog,Intermediate,9615.0,,A,,BAO_0000218,12500,,,1,CHEMBL620054,,,Canis lupus familiaris,N,1,1969.0,
6645,The compound was tested for plasma clearance in dog at dose of 3-10 mgkg,Intermediate,9615.0,,A,,BAO_0000218,12500,,,1,CHEMBL620055,,,Canis lupus familiaris,N,1,1969.0,
6646,Plasma protein binding was determined after intravenous administration of 1 mg/kg in dog,Intermediate,9615.0,,A,,BAO_0000218,4709,,,1,CHEMBL620056,,,Canis lupus familiaris,N,1,,
6647,In vitro relative rate of metabolism was determined in dog liver microsomes,Intermediate,9615.0,,A,,BAO_0000218,5542,,,1,CHEMBL620057,,,Canis lupus familiaris,N,1,2107.0,
6648,Relative bioavailability after oral dose of compound at 3 mg/kg in dogs,Intermediate,9615.0,,A,,BAO_0000218,17594,,,1,CHEMBL618939,,,Canis lupus familiaris,N,1,,
6649,Compound was evaluated for half-life period in dogs at a dose of 5 mpk perorally,Intermediate,9615.0,,A,,BAO_0000218,2652,,,1,CHEMBL618940,,,Canis lupus familiaris,N,1,,
6650,Half life after intravenous administration in dogs at 1.2 uM/kg,Intermediate,9615.0,,A,,BAO_0000218,17764,,,1,CHEMBL618941,,,Canis lupus familiaris,N,1,,
6651,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 30 minutes,Intermediate,10090.0,,A,,BAO_0000218,6599,,42.0,1,CHEMBL624473,CCRF S-180,,Mus musculus,N,1,2048.0,
6652,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 4 hours,Intermediate,10090.0,,A,,BAO_0000218,6599,,42.0,1,CHEMBL624474,CCRF S-180,,Mus musculus,N,1,2048.0,
6653,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 8 hours,Intermediate,10090.0,,A,,BAO_0000218,6599,,42.0,1,CHEMBL624475,CCRF S-180,,Mus musculus,N,1,2048.0,
6654,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 1 hour,Intermediate,10090.0,,A,,BAO_0000218,6599,,42.0,1,CHEMBL624476,CCRF S-180,,Mus musculus,N,1,,
6655,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/muscle bearing S180 tumor cell line for 2 hours,Intermediate,10090.0,,A,,BAO_0000218,6599,,42.0,1,CHEMBL623478,CCRF S-180,,Mus musculus,N,1,,
6656,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 30 minutes,Intermediate,10090.0,,A,,BAO_0000218,6599,,42.0,1,CHEMBL623479,CCRF S-180,,Mus musculus,N,1,,
6657,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/muscle bearing S180 tumor cell line for 4 hours,Intermediate,10090.0,,A,,BAO_0000218,6599,,42.0,1,CHEMBL623480,CCRF S-180,,Mus musculus,N,1,,
6658,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 8 hours,Intermediate,10090.0,,A,,BAO_0000218,6599,,42.0,1,CHEMBL623481,CCRF S-180,,Mus musculus,N,1,,
6659,C2 in brain of mice at the oral dose of 50 mg/kg,Intermediate,10090.0,,A,,BAO_0000218,17641,,,1,CHEMBL623482,,,Mus musculus,N,1,955.0,
6660,C2 in kidney of mice at the oral dose of 50 mg/kg,Intermediate,10090.0,,A,,BAO_0000218,17641,,,1,CHEMBL623483,,,Mus musculus,N,1,2113.0,
6661,C2 in liver of mice at the oral dose of 50 mg/kg,Intermediate,10090.0,,A,,BAO_0000218,17641,,,1,CHEMBL623484,,,Mus musculus,N,1,2107.0,
6662,C2 in lungs of mice at the oral dose of 50 mg/kg,Intermediate,10090.0,,A,,BAO_0000218,17641,,,1,CHEMBL623485,,,Mus musculus,N,1,2048.0,
6663,C2 in spleen of mice at the oral dose of 50 mg/kg,Intermediate,10090.0,,A,,BAO_0000218,17641,,,1,CHEMBL623486,,,Mus musculus,N,1,2106.0,
6664,Plasma clearance in mouse,Intermediate,10090.0,,A,,BAO_0000218,17852,,,1,CHEMBL623487,,,Mus musculus,N,1,,
6665,Clearance of compound after intravenous administration in mice at 24 uM/kg,Intermediate,10090.0,,A,,BAO_0000218,17764,,,1,CHEMBL623488,,,Mus musculus,N,1,,
6666,Clearance from mouse blood following i.v. administration of 10 mg/kg,Intermediate,10090.0,,A,,BAO_0000218,17837,,,1,CHEMBL623489,,,Mus musculus,N,1,,
6667,Clearance was evaluated in mice after intravenous administration,Intermediate,10090.0,,A,,BAO_0000218,2675,,,1,CHEMBL875157,,,Mus musculus,N,1,,
6668,Clearance was evaluated in mice after oral administration,Intermediate,10090.0,,A,,BAO_0000218,2675,,,1,CHEMBL623490,,,Mus musculus,N,1,,
6669,Pharmacokinetic property (Plasma clearance) was measured in mouse,Intermediate,10090.0,,A,,BAO_0000218,4239,,,1,CHEMBL623491,,,Mus musculus,N,1,,
6670,Plasma clearance of compound was determined at 40 mg/Kg,Intermediate,10090.0,,A,,BAO_0000218,17753,,,1,CHEMBL623492,,,Mus musculus,N,1,,
6671,Plasma clearance of at 24 mg/Kg,Intermediate,10090.0,,A,,BAO_0000218,17753,,,1,CHEMBL623493,,,Mus musculus,N,1,,
6672,Plasma clearance at 24 mg/Kg,Intermediate,10090.0,,A,,BAO_0000218,17753,,,1,CHEMBL623494,,,Mus musculus,N,1,,
6673,Plasma clearance at 5 mg/Kg,Intermediate,10090.0,,A,,BAO_0000218,17753,,,1,CHEMBL623495,,,Mus musculus,N,1,,
6674,Plasma clearance in mice,Intermediate,10090.0,,A,,BAO_0000218,5727,,,1,CHEMBL623496,,,Mus musculus,N,1,,
6675,Plasma clearance value upon iv administration in mouse,Intermediate,10090.0,,A,,BAO_0000218,2862,,,1,CHEMBL623497,,,Mus musculus,N,1,,
6676,Total plasma clearance in mice,Intermediate,10090.0,,A,,BAO_0000218,5980,,,1,CHEMBL623498,,,Mus musculus,N,1,1969.0,
6677,Clearance in mouse,Intermediate,10090.0,,A,,BAO_0000218,17592,,,1,CHEMBL623499,,,Mus musculus,N,1,,
6678,Clearance value was determined,Intermediate,10090.0,,A,,BAO_0000218,17718,,,1,CHEMBL623500,,,Mus musculus,N,1,,
6679,Plasma clearance at a dose of 10 mg/kg intravenous administration in mice.,Intermediate,10090.0,,A,,BAO_0000218,16597,,,1,CHEMBL623501,,,Mus musculus,N,1,,
6680,Calculated partition coefficient (clogP),Intermediate,,,P,,BAO_0000100,17384,,,1,CHEMBL875158,,,,U,0,,
6681,Plasma clearance for the compound was measured in mouse after an iv dose of 1 mg/kg,Intermediate,10090.0,,A,,BAO_0000218,6062,,,1,CHEMBL623502,,,Mus musculus,N,1,,
6682,Plasma clearance rate after intraperitoneal administration of 100 mg/kg in mice,Intermediate,10090.0,,A,,BAO_0000218,17734,,,1,CHEMBL623503,,,Mus musculus,N,1,,
6683,Plasma clearance was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,Intermediate,10090.0,,A,,BAO_0000218,6348,,,1,CHEMBL623504,,,Mus musculus,N,1,,
6684,In vivo total clearance was determined in murine septicemia at dose of 100 mg/kg,Intermediate,10090.0,,A,,BAO_0000218,5969,,,1,CHEMBL623505,,,Mus musculus,N,1,,
6685,In vivo total clearance was determined in murine septicemia at dose of 50 mg/kg,Intermediate,10090.0,,A,,BAO_0000218,5969,,,1,CHEMBL623506,,,Mus musculus,N,1,,
6686,In vivo total clearance was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,Intermediate,10090.0,,A,,BAO_0000218,5969,,,1,CHEMBL623507,,,Mus musculus,N,1,,
6687,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for Cmax,Intermediate,10090.0,,A,,BAO_0000218,16597,,,1,CHEMBL623508,,,Mus musculus,N,1,,
6688,Cmax after oral administration at 30 mg/kg in ICR mouse,Intermediate,10090.0,,A,,BAO_0000218,5781,,,1,CHEMBL623509,,,Mus musculus,N,1,,
6689,Cmax after peroral administration in mice at 2.4 uM/kg,Intermediate,10090.0,,A,,BAO_0000218,17764,,,1,CHEMBL875159,,,Mus musculus,N,1,,
6690,Cmax in brain of mice at the oral dose of 50 mg/kg,Intermediate,10090.0,,A,,BAO_0000218,17641,,,1,CHEMBL623510,,,Mus musculus,N,1,955.0,
6691,Cmax in kidney of mice at the oral dose of 50 mg/kg,Intermediate,10090.0,,A,,BAO_0000218,17641,,,1,CHEMBL623511,,,Mus musculus,N,1,2113.0,
6692,Cmax in liver of mice at the oral dose of 50 mg/kg,Intermediate,10090.0,,A,,BAO_0000218,17641,,,1,CHEMBL623512,,,Mus musculus,N,1,2107.0,
6693,Cmax in lungs of mice at the oral dose of 50 mg/kg,Intermediate,10090.0,,A,,BAO_0000218,17641,,,1,CHEMBL623513,,,Mus musculus,N,1,2048.0,
6694,Cmax in mice at 18 uM/kg i.p. administration,Intermediate,10090.0,,F,,BAO_0000218,17764,,,1,CHEMBL623514,,,Mus musculus,N,1,,
6695,Cmax in mice at 23 uM/kg i.v. administration,Intermediate,10090.0,,F,,BAO_0000218,17764,,,1,CHEMBL622609,,,Mus musculus,N,1,,
6696,Cmax in mice at 24 uM/kg i.p. administration,Intermediate,10090.0,,F,,BAO_0000218,17764,,,1,CHEMBL622610,,,Mus musculus,N,1,,
6697,Cmax in mice at 25 uM/kg i.p. administration,Intermediate,10090.0,,F,,BAO_0000218,17764,,,1,CHEMBL621823,,,Mus musculus,N,1,,
6698,Cmax in mice at 26 uM/kg i.p. administration,Intermediate,10090.0,,F,,BAO_0000218,17764,,,1,CHEMBL621824,,,Mus musculus,N,1,,
6699,Cmax in spleen of mice at the oral dose of 50 mg/kg,Intermediate,10090.0,,A,,BAO_0000218,17641,,,1,CHEMBL621825,,,Mus musculus,N,1,2106.0,
6700,Cmax value at a dose of 10 mg/kg intravenous administration in mice.,Intermediate,10090.0,,A,,BAO_0000218,16597,,,1,CHEMBL621826,,,Mus musculus,N,1,,
6701,Cmax value at a dose of 10 mg/kg peroral administration in mice.,Intermediate,10090.0,,A,,BAO_0000218,16597,,,1,CHEMBL621827,,,Mus musculus,N,1,,
6702,Cmax value was determined,Intermediate,10090.0,,A,,BAO_0000218,5727,,,1,CHEMBL621828,,,Mus musculus,N,1,,
6703,Cmax value in IRC mice,Intermediate,10090.0,,A,,BAO_0000218,5951,,,1,CHEMBL621829,,,Mus musculus,N,1,,
6704,Cmax value was determined at a dose of 100 mg/kg (i.p.) in Mice,Intermediate,10090.0,,A,,BAO_0000218,5506,,,1,CHEMBL621830,,,Mus musculus,N,1,,
6705,Cmax value was determined at a dose of 200 mg/kg (i.p.) in Mice,Intermediate,10090.0,,A,,BAO_0000218,5506,,,1,CHEMBL621831,,,Mus musculus,N,1,,
6706,Compound was evaluated for maximum plasma concentration by administering orally at 25 mg/kg in mice,Intermediate,10090.0,,A,,BAO_0000218,14239,,,1,CHEMBL621832,,,Mus musculus,N,1,1969.0,
6707,"Compound was evaluated for the pharmacokinetic parameter, maximum plasma concentration",Intermediate,10090.0,,A,,BAO_0000218,4890,,,1,CHEMBL624579,,,Mus musculus,N,1,1969.0,
6708,Evaluated for pharmacokinetic parameter Cmax in mouse at the dose 20 mg/kg,Intermediate,10090.0,,A,,BAO_0000218,429,,,1,CHEMBL624580,,,Mus musculus,N,1,,
6709,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 50 mg/kg/day(5 days) dose,Intermediate,6277.0,,F,,BAO_0000218,10986,,,1,CHEMBL624581,,,Acanthocheilonema viteae,N,1,,
6710,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 6.25 mg/kg/day(5 days) dose,Intermediate,6277.0,,F,,BAO_0000218,10986,,,1,CHEMBL624582,,,Acanthocheilonema viteae,N,1,,
6711,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 75 mg/kg/day(5 days) dose,Intermediate,6277.0,,F,,BAO_0000218,10986,,,1,CHEMBL624583,,,Acanthocheilonema viteae,N,1,,
6712,Inhibitory activity against human tumor cell line A0375 melanoma.,Intermediate,9606.0,,F,,BAO_0000219,13227,,455.0,1,CHEMBL624584,A-375,,Homo sapiens,N,1,,
6713,Displacement of [3H]N6-PIA binding from A1 receptor in whole rat brain membranes,Expert,10116.0,,B,,BAO_0000249,4481,Brain membranes,,1,CHEMBL624585,,,Rattus norvegicus,D,9,,
6714,Forskolin-induced cAMP production at human A1 adenosine receptor,Expert,9606.0,,F,,BAO_0000019,16931,,,1,CHEMBL875165,,,Homo sapiens,D,9,,
6715,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1; change of less than 5% of allosteric enhancement.,Autocuration,,,F,,BAO_0000219,3850,,449.0,1,CHEMBL619490,CHO,,,H,8,,
6716,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM; An increase of cAmp content of cells,Autocuration,,,F,,BAO_0000219,3850,,449.0,1,CHEMBL619491,CHO,,,H,8,,
6717,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM,Expert,,,F,,BAO_0000219,3850,,449.0,1,CHEMBL619492,CHO,,,H,8,,
6718,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration,Expert,,,F,,BAO_0000219,3850,,449.0,1,CHEMBL619493,CHO,,,H,8,,
6719,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; An increase of cAmp content of cells,Autocuration,,,F,,BAO_0000219,3850,,449.0,1,CHEMBL619494,CHO,,,H,8,,
6720,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; change of less than 5% of allosteric enhancement,Autocuration,,,F,,BAO_0000219,3850,,449.0,1,CHEMBL619495,CHO,,,H,8,,
6721,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; change of less than 5% of allosteric enhancement.,Autocuration,,,F,,BAO_0000219,3850,,449.0,1,CHEMBL619496,CHO,,,H,8,,
6722,Percent response to 10 uM PD-81723 on CHO cells expressing human A1-adenosine receptor at 0.1 uM; An increase of cAmp content of cells,Expert,9606.0,,F,,BAO_0000219,3850,,449.0,1,CHEMBL619497,CHO,,Homo sapiens,D,9,,
6723,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM,Autocuration,,,F,,BAO_0000219,3850,,449.0,1,CHEMBL619498,CHO,,,H,8,,
6724,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM; change of less than 5% of allosteric enhancement.,Autocuration,,,F,,BAO_0000219,3850,,449.0,1,CHEMBL619499,CHO,,,H,8,,
6725,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM concentration,Expert,,,F,,BAO_0000219,3850,,449.0,1,CHEMBL619500,CHO,,,H,8,,
6726,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM concentration; change of less than 5% of allosteric enhancement.,Autocuration,,,F,,BAO_0000219,3850,,449.0,1,CHEMBL619501,CHO,,,H,8,,
6727,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM; An increase of cAmp content of cells,Expert,,,F,,BAO_0000219,3850,,449.0,1,CHEMBL619502,CHO,,,H,8,,
6728,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM,Autocuration,,,F,,BAO_0000219,3850,,449.0,1,CHEMBL619503,CHO,,,H,8,,
6729,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; An increase of cAmp content of cells,Autocuration,,,F,,BAO_0000219,3850,,449.0,1,CHEMBL619504,CHO,,,H,8,,
6730,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; change of less than 5% of allosteric enhancement.,Autocuration,,,F,,BAO_0000219,3850,,449.0,1,CHEMBL621298,CHO,,,H,8,,
6731,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration,Expert,,,F,,BAO_0000219,3850,,449.0,1,CHEMBL621299,CHO,,,H,8,,
6732,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration; An increase of cAmp content of cells,Autocuration,,,F,,BAO_0000219,3850,,449.0,1,CHEMBL621300,CHO,,,H,8,,
6733,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration; change of less than 5% of allosteric enhancement.,Autocuration,,,F,,BAO_0000219,3850,,449.0,1,CHEMBL621301,CHO,,,H,8,,
6734,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; An increase of cAmp content of cells,Expert,,,F,,BAO_0000219,3850,,449.0,1,CHEMBL621302,CHO,,,H,8,,
6735,Ability to inhibit [125I]ET1 binding to vascular smooth muscle (vsm)- A10 cells,Intermediate,9986.0,,F,,BAO_0000219,12680,,164.0,1,CHEMBL621303,A10,,Oryctolagus cuniculus,N,1,,
6736,In vitro potassium channel opening activity in A10 (smooth muscle) cells,Autocuration,10116.0,,F,,BAO_0000219,1313,,164.0,1,CHEMBL621304,A10,,Rattus norvegicus,U,0,,
6737,In vitro potassium channel opening activity in A10 (smooth muscle) cells; Inactive,Autocuration,10116.0,,F,,BAO_0000219,1313,,164.0,1,CHEMBL621305,A10,,Rattus norvegicus,U,0,,
6738,Effect on membrane potential of mitochondria in A10 smooth muscle cells from rats,Intermediate,10116.0,,F,,BAO_0000219,17567,,164.0,1,CHEMBL621306,A10,,Rattus norvegicus,N,1,,
6739,Effect on membrane potential of mitochondria of A10 smooth muscle cells in rats,Intermediate,10116.0,,F,,BAO_0000219,17567,,164.0,1,CHEMBL618444,A10,,Rattus norvegicus,N,1,,
6740,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.001 uM,Intermediate,10116.0,,F,,BAO_0000219,11819,,164.0,1,CHEMBL618445,A10,,Rattus norvegicus,N,1,,
6741,Compound was tested for aerobic growth inhibition against AA8 cells after 4 hr of exposure,Intermediate,10029.0,,F,,BAO_0000219,13436,,185.0,1,CHEMBL618446,CHO-AA8,,Cricetulus griseus,N,1,,
6742,Concentration required to reduce AA8 cell numbers to 50% of controls in a growth inhibition microassay,Intermediate,10029.0,,F,,BAO_0000219,12687,,185.0,1,CHEMBL618447,CHO-AA8,,Cricetulus griseus,N,1,,
6743,Concentration of the drug to inhibit chinese hamster ovary derived cell (AA8) growth in culture,Intermediate,10029.0,,F,,BAO_0000219,12651,,185.0,1,CHEMBL618448,CHO-AA8,,Cricetulus griseus,N,1,,
6744,Cytotoxicity in a growth inhibition assay against aerobic cultures of AA8 cells was determined,Intermediate,10029.0,,F,,BAO_0000219,13300,,185.0,1,CHEMBL618449,CHO-AA8,,Cricetulus griseus,N,1,,
6745,Cytotoxicity on AA8 cell growth (reduce cell number by 50%).,Intermediate,10029.0,,F,,BAO_0000219,15296,,185.0,1,CHEMBL618637,CHO-AA8,,Cricetulus griseus,N,1,,
6746,"Cytotoxicity in chinese hamster ovary tumor cell line-AA8, by growth inhibition assay.",Intermediate,10029.0,,F,,BAO_0000219,15328,,185.0,1,CHEMBL618638,CHO-AA8,,Cricetulus griseus,N,1,,
6747,Growth inhibition activity was measured in repair proficient AA8 cells under aerobic conditions (4 hours drug exposure),Intermediate,10029.0,,F,,BAO_0000219,13302,,185.0,1,CHEMBL618639,CHO-AA8,,Cricetulus griseus,N,1,,
6748,"Growth inhibition of aerobic AA8 cells, after 18 hours exposure",Expert,10029.0,,F,,BAO_0000219,14367,,185.0,1,CHEMBL618640,CHO-AA8,,Cricetulus griseus,N,1,,
6749,In vitro cellular toxicity against chinese hamster AA8 cell line after 4 hr of compound exposure,Expert,10029.0,,F,,BAO_0000219,17002,,185.0,1,CHEMBL618641,CHO-AA8,,Cricetulus griseus,N,1,,
6750,Inhibitory activity against AA8 cell growth in aerobic condition after 4 hr of exposure,Intermediate,10029.0,,F,,BAO_0000219,13436,,185.0,1,CHEMBL618642,CHO-AA8,,Cricetulus griseus,N,1,,
6751,Inhibitory activity against aerobic growth of AA8 cells.,Intermediate,10029.0,,F,,BAO_0000219,13435,,185.0,1,CHEMBL618643,CHO-AA8,,Cricetulus griseus,N,1,,
6752,Tested for the in vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,Intermediate,10029.0,,A,,BAO_0000219,10503,,185.0,1,CHEMBL884013,CHO-AA8,,Cricetulus griseus,N,1,,
6753,In vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,Expert,10029.0,,F,,BAO_0000219,10503,,185.0,1,CHEMBL622723,CHO-AA8,,Cricetulus griseus,N,1,,
6754,Tested for the in vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,Intermediate,10029.0,,F,,BAO_0000219,10503,,185.0,1,CHEMBL622724,CHO-AA8,,Cricetulus griseus,N,1,,
6755,Tested for growth inhibition against AA8 tumor cell line(chinese hamster ovary).,Expert,10029.0,,F,,BAO_0000219,15090,,185.0,1,CHEMBL622725,CHO-AA8,,Cricetulus griseus,N,1,,
6756,Cytotoxicity against AA8 cell line,Expert,10029.0,,F,,BAO_0000219,10368,,185.0,1,CHEMBL622726,CHO-AA8,,Cricetulus griseus,N,1,,
6757,Hypersensitivity factor(HF) was determined as ratio of IC50(AA8) to IC50(UV4),Intermediate,10029.0,,F,,BAO_0000219,12651,,185.0,1,CHEMBL622727,CHO-AA8,,Cricetulus griseus,N,1,,
6758,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),Intermediate,10029.0,,A,,BAO_0000219,12687,,185.0,1,CHEMBL622728,CHO-AA8,,Cricetulus griseus,N,1,,
6759,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),Intermediate,10029.0,,F,,BAO_0000219,12687,,185.0,1,CHEMBL622729,CHO-AA8,,Cricetulus griseus,N,1,,
6760,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),Intermediate,10029.0,,A,,BAO_0000219,12687,,185.0,1,CHEMBL622730,CHO-AA8,,Cricetulus griseus,N,1,,
6761,Compound was evaluated for cytotoxicity against CHO AA8 cell lines for 4 hr at pH-7.4,Intermediate,10029.0,,F,,BAO_0000219,1890,,185.0,1,CHEMBL622731,CHO-AA8,,Cricetulus griseus,N,1,,
6762,Compound was evaluated for in vitro cytotoxicities against Chinese hamster ovary derived AA8 cell lines.,Intermediate,10029.0,,F,,BAO_0000219,10747,,185.0,1,CHEMBL622732,CHO-AA8,,Cricetulus griseus,N,1,,
6763,Compound was evaluated for in vitro cytotoxicities against Chinese hamster ovary derived AA8 cell lines.,Intermediate,10029.0,,F,,BAO_0000219,10747,,185.0,1,CHEMBL622733,CHO-AA8,,Cricetulus griseus,N,1,,
6764,Maximum tolerated dose (MTD) in C3H/HeN mice (single ip dose),Autocuration,10029.0,,F,,BAO_0000218,11616,,,1,CHEMBL622734,,,Cricetulus griseus,U,0,,
6765,Concentration required to increase radiation sensitivity by 1.3 when AA8 cells are exposed to drug for 30 min before and during irradiation under hypoxic condition.,Expert,10029.0,,F,,BAO_0000219,11616,,185.0,1,CHEMBL622735,CHO-AA8,,Cricetulus griseus,N,1,,
6766,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 1 hr under anoxic conditions,Autocuration,10029.0,,F,,BAO_0000219,3471,,185.0,1,CHEMBL618746,CHO-AA8,,Cricetulus griseus,U,0,,
6767,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 3h under anoxic conditions,Autocuration,10029.0,,F,,BAO_0000219,3471,,185.0,1,CHEMBL618747,CHO-AA8,,Cricetulus griseus,U,0,,
6768,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 4 hr under anoxic conditions,Autocuration,10029.0,,F,,BAO_0000219,3471,,185.0,1,CHEMBL620540,CHO-AA8,,Cricetulus griseus,U,0,,
6769,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 1 hr under aerobic conditions,Autocuration,10029.0,,F,,BAO_0000219,3471,,185.0,1,CHEMBL620541,CHO-AA8,,Cricetulus griseus,U,0,,
6770,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 3h under aerobic conditions,Autocuration,10029.0,,F,,BAO_0000219,3471,,185.0,1,CHEMBL620542,CHO-AA8,,Cricetulus griseus,U,0,,
6771,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 4 hr under aerobic conditions,Autocuration,10029.0,,F,,BAO_0000219,3471,,185.0,1,CHEMBL620543,CHO-AA8,,Cricetulus griseus,U,0,,
6772,Ratio of oxygen dependence of cytotoxicities of AA8 cells in aerobic condition to anoxic condition,Autocuration,10029.0,,F,,BAO_0000219,3471,,185.0,1,CHEMBL618832,CHO-AA8,,Cricetulus griseus,U,0,,
6773,Concentration required to reduce AA8 cell survival by 10%,Expert,10029.0,,F,,BAO_0000219,11616,,185.0,1,CHEMBL618833,CHO-AA8,,Cricetulus griseus,N,1,,
6774,"Concentration required to reduce cell survival to 10% of controls under hypoxic conditions, using the AA8 (chinese hamster) aerobic cells",Autocuration,10029.0,,F,,BAO_0000219,2656,,185.0,1,CHEMBL618834,CHO-AA8,,Cricetulus griseus,U,0,,
6775,Tested for the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay,Autocuration,10029.0,,F,,BAO_0000219,10518,,185.0,1,CHEMBL618835,CHO-AA8,,Cricetulus griseus,U,0,,
6776,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay,Autocuration,10029.0,,F,,BAO_0000219,10518,,185.0,1,CHEMBL618836,CHO-AA8,,Cricetulus griseus,U,0,,
6777,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay; range is 0.8-1.5,Autocuration,10029.0,,F,,BAO_0000219,10518,,185.0,1,CHEMBL618837,CHO-AA8,,Cricetulus griseus,U,0,,
6778,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay; range is 1-2,Autocuration,10029.0,,F,,BAO_0000219,10518,,185.0,1,CHEMBL618838,CHO-AA8,,Cricetulus griseus,U,0,,
6779,Ability to reduce cell density of AA8 cells to 50% after 4 hr of exposure to air,Autocuration,10029.0,,F,,BAO_0000219,16156,,185.0,1,CHEMBL618839,CHO-AA8,,Cricetulus griseus,U,0,,
6780,Aerobic cytotoxic activity was evaluated by the growth inhibition of AA8 (chinese hamster) aerobic cells,Autocuration,10029.0,,F,,BAO_0000219,2656,,185.0,1,CHEMBL618840,CHO-AA8,,Cricetulus griseus,U,0,,
6781,"Compound was evaluated for the inhibition of cell growth in culture against Chinese hamster ovary derived cell line, AA8",Autocuration,10029.0,,F,,BAO_0000019,11005,,,1,CHEMBL618841,,,Cricetulus griseus,U,0,,
6782,Concentration for 50% inhibition of AA8 cells growth under aerobic conditions after 18 hours exposure,Autocuration,10029.0,,F,,BAO_0000219,11942,,185.0,1,CHEMBL618842,CHO-AA8,,Cricetulus griseus,U,0,,
6783,Concentration required for 50% inhibition of growth of AA8 cells following 4 hr drug exposure,Autocuration,10029.0,,F,,BAO_0000219,2128,,185.0,1,CHEMBL618843,CHO-AA8,,Cricetulus griseus,U,0,,
6784,Half life period after 15 mg/kg iv dose in Dogs,Intermediate,9615.0,,A,,BAO_0000218,16907,,,1,CHEMBL618844,,,Canis lupus familiaris,N,1,,
6785,Half life period after 30 mg/kg po dose in Dogs,Intermediate,9615.0,,A,,BAO_0000218,16907,,,1,CHEMBL618845,,,Canis lupus familiaris,N,1,,
6786,Half life was measured after oral 2b administration (tested in 6 dogs),Intermediate,9615.0,,A,,BAO_0000218,9579,,,1,CHEMBL618846,,,Canis lupus familiaris,N,1,,
6787,Half life was measured in dog after oral 17b administration,Intermediate,9615.0,,A,,BAO_0000218,9579,,,1,CHEMBL618847,,,Canis lupus familiaris,N,1,,
6788,Pharmacokinetic parameter T max determined in dog after oral administration of 17b,Intermediate,9615.0,,A,,BAO_0000218,9579,,,1,CHEMBL618848,,,Canis lupus familiaris,N,1,,
6789,Pharmacokinetic parameter T max determined in dog after oral administration of 2b,Intermediate,9615.0,,A,,BAO_0000218,9579,,,1,CHEMBL618849,,,Canis lupus familiaris,N,1,,
6790,Tmax value after 15 mg/kg iv dose in Dogs,Intermediate,9615.0,,A,,BAO_0000218,16907,,,1,CHEMBL618850,,,Canis lupus familiaris,N,1,,
6791,Tmax value after 30 mg/kg po dose in Dogs,Intermediate,9615.0,,A,,BAO_0000218,16907,,,1,CHEMBL618851,,,Canis lupus familiaris,N,1,,
6792,Compound was evaluated for its half life when administered intravenously in dog,Intermediate,9615.0,,A,,BAO_0000218,3184,,,1,CHEMBL873815,,,Canis lupus familiaris,N,1,,
6793,Compound was tested for plasma half life when administered in dog perorally (1 mg/kg) and intravenously (0.2 mg/kg),Intermediate,9615.0,,A,,BAO_0000218,5017,,,1,CHEMBL618852,,,Canis lupus familiaris,N,1,1969.0,
6794,Elimination Half-life of compound was determined in dog,Intermediate,9615.0,,A,,BAO_0000218,6821,,,1,CHEMBL618853,,,Canis lupus familiaris,N,1,,
6795,Half life of compound in dog following oral administration,Intermediate,9615.0,,A,,BAO_0000218,17839,,,1,CHEMBL618854,,,Canis lupus familiaris,N,1,,
6796,Half life of compound was determined in dog,Intermediate,9615.0,,A,,BAO_0000218,17267,,,1,CHEMBL618855,,,Canis lupus familiaris,N,1,,
6797,Half life of compound was determined in dog blood,Intermediate,9615.0,,A,,BAO_0000218,4727,,,1,CHEMBL618856,,,Canis lupus familiaris,N,1,178.0,
6798,Half life after oral and iv dosing in dogs,Intermediate,9615.0,,A,,BAO_0000218,5238,,,1,CHEMBL875827,,,Canis lupus familiaris,N,1,,
6799,Half life in dogs in hours,Intermediate,9615.0,,A,,BAO_0000218,4942,,,1,CHEMBL618857,,,Canis lupus familiaris,N,1,,
6800,Half life on i.v. administration of 2 mg/kg was measured in dog,Intermediate,9615.0,,A,,BAO_0000218,6505,,,1,CHEMBL618858,,,Canis lupus familiaris,N,1,,
6801,t1/2 in dog after oral dose (1 mg/kg),Intermediate,9615.0,,A,,BAO_0000218,5130,,,1,CHEMBL618859,,,Canis lupus familiaris,N,1,,
6802,Half life was evaluated in dog,Intermediate,9615.0,,A,,BAO_0000218,1475,,,1,CHEMBL618860,,,Canis lupus familiaris,N,1,,
6803,Half life period of compound was determined after intravenous administration at 2 mg/kg,Intermediate,9615.0,,A,,BAO_0000218,17804,,,1,CHEMBL618861,,,Canis lupus familiaris,N,1,,
6804,Half life period of compound was determined after peroral administration at 2 mg/kg,Intermediate,9615.0,,A,,BAO_0000218,17804,,,1,CHEMBL622539,,,Canis lupus familiaris,N,1,,
6805,Half life period (10 mg/kg) was determined in dog,Intermediate,9615.0,,A,,BAO_0000218,6084,,,1,CHEMBL622540,,,Canis lupus familiaris,N,1,,
6806,Half life period (10 mg/kg) was determined in dog,Intermediate,9615.0,,A,,BAO_0000218,6084,,,1,CHEMBL873803,,,Canis lupus familiaris,N,1,,
6807,Half life period by iv administration in dog at a dose of 0.3 mg/kg,Intermediate,9615.0,,A,,BAO_0000218,5542,,,1,CHEMBL873804,,,Canis lupus familiaris,N,1,,
6808,Half life period by po administration in dog at a dose of 0.3 mg/kg,Intermediate,9615.0,,A,,BAO_0000218,5542,,,1,CHEMBL624311,,,Canis lupus familiaris,N,1,,
6809,Half life period in dog,Intermediate,9615.0,,A,,BAO_0000218,6084,,,1,CHEMBL624312,,,Canis lupus familiaris,N,1,,
6810,Half life period in dogs after oral administration at 1 mg/kg,Intermediate,9615.0,,A,,BAO_0000218,6241,,,1,CHEMBL624313,,,Canis lupus familiaris,N,1,,
6811,Half life period was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,Intermediate,9615.0,,A,,BAO_0000218,1916,,,1,CHEMBL624314,,,Canis lupus familiaris,N,1,,
6812,Half-life of compound was determined in dogs,Intermediate,9615.0,,A,,BAO_0000218,6621,,,1,CHEMBL624315,,,Canis lupus familiaris,N,1,,
6813,Half-life in dog plasma,Intermediate,9615.0,,A,,BAO_0000218,1696,,,1,CHEMBL624316,,,Canis lupus familiaris,N,1,1969.0,
6814,Half-life in mongrel dogs was determined,Intermediate,9615.0,,A,,BAO_0000218,17800,,,1,CHEMBL624317,,,Canis lupus familiaris,N,1,,
6815,Half-life in dog upon oral administration,Intermediate,9615.0,,A,,BAO_0000218,17657,,,1,CHEMBL624318,,,Canis lupus familiaris,N,1,,
6816,Half-life in dog upon oral administration; Unable to calculate,Intermediate,9615.0,,A,,BAO_0000218,17657,,,1,CHEMBL624319,,,Canis lupus familiaris,N,1,,
6817,Half-life was measured in dog,Intermediate,9615.0,,A,,BAO_0000218,4239,,,1,CHEMBL624496,,,Canis lupus familiaris,N,1,,
6818,Half-life was measured in dog,Intermediate,9615.0,,A,,BAO_0000218,5985,,,1,CHEMBL624497,,,Canis lupus familiaris,N,1,,
6819,Half-recovery time (T1/2) of the vascular resistance decrease at ED30 in anesthetized dogs,Intermediate,9615.0,,A,,BAO_0000218,9932,,,1,CHEMBL624498,,,Canis lupus familiaris,N,1,,
6820,Oral half life was determined,Intermediate,9615.0,,A,,BAO_0000218,5199,,,1,CHEMBL624499,,,Canis lupus familiaris,N,1,,
6821,Plasma elimination half-life (08 h) was determined in canine following intravenous (iv) administration (1 mg/kg).,Intermediate,9615.0,,A,,BAO_0000218,5199,,,1,CHEMBL624500,,,Canis lupus familiaris,N,1,1969.0,
6822,Plasma half life was evaluated,Intermediate,9615.0,,A,,BAO_0000218,1475,,,1,CHEMBL624501,,,Canis lupus familiaris,N,1,1969.0,
6823,Plasma half life was evaluated in Dog,Intermediate,9615.0,,A,,BAO_0000218,1475,,,1,CHEMBL623666,,,Canis lupus familiaris,N,1,1969.0,
6824,Plasma half life was evaluated in dog,Intermediate,9615.0,,A,,BAO_0000218,1475,,,1,CHEMBL623667,,,Canis lupus familiaris,N,1,1969.0,
6825,T1/2 (Half-life) was after oral administration at 5 mg/kg,Intermediate,9615.0,,A,,BAO_0000218,6316,,,1,CHEMBL623668,,,Canis lupus familiaris,N,1,,
6826,Tested for the half life value in dog,Intermediate,9615.0,,A,,BAO_0000218,4883,,,1,CHEMBL623669,,,Canis lupus familiaris,N,1,,
6827,Maximum time at the dose of 2 mg/kg in dog,Intermediate,9615.0,,A,,BAO_0000218,4727,,,1,CHEMBL623670,,,Canis lupus familiaris,N,1,,
6828,Maximum time was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,Intermediate,9615.0,,A,,BAO_0000218,1916,,,1,CHEMBL623671,,,Canis lupus familiaris,N,1,,
6829,Maximum time taken to reach maximum blood concentration was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,Intermediate,9615.0,,A,,BAO_0000218,1337,,,1,CHEMBL875945,,,Canis lupus familiaris,N,1,178.0,
6830,Maximum time taken to reach maximum blood concentration was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,Intermediate,9615.0,,A,,BAO_0000218,1337,,,1,CHEMBL623672,,,Canis lupus familiaris,N,1,178.0,
6831,Pharmacokinetic (PK) property (Tmax) was determined in dog at the single dose of 1 mg/kg,Intermediate,9615.0,,A,,BAO_0000218,6265,,,1,CHEMBL623673,,,Canis lupus familiaris,N,1,,
6832,Pharmacokinetic parameter Tmax was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),Intermediate,9615.0,,A,,BAO_0000218,4809,,,1,CHEMBL623674,,,Canis lupus familiaris,N,1,,
6833,Pharmacokinetic property (Tmax) was measured in dog at the dose of 0.032 mg/kg p.o.,Intermediate,9615.0,,A,,BAO_0000218,5983,,,1,CHEMBL623675,,,Canis lupus familiaris,N,1,,
6834,"Tested for the pharmacokinetic data, time required to reach Cmax (Tmax) in dog",Intermediate,9615.0,,A,,BAO_0000218,5313,,,1,CHEMBL872526,,,Canis lupus familiaris,N,1,,
6835,"Tested for the pharmacokinetic data, time required to reach Cmax (Tmax) in dog at dosage of 10 mpk",Intermediate,9615.0,,A,,BAO_0000218,5313,,,1,CHEMBL623676,,,Canis lupus familiaris,N,1,,
6836,Time for maximum plasma concentration was measured in dogs after an oral dose of 10 uM/kg,Intermediate,9615.0,,A,,BAO_0000218,17650,,,1,CHEMBL623677,,,Canis lupus familiaris,N,1,1969.0,
6837,Time taken by the compound to achieve maximum plasma concentration at a 1 mg/kg oral dose in male and female Beagle dogs.,Intermediate,9615.0,,A,,BAO_0000218,5199,,,1,CHEMBL623678,,,Canis lupus familiaris,N,1,1969.0,
6838,Time taken for maximum plasma concentration in dog,Intermediate,9615.0,,A,,BAO_0000218,933,,,1,CHEMBL623679,,,Canis lupus familiaris,N,1,1969.0,
6839,Time to reach Cmax after oral administration to dogs,Intermediate,9615.0,,A,,BAO_0000218,16367,,,1,CHEMBL623680,,,Canis lupus familiaris,N,1,,
6840,Time to reach maximum plasma concentration was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,Intermediate,9615.0,,A,,BAO_0000218,6348,,,1,CHEMBL623681,,,Canis lupus familiaris,N,1,1969.0,
6841,Tmax (time to reach maximum concentration) was after oral administration at 5 mg/kg,Intermediate,9615.0,,A,,BAO_0000218,6316,,,1,CHEMBL623682,,,Canis lupus familiaris,N,1,,
6842,Tmax after peroral administration (1 mg/kg) was determined in dog,Intermediate,9615.0,,A,,BAO_0000218,6215,,,1,CHEMBL623683,,,Canis lupus familiaris,N,1,,
6843,Tmax of compound determined in dog after iv administration at a dose of 10 mg/kg,Expert,9615.0,,A,,BAO_0000218,3598,,,1,CHEMBL623684,,,Canis lupus familiaris,N,1,,
6844,Tmax by oral administration at a dose of 10 uM/kg in dog was determined,Intermediate,9615.0,,A,,BAO_0000218,4527,,,1,CHEMBL622745,,,Canis lupus familiaris,N,1,,
6845,Tmax after peroral administration in dogs at 2.4 uM/kg,Intermediate,9615.0,,A,,BAO_0000218,17764,,,1,CHEMBL622746,,,Canis lupus familiaris,N,1,,
6846,In vivo Cmax in mice at dose of 100 mg/kg,Intermediate,10090.0,,A,,BAO_0000218,5969,,,1,CHEMBL622747,,,Mus musculus,N,1,,
6847,In vivo Cmax in mice at dose of 50 mg/kg,Intermediate,10090.0,,A,,BAO_0000218,5969,,,1,CHEMBL622748,,,Mus musculus,N,1,,
6848,Maximal concentration determined at a dose 10 mg/kg administered intraperitoneally to mice,Intermediate,10090.0,,A,,BAO_0000218,4573,,,1,CHEMBL622749,,,Mus musculus,N,1,,
6849,Maximum plasma concentration was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),Intermediate,10090.0,,A,,BAO_0000218,3277,,,1,CHEMBL622750,,,Mus musculus,N,1,1969.0,
6850,Maximum concentration in plasma was determined after intraperitoneal administration of 100 mg/kg in mice,Intermediate,10090.0,,A,,BAO_0000218,17734,,,1,CHEMBL623411,,,Mus musculus,N,1,1969.0,
6851,Maximum concentration obtained in mouse plasma was determined,Intermediate,10090.0,,A,,BAO_0000218,3132,,,1,CHEMBL875946,,,Mus musculus,N,1,1969.0,
6852,Maximum concentration obtained in mouse plasma was determined at dose 25 mg/kg,Intermediate,10090.0,,A,,BAO_0000218,3132,,,1,CHEMBL623412,,,Mus musculus,N,1,1969.0,
6853,Maximum plasma concentration of compound was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,Intermediate,10090.0,,A,,BAO_0000218,6348,,,1,CHEMBL623413,,,Mus musculus,N,1,1969.0,
6854,Maximum plasma concentration when injected i.p. in mice at a dose of 50 mg/kg,Intermediate,10090.0,,A,,BAO_0000218,17729,,,1,CHEMBL623414,,,Mus musculus,N,1,1969.0,
6855,Maximum plasma concentration when injected intravenously in mice at a dose of 20 mg/kg,Intermediate,10090.0,,A,,BAO_0000218,17729,,,1,CHEMBL623415,,,Mus musculus,N,1,1969.0,
6856,Maximum plasma concentration when injected perorally in mice at a dose of 50 mg/kg,Intermediate,10090.0,,A,,BAO_0000218,17729,,,1,CHEMBL623416,,,Mus musculus,N,1,1969.0,
6857,Maximal plasma concentration in BALB/C mice after 20 mg/kg intraperitoneal dose,Intermediate,10090.0,,A,,BAO_0000218,17728,,,1,CHEMBL623417,,,Mus musculus,N,1,1969.0,
6858,Maximal plasma concentration in BALB/C mice after 20 mg/kg intravenous dose,Intermediate,10090.0,,A,,BAO_0000218,17728,,,1,CHEMBL623418,,,Mus musculus,N,1,1969.0,
6859,Maximal plasma concentration in BALB/C mice after 50 mg/kg oral dose,Intermediate,10090.0,,A,,BAO_0000218,17728,,,1,CHEMBL623419,,,Mus musculus,N,1,1969.0,
6860,Peak concentration at a single subcutaneous administration of 40 mg/kg in mice,Intermediate,10090.0,,A,,BAO_0000218,4066,,,1,CHEMBL622816,,,Mus musculus,N,1,,
6861,Pharmacokinetic property (C(max)) was determined after ip administration of 32 mg/kg in mice,Intermediate,10090.0,,A,,BAO_0000218,6178,,,1,CHEMBL623313,,,Mus musculus,N,1,,
6862,Pharmacokinetic property (C(max)) was determined after po administration of 32 mg/kg in mice,Intermediate,10090.0,,A,,BAO_0000218,6178,,,1,CHEMBL623314,,,Mus musculus,N,1,,
6863,Pharmacokinetic studies were carried out in vivo after administration of compound at 5 mg/kg intravenously in mice,Intermediate,10090.0,,A,,BAO_0000218,3760,,,1,CHEMBL876788,,,Mus musculus,N,1,,
6864,Pharmacokinetic studies were carried out in vivo after administration of compound at 5 mg/kg perorally in mice,Intermediate,10090.0,,A,,BAO_0000218,3760,,,1,CHEMBL623315,,,Mus musculus,N,1,,
6865,Pharmacokinetic studies were carried out in vivo after administration of compound at 50 mg/kg intravenously in mice,Intermediate,10090.0,,A,,BAO_0000218,3760,,,1,CHEMBL623316,,,Mus musculus,N,1,,
6866,Pharmacokinetic studies were carried out in vivo after administration of compound at 50 mg/kg perorally in mice,Intermediate,10090.0,,A,,BAO_0000218,3760,,,1,CHEMBL623317,,,Mus musculus,N,1,,
6868,Cmax in male mice after 2 mg/kg oral dose,Intermediate,10090.0,,A,,BAO_0000218,5961,,,1,CHEMBL623319,,,Mus musculus,N,1,,
6869,Plasma concentration of 5-FU in HT-3 (human cervical cancer) xenograft mice at 1.38 mg/kg oral dose co-administered with 135 mg/kg Capecitabine,Intermediate,10090.0,,A,,BAO_0000218,6137,,,1,CHEMBL623320,,,Mus musculus,N,1,,
6870,Tested for Cmax value at the dose of 10 mg/kg when administered perorally in mouse,Intermediate,10090.0,,A,,BAO_0000218,3802,,,1,CHEMBL623321,,,Mus musculus,N,1,,
6871,Concentration in plasma (systemic) following oral dose in mouse at 0.25 hr,Intermediate,10090.0,,A,,BAO_0000218,3535,,,1,CHEMBL623322,,,Mus musculus,N,1,,
6872,Concentration in plasma (systemic) following oral dose in mouse at 1 hr,Intermediate,10090.0,,A,,BAO_0000218,3535,,,1,CHEMBL623323,,,Mus musculus,N,1,,
6873,Concentration in plasma (systemic) following oral dose in mouse at 24 hr,Intermediate,10090.0,,A,,BAO_0000218,3535,,,1,CHEMBL623324,,,Mus musculus,N,1,,
6874,Concentration in plasma (systemic) following oral dose in mouse at 2 hr,Intermediate,10090.0,,A,,BAO_0000218,3535,,,1,CHEMBL623325,,,Mus musculus,N,1,,
6875,Concentration in plasma (systemic) following oral dose in mouse at 4 hr,Intermediate,10090.0,,A,,BAO_0000218,3535,,,1,CHEMBL623326,,,Mus musculus,N,1,,
6876,Concentration in plasma (systemic) following oral dose in mouse at 6 hr,Intermediate,10090.0,,A,,BAO_0000218,3535,,,1,CHEMBL623327,,,Mus musculus,N,1,,
6877,Maximum concentration in plasma upon oral administration in mouse,Intermediate,10090.0,,A,,BAO_0000218,2862,,,1,CHEMBL623328,,,Mus musculus,N,1,1969.0,
6878,Maximum plasma concentration was evaluated in mice after oral administration,Intermediate,10090.0,,A,,BAO_0000218,2675,,,1,CHEMBL623329,,,Mus musculus,N,1,1969.0,
6879,Maximum plasma concentration was evaluated in mice after intravenous administration; Cp max Not determined,Intermediate,10090.0,,A,,BAO_0000218,2675,,,1,CHEMBL623330,,,Mus musculus,N,1,1969.0,
6880,Dose at which the compound induced fecal excretion in mice,Intermediate,10090.0,,A,,BAO_0000218,5399,,,1,CHEMBL876789,,,Mus musculus,N,1,,
6893,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.01 uM,Expert,10116.0,,F,,BAO_0000219,11819,,164.0,1,CHEMBL623333,A10,,Rattus norvegicus,N,1,,
6894,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.1 uM,Expert,10116.0,,F,,BAO_0000219,11819,,164.0,1,CHEMBL623334,A10,,Rattus norvegicus,N,1,,
6895,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 1.0 uM,Expert,10116.0,,F,,BAO_0000219,11819,,164.0,1,CHEMBL627536,A10,,Rattus norvegicus,N,1,,
6896,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 10.0 uM,Expert,10116.0,,F,,BAO_0000219,11819,,164.0,1,CHEMBL627537,A10,,Rattus norvegicus,N,1,,
6897,In vitro [14C]- creatine uptake (1 mM) was determined in rat A10 smooth muscle cells at a concentration of (1 mM),Intermediate,10116.0,,F,,BAO_0000219,16361,,164.0,1,CHEMBL627538,A10,,Rattus norvegicus,N,1,,
6898,Cytotoxicity was evaluated against A121 ovarian carcinoma human cancer cell line,Intermediate,9606.0,,F,,BAO_0000219,2288,,393.0,1,CHEMBL884106,A121,,Homo sapiens,N,1,,
6899,Anticancer activity against human ovarian carcinoma A121 cells,Intermediate,9606.0,,F,,BAO_0000219,10404,,393.0,1,CHEMBL625294,A121,,Homo sapiens,N,1,,
6900,Cytotoxic effect (tumor cell growth inhibition) on the human cell line A121 ovarian carcinoma at the dose of of 16.6 mM,Intermediate,9606.0,,F,,BAO_0000219,14790,,393.0,1,CHEMBL625295,A121,,Homo sapiens,N,1,,
6901,Cytotoxic effect (tumor cell growth inhibition) on the human cell line A121 ovarian carcinoma at the dose of of 83 mM,Intermediate,9606.0,,F,,BAO_0000219,14790,,393.0,1,CHEMBL625296,A121,,Homo sapiens,N,1,,
6902,Growth inhibition of human ovarian carcinoma (A121) cell line,Expert,9606.0,,F,,BAO_0000219,14253,,393.0,1,CHEMBL625297,A121,,Homo sapiens,N,1,,
6903,Concentration required to inhibit growth of human tumor A121 (ovarian) cell line.,Expert,9606.0,,F,,BAO_0000219,13617,,393.0,1,CHEMBL625298,A121,,Homo sapiens,N,1,,
6904,Cytotoxicity against human A121 ovarian cells,Intermediate,9606.0,,F,,BAO_0000219,1003,,393.0,1,CHEMBL625960,A121,,Homo sapiens,N,1,,
6905,Cytotoxicity was evaluated in vitro against A121 (ovarian carcinoma) human tumor cell lines,Intermediate,9606.0,,F,,BAO_0000219,830,,393.0,1,CHEMBL625961,A121,,Homo sapiens,N,1,,
6906,In vitro cytotoxicity against human ovarian carcinoma A21,Intermediate,9606.0,,F,,BAO_0000219,12307,,393.0,1,CHEMBL625962,A121,,Homo sapiens,N,1,,
6907,Inhibition of the growth against human Ovarian Carcinoma (A121) cell line after 72 hr exposure,Intermediate,9606.0,,F,,BAO_0000219,14254,,393.0,1,CHEMBL624717,A121,,Homo sapiens,N,1,,
6908,Inhibitory activity of compound against human A121 ovarian cell line.,Intermediate,9606.0,,F,,BAO_0000219,13370,,393.0,1,CHEMBL624718,A121,,Homo sapiens,N,1,,
6909,Dose at which compound exhibits cytotoxicity in the A121 ovarian carcinoma cell line.,Intermediate,9606.0,,F,,BAO_0000219,14790,,393.0,1,CHEMBL624719,A121,,Homo sapiens,N,1,,
6910,Inhibition of growth of human ovarian tumor cell line (A121) after 72 hr of drug exposure,Intermediate,9606.0,,F,,BAO_0000219,3614,,393.0,1,CHEMBL624720,A121,,Homo sapiens,N,1,,
6911,Compound was evaluated for in vitro antiproliferative activity against A172 human CNS cancer cell line,Intermediate,9606.0,,F,,BAO_0000219,2664,,622.0,1,CHEMBL624721,A 172,,Homo sapiens,N,1,,
6912,In vitro cytotoxicity against A172 human tumor cell lines.,Expert,9606.0,,F,,BAO_0000219,2037,,622.0,1,CHEMBL624722,A 172,,Homo sapiens,N,1,,
6913,Growth inhibition time for A172 Human Glioma cell growth at concentration 5 uM,Intermediate,9606.0,,F,,BAO_0000219,14539,,622.0,1,CHEMBL877597,A 172,,Homo sapiens,N,1,,
6914,Compound was evaluated for cytotoxicity against human glioblastoma (A172) cell line,Intermediate,9606.0,,F,,BAO_0000219,2836,,622.0,1,CHEMBL624723,A 172,,Homo sapiens,N,1,,
6915,Evaluated for the inhibitory concentration required to cause growth inhibition of A172Mer- cell line of central nervous system (CNS) using the MTT Cytotoxicity Assay,Intermediate,9606.0,,F,,BAO_0000219,10708,,622.0,1,CHEMBL624724,A 172,,Homo sapiens,N,1,,
6916,Association constant against A2 adenosine receptor,Autocuration,9615.0,,B,,BAO_0000224,8975,,,1,CHEMBL624725,,,Canis lupus familiaris,H,4,,
6917,In vitro effective dose that causes 50% inhibition of growth of A2 cell line - amelanotic melanoma,Intermediate,,,F,,BAO_0000219,7645,,1085.0,1,CHEMBL624726,A2,,fish,N,1,,
6918,Ratio of Ki for adenosine A2 and A1 receptor binding,Autocuration,10116.0,,B,,BAO_0000224,11377,,,1,CHEMBL857535,,,Rattus norvegicus,D,5,,
6919,In vitro cytotoxicity against A204 human rhabdomyosarcoma cancer cell line,Expert,9606.0,,F,,BAO_0000219,13528,,623.0,1,CHEMBL624727,A204,,Homo sapiens,N,1,,
6920,In vitro antitumor activity against A204 rhabdomyosarcoma tumor cell line was determined,Expert,9606.0,,F,,BAO_0000219,10160,,623.0,1,CHEMBL624728,A204,,Homo sapiens,N,1,,
6921,The compound was tested in vitro for antiproliferative activity against A2058 tumor cell lines,Intermediate,9606.0,,F,,BAO_0000219,15144,,404.0,1,CHEMBL624729,A2058,,Homo sapiens,N,1,,
6922,Growth inhibition against Human squamous cell line(A 253),Intermediate,9606.0,,F,,BAO_0000219,13160,,973.0,1,CHEMBL624730,A253 cell line,,Homo sapiens,N,1,,
6923,Growth inhibition of human squamous carcinoma cell lines following continuous (120 hours) exposure to MTX and compound A253 cell line,Intermediate,9606.0,,F,,BAO_0000219,12898,,973.0,1,CHEMBL624731,A253 cell line,,Homo sapiens,N,1,,
6924,The compound was tested for Growth inhibition of the human squamous cell carcinoma A253 cells,Intermediate,9606.0,,F,,BAO_0000219,13069,,973.0,1,CHEMBL624732,A253 cell line,,Homo sapiens,N,1,,
6925,Growth inhibition of A253 cell lines.,Intermediate,9606.0,,F,,BAO_0000219,15984,,973.0,1,CHEMBL883245,A253 cell line,,Homo sapiens,N,1,,
6926,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h),Intermediate,9606.0,,F,,BAO_0000219,15564,,973.0,1,CHEMBL624733,A253 cell line,,Homo sapiens,N,1,,
6927,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h); ND means not determined,Intermediate,9606.0,,F,,BAO_0000219,15564,,973.0,1,CHEMBL624734,A253 cell line,,Homo sapiens,N,1,,
6928,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h); ND means not determined,Intermediate,9606.0,,F,,BAO_0000219,15564,,973.0,1,CHEMBL624735,A253 cell line,,Homo sapiens,N,1,,
6929,In vitro cytotoxicity causing 50% growth inhibition was determined against A270 (human ovarian cancer)cell line,Intermediate,9606.0,,F,,BAO_0000219,4720,,478.0,1,CHEMBL621780,A2780,,Homo sapiens,N,1,,
6930,Antitumor activity of compound for 96-h exposure in A2780 human ovarian cell line,Intermediate,9606.0,,F,,BAO_0000219,16112,,478.0,1,CHEMBL877598,A2780,,Homo sapiens,N,1,,
6931,Cytotoxic activity against A2780 human ovarian carcinoma cell line,Expert,9606.0,,F,,BAO_0000219,16597,,478.0,1,CHEMBL621781,A2780,,Homo sapiens,N,1,,
6932,Cytotoxicity against human cancer cell lines A2780 (ovarian),Intermediate,9606.0,,F,,BAO_0000219,16378,,478.0,1,CHEMBL621782,A2780,,Homo sapiens,N,1,,
6933,Growth and colony formation inhibition of A2780 ovarian cancer cell lines,Expert,9606.0,,F,,BAO_0000219,16085,,478.0,1,CHEMBL621783,A2780,,Homo sapiens,N,1,,
6934,Inhibition of cell growth in human ovarian carcinoma cell line (A2780) using the 96 hour continuous exposure sulforhodamine B (SRB) growth delay assay,Intermediate,9606.0,,F,,BAO_0000219,16317,,478.0,1,CHEMBL621784,A2780,,Homo sapiens,N,1,,
6935,The compound was tested for cytotoxic activity against A2780 cell line(human ovarian carcinoma ),Intermediate,9606.0,,F,,BAO_0000219,15748,,478.0,1,CHEMBL621785,A2780,,Homo sapiens,N,1,,
6936,Inhibition of A2780 / DDP-R human ovarian carcinoma cell proliferation,Expert,9606.0,,F,,BAO_0000219,16597,,478.0,1,CHEMBL621968,A2780,,Homo sapiens,N,1,,
6937,Inhibition of A2780 / TAX-R human ovarian carcinoma cell proliferation,Expert,9606.0,,F,,BAO_0000219,16597,,478.0,1,CHEMBL621969,A2780,,Homo sapiens,N,1,,
6938,Inhibition of A2780 / TAX-S human ovarian carcinoma cell proliferation,Expert,9606.0,,F,,BAO_0000219,16597,,478.0,1,CHEMBL621970,A2780,,Homo sapiens,N,1,,
6939,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 2,Intermediate,9606.0,,F,,BAO_0000219,15608,,478.0,1,CHEMBL621971,A2780,,Homo sapiens,N,1,,
6940,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 3,Intermediate,9606.0,,F,,BAO_0000219,15608,,478.0,1,CHEMBL621972,A2780,,Homo sapiens,N,1,,
6941,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 5,Intermediate,9606.0,,F,,BAO_0000219,15608,,478.0,1,CHEMBL884108,A2780,,Homo sapiens,N,1,,
6942,Cytotoxicity on AA8 cell growth (reduce cell number by 50%).,Autocuration,10029.0,,F,,BAO_0000019,15296,,,1,CHEMBL623826,,,Cricetulus griseus,U,0,,
6943,Evaluated for cytotoxicity under aerobic conditions against AA8 cells using microassay,Autocuration,10029.0,,A,,BAO_0000219,10251,,185.0,1,CHEMBL623827,CHO-AA8,,Cricetulus griseus,U,0,,
6944,Evaluated for growth inhibition of AA8 cells under aerobic conditions,Autocuration,10029.0,,F,,BAO_0000219,10251,,185.0,1,CHEMBL623828,CHO-AA8,,Cricetulus griseus,U,0,,
6945,Evaluated for growth inhibition of AA8 cells under aerobic or hypoxic conditions,Autocuration,10029.0,,F,,BAO_0000219,10251,,185.0,1,CHEMBL623829,CHO-AA8,,Cricetulus griseus,U,0,,
6946,Evaluated for growth inhibition of AA8 cells under aerobic or hypoxic conditions (air/N2),Autocuration,10029.0,,F,,BAO_0000219,10251,,185.0,1,CHEMBL623830,CHO-AA8,,Cricetulus griseus,U,0,,
6947,Growth inhibition against CHO-derived cell line AA8,Autocuration,10029.0,,F,,BAO_0000019,11858,,,1,CHEMBL623831,,,Cricetulus griseus,U,0,,
6948,Growth inhibition against CHO-derived cell line AA8 (Non toxic at solubility limit) [RB6145 used as positive control],Autocuration,10029.0,,F,,BAO_0000219,11858,,185.0,1,CHEMBL623832,CHO-AA8,,Cricetulus griseus,U,0,,
6949,Growth inhibition in CHO subline AA8 cells exposed for 18 hr under aerobic(air) conditions,Expert,36483.0,,F,,BAO_0000219,11616,,185.0,1,CHEMBL623833,CHO-AA8,,hampster,N,1,,
6950,Growth inhibitory activity against CHO subline AA8 cells exposed for 18 hr under aerobic conditions,Expert,10029.0,,F,,BAO_0000219,11616,,185.0,1,CHEMBL623834,CHO-AA8,,Cricetulus griseus,N,1,,
6951,Tested for the concentration of the drug to reduce cell numbers to 50 percent of controls against AA8 cells in the microassay,Autocuration,10029.0,,F,,BAO_0000219,10518,,185.0,1,CHEMBL623835,CHO-AA8,,Cricetulus griseus,U,0,,
6952,Growth inhibition of aerobic chinese hamster ovary fibroblast AA8 cell line using an exposure time of 18 hours,Autocuration,10029.0,,F,,BAO_0000219,11396,,185.0,1,CHEMBL623836,CHO-AA8,,Cricetulus griseus,U,0,,
6953,IC50 (air/N2) ratio of the drug to reduce cell numbers to 50 percent of controls using AA8 cells in the microassay,Autocuration,10029.0,,F,,BAO_0000219,10518,,185.0,1,CHEMBL623837,CHO-AA8,,Cricetulus griseus,U,0,,
6954,In vitro therapeutic index as ratio of CT10 and C1.3 calculated for AA8 cells.,Expert,10029.0,,F,,BAO_0000219,11616,,185.0,1,CHEMBL623838,CHO-AA8,,Cricetulus griseus,N,1,,
6955,compound was evaluated for association constant (Ka) of isolated serum protein AAG,Autocuration,,,F,,BAO_0000019,14837,,,1,CHEMBL623839,,,,H,8,,
6956,Number of binding sites (n) of isolated serum protein AAG,Autocuration,,,F,,BAO_0000019,14837,,,1,CHEMBL623840,,,,H,8,,
6957,Association constant for binding to AATT duplex,Intermediate,,,B,,BAO_0000225,16037,,,1,CHEMBL623841,,,,M,3,,
6958,Inhibition of ABAE human fibroblast cell proliferation,Expert,9606.0,,F,,BAO_0000219,16597,,416.0,1,CHEMBL623842,ABAE,,Homo sapiens,N,1,,
6959,"Compound was evaluated for the antitumor activity against AC755 breast carcinoma for ip administration and daily x 10 schedule; Number of toxic deaths over total number of mice per group (T/C), 1/7 at dose of 25 mg/kg",Intermediate,10090.0,,F,,BAO_0000218,8831,,1064.0,1,CHEMBL623843,AC755,,Mus musculus,N,1,,
6960,Percent change in total cholesterol(TC) versus (T0)- at which drug intervention begins at a dose of 25 mg/kg in the chronic cholesterol-fed rabbit model,Expert,9986.0,,F,,BAO_0000218,13419,,,1,CHEMBL618669,,,Oryctolagus cuniculus,D,9,,
6961,Oral bioactivity expressed as %inhibition after 4 hours of drug administration (dose 25 mg/kg) in rabbit bioassay,Expert,9986.0,,F,,BAO_0000218,13419,,,1,CHEMBL618670,,,Oryctolagus cuniculus,D,9,,
6962,Inhibitory activity against angiotensin-converting enzyme (ACE).,Autocuration,,,B,,BAO_0000357,15778,,,1,CHEMBL618671,,,,H,8,,
6963,oral activity against angiotensin -converting enzyme ( ACE) and neutral endopeptidase in mouse.,Autocuration,,,B,,BAO_0000357,15778,,,1,CHEMBL618672,,,,H,8,,
6964,Effect against HIV-1 chronically infected promonocytic cell line ACH-2 cells,Intermediate,9606.0,,F,,BAO_0000219,12988,,978.0,1,CHEMBL618673,ACH-2 cell line,,Homo sapiens,N,1,,
6965,Effect against HIV-1 chronically infected promonocytic cell line ACH-2 cells in the presence of PMA(phorbol 12-myristate 13-acetate),Intermediate,9606.0,,F,,BAO_0000219,12988,,978.0,1,CHEMBL618674,ACH-2 cell line,,Homo sapiens,N,1,,
6966,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2,Autocuration,11676.0,,F,,BAO_0000219,12988,,998.0,1,CHEMBL618675,T cell line,,Human immunodeficiency virus 1,U,0,,
6967,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2 in the presence of PMA(phorbol 12-myristate 13-acetate),Autocuration,11676.0,,F,,BAO_0000219,12988,,998.0,1,CHEMBL618676,T cell line,,Human immunodeficiency virus 1,U,0,,
6968,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2i n the presence of PMA(phorbol 12-myristate 13-acetate),Autocuration,11676.0,,F,,BAO_0000219,12988,,998.0,1,CHEMBL618677,T cell line,,Human immunodeficiency virus 1,U,0,,
6969,Inhibition of growth of renal cancer ACHN cell line,Intermediate,9606.0,,F,,BAO_0000219,11843,,626.0,1,CHEMBL618678,ACHN,,Homo sapiens,N,1,,
6970,Inhibition of growth of ACHN renal cancer cell line,Intermediate,9606.0,,F,,BAO_0000219,16939,,626.0,1,CHEMBL618679,ACHN,,Homo sapiens,N,1,,
6971,Inhibitory concentration required against ACHN renal cancer cell line,Intermediate,9606.0,,F,,BAO_0000219,4782,,626.0,1,CHEMBL618680,ACHN,,Homo sapiens,N,1,,
6972,Concentration required to inhibit growth of human renal (ACHN) cell line,Expert,9606.0,,F,,BAO_0000219,6310,,626.0,1,CHEMBL618681,ACHN,,Homo sapiens,N,1,,
6973,Concentration required to inhibit growth of human renal (ACHN) cell line; nt = not tested,Intermediate,9606.0,,F,,BAO_0000219,6310,,626.0,1,CHEMBL618682,ACHN,,Homo sapiens,N,1,,
6974,Cytotoxic activity against ACHN Renal cancer cell line,Intermediate,9606.0,,F,,BAO_0000219,12858,,626.0,1,CHEMBL618683,ACHN,,Homo sapiens,N,1,,
6975,Cytotoxicity evaluation against ACHN renal cancer cells,Intermediate,9606.0,,F,,BAO_0000219,17380,,626.0,1,CHEMBL618684,ACHN,,Homo sapiens,N,1,,
6976,In vitro antitumor activity against human renal ACHN cell line,Intermediate,9606.0,,F,,BAO_0000219,5858,,626.0,1,CHEMBL618685,ACHN,,Homo sapiens,N,1,,
6977,In vitro growth inhibition of compound was determined against ACHN cell lines of Renal cancer,Intermediate,9606.0,,F,,BAO_0000219,3838,,626.0,1,CHEMBL876499,ACHN,,Homo sapiens,N,1,,
6978,In vitro growth inhibition of compound was determined against ACHN cell lines of Renal cancer,Intermediate,9606.0,,F,,BAO_0000219,3838,,626.0,1,CHEMBL618686,ACHN,,Homo sapiens,N,1,,
6979,"Tested for the cytotoxicity against the Renal cancer cell line ACHN, growth inhibition by 50% is reported",Intermediate,9606.0,,F,,BAO_0000219,5406,,626.0,1,CHEMBL618687,ACHN,,Homo sapiens,N,1,,
6980,The compound was tested in vitro for cytotoxicity against human tumor cell line ACHN (renal).,Intermediate,9606.0,,F,,BAO_0000219,4071,,626.0,1,CHEMBL618688,ACHN,,Homo sapiens,N,1,,
6981,Tested in vitro for cytotoxicity against human tumor cell line ACHN (renal).,Expert,9606.0,,F,,BAO_0000219,4071,,626.0,1,CHEMBL618689,ACHN,,Homo sapiens,N,1,,
6982,The compound was tested in vitro for cytotoxicity against human tumor cell line ACHN (renal); Not determined,Intermediate,9606.0,,F,,BAO_0000219,4071,,626.0,1,CHEMBL618690,ACHN,,Homo sapiens,N,1,,
6983,Antitumor activity was evaluated against human renal adenocarcinoma cell line ACHN.,Intermediate,9606.0,,F,,BAO_0000219,15002,,626.0,1,CHEMBL618691,ACHN,,Homo sapiens,N,1,,
6984,Compound was evaluated for in vitro activity against ACHN kidney cell lines (Human tumor cells ),Intermediate,9606.0,,F,,BAO_0000219,14769,,626.0,1,CHEMBL619373,ACHN,,Homo sapiens,N,1,,
6985,"Compound was tested for antiproliferative activity against ACHN, human renal adenocarcinoma",Intermediate,9606.0,,F,,BAO_0000219,13958,,626.0,1,CHEMBL884008,ACHN,,Homo sapiens,N,1,,
6986,Compound was tested for its effect on the proliferation of ACHN human kidney adenocarcinoma,Intermediate,9606.0,,F,,BAO_0000219,1665,,626.0,1,CHEMBL619374,ACHN,,Homo sapiens,N,1,,
6987,Compound was tested for the growth inhibition of ACHN renal tumor cell line,Intermediate,9606.0,,F,,BAO_0000219,15354,,626.0,1,CHEMBL619375,ACHN,,Homo sapiens,N,1,,
6988,Compound was tested for the growth inhibition of ACHN renal tumor cell line; ND=Not determined,Intermediate,9606.0,,F,,BAO_0000219,15354,,626.0,1,CHEMBL619376,ACHN,,Homo sapiens,N,1,,
6989,In vitro Growth Inhibitory activity against ACHN Human kidney cancer cell line,Intermediate,9606.0,,F,,BAO_0000219,13978,,626.0,1,CHEMBL619377,ACHN,,Homo sapiens,N,1,,
6990,In vitro cytotoxicity against human renal adenocarcinoma (ACHN) tumor cell line,Intermediate,9606.0,,F,,BAO_0000219,6798,,626.0,1,CHEMBL619378,ACHN,,Homo sapiens,N,1,,
6991,Tmax value after administration of 4 mg/Kg oral dose in dog,Intermediate,9615.0,,A,,BAO_0000218,2959,,,1,CHEMBL872527,,,Canis lupus familiaris,N,1,,
6992,"Time to peak response on lowering of vascular resistance, in dogs when administered intravenously",Intermediate,9615.0,,A,,BAO_0000218,9932,,,1,CHEMBL876500,,,Canis lupus familiaris,N,1,,
6993,Unbound plasma was determined in Beagle dog at a dose of 1 mg/kg by iv administration,Intermediate,9615.0,,A,,BAO_0000218,5546,,,1,CHEMBL619379,,,Canis lupus familiaris,N,1,,
6994,Volume distribution after 15 mg/kg iv dose in Dogs,Intermediate,9615.0,,A,,BAO_0000218,16907,,,1,CHEMBL619538,,,Canis lupus familiaris,N,1,,
6995,Volume distribution after 30 mg/kg po dose in Dogs,Intermediate,9615.0,,A,,BAO_0000218,16907,,,1,CHEMBL619539,,,Canis lupus familiaris,N,1,,
6996,Volume of distribution was determined in dog after a 3 mg/kg of iv dose,Intermediate,9615.0,,A,,BAO_0000218,4257,,,1,CHEMBL619540,,,Canis lupus familiaris,N,1,,
6997,Volume of distribution was determined by iv administration in dogs at a dose of 1 mg/kg,Intermediate,9615.0,,A,,BAO_0000218,4305,,,1,CHEMBL619541,,,Canis lupus familiaris,N,1,,
6998,Volume of distribution was evaluated in dog,Intermediate,9615.0,,A,,BAO_0000218,5472,,,1,CHEMBL619542,,,Canis lupus familiaris,N,1,,
6999,Terminal phase volume of distribution was measured in dog after an iv dose of 1 mg/kg,Intermediate,9615.0,,A,,BAO_0000218,6062,,,1,CHEMBL619543,,,Canis lupus familiaris,N,1,,
7000,Apparent volume of the central plasma compartment (Vc) of compound determined in dog after iv administration at a dose of 10 mg/kg,Expert,9615.0,,A,,BAO_0000218,3598,,,1,CHEMBL619544,,,Canis lupus familiaris,N,1,,
7001,The compound was tested for volume of distribution in dog,Intermediate,9615.0,,A,,BAO_0000218,12500,,,1,CHEMBL619545,,,Canis lupus familiaris,N,1,,
7002,The compound was tested for volume of distribution in dog at dose of 3-10 mgkg,Intermediate,9615.0,,A,,BAO_0000218,12500,,,1,CHEMBL619546,,,Canis lupus familiaris,N,1,,
7003,Vd (1 mg/kg) was determined in dog (in vivo),Intermediate,9615.0,,A,,BAO_0000218,6227,,,1,CHEMBL619547,,,Canis lupus familiaris,N,1,,
7004,Vd in dog,Intermediate,9615.0,,A,,BAO_0000218,6227,,,1,CHEMBL619548,,,Canis lupus familiaris,N,1,,
7005,Volume distribution was determined,Intermediate,9615.0,,A,,BAO_0000218,4219,,,1,CHEMBL619549,,,Canis lupus familiaris,N,1,,
7006,Volume of distribution in dog,Intermediate,9615.0,,A,,BAO_0000218,1696,,,1,CHEMBL619550,,,Canis lupus familiaris,N,1,,
7007,Volume of distribution by as 4 fold increase by iv administration in dogs,Intermediate,9615.0,,A,,BAO_0000218,5542,,,1,CHEMBL876501,,,Canis lupus familiaris,N,1,,
7008,Volume of distribution was determined in canine following intravenous (iv) administration of drug (1 mg/kg).,Intermediate,9615.0,,A,,BAO_0000218,5199,,,1,CHEMBL619551,,,Canis lupus familiaris,N,1,,
7009,Volume of distribution was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,Intermediate,9615.0,,A,,BAO_0000218,6348,,,1,CHEMBL619552,,,Canis lupus familiaris,N,1,,
7010,Volume distribution at the dose of 2 mg/kg in dog,Intermediate,9615.0,,A,,BAO_0000218,4727,,,1,CHEMBL619553,,,Canis lupus familiaris,N,1,,
7011,Steady state volume of distribution was determined,Intermediate,9615.0,,A,,BAO_0000218,16367,,,1,CHEMBL618722,,,Canis lupus familiaris,N,1,,
7012,Bioavailability as Vdss in dogs at 1 mg/kg intravenous dose,Intermediate,9615.0,,A,,BAO_0000218,2652,,,1,CHEMBL618723,,,Canis lupus familiaris,N,1,,
7013,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,Intermediate,9615.0,,A,,BAO_0000218,16452,,,1,CHEMBL618724,,,Canis lupus familiaris,N,1,,
7014,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,Intermediate,9615.0,,A,,BAO_0000218,16452,,,1,CHEMBL618725,,,Canis lupus familiaris,N,1,,
7015,Bioavailability in dog (dose 1 mg/kg i.v.),Intermediate,9615.0,,A,,BAO_0000218,16452,,,1,CHEMBL618726,,,Canis lupus familiaris,N,1,,
7016,Pharmacokinetic parameter volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),Intermediate,9615.0,,A,,BAO_0000218,5334,,,1,CHEMBL618727,,,Canis lupus familiaris,N,1,,
7017,Pharmacokinetic property (vdss) was measured in dog,Intermediate,9615.0,,A,,BAO_0000218,4239,,,1,CHEMBL624233,,,Canis lupus familiaris,N,1,,
7018,Steady state volume of distribution for the compound after intravenous administration of 1 mg/kg in dog,Intermediate,9615.0,,A,,BAO_0000218,4709,,,1,CHEMBL624234,,,Canis lupus familiaris,N,1,,
7019,Vdss was determined after iv 0.1 mg/kg administration in dog,Intermediate,9615.0,,A,,BAO_0000218,5600,,,1,CHEMBL624235,,,Canis lupus familiaris,N,1,,
7020,Volume displacement was calculated in dog,Intermediate,9615.0,,A,,BAO_0000218,6057,,,1,CHEMBL624236,,,Canis lupus familiaris,N,1,,
7021,Volume distribution (Vdss) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,Intermediate,9615.0,,A,,BAO_0000218,5654,,,1,CHEMBL624237,,,Canis lupus familiaris,N,1,,
7022,Volume distribution constant was determined,Intermediate,9615.0,,A,,BAO_0000218,5505,,,1,CHEMBL624238,,,Canis lupus familiaris,N,1,,
7023,Volume distribution at a dose of 1 uM/kg in dog was determined,Intermediate,9615.0,,A,,BAO_0000218,4527,,,1,CHEMBL624239,,,Canis lupus familiaris,N,1,,
7024,Volume distribution in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,Intermediate,9615.0,,A,,BAO_0000218,4521,,,1,CHEMBL875829,,,Canis lupus familiaris,N,1,,
7025,Volume distribution in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,Intermediate,9615.0,,A,,BAO_0000218,4521,,,1,CHEMBL624240,,,Canis lupus familiaris,N,1,,
7026,Volume distribution (Vdss) was measured in dog,Intermediate,9615.0,,A,,BAO_0000218,15660,,,1,CHEMBL624241,,,Canis lupus familiaris,N,1,,
7027,Volume distribution (Vdss) was measured in dog,Intermediate,9615.0,,A,,BAO_0000218,15660,,,1,CHEMBL624242,,,Canis lupus familiaris,N,1,,
7028,Volume of distribution at steady state was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,Intermediate,9615.0,,A,,BAO_0000218,6679,,,1,CHEMBL624243,,,Canis lupus familiaris,N,1,,
7029,Volume of distribution in steady state was determined in dog,Intermediate,9615.0,,A,,BAO_0000218,5145,,,1,CHEMBL624244,,,Canis lupus familiaris,N,1,,
7030,Volume of distribution of compound was determined in dog,Intermediate,9615.0,,A,,BAO_0000218,6821,,,1,CHEMBL624245,,,Canis lupus familiaris,N,1,,
7031,Volume of distribution after intravenous administration of 1 mg/kg/h in dog,Intermediate,9615.0,,A,,BAO_0000218,4137,,,1,CHEMBL624246,,,Canis lupus familiaris,N,1,,
7032,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Beagle dog (male),Intermediate,9615.0,,A,,BAO_0000218,5334,,,1,CHEMBL624247,,,Canis lupus familiaris,N,1,,
7033,Volume of distribution (Vdss) was measured in dog,Intermediate,9615.0,,A,,BAO_0000218,15660,,,1,CHEMBL624248,,,Canis lupus familiaris,N,1,,
7034,Volumes of distribution in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),Intermediate,9615.0,,A,,BAO_0000218,6642,,,1,CHEMBL624249,,,Canis lupus familiaris,N,1,,
7035,Volumes of distribution in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),Intermediate,9615.0,,A,,BAO_0000218,6641,,,1,CHEMBL624250,,,Canis lupus familiaris,N,1,,
7036,Volumes of distribution in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),Intermediate,9615.0,,A,,BAO_0000218,6642,,,1,CHEMBL624251,,,Canis lupus familiaris,N,1,,
7037,Maximum rate of depolarization of the upstroke of the action potential,Intermediate,9615.0,,A,,BAO_0000218,11659,,,1,CHEMBL624252,,,Canis lupus familiaris,N,1,,
7038,Steady state volume distribution in dog,Intermediate,9615.0,,A,,BAO_0000218,6448,,,1,CHEMBL624253,,,Canis lupus familiaris,N,1,,
7039,Steady state volume of distribution at a dose of 0.2 mg/kg i.v.,Intermediate,9615.0,,A,,BAO_0000218,5474,,,1,CHEMBL624950,,,Canis lupus familiaris,N,1,,
7040,Tested for volume of distribution at steady state upon intravenous administration of 5.0 mg/Kg dose in dog,Intermediate,9615.0,,A,,BAO_0000218,1466,,,1,CHEMBL624951,,,Canis lupus familiaris,N,1,,
7041,Volume distribution in dog after administration of 0.25 mg/kg iv; ND = not determined,Intermediate,9615.0,,A,,BAO_0000218,6535,,,1,CHEMBL875830,,,Canis lupus familiaris,N,1,,
7042,Volume distribution in dog after administration of 1 mg/kg iv,Intermediate,9615.0,,A,,BAO_0000218,6535,,,1,CHEMBL624952,,,Canis lupus familiaris,N,1,,
7043,Volume of solubility in solution after intravenous administration in dogs at 1.2 uM/kg,Intermediate,9615.0,,A,,BAO_0000218,17764,,,1,CHEMBL624953,,,Canis lupus familiaris,N,1,,
7044,Vss after intravenous administration (0.5 mg/kg) was determined in dog,Intermediate,9615.0,,A,,BAO_0000218,6215,,,1,CHEMBL624954,,,Canis lupus familiaris,N,1,,
7045,Vss on i.v. administration of 2 mg/kg was measured in dog,Intermediate,9615.0,,A,,BAO_0000218,6505,,,1,CHEMBL624955,,,Canis lupus familiaris,N,1,,
7046,Vss was determined,Intermediate,9615.0,,A,,BAO_0000218,3639,,,1,CHEMBL624956,,,Canis lupus familiaris,N,1,,
7047,Vss in dog,Intermediate,9615.0,,A,,BAO_0000218,3639,,,1,CHEMBL625129,,,Canis lupus familiaris,N,1,,
7048,Volume of distribution was measured in dog after an iv dose of 1 mg/kg,Intermediate,9615.0,,A,,BAO_0000218,6062,,,1,CHEMBL625130,,,Canis lupus familiaris,N,1,,
7049,Volume distribution in dogs,Intermediate,9615.0,,A,,BAO_0000218,4942,,,1,CHEMBL625131,,,Canis lupus familiaris,N,1,,
7050,Volume of distribution in dog,Intermediate,9615.0,,A,,BAO_0000218,17796,,,1,CHEMBL625132,,,Canis lupus familiaris,N,1,,
7051,Tested for the oral bioavailability in dog,Intermediate,9615.0,,A,,BAO_0000218,4883,,,1,CHEMBL872263,,,Canis lupus familiaris,N,1,,
7060,Bioavailability of compound in mouse blood following p.o. administration of 30 mg/kg,Intermediate,10090.0,,A,,BAO_0000218,17837,,,1,CHEMBL624336,,,Mus musculus,N,1,,
7061,Bioavailability after i.p. administration of 50 mg/kg of dose in mice,Intermediate,10090.0,,A,,BAO_0000218,17729,,,1,CHEMBL624337,,,Mus musculus,N,1,,
7062,Bioavailability after peroral administration of 50 mg/kg of dose in mice,Intermediate,10090.0,,A,,BAO_0000218,17729,,,1,CHEMBL624338,,,Mus musculus,N,1,,
7063,Bioavailability was measured in mouse,Intermediate,10090.0,,A,,BAO_0000218,4239,,,1,CHEMBL624339,,,Mus musculus,N,1,,
7064,Bioavailability in mouse,Intermediate,10090.0,,A,,BAO_0000218,17592,,,1,CHEMBL624340,,,Mus musculus,N,1,,
7065,Bioavailability was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,Intermediate,10090.0,,A,,BAO_0000218,6348,,,1,CHEMBL624341,,,Mus musculus,N,1,,
7066,Bioavailability in mouse,Intermediate,10090.0,,A,,BAO_0000218,2801,,,1,CHEMBL624342,,,Mus musculus,N,1,,
7067,Compound was evaluated for its bioavailability in mice at a dose of 1 mg/kg,Intermediate,10090.0,,A,,BAO_0000218,2801,,,1,CHEMBL624343,,,Mus musculus,N,1,,
7068,Oral bioavailability in mouse,Intermediate,10090.0,,A,,BAO_0000218,17718,,,1,CHEMBL624344,,,Mus musculus,N,1,,
7069,Oral availability at 50 mg/kg po in male mice,Intermediate,10090.0,,A,,BAO_0000218,5727,,,1,CHEMBL624345,,,Mus musculus,N,1,,
7070,Oral bioavailability in mouse (dose 10 mg/kg),Intermediate,10090.0,,A,,BAO_0000218,5302,,,1,CHEMBL624346,,,Mus musculus,N,1,,
7071,Oral bioavailability of compound determined in mouse after iv administration at a dose of 10 mg/kg,Expert,10090.0,,A,,BAO_0000218,3598,,,1,CHEMBL624347,,,Mus musculus,N,1,,
7072,"Bioavailability in male mice, 2mg/kg oral and 1 mg/kg intravenous dose",Intermediate,10090.0,,A,,BAO_0000218,5961,,,1,CHEMBL624348,,,Mus musculus,N,1,,
7074,Oral bioavailability in mouse,Intermediate,10090.0,,A,,BAO_0000218,6091,,,1,CHEMBL622754,,,Mus musculus,N,1,,
7075,Oral bioavailability in vivo in mice;ND=Not determined,Intermediate,10090.0,,A,,BAO_0000218,6091,,,1,CHEMBL622755,,,Mus musculus,N,1,,
7076,Oral bioavailability in mouse at 10 mg/kg of the compound,Intermediate,10090.0,,A,,BAO_0000218,5711,,,1,CHEMBL622756,,,Mus musculus,N,1,,
7077,Bioavailability in mouse (BALB/C) (dose 50 mg/kg i.p.),Intermediate,10090.0,,A,,BAO_0000218,17728,,,1,CHEMBL622757,,,Mus musculus,N,1,,
7078,Bioavailability in mouse (BALB/C) (dose 20 mg/kg i.v.),Intermediate,10090.0,,A,,BAO_0000218,17728,,,1,CHEMBL622758,,,Mus musculus,N,1,,
7079,Tested for bioavailability of the compound,Intermediate,10090.0,,A,,BAO_0000218,3802,,,1,CHEMBL622759,,,Mus musculus,N,1,,
7080,Tested for half life at the dose of 10 mg/kg when administered intravenously,Intermediate,10090.0,,A,,BAO_0000218,3802,,,1,CHEMBL622760,,,Mus musculus,N,1,,
7081,The plasma half life of compound was determined on EDTA prepared by mouse plasma. ,Intermediate,10090.0,,A,,BAO_0000218,14029,,,1,CHEMBL622761,,,Mus musculus,N,1,1969.0,
7082,The plasma half life of compound was determined on heparin prepared by human plasma. ,Intermediate,10090.0,,A,,BAO_0000218,14029,,,1,CHEMBL622762,,,Mus musculus,N,1,1969.0,
7083,The plasma half life of compound was determined on heparin prepared by human plasma; Not degraded,Intermediate,10090.0,,A,,BAO_0000218,14029,,,1,CHEMBL622763,,,Mus musculus,N,1,1969.0,
7084,The plasma half life of compound was determined on heparin prepared by mouse plasma. ,Intermediate,10090.0,,A,,BAO_0000218,14029,,,1,CHEMBL622764,,,Mus musculus,N,1,1969.0,
7085,The plasma half life of compound was determined on heparin prepared by mouse plasma; Not degraded,Intermediate,10090.0,,A,,BAO_0000218,14029,,,1,CHEMBL622765,,,Mus musculus,N,1,1969.0,
7086,Inhibitory concentration of compound was determined after intravenous administration in mice after 6 hours of exposure at 40 mg/Kg,Intermediate,10090.0,,F,,BAO_0000218,17753,,,1,CHEMBL622766,,,Mus musculus,N,1,,
7087,Inhibitory concentration of compound was determined after intravenous administration in mice after 8 hours of exposure at 24 mg/Kg,Intermediate,10090.0,,A,,BAO_0000218,17753,,,1,CHEMBL622767,,,Mus musculus,N,1,,
7088,Inhibitory concentration of compound was determined after intravenous administration in mice after 8 hours of exposure at 5 mg/Kg,Intermediate,10090.0,,A,,BAO_0000218,17753,,,1,CHEMBL622768,,,Mus musculus,N,1,,
7089,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,Intermediate,10090.0,,A,,BAO_0000218,10107,,,1,CHEMBL875948,,,Mus musculus,N,1,178.0,
7090,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,Intermediate,10090.0,,A,,BAO_0000218,10107,,,1,CHEMBL622769,,,Mus musculus,N,1,178.0,
7091,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,Intermediate,10090.0,,A,,BAO_0000218,10107,,,1,CHEMBL622770,,,Mus musculus,N,1,178.0,
7092,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,Intermediate,10090.0,,A,,BAO_0000218,10107,,,1,CHEMBL622771,,,Mus musculus,N,1,178.0,
7093,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,Intermediate,10090.0,,A,,BAO_0000218,10107,,,1,CHEMBL622772,,,Mus musculus,N,1,178.0,
7094,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,Intermediate,10090.0,,A,,BAO_0000218,10107,,,1,CHEMBL622773,,,Mus musculus,N,1,178.0,
7095,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,Intermediate,10090.0,,A,,BAO_0000218,10107,,,1,CHEMBL622774,,,Mus musculus,N,1,178.0,
7096,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,Intermediate,10090.0,,A,,BAO_0000218,10107,,,1,CHEMBL621725,,,Mus musculus,N,1,10000001.0,
7097,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,Intermediate,10090.0,,A,,BAO_0000218,10107,,,1,CHEMBL621726,,,Mus musculus,N,1,10000001.0,
7098,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 8,Intermediate,9606.0,,F,,BAO_0000219,15608,,478.0,1,CHEMBL621727,A2780,,Homo sapiens,N,1,,
7099,In vitro cytotoxicity against human ovarian carcinoma cell line A2780 using sulforhodamine B (SRB) assay,Expert,9606.0,,F,,BAO_0000219,3290,,478.0,1,CHEMBL622413,A2780,,Homo sapiens,N,1,,
7100,Compound was evaluated for cytotoxicity against A2780 cell line,Intermediate,9606.0,,F,,BAO_0000219,2859,,478.0,1,CHEMBL622414,A2780,,Homo sapiens,N,1,,
7101,Inhibition of A2780 cell clonogenic assay,Expert,9606.0,,F,,BAO_0000219,15688,,478.0,1,CHEMBL622415,A2780,,Homo sapiens,N,1,,
7102,Cytotoxic effect on ovarian cancer cell line (A2780),Expert,9606.0,,F,,BAO_0000219,5642,,478.0,1,CHEMBL884001,A2780,,Homo sapiens,N,1,,
7103,Concentration required to inhibit A2780 cell growth when compared with control after incubation for 96 hr at 37 C,Intermediate,9606.0,,F,,BAO_0000219,6633,,478.0,1,CHEMBL622416,A2780,,Homo sapiens,N,1,,
7104,"MDR-reversing activity was measured by vincristine accumulation in the multidrug resistant 2780AD, a subline of A2780 ovarian carcinoma cells at 10 mg/mL",Intermediate,9606.0,,F,,BAO_0000219,3906,,478.0,1,CHEMBL622417,A2780,,Homo sapiens,N,1,,
7105,50% growth inhibition of A2780 (Human ovarian carcinoma) cell line compared with untreated control cells,Expert,9606.0,,F,,BAO_0000219,6788,,478.0,1,CHEMBL622590,A2780,,Homo sapiens,N,1,,
7106,Antiproliferative activity against human A2780 cells,Expert,9606.0,,F,,BAO_0000219,17582,,478.0,1,CHEMBL622591,A2780,,Homo sapiens,N,1,,
7107,Inhibition of human A2780 cell proliferation,Expert,9606.0,,F,,BAO_0000219,17764,,478.0,1,CHEMBL622592,A2780,,Homo sapiens,N,1,,
7108,Antiproliferative effect against human A2780 cell line was determined in a whole cell 72 hr cytotoxicity assay,Expert,9606.0,,F,,BAO_0000219,17764,,478.0,1,CHEMBL622593,A2780,,Homo sapiens,N,1,,
7109,Inhibition of human A2780 cell proliferation (No data),Expert,9606.0,,F,,BAO_0000219,17764,,478.0,1,CHEMBL622594,A2780,,Homo sapiens,N,1,,
7110,Cell cytotoxicity was determined against human ovarian cancer (A2780) cell line,Intermediate,9606.0,,F,,BAO_0000219,2815,,478.0,1,CHEMBL622595,A2780,,Homo sapiens,N,1,,
7111,Compound was evaluated against human Ovarian carcinoma cell line A2780,Intermediate,9606.0,,F,,BAO_0000219,16930,,478.0,1,CHEMBL622596,A2780,,Homo sapiens,N,1,,
7112,Growth inhibition against A2780 wild-type ovarian cell lines,Expert,9606.0,,F,,BAO_0000219,17777,,478.0,1,CHEMBL622597,A2780,,Homo sapiens,N,1,,
7113,Compound was evaluated for growth inhibition against A2780 wild-type ovarian cell lines; No data,Intermediate,9606.0,,F,,BAO_0000219,17777,,478.0,1,CHEMBL622598,A2780,,Homo sapiens,N,1,,
7114,Inhibition of tubulin polymerization in human ovarian cancer cell lines,Autocuration,9606.0,,F,,BAO_0000019,16936,,,1,CHEMBL622599,,,Homo sapiens,D,5,,
7115,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780,Intermediate,9606.0,,F,,BAO_0000219,13759,,478.0,1,CHEMBL622600,A2780,,Homo sapiens,N,1,,
7116,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780-R,Intermediate,9606.0,,F,,BAO_0000219,13759,,478.0,1,CHEMBL622601,A2780,,Homo sapiens,N,1,,
7117,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780,Intermediate,9606.0,,F,,BAO_0000219,13759,,478.0,1,CHEMBL622602,A2780,,Homo sapiens,N,1,,
7118,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780-R,Intermediate,9606.0,,F,,BAO_0000219,13759,,478.0,1,CHEMBL622603,A2780,,Homo sapiens,N,1,,
7119,Compound was tested for inhibitory activity against A2780 human ovarian carcinoma cell line; activity expressed in Mean IC50 values,Intermediate,9606.0,,F,,BAO_0000219,15292,,478.0,1,CHEMBL622604,A2780,,Homo sapiens,N,1,,
7120,Compound was tested for inhibitory activity against A2780cisR human ovarian carcinoma cell line; activity expressed in Mean IC50 values,Intermediate,9606.0,,F,,BAO_0000219,15292,,478.0,1,CHEMBL622605,A2780,,Homo sapiens,N,1,,
7121,In vitro inhibition of human ovarian cell line A2780,Expert,9606.0,,F,,BAO_0000219,15069,,478.0,1,CHEMBL622606,A2780,,Homo sapiens,N,1,,
7122,"In vitro inhibition of human ovarian cell line, resistant to cisplatin (A2780cisR).",Expert,9606.0,,F,,BAO_0000219,15069,,478.0,1,CHEMBL619463,A2780,,Homo sapiens,N,1,,
7123,Concentration of compound to inhibit the growth of human A2780 ovarian carcinoma cells(in vitro),Intermediate,9606.0,,F,,BAO_0000219,14073,,478.0,1,CHEMBL619464,A2780,,Homo sapiens,N,1,,
7124,Concentration required to inhibit A2780-cell growth by 50%,Expert,9606.0,,F,,BAO_0000219,14553,,478.0,1,CHEMBL619465,A2780,,Homo sapiens,N,1,,
7125,Concentration required to inhibit the cell growth by 50 % after 96 hr A2780 leukemic cells.,Expert,9606.0,,F,,BAO_0000219,13040,,478.0,1,CHEMBL619466,A2780,,Homo sapiens,N,1,,
7126,Cytotoxic effect on human ovarian (A2780) cancer cell line,Expert,9606.0,,F,,BAO_0000219,6891,,478.0,1,CHEMBL619467,A2780,,Homo sapiens,N,1,,
7127,Cytotoxic activity in a panel of Human ovarian tumor A2780 cell line after 96h of drug exposure,Intermediate,9606.0,,F,,BAO_0000219,15569,,478.0,1,CHEMBL619468,A2780,,Homo sapiens,N,1,,
7128,Cytotoxic potency required to inhibit A2780 cell growth by 50% after cell drug contact for 96 hrs,Expert,9606.0,,F,,BAO_0000219,14190,,478.0,1,CHEMBL619469,A2780,,Homo sapiens,N,1,,
7129,Cytotoxicity measured in human ovarian cell line A2780 using sulforhodamine B (SRB) assay,Expert,9606.0,,F,,BAO_0000219,15014,,478.0,1,CHEMBL619470,A2780,,Homo sapiens,N,1,,
7130,Cytotoxicity activity of the compound was measured in human ovarian cell line A2780 using sulforhodamine B (SRB) assay,Intermediate,9606.0,,F,,BAO_0000219,15014,,478.0,1,CHEMBL619471,A2780,,Homo sapiens,N,1,,
7131,Cytotoxicity against human ovarian carcinoma A2780 cell line,Intermediate,9606.0,,F,,BAO_0000219,17496,,478.0,1,CHEMBL619472,A2780,,Homo sapiens,N,1,,
7132,"Cytotoxicity against A2780-C25, oxaliplatin-resistant Ovarian carcinoma cell line",Intermediate,9606.0,,F,,BAO_0000219,13617,,478.0,1,CHEMBL619473,A2780,,Homo sapiens,N,1,,
7133,"Cytotoxicity against A2780-CP3, cisplatin-resistant Ovarian carcinoma cell line",Intermediate,9606.0,,F,,BAO_0000219,13617,,478.0,1,CHEMBL874368,A2780,,Homo sapiens,N,1,,
7134,"Cytotoxicity against A2780-DX5, Doxorubicin-resistant Ovarian carcinoma cell line",Intermediate,9606.0,,F,,BAO_0000219,13617,,478.0,1,CHEMBL884003,A2780,,Homo sapiens,N,1,,
7135,"Cytotoxicity against A2780-WT, human ovarian carcinoma cell line",Intermediate,9606.0,,F,,BAO_0000219,13617,,478.0,1,CHEMBL622690,A2780,,Homo sapiens,N,1,,
7136,Cytotoxicity against ovarian carcinoma A2780 tumor cell lines,Intermediate,9606.0,,F,,BAO_0000219,17672,,478.0,1,CHEMBL622691,A2780,,Homo sapiens,N,1,,
7137,Dose of required to inhibit growth of cisplatin resistant human ovarian carcinoma (A2780 cisR) cell line with compound free controls as measured by the sulforhodamine B growth delay assay,Intermediate,9606.0,,F,,BAO_0000219,4544,,478.0,1,CHEMBL622692,A2780,,Homo sapiens,N,1,,
7138,Dose of required to inhibit growth of human ovarian carcinoma (A2780) cell line with compound free controls as measured by the sulforhodamine B growth delay assay,Intermediate,9606.0,,F,,BAO_0000219,4544,,478.0,1,CHEMBL623406,A2780,,Homo sapiens,N,1,,
7139,"Growth inhibition in human ovarian carcinoma cell line (A2780cisR,cisplatin-resistant) using the 96 hour exposure sulforhodamine B (SRB) growth delay assay",Intermediate,9606.0,,F,,BAO_0000219,16317,,478.0,1,CHEMBL884004,A2780,,Homo sapiens,N,1,,
7140,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780,Intermediate,9606.0,,F,,BAO_0000219,15099,,478.0,1,CHEMBL623407,A2780,,Homo sapiens,N,1,,
7141,In vitro Growth Inhibitory activity against A2780 Human ovarian cancer cell line,Intermediate,9606.0,,F,,BAO_0000219,13978,,478.0,1,CHEMBL623408,A2780,,Homo sapiens,N,1,,
7142,In vitro antitumor activity against A2780 cell line.,Expert,9606.0,,F,,BAO_0000219,12989,,478.0,1,CHEMBL623409,A2780,,Homo sapiens,N,1,,
7143,In vitro cytotoxic activity against human tumor cell line A2780 after incubation for 96 hours,Intermediate,9606.0,,F,,BAO_0000219,5574,,478.0,1,CHEMBL623410,A2780,,Homo sapiens,N,1,,
7144,In vitro cytotoxicity against A2780 human ovarian cancer cell line,Expert,9606.0,,F,,BAO_0000219,13528,,478.0,1,CHEMBL623576,A2780,,Homo sapiens,N,1,,
7145,Inhibitory activity against kidney A-CHN tumor cell growth in culture,Intermediate,9606.0,,F,,BAO_0000219,12782,,626.0,1,CHEMBL623577,ACHN,,Homo sapiens,N,1,,
7146,The IC50 value was measured on ACHN cell line in renal tumor type.,Intermediate,9606.0,,F,,BAO_0000219,14255,,626.0,1,CHEMBL623578,ACHN,,Homo sapiens,N,1,,
7147,Concentration required for killing 50% of cells of renal ACHN cell lines was determined in vitro,Intermediate,9606.0,,F,,BAO_0000219,16364,,626.0,1,CHEMBL623579,ACHN,,Homo sapiens,N,1,,
7148,In vitro lethal concentration against most sensitive ACHN cell line,Expert,9606.0,,F,,BAO_0000219,17376,,626.0,1,CHEMBL623580,ACHN,,Homo sapiens,N,1,,
7149,Tested for cytotoxic activity against renal cancer ACHN cell line,Intermediate,9606.0,,F,,BAO_0000219,12016,,626.0,1,CHEMBL623581,ACHN,,Homo sapiens,N,1,,
7150,Compound tested for growth inhibition of renal cancer cell line ACHN,Intermediate,9606.0,,F,,BAO_0000219,6058,,626.0,1,CHEMBL857456,ACHN,,Homo sapiens,N,1,,
7151,Compound was tested for 50% growth inhibition against human renal cancer ACHN cell line,Intermediate,9606.0,,F,,BAO_0000219,17708,,626.0,1,CHEMBL623582,ACHN,,Homo sapiens,N,1,,
7152,Growth inhibition of the ACHN Renal cancer cell line for 2-day in vitro assay.,Intermediate,9606.0,,F,,BAO_0000219,15176,,626.0,1,CHEMBL623583,ACHN,,Homo sapiens,N,1,,
7153,In vitro anticancer activity against ACHN renal cancer cell line,Intermediate,9606.0,,F,,BAO_0000219,2806,,626.0,1,CHEMBL623584,ACHN,,Homo sapiens,N,1,,
7154,In vitro antitumor activity against Renal cancer ACHN cell lines by 6-day assay,Intermediate,9606.0,,F,,BAO_0000219,15300,,626.0,1,CHEMBL623585,ACHN,,Homo sapiens,N,1,,
7155,Percent selectivity was evaluated in renal ACHN cell lines,Intermediate,9606.0,,F,,BAO_0000219,16364,,626.0,1,CHEMBL623586,ACHN,,Homo sapiens,N,1,,
7156,In vitro inhibitory activity against renal ACHN cancer cell line,Intermediate,9606.0,,F,,BAO_0000219,13859,,626.0,1,CHEMBL623587,ACHN,,Homo sapiens,N,1,,
7157,Tested for cytotoxicity against ACHN cell lines in renal cancer,Intermediate,9606.0,,F,,BAO_0000219,11970,,626.0,1,CHEMBL875279,ACHN,,Homo sapiens,N,1,,
7158,Tested for the in vitro cytotoxicity against ACHN renal cancer cell line,Intermediate,9606.0,,F,,BAO_0000219,2450,,626.0,1,CHEMBL623588,ACHN,,Homo sapiens,N,1,,
7159,In vitro anti tumor activity against human tumor Renal cancer cell lines was determined,Intermediate,9606.0,,F,,BAO_0000219,12696,,626.0,1,CHEMBL623589,ACHN,,Homo sapiens,N,1,,
7160,Tested in vitro for cytotoxicity in ACHN cell line of Renal cancer,Intermediate,9606.0,,F,,BAO_0000219,12400,,626.0,1,CHEMBL623590,ACHN,,Homo sapiens,N,1,,
7161,Cytotoxic effect on renal cancer line ACHN,Expert,9606.0,,F,,BAO_0000219,12888,,626.0,1,CHEMBL623591,ACHN,,Homo sapiens,N,1,,
7162,In vitro anti-cancer activity against ACHN(Renal) human tumor cell line,Intermediate,9606.0,,F,,BAO_0000219,3156,,626.0,1,CHEMBL623592,ACHN,,Homo sapiens,N,1,,
7163,In vitro inhibition of Renal Cancer ACHN cell lines,Intermediate,9606.0,,F,,BAO_0000219,3381,,626.0,1,CHEMBL623593,ACHN,,Homo sapiens,N,1,,
7164,Antitumor activity against human renal adenocarcinoma ACHN cells,Intermediate,9606.0,,F,,BAO_0000219,16747,,626.0,1,CHEMBL623594,ACHN,,Homo sapiens,N,1,,
7165,Antitumor activity against human renal adenocarcinoma ACHN cells.,Expert,9606.0,,F,,BAO_0000219,16748,,626.0,1,CHEMBL621833,ACHN,,Homo sapiens,N,1,,
7166,Inhibitory concentration required to decrease cell viability in cell growth culture against kidney cells ACHN,Intermediate,9606.0,,F,,BAO_0000219,12062,,626.0,1,CHEMBL621834,ACHN,,Homo sapiens,N,1,,
7167,Compound was evaluated for in vitro activity against ACHN kidney cell lines (Human tumor cells ),Intermediate,9606.0,,F,,BAO_0000219,14769,,626.0,1,CHEMBL621835,ACHN,,Homo sapiens,N,1,,
7168,"Cytotoxicity against NCI tumor panel, ACHN renal cancer cell line",Intermediate,9606.0,,F,,BAO_0000219,15895,,626.0,1,CHEMBL621836,ACHN,,Homo sapiens,N,1,,
7169,Concentration of compound that cause 50% cytotoxicity of ACHN renal cancer cell line,Intermediate,9606.0,,F,,BAO_0000219,17376,,626.0,1,CHEMBL621837,ACHN,,Homo sapiens,N,1,,
7170,Compound was tested for antitumor activity against ACHN renal cancer cell line(molar concentration that inhibits 50% net cell growth).,Intermediate,9606.0,,F,,BAO_0000219,14882,,626.0,1,CHEMBL875280,ACHN,,Homo sapiens,N,1,,
7171,Compound was tested for antitumor activity against ACHN renal cancer cell line(molar concentration leading to 50% net cell death).,Intermediate,9606.0,,F,,BAO_0000219,14882,,626.0,1,CHEMBL621838,ACHN,,Homo sapiens,N,1,,
7172,Cytotoxicity was tested against renal cancer ACHN tumor cell lines.,Intermediate,9606.0,,F,,BAO_0000219,15661,,626.0,1,CHEMBL621839,ACHN,,Homo sapiens,N,1,,
7173,Keff is the effective biomolecular rate constant on paraxon for reactivation at pH 7.8 at 25 degree Centigrade,Autocuration,,,A,,BAO_0000019,9680,,,1,CHEMBL621840,,,,U,0,,
7174,Compound tested for relative response using 1 uM ACh as agonist against AChM1 receptor.,Autocuration,,,F,,BAO_0000019,14579,,,1,CHEMBL621841,,,,H,8,,
7175,Antiviral activity against AD169 strain of cytomegalovirus (CMV) in HEL (human erythroleukemia) cells.,Expert,10358.0,,F,,BAO_0000218,17290,,468.0,1,CHEMBL622979,HEL,,Cytomegalovirus,N,1,,
7176,Antiviral activity against AD169 strain of cytomegalovirus (CMV); ND=No data,Intermediate,10358.0,,F,,BAO_0000218,17290,,,1,CHEMBL876595,,,Cytomegalovirus,N,1,,
7177,Compound was evaluated for its inhibitory activity against calf intestinal Adenosine deaminase (ADA),Autocuration,,,B,,BAO_0000357,15891,,,1,CHEMBL620221,,,,H,8,,
7178,Evaluated for the inhibition of calf intestinal Adenosine deaminase (ADA),Autocuration,,,B,,BAO_0000357,15890,,,1,CHEMBL620222,,,,H,8,,
7179,Inhibitory activity against ovarian tumor cell line ADDP after 72 hr continuous exposure to compound,Intermediate,9913.0,,F,,BAO_0000219,3801,,979.0,1,CHEMBL620506,ADDP cell line,,Bos taurus,N,1,,
7180,Tumor growth inhibition activity after subcutaneous transplanted tumor in ADJ-PC6 plasmacytoma cells,Intermediate,10090.0,,F,,BAO_0000219,9222,,980.0,1,CHEMBL620507,ADJ/PC6,,Mus musculus,N,1,,
7181,Tumor growth inhibition activity after subcutaneously transplanted tumor in ADJ-PC6 plasmacytoma cells,Intermediate,10090.0,,F,,BAO_0000219,9222,,980.0,1,CHEMBL620508,ADJ/PC6,,Mus musculus,N,1,,
7182,"Compound was tested for dose producing 90% reduction in tumor weight, in ADJ/PC6 mouse plasma cell tumor",Intermediate,10090.0,,F,,BAO_0000219,7257,,980.0,1,CHEMBL620509,ADJ/PC6,,Mus musculus,N,1,,
7183,Compound was tested for inhibition against ADJ/PC6 mouse plasma cell tumor at the dose of 320 mg/Kg,Intermediate,10090.0,,F,,BAO_0000219,7257,,980.0,1,CHEMBL620510,ADJ/PC6,,Mus musculus,N,1,,
7184,Compound was tested for dose required to kill 50 % of ADJ/PC6 mouse plasma cell tumor in a group,Intermediate,10090.0,,A,,BAO_0000219,7257,,980.0,1,CHEMBL620511,ADJ/PC6,,Mus musculus,N,1,,
7185,In vitro incorporation of the [3H]thymidine into the ADJ/PC6 Plasmacytoma cells,Intermediate,10090.0,,F,,BAO_0000219,8084,,980.0,1,CHEMBL620512,ADJ/PC6,,Mus musculus,N,1,,
7186,Tested for cytotoxicity against ADJ/PC6 mouse plasmacytoma,Autocuration,10090.0,,F,,BAO_0000019,14943,,,1,CHEMBL620513,,,Mus musculus,U,0,,
7187,The compound was tested for cytotoxicity against ADJ/PC6 mouse plasmacytoma; Not determined,Autocuration,10090.0,,F,,BAO_0000019,14943,,,1,CHEMBL620514,,,Mus musculus,U,0,,
7188,Tested for cytotoxicity against ADJ/PC6 plasmacytoma,Autocuration,10090.0,,F,,BAO_0000019,14943,,,1,CHEMBL620515,,,Mus musculus,U,0,,
7189,Maximum concentration determined against Bacillus subtilis ATCC 6633 after oral administration in dog(25 mg/kg),Autocuration,1423.0,,A,,BAO_0000218,10524,,,1,CHEMBL620516,,,Bacillus subtilis,U,0,,
7190,AUC value in dog after IV administration at a dose of 5 mg/kg,Intermediate,9615.0,,A,,BAO_0000218,3546,,,1,CHEMBL620517,,,Canis lupus familiaris,N,1,1969.0,
7191,AUC value in dog after oral administration at a dose of 5 mg/kg,Intermediate,9615.0,,A,,BAO_0000218,3546,,,1,CHEMBL620518,,,Canis lupus familiaris,N,1,1969.0,
7192,Cmax value in dog after oral administration at a dose of 5 mg/kg,Intermediate,9615.0,,A,,BAO_0000218,3546,,,1,CHEMBL620519,,,Canis lupus familiaris,N,1,,
7193,Bioavailability in dog after oral administration at a dose of 5 mg/kg,Intermediate,9615.0,,A,,BAO_0000218,3546,,,1,CHEMBL621386,,,Canis lupus familiaris,N,1,,
7194,Tmax value in dog after oral administration at a dose of 5 mg/kg,Intermediate,9615.0,,A,,BAO_0000218,3546,,,1,CHEMBL621387,,,Canis lupus familiaris,N,1,,
7195,Compound was evaluated for its clearance when administered intravenously in dog,Intermediate,9615.0,,A,,BAO_0000218,3184,,,1,CHEMBL621388,,,Canis lupus familiaris,N,1,,
7196,Plasma clearance in Beagle dogs after intravenous administration at a dose of 10 mg/kg,Intermediate,9615.0,,A,,BAO_0000218,16456,,,1,CHEMBL621389,,,Canis lupus familiaris,N,1,,
7197,Plasma clearance was determined in Beagle dogs after (iv) administration of a dose of 12 (uM/kg),Intermediate,9615.0,,A,,BAO_0000218,4809,,,1,CHEMBL621390,,,Canis lupus familiaris,N,1,,
7198,Calculated partition coefficient (clogP),Intermediate,,,P,,BAO_0000100,4219,,,1,CHEMBL621391,,,,U,0,,
7199,Half life in dog,Intermediate,9615.0,,A,,BAO_0000218,3748,,,1,CHEMBL621392,,,Canis lupus familiaris,N,1,,
7200,Time taken for EC90 was determined when tested in dog,Intermediate,9615.0,,A,,BAO_0000218,3132,,,1,CHEMBL621393,,,Canis lupus familiaris,N,1,,
7201,Half life (iv) was determined,Intermediate,9615.0,,A,,BAO_0000218,4219,,,1,CHEMBL621394,,,Canis lupus familiaris,N,1,,
7202,Loss of compound (%metabolized) after 30 min exposure to human liver microsomes,Intermediate,9615.0,,A,,BAO_0000218,16907,,,1,CHEMBL621395,,,Canis lupus familiaris,N,1,2107.0,
7203,Area under the curve was calculated in dog after iv administration,Intermediate,9615.0,,A,,BAO_0000218,6057,,,1,CHEMBL621396,,,Canis lupus familiaris,N,1,,
7204,Area under the curve was calculated in dog after peroral administration,Intermediate,9615.0,,A,,BAO_0000218,6057,,,1,CHEMBL621397,,,Canis lupus familiaris,N,1,,
7205,Dose-normalized area under curve in dog (p.o.) at 2.0 mpk,Intermediate,9615.0,,A,,BAO_0000218,17853,,,1,CHEMBL621398,,,Canis lupus familiaris,N,1,,
7206,pKa was evaluated in dog,Intermediate,9615.0,,A,,BAO_0000218,3639,,,1,CHEMBL618818,,,Canis lupus familiaris,N,1,,
7207,Compound was evaluated for pronounced GH response at 100 mg (n=6)(area under concentration curve was determined from 0-8 hr following morning and evening dosing with 25 mg of the compound,Intermediate,9615.0,,A,,BAO_0000218,14541,,,1,CHEMBL618819,,,Canis lupus familiaris,N,1,,
7208,Alpha-elimination half-life in Beagle dogs after intravenous administration at a dose of 10 mg/kg,Intermediate,9615.0,,A,,BAO_0000218,16456,,,1,CHEMBL618820,,,Canis lupus familiaris,N,1,,
7209,Beta-elimination half-life in Beagle dogs after intravenous administration at a dose of 10 mg/kg,Intermediate,9615.0,,A,,BAO_0000218,16456,,,1,CHEMBL873810,,,Canis lupus familiaris,N,1,,
7210,Compound was evaluated for half-life period in dogs at a dose of 5 mpk perorally,Intermediate,9615.0,,A,,BAO_0000218,2652,,,1,CHEMBL876606,,,Canis lupus familiaris,N,1,,
7211,Compound was evaluated for the half-life (t 1/2) in hours,Intermediate,9615.0,,A,,BAO_0000218,3624,,,1,CHEMBL618821,,,Canis lupus familiaris,N,1,,
7212,Half life to reach the blood concentration was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,Intermediate,9615.0,,A,,BAO_0000218,1337,,,1,CHEMBL618822,,,Canis lupus familiaris,N,1,178.0,
7213,Half life to reach the blood concentration was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,Intermediate,9615.0,,A,,BAO_0000218,1337,,,1,CHEMBL618823,,,Canis lupus familiaris,N,1,178.0,
7214,Half life after intravenous administration of 1 mg/kg in dog,Intermediate,9615.0,,A,,BAO_0000218,4709,,,1,CHEMBL618824,,,Canis lupus familiaris,N,1,,
7215,Half life was measured in dog,Intermediate,9615.0,,A,,BAO_0000218,15660,,,1,CHEMBL618825,,,Canis lupus familiaris,N,1,,
7216,Half life period in dog after 5 mg/kg dose,Intermediate,9615.0,,A,,BAO_0000218,5302,,,1,CHEMBL618826,,,Canis lupus familiaris,N,1,,
7217,Half life period was evaluated in dog; 4-4.8,Intermediate,9615.0,,A,,BAO_0000218,17791,,,1,CHEMBL618827,,,Canis lupus familiaris,N,1,,
7218,Half life was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,Intermediate,9615.0,,A,,BAO_0000218,6348,,,1,CHEMBL618828,,,Canis lupus familiaris,N,1,,
7219,Half-life was determined in dog after a3 mg/kg of iv dose,Intermediate,9615.0,,A,,BAO_0000218,4257,,,1,CHEMBL618829,,,Canis lupus familiaris,N,1,,
7220,Half-life was determined,Intermediate,9615.0,,A,,BAO_0000218,3771,,,1,CHEMBL618830,,,Canis lupus familiaris,N,1,,
7221,Half life in dogs,Intermediate,9615.0,,A,,BAO_0000218,6305,,,1,CHEMBL618831,,,Canis lupus familiaris,N,1,,
7222,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 2 mg/kg tp dog,Intermediate,9615.0,,A,,BAO_0000218,13501,,,1,CHEMBL619489,,,Canis lupus familiaris,N,1,1969.0,
7223,Apparent half-life after single intravenous bolus of 1 mg/kg in dogs,Intermediate,9615.0,,A,,BAO_0000218,17594,,,1,CHEMBL619649,,,Canis lupus familiaris,N,1,,
7224,Compound was evaluated for the half life period after iv administration in Beagle dog.,Intermediate,9615.0,,A,,BAO_0000218,3045,,,1,CHEMBL876607,,,Canis lupus familiaris,N,1,,
7225,Compound was evaluated for the half life period after oral administration in conscious dog.,Intermediate,9615.0,,A,,BAO_0000218,3043,,,1,CHEMBL619650,,,Canis lupus familiaris,N,1,,
7226,Compound was tested for half life in dog,Intermediate,9615.0,,A,,BAO_0000218,4839,,,1,CHEMBL619651,,,Canis lupus familiaris,N,1,,
7227,Compound was tested for its half life in dog,Intermediate,9615.0,,A,,BAO_0000218,4839,,,1,CHEMBL619652,,,Canis lupus familiaris,N,1,,
7228,Half life of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,Intermediate,9615.0,,A,,BAO_0000218,5802,,,1,CHEMBL619653,,,Canis lupus familiaris,N,1,,
7229,Half life of compound in dog was determined,Intermediate,9615.0,,A,,BAO_0000218,17839,,,1,CHEMBL619654,,,Canis lupus familiaris,N,1,,
7230,Half life (iv) was determined,Intermediate,9615.0,,A,,BAO_0000218,4219,,,1,CHEMBL619655,,,Canis lupus familiaris,N,1,,
7231,Half life following administration of 70 nM in canine whole blood (dose exceeding platelet binding capacity),Intermediate,9615.0,,A,,BAO_0000218,13966,,,1,CHEMBL619656,,,Canis lupus familiaris,N,1,178.0,
7232,Half life in Dog plasma at a dosage 5 mg/kg after intravenous administration,Intermediate,9615.0,,A,,BAO_0000218,3994,,,1,CHEMBL873812,,,Canis lupus familiaris,N,1,1969.0,
7233,Half life in Dog plasma at a dosage 5 mg/kg after intravenous administration,Intermediate,9615.0,,F,,BAO_0000218,3994,,,1,CHEMBL621365,,,Canis lupus familiaris,N,1,1969.0,
7234,Half life in dog,Intermediate,9615.0,,A,,BAO_0000218,4453,,,1,CHEMBL621366,,,Canis lupus familiaris,N,1,,
7235,Half life in dog plasma,Intermediate,9615.0,,A,,BAO_0000218,6535,,,1,CHEMBL621367,,,Canis lupus familiaris,N,1,1969.0,
7236,Half life in dog plasma after administration of 0.25 mg/kg iv,Intermediate,9615.0,,A,,BAO_0000218,6535,,,1,CHEMBL621368,,,Canis lupus familiaris,N,1,1969.0,
7237,Half life in dog plasma after administration of 1 mg/kg iv,Intermediate,9615.0,,A,,BAO_0000218,6535,,,1,CHEMBL621369,,,Canis lupus familiaris,N,1,1969.0,
7238,Half life in dog plasma was determined at dose 10 mg/kg,Intermediate,9615.0,,A,,BAO_0000218,3132,,,1,CHEMBL621370,,,Canis lupus familiaris,N,1,1969.0,
7239,Half life in dog was determined,Intermediate,9615.0,,A,,BAO_0000218,5374,,,1,CHEMBL621371,,,Canis lupus familiaris,N,1,,
7240,Half life in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),Intermediate,9615.0,,A,,BAO_0000218,5007,,,1,CHEMBL621372,,,Canis lupus familiaris,N,1,,
7241,Half life upon exposure to human plasma,Intermediate,9615.0,,A,,BAO_0000218,16907,,,1,CHEMBL621373,,,Canis lupus familiaris,N,1,1969.0,
7242,Half life was calculated in dog,Intermediate,9615.0,,A,,BAO_0000218,6057,,,1,CHEMBL621374,,,Canis lupus familiaris,N,1,,
7243,Half life was determined,Intermediate,9615.0,,A,,BAO_0000218,5006,,,1,CHEMBL621375,,,Canis lupus familiaris,N,1,,
7244,Half life was determined,Intermediate,9615.0,,A,,BAO_0000218,5473,,,1,CHEMBL621376,,,Canis lupus familiaris,N,1,,
7245,Half life by intravenous administration of 1.2 mg/kg in dog,Intermediate,9615.0,,A,,BAO_0000218,4368,,,1,CHEMBL619624,,,Canis lupus familiaris,N,1,,
7246,Half life in dog,Intermediate,9615.0,,A,,BAO_0000218,6448,,,1,CHEMBL875840,,,Canis lupus familiaris,N,1,,
7247,Half life in dog after intra venous administration of the compound,Intermediate,9615.0,,A,,BAO_0000218,4353,,,1,CHEMBL619625,,,Canis lupus familiaris,N,1,,
7248,Half life in dog after intra venous administration of the compound; ND means Not determined,Intermediate,9615.0,,A,,BAO_0000218,4353,,,1,CHEMBL619626,,,Canis lupus familiaris,N,1,,
7249,Half life in dog after po administration of the compound,Intermediate,9615.0,,A,,BAO_0000218,4353,,,1,CHEMBL619627,,,Canis lupus familiaris,N,1,,
7250,Half life in dog after po administration of the compound; ND means Not determined,Intermediate,9615.0,,A,,BAO_0000218,4353,,,1,CHEMBL873817,,,Canis lupus familiaris,N,1,,
7251,Half life in dog at the single oral dose of 1 mg/kg,Intermediate,9615.0,,A,,BAO_0000218,6265,,,1,CHEMBL619628,,,Canis lupus familiaris,N,1,,
7252,Half life in dogs,Intermediate,9615.0,,A,,BAO_0000218,5006,,,1,CHEMBL619629,,,Canis lupus familiaris,N,1,,
7253,Half life in dogs at 1 mg/kg oral dosing; 35-100 min,Intermediate,9615.0,,A,,BAO_0000218,5356,,,1,CHEMBL619630,,,Canis lupus familiaris,N,1,,
7254,Half life in rat,Intermediate,9615.0,,A,,BAO_0000218,405,,,1,CHEMBL619631,,,Canis lupus familiaris,N,1,,
7255,Half life in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),Intermediate,9615.0,,A,,BAO_0000218,6642,,,1,CHEMBL619632,,,Canis lupus familiaris,N,1,,
7256,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,Intermediate,10090.0,,A,,BAO_0000218,10107,,,1,CHEMBL619633,,,Mus musculus,N,1,10000001.0,
7257,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,Intermediate,10090.0,,A,,BAO_0000218,10107,,,1,CHEMBL875841,,,Mus musculus,N,1,10000001.0,
7258,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,Intermediate,10090.0,,A,,BAO_0000218,10107,,,1,CHEMBL619634,,,Mus musculus,N,1,10000001.0,
7259,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,Intermediate,10090.0,,A,,BAO_0000218,10107,,,1,CHEMBL619635,,,Mus musculus,N,1,10000001.0,
7260,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,Intermediate,10090.0,,A,,BAO_0000218,10107,,,1,CHEMBL619636,,,Mus musculus,N,1,10000001.0,
7261,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,Intermediate,10090.0,,A,,BAO_0000218,10107,,,1,CHEMBL619637,,,Mus musculus,N,1,10000004.0,
7262,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,Intermediate,10090.0,,A,,BAO_0000218,10107,,,1,CHEMBL619638,,,Mus musculus,N,1,10000004.0,
7263,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,Intermediate,10090.0,,A,,BAO_0000218,10107,,,1,CHEMBL619639,,,Mus musculus,N,1,10000004.0,
7264,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,Intermediate,10090.0,,A,,BAO_0000218,10107,,,1,CHEMBL619640,,,Mus musculus,N,1,10000004.0,
7265,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,Intermediate,10090.0,,A,,BAO_0000218,10107,,,1,CHEMBL619641,,,Mus musculus,N,1,10000004.0,
7266,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,Intermediate,10090.0,,A,,BAO_0000218,10107,,,1,CHEMBL619642,,,Mus musculus,N,1,10000004.0,
7267,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,Intermediate,10090.0,,A,,BAO_0000218,10107,,,1,CHEMBL619643,,,Mus musculus,N,1,10000004.0,
7268,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,Intermediate,10090.0,,A,,BAO_0000218,10107,,,1,CHEMBL619644,,,Mus musculus,N,1,948.0,
7269,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,Intermediate,10090.0,,A,,BAO_0000218,10107,,,1,CHEMBL621112,,,Mus musculus,N,1,948.0,
7270,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,Intermediate,10090.0,,A,,BAO_0000218,10107,,,1,CHEMBL621113,,,Mus musculus,N,1,948.0,
7271,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,Intermediate,10090.0,,A,,BAO_0000218,10107,,,1,CHEMBL621114,,,Mus musculus,N,1,948.0,
7272,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,Intermediate,10090.0,,A,,BAO_0000218,10107,,,1,CHEMBL621115,,,Mus musculus,N,1,948.0,
7273,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,Intermediate,10090.0,,A,,BAO_0000218,10107,,,1,CHEMBL621116,,,Mus musculus,N,1,948.0,
7274,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,Intermediate,10090.0,,A,,BAO_0000218,10107,,,1,CHEMBL621117,,,Mus musculus,N,1,948.0,
7275,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,Intermediate,10090.0,,A,,BAO_0000218,10107,,,1,CHEMBL621118,,,Mus musculus,N,1,2113.0,
7276,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,Intermediate,10090.0,,A,,BAO_0000218,10107,,,1,CHEMBL621119,,,Mus musculus,N,1,2113.0,
7277,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,Intermediate,10090.0,,A,,BAO_0000218,10107,,,1,CHEMBL621120,,,Mus musculus,N,1,2113.0,
7278,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,Intermediate,10090.0,,A,,BAO_0000218,10107,,,1,CHEMBL621757,,,Mus musculus,N,1,2113.0,
7279,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,Intermediate,10090.0,,A,,BAO_0000218,10107,,,1,CHEMBL621758,,,Mus musculus,N,1,2113.0,
7280,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,Intermediate,10090.0,,A,,BAO_0000218,10107,,,1,CHEMBL621759,,,Mus musculus,N,1,2113.0,
7281,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,Intermediate,10090.0,,A,,BAO_0000218,10107,,,1,CHEMBL621760,,,Mus musculus,N,1,2113.0,
7282,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,Intermediate,10090.0,,A,,BAO_0000218,10107,,,1,CHEMBL621761,,,Mus musculus,N,1,2107.0,
7283,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,Intermediate,10090.0,,A,,BAO_0000218,10107,,,1,CHEMBL621762,,,Mus musculus,N,1,2107.0,
7284,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,Intermediate,10090.0,,A,,BAO_0000218,10107,,,1,CHEMBL621763,,,Mus musculus,N,1,2107.0,
7285,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,Intermediate,10090.0,,A,,BAO_0000218,10107,,,1,CHEMBL624502,,,Mus musculus,N,1,2107.0,
7286,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,Intermediate,10090.0,,A,,BAO_0000218,10107,,,1,CHEMBL624503,,,Mus musculus,N,1,2107.0,
7287,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,Intermediate,10090.0,,A,,BAO_0000218,10107,,,1,CHEMBL624504,,,Mus musculus,N,1,2107.0,
7288,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,Intermediate,10090.0,,A,,BAO_0000218,10107,,,1,CHEMBL624505,,,Mus musculus,N,1,2107.0,
7289,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,Intermediate,10090.0,,A,,BAO_0000218,10107,,,1,CHEMBL624506,,,Mus musculus,N,1,2048.0,
7290,In vitro cytotoxicity against A2780 (human ovarian cancer),Intermediate,9606.0,,F,,BAO_0000219,5895,,478.0,1,CHEMBL624507,A2780,,Homo sapiens,N,1,,
7291,In vitro cytotoxicity against the paclitaxel sensitive human breast carcinoma cell line A2780,Intermediate,9606.0,,F,,BAO_0000219,6338,,478.0,1,CHEMBL624508,A2780,,Homo sapiens,N,1,,
7292,In vitro cytotoxicity against. ovarian carcinoma cell line A2780.,Intermediate,9606.0,,F,,BAO_0000219,15163,,478.0,1,CHEMBL624509,A2780,,Homo sapiens,N,1,,
7293,In vitro cytotoxicity against. ovarian carcinoma cell line A2780cisR (cisplatin resistant counter part of A2780).,Intermediate,9606.0,,F,,BAO_0000219,15163,,478.0,1,CHEMBL624510,A2780,,Homo sapiens,N,1,,
7294,In vitro cytotoxicity was tested against human Ovarian carcinoma A2780 cell line,Expert,9606.0,,F,,BAO_0000219,15000,,478.0,1,CHEMBL875956,A2780,,Homo sapiens,N,1,,
7295,In vitro cytotoxicity was tested against human Ovarian carcinoma A2780 cisplatin resistant cell line,Expert,9606.0,,F,,BAO_0000219,15000,,478.0,1,CHEMBL839885,A2780,,Homo sapiens,N,1,,
7296,In vitro cytotoxicity against A2780 ovarian cells using the sulforhodamine B(SRB) assay.,Expert,9606.0,,F,,BAO_0000219,14729,,478.0,1,CHEMBL624511,A2780,,Homo sapiens,N,1,,
7297,In vitro cytotoxicity against A2780 cell line,Intermediate,9606.0,,F,,BAO_0000219,17270,,478.0,1,CHEMBL624512,A2780,,Homo sapiens,N,1,,
7298,In vitro growth inhibitory activity against A2780 human ovarium carcinoma cell line was determined,Intermediate,9606.0,,F,,BAO_0000219,5685,,478.0,1,CHEMBL624513,A2780,,Homo sapiens,N,1,,
7299,In vitro inhibitory activity against human ovarian cancer A2780 cell line,Intermediate,9606.0,,F,,BAO_0000219,3563,,478.0,1,CHEMBL624514,A2780,,Homo sapiens,N,1,,
7300,In vivo cytotoxic concentration of compound against A2780 cell line after 72 hr exposure,Intermediate,9606.0,,F,,BAO_0000218,17753,,478.0,1,CHEMBL618547,A2780,,Homo sapiens,N,1,,
7301,"Inhibition of cell growth in human ovarian carcinoma cell line (A2780cisR,cisplatin-resistant)using the 96 hour continuous exposure sulforhodamine B (SRB) growth delay assay",Intermediate,9606.0,,F,,BAO_0000219,16317,,478.0,1,CHEMBL618548,A2780,,Homo sapiens,N,1,,
7302,Inhibition of tubulin polymerization in analogy of ca.,Intermediate,9606.0,,F,,BAO_0000219,16936,,478.0,1,CHEMBL618549,A2780,,Homo sapiens,N,1,,
7303,Inhibitory activity against ovarian tumor cell line A2780 after 72 hr continuous exposure to compound,Intermediate,9606.0,,F,,BAO_0000219,3801,,478.0,1,CHEMBL618550,A2780,,Homo sapiens,N,1,,
7304,Cytotoxic effect in ovarian cancer cell line (A2780),Expert,9606.0,,F,,BAO_0000219,6181,,478.0,1,CHEMBL618551,A2780,,Homo sapiens,N,1,,
7305,Tested for cytotoxicity against Ovarian carcinoma parental type A2780 cell line expressing MDR-1 (-) gene,Intermediate,9606.0,,F,,BAO_0000219,5318,,478.0,1,CHEMBL618552,A2780,,Homo sapiens,N,1,,
7306,Tested for the cytotoxicity in A2780 ovarian cell line,Intermediate,9606.0,,F,,BAO_0000219,4840,,478.0,1,CHEMBL618553,A2780,,Homo sapiens,N,1,,
7307,The compound was tested for cytotoxic activity against A2780 cell line(human ovarian carcinoma ),Intermediate,9606.0,,F,,BAO_0000219,15748,,478.0,1,CHEMBL618554,A2780,,Homo sapiens,N,1,,
7308,The compound was tested for cytotoxic activity against A2780/Cs cell line(human ovarian carcinoma,Intermediate,9606.0,,F,,BAO_0000219,15748,,478.0,1,CHEMBL618555,A2780,,Homo sapiens,N,1,,
7309,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma,Intermediate,,,F,,BAO_0000219,15748,,481.0,1,CHEMBL618556,A2780cisR,,,N,1,,
7310,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ),Intermediate,,,F,,BAO_0000219,15748,,481.0,1,CHEMBL618557,A2780cisR,,,N,1,,
7311,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ); ND means no data,Intermediate,,,F,,BAO_0000219,15748,,481.0,1,CHEMBL618558,A2780cisR,,,N,1,,
7312,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma),Intermediate,,,F,,BAO_0000219,15748,,481.0,1,CHEMBL618559,A2780cisR,,,N,1,,
7313,In vivo log of cells killed after administration of compound in A2780 cell line,Intermediate,9606.0,,F,,BAO_0000218,17753,,478.0,1,CHEMBL618560,A2780,,Homo sapiens,N,1,,
7314,Compound was tested in vivo for maximum tolerated dose after i.v. administration twice a day for 5 days in A2780 cell line,Intermediate,9606.0,,F,,BAO_0000218,17753,,478.0,1,CHEMBL618561,A2780,,Homo sapiens,N,1,,
7315,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines.;NA means not active,Intermediate,9606.0,,F,,BAO_0000219,16936,,478.0,1,CHEMBL618562,A2780,,Homo sapiens,N,1,,
7316,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell lines (at 5 uM );NA means not active,Intermediate,9606.0,,F,,BAO_0000219,16936,,478.0,1,CHEMBL618563,A2780,,Homo sapiens,N,1,,
7317,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines; ND means no data,Intermediate,9606.0,,F,,BAO_0000219,16936,,478.0,1,CHEMBL618564,A2780,,Homo sapiens,N,1,,
7318,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell lines. (at 5 uM ); ND means no data,Intermediate,9606.0,,F,,BAO_0000219,16936,,478.0,1,CHEMBL618565,A2780,,Homo sapiens,N,1,,
7319,Optimal dose required to inhibit human ovarian A2780 tumor growth after subcutaneous transplantation on athymic mice at 10 mg/kg (treatment schedule: q4dX2),Intermediate,9606.0,,F,,BAO_0000218,17528,,478.0,1,CHEMBL618566,A2780,,Homo sapiens,N,1,,
7320,Resistance factor was determined as IC50 cisplatin-resistant/parent for human A2780 ovarian cell line,Intermediate,9606.0,,F,,BAO_0000219,6633,,478.0,1,CHEMBL618567,A2780,,Homo sapiens,N,1,,
7321,Resistance index is IC50 ratio of A2780 cell line and A2780cisR cell line,Expert,9606.0,,F,,BAO_0000219,15000,,478.0,1,CHEMBL618568,A2780,,Homo sapiens,N,1,,
7322,Percentage tumor growth inhibition was calculated in respect to controls one week after the end of the treatment,Expert,9606.0,,F,,BAO_0000219,17528,,478.0,1,CHEMBL618569,A2780,,Homo sapiens,N,1,,
7323,Compound was tested for Tubulin polymerization inhibition by using human ovarian cancer cell lines.,Intermediate,9606.0,,F,,BAO_0000219,16936,,478.0,1,CHEMBL621857,A2780,,Homo sapiens,N,1,,
7324,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines.,Intermediate,9606.0,,F,,BAO_0000219,16936,,478.0,1,CHEMBL621858,A2780,,Homo sapiens,N,1,,
7325,Percent of Tubulin polymerization inhibition by using human ovarian cancer cell lines at a concentration of 5 uM,Intermediate,9606.0,,F,,BAO_0000219,16936,,478.0,1,CHEMBL621859,A2780,,Homo sapiens,N,1,,
7326,"Colchicine Binding Inhibition ( CBI ) by using human ovarian cancer cell lines at 5 uM, (values are mean of 9 over 4 concentrations +/- SD)",Intermediate,9606.0,,F,,BAO_0000219,16936,,478.0,1,CHEMBL621860,A2780,,Homo sapiens,N,1,,
7327,Compound tested for colchicine Binding Inhibition by using human ovarian cancer cell line (at 5 uM ),Intermediate,9606.0,,F,,BAO_0000219,16936,,478.0,1,CHEMBL621861,A2780,,Homo sapiens,N,1,,
7328,"Tested for colchicine binding inhibition, using human ovarian cancer cell lines (at 5 uM )",Expert,9606.0,,F,,BAO_0000219,16936,,478.0,1,CHEMBL621862,A2780,,Homo sapiens,N,1,,
7329,Compound tested for colchicine Binding Inhibition by using human ovarian carcinoma cell line (at 5 uM ),Intermediate,9606.0,,F,,BAO_0000219,16936,,478.0,1,CHEMBL621863,A2780,,Homo sapiens,N,1,,
7330,Compound was tested for colchicine Binding Inhibition by using human ovarian carcinoma cell line (at 5 uM ),Intermediate,9606.0,,F,,BAO_0000219,16936,,478.0,1,CHEMBL621864,A2780,,Homo sapiens,N,1,,
7331,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell line (at 5 uM ),Intermediate,9606.0,,F,,BAO_0000219,16936,,478.0,1,CHEMBL621865,A2780,,Homo sapiens,N,1,,
7332,In vitro antiproliferative activity against A2780 cell line,Intermediate,10090.0,,F,,BAO_0000219,17737,,478.0,1,CHEMBL621866,A2780,,Mus musculus,N,1,,
7333,Maximum tolerated dose in A2780 tumor in mice after intraperitoneal administration daily for 8 days,Expert,10090.0,,F,,BAO_0000219,17764,,478.0,1,CHEMBL621867,A2780,,Mus musculus,N,1,,
7334,In vitro cytotoxicity of compound was determined against A2780 cell lines at 37 degree C after 96 hr,Intermediate,9606.0,,F,,BAO_0000219,3830,,478.0,1,CHEMBL621868,A2780,,Homo sapiens,N,1,,
7335,In vitro cytotoxicity of compound was determined against A2780 cell lines at 37 degree C for 96 hr,Intermediate,9606.0,,F,,BAO_0000219,3829,,478.0,1,CHEMBL875282,A2780,,Homo sapiens,N,1,,
7336,Vc value in dog after IV administration at a dose of 5 mg/kg,Intermediate,9615.0,,A,,BAO_0000218,3546,,,1,CHEMBL621869,,,Canis lupus familiaris,N,1,,
7337,Half life period in dog after IV administration at a dose of 5 mg/kg,Intermediate,9615.0,,A,,BAO_0000218,3546,,,1,CHEMBL621870,,,Canis lupus familiaris,N,1,,
7338,Area under curve was determine after peroral administration at 10 mpk in Rhesus,Autocuration,9527.0,,A,,BAO_0000019,5668,,,1,CHEMBL621871,,,Cercopithecidae,U,0,,
7339,AUC (area under curve) evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,Autocuration,9527.0,,A,,BAO_0000218,3443,,,1,CHEMBL621243,,,Cercopithecidae,U,0,1969.0,
7340,AUC (area under curve) compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,Autocuration,9527.0,,A,,BAO_0000218,3443,,,1,CHEMBL621244,,,Cercopithecidae,U,0,1969.0,
7341,Area under curve determined after intravenous administration at a dose of 3 mg/kg in cynomolgus monkey,Autocuration,9541.0,,A,,BAO_0000218,4256,,,1,CHEMBL621245,,,Macaca fascicularis,U,0,,
7342,Area under curve determined after peroral administration at a dose of 10 mg/kg in cynomolgus monkey,Autocuration,9541.0,,A,,BAO_0000218,4256,,,1,CHEMBL621246,,,Macaca fascicularis,U,0,,
7343,Area under curve determined after peroral administration at a dose of 3 mg/kg in cynomolgus monkey,Autocuration,9541.0,,A,,BAO_0000218,4256,,,1,CHEMBL621247,,,Macaca fascicularis,U,0,,
7344,Oral Bioavailability in rat,Autocuration,10116.0,,A,,BAO_0000218,4256,,,1,CHEMBL618386,,,Rattus norvegicus,U,0,,
7345,Area under curve was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,Autocuration,9527.0,,A,,BAO_0000218,1916,,,1,CHEMBL618387,,,Cercopithecidae,U,0,,
7346,Area under curve value in monkey at a dose of 5 mg/kg,Autocuration,9527.0,,A,,BAO_0000218,5302,,,1,CHEMBL618388,,,Cercopithecidae,U,0,,
7347,Area under curve was determined in monkey after a 3 mg/kg of oral dose,Autocuration,9527.0,,A,,BAO_0000218,4257,,,1,CHEMBL618389,,,Cercopithecidae,U,0,,
7348,Area under curve was determined using trapezoidal rule after intravenous administration in cynomolgus monkeys,Autocuration,9527.0,,A,,BAO_0000019,5355,,,1,CHEMBL618574,,,Cercopithecidae,U,0,,
7349,Area under curve was determined using trapezoidal rule after oral administration in cynomolgus monkeys,Autocuration,9527.0,,A,,BAO_0000019,5355,,,1,CHEMBL618575,,,Cercopithecidae,U,0,,
7350,Area under curve was determined using trapezoidal rule after oral administration in cynomolgus monkeys; ND means Not determined,Autocuration,9527.0,,A,,BAO_0000019,5355,,,1,CHEMBL618576,,,Cercopithecidae,U,0,,
7351,Area under the curve for the compound calculated from 0-24 hr after intravenous administration at a dose of 10 mg/kg in monkey,Autocuration,9527.0,,A,,BAO_0000218,6078,,,1,CHEMBL618577,,,Cercopithecidae,U,0,,
7352,Area under the curve for the compound calculated from 0-24 hr after oral administration at a dose of 10 mg/kg in monkey,Autocuration,9527.0,,A,,BAO_0000218,6078,,,1,CHEMBL876487,,,Cercopithecidae,U,0,,
7353,Area under the curve was measured in monkey after an iv dose of 1 mg/kg,Autocuration,9527.0,,A,,BAO_0000218,6062,,,1,CHEMBL618578,,,Cercopithecidae,U,0,,
7354,Compound was evaluated for AUC after treatment with iv dose of 1 mgkg to female cynomolgus monkey,Autocuration,9527.0,,A,,BAO_0000218,2661,,,1,CHEMBL618579,,,Cercopithecidae,U,0,,
7355,Compound was evaluated for AUC after treatment with oral dose of 2 mgkg to female cynomolgus monkey,Autocuration,9527.0,,A,,BAO_0000019,2661,,,1,CHEMBL618580,,,Cercopithecidae,U,0,,
7356,Pharmacokinetic parameter Cmax was measured after administration into monkey at 3 mg/kg,Autocuration,9527.0,,A,,BAO_0000218,5394,,,1,CHEMBL618581,,,Cercopithecidae,U,0,,
7357,Pharmacokinetic property at the dose of 10 mg/kg (20% HPbetaCD) concentration in cynomolgus monkeys (0 to 24 hr) p.o.,Autocuration,9527.0,,A,,BAO_0000218,4397,,,1,CHEMBL618582,,,Cercopithecidae,U,0,,
7358,Area under curve value 24 hr after 2 mg/kg iv administration in monkeys,Autocuration,9527.0,,A,,BAO_0000218,17509,,,1,CHEMBL618583,,,Cercopithecidae,U,0,,
7359,Area under curve value 24 hr after 2 mg/kg oral administration in monkeys,Autocuration,9527.0,,A,,BAO_0000218,17509,,,1,CHEMBL618584,,,Cercopithecidae,U,0,,
7360,Oral AUCN in monkey (dosed at 0.5 mpk iv ),Autocuration,9527.0,,A,,BAO_0000218,6641,,,1,CHEMBL618585,,,Cercopithecidae,U,0,,
7361,Bioavailability was reported in cynomolgus monkeys (ratio of AUC in oral administration to that of intravenous administration),Autocuration,9527.0,,A,,BAO_0000218,5355,,,1,CHEMBL618586,,,Cercopithecidae,U,0,,
7362,Half life compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,Autocuration,9527.0,,A,,BAO_0000218,3443,,,1,CHEMBL618587,,,Cercopithecidae,U,0,,
7363,Half life evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,Autocuration,9527.0,,A,,BAO_0000218,3443,,,1,CHEMBL618588,,,Cercopithecidae,U,0,,
7364,Binding towards monkey plasma protein at 10 uM,Autocuration,9527.0,,A,,BAO_0000019,17409,,,1,CHEMBL618589,,,Cercopithecidae,U,0,,
7365,Binding towards monkey plasma protein at 100 uM,Autocuration,9527.0,,A,,BAO_0000019,17409,,,1,CHEMBL618590,,,Cercopithecidae,U,0,,
7366,Apparent bioavailability in squirrel monkey was determined,Autocuration,9527.0,,A,,BAO_0000218,1052,,,1,CHEMBL872262,,,Cercopithecidae,U,0,,
7367,Bioavailability was determined after oral administration of compound 18 at a dose of 1 mg/kg to rhesus monkey,Autocuration,9527.0,,A,,BAO_0000218,13501,,,1,CHEMBL618591,,,Cercopithecidae,U,0,,
7368,Bioavailability in monkey (dose 2 mg/kg),Autocuration,9443.0,,A,,BAO_0000218,17509,,,1,CHEMBL618592,,,monkey,U,0,,
7369,Compound at a dose 3 mg/kg was administered to monkey and was evaluated for bioavailability after administration into monkey at 3 mg/kg,Autocuration,9527.0,,A,,BAO_0000218,5394,,,1,CHEMBL876488,,,Cercopithecidae,U,0,,
7370,Compound was evaluated for bioavailability after treatment with oral dose of 2 mgkg to female cynomolgus monkey,Autocuration,9527.0,,A,,BAO_0000218,2661,,,1,CHEMBL618593,,,Cercopithecidae,U,0,,
7371,Bioavailability in monkey (i.d. dosing),Autocuration,9443.0,,A,,BAO_0000218,11219,,,1,CHEMBL618594,,,monkey,U,0,,
7372,Oral bioavailability after 5 mg/kg in cynomolgus monkey was determined,Autocuration,9527.0,,A,,BAO_0000218,3045,,,1,CHEMBL618595,,,Cercopithecidae,U,0,,
7373,Clearance of the drug was measured in cynomolgus,Autocuration,9527.0,,A,,BAO_0000019,17796,,,1,CHEMBL621469,,,Cercopithecidae,U,0,,
7374,Clearance was estimated in two squirrel monkeys after iv administration at 5 mg/kg,Autocuration,9527.0,,A,,BAO_0000218,1399,,,1,CHEMBL621470,,,Cercopithecidae,U,0,,
7375,Compound was evaluated for clearance after treatment with iv dose of 1 mgkg to female cynomolgus monkey,Autocuration,9527.0,,A,,BAO_0000218,2661,,,1,CHEMBL621471,,,Cercopithecidae,U,0,,
7376,Compound was tested for its plasma clearance rate in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,Autocuration,9544.0,,A,,BAO_0000218,5005,,,1,CHEMBL621472,,,Macaca mulatta,U,0,1969.0,
7377,Plasma clearance in rhesus monkey was determined,Autocuration,9527.0,,A,,BAO_0000218,17267,,,1,CHEMBL621473,,,Cercopithecidae,U,0,,
7378,Plasma clearance in monkey after administration of 1 mg/kg iv,Autocuration,9527.0,,A,,BAO_0000218,6535,,,1,CHEMBL621474,,,Cercopithecidae,U,0,,
7379,Plasma clearance in cynomolgus monkey,Autocuration,9527.0,,A,,BAO_0000218,5922,,,1,CHEMBL621475,,,Cercopithecidae,U,0,,
7380,Plasma clearance after oral administration (2.5 mg/kg) in monkey was determined,Autocuration,9527.0,,A,,BAO_0000218,6221,,,1,CHEMBL621476,,,Cercopithecidae,U,0,,
7381,Plasma clearance after peroral administration at 10 mpk in Rhesus,Autocuration,9527.0,,A,,BAO_0000218,5668,,,1,CHEMBL624290,,,Cercopithecidae,U,0,,
7382,The total clearance was determined after intravenous administration in cynomolgus monkeys,Autocuration,9527.0,,A,,BAO_0000218,5355,,,1,CHEMBL624291,,,Cercopithecidae,U,0,,
7383,The total clearance was determined after oral administration in cynomolgus monkeys; NA means Not applicable,Autocuration,9527.0,,A,,BAO_0000218,5355,,,1,CHEMBL624292,,,Cercopithecidae,U,0,,
7384,The total clearance was determined after oral administration in cynomolgus monkeys; NA means not applicable,Autocuration,9527.0,,A,,BAO_0000218,5355,,,1,CHEMBL624293,,,Cercopithecidae,U,0,,
7385,Tested for Clearance upon iv administration to african green monkey,Autocuration,9527.0,,A,,BAO_0000218,4578,,,1,CHEMBL624294,,,Cercopithecidae,U,0,,
7386,Clearance in monkey,Autocuration,9527.0,,A,,BAO_0000218,17592,,,1,CHEMBL624295,,,Cercopithecidae,U,0,,
7387,Half life in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),Intermediate,9615.0,,A,,BAO_0000218,6641,,,1,CHEMBL624296,,,Canis lupus familiaris,N,1,,
7388,Half life in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),Intermediate,9615.0,,A,,BAO_0000218,6642,,,1,CHEMBL624297,,,Canis lupus familiaris,N,1,,
7389,Half life was evaluated after intravenous administration to dogs,Intermediate,9615.0,,A,,BAO_0000218,16367,,,1,CHEMBL624298,,,Canis lupus familiaris,N,1,,
7390,Half life was evaluated in dog,Intermediate,9615.0,,A,,BAO_0000218,5472,,,1,CHEMBL624299,,,Canis lupus familiaris,N,1,,
7391,Half life was evaluated in dog,Intermediate,9615.0,,A,,BAO_0000218,5474,,,1,CHEMBL624300,,,Canis lupus familiaris,N,1,,
7392,Half life period (t1/2) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,Intermediate,9615.0,,A,,BAO_0000218,5654,,,1,CHEMBL624301,,,Canis lupus familiaris,N,1,,
7393,Half life period after intravenous administration (1 mg/kg) was determined in dog (in vivo),Intermediate,9615.0,,A,,BAO_0000218,6227,,,1,CHEMBL624302,,,Canis lupus familiaris,N,1,,
7394,Half life period after intravenous administration in dog,Intermediate,9615.0,,A,,BAO_0000218,6227,,,1,CHEMBL876026,,,Canis lupus familiaris,N,1,,
7395,Half life period after oral administration (2.5 mg/kg) in dog was determined,Intermediate,9615.0,,A,,BAO_0000218,6221,,,1,CHEMBL624303,,,Canis lupus familiaris,N,1,,
7396,Half life period at a dose of 1 uM/kg in dog was determined,Intermediate,9615.0,,A,,BAO_0000218,4527,,,1,CHEMBL624304,,,Canis lupus familiaris,N,1,,
7397,Half life period was determine after peroral administration at 10 mpk in dog,Intermediate,9615.0,,A,,BAO_0000218,5668,,,1,CHEMBL624305,,,Canis lupus familiaris,N,1,,
7398,Half life period was determine after peroral administration at 5 mpk in dog,Intermediate,9615.0,,A,,BAO_0000218,5668,,,1,CHEMBL624306,,,Canis lupus familiaris,N,1,,
7399,Half life period was determined,Intermediate,9615.0,,A,,BAO_0000218,3854,,,1,CHEMBL624307,,,Canis lupus familiaris,N,1,,
7400,Half life period was determined,Intermediate,9615.0,,A,,BAO_0000218,5505,,,1,CHEMBL624308,,,Canis lupus familiaris,N,1,,
7401,Half life period by iv administration in dog at a dose of 6 mg/kg,Intermediate,9615.0,,A,,BAO_0000218,6251,,,1,CHEMBL624309,,,Canis lupus familiaris,N,1,,
7402,Half life period was evaluated in dog,Intermediate,9615.0,,A,,BAO_0000218,1918,,,1,CHEMBL624310,,,Canis lupus familiaris,N,1,,
7403,Half life period was determined in Beagle dog at a dose of 1 mg/kg by iv administration,Intermediate,9615.0,,A,,BAO_0000218,5546,,,1,CHEMBL625003,,,Canis lupus familiaris,N,1,,
7404,Half life period was determined in Beagle dogs after (iv) administration of a dose of 12 (uM/kg),Intermediate,9615.0,,A,,BAO_0000218,4809,,,1,CHEMBL625004,,,Canis lupus familiaris,N,1,,
7405,Half life time after intravenous administration (0.5 mg/kg) was determined in dog,Intermediate,9615.0,,A,,BAO_0000218,6215,,,1,CHEMBL625005,,,Canis lupus familiaris,N,1,,
7406,Half-life period by oral administration at a dose of 10 uM/kg in dog was determined,Intermediate,9615.0,,A,,BAO_0000218,4527,,,1,CHEMBL873813,,,Canis lupus familiaris,N,1,,
7407,Half-life after oral dose of compound at 3 mg/kg in dogs,Intermediate,9615.0,,A,,BAO_0000218,17594,,,1,CHEMBL625006,,,Canis lupus familiaris,N,1,,
7408,Half-life of compound in dog following p.o. administration of 0.5 mg/kg,Intermediate,9615.0,,A,,BAO_0000218,17839,,,1,CHEMBL625007,,,Canis lupus familiaris,N,1,,
7409,Half-life of compound in dog following p.o. administration of 0.9 mg/kg,Intermediate,9615.0,,A,,BAO_0000218,17839,,,1,CHEMBL876027,,,Canis lupus familiaris,N,1,,
7410,Half-life of compound in dog following p.o. administration of 0.95 mg/kg,Intermediate,9615.0,,A,,BAO_0000218,17839,,,1,CHEMBL625008,,,Canis lupus familiaris,N,1,,
7411,Half-life of compound in dog following p.o. administration of 1 mg/kg,Intermediate,9615.0,,A,,BAO_0000218,17839,,,1,CHEMBL625009,,,Canis lupus familiaris,N,1,,
7412,Half-life of compound in plasma of dog was determined,Intermediate,9615.0,,A,,BAO_0000218,5210,,,1,CHEMBL625010,,,Canis lupus familiaris,N,1,1969.0,
7413,Half-life of compound was determined in dogs,Intermediate,9615.0,,A,,BAO_0000218,5210,,,1,CHEMBL625011,,,Canis lupus familiaris,N,1,,
7414,Half-life after administration of 4 mg/Kg oral dose in dog,Intermediate,9615.0,,A,,BAO_0000218,2959,,,1,CHEMBL621553,,,Canis lupus familiaris,N,1,,
7415,Half-life after intravenous administration of 1 mg/kg/h in dog,Intermediate,9615.0,,A,,BAO_0000218,4137,,,1,CHEMBL621554,,,Canis lupus familiaris,N,1,,
7416,Half-life in Dog,Intermediate,9615.0,,A,,BAO_0000218,5064,,,1,CHEMBL621555,,,Canis lupus familiaris,N,1,,
7417,Half-life in Dog,Intermediate,9615.0,,A,,BAO_0000218,5147,,,1,CHEMBL621556,,,Canis lupus familiaris,N,1,,
7418,Half-life in dog,Intermediate,9615.0,,A,,BAO_0000218,5145,,,1,CHEMBL621557,,,Canis lupus familiaris,N,1,,
7419,Half-life in dog after oral administration at 1 mg/kg,Intermediate,9615.0,,A,,BAO_0000218,6123,,,1,CHEMBL621558,,,Canis lupus familiaris,N,1,,
7420,Half-life in dog after oral administration at 1 mg/kg; nd is not determined,Intermediate,9615.0,,A,,BAO_0000218,6123,,,1,CHEMBL621559,,,Canis lupus familiaris,N,1,,
7421,Half-life in dogs,Intermediate,9615.0,,A,,BAO_0000218,4333,,,1,CHEMBL621560,,,Canis lupus familiaris,N,1,,
7422,Half-life in dogs; ND indicates not determined,Intermediate,9615.0,,A,,BAO_0000218,4333,,,1,CHEMBL876028,,,Canis lupus familiaris,N,1,,
7423,Half-life in plasma of dog,Intermediate,9615.0,,A,,BAO_0000218,12500,,,1,CHEMBL621561,,,Canis lupus familiaris,N,1,1969.0,
7424,Half-life in plasma of dog at dose of 3-10 mgkg,Intermediate,9615.0,,A,,BAO_0000218,12500,,,1,CHEMBL621562,,,Canis lupus familiaris,N,1,1969.0,
7425,Half-life was evaluated after i.v. administration in dog at a dose of 1 mg/kg,Intermediate,9615.0,,A,,BAO_0000218,6005,,,1,CHEMBL621563,,,Canis lupus familiaris,N,1,,
7426,Half-life was measured in dog after an iv dose of 1 mg/kg,Intermediate,9615.0,,A,,BAO_0000218,6062,,,1,CHEMBL621564,,,Canis lupus familiaris,N,1,,
7427,Half-life was measured in dogs after an oral dose of 10 uM/kg,Intermediate,9615.0,,A,,BAO_0000218,17650,,,1,CHEMBL621565,,,Canis lupus familiaris,N,1,,
7428,Half-life in vivo in dog by intravenous administration at a dose of 0.2 mg/kg,Intermediate,9615.0,,A,,BAO_0000218,5530,,,1,CHEMBL621566,,,Canis lupus familiaris,N,1,,
7429,Half-life in vivo in dog by intravenous administration at a dose of 1 mg/kg,Intermediate,9615.0,,A,,BAO_0000218,5530,,,1,CHEMBL621567,,,Canis lupus familiaris,N,1,,
7430,Half-life of the compound after 0.3 mg/kg po administration in dog,Intermediate,9615.0,,A,,BAO_0000218,5600,,,1,CHEMBL622978,,,Canis lupus familiaris,N,1,,
7431,Half-life period after intravenous administration of 0.5 mg/kg in dog was determined,Intermediate,9615.0,,A,,BAO_0000218,6039,,,1,CHEMBL873814,,,Canis lupus familiaris,N,1,,
7432,Half-life period after intravenous administration of 1.0 mg/kg in dog was determined,Intermediate,9615.0,,A,,BAO_0000218,6039,,,1,CHEMBL623219,,,Canis lupus familiaris,N,1,,
7433,Half-life period after peroral administration of 0.2 mg/kg in dog was determined,Intermediate,9615.0,,A,,BAO_0000218,6039,,,1,CHEMBL624477,,,Canis lupus familiaris,N,1,,
7434,t1/2 in dog,Intermediate,9615.0,,A,,BAO_0000218,6227,,,1,CHEMBL624478,,,Canis lupus familiaris,N,1,,
7435,Half-life period measured in dogs,Intermediate,9615.0,,A,,BAO_0000218,14541,,,1,CHEMBL624479,,,Canis lupus familiaris,N,1,,
7436,Half-life period in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,Intermediate,9615.0,,A,,BAO_0000218,4521,,,1,CHEMBL624480,,,Canis lupus familiaris,N,1,,
7437,Half-life period in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,Intermediate,9615.0,,A,,BAO_0000218,4521,,,1,CHEMBL623595,,,Canis lupus familiaris,N,1,,
7438,Half-life period was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,Intermediate,9615.0,,A,,BAO_0000218,6679,,,1,CHEMBL623596,,,Canis lupus familiaris,N,1,,
7439,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in dog plasma",Intermediate,9615.0,,A,,BAO_0000218,1116,,,1,CHEMBL623597,,,Canis lupus familiaris,N,1,1969.0,
7440,In vivo half life period was calculated at 1 mg/kg in dog,Intermediate,9615.0,,A,,BAO_0000218,5444,,,1,CHEMBL623598,,,Canis lupus familiaris,N,1,,
7441,In vivo half life period was calculated at 1 mg/kg in dog; ND=Not determined,Intermediate,9615.0,,A,,BAO_0000218,5444,,,1,CHEMBL623599,,,Canis lupus familiaris,N,1,,
7442,Longer half-life in dog (i.v.) at 0.5 mpk,Intermediate,9615.0,,A,,BAO_0000218,17853,,,1,CHEMBL623600,,,Canis lupus familiaris,N,1,,
7443,Oral bioavailability in dog (dose 5 uM/kg),Intermediate,9615.0,,A,,BAO_0000218,4353,,,1,CHEMBL623601,,,Canis lupus familiaris,N,1,,
7444,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,Intermediate,9615.0,,A,,BAO_0000218,16452,,,1,CHEMBL623602,,,Canis lupus familiaris,N,1,,
7445,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,Intermediate,9615.0,,A,,BAO_0000218,16452,,,1,CHEMBL623603,,,Canis lupus familiaris,N,1,,
7446,Bioavailability in dog (dose 1 mg/kg i.v.),Intermediate,9615.0,,A,,BAO_0000218,16452,,,1,CHEMBL623604,,,Canis lupus familiaris,N,1,,
7447,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,Intermediate,10090.0,,A,,BAO_0000218,10107,,,1,CHEMBL623605,,,Mus musculus,N,1,2048.0,
7448,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,Intermediate,10090.0,,A,,BAO_0000218,10107,,,1,CHEMBL623606,,,Mus musculus,N,1,2048.0,
7449,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,Intermediate,10090.0,,A,,BAO_0000218,10107,,,1,CHEMBL623607,,,Mus musculus,N,1,2048.0,
7450,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,Intermediate,10090.0,,A,,BAO_0000218,10107,,,1,CHEMBL623608,,,Mus musculus,N,1,2048.0,
7451,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,Intermediate,10090.0,,A,,BAO_0000218,10107,,,1,CHEMBL623609,,,Mus musculus,N,1,2048.0,
7452,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,Intermediate,10090.0,,A,,BAO_0000218,10107,,,1,CHEMBL623610,,,Mus musculus,N,1,2048.0,
7453,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,Intermediate,10090.0,,A,,BAO_0000218,10107,,,1,CHEMBL623611,,,Mus musculus,N,1,2385.0,
7454,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,Intermediate,10090.0,,A,,BAO_0000218,10107,,,1,CHEMBL623612,,,Mus musculus,N,1,2385.0,
7455,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,Intermediate,10090.0,,A,,BAO_0000218,10107,,,1,CHEMBL623613,,,Mus musculus,N,1,2385.0,
7456,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,Intermediate,10090.0,,A,,BAO_0000218,10107,,,1,CHEMBL623614,,,Mus musculus,N,1,2385.0,
7457,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,Intermediate,10090.0,,A,,BAO_0000218,10107,,,1,CHEMBL623615,,,Mus musculus,N,1,2385.0,
7458,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,Intermediate,10090.0,,A,,BAO_0000218,10107,,,1,CHEMBL623616,,,Mus musculus,N,1,2385.0,
7459,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,Intermediate,10090.0,,A,,BAO_0000218,10107,,,1,CHEMBL623617,,,Mus musculus,N,1,2385.0,
7460,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,Intermediate,10090.0,,A,,BAO_0000218,10107,,,1,CHEMBL875944,,,Mus musculus,N,1,14.0,
7461,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,Intermediate,10090.0,,A,,BAO_0000218,10107,,,1,CHEMBL623618,,,Mus musculus,N,1,14.0,
7462,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,Intermediate,10090.0,,A,,BAO_0000218,10107,,,1,CHEMBL623619,,,Mus musculus,N,1,14.0,
7463,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,Intermediate,10090.0,,A,,BAO_0000218,10107,,,1,CHEMBL623620,,,Mus musculus,N,1,14.0,
7464,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,Intermediate,10090.0,,A,,BAO_0000218,10107,,,1,CHEMBL623621,,,Mus musculus,N,1,14.0,
7465,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,Intermediate,10090.0,,A,,BAO_0000218,10107,,,1,CHEMBL623622,,,Mus musculus,N,1,14.0,
7466,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,Intermediate,10090.0,,A,,BAO_0000218,10107,,,1,CHEMBL623623,,,Mus musculus,N,1,14.0,
7467,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,Intermediate,10090.0,,A,,BAO_0000218,10107,,,1,CHEMBL623624,,,Mus musculus,N,1,2106.0,
7468,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,Intermediate,10090.0,,A,,BAO_0000218,10107,,,1,CHEMBL618521,,,Mus musculus,N,1,2106.0,
7469,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,Intermediate,10090.0,,A,,BAO_0000218,10107,,,1,CHEMBL618522,,,Mus musculus,N,1,2106.0,
7470,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,Intermediate,10090.0,,A,,BAO_0000218,10107,,,1,CHEMBL618523,,,Mus musculus,N,1,2106.0,
7471,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,Intermediate,10090.0,,A,,BAO_0000218,10107,,,1,CHEMBL618524,,,Mus musculus,N,1,2106.0,
7472,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,Intermediate,10090.0,,A,,BAO_0000218,10107,,,1,CHEMBL618525,,,Mus musculus,N,1,2106.0,
7473,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,Intermediate,10090.0,,A,,BAO_0000218,10107,,,1,CHEMBL624586,,,Mus musculus,N,1,2106.0,
7474,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,Intermediate,10090.0,,A,,BAO_0000218,10107,,,1,CHEMBL624587,,,Mus musculus,N,1,945.0,
7475,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,Intermediate,10090.0,,A,,BAO_0000218,10107,,,1,CHEMBL624588,,,Mus musculus,N,1,945.0,
7476,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,Intermediate,10090.0,,A,,BAO_0000218,10107,,,1,CHEMBL624589,,,Mus musculus,N,1,945.0,
7477,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,Intermediate,10090.0,,A,,BAO_0000218,10107,,,1,CHEMBL624590,,,Mus musculus,N,1,945.0,
7478,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,Intermediate,10090.0,,A,,BAO_0000218,10107,,,1,CHEMBL624591,,,Mus musculus,N,1,945.0,
7479,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,Intermediate,10090.0,,A,,BAO_0000218,10107,,,1,CHEMBL624592,,,Mus musculus,N,1,945.0,
7480,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,Intermediate,10090.0,,A,,BAO_0000218,10107,,,1,CHEMBL624593,,,Mus musculus,N,1,945.0,
7481,Oral bioavailability in rat,Intermediate,10116.0,,A,,BAO_0000218,4689,,,1,CHEMBL624594,,,Rattus norvegicus,N,1,,
7482,Tested for the bioavailability in rat,Intermediate,10116.0,,A,,BAO_0000218,4950,,,1,CHEMBL624595,,,Rattus norvegicus,N,1,,
7483,Bioavailability in rat (dose 1 mg/kg i.v. and 2 mg/kg p.o.),Intermediate,10116.0,,A,,BAO_0000218,5328,,,1,CHEMBL624596,,,Rattus norvegicus,N,1,,
7484,Bioavailability in rat,Intermediate,10116.0,,A,,BAO_0000218,406,,,1,CHEMBL624597,,,Rattus norvegicus,N,1,,
7485,Bioavailability in rat,Intermediate,10116.0,,A,,BAO_0000218,12500,,,1,CHEMBL624598,,,Rattus norvegicus,N,1,,
7486,Bioavailability in rat (dose 3-10 mg/kg),Intermediate,10116.0,,A,,BAO_0000218,12500,,,1,CHEMBL624599,,,Rattus norvegicus,N,1,,
7487,Bioavailability in rat,Intermediate,10116.0,,A,,BAO_0000218,5247,,,1,CHEMBL875166,,,Rattus norvegicus,N,1,,
7488,Apparent terminal elimination half-life in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,Intermediate,10116.0,,A,,BAO_0000218,4186,,,1,CHEMBL624600,,,Rattus norvegicus,N,1,1969.0,
7489,Apparent terminal elimination half-life in rat plasma after administration of 50 mg/kg dose through subcutaneous route,Intermediate,10116.0,,A,,BAO_0000218,4186,,,1,CHEMBL624601,,,Rattus norvegicus,N,1,1969.0,
7490,Half life after oral administration was determined in rats at 6 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,6647,,,1,CHEMBL624602,,,Rattus norvegicus,N,1,,
7491,Half life was determined,Intermediate,10116.0,,A,,BAO_0000218,6484,,,1,CHEMBL624603,,,Rattus norvegicus,N,1,,
7492,Half life the of compound was determined by ''Cr'' assay in rat at a dose of 10 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,3249,,,1,CHEMBL624604,,,Rattus norvegicus,N,1,,
7493,Plasma half life in rat at oral dose 2.8 mg/mk body weight,Intermediate,10116.0,,A,,BAO_0000218,6281,,,1,CHEMBL624605,,,Rattus norvegicus,N,1,1969.0,
7494,Half life in rats,Intermediate,10116.0,,A,,BAO_0000218,3307,,,1,CHEMBL624606,,,Rattus norvegicus,N,1,,
7495,Half-lives were estimated from the elimination phase of the blood conc-time curve after oral administration,Intermediate,10116.0,,A,,BAO_0000218,12058,,,1,CHEMBL624607,,,Rattus norvegicus,N,1,178.0,
7496,Hill coefficient of the compound,Intermediate,10116.0,,A,,BAO_0000218,8833,,,1,CHEMBL624608,,,Rattus norvegicus,N,1,,
7497,Compound was tested for percent hydrolysis in whole blood after a time interval of 0.5 min,Intermediate,10116.0,,A,,BAO_0000218,3193,,,1,CHEMBL624609,,,Rattus norvegicus,N,1,178.0,
7498,Compound was tested for percent hydrolysis in whole blood after a time interval of 180.0 min,Intermediate,10116.0,,A,,BAO_0000218,3193,,,1,CHEMBL624610,,,Rattus norvegicus,N,1,178.0,
7499,Compound was tested for percent hydrolysis in whole blood after a time interval of 2.0 min,Intermediate,10116.0,,A,,BAO_0000218,3193,,,1,CHEMBL624611,,,Rattus norvegicus,N,1,178.0,
7500,Compound was tested for percent hydrolysis in whole blood after a time interval of 5.0 min,Intermediate,10116.0,,A,,BAO_0000218,3193,,,1,CHEMBL624612,,,Rattus norvegicus,N,1,178.0,
7501,Compound was tested for percent hydrolysis in whole blood after a time interval of 60.0 min,Intermediate,10116.0,,A,,BAO_0000218,3193,,,1,CHEMBL875167,,,Rattus norvegicus,N,1,178.0,
7502,Compound was tested for percent hydrolysis in whole blood after a time interval of 7.0 min,Intermediate,10116.0,,A,,BAO_0000218,3193,,,1,CHEMBL624613,,,Rattus norvegicus,N,1,178.0,
7503,"Compound was tested for percent hydrolysis in whole blood, after a time interval of 15.0 min",Intermediate,10116.0,,A,,BAO_0000218,3193,,,1,CHEMBL624614,,,Rattus norvegicus,N,1,178.0,
7504,Plasma concentration at 4 hr after 30 mg/kg post dosing in rat using HPLC/MS,Intermediate,10116.0,,A,,BAO_0000218,5960,,,1,CHEMBL624392,,,Rattus norvegicus,N,1,,
7505,Biodistribution of [123I]-label in rat brain was reported at 0.33 hr post injection. Value shown is %ID/organ,Intermediate,10116.0,,A,,BAO_0000218,13950,,,1,CHEMBL624393,,,Rattus norvegicus,N,1,955.0,
7506,Biodistribution of [123I]-label in rat brain was reported at 1 hr post injection. Value shown is %ID/organ,Intermediate,10116.0,,A,,BAO_0000218,13950,,,1,CHEMBL624394,,,Rattus norvegicus,N,1,955.0,
7507,Biodistribution of [123I]-label in rat brain was reported at 2 hr post injection. Value shown is %ID/organ,Intermediate,10116.0,,A,,BAO_0000218,13950,,,1,CHEMBL624395,,,Rattus norvegicus,N,1,955.0,
7508,Biodistribution of [123I]-label in rat brain was reported at 24 hr post injection. Value shown is %ID/organ,Intermediate,10116.0,,A,,BAO_0000218,13950,,,1,CHEMBL624396,,,Rattus norvegicus,N,1,955.0,
7509,Biodistribution of [123I]-label in rat brain was reported at 4 hr post injection. Value shown is %ID/organ,Intermediate,10116.0,,A,,BAO_0000218,13950,,,1,CHEMBL624397,,,Rattus norvegicus,N,1,955.0,
7510,Biodistribution of [123I]-label in rat thyroid was reported at 0.33 hr post injection. Value shown is %ID/organ,Intermediate,10116.0,,A,,BAO_0000218,13950,,,1,CHEMBL624398,,,Rattus norvegicus,N,1,2046.0,
7511,Biodistribution of [123I]-label in rat thyroid was reported at 1 hr post injection. Value shown is %ID/organ,Intermediate,10116.0,,A,,BAO_0000218,13950,,,1,CHEMBL624399,,,Rattus norvegicus,N,1,2046.0,
7512,Biodistribution of [123I]-label in rat thyroid was reported at 2 hr post injection. Value shown is %ID/organ,Intermediate,10116.0,,A,,BAO_0000218,13950,,,1,CHEMBL624400,,,Rattus norvegicus,N,1,2046.0,
7513,Biodistribution of [123I]-label in rat thyroid was reported at 24 hr post injection. Value shown is %ID/organ,Intermediate,10116.0,,A,,BAO_0000218,13950,,,1,CHEMBL624401,,,Rattus norvegicus,N,1,2046.0,
7514,Biodistribution of [123I]-label in rat thyroid was reported at 4 hr post injection. Value shown is %ID/organ,Intermediate,10116.0,,A,,BAO_0000218,13950,,,1,CHEMBL624402,,,Rattus norvegicus,N,1,2046.0,
7515,Biodistribution in normal rat blood in the presence of 0.005 M Gd/0.01 M lig at 2 hr,Intermediate,10116.0,,A,,BAO_0000218,9866,,,1,CHEMBL624403,,,Rattus norvegicus,N,1,178.0,
7516,Biodistribution in normal rat blood in the presence of 0.01 M Gd/0.05 M lig,Intermediate,10116.0,,A,,BAO_0000218,9866,,,1,CHEMBL624404,,,Rattus norvegicus,N,1,178.0,
7517,Biodistribution in normal rat blood in the presence of NAC Gd 0.01 M lig at 2 hr,Intermediate,10116.0,,A,,BAO_0000218,9866,,,1,CHEMBL624405,,,Rattus norvegicus,N,1,178.0,
7518,Biodistribution in normal rat bone in the presence of 0.005 M Gd/0.01 M lig at 2 hr,Intermediate,10116.0,,A,,BAO_0000218,9866,,,1,CHEMBL624406,,,Rattus norvegicus,N,1,10000001.0,
7519,Biodistribution in normal rat bone in the presence of 0.01 M Gd/0.05 M lig,Intermediate,10116.0,,A,,BAO_0000218,9866,,,1,CHEMBL624407,,,Rattus norvegicus,N,1,10000001.0,
7520,Biodistribution in normal rat bone in the presence of NAC Gd 0.01 M lig at 2 hr,Intermediate,10116.0,,A,,BAO_0000218,9866,,,1,CHEMBL624408,,,Rattus norvegicus,N,1,10000001.0,
7521,Biodistribution in normal rat heart in the presence of 0.005 M Gd/0.01 M lig at 2 hr,Intermediate,10116.0,,A,,BAO_0000218,9866,,,1,CHEMBL618644,,,Rattus norvegicus,N,1,948.0,
7522,Biodistribution in normal rat heart in the presence of 0.01 M Gd/0.05 M lig,Intermediate,10116.0,,A,,BAO_0000218,9866,,,1,CHEMBL618645,,,Rattus norvegicus,N,1,948.0,
7523,Biodistribution in normal rat heart in the presence of NAC Gd 0.01 M lig at 2 hr,Intermediate,10116.0,,A,,BAO_0000218,9866,,,1,CHEMBL618646,,,Rattus norvegicus,N,1,948.0,
7524,Biodistribution in normal rat kidney in the presence of 0.005 M Gd/0.01 M lig at 2 hr,Intermediate,10116.0,,A,,BAO_0000218,9866,,,1,CHEMBL618647,,,Rattus norvegicus,N,1,2113.0,
7525,Biodistribution in normal rat kidney in the presence of 0.01 M Gd/0.05 M lig,Intermediate,10116.0,,A,,BAO_0000218,9866,,,1,CHEMBL618648,,,Rattus norvegicus,N,1,2113.0,
7526,Biodistribution in normal rat kidney in the presence of NAC Gd 0.01 M lig at 2 hr,Intermediate,10116.0,,A,,BAO_0000218,9866,,,1,CHEMBL618649,,,Rattus norvegicus,N,1,2113.0,
7527,Biodistribution in normal rat liver in the presence of 0.005 M Gd/0.01 M lig at 2 hr,Intermediate,10116.0,,A,,BAO_0000218,9866,,,1,CHEMBL618650,,,Rattus norvegicus,N,1,2107.0,
7528,Biodistribution in normal rat liver in the presence of 0.01 M Gd/0.05 M lig,Intermediate,10116.0,,A,,BAO_0000218,9866,,,1,CHEMBL618651,,,Rattus norvegicus,N,1,2107.0,
7529,Biodistribution in normal rat liver in the presence of NAC Gd 0.01 M lig at 2 hr,Intermediate,10116.0,,A,,BAO_0000218,9866,,,1,CHEMBL876497,,,Rattus norvegicus,N,1,2107.0,
7530,Biodistribution in normal rat lung in the presence of 0.005 M Gd/0.01 M lig at 2 hr,Intermediate,10116.0,,A,,BAO_0000218,9866,,,1,CHEMBL618652,,,Rattus norvegicus,N,1,2048.0,
7531,Biodistribution in normal rat lung in the presence of 0.01 M Gd/0.05 M lig,Intermediate,10116.0,,A,,BAO_0000218,9866,,,1,CHEMBL618653,,,Rattus norvegicus,N,1,2048.0,
7532,Biodistribution in normal rat lung in the presence of NAC Gd 0.01 M lig at 2 hr,Intermediate,10116.0,,A,,BAO_0000218,9866,,,1,CHEMBL618654,,,Rattus norvegicus,N,1,2048.0,
7533,Recovery rate from urine and bile was determined after iv administration at 20 mg/kg in rats; Not tested,Intermediate,10116.0,,A,,BAO_0000218,6351,,,1,CHEMBL618655,,,Rattus norvegicus,N,1,,
7534,Compound was tested for solubility in water,Intermediate,10116.0,,A,,BAO_0000218,1465,,,1,CHEMBL618656,,,Rattus norvegicus,N,1,,
7535,Solubility in phosphate buffered saline (1% DMSO) at pH 6.5 (24 hr equilibration),Intermediate,,,P,,BAO_0000100,5182,,,1,CHEMBL618657,,,,U,0,,
7536,Solubility was determined,Intermediate,10116.0,,A,,BAO_0000218,17847,,,1,CHEMBL618658,,,Rattus norvegicus,N,1,,
7537,solubility in water (ug/mL) at 37 degree C.,Intermediate,10116.0,,A,,BAO_0000218,15339,,,1,CHEMBL618659,,,Rattus norvegicus,N,1,,
7538,First pass metabolism and metabolic bioavailability using rat hepatic microsomes,Intermediate,10116.0,,A,,BAO_0000218,5202,,,1,CHEMBL618660,,,Rattus norvegicus,N,1,,
7539,In vitro stability relative to (+)-AJ76 in rat hepatocyte assay,Intermediate,10116.0,,A,,BAO_0000218,1088,,,1,CHEMBL618661,,,Rattus norvegicus,N,1,,
7540,Half life in rats,Intermediate,10116.0,,A,,BAO_0000218,3169,,,1,CHEMBL873807,,,Rattus norvegicus,N,1,,
7541,Half life in Dawley rat,Intermediate,10116.0,,A,,BAO_0000218,5353,,,1,CHEMBL618662,,,Rattus norvegicus,N,1,,
7542,Half life period after 3 mg/kg iv administration,Intermediate,10116.0,,A,,BAO_0000218,2864,,,1,CHEMBL618663,,,Rattus norvegicus,N,1,,
7543,Half life period after 3 mg/kg iv administration in rat,Intermediate,10116.0,,A,,BAO_0000218,2864,,,1,CHEMBL618664,,,Rattus norvegicus,N,1,,
7544,Half life period after 3 mg/kg iv administration in the rat,Intermediate,10116.0,,A,,BAO_0000218,2864,,,1,CHEMBL618665,,,Rattus norvegicus,N,1,,
7545,Half life period in female Sprague-Dawley rats,Intermediate,10116.0,,A,,BAO_0000218,6362,,,1,CHEMBL876498,,,Rattus norvegicus,N,1,,
7546,Half life period in rat,Intermediate,10116.0,,A,,BAO_0000218,6249,,,1,CHEMBL618666,,,Rattus norvegicus,N,1,,
7547,Half-life in rats was determined,Intermediate,10116.0,,A,,BAO_0000218,3169,,,1,CHEMBL620440,,,Rattus norvegicus,N,1,,
7548,Half-life in rats with metabolic oxidation,Intermediate,10116.0,,A,,BAO_0000218,3169,,,1,CHEMBL620441,,,Rattus norvegicus,N,1,,
7549,Half-life in rats,Intermediate,10116.0,,A,,BAO_0000218,3169,,,1,CHEMBL620442,,,Rattus norvegicus,N,1,,
7550,T 1/2 at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,Intermediate,10116.0,,A,,BAO_0000218,17260,,,1,CHEMBL620443,,,Rattus norvegicus,N,1,,
7551,T 1/2 at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,Intermediate,10116.0,,A,,BAO_0000218,17260,,,1,CHEMBL620444,,,Rattus norvegicus,N,1,,
7552,T max at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,Intermediate,10116.0,,A,,BAO_0000218,17260,,,1,CHEMBL620445,,,Rattus norvegicus,N,1,,
7553,T max at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,Intermediate,10116.0,,A,,BAO_0000218,17260,,,1,CHEMBL620446,,,Rattus norvegicus,N,1,,
7554,Biological half-life measured in plasma of rat,Intermediate,10116.0,,A,,BAO_0000218,2879,,,1,CHEMBL620447,,,Rattus norvegicus,N,1,1969.0,
7555,Biological half-life measured in plasma of rat; 22-25,Intermediate,10116.0,,A,,BAO_0000218,2879,,,1,CHEMBL621129,,,Rattus norvegicus,N,1,1969.0,
7556,Biological half-life measured in plasma of rat; 9-16,Intermediate,10116.0,,A,,BAO_0000218,2879,,,1,CHEMBL621130,,,Rattus norvegicus,N,1,1969.0,
7557,Compound was evaluated for its half life when administered intravenously in rat,Intermediate,10116.0,,A,,BAO_0000218,3184,,,1,CHEMBL873808,,,Rattus norvegicus,N,1,,
7558,Compound was evaluated for pharmacokinetic parameter percent bioavailability at 8 h,Intermediate,10116.0,,A,,BAO_0000218,4891,,,1,CHEMBL876598,,,Rattus norvegicus,N,1,,
7559,Evaluated for pharmacokinetic parameter half-life in rat at the dose 50 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,429,,,1,CHEMBL621131,,,Rattus norvegicus,N,1,,
7560,Half life (T1/2) after oral administration in rat,Intermediate,10116.0,,A,,BAO_0000218,5656,,,1,CHEMBL621132,,,Rattus norvegicus,N,1,,
7561,Half life of compound after iv administration of 20 mg/kg dose in rat,Intermediate,10116.0,,A,,BAO_0000218,4413,,,1,CHEMBL621133,,,Rattus norvegicus,N,1,,
7562,Half life of compound determined in rat after iv administration at a dose of 10 mg/kg,Expert,10116.0,,A,,BAO_0000218,3598,,,1,CHEMBL621312,,,Rattus norvegicus,N,1,,
7563,Half life of compound was determined in rat,Intermediate,10116.0,,A,,BAO_0000218,17267,,,1,CHEMBL621313,,,Rattus norvegicus,N,1,,
7564,Half life of compound was determined in rat blood,Intermediate,10116.0,,A,,BAO_0000218,4727,,,1,CHEMBL621314,,,Rattus norvegicus,N,1,178.0,
7565,Half life at 1 mg/kg was determined in rat,Intermediate,10116.0,,A,,BAO_0000218,17651,,,1,CHEMBL621315,,,Rattus norvegicus,N,1,,
7566,Half life at 10 mg/kg was determined in rat,Intermediate,10116.0,,A,,BAO_0000218,17651,,,1,CHEMBL621316,,,Rattus norvegicus,N,1,,
7567,Half life in rats,Intermediate,10116.0,,A,,BAO_0000218,401,,,1,CHEMBL621317,,,Rattus norvegicus,N,1,,
7568,Half life in rats in hours,Intermediate,10116.0,,A,,BAO_0000218,4942,,,1,CHEMBL621318,,,Rattus norvegicus,N,1,,
7569,Half life following 10 mg/kg intravenous or 50 mg/kg oral dosing in rats was determined,Intermediate,10116.0,,A,,BAO_0000218,17735,,,1,CHEMBL621319,,,Rattus norvegicus,N,1,,
7570,Half life was calculated at a single intravenous administration of 20 mg/kg in rat,Intermediate,10116.0,,A,,BAO_0000218,6056,,,1,CHEMBL621377,,,Rattus norvegicus,N,1,,
7571,Half life was determined,Intermediate,10116.0,,A,,BAO_0000218,5213,,,1,CHEMBL621378,,,Rattus norvegicus,N,1,,
7572,Half life after i.v. administration,Intermediate,10116.0,,A,,BAO_0000218,6616,,,1,CHEMBL876599,,,Rattus norvegicus,N,1,,
7573,Half life in rat after intravenous administration at a concentration 0.5 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,5937,,,1,CHEMBL621379,,,Rattus norvegicus,N,1,,
7574,Half life in rat plasma,Intermediate,10116.0,,A,,BAO_0000218,5819,,,1,CHEMBL621380,,,Rattus norvegicus,N,1,1969.0,
7575,Half life in rat plasma; Not detected,Intermediate,10116.0,,A,,BAO_0000218,5819,,,1,CHEMBL621381,,,Rattus norvegicus,N,1,1969.0,
7576,Half life in rats,Intermediate,10116.0,,A,,BAO_0000218,6803,,,1,CHEMBL618515,,,Rattus norvegicus,N,1,,
7577,Half life period of compound was determined after peroral administration,Intermediate,10116.0,,A,,BAO_0000218,17804,,,1,CHEMBL618516,,,Rattus norvegicus,N,1,,
7578,Half life period of compound was determined at a dose of 3 mg/kg by intravenous administration,Intermediate,10116.0,,A,,BAO_0000218,17804,,,1,CHEMBL618517,,,Rattus norvegicus,N,1,,
7579,Half life period in rat,Intermediate,10116.0,,A,,BAO_0000218,5948,,,1,CHEMBL618518,,,Rattus norvegicus,N,1,,
7580,Half life period was evaluated against Sprague-Dawley rats at a dose of 15 mg/kg after iv administration,Intermediate,10116.0,,A,,BAO_0000218,1916,,,1,CHEMBL618519,,,Rattus norvegicus,N,1,,
7581,Half life period was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after po administration,Intermediate,10116.0,,A,,BAO_0000218,1916,,,1,CHEMBL618698,,,Rattus norvegicus,N,1,,
7582,Half life period was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after po administration; Not available,Intermediate,10116.0,,A,,BAO_0000218,1916,,,1,CHEMBL618862,,,Rattus norvegicus,N,1,,
7583,Half life period was determined after intravenous administration at a dose 5 mg/kg to male Sprague-Dawley rats,Intermediate,10116.0,,A,,BAO_0000218,4890,,,1,CHEMBL618863,,,Rattus norvegicus,N,1,,
7584,Half life period was determined for compound after intravenous administration in rats at 24 uM/kg,Intermediate,10116.0,,A,,BAO_0000218,17764,,,1,CHEMBL618864,,,Rattus norvegicus,N,1,,
7585,Half life time in rat the dose of 2 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,4727,,,1,CHEMBL618865,,,Rattus norvegicus,N,1,,
7586,Half-life 24 hr after 10 mg/kg iv administration in rats,Intermediate,10116.0,,A,,BAO_0000218,17509,,,1,CHEMBL618866,,,Rattus norvegicus,N,1,,
7587,Half-life 24 hr after 2 mg/kg iv administration in rats,Intermediate,10116.0,,A,,BAO_0000218,17509,,,1,CHEMBL618867,,,Rattus norvegicus,N,1,,
7588,Half-life consistent with the observed metabolic steady state in rats,Intermediate,10116.0,,A,,BAO_0000218,6597,,,1,CHEMBL875828,,,Rattus norvegicus,N,1,,
7589,Half-life following 10 mg/kg intravenous or 50 mg/kg oral dosing in rats was determined,Intermediate,10116.0,,A,,BAO_0000218,17735,,,1,CHEMBL618868,,,Rattus norvegicus,N,1,,
7590,Half-life for oxidative metabolic stability was determined using male human,Intermediate,10116.0,,A,,BAO_0000218,6597,,,1,CHEMBL618869,,,Rattus norvegicus,N,1,,
7591,"Half-life in fischer rats at 5 mg/kg dose, administered intravenously",Intermediate,10116.0,,A,,BAO_0000218,17670,,,1,CHEMBL618870,,,Rattus norvegicus,N,1,,
7592,Half-life in rat plasma,Intermediate,10116.0,,A,,BAO_0000218,1696,,,1,CHEMBL618871,,,Rattus norvegicus,N,1,1969.0,
7593,Half-life in rat plasma was determined,Intermediate,10116.0,,A,,BAO_0000218,1742,,,1,CHEMBL618872,,,Rattus norvegicus,N,1,1969.0,
7594,Half-life in rats was determined,Intermediate,10116.0,,A,,BAO_0000218,17800,,,1,CHEMBL873816,,,Rattus norvegicus,N,1,,
7595,Area under curve of acid 2a was determined by HPLC at a dosage of 54.5 mg/kg administered intragastrically by gavage method in dog,Autocuration,,,A,,BAO_0000218,12923,,,1,CHEMBL618873,,,,U,0,,
7596,Area under curve after oral dose of 0.1 mg//kg,Autocuration,,,A,,BAO_0000019,11954,,,1,CHEMBL621602,,,,U,0,,
7597,Area under curve after oral dose of 0.3 mg/kg,Autocuration,,,A,,BAO_0000218,11954,,,1,CHEMBL621603,,,,U,0,,
7598,Area under curve after oral dose of 1 mg/kg,Autocuration,,,A,,BAO_0000218,11954,,,1,CHEMBL621604,,,,U,0,,
7599,Area under curve after oral dose of 10 mg/kg,Autocuration,,,A,,BAO_0000218,11954,,,1,CHEMBL621605,,,,U,0,,
7600,Area under curve after oral dose of 23.4 mg/kg,Autocuration,,,A,,BAO_0000218,11954,,,1,CHEMBL621606,,,,U,0,,
7601,Area under curve after oral dose of 3 mg/kg,Autocuration,,,A,,BAO_0000218,11954,,,1,CHEMBL621607,,,,U,0,,
7602,Area under curve after oral dose of 3.87 mg/kg,Autocuration,,,A,,BAO_0000218,11954,,,1,CHEMBL621608,,,,U,0,,
7603,Area under curve was determined,Autocuration,,,A,,BAO_0000019,5237,,,1,CHEMBL621609,,,,U,0,,
7604,Area under curve at a dose of 10 mg/kg,Autocuration,,,A,,BAO_0000218,4026,,,1,CHEMBL621610,,,,U,0,,
7605,Area under curve was determined; ND=No data,Intermediate,10116.0,,A,,BAO_0000218,5237,,,1,CHEMBL621611,,,Rattus norvegicus,N,1,,
7606,Area under curve was evaluated in rat brain when administered intraperitoneally at a dose of 10 mg/kg for 4 or 6 hours,Intermediate,10116.0,,A,,BAO_0000218,14793,,,1,CHEMBL621612,,,Rattus norvegicus,N,1,,
7607,Area under curve was evaluated in rat brain when administered intraperitoneally at a dose of 10 mg/kg for infinite hours,Intermediate,10116.0,,A,,BAO_0000218,14793,,,1,CHEMBL622308,,,Rattus norvegicus,N,1,,
7608,Area under curve was evaluated in rat brain when administered intravenously at a dose of 10 mg/kg for 4 or 6 hours,Intermediate,10116.0,,A,,BAO_0000218,14793,,,1,CHEMBL622309,,,Rattus norvegicus,N,1,,
7609,Area under curve was evaluated in rat brain when administered intravenously at a dose of 10 mg/kg for infinite hours,Intermediate,10116.0,,A,,BAO_0000218,14793,,,1,CHEMBL622310,,,Rattus norvegicus,N,1,,
7610,Area under curve was evaluated in rat brain when administered perorally at a dose of 100 mg/kg for 4 or 6 hours,Intermediate,10116.0,,A,,BAO_0000218,14793,,,1,CHEMBL622311,,,Rattus norvegicus,N,1,,
7611,Area under curve was evaluated in rat brain when administered perorally at a dose of 100 mg/kg for infinite hours; Not calculated,Intermediate,10116.0,,A,,BAO_0000218,14793,,,1,CHEMBL622312,,,Rattus norvegicus,N,1,,
7612,Area under curve was evaluated in rat brain when administered perorally at a dose of 10 mg/kg for 4 or 6 hours,Intermediate,10116.0,,A,,BAO_0000218,14793,,,1,CHEMBL622931,,,Rattus norvegicus,N,1,,
7613,Area under curve was evaluated in rat brain when administered perorally at a dose of 10 mg/kg for infinite hours; Not calculated,Intermediate,10116.0,,A,,BAO_0000218,14793,,,1,CHEMBL622932,,,Rattus norvegicus,N,1,,
7614,Area under curve was evaluated in rat plasma when administered intraperitoneally at a dose of 10 mg/kg for 4 or 6 hours,Intermediate,10116.0,,A,,BAO_0000218,14793,,,1,CHEMBL622736,,,Rattus norvegicus,N,1,1969.0,
7615,Area under curve was evaluated in rat plasma when administered intraperitoneally at a dose of 10 mg/kg for infinite hours,Intermediate,10116.0,,A,,BAO_0000218,14793,,,1,CHEMBL622737,,,Rattus norvegicus,N,1,1969.0,
7616,Area under curve was evaluated in rat plasma when administered intravenously at a dose of 10 mg/kg for 4 or 6 hours,Intermediate,10116.0,,A,,BAO_0000218,14793,,,1,CHEMBL622738,,,Rattus norvegicus,N,1,1969.0,
7617,Area under curve was evaluated in rat plasma when administered intravenously at a dose of 10 mg/kg for infinite hours,Intermediate,10116.0,,A,,BAO_0000218,14793,,,1,CHEMBL622739,,,Rattus norvegicus,N,1,1969.0,
7618,Area under curve was evaluated in rat plasma when administered perorally at a dose of 100 mg/kg for 4 or 6 hours,Intermediate,10116.0,,A,,BAO_0000218,14793,,,1,CHEMBL622740,,,Rattus norvegicus,N,1,1969.0,
7619,Area under curve was evaluated in rat plasma when administered perorally at a dose of 100 mg/kg for infinite hours,Intermediate,10116.0,,A,,BAO_0000218,14793,,,1,CHEMBL622741,,,Rattus norvegicus,N,1,1969.0,
7620,Area under curve was evaluated in rat plasma when administered perorally at a dose of 10 mg/kg for 4 or 6 hours,Intermediate,10116.0,,A,,BAO_0000218,14793,,,1,CHEMBL622742,,,Rattus norvegicus,N,1,1969.0,
7621,Area under curve was evaluated in rat plasma when administered perorally at a dose of 10 mg/kg for infinite hours,Intermediate,10116.0,,A,,BAO_0000218,14793,,,1,CHEMBL622743,,,Rattus norvegicus,N,1,1969.0,
7622,AUC in mice,Intermediate,10090.0,,A,,BAO_0000218,11637,,,1,CHEMBL622744,,,Mus musculus,N,1,1969.0,
7623,Area under curve was measured from the graph obtained from concentration Vs time,Autocuration,,,A,,BAO_0000019,11149,,,1,CHEMBL624134,,,,U,0,,
7624,Area under curve value of compound per hour after oral administration,Autocuration,,,A,,BAO_0000019,10016,,,1,CHEMBL624135,,,,U,0,,
7625,Area under curve was determined after oral administration in rats,Intermediate,10116.0,,A,,BAO_0000218,17796,,,1,CHEMBL624136,,,Rattus norvegicus,N,1,,
7626,Area under curve was determined after oral administration in rats; No data,Intermediate,10116.0,,A,,BAO_0000218,17796,,,1,CHEMBL624137,,,Rattus norvegicus,N,1,,
7627,Area under curve was determined after oral administration in rats;No data,Intermediate,10116.0,,A,,BAO_0000218,17796,,,1,CHEMBL624320,,,Rattus norvegicus,N,1,,
7628,Area under curve was determined by HPLC at a dosage of 2.27 mg/kg administered intravenously by bolus method in dog,Intermediate,9615.0,,A,,BAO_0000218,12923,,,1,CHEMBL624321,,,Canis lupus familiaris,N,1,,
7629,Area under curve was determined for the compound after iv dose of 4.74 mg/kg in rats,Intermediate,10116.0,,A,,BAO_0000218,15372,,,1,CHEMBL624322,,,Rattus norvegicus,N,1,,
7630,Area under curve was determined for the compound after iv dose of 5.06 in rats,Intermediate,10116.0,,A,,BAO_0000218,15372,,,1,CHEMBL624323,,,Rattus norvegicus,N,1,,
7631,Area under curve was determined for the compound after iv dose of 5.10 mg/kg in rats,Intermediate,10116.0,,A,,BAO_0000218,15372,,,1,CHEMBL624324,,,Rattus norvegicus,N,1,,
7632,Area under curve was determined for the compound after po dose of 5.01 mg/kg in rats,Intermediate,10116.0,,A,,BAO_0000218,15372,,,1,CHEMBL624325,,,Rattus norvegicus,N,1,,
7633,Area under curve was determined for the compound after po dose of 5.03 mg/kg in rats,Intermediate,10116.0,,A,,BAO_0000218,15372,,,1,CHEMBL624326,,,Rattus norvegicus,N,1,,
7634,Area under curve was determined for the compound after po dose of 5.22 mg/kg in rats,Intermediate,10116.0,,A,,BAO_0000218,15372,,,1,CHEMBL624327,,,Rattus norvegicus,N,1,,
7635,Area under curve was determined for the compound after po dose of 5.46 mg/kg in rats,Intermediate,10116.0,,A,,BAO_0000218,15372,,,1,CHEMBL624328,,,Rattus norvegicus,N,1,,
7636,Area under curve was determined in Dogs after peroral administration,Intermediate,9615.0,,A,,BAO_0000218,14169,,,1,CHEMBL627848,,,Canis lupus familiaris,N,1,,
7637,Area under curve was determined in Rats after peroral administration,Intermediate,10116.0,,A,,BAO_0000218,14169,,,1,CHEMBL627849,,,Rattus norvegicus,N,1,,
7638,Area under curve was determined in carotid blood of rat when administered intradermally,Intermediate,10116.0,,A,,BAO_0000218,14258,,,1,CHEMBL627850,,,Rattus norvegicus,N,1,,
7639,Area under curve was determined in portal blood of rat when administered intradermally,Intermediate,10116.0,,A,,BAO_0000218,14258,,,1,CHEMBL627851,,,Rattus norvegicus,N,1,,
7640,Area under curve was determined using 0.4% Methyl cellulose (MC) as vehicle. Compound was administered intravenously to nude mice at a dose of 25 mg/kg,Intermediate,10090.0,,A,,BAO_0000218,15011,,,1,CHEMBL627852,,,Mus musculus,N,1,,
7641,Area under curve was determined using 0.4% Methyl cellulose (MC) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg,Intermediate,10090.0,,A,,BAO_0000218,15011,,,1,CHEMBL627853,,,Mus musculus,N,1,,
7642,Area under curve was determined using 0.4% Methyl cellulose (MC) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg (micronized sample),Intermediate,10090.0,,A,,BAO_0000218,15011,,,1,CHEMBL627854,,,Mus musculus,N,1,,
7643,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered intravenously to nude mice at a dose of 25 mg/kg,Intermediate,10090.0,,A,,BAO_0000218,15011,,,1,CHEMBL627855,,,Mus musculus,N,1,,
7644,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered intravenously to nude mice at a dose of 25 mg/kg (run time 7 hr),Intermediate,10090.0,,A,,BAO_0000218,15011,,,1,CHEMBL627856,,,Mus musculus,N,1,,
7645,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg,Intermediate,10090.0,,A,,BAO_0000218,15011,,,1,CHEMBL875339,,,Mus musculus,N,1,,
7646,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg (Run time = 7 hr),Intermediate,10090.0,,A,,BAO_0000218,15011,,,1,CHEMBL627857,,,Mus musculus,N,1,,
7647,Biodistribution of the radiolabeled compound (2-5 uCi) in rat spleen 65 mins after i.v. administration,Intermediate,10116.0,,A,,BAO_0000218,11195,,,1,CHEMBL627858,,,Rattus norvegicus,N,1,2106.0,
7648,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in blood; Expressed as percent dose/organ,Intermediate,10116.0,,A,,BAO_0000218,10130,,,1,CHEMBL627859,,,Rattus norvegicus,N,1,178.0,
7649,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in brain; Expressed as percent dose/organ,Intermediate,10116.0,,A,,BAO_0000218,10130,,,1,CHEMBL627860,,,Rattus norvegicus,N,1,955.0,
7650,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in heart; Expressed as percent dose/organ,Intermediate,10116.0,,A,,BAO_0000218,10130,,,1,CHEMBL627019,,,Rattus norvegicus,N,1,948.0,
7651,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in liver; Expressed as percent dose/organ,Intermediate,10116.0,,A,,BAO_0000218,10130,,,1,CHEMBL627020,,,Rattus norvegicus,N,1,2107.0,
7652,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in lung; Expressed as percent dose/organ,Intermediate,10116.0,,A,,BAO_0000218,10130,,,1,CHEMBL627021,,,Rattus norvegicus,N,1,2048.0,
7653,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in muscle; Expressed as percent dose/organ,Intermediate,10116.0,,A,,BAO_0000218,10130,,,1,CHEMBL627022,,,Rattus norvegicus,N,1,2385.0,
7654,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in skin; Expressed as percent dose/organ,Intermediate,10116.0,,A,,BAO_0000218,10130,,,1,CHEMBL627023,,,Rattus norvegicus,N,1,,
7655,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in spleen; Expressed as percent dose/organ,Intermediate,10116.0,,A,,BAO_0000218,10130,,,1,CHEMBL627024,,,Rattus norvegicus,N,1,2106.0,
7656,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in thyroid; Expressed as percent dose/organ,Intermediate,10116.0,,A,,BAO_0000218,10130,,,1,CHEMBL627025,,,Rattus norvegicus,N,1,2046.0,
7657,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in kidney; Expressed as percent dose/organ,Intermediate,10116.0,,A,,BAO_0000218,10130,,,1,CHEMBL627026,,,Rattus norvegicus,N,1,2113.0,
7658,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in blood; Expressed as percent dose/organ,Intermediate,10116.0,,A,,BAO_0000218,10130,,,1,CHEMBL627027,,,Rattus norvegicus,N,1,178.0,
7659,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in brain; Expressed as percent dose/organ,Intermediate,10116.0,,A,,BAO_0000218,10130,,,1,CHEMBL627028,,,Rattus norvegicus,N,1,955.0,
7660,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in heart; Expressed as percent dose/organ,Intermediate,10116.0,,A,,BAO_0000218,10130,,,1,CHEMBL627029,,,Rattus norvegicus,N,1,948.0,
7661,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in kidney; Expressed as percent dose/organ,Intermediate,10116.0,,A,,BAO_0000218,10130,,,1,CHEMBL627030,,,Rattus norvegicus,N,1,2113.0,
7662,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in liver; Expressed as percent dose/organ,Intermediate,10116.0,,A,,BAO_0000218,10130,,,1,CHEMBL627031,,,Rattus norvegicus,N,1,2107.0,
7663,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in lung; Expressed as percent dose/organ,Intermediate,10116.0,,A,,BAO_0000218,10130,,,1,CHEMBL627032,,,Rattus norvegicus,N,1,2048.0,
7664,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in muscle; Expressed as percent dose/organ,Intermediate,10116.0,,A,,BAO_0000218,10130,,,1,CHEMBL627033,,,Rattus norvegicus,N,1,2385.0,
7665,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in skin; Expressed as percent dose/organ,Intermediate,10116.0,,A,,BAO_0000218,10130,,,1,CHEMBL627034,,,Rattus norvegicus,N,1,,
7666,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in spleen; Expressed as percent dose/organ,Intermediate,10116.0,,A,,BAO_0000218,10130,,,1,CHEMBL627035,,,Rattus norvegicus,N,1,2106.0,
7667,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in thyroid; Expressed as percent dose/organ,Intermediate,10116.0,,A,,BAO_0000218,10130,,,1,CHEMBL627036,,,Rattus norvegicus,N,1,2046.0,
7668,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in blood; Expressed as percent dose/organ,Intermediate,10116.0,,A,,BAO_0000218,10130,,,1,CHEMBL875340,,,Rattus norvegicus,N,1,178.0,
7669,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in heart; Expressed as percent dose/organ,Intermediate,10116.0,,A,,BAO_0000218,10130,,,1,CHEMBL627037,,,Rattus norvegicus,N,1,948.0,
7670,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in kidney; Expressed as percent dose/organ,Intermediate,10116.0,,A,,BAO_0000218,10130,,,1,CHEMBL627038,,,Rattus norvegicus,N,1,2113.0,
7671,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in liver; Expressed as percent dose/organ,Intermediate,10116.0,,A,,BAO_0000218,10130,,,1,CHEMBL627039,,,Rattus norvegicus,N,1,2107.0,
7672,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in muscle; Expressed as percent dose/organ,Intermediate,10116.0,,A,,BAO_0000218,10130,,,1,CHEMBL627040,,,Rattus norvegicus,N,1,2385.0,
7673,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in spleen; Expressed as percent dose/organ,Intermediate,10116.0,,A,,BAO_0000218,10130,,,1,CHEMBL624663,,,Rattus norvegicus,N,1,2106.0,
7674,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in thyroid; Expressed as percent dose/organ,Intermediate,10116.0,,A,,BAO_0000218,10130,,,1,CHEMBL625963,,,Rattus norvegicus,N,1,2046.0,
7675,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in brain; Expressed as percent dose/organ,Intermediate,10116.0,,A,,BAO_0000218,10130,,,1,CHEMBL876799,,,Rattus norvegicus,N,1,955.0,
7676,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in lung; Expressed as percent dose/organ,Intermediate,10116.0,,A,,BAO_0000218,10130,,,1,CHEMBL626133,,,Rattus norvegicus,N,1,2048.0,
7677,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in skin; Expressed as percent dose/organ,Intermediate,10116.0,,A,,BAO_0000218,10130,,,1,CHEMBL626134,,,Rattus norvegicus,N,1,,
7678,In vivo concentration in rat liver exposure 8 hour after oral administration 50 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,6295,,,1,CHEMBL626135,,,Rattus norvegicus,N,1,,
7679,In vivo concentration in rat liver exposure 8 hour after oral administration 50 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,6296,,,1,CHEMBL626136,,,Rattus norvegicus,N,1,,
7680,In vivo concentration in rat liver exposure 8 hour after oral administration 50 mg/kg; Below detection limit,Intermediate,10116.0,,A,,BAO_0000218,6296,,,1,CHEMBL626137,,,Rattus norvegicus,N,1,,
7681,In vivo concentration in rat plasma exposure at 8 hour after oral administration 50 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,6295,,,1,CHEMBL626138,,,Rattus norvegicus,N,1,,
7682,In vivo concentration in rat plasma exposure at 8 hour after oral administration 50 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,6296,,,1,CHEMBL626139,,,Rattus norvegicus,N,1,,
7683,C max at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,Intermediate,10116.0,,A,,BAO_0000218,17260,,,1,CHEMBL626140,,,Rattus norvegicus,N,1,,
7684,C max at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,Intermediate,10116.0,,A,,BAO_0000218,17260,,,1,CHEMBL626141,,,Rattus norvegicus,N,1,,
7685,C24h in rat p.o. at 20 mg/kg concentration,Intermediate,10116.0,,A,,BAO_0000218,17686,,,1,CHEMBL626142,,,Rattus norvegicus,N,1,,
7686,Biodistribution in normal rat muscle in the presence of 0.005 M Gd/0.01 M lig at 2 hr,Intermediate,10116.0,,A,,BAO_0000218,9866,,,1,CHEMBL627930,,,Rattus norvegicus,N,1,2385.0,
7687,Biodistribution in normal rat muscle in the presence of 0.01 M Gd/0.05 M lig,Intermediate,10116.0,,A,,BAO_0000218,9866,,,1,CHEMBL627931,,,Rattus norvegicus,N,1,2385.0,
7688,Biodistribution in normal rat muscle in the presence of NAC Gd 0.01 M lig at 2 hr,Intermediate,10116.0,,A,,BAO_0000218,9866,,,1,CHEMBL627932,,,Rattus norvegicus,N,1,2385.0,
7689,Biodistribution in normal rat spleen in the presence of 0.005 M Gd/0.01 M lig at 2 hr,Intermediate,10116.0,,A,,BAO_0000218,9866,,,1,CHEMBL627933,,,Rattus norvegicus,N,1,2106.0,
7690,Biodistribution in normal rat spleen in the presence of 0.01 M Gd/0.05 M lig,Intermediate,10116.0,,A,,BAO_0000218,9866,,,1,CHEMBL627934,,,Rattus norvegicus,N,1,2106.0,
7691,Biodistribution in normal rat spleen in the presence of NAC Gd 0.01 M lig at 2 hr,Intermediate,10116.0,,A,,BAO_0000218,9866,,,1,CHEMBL627935,,,Rattus norvegicus,N,1,2106.0,
7692,Biodistribution in rat blood in the presence of 0.001 M/0.008 M GdDTPA-AEP,Intermediate,10116.0,,A,,BAO_0000218,9866,,,1,CHEMBL627936,,,Rattus norvegicus,N,1,178.0,
7693,Biodistribution in rat blood in the presence of 0.01 M GdDTPA-BDP,Intermediate,10116.0,,A,,BAO_0000218,9866,,,1,CHEMBL627937,,,Rattus norvegicus,N,1,178.0,
7694,Biodistribution in rat blood in the presence of 0.01 M/0.01 M GdDTPA-AEP,Intermediate,10116.0,,A,,BAO_0000218,9866,,,1,CHEMBL627938,,,Rattus norvegicus,N,1,178.0,
7695,Biodistribution in rat blood in the presence of 0.05 M Gd/0.15 M lig,Intermediate,10116.0,,A,,BAO_0000218,9866,,,1,CHEMBL627939,,,Rattus norvegicus,N,1,178.0,
7696,Biodistribution in rat blood in the presence of 0.05 M GdDTPA-BDP,Intermediate,10116.0,,A,,BAO_0000218,9866,,,1,CHEMBL627940,,,Rattus norvegicus,N,1,178.0,
7697,Biodistribution in rat blood in the presence of 0.05 M/0.05 M GdDTPA-AEP,Intermediate,10116.0,,A,,BAO_0000218,9866,,,1,CHEMBL627941,,,Rattus norvegicus,N,1,178.0,
7698,Biodistribution in rat blood in the presence of 0.05 M/0.08 M GdDTPA-HPDP,Intermediate,10116.0,,A,,BAO_0000218,9866,,,1,CHEMBL876800,,,Rattus norvegicus,N,1,178.0,
7699,Biodistribution in rat blood in the presence of 0.10 M GdDTPA-BDP,Intermediate,10116.0,,A,,BAO_0000218,9866,,,1,CHEMBL627942,,,Rattus norvegicus,N,1,178.0,
7700,Biodistribution in rat blood in the presence of 0.10 M/0.11 M GdDTPA-AEP,Intermediate,10116.0,,A,,BAO_0000218,9866,,,1,CHEMBL627943,,,Rattus norvegicus,N,1,178.0,
7701,Biodistribution in rat blood in the presence of 50 Gd/kg at 15 min,Intermediate,10116.0,,A,,BAO_0000218,9866,,,1,CHEMBL627944,,,Rattus norvegicus,N,1,178.0,
7702,Biodistribution in rat blood in the presence of 50 Gd/kg at 2 hr,Intermediate,10116.0,,A,,BAO_0000218,9866,,,1,CHEMBL627945,,,Rattus norvegicus,N,1,178.0,
7703,Biodistribution in rat blood in the presence of 50 Gd/kg at 6 hr,Intermediate,10116.0,,A,,BAO_0000218,9866,,,1,CHEMBL628584,,,Rattus norvegicus,N,1,178.0,
7704,Biodistribution in rat blood in the presence of GdDTPA at 15 min,Intermediate,10116.0,,A,,BAO_0000218,9866,,,1,CHEMBL628585,,,Rattus norvegicus,N,1,178.0,
7705,Biodistribution in rat blood in the presence of GdDTPA at 1 hr,Intermediate,10116.0,,A,,BAO_0000218,9866,,,1,CHEMBL628586,,,Rattus norvegicus,N,1,178.0,
7706,Biodistribution in rat blood in the presence of GdDTPA at 30 min,Intermediate,10116.0,,A,,BAO_0000218,9866,,,1,CHEMBL628587,,,Rattus norvegicus,N,1,178.0,
7707,Biodistribution in rat blood in the presence of GdDTPA at 4 hr,Intermediate,10116.0,,A,,BAO_0000218,9866,,,1,CHEMBL628588,,,Rattus norvegicus,N,1,178.0,
7708,Biodistribution in rat blood in the presence of GdDTPA-BDP at 15 min,Intermediate,10116.0,,A,,BAO_0000218,9866,,,1,CHEMBL628589,,,Rattus norvegicus,N,1,178.0,
7709,Biodistribution in rat blood in the presence of GdDTPA-BDP at 30 min,Intermediate,10116.0,,A,,BAO_0000218,9866,,,1,CHEMBL625304,,,Rattus norvegicus,N,1,178.0,
7710,Biodistribution in rat blood in the presence of GdDTPA-BDP at 4 hr,Intermediate,10116.0,,A,,BAO_0000218,9866,,,1,CHEMBL625305,,,Rattus norvegicus,N,1,178.0,
7711,Biodistribution in rat blood in the presence of GdDTPA-BDPat 1 hr,Intermediate,10116.0,,A,,BAO_0000218,9866,,,1,CHEMBL625306,,,Rattus norvegicus,N,1,178.0,
7712,Biodistribution in rat blood in the presence of GdDTPA-HPDP at 15 min,Intermediate,10116.0,,A,,BAO_0000218,9866,,,1,CHEMBL625307,,,Rattus norvegicus,N,1,178.0,
7713,Biodistribution in rat blood in the presence of GdDTPA-HPDP at 30 min,Intermediate,10116.0,,A,,BAO_0000218,9866,,,1,CHEMBL625308,,,Rattus norvegicus,N,1,178.0,
7714,Biodistribution in rat blood in the presence of GdDTPA-HPDP at 4 hr,Intermediate,10116.0,,A,,BAO_0000218,9866,,,1,CHEMBL627740,,,Rattus norvegicus,N,1,178.0,
7715,Biodistribution in rat blood in the presence of GdDTPA-HPDPat 1 hr,Intermediate,10116.0,,A,,BAO_0000218,9866,,,1,CHEMBL627741,,,Rattus norvegicus,N,1,178.0,
7716,Biodistribution in rat blood in the presence of NAC Gd/0.01 M GdDTPA-HPDP,Intermediate,10116.0,,A,,BAO_0000218,9866,,,1,CHEMBL627742,,,Rattus norvegicus,N,1,178.0,
7717,Biodistribution in rat blood in the presence of NCA Gd/0.01 M lip,Intermediate,10116.0,,A,,BAO_0000218,9866,,,1,CHEMBL627743,,,Rattus norvegicus,N,1,178.0,
7718,Biodistribution in rat blood in the presence of NCAGd/0.01 M lig,Intermediate,10116.0,,A,,BAO_0000218,9866,,,1,CHEMBL627744,,,Rattus norvegicus,N,1,178.0,
7719,Biodistribution in rat bone in the presence of 0.01 M GdDTPA-BDP,Intermediate,10116.0,,A,,BAO_0000218,9866,,,1,CHEMBL627745,,,Rattus norvegicus,N,1,10000001.0,
7720,Biodistribution in rat bone in the presence of 0.01 M/0.01 M GdDTPA-AEP,Intermediate,10116.0,,A,,BAO_0000218,9866,,,1,CHEMBL627746,,,Rattus norvegicus,N,1,10000001.0,
7721,Biodistribution in rat bone in the presence of 0.01 M/0.08 M GdDTPA-AEP,Intermediate,10116.0,,A,,BAO_0000218,9866,,,1,CHEMBL627747,,,Rattus norvegicus,N,1,10000001.0,
7722,Biodistribution in rat bone in the presence of 0.05 M Gd/0.15 M lig,Intermediate,10116.0,,A,,BAO_0000218,9866,,,1,CHEMBL876810,,,Rattus norvegicus,N,1,10000001.0,
7723,Biodistribution in rat bone in the presence of 0.05 M GdDTPA-BDP,Intermediate,10116.0,,A,,BAO_0000218,9866,,,1,CHEMBL627748,,,Rattus norvegicus,N,1,10000001.0,
7724,Biodistribution in rat bone in the presence of 0.05 M/0.05 M GdDTPA-AEP,Intermediate,10116.0,,A,,BAO_0000218,9866,,,1,CHEMBL627749,,,Rattus norvegicus,N,1,10000001.0,
7725,Biodistribution in rat bone in the presence of 0.05 M/0.08 M GdDTPA-HPDP,Intermediate,10116.0,,A,,BAO_0000218,9866,,,1,CHEMBL627750,,,Rattus norvegicus,N,1,10000001.0,
7726,Biodistribution in rat bone in the presence of 0.10 M GdDTPA-BDP,Intermediate,10116.0,,A,,BAO_0000218,9866,,,1,CHEMBL618728,,,Rattus norvegicus,N,1,10000001.0,
7727,Biodistribution in rat bone in the presence of 0.10 M/0.11 M GdDTPA-AEP,Intermediate,10116.0,,A,,BAO_0000218,9866,,,1,CHEMBL618729,,,Rattus norvegicus,N,1,10000001.0,
7728,Biodistribution in rat bone in the presence of GdDTPA at 15 min,Intermediate,10116.0,,A,,BAO_0000218,9866,,,1,CHEMBL618730,,,Rattus norvegicus,N,1,10000001.0,
7729,Biodistribution in rat bone in the presence of GdDTPA at 1 hr,Intermediate,10116.0,,A,,BAO_0000218,9866,,,1,CHEMBL618731,,,Rattus norvegicus,N,1,10000001.0,
7730,Biodistribution in rat bone in the presence of GdDTPA at 30 min,Intermediate,10116.0,,A,,BAO_0000218,9866,,,1,CHEMBL618732,,,Rattus norvegicus,N,1,10000001.0,
7731,Biodistribution in rat bone in the presence of GdDTPA at 4 hr,Intermediate,10116.0,,A,,BAO_0000218,9866,,,1,CHEMBL618733,,,Rattus norvegicus,N,1,10000001.0,
7732,Biodistribution in rat bone in the presence of GdDTPA-BDP at 15 min,Intermediate,10116.0,,A,,BAO_0000218,9866,,,1,CHEMBL618734,,,Rattus norvegicus,N,1,10000001.0,
7733,Biodistribution in rat bone in the presence of GdDTPA-BDP at 1 hr,Intermediate,10116.0,,A,,BAO_0000218,9866,,,1,CHEMBL618735,,,Rattus norvegicus,N,1,10000001.0,
7734,Biodistribution in rat bone in the presence of GdDTPA-BDP at 30 min,Intermediate,10116.0,,A,,BAO_0000218,9866,,,1,CHEMBL876602,,,Rattus norvegicus,N,1,10000001.0,
7735,Biodistribution in rat bone in the presence of GdDTPA-BDP at 4 hr,Intermediate,10116.0,,A,,BAO_0000218,9866,,,1,CHEMBL618736,,,Rattus norvegicus,N,1,10000001.0,
7736,Biodistribution in rat bone in the presence of GdDTPA-HPDP at 15 min,Intermediate,10116.0,,A,,BAO_0000218,9866,,,1,CHEMBL618737,,,Rattus norvegicus,N,1,10000001.0,
7737,Biodistribution in rat bone in the presence of GdDTPA-HPDP at 1 hr,Intermediate,10116.0,,A,,BAO_0000218,9866,,,1,CHEMBL618738,,,Rattus norvegicus,N,1,10000001.0,
7738,Biodistribution in rat bone in the presence of GdDTPA-HPDP at 30 min,Intermediate,10116.0,,A,,BAO_0000218,9866,,,1,CHEMBL618739,,,Rattus norvegicus,N,1,10000001.0,
7739,Biodistribution in rat bone in the presence of GdDTPA-HPDP at 4 hr,Intermediate,10116.0,,A,,BAO_0000218,9866,,,1,CHEMBL618740,,,Rattus norvegicus,N,1,10000001.0,
7740,Biodistribution in rat bone in the presence of NAC Gd/0.01 M GdDTPA-HPDP,Intermediate,10116.0,,A,,BAO_0000218,9866,,,1,CHEMBL618741,,,Rattus norvegicus,N,1,10000001.0,
7741,Biodistribution in rat bone in the presence of NCA Gd/0.01 M lip,Intermediate,10116.0,,A,,BAO_0000218,9866,,,1,CHEMBL618742,,,Rattus norvegicus,N,1,10000001.0,
7742,Biodistribution in rat bone in the presence of NCAGd/0.01 M lig,Intermediate,10116.0,,A,,BAO_0000218,9866,,,1,CHEMBL618743,,,Rattus norvegicus,N,1,10000001.0,
7743,Half-life from rat plasma at a single oral dose of 25 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,17752,,,1,CHEMBL618744,,,Rattus norvegicus,N,1,1969.0,
7744,Half-life in male rat,Intermediate,10116.0,,A,,BAO_0000218,5610,,,1,CHEMBL618745,,,Rattus norvegicus,N,1,,
7745,Half-life in rat after peroral administration at 10 mg/kg concentration,Intermediate,10116.0,,A,,BAO_0000218,5939,,,1,CHEMBL620479,,,Rattus norvegicus,N,1,,
7746,Half-life in rat after peroral administration at 5 mg/kg concentration,Intermediate,10116.0,,A,,BAO_0000218,5939,,,1,CHEMBL620480,,,Rattus norvegicus,N,1,,
7747,Half-life in rat at a dose of 3 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,17771,,,1,CHEMBL620481,,,Rattus norvegicus,N,1,,
7748,Half-life was evaluated in rats,Intermediate,10116.0,,A,,BAO_0000218,1974,,,1,CHEMBL620482,,,Rattus norvegicus,N,1,,
7749,Half-life was measured in rat,Intermediate,10116.0,,A,,BAO_0000218,4239,,,1,CHEMBL876603,,,Rattus norvegicus,N,1,,
7750,Half-life period for the compound was determined in rats at 50 mg/kg dose,Intermediate,10116.0,,A,,BAO_0000218,6681,,,1,CHEMBL620483,,,Rattus norvegicus,N,1,,
7751,Half-life period in rats after intravenous administration at 5 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,17752,,,1,CHEMBL620484,,,Rattus norvegicus,N,1,,
7752,Half-life period in rat at 10 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,6046,,,1,CHEMBL620485,,,Rattus norvegicus,N,1,,
7753,"Half-life period was determined in rats at 10 mg/kg, p.o. dose",Intermediate,10116.0,,A,,BAO_0000218,6685,,,1,CHEMBL620486,,,Rattus norvegicus,N,1,,
7754,"Half-life period was determined in rats at 20 mg/kg, i.p. dose",Intermediate,10116.0,,A,,BAO_0000218,6685,,,1,CHEMBL620487,,,Rattus norvegicus,N,1,,
7755,"Half-life period was determined in rats at 2 mg/kg, i.v. dose",Intermediate,10116.0,,A,,BAO_0000218,6685,,,1,CHEMBL620488,,,Rattus norvegicus,N,1,,
7756,Half-life time in rat the dose of 2 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,4727,,,1,CHEMBL620489,,,Rattus norvegicus,N,1,,
7757,Half-life was estimated from the elimination phase of the oral [C] vs time curves in 4 rats,Intermediate,10116.0,,A,,BAO_0000218,1088,,,1,CHEMBL620490,,,Rattus norvegicus,N,1,,
7758,In vivo activity against Staphylococcus aureus when administered orally for 1 hr in rat at a dose of 15 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,5610,,,1,CHEMBL620491,,,Rattus norvegicus,N,1,,
7759,"In vivo half life of compound in rat plasma after a oral dose of 10 mg/kg (in water, N=4)",Intermediate,10116.0,,A,,BAO_0000218,3032,,,1,CHEMBL876604,,,Rattus norvegicus,N,1,1969.0,
7760,Oral half life was determined,Intermediate,10116.0,,A,,BAO_0000218,5199,,,1,CHEMBL620492,,,Rattus norvegicus,N,1,,
7761,"Pharmacokinetic Parameter, half life period measured in Female Wistar Rats at 100 mg/kg by po administration",Intermediate,10116.0,,A,,BAO_0000218,14941,,,1,CHEMBL620493,,,Rattus norvegicus,N,1,,
7762,Pharmacokinetic property (t1/2) in rat,Intermediate,10116.0,,A,,BAO_0000218,4408,,,1,CHEMBL620494,,,Rattus norvegicus,N,1,,
7763,Plasma elimination half-life was determined,Intermediate,10116.0,,A,,BAO_0000218,2552,,,1,CHEMBL620495,,,Rattus norvegicus,N,1,1969.0,
7764,Plasma elimination half-life was determined in female Sprague-Dawley rats following intravenous (iv) administration of drug (1 mg/kg).,Intermediate,10116.0,,A,,BAO_0000218,5199,,,1,CHEMBL620496,,,Rattus norvegicus,N,1,1969.0,
7765,Plasma half life was observed after intravenous administration in rat,Intermediate,10116.0,,A,,BAO_0000218,15662,,,1,CHEMBL620497,,,Rattus norvegicus,N,1,1969.0,
7766,Plasma half-life was determined,Intermediate,10116.0,,A,,BAO_0000218,1465,,,1,CHEMBL620498,,,Rattus norvegicus,N,1,1969.0,
7767,Plasma half-life following oral administration in Fisher rats,Intermediate,10116.0,,A,,BAO_0000218,1446,,,1,CHEMBL620499,,,Rattus norvegicus,N,1,1969.0,
7768,Plasma half-life in rat,Intermediate,10116.0,,A,,BAO_0000218,6824,,,1,CHEMBL620500,,,Rattus norvegicus,N,1,1969.0,
7769,Plasmatic Half-life after intravenous administration to rat,Intermediate,10116.0,,A,,BAO_0000218,17533,,,1,CHEMBL873809,,,Rattus norvegicus,N,1,1969.0,
7770,T1/2 (half life) of compound after 2 hr iv infusion of 8.4 mg/kg in three rat,Intermediate,10116.0,,A,,BAO_0000218,5979,,,1,CHEMBL620501,,,Rattus norvegicus,N,1,,
7771,Terminal half life after intravenous administration (1 mg/kg) in rat,Intermediate,10116.0,,A,,BAO_0000218,4689,,,1,CHEMBL620502,,,Rattus norvegicus,N,1,,
7772,Terminal half life in Rat at a oral dose of 5 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,4689,,,1,CHEMBL620503,,,Rattus norvegicus,N,1,,
7773,Terminal phase half-life was evaluated in vivo in rat at a dose of 5 mg/kg by intra venous administration,Intermediate,10116.0,,A,,BAO_0000218,2463,,,1,CHEMBL620504,,,Rattus norvegicus,N,1,,
7774,Tested for half life value after intravenous administration at dose of 0.2 mg/kg in rat,Intermediate,10116.0,,A,,BAO_0000218,4883,,,1,CHEMBL876605,,,Rattus norvegicus,N,1,,
7775,Tested for half life value after oral administration at dosage of 4 mg/kg in rat,Intermediate,10116.0,,A,,BAO_0000218,4883,,,1,CHEMBL620505,,,Rattus norvegicus,N,1,,
7776,plasma half life was observed after intravenous administration in rat,Intermediate,10116.0,,A,,BAO_0000218,15662,,,1,CHEMBL873811,,,Rattus norvegicus,N,1,1969.0,
7777,Half life of compound determined in rat after iv administration at a dose of 10 mg/kg,Expert,10116.0,,A,,BAO_0000218,3598,,,1,CHEMBL624016,,,Rattus norvegicus,N,1,,
7778,Half life of compound determined in rat,Intermediate,10116.0,,A,,BAO_0000218,4576,,,1,CHEMBL624017,,,Rattus norvegicus,N,1,,
7779,Mean residence time determined in rat,Intermediate,10116.0,,A,,BAO_0000218,4576,,,1,CHEMBL624018,,,Rattus norvegicus,N,1,,
7780,Plasma half life determined in rat,Intermediate,10116.0,,A,,BAO_0000218,4576,,,1,CHEMBL624019,,,Rattus norvegicus,N,1,,
7781,Compound was evaluated for Tmax in brain after intravenous administration in male rats,Intermediate,10116.0,,A,,BAO_0000218,4910,,,1,CHEMBL624020,,,Rattus norvegicus,N,1,955.0,
7782,Compound was evaluated for pharmacokinetic parameter maximum time period,Intermediate,10116.0,,A,,BAO_0000218,4891,,,1,CHEMBL624201,,,Rattus norvegicus,N,1,,
7783,Evaluated for pharmacokinetic parameter tmax in rat at the dose 50 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,429,,,1,CHEMBL872528,,,Rattus norvegicus,N,1,,
7784,In vivo Tmax was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,Intermediate,10116.0,,A,,BAO_0000218,5974,,,1,CHEMBL624202,,,Rattus norvegicus,N,1,,
7785,In vivo Tmax was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,Intermediate,10116.0,,A,,BAO_0000218,5974,,,1,CHEMBL624203,,,Rattus norvegicus,N,1,,
7786,In vivo Tmax was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,Intermediate,10116.0,,A,,BAO_0000218,5974,,,1,CHEMBL624350,,,Rattus norvegicus,N,1,,
7787,In vivo Tmax was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,Intermediate,10116.0,,A,,BAO_0000218,5974,,,1,CHEMBL621320,,,Rattus norvegicus,N,1,,
7788,In vivo maximum time required for clearance of compound after oral (po) administration at a dose of 10 mg/kg was measured in rats,Intermediate,10116.0,,A,,BAO_0000218,17582,,,1,CHEMBL621321,,,Rattus norvegicus,N,1,,
7789,Maximum time (Tmax) required to reach Cmax in rats,Intermediate,10116.0,,A,,BAO_0000218,4026,,,1,CHEMBL621322,,,Rattus norvegicus,N,1,,
7790,Maximum time constant was determined after oral administration at a dose 10 mg/kg to male Sprague-Dawley rats,Intermediate,10116.0,,A,,BAO_0000218,4890,,,1,CHEMBL621323,,,Rattus norvegicus,N,1,,
7791,Maximum time of clearance of compound in rats after peroral administration,Intermediate,10116.0,,A,,BAO_0000218,6571,,,1,CHEMBL621324,,,Rattus norvegicus,N,1,,
7792,Maximum time at the dose of 2 mg/kg in rat,Intermediate,10116.0,,A,,BAO_0000218,4727,,,1,CHEMBL621325,,,Rattus norvegicus,N,1,,
7793,Maximum time to achieve peak plasma concentration was determined in rat at 1 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,17651,,,1,CHEMBL875837,,,Rattus norvegicus,N,1,1969.0,
7794,Maximum time to achieve peak plasma concentration was determined in rat at 10 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,17651,,,1,CHEMBL621326,,,Rattus norvegicus,N,1,1969.0,
7795,Tmax in Guinea pig (PO dose),Intermediate,10116.0,,A,,BAO_0000218,14465,,,1,CHEMBL621327,,,Rattus norvegicus,N,1,,
7796,"Pharmacokinetic Parameter, Tmax is the time at which maximum concentration (Cmax) is reached in Female Wistar Rats at 100 mg/kg by po administration",Intermediate,10116.0,,A,,BAO_0000218,14941,,,1,CHEMBL621328,,,Rattus norvegicus,N,1,,
7797,Pharmacokinetic parameter (Tmax) in rat,Intermediate,10116.0,,A,,BAO_0000218,5960,,,1,CHEMBL621329,,,Rattus norvegicus,N,1,,
7798,Pharmacokinetic parameter (Tmax) was estimated,Intermediate,10116.0,,A,,BAO_0000218,5022,,,1,CHEMBL621330,,,Rattus norvegicus,N,1,,
7799,Pharmacokinetic property (Tmax) in rat,Intermediate,10116.0,,A,,BAO_0000218,4408,,,1,CHEMBL621331,,,Rattus norvegicus,N,1,,
7800,Pharmacokinetic property (Tmax) was measured in rat at the dose of 0.32 mg/kg p.o.,Intermediate,10116.0,,A,,BAO_0000218,5983,,,1,CHEMBL621332,,,Rattus norvegicus,N,1,,
7801,T max in Rat at a oral dose of 5 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,4689,,,1,CHEMBL621333,,,Rattus norvegicus,N,1,,
7802,T max was determined at 10 mg/kg po dose in rats,Intermediate,10116.0,,A,,BAO_0000218,2792,,,1,CHEMBL621334,,,Rattus norvegicus,N,1,,
7803,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg (run time 7 hr),Intermediate,10090.0,,A,,BAO_0000218,15011,,,1,CHEMBL621335,,,Mus musculus,N,1,,
7804,Area under curve was evaluated after intravenous injection of 1 mg/kg of compound in dogs,Intermediate,9615.0,,A,,BAO_0000218,14180,,,1,CHEMBL621336,,,Canis lupus familiaris,N,1,,
7805,Area under curve was evaluated after intravenous injection of 1 mg/kg of compound in rats,Intermediate,10116.0,,A,,BAO_0000218,14180,,,1,CHEMBL621337,,,Rattus norvegicus,N,1,,
7806,Area under curve was measured after i.v. administration into Beagle dog.,Intermediate,9615.0,,A,,BAO_0000218,14599,,,1,CHEMBL621338,,,Canis lupus familiaris,N,1,,
7807,Area under curve was measured after iv administration into Beagle dog,Intermediate,9615.0,,A,,BAO_0000218,14599,,,1,CHEMBL875838,,,Canis lupus familiaris,N,1,,
7808,Area under curve was measured after po administration into Beagle dog,Intermediate,9615.0,,A,,BAO_0000218,14599,,,1,CHEMBL621339,,,Canis lupus familiaris,N,1,,
7809,Area under curve was measured after po administration into Beagle dog.,Intermediate,9615.0,,A,,BAO_0000218,14599,,,1,CHEMBL621340,,,Canis lupus familiaris,N,1,,
7810,Area under curve was measured at peroral dose of 3 mg/kg,Autocuration,,,A,,BAO_0000218,15675,,,1,CHEMBL621341,,,,U,0,,
7811,Area under curve was measured by using concentration Vs time,Autocuration,,,A,,BAO_0000019,12706,,,1,CHEMBL621342,,,,U,0,,
7812,Area under curve was measured by using concentration Vs time; not tested,Autocuration,,,A,,BAO_0000019,12706,,,1,CHEMBL621343,,,,U,0,,
7813,Area under curve(AUC) was measured in mice after oral administration (50 mg/kg),Intermediate,10090.0,,A,,BAO_0000218,9750,,,1,CHEMBL621344,,,Mus musculus,N,1,,
7814,Area under curve(AUC) was measured in mice after oral administration.,Intermediate,10090.0,,A,,BAO_0000218,9750,,,1,CHEMBL621345,,,Mus musculus,N,1,,
7815,Area under curve(AUC) value of the compound,Autocuration,,,A,,BAO_0000019,14691,,,1,CHEMBL621346,,,,U,0,,
7816,Area under curve(AUC) value of the compound in dogs at 0.5 mg/kg dose upon oral administration,Autocuration,,,A,,BAO_0000218,14691,,,1,CHEMBL621347,,,,U,0,,
7817,Area under curve(AUC) value of the compound in dogs at 1 mg/kg dose upon oral administration,Intermediate,9615.0,,A,,BAO_0000218,14691,,,1,CHEMBL621348,,,Canis lupus familiaris,N,1,,
7818,Area under curve(carotid artery) was determined by the availability in blood,Autocuration,,,A,,BAO_0000019,2939,,,1,CHEMBL621349,,,,U,0,178.0,
7819,Area under curve(carotid artery) was determined by the availability in blood; ND means no data,Autocuration,,,A,,BAO_0000019,2939,,,1,CHEMBL621350,,,,U,0,178.0,
7820,Area under curve(carotid artery) was determined by the availability in blood; No data,Autocuration,,,A,,BAO_0000019,2939,,,1,CHEMBL875839,,,,U,0,178.0,
7821,Area under curve(portal vein) was determined by the availability in blood,Autocuration,,,A,,BAO_0000019,2939,,,1,CHEMBL620211,,,,U,0,178.0,
7822,Area under curve(portal vein) was determined by the availability in blood; ND means no data,Autocuration,,,A,,BAO_0000019,2939,,,1,CHEMBL620212,,,,U,0,178.0,
7823,Area under curve(portal vein) was determined by the availability in blood; No data,Autocuration,,,A,,BAO_0000019,2939,,,1,CHEMBL620213,,,,U,0,178.0,
7824,"Area under plasma concentration vs time curve observed in Rhesus monkeys after, iv administration of single 30 mg/kg dose",Intermediate,9544.0,,A,,BAO_0000218,9552,,,1,CHEMBL620214,,,Macaca mulatta,N,1,1969.0,
7825,"Area under plasma concentration vs time curve observed in Rhesus monkeys after, iv administration of single 30 mg/kg dose",Intermediate,9544.0,,A,,BAO_0000218,9552,,,1,CHEMBL620215,,,Macaca mulatta,N,1,1969.0,
7826,Area under plasma concentration vs time curve observed in Rhesus monkeys after oral administration of single 30 mg/kg dose,Intermediate,9544.0,,A,,BAO_0000218,9552,,,1,CHEMBL620216,,,Macaca mulatta,N,1,1969.0,
7827,"Area under plasma concentration vs time curve observed in female mongrel dogs after, iv administration of single 15 mg/kg dose",Intermediate,9615.0,,A,,BAO_0000218,9552,,,1,CHEMBL620888,,,Canis lupus familiaris,N,1,1969.0,
7828,"Area under plasma concentration vs time curve observed in female mongrel dogs after, oral administration of single 15 mg/kg dose",Intermediate,9615.0,,A,,BAO_0000218,9552,,,1,CHEMBL620889,,,Canis lupus familiaris,N,1,1969.0,
7829,Area under plasma concentration vs time curve observed in rats for 0-3 h,Autocuration,,,A,,BAO_0000019,9552,,,1,CHEMBL620890,,,,U,0,1969.0,
7830,Area under plasma time curve determined in male rat,Intermediate,10116.0,,A,,BAO_0000218,11911,,,1,CHEMBL620891,,,Rattus norvegicus,N,1,1969.0,
7831,Area under the MAP curve measured over 5 min.,Autocuration,,,A,,BAO_0000019,16618,,,1,CHEMBL620892,,,,U,0,,
7832,Area under the concentration time curve (AUC) taken for 0-24 hr was measured when administered through iv route in mice,Intermediate,10090.0,,A,,BAO_0000218,14387,,,1,CHEMBL621079,,,Mus musculus,N,1,,
7833,Area under the concentration time curve (AUC) taken for 0-24 hr was measured when administered through oral route in mice,Intermediate,10090.0,,A,,BAO_0000218,14387,,,1,CHEMBL621080,,,Mus musculus,N,1,,
7834,Area under the concentration vs time curve in dog at 10 mg/kg oral dose,Intermediate,9615.0,,A,,BAO_0000218,12836,,,1,CHEMBL621081,,,Canis lupus familiaris,N,1,,
7835,Area under the concentration vs time curve in hamster at 10 mg/kg oral dose,Intermediate,10026.0,,A,,BAO_0000218,12836,,,1,CHEMBL621082,,,Cricetinae,N,1,,
7836,Area under the concentration vs time curve in rat at 10 mg/kg oral dose,Intermediate,10116.0,,A,,BAO_0000218,12836,,,1,CHEMBL621083,,,Rattus norvegicus,N,1,,
7837,Area under the concentration-time curve from time zero to infinity after intravenous administration of 2.5 mg/kg in dogs,Intermediate,9615.0,,A,,BAO_0000218,14339,,,1,CHEMBL621084,,,Canis lupus familiaris,N,1,,
7838,Area under the concentration-time curve from time zero to infinity in oral (5 mg/kg) fasted dogs,Intermediate,9615.0,,A,,BAO_0000218,14339,,,1,CHEMBL621085,,,Canis lupus familiaris,N,1,,
7839,Area under the concentration-time curve from time zero to infinity in oral (5 mg/kg) fed dogs,Intermediate,9615.0,,A,,BAO_0000218,14339,,,1,CHEMBL621086,,,Canis lupus familiaris,N,1,,
7840,Area under the concentration/ time determined against Bacillus subtilis ATCC 6633 after oral administration in dog(25 mg/kg),Intermediate,9615.0,,A,,BAO_0000218,10524,,,1,CHEMBL621087,,,Canis lupus familiaris,N,1,,
7841,Area under the concentration/ time in plasma after oral administration in dog (25 mg/kg),Intermediate,9615.0,,A,,BAO_0000218,9994,,,1,CHEMBL622607,,,Canis lupus familiaris,N,1,,
7842,Serum AUC in marmosets (IV dose),Intermediate,9615.0,,A,,BAO_0000218,11325,,,1,CHEMBL622608,,,Canis lupus familiaris,N,1,,
7843,Area under the curve after intravenous administration at a dose of 10 umol/kg,Autocuration,,,A,,BAO_0000019,12536,,,1,CHEMBL624481,,,,U,0,,
7844,Area under the curve after intravenous administration at a dose of 2 umol/kg,Autocuration,,,A,,BAO_0000019,12536,,,1,CHEMBL624482,,,,U,0,,
7845,Area under the curve after intravenous administration at a dose of 4 umol/kg,Autocuration,,,A,,BAO_0000019,12536,,,1,CHEMBL624483,,,,U,0,,
7846,Area under the curve after intravenous administration at a dose of 40 umol/kg,Autocuration,,,A,,BAO_0000019,12536,,,1,CHEMBL624484,,,,U,0,,
7847,Area under the curve after intravenous administration at a dose of 5 umol/kg,Autocuration,,,A,,BAO_0000019,12536,,,1,CHEMBL624485,,,,U,0,,
7848,Area under the curve for fumarate salt was evaluated in F344 Rats.,Intermediate,10116.0,,A,,BAO_0000218,15556,,,1,CHEMBL624486,,,Rattus norvegicus,N,1,,
7849,Area under the curve for the compound was calculated.,Autocuration,,,A,,BAO_0000019,2809,,,1,CHEMBL624487,,,,U,0,,
7850,Area under the curve in concentration/ time,Autocuration,,,A,,BAO_0000019,9511,,,1,CHEMBL624488,,,,U,0,,
7851,Area under the curve administered intraintestinal in rats.,Intermediate,10116.0,,A,,BAO_0000218,12818,,,1,CHEMBL624489,,,Rattus norvegicus,N,1,,
7852,Area under the curve administered intravenously in rats.,Intermediate,10116.0,,A,,BAO_0000218,12818,,,1,CHEMBL625184,,,Rattus norvegicus,N,1,,
7853,Area under the curve during intravenous administration,Autocuration,,,A,,BAO_0000019,15118,,,1,CHEMBL625185,,,,U,0,,
7854,Area under the curve during intravenous administration; Not determined,Autocuration,,,A,,BAO_0000019,15118,,,1,CHEMBL875954,,,,U,0,,
7855,Area under the curve during systemic administration,Autocuration,,,A,,BAO_0000019,15118,,,1,CHEMBL625186,,,,U,0,,
7856,Area under the curve during systemic administration; Not determined,Autocuration,,,A,,BAO_0000019,15118,,,1,CHEMBL625187,,,,U,0,,
7857,Area under the curve was calculated for the compound.,Autocuration,,,A,,BAO_0000019,2632,,,1,CHEMBL625188,,,,U,0,,
7858,Area under the curve was determined after intravenous administration of 1.8 mg/kg in male Beagle dogs,Intermediate,9615.0,,A,,BAO_0000218,14346,,,1,CHEMBL625189,,,Canis lupus familiaris,N,1,,
7859,Area under the curve was determined after intravenous administration of 10 mg/kg in male Beagle dogs,Intermediate,9615.0,,A,,BAO_0000218,14346,,,1,CHEMBL625190,,,Canis lupus familiaris,N,1,,
7860,Area under the curve was determined after intravenous administration of 2.5 mg/kg in male Dawley rats,Intermediate,10116.0,,A,,BAO_0000218,14346,,,1,CHEMBL621733,,,Rattus norvegicus,N,1,,
7861,Area under the curve was determined after intravenous administration of 2.6 mg/kg in male Dawley rats,Intermediate,10116.0,,A,,BAO_0000218,14346,,,1,CHEMBL621734,,,Rattus norvegicus,N,1,,
7862,C6h was measured as concentration obtained after 6 hr of oral administration in air pouch exudate after oral administration to male F344 rats,Intermediate,10116.0,,A,,BAO_0000218,11149,,,1,CHEMBL621735,,,Rattus norvegicus,N,1,,
7863,Clearance of the drug was measured in the plasma of rat; No data,Intermediate,10116.0,,A,,BAO_0000218,17796,,,1,CHEMBL621736,,,Rattus norvegicus,N,1,1969.0,
7864,The pharmacokinetic parameter plasma clearance in vivo in rats,Intermediate,10116.0,,A,,BAO_0000218,5247,,,1,CHEMBL621737,,,Rattus norvegicus,N,1,1969.0,
7865,Plasma clearance at the dose of 2 mg/kg in rat,Intermediate,10116.0,,A,,BAO_0000218,4727,,,1,CHEMBL621738,,,Rattus norvegicus,N,1,,
7866,CL (clearance) of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 16 mg/kg peroral administration,Intermediate,10116.0,,A,,BAO_0000218,5654,,,1,CHEMBL622806,,,Rattus norvegicus,N,1,,
7867,CL (clearance) of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 20 mg/kg peroral administration,Intermediate,10116.0,,A,,BAO_0000218,5654,,,1,CHEMBL623519,,,Rattus norvegicus,N,1,,
7868,CL at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,Intermediate,10116.0,,A,,BAO_0000218,17260,,,1,CHEMBL623520,,,Rattus norvegicus,N,1,,
7869,Clearance measured after intravenous bolus administration of 50 mg/kg of compound to rats,Intermediate,10116.0,,A,,BAO_0000218,17065,,,1,CHEMBL623521,,,Rattus norvegicus,N,1,,
7870,Clearance in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,17671,,,1,CHEMBL623522,,,Rattus norvegicus,N,1,,
7871,Clearance rate in rat,Intermediate,10116.0,,A,,BAO_0000218,6672,,,1,CHEMBL623523,,,Rattus norvegicus,N,1,,
7872,Clearance rate in rat,Intermediate,10116.0,,A,,BAO_0000218,6673,,,1,CHEMBL623690,,,Rattus norvegicus,N,1,,
7873,Clearance (Cl) of compound (10 mg/kg) after iv administration was determined in Sprague-Dawley rat,Intermediate,10116.0,,A,,BAO_0000218,5978,,,1,CHEMBL623691,,,Rattus norvegicus,N,1,,
7874,Clearance (Cl) of compound (9.83 mg/kg) after iv administration was determined in Sprague-Dawley rat,Intermediate,10116.0,,A,,BAO_0000218,5978,,,1,CHEMBL623692,,,Rattus norvegicus,N,1,,
7875,Clearance (Cl) of compound (9.84 mg/kg) after iv administration was determined in Sprague-Dawley rat,Intermediate,10116.0,,A,,BAO_0000218,5978,,,1,CHEMBL623693,,,Rattus norvegicus,N,1,,
7876,Clearance (Cl) of compound (9.92 mg/kg) after iv administration was determined in Sprague-Dawley rat,Intermediate,10116.0,,A,,BAO_0000218,5978,,,1,CHEMBL623694,,,Rattus norvegicus,N,1,,
7877,Clearance of compound after iv administration of 20 mg/kg dose in rat,Intermediate,10116.0,,A,,BAO_0000218,4413,,,1,CHEMBL623695,,,Rattus norvegicus,N,1,,
7878,Compound was evaluated for clearance after treatment with iv dose of 1 mgkg to female wistar rats,Intermediate,10116.0,,A,,BAO_0000218,2661,,,1,CHEMBL623696,,,Rattus norvegicus,N,1,,
7879,Compound was evaluated for clearance after treatment with iv dose of 1 mgkg to male wistar rats,Intermediate,10116.0,,A,,BAO_0000218,2661,,,1,CHEMBL623697,,,Rattus norvegicus,N,1,,
7880,Compound was tested for its plasma clearance rate in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,Intermediate,9544.0,,A,,BAO_0000218,5005,,,1,CHEMBL623698,,,Macaca mulatta,U,0,1969.0,
7881,Compound was tested for its plasma clearance rate in Sprague Dawley rats,Intermediate,10116.0,,A,,BAO_0000218,5005,,,1,CHEMBL623699,,,Rattus norvegicus,U,0,1969.0,
7882,Mean (%CV) PK parameters for CL(mL/min/kg).,Intermediate,10116.0,,A,,BAO_0000218,15765,,,1,CHEMBL623700,,,Rattus norvegicus,N,1,,
7883,Pharmacokinetic studies were carried out to determine the clearance after administration at 20 mg/kg intravenously in rat,Intermediate,10116.0,,A,,BAO_0000218,3747,,,1,CHEMBL623701,,,Rattus norvegicus,N,1,,
7884,Pharmacokinetic parameter plasma clearance was determined at when a dose of 1 mg/kg is administered,Intermediate,10116.0,,A,,BAO_0000218,16366,,,1,CHEMBL623702,,,Rattus norvegicus,N,1,1969.0,
7885,Plasma Clearance measured at steady-state following iv infusion at 0.6 mg/kg/h in rats,Intermediate,10116.0,,A,,BAO_0000218,4199,,,1,CHEMBL623703,,,Rattus norvegicus,N,1,,
7886,Plasma clearance in rat was determined,Intermediate,10116.0,,A,,BAO_0000218,17267,,,1,CHEMBL623704,,,Rattus norvegicus,N,1,,
7887,Plasma clearance in rat after administration of 2 mg/kg iv,Intermediate,10116.0,,A,,BAO_0000218,6535,,,1,CHEMBL623705,,,Rattus norvegicus,N,1,,
7888,Plasma clearance in rat after administration of 2 mg/kg iv,Intermediate,10116.0,,A,,BAO_0000218,6535,,,1,CHEMBL623706,,,Rattus norvegicus,N,1,,
7889,Plasma clearance was determined,Intermediate,10116.0,,A,,BAO_0000218,5041,,,1,CHEMBL623707,,,Rattus norvegicus,N,1,,
7890,Plasma clearance in rat,Intermediate,10116.0,,A,,BAO_0000218,5960,,,1,CHEMBL623708,,,Rattus norvegicus,N,1,,
7891,Plasma clearance in rat after intravenous administration at a concentration 0.5 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,5937,,,1,CHEMBL623709,,,Rattus norvegicus,N,1,,
7892,Plasma clearance in rat by iv administration,Intermediate,10116.0,,A,,BAO_0000218,5871,,,1,CHEMBL623710,,,Rattus norvegicus,N,1,,
7893,Plasma clearance in rat by iv administration at a dose of 3 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,5874,,,1,CHEMBL623711,,,Rattus norvegicus,N,1,,
7894,Plasma clearance in rat p.o.,Intermediate,10116.0,,A,,BAO_0000218,6504,,,1,CHEMBL623712,,,Rattus norvegicus,N,1,,
7895,Plasma clearance in rats,Intermediate,10116.0,,A,,BAO_0000218,6803,,,1,CHEMBL623713,,,Rattus norvegicus,N,1,,
7896,Plasma clearance was determined; ND denotes no data,Intermediate,10116.0,,A,,BAO_0000218,5041,,,1,CHEMBL623714,,,Rattus norvegicus,N,1,,
7897,Plasma clearance was determined; ND denotes not determined,Intermediate,10116.0,,A,,BAO_0000218,5041,,,1,CHEMBL623715,,,Rattus norvegicus,N,1,,
7898,Plasma clearance was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after iv administration,Intermediate,10116.0,,A,,BAO_0000218,1916,,,1,CHEMBL623716,,,Rattus norvegicus,N,1,,
7899,Plasma clearance was determined in female Sprague-Dawley rats following intravenous (iv) administration of drug (1 mg/kg).,Intermediate,10116.0,,A,,BAO_0000218,5199,,,1,CHEMBL622980,,,Rattus norvegicus,N,1,,
7900,Plasma administration to rats,Intermediate,10116.0,,A,,BAO_0000218,16367,,,1,CHEMBL622981,,,Rattus norvegicus,N,1,,
7901,Plasma clearance of the compound in female Sprague-Dawley rats,Intermediate,10116.0,,A,,BAO_0000218,6362,,,1,CHEMBL622982,,,Rattus norvegicus,N,1,,
7902,Plasma clearance was observed after intravenous administration in rat,Intermediate,10116.0,,A,,BAO_0000218,15662,,,1,CHEMBL622983,,,Rattus norvegicus,N,1,,
7903,Systemic clearance after intravenous administration (5.0 mg/kg) was determined in rat,Intermediate,10116.0,,A,,BAO_0000218,6215,,,1,CHEMBL622984,,,Rattus norvegicus,N,1,,
7904,Tested for systemic clearance upon intravenous administration of 5.0 mg/Kg dose in rat,Intermediate,10116.0,,A,,BAO_0000218,1466,,,1,CHEMBL622985,,,Rattus norvegicus,N,1,,
7905,plasma clearance was observed after intravenous administration in rat,Intermediate,10116.0,,A,,BAO_0000218,15662,,,1,CHEMBL623631,,,Rattus norvegicus,N,1,1969.0,
7906,In vivo CL/F determined,Intermediate,10116.0,,A,,BAO_0000218,4723,,,1,CHEMBL623632,,,Rattus norvegicus,N,1,,
7907,Pharmacokinetic parameter plasma clearance was determined at 2 mg/kg i.v. dose in rats,Intermediate,10116.0,,A,,BAO_0000218,2792,,,1,CHEMBL623633,,,Rattus norvegicus,N,1,1969.0,
7908,Pharmacokinetic parameter plasma clearance was determined at 5 mg/kg i.v. dose in rats,Intermediate,10116.0,,A,,BAO_0000218,2792,,,1,CHEMBL623634,,,Rattus norvegicus,N,1,1969.0,
7909,Compound was tested for the lower blood clearance in rat,Intermediate,10116.0,,A,,BAO_0000218,5213,,,1,CHEMBL623635,,,Rattus norvegicus,N,1,,
7910,Evaluated for the low clearance in rat (in vivo),Intermediate,10116.0,,A,,BAO_0000218,4687,,,1,CHEMBL621195,,,Rattus norvegicus,N,1,,
7911,Pharmacokinetic property (CLb)of the compound was determined in rat,Intermediate,10116.0,,A,,BAO_0000218,3371,,,1,CHEMBL621196,,,Rattus norvegicus,N,1,,
7912,Rapid clearance after intravenous administration in rat was determined,Intermediate,10116.0,,A,,BAO_0000218,4690,,,1,CHEMBL875287,,,Rattus norvegicus,N,1,,
7913,Clearance measured in rat,Intermediate,10116.0,,A,,BAO_0000218,5702,,,1,CHEMBL621197,,,Rattus norvegicus,N,1,,
7914,Compound was evaluated for plasma clearance in rat,Intermediate,10116.0,,A,,BAO_0000218,740,,,1,CHEMBL621198,,,Rattus norvegicus,N,1,1969.0,
7915,Low plasma clearance was calculated in rat,Intermediate,10116.0,,A,,BAO_0000218,4853,,,1,CHEMBL621199,,,Rattus norvegicus,N,1,1969.0,
7916,Pharmacokinetic property (Clp) in rat,Intermediate,10116.0,,A,,BAO_0000218,5789,,,1,CHEMBL621200,,,Rattus norvegicus,N,1,,
7917,Plasma clearance in dog at a dose of 1 uM/kg in rat was determined,Intermediate,10116.0,,A,,BAO_0000218,4527,,,1,CHEMBL621201,,,Rattus norvegicus,N,1,,
7918,Plasma clearance in rat at a dose of 10 uM/kg in rat was determined,Intermediate,10116.0,,A,,BAO_0000218,4527,,,1,CHEMBL621202,,,Rattus norvegicus,N,1,,
7919,Plasma clearance after IV dosing at 0.5 mg/kg in rat,Intermediate,10116.0,,A,,BAO_0000218,6518,,,1,CHEMBL621203,,,Rattus norvegicus,N,1,,
7920,Plasma clearance after IV dosing at 1 mg/kg in rat,Intermediate,10116.0,,A,,BAO_0000218,6518,,,1,CHEMBL621204,,,Rattus norvegicus,N,1,,
7921,Biodistribution in rat heart in the presence of 0.01 M Gd/0.01 M GdDTPA-AEP,Intermediate,10116.0,,A,,BAO_0000218,9866,,,1,CHEMBL621205,,,Rattus norvegicus,N,1,948.0,
7922,Biodistribution in rat heart in the presence of 0.01 M GdDTPA-BDP,Intermediate,10116.0,,A,,BAO_0000218,9866,,,1,CHEMBL621206,,,Rattus norvegicus,N,1,948.0,
7923,Biodistribution in rat heart in the presence of 0.01 M/0.08 M GdDTPA-AEP,Intermediate,10116.0,,A,,BAO_0000218,9866,,,1,CHEMBL621207,,,Rattus norvegicus,N,1,948.0,
7924,Biodistribution in rat heart in the presence of 0.05 M /0.05 M GdDTPA-AEP,Intermediate,10116.0,,A,,BAO_0000218,9866,,,1,CHEMBL621208,,,Rattus norvegicus,N,1,948.0,
7925,Biodistribution in rat heart in the presence of 0.05 M Gd/0.15 M lig,Intermediate,10116.0,,A,,BAO_0000218,9866,,,1,CHEMBL621209,,,Rattus norvegicus,N,1,948.0,
7926,Biodistribution in rat heart in the presence of 0.05 M GdDTPA-BDP,Intermediate,10116.0,,A,,BAO_0000218,9866,,,1,CHEMBL876484,,,Rattus norvegicus,N,1,948.0,
7927,Biodistribution in rat heart in the presence of 0.05 M/0.08 M GdDTPA-HPDP,Intermediate,10116.0,,A,,BAO_0000218,9866,,,1,CHEMBL621210,,,Rattus norvegicus,N,1,948.0,
7928,Biodistribution in rat heart in the presence of 0.10 M GdDTPA-BDP,Intermediate,10116.0,,A,,BAO_0000218,9866,,,1,CHEMBL621211,,,Rattus norvegicus,N,1,948.0,
7929,Biodistribution in rat heart in the presence of 0.10 M/0.11 M GdDTPA-AEP,Intermediate,10116.0,,A,,BAO_0000218,9866,,,1,CHEMBL621212,,,Rattus norvegicus,N,1,948.0,
7930,Biodistribution in rat heart in the presence of GdDTPA at 15 min,Intermediate,10116.0,,A,,BAO_0000218,9866,,,1,CHEMBL621213,,,Rattus norvegicus,N,1,948.0,
7931,Biodistribution in rat heart in the presence of GdDTPA at 1 hr,Intermediate,10116.0,,A,,BAO_0000218,9866,,,1,CHEMBL621214,,,Rattus norvegicus,N,1,948.0,
7932,Biodistribution in rat heart in the presence of GdDTPA at 30 min,Intermediate,10116.0,,A,,BAO_0000218,9866,,,1,CHEMBL621215,,,Rattus norvegicus,N,1,948.0,
7933,Biodistribution in rat heart in the presence of GdDTPA at 4 hr,Intermediate,10116.0,,A,,BAO_0000218,9866,,,1,CHEMBL621216,,,Rattus norvegicus,N,1,948.0,
7934,Biodistribution in rat heart in the presence of GdDTPA-BDP at 1 hr,Intermediate,10116.0,,A,,BAO_0000218,9866,,,1,CHEMBL621217,,,Rattus norvegicus,N,1,948.0,
7935,Biodistribution in rat heart in the presence of GdDTPA-BDP at 30 min,Intermediate,10116.0,,A,,BAO_0000218,9866,,,1,CHEMBL621218,,,Rattus norvegicus,N,1,948.0,
7936,Biodistribution in rat heart in the presence of GdDTPA-BDP at 4 hr,Intermediate,10116.0,,A,,BAO_0000218,9866,,,1,CHEMBL621219,,,Rattus norvegicus,N,1,948.0,
7937,Biodistribution in rat heart in the presence of GdDTPA-BDPat 15 min,Intermediate,10116.0,,A,,BAO_0000218,9866,,,1,CHEMBL621220,,,Rattus norvegicus,N,1,948.0,
7938,Biodistribution in rat heart in the presence of GdDTPA-HPDP at 1 hr,Intermediate,10116.0,,A,,BAO_0000218,9866,,,1,CHEMBL621221,,,Rattus norvegicus,N,1,948.0,
7939,Biodistribution in rat heart in the presence of GdDTPA-HPDP at 30 min,Intermediate,10116.0,,A,,BAO_0000218,9866,,,1,CHEMBL621222,,,Rattus norvegicus,N,1,948.0,
7940,Biodistribution in rat heart in the presence of GdDTPA-HPDP at 4 hr,Intermediate,10116.0,,A,,BAO_0000218,9866,,,1,CHEMBL621223,,,Rattus norvegicus,N,1,948.0,
7941,Biodistribution in rat heart in the presence of GdDTPA-HPDPat 15 min,Intermediate,10116.0,,A,,BAO_0000218,9866,,,1,CHEMBL876485,,,Rattus norvegicus,N,1,948.0,
7942,Biodistribution in rat heart in the presence of NAC Gd/0.01 M GdDTPA-HPDP,Intermediate,10116.0,,A,,BAO_0000218,9866,,,1,CHEMBL621224,,,Rattus norvegicus,N,1,948.0,
7943,Biodistribution in rat heart in the presence of NCA Gd/0.01 M lip,Intermediate,10116.0,,A,,BAO_0000218,9866,,,1,CHEMBL621225,,,Rattus norvegicus,N,1,948.0,
7944,Biodistribution in rat heart in the presence of NCAGd/0.01 M lig,Intermediate,10116.0,,A,,BAO_0000218,9866,,,1,CHEMBL621226,,,Rattus norvegicus,N,1,948.0,
7945,Biodistribution in rat kidney in the presence of 0.01 M GdDTPA-BDP,Intermediate,10116.0,,A,,BAO_0000218,9866,,,1,CHEMBL621227,,,Rattus norvegicus,N,1,2113.0,
7946,Biodistribution in rat kidney in the presence of 0.01 M/0.01 M GdDTPA-AEP,Intermediate,10116.0,,A,,BAO_0000218,9866,,,1,CHEMBL621228,,,Rattus norvegicus,N,1,2113.0,
7947,Biodistribution in rat kidney in the presence of 0.01 M/0.08 M GdDTPA-AEP,Intermediate,10116.0,,A,,BAO_0000218,9866,,,1,CHEMBL621229,,,Rattus norvegicus,N,1,2113.0,
7948,Biodistribution in rat kidney in the presence of 0.05 M Gd/0.15 M lig,Intermediate,10116.0,,A,,BAO_0000218,9866,,,1,CHEMBL621230,,,Rattus norvegicus,N,1,2113.0,
7949,Biodistribution in rat kidney in the presence of 0.05 M GdDTPA-BDP; ND=No data,Intermediate,10116.0,,A,,BAO_0000218,9866,,,1,CHEMBL621231,,,Rattus norvegicus,N,1,2113.0,
7950,Biodistribution in rat kidney in the presence of 0.05 M/0.05 M GdDTPA-AEP,Intermediate,10116.0,,A,,BAO_0000218,9866,,,1,CHEMBL621232,,,Rattus norvegicus,N,1,2113.0,
7951,Biodistribution in rat kidney in the presence of 0.05 M/0.08 M GdDTPA-HPDP,Intermediate,10116.0,,A,,BAO_0000218,9866,,,1,CHEMBL621233,,,Rattus norvegicus,N,1,2113.0,
7952,Biodistribution in rat kidney in the presence of 0.10 M GdDTPA-BDP,Intermediate,10116.0,,A,,BAO_0000218,9866,,,1,CHEMBL621234,,,Rattus norvegicus,N,1,2113.0,
7953,Biodistribution in rat kidney in the presence of 0.10 M/0.11 M GdDTPA-AEP; ND=No data,Intermediate,10116.0,,A,,BAO_0000218,9866,,,1,CHEMBL621235,,,Rattus norvegicus,N,1,2113.0,
7954,Biodistribution in rat kidney in the presence of NAC Gd/0.01 M GdDTPA-HPDP,Intermediate,10116.0,,A,,BAO_0000218,9866,,,1,CHEMBL621236,,,Rattus norvegicus,N,1,2113.0,
7955,Biodistribution in rat kidney in the presence of NCA Gd/0.01 M lip,Intermediate,10116.0,,A,,BAO_0000218,9866,,,1,CHEMBL621237,,,Rattus norvegicus,N,1,2113.0,
7956,Biodistribution in rat kidney in the presence of NCAGd/0.01 M lig,Intermediate,10116.0,,A,,BAO_0000218,9866,,,1,CHEMBL876486,,,Rattus norvegicus,N,1,2113.0,
7957,Biodistribution in rat l. intestine in the presence of 0.01 M carrier at 1 hr,Intermediate,10116.0,,A,,BAO_0000218,9866,,,1,CHEMBL622436,,,Rattus norvegicus,N,1,160.0,
7958,Biodistribution in rat l. intestine in the presence of 50 Gd/kg at 2 hr,Intermediate,10116.0,,A,,BAO_0000218,9866,,,1,CHEMBL622437,,,Rattus norvegicus,N,1,160.0,
7959,Biodistribution in rat l. intestine in the presence of 50 Gd/kg at 6 hr,Intermediate,10116.0,,A,,BAO_0000218,9866,,,1,CHEMBL622438,,,Rattus norvegicus,N,1,160.0,
7960,Biodistribution in rat liver by in the presence 50 Gd/kg at 15 min,Intermediate,10116.0,,A,,BAO_0000218,9866,,,1,CHEMBL622439,,,Rattus norvegicus,N,1,2107.0,
7961,Biodistribution in rat liver by in the presence of 0.05 M Gd/0.15 M lig,Intermediate,10116.0,,A,,BAO_0000218,9866,,,1,CHEMBL622440,,,Rattus norvegicus,N,1,2107.0,
7962,Biodistribution in rat liver by in the presence of NCAGd/0.01 M lig,Intermediate,10116.0,,A,,BAO_0000218,9866,,,1,CHEMBL622441,,,Rattus norvegicus,N,1,2107.0,
7963,Biodistribution in rat liver in the presence of 0.001 M/0.008 M GdDTPA-AEP,Intermediate,10116.0,,A,,BAO_0000218,9866,,,1,CHEMBL622442,,,Rattus norvegicus,N,1,2107.0,
7964,Biodistribution in rat liver in the presence of 0.01 M GdDTPA-BDP,Intermediate,10116.0,,A,,BAO_0000218,9866,,,1,CHEMBL622443,,,Rattus norvegicus,N,1,2107.0,
7965,Biodistribution in rat liver in the presence of 0.01 M/0.01 M GdDTPA-AEP,Intermediate,10116.0,,A,,BAO_0000218,9866,,,1,CHEMBL622444,,,Rattus norvegicus,N,1,2107.0,
7966,Biodistribution in rat liver in the presence of 0.05 M GdDTPA-BDP,Intermediate,10116.0,,A,,BAO_0000218,9866,,,1,CHEMBL622445,,,Rattus norvegicus,N,1,2107.0,
7967,Biodistribution in rat liver in the presence of 0.05 M/0.05 M GdDTPA-AEP,Intermediate,10116.0,,A,,BAO_0000218,9866,,,1,CHEMBL622446,,,Rattus norvegicus,N,1,2107.0,
7968,Biodistribution in rat liver in the presence of 0.05 M/0.08 M GdDTPA-HPDP,Intermediate,10116.0,,A,,BAO_0000218,9866,,,1,CHEMBL622447,,,Rattus norvegicus,N,1,2107.0,
7969,Biodistribution in rat liver in the presence of 0.10 M GdDTPA-BDP,Intermediate,10116.0,,A,,BAO_0000218,9866,,,1,CHEMBL622448,,,Rattus norvegicus,N,1,2107.0,
7970,Biodistribution in rat liver in the presence of 0.10 M/0.11 M GdDTPA-AEP; ND=No data,Intermediate,10116.0,,A,,BAO_0000218,9866,,,1,CHEMBL622449,,,Rattus norvegicus,N,1,2107.0,
7971,Biodistribution in rat liver in the presence of 50 Gd/kg at 2 hr,Intermediate,10116.0,,A,,BAO_0000218,9866,,,1,CHEMBL622450,,,Rattus norvegicus,N,1,2107.0,
7972,Biodistribution in rat liver in the presence of 50 Gd/kg at at 6 hr,Intermediate,10116.0,,A,,BAO_0000218,9866,,,1,CHEMBL622451,,,Rattus norvegicus,N,1,2107.0,
7973,Biodistribution in rat liver in the presence of GdDTPA at 15 min,Intermediate,10116.0,,A,,BAO_0000218,9866,,,1,CHEMBL622452,,,Rattus norvegicus,N,1,2107.0,
7974,Biodistribution in rat liver in the presence of GdDTPA at 1 hr,Intermediate,10116.0,,A,,BAO_0000218,9866,,,1,CHEMBL622453,,,Rattus norvegicus,N,1,2107.0,
7975,Biodistribution in rat liver in the presence of GdDTPA at 30 min,Intermediate,10116.0,,A,,BAO_0000218,9866,,,1,CHEMBL622454,,,Rattus norvegicus,N,1,2107.0,
7976,Biodistribution in rat liver in the presence of GdDTPA at 4 hr,Intermediate,10116.0,,A,,BAO_0000218,9866,,,1,CHEMBL622455,,,Rattus norvegicus,N,1,2107.0,
7977,Biodistribution in rat liver in the presence of GdDTPA-BDP at 15 min,Intermediate,10116.0,,A,,BAO_0000218,9866,,,1,CHEMBL876024,,,Rattus norvegicus,N,1,2107.0,
7978,T max was determined at 3 mg/kg po dose in rats,Intermediate,10116.0,,A,,BAO_0000218,2792,,,1,CHEMBL622456,,,Rattus norvegicus,N,1,,
7979,"The Tmax value in female wistar rat at 100 mg/kg, p.o. dose",Intermediate,10116.0,,A,,BAO_0000218,15078,,,1,CHEMBL622457,,,Rattus norvegicus,N,1,,
7980,"The Tmax value in male wistar rat at 100 mg/kg, p.o. dose",Intermediate,10116.0,,A,,BAO_0000218,15078,,,1,CHEMBL622458,,,Rattus norvegicus,N,1,,
7981,The time to reach maximum concentration of compound was measured at the dose of 100 umol/kg,Intermediate,10116.0,,A,,BAO_0000218,15022,,,1,CHEMBL622459,,,Rattus norvegicus,N,1,,
7982,The time to reach maximum concentration of compound was measured at the dose of 300 umol/kg,Intermediate,10116.0,,A,,BAO_0000218,15022,,,1,CHEMBL873343,,,Rattus norvegicus,N,1,,
7983,The time to reach maximum concentration of compound was measured at the dose of 30 umol/kg,Intermediate,10116.0,,A,,BAO_0000218,15022,,,1,CHEMBL622460,,,Rattus norvegicus,N,1,,
7984,Time for maximum plasma concentration determined in rat,Intermediate,10116.0,,A,,BAO_0000218,4576,,,1,CHEMBL622461,,,Rattus norvegicus,N,1,1969.0,
7985,Time for maximum plasma concentration reached by compound was determined in rats at 50 mg/kg dose,Intermediate,10116.0,,A,,BAO_0000218,6681,,,1,CHEMBL622462,,,Rattus norvegicus,N,1,1969.0,
7986,Time of maximum concentration of the drug when administered orally a dose of 10 mg/kg to a fasting rat,Intermediate,10116.0,,A,,BAO_0000218,16365,,,1,CHEMBL622463,,,Rattus norvegicus,N,1,,
7987,Time of maximum concentration of the drug when administered orally a dose of 1 mg/kg to a fasting rat,Intermediate,10116.0,,A,,BAO_0000218,16365,,,1,CHEMBL622464,,,Rattus norvegicus,N,1,,
7988,Time of maximum concentration of the drug when administered orally a dose of 30 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,16365,,,1,CHEMBL622465,,,Rattus norvegicus,N,1,,
7989,Time of maximum concentration of the drug when administered orally a dose of 3 mg/kg to a fasting rat,Intermediate,10116.0,,A,,BAO_0000218,16365,,,1,CHEMBL622466,,,Rattus norvegicus,N,1,,
7990,Time of maximum concentration of the drug when administered orally at dose of 3 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,16365,,,1,CHEMBL622467,,,Rattus norvegicus,N,1,,
7991,Time of maximum plasma concentration in rat,Intermediate,10116.0,,A,,BAO_0000218,6824,,,1,CHEMBL622468,,,Rattus norvegicus,N,1,1969.0,
7992,"Time required by compound for reaching maximum plasma concentration was determined in rats at 10 mg/kg, p.o. dose",Intermediate,10116.0,,A,,BAO_0000218,6685,,,1,CHEMBL876025,,,Rattus norvegicus,N,1,1969.0,
7993,"Time required by compound for reaching maximum plasma concentration was determined in rats at 20 mg/kg, i.p. dose",Intermediate,10116.0,,A,,BAO_0000218,6685,,,1,CHEMBL622469,,,Rattus norvegicus,N,1,1969.0,
7994,"Time required by compound for reaching maximum plasma concentration was determined in rats at 2 mg/kg, i.v. dose; n/a: not applicable",Intermediate,10116.0,,A,,BAO_0000218,6685,,,1,CHEMBL622470,,,Rattus norvegicus,N,1,1969.0,
7995,Time required to reach maximum concentration (Cmax) after oral administration in rat,Intermediate,10116.0,,A,,BAO_0000218,15662,,,1,CHEMBL622471,,,Rattus norvegicus,N,1,,
7996,Time required to reach maximum concentration in rat plasma,Intermediate,10116.0,,A,,BAO_0000218,1742,,,1,CHEMBL622472,,,Rattus norvegicus,N,1,1969.0,
7997,Time taken by the compound to achieve maximum concentration in rat plasma at 30 mg/Kg upon oral administration.,Intermediate,10116.0,,A,,BAO_0000218,2774,,,1,CHEMBL622473,,,Rattus norvegicus,N,1,1969.0,
7998,Time taken by the compound to achieve maximum plasma concentration at a 1 mg/kg oral dose in female Sprague-Dawley rats,Intermediate,10116.0,,A,,BAO_0000218,5199,,,1,CHEMBL624282,,,Rattus norvegicus,N,1,1969.0,
7999,Time taken for maximum plasma concentration for the compound in solution form (formulation) was determined in rats at peroral dose of 5 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,12873,,,1,CHEMBL624283,,,Rattus norvegicus,N,1,1969.0,
8000,Time taken for maximum plasma concentration for the compound in suspension form (formulation) was determined in rats at peroral dose of 5 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,12873,,,1,CHEMBL624284,,,Rattus norvegicus,N,1,1969.0,
8001,Time taken to reach maximum concentration in plasma was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after po administration,Intermediate,10116.0,,A,,BAO_0000218,1916,,,1,CHEMBL624285,,,Rattus norvegicus,N,1,1969.0,
8002,Time to reach Cmax after oral administration to rats,Intermediate,10116.0,,A,,BAO_0000218,16367,,,1,CHEMBL624286,,,Rattus norvegicus,N,1,,
8003,Time to reach Cmax when a dose of 1 mg/kg is administered orally,Intermediate,10116.0,,A,,BAO_0000218,16366,,,1,CHEMBL624287,,,Rattus norvegicus,N,1,,
8004,Time to reach maximum concentration following oral administration of 200 mg/kg in rat; value ranges from 2-4,Intermediate,10116.0,,A,,BAO_0000218,216,,,1,CHEMBL624288,,,Rattus norvegicus,N,1,,
8005,Time to reach maximum plasma concentration was evaluated at an intravenous dose of 3 mg/kg; Not applicable,Intermediate,10116.0,,A,,BAO_0000218,6410,,,1,CHEMBL624289,,,Rattus norvegicus,N,1,1969.0,
8006,Time to reach maximum plasma concentration was evaluated at an oral dose of 30 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,6410,,,1,CHEMBL873344,,,Rattus norvegicus,N,1,1969.0,
8007,Tmax after peroral administration (10 mg/kg) was determined in rat,Intermediate,10116.0,,A,,BAO_0000218,6215,,,1,CHEMBL619623,,,Rattus norvegicus,N,1,,
8008,Tmax of compound determined in rat after iv administration at a dose of 10 mg/kg,Expert,10116.0,,A,,BAO_0000218,3598,,,1,CHEMBL621399,,,Rattus norvegicus,N,1,,
8009,Tmax by oral administration at a dose of 100 uM/kg in rat was determined,Intermediate,10116.0,,A,,BAO_0000218,4527,,,1,CHEMBL621400,,,Rattus norvegicus,N,1,,
8010,"Tmax in fischer rats at 5 mg/kg dose, administered intravenously",Intermediate,10116.0,,A,,BAO_0000218,17670,,,1,CHEMBL621401,,,Rattus norvegicus,N,1,,
8011,Tmax was determined,Intermediate,10116.0,,A,,BAO_0000218,1465,,,1,CHEMBL621402,,,Rattus norvegicus,N,1,,
8012,Tmax was determined,Intermediate,10116.0,,A,,BAO_0000218,2552,,,1,CHEMBL621403,,,Rattus norvegicus,N,1,,
8013,Tmax after oral administration in rat,Intermediate,10116.0,,A,,BAO_0000218,5656,,,1,CHEMBL621121,,,Rattus norvegicus,N,1,,
8014,Tmax after peroral administration in rats at 2.4 uM/kg,Intermediate,10116.0,,A,,BAO_0000218,17764,,,1,CHEMBL872525,,,Rattus norvegicus,N,1,,
8015,Tmax in male rat,Intermediate,10116.0,,A,,BAO_0000218,5610,,,1,CHEMBL621122,,,Rattus norvegicus,N,1,,
8016,Tmax in rat at 10 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,6046,,,1,CHEMBL621123,,,Rattus norvegicus,N,1,,
8017,Tmax in rat by po administration at a dose of 40 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,5874,,,1,CHEMBL621124,,,Rattus norvegicus,N,1,,
8018,Tmax in rats,Intermediate,10116.0,,A,,BAO_0000218,17596,,,1,CHEMBL621125,,,Rattus norvegicus,N,1,,
8019,Tmax was measured in rats after peroral administration at 5 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,17804,,,1,CHEMBL621126,,,Rattus norvegicus,N,1,,
8020,Tmax value after oral dose at a dose of 10 mg/kg in rats.,Intermediate,10116.0,,A,,BAO_0000218,1908,,,1,CHEMBL621127,,,Rattus norvegicus,N,1,,
8021,Tmax value after administration of 20 mg/Kg oral dose in rat,Intermediate,10116.0,,A,,BAO_0000218,2959,,,1,CHEMBL621128,,,Rattus norvegicus,N,1,,
8022,Tmax value at a dose of 10 mg/kg in male SD rats,Intermediate,10116.0,,A,,BAO_0000218,6757,,,1,CHEMBL618263,,,Rattus norvegicus,N,1,,
8023,Tmax value at a dose of 100 mg/kg in male SD rats,Intermediate,10116.0,,A,,BAO_0000218,6757,,,1,CHEMBL618264,,,Rattus norvegicus,N,1,,
8024,Tmax value at a dose of 50 mg/kg in male SD rats,Intermediate,10116.0,,A,,BAO_0000218,6757,,,1,CHEMBL618265,,,Rattus norvegicus,N,1,,
8025,Total concentration in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,Intermediate,10116.0,,A,,BAO_0000218,4186,,,1,CHEMBL618266,,,Rattus norvegicus,N,1,1969.0,
8026,time required to reach maximum concentration (Cmax) after oral administration in rat,Intermediate,10116.0,,A,,BAO_0000218,15662,,,1,CHEMBL618267,,,Rattus norvegicus,N,1,,
8027,Evaluated for pharmacokinetic parameter urine recovery in rat at the dose 50 mg/kg ( 0-24 hr ),Intermediate,10116.0,,A,,BAO_0000218,429,,,1,CHEMBL618450,,,Rattus norvegicus,N,1,1088.0,
8028,Evaluated for pharmacokinetic parameter urine recovery in rat at the dose 50 mg/kg (0-24 hr),Intermediate,10116.0,,A,,BAO_0000218,429,,,1,CHEMBL618451,,,Rattus norvegicus,N,1,1088.0,
8029,Unbound plasma was determined in Sprague-Dawley rats at a dose of 1 mg/kg by iv administration,Intermediate,10116.0,,A,,BAO_0000218,5546,,,1,CHEMBL618452,,,Rattus norvegicus,N,1,,
8030,Amount of urine output was measured in rat at a dose of 1 mg/kg/po,Intermediate,10116.0,,A,,BAO_0000218,3173,,,1,CHEMBL618453,,,Rattus norvegicus,N,1,1088.0,
8031,Amount of urine output was measured in rat at a dose of 10 mg/kg/po,Intermediate,10116.0,,A,,BAO_0000218,3173,,,1,CHEMBL618454,,,Rattus norvegicus,N,1,1088.0,
8032,Amount of urine output was measured in rat at a dose of 10 mg/kg/po; NT-Not tested,Intermediate,10116.0,,A,,BAO_0000218,3173,,,1,CHEMBL618455,,,Rattus norvegicus,N,1,1088.0,
8033,Volume of distribution was determined in rat after a 3 mg/kg of iv dose,Intermediate,10116.0,,A,,BAO_0000218,4257,,,1,CHEMBL618456,,,Rattus norvegicus,N,1,,
8034,Compound distribution in rat tissues was determined,Intermediate,10116.0,,A,,BAO_0000218,6011,,,1,CHEMBL618457,,,Rattus norvegicus,N,1,,
8035,Volume of distribution was evaluated in rat,Intermediate,10116.0,,A,,BAO_0000218,5472,,,1,CHEMBL618458,,,Rattus norvegicus,N,1,,
8036,Area under the curve was determined after intravenous administration of 2.7 mg/kg in male Dawley rats,Intermediate,10116.0,,A,,BAO_0000218,14346,,,1,CHEMBL618459,,,Rattus norvegicus,N,1,,
8037,Area under the curve was determined after intravenous administration of 2.8 mg/kg in male Dawley rats,Intermediate,10116.0,,A,,BAO_0000218,14346,,,1,CHEMBL876733,,,Rattus norvegicus,N,1,,
8038,Area under the curve was determined after intravenous administration of 4.9 mg/kg in male Beagle dogs,Intermediate,9615.0,,A,,BAO_0000218,14346,,,1,CHEMBL618460,,,Canis lupus familiaris,N,1,,
8039,Area under the curve was determined after intravenous administration of 5.1 mg/kg in male Dawley rats,Intermediate,10116.0,,A,,BAO_0000218,14346,,,1,CHEMBL618461,,,Rattus norvegicus,N,1,,
8040,Area under the curve was determined after oral administration (300 uM/Kg),Autocuration,,,A,,BAO_0000019,15469,,,1,CHEMBL618462,,,,U,0,,
8041,Area under the curve was determined after peroral administration of 5.0 mg/kg in male Dawley rats,Intermediate,10116.0,,A,,BAO_0000218,14346,,,1,CHEMBL618463,,,Rattus norvegicus,N,1,,
8042,Area under the curve was determined after peroral administration of 5.1 mg/kg in mal Dawley rats,Intermediate,10116.0,,A,,BAO_0000218,14346,,,1,CHEMBL618464,,,Rattus norvegicus,N,1,,
8043,Area under the curve was determined after peroral administration of 5.1 mg/kg in male Dawley rats,Intermediate,10116.0,,A,,BAO_0000218,14346,,,1,CHEMBL618465,,,Rattus norvegicus,N,1,,
8044,Area under the curve was determined after peroral administration of 5.2 mg/kg in mal Dawley rats,Intermediate,10116.0,,A,,BAO_0000218,14346,,,1,CHEMBL618466,,,Rattus norvegicus,N,1,,
8045,Area under the curve was determined after peroral administration of 5.2 mg/kg in male Dawley rats,Intermediate,10116.0,,A,,BAO_0000218,14346,,,1,CHEMBL618467,,,Rattus norvegicus,N,1,,
8046,Area under the curve was determined for the compound after iv dose of 4.97 mg/kg in rats,Intermediate,10116.0,,A,,BAO_0000218,15372,,,1,CHEMBL618468,,,Rattus norvegicus,N,1,,
8047,Area under the plasma concentration was determined in fasted Beagle dogs after peroral administration of 100 mg/kg,Intermediate,9615.0,,A,,BAO_0000218,12935,,,1,CHEMBL618469,,,Canis lupus familiaris,N,1,1969.0,
8048,Area under the plasma concentration was determined in fasted Beagle dogs after peroral administration of 20 mg/kg,Intermediate,9615.0,,A,,BAO_0000218,12935,,,1,CHEMBL618470,,,Canis lupus familiaris,N,1,1969.0,
8049,Plasma drug AUC in rat (PO dose),Autocuration,,,A,,BAO_0000218,14813,,,1,CHEMBL618471,,,,U,0,,
8050,Area under the tumor growth curve (AUC) in the B-6 Melanoma Model in C57/b1 mice at the dose of 1 mg/kg.,Intermediate,10090.0,,A,,BAO_0000218,15792,,,1,CHEMBL618472,,,Mus musculus,N,1,,
8051,Area under was determined at a dose of 30 mg/kg,Autocuration,,,A,,BAO_0000218,3579,,,1,CHEMBL618473,,,,U,0,,
8052,Average area under curve for compound at 1 mg/kg dose intravenous administration to Ferret,Intermediate,9669.0,,A,,BAO_0000218,12487,,,1,CHEMBL621699,,,Mustela putorius furo,N,1,,
8053,Average area under curve for the compound at 10 mg/kg dose after intraduodenal administration to rat,Intermediate,10116.0,,A,,BAO_0000218,12487,,,1,CHEMBL621700,,,Rattus norvegicus,N,1,,
8054,Average area under curve for the compound at 1 mg/kg dose after intravenous administration to rat,Intermediate,10116.0,,A,,BAO_0000218,12487,,,1,CHEMBL621701,,,Rattus norvegicus,N,1,,
8055,Average area under curve at 10 mg/kg dose after intraduodenal administration to Ferret,Intermediate,9669.0,,A,,BAO_0000218,12487,,,1,CHEMBL621702,,,Mustela putorius furo,N,1,,
8056,Average area under curve at 10 mg/kg intraduodenal administration to salt depleted dog,Intermediate,9615.0,,A,,BAO_0000218,12487,,,1,CHEMBL621703,,,Canis lupus familiaris,N,1,,
8057,Average area under curve at 1 mg/kg intravenous administration to salt depleted dog,Intermediate,9615.0,,A,,BAO_0000218,12487,,,1,CHEMBL621704,,,Canis lupus familiaris,N,1,,
8058,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 1.0(pmol/g/h)",Intermediate,10116.0,,A,,BAO_0000218,12902,,,1,CHEMBL624259,,,Rattus norvegicus,N,1,,
8059,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 2.0(pmol/g/h)",Intermediate,10116.0,,A,,BAO_0000218,12902,,,1,CHEMBL624260,,,Rattus norvegicus,N,1,,
8060,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 4.0(pmol/g/h)",Intermediate,10116.0,,A,,BAO_0000218,12902,,,1,CHEMBL624430,,,Rattus norvegicus,N,1,,
8061,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 5.0(pmol/g/h)",Intermediate,10116.0,,A,,BAO_0000218,12902,,,1,CHEMBL624431,,,Rattus norvegicus,N,1,,
8062,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 54.0(pmol/g/h)",Intermediate,10116.0,,A,,BAO_0000218,12902,,,1,CHEMBL624432,,,Rattus norvegicus,N,1,,
8063,"Bioavailability in male Sprague-Dawley rats, after the po administration at a dose of 10.0(pmol/g/h)",Intermediate,10116.0,,A,,BAO_0000218,12902,,,1,CHEMBL624433,,,Rattus norvegicus,N,1,,
8064,"Bioavailability in male Sprague-Dawley rats, after the po administration at a dose of 20.0(pmol/g/h)",Intermediate,10116.0,,A,,BAO_0000218,12902,,,1,CHEMBL624434,,,Rattus norvegicus,N,1,,
8065,"Bioavailability in male Sprague-Dawley rats, after the po administration at a dose of 40.0(pmol/g/h)",Intermediate,10116.0,,A,,BAO_0000218,12902,,,1,CHEMBL624435,,,Rattus norvegicus,N,1,,
8066,Bioavailability in mouse brain after intravenous administration of 105.1 mg/kg of dose,Intermediate,10090.0,,A,,BAO_0000218,12745,,,1,CHEMBL618570,,,Mus musculus,N,1,,
8067,Bioavailability in mouse brain after intravenous administration of equimolar doses of ( 2'F-ara-ddI + 2'F-ara-ddP),Intermediate,10090.0,,A,,BAO_0000218,12745,,,1,CHEMBL618571,,,Mus musculus,N,1,,
8068,Bioavailability in mouse brain after oral administration of 100 mg/kg of dose,Intermediate,10090.0,,A,,BAO_0000218,12745,,,1,CHEMBL618572,,,Mus musculus,N,1,,
8069,Bioavailability in mouse brain after oral administration of equimolar doses of ( 2'F-ara-ddI + 2'F-ara-ddP),Intermediate,10090.0,,A,,BAO_0000218,12745,,,1,CHEMBL618573,,,Mus musculus,N,1,,
8070,Bioavailability in mouse serum after intravenous administration of 105.1 mg/kg of dose,Intermediate,10090.0,,A,,BAO_0000218,12745,,,1,CHEMBL619267,,,Mus musculus,N,1,,
8071,Bioavailability in mouse serum after intravenous administration of equimolar doses of ( 2'F-ara-ddI + 2'F-ara-ddP),Intermediate,10090.0,,A,,BAO_0000218,12745,,,1,CHEMBL619431,,,Mus musculus,N,1,,
8072,Bioavailability in mouse serum after oral administration of 100 mg/kg of dose,Intermediate,10090.0,,A,,BAO_0000218,12745,,,1,CHEMBL619432,,,Mus musculus,N,1,,
8073,Bioavailability in mouse serum after oral administration of equimolar doses of ( 2'F-ara-ddI + 2'F-ara-ddP),Intermediate,10090.0,,A,,BAO_0000218,12745,,,1,CHEMBL619433,,,Mus musculus,N,1,,
8074,AUC in mice after oral dose (50 mg/kg),Autocuration,,,A,,BAO_0000218,13298,,,1,CHEMBL619434,,,,U,0,1969.0,
8075,Blood level after oral administration in mice (50 mg/kg) was determined by bioassay procedure and represent total activity present in the serum,Intermediate,10090.0,,A,,BAO_0000218,12226,,,1,CHEMBL619435,,,Mus musculus,N,1,1977.0,
8076,AUC (0-4 hr) ug/ml/h,Autocuration,,,A,,BAO_0000019,12634,,,1,CHEMBL619436,,,,U,0,1969.0,
8077,Compound at a dose of 10 mg/kg was orally administered to rats and Area under curve was reported,Intermediate,10116.0,,A,,BAO_0000218,14810,,,1,CHEMBL619437,,,Rattus norvegicus,N,1,,
8078,Compound evaluated for AUC = Area under the nucleoside serum or brain concentration versus time curve after iv administration,Autocuration,,,A,,BAO_0000218,13889,,,1,CHEMBL619438,,,,U,0,,
8079,Compound was evaluated for Area under curve in mice,Intermediate,10090.0,,A,,BAO_0000218,10018,,,1,CHEMBL619439,,,Mus musculus,N,1,,
8080,Compound was evaluated for area under curve doses in rat at 100 mg/kg po,Intermediate,10116.0,,A,,BAO_0000218,8758,,,1,CHEMBL619440,,,Rattus norvegicus,N,1,,
8081,Compound was evaluated for area under curve doses in rat at 100 mg/kg po,Autocuration,,,F,,BAO_0000218,8758,,,1,CHEMBL619441,,,,U,0,,
8082,Compound was evaluated for area under curve doses in rat at 50 mg/kg po,Intermediate,10116.0,,A,,BAO_0000218,8758,,,1,CHEMBL619442,,,Rattus norvegicus,N,1,,
8083,Compound was evaluated for area under curve of growth hormone release after chronic oral dosing at 0.5 mpk on day 1,Autocuration,,,A,,BAO_0000019,2249,,,1,CHEMBL875156,,,,U,0,,
8084,Compound was evaluated for area under curve of growth hormone release after chronic oral dosing at 0.5 mpk on day 4,Autocuration,,,A,,BAO_0000019,2249,,,1,CHEMBL619443,,,,U,0,,
8085,Compound was evaluated for area under curve of growth hormone release after chronic oral dosing at 1.0 mpk on day 1,Autocuration,,,A,,BAO_0000019,2249,,,1,CHEMBL619444,,,,U,0,,
8086,Compound was evaluated for area under curve of growth hormone release after chronic oral dosing at 1.0 mpk on day 4,Autocuration,,,A,,BAO_0000019,2249,,,1,CHEMBL623464,,,,U,0,,
8087,Compound was evaluated for area under curve when administered through oral route in mouse,Intermediate,10090.0,,A,,BAO_0000218,15115,,,1,CHEMBL623465,,,Mus musculus,N,1,,
8088,Plasma clearance after oral administration at a dose of 2 mg/kg in rat; no data,Intermediate,10116.0,,A,,BAO_0000218,6518,,,1,CHEMBL623466,,,Rattus norvegicus,N,1,,
8089,Plasma clearance after oral administration at a dose of 4 mg/kg in rat; no data,Intermediate,10116.0,,A,,BAO_0000218,6518,,,1,CHEMBL623467,,,Rattus norvegicus,N,1,,
8090,Plasma clearance in rat,Intermediate,10116.0,,A,,BAO_0000218,6249,,,1,CHEMBL623468,,,Rattus norvegicus,N,1,,
8091,Plasma clearance was evaluated in vivo in rat at a dose of 5 mg/kg by intra venous administration,Intermediate,10116.0,,A,,BAO_0000218,2463,,,1,CHEMBL622660,,,Rattus norvegicus,N,1,,
8092,Plasma clearance rate in Sprague-Dawley rats,Intermediate,10116.0,,A,,BAO_0000218,4969,,,1,CHEMBL622661,,,Rattus norvegicus,N,1,,
8093,CLtot at a dose of 4 mg/kg in Rat Plasma after iv administration,Intermediate,10116.0,,F,,BAO_0000218,17720,,,1,CHEMBL622662,,,Rattus norvegicus,N,1,,
8094,Pharmacokinetic property (total body clearance) in rat,Intermediate,10116.0,,A,,BAO_0000218,3457,,,1,CHEMBL622663,,,Rattus norvegicus,N,1,,
8095,Pharmacokinetic property (CLtot)of the compound was measured in rat at the dose of 0.32 mg/kg i.v.,Intermediate,10116.0,,A,,BAO_0000218,5983,,,1,CHEMBL622664,,,Rattus norvegicus,N,1,,
8096,In vivo concentration in rat liver exposure 0-8 hour after oral administration 50 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,6295,,,1,CHEMBL622665,,,Rattus norvegicus,N,1,,
8097,In vivo concentration in rat liver exposure 0-8 hour after oral administration 50 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,6296,,,1,CHEMBL622666,,,Rattus norvegicus,N,1,,
8098,Cl in rat i.v. at 2 mg/kg concentration,Intermediate,10116.0,,A,,BAO_0000218,17686,,,1,CHEMBL621615,,,Rattus norvegicus,N,1,,
8099,Clearance of compound after intravenous administration in rats at 24 uM/kg,Intermediate,10116.0,,A,,BAO_0000218,17764,,,1,CHEMBL621616,,,Rattus norvegicus,N,1,,
8100,Clearance was determined,Intermediate,10116.0,,A,,BAO_0000218,5503,,,1,CHEMBL621617,,,Rattus norvegicus,N,1,,
8101,Clearance by intravenous administration of 3.4 mg/kg in rat,Intermediate,10116.0,,A,,BAO_0000218,4368,,,1,CHEMBL621618,,,Rattus norvegicus,N,1,,
8102,Clearance was evaluated after i.v. administration in rat at a dose of 1 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,6005,,,1,CHEMBL621619,,,Rattus norvegicus,N,1,,
8103,Clearance rate after i.v. administration in rats,Intermediate,10116.0,,A,,BAO_0000218,5031,,,1,CHEMBL621620,,,Rattus norvegicus,N,1,,
8104,Clearance was determined after intravenous administration at a dose 5 mg/kg to male Sprague-Dawley rats,Intermediate,10116.0,,A,,BAO_0000218,4890,,,1,CHEMBL621786,,,Rattus norvegicus,N,1,,
8105,Clearance was determined by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat,Intermediate,10116.0,,A,,BAO_0000218,5182,,,1,CHEMBL621787,,,Rattus norvegicus,N,1,,
8106,Clearance (Cl) of compound after 2 h iv infusion of 8.4 mg/kg in three rat,Intermediate,10116.0,,A,,BAO_0000218,5979,,,1,CHEMBL621788,,,Rattus norvegicus,N,1,,
8107,Clearance (Cl) after oral administration in rat,Intermediate,10116.0,,A,,BAO_0000218,5656,,,1,CHEMBL621789,,,Rattus norvegicus,N,1,,
8108,Compound clearance in rats was measured after intravenous administration at 3 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,17804,,,1,CHEMBL621790,,,Rattus norvegicus,N,1,,
8109,Compound was tested for plasma clearance in rat,Intermediate,10116.0,,A,,BAO_0000218,4839,,,1,CHEMBL621791,,,Rattus norvegicus,N,1,1969.0,
8110,In vitro microsome metabolism clearance in rat was determined,Intermediate,10116.0,,A,,BAO_0000218,5041,Microsomes,,1,CHEMBL621792,,,Rattus norvegicus,N,1,,
8111,In vitro microsome metabolism clearance in rat was determined; ND denotes no data,Intermediate,10116.0,,A,,BAO_0000218,5041,Microsomes,,1,CHEMBL621793,,,Rattus norvegicus,N,1,,
8112,In vivo Clearance (Cl) was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,Intermediate,10116.0,,A,,BAO_0000218,5974,,,1,CHEMBL621794,,,Rattus norvegicus,N,1,,
8113,In vivo plasma clearance was determined,Intermediate,10116.0,,A,,BAO_0000218,5496,,,1,CHEMBL621795,,,Rattus norvegicus,N,1,1969.0,
8114,Pharmacokinetic property (Clearance) for the compound (5 mg/kg iv) was determined in rats,Intermediate,10116.0,,A,,BAO_0000218,5739,,,1,CHEMBL621796,,,Rattus norvegicus,N,1,,
8115,Pharmacokinetic property (Clearance) in rat hepatocyte i.v.,Intermediate,10116.0,,A,,BAO_0000218,5676,,401.0,1,CHEMBL621797,Hepatocyte,,Rattus norvegicus,N,1,2107.0,
8116,Pharmacokinetic property (Plasma clearance) was measured in rat,Intermediate,10116.0,,A,,BAO_0000218,4239,,,1,CHEMBL621798,,,Rattus norvegicus,N,1,,
8117,Pharmacokinetic property (clearance) in rat i.v.,Intermediate,10116.0,,A,,BAO_0000218,5676,,,1,CHEMBL621799,,,Rattus norvegicus,N,1,,
8118,"Plasma Clearance was evaluated in rats, iv",Intermediate,10116.0,,A,,BAO_0000218,1918,,,1,CHEMBL621800,,,Rattus norvegicus,N,1,,
8119,Plasma clearance (in vivo) in rats was determined,Intermediate,10116.0,,A,,BAO_0000218,17800,,,1,CHEMBL621801,,,Rattus norvegicus,N,1,,
8120,Plasma clearance for the compound was calculated at a single intravenous administration of 20 mg/kg in rat,Intermediate,10116.0,,A,,BAO_0000218,6056,,,1,CHEMBL621802,,,Rattus norvegicus,N,1,,
8121,Plasma clearance was determined,Intermediate,10116.0,,A,,BAO_0000218,5496,,,1,CHEMBL618596,,,Rattus norvegicus,N,1,,
8122,Plasma clearance in rat after peroral administration at 10 mg/kg concentration,Intermediate,10116.0,,A,,BAO_0000218,5939,,,1,CHEMBL618597,,,Rattus norvegicus,N,1,,
8123,Plasma clearance in rat after peroral administration at 5 mg/kg concentration,Intermediate,10116.0,,A,,BAO_0000218,5939,,,1,CHEMBL618598,,,Rattus norvegicus,N,1,,
8124,Plasma clearance in rats,Intermediate,10116.0,,A,,BAO_0000218,17752,,,1,CHEMBL618599,,,Rattus norvegicus,N,1,,
8125,Plasma clearance rate determined in rat,Intermediate,10116.0,,A,,BAO_0000218,4576,,,1,CHEMBL618600,,,Rattus norvegicus,N,1,,
8126,Plasma clearance was determined in rat,Intermediate,10116.0,,A,,BAO_0000218,6011,,,1,CHEMBL618601,,,Rattus norvegicus,N,1,,
8127,Plasma clearance was determined,Intermediate,10116.0,,A,,BAO_0000218,5510,,,1,CHEMBL618602,,,Rattus norvegicus,N,1,,
8128,Plasma clearance value in rat,Intermediate,10116.0,,A,,BAO_0000218,5948,,,1,CHEMBL618603,,,Rattus norvegicus,N,1,,
8129,Clearance rate constant using isolated perfused rat liver (IPRL) assay,Intermediate,10116.0,,A,,BAO_0000218,6125,,,1,CHEMBL618604,,,Rattus norvegicus,N,1,2107.0,
8130,Clearance in rat,Intermediate,10116.0,,A,,BAO_0000218,4839,,,1,CHEMBL618605,,,Rattus norvegicus,N,1,,
8131,Total body clearance in rat i.v. at 2 mg/kg concentration,Intermediate,10116.0,,A,,BAO_0000218,17686,,,1,CHEMBL618606,,,Rattus norvegicus,N,1,,
8132,Clearance of compound in rats after intravenous administration,Intermediate,10116.0,,A,,BAO_0000218,6571,,,1,CHEMBL618607,,,Rattus norvegicus,N,1,,
8133,Clearance after iv administration to rats,Intermediate,10116.0,,A,,BAO_0000218,3364,,,1,CHEMBL618608,,,Rattus norvegicus,N,1,,
8134,Clearance at an iv dose of 12 mg/Kg and po dose of 23 mg/Kg,Intermediate,10116.0,,A,,BAO_0000218,13569,,,1,CHEMBL618609,,,Rattus norvegicus,N,1,,
8135,Clearance at an iv dose of 14 mg/Kg and po dose of 15 mg/Kg,Intermediate,10116.0,,A,,BAO_0000218,13569,,,1,CHEMBL618610,,,Rattus norvegicus,N,1,,
8136,Clearance at an iv dose of 15 mg/Kg and po dose of 30 mg/Kg,Intermediate,10116.0,,A,,BAO_0000218,13569,,,1,CHEMBL618611,,,Rattus norvegicus,N,1,,
8137,Clearance at an iv dose of 15 mg/Kg and po dose of 30.2 mg/Kg,Intermediate,10116.0,,A,,BAO_0000218,13569,,,1,CHEMBL618612,,,Rattus norvegicus,N,1,,
8138,Clearance at an iv dose of 15.6 mg/Kg and po dose of 31.2 mg/Kg,Intermediate,10116.0,,A,,BAO_0000218,13569,,,1,CHEMBL618613,,,Rattus norvegicus,N,1,,
8139,Clearance at an iv dose of 15.7 mg/Kg and po dose of 31.4 mg/Kg,Intermediate,10116.0,,A,,BAO_0000218,13569,,,1,CHEMBL621076,,,Rattus norvegicus,N,1,,
8140,Clearance at an iv dose of 16 mg/Kg and po dose of 35 mg/Kg,Intermediate,10116.0,,A,,BAO_0000218,13569,,,1,CHEMBL621077,,,Rattus norvegicus,N,1,,
8141,"Clearance in fischer rats at 5 mg/kg dose, administered intravenously",Intermediate,10116.0,,A,,BAO_0000218,17670,,,1,CHEMBL621078,,,Rattus norvegicus,N,1,,
8142,Clearance in rat,Intermediate,10116.0,,A,,BAO_0000218,5970,,,1,CHEMBL621251,,,Rattus norvegicus,N,1,,
8143,Clearance in rat after oral administration at 10 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,6495,,,1,CHEMBL621252,,,Rattus norvegicus,N,1,,
8144,Clearance in rat.,Intermediate,10116.0,,A,,BAO_0000218,4590,,,1,CHEMBL621253,,,Rattus norvegicus,N,1,,
8145,Clearance rate following an oral dose of 20 mg/kg in rats,Intermediate,10116.0,,A,,BAO_0000218,6193,,,1,CHEMBL621254,,,Rattus norvegicus,N,1,,
8146,Compound was evaluated for the rate of clearance in rat upon intravenous administration.,Intermediate,10116.0,,A,,BAO_0000218,2832,,,1,CHEMBL621255,,,Rattus norvegicus,N,1,,
8147,Compound was tested for plasma clearance in rats after 5 mg/kg of intravenous dosing,Intermediate,10116.0,,A,,BAO_0000218,1052,,,1,CHEMBL621256,,,Rattus norvegicus,N,1,1969.0,
8148,Biodistribution in rat liver in the presence of GdDTPA-BDP at 1 hr,Intermediate,10116.0,,A,,BAO_0000218,9866,,,1,CHEMBL621257,,,Rattus norvegicus,N,1,2107.0,
8149,Biodistribution in rat liver in the presence of GdDTPA-BDP at 30 min,Intermediate,10116.0,,A,,BAO_0000218,9866,,,1,CHEMBL621258,,,Rattus norvegicus,N,1,2107.0,
8150,Biodistribution in rat liver in the presence of GdDTPA-BDP at 4 hr,Intermediate,10116.0,,A,,BAO_0000218,9866,,,1,CHEMBL621259,,,Rattus norvegicus,N,1,2107.0,
8151,Biodistribution in rat liver in the presence of GdDTPA-HPDP at 15 min,Intermediate,10116.0,,A,,BAO_0000218,9866,,,1,CHEMBL621260,,,Rattus norvegicus,N,1,2107.0,
8152,Biodistribution in rat liver in the presence of GdDTPA-HPDP at 1 hr,Intermediate,10116.0,,A,,BAO_0000218,9866,,,1,CHEMBL876494,,,Rattus norvegicus,N,1,2107.0,
8153,Biodistribution in rat liver in the presence of GdDTPA-HPDP at 30 min,Intermediate,10116.0,,A,,BAO_0000218,9866,,,1,CHEMBL621261,,,Rattus norvegicus,N,1,2107.0,
8154,Biodistribution in rat liver in the presence of GdDTPA-HPDP at 4 hr,Intermediate,10116.0,,A,,BAO_0000218,9866,,,1,CHEMBL621262,,,Rattus norvegicus,N,1,2107.0,
8155,Biodistribution in rat liver in the presence of NAC Gd/0.01 M GdDTPA-HPDP,Intermediate,10116.0,,A,,BAO_0000218,9866,,,1,CHEMBL621263,,,Rattus norvegicus,N,1,2107.0,
8156,Biodistribution in rat liver in the presence of NCA Gd/0.01 M lip,Intermediate,10116.0,,A,,BAO_0000218,9866,,,1,CHEMBL621264,,,Rattus norvegicus,N,1,2107.0,
8157,Biodistribution in rat muscle in the presence of 0.01 M GdDTPA-BDP,Intermediate,10116.0,,A,,BAO_0000218,9866,,,1,CHEMBL621265,,,Rattus norvegicus,N,1,2385.0,
8158,Biodistribution in rat muscle in the presence of 0.05 M Gd/0.15 M lig,Intermediate,10116.0,,A,,BAO_0000218,9866,,,1,CHEMBL621266,,,Rattus norvegicus,N,1,2385.0,
8159,Biodistribution in rat muscle in the presence of 0.05 M GdDTPA-BDP,Intermediate,10116.0,,A,,BAO_0000218,9866,,,1,CHEMBL621267,,,Rattus norvegicus,N,1,2385.0,
8160,Biodistribution in rat muscle in the presence of 0.10 M GdDTPA-BDP,Intermediate,10116.0,,A,,BAO_0000218,9866,,,1,CHEMBL621268,,,Rattus norvegicus,N,1,2385.0,
8161,Biodistribution in rat muscle in the presence of GdDTPA-BDP at 1 hr,Intermediate,10116.0,,A,,BAO_0000218,9866,,,1,CHEMBL621269,,,Rattus norvegicus,N,1,2385.0,
8162,Biodistribution in rat muscle in the presence of GdDTPA-BDP at 4 hr,Intermediate,10116.0,,A,,BAO_0000218,9866,,,1,CHEMBL621270,,,Rattus norvegicus,N,1,2385.0,
8163,Biodistribution in rat muscle in the presence of GdDTPA-BDPat 15 min,Intermediate,10116.0,,A,,BAO_0000218,9866,,,1,CHEMBL621271,,,Rattus norvegicus,N,1,2385.0,
8164,Biodistribution in rat muscle in the presence of GdDTPA-BDPat 30 min,Intermediate,10116.0,,A,,BAO_0000218,9866,,,1,CHEMBL621272,,,Rattus norvegicus,N,1,2385.0,
8165,Biodistribution in rat muscle in the presence of GdDTPA-HPDP at 1 hr,Intermediate,10116.0,,A,,BAO_0000218,9866,,,1,CHEMBL621273,,,Rattus norvegicus,N,1,2385.0,
8166,Biodistribution in rat muscle in the presence of GdDTPA-HPDP at 4 hr,Intermediate,10116.0,,A,,BAO_0000218,9866,,,1,CHEMBL621274,,,Rattus norvegicus,N,1,2385.0,
8167,Biodistribution in rat muscle in the presence of GdDTPA-HPDPat 15 min,Intermediate,10116.0,,A,,BAO_0000218,9866,,,1,CHEMBL876495,,,Rattus norvegicus,N,1,2385.0,
8168,Biodistribution in rat muscle in the presence of GdDTPA-HPDPat 30 min,Intermediate,10116.0,,A,,BAO_0000218,9866,,,1,CHEMBL621275,,,Rattus norvegicus,N,1,2385.0,
8169,Biodistribution in rat muscle in the presence of NCA Gd/0.01 M lip,Intermediate,10116.0,,A,,BAO_0000218,9866,,,1,CHEMBL621276,,,Rattus norvegicus,N,1,2385.0,
8170,Biodistribution in rat muscle in the presence of NCAGd/0.01 M lig,Intermediate,10116.0,,A,,BAO_0000218,9866,,,1,CHEMBL621277,,,Rattus norvegicus,N,1,2385.0,
8171,Biodistribution in rat s. intestine in the presence of 50 Gd/kg at 2 hr,Intermediate,10116.0,,A,,BAO_0000218,9866,,,1,CHEMBL621278,,,Rattus norvegicus,N,1,160.0,
8172,Biodistribution in rat s. intestine in the presence of 50 Gd/kg at 6 hr,Intermediate,10116.0,,A,,BAO_0000218,9866,,,1,CHEMBL621279,,,Rattus norvegicus,N,1,160.0,
8173,Biodistribution in rat s. intestine in the presence of NCA (No carrier added),Intermediate,10116.0,,A,,BAO_0000218,9866,,,1,CHEMBL621280,,,Rattus norvegicus,N,1,160.0,
8174,Biodistribution in rat spleen in the presence of 0.01 M GdDTPA-BDP,Intermediate,10116.0,,A,,BAO_0000218,9866,,,1,CHEMBL621281,,,Rattus norvegicus,N,1,2106.0,
8175,Biodistribution in rat spleen in the presence of 0.05 M Gd/0.15 M lig; ND=No data,Intermediate,10116.0,,A,,BAO_0000218,9866,,,1,CHEMBL621282,,,Rattus norvegicus,N,1,2106.0,
8176,Biodistribution in rat spleen in the presence of 0.05 M GdDTPA-BDP; ND=No data,Intermediate,10116.0,,A,,BAO_0000218,9866,,,1,CHEMBL621283,,,Rattus norvegicus,N,1,2106.0,
8177,Biodistribution in rat spleen in the presence of 0.10 M GdDTPA-BDP,Intermediate,10116.0,,A,,BAO_0000218,9866,,,1,CHEMBL621284,,,Rattus norvegicus,N,1,2106.0,
8178,Biodistribution in rat spleen in the presence of 50 Gd/kg at 15 min,Intermediate,10116.0,,A,,BAO_0000218,9866,,,1,CHEMBL621285,,,Rattus norvegicus,N,1,2106.0,
8179,Biodistribution in rat spleen in the presence of 50 Gd/kg at 2 hr,Intermediate,10116.0,,A,,BAO_0000218,9866,,,1,CHEMBL621286,,,Rattus norvegicus,N,1,2106.0,
8180,Biodistribution in rat spleen in the presence of 50 Gd/kg at 6 hr,Intermediate,10116.0,,A,,BAO_0000218,9866,,,1,CHEMBL623220,,,Rattus norvegicus,N,1,2106.0,
8181,Biodistribution in rat spleen in the presence of NCA Gd/0.01 M lip,Intermediate,10116.0,,A,,BAO_0000218,9866,,,1,CHEMBL623221,,,Rattus norvegicus,N,1,2106.0,
8182,Biodistribution in rat spleen in the presence of NCAGd/0.01 M lig,Intermediate,10116.0,,A,,BAO_0000218,9866,,,1,CHEMBL876029,,,Rattus norvegicus,N,1,2106.0,
8183,Biodistribution in rat stomach in the presence of 50 Gd/kg at 15 min,Intermediate,10116.0,,A,,BAO_0000218,9866,,,1,CHEMBL623222,,,Rattus norvegicus,N,1,945.0,
8184,Biodistribution in rat stomach in the presence of 50 Gd/kg at 2 hr,Intermediate,10116.0,,A,,BAO_0000218,9866,,,1,CHEMBL623223,,,Rattus norvegicus,N,1,945.0,
8185,Biodistribution in rat stomach in the presence of 50 Gd/kg at 6 h; ND=No data,Intermediate,10116.0,,A,,BAO_0000218,9866,,,1,CHEMBL621445,,,Rattus norvegicus,N,1,945.0,
8186,Biodistribution of [123I]-label in rat blood was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,Intermediate,10116.0,,A,,BAO_0000218,13950,,,1,CHEMBL621446,,,Rattus norvegicus,N,1,178.0,
8187,Biodistribution of [123I]-label in rat blood was reported at 1 hr post injection. Value shown is %ID/g of tissue,Intermediate,10116.0,,A,,BAO_0000218,13950,,,1,CHEMBL621447,,,Rattus norvegicus,N,1,178.0,
8188,Biodistribution of [123I]-label in rat blood was reported at 2 hr post injection. Value shown is %ID/g of tissue,Intermediate,10116.0,,A,,BAO_0000218,13950,,,1,CHEMBL619681,,,Rattus norvegicus,N,1,178.0,
8189,Biodistribution of [123I]-label in rat blood was reported at 24 hr post injection. Value shown is %ID/g of tissue,Intermediate,10116.0,,A,,BAO_0000218,13950,,,1,CHEMBL619682,,,Rattus norvegicus,N,1,178.0,
8190,Biodistribution of [123I]-label in rat blood was reported at 4 hr post injection. Value shown is %ID/g of tissue,Intermediate,10116.0,,A,,BAO_0000218,13950,,,1,CHEMBL619683,,,Rattus norvegicus,N,1,178.0,
8191,Biodistribution of [123I]-label in rat brain was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,Intermediate,10116.0,,A,,BAO_0000218,13950,,,1,CHEMBL619684,,,Rattus norvegicus,N,1,955.0,
8192,Biodistribution of [123I]-label in rat brain was reported at 1 hr post injection. Value shown is %ID/g of tissue,Intermediate,10116.0,,A,,BAO_0000218,13950,,,1,CHEMBL619685,,,Rattus norvegicus,N,1,955.0,
8193,Biodistribution of [123I]-label in rat brain was reported at 2 hr post injection. Value shown is %ID/g of tissue,Intermediate,10116.0,,A,,BAO_0000218,13950,,,1,CHEMBL619686,,,Rattus norvegicus,N,1,955.0,
8194,Biodistribution of [123I]-label in rat brain was reported at 24 hr post injection. Value shown is %ID/g of tissue,Intermediate,10116.0,,A,,BAO_0000218,13950,,,1,CHEMBL619687,,,Rattus norvegicus,N,1,955.0,
8195,Biodistribution of [123I]-label in rat brain was reported at 4 hr post injection. Value shown is %ID/g of tissue,Intermediate,10116.0,,A,,BAO_0000218,13950,,,1,CHEMBL619688,,,Rattus norvegicus,N,1,955.0,
8196,Biodistribution of [123I]-label in rat heart was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,Intermediate,10116.0,,A,,BAO_0000218,13950,,,1,CHEMBL619689,,,Rattus norvegicus,N,1,948.0,
8197,Biodistribution of [123I]-label in rat heart was reported at 1 hr post injection. Value shown is %ID/g of tissue,Intermediate,10116.0,,A,,BAO_0000218,13950,,,1,CHEMBL619690,,,Rattus norvegicus,N,1,948.0,
8198,Biodistribution of [123I]-label in rat heart was reported at 2 hr post injection. Value shown is %ID/g of tissue,Intermediate,10116.0,,A,,BAO_0000218,13950,,,1,CHEMBL619691,,,Rattus norvegicus,N,1,948.0,
8199,Terminal phase volume of distribution was measured in rat after an iv dose of 1 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,6062,,,1,CHEMBL619692,,,Rattus norvegicus,N,1,,
8200,Apparent volume of the central plasma compartment (Vc) of compound determined in rat after iv administration at a dose of 10 mg/kg,Expert,10116.0,,A,,BAO_0000218,3598,,,1,CHEMBL619693,,,Rattus norvegicus,N,1,,
8201,Vc value after IV dose at a dose of 5 mg/kg in rats.,Intermediate,10116.0,,A,,BAO_0000218,1908,,,1,CHEMBL619694,,,Rattus norvegicus,N,1,,
8202,Apparent volume of distribution at 10 mg/kg in rat upon intravenous administration,Intermediate,10116.0,,A,,BAO_0000218,17596,,,1,CHEMBL619695,,,Rattus norvegicus,N,1,,
8203,Compound was evaluated for pharmacokinetic parameter volume of distribution,Intermediate,10116.0,,A,,BAO_0000218,4891,,,1,CHEMBL619696,,,Rattus norvegicus,N,1,,
8204,Compound was evaluated for volume of distribution in rat,Intermediate,10116.0,,A,,BAO_0000218,740,,,1,CHEMBL619697,,,Rattus norvegicus,N,1,,
8205,Steady state volume distribution was determined; steady state(ss),Intermediate,10116.0,,A,,BAO_0000218,16366,,,1,CHEMBL619698,,,Rattus norvegicus,N,1,,
8206,Steady state volume of distribution after iv administration to rats,Intermediate,10116.0,,A,,BAO_0000218,3364,,,1,CHEMBL619699,,,Rattus norvegicus,N,1,,
8207,Steady state volume of distribution dosing at 3 mg/kg iv,Intermediate,10116.0,,A,,BAO_0000218,2552,,,1,CHEMBL619700,,,Rattus norvegicus,N,1,,
8208,The compound was evaluated for volume of distribution in rat,Intermediate,10116.0,,A,,BAO_0000218,406,,,1,CHEMBL619701,,,Rattus norvegicus,N,1,,
8209,The compound was tested for volume of distribution in rat,Intermediate,10116.0,,A,,BAO_0000218,12500,,,1,CHEMBL619702,,,Rattus norvegicus,N,1,,
8210,The compound was tested for volume of distribution in rat at dose of 3-10 mgkg,Intermediate,10116.0,,A,,BAO_0000218,12500,,,1,CHEMBL620335,,,Rattus norvegicus,N,1,,
8211,Volume distribution (VD) after oral administration in rat,Intermediate,10116.0,,A,,BAO_0000218,5656,,,1,CHEMBL620336,,,Rattus norvegicus,N,1,,
8212,Volume distribution of compound in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,17671,,,1,CHEMBL620337,,,Rattus norvegicus,N,1,,
8213,Volume distribution in rat,Intermediate,10116.0,,A,,BAO_0000218,1094,,,1,CHEMBL620520,,,Rattus norvegicus,N,1,,
8214,Volume distribution in rat,Intermediate,10116.0,,A,,BAO_0000218,5833,,,1,CHEMBL620521,,,Rattus norvegicus,N,1,,
8215,Volume distribution in rat after peroral administration at 10 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,5939,,,1,CHEMBL875825,,,Rattus norvegicus,N,1,,
8216,Volume distribution in rat after peroral administration at 5 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,5939,,,1,CHEMBL620522,,,Rattus norvegicus,N,1,,
8217,Volume distribution was evaluated after i.v. administration in rat at a dose of 1 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,6005,,,1,CHEMBL620523,,,Rattus norvegicus,N,1,,
8218,Volume of distribution in rat.,Intermediate,10116.0,,A,,BAO_0000218,1696,,,1,CHEMBL620524,,,Rattus norvegicus,N,1,,
8219,Volume of distribution in rat,Intermediate,10116.0,,A,,BAO_0000218,6672,,,1,CHEMBL620525,,,Rattus norvegicus,N,1,,
8220,Volume of distribution in rat,Intermediate,10116.0,,A,,BAO_0000218,6673,,,1,CHEMBL620526,,,Rattus norvegicus,N,1,,
8221,Volume of distribution in rat by iv administration,Intermediate,10116.0,,A,,BAO_0000218,5871,,,1,CHEMBL620527,,,Rattus norvegicus,N,1,,
8222,Volume of distribution in rats,Intermediate,10116.0,,A,,BAO_0000218,6803,,,1,CHEMBL620528,,,Rattus norvegicus,N,1,,
8223,Volume of distribution was determined in female Sprague-Dawley rats following intravenous (iv) administration of drug (1 mg/kg).,Intermediate,10116.0,,A,,BAO_0000218,5199,,,1,CHEMBL620529,,,Rattus norvegicus,N,1,,
8224,Volume distribution at the dose of 2 mg/kg in rat,Intermediate,10116.0,,A,,BAO_0000218,4727,,,1,CHEMBL620530,,,Rattus norvegicus,N,1,,
8225,Steady state volume of distribution was determined,Intermediate,10116.0,,A,,BAO_0000218,16367,,,1,CHEMBL620531,,,Rattus norvegicus,N,1,,
8226,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,Intermediate,9544.0,,A,,BAO_0000218,5005,,,1,CHEMBL620532,,,Macaca mulatta,U,0,,
8227,Compound was tested for its plasma volume distribution in Sprague Dawley rats,Intermediate,10116.0,,A,,BAO_0000218,5005,,,1,CHEMBL620533,,,Rattus norvegicus,U,0,,
8228,Compound was tested for its plasma volume distribution in Sprague Dawley rats; ND is not determined,Intermediate,10116.0,,A,,BAO_0000218,5005,,,1,CHEMBL620534,,,Rattus norvegicus,U,0,,
8229,Mean (%CV) PK parameters for Vdss(mL/kg).,Intermediate,10116.0,,A,,BAO_0000218,15765,,,1,CHEMBL620535,,,Rattus norvegicus,N,1,,
8230,Pharmacokinetic parameter Vdss was determined at 2 mg/kg i.v. dose in rats,Intermediate,10116.0,,A,,BAO_0000218,2792,,,1,CHEMBL875826,,,Rattus norvegicus,N,1,,
8231,Pharmacokinetic parameter Vdss was determined at 5 mg/kg i.v. dose in rats,Intermediate,10116.0,,A,,BAO_0000218,2792,,,1,CHEMBL620536,,,Rattus norvegicus,N,1,,
8232,Pharmacokinetic parameter volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Sprague-Dawley rat,Intermediate,10116.0,,A,,BAO_0000218,5334,,,1,CHEMBL620537,,,Rattus norvegicus,N,1,,
8233,Pharmacokinetic parameter volume of distribution was reported in Sprague-Dawley rat; ND=Not determined,Intermediate,10116.0,,A,,BAO_0000218,5334,,,1,CHEMBL618526,,,Rattus norvegicus,N,1,,
8234,Pharmacokinetic property (Vdss) for the compound (5 mg/kg iv) was determined in rats,Intermediate,10116.0,,A,,BAO_0000218,5739,,,1,CHEMBL618527,,,Rattus norvegicus,N,1,,
8235,Pharmacokinetic property (Vdss) in rat,Intermediate,10116.0,,A,,BAO_0000218,5789,,,1,CHEMBL618528,,,Rattus norvegicus,N,1,,
8236,Pharmacokinetic property (vdss) was measured in rat,Intermediate,10116.0,,A,,BAO_0000218,4239,,,1,CHEMBL618529,,,Rattus norvegicus,N,1,,
8237,Steady state volume of distribution for the compound after intravenous administration of 1 mg/kg in rat,Intermediate,10116.0,,A,,BAO_0000218,4709,,,1,CHEMBL618530,,,Rattus norvegicus,N,1,,
8238,Volume of distribution in rat,Intermediate,10116.0,,A,,BAO_0000218,6642,,,1,CHEMBL618531,,,Rattus norvegicus,N,1,,
8239,The pharmacokinetic parameter volume of distribution in vivo in rats,Intermediate,10116.0,,A,,BAO_0000218,5247,,,1,CHEMBL618532,,,Rattus norvegicus,N,1,,
8240,Vdss at a dose of 4 mg/kg in Rat Plasma after iv administration,Intermediate,10116.0,,F,,BAO_0000218,17720,,,1,CHEMBL618533,,,Rattus norvegicus,N,1,,
8241,Vdss in rat i.v. at 2 mg/kg concentration,Intermediate,10116.0,,A,,BAO_0000218,17686,,,1,CHEMBL618534,,,Rattus norvegicus,N,1,,
8242,Volume distribution after intravenous administration (1 mg/kg) in rat,Intermediate,10116.0,,A,,BAO_0000218,4689,,,1,CHEMBL618535,,,Rattus norvegicus,N,1,,
8243,Volume distribution of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 16 mg/kg peroral administration,Intermediate,10116.0,,A,,BAO_0000218,5654,,,1,CHEMBL618536,,,Rattus norvegicus,N,1,,
8244,Volume distribution of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 20 mg/kg peroral administration,Intermediate,10116.0,,A,,BAO_0000218,5654,,,1,CHEMBL618537,,,Rattus norvegicus,N,1,,
8245,Volume distribution at a dose of 10 uM/kg in rat was determined,Intermediate,10116.0,,A,,BAO_0000218,4527,,,1,CHEMBL618538,,,Rattus norvegicus,N,1,,
8246,Volume distribution in rat after 5 mg/kg by oral and 1 mg/kg by intravenous administration,Intermediate,10116.0,,A,,BAO_0000218,4521,,,1,CHEMBL618539,,,Rattus norvegicus,N,1,,
8247,Volume distribution was calculated in rat,Intermediate,10116.0,,A,,BAO_0000218,6057,,,1,CHEMBL618540,,,Rattus norvegicus,N,1,,
8248,Volume distribution was determined,Intermediate,10116.0,,A,,BAO_0000218,5510,,,1,CHEMBL618541,,,Rattus norvegicus,N,1,,
8249,Volume of distribution after intravenous administration was evaluated in rat,Intermediate,10116.0,,A,,BAO_0000218,2938,,,1,CHEMBL618542,,,Rattus norvegicus,N,1,,
8250,Volume of distribution at steady state was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,Intermediate,10116.0,,A,,BAO_0000218,6679,,,1,CHEMBL622544,,,Rattus norvegicus,N,1,,
8251,"Volume of distribution at steady state was determined in rats at 10 mg/kg, p.o. dose; n/a: not applicable",Intermediate,10116.0,,A,,BAO_0000218,6685,,,1,CHEMBL622545,,,Rattus norvegicus,N,1,,
8252,"Volume of distribution at steady state was determined in rats at 20 mg/kg, i.p. dose; n/a: not applicable",Intermediate,10116.0,,A,,BAO_0000218,6685,,,1,CHEMBL622546,,,Rattus norvegicus,N,1,,
8253,"Volume of distribution at steady state was determined in rats at 2 mg/kg, i.v. dose",Intermediate,10116.0,,A,,BAO_0000218,6685,,,1,CHEMBL622547,,,Rattus norvegicus,N,1,,
8254,Volume of distribution in steady state was determined in rat,Intermediate,10116.0,,A,,BAO_0000218,5145,,,1,CHEMBL622548,,,Rattus norvegicus,N,1,,
8255,Volume of distribution in steady state was determined in rats at the dose of 1.0 mpk by i.v. administration,Intermediate,10116.0,,A,,BAO_0000218,6467,,,1,CHEMBL622549,,,Rattus norvegicus,N,1,,
8256,Volume of distribution in steady state was determined in rats at the dose of 1.0 mpk by i.v. administration; ND= not determined,Intermediate,10116.0,,A,,BAO_0000218,6467,,,1,CHEMBL622550,,,Rattus norvegicus,N,1,,
8257,Compound was evaluated for area under curve when administered through oral route to mouse,Intermediate,10090.0,,A,,BAO_0000218,15115,,,1,CHEMBL622551,,,Mus musculus,N,1,,
8258,Compound was evaluated for area under curve doses in rat at 100 mg/kg po,Intermediate,10116.0,,A,,BAO_0000218,8758,,,1,CHEMBL622552,,,Rattus norvegicus,N,1,,
8259,Compound was evaluated for area under curve doses in rat at 50 mg/kg po,Intermediate,10116.0,,A,,BAO_0000218,8758,,,1,CHEMBL622553,,,Rattus norvegicus,N,1,,
8260,Compound was evaluated for its bioavailability after oral administration (100 mg) to Beagle dogs,Autocuration,,,F,,BAO_0000218,8267,,,1,CHEMBL622554,,,,U,0,,
8261,Compound was evaluated for its bioavailability after oral administration (200 mg) to Beagle dogs,Intermediate,9615.0,,A,,BAO_0000218,8267,,,1,CHEMBL622555,,,Canis lupus familiaris,N,1,,
8262,Compound was evaluated for the area under the concentration - time curve by administering intravenously at 25 mg/kg in mice,Intermediate,10090.0,,A,,BAO_0000218,14239,,,1,CHEMBL622556,,,Mus musculus,N,1,,
8263,Compound was evaluated for the area under the concentration - time curve by administering orally at 25 mg/kg in mice,Intermediate,10090.0,,A,,BAO_0000218,14239,,,1,CHEMBL622557,,,Mus musculus,N,1,,
8264,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration using Area under the time-concentration curve after 40 mg/kg intramuscular administration to mice,Intermediate,10090.0,,A,,BAO_0000218,10754,,,1,CHEMBL622558,,,Mus musculus,N,1,178.0,
8265,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration using Area under the time-concentration curve after 40 mg/kg peroral administration to mice,Intermediate,10090.0,,A,,BAO_0000218,10754,,,1,CHEMBL622559,,,Mus musculus,N,1,178.0,
8266,Compound was evaluated in vivo in for its concentration using Area under the time-concentration curve after 40 mg/kg peroral administration to dogs.,Intermediate,9615.0,,A,,BAO_0000218,10754,,,1,CHEMBL622560,,,Canis lupus familiaris,N,1,,
8267,Compound was tested for area under concentration -time curve from time 0 to time infinity in three male Wistar rats at a single 5 mg/kg oral gavage dose,Intermediate,10116.0,,A,,BAO_0000218,14681,,,1,CHEMBL622561,,,Rattus norvegicus,N,1,,
8268,Compound was tested for area under concentration -time curve from time 0 to time infinity in three male Wistar rats at a single 5 mg/kg oral gavage dose. ,Intermediate,10116.0,,A,,BAO_0000218,14681,,,1,CHEMBL622562,,,Rattus norvegicus,N,1,,
8269,Compound was tested for area under concentration -time curve from time 0 to time of last detectable concentration in three male Wistar rats at a single 5 mg/kg oral gavage dose,Intermediate,10116.0,,A,,BAO_0000218,14681,,,1,CHEMBL622563,,,Rattus norvegicus,N,1,,
8270,Concentration of compound in Central nervous system,Autocuration,,,A,,BAO_0000019,13118,,,1,CHEMBL622564,,,,U,0,,
8271,Concentration of compound in Central nervous system; Not detectable,Autocuration,,,A,,BAO_0000019,13118,,,1,CHEMBL622565,,,,U,0,,
8272,"Concentration of diester in the blood, following oral administration in mice",Intermediate,10090.0,,A,,BAO_0000218,13318,,,1,CHEMBL622566,,,Mus musculus,N,1,,
8273,"Concentration of monoester in the blood, following oral administration in mice",Intermediate,10090.0,,A,,BAO_0000218,13318,,,1,CHEMBL624515,,,Mus musculus,N,1,,
8274,Concentration of the 9-[2-(Phosphonomethoxy)ethoxy]adenine in the blood following oral administration in mice,Intermediate,10090.0,,A,,BAO_0000218,13318,,,1,CHEMBL624516,,,Mus musculus,N,1,,
8275,Evaluated for Pharmacokinetic property: Area under the curve,Autocuration,,,A,,BAO_0000019,15692,,,1,CHEMBL624517,,,,U,0,,
8276,In vivo antitumor efficacy expressed as plasma area under the curve 0.4 hr after a peroral dose of 25 mg/kg in nude mice,Intermediate,10090.0,,A,,BAO_0000218,14839,,,1,CHEMBL624518,,,Mus musculus,N,1,,
8277,In vivo antitumor efficacy expressed as plasma area under the curve 0.4 hr after iv dose of 25 mg/kg in nude mice,Intermediate,9541.0,,A,,BAO_0000218,14839,,,1,CHEMBL624519,,,Macaca fascicularis,N,1,,
8278,In vivo antitumor efficacy in cynomolgus monkeys 0-48 hr after iv dose of 5 mg/kg expressed as Area under the curve,Intermediate,9541.0,,A,,BAO_0000218,14839,,,1,CHEMBL624520,,,Macaca fascicularis,N,1,,
8279,In vivo antitumor efficacy in cynomolgus monkeys 0-48 hr after peroral dose of 10 mg/kg expressed as Area under the curve,Intermediate,9541.0,,A,,BAO_0000218,14839,,,1,CHEMBL624521,,,Macaca fascicularis,N,1,,
8280,In vivo antitumor efficacy in cynomolgus monkeys 0-48 hr after peroral dose of 5 mg/kg expressed as Area under the curve,Intermediate,9541.0,,A,,BAO_0000218,14839,,,1,CHEMBL624522,,,Macaca fascicularis,N,1,,
8281,In vivo antitumor efficacy in cynomolgus monkeys 0-8 hours after peroral dose of 25 mg/kg expressed as Area under the curve,Intermediate,9541.0,,A,,BAO_0000218,14839,,,1,CHEMBL624523,,,Macaca fascicularis,N,1,,
8282,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 10 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-8 hr)",Intermediate,9541.0,,A,,BAO_0000218,14839,,,1,CHEMBL624409,,,Macaca fascicularis,N,1,,
8283,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as HCl salt in saline solution, iv and the total drug exposure was determined. (0-8 hr)",Intermediate,9541.0,,A,,BAO_0000218,14839,,,1,CHEMBL624410,,,Macaca fascicularis,N,1,,
8284,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-8 hr)",Intermediate,9541.0,,A,,BAO_0000218,14839,,,1,CHEMBL624411,,,Macaca fascicularis,N,1,,
8285,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as the micronised free base in corn oil, iv and the total drug exposure was determined. (0-8 hr)",Intermediate,9541.0,,A,,BAO_0000218,14839,,,1,CHEMBL623531,,,Macaca fascicularis,N,1,,
8286,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as the micronised free base in corn oil, perorally and the total drug exposure was determined (0-8 hr)",Intermediate,9541.0,,A,,BAO_0000218,14839,,,1,CHEMBL623532,,,Macaca fascicularis,N,1,,
8287,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 5 mg/kg, as HCl salt in saline solution, intravenously and the total drug exposure was determined (0-8 hr)",Intermediate,9541.0,,A,,BAO_0000218,14839,,,1,CHEMBL623533,,,Macaca fascicularis,N,1,,
8288,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 5 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-8 hr)",Intermediate,9541.0,,A,,BAO_0000218,14839,,,1,CHEMBL623534,,,Macaca fascicularis,N,1,,
8289,In vivo antitumor efficacy in nude mice 0-24 hr after intravenous dose of 25 mg/kg expressed as Area under the curve,Intermediate,10090.0,,A,,BAO_0000218,14839,,,1,CHEMBL623535,,,Mus musculus,N,1,,
8290,In vivo antitumor efficacy in nude mice 0-24 hr after iperoral dose of 25 mg/kg expressed as Area under the curve,Intermediate,10090.0,,A,,BAO_0000218,14839,,,1,CHEMBL623536,,,Mus musculus,N,1,,
8291,In vivo antitumor efficacy in nude mice 0-24 hr after iv dose of 25 mg/kg expressed as Area under the curve,Intermediate,10090.0,,A,,BAO_0000218,14839,,,1,CHEMBL623537,,,Mus musculus,N,1,,
8292,In vivo antitumor efficacy in nude mice 0-24 hr after peroral dose of 25 mg/kg expressed as Area under the curve,Intermediate,10090.0,,A,,BAO_0000218,14839,,,1,CHEMBL623538,,,Mus musculus,N,1,,
8293,In vivo antitumor efficacy in nude mice after peroral dose of 10 mg/kg expressed as Area under the curve,Intermediate,10090.0,,A,,BAO_0000218,14839,,,1,CHEMBL623539,,,Mus musculus,N,1,,
8294,In vivo antitumor efficacy in nude mice after peroral dose of 25 mg/kg expressed as Area under the curve,Intermediate,10090.0,,A,,BAO_0000218,14839,,,1,CHEMBL623540,,,Mus musculus,N,1,,
8295,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, iv and the total drug exposure was determined.",Intermediate,10090.0,,A,,BAO_0000218,14839,,,1,CHEMBL623541,,,Mus musculus,N,1,,
8296,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, iv and the total drug exposure was determined. (0-24hr)",Intermediate,10090.0,,A,,BAO_0000218,14839,,,1,CHEMBL623542,,,Mus musculus,N,1,,
8297,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, iv and the total drug exposure was determined. (0-4 hr)",Intermediate,10090.0,,A,,BAO_0000218,14839,,,1,CHEMBL623543,,,Mus musculus,N,1,,
8298,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined",Intermediate,10090.0,,A,,BAO_0000218,14839,,,1,CHEMBL623544,,,Mus musculus,N,1,,
8299,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-24hr)",Intermediate,10090.0,,A,,BAO_0000218,14839,,,1,CHEMBL623545,,,Mus musculus,N,1,,
8300,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-4 hr)",Intermediate,10090.0,,A,,BAO_0000218,14839,,,1,CHEMBL623546,,,Mus musculus,N,1,,
8301,Evaluated for plasma clearance after iv administration of 5 mg/kg to male Sprague-Dawley rats,Intermediate,10116.0,,A,,BAO_0000218,5408,,,1,CHEMBL623547,,,Rattus norvegicus,N,1,1969.0,
8302,High i.v. clearance in Dawley rats,Intermediate,10116.0,,A,,BAO_0000218,6827,,,1,CHEMBL623548,,,Rattus norvegicus,N,1,,
8303,In vitro clearance in rat liver microsomes,Intermediate,10116.0,,A,,BAO_0000218,17538,Microsomes,,1,CHEMBL623549,,,Rattus norvegicus,N,1,2107.0,
8304,Intrinsic clearance in rat liver microsomes was determined,Intermediate,10116.0,,A,,BAO_0000218,6331,Microsomes,,1,CHEMBL623550,,,Rattus norvegicus,N,1,2107.0,
8305,Intrinsic clearance in rat hepatocytes was determined,Intermediate,10116.0,,A,,BAO_0000218,5948,,401.0,1,CHEMBL875276,Hepatocyte,,Rattus norvegicus,N,1,2107.0,
8306,Plasma Clearance was determined,Intermediate,10116.0,,A,,BAO_0000218,4026,,,1,CHEMBL621872,,,Rattus norvegicus,N,1,,
8307,Plasma clearance after intravenous administration of 0.4 mg/kg of dose in rats was determined,Intermediate,10116.0,,A,,BAO_0000218,6647,,,1,CHEMBL621873,,,Rattus norvegicus,N,1,,
8308,Plasma clearance in rat.,Intermediate,10116.0,,A,,BAO_0000218,1696,,,1,CHEMBL621874,,,Rattus norvegicus,N,1,,
8309,Plasma clearance in rats,Intermediate,10116.0,,A,,BAO_0000218,6597,,,1,CHEMBL621875,,,Rattus norvegicus,N,1,,
8310,Plasma clearance was estimated from the AUC after 5 mg/kg intravenous dosing in rats,Intermediate,10116.0,,A,,BAO_0000218,347,,,1,CHEMBL621876,,,Rattus norvegicus,N,1,,
8311,Plasma clearance was evaluated after 10 uM/kg of intra arterial administration,Intermediate,10116.0,,A,,BAO_0000218,16423,,,1,CHEMBL621877,,,Rattus norvegicus,N,1,,
8312,Plasma clearance was measured in rat,Intermediate,10116.0,,A,,BAO_0000218,2879,,,1,CHEMBL621878,,,Rattus norvegicus,N,1,,
8313,Clearance after iv administration to Sprague-Dawley rat at dosage of 0.2 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,4883,,,1,CHEMBL621879,,,Rattus norvegicus,N,1,,
8314,"Tested for the plasma clearance in Dawley rat at a dose of 1 mg/kg intravenous, 2 mg/kg orally",Intermediate,10116.0,,A,,BAO_0000218,5328,,,1,CHEMBL621880,,,Rattus norvegicus,N,1,1969.0,
8315,The clearance rate in mature male rat at a intravenous dose of 3 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,5160,,,1,CHEMBL621881,,,Rattus norvegicus,N,1,,
8316,Total body clearance was evaluated for the compound after i.v. administration at a dose of 5 mg/kg was measured in rats,Intermediate,10116.0,,A,,BAO_0000218,17582,,,1,CHEMBL621882,,,Rattus norvegicus,N,1,,
8317,Total clearance at 1 mg/kg was determined in rat,Intermediate,10116.0,,A,,BAO_0000218,17651,,,1,CHEMBL875283,,,Rattus norvegicus,N,1,,
8318,Total clearance at 10 mg/kg was determined in rat,Intermediate,10116.0,,A,,BAO_0000218,17651,,,1,CHEMBL621883,,,Rattus norvegicus,N,1,,
8319,Clearance in rat,Intermediate,10116.0,,A,,BAO_0000218,6596,,,1,CHEMBL621884,,,Rattus norvegicus,N,1,,
8320,Plasma clearance rate determined in rats,Intermediate,10116.0,,A,,BAO_0000218,4796,,,1,CHEMBL621885,,,Rattus norvegicus,N,1,,
8321,Clearance of compound in rat was evaluated,Intermediate,10116.0,,A,,BAO_0000218,6850,,,1,CHEMBL621886,,,Rattus norvegicus,N,1,,
8322,Plasma concentration in rats after 7 hr at 30mg/kg oral dose,Intermediate,10116.0,,A,,BAO_0000218,5932,,,1,CHEMBL621887,,,Rattus norvegicus,N,1,1969.0,
8323,Pharmacokinetic property (blood clearance) in rat,Intermediate,10116.0,,A,,BAO_0000218,3371,,,1,CHEMBL621888,,,Rattus norvegicus,N,1,,
8324,Plasma clearance in rat,Intermediate,10116.0,,A,,BAO_0000218,2083,,,1,CHEMBL621889,,,Rattus norvegicus,N,1,,
8325,Plasma clearance in rats,Intermediate,10116.0,,A,,BAO_0000218,4942,,,1,CHEMBL621890,,,Rattus norvegicus,N,1,,
8326,Intrinsic clearance of compound against NADPH-fortified rat liver microsomes,Intermediate,10116.0,,A,,BAO_0000218,6838,Microsomes,,1,CHEMBL621891,,,Rattus norvegicus,N,1,2107.0,
8327,Clearance in Dawley rat,Intermediate,10116.0,,A,,BAO_0000218,5353,,,1,CHEMBL621892,,,Rattus norvegicus,N,1,,
8328,Clearance rat,Intermediate,10116.0,,A,,BAO_0000218,6641,,,1,CHEMBL621893,,,Rattus norvegicus,N,1,,
8329,Clearance rat (dosed at 0.5 mpk IV and 2.0 mpk po.),Intermediate,10116.0,,A,,BAO_0000218,6641,,,1,CHEMBL621894,,,Rattus norvegicus,N,1,,
8330,Clearance rat; Not determined,Intermediate,10116.0,,A,,BAO_0000218,6641,,,1,CHEMBL621895,,,Rattus norvegicus,N,1,,
8331,Clearance rate was determined in rat at a dose of 1 mpk i.v.,Intermediate,10116.0,,A,,BAO_0000218,6444,,,1,CHEMBL875284,,,Rattus norvegicus,N,1,,
8332,Clearance rate was determined in rat at a dose of 1 mpk i.v.; ND means not determined,Intermediate,10116.0,,A,,BAO_0000218,6444,,,1,CHEMBL618699,,,Rattus norvegicus,N,1,,
8333,Clearance rate was determined in rat at a dose of 1 mpk i.v.; ND=not determined,Intermediate,10116.0,,A,,BAO_0000218,6444,,,1,CHEMBL618700,,,Rattus norvegicus,N,1,,
8334,Clearance was determined by iv administration (1.5 mg/kg) in fasted male Sprague-Dawley rats,Intermediate,10116.0,,A,,BAO_0000218,6211,,,1,CHEMBL618701,,,Rattus norvegicus,N,1,,
8335,"Clearance in plasma calculated from Time-Course plasma concentrations in rats at a dose of 2.5 mg/kg, iv",Intermediate,10116.0,,A,,BAO_0000218,12873,,,1,CHEMBL876600,,,Rattus norvegicus,N,1,1969.0,
8336,Clearance of compound in rat after 1 mg/kg i.v. administration,Intermediate,10116.0,,A,,BAO_0000218,6570,,,1,CHEMBL618702,,,Rattus norvegicus,N,1,,
8337,Compound was evaluated for Hepatic clearance in rat,Intermediate,10116.0,,A,,BAO_0000218,3341,,,1,CHEMBL618703,,,Rattus norvegicus,N,1,,
8338,In vivo clearance after 5 mg/kg dose,Intermediate,10116.0,,A,,BAO_0000218,4891,,,1,CHEMBL618704,,,Rattus norvegicus,N,1,,
8339,Compound was tested for plasma clearance in rats,Intermediate,10116.0,,A,,BAO_0000218,1094,,,1,CHEMBL618705,,,Rattus norvegicus,N,1,1969.0,
8340,Hepatic clearance after intravenous administration was evaluated in rat,Intermediate,10116.0,,A,,BAO_0000218,2938,,,1,CHEMBL618706,,,Rattus norvegicus,N,1,,
8341,Lower clearance in rat (i.v.) at 0.5 mpk,Intermediate,10116.0,,A,,BAO_0000218,17853,,,1,CHEMBL618707,,,Rattus norvegicus,N,1,,
8342,Pharmacokinetic parameter expressed as plasma clearance in rat,Intermediate,10116.0,,A,,BAO_0000218,6049,,,1,CHEMBL618708,,,Rattus norvegicus,N,1,1969.0,
8343,Pharmacokinetic property (Clp) in rat,Intermediate,10116.0,,A,,BAO_0000218,5789,,,1,CHEMBL618709,,,Rattus norvegicus,N,1,,
8344,Plasma clearance in Sprague-Dawley rats,Intermediate,10116.0,,A,,BAO_0000218,4514,,,1,CHEMBL618710,,,Rattus norvegicus,N,1,,
8345,Plasma clearance (Clp) in rat,Intermediate,10116.0,,A,,BAO_0000218,6448,,,1,CHEMBL618711,,,Rattus norvegicus,N,1,,
8346,Plasma clearance for the compound was measured in rat after an iv dose of 1 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,6062,,,1,CHEMBL618712,,,Rattus norvegicus,N,1,,
8347,Plasma clearance in fasted male Sprague dawely rats on administration of 0.5 mg/Kg i.v. of the compound,Intermediate,10116.0,,A,,BAO_0000218,5710,,,1,CHEMBL618713,,,Rattus norvegicus,N,1,,
8348,Plasma clearance after intravenous administration of 1 mg/kg in rat,Intermediate,10116.0,,A,,BAO_0000218,4709,,,1,CHEMBL618714,,,Rattus norvegicus,N,1,,
8349,Plasma clearance in rat after 5 mg/kg by oral and 1 mg/kg by intravenous administration,Intermediate,10116.0,,A,,BAO_0000218,4521,,,1,CHEMBL618715,,,Rattus norvegicus,N,1,,
8350,Plasma clearance in rat was determined,Intermediate,10116.0,,A,,BAO_0000218,1742,,,1,CHEMBL618716,,,Rattus norvegicus,N,1,,
8351,Plasma clearance measured in rat,Intermediate,10116.0,,A,,BAO_0000218,6057,,,1,CHEMBL876601,,,Rattus norvegicus,N,1,,
8352,Plasma clearance was calculated in rat,Intermediate,10116.0,,A,,BAO_0000218,6057,,,1,CHEMBL618717,,,Rattus norvegicus,N,1,,
8353,Plasma clearance in rat,Intermediate,10116.0,,A,,BAO_0000218,5145,,,1,CHEMBL618718,,,Rattus norvegicus,N,1,,
8354,Plasma clearance in rat,Intermediate,10116.0,,A,,BAO_0000218,5833,,,1,CHEMBL618719,,,Rattus norvegicus,N,1,,
8355,Plasma clearance in rat,Intermediate,10116.0,,A,,BAO_0000218,6453,,,1,CHEMBL618720,,,Rattus norvegicus,N,1,,
8356,Plasma clearance in rat,Intermediate,10116.0,,A,,BAO_0000218,6640,,,1,CHEMBL618721,,,Rattus norvegicus,N,1,,
8357,Plasma clearance in rats,Intermediate,10116.0,,A,,BAO_0000218,6305,,,1,CHEMBL621477,,,Rattus norvegicus,N,1,,
8358,Plasma clearance in rat,Intermediate,10116.0,,A,,BAO_0000218,6642,,,1,CHEMBL621478,,,Rattus norvegicus,N,1,,
8359,Plasma clearance was evaluated in rat,Intermediate,10116.0,,A,,BAO_0000218,5472,,,1,CHEMBL621479,,,Rattus norvegicus,N,1,,
8360,Plasma clearance was evaluated in rat; Not tested,Intermediate,10116.0,,A,,BAO_0000218,5472,,,1,CHEMBL621480,,,Rattus norvegicus,N,1,,
8361,Plasma clearance rate was determined for the compound in rat,Intermediate,10116.0,,A,,BAO_0000218,5144,,,1,CHEMBL621481,,,Rattus norvegicus,N,1,,
8362,"Plasma clearance rate was determined in rats at 10mg/kg, p.o. dose; n/a: not applicable",Intermediate,10116.0,,A,,BAO_0000218,6685,,,1,CHEMBL621482,,,Rattus norvegicus,N,1,,
8363,"Plasma clearance rate was determined in rats at 20 mg/kg, i.p. dose; n/a: not applicable",Intermediate,10116.0,,A,,BAO_0000218,6685,,,1,CHEMBL621483,,,Rattus norvegicus,N,1,,
8364,"Plasma clearance rate was determined in rats at 2 mg/kg, i.v. dose",Intermediate,10116.0,,A,,BAO_0000218,6685,,,1,CHEMBL621484,,,Rattus norvegicus,N,1,,
8365,Biodistribution of [123I]-label in rat heart was reported at 24 hr post injection. Value shown is %ID/g of tissue,Intermediate,10116.0,,A,,BAO_0000218,13950,,,1,CHEMBL621485,,,Rattus norvegicus,N,1,948.0,
8366,Biodistribution of [123I]-label in rat heart was reported at 4 hr post injection. Value shown is %ID/g of tissue,Intermediate,10116.0,,A,,BAO_0000218,13950,,,1,CHEMBL621486,,,Rattus norvegicus,N,1,948.0,
8367,Biodistribution of [123I]-label in rat intestine was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,Intermediate,10116.0,,A,,BAO_0000218,13950,,,1,CHEMBL621487,,,Rattus norvegicus,N,1,160.0,
8368,Biodistribution of [123I]-label in rat intestine was reported at 1 hr post injection. Value shown is %ID/g of tissue,Intermediate,10116.0,,A,,BAO_0000218,13950,,,1,CHEMBL621488,,,Rattus norvegicus,N,1,160.0,
8369,Biodistribution of [123I]-label in rat intestine was reported at 2 hr post injection. Value shown is %ID/g of tissue,Intermediate,10116.0,,A,,BAO_0000218,13950,,,1,CHEMBL621489,,,Rattus norvegicus,N,1,160.0,
8370,Biodistribution of [123I]-label in rat intestine was reported at 24 hr post injection. Value shown is %ID/g of tissue,Intermediate,10116.0,,A,,BAO_0000218,13950,,,1,CHEMBL621490,,,Rattus norvegicus,N,1,160.0,
8371,Biodistribution of [123I]-label in rat intestine was reported at 4 hr post injection. Value shown is %ID/g of tissue,Intermediate,10116.0,,A,,BAO_0000218,13950,,,1,CHEMBL621491,,,Rattus norvegicus,N,1,160.0,
8372,Biodistribution of [123I]-label in rat kidneys was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,Intermediate,10116.0,,A,,BAO_0000218,13950,,,1,CHEMBL621492,,,Rattus norvegicus,N,1,2113.0,
8373,Biodistribution of [123I]-label in rat kidneys was reported at 1 h post injection. Value shown is %ID/g of tissue,Intermediate,10116.0,,A,,BAO_0000218,13950,,,1,CHEMBL621493,,,Rattus norvegicus,N,1,2113.0,
8374,Biodistribution of [123I]-label in rat kidneys was reported at 2 hr post injection. Value shown is %ID/g of tissue,Intermediate,10116.0,,A,,BAO_0000218,13950,,,1,CHEMBL621494,,,Rattus norvegicus,N,1,2113.0,
8375,Biodistribution of [123I]-label in rat kidneys was reported at 24 hr post injection. Value shown is %ID/g of tissue,Intermediate,10116.0,,A,,BAO_0000218,13950,,,1,CHEMBL621495,,,Rattus norvegicus,N,1,2113.0,
8376,Biodistribution of [123I]-label in rat kidneys was reported at 4 hr post injection. Value shown is %ID/g of tissue,Intermediate,10116.0,,A,,BAO_0000218,13950,,,1,CHEMBL621496,,,Rattus norvegicus,N,1,2113.0,
8377,Biodistribution of [123I]-label in rat liver was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,Intermediate,10116.0,,A,,BAO_0000218,13950,,,1,CHEMBL621497,,,Rattus norvegicus,N,1,2107.0,
8378,Biodistribution of [123I]-label in rat liver was reported at 1 hr post injection. Value shown is %ID/g of tissue,Intermediate,10116.0,,A,,BAO_0000218,13950,,,1,CHEMBL621498,,,Rattus norvegicus,N,1,2107.0,
8379,Biodistribution of [123I]-label in rat liver was reported at 2 hr post injection. Value shown is %ID/g of tissue,Intermediate,10116.0,,A,,BAO_0000218,13950,,,1,CHEMBL621499,,,Rattus norvegicus,N,1,2107.0,
8380,Biodistribution of [123I]-label in rat liver was reported at 24 h post injection. Value shown is %ID/g of tissue,Intermediate,10116.0,,A,,BAO_0000218,13950,,,1,CHEMBL618634,,,Rattus norvegicus,N,1,2107.0,
8381,Biodistribution of [123I]-label in rat liver was reported at 4 hr post injection. Value shown is %ID/g of tissue,Intermediate,10116.0,,A,,BAO_0000218,13950,,,1,CHEMBL618635,,,Rattus norvegicus,N,1,2107.0,
8382,Biodistribution of [123I]-label in rat lung was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,Intermediate,10116.0,,A,,BAO_0000218,13950,,,1,CHEMBL618636,,,Rattus norvegicus,N,1,2048.0,
8383,Biodistribution of [123I]-label in rat lung was reported at 1 hr post injection. Value shown is %ID/g of tissue,Intermediate,10116.0,,A,,BAO_0000218,13950,,,1,CHEMBL619737,,,Rattus norvegicus,N,1,2048.0,
8384,Biodistribution of [123I]-label in rat lung was reported at 2 hr post injection. Value shown is %ID/g of tissue,Intermediate,10116.0,,A,,BAO_0000218,13950,,,1,CHEMBL619738,,,Rattus norvegicus,N,1,2048.0,
8385,Biodistribution of [123I]-label in rat lung was reported at 24 hr post injection. Value shown is %ID/g of tissue,Intermediate,10116.0,,A,,BAO_0000218,13950,,,1,CHEMBL624329,,,Rattus norvegicus,N,1,2048.0,
8386,Biodistribution of [123I]-label in rat lung was reported at 4 hr post injection. Value shown is %ID/g of tissue,Intermediate,10116.0,,A,,BAO_0000218,13950,,,1,CHEMBL624330,,,Rattus norvegicus,N,1,2048.0,
8387,Biodistribution of [123I]-label in rat muscle was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,Intermediate,10116.0,,A,,BAO_0000218,13950,,,1,CHEMBL624331,,,Rattus norvegicus,N,1,2385.0,
8388,Biodistribution of [123I]-label in rat muscle was reported at 1 hr post injection. Value shown is %ID/g of tissue,Intermediate,10116.0,,A,,BAO_0000218,13950,,,1,CHEMBL624332,,,Rattus norvegicus,N,1,2385.0,
8389,Biodistribution of [123I]-label in rat muscle was reported at 2 hr post injection. Value shown is %ID/g of tissue,Intermediate,10116.0,,A,,BAO_0000218,13950,,,1,CHEMBL624333,,,Rattus norvegicus,N,1,2385.0,
8390,Biodistribution of [123I]-label in rat muscle was reported at 24 hr post injection. Value shown is %ID/g of tissue,Intermediate,10116.0,,A,,BAO_0000218,13950,,,1,CHEMBL624334,,,Rattus norvegicus,N,1,2385.0,
8391,Biodistribution of [123I]-label in rat muscle was reported at 4 hr post injection. Value shown is %ID/g of tissue,Intermediate,10116.0,,A,,BAO_0000218,13950,,,1,CHEMBL624335,,,Rattus norvegicus,N,1,2385.0,
8392,Biodistribution of [123I]-label in rat spleen was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,Intermediate,10116.0,,A,,BAO_0000218,13950,,,1,CHEMBL620016,,,Rattus norvegicus,N,1,2106.0,
8393,Biodistribution of [123I]-label in rat spleen was reported at 1 hr post injection. Value shown is %ID/g of tissue,Intermediate,10116.0,,A,,BAO_0000218,13950,,,1,CHEMBL620169,,,Rattus norvegicus,N,1,2106.0,
8394,Biodistribution of [123I]-label in rat spleen was reported at 2 hr post injection. Value shown is %ID/g of tissue,Intermediate,10116.0,,A,,BAO_0000218,13950,,,1,CHEMBL620170,,,Rattus norvegicus,N,1,2106.0,
8395,Biodistribution of [123I]-label in rat spleen was reported at 24 h post injection. Value shown is %ID/g of tissue,Intermediate,10116.0,,A,,BAO_0000218,13950,,,1,CHEMBL620171,,,Rattus norvegicus,N,1,2106.0,
8396,Biodistribution of [123I]-label in rat spleen was reported at 4 hr post injection. Value shown is %ID/g of tissue,Intermediate,10116.0,,A,,BAO_0000218,13950,,,1,CHEMBL620172,,,Rattus norvegicus,N,1,2106.0,
8397,Biodistribution of [123I]-label in rat stomach was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,Intermediate,10116.0,,A,,BAO_0000218,13950,,,1,CHEMBL620173,,,Rattus norvegicus,N,1,945.0,
8398,Biodistribution of [123I]-label in rat stomach was reported at 1 h post injection. Value shown is %ID/g of tissue,Intermediate,10116.0,,A,,BAO_0000218,13950,,,1,CHEMBL620174,,,Rattus norvegicus,N,1,945.0,
8399,Biodistribution of [123I]-label in rat stomach was reported at 2 hr post injection. Value shown is %ID/g of tissue,Intermediate,10116.0,,A,,BAO_0000218,13950,,,1,CHEMBL620175,,,Rattus norvegicus,N,1,945.0,
8400,Biodistribution of [123I]-label in rat stomach was reported at 24 hr post injection. Value shown is %ID/g of tissue,Intermediate,10116.0,,A,,BAO_0000218,13950,,,1,CHEMBL620176,,,Rattus norvegicus,N,1,945.0,
8401,Biodistribution of [123I]-label in rat stomach was reported at 4 hr post injection. Value shown is %ID/g of tissue,Intermediate,10116.0,,A,,BAO_0000218,13950,,,1,CHEMBL620177,,,Rattus norvegicus,N,1,945.0,
8402,Distribution of [123I]-label in rat brain (cerebellum) was reported at 20 min post injection. Value shown is %ID/g of tissue,Intermediate,10116.0,,A,,BAO_0000218,13950,,,1,CHEMBL620178,,,Rattus norvegicus,N,1,2037.0,
8403,Distribution of [123I]-label in rat brain (cerebellum) was reported at 60 min post injection. Value shown is %ID/g of tissue,Intermediate,10116.0,,A,,BAO_0000218,13950,,,1,CHEMBL620179,,,Rattus norvegicus,N,1,2037.0,
8404,Distribution of [123I]-label in rat brain (diencephalon) was reported at 20 min post injection. Value shown is %ID/g of tissue,Intermediate,10116.0,,A,,BAO_0000218,13950,,,1,CHEMBL620180,,,Rattus norvegicus,N,1,,
8405,Volume of distribution of compound in rat after 1 mg/kg i.v. administration,Intermediate,10116.0,,A,,BAO_0000218,6570,,,1,CHEMBL620181,,,Rattus norvegicus,N,1,,
8406,Volume of distribution of compound in rats after intravenous administration,Intermediate,10116.0,,A,,BAO_0000218,6571,,,1,CHEMBL620182,,,Rattus norvegicus,N,1,,
8407,Volume of distribution in rat,Intermediate,10116.0,,A,,BAO_0000218,6453,,,1,CHEMBL620183,,,Rattus norvegicus,N,1,,
8408,Volume of distribution was determined in rat at a dose of 1 mpk i.v.,Intermediate,10116.0,,A,,BAO_0000218,6444,,,1,CHEMBL620184,,,Rattus norvegicus,N,1,,
8409,Volume of distribution was determined in rat at a dose of 1 mpk i.v.; ND means not determined,Intermediate,10116.0,,A,,BAO_0000218,6444,,,1,CHEMBL620185,,,Rattus norvegicus,N,1,,
8410,Volume of distribution was determined in rat at a dose of 1 mpk i.v.; ND=not determined,Intermediate,10116.0,,A,,BAO_0000218,6444,,,1,CHEMBL620186,,,Rattus norvegicus,N,1,,
8411,Volume of distribution was determined in Dawley rat,Intermediate,10116.0,,A,,BAO_0000218,5353,,,1,CHEMBL620187,,,Rattus norvegicus,N,1,,
8412,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Sprague-Dawley rat,Intermediate,10116.0,,A,,BAO_0000218,5334,,,1,CHEMBL620188,,,Rattus norvegicus,N,1,,
8413,Volume of distribution was reported in Sprague-Dawley rat,Intermediate,10116.0,,A,,BAO_0000218,5334,,,1,CHEMBL620189,,,Rattus norvegicus,N,1,,
8414,Volumes of distribution in rat after peroral administration,Intermediate,10116.0,,A,,BAO_0000218,6641,,,1,CHEMBL620190,,,Rattus norvegicus,N,1,,
8415,Volumes of distribution in rat after po administration,Intermediate,10116.0,,A,,BAO_0000218,6641,,,1,CHEMBL620191,,,Rattus norvegicus,N,1,,
8416,Volumes of distribution in rat after po administration; Not determined,Intermediate,10116.0,,A,,BAO_0000218,6641,,,1,CHEMBL620192,,,Rattus norvegicus,N,1,,
8417,Pharmacokinetic property (Volume) in rat i.v.,Intermediate,10116.0,,A,,BAO_0000218,5676,,,1,CHEMBL620193,,,Rattus norvegicus,N,1,,
8418,Apparent volume of distribution when 3 mg/Kg dose was administered intravenously,Intermediate,10116.0,,A,,BAO_0000218,6410,,,1,CHEMBL620194,,,Rattus norvegicus,N,1,,
8419,"Volume distribution in fischer rats at 5 mg/kg dose, administered intravenously",Intermediate,10116.0,,A,,BAO_0000218,17670,,,1,CHEMBL876730,,,Rattus norvegicus,N,1,,
8420,Volume distribution in rat after oral administration at 10 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,6495,,,1,CHEMBL620195,,,Rattus norvegicus,N,1,,
8421,Evaluated for Volume of distribution after iv administration of 5 mg/kg to male Sprague-Dawley rats,Intermediate,10116.0,,A,,BAO_0000218,5408,,,1,CHEMBL620196,,,Rattus norvegicus,N,1,,
8422,Tested for volume of distribution after intravenous administration to Sprague-Dawley rat at dosage of 0.2 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,4883,,,1,CHEMBL620197,,,Rattus norvegicus,N,1,,
8423,Volume of distribution after oral administration of 6 mg/kg of dose in rats was determined,Intermediate,10116.0,,A,,BAO_0000218,6647,,,1,CHEMBL620198,,,Rattus norvegicus,N,1,,
8424,Volume of distribution in rats,Intermediate,10116.0,,A,,BAO_0000218,6495,,,1,CHEMBL620199,,,Rattus norvegicus,N,1,,
8425,Compound was evaluated for volume of distribution (steady state) after treatment with iv dose of 1 mgkg to female wistar rats,Intermediate,10116.0,,A,,BAO_0000218,2661,,,1,CHEMBL620200,,,Rattus norvegicus,N,1,,
8426,Compound was evaluated for volume of distribution (steady state) after treatment with iv dose of 1 mgkg to male wistar rats,Intermediate,10116.0,,A,,BAO_0000218,2661,,,1,CHEMBL620201,,,Rattus norvegicus,N,1,,
8427,In vivo Volume distribution (Vss) was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,Intermediate,10116.0,,A,,BAO_0000218,5974,,,1,CHEMBL620202,,,Rattus norvegicus,N,1,,
8428,In vivo Volume distribution (Vss) was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,Intermediate,10116.0,,A,,BAO_0000218,5974,,,1,CHEMBL620203,,,Rattus norvegicus,N,1,,
8429,In vivo Volume distribution (Vss) was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat;no value,Intermediate,10116.0,,A,,BAO_0000218,5974,,,1,CHEMBL620204,,,Rattus norvegicus,N,1,,
8430,In vivo Volume distribution (Vss) was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,Intermediate,10116.0,,A,,BAO_0000218,5974,,,1,CHEMBL620205,,,Rattus norvegicus,N,1,,
8431,Pharmacokinetic parameter (Vss) in rat,Intermediate,10116.0,,A,,BAO_0000218,5960,,,1,CHEMBL624664,,,Rattus norvegicus,N,1,,
8432,Pharmacokinetic property (Volume) in rat i.v.,Intermediate,10116.0,,A,,BAO_0000218,5676,,,1,CHEMBL624665,,,Rattus norvegicus,N,1,,
8433,Pharmacokinetic property (Vss) in rat,Intermediate,10116.0,,A,,BAO_0000218,5948,,,1,CHEMBL624666,,,Rattus norvegicus,N,1,,
8434,Steady state volume distribution (Vss) of compound after 2 hr iv infusion of 8.4 mg/kg in three rat,Intermediate,10116.0,,A,,BAO_0000218,5979,,,1,CHEMBL624667,,,Rattus norvegicus,N,1,,
8435,Steady state volume distribution (Vss) of compound after iv administration was determined in Sprague-Dawley rat,Intermediate,10116.0,,A,,BAO_0000218,5978,,,1,CHEMBL624668,,,Rattus norvegicus,N,1,,
8436,Steady state volume distribution (Vss) of compound (10 mg/kg) after iv administration was determined in Sprague-Dawley rat,Intermediate,10116.0,,A,,BAO_0000218,5978,,,1,CHEMBL624669,,,Rattus norvegicus,N,1,,
8437,Steady state volume distribution (Vss) of compound(9.83 mg/kg) after iv administration was determined in Sprague-Dawley rat,Intermediate,10116.0,,A,,BAO_0000218,5978,,,1,CHEMBL624670,,,Rattus norvegicus,N,1,,
8438,Steady state volume distribution (Vss) of compound(9.84 mg/kg) after iv administration was determined in Sprague-Dawley rat,Intermediate,10116.0,,A,,BAO_0000218,5978,,,1,CHEMBL624671,,,Rattus norvegicus,N,1,,
8439,Steady state volume distribution in rat,Intermediate,10116.0,,A,,BAO_0000218,6448,,,1,CHEMBL624672,,,Rattus norvegicus,N,1,,
8440,"Steady state volume of distribution calculated from Time-Course plasma concentrations in rats at a dose of 2.5 mg/kg, iv.",Intermediate,10116.0,,A,,BAO_0000218,12873,,,1,CHEMBL624673,,,Rattus norvegicus,N,1,1969.0,
8441,Steady state volume of distribution determined in rat,Intermediate,10116.0,,A,,BAO_0000218,4576,,,1,CHEMBL624674,,,Rattus norvegicus,N,1,,
8442,Steady-state volume of distribution was evaluated for the compound after i.v. administration at a dose of 5 mg/kg was measured in rats,Intermediate,10116.0,,A,,BAO_0000218,17582,,,1,CHEMBL624675,,,Rattus norvegicus,N,1,,
8443,Tested for volume of distribution at steady state upon intravenous administration of 5.0 mg/Kg dose in rat,Intermediate,10116.0,,A,,BAO_0000218,1466,,,1,CHEMBL621728,,,Rattus norvegicus,N,1,,
8444,Volume at steady state distribution by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat was determined,Intermediate,10116.0,,A,,BAO_0000218,5182,,,1,CHEMBL621729,,,Rattus norvegicus,N,1,,
8445,Volume at steady state distribution by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat was determined; NC means not calculated,Intermediate,10116.0,,A,,BAO_0000218,5182,,,1,CHEMBL621730,,,Rattus norvegicus,N,1,,
8446,Volume distribution in rat after administration of 2 mg/kg iv,Intermediate,10116.0,,A,,BAO_0000218,6535,,,1,CHEMBL621731,,,Rattus norvegicus,N,1,,
8447,Volume distribution in rat after administration of 2 mg/kg iv,Intermediate,10116.0,,A,,BAO_0000218,6535,,,1,CHEMBL621732,,,Rattus norvegicus,N,1,,
8448,Volume in steady state distribution value was determined,Intermediate,10116.0,,A,,BAO_0000218,5041,,,1,CHEMBL621908,,,Rattus norvegicus,N,1,,
8449,Volume in steady state distribution value was determined; ND denotes no data,Intermediate,10116.0,,A,,BAO_0000218,5041,,,1,CHEMBL875347,,,Rattus norvegicus,N,1,,
8450,Volume in steady state distribution value was determined; ND denotes not determined,Intermediate,10116.0,,A,,BAO_0000218,5041,,,1,CHEMBL621909,,,Rattus norvegicus,N,1,,
8451,Volume of distribution at a steady state measured after intravenous bolus administration of 50 mg/kg of compound to rats,Intermediate,10116.0,,A,,BAO_0000218,17065,,,1,CHEMBL621910,,,Rattus norvegicus,N,1,,
8452,Volume of distribution at steady state was evaluated in rats,Intermediate,10116.0,,A,,BAO_0000218,6597,,,1,CHEMBL621911,,,Rattus norvegicus,N,1,,
8453,Volume of distribution at steady state was observed after intravenous administration in rat,Intermediate,10116.0,,A,,BAO_0000218,15662,,,1,CHEMBL621912,,,Rattus norvegicus,N,1,,
8454,Volume of distribution in steady state was determined in rat,Intermediate,10116.0,,A,,BAO_0000218,6485,,,1,CHEMBL621913,,,Rattus norvegicus,N,1,,
8455,Volume of distribution in steady state was determined in rat,Intermediate,10116.0,,A,,BAO_0000218,17655,,,1,CHEMBL621914,,,Rattus norvegicus,N,1,,
8456,Volume of distribution after i.v. administration,Intermediate,10116.0,,A,,BAO_0000218,6616,,,1,CHEMBL621915,,,Rattus norvegicus,N,1,,
8457,Volume of distribution was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after iv administration,Intermediate,10116.0,,A,,BAO_0000218,1916,,,1,CHEMBL621916,,,Rattus norvegicus,N,1,,
8458,"Biodistribution of compound (oxidized form) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO solution",Intermediate,10090.0,,A,,BAO_0000218,16438,,,1,CHEMBL621917,,,Mus musculus,N,1,2107.0,
8459,"Biodistribution of compound (oxidized form) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",Intermediate,10090.0,,A,,BAO_0000218,16438,,,1,CHEMBL621918,,,Mus musculus,N,1,2107.0,
8460,Biodistribution of compound (oxidized form) in spleen tissue,Intermediate,10090.0,,A,,BAO_0000218,16438,,,1,CHEMBL621919,,,Mus musculus,N,1,2106.0,
8461,"Biodistribution of compound (oxidized form) in spleen tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",Intermediate,10090.0,,A,,BAO_0000218,16438,,,1,CHEMBL621920,,,Mus musculus,N,1,2106.0,
8462,"Biodistribution of compound (oxidized form) in spleen tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",Intermediate,10090.0,,A,,BAO_0000218,16438,,,1,CHEMBL621921,,,Mus musculus,N,1,2106.0,
8463,"Biodistribution of compound (oxidized form) in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO",Intermediate,10090.0,,A,,BAO_0000218,16438,,,1,CHEMBL622401,,,Mus musculus,N,1,2106.0,
8464,"Biodistribution of compound (oxidized form) in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",Intermediate,10090.0,,A,,BAO_0000218,16438,,,1,CHEMBL875348,,,Mus musculus,N,1,2106.0,
8465,"Biodistribution of compound (oxidized form) in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO solution",Intermediate,10090.0,,A,,BAO_0000218,16438,,,1,CHEMBL622402,,,Mus musculus,N,1,2106.0,
8466,Biodistribution of compound (total concentration of both oxidized and reduced forms) in blood,Intermediate,10090.0,,A,,BAO_0000218,16438,,,1,CHEMBL622403,,,Mus musculus,N,1,178.0,
8467,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO",Intermediate,10090.0,,A,,BAO_0000218,16438,,,1,CHEMBL622404,,,Mus musculus,N,1,178.0,
8468,Biodistribution of compound (total concentration of both oxidized and reduced forms) in brain tissues,Intermediate,10090.0,,A,,BAO_0000218,16438,,,1,CHEMBL622405,,,Mus musculus,N,1,955.0,
8469,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in brain tissues, animals were sacrificed 10 minutes after dosing, in DMSO",Intermediate,10090.0,,A,,BAO_0000218,16438,,,1,CHEMBL622406,,,Mus musculus,N,1,955.0,
8470,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO",Intermediate,10090.0,,A,,BAO_0000218,16438,,,1,CHEMBL622407,,,Mus musculus,N,1,955.0,
8471,Biodistribution of compound (total concentration of both oxidized and reduced forms) in heart tissues,Intermediate,10090.0,,A,,BAO_0000218,16438,,,1,CHEMBL622408,,,Mus musculus,N,1,948.0,
8472,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in heart tissues, animals were sacrificed 10 minutes after dosing, in DMSO",Intermediate,10090.0,,A,,BAO_0000218,16438,,,1,CHEMBL622409,,,Mus musculus,N,1,948.0,
8473,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in heart tissues, animals were sacrificed 60 minutes after dosing, in DMSO",Intermediate,10090.0,,A,,BAO_0000218,16438,,,1,CHEMBL622410,,,Mus musculus,N,1,948.0,
8474,Biodistribution of compound (total concentration of both oxidized and reduced forms) in kidney,Intermediate,10090.0,,A,,BAO_0000218,16438,,,1,CHEMBL622411,,,Mus musculus,N,1,2113.0,
8475,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in kidney tissues, animals were sacrificed 60 minutes after dosing in DMSO",Intermediate,10090.0,,A,,BAO_0000218,16438,,,1,CHEMBL627864,,,Mus musculus,N,1,2113.0,
8476,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in kidney tissues, animals were sacrificed 60 minutes after dosing, in DMSO",Intermediate,10090.0,,A,,BAO_0000218,16438,,,1,CHEMBL627865,,,Mus musculus,N,1,2113.0,
8477,Biodistribution of compound (total concentration of both oxidized and reduced forms) in liver,Intermediate,10090.0,,A,,BAO_0000218,16438,,,1,CHEMBL627866,,,Mus musculus,N,1,2107.0,
8478,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO",Intermediate,10090.0,,A,,BAO_0000218,16438,,,1,CHEMBL627751,,,Mus musculus,N,1,2107.0,
8479,Biodistribution of compound (total concentration of both oxidized and reduced forms) in spleen,Intermediate,10090.0,,A,,BAO_0000218,16438,,,1,CHEMBL627752,,,Mus musculus,N,1,2106.0,
8480,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in spleen tissues, animals were sacrificed 60 minutes after dosing in DMSO",Intermediate,10090.0,,A,,BAO_0000218,16438,,,1,CHEMBL627753,,,Mus musculus,N,1,2106.0,
8481,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO",Intermediate,10090.0,,A,,BAO_0000218,16438,,,1,CHEMBL627754,,,Mus musculus,N,1,2106.0,
8482,Cellular uptake kinetics of Porphycenes saturation cell level (cs) in SSK2 murine fibrosarcoma cells,Intermediate,10090.0,,A,,BAO_0000218,12467,,,1,CHEMBL627755,,,Mus musculus,N,1,,
8483,Biodistribution of radioactivity in normal mice (ICR) brain after 1 hour of intravenous injection of [125I]-16(IMPY),Intermediate,10090.0,,A,,BAO_0000218,17208,,,1,CHEMBL627756,,,Mus musculus,N,1,955.0,
8484,Biodistribution of radioactivity in normal mice (ICR) brain after 2 hours of intravenous injection of [125I]-16(IMPY),Intermediate,10090.0,,A,,BAO_0000218,17208,,,1,CHEMBL627757,,,Mus musculus,N,1,955.0,
8485,Biodistribution of radioactivity in normal mice (ICR) brain after 2 minutes of intravenous injection of [125I]-16(IMPY),Intermediate,10090.0,,A,,BAO_0000218,17208,,,1,CHEMBL627758,,,Mus musculus,N,1,955.0,
8486,Biodistribution of radioactivity in normal mice (ICR) brain after 24 hours of intravenous injection of [125I]-16(IMPY),Intermediate,10090.0,,A,,BAO_0000218,17208,,,1,CHEMBL627759,,,Mus musculus,N,1,955.0,
8487,Biodistribution of radioactivity in normal mice (ICR) brain after 30 minutes of intravenous injection of [125I]-16(IMPY),Intermediate,10090.0,,A,,BAO_0000218,17208,,,1,CHEMBL627760,,,Mus musculus,N,1,955.0,
8488,Biodistribution of radioactivity in normal mice (ICR) brain after 6 hours of intravenous injection of [125I]-16(IMPY),Intermediate,10090.0,,A,,BAO_0000218,17208,,,1,CHEMBL627761,,,Mus musculus,N,1,955.0,
8489,Biodistribution of radioactivity in normal mice (ICR) heart after 1 hour of intravenous injection of [125I]-16(IMPY),Intermediate,10090.0,,A,,BAO_0000218,17208,,,1,CHEMBL876811,,,Mus musculus,N,1,948.0,
8490,Biodistribution of radioactivity in normal mice (ICR) heart after 2 hours of intravenous injection of [125I]-16(IMPY),Intermediate,10090.0,,A,,BAO_0000218,17208,,,1,CHEMBL627762,,,Mus musculus,N,1,948.0,
8491,Biodistribution of radioactivity in normal mice (ICR) heart after 2 minutes of intravenous injection of [125I]-16(IMPY),Intermediate,10090.0,,A,,BAO_0000218,17208,,,1,CHEMBL627763,,,Mus musculus,N,1,948.0,
8492,Biodistribution of radioactivity in normal mice (ICR) heart after 24 hours of intravenous injection of [125I]-16(IMPY),Intermediate,10090.0,,A,,BAO_0000218,17208,,,1,CHEMBL627764,,,Mus musculus,N,1,948.0,
8493,Biodistribution of radioactivity in normal mice (ICR) heart after 30 minutes of intravenous injection of [125I]-16(IMPY),Intermediate,10090.0,,A,,BAO_0000218,17208,,,1,CHEMBL627765,,,Mus musculus,N,1,948.0,
8494,Biodistribution of radioactivity in normal mice (ICR) heart after 6 hours of intravenous injection of [125I]-16(IMPY),Intermediate,10090.0,,A,,BAO_0000218,17208,,,1,CHEMBL627766,,,Mus musculus,N,1,948.0,
8495,Biodistribution of radioactivity in normal mice (ICR) kidney after 1 hour of intravenous injection of [125I]-16(IMPY),Intermediate,10090.0,,A,,BAO_0000218,17208,,,1,CHEMBL627767,,,Mus musculus,N,1,2113.0,
8496,Biodistribution of radioactivity in normal mice (ICR) kidney after 2 hours of intravenous injection of [125I]-16(IMPY),Intermediate,10090.0,,A,,BAO_0000218,17208,,,1,CHEMBL627768,,,Mus musculus,N,1,2113.0,
8497,Biodistribution of radioactivity in normal mice (ICR) kidney after 2 minutes of intravenous injection of [125I]-16(IMPY),Intermediate,10090.0,,A,,BAO_0000218,17208,,,1,CHEMBL628422,,,Mus musculus,N,1,2113.0,
8498,Biodistribution of radioactivity in normal mice (ICR) kidney after 24 hours of intravenous injection of [125I]-16(IMPY),Intermediate,10090.0,,A,,BAO_0000218,17208,,,1,CHEMBL628423,,,Mus musculus,N,1,2113.0,
8499,Plasma clearance value at intravenous dose of 1 mg/kg (2 mg/kg po (cassette dosing) in Dawley rat,Intermediate,10116.0,,A,,BAO_0000218,5089,,,1,CHEMBL628424,,,Rattus norvegicus,N,1,,
8500,Plasma clearance value at intravenous dose of 1 mg/kg (2 mg/kg po (cassette dosing)) in Dawley rat,Intermediate,10116.0,,A,,BAO_0000218,5089,,,1,CHEMBL628425,,,Rattus norvegicus,N,1,,
8501,Plasma clearance value was determined in rat after a 3 mg/kg of iv dose,Intermediate,10116.0,,A,,BAO_0000218,4257,,,1,CHEMBL628426,,,Rattus norvegicus,N,1,,
8502,Plasma clearance was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,Intermediate,10116.0,,A,,BAO_0000218,6679,,,1,CHEMBL628427,,,Rattus norvegicus,N,1,,
8503,Plasma clearance was determined in Sprague-Dawley rats at a dose of 1 mg/kg by iv administration,Intermediate,10116.0,,A,,BAO_0000218,5546,,,1,CHEMBL626938,,,Rattus norvegicus,N,1,,
8504,Plasma clearance was evaluated at 1 mg/kg of iv administration in Sprague-Dawley rats,Intermediate,10116.0,,A,,BAO_0000218,6141,,,1,CHEMBL626939,,,Rattus norvegicus,N,1,,
8505,Plasma clearance was reported after intravenous administration at a dose of 1 mg/kg in Sprague-Dawley rat,Intermediate,10116.0,,A,,BAO_0000218,5334,,,1,CHEMBL626940,,,Rattus norvegicus,N,1,,
8506,Plasma clearance was reported after oral administration at a dose of 2 mg/kg in Sprague-Dawley rat,Intermediate,10116.0,,A,,BAO_0000218,5334,,,1,CHEMBL626941,,,Rattus norvegicus,N,1,,
8507,Plasma clearance was reported in Sprague-Dawley rat,Intermediate,10116.0,,A,,BAO_0000218,5334,,,1,CHEMBL626942,,,Rattus norvegicus,N,1,,
8508,Plasma clearance after intravenous administration (1 mg/kg) in rat,Intermediate,10116.0,,A,,BAO_0000218,4689,,,1,CHEMBL876812,,,Rattus norvegicus,N,1,,
8509,Plasma clearance of compound in rats was evaluated,Intermediate,10116.0,,A,,BAO_0000218,6848,,,1,CHEMBL626943,,,Rattus norvegicus,N,1,,
8510,Plasma clearance of compound in rats was evaluated; ND indicates not determined,Intermediate,10116.0,,A,,BAO_0000218,6848,,,1,CHEMBL626944,,,Rattus norvegicus,N,1,,
8511,Plasma clearance in rats at the dose of 1.0 mpk by i.v. administration,Intermediate,10116.0,,A,,BAO_0000218,6467,,,1,CHEMBL626945,,,Rattus norvegicus,N,1,,
8512,Plasma clearance in rats at the dose of 1.0 mpk by i.v. administration; ND= not determined,Intermediate,10116.0,,A,,BAO_0000218,6467,,,1,CHEMBL626946,,,Rattus norvegicus,N,1,,
8513,Plasma clearance rate in Sprague-Dawley rats,Intermediate,10116.0,,A,,BAO_0000218,4956,,,1,CHEMBL626856,,,Rattus norvegicus,N,1,,
8514,Plasma clearance was determined in rat after intravenous administration (0.5 mg/kg),Intermediate,10116.0,,A,,BAO_0000218,5529,,,1,CHEMBL626857,,,Rattus norvegicus,N,1,,
8515,The compound was evaluated for plasma clearance in rat,Intermediate,10116.0,,A,,BAO_0000218,406,,,1,CHEMBL626858,,,Rattus norvegicus,N,1,1969.0,
8516,Total plasma clearance in rat,Intermediate,10116.0,,A,,BAO_0000218,17655,,,1,CHEMBL627018,,,Rattus norvegicus,N,1,1969.0,
8517,Absorption behavior was judged by the peak blood concentration determined after oral dose of 30 mg/kg in rats.,Intermediate,10116.0,,A,,BAO_0000218,3293,,,1,CHEMBL625331,,,Rattus norvegicus,N,1,178.0,
8518,Blood level after a 10 mg/kg oral dose in rat expressed as Cmax was determined,Intermediate,10116.0,,A,,BAO_0000218,4075,,,1,CHEMBL625332,,,Rattus norvegicus,N,1,178.0,
8519,C max was determined at 10 mg/kg po dose in rats,Intermediate,10116.0,,A,,BAO_0000218,2792,,,1,CHEMBL877590,,,Rattus norvegicus,N,1,,
8520,C max was determined at 3 mg/kg po dose in rats,Intermediate,10116.0,,A,,BAO_0000218,2792,,,1,CHEMBL625333,,,Rattus norvegicus,N,1,,
8521,Cmax after repeated oral dose of compound at 1 mg/kg in rats,Intermediate,10116.0,,A,,BAO_0000218,17594,,,1,CHEMBL625334,,,Rattus norvegicus,N,1,,
8522,Cmax after single intravenous bolus of 1 mg/kg in rats,Intermediate,10116.0,,A,,BAO_0000218,17594,,,1,CHEMBL625335,,,Rattus norvegicus,N,1,,
8523,Cmax of compound at 5 mg/kg after po administration was determined in rat,Intermediate,10116.0,,A,,BAO_0000218,4762,,,1,CHEMBL625336,,,Rattus norvegicus,N,1,,
8524,Cmax 24 hr after 10 mg/kg oral administration in rats,Intermediate,10116.0,,A,,BAO_0000218,17509,,,1,CHEMBL625337,,,Rattus norvegicus,N,1,,
8525,Cmax 24 hr after 2 mg/kg oral administration in rats,Intermediate,10116.0,,A,,BAO_0000218,17509,,,1,CHEMBL625338,,,Rattus norvegicus,N,1,,
8526,Cmax in plasma was determined upon peroral administration of 10.0 mg/Kg dose in rat,Intermediate,10116.0,,A,,BAO_0000218,1466,,,1,CHEMBL625339,,,Rattus norvegicus,N,1,1969.0,
8527,Cmax in rat after administration of 2 mg/kg iv,Intermediate,10116.0,,A,,BAO_0000218,6535,,,1,CHEMBL625340,,,Rattus norvegicus,N,1,,
8528,Cmax in rat after administration of 2 mg/kg iv,Intermediate,10116.0,,A,,BAO_0000218,6535,,,1,CHEMBL625341,,,Rattus norvegicus,N,1,,
8529,Cmax in rats determined 6 hours after oral dosing of 20 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,3169,,,1,CHEMBL622687,,,Rattus norvegicus,N,1,,
8530,Cmax wa determined in rat plasma at 30 mg/kg after po administration,Intermediate,10116.0,,A,,BAO_0000218,6515,,,1,CHEMBL622688,,,Rattus norvegicus,N,1,1969.0,
8531,Cmax was calculated as maximum concentration reached in the blood after oral administration to male F344 rats,Intermediate,10116.0,,A,,BAO_0000218,11149,,,1,CHEMBL622689,,,Rattus norvegicus,N,1,178.0,
8532,Cmax was calculated as maximum concentration reached in the blood in air pouch exudate after oral administration to male F344 rats,Intermediate,10116.0,,A,,BAO_0000218,11149,,,1,CHEMBL620295,,,Rattus norvegicus,N,1,178.0,
8533,Cmax after 10 mg/kg oral administration in rat,Intermediate,10116.0,,A,,BAO_0000218,17858,,,1,CHEMBL620296,,,Rattus norvegicus,N,1,,
8534,Cmax after IV dosing at 0.5 mg/kg in rat; no data,Intermediate,10116.0,,A,,BAO_0000218,6518,,,1,CHEMBL620297,,,Rattus norvegicus,N,1,,
8535,Cmax after IV dosing at 1 mg/kg in rat; no data,Intermediate,10116.0,,A,,BAO_0000218,6518,,,1,CHEMBL620298,,,Rattus norvegicus,N,1,,
8536,Cmax after oral administration at 20 mpk in rats,Intermediate,10116.0,,A,,BAO_0000218,4426,,,1,CHEMBL620299,,,Rattus norvegicus,N,1,,
8537,Cmax after oral administration at 20 mpk in rats; Not performed.,Intermediate,10116.0,,A,,BAO_0000218,4426,,,1,CHEMBL620300,,,Rattus norvegicus,N,1,,
8538,Cmax after oral administration at 20 mpk in rats d; Not performed.,Intermediate,10116.0,,A,,BAO_0000218,4426,,,1,CHEMBL620301,,,Rattus norvegicus,N,1,,
8539,Cmax after oral administration in rat,Intermediate,10116.0,,A,,BAO_0000218,5656,,,1,CHEMBL620302,,,Rattus norvegicus,N,1,,
8540,Cmax after oral administration at a dose of 2 mg/kg in rat,Intermediate,10116.0,,A,,BAO_0000218,6518,,,1,CHEMBL620303,,,Rattus norvegicus,N,1,,
8541,Cmax after oral administration at a dose of 4 mg/kg in rat,Intermediate,10116.0,,A,,BAO_0000218,6518,,,1,CHEMBL620304,,,Rattus norvegicus,N,1,,
8542,Cmax in rats after 20 mg/kg oral dose,Intermediate,10116.0,,A,,BAO_0000218,6113,,,1,CHEMBL620305,,,Rattus norvegicus,N,1,,
8543,Cmax after peroral administration in rats at 2.4 uM/kg,Intermediate,10116.0,,A,,BAO_0000218,17764,,,1,CHEMBL620306,,,Rattus norvegicus,N,1,,
8544,Cmax at the dose of 2 mg/Kg administered perorally in rats,Intermediate,10116.0,,A,,BAO_0000218,4756,,,1,CHEMBL620307,,,Rattus norvegicus,N,1,,
8545,Cmax at the dose of 5 mg/Kg administered perorally in rats,Intermediate,10116.0,,A,,BAO_0000218,4756,,,1,CHEMBL620308,,,Rattus norvegicus,N,1,,
8546,Cmax by administering at 20 mg/kg p.o. in rats,Intermediate,10116.0,,A,,BAO_0000218,6402,,,1,CHEMBL620309,,,Rattus norvegicus,N,1,,
8547,Cmax in male rat,Intermediate,10116.0,,A,,BAO_0000218,5610,,,1,CHEMBL620310,,,Rattus norvegicus,N,1,,
8548,Cmax in rat,Intermediate,10116.0,,A,,BAO_0000218,5207,,,1,CHEMBL620311,,,Rattus norvegicus,N,1,,
8549,Cmax in rat,Intermediate,10116.0,,A,,BAO_0000218,6011,,,1,CHEMBL620312,,,Rattus norvegicus,N,1,,
8550,Cmax in rat,Intermediate,10116.0,,A,,BAO_0000218,6504,,,1,CHEMBL620313,,,Rattus norvegicus,N,1,,
8551,Cmax in rat at 10 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,6046,,,1,CHEMBL620314,,,Rattus norvegicus,N,1,,
8552,Cmax in rat at the dose of 1 mg/kg i.v.,Intermediate,10116.0,,A,,BAO_0000218,6504,,,1,CHEMBL620315,,,Rattus norvegicus,N,1,,
8553,Cmax in rat by po administration at a dose of 40 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,5874,,,1,CHEMBL620316,,,Rattus norvegicus,N,1,,
8554,Cmax in rat p.o. at 20 mg/kg concentration,Intermediate,10116.0,,A,,BAO_0000218,17686,,,1,CHEMBL620317,,,Rattus norvegicus,N,1,,
8555,Cmax in rats,Intermediate,10116.0,,A,,BAO_0000218,5836,,,1,CHEMBL620318,,,Rattus norvegicus,N,1,,
8556,Cmax in rats,Intermediate,10116.0,,A,,BAO_0000218,17596,,,1,CHEMBL620319,,,Rattus norvegicus,N,1,,
8557,Cmax was evaluated after 20 uM/kg of peroral administration,Intermediate,10116.0,,A,,BAO_0000218,16423,,,1,CHEMBL620320,,,Rattus norvegicus,N,1,,
8558,Cmax was measured in rats after peroral administration at 3 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,17804,,,1,CHEMBL620321,,,Rattus norvegicus,N,1,,
8559,Cmax value after oral dose at a dose of 10 mg/kg in rats.,Intermediate,10116.0,,A,,BAO_0000218,1908,,,1,CHEMBL620322,,,Rattus norvegicus,N,1,,
8560,Distribution of [123I]-label in rat brain (diencephalon) was reported at 60 min post injection. Value shown is %ID/g of tissue,Intermediate,10116.0,,A,,BAO_0000218,13950,,,1,CHEMBL620323,,,Rattus norvegicus,N,1,,
8561,Distribution of [123I]-label in rat brain (frontal cortex) was reported at 20 min post injection. Value shown is %ID/g of tissue,Intermediate,10116.0,,A,,BAO_0000218,13950,,,1,CHEMBL620324,,,Rattus norvegicus,N,1,1870.0,
8562,Distribution of [123I]-label in rat brain (frontal cortex) was reported at 60 min post injection. Value shown is %ID/g of tissue,Intermediate,10116.0,,A,,BAO_0000218,13950,,,1,CHEMBL620325,,,Rattus norvegicus,N,1,1870.0,
8563,Distribution of [123I]-label in rat brain (hippocampus) was reported at 20 min post injection. Value shown is %ID/g of tissue,Intermediate,10116.0,,A,,BAO_0000218,13950,,,1,CHEMBL620326,,,Rattus norvegicus,N,1,10000000.0,
8564,Distribution of [123I]-label in rat brain (hippocampus) was reported at 60 min post injection. Value shown is %ID/g of tissue,Intermediate,10116.0,,A,,BAO_0000218,13950,,,1,CHEMBL620327,,,Rattus norvegicus,N,1,10000000.0,
8565,Distribution of [123I]-label in rat brain (medulla pons) was reported at 20 min post injection. Value shown is %ID/g of tissue,Intermediate,10116.0,,A,,BAO_0000218,13950,,,1,CHEMBL620328,,,Rattus norvegicus,N,1,,
8566,Distribution of [123I]-label in rat brain (medulla pons) was reported at 60 min post injection. Value shown is %ID/g of tissue,Intermediate,10116.0,,A,,BAO_0000218,13950,,,1,CHEMBL620329,,,Rattus norvegicus,N,1,,
8567,Distribution of [123I]-label in rat brain (midbrain) was reported at 20 min post injection. Value shown is %ID/g of tissue,Intermediate,10116.0,,A,,BAO_0000218,13950,,,1,CHEMBL620330,,,Rattus norvegicus,N,1,1891.0,
8568,Distribution of [123I]-label in rat brain (midbrain) was reported at 60 min post injection. Value shown is %ID/g of tissue,Intermediate,10116.0,,A,,BAO_0000218,13950,,,1,CHEMBL875286,,,Rattus norvegicus,N,1,1891.0,
8569,Distribution of [123I]-label in rat brain (posterior cortex) was reported at 20 min post injection. Value shown is %ID/g of tissue,Intermediate,10116.0,,A,,BAO_0000218,13950,,,1,CHEMBL620331,,,Rattus norvegicus,N,1,,
8570,Distribution of [123I]-label in rat brain (posterior cortex) was reported at 60 min post injection. Value shown is %ID/g of tissue,Intermediate,10116.0,,A,,BAO_0000218,13950,,,1,CHEMBL620332,,,Rattus norvegicus,N,1,,
8571,Distribution of [123I]-label in rat brain (striatum) was reported at 20 min post injection. Value shown is %ID/g of tissue,Intermediate,10116.0,,A,,BAO_0000218,13950,,,1,CHEMBL620333,,,Rattus norvegicus,N,1,2435.0,
8572,Distribution of [123I]-label in rat brain (striatum) was reported at 60 min post injection. Value shown is %ID/g of tissue,Intermediate,10116.0,,A,,BAO_0000218,13950,,,1,CHEMBL620334,,,Rattus norvegicus,N,1,2435.0,
8573,Radioactivity distribution in blood of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,Intermediate,10116.0,,A,,BAO_0000218,16434,,,1,CHEMBL621015,,,Rattus norvegicus,N,1,178.0,
8574,Radioactivity distribution in blood of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,Intermediate,10116.0,,A,,BAO_0000218,16434,,,1,CHEMBL621016,,,Rattus norvegicus,N,1,178.0,
8575,Radioactivity distribution in blood of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,Intermediate,10116.0,,A,,BAO_0000218,16434,,,1,CHEMBL621191,,,Rattus norvegicus,N,1,178.0,
8576,Radioactivity distribution in blood of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,Intermediate,10116.0,,A,,BAO_0000218,16434,,,1,CHEMBL621192,,,Rattus norvegicus,N,1,178.0,
8577,Radioactivity distribution in blood of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,Intermediate,10116.0,,A,,BAO_0000218,16434,,,1,CHEMBL621193,,,Rattus norvegicus,N,1,178.0,
8578,Radioactivity distribution in blood of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,Intermediate,10116.0,,A,,BAO_0000218,16434,,,1,CHEMBL621194,,,Rattus norvegicus,N,1,178.0,
8579,Radioactivity distribution in blood of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,Intermediate,10116.0,,A,,BAO_0000218,16434,,,1,CHEMBL624204,,,Rattus norvegicus,N,1,178.0,
8580,Radioactivity distribution in blood of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,Intermediate,10116.0,,A,,BAO_0000218,16434,,,1,CHEMBL624205,,,Rattus norvegicus,N,1,178.0,
8581,Radioactivity distribution in blood of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,Intermediate,10116.0,,A,,BAO_0000218,16435,,,1,CHEMBL624206,,,Rattus norvegicus,N,1,178.0,
8582,Radioactivity distribution in blood of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,Intermediate,10116.0,,A,,BAO_0000218,16435,,,1,CHEMBL624207,,,Rattus norvegicus,N,1,178.0,
8583,Radioactivity distribution in blood of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,Intermediate,10116.0,,A,,BAO_0000218,16435,,,1,CHEMBL624208,,,Rattus norvegicus,N,1,178.0,
8584,Radioactivity distribution in blood of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,Intermediate,10116.0,,A,,BAO_0000218,16435,,,1,CHEMBL624209,,,Rattus norvegicus,N,1,178.0,
8585,Radioactivity distribution in blood of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,Intermediate,10116.0,,A,,BAO_0000218,16435,,,1,CHEMBL624210,,,Rattus norvegicus,N,1,178.0,
8586,Radioactivity distribution in blood of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,Intermediate,10116.0,,A,,BAO_0000218,16435,,,1,CHEMBL624211,,,Rattus norvegicus,N,1,178.0,
8587,Radioactivity distribution in blood of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,Intermediate,10116.0,,A,,BAO_0000218,16435,,,1,CHEMBL624212,,,Rattus norvegicus,N,1,178.0,
8588,Radioactivity distribution in blood of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,Intermediate,10116.0,,A,,BAO_0000218,16435,,,1,CHEMBL624213,,,Rattus norvegicus,N,1,178.0,
8589,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,Intermediate,10116.0,,A,,BAO_0000218,16434,,,1,CHEMBL876611,,,Rattus norvegicus,N,1,178.0,
8590,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,Intermediate,10116.0,,A,,BAO_0000218,16434,,,1,CHEMBL624214,,,Rattus norvegicus,N,1,178.0,
8591,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,Intermediate,10116.0,,A,,BAO_0000218,16434,,,1,CHEMBL624215,,,Rattus norvegicus,N,1,178.0,
8592,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,Intermediate,10116.0,,A,,BAO_0000218,16435,,,1,CHEMBL624216,,,Rattus norvegicus,N,1,178.0,
8593,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,Intermediate,10116.0,,A,,BAO_0000218,16435,,,1,CHEMBL624217,,,Rattus norvegicus,N,1,178.0,
8594,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,Intermediate,10116.0,,A,,BAO_0000218,16435,,,1,CHEMBL624218,,,Rattus norvegicus,N,1,178.0,
8595,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,Intermediate,10116.0,,A,,BAO_0000218,16435,,,1,CHEMBL624219,,,Rattus norvegicus,N,1,178.0,
8596,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,Intermediate,10116.0,,A,,BAO_0000218,16435,,,1,CHEMBL624220,,,Rattus norvegicus,N,1,178.0,
8597,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,Intermediate,10116.0,,A,,BAO_0000218,16435,,,1,CHEMBL624221,,,Rattus norvegicus,N,1,178.0,
8598,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,Intermediate,10116.0,,A,,BAO_0000218,16434,,,1,CHEMBL624222,,,Rattus norvegicus,N,1,,
8599,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,Intermediate,10116.0,,A,,BAO_0000218,16434,,,1,CHEMBL624223,,,Rattus norvegicus,N,1,,
8600,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,Intermediate,10116.0,,A,,BAO_0000218,16434,,,1,CHEMBL624224,,,Rattus norvegicus,N,1,,
8601,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,Intermediate,10116.0,,A,,BAO_0000218,16434,,,1,CHEMBL624225,,,Rattus norvegicus,N,1,,
8602,Volume of solubility in solution after intravenous administration in rats at 24 uM/kg,Intermediate,10116.0,,A,,BAO_0000218,17764,,,1,CHEMBL622420,,,Rattus norvegicus,N,1,,
8603,Volume of steady state distribution after i.v. administration in rats,Intermediate,10116.0,,A,,BAO_0000218,5031,,,1,CHEMBL622421,,,Rattus norvegicus,N,1,,
8604,Vss after intravenous administration (5.0 mg/kg) was determined in rat,Intermediate,10116.0,,A,,BAO_0000218,6215,,,1,CHEMBL622422,,,Rattus norvegicus,N,1,,
8605,Vss in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,17671,,,1,CHEMBL622423,,,Rattus norvegicus,N,1,,
8606,Vss was determined,Intermediate,10116.0,,A,,BAO_0000218,17752,,,1,CHEMBL622424,,,Rattus norvegicus,N,1,,
8607,Vss in rat,Intermediate,10116.0,,A,,BAO_0000218,6596,,,1,CHEMBL622425,,,Rattus norvegicus,N,1,,
8608,Vss was evaluated after 10 uM/kg of intra arterial administration,Intermediate,10116.0,,A,,BAO_0000218,16423,,,1,CHEMBL876612,,,Rattus norvegicus,N,1,,
8609,volume of distribution at steady state was observed after intravenous administration in rat,Intermediate,10116.0,,A,,BAO_0000218,15662,,,1,CHEMBL622426,,,Rattus norvegicus,N,1,,
8610,Volume of distribution was measured in rat after an iv dose of 1 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,6062,,,1,CHEMBL622427,,,Rattus norvegicus,N,1,,
8611,Pharmacokinetic (PK) parameter Vz in rat,Intermediate,10116.0,,A,,BAO_0000218,5874,,,1,CHEMBL622428,,,Rattus norvegicus,N,1,,
8612,Volume distribution in rats,Intermediate,10116.0,,A,,BAO_0000218,4942,,,1,CHEMBL622429,,,Rattus norvegicus,N,1,,
8613,Volume of distribution in rat; No data,Intermediate,10116.0,,A,,BAO_0000218,17796,,,1,CHEMBL622430,,,Rattus norvegicus,N,1,,
8614,Volume of distribution was determined after intravenous administration at a dose 5 mg/kg to male Sprague-Dawley rats,Intermediate,10116.0,,A,,BAO_0000218,4890,,,1,CHEMBL622431,,,Rattus norvegicus,N,1,,
8615,% absorption predicted from in vitro rat ileum transport studies,Intermediate,10116.0,,A,,BAO_0000218,15765,,,1,CHEMBL622432,,,Rattus norvegicus,N,1,2116.0,
8616,Bioavailability at an iv dose of 12 mg/Kg and po dose of 23 mg/Kg,Intermediate,10116.0,,A,,BAO_0000218,13569,,,1,CHEMBL622433,,,Rattus norvegicus,N,1,,
8617,Bioavailability at an iv dose of 14 mg/Kg and po dose of 15 mg/Kg,Intermediate,10116.0,,A,,BAO_0000218,13569,,,1,CHEMBL622434,,,Rattus norvegicus,N,1,,
8618,Bioavailability at an iv dose of 14 mg/Kg and po dose of 28 mg/Kg,Intermediate,10116.0,,A,,BAO_0000218,13569,,,1,CHEMBL622435,,,Rattus norvegicus,N,1,,
8619,Bioavailability (dose 15 mg/kg i.v. and 30 mg/kg p.o.),Intermediate,10116.0,,A,,BAO_0000218,13569,,,1,CHEMBL618748,,,Rattus norvegicus,N,1,,
8620,Bioavailability at an iv dose of 15 mg/Kg and po dose of 30.2 mg/Kg,Intermediate,10116.0,,A,,BAO_0000218,13569,,,1,CHEMBL618749,,,Rattus norvegicus,N,1,,
8621,Bioavailability at an iv dose of 15.6 mg/Kg and po dose of 31.2 mg/Kg,Intermediate,10116.0,,A,,BAO_0000218,13569,,,1,CHEMBL618750,,,Rattus norvegicus,N,1,,
8622,Bioavailability at an iv dose of 15.7 mg/Kg and po dose of 31.4 mg/Kg,Intermediate,10116.0,,A,,BAO_0000218,13569,,,1,CHEMBL618751,,,Rattus norvegicus,N,1,,
8623,Bioavailability at an iv dose of 16 mg/Kg and po dose of 35 mg/Kg,Intermediate,10116.0,,A,,BAO_0000218,13569,,,1,CHEMBL618752,,,Rattus norvegicus,N,1,,
8624,Oral bioavailability in rat,Intermediate,10116.0,,A,,BAO_0000218,4576,,,1,CHEMBL618753,,,Rattus norvegicus,N,1,,
8625,Oral bioavailability estimated by measurement of the circulating plasma levels of BMS-183920 after intravenous and oral dosing to rats for 4 determinations,Intermediate,10116.0,,A,,BAO_0000218,750,,,1,CHEMBL618754,,,Rattus norvegicus,N,1,1969.0,
8626,Oral bioavailability in rat,Intermediate,10116.0,,A,,BAO_0000218,750,,,1,CHEMBL618755,,,Rattus norvegicus,N,1,,
8627,Oral bioavailability in rat,Intermediate,10116.0,,A,,BAO_0000218,4590,,,1,CHEMBL618756,,,Rattus norvegicus,N,1,,
8628,Oral bioavailability in rat,Intermediate,10116.0,,A,,BAO_0000218,1716,,,1,CHEMBL618757,,,Rattus norvegicus,N,1,,
8629,Bioavailability in rat,Intermediate,10116.0,,A,,BAO_0000218,1974,,,1,CHEMBL618758,,,Rattus norvegicus,N,1,,
8630,Oral bioavailability in rat (dose 30 mg/kg),Intermediate,10116.0,,A,,BAO_0000218,4502,,,1,CHEMBL621088,,,Rattus norvegicus,N,1,,
8631,Pharmacokinetic property (cLogP) in rat,Intermediate,10116.0,,A,,BAO_0000218,3371,,,1,CHEMBL621089,,,Rattus norvegicus,N,1,,
8632,Hyperglycemic activity and change in blood glucose concentration was reported 2 hours after administration of 100 mg/Kg perorally,Intermediate,10116.0,,F,,BAO_0000218,9099,,,1,CHEMBL621090,,,Rattus norvegicus,N,1,178.0,
8633,Hyperglycemic activity and change in blood glucose concentration was reported 4 hours after administration of 100 mg/Kg perorally,Intermediate,10116.0,,F,,BAO_0000218,9099,,,1,CHEMBL621091,,,Rattus norvegicus,N,1,178.0,
8634,Clearance in rat.,Intermediate,10116.0,,A,,BAO_0000218,4590,,,1,CHEMBL876731,,,Rattus norvegicus,N,1,,
8635,Compound was evaluated for its clearance when administered intravenously in rat,Intermediate,10116.0,,A,,BAO_0000218,3184,,,1,CHEMBL621092,,,Rattus norvegicus,N,1,,
8636,Plasma clearance in Male Sprague-Dawley rats after intravenous administration at a dose of 10 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,16456,,,1,CHEMBL621093,,,Rattus norvegicus,N,1,,
8637,Blood: Brain distribution ratio is determined in rat,Intermediate,10116.0,,A,,BAO_0000218,4199,,,1,CHEMBL621094,,,Rattus norvegicus,N,1,,
8638,Blood: Brain distribution ratio is determined in rat; NQ: non quantifable,Intermediate,10116.0,,A,,BAO_0000218,4199,,,1,CHEMBL621095,,,Rattus norvegicus,N,1,,
8639,Blood: Brain distribution ratio is determined in rat; NQ:non quantifable,Intermediate,10116.0,,A,,BAO_0000218,4199,,,1,CHEMBL621096,,,Rattus norvegicus,N,1,,
8640,"Biodistribution in Sprague-Dawley rat kidneys(2) 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Intermediate,10116.0,,A,,BAO_0000218,8677,,,1,CHEMBL621097,,,Rattus norvegicus,N,1,2113.0,
8641,Percent dose excreted in 0-48 hours administered ip to male rat,Intermediate,10116.0,,F,,BAO_0000218,7449,,,1,CHEMBL621098,,,Rattus norvegicus,N,1,,
8642,Uptake of radioligand [125I]FIDA1 by cerebellum in rat after 120 minutes after an intravenous injection is given (average of 3 rats),Intermediate,10116.0,,A,,BAO_0000218,11977,,,1,CHEMBL621099,,,Rattus norvegicus,N,1,2037.0,
8643,Uptake of radioligand [125I]FIDA1 by cerebellum in rat after 2 minutes after an intravenous injection is given (average of 3 rats),Intermediate,10116.0,,A,,BAO_0000218,11977,,,1,CHEMBL621100,,,Rattus norvegicus,N,1,2037.0,
8644,Uptake of radioligand [125I]-FIDA1 by cerebellum in rat after 30 minutes after an intravenous injection is given (average of 2 rats),Intermediate,10116.0,,A,,BAO_0000218,11977,,,1,CHEMBL621101,,,Rattus norvegicus,N,1,2037.0,
8645,Uptake of radioligand [125I]FIDA1 by cerebellum in rat after 30 minutes after an intravenous injection is given (average of 3 rats),Intermediate,10116.0,,A,,BAO_0000218,11977,,,1,CHEMBL621102,,,Rattus norvegicus,N,1,2037.0,
8646,Uptake of radioligand [125I]FIDA1 by cerebellum in rat after 60 minutes after an intravenous injection is given (average of 3 rats),Intermediate,10116.0,,A,,BAO_0000218,11977,,,1,CHEMBL876732,,,Rattus norvegicus,N,1,2037.0,
8647,Uptake of radioligand [125I]-FIDA1 by cortex in rat after 120 minutes after an intravenous injection is given (average of 3 rats),Intermediate,10116.0,,A,,BAO_0000218,11977,,,1,CHEMBL621103,,,Rattus norvegicus,N,1,,
8648,Uptake of radioligand [125I]FIDA1 by cortex in rat after 2 minutes after an intravenous injection is given (average of 3 rats),Intermediate,10116.0,,A,,BAO_0000218,11977,,,1,CHEMBL621104,,,Rattus norvegicus,N,1,,
8649,Uptake of radioligand [125I]FIDA1 by cortex in rat after 30 minutes after an intravenous injection is given (average of 2 rats),Intermediate,10116.0,,A,,BAO_0000218,11977,,,1,CHEMBL621105,,,Rattus norvegicus,N,1,,
8650,Uptake of radioligand [125I]-FIDA1 by cortex in rat after 30 minutes after an intravenous injection is given (average of 3 rats),Intermediate,10116.0,,A,,BAO_0000218,11977,,,1,CHEMBL621106,,,Rattus norvegicus,N,1,,
8651,Uptake of radioligand [125I]FIDA1 by cortex in rat after 60 minutes after an intravenous injection is given (average of 3 rats),Intermediate,10116.0,,A,,BAO_0000218,11977,,,1,CHEMBL621107,,,Rattus norvegicus,N,1,,
8652,Uptake of radioligand [125I]FIDA1 by hippo-campus in rat after 120 minutes after an intravenous injection is given (average of 3 rats),Intermediate,10116.0,,A,,BAO_0000218,11977,,,1,CHEMBL621108,,,Rattus norvegicus,N,1,,
8653,Uptake of radioligand [125I]FIDA1 by hippo-campus in rat after 2 minutes after an intravenous injection is given (average of 3 rats),Intermediate,10116.0,,A,,BAO_0000218,11977,,,1,CHEMBL621109,,,Rattus norvegicus,N,1,,
8654,Biodistribution of radioactivity in normal mice (ICR) kidney after 30 minutes of intravenous injection of [125I]-16(IMPY),Intermediate,10090.0,,A,,BAO_0000218,17208,,,1,CHEMBL621110,,,Mus musculus,N,1,2113.0,
8655,Biodistribution of radioactivity in normal mice (ICR) kidney after 6 hours of intravenous injection of [125I]-16(IMPY),Intermediate,10090.0,,A,,BAO_0000218,17208,,,1,CHEMBL621111,,,Mus musculus,N,1,2113.0,
8656,Biodistribution of radioactivity in normal mice (ICR) liver after 1 hour of intravenous injection of [125I]-16(IMPY),Intermediate,10090.0,,A,,BAO_0000218,17208,,,1,CHEMBL622541,,,Mus musculus,N,1,2107.0,
8657,Biodistribution of radioactivity in normal mice (ICR) liver after 2 hours of intravenous injection of [125I]-16(IMPY),Intermediate,10090.0,,A,,BAO_0000218,17208,,,1,CHEMBL622542,,,Mus musculus,N,1,2107.0,
8658,Biodistribution of radioactivity in normal mice (ICR) liver after 2 minutes of intravenous injection of [125I]-16(IMPY),Intermediate,10090.0,,A,,BAO_0000218,17208,,,1,CHEMBL622543,,,Mus musculus,N,1,2107.0,
8659,Biodistribution of radioactivity in normal mice (ICR) liver after 24 hours of intravenous injection of [125I]-16(IMPY),Intermediate,10090.0,,A,,BAO_0000218,17208,,,1,CHEMBL624412,,,Mus musculus,N,1,2107.0,
8660,Biodistribution of radioactivity in normal mice (ICR) liver after 30 minutes of intravenous injection of [125I]-16(IMPY),Intermediate,10090.0,,A,,BAO_0000218,17208,,,1,CHEMBL624413,,,Mus musculus,N,1,2107.0,
8661,Biodistribution of radioactivity in normal mice (ICR) liver after 6 hours of intravenous injection of [125I]-16(IMPY),Intermediate,10090.0,,A,,BAO_0000218,17208,,,1,CHEMBL624414,,,Mus musculus,N,1,2107.0,
8662,Biodistribution of radioactivity in normal mice (ICR) lung after 1 hour of intravenous injection of [125I]-16(IMPY),Intermediate,10090.0,,A,,BAO_0000218,17208,,,1,CHEMBL624415,,,Mus musculus,N,1,2048.0,
8663,Biodistribution of radioactivity in normal mice (ICR) lung after 2 hours of intravenous injection of [125I]-16(IMPY),Intermediate,10090.0,,A,,BAO_0000218,17208,,,1,CHEMBL624416,,,Mus musculus,N,1,2048.0,
8664,Biodistribution of radioactivity in normal mice (ICR) lung after 2 minutes of intravenous injection of [125I]-16(IMPY),Intermediate,10090.0,,A,,BAO_0000218,17208,,,1,CHEMBL624417,,,Mus musculus,N,1,2048.0,
8665,Biodistribution of radioactivity in normal mice (ICR) lung after 24 hours of intravenous injection of [125I]-16(IMPY),Intermediate,10090.0,,A,,BAO_0000218,17208,,,1,CHEMBL624418,,,Mus musculus,N,1,2048.0,
8666,Biodistribution of radioactivity in normal mice (ICR) lung after 30 minutes of intravenous injection of [125I]-16(IMPY),Intermediate,10090.0,,A,,BAO_0000218,17208,,,1,CHEMBL624419,,,Mus musculus,N,1,2048.0,
8667,Biodistribution of radioactivity in normal mice (ICR) lung after 6 hours of intravenous injection of [125I]-16(IMPY),Intermediate,10090.0,,A,,BAO_0000218,17208,,,1,CHEMBL624420,,,Mus musculus,N,1,2048.0,
8668,Biodistribution of radioactivity in normal mice (ICR) muscle after 1 hr of intravenous injection of [125I]-16(IMPY),Intermediate,10090.0,,A,,BAO_0000218,17208,,,1,CHEMBL624421,,,Mus musculus,N,1,2385.0,
8669,Biodistribution of radioactivity in normal mice (ICR) muscle after 2 hours of intravenous injection of [125I]-16(IMPY),Intermediate,10090.0,,A,,BAO_0000218,17208,,,1,CHEMBL624422,,,Mus musculus,N,1,2385.0,
8670,Biodistribution of radioactivity in normal mice (ICR) muscle after 2 minutes of intravenous injection of [125I]-16(IMPY),Intermediate,10090.0,,A,,BAO_0000218,17208,,,1,CHEMBL624423,,,Mus musculus,N,1,2385.0,
8671,Biodistribution of radioactivity in normal mice (ICR) muscle after 24 hours of intravenous injection of [125I]-16(IMPY),Intermediate,10090.0,,A,,BAO_0000218,17208,,,1,CHEMBL625123,,,Mus musculus,N,1,2385.0,
8672,Biodistribution of radioactivity in normal mice (ICR) muscle after 30 minutes of intravenous injection of [125I]-16(IMPY),Intermediate,10090.0,,A,,BAO_0000218,17208,,,1,CHEMBL625124,,,Mus musculus,N,1,2385.0,
8673,Biodistribution of radioactivity in normal mice (ICR) muscle after 6 hours of intravenous injection of [125I]-16(IMPY),Intermediate,10090.0,,A,,BAO_0000218,17208,,,1,CHEMBL625125,,,Mus musculus,N,1,2385.0,
8674,Biodistribution of radioactivity in normal mice (ICR) skin after 1 hour of intravenous injection of [125I]-16(IMPY),Intermediate,10090.0,,A,,BAO_0000218,17208,,,1,CHEMBL625126,,,Mus musculus,N,1,14.0,
8675,Biodistribution of radioactivity in normal mice (ICR) skin after 2 hours of intravenous injection of [125I]-16(IMPY),Intermediate,10090.0,,A,,BAO_0000218,17208,,,1,CHEMBL626947,,,Mus musculus,N,1,14.0,
8676,Biodistribution of radioactivity in normal mice (ICR) skin after 2 minutes of intravenous injection of [125I]-16(IMPY),Intermediate,10090.0,,A,,BAO_0000218,17208,,,1,CHEMBL626948,,,Mus musculus,N,1,14.0,
8677,Biodistribution of radioactivity in normal mice (ICR) skin after 24 hours of intravenous injection of [125I]-16(IMPY),Intermediate,10090.0,,A,,BAO_0000218,17208,,,1,CHEMBL626949,,,Mus musculus,N,1,14.0,
8678,Biodistribution of radioactivity in normal mice (ICR) skin after 30 minutes of intravenous injection of [125I]-16(IMPY),Intermediate,10090.0,,A,,BAO_0000218,17208,,,1,CHEMBL626950,,,Mus musculus,N,1,14.0,
8679,Biodistribution of radioactivity in normal mice (ICR) skin after 6 hours of intravenous injection of [125I]-16(IMPY),Intermediate,10090.0,,A,,BAO_0000218,17208,,,1,CHEMBL626951,,,Mus musculus,N,1,14.0,
8680,Biodistribution of radioactivity in normal mice (ICR) spleen after 1 hour of intravenous injection of [125I]-16(IMPY),Intermediate,10090.0,,A,,BAO_0000218,17208,,,1,CHEMBL626952,,,Mus musculus,N,1,2106.0,
8681,Biodistribution of radioactivity in normal mice (ICR) spleen after 2 hours of intravenous injection of [125I]-16(IMPY),Intermediate,10090.0,,A,,BAO_0000218,17208,,,1,CHEMBL626953,,,Mus musculus,N,1,2106.0,
8682,Biodistribution of radioactivity in normal mice (ICR) spleen after 2 minutes of intravenous injection of [125I]-16(IMPY),Intermediate,10090.0,,A,,BAO_0000218,17208,,,1,CHEMBL626954,,,Mus musculus,N,1,2106.0,
8683,Biodistribution of radioactivity in normal mice (ICR) spleen after 24 hours of intravenous injection of [125I]-16(IMPY),Intermediate,10090.0,,A,,BAO_0000218,17208,,,1,CHEMBL626955,,,Mus musculus,N,1,2106.0,
8684,Biodistribution of radioactivity in normal mice (ICR) spleen after 30 minutes of intravenous injection of [125I]-16(IMPY),Intermediate,10090.0,,A,,BAO_0000218,17208,,,1,CHEMBL626956,,,Mus musculus,N,1,2106.0,
8685,Biodistribution of radioactivity in normal mice (ICR) spleen after 6 hours of intravenous injection of [125I]-16(IMPY),Intermediate,10090.0,,A,,BAO_0000218,17208,,,1,CHEMBL626957,,,Mus musculus,N,1,2106.0,
8686,Biodistribution of radioactivity in normal mice blood after 1 hour of intravenous injection of [125I]-16(IMPY),Intermediate,10090.0,,A,,BAO_0000218,17208,,,1,CHEMBL626958,,,Mus musculus,N,1,178.0,
8687,Biodistribution of radioactivity in normal mice blood after 2 hours of intravenous injection of [125I]-16(IMPY),Intermediate,10090.0,,A,,BAO_0000218,17208,,,1,CHEMBL626959,,,Mus musculus,N,1,178.0,
8688,Biodistribution of radioactivity in normal mice blood after 2 minutes of intravenous injection of [125I]-16(IMPY),Intermediate,10090.0,,A,,BAO_0000218,17208,,,1,CHEMBL626960,,,Mus musculus,N,1,178.0,
8689,Biodistribution of radioactivity in normal mice blood after 24 hours of intravenous injection of [125I]-16(IMPY),Intermediate,10090.0,,A,,BAO_0000218,17208,,,1,CHEMBL626961,,,Mus musculus,N,1,178.0,
8690,Biodistribution of radioactivity in normal mice blood after 30 minutes of intravenous injection of [125I]-16(IMPY),Intermediate,10090.0,,A,,BAO_0000218,17208,,,1,CHEMBL627589,,,Mus musculus,N,1,178.0,
8691,Biodistribution of radioactivity in normal mice blood after 6 hours of intravenous injection of [125I]-16(IMPY),Intermediate,10090.0,,A,,BAO_0000218,17208,,,1,CHEMBL627590,,,Mus musculus,N,1,178.0,
8692,Time taken for EC90 was determined when tested in mouse,Intermediate,10090.0,,A,,BAO_0000218,3132,,,1,CHEMBL627591,,,Mus musculus,N,1,,
8693,Time taken for EC90 was determined when tested in mouse at dose 25 mg/kg,Intermediate,10090.0,,A,,BAO_0000218,3132,,,1,CHEMBL627592,,,Mus musculus,N,1,,
8694,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for half life (T1/2),Intermediate,10090.0,,A,,BAO_0000218,16597,,,1,CHEMBL627593,,,Mus musculus,N,1,,
8695,Half life in mice,Intermediate,10090.0,,A,,BAO_0000218,5727,,,1,CHEMBL627594,,,Mus musculus,N,1,,
8696,Half life period in mouse after 10 mg/Kg dose,Intermediate,10090.0,,A,,BAO_0000218,5302,,,1,CHEMBL876813,,,Mus musculus,N,1,,
8697,Half life period in mouse after 10 mg/kg dose,Intermediate,10090.0,,A,,BAO_0000218,5302,,,1,CHEMBL627595,,,Mus musculus,N,1,,
8698,Half life was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,Intermediate,10090.0,,A,,BAO_0000218,6348,,,1,CHEMBL627596,,,Mus musculus,N,1,,
8699,Cmax value at 5 mg/kg po was determined in rat,Intermediate,10116.0,,A,,BAO_0000218,5964,,,1,CHEMBL627597,,,Rattus norvegicus,N,1,,
8700,Cmax value evaluated in rat,Intermediate,10116.0,,A,,BAO_0000218,6078,,,1,CHEMBL627598,,,Rattus norvegicus,N,1,,
8701,Cmax value was calculated by applying at a dose of 10 mg/Kg ip in rat brain,Intermediate,10116.0,,A,,BAO_0000218,5206,,,1,CHEMBL627599,,,Rattus norvegicus,N,1,955.0,
8702,Cmax value after administration of 20 mg/Kg oral dose in rat,Intermediate,10116.0,,A,,BAO_0000218,2959,,,1,CHEMBL627600,,,Rattus norvegicus,N,1,,
8703,Cmax value at 1 mg/kg po in rat,Intermediate,10116.0,,A,,BAO_0000218,5964,,,1,CHEMBL627601,,,Rattus norvegicus,N,1,,
8704,Cmax value at 5 mg/kg po in rat,Intermediate,10116.0,,A,,BAO_0000218,5964,,,1,CHEMBL627776,,,Rattus norvegicus,N,1,,
8705,Cmax value at a dose of 10 mg/kg in male SD rats,Intermediate,10116.0,,A,,BAO_0000218,6757,,,1,CHEMBL627777,,,Rattus norvegicus,N,1,,
8706,Cmax value at a dose of 100 mg/kg in male SD rats,Intermediate,10116.0,,A,,BAO_0000218,6757,,,1,CHEMBL627778,,,Rattus norvegicus,N,1,,
8707,Cmax value at a dose of 50 mg/kg in male SD rats,Intermediate,10116.0,,A,,BAO_0000218,6757,,,1,CHEMBL627779,,,Rattus norvegicus,N,1,,
8708,Cmax value in rats at 10 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,17617,,,1,CHEMBL876814,,,Rattus norvegicus,N,1,,
8709,Cmax value was evaluated in rats at a dose of 20 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,1445,,,1,CHEMBL627780,,,Rattus norvegicus,N,1,,
8710,Cmax value was determined after peroral administration of 20 mg/kg in rat,Intermediate,10116.0,,A,,BAO_0000218,6082,,,1,CHEMBL627781,,,Rattus norvegicus,N,1,,
8711,Cmax value was determined between 15 and 30 minutes post administration in fisher rats; value ranges from 200-500,Intermediate,10116.0,,A,,BAO_0000218,1446,,,1,CHEMBL627782,,,Rattus norvegicus,N,1,,
8712,Compound was evaluated for its pharmacokinetic parameter maximum plasma concentration (Cmax) after oral administration to rats,Intermediate,10116.0,,A,,BAO_0000218,5407,,,1,CHEMBL627783,,,Rattus norvegicus,N,1,1969.0,
8713,Compound was evaluated for maximal plasma concentration in rat upon 5 mg/kg upon oral administration,Intermediate,10116.0,,A,,BAO_0000218,2690,,,1,CHEMBL627784,,,Rattus norvegicus,N,1,1969.0,
8714,Compound was evaluated for maximum concentration after treatment with oral dose of 2 mgkg to female wistar rats,Intermediate,10116.0,,A,,BAO_0000218,2661,,,1,CHEMBL627785,,,Rattus norvegicus,N,1,,
8715,Compound was evaluated for maximum concentration after treatment with oral dose of 2 mgkg to male wistar rats,Intermediate,10116.0,,A,,BAO_0000218,2661,,,1,CHEMBL627786,,,Rattus norvegicus,N,1,,
8716,Compound was evaluated for pharmacokinetic parameter maximum plasma concentration,Intermediate,10116.0,,A,,BAO_0000218,4891,,,1,CHEMBL627787,,,Rattus norvegicus,N,1,1969.0,
8717,Compound was evaluated for plasma concentration in rats when administered at 20 mg/kg in methocel at 0.5 hr,Intermediate,10116.0,,A,,BAO_0000218,2807,,,1,CHEMBL627788,,,Rattus norvegicus,N,1,1969.0,
8718,Compound was evaluated for plasma concentration in rats when administered at 20 mg/kg in methocel at 1 hr,Intermediate,10116.0,,A,,BAO_0000218,2807,,,1,CHEMBL626579,,,Rattus norvegicus,N,1,1969.0,
8719,Compound was evaluated for plasma concentration in rats when administered at 20 mg/kg in methocel at 2 hr,Intermediate,10116.0,,A,,BAO_0000218,2807,,,1,CHEMBL626580,,,Rattus norvegicus,N,1,1969.0,
8720,Compound was evaluated for the pharmacokinetic property in rats after an oral dose of 10 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,3634,,,1,CHEMBL876815,,,Rattus norvegicus,N,1,,
8721,Compound was tested for plasma concentration in rats when administered at 20 mg/kg in 1% methocel at 1 hr,Intermediate,10116.0,,A,,BAO_0000218,1881,,,1,CHEMBL626581,,,Rattus norvegicus,N,1,1969.0,
8722,Compound was tested for plasma concentration in rats when administered at 20 mg/kg in 1% methocel at 2 hr,Intermediate,10116.0,,A,,BAO_0000218,1881,,,1,CHEMBL626582,,,Rattus norvegicus,N,1,1969.0,
8723,Evaluated for pharmacokinetic parameter Cmax in rat at the dose 50 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,429,,,1,CHEMBL626583,,,Rattus norvegicus,N,1,,
8724,In vivo Cmax was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,Intermediate,10116.0,,A,,BAO_0000218,5974,,,1,CHEMBL626205,,,Rattus norvegicus,N,1,,
8725,In vivo Cmax was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,Intermediate,10116.0,,A,,BAO_0000218,5974,,,1,CHEMBL626206,,,Rattus norvegicus,N,1,,
8726,In vivo Cmax was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,Intermediate,10116.0,,A,,BAO_0000218,5974,,,1,CHEMBL626207,,,Rattus norvegicus,N,1,,
8727,In vivo Cmax was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,Intermediate,10116.0,,A,,BAO_0000218,5974,,,1,CHEMBL623882,,,Rattus norvegicus,N,1,,
8728,Maximal concentration in male Sprague-Dawley rats after 5 mg/kg intravenous dose,Intermediate,10116.0,,A,,BAO_0000218,17582,,,1,CHEMBL623883,,,Rattus norvegicus,N,1,,
8729,Maximal concentration in male Sprague-Dawley rats after 10 mg/kg oral dose,Intermediate,10116.0,,A,,BAO_0000218,17582,,,1,CHEMBL623884,,,Rattus norvegicus,N,1,,
8730,"In vivo maximum concentration of compound in rat plasma after a oral dose of 10 mg/kg (in water, N=4)",Intermediate,10116.0,,A,,BAO_0000218,3032,,,1,CHEMBL623885,,,Rattus norvegicus,N,1,1969.0,
8731,In vivo maximum concentration in rat plasma exposure after oral administration 50 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,6295,,,1,CHEMBL623886,,,Rattus norvegicus,N,1,1969.0,
8732,Maximal concentration in rat was determined,Intermediate,10116.0,,A,,BAO_0000218,6619,,,1,CHEMBL623887,,,Rattus norvegicus,N,1,,
8733,Maximal concentration after i.v. administration,Intermediate,10116.0,,A,,BAO_0000218,6616,,,1,CHEMBL623888,,,Rattus norvegicus,N,1,,
8734,Maximal concentration (Cmax) in the rat plasma at a dose of 10 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,3249,,,1,CHEMBL623889,,,Rattus norvegicus,N,1,1969.0,
8735,Maximal plasma concentration in rat after oral administration at 50 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,17791,,,1,CHEMBL623890,,,Rattus norvegicus,N,1,1969.0,
8736,Cmax in rat plasma after oral dose (50 mg/Kg),Intermediate,10116.0,,A,,BAO_0000218,17791,,,1,CHEMBL623891,,,Rattus norvegicus,N,1,1969.0,
8737,Maximal plasma concentration was determined.,Intermediate,10116.0,,A,,BAO_0000218,1360,,,1,CHEMBL623892,,,Rattus norvegicus,N,1,1969.0,
8738,Maximal plasma drug concentration was determined,Intermediate,10116.0,,A,,BAO_0000218,2552,,,1,CHEMBL623893,,,Rattus norvegicus,N,1,1969.0,
8739,Maximal concentration in rats after peroral administration,Intermediate,10116.0,,A,,BAO_0000218,6571,,,1,CHEMBL877616,,,Rattus norvegicus,N,1,,
8740,Maximum concentration in rat after 2 mg/kg peroral administration,Intermediate,10116.0,,A,,BAO_0000218,6570,,,1,CHEMBL623894,,,Rattus norvegicus,N,1,,
8741,Maximum concentration in rat plasma after 5 mg/kg oral gavage,Intermediate,10116.0,,A,,BAO_0000218,6567,,,1,CHEMBL623895,,,Rattus norvegicus,N,1,1969.0,
8742,Maximum concentration of compound in rat was evaluated.,Intermediate,10116.0,,A,,BAO_0000218,3031,,,1,CHEMBL623896,,,Rattus norvegicus,N,1,,
8743,Maximum concentration at 0.5 hr by peroral administration at a dose of 20 mg/kg in rats,Intermediate,10116.0,,A,,BAO_0000218,3436,,,1,CHEMBL623897,,,Rattus norvegicus,N,1,,
8744,Maximum concentration at 2 hr by peroral administration at a dose of 20 mg/kg in rats,Intermediate,10116.0,,A,,BAO_0000218,3436,,,1,CHEMBL623898,,,Rattus norvegicus,N,1,,
8745,Maximum concentration at 4 hr after administration of 5 mg/kg dose peroral in rat,Intermediate,10116.0,,A,,BAO_0000218,2083,,,1,CHEMBL623899,,,Rattus norvegicus,N,1,,
8746,Maximum concentration at 4 hr by peroral administration at a dose of 20 mg/kg in rats,Intermediate,10116.0,,A,,BAO_0000218,3436,,,1,CHEMBL623900,,,Rattus norvegicus,N,1,,
8747,Maximum concentration by oral administration at a dose of 100 uM/kg in rat was determined,Intermediate,10116.0,,A,,BAO_0000218,4527,,,1,CHEMBL623901,,,Rattus norvegicus,N,1,,
8748,Maximum concentration was evaluated in rats,Intermediate,10116.0,,A,,BAO_0000218,1974,,,1,CHEMBL623902,,,Rattus norvegicus,N,1,,
8749,Maximum concentration in CSF at 30 min following 24 mg/kg subcutaneous dose in rats,Intermediate,10116.0,,A,,BAO_0000218,3307,,,1,CHEMBL623903,,,Rattus norvegicus,N,1,1359.0,
8750,Maximum concentration in plasma at 30 min following 24 mg/kg subcutaneous dose in rats,Intermediate,10116.0,,A,,BAO_0000218,3307,,,1,CHEMBL623904,,,Rattus norvegicus,N,1,1969.0,
8751,Maximum concentration in plasma was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after po administration,Intermediate,10116.0,,A,,BAO_0000218,1916,,,1,CHEMBL877617,,,Rattus norvegicus,N,1,1969.0,
8752,Maximum concentration in portal vein was determined at a concentration of 10 mg/kg in rats,Intermediate,10116.0,,A,,BAO_0000218,1500,,,1,CHEMBL623905,,,Rattus norvegicus,N,1,,
8753,Maximum concentration in portal vein was determined at a concentration of 20 mg/kg in rats,Intermediate,10116.0,,A,,BAO_0000218,1500,,,1,CHEMBL623906,,,Rattus norvegicus,N,1,,
8754,Maximum concentration in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,Intermediate,10116.0,,A,,BAO_0000218,4186,,,1,CHEMBL623907,,,Rattus norvegicus,N,1,1969.0,
8755,Radioactivity distribution in bone of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,Intermediate,10116.0,,A,,BAO_0000218,16434,,,1,CHEMBL623908,,,Rattus norvegicus,N,1,,
8756,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 30 min.,Intermediate,10116.0,,A,,BAO_0000218,16434,,,1,CHEMBL623909,,,Rattus norvegicus,N,1,,
8757,Radioactivity distribution in bone of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,Intermediate,10116.0,,A,,BAO_0000218,16434,,,1,CHEMBL623910,,,Rattus norvegicus,N,1,,
8758,Radioactivity distribution in bone of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,Intermediate,10116.0,,A,,BAO_0000218,16434,,,1,CHEMBL623911,,,Rattus norvegicus,N,1,,
8759,Radioactivity distribution in bone of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,Intermediate,10116.0,,A,,BAO_0000218,16435,,,1,CHEMBL623912,,,Rattus norvegicus,N,1,,
8760,Radioactivity distribution in bone of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,Intermediate,10116.0,,A,,BAO_0000218,16435,,,1,CHEMBL624616,,,Rattus norvegicus,N,1,,
8761,Radioactivity distribution in bone of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,Intermediate,10116.0,,A,,BAO_0000218,16435,,,1,CHEMBL624617,,,Rattus norvegicus,N,1,,
8762,Radioactivity distribution in bone of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,Intermediate,10116.0,,A,,BAO_0000218,16435,,,1,CHEMBL624618,,,Rattus norvegicus,N,1,,
8763,Radioactivity distribution in bone of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,Intermediate,10116.0,,A,,BAO_0000218,16435,,,1,CHEMBL624619,,,Rattus norvegicus,N,1,,
8764,Radioactivity distribution in bone of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,Intermediate,10116.0,,A,,BAO_0000218,16435,,,1,CHEMBL624794,,,Rattus norvegicus,N,1,,
8765,Radioactivity distribution in bone of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,Intermediate,10116.0,,A,,BAO_0000218,16435,,,1,CHEMBL624795,,,Rattus norvegicus,N,1,,
8766,Radioactivity distribution in bone of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,Intermediate,10116.0,,A,,BAO_0000218,16435,,,1,CHEMBL623921,,,Rattus norvegicus,N,1,,
8767,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,Intermediate,10116.0,,A,,BAO_0000218,16434,,,1,CHEMBL623922,,,Rattus norvegicus,N,1,,
8768,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,Intermediate,10116.0,,A,,BAO_0000218,16434,,,1,CHEMBL623923,,,Rattus norvegicus,N,1,,
8769,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,Intermediate,10116.0,,A,,BAO_0000218,16434,,,1,CHEMBL623924,,,Rattus norvegicus,N,1,,
8770,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,Intermediate,10116.0,,A,,BAO_0000218,16435,,,1,CHEMBL623925,,,Rattus norvegicus,N,1,,
8771,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,Intermediate,10116.0,,A,,BAO_0000218,16435,,,1,CHEMBL623926,,,Rattus norvegicus,N,1,,
8772,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,Intermediate,10116.0,,A,,BAO_0000218,16435,,,1,CHEMBL623927,,,Rattus norvegicus,N,1,,
8773,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,Intermediate,10116.0,,A,,BAO_0000218,16435,,,1,CHEMBL623928,,,Rattus norvegicus,N,1,,
8774,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,Intermediate,10116.0,,A,,BAO_0000218,16435,,,1,CHEMBL623929,,,Rattus norvegicus,N,1,,
8775,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,Intermediate,10116.0,,A,,BAO_0000218,16435,,,1,CHEMBL623930,,,Rattus norvegicus,N,1,,
8776,Radioactivity distribution in brain of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,Intermediate,10116.0,,A,,BAO_0000218,16434,,,1,CHEMBL623931,,,Rattus norvegicus,N,1,955.0,
8777,Radioactivity distribution in brain of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,Intermediate,10116.0,,A,,BAO_0000218,16434,,,1,CHEMBL622165,,,Rattus norvegicus,N,1,955.0,
8778,Radioactivity distribution in brain of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,Intermediate,10116.0,,A,,BAO_0000218,16434,,,1,CHEMBL621249,,,Rattus norvegicus,N,1,955.0,
8779,Radioactivity distribution in brain of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,Intermediate,10116.0,,A,,BAO_0000218,16434,,,1,CHEMBL621250,,,Rattus norvegicus,N,1,955.0,
8780,Radioactivity distribution in brain of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,Intermediate,10116.0,,A,,BAO_0000218,16434,,,1,CHEMBL621448,,,Rattus norvegicus,N,1,955.0,
8781,Radioactivity distribution in brain of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,Intermediate,10116.0,,A,,BAO_0000218,16434,,,1,CHEMBL621449,,,Rattus norvegicus,N,1,955.0,
8782,Radioactivity distribution in brain of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,Intermediate,10116.0,,A,,BAO_0000218,16434,,,1,CHEMBL621450,,,Rattus norvegicus,N,1,955.0,
8783,Radioactivity distribution in brain of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,Intermediate,10116.0,,A,,BAO_0000218,16434,,,1,CHEMBL621451,,,Rattus norvegicus,N,1,955.0,
8784,Radioactivity distribution in brain of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,Intermediate,10116.0,,A,,BAO_0000218,16435,,,1,CHEMBL621452,,,Rattus norvegicus,N,1,955.0,
8785,Radioactivity distribution in brain of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,Intermediate,10116.0,,A,,BAO_0000218,16435,,,1,CHEMBL621453,,,Rattus norvegicus,N,1,955.0,
8786,Radioactivity distribution in brain of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,Intermediate,10116.0,,A,,BAO_0000218,16435,,,1,CHEMBL621454,,,Rattus norvegicus,N,1,955.0,
8787,Radioactivity distribution in brain of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,Intermediate,10116.0,,A,,BAO_0000218,16435,,,1,CHEMBL621455,,,Rattus norvegicus,N,1,955.0,
8788,Radioactivity distribution in brain of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,Intermediate,10116.0,,A,,BAO_0000218,16435,,,1,CHEMBL621456,,,Rattus norvegicus,N,1,955.0,
8789,Radioactivity distribution in brain of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,Intermediate,10116.0,,A,,BAO_0000218,16435,,,1,CHEMBL625145,,,Rattus norvegicus,N,1,955.0,
8790,Radioactivity distribution in brain of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,Intermediate,10116.0,,A,,BAO_0000218,16435,,,1,CHEMBL875847,,,Rattus norvegicus,N,1,955.0,
8791,Radioactivity distribution in brain of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,Intermediate,10116.0,,A,,BAO_0000218,16435,,,1,CHEMBL625146,,,Rattus norvegicus,N,1,955.0,
8792,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,Intermediate,10116.0,,A,,BAO_0000218,16434,,,1,CHEMBL625147,,,Rattus norvegicus,N,1,955.0,
8793,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,Intermediate,10116.0,,A,,BAO_0000218,16434,,,1,CHEMBL625148,,,Rattus norvegicus,N,1,955.0,
8794,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,Intermediate,10116.0,,A,,BAO_0000218,16434,,,1,CHEMBL625149,,,Rattus norvegicus,N,1,955.0,
8795,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,Intermediate,10116.0,,A,,BAO_0000218,16435,,,1,CHEMBL625150,,,Rattus norvegicus,N,1,955.0,
8796,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,Intermediate,10116.0,,A,,BAO_0000218,16435,,,1,CHEMBL625151,,,Rattus norvegicus,N,1,955.0,
8797,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,Intermediate,10116.0,,A,,BAO_0000218,16435,,,1,CHEMBL625152,,,Rattus norvegicus,N,1,955.0,
8798,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,Intermediate,10116.0,,A,,BAO_0000218,16435,,,1,CHEMBL625153,,,Rattus norvegicus,N,1,955.0,
8799,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,Intermediate,10116.0,,A,,BAO_0000218,16435,,,1,CHEMBL625154,,,Rattus norvegicus,N,1,955.0,
8800,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,Intermediate,10116.0,,A,,BAO_0000218,16435,,,1,CHEMBL625155,,,Rattus norvegicus,N,1,955.0,
8801,Uptake of radioligand [125I]FIDA1 by hippo-campus in rat after 30 minutes after an intravenous injection is given (average of 2 rats),Intermediate,10116.0,,A,,BAO_0000218,11977,,,1,CHEMBL625156,,,Rattus norvegicus,N,1,,
8802,Uptake of radioligand [125I]-FIDA1 by hippo-campus in rat after 60 minutes after an intravenous injection is given (average of 3 rats),Intermediate,10116.0,,A,,BAO_0000218,11977,,,1,CHEMBL624354,,,Rattus norvegicus,N,1,,
8803,Uptake of radioligand [125I]FIDA1 by hippocampus in rat after 120 minutes after an intravenous injection is given (average of 3 rats),Intermediate,10116.0,,A,,BAO_0000218,11977,,,1,CHEMBL624355,,,Rattus norvegicus,N,1,10000000.0,
8804,Uptake of radioligand [125I]FIDA1 by hippocampus in rat after 2 minutes after an intravenous injection is given (average of 3 rats),Intermediate,10116.0,,A,,BAO_0000218,11977,,,1,CHEMBL624356,,,Rattus norvegicus,N,1,10000000.0,
8805,Uptake of radioligand [125I]-FIDA1 by hippocampus in rat after 30 minutes after an intravenous injection is given (average of 3 rats),Intermediate,10116.0,,A,,BAO_0000218,11977,,,1,CHEMBL624357,,,Rattus norvegicus,N,1,10000000.0,
8806,Uptake of radioligand [125I]FIDA1 by hippocampus in rat after 60 minutes after an intravenous injection is given (average of 3 rats),Intermediate,10116.0,,A,,BAO_0000218,11977,,,1,CHEMBL624358,,,Rattus norvegicus,N,1,10000000.0,
8807,Uptake of radioligand [125I]FIDA1 by striatum in rat after 120 minutes after an intravenous injection is given (average of 3 rats),Intermediate,10116.0,,A,,BAO_0000218,11977,,,1,CHEMBL624359,,,Rattus norvegicus,N,1,2435.0,
8808,Uptake of radioligand [125I]FIDA1 by striatum in rat after 2 minutes after an intravenous injection is given (average of 3 rats),Intermediate,10116.0,,A,,BAO_0000218,11977,,,1,CHEMBL624360,,,Rattus norvegicus,N,1,2435.0,
8809,Uptake of radioligand [125I]FIDA1 by striatum in rat after 30 minutes after an intravenous injection is given (average of 2 rats),Intermediate,10116.0,,A,,BAO_0000218,11977,,,1,CHEMBL624361,,,Rattus norvegicus,N,1,2435.0,
8810,Uptake of radioligand [125I]FIDA1 by striatum in rat after 30 minutes after an intravenous injection is given (average of 3 rats),Intermediate,10116.0,,A,,BAO_0000218,11977,,,1,CHEMBL624362,,,Rattus norvegicus,N,1,2435.0,
8811,Uptake of radioligand [125I]FIDA1 by striatum in rat after 60 minutes after an intravenous injection is given (average of 3 rats),Intermediate,10116.0,,A,,BAO_0000218,11977,,,1,CHEMBL624363,,,Rattus norvegicus,N,1,2435.0,
8812,Biodistribution of radioligand [125I]FIDA1 in blood of rat after 120 minutes after an intravenous injection is given (average of 3 rats),Intermediate,10116.0,,A,,BAO_0000218,11977,,,1,CHEMBL624364,,,Rattus norvegicus,N,1,178.0,
8813,Biodistribution of radioligand [125I]FIDA1 in blood of rat after 2 minutes after an intravenous injection is given (average of 3 rats),Intermediate,10116.0,,A,,BAO_0000218,11977,,,1,CHEMBL624365,,,Rattus norvegicus,N,1,178.0,
8814,Biodistribution of radioligand [125I]FIDA1 in blood of rat after 30 minutes after an intravenous injection is given (average of 3 rats),Intermediate,10116.0,,A,,BAO_0000218,11977,,,1,CHEMBL624366,,,Rattus norvegicus,N,1,178.0,
8815,Biodistribution of radioligand [125I]FIDA1 in blood of rat after 60 minutes after an intravenous injection is given (average of 3 rats),Intermediate,10116.0,,A,,BAO_0000218,11977,,,1,CHEMBL624367,,,Rattus norvegicus,N,1,178.0,
8816,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 120 minutes after an intravenous injection is given (average of 3 rats),Intermediate,10116.0,,A,,BAO_0000218,11977,,,1,CHEMBL624368,,,Rattus norvegicus,N,1,955.0,
8817,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 2 minutes after an intravenous injection is given (average of 3 rats),Intermediate,10116.0,,A,,BAO_0000218,11977,,,1,CHEMBL624369,,,Rattus norvegicus,N,1,955.0,
8818,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 30 minutes after an intravenous injection is given (average of 2 rats),Intermediate,10116.0,,A,,BAO_0000218,11977,,,1,CHEMBL624370,,,Rattus norvegicus,N,1,955.0,
8819,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 30 minutes after an intravenous injection is given (average of 3 rats),Intermediate,10116.0,,A,,BAO_0000218,11977,,,1,CHEMBL625069,,,Rattus norvegicus,N,1,955.0,
8820,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 60 minutes after an intravenous injection is given (average of 3 rats),Intermediate,10116.0,,A,,BAO_0000218,11977,,,1,CHEMBL625070,,,Rattus norvegicus,N,1,955.0,
8821,Biodistribution of radioligand [125I]-FIDA1 in heart of rat after 120 minutes after an intravenous injection is given (average of 3 rats),Intermediate,10116.0,,A,,BAO_0000218,11977,,,1,CHEMBL626051,,,Rattus norvegicus,N,1,948.0,
8822,Biodistribution of radioligand [125I]FIDA1 in heart of rat after 2 minutes after an intravenous injection is given (average of 3 rats),Intermediate,10116.0,,A,,BAO_0000218,11977,,,1,CHEMBL626052,,,Rattus norvegicus,N,1,948.0,
8823,Biodistribution of radioligand [125I]FIDA1 in heart of rat after 30 minutes after an intravenous injection is given (average of 2 rats),Intermediate,10116.0,,A,,BAO_0000218,11977,,,1,CHEMBL626053,,,Rattus norvegicus,N,1,948.0,
8824,Biodistribution of radioligand [125I]FIDA1 in heart of rat after 30 minutes after an intravenous injection is given (average of 3 rats),Intermediate,10116.0,,A,,BAO_0000218,11977,,,1,CHEMBL626054,,,Rattus norvegicus,N,1,948.0,
8825,Biodistribution of radioligand [125I]FIDA1 in heart of rat after 60 minutes after an intravenous injection is given (average of 3 rats),Intermediate,10116.0,,A,,BAO_0000218,11977,,,1,CHEMBL626055,,,Rattus norvegicus,N,1,948.0,
8826,Biodistribution of radioligand [125I]FIDA1 in kidney of rat after 120 minutes after an intravenous injection is given (average of 3 rats),Intermediate,10116.0,,A,,BAO_0000218,11977,,,1,CHEMBL626056,,,Rattus norvegicus,N,1,2113.0,
8827,Biodistribution of radioligand [125I]-FIDA1 in kidney of rat after 2 minutes after an intravenous injection is given (average of 3 rats),Intermediate,10116.0,,A,,BAO_0000218,11977,,,1,CHEMBL626057,,,Rattus norvegicus,N,1,2113.0,
8828,Biodistribution of radioligand [125I]FIDA1 in kidney of rat after 30 minutes after an intravenous injection is given (average of 3 rats),Intermediate,10116.0,,A,,BAO_0000218,11977,,,1,CHEMBL625193,,,Rattus norvegicus,N,1,2113.0,
8829,Biodistribution of radioligand [125I]FIDA1 in kidney of rat after 60 minutes after an intravenous injection is given (average of 3 rats),Intermediate,10116.0,,A,,BAO_0000218,11977,,,1,CHEMBL625194,,,Rattus norvegicus,N,1,2113.0,
8830,Biodistribution of radioligand [125I]FIDA1 in liver of rat after 120 minutes after an intravenous injection is given (average of 3 rats),Intermediate,10116.0,,A,,BAO_0000218,11977,,,1,CHEMBL625195,,,Rattus norvegicus,N,1,2107.0,
8831,Biodistribution of radioligand [125I]-FIDA1 in liver of rat after 2 minutes after an intravenous injection is given (average of 3 rats),Intermediate,10116.0,,A,,BAO_0000218,11977,,,1,CHEMBL625196,,,Rattus norvegicus,N,1,2107.0,
8832,Biodistribution of radioligand [125I]FIDA1 in liver of rat after 30 minutes after an intravenous injection is given (average of 2 rats),Intermediate,10116.0,,A,,BAO_0000218,11977,,,1,CHEMBL625197,,,Rattus norvegicus,N,1,2107.0,
8833,Biodistribution of radioligand [125I]FIDA1 in liver of rat after 30 minutes after an intravenous injection is given (average of 3 rats),Intermediate,10116.0,,A,,BAO_0000218,11977,,,1,CHEMBL625198,,,Rattus norvegicus,N,1,2107.0,
8834,Biodistribution of radioligand [125I]FIDA1 in liver of rat after 60 minutes after an intravenous injection is given (average of 3 rats),Intermediate,10116.0,,A,,BAO_0000218,11977,,,1,CHEMBL627929,,,Rattus norvegicus,N,1,2107.0,
8835,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 120 minutes after an intravenous injection is given (average of 3 rats),Intermediate,10116.0,,A,,BAO_0000218,11977,,,1,CHEMBL627074,,,Rattus norvegicus,N,1,2048.0,
8836,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 2 minutes after an intravenous injection is given (average of 3 rats),Intermediate,10116.0,,A,,BAO_0000218,11977,,,1,CHEMBL627075,,,Rattus norvegicus,N,1,2048.0,
8837,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 30 minutes after an intravenous injection is given (average of 2 rats),Intermediate,10116.0,,A,,BAO_0000218,11977,,,1,CHEMBL627076,,,Rattus norvegicus,N,1,2048.0,
8838,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 30 minutes after an intravenous injection is given (average of 3 rats),Intermediate,10116.0,,A,,BAO_0000218,11977,,,1,CHEMBL627077,,,Rattus norvegicus,N,1,2048.0,
8839,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 60 minutes after an intravenous injection is given (average of 3 rats),Intermediate,10116.0,,A,,BAO_0000218,11977,,,1,CHEMBL627078,,,Rattus norvegicus,N,1,2048.0,
8840,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 120 minutes after an intravenous injection is given (average of 2 rats),Intermediate,10116.0,,A,,BAO_0000218,11977,,,1,CHEMBL627079,,,Rattus norvegicus,N,1,2385.0,
8841,Half life (t1/2) determined at a dose 10 mg/kg administered intraperitoneally to mice,Intermediate,10090.0,,A,,BAO_0000218,4573,,,1,CHEMBL873824,,,Mus musculus,N,1,,
8842,Half life in mouse plasma was determined at dose 25 mg/kg,Intermediate,10090.0,,A,,BAO_0000218,3132,,,1,CHEMBL627080,,,Mus musculus,N,1,1969.0,
8843,Half life was determined,Intermediate,10090.0,,A,,BAO_0000218,17718,,,1,CHEMBL627081,,,Mus musculus,N,1,,
8844,Half life in BALB/C mice at the dose of 20 mg/kg by i.v. administration,Intermediate,10090.0,,A,,BAO_0000218,17728,,,1,CHEMBL627082,,,Mus musculus,N,1,,
8845,Half-life in male mice after 1 mg/kg intravenous dose,Intermediate,10090.0,,A,,BAO_0000218,5961,,,1,CHEMBL627083,,,Mus musculus,N,1,,
8847,Half life in mice plasma,Intermediate,10090.0,,A,,BAO_0000218,17731,,,1,CHEMBL627085,,,Mus musculus,N,1,1969.0,
8848,Half life in mouse,Intermediate,10090.0,,A,,BAO_0000218,17592,,,1,CHEMBL627086,,,Mus musculus,N,1,,
8849,Half life in mouse plasma at dose 25 mg/kg,Intermediate,10090.0,,A,,BAO_0000218,3132,,,1,CHEMBL627087,,,Mus musculus,N,1,1969.0,
8850,Half life when injected i.p. in mice at a dose of 50 mg/kg was determined,Intermediate,10090.0,,A,,BAO_0000218,17729,,,1,CHEMBL627088,,,Mus musculus,N,1,,
8851,Half life when injected intravenously in mice at a dose of 20 mg/kg was determined,Intermediate,10090.0,,A,,BAO_0000218,17729,,,1,CHEMBL627089,,,Mus musculus,N,1,,
8852,Half life when injected perorally in mice at a dose of 50 mg/kg was determined,Intermediate,10090.0,,A,,BAO_0000218,17729,,,1,CHEMBL627090,,,Mus musculus,N,1,,
8853,Half life was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),Intermediate,10090.0,,A,,BAO_0000218,3277,,,1,CHEMBL627091,,,Mus musculus,N,1,,
8854,"Half life was evaluated at 5 mg/kg of compound dose, administered perorally in mice",Intermediate,10090.0,,A,,BAO_0000218,3760,,,1,CHEMBL627092,,,Mus musculus,N,1,,
8855,"Half life was evaluated at 50 mg/kg of compound dose, administered perorally in mice",Intermediate,10090.0,,A,,BAO_0000218,3760,,,1,CHEMBL876785,,,Mus musculus,N,1,,
8856,Half-life by iv administration in mouse,Intermediate,10090.0,,A,,BAO_0000218,2862,,,1,CHEMBL627093,,,Mus musculus,N,1,,
8857,Half-life by oral administration in mouse,Intermediate,10090.0,,A,,BAO_0000218,2862,,,1,CHEMBL627094,,,Mus musculus,N,1,,
8858,Half-life in mice,Intermediate,10090.0,,A,,BAO_0000218,5980,,,1,CHEMBL627095,,,Mus musculus,N,1,,
8859,Half-life using mouse brain homogenate,Intermediate,10090.0,,A,,BAO_0000218,6159,,,1,CHEMBL627096,,,Mus musculus,N,1,955.0,
8860,Half-life was measured in mice,Intermediate,10090.0,,A,,BAO_0000218,6254,,,1,CHEMBL627097,,,Mus musculus,N,1,,
8861,Half-life was measured in mouse after an iv dose of 1 mg/kg,Intermediate,10090.0,,A,,BAO_0000218,6062,,,1,CHEMBL627098,,,Mus musculus,N,1,,
8862,Half-life period was determined in mouse blood,Intermediate,10090.0,,A,,BAO_0000218,1574,,,1,CHEMBL627099,,,Mus musculus,N,1,178.0,
8863,"Half-times of inhibition of PEP in in an ex vivo enzyme studies, using mice brain",Intermediate,10090.0,,A,,BAO_0000218,56,,,1,CHEMBL627100,,,Mus musculus,N,1,955.0,
8864,Plasma half life in mouse,Intermediate,10090.0,,A,,BAO_0000218,993,,,1,CHEMBL627101,,,Mus musculus,N,1,1969.0,
8865,Stability of the peptide in the presence of mouse serum,Intermediate,10090.0,,A,,BAO_0000218,6652,,,1,CHEMBL627102,,,Mus musculus,N,1,,
8866,Terminal half life of compound was determined in mouse,Intermediate,10090.0,,A,,BAO_0000218,17852,,,1,CHEMBL627103,,,Mus musculus,N,1,,
8867,Terminal half life was evaluated in mice after intravenous administration,Intermediate,10090.0,,A,,BAO_0000218,2675,,,1,CHEMBL627104,,,Mus musculus,N,1,,
8868,Terminal half life was evaluated in mice after oral administration,Intermediate,10090.0,,A,,BAO_0000218,2675,,,1,CHEMBL627105,,,Mus musculus,N,1,,
8869,The compound was evaluated for half life (release of DOX) in mice at 37 degree Celsius at the pH 5.,Intermediate,10090.0,,A,,BAO_0000218,499,,,1,CHEMBL876786,,,Mus musculus,N,1,,
8870,The compound was evaluated for half life (release of DOX) in mice at 37 degree Celsius at the pH 7.,Intermediate,10090.0,,A,,BAO_0000218,499,,,1,CHEMBL873825,,,Mus musculus,N,1,,
8871,The compound was evaluated for half life (release of DOX) in mice at 37 degree Celsius at the pH 7; ND means no data,Intermediate,10090.0,,A,,BAO_0000218,499,,,1,CHEMBL627106,,,Mus musculus,N,1,,
8872,half life period is evaluated by administering intravenously at 25 mg/kg in mice,Intermediate,10090.0,,A,,BAO_0000218,14239,,,1,CHEMBL626336,,,Mus musculus,N,1,,
8873,"Half life beta(2,4,6,8h) value was determined at a dose of 200 mg/kg (i.p.) in Mice",Intermediate,10090.0,,A,,BAO_0000218,5506,,,1,CHEMBL877462,,,Mus musculus,N,1,,
8874,"Half life beta(2,4,6,8h) value was determined at a dose of 200 mg/kg (i.p.) in Mice; NC: not calculable",Intermediate,10090.0,,A,,BAO_0000218,5506,,,1,CHEMBL626337,,,Mus musculus,N,1,,
8875,Half life after intraperitoneal administration of 100 mg/kg in mice,Intermediate,10090.0,,A,,BAO_0000218,17734,,,1,CHEMBL626338,,,Mus musculus,N,1,,
8876,Half life in BALB/C mice at the dose of 20 mg/kg by i.p. administration,Intermediate,10090.0,,A,,BAO_0000218,17728,,,1,CHEMBL626339,,,Mus musculus,N,1,,
8877,Half life in BALB/C mice at the dose of 20 mg/kg by i.v. administration,Intermediate,10090.0,,A,,BAO_0000218,17728,,,1,CHEMBL626340,,,Mus musculus,N,1,,
8878,Half life in BALB/C mice at the dose of 20 mg/kg by p.o. administration,Intermediate,10090.0,,A,,BAO_0000218,17728,,,1,CHEMBL625377,,,Mus musculus,N,1,,
8879,Half life in BALB/C mice at the dose of 50 mg/kg by i.p. administration,Intermediate,10090.0,,A,,BAO_0000218,17728,,,1,CHEMBL625378,,,Mus musculus,N,1,,
8880,Half life in BALB/C mice at the dose of 50 mg/kg by p.o. administration,Intermediate,10090.0,,A,,BAO_0000218,17728,,,1,CHEMBL625379,,,Mus musculus,N,1,,
8881,Metabolism of compound in mini pig S9 microsomes ('+''indicates <20% largest observed peak),Autocuration,9823.0,,A,,BAO_0000251,14294,Microsomes,,1,CHEMBL625380,,,Sus scrofa,U,0,,
8882,Metabolism of compound in mini pig S9 microsomes ('++++' indicates largest observed peak),Autocuration,9823.0,,A,,BAO_0000251,14294,Microsomes,,1,CHEMBL625381,,,Sus scrofa,U,0,,
8883,Stability to porcine renal DHP-I,Autocuration,9823.0,,A,,BAO_0000019,6056,,,1,CHEMBL625382,,,Sus scrofa,U,0,,
8884,Compound was tested for its half-life period at an intravenous dose of 30 ug/kg,Autocuration,9823.0,,A,,BAO_0000218,1317,,,1,CHEMBL873828,,,Sus scrofa,U,0,,
8885,Compound was tested for its half-life period at an intravenous dose of 3 ug/kg,Autocuration,9823.0,,A,,BAO_0000218,1317,,,1,CHEMBL625383,,,Sus scrofa,U,0,,
8886,Half-life of the parent prodrug in porcine esterase solution,Autocuration,9823.0,,A,,BAO_0000019,5229,,,1,CHEMBL625384,,,Sus scrofa,U,0,,
8887,"First order rate constant, k was determined in in pig liver Esterase",Autocuration,9823.0,,A,,BAO_0000019,4231,,,1,CHEMBL625385,,,Sus scrofa,U,0,,
8888,Half life of the in pig liver Esterase,Autocuration,9823.0,,A,,BAO_0000221,4231,,,1,CHEMBL625386,,,Sus scrofa,U,0,2107.0,
8889,Tested for half life period at 37 degree Celsius in PBS buffer at 11.8 pH containing porcine liver esterase,Autocuration,9823.0,,A,,BAO_0000221,5318,,,1,CHEMBL623571,,,Sus scrofa,U,0,2107.0,
8890,Tested for half life period at 37 degree Celsius in PBS buffer at 7.3 pH containing porcine liver esterase,Autocuration,9823.0,,A,,BAO_0000221,5318,,,1,CHEMBL623572,,,Sus scrofa,U,0,2107.0,
8891,Tested for half life period at 37 degree Celsius in PBS buffer at 7.3 pH in containing porcine liver esterase,Autocuration,9823.0,,A,,BAO_0000221,5318,,,1,CHEMBL623573,,,Sus scrofa,U,0,2107.0,
8892,Compound was evaluated for esterase half-life (t 1/2) period using Pig Liver Esterase (PLE) assay,Autocuration,9823.0,,A,,BAO_0000221,3305,,,1,CHEMBL623574,,,Sus scrofa,U,0,2107.0,
8893,Compound was evaluated for esterase half-life (t 1/2) period using Pig Liver Esterase (PLE) assay; ND is not determined,Autocuration,9823.0,,A,,BAO_0000221,3305,,,1,CHEMBL623575,,,Sus scrofa,U,0,2107.0,
8894,Half-life in the presence of pig liver esterase(PLE) was evaluated.,Autocuration,9823.0,,A,,BAO_0000221,2842,,,1,CHEMBL623749,,,Sus scrofa,U,0,2107.0,
8895,Half-life in the presence of pig liver esterase(PLE) was evaluated; Stable,Autocuration,9823.0,,A,,BAO_0000221,2842,,,1,CHEMBL623750,,,Sus scrofa,U,0,2107.0,
8896,Half-life in vitro in pig liver,Autocuration,9823.0,,A,,BAO_0000221,889,,,1,CHEMBL623751,,,Sus scrofa,U,0,2107.0,
8897,Half-life time was determined for esterase-catalyzed hydrolysis of the phenol ester bond in porcine liver esterase,Autocuration,9823.0,,A,,BAO_0000221,1904,,,1,CHEMBL623752,,,Sus scrofa,U,0,2107.0,
8898,Maximum concentration in rat plasma after administration of 50 mg/kg dose through subcutaneous route,Intermediate,10116.0,,A,,BAO_0000218,4186,,,1,CHEMBL623753,,,Rattus norvegicus,N,1,1969.0,
8899,Maximum concentration in rat plasma at 30 mg/Kg upon oral administration.,Intermediate,10116.0,,A,,BAO_0000218,2774,,,1,CHEMBL623754,,,Rattus norvegicus,N,1,1969.0,
8900,Maximum concentration in rat plasma was determined,Intermediate,10116.0,,A,,BAO_0000218,1742,,,1,CHEMBL623755,,,Rattus norvegicus,N,1,1969.0,
8901,Maximum concentration in rats,Intermediate,10116.0,,A,,BAO_0000218,3169,,,1,CHEMBL623756,,,Rattus norvegicus,N,1,,
8902,Maximum concentration in rats at 1-2 hours,Intermediate,10116.0,,A,,BAO_0000218,3169,,,1,CHEMBL623757,,,Rattus norvegicus,N,1,,
8903,Maximum concentration in rats at 1 hr was determined when dosed at 20 mg/Kg perorally,Intermediate,10116.0,,A,,BAO_0000218,2081,,,1,CHEMBL623758,,,Rattus norvegicus,N,1,,
8904,Maximum concentration in whole brain at 30 min following 24 mg/kg subcutaneous dose in rats,Intermediate,10116.0,,A,,BAO_0000218,3307,,,1,CHEMBL623759,,,Rattus norvegicus,N,1,955.0,
8905,Maximum concentration at the dose of 2 mg/kg in rat,Intermediate,10116.0,,A,,BAO_0000218,4727,,,1,CHEMBL623760,,,Rattus norvegicus,N,1,,
8906,Maximum concentration was evaluated in rats,Intermediate,10116.0,,A,,BAO_0000218,6597,,,1,CHEMBL623761,,,Rattus norvegicus,N,1,,
8907,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 10 mg/kg to a fasting rat,Intermediate,10116.0,,A,,BAO_0000218,16365,,,1,CHEMBL623762,,,Rattus norvegicus,N,1,1969.0,
8908,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 1 mg/kg to a fasting rat,Intermediate,10116.0,,A,,BAO_0000218,16365,,,1,CHEMBL877594,,,Rattus norvegicus,N,1,1969.0,
8909,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 30 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,16365,,,1,CHEMBL623763,,,Rattus norvegicus,N,1,1969.0,
8910,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 3 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,16365,,,1,CHEMBL623764,,,Rattus norvegicus,N,1,1969.0,
8911,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 3 mg/kg to a fasting rat,Intermediate,10116.0,,A,,BAO_0000218,16365,,,1,CHEMBL623765,,,Rattus norvegicus,N,1,1969.0,
8912,Maximum concentration value was evaluated for high sustained blood levels in rat after 1 hr of administration,Intermediate,10116.0,,A,,BAO_0000218,2591,,,1,CHEMBL623766,,,Rattus norvegicus,N,1,178.0,
8913,Maximum concentration value was evaluated for high sustained blood levels in rat after 2 hr of administration,Intermediate,10116.0,,A,,BAO_0000218,2591,,,1,CHEMBL623767,,,Rattus norvegicus,N,1,178.0,
8914,Maximum concentration value was evaluated for high sustained blood levels in rat after 30 min of administration,Intermediate,10116.0,,A,,BAO_0000218,2591,,,1,CHEMBL623768,,,Rattus norvegicus,N,1,178.0,
8915,Maximum plasma concentration (Cmax) of compound (19.2 mg/kg) after po administration was determined Sprague-Dawley rat,Intermediate,10116.0,,A,,BAO_0000218,5978,,,1,CHEMBL623769,,,Rattus norvegicus,N,1,1969.0,
8916,Maximum plasma concentration (Cmax) of compound (19.76 mg/kg) after po administration was determined Sprague-Dawley rat,Intermediate,10116.0,,A,,BAO_0000218,5978,,,1,CHEMBL623770,,,Rattus norvegicus,N,1,1969.0,
8917,Maximum plasma concentration (Cmax) of compound (20.73 mg/kg) after po administration was determined Sprague-Dawley rat,Intermediate,10116.0,,A,,BAO_0000218,5978,,,1,CHEMBL623771,,,Rattus norvegicus,N,1,1969.0,
8918,Maximum plasma concentration (Cmax) of compound (25 mg/kg) after po administration was determined Sprague-Dawley rat,Intermediate,10116.0,,A,,BAO_0000218,5978,,,1,CHEMBL623772,,,Rattus norvegicus,N,1,1969.0,
8919,Maximum plasma concentration (Cmax) of compound (9.83 mg/kg) after iv administration was determined Sprague-Dawley rat,Intermediate,10116.0,,A,,BAO_0000218,5978,,,1,CHEMBL623773,,,Rattus norvegicus,N,1,1969.0,
8920,Maximum plasma concentration (Cmax) of compound (9.84 mg/kg) after iv administration was determined Sprague-Dawley rat,Intermediate,10116.0,,A,,BAO_0000218,5978,,,1,CHEMBL623774,,,Rattus norvegicus,N,1,1969.0,
8921,Maximum plasma concentration (Cmax) of compound (9.92 mg/kg) after iv administration was determined Sprague-Dawley rat,Intermediate,10116.0,,A,,BAO_0000218,5978,,,1,CHEMBL623775,,,Rattus norvegicus,N,1,1969.0,
8922,Cmax in rat (PO dose),Intermediate,10116.0,,A,,BAO_0000218,14465,,,1,CHEMBL623776,,,Rattus norvegicus,N,1,,
8923,Maximum plasma concentration determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,Intermediate,10116.0,,A,,BAO_0000218,4723,,,1,CHEMBL622191,,,Rattus norvegicus,N,1,1969.0,
8924,Maximum plasma concentration determined after 3 mg/kg oral administration in potassium oxonate treated rats,Intermediate,10116.0,,A,,BAO_0000218,4723,,,1,CHEMBL622192,,,Rattus norvegicus,N,1,1969.0,
8925,Maximum plasma concentration determined in rat,Intermediate,10116.0,,A,,BAO_0000218,4576,,,1,CHEMBL622193,,,Rattus norvegicus,N,1,1969.0,
8926,Maximum plasma concentration for the compound in solution form (formulation) was determined in rats at peroral dose of 5 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,12873,,,1,CHEMBL622194,,,Rattus norvegicus,N,1,1969.0,
8927,Maximum plasma concentration for the compound in suspension form (formulation) was determined in rats at peroral dose of 5 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,12873,,,1,CHEMBL622195,,,Rattus norvegicus,N,1,1969.0,
8928,Maximum plasma concentration in rat,Intermediate,10116.0,,A,,BAO_0000218,6824,,,1,CHEMBL622196,,,Rattus norvegicus,N,1,1969.0,
8929,Maximum plasma concentration measured after intravenous bolus administration of 50 mg/kg of compound to rats,Intermediate,10116.0,,A,,BAO_0000218,17065,,,1,CHEMBL622197,,,Rattus norvegicus,N,1,1969.0,
8930,Maximum plasma concentration of compound present in rats at the dose of 37 mg/kg in 15 min,Intermediate,10116.0,,A,,BAO_0000218,2932,,,1,CHEMBL622198,,,Rattus norvegicus,N,1,1969.0,
8931,Maximum plasma concentration of compound present in rats at the dose of 38 mg/kg in 15 min,Intermediate,10116.0,,A,,BAO_0000218,2932,,,1,CHEMBL622199,,,Rattus norvegicus,N,1,1969.0,
8932,Maximum plasma concentration of compound was measured in rat,Intermediate,10116.0,,A,,BAO_0000218,2879,,,1,CHEMBL622200,,,Rattus norvegicus,N,1,1969.0,
8933,Maximum plasma concentration after 20 mg/kg oral administration in rat,Intermediate,10116.0,,A,,BAO_0000218,2864,,,1,CHEMBL622201,,,Rattus norvegicus,N,1,1969.0,
8934,Maximum plasma concentration after oral administration to rats,Intermediate,10116.0,,A,,BAO_0000218,16367,,,1,CHEMBL623990,,,Rattus norvegicus,N,1,1969.0,
8935,Maximum plasma concentration at a concentration of 15 mg/kg perorally in rats along with 100 mg/kg of compound 11,Intermediate,10116.0,,A,,BAO_0000218,17717,,,1,CHEMBL623991,,,Rattus norvegicus,N,1,1969.0,
8936,"Maximum plasma concentration at a concentration of 3 mg/kg in rats, intravenously",Intermediate,10116.0,,A,,BAO_0000218,17717,,,1,CHEMBL623992,,,Rattus norvegicus,N,1,1969.0,
8937,Maximum plasma concentration at a concentration of 60 mg/kg perorally in rats along with 100 mg/kg of compound 11,Intermediate,10116.0,,A,,BAO_0000218,17717,,,1,CHEMBL623993,,,Rattus norvegicus,N,1,1969.0,
8938,Maximum plasma concentration at a concentration of 60 mg/kg perorally in rats along with control,Intermediate,10116.0,,A,,BAO_0000218,17717,,,1,CHEMBL623994,,,Rattus norvegicus,N,1,1969.0,
8939,Maximum plasma concentration at a dose of 100 mg/kg in Rat Plasma after iv administration,Intermediate,10116.0,,F,,BAO_0000218,17720,,,1,CHEMBL623995,,,Rattus norvegicus,N,1,1969.0,
8940,Maximum plasma concentration at a dose of 4 mg/kg in Rat Plasma after iv administration,Intermediate,10116.0,,F,,BAO_0000218,17720,,,1,CHEMBL623996,,,Rattus norvegicus,N,1,1969.0,
8941,Maximum plasma concentration at a dose of 50 mg/kg in Rat Plasma after iv administration,Intermediate,10116.0,,F,,BAO_0000218,17720,,,1,CHEMBL623997,,,Rattus norvegicus,N,1,1969.0,
8942,Maximum plasma concentration dosed orally in rats,Intermediate,10116.0,,A,,BAO_0000218,4516,,,1,CHEMBL623998,,,Rattus norvegicus,N,1,1969.0,
8943,Maximum plasma concentration dosed orally in rats after 6 hours,Intermediate,10116.0,,A,,BAO_0000218,4516,,,1,CHEMBL623999,,,Rattus norvegicus,N,1,1969.0,
8944,Maximum plasma concentration dosed orally in rats after 6 hours; ND is not detected,Intermediate,10116.0,,A,,BAO_0000218,4516,,,1,CHEMBL624000,,,Rattus norvegicus,N,1,1969.0,
8945,Maximum plasma concentration at a 1 mg/kg oral dose in female Sprague-Dawley rats,Intermediate,10116.0,,A,,BAO_0000218,5199,,,1,CHEMBL624001,,,Rattus norvegicus,N,1,1969.0,
8946,Maximum plasma concentration in rat after po administration,Intermediate,10116.0,,A,,BAO_0000218,17538,,,1,CHEMBL624002,,,Rattus norvegicus,N,1,1969.0,
8947,"Maximum plasma concentration in rats at 10 mg/kg, p.o. dose",Intermediate,10116.0,,A,,BAO_0000218,6685,,,1,CHEMBL624003,,,Rattus norvegicus,N,1,1969.0,
8948,"Maximum plasma concentration in rats at 20mg/kg, i.p. dose",Intermediate,10116.0,,A,,BAO_0000218,6685,,,1,CHEMBL624004,,,Rattus norvegicus,N,1,1969.0,
8949,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,Intermediate,10116.0,,A,,BAO_0000218,16434,,,1,CHEMBL624005,,,Rattus norvegicus,N,1,948.0,
8950,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,Intermediate,10116.0,,A,,BAO_0000218,16434,,,1,CHEMBL624006,,,Rattus norvegicus,N,1,948.0,
8951,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,Intermediate,10116.0,,A,,BAO_0000218,16434,,,1,CHEMBL624007,,,Rattus norvegicus,N,1,948.0,
8952,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,Intermediate,10116.0,,A,,BAO_0000218,16434,,,1,CHEMBL624008,,,Rattus norvegicus,N,1,948.0,
8953,Radioactivity distribution in heart of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,Intermediate,10116.0,,A,,BAO_0000218,16434,,,1,CHEMBL624009,,,Rattus norvegicus,N,1,948.0,
8954,Radioactivity distribution in heart of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,Intermediate,10116.0,,A,,BAO_0000218,16434,,,1,CHEMBL874387,,,Rattus norvegicus,N,1,948.0,
8955,Radioactivity distribution in heart of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,Intermediate,10116.0,,A,,BAO_0000218,16434,,,1,CHEMBL624010,,,Rattus norvegicus,N,1,948.0,
8956,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 60 min.,Intermediate,10116.0,,A,,BAO_0000218,16434,,,1,CHEMBL624011,,,Rattus norvegicus,N,1,948.0,
8957,Radioactivity distribution in heart of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,Intermediate,10116.0,,A,,BAO_0000218,16435,,,1,CHEMBL624012,,,Rattus norvegicus,N,1,948.0,
8958,Radioactivity distribution in heart of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,Intermediate,10116.0,,A,,BAO_0000218,16435,,,1,CHEMBL624013,,,Rattus norvegicus,N,1,948.0,
8959,Radioactivity distribution in heart of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,Intermediate,10116.0,,A,,BAO_0000218,16435,,,1,CHEMBL624736,,,Rattus norvegicus,N,1,948.0,
8960,Radioactivity distribution in heart of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,Intermediate,10116.0,,A,,BAO_0000218,16435,,,1,CHEMBL624737,,,Rattus norvegicus,N,1,948.0,
8961,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,Intermediate,10116.0,,A,,BAO_0000218,16434,,,1,CHEMBL624738,,,Rattus norvegicus,N,1,948.0,
8962,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,Intermediate,10116.0,,A,,BAO_0000218,16434,,,1,CHEMBL624739,,,Rattus norvegicus,N,1,948.0,
8963,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,Intermediate,10116.0,,A,,BAO_0000218,16434,,,1,CHEMBL624740,,,Rattus norvegicus,N,1,948.0,
8964,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,Intermediate,10116.0,,A,,BAO_0000218,16435,,,1,CHEMBL624896,,,Rattus norvegicus,N,1,948.0,
8965,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,Intermediate,10116.0,,A,,BAO_0000218,16435,,,1,CHEMBL624897,,,Rattus norvegicus,N,1,948.0,
8966,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,Intermediate,10116.0,,A,,BAO_0000218,16435,,,1,CHEMBL624108,,,Rattus norvegicus,N,1,948.0,
8967,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,Intermediate,10116.0,,A,,BAO_0000218,16435,,,1,CHEMBL624109,,,Rattus norvegicus,N,1,948.0,
8968,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,Intermediate,10116.0,,A,,BAO_0000218,16435,,,1,CHEMBL624110,,,Rattus norvegicus,N,1,948.0,
8969,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,Intermediate,10116.0,,A,,BAO_0000218,16435,,,1,CHEMBL624111,,,Rattus norvegicus,N,1,948.0,
8970,Radioactivity distribution in heart of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,Intermediate,10116.0,,A,,BAO_0000218,16435,,,1,CHEMBL624112,,,Rattus norvegicus,N,1,948.0,
8971,Radioactivity distribution in heart of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,Intermediate,10116.0,,A,,BAO_0000218,16435,,,1,CHEMBL624113,,,Rattus norvegicus,N,1,948.0,
8972,Radioactivity distribution in heart of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,Intermediate,10116.0,,A,,BAO_0000218,16435,,,1,CHEMBL619709,,,Rattus norvegicus,N,1,948.0,
8973,Radioactivity distribution in heart of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,Intermediate,10116.0,,A,,BAO_0000218,16435,,,1,CHEMBL619710,,,Rattus norvegicus,N,1,948.0,
8974,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,Intermediate,10116.0,,A,,BAO_0000218,16434,,,1,CHEMBL619711,,,Rattus norvegicus,N,1,2113.0,
8975,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,Intermediate,10116.0,,A,,BAO_0000218,16434,,,1,CHEMBL619712,,,Rattus norvegicus,N,1,2113.0,
8976,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,Intermediate,10116.0,,A,,BAO_0000218,16434,,,1,CHEMBL619713,,,Rattus norvegicus,N,1,2113.0,
8977,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,Intermediate,10116.0,,A,,BAO_0000218,16434,,,1,CHEMBL619714,,,Rattus norvegicus,N,1,2113.0,
8978,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,Intermediate,10116.0,,A,,BAO_0000218,16434,,,1,CHEMBL619715,,,Rattus norvegicus,N,1,2113.0,
8979,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,Intermediate,10116.0,,A,,BAO_0000218,16434,,,1,CHEMBL619716,,,Rattus norvegicus,N,1,2113.0,
8980,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,Intermediate,10116.0,,A,,BAO_0000218,16434,,,1,CHEMBL619717,,,Rattus norvegicus,N,1,2113.0,
8981,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,Intermediate,10116.0,,A,,BAO_0000218,16434,,,1,CHEMBL619718,,,Rattus norvegicus,N,1,2113.0,
8982,Radioactivity distribution in kidney of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,Intermediate,10116.0,,A,,BAO_0000218,16435,,,1,CHEMBL619719,,,Rattus norvegicus,N,1,2113.0,
8983,Radioactivity distribution in kidney of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,Intermediate,10116.0,,A,,BAO_0000218,16435,,,1,CHEMBL875329,,,Rattus norvegicus,N,1,2113.0,
8984,Radioactivity distribution in kidney of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,Intermediate,10116.0,,A,,BAO_0000218,16435,,,1,CHEMBL619720,,,Rattus norvegicus,N,1,2113.0,
8985,Radioactivity distribution in kidney of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,Intermediate,10116.0,,A,,BAO_0000218,16435,,,1,CHEMBL619721,,,Rattus norvegicus,N,1,2113.0,
8986,Radioactivity distribution in kidney of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,Intermediate,10116.0,,A,,BAO_0000218,16435,,,1,CHEMBL619722,,,Rattus norvegicus,N,1,2113.0,
8987,Radioactivity distribution in kidney of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,Intermediate,10116.0,,A,,BAO_0000218,16435,,,1,CHEMBL619723,,,Rattus norvegicus,N,1,2113.0,
8988,Radioactivity distribution in kidney of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,Intermediate,10116.0,,A,,BAO_0000218,16435,,,1,CHEMBL619724,,,Rattus norvegicus,N,1,2113.0,
8989,Radioactivity distribution in kidney of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,Intermediate,10116.0,,A,,BAO_0000218,16435,,,1,CHEMBL619725,,,Rattus norvegicus,N,1,2113.0,
8990,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,Intermediate,10116.0,,A,,BAO_0000218,16434,,,1,CHEMBL619726,,,Rattus norvegicus,N,1,2113.0,
8991,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,Intermediate,10116.0,,A,,BAO_0000218,16434,,,1,CHEMBL619727,,,Rattus norvegicus,N,1,2113.0,
8992,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,Intermediate,10116.0,,A,,BAO_0000218,16434,,,1,CHEMBL619728,,,Rattus norvegicus,N,1,2113.0,
8993,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,Intermediate,10116.0,,A,,BAO_0000218,16435,,,1,CHEMBL619729,,,Rattus norvegicus,N,1,2113.0,
8994,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 120 minutes after an intravenous injection is given (average of 3 rats),Intermediate,10116.0,,A,,BAO_0000218,11977,,,1,CHEMBL619730,,,Rattus norvegicus,N,1,2385.0,
8995,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 2 minutes after an intravenous injection is given (average of 3 rats),Intermediate,10116.0,,A,,BAO_0000218,11977,,,1,CHEMBL619731,,,Rattus norvegicus,N,1,2385.0,
8996,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 30 minutes after an intravenous injection is given (average of 2 rats),Intermediate,10116.0,,A,,BAO_0000218,11977,,,1,CHEMBL619732,,,Rattus norvegicus,N,1,2385.0,
8997,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 30 minutes after an intravenous injection is given (average of 3 rats),Intermediate,10116.0,,A,,BAO_0000218,11977,,,1,CHEMBL619733,,,Rattus norvegicus,N,1,2385.0,
8998,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 60 minutes after an intravenous injection is given (average of 3 rats),Intermediate,10116.0,,A,,BAO_0000218,11977,,,1,CHEMBL619734,,,Rattus norvegicus,N,1,2385.0,
8999,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 120 minutes after an intravenous injection is given (average of 3 rats),Intermediate,10116.0,,A,,BAO_0000218,11977,,,1,CHEMBL619735,,,Rattus norvegicus,N,1,14.0,
9000,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 2 minutes after an intravenous injection is given (average of 3 rats),Intermediate,10116.0,,A,,BAO_0000218,11977,,,1,CHEMBL875330,,,Rattus norvegicus,N,1,14.0,
9001,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 30 minutes after an intravenous injection is given (average of 2 rats),Intermediate,10116.0,,A,,BAO_0000218,11977,,,1,CHEMBL628465,,,Rattus norvegicus,N,1,14.0,
9002,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 30 minutes after an intravenous injection is given (average of 3 rats),Intermediate,10116.0,,A,,BAO_0000218,11977,,,1,CHEMBL628466,,,Rattus norvegicus,N,1,14.0,
9003,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 60 minutes after an intravenous injection is given (average of 3 rats),Intermediate,10116.0,,A,,BAO_0000218,11977,,,1,CHEMBL628467,,,Rattus norvegicus,N,1,14.0,
9004,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 120 minutes after an intravenous injection is given (average of 3 rats),Intermediate,10116.0,,A,,BAO_0000218,11977,,,1,CHEMBL628468,,,Rattus norvegicus,N,1,2106.0,
9005,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 2 minutes after an intravenous injection is given (average of 3 rats),Intermediate,10116.0,,A,,BAO_0000218,11977,,,1,CHEMBL628469,,,Rattus norvegicus,N,1,2106.0,
9006,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 30 minutes after an intravenous injection is given (average of 2 rats),Intermediate,10116.0,,A,,BAO_0000218,11977,,,1,CHEMBL628470,,,Rattus norvegicus,N,1,2106.0,
9007,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 30 minutes after an intravenous injection is given (average of 3 rats),Intermediate,10116.0,,A,,BAO_0000218,11977,,,1,CHEMBL628471,,,Rattus norvegicus,N,1,2106.0,
9008,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 60 minutes after an intravenous injection is given (average of 3 rats),Intermediate,10116.0,,A,,BAO_0000218,11977,,,1,CHEMBL628472,,,Rattus norvegicus,N,1,2106.0,
9009,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 120 minutes after an intravenous injection is given (average of 3 rats),Intermediate,10116.0,,A,,BAO_0000218,11977,,,1,CHEMBL625191,,,Rattus norvegicus,N,1,2046.0,
9010,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 2 minutes after an intravenous injection is given (average of 3 rats),Intermediate,10116.0,,A,,BAO_0000218,11977,,,1,CHEMBL625192,,,Rattus norvegicus,N,1,2046.0,
9011,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 30 minutes after an intravenous injection is given (average of 2 rats),Intermediate,10116.0,,A,,BAO_0000218,11977,,,1,CHEMBL875337,,,Rattus norvegicus,N,1,2046.0,
9012,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 30 minutes after an intravenous injection is given (average of 3 rats),Intermediate,10116.0,,A,,BAO_0000218,11977,,,1,CHEMBL626341,,,Rattus norvegicus,N,1,2046.0,
9013,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 60 minutes after an intravenous injection is given (average of 3 rats),Intermediate,10116.0,,A,,BAO_0000218,11977,,,1,CHEMBL626342,,,Rattus norvegicus,N,1,2046.0,
9014,Biodistribution of radioligand [125I]-FIDA1 in liver of rat after 2 minutes after an intravenous injection is given (average of 3 rats),Intermediate,10116.0,,A,,BAO_0000218,11977,,,1,CHEMBL621943,,,Rattus norvegicus,N,1,2107.0,
9015,Half life in rats,Intermediate,10116.0,,A,,BAO_0000218,3748,,,1,CHEMBL621944,,,Rattus norvegicus,N,1,,
9016,Mean percent inhibition of joint damage reduction in fasted rats at 35 mg/kg administered orally twice daily,Intermediate,10116.0,,A,,BAO_0000218,15765,,,1,CHEMBL621945,,,Rattus norvegicus,N,1,,
9017,Compound was evaluated for rate of clearance by using IPRL (Isolated Perfused Rat Liver),Intermediate,10116.0,,A,,BAO_0000218,4871,,,1,CHEMBL621946,,,Rattus norvegicus,N,1,,
9018,Compound was evaluated for rate of clearance by using IPRL (Isolated Perfused Rat Liver); ND=Not determined,Intermediate,10116.0,,A,,BAO_0000218,4871,,,1,CHEMBL621947,,,Rattus norvegicus,N,1,,
9019,Compound was evaluated for rate of clearance in IPRL (Isolated Perfused Rat Liver),Intermediate,10116.0,,A,,BAO_0000218,4872,,,1,CHEMBL621948,,,Rattus norvegicus,N,1,,
9020,Compound was evaluated for rate of clearance in IPRL (Isolated Perfused Rat Liver); ND=Not determined,Intermediate,10116.0,,A,,BAO_0000218,4872,,,1,CHEMBL621949,,,Rattus norvegicus,N,1,,
9021,Rate constant (k) of clearance from isolated perfused rat liver (IPRL),Intermediate,10116.0,,A,,BAO_0000218,5413,,,1,CHEMBL621950,,,Rattus norvegicus,N,1,,
9022,Tested for rate of clearance from isolated perfused rat liver (IPRL) and expressed in terms of rate constant (k); not determined,Intermediate,10116.0,,A,,BAO_0000218,5413,,,1,CHEMBL621951,,,Rattus norvegicus,N,1,,
9023,Maximal blood concentration after oral administration of a 30 uM/kg dose of compound,Intermediate,10116.0,,A,,BAO_0000218,15272,,,1,CHEMBL621952,,,Rattus norvegicus,N,1,178.0,
9024,Stability (%) in rat liver microsomes,Intermediate,10116.0,,A,,BAO_0000218,4689,,,1,CHEMBL621953,,,Rattus norvegicus,N,1,2107.0,
9025,Area under curve was calculated after intravenous administration,Intermediate,10116.0,,A,,BAO_0000218,6057,,,1,CHEMBL621954,,,Rattus norvegicus,N,1,,
9026,Area under the curve was calculated after iv administration in rat,Intermediate,10116.0,,A,,BAO_0000218,6057,,,1,CHEMBL621955,,,Rattus norvegicus,N,1,,
9027,Area under the curve was calculated in rat after peroral administration,Intermediate,10116.0,,A,,BAO_0000218,6057,,,1,CHEMBL621956,,,Rattus norvegicus,N,1,,
9028,Dose-normalized AUC was determined by po administration (10 mg/kg) in fasted male Sprague-Dawley rats,Intermediate,10116.0,,A,,BAO_0000218,6211,,,1,CHEMBL621957,,,Rattus norvegicus,N,1,,
9029,Dose-normalized AUC measured in fasted male Sprague dawely rats when the compound was administered at a peroral dose of 2 mg/Kg,Intermediate,10116.0,,A,,BAO_0000218,5710,,,1,CHEMBL621958,,,Rattus norvegicus,N,1,,
9030,Dose-normalized AUC measured in fasted male Sprague dawely rats when the compound was administered at a peroral of 2 mg/Kg,Intermediate,10116.0,,A,,BAO_0000218,5710,,,1,CHEMBL621959,,,Rattus norvegicus,N,1,,
9031,Dose-normalized area under curve in rat (i.v.) at 0.5 mpk,Intermediate,10116.0,,A,,BAO_0000218,17853,,,1,CHEMBL621960,,,Rattus norvegicus,N,1,,
9032,Dose-normalized area under curve in rat (p.o.) at 2.0 mpk,Intermediate,10116.0,,A,,BAO_0000218,17853,,,1,CHEMBL621961,,,Rattus norvegicus,N,1,,
9033,p value of the compound,Intermediate,10116.0,,A,,BAO_0000218,15765,,,1,CHEMBL621962,,,Rattus norvegicus,N,1,,
9034,p value of the compound,Intermediate,10116.0,,F,,BAO_0000218,15765,,,1,CHEMBL876787,,,Rattus norvegicus,N,1,,
9035,p value of the compound,Intermediate,10116.0,,A,,BAO_0000218,15765,,,1,CHEMBL621963,,,Rattus norvegicus,N,1,,
9036,pH of the gastric juice (Control value = 1.42+/-0.02) of stomach content of pylorus ligated rats was measured (10 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),Intermediate,10116.0,,A,,BAO_0000218,6175,,,1,CHEMBL622637,,,Rattus norvegicus,N,1,945.0,
9037,pH of the gastric juice (Control value = 1.42+/-0.02) of stomach content of pylorus ligated rats was measured (20 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),Intermediate,10116.0,,A,,BAO_0000218,6175,,,1,CHEMBL622638,,,Rattus norvegicus,N,1,945.0,
9038,pH of the gastric juice (Control value = 1.42+/-0.02) of stomach content of pylorus ligated rats was measured (5 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),Intermediate,10116.0,,A,,BAO_0000218,6175,,,1,CHEMBL626561,,,Rattus norvegicus,N,1,945.0,
9039,Negative log of minimum effective dose (moles per kilogram) in rabbits (hypnotic),Autocuration,9986.0,,F,,BAO_0000019,7991,,,1,CHEMBL626562,,,Oryctolagus cuniculus,U,0,,
9040,Evaluated for pharmacokinetic parameter area under curve in rabbit at the dose 20 mg/kg ( 0-4 hr ),Autocuration,9986.0,,A,,BAO_0000218,429,,,1,CHEMBL626563,,,Oryctolagus cuniculus,U,0,,
9041,Evaluated for pharmacokinetic parameter area under curve in rabbit at the dose 20 mg/kg (0-4 hr ),Autocuration,9986.0,,A,,BAO_0000218,429,,,1,CHEMBL626564,,,Oryctolagus cuniculus,U,0,,
9042,Clearance was measured at the concentration of 1.11 mg/kg in rabbit blood sample,Autocuration,9986.0,,A,,BAO_0000218,6253,,,1,CHEMBL626565,,,Oryctolagus cuniculus,U,0,,
9043,Clearance was measured at the concentration of 2.0 mg/kg in rabbit blood sample,Autocuration,9986.0,,A,,BAO_0000218,6253,,,1,CHEMBL626566,,,Oryctolagus cuniculus,U,0,,
9044,Clearance rate in rabbits,Autocuration,9986.0,,A,,BAO_0000218,3615,,,1,CHEMBL626567,,,Oryctolagus cuniculus,U,0,,
9045,Plasma clearance was determined in rabbit at a dose of 5 mg/kg/h administered i.v.,Autocuration,9986.0,,A,,BAO_0000218,4059,,,1,CHEMBL626568,,,Oryctolagus cuniculus,U,0,,
9046,Clearance in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 4.9 mg/kg,Autocuration,9986.0,,A,,BAO_0000218,5124,,,1,CHEMBL626569,,,Oryctolagus cuniculus,U,0,,
9047,Clearance in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 5 mg/kg,Autocuration,9986.0,,A,,BAO_0000218,5124,,,1,CHEMBL626570,,,Oryctolagus cuniculus,U,0,,
9048,Clearance in male New Zealand white rabbits after i.v. administration at 2.0 mg/kg,Autocuration,9986.0,,A,,BAO_0000218,5124,,,1,CHEMBL626571,,,Oryctolagus cuniculus,U,0,,
9049,Evaluated for pharmacokinetic parameter Cmax in rabbit at the dose 20 mg/kg,Autocuration,9986.0,,A,,BAO_0000218,429,,,1,CHEMBL626572,,,Oryctolagus cuniculus,U,0,,
9050,Maximum plasma concentration was determined in rabbit at a dose of 5 mg/kg/h administered i.v.,Autocuration,9986.0,,A,,BAO_0000218,4059,,,1,CHEMBL626573,,,Oryctolagus cuniculus,U,0,1969.0,
9051,Oxidation by dutch rabbit liver microsomes in presence of NADPH/O2,Autocuration,9986.0,,A,,BAO_0000251,9659,Microsomes,,1,CHEMBL626574,,,Oryctolagus cuniculus,U,0,2107.0,
9052,Oxidation by dutch rabbit liver microsomes in presence of cumene hydroperoxide,Autocuration,9986.0,,A,,BAO_0000251,9659,Microsomes,,1,CHEMBL626575,,,Oryctolagus cuniculus,U,0,2107.0,
9053,Dose at which bioavailability of intravenously administered compound was tested in rabbit,Autocuration,9986.0,,A,,BAO_0000218,3639,,,1,CHEMBL626576,,,Oryctolagus cuniculus,U,0,,
9054,Dose at which bioavailability of perorally administered compound was tested in rabbit,Autocuration,9986.0,,A,,BAO_0000218,3639,,,1,CHEMBL626577,,,Oryctolagus cuniculus,U,0,,
9055,The compound was tested for its bioavailability in rabbit (by oral dosage).,Autocuration,9986.0,,A,,BAO_0000218,3639,,,1,CHEMBL626578,,,Oryctolagus cuniculus,U,0,,
9056,Mean retention time in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 4.9 mg/kg,Autocuration,9986.0,,A,,BAO_0000218,5124,,,1,CHEMBL625263,,,Oryctolagus cuniculus,U,0,,
9057,Mean retention time in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 5 mg/kg,Autocuration,9986.0,,A,,BAO_0000218,5124,,,1,CHEMBL625264,,,Oryctolagus cuniculus,U,0,,
9058,Mean retention time in male New Zealand white rabbits after i.v. administration at 2.0 mg/kg,Autocuration,9986.0,,A,,BAO_0000218,5124,,,1,CHEMBL625265,,,Oryctolagus cuniculus,U,0,,
9059,Metabolism of compound in rabbit S9 microsomes ('+''indicates <20% largest observed peak),Autocuration,9986.0,,A,,BAO_0000251,14294,Microsomes,,1,CHEMBL625266,,,Oryctolagus cuniculus,U,0,,
9060,Metabolism of compound in rabbit S9 microsomes ('++++' indicates largest observed peak),Autocuration,9986.0,,A,,BAO_0000251,14294,Microsomes,,1,CHEMBL876796,,,Oryctolagus cuniculus,U,0,,
9061,Evaluated for pharmacokinetic parameter half-life in rabbit at the dose 20 mg/kg,Autocuration,9986.0,,A,,BAO_0000218,429,,,1,CHEMBL625267,,,Oryctolagus cuniculus,U,0,,
9062,Plasma half-life in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 4.9 mg/kg,Autocuration,9986.0,,A,,BAO_0000218,5124,,,1,CHEMBL625268,,,Oryctolagus cuniculus,U,0,1969.0,
9063,Plasma half-life in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 5 mg/kg,Autocuration,9986.0,,A,,BAO_0000218,5124,,,1,CHEMBL625269,,,Oryctolagus cuniculus,U,0,1969.0,
9064,Plasma half-life in male New Zealand white rabbits after i.v. administration at 2.0 mg/kg,Autocuration,9986.0,,A,,BAO_0000218,5124,,,1,CHEMBL624689,,,Oryctolagus cuniculus,U,0,1969.0,
9065,Evaluated for pharmacokinetic parameter tmax in rabbit at the dose 20 mg/kg,Autocuration,9986.0,,A,,BAO_0000218,429,,,1,CHEMBL624690,,,Oryctolagus cuniculus,U,0,,
9066,Evaluated for pharmacokinetic parameter urine recovery in rabbit at the dose 20 mg/kg ( 0-24 hr ),Autocuration,9986.0,,A,,BAO_0000218,429,,,1,CHEMBL624691,,,Oryctolagus cuniculus,U,0,1088.0,
9067,Evaluated for pharmacokinetic parameter urine recovery in rabbit at the dose 20 mg/kg (0-24 hr),Autocuration,9986.0,,A,,BAO_0000218,429,,,1,CHEMBL624692,,,Oryctolagus cuniculus,U,0,1088.0,
9068,The compound was evaluated for volume of distribution in rabbit at a dose of 5 mg/kg/h administered i.v.,Autocuration,9986.0,,A,,BAO_0000218,4059,,,1,CHEMBL624693,,,Oryctolagus cuniculus,U,0,,
9069,Volume of distribution after intravenous administration of 1 mg/kg/h in dog,Autocuration,9986.0,,A,,BAO_0000218,4137,,,1,CHEMBL624694,,,Oryctolagus cuniculus,U,0,,
9070,In vitro Biological half-life in crude homogenate of rabbit renal cortex,Autocuration,9986.0,,A,,BAO_0000221,11672,,,1,CHEMBL877596,,,Oryctolagus cuniculus,U,0,,
9071,Time within which only 10% of the drug was degraded,Autocuration,9986.0,,A,,BAO_0000019,12886,,,1,CHEMBL624695,,,Oryctolagus cuniculus,U,0,,
9072,Half life period in rabbit liver homogenate,Autocuration,9986.0,,A,,BAO_0000221,3853,,,1,CHEMBL624696,,,Oryctolagus cuniculus,U,0,2107.0,
9073,Half life value in rabbits,Autocuration,9986.0,,A,,BAO_0000019,3615,,,1,CHEMBL624697,,,Oryctolagus cuniculus,U,0,,
9074,Half-life was measured at the concentration of 1.11 mg/kg in rabbit blood sample,Autocuration,9986.0,,A,,BAO_0000218,6253,,,1,CHEMBL624698,,,Oryctolagus cuniculus,U,0,178.0,
9075,Half-life was measured at the concentration of 2.0 mg/kg in rabbit blood sample,Autocuration,9986.0,,A,,BAO_0000218,6253,,,1,CHEMBL624699,,,Oryctolagus cuniculus,U,0,178.0,
9076,Half-life period in rabbits following intravenous administration at 2 mg/kg,Autocuration,9986.0,,A,,BAO_0000218,6077,,,1,CHEMBL624700,,,Oryctolagus cuniculus,U,0,,
9077,AUC 0-8 hr value in rats at 10 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,17617,,,1,CHEMBL622903,,,Rattus norvegicus,N,1,1969.0,
9078,AUC after administration at 2000 mg/kg/day in rats,Intermediate,10116.0,,A,,BAO_0000218,17594,,,1,CHEMBL622904,,,Rattus norvegicus,N,1,1969.0,
9079,AUC of compound for a 2 mpk po dose of the sodium salt in rats.,Intermediate,10116.0,,A,,BAO_0000218,6149,,,1,CHEMBL622905,,,Rattus norvegicus,N,1,1969.0,
9080,AUC at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,Intermediate,10116.0,,A,,BAO_0000218,17260,,,1,CHEMBL622906,,,Rattus norvegicus,N,1,1969.0,
9081,AUC at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,Intermediate,10116.0,,A,,BAO_0000218,17260,,,1,CHEMBL622907,,,Rattus norvegicus,N,1,1969.0,
9082,AUC in rat after oral administration at 10.5 mg/kg dose,Intermediate,10116.0,,A,,BAO_0000218,6644,,,1,CHEMBL622908,,,Rattus norvegicus,N,1,1969.0,
9083,AUC in rat after oral administration at 11.2 mg/kg dose,Intermediate,10116.0,,A,,BAO_0000218,6644,,,1,CHEMBL622909,,,Rattus norvegicus,N,1,1969.0,
9084,AUC in rat after oral administration at 9.7 mg/kg dose,Intermediate,10116.0,,A,,BAO_0000218,6644,,,1,CHEMBL622910,,,Rattus norvegicus,N,1,1969.0,
9085,AUC in rat brain after oral administration at 10 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,6495,,,1,CHEMBL622911,,,Rattus norvegicus,N,1,955.0,
9086,AUC in rat p.o.,Intermediate,10116.0,,A,,BAO_0000218,6504,,,1,CHEMBL622912,,,Rattus norvegicus,N,1,1969.0,
9087,AUC in rat p.o. at 20 mg/kg concentration,Intermediate,10116.0,,A,,BAO_0000218,17686,,,1,CHEMBL622913,,,Rattus norvegicus,N,1,1969.0,
9088,AUC in rat plasma after oral administration at 10 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,6495,,,1,CHEMBL622914,,,Rattus norvegicus,N,1,1969.0,
9089,AUC in rats,Intermediate,10116.0,,A,,BAO_0000218,216,,,1,CHEMBL622915,,,Rattus norvegicus,N,1,1969.0,
9090,AUC value after IV dose at a dose of 5 mg/kg in rats.,Intermediate,10116.0,,A,,BAO_0000218,1908,,,1,CHEMBL622916,,,Rattus norvegicus,N,1,1969.0,
9091,AUC value after oral dose at a dose of 10 mg/kg in rats.,Intermediate,10116.0,,A,,BAO_0000218,1908,,,1,CHEMBL622917,,,Rattus norvegicus,N,1,1969.0,
9092,"Maximum plasma concentration in rats at 2 mg/kg, i.v. dose; n/a: not applicable",Intermediate,10116.0,,A,,BAO_0000218,6685,,,1,CHEMBL622918,,,Rattus norvegicus,N,1,1969.0,
9093,Maximum plasma concentration in rats when a oral dose of 200 mg/kg was given,Intermediate,10116.0,,A,,BAO_0000218,216,,,1,CHEMBL622919,,,Rattus norvegicus,N,1,1969.0,
9094,Maximum plasma concentration was evaluated in rat,Intermediate,10116.0,,A,,BAO_0000218,6049,,,1,CHEMBL622920,,,Rattus norvegicus,N,1,1969.0,
9095,Maximum plasma concentration was evaluated in vivo in rat at a dose of 5 mg/kg by oral administration,Intermediate,10116.0,,A,,BAO_0000218,2463,,,1,CHEMBL622921,,,Rattus norvegicus,N,1,1969.0,
9096,Maximum plasma concentration reached by compound was determined after 2 mg/kg (p.o.) administration,Intermediate,10116.0,,A,,BAO_0000218,6679,,,1,CHEMBL622922,,,Rattus norvegicus,N,1,1969.0,
9097,Maximum plasma concentration reached by compound was determined in rats at 50 mg/kg dose,Intermediate,10116.0,,A,,BAO_0000218,6681,,,1,CHEMBL622923,,,Rattus norvegicus,N,1,1969.0,
9098,Maximum plasma concentration was determined after oral administration at a dose 10 mg/kg to male Sprague-Dawley rats,Intermediate,10116.0,,A,,BAO_0000218,4890,,,1,CHEMBL877604,,,Rattus norvegicus,N,1,1969.0,
9099,Maximum plasma concentration was evaluated in rats at an intravenous dose of 3 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,6410,,,1,CHEMBL622924,,,Rattus norvegicus,N,1,1969.0,
9100,Maximum plasma concentration was evaluated in rats at an oral dose of 30 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,6410,,,1,CHEMBL622925,,,Rattus norvegicus,N,1,1969.0,
9101,Maximum plasma concentration was measured when a dose of 1 mg/kg is administered orally,Intermediate,10116.0,,A,,BAO_0000218,16366,,,1,CHEMBL622926,,,Rattus norvegicus,N,1,1969.0,
9102,Maximum plasma concentration (Cmax) in rat (in vivo) at a dose of 10 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,6227,,,1,CHEMBL623625,,,Rattus norvegicus,N,1,1969.0,
9103,Maximum plasma drug concentration of compound determined in rat after iv administration at a dose of 10 mg/kg,Expert,10116.0,,A,,BAO_0000218,3598,,,1,CHEMBL623626,,,Rattus norvegicus,N,1,1969.0,
9104,Maximum plasma drug concentration was determined,Intermediate,10116.0,,A,,BAO_0000218,1465,,,1,CHEMBL623627,,,Rattus norvegicus,N,1,1969.0,
9105,Maximum concentration by intravenous administration of 3.4 mg/kg in rat,Intermediate,10116.0,,A,,BAO_0000218,4368,,,1,CHEMBL623628,,,Rattus norvegicus,N,1,,
9106,Mean peak plasma concentration was observed after intravenous administration in rat,Intermediate,10116.0,,A,,BAO_0000218,15662,,,1,CHEMBL623629,,,Rattus norvegicus,N,1,1969.0,
9107,Mean peak plasma concentration was observed after oral administration in rat,Intermediate,10116.0,,A,,BAO_0000218,15662,,,1,CHEMBL623630,,,Rattus norvegicus,N,1,1969.0,
9108,Peak concentration (Cmax) at a dose of 10 mg/kg in rats,Intermediate,10116.0,,A,,BAO_0000218,5355,,,1,CHEMBL623804,,,Rattus norvegicus,N,1,,
9109,Peak concentration (Cmax) at a dose of 20 mg/kg in rats,Intermediate,10116.0,,A,,BAO_0000218,5355,,,1,CHEMBL623805,,,Rattus norvegicus,N,1,,
9110,Peak oral plasma concentration was determined in rats by oral administration,Intermediate,10116.0,,A,,BAO_0000218,1567,,,1,CHEMBL623806,,,Rattus norvegicus,N,1,1969.0,
9111,Peak plasma concentration (Cmax) was determined,Intermediate,10116.0,,A,,BAO_0000218,4026,,,1,CHEMBL623807,,,Rattus norvegicus,N,1,1969.0,
9112,Peak plasma concentration (Cmax) following an oral dose of 20 mg/kg in rats,Intermediate,10116.0,,A,,BAO_0000218,6193,,,1,CHEMBL623808,,,Rattus norvegicus,N,1,1969.0,
9113,Peak plasma concentration (Cmax) in rats,Intermediate,10116.0,,A,,BAO_0000218,4026,,,1,CHEMBL623809,,,Rattus norvegicus,N,1,1969.0,
9114,Peak plasma concentration at 1 mg/kg peroral administration,Intermediate,10116.0,,A,,BAO_0000218,6485,,,1,CHEMBL623810,,,Rattus norvegicus,N,1,1969.0,
9115,Peak plasma concentration in rat,Intermediate,10116.0,,A,,BAO_0000218,17655,,,1,CHEMBL623811,,,Rattus norvegicus,N,1,1969.0,
9116,"Pharmacokinetic Parameter, Cmax is observed maximum plasma concentration in Female Wistar Rats at 100 mg/kg by po administration",Intermediate,10116.0,,A,,BAO_0000218,14941,,,1,CHEMBL623812,,,Rattus norvegicus,N,1,1969.0,
9117,Pharmacokinetic parameter Cmax was measured after administration into rat at 10 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,5394,,,1,CHEMBL877605,,,Rattus norvegicus,N,1,,
9118,Pharmacokinetic property (Cmax) in rat,Intermediate,10116.0,,A,,BAO_0000218,4408,,,1,CHEMBL623813,,,Rattus norvegicus,N,1,,
9119,Pharmacokinetic property (Cmax) was measured in rat at the dose of 0.32 mg/kg p.o.,Intermediate,10116.0,,A,,BAO_0000218,5983,,,1,CHEMBL623814,,,Rattus norvegicus,N,1,,
9120,Cmax in rat after 3mg/kg oral dose,Intermediate,10116.0,,A,,BAO_0000218,4878,,,1,CHEMBL623815,,,Rattus norvegicus,N,1,,
9121,Clearance in Sprague-Dawley rats after 2mg/kg oral dose,Intermediate,10116.0,,A,Sprague-Dawley,BAO_0000218,5862,,,1,CHEMBL623816,,,Rattus norvegicus,N,1,,
9122,Cmax in rats after 20 mg/kg oral dose,Intermediate,10116.0,,A,,BAO_0000218,4517,,,1,CHEMBL623145,,,Rattus norvegicus,N,1,,
9123,Cmax in rat plasma after 30mg/kg oral dose,Intermediate,10116.0,,A,,BAO_0000218,5932,,,1,CHEMBL623146,,,Rattus norvegicus,N,1,1969.0,
9124,Plasma concentration after oral administration of 100 mg/kg to rats,Intermediate,10116.0,,A,,BAO_0000218,5436,,,1,CHEMBL623147,,,Rattus norvegicus,N,1,1969.0,
9125,Tested for concentration in brain after intravenous administration (4.7 mg/kg) to male rats,Intermediate,10116.0,,A,,BAO_0000218,4910,,,1,CHEMBL623042,,,Rattus norvegicus,N,1,955.0,
9126,Tested for the Cmax in rat at 10 mg/kg per orally,Intermediate,10116.0,,A,,BAO_0000218,4950,,,1,CHEMBL623043,,,Rattus norvegicus,N,1,,
9127,"The Cmax value in female wistar rat at 100 mg/kg, p.o. dose",Intermediate,10116.0,,A,,BAO_0000218,15078,,,1,CHEMBL623044,,,Rattus norvegicus,N,1,,
9128,"The Cmax value in male wistar rat at 100 mg/kg, p.o. dose",Intermediate,10116.0,,A,,BAO_0000218,15078,,,1,CHEMBL623045,,,Rattus norvegicus,N,1,,
9129,Bioavailability as oral Cmax in rats at 30 mins,Intermediate,10116.0,,A,,BAO_0000218,3360,,,1,CHEMBL623046,,,Rattus norvegicus,N,1,,
9130,Bioavailability as oral Cmax in rats at 6hr,Intermediate,10116.0,,A,,BAO_0000218,3360,,,1,CHEMBL623226,,,Rattus norvegicus,N,1,,
9131,The maximum concentration of compound was measured at the dose of 100 umol/kg,Intermediate,10116.0,,A,,BAO_0000218,15022,,,1,CHEMBL623227,,,Rattus norvegicus,N,1,,
9132,The maximum concentration of compound was measured at the dose of 300 umol/kg,Intermediate,10116.0,,A,,BAO_0000218,15022,,,1,CHEMBL623228,,,Rattus norvegicus,N,1,,
9133,The maximum concentration of compound was measured at the dose of 30 umol/kg,Intermediate,10116.0,,A,,BAO_0000218,15022,,,1,CHEMBL623229,,,Rattus norvegicus,N,1,,
9134,The maximum plasma levels for the compounds were determined by LC-MS.,Intermediate,10116.0,,A,,BAO_0000218,5160,,,1,CHEMBL623230,,,Rattus norvegicus,N,1,1969.0,
9135,mean peak plasma concentration was observed after intravenous administration in rat,Intermediate,10116.0,,A,,BAO_0000218,15662,,,1,CHEMBL623231,,,Rattus norvegicus,N,1,1969.0,
9136,mean peak plasma concentration was observed after oral administration in rat,Intermediate,10116.0,,A,,BAO_0000218,15662,,,1,CHEMBL623232,,,Rattus norvegicus,N,1,1969.0,
9137,Concentration in the plasma after intravenous administration of 1 mg/kg in rat,Intermediate,10116.0,,A,,BAO_0000218,4709,,,1,CHEMBL623233,,,Rattus norvegicus,N,1,,
9138,Concentration in plasma (portal) following oral dose in rats at 0.25 hr,Intermediate,10116.0,,A,,BAO_0000218,3535,,,1,CHEMBL623234,,,Rattus norvegicus,N,1,,
9139,Concentration in plasma (portal) following oral dose in rats at 1 hr,Intermediate,10116.0,,A,,BAO_0000218,3535,,,1,CHEMBL623235,,,Rattus norvegicus,N,1,,
9140,Concentration in plasma (portal) following oral dose in rats at 2 hr,Intermediate,10116.0,,A,,BAO_0000218,3535,,,1,CHEMBL623236,,,Rattus norvegicus,N,1,,
9141,Concentration in plasma (systemic) following oral dose in rats at 0.25 hr,Intermediate,10116.0,,A,,BAO_0000218,3535,,,1,CHEMBL623237,,,Rattus norvegicus,N,1,,
9142,Concentration in plasma (systemic) following oral dose in rats at 1 hr,Intermediate,10116.0,,A,,BAO_0000218,3535,,,1,CHEMBL623238,,,Rattus norvegicus,N,1,,
9143,Concentration in plasma (systemic) following oral dose in rats at 2 hr,Intermediate,10116.0,,A,,BAO_0000218,3535,,,1,CHEMBL623239,,,Rattus norvegicus,N,1,,
9144,Compound was evaluated for the plasma concentration in rats versus time curves (AUC) in vivo,Intermediate,10116.0,,A,,BAO_0000218,5005,,,1,CHEMBL623240,,,Rattus norvegicus,U,0,1969.0,
9145,"Concentration (30 mg/kg, p.o.) in rat hypothalamus after 2 hours",Intermediate,10116.0,,A,,BAO_0000218,6326,,,1,CHEMBL623241,,,Rattus norvegicus,N,1,1898.0,
9146,"Concentration (30 mg/kg, p.o.) in rat hypothalamus after 6 hours",Intermediate,10116.0,,A,,BAO_0000218,6326,,,1,CHEMBL623242,,,Rattus norvegicus,N,1,1898.0,
9147,"Concentration (30 mg/kg, p.o.) in rat plasma after 2 hours",Intermediate,10116.0,,A,,BAO_0000218,6326,,,1,CHEMBL874394,,,Rattus norvegicus,N,1,,
9148,"Concentration (30 mg/kg, p.o.) in rat plasma after 6 hours",Intermediate,10116.0,,A,,BAO_0000218,6326,,,1,CHEMBL623243,,,Rattus norvegicus,N,1,,
9149,Kidney concentration was determined after 5 min. of intravenous administration to rats (n=4) at dose of 20 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,17411,,,1,CHEMBL623244,,,Rattus norvegicus,N,1,,
9150,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,Intermediate,10116.0,,A,,BAO_0000218,16435,,,1,CHEMBL623245,,,Rattus norvegicus,N,1,2113.0,
9151,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,Intermediate,10116.0,,A,,BAO_0000218,16435,,,1,CHEMBL623246,,,Rattus norvegicus,N,1,2113.0,
9152,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,Intermediate,10116.0,,A,,BAO_0000218,16435,,,1,CHEMBL623247,,,Rattus norvegicus,N,1,2113.0,
9153,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,Intermediate,10116.0,,A,,BAO_0000218,16435,,,1,CHEMBL623248,,,Rattus norvegicus,N,1,2113.0,
9154,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,Intermediate,10116.0,,A,,BAO_0000218,16435,,,1,CHEMBL623249,,,Rattus norvegicus,N,1,2113.0,
9155,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,Intermediate,10116.0,,A,,BAO_0000218,16434,,,1,CHEMBL625072,,,Rattus norvegicus,N,1,2107.0,
9156,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,Intermediate,10116.0,,A,,BAO_0000218,16434,,,1,CHEMBL625073,,,Rattus norvegicus,N,1,2107.0,
9157,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,Intermediate,10116.0,,A,,BAO_0000218,16434,,,1,CHEMBL625074,,,Rattus norvegicus,N,1,2107.0,
9158,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,Intermediate,10116.0,,A,,BAO_0000218,16434,,,1,CHEMBL625075,,,Rattus norvegicus,N,1,2107.0,
9159,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 120 min.,Intermediate,10116.0,,A,,BAO_0000218,16434,,,1,CHEMBL625076,,,Rattus norvegicus,N,1,2107.0,
9160,Radioactivity distribution in liver of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,Intermediate,10116.0,,A,,BAO_0000218,16434,,,1,CHEMBL625077,,,Rattus norvegicus,N,1,2107.0,
9161,Radioactivity distribution in liver of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,Intermediate,10116.0,,A,,BAO_0000218,16434,,,1,CHEMBL625078,,,Rattus norvegicus,N,1,2107.0,
9162,Radioactivity distribution in liver of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,Intermediate,10116.0,,A,,BAO_0000218,16434,,,1,CHEMBL874395,,,Rattus norvegicus,N,1,2107.0,
9163,Radioactivity distribution in liver of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,Intermediate,10116.0,,A,,BAO_0000218,16435,,,1,CHEMBL625079,,,Rattus norvegicus,N,1,2107.0,
9164,Radioactivity distribution in liver of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,Intermediate,10116.0,,A,,BAO_0000218,16435,,,1,CHEMBL625080,,,Rattus norvegicus,N,1,2107.0,
9165,Radioactivity distribution in liver of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,Intermediate,10116.0,,A,,BAO_0000218,16435,,,1,CHEMBL625081,,,Rattus norvegicus,N,1,2107.0,
9166,Radioactivity distribution in liver of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,Intermediate,10116.0,,A,,BAO_0000218,16435,,,1,CHEMBL625082,,,Rattus norvegicus,N,1,2107.0,
9167,Radioactivity distribution in liver of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,Intermediate,10116.0,,A,,BAO_0000218,16435,,,1,CHEMBL625083,,,Rattus norvegicus,N,1,2107.0,
9168,Radioactivity distribution in liver of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,Intermediate,10116.0,,A,,BAO_0000218,16435,,,1,CHEMBL625084,,,Rattus norvegicus,N,1,2107.0,
9169,Radioactivity distribution in liver of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,Intermediate,10116.0,,A,,BAO_0000218,16435,,,1,CHEMBL625085,,,Rattus norvegicus,N,1,2107.0,
9170,Radioactivity distribution in liver of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,Intermediate,10116.0,,A,,BAO_0000218,16435,,,1,CHEMBL625086,,,Rattus norvegicus,N,1,2107.0,
9171,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,Intermediate,10116.0,,A,,BAO_0000218,16434,,,1,CHEMBL625087,,,Rattus norvegicus,N,1,2107.0,
9172,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,Intermediate,10116.0,,A,,BAO_0000218,16434,,,1,CHEMBL625088,,,Rattus norvegicus,N,1,2107.0,
9173,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,Intermediate,10116.0,,A,,BAO_0000218,16434,,,1,CHEMBL622205,,,Rattus norvegicus,N,1,2107.0,
9174,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,Intermediate,10116.0,,A,,BAO_0000218,16435,,,1,CHEMBL622206,,,Rattus norvegicus,N,1,2107.0,
9175,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,Intermediate,10116.0,,A,,BAO_0000218,16435,,,1,CHEMBL622207,,,Rattus norvegicus,N,1,2107.0,
9176,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,Intermediate,10116.0,,A,,BAO_0000218,16435,,,1,CHEMBL622366,,,Rattus norvegicus,N,1,2107.0,
9177,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,Intermediate,10116.0,,A,,BAO_0000218,16435,,,1,CHEMBL622367,,,Rattus norvegicus,N,1,2107.0,
9178,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,Intermediate,10116.0,,A,,BAO_0000218,16435,,,1,CHEMBL875331,,,Rattus norvegicus,N,1,2107.0,
9179,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,Intermediate,10116.0,,A,,BAO_0000218,16435,,,1,CHEMBL622368,,,Rattus norvegicus,N,1,2107.0,
9180,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,Intermediate,10116.0,,A,,BAO_0000218,16434,,,1,CHEMBL622369,,,Rattus norvegicus,N,1,2048.0,
9181,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,Intermediate,10116.0,,A,,BAO_0000218,16434,,,1,CHEMBL622370,,,Rattus norvegicus,N,1,2048.0,
9182,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,Intermediate,10116.0,,A,,BAO_0000218,16434,,,1,CHEMBL622371,,,Rattus norvegicus,N,1,2048.0,
9183,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,Intermediate,10116.0,,A,,BAO_0000218,16434,,,1,CHEMBL622372,,,Rattus norvegicus,N,1,2048.0,
9184,Radioactivity distribution in lung of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,Intermediate,10116.0,,A,,BAO_0000218,16434,,,1,CHEMBL622373,,,Rattus norvegicus,N,1,2048.0,
9185,Radioactivity distribution in lung of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,Intermediate,10116.0,,A,,BAO_0000218,16434,,,1,CHEMBL622374,,,Rattus norvegicus,N,1,2048.0,
9186,Radioactivity distribution in lung of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,Intermediate,10116.0,,A,,BAO_0000218,16434,,,1,CHEMBL622375,,,Rattus norvegicus,N,1,2048.0,
9187,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 60 min.,Intermediate,10116.0,,A,,BAO_0000218,16434,,,1,CHEMBL622376,,,Rattus norvegicus,N,1,2048.0,
9188,Radioactivity distribution in lung of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,Intermediate,10116.0,,A,,BAO_0000218,16435,,,1,CHEMBL622377,,,Rattus norvegicus,N,1,2048.0,
9189,Radioactivity distribution in lung of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,Intermediate,10116.0,,A,,BAO_0000218,16435,,,1,CHEMBL622378,,,Rattus norvegicus,N,1,2048.0,
9190,Radioactivity distribution in lung of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,Intermediate,10116.0,,A,,BAO_0000218,16435,,,1,CHEMBL622379,,,Rattus norvegicus,N,1,2048.0,
9191,Radioactivity distribution in lung of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,Intermediate,10116.0,,A,,BAO_0000218,16435,,,1,CHEMBL622380,,,Rattus norvegicus,N,1,2048.0,
9192,Radioactivity distribution in lung of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,Intermediate,10116.0,,A,,BAO_0000218,16435,,,1,CHEMBL622381,,,Rattus norvegicus,N,1,2048.0,
9193,Radioactivity distribution in lung of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,Intermediate,10116.0,,A,,BAO_0000218,16435,,,1,CHEMBL622382,,,Rattus norvegicus,N,1,2048.0,
9194,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 120 min,Intermediate,10116.0,,A,,BAO_0000218,16434,,,1,CHEMBL622383,,,Rattus norvegicus,N,1,2048.0,
9195,pH of the gastric juice (Control value = 1.44+/-0.01) of stomach content of pylorus ligated rats was measured ( 5 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),Intermediate,10116.0,,A,,BAO_0000218,6175,,,1,CHEMBL875332,,,Rattus norvegicus,N,1,945.0,
9196,pH of the gastric juice (Control value = 1.44+/-0.01) of stomach content of pylorus ligated rats was measured (10 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),Intermediate,10116.0,,A,,BAO_0000218,6175,,,1,CHEMBL622384,,,Rattus norvegicus,N,1,945.0,
9197,pH of the gastric juice (control value = 1.39+/-0.02) of stomach content of pylorus ligated rats was measured (2.5 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),Intermediate,10116.0,,A,,BAO_0000218,6175,,,1,CHEMBL622385,,,Rattus norvegicus,N,1,945.0,
9198,pH of the gastric juice (control value = 1.39+/-0.02) of stomach content of pylorus ligated rats was measured (5 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),Intermediate,10116.0,,A,,BAO_0000218,6175,,,1,CHEMBL622386,,,Rattus norvegicus,N,1,945.0,
9199,The compound was tested for the plasma binding in rat,Intermediate,10116.0,,A,,BAO_0000218,10839,,,1,CHEMBL622387,,,Rattus norvegicus,N,1,,
9200,"Plasma concentration after intravenous aministration at 1hr, (1 mg/kg, n=3)",Intermediate,10116.0,,A,,BAO_0000218,16459,,,1,CHEMBL622388,,,Rattus norvegicus,N,1,,
9201,"Plasma concentration after intravenous aministration at 30 min. (1 mg/kg, n=3)",Intermediate,10116.0,,A,,BAO_0000218,16459,,,1,CHEMBL622389,,,Rattus norvegicus,N,1,,
9202,"Plasma concentration after intravenous aministration at 60 min. (1 mg/kg, n=3)",Intermediate,10116.0,,A,,BAO_0000218,16459,,,1,CHEMBL622390,,,Rattus norvegicus,N,1,,
9203,Plasma concentration after oral aministration at 1 hr. (10 mg/kg),Intermediate,10116.0,,A,,BAO_0000218,16459,,,1,CHEMBL622391,,,Rattus norvegicus,N,1,,
9204,Plasma concentration after oral aministration at 2 hr. (10 mg/kg),Intermediate,10116.0,,A,,BAO_0000218,16459,,,1,CHEMBL622392,,,Rattus norvegicus,N,1,,
9205,Plasma concentration after oral aministration at 4 hr. (10 mg/kg),Intermediate,10116.0,,A,,BAO_0000218,16459,,,1,CHEMBL622393,,,Rattus norvegicus,N,1,,
9206,Plasma level at 2 hr after administration of the compound,Intermediate,10116.0,,A,,BAO_0000218,3278,,,1,CHEMBL622394,,,Rattus norvegicus,N,1,,
9207,plasma level at 2 hr after administration of the compound,Intermediate,10116.0,,A,,BAO_0000218,3278,,,1,CHEMBL622395,,,Rattus norvegicus,N,1,,
9208,Stability in rat serum measured as % recovery at 1 min,Intermediate,10116.0,,A,,BAO_0000218,4684,,,1,CHEMBL622396,,,Rattus norvegicus,N,1,1977.0,
9209,Stability in rat serum measured as % recovery at 10 min,Intermediate,10116.0,,A,,BAO_0000218,4684,,,1,CHEMBL624894,,,Rattus norvegicus,N,1,1977.0,
9210,Stability in rat serum measured as % recovery at 10 mins,Intermediate,10116.0,,A,,BAO_0000218,4684,,,1,CHEMBL624895,,,Rattus norvegicus,N,1,1977.0,
9211,Stability in rat serum measured as % recovery at 2 hr,Intermediate,10116.0,,A,,BAO_0000218,4684,,,1,CHEMBL624058,,,Rattus norvegicus,N,1,1977.0,
9212,Stability in rat serum measured as % recovery at 3 min,Intermediate,10116.0,,A,,BAO_0000218,4684,,,1,CHEMBL624059,,,Rattus norvegicus,N,1,1977.0,
9213,Stability in rat serum measured as % recovery at 3 mins,Intermediate,10116.0,,A,,BAO_0000218,4684,,,1,CHEMBL624060,,,Rattus norvegicus,N,1,1977.0,
9214,Stability in rat serum measured as % recovery at 5 min,Intermediate,10116.0,,A,,BAO_0000218,4684,,,1,CHEMBL624061,,,Rattus norvegicus,N,1,1977.0,
9215,Stability in rat serum measured as % recovery at 5 mins,Intermediate,10116.0,,A,,BAO_0000218,4684,,,1,CHEMBL624062,,,Rattus norvegicus,N,1,1977.0,
9216,Alpha-elimination half-life in Male Sprague-Dawley rats after intravenous administration at a dose of 10 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,16456,,,1,CHEMBL624063,,,Rattus norvegicus,N,1,,
9217,Beta-elimination half-life in Male Sprague-Dawley rats after intravenous administration at a dose of 10 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,16456,,,1,CHEMBL624064,,,Rattus norvegicus,N,1,,
9218,Half life in plasma was determined against ovariectomized rats; t 1/2 (h) is short in plasma,Intermediate,10116.0,,A,,BAO_0000218,723,,,1,CHEMBL624065,,,Rattus norvegicus,N,1,1969.0,
9219,Half life in plasma was determined against ovariectomized rats; t1/2 is longer in plasma.,Intermediate,10116.0,,A,,BAO_0000218,723,,,1,CHEMBL624066,,,Rattus norvegicus,N,1,1969.0,
9220,Half life tested in mature male rat at a dose of 30 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,5160,,,1,CHEMBL877490,,,Rattus norvegicus,N,1,,
9221,Half life after intravenous administration of 1 mg/kg in rat,Intermediate,10116.0,,A,,BAO_0000218,4709,,,1,CHEMBL874442,,,Rattus norvegicus,N,1,,
9222,Half life period after administration (30 mg/kg) in rat,Intermediate,10116.0,,A,,BAO_0000218,5633,,,1,CHEMBL626890,,,Rattus norvegicus,N,1,,
9223,Half life period in rat after 5 mg/Kg dose,Intermediate,10116.0,,A,,BAO_0000218,5302,,,1,CHEMBL626891,,,Rattus norvegicus,N,1,,
9224,Half life period in rat after 5 mg/kg dose,Intermediate,10116.0,,A,,BAO_0000218,5302,,,1,CHEMBL626892,,,Rattus norvegicus,N,1,,
9225,Half life period was determined,Intermediate,10116.0,,A,,BAO_0000218,17791,,,1,CHEMBL626893,,,Rattus norvegicus,N,1,,
9226,Half life period was evaluated in rat,Intermediate,10116.0,,A,,BAO_0000218,17791,,,1,CHEMBL626894,,,Rattus norvegicus,N,1,,
9227,Half life period was evaluated in rat; 0.5-1.0,Intermediate,10116.0,,A,,BAO_0000218,17791,,,1,CHEMBL626895,,,Rattus norvegicus,N,1,,
9228,Half life period was evaluated in rat; 5.9-7.5,Intermediate,10116.0,,A,,BAO_0000218,17791,,,1,CHEMBL626896,,,Rattus norvegicus,N,1,,
9229,Half-life in rat plasma,Intermediate,10116.0,,A,,BAO_0000218,14512,,,1,CHEMBL626897,,,Rattus norvegicus,N,1,1969.0,
9230,Half-life time in rat was determined,Intermediate,10116.0,,A,,BAO_0000218,6230,,,1,CHEMBL626898,,,Rattus norvegicus,N,1,,
9231,Terminal half-life after iv administration to rats,Intermediate,10116.0,,A,,BAO_0000218,3364,,,1,CHEMBL626899,,,Rattus norvegicus,N,1,,
9232,Tested for iv terminal half-life dosed as a solution in male Han Wistar rats,Intermediate,10116.0,,A,,BAO_0000218,6874,,,1,CHEMBL626900,,,Rattus norvegicus,N,1,,
9233,Time required to return to 50% inhibition of pressor response after AI-challenge in normotensive rats at 0.5 umol/kg,Intermediate,10116.0,,A,,BAO_0000218,857,,,1,CHEMBL626901,,,Rattus norvegicus,N,1,,
9234,Time required to return to 50% inhibition of pressor response after AI-challenge in normotensive rats at 0.5 umol/kg (iv),Intermediate,10116.0,,A,,BAO_0000218,858,,,1,CHEMBL626902,,,Rattus norvegicus,N,1,,
9235,Time required to return to 50% inhibition of pressor response after AI-challenge in normotensive rats at 5 umol/kg (iv),Intermediate,10116.0,,A,,BAO_0000218,858,,,1,CHEMBL626903,,,Rattus norvegicus,N,1,,
9236,Time for peak concentration (tmax) at a dose of 10 mg/kg in rats,Intermediate,10116.0,,A,,BAO_0000218,5355,,,1,CHEMBL874443,,,Rattus norvegicus,N,1,,
9237,Time for peak concentration (tmax) at a dose of 20 mg/kg in rats,Intermediate,10116.0,,A,,BAO_0000218,5355,,,1,CHEMBL626904,,,Rattus norvegicus,N,1,,
9238,Half life in rats,Intermediate,10116.0,,A,,BAO_0000218,6305,,,1,CHEMBL626905,,,Rattus norvegicus,N,1,,
9239,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 4 mg/kg to rat,Intermediate,10116.0,,A,,BAO_0000218,13501,,,1,CHEMBL873830,,,Rattus norvegicus,N,1,1969.0,
9240,Apparent half-life after single intravenous bolus of 1 mg/kg in rats,Intermediate,10116.0,,A,,BAO_0000218,17594,,,1,CHEMBL626906,,,Rattus norvegicus,N,1,,
9241,Apparent terminal elimination half-life in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,Intermediate,10116.0,,A,,BAO_0000218,4186,,,1,CHEMBL631076,,,Rattus norvegicus,N,1,1969.0,
9242,Biological half-life was measured in plasma of rats,Intermediate,10116.0,,A,,BAO_0000218,2932,,,1,CHEMBL631077,,,Rattus norvegicus,N,1,1969.0,
9243,Circulatory half life measured after intravenous bolus administration of 50 mg/kg of compound to rats,Intermediate,10116.0,,A,,BAO_0000218,17065,,,1,CHEMBL631078,,,Rattus norvegicus,N,1,,
9244,Compound demonstarted an oral bioavailability of 6% with the half-life time as given in rats.,Intermediate,10116.0,,A,,BAO_0000218,15765,,,1,CHEMBL631079,,,Rattus norvegicus,N,1,,
9245,Compound was evaluated for half life (t1/2) upon intravenous administration of 1 mg/Kg in rats,Intermediate,10116.0,,A,,BAO_0000218,2713,,,1,CHEMBL631080,,,Rattus norvegicus,N,1,,
9246,Compound was evaluated for half life after treatment with iv dose of 1 mgkg to female wistar rats,Intermediate,10116.0,,A,,BAO_0000218,2661,,,1,CHEMBL631081,,,Rattus norvegicus,N,1,,
9247,Compound was evaluated for half life after treatment with iv dose of 1 mgkg to male wistar rats,Intermediate,10116.0,,A,,BAO_0000218,2661,,,1,CHEMBL631239,,,Rattus norvegicus,N,1,,
9248,Compound was evaluated for plasma half life in rat,Intermediate,10116.0,,A,,BAO_0000218,740,,,1,CHEMBL631240,,,Rattus norvegicus,N,1,1969.0,
9249,AUC value at a dose of 5 mg/kg (p.o.) in rats,Intermediate,10116.0,,A,,BAO_0000218,6597,,,1,CHEMBL631241,,,Rattus norvegicus,N,1,1969.0,
9250,AUC value after administration of 20 mg/Kg oral dose in rat,Intermediate,10116.0,,A,,BAO_0000218,2959,,,1,CHEMBL631242,,,Rattus norvegicus,N,1,1969.0,
9251,AUC0-24 after repeated oral dose of compound at 1 mg/kg in rats,Intermediate,10116.0,,A,,BAO_0000218,17594,,,1,CHEMBL631243,,,Rattus norvegicus,N,1,1969.0,
9252,AUC0-96 after administration at 50 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,17596,,,1,CHEMBL874444,,,Rattus norvegicus,N,1,1969.0,
9253,AUC0-infinity after single intravenous bolus of 1 mg/kg in rats,Intermediate,10116.0,,A,,BAO_0000218,17594,,,1,CHEMBL631244,,,Rattus norvegicus,N,1,1969.0,
9254,"Absorption behavior was judged by the area under the curve, determined after oral dose of 30 mg/kg in rats.",Intermediate,10116.0,,A,,BAO_0000218,3293,,,1,CHEMBL631245,,,Rattus norvegicus,N,1,,
9255,Area under curve (0-24 hr) at a dose of 10 mg/kg in male SD rats,Intermediate,10116.0,,A,,BAO_0000218,6757,,,1,CHEMBL627162,,,Rattus norvegicus,N,1,,
9256,Area under curve (0-24 hr) at a dose of 100 mg/kg in male SD rats,Intermediate,10116.0,,A,,BAO_0000218,6757,,,1,CHEMBL627163,,,Rattus norvegicus,N,1,,
9257,Area under curve (0-24 hr) at a dose of 50 mg/kg in male SD rats,Intermediate,10116.0,,A,,BAO_0000218,6757,,,1,CHEMBL627164,,,Rattus norvegicus,N,1,,
9258,Area under curve (AUC) at a dose 1 mg/kg was determined in rat kidney,Intermediate,10116.0,,A,,BAO_0000218,5979,,,1,CHEMBL627165,,,Rattus norvegicus,N,1,2113.0,
9259,Area under curve (AUC) at a dose 1 mg/kg was determined in rat liver,Intermediate,10116.0,,A,,BAO_0000218,5979,,,1,CHEMBL627166,,,Rattus norvegicus,N,1,,
9260,Area under curve (AUC) at a dose 1 mg/kg was determined in rat lung,Intermediate,10116.0,,A,,BAO_0000218,5979,,,1,CHEMBL627167,,,Rattus norvegicus,N,1,,
9261,Area under curve (AUC) at a dose of 30 mg/kg in rats,Intermediate,10116.0,,A,,BAO_0000218,4026,,,1,CHEMBL627822,,,Rattus norvegicus,N,1,,
9262,Area under curve (AUC) was calculated using trapezoidal rule at a dose of 20 mg/kg in rats,Intermediate,10116.0,,A,,BAO_0000218,5355,,,1,CHEMBL627823,,,Rattus norvegicus,N,1,,
9263,Area under curve (AUC) was calculated using trapezoidal rule. at a dose of 10 mg/kg in rats,Intermediate,10116.0,,A,,BAO_0000218,5355,,,1,CHEMBL627824,,,Rattus norvegicus,N,1,,
9264,Area under curve (AUC) was calculated using trapezoidal rule at a dose of 20 mg/kg in rats,Intermediate,10116.0,,A,,BAO_0000218,5355,,,1,CHEMBL627825,,,Rattus norvegicus,N,1,,
9265,Area under curve (AUC0-24 h) after administration (30 mg/kg) in rat,Intermediate,10116.0,,A,,BAO_0000218,5633,,,1,CHEMBL627826,,,Rattus norvegicus,N,1,,
9266,Area under curve (Pharmacokinetic property) was determined,Intermediate,10116.0,,A,,BAO_0000218,1716,,,1,CHEMBL627827,,,Rattus norvegicus,N,1,,
9267,Area under curve (Pharmacokinetic property) of the compound; Not determined,Intermediate,10116.0,,A,,BAO_0000218,1716,,,1,CHEMBL627828,,,Rattus norvegicus,N,1,,
9268,Area under curve after intravenous administration (1 mg/kg) in rat,Intermediate,10116.0,,A,,BAO_0000218,4689,,,1,CHEMBL627829,,,Rattus norvegicus,N,1,,
9269,Area under curve by intravenous administration at a dose of 10 uM/kg in rat was determined,Intermediate,10116.0,,A,,BAO_0000218,4527,,,1,CHEMBL627830,,,Rattus norvegicus,N,1,,
9270,Area under curve by oral administration at a dose of 100 uM/kg in rat was determined,Intermediate,10116.0,,A,,BAO_0000218,4527,,,1,CHEMBL627831,,,Rattus norvegicus,N,1,,
9271,Area under curve in male SD rats was observed after oral administration in rat,Intermediate,10116.0,,A,,BAO_0000218,15662,,,1,CHEMBL627832,,,Rattus norvegicus,N,1,,
9272,Area under curve of compound after iv administration of 20 mg/kg dose in rat,Intermediate,10116.0,,A,,BAO_0000218,4413,,,1,CHEMBL627833,,,Rattus norvegicus,N,1,,
9273,Area under curve of compound determined in rat after iv administration at a dose of 10 mg/kg,Expert,10116.0,,A,,BAO_0000218,3598,,,1,CHEMBL627834,,,Rattus norvegicus,N,1,,
9274,Area under curve of compound from zero time to infinity determined in rat after iv administration at a dose of 10 mg/kg,Expert,10116.0,,A,,BAO_0000218,3598,,,1,CHEMBL628004,,,Rattus norvegicus,N,1,,
9275,Area under curve at 5 mg/kg po was determined in rat,Intermediate,10116.0,,A,,BAO_0000218,5964,,,1,CHEMBL628005,,,Rattus norvegicus,N,1,,
9276,Area under curve in Rat at a oral dose of 5 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,4689,,,1,CHEMBL628006,,,Rattus norvegicus,N,1,,
9277,Area under curve in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,Intermediate,10116.0,,A,,BAO_0000218,4186,,,1,CHEMBL628007,,,Rattus norvegicus,N,1,,
9278,Area under curve was determined,Intermediate,10116.0,,A,,BAO_0000218,5510,,,1,CHEMBL625676,,,Rattus norvegicus,N,1,,
9279,Area under curve after 10 mg/kg oral administration in rat at 0-24 hr,Intermediate,10116.0,,A,,BAO_0000218,17858,,,1,CHEMBL631309,,,Rattus norvegicus,N,1,,
9280,Area under curve after intravenous administration at 3 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,17804,,,1,CHEMBL631310,,,Rattus norvegicus,N,1,,
9281,Area under curve after peroral administration at 10 mg/kg in rat for 0-6 h,Intermediate,10116.0,,A,,BAO_0000218,6106,,,1,CHEMBL631311,,,Rattus norvegicus,N,1,,
9282,Area under curve at 4 hr in rat,Intermediate,10116.0,,A,,BAO_0000218,5964,,,1,CHEMBL631312,,,Rattus norvegicus,N,1,,
9283,Area under curve at a dose of 30 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,4026,,,1,CHEMBL631313,,,Rattus norvegicus,N,1,,
9284,Area under curve at the dose of 2 mg/Kg administered perorally in rats,Intermediate,10116.0,,A,,BAO_0000218,4756,,,1,CHEMBL631314,,,Rattus norvegicus,N,1,,
9285,Area under curve at the dose of 5 mg/Kg administered perorally in rats,Intermediate,10116.0,,A,,BAO_0000218,4756,,,1,CHEMBL631315,,,Rattus norvegicus,N,1,,
9286,Area under curve for a 2-mpk po dose in SD rats,Intermediate,10116.0,,A,,BAO_0000218,5862,,,1,CHEMBL631316,,,Rattus norvegicus,N,1,,
9287,Area under curve in SD rats,Intermediate,10116.0,,A,,BAO_0000218,5862,,,1,CHEMBL631317,,,Rattus norvegicus,N,1,,
9288,Area under curve in rat after oral administration at 13 mg/kg dose,Intermediate,10116.0,,A,,BAO_0000218,6644,,,1,CHEMBL874471,,,Rattus norvegicus,N,1,,
9289,Area under curve in rat by po administration at 0-24 hr,Intermediate,10116.0,,A,,BAO_0000218,5871,,,1,CHEMBL631318,,,Rattus norvegicus,N,1,,
9290,Area under curve in rat plasma,Intermediate,10116.0,,A,,BAO_0000218,5919,,,1,CHEMBL631319,,,Rattus norvegicus,N,1,1969.0,
9291,Area under curve in rat plasma for 0-4 hr after peroral administration at 10 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,5939,,,1,CHEMBL631320,,,Rattus norvegicus,N,1,,
9292,Area under curve in rat plasma for 0-4 hr after peroral administration at 5 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,5939,,,1,CHEMBL631321,,,Rattus norvegicus,N,1,,
9293,Area under curve was evaluated in rat at 3 mg/kg dose administered intravenously,Intermediate,10116.0,,A,,BAO_0000218,10,,,1,CHEMBL631322,,,Rattus norvegicus,N,1,,
9294,Area under curve was measured from the graph obtained from concentration Vs time after oral administration to male F344 rats,Intermediate,10116.0,,A,,BAO_0000218,11149,,,1,CHEMBL631323,,,Rattus norvegicus,N,1,,
9295,Area under curve value in rat at a dose of 5 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,5302,,,1,CHEMBL631324,,,Rattus norvegicus,N,1,,
9296,Area under curve was determined after oral administration in rats,Intermediate,10116.0,,A,,BAO_0000218,17796,,,1,CHEMBL631325,,,Rattus norvegicus,N,1,,
9297,Area under curve was determined after oral administration at a dose 10 mg/kg to male Sprague-Dawley rats,Intermediate,10116.0,,A,,BAO_0000218,4890,,,1,CHEMBL631326,,,Rattus norvegicus,N,1,,
9298,Area under curve was determined after peroral administration in rat,Intermediate,10116.0,,A,,BAO_0000218,6011,,,1,CHEMBL631327,,,Rattus norvegicus,N,1,,
9299,Area under curve was determined at a dose 30 mpk administered orally.,Intermediate,10116.0,,A,,BAO_0000218,5375,,,1,CHEMBL631328,,,Rattus norvegicus,N,1,,
9300,Area under curve was determined for compound after intravenous administration in rats at 24 uM/kg,Intermediate,10116.0,,A,,BAO_0000218,17764,,,1,CHEMBL631329,,,Rattus norvegicus,N,1,,
9301,Area under curve was determined for the compound by intravenous administration of 3.4 mg/kg in rat,Intermediate,10116.0,,A,,BAO_0000218,4368,,,1,CHEMBL627217,,,Rattus norvegicus,N,1,,
9302,Area under curve was determined in male rat,Intermediate,10116.0,,A,,BAO_0000218,5610,,,1,CHEMBL626352,,,Rattus norvegicus,N,1,,
9303,Area under curve was determined in rat after PO administration,Intermediate,10116.0,,A,,BAO_0000218,5833,,,1,CHEMBL626353,,,Rattus norvegicus,N,1,,
9304,Area under curve was determined in rat after a 3 mg/kg of oral dose,Intermediate,10116.0,,A,,BAO_0000218,4257,,,1,CHEMBL626354,,,Rattus norvegicus,N,1,,
9305,Area under curve was determined in rat after oral administration at a concentration 1 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,5937,,,1,CHEMBL626355,,,Rattus norvegicus,N,1,,
9306,Area under curve was determined in rat after oral administration at a concentration 30 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,5932,,,1,CHEMBL626356,,,Rattus norvegicus,N,1,,
9307,Area under curve was determined in rat after oral administration at a concentration 30 mg/kg; NA= Not active,Intermediate,10116.0,,A,,BAO_0000218,5932,,,1,CHEMBL626357,,,Rattus norvegicus,N,1,,
9308,Liver concentration was determined after 5 min. of intravenous administration to rats (n=4) at dose of 20 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,17411,,,1,CHEMBL626358,,,Rattus norvegicus,N,1,,
9309,Lung concentration was determined after 5 min. of intravenous administration to rats (n=4) at dose of 20 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,17411,,,1,CHEMBL626359,,,Rattus norvegicus,N,1,,
9310,Peak plasma concentration in rat at a dose of 3 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,17771,,,1,CHEMBL626360,,,Rattus norvegicus,N,1,1969.0,
9311,Plasma concentration at 2 hr in rats was evaluated.,Intermediate,10116.0,,A,,BAO_0000218,1628,,,1,CHEMBL626361,,,Rattus norvegicus,N,1,,
9312,Plasma concentration at 2 hr in rats was evaluated; Not available,Intermediate,10116.0,,A,,BAO_0000218,1628,,,1,CHEMBL626362,,,Rattus norvegicus,N,1,,
9313,Serum concentration was determined after 5 min. of intravenous administration to rats (n=4) at dose of 20 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,17411,,,1,CHEMBL626363,,,Rattus norvegicus,N,1,,
9314,Tested for concentration in brain after 0.25 hrs of intravenous administration (5 mg/kg) to male rats,Intermediate,10116.0,,A,,BAO_0000218,4910,,,1,CHEMBL626970,,,Rattus norvegicus,N,1,,
9315,Tested for concentration in brain after 2 hrs of intravenous administration (5 mg/kg) to male rats,Intermediate,10116.0,,A,,BAO_0000218,4910,,,1,CHEMBL626971,,,Rattus norvegicus,N,1,,
9316,Tested for plasma concentration after 0.25 hrs of intravenous administration (5 mg/kg) to male rats,Intermediate,10116.0,,A,,BAO_0000218,4910,,,1,CHEMBL626972,,,Rattus norvegicus,N,1,1969.0,
9317,Tested for plasma concentration after 2 hrs of intravenous administration (5 mg/kg) to male rats,Intermediate,10116.0,,A,,BAO_0000218,4910,,,1,CHEMBL626973,,,Rattus norvegicus,N,1,1969.0,
9318,Tested for plasma concentration in the after 0.25 hrs of intravenous administration (5 mg/kg) to male rats,Intermediate,10116.0,,A,,BAO_0000218,4910,,,1,CHEMBL626974,,,Rattus norvegicus,N,1,1969.0,
9319,Tested for plasma concentration in the after 2 hrs of intravenous administration (5 mg/kg) to male rats,Intermediate,10116.0,,A,,BAO_0000218,4910,,,1,CHEMBL874592,,,Rattus norvegicus,N,1,1969.0,
9320,Percentage converted to BMS-191011 after 30 min incubation in rat plasma at 37 degree C,Intermediate,10116.0,,A,,BAO_0000218,5510,,,1,CHEMBL626975,,,Rattus norvegicus,N,1,,
9321,Percentage converted to BMS-191011 after 30 min incubation in rat plasma at 37 degree C; Converted to an unknown compound,Intermediate,10116.0,,A,,BAO_0000218,5510,,,1,CHEMBL626976,,,Rattus norvegicus,N,1,,
9322,Percentage converted to BMS-191011 after 30 min incubation in rat plasma at 37 degree C; Not determined,Intermediate,10116.0,,A,,BAO_0000218,5510,,,1,CHEMBL626977,,,Rattus norvegicus,N,1,,
9323,Percentage converted to BMS-191011 after 30 min incubation in rat plasma at 37 degree C; Not tested,Intermediate,10116.0,,A,,BAO_0000218,5510,,,1,CHEMBL626978,,,Rattus norvegicus,N,1,,
9324,PK study was carried to determine the relative absorption ranking in rat.,Intermediate,10116.0,,A,,BAO_0000218,16427,,,1,CHEMBL626979,,,Rattus norvegicus,N,1,,
9325,Maximum plasma concentration in Rat at a oral dose of 5 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,4689,,,1,CHEMBL626980,,,Rattus norvegicus,N,1,1969.0,
9326,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.57-0.75 % dose/g",Intermediate,10116.0,,A,,BAO_0000218,11450,,,1,CHEMBL626981,,,Rattus norvegicus,N,1,178.0,
9327,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.06-0.63 % dose/g",Intermediate,10116.0,,A,,BAO_0000218,11450,,,1,CHEMBL626982,,,Rattus norvegicus,N,1,178.0,
9328,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.40-0.55 % dose/g",Intermediate,10116.0,,A,,BAO_0000218,11450,,,1,CHEMBL626983,,,Rattus norvegicus,N,1,178.0,
9329,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.28-0.37% dose/g",Intermediate,10116.0,,A,,BAO_0000218,11450,,,1,CHEMBL622522,,,Rattus norvegicus,N,1,178.0,
9330,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.56-0.74 % dose/g",Intermediate,10116.0,,A,,BAO_0000218,11450,,,1,CHEMBL622523,,,Rattus norvegicus,N,1,178.0,
9331,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from % dose/g",Intermediate,10116.0,,A,,BAO_0000218,11450,,,1,CHEMBL622524,,,Rattus norvegicus,N,1,178.0,
9332,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 2.20-2.85 % dose/g",Intermediate,10116.0,,A,,BAO_0000218,11450,,,1,CHEMBL622525,,,Rattus norvegicus,N,1,955.0,
9333,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.16-1.76 % dose/g",Intermediate,10116.0,,A,,BAO_0000218,11450,,,1,CHEMBL622526,,,Rattus norvegicus,N,1,955.0,
9334,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.96-3.72 % dose/g",Intermediate,10116.0,,A,,BAO_0000218,11450,,,1,CHEMBL619849,,,Rattus norvegicus,N,1,955.0,
9335,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 2.57-3.59 % dose/g",Intermediate,10116.0,,A,,BAO_0000218,11450,,,1,CHEMBL619850,,,Rattus norvegicus,N,1,955.0,
9336,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.36-1.53 % dose/g",Intermediate,10116.0,,A,,BAO_0000218,11450,,,1,CHEMBL623864,,,Rattus norvegicus,N,1,955.0,
9337,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.81-1.08 % dose/g",Intermediate,10116.0,,A,,BAO_0000218,11450,,,1,CHEMBL623865,,,Rattus norvegicus,N,1,955.0,
9338,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.84-0.98 % dose/g",Intermediate,10116.0,,A,,BAO_0000218,11450,,,1,CHEMBL623866,,,Rattus norvegicus,N,1,948.0,
9339,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.06-0.53 % dose/g",Intermediate,10116.0,,A,,BAO_0000218,11450,,,1,CHEMBL623867,,,Rattus norvegicus,N,1,948.0,
9340,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.22-1.48 % dose/g",Intermediate,10116.0,,A,,BAO_0000218,11450,,,1,CHEMBL877615,,,Rattus norvegicus,N,1,948.0,
9341,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.85-1.13 % dose/g",Intermediate,10116.0,,A,,BAO_0000218,11450,,,1,CHEMBL623868,,,Rattus norvegicus,N,1,948.0,
9342,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.55-0.63 % dose/g",Intermediate,10116.0,,A,,BAO_0000218,11450,,,1,CHEMBL623869,,,Rattus norvegicus,N,1,948.0,
9343,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.33-0.42 % dose/g",Intermediate,10116.0,,A,,BAO_0000218,11450,,,1,CHEMBL623870,,,Rattus norvegicus,N,1,948.0,
9344,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 5 min,Intermediate,10116.0,,A,,BAO_0000218,16434,,,1,CHEMBL623871,,,Rattus norvegicus,N,1,2048.0,
9345,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,Intermediate,10116.0,,A,,BAO_0000218,16434,,,1,CHEMBL623872,,,Rattus norvegicus,N,1,2048.0,
9346,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,Intermediate,10116.0,,A,,BAO_0000218,16435,,,1,CHEMBL622129,,,Rattus norvegicus,N,1,2048.0,
9347,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,Intermediate,10116.0,,A,,BAO_0000218,16435,,,1,CHEMBL622130,,,Rattus norvegicus,N,1,2048.0,
9348,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,Intermediate,10116.0,,A,,BAO_0000218,16435,,,1,CHEMBL622131,,,Rattus norvegicus,N,1,2048.0,
9349,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,Intermediate,10116.0,,A,,BAO_0000218,16435,,,1,CHEMBL622132,,,Rattus norvegicus,N,1,2048.0,
9350,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,Intermediate,10116.0,,A,,BAO_0000218,16435,,,1,CHEMBL622133,,,Rattus norvegicus,N,1,2048.0,
9351,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,Intermediate,10116.0,,A,,BAO_0000218,16435,,,1,CHEMBL622134,,,Rattus norvegicus,N,1,2048.0,
9352,Radioactivity distribution in lungs of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,Intermediate,10116.0,,A,,BAO_0000218,16435,,,1,CHEMBL622135,,,Rattus norvegicus,N,1,2048.0,
9353,Radioactivity distribution in lungs of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,Intermediate,10116.0,,A,,BAO_0000218,16435,,,1,CHEMBL622136,,,Rattus norvegicus,N,1,2048.0,
9354,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,Intermediate,10116.0,,A,,BAO_0000218,16434,,,1,CHEMBL622137,,,Rattus norvegicus,N,1,2385.0,
9355,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,Intermediate,10116.0,,A,,BAO_0000218,16434,,,1,CHEMBL622138,,,Rattus norvegicus,N,1,2385.0,
9356,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,Intermediate,10116.0,,A,,BAO_0000218,16434,,,1,CHEMBL623017,,,Rattus norvegicus,N,1,2385.0,
9357,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,Intermediate,10116.0,,A,,BAO_0000218,16434,,,1,CHEMBL623018,,,Rattus norvegicus,N,1,2385.0,
9358,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,Intermediate,10116.0,,A,,BAO_0000218,16434,,,1,CHEMBL623019,,,Rattus norvegicus,N,1,2385.0,
9359,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,Intermediate,10116.0,,A,,BAO_0000218,16434,,,1,CHEMBL623020,,,Rattus norvegicus,N,1,2385.0,
9360,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 5 min.,Intermediate,10116.0,,A,,BAO_0000218,16434,,,1,CHEMBL623021,,,Rattus norvegicus,N,1,2385.0,
9361,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 60 min.,Intermediate,10116.0,,A,,BAO_0000218,16434,,,1,CHEMBL623022,,,Rattus norvegicus,N,1,2385.0,
9362,Radioactivity distribution in muscle of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,Intermediate,10116.0,,A,,BAO_0000218,16435,,,1,CHEMBL623023,,,Rattus norvegicus,N,1,2385.0,
9363,Radioactivity distribution in muscle of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,Intermediate,10116.0,,A,,BAO_0000218,16435,,,1,CHEMBL623024,,,Rattus norvegicus,N,1,2385.0,
9364,Radioactivity distribution in muscle of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,Intermediate,10116.0,,A,,BAO_0000218,16435,,,1,CHEMBL623025,,,Rattus norvegicus,N,1,2385.0,
9365,Radioactivity distribution in muscle of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,Intermediate,10116.0,,A,,BAO_0000218,16435,,,1,CHEMBL620545,,,Rattus norvegicus,N,1,2385.0,
9366,Radioactivity distribution in muscle of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,Intermediate,10116.0,,A,,BAO_0000218,16435,,,1,CHEMBL620546,,,Rattus norvegicus,N,1,2385.0,
9367,Radioactivity distribution in muscle of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,Intermediate,10116.0,,A,,BAO_0000218,16435,,,1,CHEMBL620547,,,Rattus norvegicus,N,1,2385.0,
9368,Radioactivity distribution in muscle of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,Intermediate,10116.0,,A,,BAO_0000218,16435,,,1,CHEMBL620548,,,Rattus norvegicus,N,1,2385.0,
9369,Radioactivity distribution in muscle of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,Intermediate,10116.0,,A,,BAO_0000218,16435,,,1,CHEMBL620549,,,Rattus norvegicus,N,1,2385.0,
9370,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,Intermediate,10116.0,,A,,BAO_0000218,16434,,,1,CHEMBL620550,,,Rattus norvegicus,N,1,2385.0,
9371,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 5 min,Intermediate,10116.0,,A,,BAO_0000218,16434,,,1,CHEMBL620551,,,Rattus norvegicus,N,1,2385.0,
9372,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,Intermediate,10116.0,,A,,BAO_0000218,16434,,,1,CHEMBL620552,,,Rattus norvegicus,N,1,2385.0,
9373,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,Intermediate,10116.0,,A,,BAO_0000218,16435,,,1,CHEMBL620553,,,Rattus norvegicus,N,1,2385.0,
9374,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,Intermediate,10116.0,,A,,BAO_0000218,16435,,,1,CHEMBL620554,,,Rattus norvegicus,N,1,2385.0,
9375,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,Intermediate,10116.0,,A,,BAO_0000218,16435,,,1,CHEMBL875845,,,Rattus norvegicus,N,1,2385.0,
9376,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,Intermediate,10116.0,,A,,BAO_0000218,16435,,,1,CHEMBL620555,,,Rattus norvegicus,N,1,2385.0,
9377,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,Intermediate,10116.0,,A,,BAO_0000218,16435,,,1,CHEMBL620556,,,Rattus norvegicus,N,1,2385.0,
9378,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,Intermediate,10116.0,,A,,BAO_0000218,16435,,,1,CHEMBL620557,,,Rattus norvegicus,N,1,2385.0,
9379,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,Intermediate,10116.0,,A,,BAO_0000218,16434,,,1,CHEMBL620558,,,Rattus norvegicus,N,1,,
9380,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,Intermediate,10116.0,,A,,BAO_0000218,16434,,,1,CHEMBL620559,,,Rattus norvegicus,N,1,,
9381,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,Intermediate,10116.0,,A,,BAO_0000218,16434,,,1,CHEMBL622939,,,Rattus norvegicus,N,1,,
9382,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,Intermediate,10116.0,,A,,BAO_0000218,16434,,,1,CHEMBL622940,,,Rattus norvegicus,N,1,,
9383,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,Intermediate,10116.0,,A,,BAO_0000218,16434,,,1,CHEMBL622941,,,Rattus norvegicus,N,1,,
9384,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,Intermediate,10116.0,,A,,BAO_0000218,16434,,,1,CHEMBL622942,,,Rattus norvegicus,N,1,,
9385,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,Intermediate,10116.0,,A,,BAO_0000218,16434,,,1,CHEMBL622943,,,Rattus norvegicus,N,1,,
9386,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,Intermediate,10116.0,,A,,BAO_0000218,16434,,,1,CHEMBL622944,,,Rattus norvegicus,N,1,,
9387,Radioactivity distribution in pancreas of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,Intermediate,10116.0,,A,,BAO_0000218,16435,,,1,CHEMBL622945,,,Rattus norvegicus,N,1,,
9388,Radioactivity distribution in pancreas of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,Intermediate,10116.0,,A,,BAO_0000218,16435,,,1,CHEMBL622946,,,Rattus norvegicus,N,1,,
9389,Compound was evaluated for terminal half life in rat,Intermediate,10116.0,,A,,BAO_0000218,3341,,,1,CHEMBL622947,,,Rattus norvegicus,N,1,,
9390,Compound was evaluated in vivo in rat for the plasma half-life at a iv dose of 3 mg/kg and oral dose of 10 mg/kg and experiment by using concentration vs time curve,Intermediate,10116.0,,A,,BAO_0000218,3634,,,1,CHEMBL622948,,,Rattus norvegicus,N,1,1969.0,
9391,Compound was evaluated in vivo in rat for the plasma half-life at a oral dose of 20 mg/kg experiment by using concentration vs time curve,Intermediate,10116.0,,A,,BAO_0000218,3634,,,1,CHEMBL622949,,,Rattus norvegicus,N,1,1969.0,
9392,Compound was tested for its half life in rat,Intermediate,10116.0,,A,,BAO_0000218,4839,,,1,CHEMBL622950,,,Rattus norvegicus,N,1,,
9393,Compound was tested for its plasma half life in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po; ND is not determined.,Intermediate,9544.0,,A,,BAO_0000218,5005,,,1,CHEMBL622951,,,Macaca mulatta,U,0,1969.0,
9394,Compound was tested for its plasma half life in Sprague Dawley rats,Intermediate,10116.0,,A,,BAO_0000366,5005,,,1,CHEMBL622952,,,Rattus norvegicus,U,0,1969.0,
9395,Compound was tested for its plasma half life in Sprague Dawley rats; ND is not determined,Intermediate,10116.0,,A,,BAO_0000366,5005,,,1,CHEMBL622953,,,Rattus norvegicus,U,0,1969.0,
9396,Compound was tested for plasma half-life period in rat,Intermediate,10116.0,,A,,BAO_0000218,1094,,,1,CHEMBL873818,,,Rattus norvegicus,N,1,1969.0,
9397,Elimination half life after i.v. administration of compound in rats,Intermediate,10116.0,,A,,BAO_0000218,5031,,,1,CHEMBL622954,,,Rattus norvegicus,N,1,,
9398,Elimination half-life after IV dosing at 0.5 mg/kg in rat,Intermediate,10116.0,,A,,BAO_0000218,6518,,,1,CHEMBL622955,,,Rattus norvegicus,N,1,,
9399,Elimination half-life after IV dosing at 1 mg/kg in rat,Intermediate,10116.0,,A,,BAO_0000218,6518,,,1,CHEMBL875229,,,Rattus norvegicus,N,1,,
9400,Elimination half-life after oral administration at a dose of 2 mg/kg in rat,Intermediate,10116.0,,A,,BAO_0000218,6518,,,1,CHEMBL622956,,,Rattus norvegicus,N,1,,
9401,Elimination half-life after oral administration at a dose of 4 mg/kg in rat,Intermediate,10116.0,,A,,BAO_0000218,6518,,,1,CHEMBL622957,,,Rattus norvegicus,N,1,,
9402,Evaluated for half-life after iv administration of 1 mg/kg to male Sprague-Dawley rats in brain; not determined,Intermediate,10116.0,,A,,BAO_0000218,5408,,,1,CHEMBL622958,,,Rattus norvegicus,N,1,955.0,
9403,Evaluated for half-life after iv administration of 1 mg/kg to male Sprague-Dawley rats in plasma,Intermediate,10116.0,,A,,BAO_0000218,5408,,,1,CHEMBL622959,,,Rattus norvegicus,N,1,1969.0,
9404,Evaluated for half-life after iv administration of 5 mg/kg to male Sprague-Dawley rats in brain,Intermediate,10116.0,,A,,BAO_0000218,5408,,,1,CHEMBL622960,,,Rattus norvegicus,N,1,955.0,
9405,Evaluated for half-life after iv administration of 5 mg/kg to male Sprague-Dawley rats in plasma,Intermediate,10116.0,,A,,BAO_0000218,5408,,,1,CHEMBL622961,,,Rattus norvegicus,N,1,1969.0,
9406,Evaluated for the half life in rat (in vivo),Intermediate,10116.0,,A,,BAO_0000218,4687,,,1,CHEMBL622962,,,Rattus norvegicus,N,1,,
9407,Hafl life in rat,Intermediate,10116.0,,A,,BAO_0000218,6640,,,1,CHEMBL622963,,,Rattus norvegicus,N,1,,
9408,Hafl life rat,Intermediate,10116.0,,A,,BAO_0000218,6640,,,1,CHEMBL622964,,,Rattus norvegicus,N,1,,
9409,Hafl life rat,Intermediate,10116.0,,A,,BAO_0000218,6641,,,1,CHEMBL622965,,,Rattus norvegicus,N,1,,
9410,Hafl life rat; Not determined,Intermediate,10116.0,,A,,BAO_0000218,6640,,,1,CHEMBL622966,,,Rattus norvegicus,N,1,,
9411,Hafl life rat; Not determined,Intermediate,10116.0,,A,,BAO_0000218,6641,,,1,CHEMBL622967,,,Rattus norvegicus,N,1,,
9412,Half life in kidney was determined after intravenous administration to rats (n=4) at dose of 20 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,17411,,,1,CHEMBL622968,,,Rattus norvegicus,N,1,2113.0,
9413,Half life in liver was determined after intravenous administration to rats (n=4) at dose of 20 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,17411,,,1,CHEMBL622969,,,Rattus norvegicus,N,1,2107.0,
9414,Half life in lung was determined after intravenous administration to rats (n=4) at dose of 20 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,17411,,,1,CHEMBL875327,,,Rattus norvegicus,N,1,2048.0,
9415,Half life in rat after 1 mg/kg i.v. administration,Intermediate,10116.0,,A,,BAO_0000218,6570,,,1,CHEMBL628638,,,Rattus norvegicus,N,1,,
9416,Half life in rat after 2 mg/kg peroral administration,Intermediate,10116.0,,A,,BAO_0000218,6570,,,1,CHEMBL628639,,,Rattus norvegicus,N,1,,
9417,Half life in serum was determined after intravenous administration to rats (n=4) at dose of 20 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,17411,,,1,CHEMBL625840,,,Rattus norvegicus,N,1,,
9418,Half life of 10 mg/kg oral dose determined in rats,Intermediate,10116.0,,A,,BAO_0000218,4722,,,1,CHEMBL625841,,,Rattus norvegicus,N,1,,
9419,Half life of compound (10 mg/kg) after iv administration was determined in Sprague-Dawley rat,Intermediate,10116.0,,A,,BAO_0000218,5978,,,1,CHEMBL625842,,,Rattus norvegicus,N,1,,
9420,Half life of compound (19.2 mg/kg) after po administration was determined in Sprague-Dawley rat,Intermediate,10116.0,,A,,BAO_0000218,5978,,,1,CHEMBL625843,,,Rattus norvegicus,N,1,,
9421,Half life of compound (20.73 mg/kg) after po administration was determined in Sprague-Dawley rat,Intermediate,10116.0,,A,,BAO_0000218,5978,,,1,CHEMBL625844,,,Rattus norvegicus,N,1,,
9422,Half life of compound (25 mg/kg) after po administration was determined in Sprague-Dawley rat,Intermediate,10116.0,,A,,BAO_0000218,5978,,,1,CHEMBL873822,,,Rattus norvegicus,N,1,,
9423,Half life of compound (9.83 mg/kg) after iv administration was determined in Sprague-Dawley rat,Intermediate,10116.0,,A,,BAO_0000218,5978,,,1,CHEMBL625845,,,Rattus norvegicus,N,1,,
9424,Half life of compound (9.84 mg/kg) after iv administration was determined in Sprague-Dawley rat,Intermediate,10116.0,,A,,BAO_0000218,5978,,,1,CHEMBL627059,,,Rattus norvegicus,N,1,,
9425,Half life of compound (9.84 mg/kg) after po administration was determined in Sprague-Dawley rat,Intermediate,10116.0,,A,,BAO_0000218,5978,,,1,CHEMBL627060,,,Rattus norvegicus,N,1,,
9426,Half life of compound (9.92 mg/kg) after iv administration was determined in Sprague-Dawley rat,Intermediate,10116.0,,A,,BAO_0000218,5978,,,1,CHEMBL627061,,,Rattus norvegicus,N,1,,
9427,Half life of compound at 5 mg/kg after po administration was determined in rat,Intermediate,10116.0,,A,,BAO_0000218,4762,,,1,CHEMBL627709,,,Rattus norvegicus,N,1,,
9428,Half life of compound determined after intravenous administration to rat,Intermediate,10116.0,,A,,BAO_0000218,5327,,,1,CHEMBL627710,,,Rattus norvegicus,N,1,,
9429,Half life of compound was determined in rat,Intermediate,10116.0,,A,,BAO_0000218,4847,,,1,CHEMBL627711,,,Rattus norvegicus,N,1,,
9430,Half life at a dose of 4 mg/kg in Rat Plasma after iv administration,Intermediate,10116.0,,A,,BAO_0000218,17720,,,1,CHEMBL627712,,,Rattus norvegicus,N,1,1969.0,
9431,Half life determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,Intermediate,10116.0,,A,,BAO_0000218,4723,,,1,CHEMBL627713,,,Rattus norvegicus,N,1,,
9432,Half life determined after 3 mg/kg oral administration in potassium oxonate treated rats,Intermediate,10116.0,,A,,BAO_0000218,4723,,,1,CHEMBL627714,,,Rattus norvegicus,N,1,,
9433,Half life determined after intravenous administration at a dose of 3 mg/kg in cynomolgus monkey,Intermediate,9541.0,,A,,BAO_0000218,4256,,,1,CHEMBL627889,,,Macaca fascicularis,U,0,,
9434,Half life determined in rat by intravenous administration,Intermediate,10116.0,,A,,BAO_0000218,4256,,,1,CHEMBL627890,,,Rattus norvegicus,U,0,,
9435,Half life determined in rats after iv administration,Intermediate,10116.0,,A,,BAO_0000218,4722,,,1,CHEMBL627891,,,Rattus norvegicus,N,1,,
9436,Half life in rat plasma after administration of 2 mg/kg iv,Intermediate,10116.0,,A,,BAO_0000218,6535,,,1,CHEMBL627892,,,Rattus norvegicus,N,1,1969.0,
9437,Half life in rat plasma after administration of 2 mg/kg iv,Intermediate,10116.0,,A,,BAO_0000218,6535,,,1,CHEMBL627893,,,Rattus norvegicus,N,1,1969.0,
9438,Half life in rat plasma was determined,Intermediate,10116.0,,A,,BAO_0000218,1435,,,1,CHEMBL627894,,,Rattus norvegicus,N,1,1969.0,
9439,Half life in rat plasma was determined; NA means not applicable,Intermediate,10116.0,,A,,BAO_0000218,1435,,,1,CHEMBL627895,,,Rattus norvegicus,N,1,1969.0,
9440,Half life in rat was tested,Intermediate,10116.0,,A,,BAO_0000218,5206,,,1,CHEMBL627896,,,Rattus norvegicus,N,1,,
9441,Half life measured in rat plasma,Intermediate,10116.0,,A,,BAO_0000218,6080,,,1,CHEMBL627897,,,Rattus norvegicus,N,1,1969.0,
9442,Half life recorded in rats,Intermediate,10116.0,,A,,BAO_0000218,4449,,,1,CHEMBL627898,,,Rattus norvegicus,N,1,,
9443,Half life was calculated,Intermediate,10116.0,,A,,BAO_0000218,6057,,,1,CHEMBL627899,,,Rattus norvegicus,N,1,,
9444,Half life was calculated in rat,Intermediate,10116.0,,A,,BAO_0000218,6057,,,1,CHEMBL873823,,,Rattus norvegicus,N,1,,
9445,Half life was determined,Intermediate,10116.0,,A,,BAO_0000218,3747,,,1,CHEMBL627900,,,Rattus norvegicus,N,1,,
9446,Half life after 10 mg/kg oral administration in rat,Intermediate,10116.0,,A,,BAO_0000218,17858,,,1,CHEMBL627901,,,Rattus norvegicus,N,1,,
9447,Half life after administering orally a dose of 10 mg/kg to a fasting rat,Intermediate,10116.0,,A,,BAO_0000218,16365,,,1,CHEMBL627902,,,Rattus norvegicus,N,1,,
9448,Half life after administering orally a dose of 30 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,16365,,,1,CHEMBL627903,,,Rattus norvegicus,N,1,,
9449,Area under the curve (Concentration) was determined for the compound as AUC with limits 0-8 after i.v. administration in rats,Intermediate,10116.0,,A,,BAO_0000218,5031,,,1,CHEMBL627904,,,Rattus norvegicus,N,1,,
9450,Area under the curve determined under pharmacokinetic behavior of the 10 mg/kg oral dose of compound for 0-6 hours,Intermediate,10116.0,,A,,BAO_0000218,4722,,,1,CHEMBL627905,,,Rattus norvegicus,N,1,,
9451,Area under the curve for the compound calculated from 0-24 hr after intravenous administration at a dose of 10 mg/kg in rat,Intermediate,10116.0,,A,,BAO_0000218,6078,,,1,CHEMBL627906,,,Rattus norvegicus,N,1,,
9452,Area under the curve for the compound calculated from 0-24 hr after oral administration at a dose of 10 mg/kg in rat,Intermediate,10116.0,,A,,BAO_0000218,6078,,,1,CHEMBL627907,,,Rattus norvegicus,N,1,,
9453,Area under the curve for the compound calculated from 0-6 hr after oral administration at a dose of 10 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,6078,,,1,CHEMBL876783,,,Rattus norvegicus,N,1,,
9454,Area under the curve for the compound calculated from 0-6 hr after oral administration at a dose of 10 mg/kg; activity was not determined,Intermediate,10116.0,,A,,BAO_0000218,6078,,,1,CHEMBL627908,,,Rattus norvegicus,N,1,,
9455,Area under the curve measured after intravenous bolus administration of 50 mg/kg of compound to rats,Intermediate,10116.0,,A,,BAO_0000218,17065,,,1,CHEMBL627909,,,Rattus norvegicus,N,1,,
9456,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats,Intermediate,10116.0,,A,,BAO_0000218,1353,,,1,CHEMBL627910,,,Rattus norvegicus,N,1,,
9457,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats(0-1),Intermediate,10116.0,,A,,BAO_0000218,1353,,,1,CHEMBL627911,,,Rattus norvegicus,N,1,,
9458,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats(0-2),Intermediate,10116.0,,A,,BAO_0000218,1353,,,1,CHEMBL627912,,,Rattus norvegicus,N,1,,
9459,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats(0-5),Intermediate,10116.0,,A,,BAO_0000218,1353,,,1,CHEMBL627913,,,Rattus norvegicus,N,1,,
9460,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats(5-10),Intermediate,10116.0,,A,,BAO_0000218,1353,,,1,CHEMBL627914,,,Rattus norvegicus,N,1,,
9461,Area under the curve was evaluated after 10 uM/kg of intra arterial administration,Intermediate,10116.0,,A,,BAO_0000218,16423,,,1,CHEMBL627915,,,Rattus norvegicus,N,1,,
9462,Area under the curve was evaluated after 20 uM/kg of peroral administration,Intermediate,10116.0,,A,,BAO_0000218,16423,,,1,CHEMBL627916,,,Rattus norvegicus,N,1,,
9463,Area under the curve was measured in rat after an iv dose of 1 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,6062,,,1,CHEMBL627917,,,Rattus norvegicus,N,1,,
9464,Area under the curve was calculated for the compound at a single intravenous administration of 20 mg/kg in rat,Intermediate,10116.0,,A,,BAO_0000218,6056,,,1,CHEMBL627918,,,Rattus norvegicus,N,1,,
9465,Area under the curve was determined by administering the compound at a dose of 1 mg/kg intravenously in male wistar rat,Intermediate,10116.0,,A,,BAO_0000218,5182,,,1,CHEMBL627919,,,Rattus norvegicus,N,1,,
9466,Area under the curve was evaluated at an intravenous dose of 3 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,6410,,,1,CHEMBL627920,,,Rattus norvegicus,N,1,,
9467,Area under the curve was evaluated at an oral dose of 30 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,6410,,,1,CHEMBL627921,,,Rattus norvegicus,N,1,,
9468,Area under the effect time curves from time 0-24 hr determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,Intermediate,10116.0,,A,,BAO_0000218,4723,,,1,CHEMBL627922,,,Rattus norvegicus,N,1,,
9469,Area under the effect time curves from time 0-24 hr determined after 3 mg/kg oral administration in potassium oxonate treated rats,Intermediate,10116.0,,A,,BAO_0000218,4723,,,1,CHEMBL876784,,,Rattus norvegicus,N,1,,
9470,Area under the effect time curves from time 0-6 hr determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,Intermediate,10116.0,,A,,BAO_0000218,4723,,,1,CHEMBL627923,,,Rattus norvegicus,N,1,,
9471,Area under the effect time curves from time 0-6 hr determined after 3 mg/kg oral administration in potassium oxonate treated rats,Intermediate,10116.0,,A,,BAO_0000218,4723,,,1,CHEMBL626208,,,Rattus norvegicus,N,1,,
9472,Area under the effect time curves from time 0-infinity hr determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,Intermediate,10116.0,,A,,BAO_0000218,4723,,,1,CHEMBL626209,,,Rattus norvegicus,N,1,,
9473,Area under the effect time curves from time 0-infinity hr determined after 3 mg/kg oral administration in potassium oxonate treated rats,Intermediate,10116.0,,A,,BAO_0000218,4723,,,1,CHEMBL626210,,,Rattus norvegicus,N,1,,
9474,Area under the plasma concentration curve was evaluated in vivo in rat at a dose of 5 mg/kg by oral administration,Intermediate,10116.0,,A,,BAO_0000218,2463,,,1,CHEMBL627994,,,Rattus norvegicus,N,1,1969.0,
9475,Bioavailability from area under the curve at time 0 to infinity after intravenous administration of 1 mg/kg in rat,Intermediate,10116.0,,A,,BAO_0000218,4709,,,1,CHEMBL627995,,,Rattus norvegicus,N,1,,
9476,Blood level after a 10 mg/kg oral dose in rat expressed as AUC was determined,Intermediate,10116.0,,A,,BAO_0000218,4075,,,1,CHEMBL627996,,,Rattus norvegicus,N,1,,
9477,Compound at a dose 10 mg/kg was administered orally to rat and the pharmacokinetic parameter area under curve (AUC) was measured,Intermediate,10116.0,,A,,BAO_0000218,5394,,,1,CHEMBL627997,,,Rattus norvegicus,N,1,,
9478,Compound was evaluated for AUC after treatment with iv dose of 1 mgkg to female wistar rats,Intermediate,10116.0,,A,,BAO_0000218,2661,,,1,CHEMBL627998,,,Rattus norvegicus,N,1,,
9479,Compound was evaluated for AUC after treatment with iv dose of 1 mgkg to male wistar rats,Intermediate,10116.0,,A,,BAO_0000218,2661,,,1,CHEMBL628640,,,Rattus norvegicus,N,1,,
9480,Compound was evaluated for AUC after treatment with oral dose of 2 mgkg to female wistar rats,Intermediate,10116.0,,A,,BAO_0000218,2661,,,1,CHEMBL628641,,,Rattus norvegicus,N,1,,
9481,Compound was evaluated for AUC after treatment with oral dose of 2 mgkg to male wistar rats,Intermediate,10116.0,,A,,BAO_0000218,2661,,,1,CHEMBL628642,,,Rattus norvegicus,N,1,,
9482,Compound was evaluated for area under the curve expressed as (h*ug/ml),Intermediate,10116.0,,A,,BAO_0000218,17791,,,1,CHEMBL628643,,,Rattus norvegicus,N,1,,
9483,Compound was tested for area under curve in rat,Intermediate,10116.0,,A,,BAO_0000218,2591,,,1,CHEMBL628644,,,Rattus norvegicus,N,1,,
9484,Concentration in rat plasma after 5 mg/kg oral gavage for 8 hours,Intermediate,10116.0,,A,,BAO_0000218,6567,,,1,CHEMBL628645,,,Rattus norvegicus,N,1,,
9485,Dose-normalized AUC was determined by po administration (10 mg/kg) in fasted male Sprague-Dawley rats,Intermediate,10116.0,,A,,BAO_0000218,6211,,,1,CHEMBL628646,,,Rattus norvegicus,N,1,,
9486,Dose-normalized AUC was determined in rat after peroral administration (2 mg/kg),Intermediate,10116.0,,A,,BAO_0000218,5529,,,1,CHEMBL628647,,,Rattus norvegicus,N,1,,
9487,Evaluated for AUC after iv administration of 1 mg/kg to male Sprague-Dawley rats in brain; not determined,Intermediate,10116.0,,A,,BAO_0000218,5408,,,1,CHEMBL628648,,,Rattus norvegicus,N,1,,
9488,Evaluated for AUC after iv administration of 1 mg/kg to male Sprague-Dawley rats in plasma,Intermediate,10116.0,,A,,BAO_0000218,5408,,,1,CHEMBL625358,,,Rattus norvegicus,N,1,,
9489,Evaluated for AUC after iv administration of 5 mg/kg to male Sprague-Dawley rats in brain,Intermediate,10116.0,,A,,BAO_0000218,5408,,,1,CHEMBL625359,,,Rattus norvegicus,N,1,,
9490,Evaluated for AUC after iv administration of 5 mg/kg to male Sprague-Dawley rats in plasma,Intermediate,10116.0,,A,,BAO_0000218,5408,,,1,CHEMBL625360,,,Rattus norvegicus,N,1,,
9491,Evaluated for pharmacokinetic parameter area under curve in rat at the dose 50 mg/kg ( 0-8 hr ),Intermediate,10116.0,,A,,BAO_0000218,429,,,1,CHEMBL625361,,,Rattus norvegicus,N,1,,
9492,Evaluated for pharmacokinetic parameter area under curve in rat at the dose 50 mg/kg (0-8 hr ),Intermediate,10116.0,,A,,BAO_0000218,429,,,1,CHEMBL625362,,,Rattus norvegicus,N,1,,
9493,Evaluated for pharmacokinetic parameter area under curve in rat at the dose 50 mg/kg (0-8 hr),Intermediate,10116.0,,A,,BAO_0000218,429,,,1,CHEMBL625363,,,Rattus norvegicus,N,1,,
9494,Hepatic portal AUC was determined by pharmacokinetic study conducted in portal vein cannulated rats,Intermediate,10116.0,,A,,BAO_0000218,4796,,,1,CHEMBL625364,,,Rattus norvegicus,N,1,,
9495,In vivo Area under curve (AUC) was determined after intravenous administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,Intermediate,10116.0,,A,,BAO_0000218,5974,,,1,CHEMBL625365,,,Rattus norvegicus,N,1,,
9496,In vivo Area under curve (AUC) was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,Intermediate,10116.0,,A,,BAO_0000218,5974,,,1,CHEMBL625366,,,Rattus norvegicus,N,1,,
9497,In vivo Area under curve (AUC) was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,Intermediate,10116.0,,A,,BAO_0000218,5974,,,1,CHEMBL625367,,,Rattus norvegicus,N,1,,
9498,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.98-2.56 % dose/g",Intermediate,10116.0,,A,,BAO_0000218,11450,,,1,CHEMBL625368,,,Rattus norvegicus,N,1,2113.0,
9499,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.15-1.43 % dose/g",Intermediate,10116.0,,A,,BAO_0000218,11450,,,1,CHEMBL625369,,,Rattus norvegicus,N,1,2113.0,
9500,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 3.43-4.52 % dose/g",Intermediate,10116.0,,A,,BAO_0000218,11450,,,1,CHEMBL625370,,,Rattus norvegicus,N,1,2113.0,
9501,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 2.12-3.14 % dose/g",Intermediate,10116.0,,A,,BAO_0000218,11450,,,1,CHEMBL625371,,,Rattus norvegicus,N,1,2113.0,
9502,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.40-1.60 % dose/g",Intermediate,10116.0,,A,,BAO_0000218,11450,,,1,CHEMBL625372,,,Rattus norvegicus,N,1,2113.0,
9503,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.74-0.85 % dose/g",Intermediate,10116.0,,A,,BAO_0000218,11450,,,1,CHEMBL625373,,,Rattus norvegicus,N,1,2113.0,
9504,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.31-1.45 % dose/g",Intermediate,10116.0,,A,,BAO_0000218,11450,,,1,CHEMBL625374,,,Rattus norvegicus,N,1,2107.0,
9505,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.08-0.90 % dose/g",Intermediate,10116.0,,A,,BAO_0000218,11450,,,1,CHEMBL877593,,,Rattus norvegicus,N,1,2107.0,
9506,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 2.02-2.78 % dose/g",Intermediate,10116.0,,A,,BAO_0000218,11450,,,1,CHEMBL625375,,,Rattus norvegicus,N,1,2107.0,
9507,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 1.64-2.38 % dose/g",Intermediate,10116.0,,A,,BAO_0000218,11450,,,1,CHEMBL625376,,,Rattus norvegicus,N,1,2107.0,
9508,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.95-1.07 % dose/g",Intermediate,10116.0,,A,,BAO_0000218,11450,,,1,CHEMBL621973,,,Rattus norvegicus,N,1,2107.0,
9509,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.61-0.81 % dose/g",Intermediate,10116.0,,A,,BAO_0000218,11450,,,1,CHEMBL621974,,,Rattus norvegicus,N,1,2107.0,
9510,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 5.01-7.13 % dose/g",Intermediate,10116.0,,A,,BAO_0000218,11450,,,1,CHEMBL621975,,,Rattus norvegicus,N,1,2048.0,
9511,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.51-3.71 % dose/g",Intermediate,10116.0,,A,,BAO_0000218,11450,,,1,CHEMBL622166,,,Rattus norvegicus,N,1,2048.0,
9512,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 10.84-13.77 % dose/g",Intermediate,10116.0,,A,,BAO_0000218,11450,,,1,CHEMBL622167,,,Rattus norvegicus,N,1,2048.0,
9513,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 5.92-8.51% dose/g",Intermediate,10116.0,,A,,BAO_0000218,11450,,,1,CHEMBL622168,,,Rattus norvegicus,N,1,2048.0,
9514,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 3.37-3.94 % dose/g",Intermediate,10116.0,,A,,BAO_0000218,11450,,,1,CHEMBL622169,,,Rattus norvegicus,N,1,2048.0,
9515,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 1.87-2.12 % dose/g",Intermediate,10116.0,,A,,BAO_0000218,11450,,,1,CHEMBL622170,,,Rattus norvegicus,N,1,2048.0,
9516,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 37.97-75.23 % dose/g",Intermediate,10116.0,,A,,BAO_0000218,11450,,,1,CHEMBL622171,,,Rattus norvegicus,N,1,2046.0,
9517,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 5.03-36.88 % dose/g",Intermediate,10116.0,,A,,BAO_0000218,11450,,,1,CHEMBL622172,,,Rattus norvegicus,N,1,2046.0,
9518,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 13.20-17.31 % dose/g",Intermediate,10116.0,,A,,BAO_0000218,11450,,,1,CHEMBL622173,,,Rattus norvegicus,N,1,2046.0,
9519,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 7.87-16.51 % dose/g",Intermediate,10116.0,,A,,BAO_0000218,11450,,,1,CHEMBL622174,,,Rattus norvegicus,N,1,2046.0,
9520,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 81.37-166.09 % dose/g",Intermediate,10116.0,,A,,BAO_0000218,11450,,,1,CHEMBL622175,,,Rattus norvegicus,N,1,2046.0,
9521,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 31.90-39.98 % dose/g",Intermediate,10116.0,,A,,BAO_0000218,11450,,,1,CHEMBL622176,,,Rattus norvegicus,N,1,2046.0,
9522,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.41-0.83 % dose/g",Intermediate,10116.0,,A,,BAO_0000218,11450,,,1,CHEMBL622177,,,Rattus norvegicus,N,1,2046.0,
9523,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.05-0.38 % dose/g",Intermediate,10116.0,,A,,BAO_0000218,11450,,,1,CHEMBL622178,,,Rattus norvegicus,N,1,2046.0,
9524,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.16-0.20 % dose/g",Intermediate,10116.0,,A,,BAO_0000218,11450,,,1,CHEMBL622179,,,Rattus norvegicus,N,1,2046.0,
9525,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.08-0.17 % dose/g",Intermediate,10116.0,,A,,BAO_0000218,11450,,,1,CHEMBL622180,,,Rattus norvegicus,N,1,2046.0,
9526,Radioactivity distribution in pancreas of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,Intermediate,10116.0,,A,,BAO_0000218,16435,,,1,CHEMBL622181,,,Rattus norvegicus,N,1,,
9527,Radioactivity distribution in pancreas of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,Intermediate,10116.0,,A,,BAO_0000218,16435,,,1,CHEMBL622182,,,Rattus norvegicus,N,1,,
9528,Radioactivity distribution in pancreas of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,Intermediate,10116.0,,A,,BAO_0000218,16435,,,1,CHEMBL622183,,,Rattus norvegicus,N,1,,
9529,Radioactivity distribution in pancreas of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,Intermediate,10116.0,,A,,BAO_0000218,16435,,,1,CHEMBL622184,,,Rattus norvegicus,N,1,,
9530,Radioactivity distribution in pancreas of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,Intermediate,10116.0,,A,,BAO_0000218,16435,,,1,CHEMBL622185,,,Rattus norvegicus,N,1,,
9531,Radioactivity distribution in pancreas of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,Intermediate,10116.0,,A,,BAO_0000218,16435,,,1,CHEMBL622186,,,Rattus norvegicus,N,1,,
9532,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,Intermediate,10116.0,,A,,BAO_0000218,16434,,,1,CHEMBL622187,,,Rattus norvegicus,N,1,,
9533,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 5 min,Intermediate,10116.0,,A,,BAO_0000218,16434,,,1,CHEMBL625002,,,Rattus norvegicus,N,1,,
9534,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 60 min,Intermediate,10116.0,,A,,BAO_0000218,16434,,,1,CHEMBL622090,,,Rattus norvegicus,N,1,,
9535,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,Intermediate,10116.0,,A,,BAO_0000218,16435,,,1,CHEMBL622091,,,Rattus norvegicus,N,1,,
9536,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,Intermediate,10116.0,,A,,BAO_0000218,16435,,,1,CHEMBL622092,,,Rattus norvegicus,N,1,,
9537,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,Intermediate,10116.0,,A,,BAO_0000218,16435,,,1,CHEMBL622093,,,Rattus norvegicus,N,1,,
9538,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,Intermediate,10116.0,,A,,BAO_0000218,16435,,,1,CHEMBL622094,,,Rattus norvegicus,N,1,,
9539,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,Intermediate,10116.0,,A,,BAO_0000218,16435,,,1,CHEMBL622095,,,Rattus norvegicus,N,1,,
9540,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,Intermediate,10116.0,,A,,BAO_0000218,16435,,,1,CHEMBL622264,,,Rattus norvegicus,N,1,,
9541,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,Intermediate,10116.0,,A,,BAO_0000218,16434,,,1,CHEMBL622265,,,Rattus norvegicus,N,1,2106.0,
9542,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,Intermediate,10116.0,,A,,BAO_0000218,16434,,,1,CHEMBL622266,,,Rattus norvegicus,N,1,2106.0,
9543,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,Intermediate,10116.0,,A,,BAO_0000218,16434,,,1,CHEMBL622267,,,Rattus norvegicus,N,1,2106.0,
9544,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,Intermediate,10116.0,,A,,BAO_0000218,16434,,,1,CHEMBL622268,,,Rattus norvegicus,N,1,2106.0,
9545,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,Intermediate,10116.0,,A,,BAO_0000218,16434,,,1,CHEMBL622269,,,Rattus norvegicus,N,1,2106.0,
9546,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,Intermediate,10116.0,,A,,BAO_0000218,16434,,,1,CHEMBL625071,,,Rattus norvegicus,N,1,2106.0,
9547,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,Intermediate,10116.0,,A,,BAO_0000218,16434,,,1,CHEMBL621621,,,Rattus norvegicus,N,1,2106.0,
9548,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,Intermediate,10116.0,,A,,BAO_0000218,16434,,,1,CHEMBL621622,,,Rattus norvegicus,N,1,2106.0,
9549,Radioactivity distribution in spleen of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,Intermediate,10116.0,,A,,BAO_0000218,16435,,,1,CHEMBL621623,,,Rattus norvegicus,N,1,2106.0,
9550,Radioactivity distribution in spleen of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,Intermediate,10116.0,,A,,BAO_0000218,16435,,,1,CHEMBL621624,,,Rattus norvegicus,N,1,2106.0,
9551,Radioactivity distribution in spleen of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,Intermediate,10116.0,,A,,BAO_0000218,16435,,,1,CHEMBL621625,,,Rattus norvegicus,N,1,2106.0,
9552,Radioactivity distribution in spleen of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,Intermediate,10116.0,,A,,BAO_0000218,16435,,,1,CHEMBL621626,,,Rattus norvegicus,N,1,2106.0,
9553,Radioactivity distribution in spleen of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,Intermediate,10116.0,,A,,BAO_0000218,16435,,,1,CHEMBL621627,,,Rattus norvegicus,N,1,2106.0,
9554,Radioactivity distribution in spleen of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,Intermediate,10116.0,,A,,BAO_0000218,16435,,,1,CHEMBL621628,,,Rattus norvegicus,N,1,2106.0,
9555,Radioactivity distribution in spleen of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,Intermediate,10116.0,,A,,BAO_0000218,16435,,,1,CHEMBL875328,,,Rattus norvegicus,N,1,2106.0,
9556,Radioactivity distribution in spleen of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,Intermediate,10116.0,,A,,BAO_0000218,16435,,,1,CHEMBL621629,,,Rattus norvegicus,N,1,2106.0,
9557,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,Intermediate,10116.0,,A,,BAO_0000218,16434,,,1,CHEMBL621630,,,Rattus norvegicus,N,1,2106.0,
9558,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,Intermediate,10116.0,,A,,BAO_0000218,16434,,,1,CHEMBL621631,,,Rattus norvegicus,N,1,2106.0,
9559,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,Intermediate,10116.0,,A,,BAO_0000218,16434,,,1,CHEMBL621632,,,Rattus norvegicus,N,1,2106.0,
9560,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,Intermediate,10116.0,,A,,BAO_0000218,16435,,,1,CHEMBL621633,,,Rattus norvegicus,N,1,2106.0,
9561,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,Intermediate,10116.0,,A,,BAO_0000218,16435,,,1,CHEMBL621634,,,Rattus norvegicus,N,1,2106.0,
9562,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,Intermediate,10116.0,,A,,BAO_0000218,16435,,,1,CHEMBL621635,,,Rattus norvegicus,N,1,2106.0,
9563,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,Intermediate,10116.0,,A,,BAO_0000218,16435,,,1,CHEMBL621636,,,Rattus norvegicus,N,1,2106.0,
9564,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,Intermediate,10116.0,,A,,BAO_0000218,16435,,,1,CHEMBL621637,,,Rattus norvegicus,N,1,2106.0,
9565,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,Intermediate,10116.0,,A,,BAO_0000218,16435,,,1,CHEMBL621638,,,Rattus norvegicus,N,1,2106.0,
9566,Radioactivity distribution in testis of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,Intermediate,10116.0,,A,,BAO_0000218,16434,,,1,CHEMBL618883,,,Rattus norvegicus,N,1,,
9567,Radioactivity distribution in testis of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,Intermediate,10116.0,,A,,BAO_0000218,16434,,,1,CHEMBL618884,,,Rattus norvegicus,N,1,,
9568,Radioactivity distribution in testis of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,Intermediate,10116.0,,A,,BAO_0000218,16434,,,1,CHEMBL628627,,,Rattus norvegicus,N,1,,
9569,Radioactivity distribution in testis of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,Intermediate,10116.0,,A,,BAO_0000218,16434,,,1,CHEMBL628628,,,Rattus norvegicus,N,1,,
9570,Radioactivity distribution in testis of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,Intermediate,10116.0,,A,,BAO_0000218,16434,,,1,CHEMBL628629,,,Rattus norvegicus,N,1,,
9571,Half life after administering orally a dose of 3 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,16365,,,1,CHEMBL628630,,,Rattus norvegicus,N,1,,
9572,Half life after administering orally a dose of 3 mg/kg to a fasting rat,Intermediate,10116.0,,A,,BAO_0000218,16365,,,1,CHEMBL628631,,,Rattus norvegicus,N,1,,
9573,Half life after administering intravenously a dose of 1 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,16365,,,1,CHEMBL628632,,,Rattus norvegicus,N,1,,
9574,Half life after oral dosing in rats,Intermediate,10116.0,,A,,BAO_0000218,526,,,1,CHEMBL628633,,,Rattus norvegicus,N,1,,
9575,Half life after the administered orally a dose of 1 mg/kg to a fasting rat,Intermediate,10116.0,,A,,BAO_0000218,16365,,,1,CHEMBL628634,,,Rattus norvegicus,N,1,,
9576,Half life by intravenous administration of 3.4 mg/kg in rat,Intermediate,10116.0,,A,,BAO_0000218,4368,,,1,CHEMBL627789,,,Rattus norvegicus,N,1,,
9577,Half life in rat,Intermediate,10116.0,,A,,BAO_0000218,3371,,,1,CHEMBL627790,,,Rattus norvegicus,N,1,,
9578,Half life in rat,Intermediate,10116.0,,A,,BAO_0000218,6448,,,1,CHEMBL627791,,,Rattus norvegicus,N,1,,
9579,Half life in rat,Intermediate,10116.0,,A,,BAO_0000218,6453,,,1,CHEMBL627792,,,Rattus norvegicus,N,1,,
9580,Half life in rat after intravenous administration of the compound,Intermediate,10116.0,,A,,BAO_0000218,4353,,,1,CHEMBL627793,,,Rattus norvegicus,N,1,,
9581,Half life in rat after intravenous administration of the compound; nf:unable to estimate plasma elimination half life,Intermediate,10116.0,,A,,BAO_0000218,4353,,,1,CHEMBL627794,,,Rattus norvegicus,N,1,1969.0,
9582,Half life in rat after po administration of the compound,Intermediate,10116.0,,A,,BAO_0000218,4353,,,1,CHEMBL627795,,,Rattus norvegicus,N,1,,
9583,Half life in rat after po administration of the compound; ND means Not determined,Intermediate,10116.0,,A,,BAO_0000218,4353,,,1,CHEMBL627796,,,Rattus norvegicus,N,1,,
9584,Half life in rat after po administration of the compound; nf: unable to estimate plasma elimination half life,Intermediate,10116.0,,A,,BAO_0000218,4353,,,1,CHEMBL875335,,,Rattus norvegicus,N,1,1969.0,
9585,Half life in rat after po administration of the compound; nf:unable to estimate plasma elimination half life,Intermediate,10116.0,,A,,BAO_0000218,4353,,,1,CHEMBL627797,,,Rattus norvegicus,N,1,1969.0,
9586,Half life in rat i.v.,Intermediate,10116.0,,A,,BAO_0000218,5789,,,1,CHEMBL627798,,,Rattus norvegicus,N,1,,
9587,Half life in rat i.v. at 2 mg/kg concentration,Intermediate,10116.0,,A,,BAO_0000218,17686,,,1,CHEMBL627799,,,Rattus norvegicus,N,1,,
9588,Half life in rats,Intermediate,10116.0,,A,,BAO_0000218,6495,,,1,CHEMBL627800,,,Rattus norvegicus,N,1,,
9589,Half life in rats after intravenous administration,Intermediate,10116.0,,A,,BAO_0000218,484,,,1,CHEMBL627801,,,Rattus norvegicus,N,1,,
9590,Half life in rats at the dose of 1.0 mpk by i.v. administration,Intermediate,10116.0,,A,,BAO_0000218,6467,,,1,CHEMBL627802,,,Rattus norvegicus,N,1,,
9591,Half life in rat,Expert,10116.0,,A,,BAO_0000218,6642,,,1,CHEMBL627803,,,Rattus norvegicus,N,1,,
9592,Half life was evaluated after intravenous administration to rats,Intermediate,10116.0,,A,,BAO_0000218,16367,,,1,CHEMBL873820,,,Rattus norvegicus,N,1,,
9593,Half life was evaluated by addition of 2 mM of 2-mercaptoethanol for inactivation of semicarbazide-sensitive amine oxidase (SSAO),Intermediate,10116.0,,A,,BAO_0000218,1369,,,1,CHEMBL627804,,,Rattus norvegicus,N,1,,
9594,Half life was evaluated in rat,Intermediate,10116.0,,A,,BAO_0000218,5472,,,1,CHEMBL627805,,,Rattus norvegicus,N,1,,
9595,Half life was evaluated in rat,Intermediate,10116.0,,A,,BAO_0000218,6049,,,1,CHEMBL627806,,,Rattus norvegicus,N,1,,
9596,Half life was evaluated in rat; Not tested,Intermediate,10116.0,,A,,BAO_0000218,5472,,,1,CHEMBL627107,,,Rattus norvegicus,N,1,,
9597,Half life was evaluated when a dose of 1 mg/kg was administered intravenously to rats,Intermediate,10116.0,,A,,BAO_0000218,16366,,,1,CHEMBL627108,,,Rattus norvegicus,N,1,,
9598,Half life was measured as time taken to reach the half of the initial dose in air pouch exudate after oral administration to male F344 rats,Intermediate,10116.0,,A,,BAO_0000218,11149,,,1,CHEMBL627109,,,Rattus norvegicus,N,1,,
9599,Half life was measured as time taken to reach the half of the initial dose in the blood after oral administration to male F344 rats,Intermediate,10116.0,,A,,BAO_0000218,11149,,,1,CHEMBL627110,,,Rattus norvegicus,N,1,178.0,
9600,Half life was measured in monkey at dose of 10 mg/kg by po administration,Intermediate,9443.0,,A,,BAO_0000218,2891,,,1,CHEMBL627111,,,Primates,U,0,,
9601,Half life was measured in monkey at dose of 10 mg/kg by po administration,Intermediate,9443.0,,A,,BAO_0000218,2891,,,1,CHEMBL627112,,,Primates,U,0,,
9602,Half life was measured in rat at dose of 30 mg/kg by iv administration,Intermediate,10116.0,,A,,BAO_0000218,2891,,,1,CHEMBL627113,,,Rattus norvegicus,U,0,,
9603,Half life was measured in rat at dose of 30 mg/kg by po administration,Intermediate,10116.0,,A,,BAO_0000218,2891,,,1,CHEMBL627114,,,Rattus norvegicus,U,0,,
9604,Half life (t1/2) was determined,Intermediate,10116.0,,A,,BAO_0000218,4026,,,1,CHEMBL627115,,,Rattus norvegicus,N,1,,
9605,Half life period at a dose of 10 uM/kg in rat was determined,Intermediate,10116.0,,A,,BAO_0000218,4527,,,1,CHEMBL627116,,,Rattus norvegicus,N,1,,
9606,Half life period by oral administration at a dose of 100 uM/kg in rat was determined; ND is not determined,Intermediate,10116.0,,A,,BAO_0000218,4527,,,1,CHEMBL627117,,,Rattus norvegicus,N,1,,
9607,Half life period was determined,Intermediate,10116.0,,A,,BAO_0000218,5503,,,1,CHEMBL627118,,,Rattus norvegicus,N,1,,
9608,Half life period after intravenous administration at 20 mpk in rats,Intermediate,10116.0,,A,,BAO_0000218,4426,,,1,CHEMBL627119,,,Rattus norvegicus,N,1,,
9609,Half life period after intravenous administration at 20 mpk in rats; Not performed.,Intermediate,10116.0,,A,,BAO_0000218,4426,,,1,CHEMBL627120,,,Rattus norvegicus,N,1,,
9610,Half life period after intravenous administration in rat,Intermediate,10116.0,,A,,BAO_0000218,6109,,,1,CHEMBL626922,,,Rattus norvegicus,N,1,,
9611,Half life period as average of four rats at each dose of 5 mg/kg intravenous and 16 mg/kg peroral administration,Intermediate,10116.0,,A,,BAO_0000218,5654,,,1,CHEMBL626923,,,Rattus norvegicus,N,1,,
9612,Half life period as average of four rats at each dose of 5 mg/kg intravenous and 20 mg/kg peroral administration,Intermediate,10116.0,,A,,BAO_0000218,5654,,,1,CHEMBL626924,,,Rattus norvegicus,N,1,,
9613,Half life period in 80% rat plasma at 37 degree Centigrade,Intermediate,10116.0,,A,,BAO_0000218,4755,,,1,CHEMBL626925,,,Rattus norvegicus,N,1,1969.0,
9614,Half life period in SD rats,Intermediate,10116.0,,A,,BAO_0000218,5862,,,1,CHEMBL626926,,,Rattus norvegicus,N,1,,
9615,Half life period in human plasma at 25 degree Celsius temperature (pH 7.4),Intermediate,10116.0,,A,,BAO_0000218,1515,,,1,CHEMBL626927,,,Rattus norvegicus,N,1,1969.0,
9616,Half life period in human plasma at 37 degree Celsius temperature (pH 7.4),Intermediate,10116.0,,A,,BAO_0000218,1515,,,1,CHEMBL626928,,,Rattus norvegicus,N,1,1969.0,
9617,Half life period in human plasma at 37 degree Celsius temperature (pH 7.4); ND means no data,Intermediate,10116.0,,A,,BAO_0000218,1515,,,1,CHEMBL626929,,,Rattus norvegicus,N,1,1969.0,
9618,Half life period in human plasma at 37 degree Celsius temperature (pH 7.4); ND means no data,Intermediate,10116.0,,A,,BAO_0000218,1515,,,1,CHEMBL626930,,,Rattus norvegicus,N,1,1969.0,
9619,Half life period in rat,Intermediate,10116.0,,A,,BAO_0000218,5960,,,1,CHEMBL626931,,,Rattus norvegicus,N,1,,
9620,Half life period in rat,Intermediate,10116.0,,A,,BAO_0000218,6103,,,1,CHEMBL626932,,,Rattus norvegicus,N,1,,
9621,Half life period in rat,Intermediate,10116.0,,A,,BAO_0000218,6317,,,1,CHEMBL626933,,,Rattus norvegicus,N,1,,
9622,Half life period in rat after oral administration at 10.5 mg/kg dose,Intermediate,10116.0,,A,,BAO_0000218,6644,,,1,CHEMBL873826,,,Rattus norvegicus,N,1,,
9623,Half life period in rat after oral administration at 11.2 mg/kg dose,Intermediate,10116.0,,A,,BAO_0000218,6644,,,1,CHEMBL626934,,,Rattus norvegicus,N,1,,
9624,Half life period in rat after oral administration at 13 mg/kg dose,Intermediate,10116.0,,A,,BAO_0000218,6644,,,1,CHEMBL626935,,,Rattus norvegicus,N,1,,
9625,Half life period in rat after oral administration at 9.7 mg/kg dose,Intermediate,10116.0,,A,,BAO_0000218,6644,,,1,CHEMBL626936,,,Rattus norvegicus,N,1,,
9626,In vivo Area under curve (AUC) was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,Intermediate,10116.0,,A,,BAO_0000218,5974,,,1,CHEMBL626937,,,Rattus norvegicus,N,1,,
9627,In vivo area under curve in rat plasma exposure after oral administration 50 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,6295,,,1,CHEMBL625906,,,Rattus norvegicus,N,1,,
9628,In vivo area under curve in rat plasma exposure after oral administration 50 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,6296,,,1,CHEMBL625907,,,Rattus norvegicus,N,1,,
9629,PK study was carried to determine AUC (area under curve) value in rat,Intermediate,10116.0,,A,,BAO_0000218,16427,,,1,CHEMBL625908,,,Rattus norvegicus,N,1,,
9630,Pharmacokinetic parameter AUC after intravenous administration to rats,Intermediate,10116.0,,A,,BAO_0000218,16367,,,1,CHEMBL625909,,,Rattus norvegicus,N,1,,
9631,Pharmacokinetic parameter AUC after oral administration to rats,Intermediate,10116.0,,A,,BAO_0000218,16367,,,1,CHEMBL625910,,,Rattus norvegicus,N,1,,
9632,Pharmacokinetic parameter AUC was evaluated intravenous administration of 3 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,16365,,,1,CHEMBL625911,,,Rattus norvegicus,N,1,,
9633,Pharmacokinetic parameter AUC was evaluated when a dose of 10 mg/kg is administered orally to a fasting rat,Intermediate,10116.0,,A,,BAO_0000218,16365,,,1,CHEMBL625912,,,Rattus norvegicus,N,1,,
9634,Pharmacokinetic parameter AUC was evaluated when a dose of 1 mg/kg is administered orally to a fasting rat,Intermediate,10116.0,,A,,BAO_0000218,16365,,,1,CHEMBL626538,,,Rattus norvegicus,N,1,,
9635,Pharmacokinetic parameter AUC was evaluated when a dose of 30 mg/kg is administered orally,Intermediate,10116.0,,A,,BAO_0000218,16365,,,1,CHEMBL876794,,,Rattus norvegicus,N,1,,
9636,Pharmacokinetic parameter AUC was evaluated when a dose of 3 mg/kg is administered orally,Intermediate,10116.0,,A,,BAO_0000218,16365,,,1,CHEMBL626539,,,Rattus norvegicus,N,1,,
9637,Pharmacokinetic parameter AUC was evaluated when a dose of 3 mg/kg is administered orally to a fasting rat,Intermediate,10116.0,,A,,BAO_0000218,16365,,,1,CHEMBL626540,,,Rattus norvegicus,N,1,,
9638,Pharmacokinetic parameter area under curve (AUC) was measured after administration into monkey at 3 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,5394,,,1,CHEMBL626541,,,Rattus norvegicus,N,1,,
9639,Pharmacokinetic parameter area under curve (AUC) was measured after administration into rat at 10 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,5394,,,1,CHEMBL626542,,,Rattus norvegicus,N,1,,
9640,Pharmacokinetic parameter area under curve was determined at 10 mg/kg po dose in rats,Intermediate,10116.0,,A,,BAO_0000218,2792,,,1,CHEMBL626543,,,Rattus norvegicus,N,1,,
9641,Pharmacokinetic parameter area under curve was determined at 2 mg/kg i.v. dose in rats,Intermediate,10116.0,,A,,BAO_0000218,2792,,,1,CHEMBL626544,,,Rattus norvegicus,N,1,,
9642,Pharmacokinetic parameter area under curve was determined at 3 mg/kg po dose in rats,Intermediate,10116.0,,A,,BAO_0000218,2792,,,1,CHEMBL626545,,,Rattus norvegicus,N,1,,
9643,Pharmacokinetic parameter area under curve was determined at 5 mg/kg i.v. dose in rats,Intermediate,10116.0,,A,,BAO_0000218,2792,,,1,CHEMBL626546,,,Rattus norvegicus,N,1,,
9644,Pharmacokinetic parameter area under curve was reported,Intermediate,10116.0,,A,,BAO_0000218,5334,,,1,CHEMBL626547,,,Rattus norvegicus,N,1,,
9645,Pharmacokinetic property (AUC) in rat,Intermediate,10116.0,,A,,BAO_0000218,4408,,,1,CHEMBL626548,,,Rattus norvegicus,N,1,,
9646,Pharmacokinetic property (AUC) was measured in rat at the dose of 0.32 mg/kg p.o.,Intermediate,10116.0,,A,,BAO_0000218,5983,,,1,CHEMBL626549,,,Rattus norvegicus,N,1,,
9647,Pharmacokinetic property at the dose of 10 mg/kg (20% HPbetaCD) concentration in rat (0 to 6 hr) p.o.,Intermediate,10116.0,,A,,BAO_0000218,4397,,,1,CHEMBL626550,,,Rattus norvegicus,N,1,,
9648,Pharmacokinetic property at the dose of 10 mg/kg (20% HPbetaCD) concentration in rat (0 to 6 hr) p.o.; Not tested,Intermediate,10116.0,,A,,BAO_0000218,4397,,,1,CHEMBL626551,,,Rattus norvegicus,N,1,,
9649,Pharmacokinetic property was determined,Intermediate,10116.0,,A,,BAO_0000218,5491,,,1,CHEMBL623777,,,Rattus norvegicus,N,1,,
9650,Pharmacokinetic property when administered intravenously in rat at 2 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,5491,,,1,CHEMBL623778,,,Rattus norvegicus,N,1,,
9651,Pharmacokinetic property when administered intravenously in rat at 2 mg/kg; Not tested,Intermediate,10116.0,,A,,BAO_0000218,5491,,,1,CHEMBL623779,,,Rattus norvegicus,N,1,,
9652,Pharmacokinetic property( plasma concentration) was determined upon 10 mg/kg in 1% methylcellulose peroral administration in rats,Intermediate,10116.0,,A,,BAO_0000218,4199,,,1,CHEMBL623780,,,Rattus norvegicus,N,1,1969.0,
9653,Pharmacokinetic property( plasma concentration) was determined upon 2 mg/kg in 1% methylcellulose peroral administration in rats,Intermediate,10116.0,,A,,BAO_0000218,4199,,,1,CHEMBL622015,,,Rattus norvegicus,N,1,1969.0,
9654,Pharmacokinetic property( plasma concentration) was determined upon 3 mg/kg in 1% methylcellulose peroral administration in rats,Intermediate,10116.0,,A,,BAO_0000218,4199,,,1,CHEMBL622016,,,Rattus norvegicus,N,1,1969.0,
9655,"Pharmacokinetic property, AUC determined by rapid rat PK assay observed at 0.25 h",Intermediate,10116.0,,A,,BAO_0000218,5173,,,1,CHEMBL622017,,,Rattus norvegicus,N,1,,
9656,"Pharmacokinetic property, AUC determined by rapid rat PK assay observed at 0.5 h",Intermediate,10116.0,,A,,BAO_0000218,5173,,,1,CHEMBL622018,,,Rattus norvegicus,N,1,,
9657,"Pharmacokinetic property, AUC determined by rapid rat PK assay observed at 1 h",Intermediate,10116.0,,A,,BAO_0000218,5173,,,1,CHEMBL622019,,,Rattus norvegicus,N,1,,
9658,"Pharmacokinetic property, AUC determined by rapid rat PK assay observed at 2 h",Intermediate,10116.0,,A,,BAO_0000218,5173,,,1,CHEMBL622020,,,Rattus norvegicus,N,1,,
9659,Pharmacokinetic parameter AUC was determined when a dose of 1 mg/kg was administered intravenously,Intermediate,10116.0,,A,,BAO_0000218,16366,,,1,CHEMBL622021,,,Rattus norvegicus,N,1,,
9660,Pharmacokinetic parameter AUC was determined when a dose of 1 mg/kg was administered orally,Intermediate,10116.0,,A,,BAO_0000218,16366,,,1,CHEMBL622022,,,Rattus norvegicus,N,1,,
9661,Plasma concentration expressed as area under curve after intravenous administration was determined in rat,Intermediate,10116.0,,A,,BAO_0000218,5327,,,1,CHEMBL622023,,,Rattus norvegicus,N,1,,
9662,Plasma concentration for the compound was determined in rats at 50 mg/kg dose,Intermediate,10116.0,,A,,BAO_0000218,6681,,,1,CHEMBL622024,,,Rattus norvegicus,N,1,,
9663,Plasma concentration was calculated in rats at a peroral dose of 5 mg/kg of solution (formulation of compound),Intermediate,10116.0,,A,,BAO_0000218,12873,,,1,CHEMBL622693,,,Rattus norvegicus,N,1,,
9664,Plasma concentration was calculated in rats at a peroral dose of 5 mg/kg of suspension (formulation of compound),Intermediate,10116.0,,A,,BAO_0000218,12873,,,1,CHEMBL622694,,,Rattus norvegicus,N,1,,
9665,"Plasma concentration was determined in rats at 10 mg/kg, p.o. dose",Intermediate,10116.0,,A,,BAO_0000218,6685,,,1,CHEMBL622695,,,Rattus norvegicus,N,1,,
9666,"Plasma concentration was determined in rats at 20 mg/kg, i.p. dose",Intermediate,10116.0,,A,,BAO_0000218,6685,,,1,CHEMBL622696,,,Rattus norvegicus,N,1,,
9667,"Plasma concentration was determined in rats at 2 mg/kg, i.v. dose",Intermediate,10116.0,,A,,BAO_0000218,6685,,,1,CHEMBL622697,,,Rattus norvegicus,N,1,,
9668,"Reduction in area under curve was determined in fa/fa Zucker rats by oral glucose tolerance test following a single i.p. dose (20 mg/kg, 30 min pre-treatment)",Intermediate,10116.0,,A,,BAO_0000218,6619,,,1,CHEMBL622874,,,Rattus norvegicus,N,1,,
9669,"Reduction in area under curve was determined in fa/fa Zucker rats by oral glucose tolerance test following a single i.p. dose (30 mg/kg, 30 min pre-treatment)",Intermediate,10116.0,,A,,BAO_0000218,6619,,,1,CHEMBL622875,,,Rattus norvegicus,N,1,,
9670,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 30 mg/kg; Not significant,Intermediate,10116.0,,A,,BAO_0000218,10363,,,1,CHEMBL622876,,,Rattus norvegicus,N,1,,
9671,Systemic AUC was determined by pharmacokinetic study conducted in portal vein cannulated rats,Intermediate,10116.0,,A,,BAO_0000218,4796,,,1,CHEMBL622877,,,Rattus norvegicus,N,1,,
9672,Tested for concentration in brain after intravenous administration (4.7 mg/kg) to male rats,Intermediate,10116.0,,A,,BAO_0000218,4910,,,1,CHEMBL622878,,,Rattus norvegicus,N,1,,
9673,Tested for plasma concentration after intravenous administration (4.7 mg/kg) to male rats,Intermediate,10116.0,,A,,BAO_0000218,4910,,,1,CHEMBL622879,,,Rattus norvegicus,N,1,1969.0,
9674,Tested for the pharmacokinetic parameter in rat and expressed as area under curve,Intermediate,10116.0,,A,,BAO_0000218,4839,,,1,CHEMBL877602,,,Rattus norvegicus,N,1,,
9675,"The AUC(0-infinitive) value in female wistar rat at 100 mg/kg, p.o. dose",Intermediate,10116.0,,A,,BAO_0000218,15078,,,1,CHEMBL622880,,,Rattus norvegicus,N,1,,
9676,"The AUC(0-infinitive) value in male wistar rat at 100 mg/kg, p.o. dose",Intermediate,10116.0,,A,,BAO_0000218,15078,,,1,CHEMBL622881,,,Rattus norvegicus,N,1,,
9677,"The AUC(0-t)value in female wistar rat at 100 mg/kg, p.o. dose",Intermediate,10116.0,,A,,BAO_0000218,15078,,,1,CHEMBL622882,,,Rattus norvegicus,N,1,,
9678,"The AUC(0-t)value in male wistar rat at 100 mg/kg, p.o. dose",Intermediate,10116.0,,A,,BAO_0000218,15078,,,1,CHEMBL622883,,,Rattus norvegicus,N,1,,
9679,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 2.16-2.39% dose/g",Intermediate,10116.0,,A,,BAO_0000218,11450,,,1,CHEMBL622884,,,Rattus norvegicus,N,1,2046.0,
9680,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.99-1.40 % dose/g",Intermediate,10116.0,,A,,BAO_0000218,11450,,,1,CHEMBL622885,,,Rattus norvegicus,N,1,2046.0,
9681,Antidiuretic activity expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg.,Intermediate,10116.0,,A,,BAO_0000218,8151,,,1,CHEMBL622886,,,Rattus norvegicus,N,1,,
9682,Antidiuretic activity expressed as Na+(sodium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg,Intermediate,10116.0,,A,,BAO_0000218,8151,,,1,CHEMBL622887,,,Rattus norvegicus,N,1,,
9683,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 100 mg/Kg,Intermediate,10116.0,,A,,BAO_0000218,8151,,,1,CHEMBL622888,,,Rattus norvegicus,N,1,1088.0,
9684,"Biodistribution in Sprague-Dawley rat blood 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Intermediate,10116.0,,A,,BAO_0000218,8677,,,1,CHEMBL622889,,,Rattus norvegicus,N,1,178.0,
9685,"Biodistribution in Sprague-Dawley rat blood 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",Intermediate,10116.0,,A,,BAO_0000218,8677,,,1,CHEMBL622890,,,Rattus norvegicus,N,1,178.0,
9686,"Biodistribution in Sprague-Dawley rat blood 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Intermediate,10116.0,,A,,BAO_0000218,8677,,,1,CHEMBL622891,,,Rattus norvegicus,N,1,178.0,
9687,"Biodistribution in Sprague-Dawley rat blood 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",Intermediate,10116.0,,A,,BAO_0000218,8677,,,1,CHEMBL877603,,,Rattus norvegicus,N,1,178.0,
9688,"Biodistribution in Sprague-Dawley rat brain 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Intermediate,10116.0,,A,,BAO_0000218,8677,,,1,CHEMBL622892,,,Rattus norvegicus,N,1,955.0,
9689,"Biodistribution in Sprague-Dawley rat brain 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",Intermediate,10116.0,,A,,BAO_0000218,8677,,,1,CHEMBL622893,,,Rattus norvegicus,N,1,955.0,
9690,"Biodistribution in Sprague-Dawley rat brain 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Intermediate,10116.0,,A,,BAO_0000218,8677,,,1,CHEMBL622894,,,Rattus norvegicus,N,1,955.0,
9691,"Biodistribution in Sprague-Dawley rat brain 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",Intermediate,10116.0,,A,,BAO_0000218,8677,,,1,CHEMBL622895,,,Rattus norvegicus,N,1,955.0,
9692,Biodistribution in Sprague-Dawley rat brain 2 minutes after intravenous administration.,Intermediate,10116.0,,A,,BAO_0000218,8677,,,1,CHEMBL622896,,,Rattus norvegicus,N,1,955.0,
9693,"Biodistribution in Sprague-Dawley rat heart 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Intermediate,10116.0,,A,,BAO_0000218,8677,,,1,CHEMBL622897,,,Rattus norvegicus,N,1,948.0,
9694,"Biodistribution in Sprague-Dawley rat heart 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Intermediate,10116.0,,A,,BAO_0000218,8677,,,1,CHEMBL622898,,,Rattus norvegicus,N,1,948.0,
9695,"Biodistribution in Sprague-Dawley rat heart 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",Intermediate,10116.0,,A,,BAO_0000218,8677,,,1,CHEMBL622899,,,Rattus norvegicus,N,1,948.0,
9696,"Biodistribution in Sprague-Dawley rat kidneys(2) 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Intermediate,10116.0,,A,,BAO_0000218,8677,,,1,CHEMBL622900,,,Rattus norvegicus,N,1,2113.0,
9697,"Biodistribution in Sprague-Dawley rat kidneys(2) 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",Intermediate,10116.0,,A,,BAO_0000218,8677,,,1,CHEMBL624114,,,Rattus norvegicus,N,1,2113.0,
9698,"Biodistribution in Sprague-Dawley rat kidneys(2) 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Intermediate,10116.0,,A,,BAO_0000218,8677,,,1,CHEMBL624115,,,Rattus norvegicus,N,1,2113.0,
9699,"Biodistribution in Sprague-Dawley rat kidneys(2) 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",Intermediate,10116.0,,A,,BAO_0000218,8677,,,1,CHEMBL624116,,,Rattus norvegicus,N,1,2113.0,
9700,"Biodistribution in Sprague-Dawley rat liver 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Intermediate,10116.0,,A,,BAO_0000218,8677,,,1,CHEMBL624117,,,Rattus norvegicus,N,1,2107.0,
9701,"Biodistribution in Sprague-Dawley rat liver 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",Intermediate,10116.0,,A,,BAO_0000218,8677,,,1,CHEMBL624118,,,Rattus norvegicus,N,1,2107.0,
9702,"Biodistribution in Sprague-Dawley rat liver 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Intermediate,10116.0,,A,,BAO_0000218,8677,,,1,CHEMBL624119,,,Rattus norvegicus,N,1,2107.0,
9703,"Biodistribution in Sprague-Dawley rat liver 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",Intermediate,10116.0,,A,,BAO_0000218,8677,,,1,CHEMBL624120,,,Rattus norvegicus,N,1,2107.0,
9704,"Biodistribution in Sprague-Dawley rat lungs(2) 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Intermediate,10116.0,,A,,BAO_0000218,8677,,,1,CHEMBL624121,,,Rattus norvegicus,N,1,2048.0,
9705,"Biodistribution in Sprague-Dawley rat lungs(2) 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",Intermediate,10116.0,,A,,BAO_0000218,8677,,,1,CHEMBL624122,,,Rattus norvegicus,N,1,2048.0,
9706,"Biodistribution in Sprague-Dawley rat lungs(2) 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Intermediate,10116.0,,A,,BAO_0000218,8677,,,1,CHEMBL624123,,,Rattus norvegicus,N,1,2048.0,
9707,"Biodistribution in Sprague-Dawley rat lungs(2) 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",Intermediate,10116.0,,A,,BAO_0000218,8677,,,1,CHEMBL624124,,,Rattus norvegicus,N,1,2048.0,
9708,"Biodistribution in Sprague-Dawley rat muscle 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Intermediate,10116.0,,A,,BAO_0000218,8677,,,1,CHEMBL624125,,,Rattus norvegicus,N,1,2385.0,
9709,"Biodistribution in Sprague-Dawley rat muscle 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",Intermediate,10116.0,,A,,BAO_0000218,8677,,,1,CHEMBL624126,,,Rattus norvegicus,N,1,2385.0,
9710,"Biodistribution in Sprague-Dawley rat muscle 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Intermediate,10116.0,,A,,BAO_0000218,8677,,,1,CHEMBL624127,,,Rattus norvegicus,N,1,2385.0,
9711,"Biodistribution in Sprague-Dawley rat muscle 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",Intermediate,10116.0,,A,,BAO_0000218,8677,,,1,CHEMBL624128,,,Rattus norvegicus,N,1,2385.0,
9712,"Biodistribution in Sprague-Dawley rat skin 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Intermediate,10116.0,,A,,BAO_0000218,8677,,,1,CHEMBL624129,,,Rattus norvegicus,N,1,14.0,
9713,"Biodistribution in Sprague-Dawley rat skin 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",Intermediate,10116.0,,A,,BAO_0000218,8677,,,1,CHEMBL624130,,,Rattus norvegicus,N,1,14.0,
9714,"Biodistribution in Sprague-Dawley rat skin 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Intermediate,10116.0,,A,,BAO_0000218,8677,,,1,CHEMBL622340,,,Rattus norvegicus,N,1,14.0,
9715,"Biodistribution in Sprague-Dawley rat skin 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",Intermediate,10116.0,,A,,BAO_0000218,8677,,,1,CHEMBL622341,,,Rattus norvegicus,N,1,14.0,
9716,"Biodistribution in Sprague-Dawley rat small intestine 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Intermediate,10116.0,,A,,BAO_0000218,8677,,,1,CHEMBL622342,,,Rattus norvegicus,N,1,160.0,
9717,"Biodistribution in Sprague-Dawley rat small intestine 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",Intermediate,10116.0,,A,,BAO_0000218,8677,,,1,CHEMBL622343,,,Rattus norvegicus,N,1,160.0,
9718,"Biodistribution in Sprague-Dawley rat small intestine 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Intermediate,10116.0,,A,,BAO_0000218,8677,,,1,CHEMBL622344,,,Rattus norvegicus,N,1,160.0,
9719,"Biodistribution in Sprague-Dawley rat small intestine 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",Intermediate,10116.0,,A,,BAO_0000218,8677,,,1,CHEMBL622345,,,Rattus norvegicus,N,1,160.0,
9720,"Biodistribution in Sprague-Dawley rat spleen 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Intermediate,10116.0,,A,,BAO_0000218,8677,,,1,CHEMBL622346,,,Rattus norvegicus,N,1,2106.0,
9721,"Biodistribution in Sprague-Dawley rat spleen 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",Intermediate,10116.0,,A,,BAO_0000218,8677,,,1,CHEMBL622347,,,Rattus norvegicus,N,1,2106.0,
9722,"Biodistribution in Sprague-Dawley rat spleen 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Intermediate,10116.0,,A,,BAO_0000218,8677,,,1,CHEMBL622348,,,Rattus norvegicus,N,1,2106.0,
9723,"Biodistribution in Sprague-Dawley rat spleen 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",Intermediate,10116.0,,A,,BAO_0000218,8677,,,1,CHEMBL622349,,,Rattus norvegicus,N,1,2106.0,
9724,Radioactivity distribution in testis of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,Intermediate,10116.0,,A,,BAO_0000218,16434,,,1,CHEMBL622350,,,Rattus norvegicus,N,1,,
9725,Radioactivity distribution in testis of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,Intermediate,10116.0,,A,,BAO_0000218,16434,,,1,CHEMBL622351,,,Rattus norvegicus,N,1,,
9726,Radioactivity distribution in testis of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,Intermediate,10116.0,,A,,BAO_0000218,16434,,,1,CHEMBL622352,,,Rattus norvegicus,N,1,,
9727,Radioactivity distribution in testis of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,Intermediate,10116.0,,A,,BAO_0000218,16435,,,1,CHEMBL622353,,,Rattus norvegicus,N,1,,
9728,Radioactivity distribution in testis of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,Intermediate,10116.0,,A,,BAO_0000218,16435,,,1,CHEMBL622354,,,Rattus norvegicus,N,1,,
9729,Radioactivity distribution in testis of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,Intermediate,10116.0,,A,,BAO_0000218,16435,,,1,CHEMBL622355,,,Rattus norvegicus,N,1,,
9730,Radioactivity distribution in testis of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,Intermediate,10116.0,,A,,BAO_0000218,16435,,,1,CHEMBL622356,,,Rattus norvegicus,N,1,,
9731,Radioactivity distribution in testis of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,Intermediate,10116.0,,A,,BAO_0000218,16435,,,1,CHEMBL622357,,,Rattus norvegicus,N,1,,
9732,Radioactivity distribution in testis of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,Intermediate,10116.0,,A,,BAO_0000218,16435,,,1,CHEMBL622358,,,Rattus norvegicus,N,1,,
9733,Radioactivity distribution in testis of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,Intermediate,10116.0,,A,,BAO_0000218,16435,,,1,CHEMBL622359,,,Rattus norvegicus,N,1,,
9734,Radioactivity distribution in testis of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,Intermediate,10116.0,,A,,BAO_0000218,16435,,,1,CHEMBL874393,,,Rattus norvegicus,N,1,,
9735,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,Intermediate,10116.0,,A,,BAO_0000218,16434,,,1,CHEMBL622872,,,Rattus norvegicus,N,1,,
9736,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,Intermediate,10116.0,,A,,BAO_0000218,16434,,,1,CHEMBL622873,,,Rattus norvegicus,N,1,,
9737,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,Intermediate,10116.0,,A,,BAO_0000218,16434,,,1,CHEMBL623047,,,Rattus norvegicus,N,1,,
9738,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,Intermediate,10116.0,,A,,BAO_0000218,16435,,,1,CHEMBL623048,,,Rattus norvegicus,N,1,,
9739,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,Intermediate,10116.0,,A,,BAO_0000218,16435,,,1,CHEMBL623049,,,Rattus norvegicus,N,1,,
9740,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,Intermediate,10116.0,,A,,BAO_0000218,16435,,,1,CHEMBL623050,,,Rattus norvegicus,N,1,,
9741,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,Intermediate,10116.0,,A,,BAO_0000218,16435,,,1,CHEMBL623051,,,Rattus norvegicus,N,1,,
9742,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,Intermediate,10116.0,,A,,BAO_0000218,16435,,,1,CHEMBL623052,,,Rattus norvegicus,N,1,,
9743,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,Intermediate,10116.0,,A,,BAO_0000218,16435,,,1,CHEMBL626343,,,Rattus norvegicus,N,1,,
9744,Radioactivity distribution in tumor of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,Intermediate,10116.0,,A,,BAO_0000218,16434,,,1,CHEMBL626344,,,Rattus norvegicus,N,1,,
9745,Radioactivity distribution in tumor of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,Intermediate,10116.0,,A,,BAO_0000218,16434,,,1,CHEMBL626345,,,Rattus norvegicus,N,1,,
9746,Radioactivity distribution in tumor of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,Intermediate,10116.0,,A,,BAO_0000218,16434,,,1,CHEMBL626346,,,Rattus norvegicus,N,1,,
9747,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,Intermediate,10116.0,,A,,BAO_0000218,16434,,,1,CHEMBL626347,,,Rattus norvegicus,N,1,,
9748,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,Intermediate,10116.0,,A,,BAO_0000218,16434,,,1,CHEMBL626348,,,Rattus norvegicus,N,1,,
9749,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,Intermediate,10116.0,,A,,BAO_0000218,16434,,,1,CHEMBL626349,,,Rattus norvegicus,N,1,,
9750,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,Intermediate,10116.0,,F,,BAO_0000218,16435,,,1,CHEMBL626350,,,Rattus norvegicus,N,1,,
9751,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,Intermediate,10116.0,,A,,BAO_0000218,16435,,,1,CHEMBL626351,,,Rattus norvegicus,N,1,,
9752,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,Intermediate,10116.0,,A,,BAO_0000218,16435,,,1,CHEMBL627650,,,Rattus norvegicus,N,1,,
9753,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,Intermediate,10116.0,,F,,BAO_0000218,16435,,,1,CHEMBL627651,,,Rattus norvegicus,N,1,,
9754,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,Intermediate,10116.0,,A,,BAO_0000218,16435,,,1,CHEMBL627652,,,Rattus norvegicus,N,1,,
9755,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,Intermediate,10116.0,,A,,BAO_0000218,16435,,,1,CHEMBL627653,,,Rattus norvegicus,N,1,,
9756,Tissue biodistribution into estrogen-primed immature female rat blood at 1 hr blocked time interval,Intermediate,10116.0,,A,,BAO_0000218,13091,,,1,CHEMBL627654,,,Rattus norvegicus,N,1,,
9757,Tissue biodistribution into estrogen-primed immature female rat blood at 1 hr low time interval,Intermediate,10116.0,,A,,BAO_0000218,13091,,,1,CHEMBL627835,,,Rattus norvegicus,N,1,,
9758,Tissue biodistribution into estrogen-primed immature female rat blood at 1 hr time interval,Intermediate,10116.0,,A,,BAO_0000218,13091,,,1,CHEMBL627836,,,Rattus norvegicus,N,1,,
9759,Tissue biodistribution into estrogen-primed immature female rat blood at 3 hr time interval,Intermediate,10116.0,,A,,BAO_0000218,13091,,,1,CHEMBL627837,,,Rattus norvegicus,N,1,,
9760,Tissue biodistribution into estrogen-primed immature female rat bone at 1 hr blocked time interval,Intermediate,10116.0,,A,,BAO_0000218,13091,,,1,CHEMBL627838,,,Rattus norvegicus,N,1,,
9761,Tissue biodistribution into estrogen-primed immature female rat bone at 1 hr low time interval,Intermediate,10116.0,,A,,BAO_0000218,13091,,,1,CHEMBL875338,,,Rattus norvegicus,N,1,,
9762,Tissue biodistribution into estrogen-primed immature female rat bone at 1 hr time interval,Intermediate,10116.0,,A,,BAO_0000218,13091,,,1,CHEMBL627839,,,Rattus norvegicus,N,1,,
9763,Tissue biodistribution into estrogen-primed immature female rat bone at 3 hr time interval,Intermediate,10116.0,,A,,BAO_0000218,13091,,,1,CHEMBL627840,,,Rattus norvegicus,N,1,,
9764,Tissue biodistribution into estrogen-primed immature female rat brain at 1 hr blocked time interval,Intermediate,10116.0,,A,,BAO_0000218,13091,,,1,CHEMBL627841,,,Rattus norvegicus,N,1,,
9765,Tissue biodistribution into estrogen-primed immature female rat brain at 1 hr low time interval,Intermediate,10116.0,,A,,BAO_0000218,13091,,,1,CHEMBL627842,,,Rattus norvegicus,N,1,,
9766,Tissue biodistribution into estrogen-primed immature female rat brain at 1 hr time interval,Intermediate,10116.0,,A,,BAO_0000218,13091,,,1,CHEMBL627843,,,Rattus norvegicus,N,1,,
9767,Tissue biodistribution into estrogen-primed immature female rat brain at 3 hr time interval,Intermediate,10116.0,,A,,BAO_0000218,13091,,,1,CHEMBL627844,,,Rattus norvegicus,N,1,,
9768,Tissue biodistribution into estrogen-primed immature female rat fat at 1 hr blocked time interval,Intermediate,10116.0,,A,,BAO_0000218,13091,,,1,CHEMBL627845,,,Rattus norvegicus,N,1,,
9769,Half life period in rat by iv administration at a dose of 3 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,5874,,,1,CHEMBL627846,,,Rattus norvegicus,N,1,,
9770,Half life period in rat plasma at 25 degree Centigrade temperature (pH 7.4),Intermediate,10116.0,,A,,BAO_0000218,1515,,,1,CHEMBL627847,,,Rattus norvegicus,N,1,1969.0,
9771,Half life period in rat plasma at 37 degree Celsius temperature (pH 7.4),Intermediate,10116.0,,A,,BAO_0000218,1515,,,1,CHEMBL873821,,,Rattus norvegicus,N,1,1969.0,
9772,Half life period in rat plasma at 37 degree Celsius temperature (pH 7.4); ND means no data,Intermediate,10116.0,,A,,BAO_0000218,1515,,,1,CHEMBL626079,,,Rattus norvegicus,N,1,1969.0,
9773,Half life period in rat plasma at 37 degree Celsius temperature (pH 7.4); ND means no data,Intermediate,10116.0,,A,,BAO_0000218,1515,,,1,CHEMBL626080,,,Rattus norvegicus,N,1,1969.0,
9774,Half life period was evaluated in rat plasma,Intermediate,10116.0,,A,,BAO_0000218,5491,,,1,CHEMBL626081,,,Rattus norvegicus,N,1,1969.0,
9775,Half life period was evaluated in rat plasma; Not tested,Intermediate,10116.0,,A,,BAO_0000218,5491,,,1,CHEMBL875344,,,Rattus norvegicus,N,1,1969.0,
9776,Half life period was evaluated in rats,Intermediate,10116.0,,A,,BAO_0000218,1918,,,1,CHEMBL626082,,,Rattus norvegicus,N,1,,
9777,"Half life period was evaluated in rats, iv",Intermediate,10116.0,,A,,BAO_0000218,1918,,,1,CHEMBL626250,,,Rattus norvegicus,N,1,,
9778,Half life period after intravenous administration at 5 mg/kg in rat,Intermediate,10116.0,,A,,BAO_0000218,6113,,,1,CHEMBL626251,,,Rattus norvegicus,N,1,,
9779,Half life period was determined in Sprague-Dawley rats at a dose of 1 mg/kg by iv administration,Intermediate,10116.0,,A,,BAO_0000218,5546,,,1,CHEMBL626252,,,Rattus norvegicus,N,1,,
9780,Half life period was determined in rat after iv administration at a dose of 5 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,5553,,,1,CHEMBL626253,,,Rattus norvegicus,N,1,,
9781,Half life stability of compound was evaluated in rat plasma,Intermediate,10116.0,,A,,BAO_0000218,4188,,,1,CHEMBL626254,,,Rattus norvegicus,N,1,1969.0,
9782,Half life time after intravenous administration (5.0 mg/kg) was determined in rat,Intermediate,10116.0,,A,,BAO_0000218,6215,,,1,CHEMBL626255,,,Rattus norvegicus,N,1,,
9783,Half life time was evaluated at 1 mg/kg of iv administration in Sprague-Dawley rats,Intermediate,10116.0,,A,,BAO_0000218,6141,,,1,CHEMBL626256,,,Rattus norvegicus,N,1,,
9784,Half life was determined by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat,Intermediate,10116.0,,A,,BAO_0000218,5182,,,1,CHEMBL626257,,,Rattus norvegicus,N,1,,
9785,Half life was determined by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat; NC means not calculated,Intermediate,10116.0,,A,,BAO_0000218,5182,,,1,CHEMBL626258,,,Rattus norvegicus,N,1,,
9786,Half life was measured in fasted male administration of compound 0.5 mg/Kg i.v.,Intermediate,10116.0,,A,,BAO_0000218,5710,,,1,CHEMBL626259,,,Rattus norvegicus,N,1,,
9787,Half in rat i.v.,Intermediate,10116.0,,A,,BAO_0000218,5789,,,1,CHEMBL626260,,,Rattus norvegicus,N,1,,
9788,Half period in rat after intravenous administration,Intermediate,10116.0,,A,,BAO_0000218,6011,,,1,CHEMBL875345,,,Rattus norvegicus,N,1,,
9789,Half-life after repeated oral dose of compound at 1 mg/kg in rats,Intermediate,10116.0,,A,,BAO_0000218,17594,,,1,CHEMBL626261,,,Rattus norvegicus,N,1,,
9790,Half-life measured in in vitro Cathepsin B assay in rat liver,Intermediate,10116.0,,A,,BAO_0000218,12357,,,1,CHEMBL626262,,,Rattus norvegicus,N,1,2107.0,
9791,Half-life of compound was determined in rats,Intermediate,10116.0,,A,,BAO_0000218,5210,,,1,CHEMBL626263,,,Rattus norvegicus,N,1,,
9792,Half-life at 10 mg/kg in rat upon intravenous administration,Intermediate,10116.0,,A,,BAO_0000218,17596,,,1,CHEMBL625270,,,Rattus norvegicus,N,1,,
9793,Half-life determined in rat,Intermediate,10116.0,,A,,BAO_0000218,6672,,,1,CHEMBL625271,,,Rattus norvegicus,N,1,,
9794,Half-life determined in rat,Intermediate,10116.0,,A,,BAO_0000218,6673,,,1,CHEMBL625272,,,Rattus norvegicus,N,1,,
9795,Half-life in brain after intravenous administration (4.7 mg/kg) to male rats,Intermediate,10116.0,,A,,BAO_0000218,4910,,,1,CHEMBL625273,,,Rattus norvegicus,N,1,955.0,
9796,"Half-life in chemical and enzymatic hydrolysis, in 80% rat plasma",Intermediate,10116.0,,A,,BAO_0000218,3741,,,1,CHEMBL625274,,,Rattus norvegicus,N,1,1969.0,
9797,Half-life in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,17671,,,1,CHEMBL625275,,,Rattus norvegicus,N,1,,
9798,Half-life in plasma after intravenous administration (4.7 mg/kg) to male rats,Intermediate,10116.0,,A,,BAO_0000218,4910,,,1,CHEMBL625276,,,Rattus norvegicus,N,1,1969.0,
9799,Half-life in rat plasma,Intermediate,10116.0,,A,,BAO_0000218,17537,,,1,CHEMBL625277,,,Rattus norvegicus,N,1,1969.0,
9800,Half-life in rat plasma was determined,Intermediate,10116.0,,A,,BAO_0000218,4965,,,1,CHEMBL625278,,,Rattus norvegicus,N,1,1969.0,
9801,Half-life in rat plasma; Not tested,Intermediate,10116.0,,A,,BAO_0000218,17537,,,1,CHEMBL625279,,,Rattus norvegicus,N,1,1969.0,
9802,Half-life in rat serum,Intermediate,10116.0,,A,,BAO_0000218,6124,,,1,CHEMBL625280,,,Rattus norvegicus,N,1,1977.0,
9803,Half-life in rat serum; na is not available,Intermediate,10116.0,,A,,BAO_0000218,6124,,,1,CHEMBL876797,,,Rattus norvegicus,N,1,1977.0,
9804,Half-life was calculated in rat,Intermediate,10116.0,,A,,BAO_0000218,6078,,,1,CHEMBL625281,,,Rattus norvegicus,N,1,,
9805,Half-life was calculated in rat plasma,Intermediate,10116.0,,A,,BAO_0000218,17668,,,1,CHEMBL873827,,,Rattus norvegicus,N,1,1969.0,
9806,Half-life was determined,Intermediate,10116.0,,A,,BAO_0000218,3185,,,1,CHEMBL625282,,,Rattus norvegicus,N,1,,
9807,Half-life was determined,Intermediate,10116.0,,A,,BAO_0000218,4883,,,1,CHEMBL625283,,,Rattus norvegicus,N,1,,
9808,Half-life after administration of 20 mg/Kg oral dose in rat,Intermediate,10116.0,,A,,BAO_0000218,2959,,,1,CHEMBL625284,,,Rattus norvegicus,N,1,,
9809,Half-life after administration of 3.2 mg/kg intravenously in male rat,Intermediate,10116.0,,A,,BAO_0000218,4029,,,1,CHEMBL625285,,,Rattus norvegicus,N,1,,
9810,Half-life after intravenous administration in female rat,Intermediate,10116.0,,A,,BAO_0000218,4029,,,1,CHEMBL625286,,,Rattus norvegicus,N,1,,
9811,Half-life after intravenous administration in male rat,Intermediate,10116.0,,A,,BAO_0000218,4029,,,1,CHEMBL625287,,,Rattus norvegicus,N,1,,
9812,Half-life after intravenous dose in rat,Intermediate,10116.0,,A,,BAO_0000218,6180,,,1,CHEMBL625288,,,Rattus norvegicus,N,1,,
9813,Half-life in a rat liver homogenate preparation,Intermediate,10116.0,,A,,BAO_0000218,1557,,,1,CHEMBL625289,,,Rattus norvegicus,N,1,2107.0,
9814,Half-life in plasma of rat,Intermediate,10116.0,,A,,BAO_0000218,12500,,,1,CHEMBL625290,,,Rattus norvegicus,N,1,1969.0,
9815,Half-life in plasma of rat at dose of 3-10 mgkg,Intermediate,10116.0,,A,,BAO_0000218,12500,,,1,CHEMBL876798,,,Rattus norvegicus,N,1,1969.0,
9816,Half-life in rat,Intermediate,10116.0,,A,,BAO_0000218,5064,,,1,CHEMBL625291,,,Rattus norvegicus,N,1,,
9817,Half-life in rat,Intermediate,10116.0,,A,,BAO_0000218,5145,,,1,CHEMBL625292,,,Rattus norvegicus,N,1,,
9818,Half-life in rat,Intermediate,10116.0,,A,,BAO_0000218,5147,,,1,CHEMBL625293,,,Rattus norvegicus,N,1,,
9819,Half-life in rat,Intermediate,10116.0,,A,,BAO_0000218,5833,,,1,CHEMBL622832,,,Rattus norvegicus,N,1,,
9820,Half-life in rat,Intermediate,10116.0,,A,,BAO_0000218,6596,,,1,CHEMBL622833,,,Rattus norvegicus,N,1,,
9821,Half-life in rat,Intermediate,10116.0,,A,,BAO_0000218,17655,,,1,CHEMBL622834,,,Rattus norvegicus,N,1,,
9822,Half-life in rat after oral administration at 10 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,6495,,,1,CHEMBL622835,,,Rattus norvegicus,N,1,,
9823,Half-life in rat after po administration at a dose of 10 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,17538,,,1,CHEMBL622836,,,Rattus norvegicus,N,1,,
9824,Half-life in rat after po administration at a dose of 10 mg/kg; nd is not determined,Intermediate,10116.0,,A,,BAO_0000218,17538,,,1,CHEMBL622837,,,Rattus norvegicus,N,1,,
9825,Half-life in rat at 3 mg/kg dose administered intravenously,Intermediate,10116.0,,A,,BAO_0000218,10,,,1,CHEMBL622838,,,Rattus norvegicus,N,1,,
9826,Half-life in rat brain homogenate,Intermediate,10116.0,,A,,BAO_0000218,17669,,,1,CHEMBL622839,,,Rattus norvegicus,N,1,955.0,
9827,Half-life in rat plasma,Intermediate,10116.0,,A,,BAO_0000218,17065,,,1,CHEMBL622840,,,Rattus norvegicus,N,1,1969.0,
9828,Half-life in rats,Intermediate,10116.0,,A,,BAO_0000218,4333,,,1,CHEMBL622841,,,Rattus norvegicus,N,1,,
9829,Half-life in Dawley rats,Intermediate,10116.0,,A,,BAO_0000218,6827,,,1,CHEMBL622842,,,Rattus norvegicus,N,1,,
9830,Half-life in vitro in rat plasma,Intermediate,10116.0,,A,,BAO_0000218,889,,,1,CHEMBL622843,,,Rattus norvegicus,N,1,1969.0,
9831,Half-life in vitro in rat plasma; No detectable degradation over 2 hr; no detectable degradation over 2 hours,Intermediate,10116.0,,A,,BAO_0000218,889,,,1,CHEMBL622844,,,Rattus norvegicus,N,1,1969.0,
9832,"The area under concentration-time curve(AUC) was determined at 20 mg/kg of compound dose, administered intravenously in rat",Intermediate,10116.0,,A,,BAO_0000218,3747,,,1,CHEMBL622845,,,Rattus norvegicus,N,1,,
9833,The area under the curve of compound was measured at the dose of 100 umol/kg,Intermediate,10116.0,,A,,BAO_0000218,15022,,,1,CHEMBL622846,,,Rattus norvegicus,N,1,,
9834,The area under the curve of compound was measured at the dose of 300 umol/kg,Intermediate,10116.0,,A,,BAO_0000218,15022,,,1,CHEMBL622847,,,Rattus norvegicus,N,1,,
9835,The area under the curve of compound was measured at the dose of 30 umol/kg,Intermediate,10116.0,,A,,BAO_0000218,15022,,,1,CHEMBL622848,,,Rattus norvegicus,N,1,,
9836,Bioavailability as oral AUC in rats,Intermediate,10116.0,,A,,BAO_0000218,3360,,,1,CHEMBL622849,,,Rattus norvegicus,N,1,,
9837,The plasma concentration versus time curve (AUC) was determined,Intermediate,10116.0,,A,,BAO_0000218,5334,,,1,CHEMBL622850,,,Rattus norvegicus,N,1,1969.0,
9838,Total concentration in kidney was determined after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,17411,,,1,CHEMBL876807,,,Rattus norvegicus,N,1,,
9839,Total concentration in liver was determined after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,17411,,,1,CHEMBL622851,,,Rattus norvegicus,N,1,,
9840,Total concentration in lung was determined after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,17411,,,1,CHEMBL622852,,,Rattus norvegicus,N,1,,
9841,Total concentration in rat after 1 mg/kg i.v. administration in 24 hours,Intermediate,10116.0,,A,,BAO_0000218,6570,,,1,CHEMBL622853,,,Rattus norvegicus,N,1,,
9842,Total concentration in rat after 2 mg/kg peroral administration in 24 hours,Intermediate,10116.0,,A,,BAO_0000218,6570,,,1,CHEMBL622854,,,Rattus norvegicus,N,1,,
9843,Total concentration in serum was determined after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,17411,,,1,CHEMBL622855,,,Rattus norvegicus,N,1,,
9844,"Pharmacokinetic Parameter, AUC (0-infinity) is the area under the plasma concentration versus time curve extrapolated to infinity in Female Wistar Rats at 100 mg/kg by po administration",Intermediate,10116.0,,A,,BAO_0000218,14941,,,1,CHEMBL622856,,,Rattus norvegicus,N,1,1969.0,
9845,"Pharmacokinetic Parameter, AUC (0-t) is the area under the plasma concentration versus time curve in Female Wistar Rats at 100 mg/kg by po administration",Intermediate,10116.0,,A,,BAO_0000218,14941,,,1,CHEMBL622857,,,Rattus norvegicus,N,1,1969.0,
9846,AUC in rat after po administration at a dose of 10 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,17538,,,1,CHEMBL622858,,,Rattus norvegicus,N,1,1969.0,
9847,Area under the plasma concentration-time curve in rats after oral administration at 25 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,17752,,,1,CHEMBL622859,,,Rattus norvegicus,N,1,1969.0,
9848,Area under curve value 24 hr after 10 mg/kg iv administration in rats,Intermediate,10116.0,,A,,BAO_0000218,17509,,,1,CHEMBL622860,,,Rattus norvegicus,N,1,,
9849,Area under curve value 24 hr after 10 mg/kg oral administration in rats,Intermediate,10116.0,,A,,BAO_0000218,17509,,,1,CHEMBL622861,,,Rattus norvegicus,N,1,,
9850,Area under curve value 24 hr after 2 mg/kg iv administration in rats,Intermediate,10116.0,,A,,BAO_0000218,17509,,,1,CHEMBL622862,,,Rattus norvegicus,N,1,,
9851,Area under curve value 24 hr after 2 mg/kg oral administration in rats,Intermediate,10116.0,,A,,BAO_0000218,17509,,,1,CHEMBL622863,,,Rattus norvegicus,N,1,,
9852,Area under curve value 6 hr after po administration in rat,Intermediate,10116.0,,A,,BAO_0000218,17509,,,1,CHEMBL623817,,,Rattus norvegicus,N,1,,
9853,Area under the curve at a concentration of 15 mg/kg perorally in rats along with 100 mg/kg of compound 11,Intermediate,10116.0,,A,,BAO_0000218,17717,,,1,CHEMBL623818,,,Rattus norvegicus,N,1,,
9854,"Area under the curve at a concentration of 3 mg/kg in rats, intravenously",Intermediate,10116.0,,A,,BAO_0000218,17717,,,1,CHEMBL623819,,,Rattus norvegicus,N,1,,
9855,Area under the curve at a concentration of 60 mg/kg perorally in rats along with 100 mg/kg of compound 11,Intermediate,10116.0,,A,,BAO_0000218,17717,,,1,CHEMBL623820,,,Rattus norvegicus,N,1,,
9856,Area under the curve at a concentration of 60 mg/kg perorally in rats along with control,Intermediate,10116.0,,A,,BAO_0000218,17717,,,1,CHEMBL623821,,,Rattus norvegicus,N,1,,
9857,AUC normalized for dose (AUCN) in rat,Intermediate,10116.0,,A,,BAO_0000218,6642,,,1,CHEMBL623822,,,Rattus norvegicus,N,1,1969.0,
9858,Area under curve in rat after p.o. administration,Intermediate,10116.0,,A,,BAO_0000218,6640,,,1,CHEMBL623823,,,Rattus norvegicus,N,1,,
9859,Area under curve in rat after p.o. administration,Intermediate,10116.0,,A,,BAO_0000218,6641,,,1,CHEMBL623824,,,Rattus norvegicus,N,1,,
9860,Area under curve in rat after p.o. administration; Not determined,Intermediate,10116.0,,A,,BAO_0000218,6641,,,1,CHEMBL623825,,,Rattus norvegicus,N,1,,
9861,Area under curve in rat after peroral administration,Intermediate,10116.0,,A,,BAO_0000218,6641,,,1,CHEMBL622070,,,Rattus norvegicus,N,1,,
9862,Area under curve (carotid artery) value of the compound,Intermediate,10116.0,,A,,BAO_0000218,3603,,,1,CHEMBL622071,,,Rattus norvegicus,N,1,,
9863,Bioavailability expressed as the area under curve of rat carotid artery,Intermediate,10116.0,,A,,BAO_0000218,3550,,,1,CHEMBL622072,,,Rattus norvegicus,N,1,,
9864,Area under curve in male SD rats was observed after intravenous administration in rat,Intermediate,10116.0,,A,,BAO_0000218,15662,,,1,CHEMBL622073,,,Rattus norvegicus,N,1,,
9865,Area under curve of the compound was determined,Intermediate,10116.0,,A,,BAO_0000218,17720,,,1,CHEMBL622074,,,Rattus norvegicus,N,1,,
9866,Compound was evaluated for its pharmacokinetic parameter maximum area under curve AUCmax,Intermediate,10116.0,,A,,BAO_0000218,5407,,,1,CHEMBL622075,,,Rattus norvegicus,N,1,,
9867,Area under the plasma concentration-time curve in rats after oral administration at 20 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,17752,,,1,CHEMBL622076,,,Rattus norvegicus,N,1,1969.0,
9868,Area under the plasma concentration-time curve in rats following oral administration at 20 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,17752,,,1,CHEMBL622077,,,Rattus norvegicus,N,1,1969.0,
9869,Area under curve (portal vein) value of the compound,Intermediate,10116.0,,A,,BAO_0000218,3603,,,1,CHEMBL622078,,,Rattus norvegicus,N,1,,
9870,Bioavailability expressed as the area under curve of rat portal vein,Intermediate,10116.0,,A,,BAO_0000218,3550,,,1,CHEMBL622079,,,Rattus norvegicus,N,1,,
9871,Area Under plasma concentration time curve in rat upon peroral administration,Intermediate,10116.0,,A,,BAO_0000218,17655,,,1,CHEMBL622080,,,Rattus norvegicus,N,1,1969.0,
9872,In vivo area under curve was determined for the compound after i.v. administration at a dose of 5 mg/kg in rats,Intermediate,10116.0,,A,,BAO_0000218,17582,,,1,CHEMBL877612,,,Rattus norvegicus,N,1,,
9873,In vivo area under curve was determined for the compound after oral (po) administration at a dose of 10 mg/kg in rats,Intermediate,10116.0,,A,,BAO_0000218,17582,,,1,CHEMBL622081,,,Rattus norvegicus,N,1,,
9874,Compound was evaluated for oral bioavailability in rats,Intermediate,10116.0,,A,,BAO_0000218,17791,,,1,CHEMBL622082,,,Rattus norvegicus,N,1,,
9875,Compound was evaluated for oral bioavailability in rats after iv administration,Intermediate,10116.0,,A,,BAO_0000218,17791,,,1,CHEMBL622083,,,Rattus norvegicus,N,1,,
9876,Compound was evaluated for oral bioavailability in rats; 30-80,Intermediate,10116.0,,A,,BAO_0000218,17791,,,1,CHEMBL622084,,,Rattus norvegicus,N,1,,
9877,Compound was evaluated for oral bioavailability in rats; 50-60,Intermediate,10116.0,,A,,BAO_0000218,17791,,,1,CHEMBL622085,,,Rattus norvegicus,N,1,,
9878,Compound was evaluated for oral bioavailability in rats; no data,Intermediate,10116.0,,A,,BAO_0000218,17791,,,1,CHEMBL622086,,,Rattus norvegicus,N,1,,
9879,Compound was evaluated for oral bioavailability in rats; peptide,Intermediate,10116.0,,A,,BAO_0000218,17791,,,1,CHEMBL622087,,,Rattus norvegicus,N,1,,
9880,"Distribution of radioactivity in blood of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.03-0.03",Intermediate,10116.0,,A,,BAO_0000218,7768,,,1,CHEMBL622088,,,Rattus norvegicus,N,1,178.0,
9881,"Distribution of radioactivity in blood of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range-0.9-1.03",Intermediate,10116.0,,A,,BAO_0000218,7768,,,1,CHEMBL622089,,,Rattus norvegicus,N,1,178.0,
9882,"Distribution of radioactivity in blood of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range = 0.88-1.15",Intermediate,10116.0,,A,,BAO_0000218,7768,,,1,CHEMBL623685,,,Rattus norvegicus,N,1,178.0,
9883,"Distribution of radioactivity in blood of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range = 0.71-0.87",Intermediate,10116.0,,A,,BAO_0000218,7768,,,1,CHEMBL623686,,,Rattus norvegicus,N,1,178.0,
9884,"Biodistribution in Sprague-Dawley rat stomach 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Intermediate,10116.0,,A,,BAO_0000218,8677,,,1,CHEMBL623687,,,Rattus norvegicus,N,1,945.0,
9885,"Biodistribution in Sprague-Dawley rat stomach 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",Intermediate,10116.0,,A,,BAO_0000218,8677,,,1,CHEMBL623688,,,Rattus norvegicus,N,1,945.0,
9886,"Biodistribution in Sprague-Dawley rat stomach 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Intermediate,10116.0,,A,,BAO_0000218,8677,,,1,CHEMBL623689,,,Rattus norvegicus,N,1,945.0,
9887,"Biodistribution in Sprague-Dawley rat stomach 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",Intermediate,10116.0,,A,,BAO_0000218,8677,,,1,CHEMBL622485,,,Rattus norvegicus,N,1,945.0,
9888,"Biodistribution in Sprague-Dawley rat thyroid 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Intermediate,10116.0,,A,,BAO_0000218,8677,,,1,CHEMBL622486,,,Rattus norvegicus,N,1,2046.0,
9889,"Biodistribution in Sprague-Dawley rat thyroid 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",Intermediate,10116.0,,A,,BAO_0000218,8677,,,1,CHEMBL877613,,,Rattus norvegicus,N,1,2046.0,
9890,"Biodistribution in Sprague-Dawley rat thyroid 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Intermediate,10116.0,,A,,BAO_0000218,8677,,,1,CHEMBL622487,,,Rattus norvegicus,N,1,2046.0,
9891,"Biodistribution in Sprague-Dawley rat thyroid 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",Intermediate,10116.0,,A,,BAO_0000218,8677,,,1,CHEMBL622488,,,Rattus norvegicus,N,1,2046.0,
9892,"Biodistribution in Sprague-Dawley rats heart 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",Intermediate,10116.0,,A,,BAO_0000218,8677,,,1,CHEMBL622489,,,Rattus norvegicus,N,1,948.0,
9893,Compound was evaluated for percent dimer tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine,Intermediate,10116.0,,A,,BAO_0000218,6899,,,1,CHEMBL622490,,,Rattus norvegicus,N,1,1088.0,
9894,Compound was evaluated for percent dimer tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine; na - not available,Intermediate,10116.0,,A,,BAO_0000218,6899,,,1,CHEMBL622491,,,Rattus norvegicus,N,1,1088.0,
9895,Compound was evaluated for percent dose tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in liver,Intermediate,10116.0,,A,,BAO_0000218,6899,,,1,CHEMBL622492,,,Rattus norvegicus,N,1,2107.0,
9896,Compound was evaluated for percent thiol tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine,Intermediate,10116.0,,A,,BAO_0000218,6899,,,1,CHEMBL622493,,,Rattus norvegicus,N,1,1088.0,
9897,Compound was evaluated for percent thiol tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine; na - not available,Intermediate,10116.0,,A,,BAO_0000218,6899,,,1,CHEMBL622494,,,Rattus norvegicus,N,1,1088.0,
9898,"Compound was evaluated for the biodistribution in Sprague-Dawley rats in muscle 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Intermediate,10116.0,,A,,BAO_0000218,8677,,,1,CHEMBL622495,,,Rattus norvegicus,N,1,2385.0,
9899,Compound was evaluated for tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in rat kidney,Intermediate,10116.0,,A,,BAO_0000218,6899,,,1,CHEMBL622496,,,Rattus norvegicus,N,1,,
9900,Compound was evaluated for tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine,Intermediate,10116.0,,A,,BAO_0000218,6899,,,1,CHEMBL622497,,,Rattus norvegicus,N,1,1088.0,
9901,Percent of radioactive dose in urine and faeces excreted in 0-24 hr by rats,Intermediate,10116.0,,A,,BAO_0000218,2189,,,1,CHEMBL622498,,,Rattus norvegicus,N,1,,
9902,Percent of radioactive dose in urine and feces excreted in 0-24 hr by rats,Intermediate,10116.0,,A,,BAO_0000218,2189,,,1,CHEMBL624918,,,Rattus norvegicus,N,1,1088.0,
9903,Percent of radioactive dose in urine and feces excreted in 0-24 hr by rats; NA is <10% inhibition at 1 uM for binding data,Intermediate,10116.0,,A,,BAO_0000218,2189,,,1,CHEMBL624919,,,Rattus norvegicus,N,1,1088.0,
9904,Biodistribution of compound in rat blood after 5 min of administration,Intermediate,10116.0,,A,,BAO_0000218,10839,,,1,CHEMBL624920,,,Rattus norvegicus,N,1,178.0,
9905,Biodistribution of compound in rat blood after 5 min of administration.,Intermediate,10116.0,,A,,BAO_0000218,10839,,,1,CHEMBL624921,,,Rattus norvegicus,N,1,178.0,
9906,Biodistribution of compound in rat brain after 5 min of administration,Intermediate,10116.0,,A,,BAO_0000218,10839,,,1,CHEMBL624922,,,Rattus norvegicus,N,1,955.0,
9907,Biodistribution of compound in rat heart after 5 min of administration,Intermediate,10116.0,,A,,BAO_0000218,10839,,,1,CHEMBL624923,,,Rattus norvegicus,N,1,948.0,
9908,Biodistribution of compound in rat heart after 5 min of administration.,Intermediate,10116.0,,A,,BAO_0000218,10839,,,1,CHEMBL624924,,,Rattus norvegicus,N,1,948.0,
9909,Biodistribution of compound in rat kidney after 5 min of administration,Intermediate,10116.0,,A,,BAO_0000218,10839,,,1,CHEMBL624925,,,Rattus norvegicus,N,1,2113.0,
9910,Biodistribution of compound in rat kidney after 5 min of administration.,Intermediate,10116.0,,A,,BAO_0000218,10839,,,1,CHEMBL624926,,,Rattus norvegicus,N,1,2113.0,
9911,Biodistribution of compound in rat liver after 5 min of administration,Intermediate,10116.0,,A,,BAO_0000218,10839,,,1,CHEMBL624927,,,Rattus norvegicus,N,1,2107.0,
9912,Biodistribution of compound in rat liver after 5 min of administration.,Intermediate,10116.0,,A,,BAO_0000218,10839,,,1,CHEMBL874402,,,Rattus norvegicus,N,1,2107.0,
9913,Biodistribution of compound in rat lung after 5 min of administration,Intermediate,10116.0,,A,,BAO_0000218,10839,,,1,CHEMBL624928,,,Rattus norvegicus,N,1,2048.0,
9914,Biodistribution of compound in rat lung after 5 min of administration.,Intermediate,10116.0,,A,,BAO_0000218,10839,,,1,CHEMBL624929,,,Rattus norvegicus,N,1,2048.0,
9915,Biodistribution of compound in rat muscle after 5 min of administration,Intermediate,10116.0,,A,,BAO_0000218,10839,,,1,CHEMBL624930,,,Rattus norvegicus,N,1,2385.0,
9916,Biodistribution of compound in rat muscle after 5 min of administration.,Intermediate,10116.0,,A,,BAO_0000218,10839,,,1,CHEMBL624931,,,Rattus norvegicus,N,1,2385.0,
9917,In vivo heart distribution of free doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,Intermediate,10116.0,,A,,BAO_0000218,4043,,,1,CHEMBL624932,,,Rattus norvegicus,N,1,948.0,
9918,In vivo heart distribution of total doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,Intermediate,10116.0,,A,,BAO_0000218,4043,,,1,CHEMBL624933,,,Rattus norvegicus,N,1,948.0,
9919,In vivo liver distribution of free doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,Intermediate,10116.0,,A,,BAO_0000218,4043,,,1,CHEMBL624934,,,Rattus norvegicus,N,1,2107.0,
9920,In vivo liver distribution of total doxorubicin after 6 h intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,Intermediate,10116.0,,A,,BAO_0000218,4043,,,1,CHEMBL624935,,,Rattus norvegicus,N,1,2107.0,
9921,In vivo plasma distribution of free doxorubicin after 6 h intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,Intermediate,10116.0,,A,,BAO_0000218,4043,,,1,CHEMBL624936,,,Rattus norvegicus,N,1,,
9922,In vivo plasma distribution of total doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,Intermediate,10116.0,,A,,BAO_0000218,4043,,,1,CHEMBL624937,,,Rattus norvegicus,N,1,,
9923,In vivo spleen distribution of free doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,Intermediate,10116.0,,A,,BAO_0000218,4043,,,1,CHEMBL624938,,,Rattus norvegicus,N,1,2106.0,
9924,In vivo spleen distribution of total doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,Intermediate,10116.0,,A,,BAO_0000218,4043,,,1,CHEMBL624939,,,Rattus norvegicus,N,1,2106.0,
9925,In vivo tumor distribution of free doxorubicin after 6 h intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,Intermediate,10116.0,,A,,BAO_0000218,4043,,,1,CHEMBL624940,,,Rattus norvegicus,N,1,,
9926,In vivo tumor distribution of total doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,Intermediate,10116.0,,A,,BAO_0000218,4043,,,1,CHEMBL874403,,,Rattus norvegicus,N,1,,
9927,Compound was tested for the duration that the plasma drug concentrations remained above the IC95,Intermediate,10116.0,,A,,BAO_0000218,1446,,,1,CHEMBL624941,,,Rattus norvegicus,N,1,,
9928,Dose required to lower urine osmolality to 300 mOsm/kg in rat,Intermediate,10116.0,,A,,BAO_0000218,9971,,,1,CHEMBL624942,,,Rattus norvegicus,N,1,1088.0,
9929,Dose required to lower urine osmolality to 300 mOsm/kg in rat; NT=Not tested,Intermediate,10116.0,,A,,BAO_0000218,9971,,,1,CHEMBL624943,,,Rattus norvegicus,N,1,1088.0,
9930,% Bioavailability after 1 day of the drug administration in rats,Intermediate,10116.0,,A,,BAO_0000218,5765,,,1,CHEMBL624944,,,Rattus norvegicus,N,1,,
9931,% Bioavailability after 4 day of the drug administration in rats,Intermediate,10116.0,,A,,BAO_0000218,5765,,,1,CHEMBL624945,,,Rattus norvegicus,N,1,,
9932,Absolute bioavailability was evaluated in rat,Intermediate,10116.0,,A,,BAO_0000218,4257,,,1,CHEMBL624946,,,Rattus norvegicus,N,1,,
9933,Tissue biodistribution into estrogen-primed immature female rat fat at 1 hr low time interval,Intermediate,10116.0,,A,,BAO_0000218,13091,,,1,CHEMBL624947,,,Rattus norvegicus,N,1,,
9934,Tissue biodistribution into estrogen-primed immature female rat fat at 1 hr time interval,Intermediate,10116.0,,A,,BAO_0000218,13091,,,1,CHEMBL624948,,,Rattus norvegicus,N,1,,
9935,Tissue biodistribution into estrogen-primed immature female rat fat at 3 hr time interval,Intermediate,10116.0,,A,,BAO_0000218,13091,,,1,CHEMBL624949,,,Rattus norvegicus,N,1,,
9936,Tissue biodistribution into estrogen-primed immature female rat kidney at 1 hr blocked time interval,Intermediate,10116.0,,A,,BAO_0000218,13091,,,1,CHEMBL622025,,,Rattus norvegicus,N,1,2113.0,
9937,Tissue biodistribution into estrogen-primed immature female rat kidney at 1 hr low time interval,Intermediate,10116.0,,A,,BAO_0000218,13091,,,1,CHEMBL622026,,,Rattus norvegicus,N,1,2113.0,
9938,Tissue biodistribution into estrogen-primed immature female rat kidney at 1 hr time interval,Intermediate,10116.0,,A,,BAO_0000218,13091,,,1,CHEMBL622027,,,Rattus norvegicus,N,1,2113.0,
9939,Tissue biodistribution into estrogen-primed immature female rat kidney at 3 hr time interval,Intermediate,10116.0,,A,,BAO_0000218,13091,,,1,CHEMBL622028,,,Rattus norvegicus,N,1,2113.0,
9940,Tissue biodistribution into estrogen-primed immature female rat liver at 1 hr blocked time interval,Intermediate,10116.0,,A,,BAO_0000218,13091,,,1,CHEMBL622029,,,Rattus norvegicus,N,1,2107.0,
9941,Tissue biodistribution into estrogen-primed immature female rat liver at 1 hr low time interval,Intermediate,10116.0,,A,,BAO_0000218,13091,,,1,CHEMBL622208,,,Rattus norvegicus,N,1,2107.0,
9942,Tissue biodistribution into estrogen-primed immature female rat liver at 1 hr time interval,Intermediate,10116.0,,A,,BAO_0000218,13091,,,1,CHEMBL622209,,,Rattus norvegicus,N,1,2107.0,
9943,Tissue biodistribution into estrogen-primed immature female rat liver at 3 hr time interval,Intermediate,10116.0,,A,,BAO_0000218,13091,,,1,CHEMBL622210,,,Rattus norvegicus,N,1,2107.0,
9944,Tissue biodistribution into estrogen-primed immature female rat lung at 1 hr blocked time interval,Intermediate,10116.0,,A,,BAO_0000218,13091,,,1,CHEMBL622211,,,Rattus norvegicus,N,1,,
9945,Tissue biodistribution into estrogen-primed immature female rat lung at 1 hr low time interval,Intermediate,10116.0,,A,,BAO_0000218,13091,,,1,CHEMBL622212,,,Rattus norvegicus,N,1,,
9946,Tissue biodistribution into estrogen-primed immature female rat lung at 1 hr time interval,Intermediate,10116.0,,A,,BAO_0000218,13091,,,1,CHEMBL622213,,,Rattus norvegicus,N,1,,
9947,Tissue biodistribution into estrogen-primed immature female rat lung at 3 hr time interval,Intermediate,10116.0,,A,,BAO_0000218,13091,,,1,CHEMBL874404,,,Rattus norvegicus,N,1,,
9948,Tissue biodistribution into estrogen-primed immature female rat muscle at 1 hr blocked time interval,Intermediate,10116.0,,A,,BAO_0000218,13091,,,1,CHEMBL620452,,,Rattus norvegicus,N,1,2385.0,
9949,Tissue biodistribution into estrogen-primed immature female rat muscle at 1 hr low time interval,Intermediate,10116.0,,A,,BAO_0000218,13091,,,1,CHEMBL620453,,,Rattus norvegicus,N,1,2385.0,
9950,Tissue biodistribution into estrogen-primed immature female rat muscle at 1 hr time interval,Intermediate,10116.0,,A,,BAO_0000218,13091,,,1,CHEMBL620454,,,Rattus norvegicus,N,1,2385.0,
9951,Tissue biodistribution into estrogen-primed immature female rat muscle at 3 hr time interval,Intermediate,10116.0,,A,,BAO_0000218,13091,,,1,CHEMBL624067,,,Rattus norvegicus,N,1,2385.0,
9952,Tissue biodistribution into estrogen-primed immature female rat ovaries at 1 hr blocked time interval,Intermediate,10116.0,,A,,BAO_0000218,13091,,,1,CHEMBL624068,,,Rattus norvegicus,N,1,,
9953,Tissue biodistribution into estrogen-primed immature female rat ovaries at 1 hr low time interval,Intermediate,10116.0,,A,,BAO_0000218,13091,,,1,CHEMBL624069,,,Rattus norvegicus,N,1,992.0,
9954,Tissue biodistribution into estrogen-primed immature female rat ovaries at 1 hr time interval,Intermediate,10116.0,,A,,BAO_0000218,13091,,,1,CHEMBL624070,,,Rattus norvegicus,N,1,992.0,
9955,Tissue biodistribution into estrogen-primed immature female rat ovaries at 3 hr time interval,Intermediate,10116.0,,A,,BAO_0000218,13091,,,1,CHEMBL624071,,,Rattus norvegicus,N,1,992.0,
9956,Tissue biodistribution into estrogen-primed immature female rat uterus at 1 hr blocked time interval,Intermediate,10116.0,,A,,BAO_0000218,13091,,,1,CHEMBL624072,,,Rattus norvegicus,N,1,995.0,
9957,Tissue biodistribution into estrogen-primed immature female rat uterus at 1 hr low time interval,Intermediate,10116.0,,A,,BAO_0000218,13091,,,1,CHEMBL624073,,,Rattus norvegicus,N,1,995.0,
9958,Tissue biodistribution into estrogen-primed immature female rat uterus at 1 hr time interval,Intermediate,10116.0,,A,,BAO_0000218,13091,,,1,CHEMBL624788,,,Rattus norvegicus,N,1,995.0,
9959,Tissue biodistribution into estrogen-primed immature female rat uterus at 3 hr time interval,Intermediate,10116.0,,A,,BAO_0000218,13091,,,1,CHEMBL624789,,,Rattus norvegicus,N,1,995.0,
9960,Tissue biodistribution into estrogen-primed immature female rat uterus/blood at 1 hr blocked time interval,Intermediate,10116.0,,A,,BAO_0000218,13091,,,1,CHEMBL624790,,,Rattus norvegicus,N,1,,
9961,Tissue biodistribution into estrogen-primed immature female rat uterus/blood at 1 hr low time interval,Intermediate,10116.0,,A,,BAO_0000218,13091,,,1,CHEMBL624791,,,Rattus norvegicus,N,1,,
9962,Tissue biodistribution into estrogen-primed immature female rat uterus/blood at 1 hr time interval,Intermediate,10116.0,,A,,BAO_0000218,13091,,,1,CHEMBL624792,,,Rattus norvegicus,N,1,,
9963,Tissue biodistribution into estrogen-primed immature female rat uterus/blood at 3 hr time interval,Intermediate,10116.0,,A,,BAO_0000218,13091,,,1,CHEMBL624793,,,Rattus norvegicus,N,1,,
9964,Tissue biodistribution into estrogen-primed immature female rat uterus/muscle at 1 hr blocked time interval,Intermediate,10116.0,,A,,BAO_0000218,13091,,,1,CHEMBL877491,,,Rattus norvegicus,N,1,2385.0,
9965,Tissue biodistribution into estrogen-primed immature female rat uterus/muscle at 1 hr low time interval,Intermediate,10116.0,,A,,BAO_0000218,13091,,,1,CHEMBL624957,,,Rattus norvegicus,N,1,2385.0,
9966,Tissue biodistribution into estrogen-primed immature female rat uterus/muscle at 1 hr time interval,Intermediate,10116.0,,A,,BAO_0000218,13091,,,1,CHEMBL624958,,,Rattus norvegicus,N,1,2385.0,
9967,Tissue biodistribution into estrogen-primed immature female rat uterus/muscle at 3 hr time interval,Intermediate,10116.0,,A,,BAO_0000218,13091,,,1,CHEMBL624959,,,Rattus norvegicus,N,1,2385.0,
9968,Dissociation constant was determined,Intermediate,10116.0,,A,,BAO_0000218,11977,,,1,CHEMBL624960,,,Rattus norvegicus,N,1,,
9969,"Pharmacokinetic Parameter, Kel is elimination rate constant in Female Wistar Rats at 100 mg/kg by po administration",Intermediate,10116.0,,A,,BAO_0000218,14941,,,1,CHEMBL624961,,,Rattus norvegicus,N,1,,
9970,"The Kel value in female wistar rat at 100 mg/kg, p.o. dose",Intermediate,10116.0,,A,,BAO_0000218,15078,,,1,CHEMBL624962,,,Rattus norvegicus,N,1,,
9971,"The Kel value in male wistar rat at 100 mg/kg, p.o. dose",Intermediate,10116.0,,A,,BAO_0000218,15078,,,1,CHEMBL624963,,,Rattus norvegicus,N,1,,
9972,Observed rate constant in 80% rat plasma at 37 degree Centigrade,Intermediate,10116.0,,A,,BAO_0000218,4755,,,1,CHEMBL624964,,,Rattus norvegicus,N,1,,
9973,LogP value was evaluated in the in situ rat gut perfusion assay,Intermediate,10116.0,,A,,BAO_0000218,589,,,1,CHEMBL624965,,,Rattus norvegicus,N,1,,
9974,In vivo retention time was evaluated for the compound after i.v. administration at a dose of 5 mg/kg was measured in rats,Intermediate,10116.0,,A,,BAO_0000218,17582,,,1,CHEMBL624966,,,Rattus norvegicus,N,1,,
9975,Mean residence time (Pharmacokinetic property) after i.v. administration in rats,Intermediate,10116.0,,A,,BAO_0000218,5031,,,1,CHEMBL624967,,,Rattus norvegicus,N,1,,
9976,Mean-residence time of compound after intravenous administration in rats at 24 uM/kg,Intermediate,10116.0,,A,,BAO_0000218,17764,,,1,CHEMBL624968,,,Rattus norvegicus,N,1,,
9977,Mean residence time at a dose of 4 mg/kg in Rat Plasma after iv administration,Intermediate,10116.0,,A,,BAO_0000218,17720,,,1,CHEMBL624969,,,Rattus norvegicus,N,1,,
9978,Streptococcal cell wall-washed arthritis model in rats at 10.0 mg/kg peroral dose,Expert,10116.0,,F,,BAO_0000218,2862,,,1,CHEMBL624970,,,Rattus norvegicus,N,1,,
9979,Half-life was evaluated after 10 uM/kg of intra arterial administration,Intermediate,10116.0,,A,,BAO_0000218,16423,,,1,CHEMBL624971,,,Rattus norvegicus,N,1,,
9980,Half-life was evaluated after 20 uM/kg of peroral administration,Intermediate,10116.0,,A,,BAO_0000218,16423,,,1,CHEMBL624972,,,Rattus norvegicus,N,1,,
9981,Half-life was evaluated after i.v. administration in rat at a dose of 1 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,6005,,,1,CHEMBL624973,,,Rattus norvegicus,N,1,,
9982,Half-life was evaluated in plasma of rat,Intermediate,10116.0,,A,,BAO_0000218,2938,,,1,CHEMBL624974,,,Rattus norvegicus,N,1,1969.0,
9983,Half-life was evaluated in rats at an intravenous dose of 3 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,6410,,,1,CHEMBL624975,,,Rattus norvegicus,N,1,,
9984,Half-life was evaluated in rats at an oral dose of 30 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,6410,,,1,CHEMBL877492,,,Rattus norvegicus,N,1,,
9985,Half-life was measured in rat after an iv dose of 1 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,6062,,,1,CHEMBL624976,,,Rattus norvegicus,N,1,,
9986,Half-life period of compound in rats after peroral administration,Intermediate,10116.0,,A,,BAO_0000218,6571,,,1,CHEMBL624977,,,Rattus norvegicus,N,1,,
9987,Half-life period of compound was measured in rat plasma.,Intermediate,10116.0,,A,,BAO_0000218,3136,,,1,CHEMBL626848,,,Rattus norvegicus,N,1,1969.0,
9988,Half-life period of compound was measured in rat plasma; ND is not determined,Intermediate,10116.0,,A,,BAO_0000218,3136,,,1,CHEMBL626849,,,Rattus norvegicus,N,1,1969.0,
9989,Half-life period of compound was measured in rat plasma; not determined,Intermediate,10116.0,,A,,BAO_0000218,3136,,,1,CHEMBL626850,,,Rattus norvegicus,N,1,1969.0,
9990,Half-life period in rat after 5 mg/kg by oral and 1 mg/kg by intravenous administration,Intermediate,10116.0,,A,,BAO_0000218,4521,,,1,CHEMBL626851,,,Rattus norvegicus,N,1,,
9991,Half-life period in rat by iv administration,Intermediate,10116.0,,A,,BAO_0000218,5871,,,1,CHEMBL626852,,,Rattus norvegicus,N,1,,
9992,Half-life period in rats following intravenous administration at 2 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,6077,,,1,CHEMBL626853,,,Rattus norvegicus,N,1,,
9993,Half-life period was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,Intermediate,10116.0,,A,,BAO_0000218,6679,,,1,CHEMBL626854,,,Rattus norvegicus,N,1,,
9994,Half-life period was determined for the compound in rat,Intermediate,10116.0,,A,,BAO_0000218,5144,,,1,CHEMBL627486,,,Rattus norvegicus,N,1,,
9995,"Half-life period was evaluated in rat, after administering 1 mg/kg intravenously",Intermediate,10116.0,,A,,BAO_0000218,4498,,,1,CHEMBL627487,,,Rattus norvegicus,N,1,,
9996,"Half-life period was evaluated in rat, after administering 10 mg/kg orally",Intermediate,10116.0,,A,,BAO_0000218,4498,,,1,CHEMBL627488,,,Rattus norvegicus,N,1,,
9997,Half-life value after IV dose at a dose of 5 mg/kg in rats.,Intermediate,10116.0,,A,,BAO_0000218,1908,,,1,CHEMBL627489,,,Rattus norvegicus,N,1,,
9998,Half-life was determined by iv administration (1.5 mg/kg) in fasted male Sprague-Dawley rats,Intermediate,10116.0,,A,,BAO_0000218,6211,,,1,CHEMBL627490,,,Rattus norvegicus,N,1,,
9999,Half-life was determined in rat after intravenous administration (0.5 mg/kg),Intermediate,10116.0,,A,,BAO_0000218,5529,,,1,CHEMBL873829,,,Rattus norvegicus,N,1,,
10000,Half-life was determined in rat at a dose of 1 mpk i.v.,Intermediate,10116.0,,A,,BAO_0000218,6444,,,1,CHEMBL627655,,,Rattus norvegicus,N,1,,
10001,Half-life was determined in rat at a dose of 1 mpk i.v.; ND means not determined,Intermediate,10116.0,,A,,BAO_0000218,6444,,,1,CHEMBL625994,,,Rattus norvegicus,N,1,,
10002,Half-life was determined in rat at a dose of 1 mpk i.v.; ND=not determined,Intermediate,10116.0,,A,,BAO_0000218,6444,,,1,CHEMBL625995,,,Rattus norvegicus,N,1,,
10003,Half-life in rat,Intermediate,10116.0,,A,,BAO_0000218,5207,,,1,CHEMBL625996,,,Rattus norvegicus,N,1,,
10004,In vitro half life in rat plasma,Intermediate,10116.0,,A,,BAO_0000218,530,,,1,CHEMBL625850,,,Rattus norvegicus,N,1,1969.0,
10005,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in rat plasma",Intermediate,10116.0,,A,,BAO_0000218,1116,,,1,CHEMBL625851,,,Rattus norvegicus,N,1,1969.0,
10006,In vitro half life in rat,Intermediate,10116.0,,A,,BAO_0000218,3219,,,1,CHEMBL625852,,,Rattus norvegicus,N,1,,
10007,In vivo half life period after intravenous administration in rat,Intermediate,10116.0,,A,,BAO_0000218,6109,,,1,CHEMBL625853,,,Rattus norvegicus,N,1,,
10008,In vivo half-life period for compound after i.v. administration at a dose of 5 mg/kg was measured in rats,Intermediate,10116.0,,A,,BAO_0000218,17582,,,1,CHEMBL625854,,,Rattus norvegicus,N,1,,
10009,In vivo half-life period for compound after oral (po) administration at a dose of 10 mg/kg was measured in rats,Intermediate,10116.0,,A,,BAO_0000218,17582,,,1,CHEMBL874450,,,Rattus norvegicus,N,1,,
10010,In vivo t1/2 was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,Intermediate,10116.0,,A,,BAO_0000218,5974,,,1,CHEMBL625855,,,Rattus norvegicus,N,1,,
10011,In vivo t1/2 was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,Intermediate,10116.0,,A,,BAO_0000218,5974,,,1,CHEMBL625856,,,Rattus norvegicus,N,1,,
10012,In vivo t1/2 was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,Intermediate,10116.0,,A,,BAO_0000218,5974,,,1,CHEMBL625857,,,Rattus norvegicus,N,1,,
10013,In vivo t1/2 was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,Intermediate,10116.0,,A,,BAO_0000218,5974,,,1,CHEMBL873831,,,Rattus norvegicus,N,1,,
10014,Longer half-life in rat (i.v.) at 0.5 mpk,Intermediate,10116.0,,A,,BAO_0000218,17853,,,1,CHEMBL625858,,,Rattus norvegicus,N,1,,
10015,Longer half-life in rat (p.o.) at 2.0 mpk,Intermediate,10116.0,,A,,BAO_0000218,17853,,,1,CHEMBL625859,,,Rattus norvegicus,N,1,,
10016,Pharmacokinetic property (half life) in rat,Intermediate,10116.0,,A,,BAO_0000218,3457,,,1,CHEMBL625860,,,Rattus norvegicus,N,1,,
10017,Pharmacokinetic parameter half-life was determined at 10 mg/kg po dose in rats,Intermediate,10116.0,,A,,BAO_0000218,2792,,,1,CHEMBL625861,,,Rattus norvegicus,N,1,,
10018,Pharmacokinetic parameter half-life was determined at 2 mg/kg i.v. dose in rats,Intermediate,10116.0,,A,,BAO_0000218,2792,,,1,CHEMBL625862,,,Rattus norvegicus,N,1,,
10019,Pharmacokinetic parameter half-life was determined at 3 mg/kg po dose in rats,Intermediate,10116.0,,A,,BAO_0000218,2792,,,1,CHEMBL625863,,,Rattus norvegicus,N,1,,
10020,Pharmacokinetic parameter half-life was determined at 5 mg/kg i.v. dose in rats,Intermediate,10116.0,,A,,BAO_0000218,2792,,,1,CHEMBL625864,,,Rattus norvegicus,N,1,,
10021,Pharmacokinetic property (t1/2) for the compound (5 mg/kg iv) was determined in rats,Intermediate,10116.0,,A,,BAO_0000218,5739,,,1,CHEMBL625865,,,Rattus norvegicus,N,1,,
10022,Pharmacokinetic half time was determined intravenously in rats.,Intermediate,10116.0,,A,,BAO_0000218,15765,,,1,CHEMBL625866,,,Rattus norvegicus,N,1,,
10023,Plasma half life in rat after 5 mg/kg oral gavage; 6-8 hours,Intermediate,10116.0,,A,,BAO_0000218,6567,,,1,CHEMBL625867,,,Rattus norvegicus,N,1,1969.0,
10024,Plasma half life of hydrolysis of the compound,Intermediate,10116.0,,A,,BAO_0000218,2448,,,1,CHEMBL625868,,,Rattus norvegicus,N,1,1969.0,
10025,Plasma half life was reported after a intravenous dose of 1 mg/kg in Dawley rat,Intermediate,10116.0,,A,,BAO_0000218,5423,,,1,CHEMBL625869,,,Rattus norvegicus,N,1,1969.0,
10026,Plasma half life period was calculated in rat,Intermediate,10116.0,,A,,BAO_0000218,4853,,,1,CHEMBL874451,,,Rattus norvegicus,N,1,1969.0,
10027,Plasma half-life in Sprague-Dawley rats,Intermediate,10116.0,,A,,BAO_0000218,4514,,,1,CHEMBL625870,,,Rattus norvegicus,N,1,1969.0,
10028,Plasma half-life in Sprague-Dawley rats; Not determined,Intermediate,10116.0,,A,,BAO_0000218,4514,,,1,CHEMBL625871,,,Rattus norvegicus,N,1,1969.0,
10029,Plasma half-life in rats,Intermediate,10116.0,,A,,BAO_0000218,1500,,,1,CHEMBL625872,,,Rattus norvegicus,N,1,1969.0,
10030,Plasma half-life in rats; <MQL,Intermediate,10116.0,,A,,BAO_0000218,1500,,,1,CHEMBL625873,,,Rattus norvegicus,N,1,1969.0,
10031,Plasma half-life period (0-8 h) was determined,Intermediate,10116.0,,A,,BAO_0000218,5334,,,1,CHEMBL625874,,,Rattus norvegicus,N,1,1969.0,
10032,Plasma half-life period (0-8 h) was determined in Sprague-Dawley rat,Intermediate,10116.0,,A,,BAO_0000218,5334,,,1,CHEMBL625875,,,Rattus norvegicus,N,1,1969.0,
10033,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Sprague-Dawley rat,Intermediate,10116.0,,A,,BAO_0000218,5334,,,1,CHEMBL625876,,,Rattus norvegicus,N,1,1969.0,
10034,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg in Sprague-Dawley rat,Intermediate,10116.0,,A,,BAO_0000218,5334,,,1,CHEMBL631258,,,Rattus norvegicus,N,1,1969.0,
10035,Plasma half-life was determined in Sprague-Dawley rats after 0-8 h administration of the compound,Intermediate,10116.0,,A,,BAO_0000218,4956,,,1,CHEMBL631259,,,Rattus norvegicus,N,1,1969.0,
10036,Plasma half-life was determined in Sprague-Dawley rats after 0-8 hr administration of the compound; Not determined,Intermediate,10116.0,,A,,BAO_0000218,4956,,,1,CHEMBL631260,,,Rattus norvegicus,N,1,1969.0,
10037,"Distribution of radioactivity in blood of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range = 0.68-1.03",Intermediate,10116.0,,A,,BAO_0000218,7768,,,1,CHEMBL631261,,,Rattus norvegicus,N,1,178.0,
10038,"Distribution of radioactivity in blood of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.45-0.48",Intermediate,10116.0,,A,,BAO_0000218,7768,,,1,CHEMBL631262,,,Rattus norvegicus,N,1,178.0,
10039,"Distribution of radioactivity in blood of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range-0.81-1",Intermediate,10116.0,,A,,BAO_0000218,7768,,,1,CHEMBL631263,,,Rattus norvegicus,N,1,178.0,
10040,"Distribution of radioactivity in brain tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.007-0.008",Intermediate,10116.0,,A,,BAO_0000218,7768,,,1,CHEMBL631264,,,Rattus norvegicus,N,1,,
10041,"Distribution of radioactivity in brain tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.18-0.22",Intermediate,10116.0,,A,,BAO_0000218,7768,,,1,CHEMBL631265,,,Rattus norvegicus,N,1,,
10042,"Distribution of radioactivity in brain tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.77-0.97",Intermediate,10116.0,,A,,BAO_0000218,7768,,,1,CHEMBL631266,,,Rattus norvegicus,N,1,,
10043,"Distribution of radioactivity in brain tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.08-0.13",Intermediate,10116.0,,A,,BAO_0000218,7768,,,1,CHEMBL631267,,,Rattus norvegicus,N,1,,
10044,"Distribution of radioactivity in brain tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.25-0.37",Intermediate,10116.0,,A,,BAO_0000218,7768,,,1,CHEMBL631268,,,Rattus norvegicus,N,1,,
10045,"Distribution of radioactivity in brain tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.03-0.04",Intermediate,10116.0,,A,,BAO_0000218,7768,,,1,CHEMBL631269,,,Rattus norvegicus,N,1,,
10046,"Distribution of radioactivity in brain tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.74-0.94",Intermediate,10116.0,,A,,BAO_0000218,7768,,,1,CHEMBL631270,,,Rattus norvegicus,N,1,,
10047,"Distribution of radioactivity in heart tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.02-0.02",Intermediate,10116.0,,A,,BAO_0000218,7768,,,1,CHEMBL631271,,,Rattus norvegicus,N,1,948.0,
10048,"Distribution of radioactivity in heart tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.5-0.63",Intermediate,10116.0,,A,,BAO_0000218,7768,,,1,CHEMBL631272,,,Rattus norvegicus,N,1,948.0,
10049,"Distribution of radioactivity in heart tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 1.35-1.55",Intermediate,10116.0,,A,,BAO_0000218,7768,,,1,CHEMBL631273,,,Rattus norvegicus,N,1,948.0,
10050,"Distribution of radioactivity in heart tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.24-0.38",Intermediate,10116.0,,A,,BAO_0000218,7768,,,1,CHEMBL631274,,,Rattus norvegicus,N,1,948.0,
10051,"Distribution of radioactivity in heart tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.55-0.82",Intermediate,10116.0,,A,,BAO_0000218,7768,,,1,CHEMBL631275,,,Rattus norvegicus,N,1,948.0,
10052,"Distribution of radioactivity in heart tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.16-0.2",Intermediate,10116.0,,A,,BAO_0000218,7768,,,1,CHEMBL626984,,,Rattus norvegicus,N,1,948.0,
10053,"Distribution of radioactivity in heart tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 1.13-1.29",Intermediate,10116.0,,A,,BAO_0000218,7768,,,1,CHEMBL626985,,,Rattus norvegicus,N,1,948.0,
10054,"Distribution of radioactivity in liver tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.02-0.02",Intermediate,10116.0,,A,,BAO_0000218,7768,,,1,CHEMBL626986,,,Rattus norvegicus,N,1,2107.0,
10055,"Distribution of radioactivity in liver tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.71-0.93",Intermediate,10116.0,,A,,BAO_0000218,7768,,,1,CHEMBL626987,,,Rattus norvegicus,N,1,2107.0,
10056,"Distribution of radioactivity in liver tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 2.91-3.53",Intermediate,10116.0,,A,,BAO_0000218,7768,,,1,CHEMBL626988,,,Rattus norvegicus,N,1,2107.0,
10057,"Distribution of radioactivity in liver tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.42-0.62",Intermediate,10116.0,,A,,BAO_0000218,7768,,,1,CHEMBL626989,,,Rattus norvegicus,N,1,2107.0,
10058,"Distribution of radioactivity in liver tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.97-1.41",Intermediate,10116.0,,A,,BAO_0000218,7768,,,1,CHEMBL626990,,,Rattus norvegicus,N,1,2107.0,
10059,"Distribution of radioactivity in liver tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.19-0.23",Intermediate,10116.0,,A,,BAO_0000218,7768,,,1,CHEMBL626991,,,Rattus norvegicus,N,1,2107.0,
10060,"Distribution of radioactivity in liver tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 2.49-2.82",Intermediate,10116.0,,A,,BAO_0000218,7768,,,1,CHEMBL626992,,,Rattus norvegicus,N,1,2107.0,
10061,"Distribution of radioactivity in lung tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.02-0.03",Intermediate,10116.0,,A,,BAO_0000218,7768,,,1,CHEMBL626993,,,Rattus norvegicus,N,1,2048.0,
10062,"Distribution of radioactivity in lung tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.66-0.77",Intermediate,10116.0,,A,,BAO_0000218,7768,,,1,CHEMBL874593,,,Rattus norvegicus,N,1,2048.0,
10063,"Distribution of radioactivity in lung tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 1.17-1.42",Intermediate,10116.0,,A,,BAO_0000218,7768,,,1,CHEMBL626994,,,Rattus norvegicus,N,1,2048.0,
10064,"Distribution of radioactivity in lung tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.47-0.58",Intermediate,10116.0,,A,,BAO_0000218,7768,,,1,CHEMBL626995,,,Rattus norvegicus,N,1,2048.0,
10065,"Distribution of radioactivity in lung tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.65-0.87",Intermediate,10116.0,,A,,BAO_0000218,7768,,,1,CHEMBL626190,,,Rattus norvegicus,N,1,2048.0,
10066,"Distribution of radioactivity in lung tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.28-0.31",Intermediate,10116.0,,A,,BAO_0000218,7768,,,1,CHEMBL626191,,,Rattus norvegicus,N,1,2048.0,
10067,"Distribution of radioactivity in lung tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.98-1.22",Intermediate,10116.0,,A,,BAO_0000218,7768,,,1,CHEMBL626364,,,Rattus norvegicus,N,1,2048.0,
10068,"Distribution of radioactivity in thyroid tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 406-499",Intermediate,10116.0,,A,,BAO_0000218,7768,,,1,CHEMBL626365,,,Rattus norvegicus,N,1,2046.0,
10069,"Distribution of radioactivity in thyroid tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 53.0-96",Intermediate,10116.0,,A,,BAO_0000218,7768,,,1,CHEMBL626366,,,Rattus norvegicus,N,1,2046.0,
10070,"Distribution of radioactivity in thyroid tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 6.65-8.0.8",Intermediate,10116.0,,A,,BAO_0000218,7768,,,1,CHEMBL626367,,,Rattus norvegicus,N,1,2046.0,
10071,"Distribution of radioactivity in thyroid tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 92-159",Intermediate,10116.0,,A,,BAO_0000218,7768,,,1,CHEMBL626368,,,Rattus norvegicus,N,1,2046.0,
10072,"Distribution of radioactivity in thyroid tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 18.74-30.84",Intermediate,10116.0,,A,,BAO_0000218,7768,,,1,CHEMBL626369,,,Rattus norvegicus,N,1,2046.0,
10073,"Distribution of radioactivity in thyroid tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 156-207",Intermediate,10116.0,,A,,BAO_0000218,7768,,,1,CHEMBL626370,,,Rattus norvegicus,N,1,2046.0,
10074,"Bioavailability (F) was evaluated in rat, after administering 1 mg/kg intravenously",Intermediate,10116.0,,A,,BAO_0000218,4498,,,1,CHEMBL626371,,,Rattus norvegicus,N,1,,
10075,"Bioavailability (F) was evaluated in rat, after administering 10 mg/kg orally",Intermediate,10116.0,,A,,BAO_0000218,4498,,,1,CHEMBL626372,,,Rattus norvegicus,N,1,,
10076,Bioavailability after a dose of 10 mg/kg p.o.,Intermediate,10116.0,,A,,BAO_0000218,3603,,,1,CHEMBL626373,,,Rattus norvegicus,N,1,,
10077,Bioavailability after peroral administration (10 mg/kg) was determined in rat,Intermediate,10116.0,,A,,BAO_0000218,6215,,,1,CHEMBL626374,,,Rattus norvegicus,N,1,,
10078,Bioavailability in fasted male administration of 2 mg/Kg of compound p.o.,Intermediate,10116.0,,A,,BAO_0000218,5710,,,1,CHEMBL626375,,,Rattus norvegicus,N,1,,
10079,Oral bioavailability in rat (Sprague-Dawley) (fasted male) (dose 2 mg/kg),Intermediate,10116.0,,A,,BAO_0000218,5710,,,1,CHEMBL626376,,,Rattus norvegicus,N,1,,
10080,Bioavailability in rat po was determined,Intermediate,10116.0,,A,,BAO_0000218,5676,,,1,CHEMBL626377,,,Rattus norvegicus,N,1,,
10081,Bioavailability of compound at 10 mg/kg in rat after oral administration,Intermediate,10116.0,,A,,BAO_0000218,17667,,,1,CHEMBL626378,,,Rattus norvegicus,N,1,,
10082,Bioavailability of compound at 3 mg/kg in rat after i.v. administration,Intermediate,10116.0,,A,,BAO_0000218,17667,,,1,CHEMBL626379,,,Rattus norvegicus,N,1,,
10083,Bioavailability in rat (dose 1 mg/kg i.v. and 2 mg/kg p.o.),Intermediate,10116.0,,A,,BAO_0000218,6848,,,1,CHEMBL626380,,,Rattus norvegicus,N,1,,
10084,Bioavailability in rat (dose 1 mg/kg i.v. and 2 mg/kg p.o.),Intermediate,10116.0,,A,,BAO_0000218,6848,,,1,CHEMBL626381,,,Rattus norvegicus,N,1,,
10085,Bioavailability in rat,Intermediate,10116.0,,A,,BAO_0000218,17267,,,1,CHEMBL626382,,,Rattus norvegicus,N,1,,
10086,Bioavailability in rat (Sprague-Dawley) (female),Intermediate,10116.0,,A,,BAO_0000218,6362,,,1,CHEMBL626383,,,Rattus norvegicus,N,1,,
10087,Bioavailability in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,17671,,,1,CHEMBL874652,,,Rattus norvegicus,N,1,,
10088,Bioavailability in rat (Sprague-Dawley) (male) (dose 10-20 mg/kg),Intermediate,10116.0,,A,,BAO_0000218,17671,,,1,CHEMBL626384,,,Rattus norvegicus,N,1,,
10089,Bioavailability in rat (Sprague-Dawley) (male) (dose 1 mg/kg i.v. and 3 mg/kg p.o.) measured from 0.3 to 6 hr,Intermediate,10116.0,,A,,BAO_0000218,4333,,,1,CHEMBL626385,,,Rattus norvegicus,N,1,,
10090,Bioavailability in rat at an oral dose of 2 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,6077,,,1,CHEMBL626386,,,Rattus norvegicus,N,1,,
10091,Bioavailability in rat,Intermediate,10116.0,,A,,BAO_0000218,3278,,,1,CHEMBL626387,,,Rattus norvegicus,N,1,,
10092,Bioavailability in rat,Intermediate,10116.0,,A,,BAO_0000218,5964,,,1,CHEMBL626388,,,Rattus norvegicus,N,1,,
10093,Bioavailability in rat,Intermediate,10116.0,,A,,BAO_0000218,4884,,,1,CHEMBL626389,,,Rattus norvegicus,N,1,,
10094,Bioavailability in rat,Intermediate,10116.0,,A,,BAO_0000218,4905,,,1,CHEMBL626390,,,Rattus norvegicus,N,1,,
10095,Bioavailability in rat was reported at the dose of 6 mg/kg in 25% PEG-300,Intermediate,10116.0,,A,,BAO_0000218,4884,,,1,CHEMBL626391,,,Rattus norvegicus,N,1,,
10096,Bioavailability in rat,Intermediate,10116.0,,A,,BAO_0000218,6850,,,1,CHEMBL626392,,,Rattus norvegicus,N,1,,
10097,Oral bioavailability in rat,Intermediate,10116.0,,A,,BAO_0000218,2864,,,1,CHEMBL626393,,,Rattus norvegicus,N,1,,
10098,Bioavailability was determined in rat,Intermediate,10116.0,,A,,BAO_0000218,5780,,,1,CHEMBL623026,,,Rattus norvegicus,N,1,,
10099,Bioavailability,Intermediate,10116.0,,A,,BAO_0000218,1465,,,1,CHEMBL623027,,,Rattus norvegicus,N,1,,
10100,Bioavailability,Intermediate,10116.0,,A,,BAO_0000218,5199,,,1,CHEMBL623028,,,Rattus norvegicus,N,1,,
10101,Bioavailability in rat after 1 day dosing,Intermediate,10116.0,,A,,BAO_0000218,5765,,,1,CHEMBL623029,,,Rattus norvegicus,N,1,,
10102,Bioavailability in rat after 4 day dosing,Intermediate,10116.0,,A,,BAO_0000218,5765,,,1,CHEMBL623030,,,Rattus norvegicus,N,1,,
10103,Bioavailability after IV dosing at 0.5 mg/kg in rat; no data,Intermediate,10116.0,,A,,BAO_0000218,6518,,,1,CHEMBL623031,,,Rattus norvegicus,N,1,,
10104,Bioavailability after IV dosing at 1 mg/kg in rat; no data,Intermediate,10116.0,,A,,BAO_0000218,6518,,,1,CHEMBL623032,,,Rattus norvegicus,N,1,,
10105,Bioavailability after oral administration at a dose of 2 mg/kg in rat,Intermediate,10116.0,,A,,BAO_0000218,6518,,,1,CHEMBL623033,,,Rattus norvegicus,N,1,,
10106,Bioavailability after oral administration at a dose of 4 mg/kg in rat,Intermediate,10116.0,,A,,BAO_0000218,6518,,,1,CHEMBL623034,,,Rattus norvegicus,N,1,,
10107,Bioavailability at 4 hr after administration of 5 mg/kg dose peroral in rat,Intermediate,10116.0,,A,,BAO_0000218,2083,,,1,CHEMBL623035,,,Rattus norvegicus,N,1,,
10108,Bioavailability at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,Intermediate,10116.0,,A,,BAO_0000218,17260,,,1,CHEMBL623036,,,Rattus norvegicus,N,1,,
10109,Bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v. and 2 mg/kg p.o.),Intermediate,10116.0,,A,,BAO_0000218,4956,,,1,CHEMBL623037,,,Rattus norvegicus,N,1,,
10110,Bioavailability by intravenous administration of 3.4 mg/kg in rat,Intermediate,10116.0,,A,,BAO_0000218,4368,,,1,CHEMBL623038,,,Rattus norvegicus,N,1,,
10111,Bioavailability from rat plasma at a single oral dose of 25 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,17752,,,1,CHEMBL874385,,,Rattus norvegicus,N,1,1969.0,
10112,Bioavailability in rat (Fisher) (fasted),Intermediate,10116.0,,A,,BAO_0000218,1446,,,1,CHEMBL623039,,,Rattus norvegicus,N,1,,
10113,Bioavailability in monkey after po administration of 10 mg/kg dose,Intermediate,9443.0,,A,,BAO_0000218,2891,,,1,CHEMBL623040,,,Primates,U,0,,
10114,Oral bioavailability in monkey (dose 10 mg/kg),Intermediate,9443.0,,A,,BAO_0000218,2891,,,1,CHEMBL623041,,,Primates,U,0,,
10115,Bioavailability in rat,Intermediate,10116.0,,A,,BAO_0000218,6672,,,1,CHEMBL623741,,,Rattus norvegicus,N,1,,
10116,Bioavailability in rat,Intermediate,10116.0,,A,,BAO_0000218,6673,,,1,CHEMBL623742,,,Rattus norvegicus,N,1,,
10117,Bioavailability in rat,Intermediate,10116.0,,A,,BAO_0000218,17655,,,1,CHEMBL623743,,,Rattus norvegicus,N,1,,
10118,Bioavailability in rat,Intermediate,10116.0,,A,,BAO_0000218,17796,,,1,CHEMBL623744,,,Rattus norvegicus,N,1,,
10119,Bioavailability in rat (dose 2.0 mg/kg p.o.),Intermediate,10116.0,,A,,BAO_0000218,17853,,,1,CHEMBL623745,,,Rattus norvegicus,N,1,,
10120,Bioavailability in rat (dose 5 mg/kg p.o. and 1 mg/kg i.v.),Intermediate,10116.0,,A,,BAO_0000218,4521,,,1,CHEMBL623746,,,Rattus norvegicus,N,1,,
10121,Oral bioavailability in rat (dose 5 mg/kg p.o.),Intermediate,10116.0,,A,,BAO_0000218,4940,,,1,CHEMBL623747,,,Rattus norvegicus,N,1,,
10122,Bioavailability in rat after po administration of 30 mg/kg dose,Intermediate,10116.0,,A,,BAO_0000218,2891,,,1,CHEMBL623748,,,Rattus norvegicus,U,0,,
10123,Bioavailability in rat after po administration of 30 mg/kg dose,Intermediate,10116.0,,A,,BAO_0000218,2891,,,1,CHEMBL623916,,,Rattus norvegicus,U,0,,
10124,Bioavailability in rat after 5 mg/kg by oral and 1 mg/kg by intravenous administration,Intermediate,10116.0,,A,,BAO_0000218,4521,,,1,CHEMBL623917,,,Rattus norvegicus,N,1,,
10125,Bioavailability in rat (dose 2 mg/kg i.v.),Intermediate,10116.0,,A,,BAO_0000218,17686,,,1,CHEMBL623918,,,Rattus norvegicus,N,1,,
10126,Bioavailability in rat,Intermediate,10116.0,,A,,BAO_0000218,17796,,,1,CHEMBL874386,,,Rattus norvegicus,N,1,,
10127,Bioavailability in rat; Only traces detected in rat plasma,Intermediate,10116.0,,A,,BAO_0000218,17796,,,1,CHEMBL623919,,,Rattus norvegicus,N,1,1969.0,
10128,Bioavailability in rat,Intermediate,10116.0,,A,,BAO_0000218,5064,,,1,CHEMBL623920,,,Rattus norvegicus,N,1,,
10129,Bioavailability upon oral administration of compound,Intermediate,10116.0,,A,,BAO_0000218,5147,,,1,CHEMBL623148,,,Rattus norvegicus,N,1,,
10130,Oral bioavailability in rat (Sprague-Dawley) (dose 15 mg/kg),Intermediate,10116.0,,A,,BAO_0000218,1916,,,1,CHEMBL623149,,,Rattus norvegicus,N,1,,
10131,Bioavailability in rat,Intermediate,10116.0,,A,,BAO_0000218,6049,,,1,CHEMBL623150,,,Rattus norvegicus,N,1,,
10132,"Bioavailability was evaluated in rats at a dose of 20 mg/kg, under fasting state",Intermediate,10116.0,,A,,BAO_0000218,1445,,,1,CHEMBL623151,,,Rattus norvegicus,N,1,,
10133,"Bioavailability was evaluated in rats at a dose of 20 mg/kg, under fed state",Intermediate,10116.0,,A,,BAO_0000218,1445,,,1,CHEMBL623152,,,Rattus norvegicus,N,1,,
10134,Streptococcal cell wall-washed arthritis model in rats at 3.0 mg/kg peroral dose,Expert,10116.0,,F,,BAO_0000218,2862,,,1,CHEMBL623153,,,Rattus norvegicus,N,1,,
10135,Streptococcal cell wall-washed arthritis model in rats at 30.0 mg/kg peroral dose,Expert,10116.0,,F,,BAO_0000218,2862,,,1,CHEMBL623154,,,Rattus norvegicus,N,1,,
10136,In vitro and metabolic stability was determined,Intermediate,10116.0,,A,,BAO_0000218,4194,,,1,CHEMBL623155,,,Rattus norvegicus,N,1,,
10137,In vitro metabolic stability in rat hepatocytes,Intermediate,10116.0,,A,,BAO_0000218,4194,,,1,CHEMBL623156,,,Rattus norvegicus,N,1,,
10138,In vitro metabolic stability in rat was measured as pmol/min/mg/protein,Intermediate,10116.0,,A,,BAO_0000218,5486,,,1,CHEMBL623157,,,Rattus norvegicus,N,1,,
10139,Metabolic rate for compound was observed in rat hepatocytes,Intermediate,10116.0,,A,,BAO_0000218,17582,,401.0,1,CHEMBL623158,Hepatocyte,,Rattus norvegicus,N,1,2107.0,
10140,In vitro metabolic stability determined after 30 min of incubation in rat hepatic microsomes,Intermediate,10116.0,,A,,BAO_0000218,5600,,,1,CHEMBL623159,,,Rattus norvegicus,N,1,,
10141,Metabolism of compound in rat S9 microsomes ('+''indicates <20% largest observed peak),Intermediate,10116.0,,A,,BAO_0000218,14294,,,1,CHEMBL874390,,,Rattus norvegicus,N,1,,
10142,Metabolism of compound in rat S9 microsomes ('++++' indicates largest observed peak),Intermediate,10116.0,,A,,BAO_0000218,14294,,,1,CHEMBL623160,,,Rattus norvegicus,N,1,,
10143,Metabolism of compound in rat S9 microsomes; Trace,Intermediate,10116.0,,A,,BAO_0000218,14294,,,1,CHEMBL623161,,,Rattus norvegicus,N,1,,
10144,Metabolism was measured as percent loss at 4 hr in rat hepatocytes,Intermediate,10116.0,,A,,BAO_0000218,17847,,,1,CHEMBL623162,,,Rattus norvegicus,N,1,,
10145,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex 5-HIAA,Intermediate,10116.0,,A,,BAO_0000218,11020,,,1,CHEMBL623163,,,Rattus norvegicus,N,1,,
10146,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex 5-HT,Intermediate,10116.0,,A,,BAO_0000218,11020,,,1,CHEMBL623164,,,Rattus norvegicus,N,1,,
10147,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex DA,Intermediate,10116.0,,A,,BAO_0000218,11020,,,1,CHEMBL623165,,,Rattus norvegicus,N,1,,
10148,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex DOPAC,Intermediate,10116.0,,A,,BAO_0000218,11020,,,1,CHEMBL623166,,,Rattus norvegicus,N,1,,
10149,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex HVA,Intermediate,10116.0,,A,,BAO_0000218,11020,,,1,CHEMBL624983,,,Rattus norvegicus,N,1,,
10150,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex NE,Intermediate,10116.0,,A,,BAO_0000218,11020,,,1,CHEMBL624984,,,Rattus norvegicus,N,1,,
10151,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Hippocampus 5-HIAA,Intermediate,10116.0,,A,,BAO_0000218,11020,,,1,CHEMBL624985,,,Rattus norvegicus,N,1,,
10152,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus 5-HT,Intermediate,10116.0,,A,,BAO_0000218,11020,,,1,CHEMBL622970,,,Rattus norvegicus,N,1,,
10153,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus DA; below level of detection,Intermediate,10116.0,,A,,BAO_0000218,11020,,,1,CHEMBL622971,,,Rattus norvegicus,N,1,,
10154,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus DA; below the levels of detection,Intermediate,10116.0,,A,,BAO_0000218,11020,,,1,CHEMBL622972,,,Rattus norvegicus,N,1,,
10155,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus DOPAC; below level of detection,Intermediate,10116.0,,A,,BAO_0000218,11020,,,1,CHEMBL622973,,,Rattus norvegicus,N,1,,
10156,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus DOPAC; below the levels of detection,Intermediate,10116.0,,A,,BAO_0000218,11020,,,1,CHEMBL622974,,,Rattus norvegicus,N,1,,
10157,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus HVA; below level of detection,Intermediate,10116.0,,A,,BAO_0000218,11020,,,1,CHEMBL622975,,,Rattus norvegicus,N,1,,
10158,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus HVA; below the levels of detection,Intermediate,10116.0,,A,,BAO_0000218,11020,,,1,CHEMBL622976,,,Rattus norvegicus,N,1,,
10159,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus NE,Intermediate,10116.0,,A,,BAO_0000218,11020,,,1,CHEMBL622977,,,Rattus norvegicus,N,1,,
10160,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex 5-HIAA,Intermediate,10116.0,,A,,BAO_0000218,11020,,,1,CHEMBL624351,,,Rattus norvegicus,N,1,,
10161,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex 5-HT,Intermediate,10116.0,,A,,BAO_0000218,11020,,,1,CHEMBL624352,,,Rattus norvegicus,N,1,,
10162,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex DA,Intermediate,10116.0,,A,,BAO_0000218,11020,,,1,CHEMBL624353,,,Rattus norvegicus,N,1,,
10163,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex DOPAC,Intermediate,10116.0,,A,,BAO_0000218,11020,,,1,CHEMBL622397,,,Rattus norvegicus,N,1,,
10164,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex HVA,Intermediate,10116.0,,A,,BAO_0000218,11020,,,1,CHEMBL622398,,,Rattus norvegicus,N,1,,
10165,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex NE,Intermediate,10116.0,,A,,BAO_0000218,11020,,,1,CHEMBL622399,,,Rattus norvegicus,N,1,,
10166,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex DA,Intermediate,10116.0,,A,,BAO_0000218,11020,,,1,CHEMBL622400,,,Rattus norvegicus,N,1,,
10167,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus 5-HIAA,Intermediate,10116.0,,A,,BAO_0000218,11020,,,1,CHEMBL628428,,,Rattus norvegicus,N,1,,
10168,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus 5-HT,Intermediate,10116.0,,A,,BAO_0000218,11020,,,1,CHEMBL628590,,,Rattus norvegicus,N,1,,
10169,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus DA; below level of detection,Intermediate,10116.0,,A,,BAO_0000218,11020,,,1,CHEMBL628591,,,Rattus norvegicus,N,1,,
10170,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus DA; below the levels of detection,Intermediate,10116.0,,A,,BAO_0000218,11020,,,1,CHEMBL628592,,,Rattus norvegicus,N,1,,
10171,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus DOPAC; below level of detection,Intermediate,10116.0,,A,,BAO_0000218,11020,,,1,CHEMBL628593,,,Rattus norvegicus,N,1,,
10172,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus DOPAC; below the levels of detection,Intermediate,10116.0,,A,,BAO_0000218,11020,,,1,CHEMBL875333,,,Rattus norvegicus,N,1,,
10173,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus HVA; below level of detection,Intermediate,10116.0,,A,,BAO_0000218,11020,,,1,CHEMBL628594,,,Rattus norvegicus,N,1,,
10174,Plasma half-life was determined in Sprague-Dawley rats after 0-8 hr of administration,Intermediate,10116.0,,A,,BAO_0000218,4969,,,1,CHEMBL628595,,,Rattus norvegicus,N,1,1969.0,
10175,Stability in rat plasma was determined,Intermediate,10116.0,,A,,BAO_0000218,6737,,,1,CHEMBL628596,,,Rattus norvegicus,N,1,1969.0,
10176,Stability in rat plasma was determined; ND= no data,Intermediate,10116.0,,A,,BAO_0000218,6737,,,1,CHEMBL628597,,,Rattus norvegicus,N,1,1969.0,
10177,Tested for plasma half life period in rat (0-8 hr),Intermediate,10116.0,,A,,BAO_0000218,5089,,,1,CHEMBL628598,,,Rattus norvegicus,N,1,1969.0,
10178,Tested for plasma half life period in rat (0-8 hr); Not determined,Intermediate,10116.0,,A,,BAO_0000218,5089,,,1,CHEMBL628599,,,Rattus norvegicus,N,1,1969.0,
10179,Tested for t1/2 upon intravenous administration of 5.0 mg/Kg dose in rat,Intermediate,10116.0,,A,,BAO_0000218,1466,,,1,CHEMBL628600,,,Rattus norvegicus,N,1,,
10180,Tested for t1/2 upon peroral administration of 10.0 mg/Kg dose in rat,Intermediate,10116.0,,A,,BAO_0000218,1466,,,1,CHEMBL628601,,,Rattus norvegicus,N,1,,
10181,Tested for the half life in rat,Intermediate,10116.0,,A,,BAO_0000218,4950,,,1,CHEMBL628602,,,Rattus norvegicus,N,1,,
10182,Tested in vitro for the time for half reactivation against rat small intestinal glucoamylase,Intermediate,10116.0,,A,,BAO_0000218,2412,,,1,CHEMBL628603,,,Rattus norvegicus,N,1,,
10183,Tested in vitro for the time for half reactivation against rat small intestinal glucoamylase; ND=Not determined,Intermediate,10116.0,,A,,BAO_0000218,2412,,,1,CHEMBL628604,,,Rattus norvegicus,N,1,,
10184,Tested in vitro for the time for half reactivation against rat small intestinal isomaltase,Intermediate,10116.0,,A,,BAO_0000218,2412,,,1,CHEMBL628605,,,Rattus norvegicus,N,1,,
10185,Tested in vitro for the time for half reactivation against rat small intestinal isomaltase; ND=Not determined,Intermediate,10116.0,,A,,BAO_0000218,2412,,,1,CHEMBL628606,,,Rattus norvegicus,N,1,,
10186,Tested in vitro for the time for half reactivation against rat small intestinal sucrase,Intermediate,10116.0,,A,,BAO_0000218,2412,,,1,CHEMBL628607,,,Rattus norvegicus,N,1,,
10187,The biological half life the compound was measured at the dose of 100 umol/kg,Intermediate,10116.0,,A,,BAO_0000218,15022,,,1,CHEMBL628608,,,Rattus norvegicus,N,1,,
10188,The biological half life the compound was measured at the dose of 30 umol/kg,Intermediate,10116.0,,A,,BAO_0000218,15022,,,1,CHEMBL628609,,,Rattus norvegicus,N,1,,
10189,The compound was evaluated for plasma half life period in rat,Intermediate,10116.0,,A,,BAO_0000218,406,,,1,CHEMBL628610,,,Rattus norvegicus,N,1,1969.0,
10190,"The half life value in female wistar rat at 100 mg/kg, p.o. dose",Intermediate,10116.0,,A,,BAO_0000218,15078,,,1,CHEMBL873819,,,Rattus norvegicus,N,1,,
10191,"The half life value in male wistar rat at 100 mg/kg, p.o. dose",Intermediate,10116.0,,A,,BAO_0000218,15078,,,1,CHEMBL628611,,,Rattus norvegicus,N,1,,
10192,The pharmacokinetic parameter half-life period in vivo in rats,Intermediate,10116.0,,A,,BAO_0000218,5247,,,1,CHEMBL628612,,,Rattus norvegicus,N,1,,
10193,"The pharmacokinetic property, Half-life was determined",Intermediate,10116.0,,A,,BAO_0000218,5041,,,1,CHEMBL628613,,,Rattus norvegicus,N,1,,
10194,"The pharmacokinetic property, Half-life in rat in vivo",Intermediate,10116.0,,A,,BAO_0000218,5041,,,1,CHEMBL628614,,,Rattus norvegicus,N,1,,
10195,"The pharmacokinetic property, Half-life was determined; ND denotes no data",Intermediate,10116.0,,A,,BAO_0000218,5041,,,1,CHEMBL628615,,,Rattus norvegicus,N,1,,
10196,"The pharmacokinetic property, Half-life was determined; ND denotes not determined",Intermediate,10116.0,,A,,BAO_0000218,5041,,,1,CHEMBL628616,,,Rattus norvegicus,N,1,,
10197,The plasma half life period in rats,Intermediate,10116.0,,A,,BAO_0000218,3918,,,1,CHEMBL627924,,,Rattus norvegicus,N,1,1969.0,
10198,The release rate of the free drug from the substrate in rat liver lysosomal preparation by rat liver lysosomal assay,Intermediate,10116.0,,A,,BAO_0000218,2906,,,1,CHEMBL627925,,,Rattus norvegicus,N,1,2107.0,
10199,half life in rats at the dose of 1.0 mpk by i.v. administration; ND= not determined,Intermediate,10116.0,,A,,BAO_0000218,6467,,,1,CHEMBL627926,,,Rattus norvegicus,N,1,,
10200,t1/2 (apparent elimination)of the compound was determined,Intermediate,10116.0,,A,,BAO_0000218,5510,,,1,CHEMBL627927,,,Rattus norvegicus,N,1,,
10201,t1/2 value in rat,Intermediate,10116.0,,A,,BAO_0000218,3788,,,1,CHEMBL627928,,,Rattus norvegicus,N,1,,
10202,Half life in rat,Intermediate,10116.0,,A,,BAO_0000218,17796,,,1,CHEMBL627539,,,Rattus norvegicus,N,1,,
10203,"Half life period calculated from Time-Course plasma concentrations in rats at a dose of 2.5 mg/kg, iv",Intermediate,10116.0,,A,,BAO_0000218,12873,,,1,CHEMBL876790,,,Rattus norvegicus,N,1,1969.0,
10204,Pharmacokinetic property (t1/2beta) was measured in rat at the dose of 0.32 mg/kg i.v.,Intermediate,10116.0,,A,,BAO_0000218,5983,,,1,CHEMBL858186,,,Rattus norvegicus,N,1,,
10205,Half-life period in fasted rats,Intermediate,10116.0,,A,,BAO_0000218,15765,,,1,CHEMBL627540,,,Rattus norvegicus,N,1,,
10206,Compound was evaluated for maximum time to reach Cmax after treatment with oral dose of 2 mgkg to female wistar rats,Intermediate,10116.0,,A,,BAO_0000218,2661,,,1,CHEMBL627541,,,Rattus norvegicus,N,1,,
10207,Compound was evaluated for maximum time to reach Cmax after treatment with oral dose of 2 mgkg to male wistar rats,Intermediate,10116.0,,A,,BAO_0000218,2661,,,1,CHEMBL627715,,,Rattus norvegicus,N,1,,
10208,Evaluated for pharmacokinetic parameter tmax in rat at the dose 50 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,429,,,1,CHEMBL627716,,,Rattus norvegicus,N,1,,
10209,Maximum time required to achieve Cmax was determined in rat,Intermediate,10116.0,,A,,BAO_0000218,17655,,,1,CHEMBL627717,,,Rattus norvegicus,N,1,,
10210,Time calculated to reach Cmax at a concentration of 15 mg/kg perorally in rats along with 100 mg/kg of compound 11,Intermediate,10116.0,,A,,BAO_0000218,17717,,,1,CHEMBL627718,,,Rattus norvegicus,N,1,,
10211,Time calculated to reach Cmax at a concentration of 60 mg/kg perorally in rats along with 100 mg/kg of compound 11,Intermediate,10116.0,,A,,BAO_0000218,17717,,,1,CHEMBL627719,,,Rattus norvegicus,N,1,,
10212,Time calculated to reach Cmax at a concentration of 60 mg/kg perorally in rats along with control,Intermediate,10116.0,,A,,BAO_0000218,17717,,,1,CHEMBL627720,,,Rattus norvegicus,N,1,,
10213,Time to reach maximum concentration in rat after 2 mg/kg peroral administration,Intermediate,10116.0,,A,,BAO_0000218,6570,,,1,CHEMBL627721,,,Rattus norvegicus,N,1,,
10214,Time to reach maximum concentration in rat after 2 mg/kg peroral administration; 4-6,Intermediate,10116.0,,A,,BAO_0000218,6570,,,1,CHEMBL627722,,,Rattus norvegicus,N,1,,
10215,Tmax of compound (19.2 mg/kg) after po administration was determined in Sprague-Dawley rat,Intermediate,10116.0,,A,,BAO_0000218,5978,,,1,CHEMBL627723,,,Rattus norvegicus,N,1,,
10216,Tmax of compound (19.76 mg/kg) after po administration was determined in Sprague-Dawley rat,Intermediate,10116.0,,A,,BAO_0000218,5978,,,1,CHEMBL626058,,,Rattus norvegicus,N,1,,
10217,Tmax of compound (20.73 mg/kg) after po administration was determined in Sprague-Dawley rat,Intermediate,10116.0,,A,,BAO_0000218,5978,,,1,CHEMBL626059,,,Rattus norvegicus,N,1,,
10218,Tmax of compound (25 mg/kg) after po administration was determined in Sprague-Dawley rat,Intermediate,10116.0,,A,,BAO_0000218,5978,,,1,CHEMBL626060,,,Rattus norvegicus,N,1,,
10219,Tmax at a dose of 4 mg/kg in Rat Plasma after iv administration,Intermediate,10116.0,,A,,BAO_0000218,17720,,,1,CHEMBL626061,,,Rattus norvegicus,N,1,1969.0,
10220,Tmax determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,Intermediate,10116.0,,A,,BAO_0000218,4723,,,1,CHEMBL876791,,,Rattus norvegicus,N,1,,
10221,Tmax determined after 3 mg/kg oral administration in potassium oxonate treated rats,Intermediate,10116.0,,A,,BAO_0000218,4723,,,1,CHEMBL626062,,,Rattus norvegicus,N,1,,
10222,Tmax at the dose of 2 mg/Kg administered perorally in rats,Intermediate,10116.0,,A,,BAO_0000218,4756,,,1,CHEMBL626063,,,Rattus norvegicus,N,1,,
10223,Tmax at the dose of 5 mg/Kg administered perorally in rats,Intermediate,10116.0,,A,,BAO_0000218,4756,,,1,CHEMBL626064,,,Rattus norvegicus,N,1,,
10224,tmax at a dose of 100 mg/kg in Rat Plasma after iv administration,Intermediate,10116.0,,A,,BAO_0000218,17720,,,1,CHEMBL626065,,,Rattus norvegicus,N,1,1969.0,
10225,tmax at a dose of 50 mg/kg in Rat Plasma after iv administration,Intermediate,10116.0,,A,,BAO_0000218,17720,,,1,CHEMBL626066,,,Rattus norvegicus,N,1,1969.0,
10226,tmax upon peroral administration of 10.0 mg/Kg dose in rat,Intermediate,10116.0,,A,,BAO_0000218,1466,,,1,CHEMBL626067,,,Rattus norvegicus,N,1,,
10227,Percent total excretion of 3-(thiomethyl)acetaminophen glucuronide,Intermediate,10116.0,,F,,BAO_0000218,7449,,,1,CHEMBL626068,,,Rattus norvegicus,N,1,,
10228,Percent total excretion of 3-(thiomethyl)acetaminophen sulfate,Intermediate,10116.0,,F,,BAO_0000218,7449,,,1,CHEMBL626069,,,Rattus norvegicus,N,1,,
10229,Percent total excretion of 3-methoxyacetaminophen glucuronide,Intermediate,10116.0,,F,,BAO_0000218,7449,,,1,CHEMBL626070,,,Rattus norvegicus,N,1,,
10230,Percent total excretion of N-methoxyacetaminophen glucuronide,Intermediate,10116.0,,F,,BAO_0000218,7449,,,1,CHEMBL626071,,,Rattus norvegicus,N,1,,
10231,Percent total excretion of N-methoxyacetaminophen sulfate,Intermediate,10116.0,,F,,BAO_0000218,7449,,,1,CHEMBL626072,,,Rattus norvegicus,N,1,,
10232,Percent total excretion of acetaminophen,Intermediate,10116.0,,F,,BAO_0000218,7449,,,1,CHEMBL626073,,,Rattus norvegicus,N,1,,
10233,"Distribution of radioactivity in thyroid tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 6.19-7.22",Intermediate,10116.0,,A,,BAO_0000218,7768,,,1,CHEMBL626741,,,Rattus norvegicus,N,1,2046.0,
10234,"Percent instability was measured by Rat S9 liver slice metabolism assay, in vitro",Intermediate,10116.0,,A,,BAO_0000218,17655,,,1,CHEMBL626742,,,Rattus norvegicus,N,1,,
10235,Plasma clearance following 10 mg/kg intravenous or 50 mg/kg oral dosing in rats,Intermediate,10116.0,,A,,BAO_0000218,17735,,,1,CHEMBL626743,,,Rattus norvegicus,N,1,,
10236,Plasma concentration at 4 hr after 30 mg/kg post dosing in rat using HPLC/MS,Intermediate,10116.0,,A,,BAO_0000218,5960,,,1,CHEMBL876792,,,Rattus norvegicus,N,1,,
10237,Volume of distribution following 10 mg/kg intravenous or 50 mg/kg oral dosing in rats was determined,Intermediate,10116.0,,A,,BAO_0000218,17735,,,1,CHEMBL626744,,,Rattus norvegicus,N,1,,
10238,Compound was tested for antidiuretic activity in rats,Intermediate,10116.0,,A,,BAO_0000218,7116,,,1,CHEMBL626745,,,Rattus norvegicus,N,1,,
10239,AUC in rat after 3mg/kg oral dose,Intermediate,10116.0,,A,,BAO_0000218,4878,,,1,CHEMBL626746,,,Rattus norvegicus,N,1,1969.0,
10240,Ratio in brain to that of rat plasma for 2 hr after peroral administration at 10 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,5939,,,1,CHEMBL626747,,,Rattus norvegicus,N,1,,
10241,Ratio in brain to that of rat plasma for 2 hr after peroral administration at 5 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,5939,,,1,CHEMBL626748,,,Rattus norvegicus,N,1,,
10242,Bioavailability administered orally at a dose of 10 mg/kg to rats,Intermediate,10116.0,,A,,BAO_0000218,16367,,,1,CHEMBL626749,,,Rattus norvegicus,N,1,,
10243,Oral Bioavailability was determined,Intermediate,10116.0,,A,,BAO_0000218,16366,,,1,CHEMBL626750,,,Rattus norvegicus,N,1,,
10244,Oral bioavailability in rat,Intermediate,10116.0,,A,,BAO_0000218,4426,,,1,CHEMBL626751,,,Rattus norvegicus,N,1,,
10245,Oral bioavailability in rat; Not performed.,Intermediate,10116.0,,A,,BAO_0000218,4426,,,1,CHEMBL626913,,,Rattus norvegicus,N,1,,
10246,Bioavailability,Intermediate,10116.0,,A,,BAO_0000218,5041,,,1,CHEMBL626914,,,Rattus norvegicus,N,1,,
10247,Bioavailability was determined; ND denotes no data,Intermediate,10116.0,,A,,BAO_0000218,5041,,,1,CHEMBL626915,,,Rattus norvegicus,N,1,,
10248,Biliary excretion when administered intravenously at a dose of 2.5 mg/kg in rats,Intermediate,10116.0,,A,,BAO_0000218,1500,,,1,CHEMBL626916,,,Rattus norvegicus,N,1,,
10249,Biliary excretion when administered intravenously at a dose of 5 mg/kg in rats,Intermediate,10116.0,,A,,BAO_0000218,1500,,,1,CHEMBL626917,,,Rattus norvegicus,N,1,,
10250,Binding towards rat plasma protein at 10 uM,Intermediate,10116.0,,A,,BAO_0000218,17409,,,1,CHEMBL626918,,,Rattus norvegicus,N,1,,
10251,Binding towards rat plasma protein at 100 uM,Intermediate,10116.0,,A,,BAO_0000218,17409,,,1,CHEMBL626919,,,Rattus norvegicus,N,1,,
10252,Bioavailability in rat (dose 20 mg/kg p.o.),Intermediate,10116.0,,A,,BAO_0000218,2959,,,1,CHEMBL626920,,,Rattus norvegicus,N,1,,
10253,Bioavailability was determined after oral administration of compound 18 at a dose of 4 mg/kg to rat,Intermediate,10116.0,,A,,BAO_0000218,13501,,,1,CHEMBL621976,,,Rattus norvegicus,N,1,,
10254,Bioavailability in rat after 5 mg/kg oral gavage,Intermediate,10116.0,,A,,BAO_0000218,6567,,,1,CHEMBL877599,,,Rattus norvegicus,N,1,,
10255,Bioavailability in rat,Intermediate,10116.0,,A,,BAO_0000218,6571,,,1,CHEMBL621977,,,Rattus norvegicus,N,1,,
10256,Bioavailability in rat (dose 1 mg/kg i.v.),Intermediate,10116.0,,A,,BAO_0000218,6715,,,1,CHEMBL621978,,,Rattus norvegicus,N,1,,
10257,Bioavailability in rat (dose 3 mg/kg p.o.),Intermediate,10116.0,,A,,BAO_0000218,6715,,,1,CHEMBL621979,,,Rattus norvegicus,N,1,,
10258,Oral bioavailability in rat,Intermediate,10116.0,,A,,BAO_0000218,2932,,,1,CHEMBL621980,,,Rattus norvegicus,N,1,,
10259,Bioavailability of the compound in rats after administration of 30 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,4171,,,1,CHEMBL621981,,,Rattus norvegicus,N,1,,
10260,Bioavailability after administration of 10 mg/kg in rats,Intermediate,10116.0,,A,,BAO_0000218,17509,,,1,CHEMBL621982,,,Rattus norvegicus,N,1,,
10261,Bioavailability after administration of 2 mg/kg in rats,Intermediate,10116.0,,A,,BAO_0000218,17509,,,1,CHEMBL882953,,,Rattus norvegicus,N,1,,
10262,Bioavailability by oral administration at a dose of 100 uM/kg in rat was determined,Intermediate,10116.0,,A,,BAO_0000218,4527,,,1,CHEMBL621983,,,Rattus norvegicus,N,1,,
10263,Bioavailability in dogs was determined; high,Intermediate,10116.0,,A,,BAO_0000218,4026,,,1,CHEMBL621984,,,Rattus norvegicus,N,1,,
10264,Bioavailability in monkey after intravenous administration at 1 mpk,Intermediate,10116.0,,A,,BAO_0000218,6659,,,1,CHEMBL621985,,,Rattus norvegicus,N,1,,
10265,Bioavailability in monkey after peroral administration at 10 mpk,Intermediate,10116.0,,A,,BAO_0000218,6659,,,1,CHEMBL621986,,,Rattus norvegicus,N,1,,
10266,Bioavailability in rat after intravenous administration at 1 mpk,Intermediate,10116.0,,A,,BAO_0000218,6659,,,1,CHEMBL621987,,,Rattus norvegicus,N,1,,
10267,Bioavailability in rat after intravenous administration at 2 mpk,Intermediate,10116.0,,F,,BAO_0000218,6659,,,1,CHEMBL877600,,,Rattus norvegicus,N,1,,
10268,Bioavailability in rat after peroral administration at 30 mpk,Intermediate,10116.0,,A,,BAO_0000218,6659,,,1,CHEMBL621988,,,Rattus norvegicus,N,1,,
10269,Bioavailability in rat after peroral administration at at 100 mpk,Intermediate,10116.0,,F,,BAO_0000218,6659,,,1,CHEMBL621989,,,Rattus norvegicus,N,1,,
10270,Bioavailability in rats was evaluated,Intermediate,10116.0,,A,,BAO_0000218,6597,,,1,CHEMBL621990,,,Rattus norvegicus,N,1,,
10271,Bioavailability was calculated after an intravenous dose of 0.3 mg/Kg in rats after 6 hr,Intermediate,10116.0,,A,,BAO_0000218,1202,,,1,CHEMBL621991,,,Rattus norvegicus,N,1,,
10272,Bioavailability was calculated after an intravenous dose of 1 mg/Kg in rats after 6 hr,Intermediate,10116.0,,A,,BAO_0000218,1202,,,1,CHEMBL621992,,,Rattus norvegicus,N,1,,
10273,Bioavailability was calculated after peroral dose of 3.0 mg/Kg in rats after 4 hr,Intermediate,10116.0,,A,,BAO_0000218,1202,,,1,CHEMBL621993,,,Rattus norvegicus,N,1,,
10274,Bioavailability was calculated after peroral dose of 3.0 mg/Kg in rats after 6 hr,Intermediate,10116.0,,A,,BAO_0000218,1202,,,1,CHEMBL621994,,,Rattus norvegicus,N,1,,
10275,Bioavailability in rat,Intermediate,10116.0,,A,,BAO_0000218,5207,,,1,CHEMBL621995,,,Rattus norvegicus,N,1,,
10276,Bioavailability in rat,Intermediate,10116.0,,A,,BAO_0000218,5970,,,1,CHEMBL621996,,,Rattus norvegicus,N,1,,
10277,Oral bioavailability in rat (dose 10 mg/kg),Intermediate,10116.0,,A,,BAO_0000218,17538,,,1,CHEMBL621997,,,Rattus norvegicus,N,1,,
10278,Bioavailability in rat after po administration at a dose of 10 mg/kg; nd is not determined,Intermediate,10116.0,,A,,BAO_0000218,17538,,,1,CHEMBL621998,,,Rattus norvegicus,N,1,,
10279,Bioavailability upon peroral administration of 10.0 mg/Kg dose in rat,Intermediate,10116.0,,A,,BAO_0000218,1466,,,1,CHEMBL621999,,,Rattus norvegicus,N,1,,
10280,Oral bioavailability in rat,Intermediate,10116.0,,A,,BAO_0000218,2879,,,1,CHEMBL622000,,,Rattus norvegicus,N,1,,
10281,Bioavailability was measured in rat after oral administration; 2-4,Intermediate,10116.0,,A,,BAO_0000218,2879,,,1,CHEMBL622001,,,Rattus norvegicus,N,1,,
10282,Bioavailability was measured in rat after oral administration; 3-7,Intermediate,10116.0,,A,,BAO_0000218,2879,,,1,CHEMBL622002,,,Rattus norvegicus,N,1,,
10283,Bioavailability in rat (intraduodenal administration),Intermediate,10116.0,,A,,BAO_0000218,3777,,,1,CHEMBL622003,,,Rattus norvegicus,N,1,,
10284,Bioavailability in rat (intraduodenal administration),Intermediate,10116.0,,A,,BAO_0000218,3777,,,1,CHEMBL877601,,,Rattus norvegicus,N,1,,
10285,Oral bioavailability in rat,Intermediate,10116.0,,A,,BAO_0000218,3777,,,1,CHEMBL624871,,,Rattus norvegicus,N,1,,
10286,Oral bioavailability in rat,Intermediate,10116.0,,A,,BAO_0000218,3777,,,1,CHEMBL622004,,,Rattus norvegicus,N,1,,
10287,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg p.o.),Intermediate,10116.0,,A,,BAO_0000218,5423,,,1,CHEMBL882954,,,Rattus norvegicus,N,1,,
10288,Bioavailability was evaluated when a dose of 3 mg/kg was administered orally,Intermediate,10116.0,,A,,BAO_0000218,16365,,,1,CHEMBL622005,,,Rattus norvegicus,N,1,,
10289,Bioavailability was evaluated when a dose of 3 mg/kg was administered orally to a fasting rat,Intermediate,10116.0,,A,,BAO_0000218,16365,,,1,CHEMBL622006,,,Rattus norvegicus,N,1,,
10290,Bioavailability was measured in rat,Intermediate,10116.0,,A,,BAO_0000218,4239,,,1,CHEMBL622007,,,Rattus norvegicus,N,1,,
10291,Bioavailability was reported,Intermediate,10116.0,,A,,BAO_0000218,5438,,,1,CHEMBL622008,,,Rattus norvegicus,N,1,,
10292,Bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),Intermediate,10116.0,,A,,BAO_0000218,5334,,,1,CHEMBL622009,,,Rattus norvegicus,N,1,,
10293,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg),Intermediate,10116.0,,A,,BAO_0000218,5334,,,1,CHEMBL622010,,,Rattus norvegicus,N,1,,
10294,Bioavailability was determined upon 10 mg/kg in 1% methylcellulose peroral administration in rats,Intermediate,10116.0,,A,,BAO_0000218,4199,,,1,CHEMBL622011,,,Rattus norvegicus,N,1,,
10295,Bioavailability in rat (dose 2 mg/kg in 1% methylcellulose p.o.),Intermediate,10116.0,,A,,BAO_0000218,4199,,,1,CHEMBL622012,,,Rattus norvegicus,N,1,,
10296,Bioavailability in rat (dose 3 mg/kg in 1% methylcellulose ),Intermediate,10116.0,,A,,BAO_0000218,4199,,,1,CHEMBL622013,,,Rattus norvegicus,N,1,,
10297,Bioavailability was determined after intravenous administration at a dose 5 mg/kg to male Sprague-Dawley rats,Intermediate,10116.0,,A,,BAO_0000218,4890,,,1,CHEMBL622014,,,Rattus norvegicus,N,1,,
10298,Bioavailability was determined at 3 mg/kg po dose in rats,Intermediate,10116.0,,A,,BAO_0000218,2792,,,1,CHEMBL624749,,,Rattus norvegicus,N,1,,
10299,Oral bioavailability in rat (dose 2 mg/kg),Intermediate,10116.0,,A,,BAO_0000218,5529,,,1,CHEMBL624750,,,Rattus norvegicus,N,1,,
10300,"Bioavailability was determined in rats at 10 mg/kg, p.o. dose",Intermediate,10116.0,,A,,BAO_0000218,6685,,,1,CHEMBL624751,,,Rattus norvegicus,N,1,,
10301,"Bioavailability was determined in rats at 20 mg/kg, i.p. dose; n/a: not applicable",Intermediate,10116.0,,A,,BAO_0000218,6685,,,1,CHEMBL624752,,,Rattus norvegicus,N,1,,
10302,"Bioavailability was determined in rats at 2 mg/kg, i.v. dose; n/a: not applicable",Intermediate,10116.0,,A,,BAO_0000218,6685,,,1,CHEMBL624753,,,Rattus norvegicus,N,1,,
10303,Bioavailability was evaluated in rat after peroral administration at a dose of 1 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,6005,,,1,CHEMBL624754,,,Rattus norvegicus,N,1,,
10304,Bioavailability was evaluated in rats at an intravenous dose of 3 mg/kg; Not applicable,Intermediate,10116.0,,A,,BAO_0000218,6410,,,1,CHEMBL624755,,,Rattus norvegicus,N,1,,
10305,Bioavailability was evaluated in rats at an oral dose of 30 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,6410,,,1,CHEMBL624756,,,Rattus norvegicus,N,1,,
10306,Bioavailability in rat,Intermediate,10116.0,,A,,BAO_0000218,6103,,,1,CHEMBL624757,,,Rattus norvegicus,N,1,,
10307,Bioavailability was evaluated in rats at an intravenous dose of 3 mg/kg; Not applicable,Intermediate,10116.0,,A,,BAO_0000218,6410,,,1,CHEMBL624758,,,Rattus norvegicus,N,1,,
10308,Bioavailability was evaluated in rats at an oral dose of 30 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,6410,,,1,CHEMBL622270,,,Rattus norvegicus,N,1,,
10309,Bioavailability in rat (Sprague-Dawley),Intermediate,10116.0,,A,,BAO_0000218,5353,,,1,CHEMBL622271,,,Rattus norvegicus,N,1,,
10310,Bioavailability in rat at the dose of 2 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,4727,,,1,CHEMBL622272,,,Rattus norvegicus,N,1,,
10311,Oral bioavailability in rat,Intermediate,10116.0,,A,,BAO_0000218,17804,,,1,CHEMBL622273,,,Rattus norvegicus,N,1,,
10312,Bioavailability in rat (cannulated) (dose 2 mg/kg),Intermediate,10116.0,,A,,BAO_0000218,5809,,,1,CHEMBL622274,,,Rattus norvegicus,N,1,,
10313,Bioavailability value of compound in rats was determined after peroral administration,Intermediate,10116.0,,A,,BAO_0000218,17804,,,1,CHEMBL622275,,,Rattus norvegicus,N,1,,
10314,Oral bioavailability in rat (dose 20 mg/kg),Intermediate,10116.0,,A,,BAO_0000218,3634,,,1,CHEMBL622276,,,Rattus norvegicus,N,1,,
10315,Oral bioavailability in rat,Intermediate,10116.0,,A,,BAO_0000218,3341,,,1,CHEMBL622277,,,Rattus norvegicus,N,1,,
10316,Oral bioavailability in rat (dose 5 mg/kg),Intermediate,10116.0,,A,,BAO_0000218,2690,,,1,CHEMBL622278,,,Rattus norvegicus,N,1,,
10317,Oral bioavailability in rat,Intermediate,10116.0,,A,,BAO_0000218,3184,,,1,CHEMBL622279,,,Rattus norvegicus,N,1,,
10318,Oral bioavailability in rat,Intermediate,10116.0,,A,,BAO_0000218,740,,,1,CHEMBL622280,,,Rattus norvegicus,N,1,,
10319,Compound was evaluated for oral bioavailability in rats; 15-27 %,Intermediate,10116.0,,A,,BAO_0000218,1806,,,1,CHEMBL624083,,,Rattus norvegicus,N,1,,
10320,Compound was evaluated for pharmacokinetic parameter percent bioavailability at 18 h,Intermediate,10116.0,,A,,BAO_0000218,4891,,,1,CHEMBL624084,,,Rattus norvegicus,N,1,,
10321,Compound was evaluated for pharmacokinetic property in rats after an oral dose of 10 mg/kg and the value was reported as oral bioavailability (F),Intermediate,10116.0,,A,,BAO_0000218,3634,,,1,CHEMBL624085,,,Rattus norvegicus,N,1,,
10322,Compound was tested for bioavailability in rats,Intermediate,10116.0,,A,,BAO_0000218,64,,,1,CHEMBL624086,,,Rattus norvegicus,N,1,,
10323,Bioavailability in rat,Intermediate,10116.0,,A,,BAO_0000218,4839,,,1,CHEMBL624087,,,Rattus norvegicus,N,1,,
10324,Oral bioavailability in rat,Intermediate,10116.0,,A,,BAO_0000218,1094,,,1,CHEMBL624088,,,Rattus norvegicus,N,1,,
10325,Compound was tested for oral bioavailability in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po.,Intermediate,9544.0,,A,,BAO_0000218,5005,,,1,CHEMBL624089,,,Macaca mulatta,U,0,,
10326,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v. and 2 mg/kg p.o.),Intermediate,10116.0,,A,,BAO_0000218,5005,,,1,CHEMBL624090,,,Rattus norvegicus,U,0,,
10327,Evaluated for the bioavailability in rat (in vivo),Intermediate,10116.0,,A,,BAO_0000218,4687,,,1,CHEMBL624091,,,Rattus norvegicus,N,1,,
10328,F value of compound in rats was determined after peroral administration,Intermediate,10116.0,,A,,BAO_0000218,17804,,,1,CHEMBL624092,,,Rattus norvegicus,N,1,,
10329,In vivo Oral bioavailability (F)was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,Intermediate,10116.0,,A,,BAO_0000218,5974,,,1,CHEMBL624093,,,Rattus norvegicus,N,1,,
10330,In vivo Oral bioavailability (F)was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,Intermediate,10116.0,,A,,BAO_0000218,5974,,,1,CHEMBL624094,,,Rattus norvegicus,N,1,,
10331,In vivo Oral bioavailability (F)was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,Intermediate,10116.0,,A,,BAO_0000218,5974,,,1,CHEMBL624095,,,Rattus norvegicus,N,1,,
10332,In vivo Oral bioavailability (F)was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,Intermediate,10116.0,,A,,BAO_0000218,5974,,,1,CHEMBL624096,,,Rattus norvegicus,N,1,,
10333,"In vivo percent of absolute bioavailability obtained from blood plasma levels analyzed by means of GC/MS (dose 5 uM/kg i.v. and 40 uM/kg, p.o.)",Intermediate,10116.0,,A,,BAO_0000218,1088,,,1,CHEMBL624097,,,Rattus norvegicus,N,1,,
10334,Maximum fall in carotid flow in rat,Intermediate,10116.0,,A,,BAO_0000218,1742,,,1,CHEMBL624098,,,Rattus norvegicus,N,1,,
10335,Oral Bioavailability after intravenous administration (1 mg/kg) in rat,Intermediate,10116.0,,A,,BAO_0000218,4689,,,1,CHEMBL874392,,,Rattus norvegicus,N,1,,
10336,Oral bioavailability in rat (dose 5 mg/kg),Intermediate,10116.0,,A,,BAO_0000218,2463,,,1,CHEMBL624099,,,Rattus norvegicus,N,1,,
10337,Oral bioavailability (F%) of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 16 mg/kg peroral administration,Intermediate,10116.0,,A,,BAO_0000218,5654,,,1,CHEMBL624100,,,Rattus norvegicus,N,1,,
10338,Oral bioavailability (F%) of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 20 mg/kg peroral administration,Intermediate,10116.0,,A,,BAO_0000218,5654,,,1,CHEMBL624101,,,Rattus norvegicus,N,1,,
10339,Oral bioavailability in rat (male Wistar),Intermediate,10116.0,,A,,BAO_0000218,6874,,,1,CHEMBL624102,,,Rattus norvegicus,N,1,,
10340,Oral bioavailability after administration (30 mg/kg) in rat; good,Intermediate,10116.0,,A,,BAO_0000218,5633,,,1,CHEMBL624103,,,Rattus norvegicus,N,1,,
10341,Oral bioavailability at the dose of 2 mg/kg in rat,Intermediate,10116.0,,A,,BAO_0000218,5496,,,1,CHEMBL624104,,,Rattus norvegicus,N,1,,
10342,Oral bioavailability determined in rats,Intermediate,10116.0,,A,,BAO_0000218,2358,,,1,CHEMBL624105,,,Rattus norvegicus,N,1,,
10343,Oral bioavailability in rat (Sprague-Dawley) (male) (dose 50 mg/kg p.o.),Intermediate,10116.0,,A,,BAO_0000218,16456,,,1,CHEMBL624106,,,Rattus norvegicus,N,1,,
10344,Oral bioavailability in rat (dose single 10 mg/kg),Intermediate,10116.0,,A,,BAO_0000218,5302,,,1,CHEMBL624107,,,Rattus norvegicus,N,1,,
10345,Oral bioavailability in rat (dose single 10 mg/kg),Intermediate,10116.0,,A,,BAO_0000218,5302,,,1,CHEMBL623943,,,Rattus norvegicus,N,1,,
10346,Oral bioavailability in rat (dose 5 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,5302,,,1,CHEMBL623944,,,Rattus norvegicus,N,1,,
10347,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus HVA; below the levels of detection,Intermediate,10116.0,,A,,BAO_0000218,11020,,,1,CHEMBL623945,,,Rattus norvegicus,N,1,,
10348,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus NE,Intermediate,10116.0,,A,,BAO_0000218,11020,,,1,CHEMBL623946,,,Rattus norvegicus,N,1,,
10349,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex 5-HIAA,Intermediate,10116.0,,A,,BAO_0000218,11020,,,1,CHEMBL623947,,,Rattus norvegicus,N,1,,
10350,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex 5-HT,Intermediate,10116.0,,A,,BAO_0000218,11020,,,1,CHEMBL623948,,,Rattus norvegicus,N,1,,
10351,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex DA,Intermediate,10116.0,,A,,BAO_0000218,11020,,,1,CHEMBL623949,,,Rattus norvegicus,N,1,,
10352,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex DOPAC,Intermediate,10116.0,,A,,BAO_0000218,11020,,,1,CHEMBL623950,,,Rattus norvegicus,N,1,,
10353,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex HVA,Intermediate,10116.0,,A,,BAO_0000218,11020,,,1,CHEMBL874398,,,Rattus norvegicus,N,1,,
10354,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex NE,Intermediate,10116.0,,A,,BAO_0000218,11020,,,1,CHEMBL623951,,,Rattus norvegicus,N,1,,
10355,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus 5-HIAA,Intermediate,10116.0,,A,,BAO_0000218,11020,,,1,CHEMBL623952,,,Rattus norvegicus,N,1,,
10356,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus 5-HT,Intermediate,10116.0,,A,,BAO_0000218,11020,,,1,CHEMBL623953,,,Rattus norvegicus,N,1,,
10357,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus DA; below level of detection,Intermediate,10116.0,,A,,BAO_0000218,11020,,,1,CHEMBL623954,,,Rattus norvegicus,N,1,,
10358,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus DA; below the levels of detection,Intermediate,10116.0,,A,,BAO_0000218,11020,,,1,CHEMBL623955,,,Rattus norvegicus,N,1,,
10359,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus DOPAC; below level of detection,Intermediate,10116.0,,A,,BAO_0000218,11020,,,1,CHEMBL623956,,,Rattus norvegicus,N,1,,
10360,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus DOPAC; below the levels of detection,Intermediate,10116.0,,A,,BAO_0000218,11020,,,1,CHEMBL627807,,,Rattus norvegicus,N,1,,
10361,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus HVA; below level of detection,Intermediate,10116.0,,A,,BAO_0000218,11020,,,1,CHEMBL627808,,,Rattus norvegicus,N,1,,
10362,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus HVA; below the levels of detection,Intermediate,10116.0,,A,,BAO_0000218,11020,,,1,CHEMBL627809,,,Rattus norvegicus,N,1,,
10363,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus NE,Intermediate,10116.0,,A,,BAO_0000218,11020,,,1,CHEMBL627810,,,Rattus norvegicus,N,1,,
10364,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex 5-HIAA",Intermediate,10116.0,,A,,BAO_0000218,11020,,,1,CHEMBL627811,,,Rattus norvegicus,N,1,,
10365,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex 5-HT",Intermediate,10116.0,,A,,BAO_0000218,11020,,,1,CHEMBL627812,,,Rattus norvegicus,N,1,,
10366,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex DA",Intermediate,10116.0,,A,,BAO_0000218,11020,,,1,CHEMBL627813,,,Rattus norvegicus,N,1,,
10367,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex DOPAC",Intermediate,10116.0,,A,,BAO_0000218,11020,,,1,CHEMBL627814,,,Rattus norvegicus,N,1,,
10368,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex HVA",Intermediate,10116.0,,A,,BAO_0000218,11020,,,1,CHEMBL875336,,,Rattus norvegicus,N,1,,
10369,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex NE",Intermediate,10116.0,,A,,BAO_0000218,11020,,,1,CHEMBL627815,,,Rattus norvegicus,N,1,,
10370,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus 5-HIAA",Intermediate,10116.0,,A,,BAO_0000218,11020,,,1,CHEMBL627816,,,Rattus norvegicus,N,1,,
10371,"Momoamine and metabolic levels observed at 3 h postdrug against, at a dose of 20 mg/kg Hippocampus 5-HT",Intermediate,10116.0,,A,,BAO_0000218,11020,,,1,CHEMBL627817,,,Rattus norvegicus,N,1,,
10372,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus DA; below the levels of detection",Intermediate,10116.0,,A,,BAO_0000218,11020,,,1,CHEMBL627818,,,Rattus norvegicus,N,1,,
10373,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus DOPAC; below the levels of detection",Intermediate,10116.0,,A,,BAO_0000218,11020,,,1,CHEMBL627819,,,Rattus norvegicus,N,1,,
10374,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus HVA; below the levels of detection",Intermediate,10116.0,,A,,BAO_0000218,11020,,,1,CHEMBL627820,,,Rattus norvegicus,N,1,,
10375,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus NE",Intermediate,10116.0,,A,,BAO_0000218,11020,,,1,CHEMBL627821,,,Rattus norvegicus,N,1,,
10376,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex 5-HIAA,Intermediate,10116.0,,A,,BAO_0000218,11020,,,1,CHEMBL628464,,,Rattus norvegicus,N,1,,
10377,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex 5-HT,Intermediate,10116.0,,A,,BAO_0000218,11020,,,1,CHEMBL626239,,,Rattus norvegicus,N,1,,
10378,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex DA,Intermediate,10116.0,,A,,BAO_0000218,11020,,,1,CHEMBL626240,,,Rattus norvegicus,N,1,,
10379,Momoamine and metabolic levels observed at 3 h postdrug against at a dose of 20 mg/kg Frontal cortex DOPAC,Intermediate,10116.0,,A,,BAO_0000218,11020,,,1,CHEMBL626241,,,Rattus norvegicus,N,1,,
10380,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex HVA,Intermediate,10116.0,,A,,BAO_0000218,11020,,,1,CHEMBL626242,,,Rattus norvegicus,N,1,,
10381,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex NE,Intermediate,10116.0,,A,,BAO_0000218,11020,,,1,CHEMBL626243,,,Rattus norvegicus,N,1,,
10382,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus 5-HIAA,Intermediate,10116.0,,A,,BAO_0000218,11020,,,1,CHEMBL626244,,,Rattus norvegicus,N,1,,
10383,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus 5-HT; below level of detection,Intermediate,10116.0,,A,,BAO_0000218,11020,,,1,CHEMBL626907,,,Rattus norvegicus,N,1,,
10384,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus DA; below level of detection,Intermediate,10116.0,,A,,BAO_0000218,11020,,,1,CHEMBL626908,,,Rattus norvegicus,N,1,,
10385,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus DOPAC; below level of detection,Intermediate,10116.0,,A,,BAO_0000218,11020,,,1,CHEMBL626909,,,Rattus norvegicus,N,1,,
10386,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus HVA; below level of detection,Intermediate,10116.0,,A,,BAO_0000218,11020,,,1,CHEMBL626910,,,Rattus norvegicus,N,1,,
10387,Percent total excretion of acetaminophen cysteine conjugate,Intermediate,10116.0,,F,,BAO_0000218,7449,,,1,CHEMBL875342,,,Rattus norvegicus,N,1,,
10388,Percent total excretion of acetaminophen glucuronide,Intermediate,10116.0,,F,,BAO_0000218,7449,,,1,CHEMBL626911,,,Rattus norvegicus,N,1,,
10389,Percent total excretion of acetaminophen sulfate,Intermediate,10116.0,,F,,BAO_0000218,7449,,,1,CHEMBL626912,,,Rattus norvegicus,N,1,,
10390,Percent total excretion of acetaminophen-mercapturic acid,Intermediate,10116.0,,F,,BAO_0000218,7449,,,1,CHEMBL627065,,,Rattus norvegicus,N,1,,
10391,Amount of urine output was measured in rat at a dose of 10 mg/kg administered orally,Intermediate,10116.0,,A,,BAO_0000218,3172,,,1,CHEMBL627066,,,Rattus norvegicus,N,1,1088.0,
10392,Volume of distribution in Male Sprague-Dawley rats after intravenous administration at a dose of 10 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,16456,,,1,CHEMBL627067,,,Rattus norvegicus,N,1,,
10393,Biodistribution of compound in rat muscle after 5 min of administration,Autocuration,8656.0,,A,,BAO_0000218,10839,,,1,CHEMBL627068,,,ratrat,U,0,2385.0,
10394,Biodistribution of compound in rat muscle after 5 min of administration.,Autocuration,8656.0,,A,,BAO_0000218,10839,,,1,CHEMBL627069,,,ratrat,U,0,2385.0,
10395,Plasma clearance was reported after intravenous administration at a dose of 1 mg/kg in Abraham sheep (female),Autocuration,9940.0,,A,,BAO_0000218,5334,,,1,CHEMBL627070,,,Ovis aries,U,0,,
10396,Plasma clearance was reported after oral administration at a dose of 2 mg/kg in Abraham sheep (female),Autocuration,9940.0,,A,,BAO_0000218,5334,,,1,CHEMBL627071,,,Ovis aries,U,0,,
10397,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Abraham sheep (female),Autocuration,9940.0,,A,,BAO_0000218,5334,,,1,CHEMBL627072,,,Ovis aries,U,0,,
10398,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Abraham sheep (female),Autocuration,9940.0,,A,,BAO_0000218,5334,,,1,CHEMBL627073,,,Ovis aries,U,0,,
10399,Volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Abraham sheep (female),Autocuration,9940.0,,A,,BAO_0000218,5334,,,1,CHEMBL625387,,,Ovis aries,U,0,,
10400,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Abraham sheep (female),Autocuration,9940.0,,A,,BAO_0000218,5334,,,1,CHEMBL625388,,,Ovis aries,U,0,,
10401,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Abraham sheep (female),Autocuration,9940.0,,A,,BAO_0000218,5334,,,1,CHEMBL625389,,,Ovis aries,U,0,1969.0,
10402,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg in Abraham sheep (female),Autocuration,9940.0,,A,,BAO_0000218,5334,,,1,CHEMBL875343,,,Ovis aries,U,0,1969.0,
10403,Biological half life period of compound was measured against snake venom phosphodiesterase (SVPDE),Intermediate,8570.0,,A,,BAO_0000218,1735,,,1,CHEMBL876795,,,Serpentes,N,1,,
10404,Half life (t) of enzymatic phosphodiester hydrolysis of compound towards snake venom (SV-PDE) at a concentration of 4 microg,Intermediate,8570.0,,A,,BAO_0000218,1469,,,1,CHEMBL626552,,,Serpentes,N,1,,
10405,Enzymatic stability was assessed with snake venom phosphodiesterase (SV PDE) exonuclase,Intermediate,8570.0,,A,,BAO_0000218,1336,,,1,CHEMBL626553,,,Serpentes,N,1,,
10406,The human biological plasma half life of the compound,Autocuration,9606.0,,A,,BAO_0000366,12403,,,1,CHEMBL626554,,,Homo sapiens,U,0,1969.0,
10407,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 100 mg/Kg,Intermediate,10116.0,,A,,BAO_0000218,8151,,,1,CHEMBL626555,,,Rattus norvegicus,N,1,1088.0,
10408,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 120 min after iv administration compound,Intermediate,10116.0,,A,,BAO_0000218,8004,,,1,CHEMBL626556,,,Rattus norvegicus,N,1,,
10409,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 15 after iv administration of compound,Intermediate,10116.0,,A,,BAO_0000218,8004,,,1,CHEMBL626557,,,Rattus norvegicus,N,1,,
10410,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 240 min after iv administration compound,Intermediate,10116.0,,A,,BAO_0000218,8004,,,1,CHEMBL626558,,,Rattus norvegicus,N,1,,
10411,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 30 min after iv administration of compound,Intermediate,10116.0,,A,,BAO_0000218,8004,,,1,CHEMBL626559,,,Rattus norvegicus,N,1,,
10412,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 5 min after iv administration of compound,Intermediate,10116.0,,A,,BAO_0000218,8004,,,1,CHEMBL626560,,,Rattus norvegicus,N,1,,
10413,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 60 min after iv administration of compound,Intermediate,10116.0,,A,,BAO_0000218,8004,,,1,CHEMBL876803,,,Rattus norvegicus,N,1,,
10414,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 120 min after iv administration compound,Intermediate,10116.0,,A,,BAO_0000218,8004,,,1,CHEMBL627964,,,Rattus norvegicus,N,1,,
10415,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 15 min after iv administration of compound,Intermediate,10116.0,,A,,BAO_0000218,8004,,,1,CHEMBL627965,,,Rattus norvegicus,N,1,,
10416,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 240 min after iv administration compound,Intermediate,10116.0,,A,,BAO_0000218,8004,,,1,CHEMBL627966,,,Rattus norvegicus,N,1,,
10417,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 30 min after iv administration of compound,Intermediate,10116.0,,A,,BAO_0000218,8004,,,1,CHEMBL627967,,,Rattus norvegicus,N,1,,
10418,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 5 min after iv administration of compound,Intermediate,10116.0,,A,,BAO_0000218,8004,,,1,CHEMBL627968,,,Rattus norvegicus,N,1,,
10419,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 60 min after iv administration of compound,Intermediate,10116.0,,A,,BAO_0000218,8004,,,1,CHEMBL627969,,,Rattus norvegicus,N,1,,
10420,Distribution of Se-75 activity in Liver of female Sprague-Dawley Rat 5 min after iv administration of compound,Intermediate,10116.0,,A,,BAO_0000218,8004,,,1,CHEMBL627970,,,Rattus norvegicus,N,1,,
10421,Distribution of Se-75 activity in blood of female Sprague-Dawley Rat 120 min after iv administration of compound,Intermediate,10116.0,,A,,BAO_0000218,8004,,,1,CHEMBL627971,,,Rattus norvegicus,N,1,178.0,
10422,Distribution of Se-75 activity in blood of female Sprague-Dawley Rat 240 min after iv administration of compound,Intermediate,10116.0,,A,,BAO_0000218,8004,,,1,CHEMBL627972,,,Rattus norvegicus,N,1,178.0,
10423,Dissociation constant against binding to human cyclophilin A,Expert,9606.0,,B,,BAO_0000357,15917,,,1,CHEMBL856029,,,Homo sapiens,D,9,,
10424,Michaelis-Menten constant for inhibitory activity against bovine liver glyoxalase II,Expert,9913.0,,B,,BAO_0000019,12396,,,1,CHEMBL627973,,,Bos taurus,H,8,,
10425,-Log C was determined by performing the electroshock minimum test,Autocuration,,,A,,BAO_0000019,7065,,,1,CHEMBL627974,,,,U,0,,
10426,-Log C was determined by performing the foot shock test,Autocuration,,,A,,BAO_0000019,7065,,,1,CHEMBL627975,,,,U,0,,
10427,-Log C was determined by performing the incl screen test,Autocuration,,,A,,BAO_0000019,7065,,,1,CHEMBL627976,,,,U,0,,
10428,-Log C was determined by performing the maximum electroshock test,Autocuration,,,A,,BAO_0000019,7065,,,1,CHEMBL627977,,,,U,0,,
10429,-Log C was determined by performing the pentylenetetrazole test,Autocuration,,,A,,BAO_0000019,7065,,,1,CHEMBL627978,,,,U,0,,
10430,Tested for experimental arotinoid inhibitory dose,Autocuration,,,A,,BAO_0000019,12415,,,1,CHEMBL627979,,,,U,0,,
10431,Negative log transformed activity,Autocuration,,,A,,BAO_0000019,10256,,,1,CHEMBL876804,,,,U,0,,
10432,"Negative log of Langmuir's alpha constant (-log alpha), which is inversely proportional to the effective binding constant (protein binding)",Autocuration,,,A,,BAO_0000019,7991,,,1,CHEMBL627980,,,,U,0,,
10433,Dissociation constant was evaluated on guinea pig bladder at M3 muscarinic receptor,Intermediate,10141.0,,A,,BAO_0000218,14342,,,1,CHEMBL627981,,,Cavia porcellus,N,1,,
10434,Dissociation constant was evaluated on guinea pig heart (force) at M2 muscarinic receptor,Intermediate,10141.0,,A,,BAO_0000218,14342,,,1,CHEMBL627982,,,Cavia porcellus,N,1,,
10435,Dissociation constant was evaluated on guinea pig heart (rate) at M2 muscarinic receptor,Intermediate,10141.0,,A,,BAO_0000218,14342,,,1,CHEMBL627983,,,Cavia porcellus,N,1,,
10436,Dissociation constant was evaluated on guinea pig ileum at M3 muscarinic receptor,Intermediate,10141.0,,A,,BAO_0000218,14342,,,1,CHEMBL627984,,,Cavia porcellus,N,1,2116.0,
10437,Solubility in water was determined; values expressed as -log,Autocuration,,,P,,BAO_0000100,6047,,,1,CHEMBL627985,,,,U,0,,
10438,Ratio of Kcat to that of Km was determined,Autocuration,,,A,,BAO_0000019,17269,,,1,CHEMBL627986,,,,U,0,,
10439,Observed first order rate constant,Autocuration,,,A,,BAO_0000019,10026,,,1,CHEMBL627987,,,,U,0,,
10440,Fraction of 88Y (%) released from chelate after incubation in serum for 15 hours,Autocuration,,,A,,BAO_0000019,14583,,,1,CHEMBL627988,,,,U,0,,
10441,Compound was evaluated for bioavailability after treatment with oral dose of 2 mgkg to female wistar rats,Intermediate,10116.0,,A,,BAO_0000218,2661,,,1,CHEMBL627989,,,Rattus norvegicus,N,1,,
10442,Compound was evaluated for bioavailability after treatment with oral dose of 2 mgkg to male wistar rats,Intermediate,10116.0,,A,,BAO_0000218,2661,,,1,CHEMBL627990,,,Rattus norvegicus,N,1,,
10443,Oral Bioavailability after administration of 10 mg/kg in male rat,Intermediate,10116.0,,A,,BAO_0000218,4029,,,1,CHEMBL876805,,,Rattus norvegicus,N,1,,
10444,Oral bioavailability in rat (dose 10 mg/kg i.v. and 50 mg/kg p.o.),Intermediate,10116.0,,A,,BAO_0000218,17735,,,1,CHEMBL627991,,,Rattus norvegicus,N,1,,
10445,Oral bioavailability in rat,Intermediate,10116.0,,A,,BAO_0000218,4576,,,1,CHEMBL627992,,,Rattus norvegicus,N,1,,
10446,Oral bioavailability after oral (po) administration at a dose of 10 mg/kg was measured in rats,Intermediate,10116.0,,A,,BAO_0000218,17582,,,1,CHEMBL627993,,,Rattus norvegicus,N,1,,
10447,Oral bioavailability at 1 mg/kg was determined in rat,Intermediate,10116.0,,A,,BAO_0000218,17651,,,1,CHEMBL622817,,,Rattus norvegicus,N,1,,
10448,Oral bioavailability at 10 mg/kg was determined in rat,Intermediate,10116.0,,A,,BAO_0000218,17651,,,1,CHEMBL622818,,,Rattus norvegicus,N,1,,
10449,"Oral bioavailability in fischer rats at 30 mg/kg dose, administered perorally",Intermediate,10116.0,,A,,BAO_0000218,17670,,,1,CHEMBL622819,,,Rattus norvegicus,N,1,,
10450,Oral bioavailability in rat,Intermediate,10116.0,,A,,BAO_0000218,5045,,,1,CHEMBL872267,,,Rattus norvegicus,N,1,,
10451,Oral bioavailability in rat,Intermediate,10116.0,,A,,BAO_0000218,1696,,,1,CHEMBL622820,,,Rattus norvegicus,N,1,,
10452,Oral bioavailability after intravenous administration in rats at 24 uM/kg,Intermediate,10116.0,,A,,BAO_0000218,17764,,,1,CHEMBL622821,,,Rattus norvegicus,N,1,,
10453,Oral bioavailability in rat,Intermediate,10116.0,,A,,BAO_0000218,6448,,,1,CHEMBL622822,,,Rattus norvegicus,N,1,,
10454,Oral bioavailability in rat,Intermediate,10116.0,,A,,BAO_0000218,6596,,,1,CHEMBL622823,,,Rattus norvegicus,N,1,,
10455,Oral bioavailability in rat,Intermediate,10116.0,,A,,BAO_0000218,17547,,,1,CHEMBL622824,,,Rattus norvegicus,N,1,,
10456,Oral bioavailability in rat at a dose of 3 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,17771,,,1,CHEMBL622825,,,Rattus norvegicus,N,1,,
10457,Oral bioavailability in rat after oral administration at 10 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,6495,,,1,CHEMBL622901,,,Rattus norvegicus,N,1,,
10458,Oral bioavailability in rat,Intermediate,10116.0,,A,,BAO_0000218,4558,,,1,CHEMBL622902,,,Rattus norvegicus,N,1,,
10459,Oral bioavailability in rat,Intermediate,10116.0,,A,,BAO_0000218,17596,,,1,CHEMBL621844,,,Rattus norvegicus,N,1,,
10460,Oral bioavailability in Dawley rats,Intermediate,10116.0,,A,,BAO_0000218,6827,,,1,CHEMBL621845,,,Rattus norvegicus,N,1,,
10461,Oral bioavailability,Intermediate,10116.0,,A,,BAO_0000218,4026,,,1,CHEMBL621846,,,Rattus norvegicus,N,1,,
10462,Oral bioavailability in rat (dose 30 mg/kg),Intermediate,10116.0,,A,,BAO_0000218,10,,,1,CHEMBL621847,,,Rattus norvegicus,N,1,,
10463,Bioavailability in rat at a concentration of 15 mg/kg perorally in rat along with 100 mg/kg 11,Intermediate,10116.0,,A,,BAO_0000218,17717,,,1,CHEMBL877609,,,Rattus norvegicus,N,1,,
10464,Bioavailability in rat (dose 3 mg/kg i.v.),Intermediate,10116.0,,A,,BAO_0000218,17717,,,1,CHEMBL621848,,,Rattus norvegicus,N,1,,
10465,Bioavailability in rat at a concentration of 60 mg/kg perorally in rat along with 100 mg/kg 11,Intermediate,10116.0,,A,,BAO_0000218,17717,,,1,CHEMBL621849,,,Rattus norvegicus,N,1,,
10466,Oral bioavailability in rat (dose 60 mg/kg p.o.),Intermediate,10116.0,,A,,BAO_0000218,17717,,,1,CHEMBL622030,,,Rattus norvegicus,N,1,,
10467,Percent oral bioavailability determined in rats,Intermediate,10116.0,,A,,BAO_0000218,4796,,,1,CHEMBL622031,,,Rattus norvegicus,N,1,,
10468,Tested for percent bioavailability after oral administration to Sprague-Dawley rat at dosage of 0.2 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,4883,,,1,CHEMBL622032,,,Rattus norvegicus,N,1,,
10469,The compound was evaluated for bioavailability in rats; 32-51,Intermediate,10116.0,,A,,BAO_0000218,2137,,,1,CHEMBL622033,,,Rattus norvegicus,N,1,,
10470,Bioavailability in rat (dose 20 mg/kg p.o.),Intermediate,10116.0,,A,,BAO_0000218,2959,,,1,CHEMBL622034,,,Rattus norvegicus,N,1,,
10471,Oral bioavailability in rat,Intermediate,10116.0,,A,,BAO_0000218,1361,,,1,CHEMBL622035,,,Rattus norvegicus,N,1,,
10472,Bioavailability percent in rat at the dose of 2 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,4727,,,1,CHEMBL882966,,,Rattus norvegicus,N,1,,
10473,Bioavailability was evaluated after 20 uM/kg of peroral administration,Intermediate,10116.0,,A,,BAO_0000218,16423,,,1,CHEMBL622036,,,Rattus norvegicus,N,1,,
10474,Oral bioavailability in rat,Intermediate,10116.0,,A,,BAO_0000218,5206,,,1,CHEMBL622037,,,Rattus norvegicus,N,1,,
10475,Oral bioavailability in rat,Intermediate,10116.0,,A,,BAO_0000218,6448,,,1,CHEMBL622038,,,Rattus norvegicus,N,1,,
10476,Bioavailability in rats,Intermediate,10116.0,,A,,BAO_0000218,17723,,,1,CHEMBL622039,,,Rattus norvegicus,N,1,,
10477,Biodistribution of radiolabeled compound in rat blood after 24 hr postinjection activity expressed as %ID/Organ,Intermediate,10116.0,,A,,BAO_0000218,17738,,,1,CHEMBL622040,,,Rattus norvegicus,N,1,178.0,
10478,Biodistribution of radiolabeled compound in rat blood after 24 hr activity expressed as %ID/Organ,Intermediate,10116.0,,A,,BAO_0000218,17738,,,1,CHEMBL622041,,,Rattus norvegicus,N,1,178.0,
10479,Biodistribution of radiolabeled compound in rat blood after 2 hr activity expressed as %ID/Organ,Intermediate,10116.0,,A,,BAO_0000218,17738,,,1,CHEMBL622042,,,Rattus norvegicus,N,1,178.0,
10480,Biodistribution of radiolabeled compound in rat blood after 30 min activity expressed as %ID/Organ,Intermediate,10116.0,,A,,BAO_0000218,17738,,,1,CHEMBL622043,,,Rattus norvegicus,N,1,178.0,
10481,Biodistribution of radiolabeled compound in rat blood after 5 min activity expressed as %ID/Organ,Intermediate,10116.0,,A,,BAO_0000218,17738,,,1,CHEMBL622044,,,Rattus norvegicus,N,1,178.0,
10482,Biodistribution of radiolabeled compound in rat bone after 24 hr activity expressed as %ID/Organ,Intermediate,10116.0,,A,,BAO_0000218,17738,,,1,CHEMBL622045,,,Rattus norvegicus,N,1,10000001.0,
10483,Biodistribution of radiolabeled compound in rat bone after 2 hr activity expressed as %ID/Organ,Intermediate,10116.0,,A,,BAO_0000218,17738,,,1,CHEMBL622046,,,Rattus norvegicus,N,1,10000001.0,
10484,Biodistribution of radiolabeled compound in rat bone after 30 min activity expressed as %ID/Organ,Intermediate,10116.0,,A,,BAO_0000218,17738,,,1,CHEMBL622047,,,Rattus norvegicus,N,1,10000001.0,
10485,Biodistribution of radiolabeled compound in rat bone after 5 min activity expressed as %ID/Organ,Intermediate,10116.0,,A,,BAO_0000218,17738,,,1,CHEMBL877610,,,Rattus norvegicus,N,1,10000001.0,
10486,Biodistribution of radiolabeled compound in rat brain after 24 hr activity expressed as %ID/Organ,Intermediate,10116.0,,A,,BAO_0000218,17738,,,1,CHEMBL622048,,,Rattus norvegicus,N,1,955.0,
10487,Biodistribution of radiolabeled compound in rat brain after 2 hr activity expressed as %ID/Organ,Intermediate,10116.0,,A,,BAO_0000218,17738,,,1,CHEMBL622049,,,Rattus norvegicus,N,1,955.0,
10488,Biodistribution of radiolabeled compound in rat brain after 30 min activity expressed as %ID/Organ,Intermediate,10116.0,,A,,BAO_0000218,17738,,,1,CHEMBL622050,,,Rattus norvegicus,N,1,955.0,
10489,Biodistribution of radiolabeled compound in rat brain after 5 min activity expressed as %ID/Organ,Intermediate,10116.0,,A,,BAO_0000218,17738,,,1,CHEMBL622051,,,Rattus norvegicus,N,1,955.0,
10490,Biodistribution of radiolabeled compound in rat fat after 24 hr activity expressed as %ID/Organ,Intermediate,10116.0,,A,,BAO_0000218,17738,,,1,CHEMBL622052,,,Rattus norvegicus,N,1,,
10491,Biodistribution of radiolabeled compound in rat fat after 2 hr activity expressed as %ID/Organ,Intermediate,10116.0,,A,,BAO_0000218,17738,,,1,CHEMBL622053,,,Rattus norvegicus,N,1,,
10492,Biodistribution of radiolabeled compound in rat fat after 30 min activity expressed as %ID/Organ,Intermediate,10116.0,,A,,BAO_0000218,17738,,,1,CHEMBL622054,,,Rattus norvegicus,N,1,,
10493,Biodistribution of radiolabeled compound in rat fat after 5 min activity expressed as %ID/Organ,Intermediate,10116.0,,A,,BAO_0000218,17738,,,1,CHEMBL622055,,,Rattus norvegicus,N,1,,
10494,Oral bioavailability in rats was determined; High,Intermediate,10116.0,,A,,BAO_0000218,5237,,,1,CHEMBL622056,,,Rattus norvegicus,N,1,,
10495,Oral bioavailability in the rat was determined,Intermediate,10116.0,,A,,BAO_0000218,5503,,,1,CHEMBL622057,,,Rattus norvegicus,N,1,,
10496,Oral bioavailability measured by the ratio of intravenous to oral area under concentration.,Intermediate,10116.0,,A,,BAO_0000218,15765,,,1,CHEMBL628008,,,Rattus norvegicus,N,1,,
10497,Oral bioavailability in rat (dose 10 mg/kg p.o. and 3 mg/kg i.v.),Intermediate,10116.0,,A,,BAO_0000218,15660,,,1,CHEMBL622058,,,Rattus norvegicus,N,1,,
10498,Oral bioavailability of compound (19.2 mg/kg) after po administration was determined in Sprague-Dawley rat,Intermediate,10116.0,,A,,BAO_0000218,5978,,,1,CHEMBL622059,,,Rattus norvegicus,N,1,,
10499,Oral bioavailability of compound (19.76 mg/kg) after po administration was determined in Sprague-Dawley rat,Intermediate,10116.0,,A,,BAO_0000218,5978,,,1,CHEMBL622060,,,Rattus norvegicus,N,1,,
10500,Oral bioavailability of compound (20.73 mg/kg) after po administration was determined in Sprague-Dawley rat,Intermediate,10116.0,,A,,BAO_0000218,5978,,,1,CHEMBL622061,,,Rattus norvegicus,N,1,,
10501,Oral bioavailability of compound (25 mg/kg) after po administration was determined in Sprague-Dawley rat,Intermediate,10116.0,,A,,BAO_0000218,5978,,,1,CHEMBL622062,,,Rattus norvegicus,N,1,,
10502,Oral bioavailability of compound at a dose of 20 mg/kg was determined after oral administration in rat,Intermediate,10116.0,,A,,BAO_0000218,5656,,,1,CHEMBL622063,,,Rattus norvegicus,N,1,,
10503,Oral bioavailability of compound determined in rat after iv administration at a dose of 10 mg/kg,Expert,10116.0,,A,,BAO_0000218,3598,,,1,CHEMBL877611,,,Rattus norvegicus,N,1,,
10504,Oral bioavailability of compound in Sprague Dawley rats,Intermediate,10116.0,,A,,BAO_0000218,4216,,,1,CHEMBL622064,,,Rattus norvegicus,N,1,,
10505,Oral bioavailability of compound in rat,Intermediate,10116.0,,A,,BAO_0000218,17839,,,1,CHEMBL622065,,,Rattus norvegicus,N,1,,
10506,Oral bioavailability in rat (dose 2 mg/kg),Intermediate,10116.0,,A,,BAO_0000218,6570,,,1,CHEMBL622066,,,Rattus norvegicus,N,1,,
10507,Oral bioavailability of compound in rat was determined,Intermediate,10116.0,,A,,BAO_0000218,5334,,,1,CHEMBL622067,,,Rattus norvegicus,N,1,,
10508,Oral bioavailability of compound in rats,Intermediate,10116.0,,A,,BAO_0000218,6886,,,1,CHEMBL622068,,,Rattus norvegicus,N,1,,
10509,Oral bioavailability of compound was determined in rats,Intermediate,10116.0,,A,,BAO_0000218,5210,,,1,CHEMBL622069,,,Rattus norvegicus,N,1,,
10510,Oral bioavailability at a dose of 30 mg/kg in rats,Intermediate,10116.0,,A,,BAO_0000218,4170,,,1,CHEMBL624796,,,Rattus norvegicus,N,1,,
10511,Oral bioavailability in rat (dose 10 mg/kg),Intermediate,10116.0,,A,,BAO_0000218,6028,,,1,CHEMBL624797,,,Rattus norvegicus,N,1,,
10512,Oral bioavailability in rat (dose 10 mg/kg),Intermediate,10116.0,,A,,BAO_0000218,6028,,,1,CHEMBL623053,,,Rattus norvegicus,N,1,,
10513,Oral bioavailability evaluated in rat,Intermediate,10116.0,,A,,BAO_0000218,6078,,,1,CHEMBL623054,,,Rattus norvegicus,N,1,,
10514,Oral bioavailability in fasted rat,Intermediate,10116.0,,A,,BAO_0000218,6168,,,1,CHEMBL623055,,,Rattus norvegicus,N,1,,
10515,Oral bioavailability in fed rat,Intermediate,10116.0,,A,,BAO_0000218,6168,,,1,CHEMBL623056,,,Rattus norvegicus,N,1,,
10516,Oral bioavailability in rat (mature male) (dose 30 mg/kg),Intermediate,10116.0,,A,,BAO_0000218,5160,,,1,CHEMBL623057,,,Rattus norvegicus,N,1,,
10517,Oral bioavailability in rat,Intermediate,10116.0,,A,,BAO_0000218,6057,,,1,CHEMBL623058,,,Rattus norvegicus,N,1,,
10518,Oral bioavailability in rat (dose 10 mg/kg p.o.),Intermediate,10116.0,,A,,BAO_0000218,6535,,,1,CHEMBL623059,,,Rattus norvegicus,N,1,,
10519,Oral bioavailability in rat after administration of 10 mg/kg po,Intermediate,10116.0,,A,,BAO_0000218,6535,,,1,CHEMBL623060,,,Rattus norvegicus,N,1,,
10520,Oral bioavailability in rat,Intermediate,10116.0,,A,,BAO_0000218,4194,,,1,CHEMBL623061,,,Rattus norvegicus,N,1,,
10521,Oral bioavailability in rat,Intermediate,10116.0,,A,,BAO_0000218,6230,,,1,CHEMBL623062,,,Rattus norvegicus,N,1,,
10522,Oral bioavailability in rat,Intermediate,10116.0,,A,,BAO_0000218,6619,,,1,CHEMBL623063,,,Rattus norvegicus,N,1,,
10523,Oral bioavailability in rat,Intermediate,10116.0,,A,,BAO_0000218,17607,,,1,CHEMBL623064,,,Rattus norvegicus,N,1,,
10524,Oral bioavailability in ratrs,Intermediate,10116.0,,A,,BAO_0000218,4942,,,1,CHEMBL623065,,,Rattus norvegicus,N,1,,
10525,Oral bioavailability in rat,Intermediate,10116.0,,A,,BAO_0000218,4942,,,1,CHEMBL623066,,,Rattus norvegicus,N,1,,
10526,Oral bioavailability in rat,Intermediate,10116.0,,A,,BAO_0000218,6646,,,1,CHEMBL623067,,,Rattus norvegicus,N,1,,
10527,Oral bioavailability in rats was determined; High,Intermediate,10116.0,,A,,BAO_0000218,5237,,,1,CHEMBL623068,,,Rattus norvegicus,N,1,,
10528,Oral bioavailability in rat,Intermediate,10116.0,,A,,BAO_0000218,6646,,,1,CHEMBL623069,,,Rattus norvegicus,N,1,,
10529,Oral bioavailability in rat,Intermediate,10116.0,,A,,BAO_0000218,4449,,,1,CHEMBL623070,,,Rattus norvegicus,N,1,,
10530,Oral bioavailability was calculated in rat,Intermediate,10116.0,,A,,BAO_0000218,6057,,,1,CHEMBL623071,,,Rattus norvegicus,N,1,,
10531,Oral bioavailability,Intermediate,10116.0,,A,,BAO_0000218,2552,,,1,CHEMBL623072,,,Rattus norvegicus,N,1,,
10532,Oral bioavailability,Intermediate,10116.0,,A,,BAO_0000218,5496,,,1,CHEMBL623073,,,Rattus norvegicus,N,1,,
10533,Oral bioavailability,Intermediate,10116.0,,A,,BAO_0000218,6484,,,1,CHEMBL623074,,,Rattus norvegicus,N,1,,
10534,Oral bioavailability,Intermediate,10116.0,,A,,BAO_0000218,6485,,,1,CHEMBL623075,,,Rattus norvegicus,N,1,,
10535,Oral bioavailability after i.v. administration,Intermediate,10116.0,,A,,BAO_0000218,6616,,,1,CHEMBL623076,,,Rattus norvegicus,N,1,,
10536,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),Intermediate,10116.0,,A,,BAO_0000218,4969,,,1,CHEMBL623077,,,Rattus norvegicus,N,1,,
10537,Oral bioavailability in rat (Sprague-Dawley),Intermediate,10116.0,,A,,BAO_0000218,5862,,,1,CHEMBL623078,,,Rattus norvegicus,N,1,,
10538,Oral bioavailability in Sprague-Dawley rats,Intermediate,10116.0,,A,,BAO_0000218,4514,,,1,CHEMBL623079,,,Rattus norvegicus,N,1,,
10539,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),Intermediate,10116.0,,A,,BAO_0000218,4514,,,1,CHEMBL623080,,,Rattus norvegicus,N,1,,
10540,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg),Intermediate,10116.0,,A,,BAO_0000218,4514,,,1,CHEMBL623081,,,Rattus norvegicus,N,1,,
10541,Oral bioavailability in Sprague-Dawley rats at a dose of 2 mg/kg by po administration,Intermediate,10116.0,,A,,BAO_0000218,5546,,,1,CHEMBL623082,,,Rattus norvegicus,N,1,,
10542,Oral bioavailability in fasted rat,Intermediate,10116.0,,A,,BAO_0000218,6168,,,1,CHEMBL874400,,,Rattus norvegicus,N,1,,
10543,Oral bioavailability in fed rat,Intermediate,10116.0,,A,,BAO_0000218,6168,,,1,CHEMBL623083,,,Rattus norvegicus,N,1,,
10544,Oral bioavailability in rat,Intermediate,10116.0,,A,,BAO_0000218,3624,,,1,CHEMBL623084,,,Rattus norvegicus,N,1,,
10545,Oral bioavailability in rat,Intermediate,10116.0,,A,,BAO_0000218,5213,,,1,CHEMBL623085,,,Rattus norvegicus,N,1,,
10546,Oral bioavailability in rat,Intermediate,10116.0,,A,,BAO_0000218,5496,,,1,CHEMBL623086,,,Rattus norvegicus,N,1,,
10547,Oral bioavailability in rat,Intermediate,10116.0,,A,,BAO_0000218,5553,,,1,CHEMBL623087,,,Rattus norvegicus,N,1,,
10548,Oral bioavailability in rat,Intermediate,10116.0,,A,,BAO_0000218,5833,,,1,CHEMBL623088,,,Rattus norvegicus,N,1,,
10549,Oral bioavailability in rat,Intermediate,10116.0,,A,,BAO_0000218,5836,,,1,CHEMBL623089,,,Rattus norvegicus,N,1,,
10550,Oral bioavailability in rat,Intermediate,10116.0,,A,,BAO_0000218,5865,,,1,CHEMBL623090,,,Rattus norvegicus,N,1,,
10551,Oral bioavailability in rat,Intermediate,10116.0,,A,,BAO_0000218,5960,,,1,CHEMBL623091,,,Rattus norvegicus,N,1,,
10552,Oral bioavailability in rat,Intermediate,10116.0,,A,,BAO_0000218,6249,,,1,CHEMBL623092,,,Rattus norvegicus,N,1,,
10553,Oral bioavailability in rat,Intermediate,10116.0,,A,,BAO_0000218,6448,,,1,CHEMBL623093,,,Rattus norvegicus,N,1,,
10554,Oral bioavailability in rat,Intermediate,10116.0,,A,,BAO_0000218,6453,,,1,CHEMBL874401,,,Rattus norvegicus,N,1,,
10555,Oral bioavailability in rat,Intermediate,10116.0,,A,,BAO_0000218,6640,,,1,CHEMBL623094,,,Rattus norvegicus,N,1,,
10556,Oral bioavailability in rat,Intermediate,10116.0,,A,,BAO_0000218,17607,,,1,CHEMBL623095,,,Rattus norvegicus,N,1,,
10557,Oral bioavailability in rat after peroral administration at 10 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,5939,,,1,CHEMBL623096,,,Rattus norvegicus,N,1,,
10558,Oral bioavailability in rat after peroral administration at 5 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,5939,,,1,CHEMBL624913,,,Rattus norvegicus,N,1,,
10559,Oral bioavailability in rat (dose 2.8 mg/kg p.o.),Intermediate,10116.0,,A,,BAO_0000218,6281,,,1,CHEMBL624914,,,Rattus norvegicus,N,1,,
10560,Oral bioavailability in rat by po administration at a dose of 40 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,5874,,,1,CHEMBL624915,,,Rattus norvegicus,N,1,,
10561,Oral bioavailability in rat; Not measured,Intermediate,10116.0,,A,,BAO_0000218,5213,,,1,CHEMBL624916,,,Rattus norvegicus,N,1,,
10562,Oral bioavailability in rat,Intermediate,10116.0,,A,,BAO_0000218,4964,,,1,CHEMBL624917,,,Rattus norvegicus,N,1,,
10563,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus NE,Intermediate,10116.0,,A,,BAO_0000218,11020,,,1,CHEMBL625157,,,Rattus norvegicus,N,1,,
10564,In vitro metabolic potential in rat liver microsomes,Intermediate,10116.0,,A,,BAO_0000218,6251,,,1,CHEMBL625158,,,Rattus norvegicus,N,1,2107.0,
10565,"Oral availability was tested for plasma levels at a dose of 40 mg/kg, after 6 hr of in fed fisher rats.",Intermediate,10116.0,,A,,BAO_0000218,1568,,,1,CHEMBL625159,,,Rattus norvegicus,N,1,,
10566,"In vivo percentage mean absolute bioavailability of compound in rat after an oral dose of 10 mg/kg (in water, N=4)",Intermediate,10116.0,,A,,BAO_0000218,3032,,,1,CHEMBL625160,,,Rattus norvegicus,N,1,,
10567,Oral bioavailability of intravenously administered compound (3 mg/kg) was tested in rats,Intermediate,10116.0,,A,,BAO_0000218,3748,,,1,CHEMBL625161,,,Rattus norvegicus,N,1,,
10568,Oral bioavailability in rat,Intermediate,10116.0,,A,,BAO_0000218,401,,,1,CHEMBL625162,,,Rattus norvegicus,N,1,,
10569,Oral bioavailability in rat,Intermediate,10116.0,,A,,BAO_0000218,6512,,,1,CHEMBL625163,,,Rattus norvegicus,N,1,,
10570,Oral bioavailability in rats at 10 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,17617,,,1,CHEMBL625164,,,Rattus norvegicus,N,1,,
10571,Oral bioavailability was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,Intermediate,10116.0,,A,,BAO_0000218,6679,,,1,CHEMBL625165,,,Rattus norvegicus,N,1,,
10572,Oral bioavailability in rat,Intermediate,10116.0,,A,,BAO_0000218,6742,,,1,CHEMBL625166,,,Rattus norvegicus,N,1,,
10573,Tested for effective permeability across the rat intestinal membrane using mass balance analysis,Intermediate,10116.0,,A,,BAO_0000218,589,,,1,CHEMBL625167,,,Rattus norvegicus,N,1,,
10574,Tested for effective permeability across the rat intestinal membrane using mass balance analysis at 0.01 mM concentration,Intermediate,10116.0,,A,,BAO_0000218,589,,,1,CHEMBL625168,,,Rattus norvegicus,N,1,,
10575,Plasma clearance of the compound,Intermediate,10116.0,,A,,BAO_0000218,3185,,,1,CHEMBL625169,,,Rattus norvegicus,N,1,,
10576,Plasma clearance at 10 mg/kg in rat upon intravenous administration,Intermediate,10116.0,,A,,BAO_0000218,17596,,,1,CHEMBL626264,,,Rattus norvegicus,N,1,,
10577,Plasma clearance upon intravenous administration of 1 mg/Kg in rats,Intermediate,10116.0,,A,,BAO_0000218,2713,,,1,CHEMBL626265,,,Rattus norvegicus,N,1,,
10578,The compound was tested for plasma clearance in rat,Intermediate,10116.0,,A,,BAO_0000218,12500,,,1,CHEMBL626266,,,Rattus norvegicus,N,1,1969.0,
10579,The compound was tested for plasma clearance in rat at dose of 3-10 mgkg,Intermediate,10116.0,,A,,BAO_0000218,12500,,,1,CHEMBL626267,,,Rattus norvegicus,N,1,1969.0,
10580,Plasma concentration upon oral administration of 1 mg/Kg in rats,Intermediate,10116.0,,A,,BAO_0000218,2713,,,1,CHEMBL626268,,,Rattus norvegicus,N,1,,
10581,Peak plasma level between 0.5 and 1.0 hour in Dawley rats; value ranges from 1021-2551,Intermediate,10116.0,,A,,BAO_0000218,1446,,,1,CHEMBL626269,,,Rattus norvegicus,N,1,,
10582,Plasma level after intravenous administration in rat model of FeCl3-induced carotid thrombosis,Intermediate,10116.0,,A,,BAO_0000218,6227,,,1,CHEMBL626270,,,Rattus norvegicus,N,1,,
10583,Plasma protein binding was determined after intravenous administration of 1 mg/kg in rat,Intermediate,10116.0,,A,,BAO_0000218,4709,,,1,CHEMBL626271,,,Rattus norvegicus,N,1,,
10584,"Rat plasma cleavage data expressed as percentage of compound remains at 24 hr in PEG400/Water, 1:1",Intermediate,10116.0,,A,,BAO_0000218,5510,,,1,CHEMBL626272,,,Rattus norvegicus,N,1,,
10585,"Rat plasma cleavage data expressed as percentage of compound remains at 24 hr in PEG400/Water, 1:1; Not determined",Intermediate,10116.0,,A,,BAO_0000218,5510,,,1,CHEMBL626273,,,Rattus norvegicus,N,1,,
10586,"Rat plasma cleavage data expressed as percentage of compound remains at 24 hr in PEG400/Water, 1:1; Not determined",Intermediate,10116.0,,A,,BAO_0000218,5510,,,1,CHEMBL875346,,,Rattus norvegicus,N,1,,
10587,"Rat plasma cleavage data expressed as percentage of compound remains at 24 hr in PEG400/Water, 1:1; Not stable",Intermediate,10116.0,,A,,BAO_0000218,5510,,,1,CHEMBL626274,,,Rattus norvegicus,N,1,,
10588,Compound was tested for protein binding in rat plasma,Intermediate,10116.0,,A,,BAO_0000218,4514,,,1,CHEMBL626275,,,Rattus norvegicus,N,1,,
10589,Compound was evaluated for absorption of radioligand following oral administration to bile duct cannulated rat. ,Intermediate,10116.0,,A,,BAO_0000218,2713,,,1,CHEMBL624646,,,Rattus norvegicus,N,1,,
10590,Compound was evaluated for absorption of radioligand upon oral administration to bile duct cannulated rats,Intermediate,10116.0,,A,,BAO_0000218,2713,,,1,CHEMBL624647,,,Rattus norvegicus,N,1,,
10591,In vitro metabolism in rat liver microsomes was evaluated to determine diminishing of glucuronidation rate,Intermediate,10116.0,,A,,BAO_0000218,5340,,,1,CHEMBL624648,,,Rattus norvegicus,N,1,2107.0,
10592,Area under curve ratio was determined (po/iv) in rat,Intermediate,10116.0,,A,,BAO_0000218,12058,,,1,CHEMBL624649,,,Rattus norvegicus,N,1,,
10593,Blood by brain ratio of the radiolabeled compound (2-5 uCi) in rat 15 mins after i.v. administration,Intermediate,10116.0,,A,,BAO_0000218,11195,,,1,CHEMBL624650,,,Rattus norvegicus,N,1,,
10594,Blood by brain ratio of the radiolabeled compound (2-5 uCi) in rat 2 mins after i.v. administration,Intermediate,10116.0,,A,,BAO_0000218,11195,,,1,CHEMBL624651,,,Rattus norvegicus,N,1,,
10595,Blood by brain ratio of the radiolabeled compound (2-5 uCi) in rat 65 mins after i.v. administration,Intermediate,10116.0,,A,,BAO_0000218,11195,,,1,CHEMBL624652,,,Rattus norvegicus,N,1,,
10596,Compound was tested for brain/plasma ratio after oral administration at 10 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,6495,,,1,CHEMBL624653,,,Rattus norvegicus,N,1,,
10597,Ratio of AUCbrain to AUCplasma,Intermediate,10116.0,,A,,BAO_0000218,6078,,,1,CHEMBL624654,,,Rattus norvegicus,N,1,,
10598,Ratio of brain to plasma,Intermediate,10116.0,,A,,BAO_0000218,5656,,,1,CHEMBL624655,,,Rattus norvegicus,N,1,,
10599,Ratio of the AUC values of brain and plasma after intravenous administration (4.7 mg/kg) to male rats was evaluated,Intermediate,10116.0,,A,,BAO_0000218,4910,,,1,CHEMBL624656,,,Rattus norvegicus,N,1,,
10600,Ratio in brain and plasma after 0.25 hrs of intravenous administration (5 mg/kg) to male rats was evaluated,Intermediate,10116.0,,A,,BAO_0000218,4910,,,1,CHEMBL624657,,,Rattus norvegicus,N,1,,
10601,Ratio in brain and plasma after 2 hrs of intravenous administration (5 mg/kg) to male rats was evaluated,Intermediate,10116.0,,A,,BAO_0000218,4910,,,1,CHEMBL624658,,,Rattus norvegicus,N,1,,
10602,Selectivity ratio for biodistribution in brain and blood of rats after 15 minutes; Expressed as percent dose/gram ratio,Intermediate,10116.0,,A,,BAO_0000218,10130,,,1,CHEMBL624659,,,Rattus norvegicus,N,1,,
10603,Selectivity ratio for biodistribution in brain and blood of rats after 2 minutes; Expressed as percent dose/gram ratio,Intermediate,10116.0,,A,,BAO_0000218,10130,,,1,CHEMBL624660,,,Rattus norvegicus,N,1,,
10604,Selectivity ratio for biodistribution in brain and blood of rats after 60 minutes; Expressed as percent dose/gram ratio,Intermediate,10116.0,,A,,BAO_0000218,10130,,,1,CHEMBL624661,,,Rattus norvegicus,N,1,,
10605,Steady state brain :blood ratio was determined,Intermediate,10116.0,,A,,BAO_0000218,5213,,,1,CHEMBL624662,,,Rattus norvegicus,N,1,,
10606,Tested for ratio in brain and plasma after 0.25 hrs of intravenous administration (5 mg/kg) to male rats,Intermediate,10116.0,,A,,BAO_0000218,4910,,,1,CHEMBL625199,,,Rattus norvegicus,N,1,,
10607,Tested for ratio in brain and plasma after 0.25 hrs of intravenous administration (5 mg/kg) to male rats; ND = not determined,Intermediate,10116.0,,A,,BAO_0000218,4910,,,1,CHEMBL625200,,,Rattus norvegicus,N,1,,
10608,Tested for ratio in brain and plasma after 2 hrs of intravenous administration (5 mg/kg) to male rats,Intermediate,10116.0,,A,,BAO_0000218,4910,,,1,CHEMBL625201,,,Rattus norvegicus,N,1,,
10609,Tested for ratio in brain and plasma after 2 hrs of intravenous administration (5 mg/kg) to male rats; ND = not determined,Intermediate,10116.0,,A,,BAO_0000218,4910,,,1,CHEMBL625202,,,Rattus norvegicus,N,1,,
10610,Percentage recovery after 3h incubation with rat hapatocytes was determined,Intermediate,10116.0,,A,,BAO_0000218,2083,,,1,CHEMBL625203,,,Rattus norvegicus,N,1,,
10611,Percentage recovery in rat hepatic microsomal fractions under oxidative conditions after 1 hour,Intermediate,10116.0,,A,,BAO_0000218,2082,,,1,CHEMBL625204,,,Rattus norvegicus,N,1,,
10612,Percentage recovery in rhesus monkey hepatic microsomal fractions under oxidative conditions after 1 hour,Intermediate,10116.0,,A,,BAO_0000218,2082,,,1,CHEMBL625205,,,Rattus norvegicus,N,1,,
10613,Recovery rate from urine and bile was determined after iv administration at 20 mg/kg in rats,Intermediate,10116.0,,A,,BAO_0000218,6351,,,1,CHEMBL625206,,,Rattus norvegicus,N,1,,
10614,"Fraction of 88Y (%) released from chelate after incubation in serum for 15 hours; not measured, No site available for protein conjugation.",Autocuration,,,A,,BAO_0000019,14583,,,1,CHEMBL625207,,,,U,0,,
10615,Fraction of 88Y (%) released from chelate after incubation in serum for 15 hours; not measured.,Autocuration,,,A,,BAO_0000019,14583,,,1,CHEMBL625208,,,,U,0,,
10616,In vivo absorption in Caco-2 cell line monolayers was determined,Intermediate,9606.0,,A,,BAO_0000218,4608,,495.0,1,CHEMBL625209,Caco-2,,Homo sapiens,N,1,,
10617,Calculated partition coefficient (clogP),Autocuration,,,P,,BAO_0000100,13668,,,1,CHEMBL625210,,,,U,0,,
10618,Area under curve was determine after peroral administration at 10 mpk in Rat,Intermediate,10116.0,,A,,BAO_0000218,5669,,,1,CHEMBL625211,,,Rattus norvegicus,N,1,,
10619,Area under curve was determine after peroral administration at 10 mpk in Rhesus,Intermediate,9544.0,,A,,BAO_0000218,5669,,,1,CHEMBL625212,,,Macaca mulatta,N,1,,
10620,Area under curve was determine after peroral administration at 160 mpk in Rat,Intermediate,10116.0,,A,,BAO_0000218,5669,,,1,CHEMBL625213,,,Rattus norvegicus,N,1,,
10621,Area under curve was determine after peroral administration at 20 mpk in Rat,Intermediate,10116.0,,A,,BAO_0000218,5669,,,1,CHEMBL625214,,,Rattus norvegicus,N,1,,
10622,Area under curve was determine after peroral administration at 50 mpk in Rat,Intermediate,10116.0,,A,,BAO_0000218,5669,,,1,CHEMBL874542,,,Rattus norvegicus,N,1,,
10623,Calculated partition coefficient (clogP) (AlogP),Autocuration,,,P,,BAO_0000100,6472,,,1,CHEMBL625215,,,,U,0,,
10624,Activated partial thromboplastin time measured,Autocuration,,,A,,BAO_0000019,15106,,,1,CHEMBL625216,,,,U,0,,
10625,Compound was evaluated for the aqueous solubility (AS) in mg/mL (Measured in 0.2 M phosphate buffer of pH 7.4),Autocuration,,,P,,BAO_0000100,15207,,,1,CHEMBL625217,,,,U,0,,
10626,Compound was evaluated for the aqueous solubility (AS) in mg/mL (Measured in 0.2 M phosphate buffer of pH 7.4); ND=Not determined (AS mg/mL),Autocuration,,,P,,BAO_0000100,15207,,,1,CHEMBL625218,,,,U,0,,
10627,AUC (Area under curve) was determined after intravenous administration at a dose 1 mg/kg in dog,Intermediate,9615.0,,A,,BAO_0000218,13941,,,1,CHEMBL622864,,,Canis lupus familiaris,N,1,1969.0,
10628,AUC (Area under curve) was determined after intravenous administration at a dose 2 mg/kg in rat.,Intermediate,10116.0,,A,,BAO_0000218,13941,,,1,CHEMBL622865,,,Rattus norvegicus,N,1,1969.0,
10629,AUC (Area under curve) was determined after peroral administration at a dose 10 mg/kg in rat.,Intermediate,10116.0,,A,,BAO_0000218,13941,,,1,CHEMBL622866,,,Rattus norvegicus,N,1,1969.0,
10630,AUC (Area under curve) was determined after peroral administration at a dose 5 mg/kg in dog,Intermediate,9615.0,,A,,BAO_0000218,13941,,,1,CHEMBL622867,,,Canis lupus familiaris,N,1,1969.0,
10631,AUC (ng h/mL) value after oral administration of 10 mg/kg in guinea pig.,Intermediate,10141.0,,A,,BAO_0000218,15240,,,1,CHEMBL876808,,,Cavia porcellus,N,1,1969.0,
10632,AUC in brain,Autocuration,,,A,,BAO_0000019,10655,,,1,CHEMBL627725,,,,U,0,955.0,
10633,AUC in serum,Autocuration,,,A,,BAO_0000019,10655,,,1,CHEMBL627726,,,,U,0,1977.0,
10634,AUC was determined,Autocuration,,,A,,BAO_0000019,6504,,,1,CHEMBL627727,,,,U,0,1969.0,
10635,AUC of the compound.,Autocuration,,,A,,BAO_0000019,10615,,,1,CHEMBL627728,,,,U,0,1969.0,
10636,AUC value (0-4 hr),Autocuration,,,A,,BAO_0000019,10353,,,1,CHEMBL627729,,,,U,0,1969.0,
10637,"AUC was measured from the graph plotted against blood plasma concentration and time at the dose of 150 uMol/kg,",Autocuration,,,A,,BAO_0000019,14907,,,1,CHEMBL627730,,,,U,0,1969.0,
10638,AUC was measured from the graph plotted against blood plasma concentration and time at the dose of 300 uMol/kg,Autocuration,,,A,,BAO_0000019,14907,,,1,CHEMBL627731,,,,U,0,1969.0,
10639,"AUC was measured from the graph plotted against blood plasma concentration and time at the dose of 300 uMol/kg,",Autocuration,,,A,,BAO_0000019,14907,,,1,CHEMBL627732,,,,U,0,1969.0,
10640,"AUC was measured from the graph plotted against blood plasma concentration and time at the dose of 700 uMol/kg,",Autocuration,,,A,,BAO_0000019,14907,,,1,CHEMBL627733,,,,U,0,1969.0,
10641,AUC(area under curve) was determined after intravenous administration in rats,Intermediate,10116.0,,A,,BAO_0000218,16359,,,1,CHEMBL627734,,,Rattus norvegicus,N,1,1969.0,
10642,AUC(area under curve) was determined after oral administration in rats,Intermediate,10116.0,,A,,BAO_0000218,16359,,,1,CHEMBL627735,,,Rattus norvegicus,N,1,1969.0,
10643,AUC(ng h/mL)values after oral administration of 10 mg/kg in guinea pig.,Intermediate,10141.0,,A,,BAO_0000218,15240,,,1,CHEMBL627736,,,Cavia porcellus,N,1,1969.0,
10644,AUC(ng h/mL)values after oral administration of 10 mg/kg in rat.,Intermediate,10116.0,,A,,BAO_0000218,15240,,,1,CHEMBL876809,,,Rattus norvegicus,N,1,1969.0,
10645,Area Under Curve after oral dosing of 100 uM/Kg,Autocuration,,,A,,BAO_0000019,15469,,,1,CHEMBL627737,,,,U,0,,
10646,Area Under Curve after oral dosing of 30 uM/Kg,Autocuration,,,A,,BAO_0000019,15469,,,1,CHEMBL627738,,,,U,0,,
10647,Area Under Curve was measured by ploting the graph between concentration verses time,Autocuration,,,A,,BAO_0000019,13520,,,1,CHEMBL627739,,,,U,0,,
10648,Area under concentration-time curve of compound was determined in dog at 25 mg/kg orally,Intermediate,9615.0,,A,,BAO_0000218,17025,,,1,CHEMBL626143,,,Canis lupus familiaris,N,1,,
10649,Area under concentration-time curve of compound was determined in monkey at 25 mg/kg orally,Autocuration,314293.0,,A,,BAO_0000218,17025,,,1,CHEMBL626144,,,Simiiformes,U,0,,
10650,Area under concentration-time curve of compound was determined in rabbit at 25 mg/kg orally,Intermediate,9986.0,,A,,BAO_0000218,17025,,,1,CHEMBL626145,,,Oryctolagus cuniculus,N,1,,
10651,Area under concentration-time curve of compound was determined in rat at 25 mg/kg orally,Intermediate,10116.0,,A,,BAO_0000218,17025,,,1,CHEMBL626146,,,Rattus norvegicus,N,1,,
10652,Area under curve (AUC) is the drug concentrations in blood samples of rats with arterial catheters at 5 min and 12 hr plotted against time,Intermediate,10116.0,,A,,BAO_0000218,12032,,,1,CHEMBL626147,,,Rattus norvegicus,N,1,178.0,
10653,Area under curve (AUC) was determined,Autocuration,,,A,,BAO_0000019,10291,,,1,CHEMBL626148,,,,U,0,,
10654,Area under curve (AUC) following ip administration at 1 mg/kg,Autocuration,,,A,,BAO_0000218,5767,,,1,CHEMBL626149,,,,U,0,,
10655,Area under curve (AUC) was determined; ND is Not determined,Autocuration,,,A,,BAO_0000019,1434,,,1,CHEMBL626150,,,,U,0,,
10656,Area under curve (AUC) was determined in dogs fed after intravenous administration of 25 mg/kg of the compound,Intermediate,9615.0,,A,,BAO_0000218,14925,,,1,CHEMBL626151,,,Canis lupus familiaris,N,1,,
10657,Area under curve (AUC) was determined in dogs fed after oral administration of 25 mg/kg of the compound,Intermediate,9615.0,,A,,BAO_0000218,14925,,,1,CHEMBL626152,,,Canis lupus familiaris,N,1,,
10658,Area under curve (AUC) was determined in fasted dogs after oral administration of 25 mg/kg of the compound,Intermediate,9615.0,,A,,BAO_0000218,14925,,,1,CHEMBL626153,,,Canis lupus familiaris,N,1,,
10659,Area under curve (AUR) was determined,Autocuration,,,A,,BAO_0000019,1434,,,1,CHEMBL626154,,,,U,0,,
10660,Area under curve at 1 uM/dg administered intravenously,Autocuration,,,A,,BAO_0000019,11883,,,1,CHEMBL626155,,,,U,0,,
10661,Area under curve at 10 uM/dg administered perorally,Autocuration,,,A,,BAO_0000019,11883,,,1,CHEMBL626156,,,,U,0,,
10662,Area under curve at 2 uM/dg administered intravenously,Autocuration,,,A,,BAO_0000019,11883,,,1,CHEMBL626157,,,,U,0,,
10663,Area under curve at 20 uM/dg administered perorally,Autocuration,,,A,,BAO_0000019,11883,,,1,CHEMBL626158,,,,U,0,,
10664,Area under curve at a peroral dose of 3 mg/kg in dog,Intermediate,9615.0,,A,,BAO_0000218,15233,,,1,CHEMBL626159,,,Canis lupus familiaris,N,1,,
10665,Area under curve at a peroral dose of 3 mg/kg in rat,Intermediate,10116.0,,A,,BAO_0000218,15233,,,1,CHEMBL626160,,,Rattus norvegicus,N,1,,
10666,Area under curve at an iv dose of 1 mg/kg in dog,Intermediate,9615.0,,A,,BAO_0000218,15233,,,1,CHEMBL626161,,,Canis lupus familiaris,N,1,,
10667,Area under curve at an iv dose of 1 mg/kg in rat,Intermediate,10116.0,,A,,BAO_0000218,15233,,,1,CHEMBL626162,,,Rattus norvegicus,N,1,,
10668,Area under curve gives the effective duration for the angiotensin II antagonist effect of the compound.,Autocuration,,,A,,BAO_0000019,12978,,,1,CHEMBL626163,,,,U,0,,
10669,Area under curve gives the effective duration for the angiotensin II antagonist effect.,Autocuration,,,A,,BAO_0000019,12978,,,1,CHEMBL626164,,,,U,0,,
10670,Area under curve measured as conc vs time after intravenous administration to mice.,Intermediate,10090.0,,A,,BAO_0000218,11355,,,1,CHEMBL626165,,,Mus musculus,N,1,,
10671,Area under curve measured as conc vs time after peroral administration to mice.,Intermediate,10090.0,,A,,BAO_0000218,11355,,,1,CHEMBL626166,,,Mus musculus,N,1,,
10672,Area under curve of acid 2a was determined by HPLC at a dosage of 2.27 mg/kg administered intravenously by bolus method in dog,Intermediate,9615.0,,A,,BAO_0000218,12923,,,1,CHEMBL626167,,,Canis lupus familiaris,N,1,,
10673,Area under curve of acid 2a was determined by HPLC at a dosage of 5.45 mg/kg administered intragastrically by capsule method in dog,Intermediate,9615.0,,A,,BAO_0000218,12923,,,1,CHEMBL626168,,,Canis lupus familiaris,N,1,,
10674,Area under curve of acid 2a was determined by HPLC at a dosage of 5.45 mg/kg administered intragastrically by gavage method in dog,Intermediate,9615.0,,A,,BAO_0000218,12923,,,1,CHEMBL877463,,,Canis lupus familiaris,N,1,,
10675,Area under curve of acid 2a was determined by HPLC at a dosage of 54.5 mg/kg administered intragastrically by capsule method in dog,Intermediate,9615.0,,A,,BAO_0000218,12923,,,1,CHEMBL626169,,,Canis lupus familiaris,N,1,,
10676,Biodistribution of radiolabeled compound in rat heart after 24 hr activity expressed as %ID/Organ,Intermediate,10116.0,,A,,BAO_0000218,17738,,,1,CHEMBL626170,,,Rattus norvegicus,N,1,948.0,
10677,Biodistribution of radiolabeled compound in rat heart after 2 hr activity expressed as %ID/Organ,Intermediate,10116.0,,A,,BAO_0000218,17738,,,1,CHEMBL626171,,,Rattus norvegicus,N,1,948.0,
10678,Biodistribution of radiolabeled compound in rat heart after 30 min activity expressed as %ID/Organ,Intermediate,10116.0,,A,,BAO_0000218,17738,,,1,CHEMBL626172,,,Rattus norvegicus,N,1,948.0,
10679,Biodistribution of radiolabeled compound in rat heart after 5 min activity expressed as %ID/Organ,Intermediate,10116.0,,A,,BAO_0000218,17738,,,1,CHEMBL626173,,,Rattus norvegicus,N,1,948.0,
10680,Biodistribution of radiolabeled compound in rat kidney after 24 hr postinjection activity expressed as %ID/Organ,Intermediate,10116.0,,A,,BAO_0000218,17738,,,1,CHEMBL626174,,,Rattus norvegicus,N,1,2113.0,
10681,Biodistribution of radiolabeled compound in rat kidney after 24 hr activity expressed as %ID/Organ,Intermediate,10116.0,,A,,BAO_0000218,17738,,,1,CHEMBL626175,,,Rattus norvegicus,N,1,2113.0,
10682,Biodistribution of radiolabeled compound in rat kidney after 2 hr activity expressed as %ID/Organ,Intermediate,10116.0,,A,,BAO_0000218,17738,,,1,CHEMBL626176,,,Rattus norvegicus,N,1,2113.0,
10683,Biodistribution of radiolabeled compound in rat kidney after 30 min activity expressed as %ID/Organ,Intermediate,10116.0,,A,,BAO_0000218,17738,,,1,CHEMBL626177,,,Rattus norvegicus,N,1,2113.0,
10684,Biodistribution of radiolabeled compound in rat kidney after 5 min activity expressed as %ID/Organ,Intermediate,10116.0,,A,,BAO_0000218,17738,,,1,CHEMBL622499,,,Rattus norvegicus,N,1,2113.0,
10685,Biodistribution of radiolabeled compound in rat liver after 24 hr postinjection activity expressed as %ID/Organ,Intermediate,10116.0,,A,,BAO_0000218,17738,,,1,CHEMBL622500,,,Rattus norvegicus,N,1,2107.0,
10686,Biodistribution of radiolabeled compound in rat liver after 24 hr activity expressed as %ID/Organ,Intermediate,10116.0,,A,,BAO_0000218,17738,,,1,CHEMBL622501,,,Rattus norvegicus,N,1,2107.0,
10687,Biodistribution of radiolabeled compound in rat liver after 2 hr activity expressed as %ID/Organ,Intermediate,10116.0,,A,,BAO_0000218,17738,,,1,CHEMBL622502,,,Rattus norvegicus,N,1,2107.0,
10688,Biodistribution of radiolabeled compound in rat liver after 30 min activity expressed as %ID/Organ,Intermediate,10116.0,,A,,BAO_0000218,17738,,,1,CHEMBL622503,,,Rattus norvegicus,N,1,2107.0,
10689,Biodistribution of radiolabeled compound in rat liver after 5 min activity expressed as %ID/Organ,Intermediate,10116.0,,A,,BAO_0000218,17738,,,1,CHEMBL877614,,,Rattus norvegicus,N,1,2107.0,
10690,Biodistribution of radiolabeled compound in rat lung after 24 hr activity expressed as %ID/Organ,Intermediate,10116.0,,A,,BAO_0000218,17738,,,1,CHEMBL624839,,,Rattus norvegicus,N,1,2048.0,
10691,Biodistribution of radiolabeled compound in rat lung after 2 hr activity expressed as %ID/Organ,Intermediate,10116.0,,A,,BAO_0000218,17738,,,1,CHEMBL624840,,,Rattus norvegicus,N,1,2048.0,
10692,Biodistribution of radiolabeled compound in rat lung after 30 min activity expressed as %ID/Organ,Intermediate,10116.0,,A,,BAO_0000218,17738,,,1,CHEMBL624841,,,Rattus norvegicus,N,1,2048.0,
10693,Biodistribution of radiolabeled compound in rat lung after 5 min activity expressed as %ID/Organ,Intermediate,10116.0,,A,,BAO_0000218,17738,,,1,CHEMBL624842,,,Rattus norvegicus,N,1,2048.0,
10694,Biodistribution of radiolabeled compound in rat muscle after 24 hr activity expressed as %ID/Organ,Intermediate,10116.0,,A,,BAO_0000218,17738,,,1,CHEMBL624843,,,Rattus norvegicus,N,1,2385.0,
10695,Biodistribution of radiolabeled compound in rat muscle after 2 hr activity expressed as %ID/Organ,Intermediate,10116.0,,A,,BAO_0000218,17738,,,1,CHEMBL624844,,,Rattus norvegicus,N,1,2385.0,
10696,Biodistribution of radiolabeled compound in rat muscle after 30 min activity expressed as %ID/Organ,Intermediate,10116.0,,A,,BAO_0000218,17738,,,1,CHEMBL624845,,,Rattus norvegicus,N,1,2385.0,
10697,Biodistribution of radiolabeled compound in rat muscle after 5 min activity expressed as %ID/Organ,Intermediate,10116.0,,A,,BAO_0000218,17738,,,1,CHEMBL621904,,,Rattus norvegicus,N,1,2385.0,
10698,Biodistribution of the radiolabeled compound (2-5 uCi) in rat blood 15 mins after i.v. administration,Intermediate,10116.0,,A,,BAO_0000218,11195,,,1,CHEMBL621905,,,Rattus norvegicus,N,1,178.0,
10699,Biodistribution of the radiolabeled compound (2-5 uCi) in rat blood 2 mins after i.v. administration,Intermediate,10116.0,,A,,BAO_0000218,11195,,,1,CHEMBL874382,,,Rattus norvegicus,N,1,178.0,
10700,Biodistribution of the radiolabeled compound (2-5 uCi) in rat blood 65 mins after i.v. administration,Intermediate,10116.0,,A,,BAO_0000218,11195,,,1,CHEMBL621906,,,Rattus norvegicus,N,1,178.0,
10701,Biodistribution of the radiolabeled compound (2-5 uCi) in rat brain 15 mins after i.v. administration,Intermediate,10116.0,,A,,BAO_0000218,11195,,,1,CHEMBL621907,,,Rattus norvegicus,N,1,955.0,
10702,Biodistribution of the radiolabeled compound (2-5 uCi) in rat brain 2 mins after i.v. administration,Intermediate,10116.0,,A,,BAO_0000218,11195,,,1,CHEMBL622096,,,Rattus norvegicus,N,1,955.0,
10703,Biodistribution of the radiolabeled compound (2-5 uCi) in rat brain 65 mins after i.v. administration,Intermediate,10116.0,,A,,BAO_0000218,11195,,,1,CHEMBL622097,,,Rattus norvegicus,N,1,955.0,
10704,Biodistribution of the radiolabeled compound (2-5 uCi) in rat heart 15 mins after i.v. administration,Intermediate,10116.0,,A,,BAO_0000218,11195,,,1,CHEMBL622098,,,Rattus norvegicus,N,1,948.0,
10705,Biodistribution of the radiolabeled compound (2-5 uCi) in rat heart 2 mins after i.v. administration,Intermediate,10116.0,,A,,BAO_0000218,11195,,,1,CHEMBL622099,,,Rattus norvegicus,N,1,948.0,
10706,Biodistribution of the radiolabeled compound (2-5 uCi) in rat heart 65 mins after i.v. administration,Intermediate,10116.0,,A,,BAO_0000218,11195,,,1,CHEMBL622100,,,Rattus norvegicus,N,1,948.0,
10707,Biodistribution of the radiolabeled compound (2-5 uCi) in rat kidney 15 mins after i.v. administration,Intermediate,10116.0,,A,,BAO_0000218,11195,,,1,CHEMBL622101,,,Rattus norvegicus,N,1,2113.0,
10708,Biodistribution of the radiolabeled compound (2-5 uCi) in rat kidney 2 mins after i.v. administration,Intermediate,10116.0,,A,,BAO_0000218,11195,,,1,CHEMBL622102,,,Rattus norvegicus,N,1,2113.0,
10709,Biodistribution of the radiolabeled compound (2-5 uCi) in rat kidney 65 mins after i.v. administration,Intermediate,10116.0,,A,,BAO_0000218,11195,,,1,CHEMBL622103,,,Rattus norvegicus,N,1,2113.0,
10710,Biodistribution of the radiolabeled compound (2-5 uCi) in rat liver 15 mins after i.v. administration,Intermediate,10116.0,,A,,BAO_0000218,11195,,,1,CHEMBL622104,,,Rattus norvegicus,N,1,2107.0,
10711,Biodistribution of the radiolabeled compound (2-5 uCi) in rat liver 2 mins after i.v. administration,Intermediate,10116.0,,A,,BAO_0000218,11195,,,1,CHEMBL622105,,,Rattus norvegicus,N,1,2107.0,
10712,Biodistribution of the radiolabeled compound (2-5 uCi) in rat liver 65 mins after i.v. administration,Intermediate,10116.0,,A,,BAO_0000218,11195,,,1,CHEMBL622106,,,Rattus norvegicus,N,1,2107.0,
10713,Biodistribution of the radiolabeled compound (2-5 uCi) in rat lung 15 mins after i.v. administration,Intermediate,10116.0,,A,,BAO_0000218,11195,,,1,CHEMBL622107,,,Rattus norvegicus,N,1,2048.0,
10714,Biodistribution of the radiolabeled compound (2-5 uCi) in rat lung 2 mins after i.v. administration,Intermediate,10116.0,,A,,BAO_0000218,11195,,,1,CHEMBL622108,,,Rattus norvegicus,N,1,2048.0,
10715,Biodistribution of the radiolabeled compound (2-5 uCi) in rat lung 65 mins after i.v. administration,Intermediate,10116.0,,A,,BAO_0000218,11195,,,1,CHEMBL622109,,,Rattus norvegicus,N,1,2048.0,
10716,Biodistribution of the radiolabeled compound (2-5 uCi) in rat muscle 15 mins after i.v. administration,Intermediate,10116.0,,A,,BAO_0000218,11195,,,1,CHEMBL622110,,,Rattus norvegicus,N,1,2385.0,
10717,Biodistribution of the radiolabeled compound (2-5 uCi) in rat muscle 2 mins after i.v. administration,Intermediate,10116.0,,A,,BAO_0000218,11195,,,1,CHEMBL622111,,,Rattus norvegicus,N,1,2385.0,
10718,Biodistribution of the radiolabeled compound (2-5 uCi) in rat muscle 65 mins after i.v. administration,Intermediate,10116.0,,A,,BAO_0000218,11195,,,1,CHEMBL874383,,,Rattus norvegicus,N,1,2385.0,
10719,Biodistribution of the radiolabeled compound (2-5 uCi) in rat skin 15 mins after i.v. administration,Intermediate,10116.0,,A,,BAO_0000218,11195,,,1,CHEMBL622112,,,Rattus norvegicus,N,1,14.0,
10720,Biodistribution of the radiolabeled compound (2-5 uCi) in rat skin 2 mins after i.v. administration,Intermediate,10116.0,,A,,BAO_0000218,11195,,,1,CHEMBL622113,,,Rattus norvegicus,N,1,14.0,
10721,Biodistribution of the radiolabeled compound (2-5 uCi) in rat skin 65 mins after i.v. administration,Intermediate,10116.0,,A,,BAO_0000218,11195,,,1,CHEMBL622114,,,Rattus norvegicus,N,1,14.0,
10722,Biodistribution of the radiolabeled compound (2-5 uCi) in rat spleen 15 mins after i.v. administration,Intermediate,10116.0,,A,,BAO_0000218,11195,,,1,CHEMBL622115,,,Rattus norvegicus,N,1,2106.0,
10723,Biodistribution of the radiolabeled compound (2-5 uCi) in rat spleen 2 mins after i.v. administration,Intermediate,10116.0,,A,,BAO_0000218,11195,,,1,CHEMBL622116,,,Rattus norvegicus,N,1,2106.0,
10724,Oral bioavailability in rat,Intermediate,10116.0,,A,,BAO_0000218,6193,,,1,CHEMBL622117,,,Rattus norvegicus,N,1,,
10725,Oral bioavailability in rat,Intermediate,10116.0,,A,,BAO_0000218,6803,,,1,CHEMBL622118,,,Rattus norvegicus,N,1,,
10726,Oral bioavailability in rats at 6 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,6647,,,1,CHEMBL622119,,,Rattus norvegicus,N,1,,
10727,Oral bioavailability in rat (dose 6 mg/kg),Intermediate,10116.0,,A,,BAO_0000218,6647,,,1,CHEMBL622120,,,Rattus norvegicus,N,1,,
10728,Oral bioavailability in rats at 6 mg/kg dose; Not tested,Intermediate,10116.0,,A,,BAO_0000218,6647,,,1,CHEMBL622121,,,Rattus norvegicus,N,1,,
10729,Oral bioavailability in rat,Intermediate,10116.0,,A,,BAO_0000218,6640,,,1,CHEMBL622122,,,Rattus norvegicus,N,1,,
10730,Oral bioavailability in rat,Intermediate,10116.0,,A,,BAO_0000218,6641,,,1,CHEMBL622123,,,Rattus norvegicus,N,1,,
10731,Oral bioavailability in rat,Intermediate,10116.0,,A,,BAO_0000218,6641,,,1,CHEMBL622124,,,Rattus norvegicus,N,1,,
10732,Bioavailability in rat,Intermediate,10116.0,,A,,BAO_0000218,6642,,,1,CHEMBL622125,,,Rattus norvegicus,N,1,,
10733,Oral bioavailability,Intermediate,10116.0,,A,,BAO_0000218,5472,,,1,CHEMBL622126,,,Rattus norvegicus,N,1,,
10734,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg),Intermediate,10116.0,,A,,BAO_0000218,6141,,,1,CHEMBL620455,,,Rattus norvegicus,N,1,,
10735,Oral bioavailability in rat,Intermediate,10116.0,,A,,BAO_0000218,4390,,,1,CHEMBL620456,,,Rattus norvegicus,N,1,,
10736,Oral bioavailability in rat,Intermediate,10116.0,,A,,BAO_0000218,5472,,,1,CHEMBL620457,,,Rattus norvegicus,N,1,,
10737,Oral bioavailability was evaluated; Not tested,Intermediate,10116.0,,A,,BAO_0000218,5472,,,1,CHEMBL620458,,,Rattus norvegicus,N,1,,
10738,Oral bioavailability,Intermediate,10116.0,,A,,BAO_0000218,5438,,,1,CHEMBL620459,,,Rattus norvegicus,N,1,,
10739,Oral bioavailability in rat by oral dosing,Intermediate,10116.0,,A,,BAO_0000218,4883,,,1,CHEMBL620460,,,Rattus norvegicus,N,1,,
10740,Oral bioavailability in rat (dose 10 mg/kg p.o.),Intermediate,10116.0,,A,,BAO_0000218,1908,,,1,CHEMBL620461,,,Rattus norvegicus,N,1,,
10741,Oral bioavailability in rat (Sprague-Dawley),Intermediate,10116.0,,A,,BAO_0000218,4853,,,1,CHEMBL620462,,,Rattus norvegicus,N,1,,
10742,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),Intermediate,10116.0,,A,,BAO_0000218,4853,,,1,CHEMBL620463,,,Rattus norvegicus,N,1,,
10743,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),Intermediate,10116.0,,A,,BAO_0000218,4853,,,1,CHEMBL620464,,,Rattus norvegicus,N,1,,
10744,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg),Intermediate,10116.0,,A,,BAO_0000218,4853,,,1,CHEMBL620465,,,Rattus norvegicus,N,1,,
10745,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg p.o.),Intermediate,10116.0,,A,,BAO_0000218,4853,,,1,CHEMBL620466,,,Rattus norvegicus,N,1,,
10746,Oral bioavailability was calculated in Spragun Dawley rat at oral dosage of 1 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,4853,,,1,CHEMBL620467,,,Rattus norvegicus,N,1,,
10747,Oral bioavailability was calculated in Spragun Dawley rat at oral dosage of 2 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,4853,,,1,CHEMBL620468,,,Rattus norvegicus,N,1,,
10748,Oral bioavailability was calculated in rats using an average of the intravenous AUC at peroral dose of 5 mgkg in solution form,Intermediate,10116.0,,A,,BAO_0000218,12873,,,1,CHEMBL620469,,,Rattus norvegicus,N,1,,
10749,Oral bioavailability was calculated in rats using an average of the intravenous AUC at peroral dose of 5 mgkg in suspension form,Intermediate,10116.0,,A,,BAO_0000218,12873,,,1,CHEMBL620470,,,Rattus norvegicus,N,1,,
10750,Oral bioavailability in rat,Intermediate,10116.0,,A,,BAO_0000218,3169,,,1,CHEMBL620471,,,Rattus norvegicus,N,1,,
10751,Oral bioavailability in rat,Intermediate,10116.0,,A,,BAO_0000218,6305,,,1,CHEMBL620472,,,Rattus norvegicus,N,1,,
10752,Oral bioavailability of compound at 5 mg/kg after po administration was determined in rat,Intermediate,10116.0,,A,,BAO_0000218,4762,,,1,CHEMBL620473,,,Rattus norvegicus,N,1,,
10753,Oral bioavailability in rat,Intermediate,10116.0,,A,,BAO_0000218,17847,,,1,CHEMBL620474,,,Rattus norvegicus,N,1,,
10754,Oral bioavailability in rat (Sprague-Dawley) (fasted male) (dose 10 mg/kg),Intermediate,10116.0,,A,,BAO_0000218,6211,,,1,CHEMBL620475,,,Rattus norvegicus,N,1,,
10755,Oral bioavailability in rat,Intermediate,10116.0,,A,,BAO_0000218,6011,,,1,CHEMBL620476,,,Rattus norvegicus,N,1,,
10756,Oral bioavailability in rat,Intermediate,10116.0,,A,,BAO_0000218,6317,,,1,CHEMBL620477,,,Rattus norvegicus,N,1,,
10757,Oral bioavailability in rat after oral administration at 10.5 mg/kg dose,Intermediate,10116.0,,A,,BAO_0000218,6644,,,1,CHEMBL620478,,,Rattus norvegicus,N,1,,
10758,Oral bioavailability in rat after oral administration at 11.2 mg/kg dose,Intermediate,10116.0,,A,,BAO_0000218,6644,,,1,CHEMBL618768,,,Rattus norvegicus,N,1,,
10759,Oral bioavailability in rat after oral administration at 13 mg/kg dose,Intermediate,10116.0,,A,,BAO_0000218,6644,,,1,CHEMBL618769,,,Rattus norvegicus,N,1,,
10760,Oral bioavailability in rat after oral administration at 9.7 mg/kg dose,Intermediate,10116.0,,A,,BAO_0000218,6644,,,1,CHEMBL618770,,,Rattus norvegicus,N,1,,
10761,Oral bioavailability (dose 20 mg/kg p.o.),Intermediate,10116.0,,A,,BAO_0000218,6113,,,1,CHEMBL618771,,,Rattus norvegicus,N,1,,
10762,Oral bioavailability was determined in rat after oral administration at a concentration 1 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,5937,,,1,CHEMBL618772,,,Rattus norvegicus,N,1,,
10763,Oral bioavailability in rat at 10 mg/kg of the compound,Intermediate,10116.0,,A,,BAO_0000218,5711,,,1,CHEMBL618773,,,Rattus norvegicus,N,1,,
10764,Bioavailability in rat at a concentration of 15 mg/kg perorally in rat along with 100 mg/kg 11,Intermediate,10116.0,,A,,BAO_0000218,17717,,,1,CHEMBL875842,,,Rattus norvegicus,N,1,,
10765,Bioavailability in rat (dose 3 mg/kg i.v.),Intermediate,10116.0,,A,,BAO_0000218,17717,,,1,CHEMBL618774,,,Rattus norvegicus,N,1,,
10766,Bioavailability in rat at a concentration of 60 mg/kg perorally in rat along with 100 mg/kg 11,Intermediate,10116.0,,A,,BAO_0000218,17717,,,1,CHEMBL618775,,,Rattus norvegicus,N,1,,
10767,Oral bioavailability in rat (dose 60 mg/kg p.o.),Intermediate,10116.0,,A,,BAO_0000218,17717,,,1,CHEMBL618776,,,Rattus norvegicus,N,1,,
10768,Percent bioavailability (F) in rats after iv administration,Intermediate,10116.0,,A,,BAO_0000218,4722,,,1,CHEMBL618777,,,Rattus norvegicus,N,1,,
10769,Percent bioavailability (F) in rats after oral dose of 10 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,4722,,,1,CHEMBL618778,,,Rattus norvegicus,N,1,,
10770,Bioavailability in rat (dose 5 uM/kg p.o.),Intermediate,10116.0,,A,,BAO_0000218,4353,,,1,CHEMBL618779,,,Rattus norvegicus,N,1,,
10771,Oral bioavailability,Intermediate,10116.0,,A,,BAO_0000218,15662,,,1,CHEMBL618780,,,Rattus norvegicus,N,1,,
10772,Bioavailability in rat (dose 2 mg/kg p.o.),Intermediate,10116.0,,A,,BAO_0000218,4756,,,1,CHEMBL618781,,,Rattus norvegicus,N,1,,
10773,Percent bioavailability at the dose of 5 mg/Kg administered perorally in rats,Intermediate,10116.0,,A,,BAO_0000218,4756,,,1,CHEMBL618782,,,Rattus norvegicus,N,1,,
10774,Oral bioavailability in rat (dose 20 mg/kg),Intermediate,10116.0,,A,,BAO_0000218,3436,,,1,CHEMBL618783,,,Rattus norvegicus,N,1,,
10775,Oral bioavailability in rat,Intermediate,10116.0,,A,,BAO_0000218,17800,,,1,CHEMBL618784,,,Rattus norvegicus,N,1,,
10776,Percent oral bioavailability evaluated in rat,Intermediate,10116.0,,A,,BAO_0000218,15762,,,1,CHEMBL618785,,,Rattus norvegicus,N,1,,
10777,Oral bioavailability in rat,Intermediate,10116.0,,A,,BAO_0000218,5089,,,1,CHEMBL618786,,,Rattus norvegicus,N,1,,
10778,Percent oral bioavailability in rat; Not determined,Intermediate,10116.0,,A,,BAO_0000218,5089,,,1,CHEMBL618787,,,Rattus norvegicus,N,1,,
10779,Oral bioavailability in rat,Intermediate,10116.0,,A,,BAO_0000218,3185,,,1,CHEMBL618788,,,Rattus norvegicus,N,1,,
10780,Bioavailability in rat,Intermediate,10116.0,,A,,BAO_0000218,5145,,,1,CHEMBL618789,,,Rattus norvegicus,N,1,,
10781,Pharmacokinetic property (oral bioavailability) in rat (dose given as a solution),Intermediate,10116.0,,A,,BAO_0000218,3457,,,1,CHEMBL618790,,,Rattus norvegicus,N,1,,
10782,Pharmacokinetic property (oral bioavailability) in rat (dose given as a suspension),Intermediate,10116.0,,A,,BAO_0000218,3457,,,1,CHEMBL618791,,,Rattus norvegicus,N,1,,
10783,Pharmacokinetic property (F) was measured in rat at the dose of 0.32 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,5983,,,1,CHEMBL875843,,,Rattus norvegicus,N,1,,
10784,Oral bioavailability in rat (dose 20 mg/kg p.o.),Intermediate,10116.0,,A,,BAO_0000218,5739,,,1,CHEMBL618792,,,Rattus norvegicus,N,1,,
10785,Cmax at a dose of 30 mg/kg in rat,Intermediate,10116.0,,A,,BAO_0000218,3579,,,1,CHEMBL623395,,,Rattus norvegicus,N,1,,
10786,Cmax in monkeys at a dose of 1 mg/kg,Autocuration,314293.0,,A,,BAO_0000218,17788,,,1,CHEMBL623396,,,Simiiformes,U,0,,
10787,Cmax in rat,Intermediate,10116.0,,A,,BAO_0000218,14956,,,1,CHEMBL623397,,,Rattus norvegicus,N,1,,
10788,Cmax in rats at a dose of 1 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,17788,,,1,CHEMBL623398,,,Rattus norvegicus,N,1,,
10789,Cmax was measured in mice after an oral dose of 50 mg/kg.,Intermediate,10090.0,,A,,BAO_0000218,9750,,,1,CHEMBL623399,,,Mus musculus,N,1,,
10790,"Cmax value at a dose of 12.7 uM/kg, po",Autocuration,,,A,,BAO_0000218,12767,,,1,CHEMBL623400,,,,U,0,,
10791,"Cmax value at a dose of 6.3 uM/kg, iv",Autocuration,,,A,,BAO_0000218,12767,,,1,CHEMBL623401,,,,U,0,,
10792,"Cmax value at a dose of 7.1 uM/kg, iv",Autocuration,,,A,,BAO_0000218,12767,,,1,CHEMBL623402,,,,U,0,,
10793,Cmax value of compound was determined after 1 hr,Autocuration,,,A,,BAO_0000218,12703,,,1,CHEMBL623403,,,,U,0,,
10794,Cmax value of the compound,Autocuration,,,A,,BAO_0000218,15778,,,1,CHEMBL623404,,,,U,0,,
10795,Cmax value administered intraintestinal in rats.,Intermediate,10116.0,,A,,BAO_0000218,12818,,,1,CHEMBL625997,,,Rattus norvegicus,N,1,,
10796,Cmax value administered perorally was determined in rat; Not determined,Intermediate,10116.0,,A,,BAO_0000218,14964,,,1,CHEMBL625998,,,Rattus norvegicus,N,1,,
10797,Cmax value at the dose of 2.3 mg/kg,Autocuration,,,A,,BAO_0000218,15808,,,1,CHEMBL625999,,,,U,0,,
10798,Cmax value at the dose of 5 mg/kg,Autocuration,,,A,,BAO_0000218,15808,,,1,CHEMBL626000,,,,U,0,,
10799,Cmax value in the period of 8 hr after dosing. ,Autocuration,,,A,,BAO_0000218,15778,,,1,CHEMBL626001,,,,U,0,,
10800,Cmax value at a oral dose of 20 mg/kg; Not tested,Autocuration,,,A,,BAO_0000218,3715,,,1,CHEMBL626002,,,,U,0,,
10801,Cmax value at a oral dose of 20 mg/kg,Autocuration,,,A,,BAO_0000218,3715,,,1,CHEMBL626003,,,,U,0,,
10802,Cmax value was determined between 15 and 30 minutes post administration in fisher rats; value ranges from 200-500,Intermediate,10116.0,,A,,BAO_0000218,1446,,,1,CHEMBL626004,,,Rattus norvegicus,N,1,,
10803,Cmax(ng /mL)values after oral administration of 10 mg/kg in guinea pig.,Intermediate,10141.0,,A,,BAO_0000218,15240,,,1,CHEMBL626005,,,Cavia porcellus,N,1,,
10804,Cmax(ng /mL)values after oral administration of 10 mg/kg in rat.,Intermediate,10116.0,,A,,BAO_0000218,15240,,,1,CHEMBL626006,,,Rattus norvegicus,N,1,,
10805,Compound at a dose of 10 mg/kg was orally administered to rats and maximum plasma concentration was reported,Intermediate,10116.0,,A,,BAO_0000218,14810,,,1,CHEMBL626007,,,Rattus norvegicus,N,1,1969.0,
10806,Compound was evaluated for maximum plasma concentration by administering orally at 25 mg/kg in mice,Intermediate,10090.0,,A,,BAO_0000218,14239,,,1,CHEMBL626008,,,Mus musculus,N,1,1969.0,
10807,Compound was evaluated for maximum plasma concentration levels in dogs for the orally delivered compound in 0.05 M citric acid,Intermediate,9615.0,,A,,BAO_0000218,12555,,,1,CHEMBL626009,,,Canis lupus familiaris,N,1,2107.0,
10808,Compound was evaluated in vivo for its concentration after a peroral administration 40 mg/kg in dogs.,Intermediate,9615.0,,A,,BAO_0000218,10754,,,1,CHEMBL626010,,,Canis lupus familiaris,N,1,,
10809,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after a intramuscular administration 40 mg/kg in mice,Intermediate,10090.0,,A,,BAO_0000218,10754,,,1,CHEMBL626011,,,Mus musculus,N,1,178.0,
10810,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after a peroral administration 40 mg/kg in mice,Intermediate,10090.0,,A,,BAO_0000218,10754,,,1,CHEMBL626012,,,Mus musculus,N,1,178.0,
10811,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after a peroral administration of 40 mg/kg in mice,Intermediate,10090.0,,A,,BAO_0000218,10754,,,1,CHEMBL626013,,,Mus musculus,N,1,178.0,
10812,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after an intramuscular administration of 40 mg/kg in mice,Intermediate,10090.0,,A,,BAO_0000218,10754,,,1,CHEMBL626014,,,Mus musculus,N,1,178.0,
10813,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after an intramuscular administration of 40 mg/kg in mice.,Intermediate,10090.0,,A,,BAO_0000218,10754,,,1,CHEMBL877496,,,Mus musculus,N,1,178.0,
10814,Compound was tested Growth Hormone(GH) release after 0.5 mg/kg administration (Po) in Beagle dogs,Intermediate,9615.0,,F,,BAO_0000218,14600,,,1,CHEMBL626015,,,Canis lupus familiaris,N,1,,
10815,Compound was tested Growth Hormone(GH) release after 10 mg/kg administration (Po) in Beagle dogs,Intermediate,9615.0,,F,,BAO_0000218,14600,,,1,CHEMBL626016,,,Canis lupus familiaris,N,1,,
10816,Compound was tested Growth Hormone(GH) release after 2.5 mg/kg administration (Po) in Beagle dogs,Intermediate,9615.0,,F,,BAO_0000218,14600,,,1,CHEMBL626017,,,Canis lupus familiaris,N,1,,
10817,Bioavailability as maximal plasma concentration in dogs,Intermediate,9615.0,,A,,BAO_0000218,13543,,,1,CHEMBL626018,,,Canis lupus familiaris,N,1,1969.0,
10818,Bioavailability as maximal plasma concentration in dogs,Intermediate,9615.0,,A,,BAO_0000218,13543,,,1,CHEMBL626692,,,Canis lupus familiaris,N,1,1969.0,
10819,Bioavailability as maximal plasma concentration in rats,Intermediate,10116.0,,A,,BAO_0000218,13543,,,1,CHEMBL626693,,,Rattus norvegicus,N,1,1969.0,
10820,Bioavailability as maximal plasma concentration in rats,Autocuration,10116.0,,A,,BAO_0000218,13543,,,1,CHEMBL626694,,,Rattus norvegicus,U,0,1969.0,
10821,Compound was tested for maximum blood concentration after 0.5 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,Intermediate,9615.0,,A,,BAO_0000218,14600,,,1,CHEMBL626695,,,Canis lupus familiaris,N,1,178.0,
10822,Compound was tested for maximum blood concentration after 10 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,Intermediate,9615.0,,A,,BAO_0000218,14600,,,1,CHEMBL626696,,,Canis lupus familiaris,N,1,178.0,
10823,Compound was tested for maximum blood concentration after 2.5 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,Intermediate,9615.0,,A,,BAO_0000218,14600,,,1,CHEMBL626697,,,Canis lupus familiaris,N,1,178.0,
10824,Compound was tested for maximum concentration in blood after 0.5 mg/kg administration (Po) in Beagle dogs; nd = Not Detectable,Intermediate,9615.0,,A,,BAO_0000218,14600,,,1,CHEMBL626859,,,Canis lupus familiaris,N,1,178.0,
10825,Compound was tested for maximum concentration in blood after 10 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,Intermediate,9615.0,,A,,BAO_0000218,14600,,,1,CHEMBL626860,,,Canis lupus familiaris,N,1,178.0,
10826,Compound was tested for maximum concentration in blood after 2.5 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,Intermediate,9615.0,,A,,BAO_0000218,14600,,,1,CHEMBL626861,,,Canis lupus familiaris,N,1,178.0,
10827,Compound was tested for maximum observed concentration in three male Wistar rats at a single 5 mg/kg oral gavage dose,Intermediate,10116.0,,A,,BAO_0000218,14681,,,1,CHEMBL626296,,,Rattus norvegicus,N,1,,
10828,Compound was tested for the max. conc. when administered perorally(po) 30 mg/kg,Autocuration,,,A,,BAO_0000218,15905,,,1,CHEMBL626297,,,,U,0,,
10829,Compound was tested for the max. plasma conc. when administered intraperitoneally (ip) 30 mg/kg.,Autocuration,,,A,,BAO_0000218,15905,,,1,CHEMBL626298,,,,U,0,1969.0,
10830,"Drug plasma level in rat was determined on the last day of dosing at 1,2,4.8 and 24 hr and ED50 was evaluated",Intermediate,10116.0,,A,,BAO_0000218,13304,,,1,CHEMBL626299,,,Rattus norvegicus,N,1,1969.0,
10831,Effect of ip administration of compound on plasma concentration of allo-pregnanolone (AP) in rats after 30 min.,Intermediate,10116.0,,A,,BAO_0000218,15137,,,1,CHEMBL626300,,,Rattus norvegicus,N,1,1969.0,
10832,Effect of ip administration of compound on plasma concentration of allotetrahydrodeoxy corticosterone(THDOC) in rats after 30 min.,Intermediate,10116.0,,A,,BAO_0000218,15137,,,1,CHEMBL626301,,,Rattus norvegicus,N,1,1969.0,
10833,Effect of ip administration of compound on plasma concentration of corticosterone (CTS) in rats after 30 min.,Intermediate,10116.0,,A,,BAO_0000218,15137,,,1,CHEMBL626962,,,Rattus norvegicus,N,1,1969.0,
10834,Effect of ip administration of compound on plasma concentration of pregnenolone (PRE) in rats after 30 min.,Intermediate,10116.0,,A,,BAO_0000218,15137,,,1,CHEMBL626963,,,Rattus norvegicus,N,1,1969.0,
10835,Effect of ip administration of compound on plasma concentration of progesterone (PRO) in rats after 30 min.,Intermediate,10116.0,,A,,BAO_0000218,15137,,,1,CHEMBL626964,,,Rattus norvegicus,N,1,1969.0,
10836,In vivo antitumor efficacy expressed as maximum plasma concentration 0.4 hr after a peroral dose of 25 mg/kg in cynomolgus monkeys,Intermediate,9541.0,,A,,BAO_0000218,14839,,,1,CHEMBL626965,,,Macaca fascicularis,N,1,1969.0,
10837,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,Intermediate,10090.0,,A,,BAO_0000218,14839,,,1,CHEMBL626966,,,Mus musculus,N,1,1969.0,
10838,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,Intermediate,10090.0,,A,,BAO_0000218,14839,,,1,CHEMBL626967,,,Mus musculus,N,1,1969.0,
10839,In vivo antitumor efficacy expressed as maximum plasma concentration after a peroral dose of 10 mg/kg in cynomolgus monkeys,Intermediate,9541.0,,A,,BAO_0000218,14839,,,1,CHEMBL626968,,,Macaca fascicularis,N,1,1969.0,
10840,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 0.89-1.24,Intermediate,10116.0,,A,,BAO_0000218,8418,,,1,CHEMBL626969,,,Rattus norvegicus,N,1,948.0,
10841,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 2.24-2.58,Intermediate,10116.0,,A,,BAO_0000218,8418,,,1,CHEMBL627126,,,Rattus norvegicus,N,1,948.0,
10842,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.24-0.28,Intermediate,10116.0,,A,,BAO_0000218,8418,,,1,CHEMBL631276,,,Rattus norvegicus,N,1,948.0,
10843,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.52-0.62,Intermediate,10116.0,,A,,BAO_0000218,8418,,,1,CHEMBL631277,,,Rattus norvegicus,N,1,948.0,
10844,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.68-0.84,Intermediate,10116.0,,A,,BAO_0000218,8418,,,1,CHEMBL631278,,,Rattus norvegicus,N,1,948.0,
10845,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.75-1.03,Intermediate,10116.0,,A,,BAO_0000218,8418,,,1,CHEMBL874457,,,Rattus norvegicus,N,1,948.0,
10846,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.96-2.46,Intermediate,10116.0,,A,,BAO_0000218,8418,,,1,CHEMBL631279,,,Rattus norvegicus,N,1,948.0,
10847,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.36-0.42,Intermediate,10116.0,,A,,BAO_0000218,8418,,,1,CHEMBL631280,,,Rattus norvegicus,N,1,948.0,
10848,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.58-0.82,Intermediate,10116.0,,A,,BAO_0000218,8418,,,1,CHEMBL631281,,,Rattus norvegicus,N,1,948.0,
10849,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.24-1.46,Intermediate,10116.0,,A,,BAO_0000218,8418,,,1,CHEMBL631968,,,Rattus norvegicus,N,1,948.0,
10850,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 2.36-3.96,Intermediate,10116.0,,A,,BAO_0000218,8418,,,1,CHEMBL631969,,,Rattus norvegicus,N,1,948.0,
10851,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.24-0.29,Intermediate,10116.0,,A,,BAO_0000218,8418,,,1,CHEMBL631970,,,Rattus norvegicus,N,1,948.0,
10852,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.39-0.74,Intermediate,10116.0,,A,,BAO_0000218,8418,,,1,CHEMBL631971,,,Rattus norvegicus,N,1,948.0,
10853,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.79-0.85,Intermediate,10116.0,,A,,BAO_0000218,8418,,,1,CHEMBL631972,,,Rattus norvegicus,N,1,948.0,
10854,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.64-0.86,Intermediate,10116.0,,A,,BAO_0000218,8418,,,1,CHEMBL630435,,,Rattus norvegicus,N,1,948.0,
10855,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 1.68-2.23,Intermediate,10116.0,,A,,BAO_0000218,8418,,,1,CHEMBL630436,,,Rattus norvegicus,N,1,948.0,
10856,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.19-0.23,Intermediate,10116.0,,A,,BAO_0000218,8418,,,1,CHEMBL630437,,,Rattus norvegicus,N,1,948.0,
10857,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.22-0.29,Intermediate,10116.0,,A,,BAO_0000218,8418,,,1,CHEMBL630438,,,Rattus norvegicus,N,1,948.0,
10858,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.58-0.75,Intermediate,10116.0,,A,,BAO_0000218,8418,,,1,CHEMBL630439,,,Rattus norvegicus,N,1,948.0,
10859,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 1.42-1.82,Intermediate,10116.0,,A,,BAO_0000218,8418,,,1,CHEMBL630440,,,Rattus norvegicus,N,1,2113.0,
10860,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 2.24-3.12,Intermediate,10116.0,,A,,BAO_0000218,8418,,,1,CHEMBL630441,,,Rattus norvegicus,N,1,2113.0,
10861,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.62-0.92,Intermediate,10116.0,,A,,BAO_0000218,8418,,,1,CHEMBL630442,,,Rattus norvegicus,N,1,2113.0,
10862,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 1.12-2.04,Intermediate,10116.0,,A,,BAO_0000218,8418,,,1,CHEMBL625234,,,Rattus norvegicus,N,1,2113.0,
10863,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 1.59-2.03,Intermediate,10116.0,,A,,BAO_0000218,8418,,,1,CHEMBL625235,,,Rattus norvegicus,N,1,2113.0,
10864,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.14-1.4,Intermediate,10116.0,,A,,BAO_0000218,8418,,,1,CHEMBL625236,,,Rattus norvegicus,N,1,2113.0,
10865,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.56-1.83,Intermediate,10116.0,,A,,BAO_0000218,8418,,,1,CHEMBL625237,,,Rattus norvegicus,N,1,2113.0,
10866,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.58-0.73,Intermediate,10116.0,,A,,BAO_0000218,8418,,,1,CHEMBL626125,,,Rattus norvegicus,N,1,2113.0,
10867,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 1.67-2.11,Intermediate,10116.0,,A,,BAO_0000218,8418,,,1,CHEMBL626126,,,Rattus norvegicus,N,1,2113.0,
10868,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.64-3.43,Intermediate,10116.0,,A,,BAO_0000218,8418,,,1,CHEMBL626127,,,Rattus norvegicus,N,1,2113.0,
10869,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 3.18-4.74,Intermediate,10116.0,,A,,BAO_0000218,8418,,,1,CHEMBL626128,,,Rattus norvegicus,N,1,2113.0,
10870,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.62-1.13,Intermediate,10116.0,,A,,BAO_0000218,8418,,,1,CHEMBL626129,,,Rattus norvegicus,N,1,2113.0,
10871,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 1.73-2.64,Intermediate,10116.0,,A,,BAO_0000218,8418,,,1,CHEMBL626130,,,Rattus norvegicus,N,1,2113.0,
10872,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 13.02-19.07,Intermediate,10116.0,,A,,BAO_0000218,8418,,,1,CHEMBL626131,,,Rattus norvegicus,N,1,2113.0,
10873,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.89-1.19,Intermediate,10116.0,,A,,BAO_0000218,8418,,,1,CHEMBL626132,,,Rattus norvegicus,N,1,2113.0,
10874,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 1.17-1.48,Intermediate,10116.0,,A,,BAO_0000218,8418,,,1,CHEMBL626752,,,Rattus norvegicus,N,1,2113.0,
10875,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.48-0.72,Intermediate,10116.0,,A,,BAO_0000218,8418,,,1,CHEMBL626753,,,Rattus norvegicus,N,1,2113.0,
10876,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.49-0.57,Intermediate,10116.0,,A,,BAO_0000218,8418,,,1,CHEMBL626754,,,Rattus norvegicus,N,1,2113.0,
10877,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.99-1.24,Intermediate,10116.0,,A,,BAO_0000218,8418,,,1,CHEMBL626755,,,Rattus norvegicus,N,1,2113.0,
10878,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 1.23-1.78,Intermediate,10116.0,,A,,BAO_0000218,8418,,,1,CHEMBL626756,,,Rattus norvegicus,N,1,2107.0,
10879,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 2.43-2.92,Intermediate,10116.0,,A,,BAO_0000218,8418,,,1,CHEMBL626757,,,Rattus norvegicus,N,1,2107.0,
10880,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.81-1.18,Intermediate,10116.0,,A,,BAO_0000218,8418,,,1,CHEMBL626758,,,Rattus norvegicus,N,1,2107.0,
10881,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 1.37-1.74,Intermediate,10116.0,,A,,BAO_0000218,8418,,,1,CHEMBL626759,,,Rattus norvegicus,N,1,2107.0,
10882,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 4.01-4.81,Intermediate,10116.0,,A,,BAO_0000218,8418,,,1,CHEMBL626760,,,Rattus norvegicus,N,1,2107.0,
10883,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5.4 mg/kg after ip administration ( 0-6 hr),Intermediate,9615.0,,A,,BAO_0000218,6996,,,1,CHEMBL626394,,,Canis lupus familiaris,N,1,,
10884,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration,Intermediate,9615.0,,A,,BAO_0000218,6996,,,1,CHEMBL626395,,,Canis lupus familiaris,N,1,,
10885,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration (0-6 hr),Intermediate,9615.0,,A,,BAO_0000218,6996,,,1,CHEMBL626396,,,Canis lupus familiaris,N,1,,
10886,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration ( 0 - 6 hr),Intermediate,9615.0,,A,,BAO_0000218,6996,,,1,CHEMBL626397,,,Canis lupus familiaris,N,1,,
10887,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration ( 0-6 hr ),Intermediate,9615.0,,A,,BAO_0000218,6996,,,1,CHEMBL626398,,,Canis lupus familiaris,N,1,,
10888,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration ( 0-6 hr),Intermediate,9615.0,,A,,BAO_0000218,6996,,,1,CHEMBL626399,,,Canis lupus familiaris,N,1,,
10889,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration,Intermediate,10116.0,,A,,BAO_0000218,6996,,,1,CHEMBL874653,,,Rattus norvegicus,N,1,,
10890,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),Intermediate,10116.0,,A,,BAO_0000218,6996,,,1,CHEMBL626400,,,Rattus norvegicus,N,1,,
10891,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration (0-5 hr),Intermediate,10116.0,,A,,BAO_0000218,6996,,,1,CHEMBL626401,,,Rattus norvegicus,N,1,,
10892,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration ( 0 - 5 hr),Intermediate,10116.0,,A,,BAO_0000218,6996,,,1,CHEMBL626402,,,Rattus norvegicus,N,1,,
10893,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr ),Intermediate,10116.0,,A,,BAO_0000218,6996,,,1,CHEMBL626403,,,Rattus norvegicus,N,1,,
10894,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),Intermediate,10116.0,,A,,BAO_0000218,6996,,,1,CHEMBL626404,,,Rattus norvegicus,N,1,,
10895,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration,Intermediate,10116.0,,A,,BAO_0000218,6996,,,1,CHEMBL626405,,,Rattus norvegicus,N,1,,
10896,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),Intermediate,10116.0,,A,,BAO_0000218,6996,,,1,CHEMBL625529,,,Rattus norvegicus,N,1,,
10897,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration (0-5 hr),Intermediate,10116.0,,A,,BAO_0000218,6996,,,1,CHEMBL625530,,,Rattus norvegicus,N,1,,
10898,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration ( 0 - 5 hr),Intermediate,10116.0,,A,,BAO_0000218,6996,,,1,CHEMBL625531,,,Rattus norvegicus,N,1,,
10899,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr ),Intermediate,10116.0,,A,,BAO_0000218,6996,,,1,CHEMBL625532,,,Rattus norvegicus,N,1,,
10900,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),Intermediate,10116.0,,A,,BAO_0000218,6996,,,1,CHEMBL625533,,,Rattus norvegicus,N,1,,
10901,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration,Intermediate,10116.0,,A,,BAO_0000218,6996,,,1,CHEMBL875474,,,Rattus norvegicus,N,1,,
10902,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),Intermediate,10116.0,,A,,BAO_0000218,6996,,,1,CHEMBL625534,,,Rattus norvegicus,N,1,,
10903,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration (0-5 hr),Intermediate,10116.0,,A,,BAO_0000218,6996,,,1,CHEMBL625535,,,Rattus norvegicus,N,1,,
10904,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration ( 0 - 5 hr),Intermediate,10116.0,,A,,BAO_0000218,6996,,,1,CHEMBL625536,,,Rattus norvegicus,N,1,,
10905,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr ),Intermediate,10116.0,,A,,BAO_0000218,6996,,,1,CHEMBL625537,,,Rattus norvegicus,N,1,,
10906,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),Intermediate,10116.0,,A,,BAO_0000218,6996,,,1,CHEMBL625538,,,Rattus norvegicus,N,1,,
10907,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration,Intermediate,10116.0,,A,,BAO_0000218,6996,,,1,CHEMBL625539,,,Rattus norvegicus,N,1,,
10908,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),Intermediate,10116.0,,A,,BAO_0000218,6996,,,1,CHEMBL625540,,,Rattus norvegicus,N,1,,
10909,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration (0-5 hr),Intermediate,10116.0,,A,,BAO_0000218,6996,,,1,CHEMBL625541,,,Rattus norvegicus,N,1,,
10910,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration ( 0 - 5 hr),Intermediate,10116.0,,A,,BAO_0000218,6996,,,1,CHEMBL625542,,,Rattus norvegicus,N,1,,
10911,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr ),Intermediate,10116.0,,A,,BAO_0000218,6996,,,1,CHEMBL625543,,,Rattus norvegicus,N,1,,
10912,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),Intermediate,10116.0,,A,,BAO_0000218,6996,,,1,CHEMBL625544,,,Rattus norvegicus,N,1,,
10913,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 0.312 mg/kg after ip administration,Intermediate,9615.0,,A,,BAO_0000218,6996,,,1,CHEMBL625545,,,Canis lupus familiaris,N,1,,
10914,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 0.3 mg/kg after ip administration (0-6 hr),Intermediate,9615.0,,A,,BAO_0000218,6996,,,1,CHEMBL625546,,,Canis lupus familiaris,N,1,,
10915,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 0.625 mg/kg after ip administration,Intermediate,9615.0,,A,,BAO_0000218,6996,,,1,CHEMBL625547,,,Canis lupus familiaris,N,1,,
10916,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 0.6 mg/kg after ip administration ( 0-6 hr),Intermediate,9615.0,,A,,BAO_0000218,6996,,,1,CHEMBL625548,,,Canis lupus familiaris,N,1,,
10917,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1.8 mg/kg after ip administration ( 0-6 hr),Intermediate,9615.0,,A,,BAO_0000218,6996,,,1,CHEMBL625549,,,Canis lupus familiaris,N,1,,
10918,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 10 mg/kg after ip administration (0-6 hr),Intermediate,9615.0,,A,,BAO_0000218,6996,,,1,CHEMBL625550,,,Canis lupus familiaris,N,1,,
10919,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 10 mg/kg after ip administration ( 0-6 hr),Intermediate,9615.0,,A,,BAO_0000218,6996,,,1,CHEMBL625551,,,Canis lupus familiaris,N,1,,
10920,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 16.2 mg/kg after ip administration ( 0-6 hr),Intermediate,9615.0,,A,,BAO_0000218,6996,,,1,CHEMBL875475,,,Canis lupus familiaris,N,1,,
10921,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1 mg/kg after ip administration ( 0-6 hr),Intermediate,9615.0,,A,,BAO_0000218,6996,,,1,CHEMBL625552,,,Canis lupus familiaris,N,1,,
10922,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1 mg/kg after ip administration (0-6 hr),Intermediate,9615.0,,A,,BAO_0000218,6996,,,1,CHEMBL625553,,,Canis lupus familiaris,N,1,,
10923,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1 mg/kg after ip administration ( 0 - 6 hr),Intermediate,9615.0,,A,,BAO_0000218,6996,,,1,CHEMBL625554,,,Canis lupus familiaris,N,1,,
10924,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1 mg/kg after ip administration ( 0-6 hr ),Intermediate,9615.0,,A,,BAO_0000218,6996,,,1,CHEMBL625555,,,Canis lupus familiaris,N,1,,
10925,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 20 mg/kg after ip administration ( 0-6 hr),Intermediate,9615.0,,A,,BAO_0000218,6996,,,1,CHEMBL625556,,,Canis lupus familiaris,N,1,,
10926,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 2 mg/kg after ip administration,Intermediate,9615.0,,A,,BAO_0000218,6996,,,1,CHEMBL624986,,,Canis lupus familiaris,N,1,,
10927,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 2 mg/kg after ip administration (0-6 hr),Intermediate,9615.0,,A,,BAO_0000218,6996,,,1,CHEMBL624987,,,Canis lupus familiaris,N,1,,
10928,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 2 mg/kg after ip administration ( 0 - 6 hr),Intermediate,9615.0,,A,,BAO_0000218,6996,,,1,CHEMBL624988,,,Canis lupus familiaris,N,1,,
10929,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 1/3 range; -2/-14,Intermediate,9615.0,,A,,BAO_0000218,9025,,,1,CHEMBL624989,,,Canis lupus familiaris,N,1,1637.0,
10930,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 1/3 range; -4/-4,Intermediate,9615.0,,A,,BAO_0000218,9025,,,1,CHEMBL624990,,,Canis lupus familiaris,N,1,1637.0,
10931,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 1/3 range; 4/7,Intermediate,9615.0,,A,,BAO_0000218,9025,,,1,CHEMBL874391,,,Canis lupus familiaris,N,1,1637.0,
10932,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 1/3/10 range; -3/0/4,Intermediate,9615.0,,A,,BAO_0000218,9025,,,1,CHEMBL624991,,,Canis lupus familiaris,N,1,1637.0,
10933,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; -6/0,Intermediate,9615.0,,A,,BAO_0000218,9025,,,1,CHEMBL624992,,,Canis lupus familiaris,N,1,1637.0,
10934,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 10/31,Intermediate,9615.0,,A,,BAO_0000218,9025,,,1,CHEMBL624993,,,Canis lupus familiaris,N,1,1637.0,
10935,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 11/-19,Intermediate,9615.0,,A,,BAO_0000218,9025,,,1,CHEMBL624994,,,Canis lupus familiaris,N,1,1637.0,
10936,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 14/6,Intermediate,9615.0,,A,,BAO_0000218,9025,,,1,CHEMBL624995,,,Canis lupus familiaris,N,1,1637.0,
10937,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 19/25,Intermediate,9615.0,,A,,BAO_0000218,9025,,,1,CHEMBL624996,,,Canis lupus familiaris,N,1,1637.0,
10938,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 19/3,Intermediate,9615.0,,A,,BAO_0000218,9025,,,1,CHEMBL624997,,,Canis lupus familiaris,N,1,1637.0,
10939,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 2/16,Intermediate,9615.0,,A,,BAO_0000218,9025,,,1,CHEMBL624998,,,Canis lupus familiaris,N,1,1637.0,
10940,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 6/2,Intermediate,9615.0,,A,,BAO_0000218,9025,,,1,CHEMBL624999,,,Canis lupus familiaris,N,1,1637.0,
10941,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 7/26,Intermediate,9615.0,,A,,BAO_0000218,9025,,,1,CHEMBL882955,,,Canis lupus familiaris,N,1,1637.0,
10942,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 8/49,Intermediate,9615.0,,A,,BAO_0000218,9025,,,1,CHEMBL625000,,,Canis lupus familiaris,N,1,1637.0,
10943,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 8/8,Intermediate,9615.0,,A,,BAO_0000218,9025,,,1,CHEMBL625001,,,Canis lupus familiaris,N,1,1637.0,
10944,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 9/-18,Intermediate,9615.0,,A,,BAO_0000218,9025,,,1,CHEMBL625089,,,Canis lupus familiaris,N,1,1637.0,
10945,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/60 range; 13/23,Intermediate,9615.0,,A,,BAO_0000218,9025,,,1,CHEMBL625090,,,Canis lupus familiaris,N,1,1637.0,
10946,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 3 range,Intermediate,9615.0,,A,,BAO_0000218,9025,,,1,CHEMBL625091,,,Canis lupus familiaris,N,1,1637.0,
10947,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 3/10 range; -7/-11,Intermediate,9615.0,,A,,BAO_0000218,9025,,,1,CHEMBL625092,,,Canis lupus familiaris,N,1,1637.0,
10948,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a of 1/3 dose range; 6/-7,Intermediate,9615.0,,A,,BAO_0000218,9025,,,1,CHEMBL625093,,,Canis lupus familiaris,N,1,1637.0,
10949,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a of 10/30 dose range; -13/19,Intermediate,9615.0,,A,,BAO_0000218,9025,,,1,CHEMBL625094,,,Canis lupus familiaris,N,1,1637.0,
10950,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a of 3/10 dose range; 30/47,Intermediate,9615.0,,A,,BAO_0000218,9025,,,1,CHEMBL625095,,,Canis lupus familiaris,N,1,1637.0,
10951,Compound was evaluated for its bioavailability in the dogs,Intermediate,9615.0,,A,,BAO_0000218,2249,,,1,CHEMBL625096,,,Canis lupus familiaris,N,1,,
10952,Compound was evaluated for its bioavailability in the rats,Intermediate,10116.0,,A,,BAO_0000218,2249,,,1,CHEMBL625097,,,Rattus norvegicus,N,1,,
10953,Compound was evaluated for oral bioavailability,Autocuration,,,A,,BAO_0000218,17515,,,1,CHEMBL882956,,,,U,0,,
10954,Compound was evaluated for percentage of Oral bioavailability in rats,Intermediate,10116.0,,A,,BAO_0000218,14541,,,1,CHEMBL625098,,,Rattus norvegicus,N,1,,
10955,Bioavailability in guinea pig,Autocuration,10141.0,,A,,BAO_0000218,12797,,,1,CHEMBL625099,,,Cavia porcellus,U,0,,
10956,Compound was evaluated for the oral bioavailability in rat,Intermediate,10116.0,,A,,BAO_0000218,12797,,,1,CHEMBL625100,,,Rattus norvegicus,N,1,,
10957,Compound was evaluated for the oral bioavailability in dog,Intermediate,9615.0,,A,,BAO_0000218,12797,,,1,CHEMBL625101,,,Canis lupus familiaris,N,1,,
10958,Compound was evaluated for the oral bioavailability in rat,Intermediate,10116.0,,A,,BAO_0000218,12797,,,1,CHEMBL874396,,,Rattus norvegicus,N,1,,
10959,Bioavailability in dog (dosed i.v.),Autocuration,9615.0,,F,,BAO_0000218,11727,,,1,CHEMBL625102,,,Canis lupus familiaris,U,0,,
10960,Compound was tested for in vivo bioavailability in dog,Intermediate,9615.0,,A,,BAO_0000218,13249,,,1,CHEMBL625103,,,Canis lupus familiaris,N,1,,
10961,Compound was tested for in vivo bioavailability in hamsters,Intermediate,10026.0,,A,,BAO_0000218,13249,,,1,CHEMBL625104,,,Cricetinae,N,1,,
10962,Compound was tested for in vivo bioavailability in monkey,Autocuration,314293.0,,A,,BAO_0000218,13249,,,1,CHEMBL625105,,,Simiiformes,U,0,,
10963,Compound was tested for in vivo bioavailability in rat,Intermediate,10116.0,,A,,BAO_0000218,13249,,,1,CHEMBL625106,,,Rattus norvegicus,N,1,,
10964,Oral bioavailability in mouse,Autocuration,10090.0,,A,,BAO_0000218,9552,,,1,CHEMBL625107,,,Mus musculus,U,0,,
10965,Compound was tested for percent of oral bioavailability in mice; 56-74,Intermediate,10090.0,,A,,BAO_0000218,9552,,,1,CHEMBL625108,,,Mus musculus,N,1,,
10966,Oral bioavailability in mouse (nude) (dose of 25 mg/kg),Autocuration,10090.0,,A,,BAO_0000218,14839,,,1,CHEMBL625109,,,Mus musculus,U,0,,
10967,Bioavailability in cynomolgus monkey (dose 25 mg/kg i.v.),Autocuration,9541.0,,A,,BAO_0000218,14839,,,1,CHEMBL625110,,,Macaca fascicularis,U,0,,
10968,Bioavailability in cynomolgus monkey (dose 5 mg/kg i.v.),Autocuration,9541.0,,A,,BAO_0000218,14839,,,1,CHEMBL625111,,,Macaca fascicularis,U,0,,
10969,Oral bioavailability in mouse (nude) (dose 25 mg/kg i.v.),Intermediate,10090.0,,A,,BAO_0000218,14839,,,1,CHEMBL625112,,,Mus musculus,N,1,,
10970,Oral bioavailability in nude mice,Intermediate,10090.0,,A,,BAO_0000218,14839,,,1,CHEMBL875334,,,Mus musculus,N,1,,
10971,Bioavailability in monkey (i.d. dosing),Autocuration,9443.0,,A,,BAO_0000218,11219,,,1,CHEMBL628617,,,Primates,U,0,,
10972,Bioavailability in rat,Autocuration,10116.0,,A,,BAO_0000218,9552,,,1,CHEMBL628618,,,Rattus norvegicus,U,0,,
10973,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 10%,Autocuration,,,A,,BAO_0000218,11732,,,1,CHEMBL628619,,,,U,0,,
10974,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 20%,Autocuration,,,A,,BAO_0000218,11732,,,1,CHEMBL628620,,,,U,0,,
10975,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 10 mg/kg, as HCl salt in saline solution, perorally and the maximum drug concentration was determined",Intermediate,9541.0,,A,,BAO_0000218,14839,,,1,CHEMBL628621,,,Macaca fascicularis,N,1,,
10976,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the maximum drug concentration was determined",Intermediate,9541.0,,A,,BAO_0000218,14839,,,1,CHEMBL628622,,,Macaca fascicularis,N,1,,
10977,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 5 mg/kg, as HCl salt in saline solution, perorally and the maximum drug concentration was determined",Intermediate,9541.0,,A,,BAO_0000218,14839,,,1,CHEMBL628623,,,Macaca fascicularis,N,1,,
10978,Maximal plasma concentration in cynomolgus monkeys after 10 mg/kg oral dose,Intermediate,9541.0,,A,,BAO_0000218,14839,,,1,CHEMBL628624,,,Macaca fascicularis,N,1,1969.0,
10979,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,Intermediate,10090.0,,A,,BAO_0000218,14839,,,1,CHEMBL628625,,,Mus musculus,N,1,1969.0,
10980,Maximal plasma concentration in cynomolgus monkeys after 5 mg/kg oral dose,Intermediate,9541.0,,A,,BAO_0000218,14839,,,1,CHEMBL628626,,,Macaca fascicularis,N,1,1969.0,
10981,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,Intermediate,10090.0,,A,,BAO_0000218,14839,,,1,CHEMBL627041,,,Mus musculus,N,1,1969.0,
10982,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,Intermediate,10090.0,,A,,BAO_0000218,14839,,,1,CHEMBL627042,,,Mus musculus,N,1,1969.0,
10983,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,Intermediate,10090.0,,A,,BAO_0000218,14839,,,1,CHEMBL627043,,,Mus musculus,N,1,1969.0,
10984,In vivo evaluation of maximum plasma concentration at a dose of 10 mg/kg,Autocuration,,,A,,BAO_0000218,13932,,,1,CHEMBL627044,,,,U,0,1969.0,
10985,Cmax in mouse plasma,Intermediate,10090.0,,A,,BAO_0000218,11637,,,1,CHEMBL627045,,,Mus musculus,N,1,1969.0,
10986,Max plasma concentration was measured by 40 mg/kg dose of peroral administration.,Autocuration,,,A,,BAO_0000218,11637,,,1,CHEMBL627046,,,,U,0,1969.0,
10987,Maximal plasma concentration in rat,Intermediate,10116.0,,A,,BAO_0000218,13960,,,1,CHEMBL627047,,,Rattus norvegicus,N,1,1969.0,
10988,Maximal plasma level when administered 1 mg/kg perorally (po) in rat,Intermediate,10116.0,,A,,BAO_0000218,15905,,,1,CHEMBL627048,,,Rattus norvegicus,N,1,1969.0,
10989,Maximum concentration at an intraduodenal dose of 5.2 mg/kg in rat,Intermediate,10116.0,,A,,BAO_0000218,14062,,,1,CHEMBL627049,,,Rattus norvegicus,N,1,,
10990,Maximum concentration at an intraduodenal dose of 6.6 mg/kg in rat,Intermediate,10116.0,,A,,BAO_0000218,14062,,,1,CHEMBL627050,,,Rattus norvegicus,N,1,,
10991,Maximum concentration at an intravenous dose of 5.5 mg/kg in rat,Intermediate,10116.0,,A,,BAO_0000218,14062,,,1,CHEMBL627051,,,Rattus norvegicus,N,1,,
10992,Maximum concentration at an intravenous dose of 6.5 mg/kg in rat,Intermediate,10116.0,,A,,BAO_0000218,14062,,,1,CHEMBL627052,,,Rattus norvegicus,N,1,,
10993,Maximum concentration at an peroral dose of 6.2 mg/kg in rat,Intermediate,10116.0,,A,,BAO_0000218,14062,,,1,CHEMBL627053,,,Rattus norvegicus,N,1,,
10994,Maximum concentration at an peroral dose of 6.3 mg/kg in rat,Intermediate,10116.0,,A,,BAO_0000218,14062,,,1,CHEMBL627054,,,Rattus norvegicus,N,1,,
10995,Maximum concentration (Cmax) using 0.4% Methyl cellulose (MC) as vehicle. compound was administered intravenously to nude mice at a dose of 25 mg/kg,Intermediate,10090.0,,A,,BAO_0000218,15011,,,1,CHEMBL627055,,,Mus musculus,N,1,,
10996,Maximum concentration (Cmax) using 0.4% Methyl cellulose (MC) as vehicle. compound was administered orally to nude mice at a dose of 25 mg/kg,Intermediate,10090.0,,A,,BAO_0000218,15011,,,1,CHEMBL627056,,,Mus musculus,N,1,,
10997,Maximum concentration (Cmax) using 0.4% Methyl cellulose (MC) as vehicle. compound was administered orally to nude mice at a dose of 25 mg/kg (micronized sample),Intermediate,10090.0,,A,,BAO_0000218,15011,,,1,CHEMBL627057,,,Mus musculus,N,1,,
10998,Maximum concentration (Cmax) using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. compound was administered intravenously to nude mice at a dose of 25 mg/kg,Intermediate,10090.0,,A,,BAO_0000218,15011,,,1,CHEMBL627058,,,Mus musculus,N,1,,
10999,Maximum concentration (Cmax) using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. compound was administered orally to nude mice at a dose of 25 mg/kg,Intermediate,10090.0,,A,,BAO_0000218,15011,,,1,CHEMBL626211,,,Mus musculus,N,1,,
11000,Maximum Concentration of the compound.,Autocuration,,,A,,BAO_0000218,10291,,,1,CHEMBL626212,,,,U,0,,
11001,Maximum Concentration was measured after iv administration into Beagle dog,Intermediate,9615.0,,A,,BAO_0000218,14599,,,1,CHEMBL626213,,,Canis lupus familiaris,N,1,,
11002,Maximum Concentration was measured after iv administration into Beagle dog.,Intermediate,9615.0,,A,,BAO_0000218,14599,,,1,CHEMBL626214,,,Canis lupus familiaris,N,1,,
11003,Maximum Concentration was measured after po administration into Beagle dog,Intermediate,9615.0,,A,,BAO_0000218,14599,,,1,CHEMBL626215,,,Canis lupus familiaris,N,1,,
11004,Maximum Concentration was measured after po administration into Beagle dog.,Intermediate,9615.0,,A,,BAO_0000218,14599,,,1,CHEMBL626216,,,Canis lupus familiaris,N,1,,
11005,Maximum blood level reached after an dose of 10.6 uM/kg intravenously,Autocuration,,,A,,BAO_0000218,12767,,,1,CHEMBL626217,,,,U,0,178.0,
11006,Maximum blood level reached after an iv dose of 12.2 uM/kg,Autocuration,,,A,,BAO_0000218,12767,,,1,CHEMBL626218,,,,U,0,178.0,
11007,Maximum blood level reached after an oral dose 14.7 uM/kg oral route,Autocuration,,,A,,BAO_0000218,12767,,,1,CHEMBL626219,,,,U,0,178.0,
11008,Maximum blood level reached after an oral dose of 14.7 uM/kg intravenous route,Autocuration,,,A,,BAO_0000218,12767,,,1,CHEMBL626220,,,,U,0,178.0,
11009,Maximum blood level reached after an oral dose of 5.0 mg/kg,Autocuration,,,A,,BAO_0000218,12767,,,1,CHEMBL626221,,,,U,0,178.0,
11010,Maximum blood level reached at dose of 10.6 uM/kg orally,Autocuration,,,A,,BAO_0000218,12767,,,1,CHEMBL626222,,,,U,0,178.0,
11011,Maximum concentration (Cmax) in guinea pigs at 2 mg/kg after oral administration,Intermediate,10141.0,,A,,BAO_0000218,14706,,,1,CHEMBL626223,,,Cavia porcellus,N,1,,
11012,Maximum concentration (Cmax) in guinea pigs at 3 mg/kg after oral administration,Intermediate,10141.0,,A,,BAO_0000218,14706,,,1,CHEMBL626224,,,Cavia porcellus,N,1,,
11013,Maximum concentration achieved in rat brain when administered intraperitoneally at a dose of 10 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,14793,,,1,CHEMBL626225,,,Rattus norvegicus,N,1,955.0,
11014,Maximum concentration achieved in rat brain when administered intravenously at a dose of 10 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,14793,,,1,CHEMBL626226,,,Rattus norvegicus,N,1,955.0,
11015,Maximum concentration achieved in rat brain when administered perorally at a dose of 100 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,14793,,,1,CHEMBL626227,,,Rattus norvegicus,N,1,955.0,
11016,Maximum concentration achieved in rat brain when administered perorally at a dose of 10 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,14793,,,1,CHEMBL626228,,,Rattus norvegicus,N,1,955.0,
11017,Maximum concentration achieved in rat plasma when administered intraperitoneally at a dose of 10 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,14793,,,1,CHEMBL626229,,,Rattus norvegicus,N,1,,
11018,Maximum concentration achieved in rat plasma when administered intravenously at a dose of 10 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,14793,,,1,CHEMBL626921,,,Rattus norvegicus,N,1,,
11019,Maximum concentration achieved in rat plasma when administered perorally at a dose of 100 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,14793,,,1,CHEMBL876793,,,Rattus norvegicus,N,1,,
11020,Maximum concentration achieved in rat plasma when administered perorally at a dose of 10 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,14793,,,1,CHEMBL625309,,,Rattus norvegicus,N,1,,
11021,Maximum concentration determined against Bacillus subtilis ATCC 6633 after oral administration in dog(25 mg/kg),Intermediate,1423.0,,A,,BAO_0000218,10524,,,1,CHEMBL625310,,,Bacillus subtilis,N,1,,
11022,Maximum concentration determined in monkeys dosed intravenously with 30 mg/kg,Autocuration,314293.0,,A,,BAO_0000218,11871,,,1,CHEMBL625311,,,Simiiformes,U,0,,
11023,Maximum concentration determined in rats dosed intravenously with 20 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,11871,,,1,CHEMBL625312,,,Rattus norvegicus,N,1,,
11024,Maximum concentration for the bioavailability at a dose of 20 mg/kg administered orally,Autocuration,,,A,,BAO_0000218,3437,,,1,CHEMBL625313,,,,U,0,,
11025,Maximum concentration in male CD-1 mice after sc administration of 20 mg/kg,Intermediate,10090.0,,A,,BAO_0000218,12038,,,1,CHEMBL625314,,,Mus musculus,N,1,,
11026,Maximum concentration in male rats after iv administration of 20 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,12038,,,1,CHEMBL625315,,,Rattus norvegicus,N,1,,
11027,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.06-1.29,Intermediate,10116.0,,A,,BAO_0000218,8418,,,1,CHEMBL625316,,,Rattus norvegicus,N,1,2107.0,
11028,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.77-2.08,Intermediate,10116.0,,A,,BAO_0000218,8418,,,1,CHEMBL625317,,,Rattus norvegicus,N,1,2107.0,
11029,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.54-0.89,Intermediate,10116.0,,A,,BAO_0000218,8418,,,1,CHEMBL625318,,,Rattus norvegicus,N,1,2107.0,
11030,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 1.57-1.66,Intermediate,10116.0,,A,,BAO_0000218,8418,,,1,CHEMBL625319,,,Rattus norvegicus,N,1,2107.0,
11031,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.06-2.71,Intermediate,10116.0,,A,,BAO_0000218,8418,,,1,CHEMBL625320,,,Rattus norvegicus,N,1,2107.0,
11032,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 2.98-3.22,Intermediate,10116.0,,A,,BAO_0000218,8418,,,1,CHEMBL625321,,,Rattus norvegicus,N,1,2107.0,
11033,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.73-1.45,Intermediate,10116.0,,A,,BAO_0000218,8418,,,1,CHEMBL625322,,,Rattus norvegicus,N,1,2107.0,
11034,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 1.03-1.31,Intermediate,10116.0,,A,,BAO_0000218,8418,,,1,CHEMBL876801,,,Rattus norvegicus,N,1,2107.0,
11035,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 6.76-10.44,Intermediate,10116.0,,A,,BAO_0000218,8418,,,1,CHEMBL625323,,,Rattus norvegicus,N,1,2107.0,
11036,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.47-1.17,Intermediate,10116.0,,A,,BAO_0000218,8418,,,1,CHEMBL625324,,,Rattus norvegicus,N,1,2107.0,
11037,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 1.12-1.44,Intermediate,10116.0,,A,,BAO_0000218,8418,,,1,CHEMBL625325,,,Rattus norvegicus,N,1,2107.0,
11038,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.38-0.57,Intermediate,10116.0,,A,,BAO_0000218,8418,,,1,CHEMBL625326,,,Rattus norvegicus,N,1,2107.0,
11039,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.75-1.14,Intermediate,10116.0,,A,,BAO_0000218,8418,,,1,CHEMBL625327,,,Rattus norvegicus,N,1,2107.0,
11040,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 1.36-1.74,Intermediate,10116.0,,A,,BAO_0000218,8418,,,1,CHEMBL625328,,,Rattus norvegicus,N,1,2107.0,
11041,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 1.05-1.5,Intermediate,10116.0,,A,,BAO_0000218,8418,,,1,CHEMBL625329,,,Rattus norvegicus,N,1,2048.0,
11042,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 3.10-3.77,Intermediate,10116.0,,A,,BAO_0000218,8418,,,1,CHEMBL625330,,,Rattus norvegicus,N,1,2048.0,
11043,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.4-0.54,Intermediate,10116.0,,A,,BAO_0000218,8418,,,1,CHEMBL627774,,,Rattus norvegicus,N,1,2048.0,
11044,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.58-0.86,Intermediate,10116.0,,A,,BAO_0000218,8418,,,1,CHEMBL627775,,,Rattus norvegicus,N,1,2048.0,
11045,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.77-0.86,Intermediate,10116.0,,A,,BAO_0000218,8418,,,1,CHEMBL627949,,,Rattus norvegicus,N,1,2048.0,
11046,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.86-1.13,Intermediate,10116.0,,A,,BAO_0000218,8418,,,1,CHEMBL627950,,,Rattus norvegicus,N,1,2048.0,
11047,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 2.26-2.89,Intermediate,10116.0,,A,,BAO_0000218,8418,,,1,CHEMBL627951,,,Rattus norvegicus,N,1,2048.0,
11048,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.54-0.7,Intermediate,10116.0,,A,,BAO_0000218,8418,,,1,CHEMBL627952,,,Rattus norvegicus,N,1,2048.0,
11049,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.6-0.66,Intermediate,10116.0,,A,,BAO_0000218,8418,,,1,CHEMBL627953,,,Rattus norvegicus,N,1,2048.0,
11050,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.35-1.74,Intermediate,10116.0,,A,,BAO_0000218,8418,,,1,CHEMBL627954,,,Rattus norvegicus,N,1,2048.0,
11051,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 3.62-7.08,Intermediate,10116.0,,A,,BAO_0000218,8418,,,1,CHEMBL627955,,,Rattus norvegicus,N,1,2048.0,
11052,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.47-0.56,Intermediate,10116.0,,A,,BAO_0000218,8418,,,1,CHEMBL627956,,,Rattus norvegicus,N,1,2048.0,
11053,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.54-1.07,Intermediate,10116.0,,A,,BAO_0000218,8418,,,1,CHEMBL876802,,,Rattus norvegicus,N,1,2048.0,
11054,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.76-0.91,Intermediate,10116.0,,A,,BAO_0000218,8418,,,1,CHEMBL627957,,,Rattus norvegicus,N,1,2048.0,
11055,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.61-0.86,Intermediate,10116.0,,A,,BAO_0000218,8418,,,1,CHEMBL627958,,,Rattus norvegicus,N,1,2048.0,
11056,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 2.11-3.79,Intermediate,10116.0,,A,,BAO_0000218,8418,,,1,CHEMBL627959,,,Rattus norvegicus,N,1,2048.0,
11057,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.3-0.36,Intermediate,10116.0,,A,,BAO_0000218,8418,,,1,CHEMBL627960,,,Rattus norvegicus,N,1,2048.0,
11058,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.36-0.44,Intermediate,10116.0,,A,,BAO_0000218,8418,,,1,CHEMBL627961,,,Rattus norvegicus,N,1,2048.0,
11059,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.5-0.65,Intermediate,10116.0,,A,,BAO_0000218,8418,,,1,CHEMBL627962,,,Rattus norvegicus,N,1,2048.0,
11060,Distribution of radiolabeled compound in intestinal contents of rat 1 hr after ip administration of dose and excess 8 microg of estradiol; fmol equivalents per 100 mg,Intermediate,10116.0,,A,,BAO_0000218,9796,,,1,CHEMBL627963,,,Rattus norvegicus,N,1,,
11061,Distribution of radiolabeled compound in intestinal contents of rat 1 hr after ip administration of dose; fmol equivalents per 100 mg,Intermediate,10116.0,,A,,BAO_0000218,9796,,,1,CHEMBL624759,,,Rattus norvegicus,N,1,,
11062,Distribution of radiolabeled compound in intestinal contents of rat 1 hr after iv administration of dose; fmol equivalents per 100 mg,Intermediate,10116.0,,A,,BAO_0000218,9796,,,1,CHEMBL624760,,,Rattus norvegicus,N,1,,
11063,Distribution of radiolabeled compound in intestinal contents of rat 4 hr after ip administration of dose; fmol equivalents per 100 mg,Intermediate,10116.0,,A,,BAO_0000218,9796,,,1,CHEMBL624761,,,Rattus norvegicus,N,1,,
11064,Distribution of radiolabeled compound in intestinal contents of rat 8 hr after ip administration of dose; fmol equivalents per 100 mg,Intermediate,10116.0,,A,,BAO_0000218,9796,,,1,CHEMBL877607,,,Rattus norvegicus,N,1,,
11065,Distribution of radiolabeled compound in liver of rat 1 hr after ip administration of dose and excess 8 microg of estradiol; fmol equivalents per 100 mg,Intermediate,10116.0,,A,,BAO_0000218,9796,,,1,CHEMBL624762,,,Rattus norvegicus,N,1,2107.0,
11066,Distribution of radiolabeled compound in liver of rat 1 hr after ip administration of dose; fmol equivalents per 100 mg,Intermediate,10116.0,,A,,BAO_0000218,9796,,,1,CHEMBL624763,,,Rattus norvegicus,N,1,2107.0,
11067,Distribution of radiolabeled compound in liver of rat 1 hr after iv administration of dose; fmol equivalents per 100 mg,Intermediate,10116.0,,A,,BAO_0000218,9796,,,1,CHEMBL624764,,,Rattus norvegicus,N,1,2107.0,
11068,Distribution of radiolabeled compound in liver of rat 4 hr after ip administration of dose; fmol equivalents per 100 mg,Intermediate,10116.0,,A,,BAO_0000218,9796,,,1,CHEMBL624765,,,Rattus norvegicus,N,1,2107.0,
11069,Distribution of radiolabeled compound in liver of rat 8 hr after ip administration of dose; fmol equivalents per 100 mg,Intermediate,10116.0,,A,,BAO_0000218,9796,,,1,CHEMBL624766,,,Rattus norvegicus,N,1,2107.0,
11070,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5.4 mg/kg after ip administration ( 0-6 hr),Intermediate,9615.0,,A,,BAO_0000218,6996,,,1,CHEMBL624767,,,Canis lupus familiaris,N,1,,
11071,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration,Intermediate,9615.0,,A,,BAO_0000218,6996,,,1,CHEMBL624768,,,Canis lupus familiaris,N,1,,
11072,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration (0-6 hr),Intermediate,9615.0,,A,,BAO_0000218,6996,,,1,CHEMBL624769,,,Canis lupus familiaris,N,1,,
11073,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration ( 0 - 6 hr),Intermediate,9615.0,,A,,BAO_0000218,6996,,,1,CHEMBL624770,,,Canis lupus familiaris,N,1,,
11074,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration ( 0-6 hr ),Intermediate,9615.0,,A,,BAO_0000218,6996,,,1,CHEMBL624771,,,Canis lupus familiaris,N,1,,
11075,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration ( 0-6 hr),Intermediate,9615.0,,A,,BAO_0000218,6996,,,1,CHEMBL624772,,,Canis lupus familiaris,N,1,,
11076,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration,Intermediate,10116.0,,A,,BAO_0000218,6996,,,1,CHEMBL624773,,,Rattus norvegicus,N,1,,
11077,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),Intermediate,10116.0,,A,,BAO_0000218,6996,,,1,CHEMBL624774,,,Rattus norvegicus,N,1,,
11078,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration (0-5 hr),Intermediate,10116.0,,A,,BAO_0000218,6996,,,1,CHEMBL624775,,,Rattus norvegicus,N,1,,
11079,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration ( 0 - 5 hr),Intermediate,10116.0,,A,,BAO_0000218,6996,,,1,CHEMBL624776,,,Rattus norvegicus,N,1,,
11080,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr ),Intermediate,10116.0,,A,,BAO_0000218,6996,,,1,CHEMBL624777,,,Rattus norvegicus,N,1,,
11081,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),Intermediate,10116.0,,A,,BAO_0000218,6996,,,1,CHEMBL624778,,,Rattus norvegicus,N,1,,
11082,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration,Intermediate,10116.0,,A,,BAO_0000218,6996,,,1,CHEMBL624779,,,Rattus norvegicus,N,1,,
11083,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration ( 0 - 5 hr),Intermediate,10116.0,,A,,BAO_0000218,6996,,,1,CHEMBL624780,,,Rattus norvegicus,N,1,,
11084,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr ),Intermediate,10116.0,,A,,BAO_0000218,6996,,,1,CHEMBL624781,,,Rattus norvegicus,N,1,,
11085,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),Intermediate,10116.0,,A,,BAO_0000218,6996,,,1,CHEMBL877608,,,Rattus norvegicus,N,1,,
11086,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration (0-5 hr),Intermediate,10116.0,,A,,BAO_0000218,6996,,,1,CHEMBL624782,,,Rattus norvegicus,N,1,,
11087,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),Intermediate,10116.0,,A,,BAO_0000218,6996,,,1,CHEMBL624783,,,Rattus norvegicus,N,1,,
11088,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration,Intermediate,10116.0,,A,,BAO_0000218,6996,,,1,CHEMBL624784,,,Rattus norvegicus,N,1,,
11089,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),Intermediate,10116.0,,A,,BAO_0000218,6996,,,1,CHEMBL624785,,,Rattus norvegicus,N,1,,
11090,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration (0-5 hr),Intermediate,10116.0,,A,,BAO_0000218,6996,,,1,CHEMBL624786,,,Rattus norvegicus,N,1,,
11091,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr ),Intermediate,10116.0,,A,,BAO_0000218,6996,,,1,CHEMBL624787,,,Rattus norvegicus,N,1,,
11092,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),Intermediate,10116.0,,A,,BAO_0000218,6996,,,1,CHEMBL628676,,,Rattus norvegicus,N,1,,
11093,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration,Intermediate,10116.0,,A,,BAO_0000218,6996,,,1,CHEMBL621842,,,Rattus norvegicus,N,1,,
11094,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),Intermediate,10116.0,,A,,BAO_0000218,6996,,,1,CHEMBL621843,,,Rattus norvegicus,N,1,,
11095,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration (0-5 hr),Intermediate,10116.0,,A,,BAO_0000218,6996,,,1,CHEMBL623873,,,Rattus norvegicus,N,1,,
11096,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration ( 0 - 5 hr),Intermediate,10116.0,,A,,BAO_0000218,6996,,,1,CHEMBL623874,,,Rattus norvegicus,N,1,,
11097,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr ),Intermediate,10116.0,,A,,BAO_0000218,6996,,,1,CHEMBL623875,,,Rattus norvegicus,N,1,,
11098,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),Intermediate,10116.0,,A,,BAO_0000218,6996,,,1,CHEMBL623876,,,Rattus norvegicus,N,1,,
11099,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 0.312 mg/kg after ip administration,Intermediate,9615.0,,A,,BAO_0000218,6996,,,1,CHEMBL623877,,,Canis lupus familiaris,N,1,,
11100,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 0.3 mg/kg after ip administration (0-6 hr),Intermediate,9615.0,,A,,BAO_0000218,6996,,,1,CHEMBL623878,,,Canis lupus familiaris,N,1,,
11101,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 0.625 mg/kg after ip administration,Intermediate,9615.0,,A,,BAO_0000218,6996,,,1,CHEMBL623879,,,Canis lupus familiaris,N,1,,
11102,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 0.6 mg/kg after ip administration ( 0-6 hr),Intermediate,9615.0,,A,,BAO_0000218,6996,,,1,CHEMBL623880,,,Canis lupus familiaris,N,1,,
11103,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1.8 mg/kg after ip administration ( 0-6 hr),Intermediate,9615.0,,A,,BAO_0000218,6996,,,1,CHEMBL623881,,,Canis lupus familiaris,N,1,,
11104,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 10 mg/kg after ip administration (0-6 hr),Intermediate,9615.0,,A,,BAO_0000218,6996,,,1,CHEMBL623957,,,Canis lupus familiaris,N,1,,
11105,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 10 mg/kg after ip administration ( 0-6 hr),Intermediate,9615.0,,A,,BAO_0000218,6996,,,1,CHEMBL623958,,,Canis lupus familiaris,N,1,,
11106,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 16.2 mg/kg after ip administration ( 0-6 hr),Intermediate,9615.0,,A,,BAO_0000218,6996,,,1,CHEMBL623959,,,Canis lupus familiaris,N,1,,
11107,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1 mg/kg after ip administration ( 0-6 hr),Intermediate,9615.0,,A,,BAO_0000218,6996,,,1,CHEMBL623960,,,Canis lupus familiaris,N,1,,
11108,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1 mg/kg after ip administration (0-6 hr),Intermediate,9615.0,,A,,BAO_0000218,6996,,,1,CHEMBL623961,,,Canis lupus familiaris,N,1,,
11109,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1 mg/kg after ip administration ( 0 - 6 hr),Intermediate,9615.0,,A,,BAO_0000218,6996,,,1,CHEMBL623962,,,Canis lupus familiaris,N,1,,
11110,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1 mg/kg after ip administration ( 0-6 hr ),Intermediate,9615.0,,A,,BAO_0000218,6996,,,1,CHEMBL624676,,,Canis lupus familiaris,N,1,,
11111,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 20 mg/kg after ip administration ( 0-6 hr),Intermediate,9615.0,,A,,BAO_0000218,6996,,,1,CHEMBL624677,,,Canis lupus familiaris,N,1,,
11112,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 2 mg/kg after ip administration,Intermediate,9615.0,,A,,BAO_0000218,6996,,,1,CHEMBL624678,,,Canis lupus familiaris,N,1,,
11113,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 2 mg/kg after ip administration (0-6 hr),Intermediate,9615.0,,A,,BAO_0000218,6996,,,1,CHEMBL624679,,,Canis lupus familiaris,N,1,,
11114,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 2 mg/kg after ip administration ( 0 - 6 hr),Intermediate,9615.0,,A,,BAO_0000218,6996,,,1,CHEMBL624680,,,Canis lupus familiaris,N,1,,
11115,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 27%,Autocuration,,,A,,BAO_0000218,11732,,,1,CHEMBL624849,,,,U,0,,
11116,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 4%,Autocuration,,,A,,BAO_0000218,11732,,,1,CHEMBL624850,,,,U,0,,
11117,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 54%,Autocuration,,,A,,BAO_0000218,11732,,,1,CHEMBL874399,,,,U,0,,
11118,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 72%,Autocuration,,,A,,BAO_0000218,11732,,,1,CHEMBL624851,,,,U,0,,
11119,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 76%,Autocuration,,,A,,BAO_0000218,11732,,,1,CHEMBL624852,,,,U,0,,
11120,Oral bioavailability in rat (dose 10 mg/kg),Autocuration,10116.0,,A,,BAO_0000218,13359,,,1,CHEMBL624853,,,Rattus norvegicus,U,0,,
11121,Oral bioavailability in rat (Sprague-Dawley),Autocuration,10116.0,,A,,BAO_0000218,16618,,,1,CHEMBL624854,,,Rattus norvegicus,U,0,,
11122,Oral bioavailability in rat,Autocuration,10116.0,,A,,BAO_0000218,13960,,,1,CHEMBL624855,,,Rattus norvegicus,U,0,,
11123,Oral bioavailability in rats was determined in vivo,Autocuration,10116.0,,A,,BAO_0000218,13917,,,1,CHEMBL624856,,,Rattus norvegicus,U,0,,
11124,Oral bioavailability in dog,Autocuration,9615.0,,A,,BAO_0000218,14266,,,1,CHEMBL882957,,,Canis lupus familiaris,U,0,,
11125,Oral bioavailability of compound in monkey,Autocuration,314293.0,,A,,BAO_0000218,12359,,,1,CHEMBL624857,,,Simiiformes,U,0,,
11126,Oral bioavailability of compound in rat,Intermediate,10116.0,,A,,BAO_0000218,12359,,,1,CHEMBL622202,,,Rattus norvegicus,N,1,,
11127,Bioavailability in rat of PMEA prodrug,Autocuration,10116.0,,A,,BAO_0000218,12359,,,1,CHEMBL622203,,,Rattus norvegicus,U,0,,
11128,Oral bioavailability of compound was evaluated relative to that of PMEA in rat; Not determined due to lack of solubility,Intermediate,10116.0,,A,,BAO_0000218,12359,,,1,CHEMBL625522,,,Rattus norvegicus,N,1,,
11129,Serum conc at 3 hours following 25 mg/kg dose,Autocuration,9544.0,,A,,BAO_0000218,10791,,,1,CHEMBL622868,,,Macaca mulatta,U,0,,
11130,Urine conc 0-5 hours following 25 mg/kg dose,Autocuration,9544.0,,A,,BAO_0000218,10791,,,1,CHEMBL622869,,,Macaca mulatta,U,0,1088.0,
11131,Urine conc 0-24 hours following 25 mg/kg dose,Autocuration,9544.0,,A,,BAO_0000218,10791,,,1,CHEMBL622870,,,Macaca mulatta,U,0,1088.0,
11132,Oral bioavailability in African green monkeys; 20-25,Autocuration,9534.0,,A,,BAO_0000218,138,,,1,CHEMBL622871,,,Chlorocebus aethiops,U,0,,
11133,Oral bioavailability in cynomolgus monkey.,Intermediate,9541.0,,A,,BAO_0000218,14521,,,1,CHEMBL620560,,,Macaca fascicularis,N,1,,
11134,Oral bioavailability in dog,Autocuration,9615.0,,A,,BAO_0000218,13953,,,1,CHEMBL620561,,,Canis lupus familiaris,U,0,,
11135,Oral bioavailability in dog at 10 mg/kg oral dose,Intermediate,9615.0,,A,,BAO_0000218,12836,,,1,CHEMBL620562,,,Canis lupus familiaris,N,1,,
11136,Oral bioavailability in hamster at 10 mg/kg oral dose,Intermediate,10026.0,,A,,BAO_0000218,12836,,,1,CHEMBL620563,,,Cricetinae,N,1,,
11137,Oral bioavailability in rat at 10 mg/kg oral dose,Intermediate,10116.0,,A,,BAO_0000218,12836,,,1,CHEMBL620564,,,Rattus norvegicus,N,1,,
11138,Oral bioavailability in rat,Autocuration,10116.0,,A,,BAO_0000218,14521,,,1,CHEMBL872265,,,Rattus norvegicus,U,0,,
11139,Oral bioavailability in rat,Autocuration,10116.0,,A,,BAO_0000218,13953,,,1,CHEMBL620565,,,Rattus norvegicus,U,0,,
11140,Oral bioavailability,Autocuration,9347.0,,A,,BAO_0000218,6799,,,1,CHEMBL620566,,,Eutheria,U,0,,
11141,Oral bioavailability was determined; range 49-102%,Autocuration,,,A,,BAO_0000218,11311,,,1,CHEMBL620567,,,,U,0,,
11142,Oral bioavailability was determined in dogs,Intermediate,9615.0,,A,,BAO_0000218,4013,,,1,CHEMBL620568,,,Canis lupus familiaris,N,1,,
11143,Oral bioavailability in rat,Autocuration,10116.0,,A,,BAO_0000218,4013,,,1,CHEMBL620569,,,Rattus norvegicus,U,0,,
11144,Oral bioavailability,Autocuration,9347.0,,A,,BAO_0000218,17591,,,1,CHEMBL620570,,,Eutheria,U,0,,
11145,Oral bioavailability was determined; Not orally available,Autocuration,,,A,,BAO_0000218,17591,,,1,CHEMBL620571,,,,U,0,,
11146,Percent bioavailability was administered by using 0.4% Methyl cellulose (MC) as vehicle to nude mice at a dose of 25 mg/kg (micronized sample),Intermediate,10090.0,,A,,BAO_0000218,15011,,,1,CHEMBL620572,,,Mus musculus,N,1,,
11147,Bioavailability in mouse (nude) (dose 0.4% Methylcellulose (MC) as vehicle 25 mg/kg),Autocuration,10090.0,,A,,BAO_0000218,15011,,,1,CHEMBL620573,,,Mus musculus,U,0,,
11148,Bioavailability in mouse (nude) using 20% aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle 25 mg/kg,Autocuration,10090.0,,A,,BAO_0000218,15011,,,1,CHEMBL620574,,,Mus musculus,U,0,,
11149,Oral bioavailability in Rhesus monkey,Autocuration,9544.0,,A,,BAO_0000218,9552,,,1,CHEMBL620575,,,Macaca mulatta,U,0,,
11150,Oral bioavailability in dog (female mongrel),Autocuration,9615.0,,A,,BAO_0000218,9552,,,1,CHEMBL620576,,,Canis lupus familiaris,U,0,,
11151,Percent oral bioavailability of perorally administered compound (30 mg/kg) was tested,Autocuration,,,A,,BAO_0000218,3639,,,1,CHEMBL875846,,,,U,0,,
11152,Oral bioavailability in dog,Autocuration,9615.0,,A,,BAO_0000218,13397,,,1,CHEMBL620577,,,Canis lupus familiaris,U,0,,
11153,Percentage Bioavailability was evaluated.,Autocuration,,,A,,BAO_0000218,3031,,,1,CHEMBL620578,,,,U,0,,
11154,Bioavailability in rat administered i.d.,Autocuration,10116.0,,A,,BAO_0000218,12818,,,1,CHEMBL620579,,,Rattus norvegicus,U,0,,
11155,Bioavailability,Autocuration,9347.0,,A,,BAO_0000218,4847,,,1,CHEMBL621248,,,Eutheria,U,0,,
11156,Bioavailability in dog (male Beagle) i.v. administration,Autocuration,9615.0,,A,,BAO_0000218,12421,,,1,CHEMBL625390,,,Canis lupus familiaris,U,0,,
11157,"Bioavailability in rat (dose 20 mg/kg p.o. in 1% methocel, and 5 mg/kg i.v. in PEG400)",Autocuration,10116.0,,A,,BAO_0000218,11966,,,1,CHEMBL625391,,,Rattus norvegicus,U,0,,
11158,Bioavailability in monkey (dose 10 mg/kg i.d. or 0.3 mg/kg i.v.),Autocuration,9443.0,,A,,BAO_0000218,11218,,,1,CHEMBL872266,,,Primates,U,0,,
11159,Oral bioavailability in rat (Sprague-Dawley) (male),Autocuration,10116.0,,A,,BAO_0000218,13129,,,1,CHEMBL625392,,,Rattus norvegicus,U,0,,
11160,The oral bioavailability was measured on rats after oral administration,Intermediate,10116.0,,A,,BAO_0000218,12350,,,1,CHEMBL625393,,,Rattus norvegicus,N,1,,
11161,Bioavailability was evaluated in rat at an intravenous dose of 3 mg/kg and peroral dose of 5 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,2231,,,1,CHEMBL625394,,,Rattus norvegicus,N,1,,
11162,Bioavailability was evaluated in rhesus monkey at an intravenous dose of 1 mg/kg and peroral dose of 1 mg/kg,Intermediate,9544.0,,A,,BAO_0000218,2231,,,1,CHEMBL625395,,,Macaca mulatta,N,1,,
11163,Bioavailability in rat (dose 10 mg/kg i.d.),Autocuration,10116.0,,A,,BAO_0000218,12187,,,1,CHEMBL625396,,,Rattus norvegicus,U,0,,
11164,Bioavailability in dog (male Beagle) i.v. administration,Autocuration,9615.0,,A,,BAO_0000218,12421,,,1,CHEMBL625397,,,Canis lupus familiaris,U,0,,
11165,Biodistribution in CD-1 mice was determined after 1 minute in Striatum(expressed as percent injected dose per gram normalized to a 25 g mouse),Intermediate,10090.0,,A,,BAO_0000218,13256,,,1,CHEMBL625398,,,Mus musculus,N,1,,
11166,Biodistribution in CD-1 mice was determined after 1 minute in blood(expressed as percent injected dose per gram normalized to a 25 g mouse),Intermediate,10090.0,,A,,BAO_0000218,13256,,,1,CHEMBL625399,,,Mus musculus,N,1,178.0,
11167,Biodistribution in CD-1 mice was determined after 1 minute in cerebellum(expressed as percent injected dose per gram normalized to a 25 g mouse),Intermediate,10090.0,,A,,BAO_0000218,13256,,,1,CHEMBL626074,,,Mus musculus,N,1,2037.0,
11168,Biodistribution in CD-1 mice was determined after 1 minute in cortex(expressed as percent injected dose per gram normalized to a 25 g mouse),Intermediate,10090.0,,A,,BAO_0000218,13256,,,1,CHEMBL626075,,,Mus musculus,N,1,,
11169,Maximum concentration in plasma (Cmax) was evaluated in rat at an intravenous dose of 3 mg/kg and peroral dose of 5 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,2231,,,1,CHEMBL626076,,,Rattus norvegicus,N,1,1969.0,
11170,Maximum concentration in plasma (Cmax) was evaluated in rhesus monkey at an intravenous dose of 1 mg/kg and peroral dose of 1 mg/kg,Intermediate,9544.0,,A,,BAO_0000218,2231,,,1,CHEMBL626077,,,Macaca mulatta,N,1,1969.0,
11171,Maximum concentration in whole blood recorded in the period 0-24 hr postdose of 1 mg/kg in rat (normalized to a 1 mg/kg dose),Intermediate,10116.0,,A,,BAO_0000218,12178,,,1,CHEMBL626078,,,Rattus norvegicus,N,1,178.0,
11172,Maximum concentration in whole blood recorded in the period 0-24 hr postdose of 2.5 mg/kg in rat (normalized to a 1 mg/kg dose),Autocuration,,,A,,BAO_0000218,12178,,,1,CHEMBL625846,,,,U,0,178.0,
11173,Maximum concentration in whole blood recorded in the period 0-24 hr postdose of 5.0 mg/kg GP (normalized to a 1 mg/kg dose),Autocuration,,,A,,BAO_0000218,12178,,,1,CHEMBL625847,,,,U,0,178.0,
11174,Maximum concentration observed in rats at an oral dose of 50 mg/kg,Expert,10116.0,,A,,BAO_0000218,15633,,,1,CHEMBL625848,,,Rattus norvegicus,N,1,,
11175,Maximum concentration of compound in plasma administered orally to rats,Intermediate,10116.0,,A,,BAO_0000218,14258,,,1,CHEMBL625849,,,Rattus norvegicus,N,1,1969.0,
11176,"Maximum concentration (10 mg/kg, orally) in plasma of dogs",Intermediate,9615.0,,A,,BAO_0000218,14224,,,1,CHEMBL626023,,,Canis lupus familiaris,N,1,1969.0,
11177,"Maximum concentration (10 mg/kg, perorally) in plasma of dogs",Intermediate,9615.0,,A,,BAO_0000218,14224,,,1,CHEMBL626024,,,Canis lupus familiaris,N,1,1969.0,
11178,"Maximum concentration (5 mg/kg, intravenously) in plasma of dogs",Intermediate,9615.0,,A,,BAO_0000218,14224,,,1,CHEMBL626025,,,Canis lupus familiaris,N,1,1969.0,
11179,Maximum concentration after 10 mg/kg by oral administration,Autocuration,,,A,,BAO_0000218,5566,,,1,CHEMBL626026,,,,U,0,,
11180,Maximum concentration at a dose of 1.5 mg/kg,Autocuration,,,A,,BAO_0000218,16935,,,1,CHEMBL626027,,,,U,0,,
11181,Maximum concentration at a dose of 2.0 mg/kg,Autocuration,,,A,,BAO_0000218,16935,,,1,CHEMBL626028,,,,U,0,,
11182,Maximum concentration in dog plasma,Intermediate,9615.0,,A,,BAO_0000218,14224,,,1,CHEMBL626029,,,Canis lupus familiaris,N,1,1969.0,
11183,Maximum concentration in plasma after administration of 10 umol/kg dose perorally,Autocuration,,,A,,BAO_0000218,12536,,,1,CHEMBL626030,,,,U,0,1969.0,
11184,Maximum concentration in plasma after administration of 2 umol/kg dose intravenously,Autocuration,,,A,,BAO_0000218,12536,,,1,CHEMBL626031,,,,U,0,1969.0,
11185,Maximum concentration in plasma after administration of 4 umol/kg dose intravenously,Autocuration,,,A,,BAO_0000218,12536,,,1,CHEMBL626032,,,,U,0,1969.0,
11186,Maximum concentration in plasma after administration of 40 umol/kg dose perorally,Autocuration,,,A,,BAO_0000218,12536,,,1,CHEMBL626033,,,,U,0,1969.0,
11187,Maximum concentration in plasma after administration of 5 umol/kg dose intravenously,Autocuration,,,A,,BAO_0000218,12536,,,1,CHEMBL626034,,,,U,0,1969.0,
11188,Maximum concentration in plasma after oral administration in dog (25 mg/kg),Intermediate,9615.0,,A,,BAO_0000218,9994,,,1,CHEMBL626035,,,Canis lupus familiaris,N,1,1969.0,
11189,Maximum concentration in plasma at Tmax,Autocuration,,,A,,BAO_0000218,1434,,,1,CHEMBL626036,,,,U,0,1969.0,
11190,Maximum concentration in plasma recorded 0-6 hr post dose in dog at 10 mg/kg oral dose,Expert,9615.0,,A,,BAO_0000218,12836,,,1,CHEMBL626037,,,Canis lupus familiaris,N,1,1969.0,
11191,Maximum concentration in plasma recorded in the period 0-6 hr post dose in hamster at 10 mg/kg oral dose,Intermediate,10026.0,,A,,BAO_0000218,12836,,,1,CHEMBL626038,,,Cricetinae,N,1,1969.0,
11192,Maximum concentration in plasma recorded in the period 0-6 hr post dose in rat at 10 mg/kg oral dose,Intermediate,10116.0,,A,,BAO_0000218,12836,,,1,CHEMBL626039,,,Rattus norvegicus,N,1,1969.0,
11193,Maximum concentration in plasma was determined by oral administration to rats at 20 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,12545,,,1,CHEMBL626040,,,Rattus norvegicus,N,1,1969.0,
11194,Maximum concentration present in the rabbit plasma following peroral administration of 10 mg/kg,Intermediate,9986.0,,A,,BAO_0000218,13856,,,1,CHEMBL626041,,,Oryctolagus cuniculus,N,1,1969.0,
11195,Maximum concentration was calculated,Autocuration,,,A,,BAO_0000218,3550,,,1,CHEMBL626042,,,,U,0,,
11196,Maximum concentration was calculated.,Autocuration,,,A,,BAO_0000218,2632,,,1,CHEMBL626043,,,,U,0,,
11197,Maximum concentration at a peroral dose of 10 mg/kg,Autocuration,,,A,,BAO_0000218,5566,,,1,CHEMBL626044,,,,U,0,,
11198,Maximum concentration of the drug at 10 uM/dg administered perorally,Autocuration,,,A,,BAO_0000218,11883,,,1,CHEMBL626045,,,,U,0,,
11199,Maximum concentration of the drug at 2 uM/dg administered intravenously,Autocuration,,,A,,BAO_0000218,11883,,,1,CHEMBL626046,,,,U,0,,
11200,"Maximum concentration of the unchanged compound in dog plasma, recorded in the period 0-6 hr post dose.",Intermediate,9615.0,,A,,BAO_0000218,14122,,,1,CHEMBL626047,,,Canis lupus familiaris,N,1,1969.0,
11201,"Maximum concentration of the unchanged compound in hamster plasma, recorded in the period 0-6 hr post dose.",Intermediate,10026.0,,A,,BAO_0000218,14122,,,1,CHEMBL626048,,,Cricetinae,N,1,1969.0,
11202,"Maximum concentration of the unchanged compound in rat plasma, recorded in the period 0-6 hr post dose.",Intermediate,10116.0,,A,,BAO_0000218,14122,,,1,CHEMBL626049,,,Rattus norvegicus,N,1,1969.0,
11203,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose in anesthetized rat at 60 mg/kg oral dose,Intermediate,10116.0,,A,,BAO_0000218,12542,,,1,CHEMBL626050,,,Rattus norvegicus,N,1,1969.0,
11204,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose in dog at 5 mg/kg oral dose,Intermediate,9615.0,,A,,BAO_0000218,12542,,,1,CHEMBL874541,,,Canis lupus familiaris,N,1,1969.0,
11205,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose in hamster at 40 mg/kg oral dose,Intermediate,10026.0,,A,,BAO_0000218,12542,,,1,CHEMBL622826,,,Cricetinae,N,1,1969.0,
11206,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose to hamster at 40 mg/kg oral dose,Intermediate,10026.0,,A,,BAO_0000218,12542,,,1,CHEMBL622827,,,Cricetinae,N,1,1969.0,
11207,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose in anesthetized rat at 25 mg/kg oral dose,Intermediate,10116.0,,A,,BAO_0000218,12542,,,1,CHEMBL622828,,,Rattus norvegicus,N,1,1969.0,
11208,Maximum concentration of unchanged drug in rat plasma in the period 0-24 hr after dosing,Intermediate,10116.0,,A,,BAO_0000218,14080,,,1,CHEMBL622829,,,Rattus norvegicus,N,1,1969.0,
11209,Maximum concentration reached following intravenous administration in male rat,Intermediate,10116.0,,A,,BAO_0000218,11911,,,1,CHEMBL876806,,,Rattus norvegicus,N,1,,
11210,Maximum concentration was determined in an aqueous sodium hydroxide solution adjusted to pH 10 at 10 mg/kg dosage administered perorally in dog,Intermediate,9615.0,,A,,BAO_0000218,13204,,,1,CHEMBL622830,,,Canis lupus familiaris,N,1,,
11211,Maximum concentration was determined in an aqueous sodium hydroxide solution adjusted to pH 10 at 5 mg/kg dosage administered perorally in rats,Intermediate,10116.0,,A,,BAO_0000218,13204,,,1,CHEMBL622831,,,Rattus norvegicus,N,1,,
11212,Maximum concentration was measured after peroral administration of 10 mg/kg of drug in male Beagle dogs,Intermediate,9615.0,,A,,BAO_0000218,14346,,,1,CHEMBL626794,,,Canis lupus familiaris,N,1,,
11213,Maximum concentration was measured after peroral administration of 5.0 mg/kg of drug in male Dawley rats,Intermediate,10116.0,,A,,BAO_0000218,14346,,,1,CHEMBL626795,,,Rattus norvegicus,N,1,,
11214,Maximum concentration was measured after peroral administration of 5.1 mg/kg of drug in male Dawley rats,Intermediate,10116.0,,A,,BAO_0000218,14346,,,1,CHEMBL626796,,,Rattus norvegicus,N,1,,
11215,Maximum concentration was measured after peroral administration of 5.2 mg/kg of drug in male Dawley rats,Intermediate,10116.0,,A,,BAO_0000218,14346,,,1,CHEMBL626797,,,Rattus norvegicus,N,1,,
11216,Maximum drug concentration is determined after oral dosing in rats.,Intermediate,10116.0,,A,,BAO_0000218,14127,,,1,CHEMBL626798,,,Rattus norvegicus,N,1,,
11217,Maximum observed concentration in oral (5 mg/kg) fasted dogs,Intermediate,9615.0,,A,,BAO_0000218,14339,,,1,CHEMBL626799,,,Canis lupus familiaris,N,1,,
11218,Maximum observed concentration in oral (5 mg/kg) fed dogs,Intermediate,9615.0,,A,,BAO_0000218,14339,,,1,CHEMBL626800,,,Canis lupus familiaris,N,1,,
11219,Maximum plasma concentration,Autocuration,,,A,,BAO_0000218,13494,,,1,CHEMBL626801,,,,U,0,1969.0,
11220,Maximum plasma concentration (Cmax) was determined in rats after intraduodenal administration of the drug,Intermediate,10116.0,,A,,BAO_0000218,14925,,,1,CHEMBL876816,,,Rattus norvegicus,N,1,1969.0,
11221,Maximum plasma concentration following oral administration of 26.3 mg/kg in rats,Intermediate,10116.0,,A,,BAO_0000218,14474,,,1,CHEMBL626802,,,Rattus norvegicus,N,1,1969.0,
11222,Maximum plasma concentration following oral administration of 3.8 mg/kg in Beagle dog,Intermediate,9615.0,,A,,BAO_0000218,14474,,,1,CHEMBL626803,,,Canis lupus familiaris,N,1,1969.0,
11223,Maximum plasma concentration following oral administration of 30 umol/kg,Autocuration,,,A,,BAO_0000218,13917,,,1,CHEMBL626804,,,,U,0,1969.0,
11224,Distribution of radiolabeled compound in plasma of rat 1 hr after ip administration of dose,Intermediate,10116.0,,A,,BAO_0000218,9796,,,1,CHEMBL626805,,,Rattus norvegicus,N,1,1969.0,
11225,Distribution of radiolabeled compound in plasma of rat 1 hr after ip administration of dose and excess 8 microg of estradiol; fmol equivalents per 100 mg,Intermediate,10116.0,,A,,BAO_0000218,9796,,,1,CHEMBL626309,,,Rattus norvegicus,N,1,1969.0,
11226,Distribution of radiolabeled compound in plasma of rat 1 hr after iv administration of dose; fmol equivalents per 100 mg,Intermediate,10116.0,,A,,BAO_0000218,9796,,,1,CHEMBL626310,,,Rattus norvegicus,N,1,1969.0,
11227,Distribution of radiolabeled compound in plasma of rat 4 hr after ip administration of dose; fmol equivalents per 100 mg,Intermediate,10116.0,,A,,BAO_0000218,9796,,,1,CHEMBL626311,,,Rattus norvegicus,N,1,1969.0,
11228,Distribution of radiolabeled compound in plasma of rat 8 hr after ip administration of dose; fmol equivalents per 100 mg,Intermediate,10116.0,,A,,BAO_0000218,9796,,,1,CHEMBL626312,,,Rattus norvegicus,N,1,1969.0,
11229,Distribution of radiolabeled compound in uterus of rat 1 hr after ip administration of dose; fmol equivalents per 100 mg,Intermediate,10116.0,,A,,BAO_0000218,9796,,,1,CHEMBL626313,,,Rattus norvegicus,N,1,995.0,
11230,Distribution of radiolabeled compound in uterus of rat 1 hr after ip administration of dose and excess 8 microg of estradiol; fmol equivalents per 100 mg,Intermediate,10116.0,,A,,BAO_0000218,9796,,,1,CHEMBL626314,,,Rattus norvegicus,N,1,995.0,
11231,Distribution of radiolabeled compound in uterus of rat 1 hr after iv administration of dose; fmol equivalents per 100 mg,Intermediate,10116.0,,A,,BAO_0000218,9796,,,1,CHEMBL626315,,,Rattus norvegicus,N,1,995.0,
11232,Distribution of radiolabeled compound in uterus of rat 4 hr after ip administration of dose; fmol equivalents per 100 mg,Intermediate,10116.0,,A,,BAO_0000218,9796,,,1,CHEMBL626316,,,Rattus norvegicus,N,1,995.0,
11233,Distribution of radiolabeled compound in uterus of rat 8 hr after ip administration of dose; fmol equivalents per 100 mg,Intermediate,10116.0,,A,,BAO_0000218,9796,,,1,CHEMBL626317,,,Rattus norvegicus,N,1,995.0,
11234,Distribution of rat erythrocytes for tube 2 on rate of aging in 2 mL of cell suspension; Minus (-),Intermediate,10116.0,,A,,BAO_0000218,8363,,,1,CHEMBL626318,,,Rattus norvegicus,N,1,,
11235,Distribution of rat erythrocytes for tube 2 on rate of aging in 2 mL of cell suspension; Plus (+),Intermediate,10116.0,,A,,BAO_0000218,8363,,,1,CHEMBL626319,,,Rattus norvegicus,N,1,,
11236,Distribution of rat erythrocytes for tube 3 on rate of aging in 2 mL of cell suspension; Minus (-),Intermediate,10116.0,,A,,BAO_0000218,8363,,,1,CHEMBL626320,,,Rattus norvegicus,N,1,,
11237,Distribution of rat erythrocytes for tube 3 on rate of aging in 2 mL of cell suspension; Plus (+),Intermediate,10116.0,,A,,BAO_0000218,8363,,,1,CHEMBL875053,,,Rattus norvegicus,N,1,,
11238,Distribution of rat erythrocytes for tube 4 on rate of aging in 2 mL of cell suspension; Minus (-),Intermediate,10116.0,,A,,BAO_0000218,8363,,,1,CHEMBL626321,,,Rattus norvegicus,N,1,,
11239,Distribution of rat erythrocytes for tube 4 on rate of aging in 2 mL of cell suspension; Plus (+),Intermediate,10116.0,,A,,BAO_0000218,8363,,,1,CHEMBL626322,,,Rattus norvegicus,N,1,,
11240,Distribution of rat erythrocytes for tube 5 on rate of aging in 2 mL of cell suspension; Minus (-),Intermediate,10116.0,,A,,BAO_0000218,8363,,,1,CHEMBL626323,,,Rattus norvegicus,N,1,,
11241,Distribution of rat erythrocytes for tube 5 on rate of aging in 2 mL of cell suspension; Plus (+),Intermediate,10116.0,,A,,BAO_0000218,8363,,,1,CHEMBL626324,,,Rattus norvegicus,N,1,,
11242,Distribution of rat erythrocytes for tube 6 on rate of aging in 2 mL of cell suspension; Minus (-),Intermediate,10116.0,,A,,BAO_0000218,8363,,,1,CHEMBL626325,,,Rattus norvegicus,N,1,,
11243,Distribution of rat erythrocytes for tube 6 on rate of aging in 2 mL of cell suspension; Plus (+),Intermediate,10116.0,,A,,BAO_0000218,8363,,,1,CHEMBL626326,,,Rattus norvegicus,N,1,,
11244,Distribution of rat erythrocytes for tube 7 on rate of aging in 2 mL of cell suspension; Plus (+),Intermediate,10116.0,,A,,BAO_0000218,8363,,,1,CHEMBL626327,,,Rattus norvegicus,N,1,,
11245,Distribution of rat erythrocytes for tube 1 on rate of aging in 2 mL of cell suspension; Minus (-),Intermediate,10116.0,,A,,BAO_0000218,8363,,,1,CHEMBL626328,,,Rattus norvegicus,N,1,,
11246,"Distribution in blood of rat 5 min after intravenous administration, injected dose/gm",Intermediate,10116.0,,A,,BAO_0000218,8684,,,1,CHEMBL626329,,,Rattus norvegicus,N,1,178.0,
11247,"Distribution in blood of rat, 15 min after intravenous administration, injected dose/gm",Intermediate,10116.0,,A,,BAO_0000218,8684,,,1,CHEMBL626330,,,Rattus norvegicus,N,1,178.0,
11248,"Distribution in blood of rat, 1 hr after intravenous administration, injected dose/gm",Intermediate,10116.0,,A,,BAO_0000218,8684,,,1,CHEMBL626331,,,Rattus norvegicus,N,1,178.0,
11249,"Distribution in blood of rat, 2 hr after intravenous administration, injected dose/gm",Intermediate,10116.0,,A,,BAO_0000218,8684,,,1,CHEMBL626332,,,Rattus norvegicus,N,1,178.0,
11250,"Distribution in blood of rat, 30 min after intravenous administration, injected dose/gm",Intermediate,10116.0,,A,,BAO_0000218,8684,,,1,CHEMBL626333,,,Rattus norvegicus,N,1,178.0,
11251,"Distribution in blood of rat, 4 hr after intravenous administration, injected dose/gm",Intermediate,10116.0,,A,,BAO_0000218,8684,,,1,CHEMBL626334,,,Rattus norvegicus,N,1,178.0,
11252,"Distribution in blood of rat, 6 hr after intravenous administration, injected dose/gm",Intermediate,10116.0,,A,,BAO_0000218,8684,,,1,CHEMBL626335,,,Rattus norvegicus,N,1,178.0,
11253,"Distribution in blood of rat, 8 hr after intravenous administration, injected dose/gm",Intermediate,10116.0,,A,,BAO_0000218,8684,,,1,CHEMBL624798,,,Rattus norvegicus,N,1,178.0,
11254,"Distribution in brain of rat, 15 min after intravenous administered, injected dose/gm",Intermediate,10116.0,,A,,BAO_0000218,8684,,,1,CHEMBL624799,,,Rattus norvegicus,N,1,955.0,
11255,"Distribution in brain of rat, 1 hr after intravenous administered, injected dose/gm",Intermediate,10116.0,,A,,BAO_0000218,8684,,,1,CHEMBL624800,,,Rattus norvegicus,N,1,955.0,
11256,"Distribution in brain of rat, 2 hr after intravenous administered, injected dose/gm",Intermediate,10116.0,,A,,BAO_0000218,8684,,,1,CHEMBL624801,,,Rattus norvegicus,N,1,955.0,
11257,"Distribution in brain of rat, 30 min after intravenous administered, injected dose/gm",Intermediate,10116.0,,A,,BAO_0000218,8684,,,1,CHEMBL624802,,,Rattus norvegicus,N,1,955.0,
11258,"Distribution in brain of rat, 4 hr after intravenous administered, injected dose/gm",Intermediate,10116.0,,A,,BAO_0000218,8684,,,1,CHEMBL624803,,,Rattus norvegicus,N,1,955.0,
11259,"Distribution in brain of rat, 5 min after intravenous administered, injected dose/gm",Intermediate,10116.0,,A,,BAO_0000218,8684,,,1,CHEMBL624804,,,Rattus norvegicus,N,1,955.0,
11260,"Distribution in brain of rat, 6 hr after intravenous administered, injected dose/gm",Intermediate,10116.0,,A,,BAO_0000218,8684,,,1,CHEMBL624805,,,Rattus norvegicus,N,1,955.0,
11261,"Distribution in brain of rat, 8 hr after intravenous administered, injected dose/gm",Intermediate,10116.0,,A,,BAO_0000218,8684,,,1,CHEMBL624806,,,Rattus norvegicus,N,1,955.0,
11262,"Distribution in rat fat 15 min after intravenous administration, injected dose/gm",Intermediate,10116.0,,A,,BAO_0000218,8684,,,1,CHEMBL624807,,,Rattus norvegicus,N,1,,
11263,"Distribution in rat fat 1 hr after intravenous administration, injected dose/gm",Intermediate,10116.0,,A,,BAO_0000218,8684,,,1,CHEMBL624808,,,Rattus norvegicus,N,1,,
11264,"Distribution in rat fat 2 hr after intravenous administration, injected dose/gm",Intermediate,10116.0,,A,,BAO_0000218,8684,,,1,CHEMBL624809,,,Rattus norvegicus,N,1,,
11265,"Distribution in rat fat 30 min after intravenous administration, injected dose/gm",Intermediate,10116.0,,A,,BAO_0000218,8684,,,1,CHEMBL624810,,,Rattus norvegicus,N,1,,
11266,"Distribution in rat fat 4 hr after intravenous administration, injected dose/gm",Intermediate,10116.0,,A,,BAO_0000218,8684,,,1,CHEMBL877618,,,Rattus norvegicus,N,1,,
11267,"Distribution in rat fat 5 min after intravenous administration, injected dose/gm",Intermediate,10116.0,,A,,BAO_0000218,8684,,,1,CHEMBL624811,,,Rattus norvegicus,N,1,,
11268,"Distribution in rat fat 6 hr after intravenous administration, injected dose/gm",Intermediate,10116.0,,A,,BAO_0000218,8684,,,1,CHEMBL624812,,,Rattus norvegicus,N,1,,
11269,"Distribution in rat fat 8 hr after intravenous administration, injected dose/gm",Intermediate,10116.0,,A,,BAO_0000218,8684,,,1,CHEMBL624813,,,Rattus norvegicus,N,1,,
11270,"Distribution in rat heart 15 min after intravenous administration, injected dose/gm",Intermediate,10116.0,,A,,BAO_0000218,8684,,,1,CHEMBL624814,,,Rattus norvegicus,N,1,,
11271,"Distribution in rat heart 1 hr after intravenous administration, injected dose/gm",Intermediate,10116.0,,A,,BAO_0000218,8684,,,1,CHEMBL624815,,,Rattus norvegicus,N,1,,
11272,"Distribution in rat heart 2 hr after intravenous administration, injected dose/gm",Intermediate,10116.0,,A,,BAO_0000218,8684,,,1,CHEMBL624816,,,Rattus norvegicus,N,1,,
11273,"Distribution in rat heart 30 min after intravenous administration, injected dose/gm",Intermediate,10116.0,,A,,BAO_0000218,8684,,,1,CHEMBL624817,,,Rattus norvegicus,N,1,,
11274,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5.4 mg/kg after ip administration ( 0-6 hr),Intermediate,9615.0,,A,,BAO_0000218,6996,,,1,CHEMBL624818,,,Canis lupus familiaris,N,1,,
11275,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration,Intermediate,9615.0,,A,,BAO_0000218,6996,,,1,CHEMBL624819,,,Canis lupus familiaris,N,1,,
11276,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration (0-6 hr),Intermediate,9615.0,,A,,BAO_0000218,6996,,,1,CHEMBL624820,,,Canis lupus familiaris,N,1,,
11277,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration ( 0 - 6 hr),Intermediate,9615.0,,A,,BAO_0000218,6996,,,1,CHEMBL624821,,,Canis lupus familiaris,N,1,,
11278,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration ( 0-6 hr ),Intermediate,9615.0,,A,,BAO_0000218,6996,,,1,CHEMBL624822,,,Canis lupus familiaris,N,1,,
11279,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration ( 0-6 hr),Intermediate,9615.0,,A,,BAO_0000218,6996,,,1,CHEMBL624823,,,Canis lupus familiaris,N,1,,
11280,Observed diffusion coefficient in organic solvent for Escherichia coli,Intermediate,562.0,,A,,BAO_0000218,15599,,,1,CHEMBL624824,,,Escherichia coli,N,1,,
11281,"Concentration of compound in blood of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",Intermediate,10116.0,,A,,BAO_0000218,9614,,,1,CHEMBL624825,,,Rattus norvegicus,N,1,178.0,
11282,"Concentration of compound in blood of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",Intermediate,10116.0,,A,,BAO_0000218,9614,,,1,CHEMBL624826,,,Rattus norvegicus,N,1,178.0,
11283,"Concentration of compound in left atrium of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",Intermediate,10116.0,,A,,BAO_0000218,9614,,,1,CHEMBL876817,,,Rattus norvegicus,N,1,2081.0,
11284,"Concentration of compound in left atrium of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",Intermediate,10116.0,,A,,BAO_0000218,9614,,,1,CHEMBL624827,,,Rattus norvegicus,N,1,2081.0,
11285,"Concentration of compound in left ventricle of of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",Intermediate,10116.0,,A,,BAO_0000218,9614,,,1,CHEMBL624828,,,Rattus norvegicus,N,1,,
11286,"Concentration of compound in left ventricle of of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",Intermediate,10116.0,,A,,BAO_0000218,9614,,,1,CHEMBL624829,,,Rattus norvegicus,N,1,,
11287,"Concentration of compound in liver of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",Intermediate,10116.0,,A,,BAO_0000218,9614,,,1,CHEMBL624830,,,Rattus norvegicus,N,1,2107.0,
11288,"Concentration of compound in liver of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",Intermediate,10116.0,,A,,BAO_0000218,9614,,,1,CHEMBL624831,,,Rattus norvegicus,N,1,2107.0,
11289,"Concentration of compound in right atrium of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",Intermediate,10116.0,,A,,BAO_0000218,9614,,,1,CHEMBL624832,,,Rattus norvegicus,N,1,2081.0,
11290,"Concentration of compound in right atrium of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",Intermediate,10116.0,,A,,BAO_0000218,9614,,,1,CHEMBL624833,,,Rattus norvegicus,N,1,2081.0,
11291,"Concentration of compound in right ventricle of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",Intermediate,10116.0,,A,,BAO_0000218,9614,,,1,CHEMBL624834,,,Rattus norvegicus,N,1,,
11292,"Concentration of compound in right ventricle of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",Intermediate,10116.0,,A,,BAO_0000218,9614,,,1,CHEMBL624835,,,Rattus norvegicus,N,1,,
11293,"Concentration of compound in spleen of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",Intermediate,10116.0,,A,,BAO_0000218,9614,,,1,CHEMBL624836,,,Rattus norvegicus,N,1,2106.0,
11294,"Concentration of compound in spleen of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",Intermediate,10116.0,,A,,BAO_0000218,9614,,,1,CHEMBL624837,,,Rattus norvegicus,N,1,2106.0,
11295,Distribution of radioactivity of radiolabeled compound in blood of female rats 30 minutes after intravenous administration,Intermediate,10116.0,,A,,BAO_0000218,9071,,,1,CHEMBL624838,,,Rattus norvegicus,N,1,178.0,
11296,Distribution of radioactivity of radiolabeled compound in blood of female rats 5 minutes after intravenous administration,Intermediate,10116.0,,A,,BAO_0000218,9071,,,1,CHEMBL622188,,,Rattus norvegicus,N,1,178.0,
11297,Distribution of radioactivity of radiolabeled compound in heart of female rats 30 minutes after intravenous administration,Intermediate,10116.0,,A,,BAO_0000218,9071,,,1,CHEMBL622189,,,Rattus norvegicus,N,1,948.0,
11298,Distribution of radioactivity of radiolabeled compound in heart of female rats 30 minutes after intravenous administration at,Intermediate,10116.0,,A,,BAO_0000218,9071,,,1,CHEMBL622190,,,Rattus norvegicus,N,1,948.0,
11299,Distribution of radioactivity of radiolabeled compound in heart of female rats 5 minutes after intravenous administration,Intermediate,10116.0,,A,,BAO_0000218,9071,,,1,CHEMBL625170,,,Rattus norvegicus,N,1,948.0,
11300,Distribution of radioactivity of radiolabeled compound in kidney of female rats 30 minutes after intravenous administration,Intermediate,10116.0,,A,,BAO_0000218,9071,,,1,CHEMBL625171,,,Rattus norvegicus,N,1,2113.0,
11301,Distribution of radioactivity of radiolabeled compound in kidney of female rats 30 minutes after intravenous administration,Intermediate,10116.0,,A,,BAO_0000218,9071,,,1,CHEMBL625172,,,Rattus norvegicus,N,1,2113.0,
11302,Distribution of radioactivity of radiolabeled compound in kidney of female rats 5 minutes after intravenous administration,Intermediate,10116.0,,A,,BAO_0000218,9071,,,1,CHEMBL625173,,,Rattus norvegicus,N,1,2113.0,
11303,Distribution of radioactivity of radiolabeled compound in liver of female rats 30 minutes after intravenous administration,Intermediate,10116.0,,A,,BAO_0000218,9071,,,1,CHEMBL625174,,,Rattus norvegicus,N,1,2107.0,
11304,Distribution of radioactivity of radiolabeled compound in liver of female rats 5 minutes after intravenous administration,Intermediate,10116.0,,A,,BAO_0000218,9071,,,1,CHEMBL625175,,,Rattus norvegicus,N,1,2107.0,
11305,Distribution of radioactivity of radiolabeled compound in liver of female rats 5 minutes after intravenous administration at,Intermediate,10116.0,,A,,BAO_0000218,9071,,,1,CHEMBL625176,,,Rattus norvegicus,N,1,2107.0,
11306,Distribution of radioactivity of radiolabeled compound in lung of female rats 30 minutes after intravenous administration,Intermediate,10116.0,,A,,BAO_0000218,9071,,,1,CHEMBL625177,,,Rattus norvegicus,N,1,2048.0,
11307,Distribution of radioactivity of radiolabeled compound in lung of female rats 5 minutes after intravenous administration,Intermediate,10116.0,,A,,BAO_0000218,9071,,,1,CHEMBL625178,,,Rattus norvegicus,N,1,2048.0,
11308,Distribution of radioactivity of radiolabeled compound in lung of female rats 5 minutes after intravenous administration at,Intermediate,10116.0,,A,,BAO_0000218,9071,,,1,CHEMBL625179,,,Rattus norvegicus,N,1,2048.0,
11309,Distribution of radioactivity of radiolabeled compound in lung of female rats 30 minutes after intravenous administration,Intermediate,10116.0,,A,,BAO_0000218,9071,,,1,CHEMBL625180,,,Rattus norvegicus,N,1,2048.0,
11310,"Original dose appeared in the bile as unchanged compound, which was eliminated at a fairly constant rate over the first 4 hr following the iv administration",Autocuration,,,A,,BAO_0000218,10677,,,1,CHEMBL625181,,,,U,0,,
11311,Percentage of dose recovered after 0-6 hr in the urine of mice was measured.,Intermediate,10090.0,,A,,BAO_0000218,9750,,,1,CHEMBL625182,,,Mus musculus,N,1,1088.0,
11312,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat blood as Percent of injected dose per gram in the organ,Intermediate,10116.0,,A,,BAO_0000218,8319,,,1,CHEMBL625183,,,Rattus norvegicus,N,1,,
11313,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat brain as Percent of injected dose in the total organ,Intermediate,10116.0,,A,,BAO_0000218,8319,,,1,CHEMBL875848,,,Rattus norvegicus,N,1,,
11314,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat brain as Percent of injected dose per gram in the organ,Intermediate,10116.0,,A,,BAO_0000218,8319,,,1,CHEMBL622260,,,Rattus norvegicus,N,1,,
11315,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat heart as Percent of injected dose in the total organ,Intermediate,10116.0,,A,,BAO_0000218,8319,,,1,CHEMBL622261,,,Rattus norvegicus,N,1,,
11316,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat heart as Percent of injected dose per gram in the organ,Intermediate,10116.0,,A,,BAO_0000218,8319,,,1,CHEMBL622262,,,Rattus norvegicus,N,1,,
11317,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat kidney as Percent of injected dose in the total organ,Intermediate,10116.0,,A,,BAO_0000218,8319,,,1,CHEMBL622263,,,Rattus norvegicus,N,1,2113.0,
11318,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat kidney as Percent of injected dose per gram in the organ,Intermediate,10116.0,,A,,BAO_0000218,8319,,,1,CHEMBL622418,,,Rattus norvegicus,N,1,2113.0,
11319,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat liver as Percent of injected dose in the total organ,Intermediate,10116.0,,A,,BAO_0000218,8319,,,1,CHEMBL622419,,,Rattus norvegicus,N,1,2107.0,
11320,Biodistribution in CD-1 mice was determined after 1 minute in femur(expressed as percent injected dose per gram normalized to a 25 g mouse),Intermediate,10090.0,,A,,BAO_0000218,13256,,,1,CHEMBL623388,,,Mus musculus,N,1,,
11321,Biodistribution in CD-1 mice was determined after 1 minute in liver(expressed as percent injected dose per gram normalized to a 25 g mouse),Intermediate,10090.0,,A,,BAO_0000218,13256,,,1,CHEMBL623389,,,Mus musculus,N,1,2107.0,
11322,Biodistribution in CD-1 mice was determined after 1 minute in lung(expressed as percent injected dose per gram normalized to a 25 g mouse),Intermediate,10090.0,,A,,BAO_0000218,13256,,,1,CHEMBL623390,,,Mus musculus,N,1,,
11323,Biodistribution in CD-1 mice was determined after 120 minutes in Striatum(expressed as percent injected dose per gram normalized to a 25 g mouse),Intermediate,10090.0,,A,,BAO_0000218,13256,,,1,CHEMBL623391,,,Mus musculus,N,1,,
11324,Biodistribution in CD-1 mice was determined after 120 minutes in blood(expressed as percent injected dose per gram normalized to a 25 g mouse),Intermediate,10090.0,,A,,BAO_0000218,13256,,,1,CHEMBL623392,,,Mus musculus,N,1,178.0,
11325,Biodistribution in CD-1 mice was determined after 120 minutes in cerebellum(expressed as percent injected dose per gram normalized to a 25 g mouse),Intermediate,10090.0,,A,,BAO_0000218,13256,,,1,CHEMBL623393,,,Mus musculus,N,1,2037.0,
11326,Biodistribution in CD-1 mice was determined after 120 minutes in cortex(expressed as percent injected dose per gram normalized to a 25 g mouse),Intermediate,10090.0,,A,,BAO_0000218,13256,,,1,CHEMBL623394,,,Mus musculus,N,1,,
11327,Biodistribution in CD-1 mice was determined after 120 minutes in femur(expressed as percent injected dose per gram normalized to a 25 g mouse),Intermediate,10090.0,,A,,BAO_0000218,13256,,,1,CHEMBL618885,,,Mus musculus,N,1,,
11328,Biodistribution in CD-1 mice was determined after 120 minutes in liver(expressed as percent injected dose per gram normalized to a 25 g mouse),Intermediate,10090.0,,A,,BAO_0000218,13256,,,1,CHEMBL618886,,,Mus musculus,N,1,2107.0,
11329,Biodistribution in CD-1 mice was determined after 120 minutes in lung(expressed as percent injected dose per gram normalized to a 25 g mouse),Intermediate,10090.0,,A,,BAO_0000218,13256,,,1,CHEMBL618887,,,Mus musculus,N,1,,
11330,Biodistribution in CD-1 mice was determined after 30 minutes in Striatum (expressed as percent injected dose per gram normalized to a 25 g mouse),Intermediate,10090.0,,A,,BAO_0000218,13256,,,1,CHEMBL619535,,,Mus musculus,N,1,,
11331,Biodistribution in CD-1 mice was determined after 30 minutes in blood (expressed as percent injected dose per gram normalized to a 25 g mouse),Intermediate,10090.0,,A,,BAO_0000218,13256,,,1,CHEMBL619536,,,Mus musculus,N,1,178.0,
11332,Biodistribution in CD-1 mice was determined after 30 minutes in cerebellum (expressed as percent injected dose per gram normalized to a 25 g mouse),Intermediate,10090.0,,A,,BAO_0000218,13256,,,1,CHEMBL619537,,,Mus musculus,N,1,2037.0,
11333,Biodistribution in CD-1 mice was determined after 30 minutes in cortex (expressed as percent injected dose per gram normalized to a 25 g mouse),Intermediate,10090.0,,A,,BAO_0000218,13256,,,1,CHEMBL619705,,,Mus musculus,N,1,,
11334,Biodistribution in CD-1 mice was determined after 30 minutes in femur (expressed as percent injected dose per gram normalized to a 25 g mouse),Intermediate,10090.0,,A,,BAO_0000218,13256,,,1,CHEMBL619706,,,Mus musculus,N,1,,
11335,Biodistribution in CD-1 mice was determined after 30 minutes in liver (expressed as percent injected dose per gram normalized to a 25 g mouse),Intermediate,10090.0,,A,,BAO_0000218,13256,,,1,CHEMBL619707,,,Mus musculus,N,1,2107.0,
11336,Biodistribution in CD-1 mice was determined after 30 minutes in lung (expressed as percent injected dose per gram normalized to a 25 g mouse),Intermediate,10090.0,,A,,BAO_0000218,13256,,,1,CHEMBL619708,,,Mus musculus,N,1,,
11337,Biodistribution in CD-1 mice was determined after 5 minute in Striatum(expressed as percent injected dose per gram normalized to a 25 g mouse),Intermediate,10090.0,,A,,BAO_0000218,13256,,,1,CHEMBL625219,,,Mus musculus,N,1,,
11338,Biodistribution in CD-1 mice was determined after 5 minute in blood(expressed as percent injected dose per gram normalized to a 25 g mouse),Intermediate,10090.0,,A,,BAO_0000218,13256,,,1,CHEMBL625220,,,Mus musculus,N,1,178.0,
11339,Biodistribution in CD-1 mice was determined after 5 minute in cerebellum(expressed as percent injected dose per gram normalized to a 25 g mouse),Intermediate,10090.0,,A,,BAO_0000218,13256,,,1,CHEMBL625221,,,Mus musculus,N,1,2037.0,
11340,Biodistribution in CD-1 mice was determined after 5 minute in cortex(expressed as percent injected dose per gram normalized to a 25 g mouse),Intermediate,10090.0,,A,,BAO_0000218,13256,,,1,CHEMBL625222,,,Mus musculus,N,1,,
11341,Biodistribution in CD-1 mice was determined after 5 minute in femur(expressed as percent injected dose per gram normalized to a 25 g mouse),Intermediate,10090.0,,A,,BAO_0000218,13256,,,1,CHEMBL625223,,,Mus musculus,N,1,,
11342,Biodistribution in CD-1 mice was determined after 5 minute in liver(expressed as percent injected dose per gram normalized to a 25 g mouse),Intermediate,10090.0,,A,,BAO_0000218,13256,,,1,CHEMBL625224,,,Mus musculus,N,1,2107.0,
11343,Biodistribution in CD-1 mice was determined after 5 minute in lung(expressed as percent injected dose per gram normalized to a 25 g mouse),Intermediate,10090.0,,A,,BAO_0000218,13256,,,1,CHEMBL625225,,,Mus musculus,N,1,,
11344,Biodistribution in Rat blood after 24 hours of iv administration,Intermediate,10116.0,,A,,BAO_0000218,8829,,,1,CHEMBL625226,,,Rattus norvegicus,N,1,178.0,
11345,Biodistribution in Rat blood after 24 hours of iv administration; per g of tissue,Intermediate,10116.0,,A,,BAO_0000218,8829,,,1,CHEMBL625227,,,Rattus norvegicus,N,1,178.0,
11346,Biodistribution in Rat blood after 30 minutes of iv administration,Intermediate,10116.0,,A,,BAO_0000218,8829,,,1,CHEMBL625228,,,Rattus norvegicus,N,1,178.0,
11347,Biodistribution in Rat blood after 30 minutes of iv administration; per g of tissue,Intermediate,10116.0,,A,,BAO_0000218,8829,,,1,CHEMBL875354,,,Rattus norvegicus,N,1,178.0,
11348,Biodistribution in Rat blood after 5 minutes of iv administration,Intermediate,10116.0,,A,,BAO_0000218,8829,,,1,CHEMBL625229,,,Rattus norvegicus,N,1,178.0,
11349,Biodistribution in Rat blood after 5 minutes of iv administration; per g of tissue,Intermediate,10116.0,,A,,BAO_0000218,8829,,,1,CHEMBL625230,,,Rattus norvegicus,N,1,178.0,
11350,Biodistribution in Rat heart after 24 hours of iv administration,Intermediate,10116.0,,A,,BAO_0000218,8829,,,1,CHEMBL625231,,,Rattus norvegicus,N,1,948.0,
11351,Biodistribution in Rat heart after 24 hours of iv administration; per g of tissue,Intermediate,10116.0,,A,,BAO_0000218,8829,,,1,CHEMBL625900,,,Rattus norvegicus,N,1,948.0,
11352,Biodistribution in Rat heart after 30 minutes of iv administration,Intermediate,10116.0,,A,,BAO_0000218,8829,,,1,CHEMBL625901,,,Rattus norvegicus,N,1,948.0,
11353,Biodistribution in Rat heart after 30 minutes of iv administration; per g of tissue,Intermediate,10116.0,,A,,BAO_0000218,8829,,,1,CHEMBL625902,,,Rattus norvegicus,N,1,948.0,
11354,Biodistribution in Rat heart after 5 minutes of iv administration,Intermediate,10116.0,,A,,BAO_0000218,8829,,,1,CHEMBL625903,,,Rattus norvegicus,N,1,948.0,
11355,Biodistribution in Rat heart after 5 minutes of iv administration; per g of tissue,Intermediate,10116.0,,A,,BAO_0000218,8829,,,1,CHEMBL625904,,,Rattus norvegicus,N,1,948.0,
11356,Biodistribution in Rat liver after 24 hours of iv administration,Intermediate,10116.0,,A,,BAO_0000218,8829,,,1,CHEMBL625905,,,Rattus norvegicus,N,1,2107.0,
11357,Biodistribution in Rat liver after 24 hours of iv administration; per g of tissue,Intermediate,10116.0,,A,,BAO_0000218,8829,,,1,CHEMBL627861,,,Rattus norvegicus,N,1,2107.0,
11358,Biodistribution in Rat liver after 30 minutes of iv administration,Intermediate,10116.0,,A,,BAO_0000218,8829,,,1,CHEMBL627862,,,Rattus norvegicus,N,1,2107.0,
11359,Biodistribution in Rat liver after 30 minutes of iv administration; per g of tissue,Intermediate,10116.0,,A,,BAO_0000218,8829,,,1,CHEMBL627863,,,Rattus norvegicus,N,1,2107.0,
11360,Biodistribution in Rat liver after 30 minutes of iv administration,Intermediate,10116.0,,A,,BAO_0000218,8829,,,1,CHEMBL627769,,,Rattus norvegicus,N,1,2107.0,
11361,Maximum plasma concentration in Beagle dogs at oral dose of 20 mg/kg and an intravenous dose of 5 mg/kg was administered,Intermediate,9615.0,,A,,BAO_0000218,13249,,,1,CHEMBL627770,,,Canis lupus familiaris,N,1,1969.0,
11362,Cmax in cynomolgus monkey (PO dose),Intermediate,9541.0,,A,,BAO_0000218,13622,,,1,CHEMBL627771,,,Macaca fascicularis,N,1,,
11363,Cmax in rat (PO dose),Intermediate,10116.0,,A,,BAO_0000218,13622,,,1,CHEMBL627772,,,Rattus norvegicus,N,1,,
11364,Cmax in rat (PO dose),Intermediate,10116.0,,A,,BAO_0000218,13622,,,1,CHEMBL627773,,,Rattus norvegicus,N,1,,
11365,Maximum plasma concentration in rats after an oral dose of 5 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,13494,,,1,CHEMBL621922,,,Rattus norvegicus,N,1,1969.0,
11366,Cmax in rat plasma after oral dose (10 mg/kg),Intermediate,10116.0,,A,,BAO_0000218,12170,,,1,CHEMBL621923,,,Rattus norvegicus,N,1,1969.0,
11367,Cmax in plasma after oral dose (10 mg/kg),Autocuration,,,A,,BAO_0000218,12170,,,1,CHEMBL621924,,,,U,0,1969.0,
11368,Maximum plasma concentration of compound was determined in dog at 25 mg/kg orally,Intermediate,9615.0,,A,,BAO_0000218,17025,,,1,CHEMBL621925,,,Canis lupus familiaris,N,1,1969.0,
11369,Maximum plasma concentration of compound was determined in monkey at 25 mg/kg orally,Autocuration,314293.0,,A,,BAO_0000218,17025,,,1,CHEMBL621926,,,Simiiformes,U,0,1969.0,
11370,Maximum plasma concentration of compound was determined in rabbit at 25 mg/kg orally,Intermediate,9986.0,,A,,BAO_0000218,17025,,,1,CHEMBL621927,,,Oryctolagus cuniculus,N,1,1969.0,
11371,Maximum plasma concentration of compound was determined in rat at 25 mg/kg orally,Intermediate,10116.0,,A,,BAO_0000218,17025,,,1,CHEMBL621928,,,Rattus norvegicus,N,1,1969.0,
11372,Maximum plasma concentration after p.o. (10 mpk) administration in rats.,Intermediate,10116.0,,A,,BAO_0000218,14187,,,1,CHEMBL621929,,,Rattus norvegicus,N,1,1969.0,
11373,Maximum plasma concentration (Cmax) after p.o. administration of 200 mg/kg in mice,Intermediate,10090.0,,A,,BAO_0000218,14816,,,1,CHEMBL621930,,,Mus musculus,N,1,1969.0,
11374,Maximum plasma concentration after oral dosing in rat,Intermediate,10116.0,,A,,BAO_0000218,17820,,,1,CHEMBL621931,,,Rattus norvegicus,N,1,1969.0,
11375,Maximum plasma concentration evaluated in 100% PEG solution at a dose of 20 mg/kg orally,Autocuration,,,A,,BAO_0000218,14380,,,1,CHEMBL621932,,,,U,0,1969.0,
11376,Maximum plasma concentration evaluated in HP-beta-CD solution at a dose of 20 mg/kg orally,Autocuration,,,A,,BAO_0000218,14380,,,1,CHEMBL621933,,,,U,0,1969.0,
11377,Maximum plasma concentration in dogs at 0.5 mg/kg dose upon oral administration,Intermediate,9615.0,,A,,BAO_0000218,14691,,,1,CHEMBL621934,,,Canis lupus familiaris,N,1,1969.0,
11378,Maximum plasma concentration in dogs at 1 mg/kg dose upon oral administration,Intermediate,9615.0,,A,,BAO_0000218,14691,,,1,CHEMBL621935,,,Canis lupus familiaris,N,1,1969.0,
11379,Maximum plasma concentration in rat upon oral administration of 40 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,13375,,,1,CHEMBL621936,,,Rattus norvegicus,N,1,1969.0,
11380,Maximum plasma concentration was determined,Autocuration,,,A,,BAO_0000218,6236,,,1,CHEMBL621937,,,,U,0,1969.0,
11381,Maximum plasma concentration was evaluated in 0.5% methylcellulose suspension at a dose of 20 mg/kg orally,Autocuration,,,A,,BAO_0000218,14380,,,1,CHEMBL621938,,,,U,0,1969.0,
11382,Maximum plasma concentration was evaluated in 0.5% methylcellulose suspension at a dose of 20 mg/kg orally,Autocuration,,,A,,BAO_0000218,14380,,,1,CHEMBL621939,,,,U,0,1969.0,
11383,Maximum plasma concentration was evaluated in 10% of PEG suspension at a dose of 20 mg/kg orally,Autocuration,,,A,,BAO_0000218,14380,,,1,CHEMBL621940,,,,U,0,1969.0,
11384,Maximum plasma concentration was evaluated in 100% of PEG solution at a dose of 20 mg/kg orally,Autocuration,,,A,,BAO_0000218,14380,,,1,CHEMBL621941,,,,U,0,1969.0,
11385,Maximum plasma concentration was evaluated in DMA:H2O solution at a dose of 20 mg/kg orally,Autocuration,,,A,,BAO_0000218,14380,,,1,CHEMBL621942,,,,U,0,1969.0,
11386,Maximum plasma concentration was evaluated in HP-beta-CD solution at a dose of 20 mg/kg orally,Autocuration,,,A,,BAO_0000218,14380,,,1,CHEMBL626178,,,,U,0,1969.0,
11387,Maximum plasma concentration was evaluated in Hp-beta-CD solution at a dose of 20 mg/kg orally,Autocuration,,,A,,BAO_0000218,14380,,,1,CHEMBL626179,,,,U,0,1969.0,
11388,Maximum plasma concentration was evaluated in saline solution at a dose of 20 mg/kg orally,Autocuration,,,A,,BAO_0000218,14380,,,1,CHEMBL626180,,,,U,0,1969.0,
11389,Plasma Cmax in rat (PO dose),Intermediate,10116.0,,A,,BAO_0000218,13622,,,1,CHEMBL626181,,,Rattus norvegicus,N,1,1969.0,
11390,Maximum serum concentration after po dose of 5.22 mg/kg in rats,Intermediate,10116.0,,A,,BAO_0000218,15372,,,1,CHEMBL626182,,,Rattus norvegicus,N,1,,
11391,Maximum serum concentration after po dose of 5.46 mg/kg in rats,Intermediate,10116.0,,A,,BAO_0000218,15372,,,1,CHEMBL626183,,,Rattus norvegicus,N,1,,
11392,Maximum serum concentration was determined for the compound after po dose of 5.01 mg/kg in rats,Intermediate,10116.0,,A,,BAO_0000218,15372,,,1,CHEMBL626184,,,Rattus norvegicus,N,1,,
11393,Maximum serum concentration was determined for the compound after po dose of 5.03 mg/kg in rats,Intermediate,10116.0,,A,,BAO_0000218,15372,,,1,CHEMBL626185,,,Rattus norvegicus,N,1,,
11394,Maximum plasma concentration (Cmax) was determined in dogs fed after oral administration of 25 mg/kg of the compound.,Intermediate,9615.0,,A,,BAO_0000218,14925,,,1,CHEMBL626186,,,Canis lupus familiaris,N,1,1969.0,
11395,Maximum plasma concentration (Cmax) was determined in fasted dogs after oral administration of 25 mg/kg of the compound.,Intermediate,9615.0,,A,,BAO_0000218,14925,,,1,CHEMBL877589,,,Canis lupus familiaris,N,1,1969.0,
11396,Maximum concentration of the drug at 1 uM/dg administered intravenously,Autocuration,,,A,,BAO_0000218,11883,,,1,CHEMBL626187,,,,U,0,,
11397,Maximum concentration of the drug at 20 uM/dg administered perorally,Autocuration,,,A,,BAO_0000218,11883,,,1,CHEMBL626188,,,,U,0,,
11398,Oral Bioavailability was measured as Maximal observed concentration (Cmax) value at dose 125 mg/kg,Autocuration,,,A,,BAO_0000218,13391,,,1,CHEMBL626189,,,,U,0,,
11399,Oral Bioavailability was measured as Maximal observed concentration (Cmax) value at dose 125 mg/kg; b = No compound detectable in blood above the detection limit of 0.1 uM,Autocuration,,,A,,BAO_0000218,13391,,,1,CHEMBL626855,,,,U,0,178.0,
11400,Oral Bioavailability was measured as Maximal observed concentration (Cmax) value at dose 125 mg/kg; b denotes No compound detectable in blood above the detection limit of 0.1 uM,Autocuration,,,A,,BAO_0000218,13391,,,1,CHEMBL623781,,,,U,0,178.0,
11401,Oral Bioavailability was measured as Maximal observed concentration (Cmax) value at dose 125 mg/kg;b = No compound detectable in blood above the detection limit of 0.1 uM,Autocuration,,,A,,BAO_0000218,13391,,,1,CHEMBL623782,,,,U,0,178.0,
11402,Oral absorption expressed as peak plasma conc (Cmax) after oral dosing of 50 mg/kg in rat,Intermediate,10116.0,,A,,BAO_0000218,16360,,,1,CHEMBL623783,,,Rattus norvegicus,N,1,1969.0,
11403,Cmax in dog plasma after 1mg/kg oral dose,Intermediate,9615.0,,A,,BAO_0000218,3673,,,1,CHEMBL623784,,,Canis lupus familiaris,N,1,1969.0,
11404,Bioavailability as maximal plasma concentration in dogs after 2.5 mg/kg oral dose,Intermediate,9615.0,,A,,BAO_0000218,14431,,,1,CHEMBL623785,,,Canis lupus familiaris,N,1,1969.0,
11405,Bioavailability as maximal plasma concentration in rats after 10 mg/kg oral dose,Intermediate,10116.0,,A,,BAO_0000218,14431,,,1,CHEMBL623786,,,Rattus norvegicus,N,1,1969.0,
11406,Oral maximum concentration in rat,Intermediate,10116.0,,A,,BAO_0000218,14964,,,1,CHEMBL623787,,,Rattus norvegicus,N,1,,
11407,Oral maximum concentration in rat,Intermediate,10116.0,,A,,BAO_0000218,14964,,,1,CHEMBL623788,,,Rattus norvegicus,N,1,,
11408,Oral plasma concentration in mice at 100 mg/kg dosage within 4-hr time frame.,Intermediate,10090.0,,A,,BAO_0000218,14209,,,1,CHEMBL623789,,,Mus musculus,N,1,1969.0,
11409,Peak concentration in blood after intravenous administration to mice,Intermediate,10090.0,,A,,BAO_0000218,11355,,,1,CHEMBL623790,,,Mus musculus,N,1,178.0,
11410,Peak concentration in blood after peroral administration to mice,Intermediate,10090.0,,A,,BAO_0000218,11355,,,1,CHEMBL623791,,,Mus musculus,N,1,178.0,
11411,Peak concentration in rat plasma was determined,Intermediate,10116.0,,A,,BAO_0000218,11966,,,1,CHEMBL623792,,,Rattus norvegicus,N,1,1969.0,
11412,Peak plasma concentration expresses the ability of compound for the release of L-Dopa in the plasma of monkey after oral administration of 0.05 mmol/kg,Autocuration,314293.0,,A,,BAO_0000218,8918,,,1,CHEMBL623793,,,Simiiformes,U,0,1969.0,
11413,Peak plasma concentration expresses the ability of compound for the release of L-Dopa in the plasma of mouse after oral administration of 0.05 mmol/kg,Intermediate,10090.0,,A,,BAO_0000218,8918,,,1,CHEMBL623794,,,Mus musculus,N,1,1969.0,
11414,Peak plasma concentration expresses the ability of compound for the release of L-Dopa in the plasma of rat after oral administration of 0.05 mmol/kg,Intermediate,10116.0,,A,,BAO_0000218,8918,,,1,CHEMBL623795,,,Rattus norvegicus,N,1,1969.0,
11415,"Distribution in rat heart 4 hr after intravenous administration, injected dose/gm",Intermediate,10116.0,,A,,BAO_0000218,8684,,,1,CHEMBL623796,,,Rattus norvegicus,N,1,,
11416,"Distribution in rat heart 5 min after intravenous administration, injected dose/gm",Intermediate,10116.0,,A,,BAO_0000218,8684,,,1,CHEMBL623797,,,Rattus norvegicus,N,1,,
11417,"Distribution in rat heart 6 hr after intravenous administration, injected dose/gm",Intermediate,10116.0,,A,,BAO_0000218,8684,,,1,CHEMBL623798,,,Rattus norvegicus,N,1,,
11418,"Distribution in rat heart 8 hr after intravenous administration, injected dose/gm",Intermediate,10116.0,,A,,BAO_0000218,8684,,,1,CHEMBL623799,,,Rattus norvegicus,N,1,,
11419,"Distribution in rat intestine 15 min after intravenous administration, injected dose/gm",Intermediate,10116.0,,A,,BAO_0000218,8684,,,1,CHEMBL624490,,,Rattus norvegicus,N,1,160.0,
11420,"Distribution in rat intestine 1 hr after intravenous administration, injected dose/gm",Intermediate,10116.0,,A,,BAO_0000218,8684,,,1,CHEMBL624491,,,Rattus norvegicus,N,1,160.0,
11421,"Distribution in rat intestine 2 hr after intravenous administration, injected dose/gm",Intermediate,10116.0,,A,,BAO_0000218,8684,,,1,CHEMBL624492,,,Rattus norvegicus,N,1,160.0,
11422,"Distribution in rat intestine 30 min after intravenous administration, injected dose/gm",Intermediate,10116.0,,A,,BAO_0000218,8684,,,1,CHEMBL624493,,,Rattus norvegicus,N,1,160.0,
11423,"Distribution in rat intestine 4 hr after intravenous administration, injected dose/gm",Intermediate,10116.0,,A,,BAO_0000218,8684,,,1,CHEMBL877595,,,Rattus norvegicus,N,1,160.0,
11424,"Distribution in rat intestine 5 min after intravenous administration, injected dose/gm",Intermediate,10116.0,,A,,BAO_0000218,8684,,,1,CHEMBL624494,,,Rattus norvegicus,N,1,160.0,
11425,"Distribution in rat intestine 6 hr after intravenous administration, injected dose/gm",Intermediate,10116.0,,A,,BAO_0000218,8684,,,1,CHEMBL624495,,,Rattus norvegicus,N,1,160.0,
11426,"Distribution in rat intestine 8 hr after intravenous administration, injected dose/gm",Intermediate,10116.0,,A,,BAO_0000218,8684,,,1,CHEMBL624681,,,Rattus norvegicus,N,1,160.0,
11427,"Distribution in rat kidney, 15 min after intravenous administration, injected dose/gm",Intermediate,10116.0,,A,,BAO_0000218,8684,,,1,CHEMBL624682,,,Rattus norvegicus,N,1,,
11428,"Distribution in rat kidney, 1 hr after intravenous administration, injected dose/gm",Intermediate,10116.0,,A,,BAO_0000218,8684,,,1,CHEMBL624683,,,Rattus norvegicus,N,1,,
11429,"Distribution in rat kidney, 2 hr after intravenous administration, injected dose/gm",Intermediate,10116.0,,A,,BAO_0000218,8684,,,1,CHEMBL624684,,,Rattus norvegicus,N,1,,
11430,"Distribution in rat kidney, 30 min after intravenous administration, injected dose/gm",Intermediate,10116.0,,A,,BAO_0000218,8684,,,1,CHEMBL624685,,,Rattus norvegicus,N,1,,
11431,"Distribution in rat kidney, 4 hr after intravenous administration, injected dose/gm",Intermediate,10116.0,,A,,BAO_0000218,8684,,,1,CHEMBL624686,,,Rattus norvegicus,N,1,,
11432,"Distribution in rat kidney, 5 min after intravenous administration, injected dose/gm",Intermediate,10116.0,,A,,BAO_0000218,8684,,,1,CHEMBL624687,,,Rattus norvegicus,N,1,,
11433,"Distribution in rat kidney, 6 hr after intravenous administration, injected dose/gm",Intermediate,10116.0,,A,,BAO_0000218,8684,,,1,CHEMBL624688,,,Rattus norvegicus,N,1,,
11434,"Distribution in rat kidney, 8 hr after intravenous administration, injected dose/gm",Intermediate,10116.0,,A,,BAO_0000218,8684,,,1,CHEMBL627161,,,Rattus norvegicus,N,1,,
11435,"Distribution in rat liver 15 min after intravenous administration, injected dose/gm",Intermediate,10116.0,,A,,BAO_0000218,8684,,,1,CHEMBL622127,,,Rattus norvegicus,N,1,,
11436,"Distribution in rat liver 1 hr after intravenous administration, injected dose/gm",Intermediate,10116.0,,A,,BAO_0000218,8684,,,1,CHEMBL622128,,,Rattus norvegicus,N,1,,
11437,"Distribution in rat liver 2 hr after intravenous administration, injected dose/gm",Intermediate,10116.0,,A,,BAO_0000218,8684,,,1,CHEMBL874384,,,Rattus norvegicus,N,1,,
11438,"Distribution in rat liver 30 min after intravenous administration, injected dose/gm",Intermediate,10116.0,,A,,BAO_0000218,8684,,,1,CHEMBL624898,,,Rattus norvegicus,N,1,,
11439,"Distribution in rat liver 4 hr after intravenous administration, injected dose/gm",Intermediate,10116.0,,A,,BAO_0000218,8684,,,1,CHEMBL624899,,,Rattus norvegicus,N,1,,
11440,"Distribution in rat liver 5 min after intravenous administration, injected dose/gm",Intermediate,10116.0,,A,,BAO_0000218,8684,,,1,CHEMBL624900,,,Rattus norvegicus,N,1,,
11441,"Distribution in rat liver 6 hr after intravenous administration, injected dose/gm",Intermediate,10116.0,,A,,BAO_0000218,8684,,,1,CHEMBL624901,,,Rattus norvegicus,N,1,,
11442,"Distribution in rat liver 8 hr after intravenous administration, injected dose/gm",Intermediate,10116.0,,A,,BAO_0000218,8684,,,1,CHEMBL624902,,,Rattus norvegicus,N,1,,
11443,"Distribution in rat lungs 15 min after intravenous administration, injected dose/gm",Intermediate,10116.0,,A,,BAO_0000218,8684,,,1,CHEMBL624903,,,Rattus norvegicus,N,1,,
11444,"Distribution in rat lungs 1 hr after intravenous administration, injected dose/gm",Intermediate,10116.0,,A,,BAO_0000218,8684,,,1,CHEMBL624904,,,Rattus norvegicus,N,1,,
11445,"Distribution in rat lungs 2 hr after intravenous administration, injected dose/gm",Intermediate,10116.0,,A,,BAO_0000218,8684,,,1,CHEMBL624905,,,Rattus norvegicus,N,1,,
11446,"Distribution in rat lungs 30 min after intravenous administration, injected dose/gm",Intermediate,10116.0,,A,,BAO_0000218,8684,,,1,CHEMBL624906,,,Rattus norvegicus,N,1,,
11447,"Distribution in rat lungs 4 hr after intravenous administration, injected dose/gm",Intermediate,10116.0,,A,,BAO_0000218,8684,,,1,CHEMBL624907,,,Rattus norvegicus,N,1,,
11448,"Distribution in rat lungs 5 min after intravenous administration, injected dose/gm",Intermediate,10116.0,,A,,BAO_0000218,8684,,,1,CHEMBL624908,,,Rattus norvegicus,N,1,,
11449,"Distribution in rat lungs 6 hr after intravenous administration, injected dose/gm",Intermediate,10116.0,,A,,BAO_0000218,8684,,,1,CHEMBL624909,,,Rattus norvegicus,N,1,,
11450,"Distribution in rat lungs 8 hr after intravenous administration, injected dose/gm",Intermediate,10116.0,,A,,BAO_0000218,8684,,,1,CHEMBL624910,,,Rattus norvegicus,N,1,,
11451,"Distribution in rat muscle 15 min after intravenous administration, injected dose/gm",Intermediate,10116.0,,A,,BAO_0000218,8684,,,1,CHEMBL624911,,,Rattus norvegicus,N,1,2385.0,
11452,"Distribution in rat muscle 1 hr after intravenous administration, injected dose/gm",Intermediate,10116.0,,A,,BAO_0000218,8684,,,1,CHEMBL874388,,,Rattus norvegicus,N,1,2385.0,
11453,"Distribution in rat muscle 2 hr after intravenous administration, injected dose/gm",Intermediate,10116.0,,A,,BAO_0000218,8684,,,1,CHEMBL624912,,,Rattus norvegicus,N,1,2385.0,
11454,"Distribution in rat muscle 30 min after intravenous administration, injected dose/gm",Intermediate,10116.0,,A,,BAO_0000218,8684,,,1,CHEMBL622930,,,Rattus norvegicus,N,1,2385.0,
11455,"Distribution in rat muscle 4 hr after intravenous administration, injected dose/gm",Intermediate,10116.0,,A,,BAO_0000218,8684,,,1,CHEMBL623121,,,Rattus norvegicus,N,1,2385.0,
11456,"Distribution in rat muscle 5 min after intravenous administration, injected dose/gm",Intermediate,10116.0,,A,,BAO_0000218,8684,,,1,CHEMBL623122,,,Rattus norvegicus,N,1,2385.0,
11457,"Distribution in rat muscle 6 hr after intravenous administration, injected dose/gm",Intermediate,10116.0,,A,,BAO_0000218,8684,,,1,CHEMBL623123,,,Rattus norvegicus,N,1,2385.0,
11458,"Distribution in rat muscle 8 hr after intravenous administration, injected dose/gm",Intermediate,10116.0,,A,,BAO_0000218,8684,,,1,CHEMBL623124,,,Rattus norvegicus,N,1,2385.0,
11459,"Distribution in rat pancreas 15 min after intravenous administration, injected dose/gm",Intermediate,10116.0,,A,,BAO_0000218,8684,,,1,CHEMBL623125,,,Rattus norvegicus,N,1,,
11460,"Distribution in rat pancreas 1 hr after intravenous administration, injected dose/gm",Intermediate,10116.0,,A,,BAO_0000218,8684,,,1,CHEMBL623126,,,Rattus norvegicus,N,1,,
11461,"Distribution in rat pancreas 2 hr after intravenous administration, injected dose/gm",Intermediate,10116.0,,A,,BAO_0000218,8684,,,1,CHEMBL623127,,,Rattus norvegicus,N,1,,
11462,"Distribution in rat pancreas 30 min after intravenous administration, injected dose/gm",Intermediate,10116.0,,A,,BAO_0000218,8684,,,1,CHEMBL623128,,,Rattus norvegicus,N,1,,
11463,"Distribution in rat pancreas 4 hr after intravenous administration, injected dose/gm",Intermediate,10116.0,,A,,BAO_0000218,8684,,,1,CHEMBL623129,,,Rattus norvegicus,N,1,,
11464,"Distribution in rat pancreas 5 min after intravenous administration, injected dose/gm",Intermediate,10116.0,,A,,BAO_0000218,8684,,,1,CHEMBL623130,,,Rattus norvegicus,N,1,,
11465,"Distribution in rat pancreas 6 hr after intravenous administration, injected dose/gm",Intermediate,10116.0,,A,,BAO_0000218,8684,,,1,CHEMBL623131,,,Rattus norvegicus,N,1,,
11466,"Distribution in rat pancreas 8 hr after intravenous administration, injected dose/gm",Intermediate,10116.0,,A,,BAO_0000218,8684,,,1,CHEMBL623132,,,Rattus norvegicus,N,1,,
11467,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat liver as Percent of injected dose per gram in the organ,Intermediate,10116.0,,A,,BAO_0000218,8319,,,1,CHEMBL623133,,,Rattus norvegicus,N,1,2107.0,
11468,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat lung as Percent of injected dose per gram in the organ,Intermediate,10116.0,,A,,BAO_0000218,8319,,,1,CHEMBL623134,,,Rattus norvegicus,N,1,,
11469,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat blood as Percent of injected dose per gram in the organ,Intermediate,10116.0,,A,,BAO_0000218,8319,,,1,CHEMBL874389,,,Rattus norvegicus,N,1,,
11470,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat brain as Percent of injected dose in the total organ,Intermediate,10116.0,,A,,BAO_0000218,8319,,,1,CHEMBL623135,,,Rattus norvegicus,N,1,,
11471,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat brain as Percent of injected dose per gram in the organ,Intermediate,10116.0,,A,,BAO_0000218,8319,,,1,CHEMBL623136,,,Rattus norvegicus,N,1,,
11472,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat heart as Percent of injected dose in the total organ,Intermediate,10116.0,,A,,BAO_0000218,8319,,,1,CHEMBL623137,,,Rattus norvegicus,N,1,,
11473,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat heart as Percent of injected dose per gram in the organ,Intermediate,10116.0,,A,,BAO_0000218,8319,,,1,CHEMBL623138,,,Rattus norvegicus,N,1,,
11474,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat kidney as Percent of injected dose in the total organ,Intermediate,10116.0,,A,,BAO_0000218,8319,,,1,CHEMBL623139,,,Rattus norvegicus,N,1,2113.0,
11475,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat kidney as Percent of injected dose per gram in the organ,Intermediate,10116.0,,A,,BAO_0000218,8319,,,1,CHEMBL623140,,,Rattus norvegicus,N,1,2113.0,
11476,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat liver as Percent of injected dose in the total organ,Intermediate,10116.0,,A,,BAO_0000218,8319,,,1,CHEMBL623141,,,Rattus norvegicus,N,1,2107.0,
11477,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat liver as Percent of injected dose per gram in the organ,Intermediate,10116.0,,A,,BAO_0000218,8319,,,1,CHEMBL623142,,,Rattus norvegicus,N,1,2107.0,
11478,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat lung as Percent of injected dose per gram in the organ,Intermediate,10116.0,,A,,BAO_0000218,8319,,,1,CHEMBL623143,,,Rattus norvegicus,N,1,,
11479,The total amount of penciclovir recovered in the urine over a 48-h period was determined by HPLC using a C18 reversed-phase column in mouse.,Intermediate,10090.0,,A,,BAO_0000218,14571,,,1,CHEMBL623144,,,Mus musculus,N,1,1088.0,
11480,The total amount of penciclovir recovered in the urine over a 48-h period was determined by HPLC using a C18 reversed-phase column in rat.,Intermediate,10116.0,,A,,BAO_0000218,14571,,,1,CHEMBL623405,,,Rattus norvegicus,N,1,1088.0,
11481,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat blood as Percent of injected dose per gram in the organ,Intermediate,10116.0,,A,,BAO_0000218,8319,,,1,CHEMBL624074,,,Rattus norvegicus,N,1,,
11482,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat brain as Percent of injected dose in the total organ,Intermediate,10116.0,,A,,BAO_0000218,8319,,,1,CHEMBL624075,,,Rattus norvegicus,N,1,,
11483,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat brain as Percent of injected dose per gram in the organ,Intermediate,10116.0,,A,,BAO_0000218,8319,,,1,CHEMBL624076,,,Rattus norvegicus,N,1,,
11484,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat heart as Percent of injected dose in the total organ,Intermediate,10116.0,,A,,BAO_0000218,8319,,,1,CHEMBL624077,,,Rattus norvegicus,N,1,,
11485,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat heart as Percent of injected dose per gram in the organ,Intermediate,10116.0,,A,,BAO_0000218,8319,,,1,CHEMBL624078,,,Rattus norvegicus,N,1,,
11486,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat kidney as Percent of injected dose in the total organ,Intermediate,10116.0,,A,,BAO_0000218,8319,,,1,CHEMBL624079,,,Rattus norvegicus,N,1,2113.0,
11487,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat kidney as Percent of injected dose per gram in the organ,Intermediate,10116.0,,A,,BAO_0000218,8319,,,1,CHEMBL624261,,,Rattus norvegicus,N,1,2113.0,
11488,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat liver as Percent of injected dose in the total organ,Intermediate,10116.0,,A,,BAO_0000218,8319,,,1,CHEMBL624262,,,Rattus norvegicus,N,1,,
11489,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat liver as Percent of injected dose per gram in the organ,Intermediate,10116.0,,A,,BAO_0000218,8319,,,1,CHEMBL624263,,,Rattus norvegicus,N,1,,
11490,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat lung as Percent of injected dose per gram in the organ,Intermediate,10116.0,,A,,BAO_0000218,8319,,,1,CHEMBL624264,,,Rattus norvegicus,N,1,,
11491,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat blood as Percent of injected dose per gram in the organ,Intermediate,10116.0,,A,,BAO_0000218,8319,,,1,CHEMBL624265,,,Rattus norvegicus,N,1,,
11492,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat brain as Percent of injected dose in the total organ,Intermediate,10116.0,,A,,BAO_0000218,8319,,,1,CHEMBL624266,,,Rattus norvegicus,N,1,,
11493,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat brain as Percent of injected dose per gram in the organ,Intermediate,10116.0,,A,,BAO_0000218,8319,,,1,CHEMBL624267,,,Rattus norvegicus,N,1,,
11494,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat heart as Percent of injected dose in the total organ,Intermediate,10116.0,,A,,BAO_0000218,8319,,,1,CHEMBL624268,,,Rattus norvegicus,N,1,,
11495,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat heart as Percent of injected dose per gram in the organ,Intermediate,10116.0,,A,,BAO_0000218,8319,,,1,CHEMBL875227,,,Rattus norvegicus,N,1,,
11496,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat kidney as Percent of injected dose in the total organ,Intermediate,10116.0,,A,,BAO_0000218,8319,,,1,CHEMBL624269,,,Rattus norvegicus,N,1,2113.0,
11497,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat kidney as Percent of injected dose per gram in the organ,Intermediate,10116.0,,A,,BAO_0000218,8319,,,1,CHEMBL624270,,,Rattus norvegicus,N,1,2113.0,
11498,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat liver as Percent of injected dose in the total organ,Intermediate,10116.0,,A,,BAO_0000218,8319,,,1,CHEMBL624271,,,Rattus norvegicus,N,1,,
11499,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat liver as Percent of injected dose per gram in the organ,Intermediate,10116.0,,A,,BAO_0000218,8319,,,1,CHEMBL624272,,,Rattus norvegicus,N,1,,
11500,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat lung as Percent of injected dose per gram in the organ,Intermediate,10116.0,,A,,BAO_0000218,8319,,,1,CHEMBL624273,,,Rattus norvegicus,N,1,,
11501,Urinary excretion in rat after 0-4 hours of oral administration at 50 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,12064,,,1,CHEMBL624274,,,Rattus norvegicus,N,1,1088.0,
11502,Urinary excretion in rat after 4-8 hours of oral administration at 50 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,12064,,,1,CHEMBL624275,,,Rattus norvegicus,N,1,1088.0,
11503,Urinary excretion in rat after 8-24 hours of oral administration at 50 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,12064,,,1,CHEMBL624276,,,Rattus norvegicus,N,1,1088.0,
11504,Urinary recovery expressed as percentage dose in male rats after iv administration of 20 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,12038,,,1,CHEMBL624277,,,Rattus norvegicus,N,1,1088.0,
11505,% dose converted to 2-amino-5-chlorophenyl sulfate,Autocuration,,,A,,BAO_0000019,14314,,,1,CHEMBL624278,,,,U,0,,
11506,% dose converted to 4-(S-amino-N-{[(4-chlorophenyl)amino]carbonyl}sulfonimidoyl)benzoic acid (compound 41),Autocuration,,,A,,BAO_0000019,14314,,,1,CHEMBL624279,,,,U,0,,
11507,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after intravenous administration of compound dose (1 mg/kg) at 0-24 hr",Intermediate,10116.0,,A,,BAO_0000218,11488,,,1,CHEMBL624280,,,Rattus norvegicus,N,1,1988.0,
11508,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after intravenous administration of compound dose (1 mg/kg) at 24-48 hr",Intermediate,10116.0,,A,,BAO_0000218,11488,,,1,CHEMBL624281,,,Rattus norvegicus,N,1,1988.0,
11509,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 0-24 hr",Intermediate,10116.0,,A,,BAO_0000218,11488,,,1,CHEMBL622933,,,Rattus norvegicus,N,1,1988.0,
11510,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 24-48 hr",Intermediate,10116.0,,A,,BAO_0000218,11488,,,1,CHEMBL622934,,,Rattus norvegicus,N,1,1988.0,
11511,Biodistribution in Rat liver after 30 minutes of iv administration; per g of tissue,Intermediate,10116.0,,A,,BAO_0000218,8829,,,1,CHEMBL622935,,,Rattus norvegicus,N,1,2107.0,
11512,Biodistribution in Rat liver after 5 minutes of iv administration,Intermediate,10116.0,,A,,BAO_0000218,8829,,,1,CHEMBL622936,,,Rattus norvegicus,N,1,2107.0,
11513,Biodistribution in Rat liver after 5 minutes of iv administration; per g of tissue,Intermediate,10116.0,,A,,BAO_0000218,8829,,,1,CHEMBL875228,,,Rattus norvegicus,N,1,2107.0,
11514,Biodistribution in Rat lung after 24 hours of iv administration,Intermediate,10116.0,,A,,BAO_0000218,8829,,,1,CHEMBL622937,,,Rattus norvegicus,N,1,2048.0,
11515,Biodistribution in Rat lung after 24 hours of iv administration; per g of tissue,Intermediate,10116.0,,A,,BAO_0000218,8829,,,1,CHEMBL622938,,,Rattus norvegicus,N,1,2048.0,
11516,Biodistribution in Rat lung after 30 minutes of iv administration,Intermediate,10116.0,,A,,BAO_0000218,8829,,,1,CHEMBL619736,,,Rattus norvegicus,N,1,2048.0,
11517,Biodistribution in Rat lung after 30 minutes of iv administration; per g of tissue,Intermediate,10116.0,,A,,BAO_0000218,8829,,,1,CHEMBL625117,,,Rattus norvegicus,N,1,2048.0,
11518,Biodistribution in Rat lung after 5 minutes of iv administration,Intermediate,10116.0,,A,,BAO_0000218,8829,,,1,CHEMBL625118,,,Rattus norvegicus,N,1,2048.0,
11519,Biodistribution in Rat lung after 5 minutes of iv administration; per g of tissue,Intermediate,10116.0,,A,,BAO_0000218,8829,,,1,CHEMBL625119,,,Rattus norvegicus,N,1,2048.0,
11520,"Biodistribution in rat cerebellum, expressed as percent I.D./g tissue",Intermediate,10116.0,,A,,BAO_0000218,14972,,,1,CHEMBL625120,,,Rattus norvegicus,N,1,2037.0,
11521,"Biodistribution in rat superior coliculus, expressed as percent I.D./g tissue",Intermediate,10116.0,,A,,BAO_0000218,14972,,,1,CHEMBL625121,,,Rattus norvegicus,N,1,,
11522,"Biodistribution in rat thalamus, expressed as percent I.D./g tissue",Intermediate,10116.0,,A,,BAO_0000218,14972,,,1,CHEMBL625122,,,Rattus norvegicus,N,1,10000006.0,
11523,Biodistribution was measured in blood of rat by injecting the radiolabeled compound intravenously and the value measured after 2 min,Intermediate,10116.0,,A,,BAO_0000218,14608,,,1,CHEMBL622204,,,Rattus norvegicus,N,1,178.0,
11524,Biodistribution was measured in blood of rat by injecting the radiolabeled compound intravenously and the value measured after 30 min,Intermediate,10116.0,,A,,BAO_0000218,14608,,,1,CHEMBL877503,,,Rattus norvegicus,N,1,178.0,
11525,Biodistribution was measured in blood of rat by injecting the radiolabeled compound intravenously and the value measured after 60 min,Intermediate,10116.0,,A,,BAO_0000218,14608,,,1,CHEMBL627127,,,Rattus norvegicus,N,1,178.0,
11526,Biodistribution was measured in hippocampus region(HP/CB) by injecting the radiolabeled compound intravenously and the value measured after 2 min,Autocuration,,,A,,BAO_0000218,14608,,,1,CHEMBL627128,,,,U,0,10000000.0,
11527,Biodistribution was measured in hippocampus region(HP/CB) by injecting the radiolabeled compound intravenously and the value measured after 30 min,Autocuration,,,A,,BAO_0000218,14608,,,1,CHEMBL627129,,,,U,0,10000000.0,
11528,Biodistribution was measured in hippocampus region(HP/CB) by injecting the radiolabeled compound intravenously and the value measured after 60 min,Autocuration,,,A,,BAO_0000218,14608,,,1,CHEMBL627130,,,,U,0,10000000.0,
11529,Biodistribution was measured in rat brain by injecting the radiolabeled compound intravenously and the value measured after 2 min,Intermediate,10116.0,,A,,BAO_0000218,14608,,,1,CHEMBL627131,,,Rattus norvegicus,N,1,955.0,
11530,Biodistribution was measured in rat brain by injecting the radiolabeled compound intravenously and the value measured after 30 min,Intermediate,10116.0,,A,,BAO_0000218,14608,,,1,CHEMBL627132,,,Rattus norvegicus,N,1,955.0,
11531,Biodistribution was measured in rat brain by injecting the radiolabeled compound intravenously and the value measured after 60 min,Intermediate,10116.0,,A,,BAO_0000218,14608,,,1,CHEMBL627133,,,Rattus norvegicus,N,1,955.0,
11532,Biodistribution was measured in rat cerebellum by injecting the radiolabeled compound intravenously and the value measured after 2 min,Intermediate,10116.0,,A,,BAO_0000218,14608,,,1,CHEMBL627134,,,Rattus norvegicus,N,1,2037.0,
11533,Biodistribution was measured in rat cerebellum by injecting the radiolabeled compound intravenously and the value measured after 30 min,Intermediate,10116.0,,A,,BAO_0000218,14608,,,1,CHEMBL627135,,,Rattus norvegicus,N,1,2037.0,
11534,Biodistribution was measured in rat cerebellum by injecting the radiolabeled compound intravenously and the value measured after 60 min,Intermediate,10116.0,,A,,BAO_0000218,14608,,,1,CHEMBL627136,,,Rattus norvegicus,N,1,2037.0,
11535,Biodistribution was measured in rat cortex by injecting the radiolabeled compound intravenously and the value measured after 2 min,Intermediate,10116.0,,A,,BAO_0000218,14608,,,1,CHEMBL628435,,,Rattus norvegicus,N,1,,
11536,Biodistribution was measured in rat cortex by injecting the radiolabeled compound intravenously and the value measured after 30 min,Intermediate,10116.0,,A,,BAO_0000218,14608,,,1,CHEMBL628436,,,Rattus norvegicus,N,1,,
11537,Biodistribution was measured in rat cortex by injecting the radiolabeled compound intravenously and the value measured after 60 min,Intermediate,10116.0,,A,,BAO_0000218,14608,,,1,CHEMBL628437,,,Rattus norvegicus,N,1,,
11538,Biodistribution was measured in rat heart by injecting the radiolabeled compound intravenously and the value measured after 2 min,Intermediate,10116.0,,A,,BAO_0000218,14608,,,1,CHEMBL628438,,,Rattus norvegicus,N,1,948.0,
11539,Biodistribution was measured in rat heart by injecting the radiolabeled compound intravenously and the value measured after 30 min,Intermediate,10116.0,,A,,BAO_0000218,14608,,,1,CHEMBL628439,,,Rattus norvegicus,N,1,948.0,
11540,Biodistribution was measured in rat heart by injecting the radiolabeled compound intravenously and the value measured after 60 min,Intermediate,10116.0,,A,,BAO_0000218,14608,,,1,CHEMBL628440,,,Rattus norvegicus,N,1,948.0,
11541,Biodistribution was measured in rat hippocampus by injecting the radiolabeled compound intravenously and the value measured after 2 min,Intermediate,10116.0,,A,,BAO_0000218,14608,,,1,CHEMBL628441,,,Rattus norvegicus,N,1,10000000.0,
11542,Biodistribution was measured in rat hippocampus by injecting the radiolabeled compound intravenously and the value measured after 30 min,Intermediate,10116.0,,A,,BAO_0000218,14608,,,1,CHEMBL628442,,,Rattus norvegicus,N,1,10000000.0,
11543,Biodistribution was measured in rat hippocampus by injecting the radiolabeled compound intravenously and the value measured after 60 min,Intermediate,10116.0,,A,,BAO_0000218,14608,,,1,CHEMBL628443,,,Rattus norvegicus,N,1,10000000.0,
11544,Biodistribution was measured in rat kidney by injecting the radiolabeled compound intravenously and the value measured after 2 min,Intermediate,10116.0,,A,,BAO_0000218,14608,,,1,CHEMBL628444,,,Rattus norvegicus,N,1,2113.0,
11545,Biodistribution was measured in rat kidney by injecting the radiolabeled compound intravenously and the value measured after 30 min,Intermediate,10116.0,,A,,BAO_0000218,14608,,,1,CHEMBL628445,,,Rattus norvegicus,N,1,2113.0,
11546,Biodistribution was measured in rat kidney by injecting the radiolabeled compound intravenously and the value measured after 60 min,Intermediate,10116.0,,A,,BAO_0000218,14608,,,1,CHEMBL877504,,,Rattus norvegicus,N,1,2113.0,
11547,Biodistribution was measured in rat liver by injecting the radiolabeled compound intravenously and the value measured after 2 min,Intermediate,10116.0,,A,,BAO_0000218,14608,,,1,CHEMBL628446,,,Rattus norvegicus,N,1,2107.0,
11548,Biodistribution was measured in rat liver by injecting the radiolabeled compound intravenously and the value measured after 30 min,Intermediate,10116.0,,A,,BAO_0000218,14608,,,1,CHEMBL626874,,,Rattus norvegicus,N,1,2107.0,
11549,Biodistribution was measured in rat liver by injecting the radiolabeled compound intravenously and the value measured after 60 min,Intermediate,10116.0,,A,,BAO_0000218,14608,,,1,CHEMBL626875,,,Rattus norvegicus,N,1,2107.0,
11550,Biodistribution was measured in rat lung by injecting the radiolabeled compound intravenously and the value measured after 2 min,Intermediate,10116.0,,A,,BAO_0000218,14608,,,1,CHEMBL626876,,,Rattus norvegicus,N,1,2048.0,
11551,Biodistribution was measured in rat lung by injecting the radiolabeled compound intravenously and the value measured after 30 min,Intermediate,10116.0,,A,,BAO_0000218,14608,,,1,CHEMBL626877,,,Rattus norvegicus,N,1,2048.0,
11552,Biodistribution was measured in rat lung by injecting the radiolabeled compound intravenously and the value measured after 60 min,Intermediate,10116.0,,A,,BAO_0000218,14608,,,1,CHEMBL626878,,,Rattus norvegicus,N,1,2048.0,
11553,Biodistribution was measured in rat muscle by injecting the radiolabeled compound intravenously and the value measured after 2 min,Intermediate,10116.0,,A,,BAO_0000218,14608,,,1,CHEMBL626879,,,Rattus norvegicus,N,1,2385.0,
11554,Peak plasma concentration expresses the ability of compound for the release of dopamine in the plasma of monkey after oral administration of 0.05 mmol/kg,Autocuration,314293.0,,A,,BAO_0000218,8918,,,1,CHEMBL626880,,,Simiiformes,U,0,1969.0,
11555,Peak plasma concentration expresses the ability of compound for the release of dopamine in the plasma of mouse after oral administration of 0.05 mmol/kg,Intermediate,10090.0,,A,,BAO_0000218,8918,,,1,CHEMBL626881,,,Mus musculus,N,1,1969.0,
11556,Peak plasma concentration expresses the ability of compound for the release of dopamine in the plasma of rat after oral administration of 0.05 mmol/kg,Intermediate,10116.0,,A,,BAO_0000218,8918,,,1,CHEMBL626882,,,Rattus norvegicus,N,1,1969.0,
11557,Peak plasma concentration was measured in dogs,Intermediate,9615.0,,A,,BAO_0000218,14470,,,1,CHEMBL626883,,,Canis lupus familiaris,N,1,1969.0,
11558,Pharmacokinetic Parameter (Cmax) was evaluated at 10 mg/kg (p.o.) in Wistar rats,Intermediate,10116.0,,A,,BAO_0000218,14393,,,1,CHEMBL626884,,,Rattus norvegicus,N,1,,
11559,Pharmacokinetic parameter (Cmax ) was evaluated in Spargue-Dawley rat when given intravenously at dose 15 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,14886,,,1,CHEMBL626885,,,Rattus norvegicus,N,1,,
11560,Pharmacokinetic parameter (Cmax ) was evaluated in Spargue-Dawley rat when given peroral at dose 30 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,14886,,,1,CHEMBL626886,,,Rattus norvegicus,N,1,,
11561,Pharmacokinetic parameter (Cmax ) was evaluated in Spargue-Dawley rat when given peroral at dose 80 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,14886,,,1,CHEMBL626887,,,Rattus norvegicus,N,1,,
11562,Pharmacokinetic parameter (Cmax) was evaluated at 10 mg/kg (p.o.) in Wistar rats,Intermediate,10116.0,,A,,BAO_0000218,14393,,,1,CHEMBL626888,,,Rattus norvegicus,N,1,,
11563,Pharmacokinetic parameter Cmax determined after intravenous administration of 15 mg/kg to dog,Intermediate,9615.0,,A,,BAO_0000218,13465,,,1,CHEMBL626889,,,Canis lupus familiaris,N,1,,
11564,Pharmacokinetic parameter Cmax determined after intravenous administration of 25 mg/kg to monkey,Autocuration,314293.0,,A,,BAO_0000218,13465,,,1,CHEMBL626761,,,Simiiformes,U,0,,
11565,Pharmacokinetic parameter Cmax determined after intravenous administration of 30 mg/kg abd antacid (CaCO3 dosed orally 10 min prior to and 60 min postdosing) to dog,Intermediate,9615.0,,A,,BAO_0000218,13465,,,1,CHEMBL626762,,,Canis lupus familiaris,N,1,,
11566,Pharmacokinetic parameter Cmax determined after intravenous administration of 30 mg/kg to dog,Intermediate,9615.0,,A,,BAO_0000218,13465,,,1,CHEMBL626763,,,Canis lupus familiaris,N,1,,
11567,Pharmacokinetic parameter Cmax determined after intravenous administration of 50 mg/kg to rat,Intermediate,10116.0,,A,,BAO_0000218,13465,,,1,CHEMBL626764,,,Rattus norvegicus,N,1,,
11568,Pharmacokinetic parameter Cmax determined after intravenous administration of 60 mg/kg to rat,Intermediate,10116.0,,A,,BAO_0000218,13465,,,1,CHEMBL626765,,,Rattus norvegicus,N,1,,
11569,Pharmacokinetic parameter Cmax determined after oral administration of 50 mg/kg to dog,Intermediate,9615.0,,A,,BAO_0000218,13465,,,1,CHEMBL626766,,,Canis lupus familiaris,N,1,,
11570,Pharmacokinetic parameter Cmax determined after oral administration of 50 mg/kg to rat,Intermediate,10116.0,,A,,BAO_0000218,13465,,,1,CHEMBL626767,,,Rattus norvegicus,N,1,,
11571,Pharmacokinetic parameter Cmax determined after oral administration of 50 mg/kg to rat; No levels,Intermediate,10116.0,,A,,BAO_0000218,13465,,,1,CHEMBL626768,,,Rattus norvegicus,N,1,,
11572,Pharmacokinetic parameter Cmax determined after peroral administration of 15 mg/kg to dog,Intermediate,9615.0,,A,,BAO_0000218,13465,,,1,CHEMBL626769,,,Canis lupus familiaris,N,1,,
11573,Pharmacokinetic parameter Cmax determined after peroral administration of 25 mg/kg to dog,Intermediate,9615.0,,A,,BAO_0000218,13465,,,1,CHEMBL874463,,,Canis lupus familiaris,N,1,,
11574,Pharmacokinetic parameter Cmax determined after peroral administration of 25 mg/kg to monkey,Autocuration,314293.0,,A,,BAO_0000218,13465,,,1,CHEMBL626770,,,Simiiformes,U,0,,
11575,Pharmacokinetic parameter Cmax determined after peroral administration of 25 mg/kg to monkey; No levels,Autocuration,314293.0,,A,,BAO_0000218,13465,,,1,CHEMBL626771,,,Simiiformes,U,0,,
11576,Pharmacokinetic parameter Cmax determined after peroral administration of 50 mg/kg to rat,Intermediate,10116.0,,A,,BAO_0000218,13465,,,1,CHEMBL626772,,,Rattus norvegicus,N,1,,
11577,Pharmacokinetic parameter Cmax for the compound was evaluated in nude cynomolgus monkeys after oral administration. ,Intermediate,9541.0,,A,,BAO_0000218,14731,,,1,CHEMBL626773,,,Macaca fascicularis,N,1,,
11578,Pharmacokinetic parameter Cmax for the compound was evaluated in nude mice after oral administration. ,Intermediate,10090.0,,A,,BAO_0000218,14731,,,1,CHEMBL626774,,,Mus musculus,N,1,,
11579,Pharmacokinetic parameter Cmax has been determined in fed Beagle dogs at a dose of 375 mg/kg,Intermediate,9615.0,,A,,BAO_0000218,13376,,,1,CHEMBL626775,,,Canis lupus familiaris,N,1,,
11580,Pharmacokinetic parameter Cmax has been determined in fed Beagle dogs at a dose of 500 mg/kg,Intermediate,9615.0,,A,,BAO_0000218,13376,,,1,CHEMBL626776,,,Canis lupus familiaris,N,1,,
11581,Maximum concentration (Cmax) in rat when administered orally,Intermediate,10116.0,,A,,BAO_0000218,14443,,,1,CHEMBL626777,,,Rattus norvegicus,N,1,,
11582,Maximal concentration in monkey plasma after 25 mg/kg oral dose,Autocuration,314293.0,,A,,BAO_0000218,13465,,,1,CHEMBL626778,,,Simiiformes,U,0,1969.0,
11583,"Mean Cmax in rats after 5 mg/kg oral dose, range (0.17-0.20)",Autocuration,10116.0,,A,,BAO_0000218,16359,,,1,CHEMBL626779,,,Rattus norvegicus,U,0,,
11584,"Mean Cmax in rats after 5 mg/kg oral dose, range (0.4-0.8)",Autocuration,10116.0,,A,,BAO_0000218,16359,,,1,CHEMBL626780,,,Rattus norvegicus,U,0,,
11585,Cmax in rat plasma after single 5 mg/kg oral cassette gavage dose,Autocuration,,,A,,BAO_0000218,15618,,,1,CHEMBL626781,,,,U,0,1969.0,
11586,Pharmacokinetic profile Cmax was evaluated in rats,Intermediate,10116.0,,A,,BAO_0000218,14554,,,1,CHEMBL632164,,,Rattus norvegicus,N,1,,
11587,Pharmacokinetic property(Cmax- maximum concentration) after oral administration in dog (25 mg/kg),Intermediate,9615.0,,A,,BAO_0000218,11537,,,1,CHEMBL632165,,,Canis lupus familiaris,N,1,,
11588,Pharmacokinetic property(Cmax- maximum concentration) after oral administration in mice (50 mg/kg),Intermediate,10090.0,,A,,BAO_0000218,11537,,,1,CHEMBL632166,,,Mus musculus,N,1,,
11589,Pharmacokinetic property(Cmax- maximum concentration) after oral administration to dog (25 mg/kg),Intermediate,9615.0,,A,,BAO_0000218,11537,,,1,CHEMBL632167,,,Canis lupus familiaris,N,1,,
11590,Pharmacokinetic property(Cmax- maximum concentration) after oral administration to mice (50 mg/kg),Intermediate,10090.0,,A,,BAO_0000218,11537,,,1,CHEMBL632168,,,Mus musculus,N,1,,
11591,Cmax in rat plasma,Autocuration,10116.0,,A,,BAO_0000218,2021,,,1,CHEMBL632169,,,Rattus norvegicus,U,0,1969.0,
11592,Cmax in dog plasma after 30mg/kg oral dose,Intermediate,9615.0,,A,,BAO_0000218,5932,,,1,CHEMBL632170,,,Canis lupus familiaris,N,1,1969.0,
11593,Cmax in rat plasma after 30mg/kg oral dose,Intermediate,10116.0,,A,,BAO_0000218,5932,,,1,CHEMBL632171,,,Rattus norvegicus,N,1,1969.0,
11594,Plasma level in rats at 30 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,17320,,,1,CHEMBL632172,,,Rattus norvegicus,N,1,1969.0,
11595,Tested for maximum plasma concentration in mice,Intermediate,10090.0,,A,,BAO_0000218,15831,,,1,CHEMBL632173,,,Mus musculus,N,1,1969.0,
11596,"The Cmax value in female wistar rat at 100 mg/kg, p.o. dose",Intermediate,10116.0,,A,,BAO_0000218,15078,,,1,CHEMBL632174,,,Rattus norvegicus,N,1,,
11597,The Cmax values in female wistar rats.,Intermediate,10116.0,,A,,BAO_0000218,14941,,,1,CHEMBL632175,,,Rattus norvegicus,N,1,,
11598,The Peak plasma concentration was measured in dogs after oral administration of 1 mg/kg dose,Intermediate,9615.0,,A,,BAO_0000218,15343,,,1,CHEMBL632176,,,Canis lupus familiaris,N,1,1969.0,
11599,The Peak plasma concentration was measured in rats after oral administration of 1 mg/kg dose,Intermediate,10116.0,,A,,BAO_0000218,15343,,,1,CHEMBL632177,,,Rattus norvegicus,N,1,1969.0,
11600,The compound tested for maximum observed plasma concentration in rats and is expressed in microgram/mL.,Intermediate,10116.0,,A,,BAO_0000218,14856,,,1,CHEMBL632178,,,Rattus norvegicus,N,1,1969.0,
11601,The compound was tested for Cmax value pharmacokinetic parameter in the male Sprague-Dawley rat.,Intermediate,10116.0,,A,,BAO_0000218,13129,,,1,CHEMBL632179,,,Rattus norvegicus,N,1,,
11602,The compound was tested for maximum blood level reached in rats at 15.9 uM/kg after peroral administration.,Intermediate,10116.0,,A,,BAO_0000218,13098,,,1,CHEMBL632180,,,Rattus norvegicus,N,1,178.0,
11603,The compound was tested for maximum blood level reached in rats at 15.9 uM/Kg after intravenous administration.,Intermediate,10116.0,,A,,BAO_0000218,13098,,,1,CHEMBL632181,,,Rattus norvegicus,N,1,178.0,
11604,The compound was tested for maximum blood level reached in rats at 15.9 uM/Kg after peroral administration.,Intermediate,10116.0,,A,,BAO_0000218,13098,,,1,CHEMBL632182,,,Rattus norvegicus,N,1,178.0,
11605,The maximum concentration observed (Cmax) in the blood sample at indicated time point (tmax) at a dose 50 mg/Kg administered orally in mice.,Autocuration,10090.0,,A,,BAO_0000218,15478,,,1,CHEMBL632183,,,Mus musculus,U,0,178.0,
11606,The maximum concentration of the compound was measured in dog at dose 5 mg/kg after peroral administration.,Intermediate,9615.0,,A,,BAO_0000218,15341,,,1,CHEMBL632184,,,Canis lupus familiaris,N,1,,
11607,The maximum concentration of the compound was measured in rat at dose 1 mg/kg after peroral administration.,Intermediate,10116.0,,A,,BAO_0000218,15341,,,1,CHEMBL874470,,,Rattus norvegicus,N,1,,
11608,"Distribution in rat skin 15 min after intravenous administration, injected dose/gm",Intermediate,10116.0,,A,,BAO_0000218,8684,,,1,CHEMBL631302,,,Rattus norvegicus,N,1,,
11609,"Distribution in rat skin 1 hr after intravenous administration, injected dose/gm",Intermediate,10116.0,,A,,BAO_0000218,8684,,,1,CHEMBL631303,,,Rattus norvegicus,N,1,,
11610,"Distribution in rat skin 2 hr after intravenous administration, injected dose/gm",Intermediate,10116.0,,A,,BAO_0000218,8684,,,1,CHEMBL631304,,,Rattus norvegicus,N,1,,
11611,"Distribution in rat skin 30 min after intravenous administration, injected dose/gm",Intermediate,10116.0,,A,,BAO_0000218,8684,,,1,CHEMBL631305,,,Rattus norvegicus,N,1,,
11612,"Distribution in rat skin 4 hr after intravenous administration, injected dose/gm",Intermediate,10116.0,,A,,BAO_0000218,8684,,,1,CHEMBL631306,,,Rattus norvegicus,N,1,,
11613,"Distribution in rat skin 5 min after intravenous administration, injected dose/gm",Intermediate,10116.0,,A,,BAO_0000218,8684,,,1,CHEMBL631307,,,Rattus norvegicus,N,1,,
11614,"Distribution in rat skin 6 hr after intravenous administration, injected dose/gm",Intermediate,10116.0,,A,,BAO_0000218,8684,,,1,CHEMBL631308,,,Rattus norvegicus,N,1,,
11615,"Distribution in rat skin 8 hr after intravenous administration, injected dose/gm",Intermediate,10116.0,,A,,BAO_0000218,8684,,,1,CHEMBL625557,,,Rattus norvegicus,N,1,,
11616,"Distribution in rat spleen 15 min after intravenous administration, injected dose/gm",Intermediate,10116.0,,A,,BAO_0000218,8684,,,1,CHEMBL625558,,,Rattus norvegicus,N,1,2106.0,
11617,"Distribution in rat spleen 1 hr after intravenous administration, injected dose/gm",Intermediate,10116.0,,A,,BAO_0000218,8684,,,1,CHEMBL625559,,,Rattus norvegicus,N,1,2106.0,
11618,"Distribution in rat spleen 2 hr after intravenous administration, injected dose/gm",Intermediate,10116.0,,A,,BAO_0000218,8684,,,1,CHEMBL625560,,,Rattus norvegicus,N,1,2106.0,
11619,"Distribution in rat spleen 30 min after intravenous administration, injected dose/gm",Intermediate,10116.0,,A,,BAO_0000218,8684,,,1,CHEMBL625561,,,Rattus norvegicus,N,1,2106.0,
11620,"Distribution in rat spleen 4 hr after intravenous administration, injected dose/gm",Intermediate,10116.0,,A,,BAO_0000218,8684,,,1,CHEMBL625562,,,Rattus norvegicus,N,1,2106.0,
11621,"Distribution in rat spleen 5 min after intravenous administration, injected dose/gm",Intermediate,10116.0,,A,,BAO_0000218,8684,,,1,CHEMBL875320,,,Rattus norvegicus,N,1,2106.0,
11622,"Distribution in rat spleen 6 hr after intravenous administration, injected dose/gm",Intermediate,10116.0,,A,,BAO_0000218,8684,,,1,CHEMBL625563,,,Rattus norvegicus,N,1,2106.0,
11623,"Distribution in rat spleen 8 hr after intravenous administration, injected dose/gm",Intermediate,10116.0,,A,,BAO_0000218,8684,,,1,CHEMBL625564,,,Rattus norvegicus,N,1,2106.0,
11624,"Distribution in rat uterus 15 min after intravenous administration, injected dose/gm",Intermediate,10116.0,,A,,BAO_0000218,8684,,,1,CHEMBL625565,,,Rattus norvegicus,N,1,995.0,
11625,"Distribution in rat uterus 1 hr after intravenous administration, injected dose/gm",Intermediate,10116.0,,A,,BAO_0000218,8684,,,1,CHEMBL625566,,,Rattus norvegicus,N,1,995.0,
11626,"Distribution in rat uterus 2 hr after intravenous administration, injected dose/gm",Intermediate,10116.0,,A,,BAO_0000218,8684,,,1,CHEMBL625567,,,Rattus norvegicus,N,1,995.0,
11627,"Distribution in rat uterus 30 min after intravenous administration, injected dose/gm",Intermediate,10116.0,,A,,BAO_0000218,8684,,,1,CHEMBL625568,,,Rattus norvegicus,N,1,995.0,
11628,"Distribution in rat uterus 4 hr after intravenous administration, injected dose/gm",Intermediate,10116.0,,A,,BAO_0000218,8684,,,1,CHEMBL628217,,,Rattus norvegicus,N,1,995.0,
11629,"Distribution in rat uterus 5 min after intravenous administration, injected dose/gm",Intermediate,10116.0,,A,,BAO_0000218,8684,,,1,CHEMBL628218,,,Rattus norvegicus,N,1,995.0,
11630,"Distribution in rat uterus 6 hr after intravenous administration, injected dose/gm",Intermediate,10116.0,,A,,BAO_0000218,8684,,,1,CHEMBL628219,,,Rattus norvegicus,N,1,995.0,
11631,"Distribution in rat uterus 8 hr after intravenous administration, injected dose/gm",Intermediate,10116.0,,A,,BAO_0000218,8684,,,1,CHEMBL628220,,,Rattus norvegicus,N,1,995.0,
11632,Distribution in the blood after 120 min of intravenous administration,Autocuration,,,A,,BAO_0000019,8926,,,1,CHEMBL628221,,,,U,0,,
11633,Distribution in the blood after 15 min of intravenous administration,Autocuration,,,A,,BAO_0000019,8926,,,1,CHEMBL628222,,,,U,0,,
11634,Distribution in the blood after 30 min of intravenous administration,Autocuration,,,A,,BAO_0000019,8926,,,1,CHEMBL628223,,,,U,0,,
11635,Distribution in the blood after 5 min of intravenous administration,Autocuration,,,A,,BAO_0000019,8926,,,1,CHEMBL628224,,,,U,0,,
11636,Distribution in the blood after 60 min of intravenous administration,Autocuration,,,A,,BAO_0000019,8926,,,1,CHEMBL628225,,,,U,0,,
11637,Distribution in the blood after 90 min of intravenous administration,Autocuration,,,A,,BAO_0000019,8926,,,1,CHEMBL628226,,,,U,0,,
11638,Distribution in the bone after 120 min of intravenous administration,Autocuration,,,A,,BAO_0000019,8926,,,1,CHEMBL628227,,,,U,0,,
11639,Distribution in the bone after 15 min of intravenous administration,Autocuration,,,A,,BAO_0000019,8926,,,1,CHEMBL875481,,,,U,0,,
11640,Distribution in the bone after 30 min of intravenous administration,Autocuration,,,A,,BAO_0000019,8926,,,1,CHEMBL628228,,,,U,0,,
11641,Distribution in the bone after 5 min of intravenous administration,Autocuration,,,A,,BAO_0000019,8926,,,1,CHEMBL628229,,,,U,0,,
11642,Distribution in the bone after 60 min of intravenous administration,Autocuration,,,A,,BAO_0000019,8926,,,1,CHEMBL628230,,,,U,0,,
11643,Distribution in the bone after 90 min of intravenous administration,Autocuration,,,A,,BAO_0000019,8926,,,1,CHEMBL628231,,,,U,0,,
11644,Distribution in the heart after 120 min of intravenous administration,Autocuration,,,A,,BAO_0000019,8926,,,1,CHEMBL628232,,,,U,0,,
11645,Distribution in the heart after 15 min of intravenous administration,Autocuration,,,A,,BAO_0000019,8926,,,1,CHEMBL628233,,,,U,0,,
11646,Distribution in the heart after 30 min of intravenous administration,Autocuration,,,A,,BAO_0000019,8926,,,1,CHEMBL628234,,,,U,0,,
11647,Distribution in the heart after 5 min of intravenous administration,Autocuration,,,A,,BAO_0000019,8926,,,1,CHEMBL628235,,,,U,0,,
11648,Distribution in the heart after 60 min of intravenous administration,Autocuration,,,A,,BAO_0000019,8926,,,1,CHEMBL628236,,,,U,0,,
11649,Distribution in the heart after 90 min of intravenous administration,Autocuration,,,A,,BAO_0000019,8926,,,1,CHEMBL628237,,,,U,0,,
11650,Distribution in the kidneys after 120 min of intravenous administration,Autocuration,,,A,,BAO_0000019,8926,,,1,CHEMBL628238,,,,U,0,,
11651,Distribution in the kidneys after 15 min of intravenous administration,Autocuration,,,A,,BAO_0000019,8926,,,1,CHEMBL628239,,,,U,0,,
11652,Distribution in the kidneys after 30 min of intravenous administration,Autocuration,,,A,,BAO_0000019,8926,,,1,CHEMBL628240,,,,U,0,,
11653,Distribution in the kidneys after 5 min of intravenous administration,Autocuration,,,A,,BAO_0000019,8926,,,1,CHEMBL628241,,,,U,0,,
11654,Distribution in the kidneys after 60 min of intravenous administration,Autocuration,,,A,,BAO_0000019,8926,,,1,CHEMBL628242,,,,U,0,,
11655,Distribution in the kidneys after 90 min of intravenous administration,Autocuration,,,A,,BAO_0000019,8926,,,1,CHEMBL875482,,,,U,0,,
11656,Distribution in the liver after 120 min of intravenous administration,Autocuration,,,A,,BAO_0000019,8926,,,1,CHEMBL628243,,,,U,0,,
11657,Distribution in the liver after 15 min of intravenous administration,Autocuration,,,A,,BAO_0000019,8926,,,1,CHEMBL628244,,,,U,0,,
11658,Distribution in the liver after 30 min of intravenous administration,Autocuration,,,A,,BAO_0000019,8926,,,1,CHEMBL628245,,,,U,0,,
11659,Distribution in the liver after 5 min of intravenous administration,Autocuration,,,A,,BAO_0000019,8926,,,1,CHEMBL628246,,,,U,0,,
11660,Distribution in the liver after 60 min of intravenous administration,Autocuration,,,A,,BAO_0000019,8926,,,1,CHEMBL628247,,,,U,0,,
11661,Distribution in the liver after 90 min of intravenous administration,Autocuration,,,A,,BAO_0000019,8926,,,1,CHEMBL628248,,,,U,0,,
11662,Distribution in the lung after 120 min of intravenous administration,Autocuration,,,A,,BAO_0000019,8926,,,1,CHEMBL628249,,,,U,0,,
11663,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in solution, iv and the total drug exposure was determined. (0-24hr)",Intermediate,10090.0,,A,,BAO_0000218,14839,,,1,CHEMBL625452,,,Mus musculus,N,1,,
11664,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in solution, perorally and the total drug exposure was determined (0-24hr)",Intermediate,10090.0,,A,,BAO_0000218,14839,,,1,CHEMBL625453,,,Mus musculus,N,1,,
11665,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, micronized free base in 20% HPbetaCD, iv and the total drug exposure was determined. (0-24hr)",Intermediate,10090.0,,A,,BAO_0000218,14839,,,1,CHEMBL625454,,,Mus musculus,N,1,,
11666,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, micronized free base in 20% HPbetaCD, perorally and the total drug exposure was determined (0-24hr)",Intermediate,10090.0,,A,,BAO_0000218,14839,,,1,CHEMBL623844,,,Mus musculus,N,1,,
11667,Integrated area under the blood concentration vs time curve for the period 0-24 hr postdose of 1 mg/kg (normalized to a 1 mg/kg dose) in rat,Intermediate,10116.0,,A,,BAO_0000218,12178,,,1,CHEMBL623845,,,Rattus norvegicus,N,1,,
11668,Integrated area under the blood concentration vs time curve for the period 0-24 hr postdose of 2.5 mg/kg (normalized to a 1 mg/kg dose) in rat,Intermediate,10116.0,,A,,BAO_0000218,12178,,,1,CHEMBL623846,,,Rattus norvegicus,N,1,,
11669,Integrated area under the blood concentration vs time curve for the period 0-24 hr postdose of 5.0 mg/kg (normalized to a 1 mg/kg dose) GP,Autocuration,,,A,,BAO_0000218,12178,,,1,CHEMBL623847,,,,U,0,,
11670,Integrated area under the plasma drug level-time curve after intraduodenal administration at a dose 10 mg/kg from portal circulation in salt-depleted cynomolgus monkeys using HPLC assay,Intermediate,9541.0,,A,,BAO_0000218,12186,,,1,CHEMBL623848,,,Macaca fascicularis,N,1,,
11671,Integrated area under the plasma drug level-time curve after intraduodenal administration at a dose 10 mg/kg from portal circulation in salt-depleted cynomolgus monkeys using renin inhibition assay,Intermediate,9541.0,,A,,BAO_0000218,12186,,,1,CHEMBL623849,,,Macaca fascicularis,N,1,,
11672,Integrated area under the plasma drug level-time curve after intraduodenal administration at a dose 10 mg/kg from systemic circulation in salt-depleted cynomolgus monkeys using HPLC assay,Intermediate,9541.0,,A,,BAO_0000218,12186,,,1,CHEMBL623850,,,Macaca fascicularis,N,1,,
11673,Integrated area under the plasma drug level-time curve after intraduodenal administration at a dose 10 mg/kg from systemic circulation in salt-depleted cynomolgus monkeys using renin inhibition assay,Intermediate,9541.0,,A,,BAO_0000218,12186,,,1,CHEMBL623851,,,Macaca fascicularis,N,1,,
11674,Integrated area under the plasma drug level-time curve was determined in portal circulation after intraduodenal dose of 10 mg/kg in monkey,Autocuration,314293.0,,A,,BAO_0000218,12187,,,1,CHEMBL623852,,,Simiiformes,U,0,,
11675,Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in ferret,Intermediate,9669.0,,A,,BAO_0000218,12187,,,1,CHEMBL624551,,,Mustela putorius furo,N,1,,
11676,"Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in ferret, determined by renin inhibition assay",Intermediate,9669.0,,A,,BAO_0000218,12187,,,1,CHEMBL624552,,,Mustela putorius furo,N,1,,
11677,Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in monkey,Autocuration,314293.0,,A,,BAO_0000218,12187,,,1,CHEMBL624553,,,Simiiformes,U,0,,
11678,Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in monkey determined by renin inhibition assay,Autocuration,314293.0,,A,,BAO_0000218,12187,,,1,CHEMBL624554,,,Simiiformes,U,0,,
11679,Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in rat,Intermediate,10116.0,,A,,BAO_0000218,12187,,,1,CHEMBL624555,,,Rattus norvegicus,N,1,,
11680,"Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in rat, determined by renin inhibition assay",Intermediate,10116.0,,A,,BAO_0000218,12187,,,1,CHEMBL624741,,,Rattus norvegicus,N,1,,
11681,"Intravenous integrated area under the concentration vs time curve, for compound in dog plasma",Intermediate,9615.0,,A,,BAO_0000218,14122,,,1,CHEMBL624742,,,Canis lupus familiaris,N,1,,
11682,"Intravenous integrated area under the concentration vs time curve, for compound in hamster plasma",Intermediate,10026.0,,A,,BAO_0000218,14122,,,1,CHEMBL624743,,,Cricetinae,N,1,,
11683,"Intravenous integrated area under the concentration vs time curve, for compound in rat plasma",Intermediate,10116.0,,A,,BAO_0000218,14122,,,1,CHEMBL877606,,,Rattus norvegicus,N,1,,
11684,Oral Bioavailability was measured as area-under-curve(AUC) value at dose 125 mg/kg,Autocuration,,,A,,BAO_0000218,13391,,,1,CHEMBL624744,,,,U,0,,
11685,Oral Bioavailability was measured as area-under-curve(AUC) value at dose 125 mg/kg; b = No compound detectable in blood above the detection limit of 0.1 uM,Autocuration,,,A,,BAO_0000218,13391,,,1,CHEMBL624745,,,,U,0,178.0,
11686,Oral Bioavailability was measured as area-under-curve(AUC) value at dose 125 mg/kg; b denotes No compound detectable in blood above the detection limit of 0.1 uM,Autocuration,,,A,,BAO_0000218,13391,,,1,CHEMBL624746,,,,U,0,178.0,
11687,Oral Bioavailability was measured as area-under-curve(AUC) value at dose 125 mg/kg;b = No compound detectable in blood above the detection limit of 0.1 uM,Autocuration,,,A,,BAO_0000218,13391,,,1,CHEMBL624747,,,,U,0,178.0,
11688,Oral absorption expressed as Area under curve was determined,Autocuration,,,A,,BAO_0000019,16360,,,1,CHEMBL624748,,,,U,0,,
11689,Oral absorption kinetics (AUC) was determined after administration of compound orally at 1 mg/kg in dogs,Intermediate,9615.0,,A,,BAO_0000218,3673,,,1,CHEMBL622504,,,Canis lupus familiaris,N,1,,
11690,"Oral integrated area under the concentration vs time curve, for compound in dog plasma",Intermediate,9615.0,,A,,BAO_0000218,14122,,,1,CHEMBL622505,,,Canis lupus familiaris,N,1,,
11691,"Oral integrated area under the concentration vs time curve, for compound in hamster plasma",Intermediate,10026.0,,A,,BAO_0000218,14122,,,1,CHEMBL622506,,,Cricetinae,N,1,,
11692,"Oral integrated area under the concentration vs time curve, for compound in hamster plasma",Intermediate,10026.0,,A,,BAO_0000218,14122,,,1,CHEMBL622507,,,Cricetinae,N,1,,
11693,"Oral integrated area under the concentration vs time curve, for compound in rat plasma",Intermediate,10116.0,,A,,BAO_0000218,14122,,,1,CHEMBL622508,,,Rattus norvegicus,N,1,,
11694,Pharmacokinetic parameter AUC in mice following a single dose intravenous administration of the compound,Autocuration,,,A,,BAO_0000019,13889,,,1,CHEMBL622509,,,,U,0,,
11695,Pharmacokinetic Parameter [Area under curve (AUC)] was evaluated at 10 mg/kg (p.o.) in Wistar rats,Intermediate,10116.0,,A,,BAO_0000218,14393,,,1,CHEMBL622510,,,Rattus norvegicus,N,1,,
11696,Pharmacokinetic parameter (AUC) was determined after administering 1 mg/kg of compound intravenously in rat no.3 belonging to phenotype EM (extensive metabolizer),Intermediate,10116.0,,A,,BAO_0000218,17279,,,1,CHEMBL622511,,,Rattus norvegicus,N,1,,
11697,Pharmacokinetic parameter AUC calculated in cynomolgus monkey when the compound was administered intravenously at 0.5 mg/kg concentration,Intermediate,9541.0,,A,,BAO_0000218,14548,,,1,CHEMBL622512,,,Macaca fascicularis,N,1,,
11698,Pharmacokinetic parameter AUC calculated in cynomolgus monkey when the compound was administered intravenously at 1 mg/kg concentration,Intermediate,9541.0,,A,,BAO_0000218,14548,,,1,CHEMBL622513,,,Macaca fascicularis,N,1,,
11699,Pharmacokinetic parameter AUC calculated in cynomolgus monkey when the compound was administered po at 5 mg/kg concentration,Intermediate,9541.0,,A,,BAO_0000218,14548,,,1,CHEMBL622514,,,Macaca fascicularis,N,1,,
11700,Pharmacokinetic parameter AUC calculated in dog when the compound was administered intravenously at 2 mg/kg concentration,Intermediate,9615.0,,A,,BAO_0000218,14548,,,1,CHEMBL622515,,,Canis lupus familiaris,N,1,,
11701,Pharmacokinetic parameter AUC calculated in dog when the compound was administered po at 5 mg/kg concentration,Intermediate,9615.0,,A,,BAO_0000218,14548,,,1,CHEMBL622516,,,Canis lupus familiaris,N,1,,
11702,Pharmacokinetic parameter AUC calculated in rat when the compound was administered intravenously at 5 mg/kg concentration,Intermediate,10116.0,,A,,BAO_0000218,14548,,,1,CHEMBL622517,,,Rattus norvegicus,N,1,,
11703,Pharmacokinetic parameter AUC calculated in rat when the compound was administered po at 12 mg/kg concentration,Intermediate,10116.0,,A,,BAO_0000218,14548,,,1,CHEMBL622518,,,Rattus norvegicus,N,1,,
11704,Pharmacokinetic parameter AUC calculated in rat when the compound was administered po at 20 mg/kg concentration,Intermediate,10116.0,,A,,BAO_0000218,14548,,,1,CHEMBL622519,,,Rattus norvegicus,N,1,,
11705,Biodistribution was measured in rat muscle by injecting the radiolabeled compound intravenously and the value measured after 30 min,Intermediate,10116.0,,A,,BAO_0000218,14608,,,1,CHEMBL622520,,,Rattus norvegicus,N,1,2385.0,
11706,Biodistribution was measured in rat muscle by injecting the radiolabeled compound intravenously and the value measured after 60 min,Intermediate,10116.0,,A,,BAO_0000218,14608,,,1,CHEMBL622521,,,Rattus norvegicus,N,1,2385.0,
11707,Biodistribution was measured in rat skin by injecting the radiolabeled compound intravenously and the value measured after 2 min,Intermediate,10090.0,,A,,BAO_0000218,14608,,,1,CHEMBL625113,,,Mus musculus,N,1,14.0,
11708,Biodistribution was measured in rat skin by injecting the radiolabeled compound intravenously and the value measured after 30 min,Intermediate,10116.0,,A,,BAO_0000218,14608,,,1,CHEMBL625114,,,Rattus norvegicus,N,1,14.0,
11709,Biodistribution was measured in rat skin by injecting the radiolabeled compound intravenously and the value measured after 60 min,Intermediate,10116.0,,A,,BAO_0000218,14608,,,1,CHEMBL874397,,,Rattus norvegicus,N,1,14.0,
11710,Biodistribution was measured in rat spleen by injecting the radiolabeled compound intravenously and the value measured after 2 min,Intermediate,10116.0,,A,,BAO_0000218,14608,,,1,CHEMBL625115,,,Rattus norvegicus,N,1,2106.0,
11711,Biodistribution was measured in rat spleen by injecting the radiolabeled compound intravenously and the value measured after 30 min,Intermediate,10116.0,,A,,BAO_0000218,14608,,,1,CHEMBL625116,,,Rattus norvegicus,N,1,2106.0,
11712,Biodistribution was measured in rat spleen by injecting the radiolabeled compound intravenously and the value measured after 60 min,Intermediate,10116.0,,A,,BAO_0000218,14608,,,1,CHEMBL623932,,,Rattus norvegicus,N,1,2106.0,
11713,Biodistribution was measured in rat striatum by injecting the radiolabeled compound intravenously and the value measured after 2 min,Intermediate,10116.0,,A,,BAO_0000218,14608,,,1,CHEMBL623933,,,Rattus norvegicus,N,1,2435.0,
11714,Biodistribution was measured in rat striatum by injecting the radiolabeled compound intravenously and the value measured after 30 min,Intermediate,10116.0,,A,,BAO_0000218,14608,,,1,CHEMBL623934,,,Rattus norvegicus,N,1,2435.0,
11715,Biodistribution was measured in rat striatum by injecting the radiolabeled compound intravenously and the value measured after 60 min,Intermediate,10116.0,,A,,BAO_0000218,14608,,,1,CHEMBL623935,,,Rattus norvegicus,N,1,2435.0,
11716,Biodistribution was measured in rat thyroid by injecting the radiolabeled compound intravenously and the value measured after 2 min,Intermediate,10116.0,,A,,BAO_0000218,14608,,,1,CHEMBL623936,,,Rattus norvegicus,N,1,2046.0,
11717,Biodistribution was measured in rat thyroid by injecting the radiolabeled compound intravenously and the value measured after 30 min,Intermediate,10116.0,,A,,BAO_0000218,14608,,,1,CHEMBL623937,,,Rattus norvegicus,N,1,2046.0,
11718,Biodistribution was measured in rat thyroid by injecting the radiolabeled compound intravenously and the value measured after 60 min,Intermediate,10116.0,,A,,BAO_0000218,14608,,,1,CHEMBL623938,,,Rattus norvegicus,N,1,2046.0,
11719,In vivo biodistribution in mice blood bearing intracerebral GL261 gliomas at the dose of 30 ug/day,Intermediate,10090.0,,A,,BAO_0000218,15383,,,1,CHEMBL623939,,,Mus musculus,N,1,,
11720,In vivo biodistribution in mice blood bearing subcutaneous B16 melanomas at the dose of 10 ug/g,Intermediate,10090.0,,A,,BAO_0000218,15383,,,1,CHEMBL623940,,,Mus musculus,N,1,,
11721,In vivo biodistribution in mice blood bearing subcutaneous B16 melanomas at the dose of 20 ug/g,Intermediate,10090.0,,A,,BAO_0000218,15383,,,1,CHEMBL623941,,,Mus musculus,N,1,,
11722,In vivo biodistribution in mice blood bearing subcutaneous B16 melanomas at the dose of 30 ug/g,Intermediate,10090.0,,A,,BAO_0000218,15383,,,1,CHEMBL627216,,,Mus musculus,N,1,,
11723,In vivo biodistribution in mice blood bearing subcutaneous B16 melanomas at the dose of 40 ug/g,Intermediate,10090.0,,A,,BAO_0000218,15383,,,1,CHEMBL623942,,,Mus musculus,N,1,,
11724,In vivo biodistribution in mice brain bearing intracerebral GL261 gliomas at the dose of 30 ug/day,Intermediate,10090.0,,A,,BAO_0000218,15383,,,1,CHEMBL618793,,,Mus musculus,N,1,955.0,
11725,In vivo biodistribution in mice brain bearing subcutaneous B16 melanomas at the dose of 30 ug/g,Intermediate,10090.0,,A,,BAO_0000218,15383,,,1,CHEMBL618794,,,Mus musculus,N,1,955.0,
11726,In vivo biodistribution in mice brain bearing subcutaneous B16 melanomas at the dose of 40 ug/g,Intermediate,10090.0,,A,,BAO_0000218,15383,,,1,CHEMBL618795,,,Mus musculus,N,1,955.0,
11727,In vivo biodistribution in mice eyes bearing subcutaneous B16 melanomas at the dose of 30 ug/g,Intermediate,10090.0,,A,,BAO_0000218,15383,,,1,CHEMBL618796,,,Mus musculus,N,1,,
11728,In vivo biodistribution in mice eyes bearing subcutaneous B16 melanomas at the dose of 40 ug/g,Intermediate,10090.0,,A,,BAO_0000218,15383,,,1,CHEMBL618797,,,Mus musculus,N,1,,
11729,In vivo biodistribution in mice kidney bearing intracerebral GL261 gliomas at the dose of 10 microg of boron/g/day,Intermediate,10090.0,,A,,BAO_0000218,15383,,,1,CHEMBL618798,,,Mus musculus,N,1,2113.0,
11730,In vivo biodistribution in mice kidney bearing intracerebral GL261 gliomas at the dose of 30 ug/day,Intermediate,10090.0,,A,,BAO_0000218,15383,,,1,CHEMBL618799,,,Mus musculus,N,1,2113.0,
11731,In vivo biodistribution in mice kidney bearing subcutaneous B16 melanomas at the dose of 10 ug/g,Intermediate,10090.0,,A,,BAO_0000218,15383,,,1,CHEMBL618800,,,Mus musculus,N,1,2113.0,
11732,In vivo biodistribution in mice kidney bearing subcutaneous B16 melanomas at the dose of 20 ug/g,Intermediate,10090.0,,A,,BAO_0000218,15383,,,1,CHEMBL618801,,,Mus musculus,N,1,2113.0,
11733,In vivo biodistribution in mice kidney bearing subcutaneous B16 melanomas at the dose of 30 ug/g,Intermediate,10090.0,,A,,BAO_0000218,15383,,,1,CHEMBL618802,,,Mus musculus,N,1,2113.0,
11734,In vivo biodistribution in mice kidney bearing subcutaneous B16 melanomas at the dose of 40 ug/g,Intermediate,10090.0,,A,,BAO_0000218,15383,,,1,CHEMBL618803,,,Mus musculus,N,1,2113.0,
11735,In vivo biodistribution in mice liver bearing intracerebral GL261 gliomas at the dose of 10 microg of boron/g/day,Intermediate,10090.0,,A,,BAO_0000218,15383,,,1,CHEMBL618804,,,Mus musculus,N,1,2107.0,
11736,In vivo biodistribution in mice liver bearing intracerebral GL261 gliomas at the dose of 30 ug/day,Intermediate,10090.0,,A,,BAO_0000218,15383,,,1,CHEMBL618805,,,Mus musculus,N,1,2107.0,
11737,In vivo biodistribution in mice liver bearing subcutaneous B16 melanomas at the dose of 10 ug/g,Intermediate,10090.0,,A,,BAO_0000218,15383,,,1,CHEMBL618806,,,Mus musculus,N,1,2107.0,
11738,In vivo biodistribution in mice liver bearing subcutaneous B16 melanomas at the dose of 20 ug/g,Intermediate,10090.0,,A,,BAO_0000218,15383,,,1,CHEMBL618807,,,Mus musculus,N,1,2107.0,
11739,In vivo biodistribution in mice liver bearing subcutaneous B16 melanomas at the dose of 30 ug/g,Intermediate,10090.0,,A,,BAO_0000218,15383,,,1,CHEMBL618808,,,Mus musculus,N,1,2107.0,
11740,In vivo biodistribution in mice liver bearing subcutaneous B16 melanomas at the dose of 40 ug/g,Intermediate,10090.0,,A,,BAO_0000218,15383,,,1,CHEMBL618809,,,Mus musculus,N,1,2107.0,
11741,In vivo biodistribution in mice muscle bearing intracerebral GL261 gliomas at the dose of 30 ug/day,Intermediate,10090.0,,A,,BAO_0000218,15383,,,1,CHEMBL618810,,,Mus musculus,N,1,2385.0,
11742,In vivo biodistribution in mice muscle bearing subcutaneous B16 melanomas at the dose of 10 ug/g,Intermediate,10090.0,,A,,BAO_0000218,15383,,,1,CHEMBL618811,,,Mus musculus,N,1,2385.0,
11743,In vivo biodistribution in mice muscle bearing subcutaneous B16 melanomas at the dose of 20 ug/g,Intermediate,10090.0,,A,,BAO_0000218,15383,,,1,CHEMBL875844,,,Mus musculus,N,1,2385.0,
11744,In vivo biodistribution in mice muscle bearing subcutaneous B16 melanomas at the dose of 30 ug/g,Intermediate,10090.0,,A,,BAO_0000218,15383,,,1,CHEMBL618812,,,Mus musculus,N,1,2385.0,
11745,In vivo biodistribution in mice muscle bearing subcutaneous B16 melanomas at the dose of 40 ug/g,Intermediate,10090.0,,A,,BAO_0000218,15383,,,1,CHEMBL618813,,,Mus musculus,N,1,2385.0,
11746,In vivo biodistribution in mice skin bearing intracerebral GL261 gliomas at the dose of 30 ug/day,Intermediate,10090.0,,A,,BAO_0000218,15383,,,1,CHEMBL618814,,,Mus musculus,N,1,,
11747,In vivo biodistribution in mice skin bearing subcutaneous B16 melanomas at the dose of 30 ug/g,Intermediate,10090.0,,A,,BAO_0000218,15383,,,1,CHEMBL618815,,,Mus musculus,N,1,,
11748,In vivo biodistribution in mice skin bearing subcutaneous B16 melanomas at the dose of 40 ug/g,Intermediate,10090.0,,A,,BAO_0000218,15383,,,1,CHEMBL618816,,,Mus musculus,N,1,,
11749,In vivo biodistribution in mice skin by pump bearing subcutaneous B16 melanomas at the dose of 30 ug/g,Intermediate,10090.0,,A,,BAO_0000218,15383,,,1,CHEMBL618817,,,Mus musculus,N,1,,
11750,In vivo biodistribution in mice skin by pump bearing subcutaneous B16 melanomas at the dose of 40 ug/g,Intermediate,10090.0,,A,,BAO_0000218,15383,,,1,CHEMBL620544,,,Mus musculus,N,1,,
11751,The maximum concentration of the compound was measured in rat at dose 30 mg/kg after intraperitoneal administration.,Intermediate,10116.0,,A,,BAO_0000218,15341,,,1,CHEMBL626230,,,Rattus norvegicus,N,1,,
11752,The maximum concentration of the compound was measured in rat at dose 30 mg/kg after intravenous administration.,Intermediate,10116.0,,A,,BAO_0000218,15341,,,1,CHEMBL626231,,,Rattus norvegicus,N,1,,
11753,The maximum concentration of the compound was measured in rat at dose 30 mg/kg after peroral administration.,Intermediate,10116.0,,A,,BAO_0000218,15341,,,1,CHEMBL626232,,,Rattus norvegicus,N,1,,
11754,The maximum plasma concentration (Cmax) is the observed peak plasma concentration after an oral dose on dog.,Intermediate,9615.0,,A,,BAO_0000218,14906,,,1,CHEMBL626233,,,Canis lupus familiaris,N,1,1969.0,
11755,The maximum plasma concentration (Cmax) is the observed peak plasma concentration after an oral dose on rat,Intermediate,10116.0,,A,,BAO_0000218,14906,,,1,CHEMBL626234,,,Rattus norvegicus,N,1,1969.0,
11756,The maximum plasma concentration (Cmax) is the observed peak plasma concentration after an oral dose on rat.,Intermediate,10116.0,,A,,BAO_0000218,14906,,,1,CHEMBL875341,,,Rattus norvegicus,N,1,1969.0,
11757,The maximum plasma concentration (100 mg/kg) administered orally in human,Intermediate,9606.0,,A,,BAO_0000218,14215,,,1,CHEMBL626235,,,Homo sapiens,N,1,1969.0,
11758,The maximum plasma concentration (12.5 mg/kg) administered intravenously in marmoset,Autocuration,9481.0,,A,,BAO_0000218,14215,,,1,CHEMBL626236,,,Callithrix,U,0,1969.0,
11759,The maximum plasma concentration (12.5 mg/kg) administered intravenously in monkey,Autocuration,314293.0,,A,,BAO_0000218,14215,,,1,CHEMBL626237,,,Simiiformes,U,0,1969.0,
11760,The maximum plasma concentration (15 mg/kg) administered intravenously in dog,Intermediate,9615.0,,A,,BAO_0000218,14215,,,1,CHEMBL626238,,,Canis lupus familiaris,N,1,1969.0,
11761,The maximum plasma concentration (200 mg/kg) administered orally in human,Intermediate,9606.0,,A,,BAO_0000218,14215,,,1,CHEMBL622412,,,Homo sapiens,N,1,1969.0,
11762,The maximum plasma concentration (25 mg/kg) administered intravenously in rat,Intermediate,10116.0,,A,,BAO_0000218,14215,,,1,CHEMBL623114,,,Rattus norvegicus,N,1,1969.0,
11763,The maximum plasma concentration (25 mg/kg) administered orally in marmoset,Autocuration,9481.0,,A,,BAO_0000218,14215,,,1,CHEMBL623115,,,Callithrix,U,0,1969.0,
11764,The maximum plasma concentration (25 mg/kg) administered orally in monkey,Autocuration,314293.0,,A,,BAO_0000218,14215,,,1,CHEMBL623116,,,Simiiformes,U,0,1969.0,
11765,The maximum plasma concentration (30 mg/kg) administered orally in dog,Autocuration,9615.0,,A,,BAO_0000218,14215,,,1,CHEMBL623117,,,Canis lupus familiaris,U,0,1969.0,
11766,The maximum plasma concentration (400 mg/kg) administered orally in human,Intermediate,9606.0,,A,,BAO_0000218,14215,,,1,CHEMBL623118,,,Homo sapiens,N,1,1969.0,
11767,The maximum plasma concentration (50 mg/kg) administered orally in fasted rat,Intermediate,10116.0,,A,,BAO_0000218,14215,,,1,CHEMBL623119,,,Rattus norvegicus,N,1,1969.0,
11768,The maximum plasma concentration (50 mg/kg) administered orally in rat,Intermediate,10116.0,,A,,BAO_0000218,14215,,,1,CHEMBL623120,,,Rattus norvegicus,N,1,1969.0,
11769,The maximum plasma concentration (800 mg/kg) administered orally in human,Intermediate,9606.0,,A,,BAO_0000218,14215,,,1,CHEMBL623286,,,Homo sapiens,N,1,1969.0,
11770,The maximum plasma concentration was measured on rats,Intermediate,10116.0,,A,,BAO_0000218,14067,,,1,CHEMBL623287,,,Rattus norvegicus,N,1,1969.0,
11771,The maximum plasma concentration was measured on rats after oral administration,Intermediate,10116.0,,A,,BAO_0000218,12350,,,1,CHEMBL623288,,,Rattus norvegicus,N,1,1969.0,
11772,Plasma drug Cmax in rat (PO dose),Intermediate,10116.0,,A,,BAO_0000218,14813,,,1,CHEMBL623289,,,Rattus norvegicus,N,1,1969.0,
11773,Time taken to reach maximum concentration after administration of 2 umol/kg dose intravenously,Autocuration,,,A,,BAO_0000218,12536,,,1,CHEMBL623290,,,,U,0,,
11774,maximum Plasma concentration in Dog was determined after Peroral administration,Intermediate,9615.0,,A,,BAO_0000218,14169,,,1,CHEMBL623291,,,Canis lupus familiaris,N,1,1969.0,
11775,maximum Plasma concentration in Rats was determined after Peroral administration,Intermediate,10116.0,,A,,BAO_0000218,14169,,,1,CHEMBL623292,,,Rattus norvegicus,N,1,1969.0,
11776,maximum concentration in plasma in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in dog,Intermediate,9615.0,,A,,BAO_0000218,15604,,,1,CHEMBL623293,,,Canis lupus familiaris,N,1,1969.0,
11777,maximum concentration in plasma in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in monkey,Autocuration,314293.0,,A,,BAO_0000218,15604,,,1,CHEMBL623294,,,Simiiformes,U,0,1969.0,
11778,maximum concentration in plasma in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in rat,Intermediate,10116.0,,A,,BAO_0000218,15604,,,1,CHEMBL623295,,,Rattus norvegicus,N,1,1969.0,
11779,maximum concentration was measured when administered through oral route in mice,Intermediate,10090.0,,A,,BAO_0000218,14387,,,1,CHEMBL623296,,,Mus musculus,N,1,,
11780,Compound was evaluated for Cmax/Tmax when administered through oral route in mouse; Value is 0.93/1,Intermediate,10090.0,,A,,BAO_0000218,15115,,,1,CHEMBL875349,,,Mus musculus,N,1,,
11781,Compound was evaluated for Cmax/Tmax when administered through oral route to mouse; Value is 0.34/1,Autocuration,314293.0,,A,,BAO_0000019,15115,,,1,CHEMBL623297,,,Simiiformes,U,0,,
11782,Compound was evaluated for Cmax/Tmax when administered through oral route to mouse; Value is 0.81/1.6,Autocuration,314293.0,,A,,BAO_0000019,15115,,,1,CHEMBL623298,,,Simiiformes,U,0,,
11783,Compound was evaluated for Cmax/Tmax when administered through oral route to mouse; Value is 1.1/1.3,Autocuration,314293.0,,A,,BAO_0000019,15115,,,1,CHEMBL623299,,,Simiiformes,U,0,,
11784,Pharmacokinetic parameter was evaluated in rats,Intermediate,10116.0,,A,,BAO_0000218,16359,,,1,CHEMBL623300,,,Rattus norvegicus,N,1,,
11785,Plasma concentration at time-0 was measured in mice at 100 mg/kg after intraperitoneal administration with 90% DMSO as vehicle,Intermediate,10090.0,,A,,BAO_0000218,12829,,,1,CHEMBL623301,,,Mus musculus,N,1,,
11786,Plasma concentration at time-0 was measured in mice at 100 mg/kg after intraperitoneal administration with saline(pH=11.4) as vehicle,Intermediate,10090.0,,A,,BAO_0000218,12829,,,1,CHEMBL623302,,,Mus musculus,N,1,,
11787,Plasma concentration at time-0 was measured in mice at 120 mg/kg after intraperitoneal administration with 90% DMSO as vehicle,Intermediate,10090.0,,A,,BAO_0000218,12829,,,1,CHEMBL623303,,,Mus musculus,N,1,,
11788,Plasma concentration at time-0 was measured in mice at 40 mg/kg after intravenous administration with saline(pH=11.4) as vehicle,Intermediate,10090.0,,A,,BAO_0000218,12829,,,1,CHEMBL623304,,,Mus musculus,N,1,,
11789,Plasma concentration at time-0 was measured in mice at 40 mg/kg after intravenous administration with 90% DMSO as vehicle,Intermediate,10090.0,,A,,BAO_0000218,12829,,,1,CHEMBL623305,,,Mus musculus,N,1,,
11790,Effect of ip administration of compound on plasma concentration of allo-pregnanolone (AP) in rats(Cerebral Cortex) after 30 min.,Intermediate,10116.0,,A,,BAO_0000218,15137,,,1,CHEMBL623306,,,Rattus norvegicus,N,1,1969.0,
11791,Effect of ip administration of compound on plasma concentration of allotetrahydrodeoxy corticosterone(THDOC) in rats(Cerebral Cortex) after 30 min.,Intermediate,10116.0,,A,,BAO_0000218,15137,,,1,CHEMBL623307,,,Rattus norvegicus,N,1,1969.0,
11792,Effect of ip administration of compound on plasma concentration of pregnenolone (PRE) in rats(Cerebral Cortex) after 30 min.,Intermediate,10116.0,,A,,BAO_0000218,15137,,,1,CHEMBL623308,,,Rattus norvegicus,N,1,1969.0,
11793,Effect of ip administration of compound on plasma concentration of progesterone (PRO) in rats(Cerebral Cortex) after 30 min.,Intermediate,10090.0,,A,,BAO_0000218,15137,,,1,CHEMBL623309,,,Mus musculus,N,1,1969.0,
11794,Plasma Concentration after 120 min of oral administration to mice,Intermediate,10090.0,,A,,BAO_0000218,13509,,,1,CHEMBL623310,,,Mus musculus,N,1,,
11795,Plasma Concentration after 30 min of oral administration to mice,Intermediate,10090.0,,A,,BAO_0000218,13509,,,1,CHEMBL623311,,,Mus musculus,N,1,,
11796,Plasma Concentration after 60 min of oral administration to mice,Intermediate,9541.0,,A,,BAO_0000218,13509,,,1,CHEMBL623312,,,Macaca fascicularis,N,1,,
11797,Plasma Concentration after 60 min of oral administration to mice; Not determined,Intermediate,10090.0,,A,,BAO_0000218,13509,,,1,CHEMBL875350,,,Mus musculus,N,1,,
11798,Plasma Concentration after 90 min of oral administration to mice,Intermediate,10090.0,,A,,BAO_0000218,13509,,,1,CHEMBL628635,,,Mus musculus,N,1,,
11799,Plasma concentration level in rat after 1 hour of oral administration at 50 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,12064,,,1,CHEMBL628636,,,Rattus norvegicus,N,1,,
11800,Plasma concentration level in rat after 15 hours of oral administration at 50 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,12064,,,1,CHEMBL628637,,,Rattus norvegicus,N,1,,
11801,Plasma concentration level in rat after 4 hours of oral administration at 50 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,12064,,,1,CHEMBL628058,,,Rattus norvegicus,N,1,,
11802,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 0-1 hr time,Intermediate,10116.0,,A,,BAO_0000218,10677,,,1,CHEMBL628059,,,Rattus norvegicus,N,1,,
11803,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 1-2 hr time,Intermediate,10116.0,,A,,BAO_0000218,10677,,,1,CHEMBL628060,,,Rattus norvegicus,N,1,,
11804,Distribution in the lung after 15 min of intravenous administration,Autocuration,,,A,,BAO_0000019,8926,,,1,CHEMBL628061,,,,U,0,,
11805,Distribution in the lung after 30 min of intravenous administration,Autocuration,,,A,,BAO_0000019,8926,,,1,CHEMBL628062,,,,U,0,,
11806,Distribution in the lung after 5 min of intravenous administration,Autocuration,,,A,,BAO_0000019,8926,,,1,CHEMBL628063,,,,U,0,,
11807,Distribution in the lung after 60 min of intravenous administration,Autocuration,,,A,,BAO_0000019,8926,,,1,CHEMBL628064,,,,U,0,,
11808,Distribution in the lung after 90 min of intravenous administration,Autocuration,,,A,,BAO_0000019,8926,,,1,CHEMBL628065,,,,U,0,,
11809,Distribution in the muscle after 120 min of intravenous administration,Autocuration,,,A,,BAO_0000019,8926,,,1,CHEMBL628066,,,,U,0,2385.0,
11810,Distribution in the muscle after 15 min of intravenous administration,Autocuration,,,A,,BAO_0000019,8926,,,1,CHEMBL628067,,,,U,0,2385.0,
11811,Distribution in the muscle after 30 min of intravenous administration,Intermediate,10090.0,,A,,BAO_0000218,8926,,,1,CHEMBL874646,,,Mus musculus,N,1,2385.0,
11812,Distribution in the muscle after 5 min of intravenous administration,Autocuration,,,A,,BAO_0000019,8926,,,1,CHEMBL628068,,,,U,0,2385.0,
11813,Distribution in the muscle after 60 min of intravenous administration,Autocuration,,,A,,BAO_0000019,8926,,,1,CHEMBL628069,,,,U,0,2385.0,
11814,Distribution in the muscle after 90 min of intravenous administration,Autocuration,,,A,,BAO_0000019,8926,,,1,CHEMBL628070,,,,U,0,2385.0,
11815,Distribution in the spleen after 120 min of intravenous administration,Autocuration,,,A,,BAO_0000019,8926,,,1,CHEMBL628071,,,,U,0,2106.0,
11816,Distribution in the spleen after 15 min of intravenous administration,Autocuration,,,A,,BAO_0000019,8926,,,1,CHEMBL628072,,,,U,0,2106.0,
11817,Distribution in the spleen after 30 min of intravenous administration,Autocuration,,,A,,BAO_0000019,8926,,,1,CHEMBL628073,,,,U,0,2106.0,
11818,Distribution in the spleen after 5 min of intravenous administration,Autocuration,,,A,,BAO_0000019,8926,,,1,CHEMBL628074,,,,U,0,2106.0,
11819,Distribution in the spleen after 60 min of intravenous administration,Autocuration,,,A,,BAO_0000019,8926,,,1,CHEMBL628075,,,,U,0,2106.0,
11820,Distribution in the spleen after 90 min of intravenous administration,Autocuration,,,A,,BAO_0000019,8926,,,1,CHEMBL628076,,,,U,0,2106.0,
11821,Evaluated for distribution at 0.5 hr after intravenous administration in adrenal cortex of female Sprague Dawley rats,Intermediate,10116.0,,A,,BAO_0000218,7570,,,1,CHEMBL628077,,,Rattus norvegicus,N,1,1235.0,
11822,Evaluated for distribution at 0.5 hr after intravenous administration in blood of female Sprague Dawley rats,Intermediate,10116.0,,A,,BAO_0000218,7570,,,1,CHEMBL628078,,,Rattus norvegicus,N,1,178.0,
11823,Evaluated for distribution at 0.5 hr after intravenous administration in liver of female Sprague Dawley rats,Intermediate,10116.0,,A,,BAO_0000218,7570,,,1,CHEMBL628079,,,Rattus norvegicus,N,1,2107.0,
11824,Evaluated for distribution at 0.5 hr after intravenous administration in ovary of female Sprague Dawley rats,Intermediate,10116.0,,A,,BAO_0000218,7570,,,1,CHEMBL628080,,,Rattus norvegicus,N,1,992.0,
11825,Evaluated for distribution at 0.5 hr after intravenous administration in thyroid of female Sprague Dawley rats,Intermediate,10116.0,,A,,BAO_0000218,7570,,,1,CHEMBL628081,,,Rattus norvegicus,N,1,2046.0,
11826,Evaluated for distribution at 24 hours after intravenous administration in adrenal cortex of female Sprague Dawley rats,Intermediate,10116.0,,A,,BAO_0000218,7570,,,1,CHEMBL628082,,,Rattus norvegicus,N,1,1235.0,
11827,Evaluated for distribution at 24 hours after intravenous administration in blood of female Sprague Dawley rats,Intermediate,10116.0,,A,,BAO_0000218,7570,,,1,CHEMBL874647,,,Rattus norvegicus,N,1,178.0,
11828,Evaluated for distribution at 24 hours after intravenous administration in liver of female Sprague Dawley rats,Intermediate,10116.0,,A,,BAO_0000218,7570,,,1,CHEMBL626406,,,Rattus norvegicus,N,1,2107.0,
11829,Evaluated for distribution at 24 hours after intravenous administration in ovary of female Sprague Dawley rats,Intermediate,10116.0,,A,,BAO_0000218,7570,,,1,CHEMBL626407,,,Rattus norvegicus,N,1,992.0,
11830,Evaluated for distribution at 24 hours after intravenous administration in thyroid of female Sprague Dawley rats,Intermediate,10116.0,,A,,BAO_0000218,7570,,,1,CHEMBL626408,,,Rattus norvegicus,N,1,2046.0,
11831,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.07-0.09",Intermediate,10116.0,,A,,BAO_0000218,8608,,,1,CHEMBL626409,,,Rattus norvegicus,N,1,178.0,
11832,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.10-0.13",Intermediate,10116.0,,A,,BAO_0000218,8608,,,1,CHEMBL626410,,,Rattus norvegicus,N,1,178.0,
11833,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.18-0.24",Intermediate,10116.0,,A,,BAO_0000218,8608,,,1,CHEMBL626411,,,Rattus norvegicus,N,1,178.0,
11834,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.19-0.24",Intermediate,10116.0,,A,,BAO_0000218,8608,,,1,CHEMBL626412,,,Rattus norvegicus,N,1,178.0,
11835,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.22-0.32",Intermediate,10116.0,,A,,BAO_0000218,8608,,,1,CHEMBL626413,,,Rattus norvegicus,N,1,178.0,
11836,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.25-0.32",Intermediate,10116.0,,A,,BAO_0000218,8608,,,1,CHEMBL626414,,,Rattus norvegicus,N,1,178.0,
11837,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.10-0.14",Intermediate,10116.0,,A,,BAO_0000218,8608,,,1,CHEMBL626415,,,Rattus norvegicus,N,1,178.0,
11838,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.25-0.34",Intermediate,10116.0,,A,,BAO_0000218,8608,,,1,CHEMBL626416,,,Rattus norvegicus,N,1,178.0,
11839,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.27-0.33",Intermediate,10116.0,,A,,BAO_0000218,8608,,,1,CHEMBL627062,,,Rattus norvegicus,N,1,178.0,
11840,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.32-0.46",Intermediate,10116.0,,A,,BAO_0000218,8608,,,1,CHEMBL627063,,,Rattus norvegicus,N,1,178.0,
11841,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.40-0.45",Intermediate,10116.0,,A,,BAO_0000218,8608,,,1,CHEMBL627064,,,Rattus norvegicus,N,1,178.0,
11842,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.44-0.52",Intermediate,10116.0,,A,,BAO_0000218,8608,,,1,CHEMBL627227,,,Rattus norvegicus,N,1,178.0,
11843,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.08-0.09",Intermediate,10116.0,,A,,BAO_0000218,8608,,,1,CHEMBL627228,,,Rattus norvegicus,N,1,178.0,
11844,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.12-0.14",Intermediate,10116.0,,A,,BAO_0000218,8608,,,1,CHEMBL627229,,,Rattus norvegicus,N,1,178.0,
11845,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.13-0.15",Intermediate,10116.0,,A,,BAO_0000218,8608,,,1,CHEMBL625792,,,Rattus norvegicus,N,1,178.0,
11846,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.15-0.20",Intermediate,10116.0,,A,,BAO_0000218,8608,,,1,CHEMBL625793,,,Rattus norvegicus,N,1,178.0,
11847,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.15-0.23",Intermediate,10116.0,,A,,BAO_0000218,8608,,,1,CHEMBL625794,,,Rattus norvegicus,N,1,178.0,
11848,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.16-0.21",Intermediate,10116.0,,A,,BAO_0000218,8608,,,1,CHEMBL625795,,,Rattus norvegicus,N,1,178.0,
11849,Pharmacokinetic parameter AUC for the compound after intravenous administration into BALB/c Mice in plasma samples.,Intermediate,10090.0,,A,,BAO_0000218,13792,,,1,CHEMBL625796,,,Mus musculus,N,1,,
11850,Pharmacokinetic parameter AUC has been determined in fed Beagle dogs at a dose of 375 mg/kg,Intermediate,9615.0,,A,,BAO_0000218,13376,,,1,CHEMBL625797,,,Canis lupus familiaris,N,1,,
11851,Pharmacokinetic parameter AUC has been determined in fed Beagle dogs at a dose of 500 mg/kg,Intermediate,9615.0,,A,,BAO_0000218,13376,,,1,CHEMBL625798,,,Canis lupus familiaris,N,1,,
11852,Pharmacokinetic parameter AUC evaluated in 0.5% methylcellulose suspension at a dose of 20 mg/kg orally,Autocuration,,,A,,BAO_0000218,14380,,,1,CHEMBL875613,,,,U,0,,
11853,Pharmacokinetic parameter AUC was evaluated in 0.5% methylcellulose suspension at a dose of 20 mg/kg orally,Autocuration,,,A,,BAO_0000218,14380,,,1,CHEMBL625799,,,,U,0,,
11854,Pharmacokinetic parameter AUC was evaluated in 10% PEG suspension at a dose of 20 mg/kg orally,Autocuration,,,A,,BAO_0000218,14380,,,1,CHEMBL625800,,,,U,0,,
11855,Pharmacokinetic parameter AUC was evaluated in 100% PEG solution at a dose of 20 mg/kg orally,Autocuration,,,A,,BAO_0000218,14380,,,1,CHEMBL625801,,,,U,0,,
11856,Pharmacokinetic parameter AUC was evaluated in DMA:H2O solution at a dose of 20 mg/kg orally,Autocuration,,,A,,BAO_0000218,14380,,,1,CHEMBL625802,,,,U,0,,
11857,Pharmacokinetic parameter AUC was evaluated in HP-beta-CD solution at a dose of 20 mg/kg orally,Autocuration,,,A,,BAO_0000218,14380,,,1,CHEMBL625803,,,,U,0,,
11858,Pharmacokinetic parameter AUC was evaluated in Hp-beta-CD solution,Autocuration,,,A,,BAO_0000019,14380,,,1,CHEMBL625804,,,,U,0,,
11859,Pharmacokinetic parameter AUC was evaluated in saline solution at a dose of 20 mg/kg orally,Autocuration,,,A,,BAO_0000218,14380,,,1,CHEMBL622530,,,,U,0,,
11860,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice brain; AUC (mM.h); not detected,Intermediate,10090.0,,A,,BAO_0000218,13701,,,1,CHEMBL622531,,,Mus musculus,N,1,,
11861,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice serum; AUC (mM.h),Intermediate,10090.0,,A,,BAO_0000218,13701,,,1,CHEMBL622532,,,Mus musculus,N,1,,
11862,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice serum; AUC 0-r (mM.h),Intermediate,10090.0,,A,,BAO_0000218,13701,,,1,CHEMBL623176,,,Mus musculus,N,1,,
11863,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice brain; AUC (mM.h),Intermediate,10090.0,,A,,BAO_0000218,13701,,,1,CHEMBL623177,,,Mus musculus,N,1,,
11864,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice serum; AUC (mM.h),Intermediate,10090.0,,A,,BAO_0000218,13701,,,1,CHEMBL623178,,,Mus musculus,N,1,,
11865,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration using FMAddA as substrate in mice brain; AUC 0-r (mM.h); not detected,Intermediate,10090.0,,A,,BAO_0000218,13701,,,1,CHEMBL623179,,,Mus musculus,N,1,,
11866,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration in mice brain; AUC (mM.h),Intermediate,10090.0,,A,,BAO_0000218,13701,,,1,CHEMBL623180,,,Mus musculus,N,1,,
11867,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration in mice brain; AUC 0-r (mM.h),Intermediate,10090.0,,A,,BAO_0000218,13701,,,1,CHEMBL623181,,,Mus musculus,N,1,,
11868,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration in mice serum; AUC 0-r (mM.h),Intermediate,10090.0,,A,,BAO_0000218,13701,,,1,CHEMBL624131,,,Mus musculus,N,1,,
11869,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration using 2`-F-ara-ddI as substrate in mice serum; AUC (mM.h),Intermediate,10090.0,,A,,BAO_0000218,13701,,,1,CHEMBL624132,,,Mus musculus,N,1,,
11870,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by oral administration in mice serum; AUC 0-r (mM.h),Intermediate,10090.0,,A,,BAO_0000218,13701,,,1,CHEMBL624133,,,Mus musculus,N,1,,
11871,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration in mice serum; AUC 0-r (mM.h).,Intermediate,10090.0,,A,,BAO_0000218,13701,,,1,CHEMBL624846,,,Mus musculus,N,1,,
11872,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by oral administration in mice serum.; AUC 0-r (mM.h),Intermediate,10090.0,,A,,BAO_0000218,13701,,,1,CHEMBL624847,,,Mus musculus,N,1,,
11873,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration in mice brain; AUC 0-r (mM.h),Intermediate,10090.0,,A,,BAO_0000218,13701,,,1,CHEMBL624848,,,Mus musculus,N,1,,
11874,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration in mice serum; AUC (mM.h),Intermediate,10090.0,,A,,BAO_0000218,13701,,,1,CHEMBL625012,,,Mus musculus,N,1,,
11875,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration in mice serum; AUC 0-r (mM.h),Intermediate,10090.0,,A,,BAO_0000218,13701,,,1,CHEMBL625013,,,Mus musculus,N,1,,
11876,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice brain; AUC 0-r (mM.h); not detected,Intermediate,10090.0,,A,,BAO_0000218,13701,,,1,CHEMBL625014,,,Mus musculus,N,1,,
11877,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice serum; AUC (mM.h),Intermediate,10090.0,,A,,BAO_0000218,13701,,,1,CHEMBL625015,,,Mus musculus,N,1,,
11878,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice serum; AUC 0-r (mM.h),Intermediate,10090.0,,A,,BAO_0000218,13701,,,1,CHEMBL625016,,,Mus musculus,N,1,,
11879,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral in mice brain; AUC (mM.h); not detected,Intermediate,10090.0,,A,,BAO_0000218,13701,,,1,CHEMBL625017,,,Mus musculus,N,1,,
11880,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration in mice brain; AUC 0-r (mM.h),Intermediate,10090.0,,A,,BAO_0000218,13701,,,1,CHEMBL625018,,,Mus musculus,N,1,,
11881,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration mice serum.; AUC 0-r (mM.h),Intermediate,10090.0,,A,,BAO_0000218,13701,,,1,CHEMBL625019,,,Mus musculus,N,1,,
11882,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice brain.; AUC 0-r (mM.h),Intermediate,10090.0,,A,,BAO_0000218,13701,,,1,CHEMBL625020,,,Mus musculus,N,1,,
11883,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice serum.,Intermediate,10090.0,,A,,BAO_0000218,13701,,,1,CHEMBL625021,,,Mus musculus,N,1,,
11884,Pharmacokinetic parameter [area under curve (AUC)] was evaluated at 10 mg/kg (p.o.) in Wistar rats,Intermediate,10116.0,,A,,BAO_0000218,14393,,,1,CHEMBL625022,,,Rattus norvegicus,N,1,,
11885,Pharmacokinetic parameter area under the curve (0-24 hr) for the compound was evaluated in nude mice after oral administration. ,Intermediate,10090.0,,A,,BAO_0000218,14731,,,1,CHEMBL625023,,,Mus musculus,N,1,,
11886,Pharmacokinetic parameter area under the curve (0-48 h) for the compound was evaluated in nude cynomolgus monkeys after oral administration,Intermediate,9541.0,,A,,BAO_0000218,14731,,,1,CHEMBL625024,,,Macaca fascicularis,N,1,,
11887,Pharmacokinetic parameter area under the curve (0-48 h) for the compound was evaluated in nude cynomolgus monkeys after oral administration. ,Intermediate,9541.0,,A,,BAO_0000218,14731,,,1,CHEMBL627626,,,Macaca fascicularis,N,1,,
11888,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered intravenously in brain,Autocuration,,,A,,BAO_0000218,13758,,,1,CHEMBL627627,,,,U,0,955.0,
11889,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered intravenously in serum,Autocuration,,,A,,BAO_0000218,13758,,,1,CHEMBL627628,,,,U,0,1977.0,
11890,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered orally in brain,Autocuration,,,A,,BAO_0000218,13758,,,1,CHEMBL627629,,,,U,0,955.0,
11891,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered orally in serum,Autocuration,,,A,,BAO_0000218,13758,,,1,CHEMBL627630,,,,U,0,1977.0,
11892,Pharmacokinetic parameter was evaluated which is represented as AUC when administered 5 mg/Kg orally; range (0.19-0.35),Autocuration,,,A,,BAO_0000019,16359,,,1,CHEMBL627631,,,,U,0,,
11893,Pharmacokinetic parameter was evaluated which is represented as AUC when administered 5 mg/kg intravenously; range (2.1-2.3),Autocuration,,,A,,BAO_0000218,16359,,,1,CHEMBL629515,,,,U,0,,
11894,In vivo biodistribution in mice spleen bearing intracerebral GL261 gliomas at the dose of 30 ug/day,Intermediate,10090.0,,A,,BAO_0000218,15383,,,1,CHEMBL629516,,,Mus musculus,N,1,2106.0,
11895,In vivo biodistribution in mice spleen bearing subcutaneous B16 melanomas at the dose of 30 ug/g,Intermediate,10090.0,,A,,BAO_0000218,15383,,,1,CHEMBL629517,,,Mus musculus,N,1,2106.0,
11896,In vivo biodistribution in mice spleen bearing subcutaneous B16 melanomas at the dose of 40 ug/g,Intermediate,10090.0,,A,,BAO_0000218,15383,,,1,CHEMBL629518,,,Mus musculus,N,1,2106.0,
11897,In vivo biodistribution in mice tumor bearing intracerebral GL261 gliomas at the dose of 30 ug/day,Intermediate,10090.0,,A,,BAO_0000218,15383,,,1,CHEMBL877499,,,Mus musculus,N,1,,
11898,In vivo biodistribution in mice tumor bearing subcutaneous B16 melanomas at the dose of 20 ug/g,Intermediate,10090.0,,A,,BAO_0000218,15383,,,1,CHEMBL629519,,,Mus musculus,N,1,,
11899,In vivo biodistribution in mice tumor bearing subcutaneous B16 melanomas at the dose of 30 ug/g,Intermediate,10090.0,,A,,BAO_0000218,15383,,,1,CHEMBL629520,,,Mus musculus,N,1,,
11900,In vivo biodistribution in mice tumor bearing subcutaneous B16 melanomas at the dose of 40 ug/g,Intermediate,10090.0,,A,,BAO_0000218,15383,,,1,CHEMBL629521,,,Mus musculus,N,1,,
11901,Ratio of biodistributions in Athymic mice bearing human Tumor (KB) xenografts in Heart (H) and Blood (B),Intermediate,10090.0,,A,,BAO_0000218,14439,,,1,CHEMBL629522,,,Mus musculus,N,1,,
11902,Ratio of biodistributions in Athymic mice bearing human Tumor (KB) xenografts in Heart (H) and Lung (L),Intermediate,10090.0,,A,,BAO_0000218,14439,,,1,CHEMBL629523,,,Mus musculus,N,1,,
11903,Ratio of biodistributions in Athymic mice bearing human Tumor (KB) xenografts in Tumor (T) and Muscle (M),Intermediate,10090.0,,A,,BAO_0000218,14439,,,1,CHEMBL629524,,,Mus musculus,N,1,,
11904,Ratio of biodistributions in Athymic mice bearing human Tumor (KB) xenografts in Tumor (T) and blood (B),Intermediate,10090.0,,A,,BAO_0000218,14439,,,1,CHEMBL629525,,,Mus musculus,N,1,,
11905,Ratio of biodistributions in Athymic mice bearing human Tumor (LS174T) xenografts in Heart (H) and Blood (B),Intermediate,10090.0,,A,,BAO_0000218,14439,,,1,CHEMBL629526,,,Mus musculus,N,1,,
11906,Ratio of biodistributions in Athymic mice bearing human Tumor (LS174T) xenografts in Heart (H) and Lung (L),Intermediate,10090.0,,A,,BAO_0000218,14439,,,1,CHEMBL629527,,,Mus musculus,N,1,,
11907,Ratio of biodistributions in Athymic mice bearing human Tumor (LS174T) xenografts in Tumor (T) and Muscle (M),Intermediate,10090.0,,A,,BAO_0000218,14439,,,1,CHEMBL629528,,,Mus musculus,N,1,,
11908,Ratio of biodistributions in Athymic mice bearing human Tumor (LS174T) xenografts in Tumor (T) and blood (B),Intermediate,10090.0,,A,,BAO_0000218,14439,,,1,CHEMBL629529,,,Mus musculus,N,1,,
11909,Ratio of biodistributions in Athymic mice bearing human Tumor (TE671) xenografts in Heart (H) and Blood (B),Intermediate,10090.0,,A,,BAO_0000218,14439,,,1,CHEMBL629530,,,Mus musculus,N,1,,
11910,Ratio of biodistributions in Athymic mice bearing human Tumor (TE671) xenografts in Heart (H) and Lung (L),Intermediate,10090.0,,A,,BAO_0000218,14439,,,1,CHEMBL629531,,,Mus musculus,N,1,,
11911,Ratio of biodistributions in Athymic mice bearing human Tumor (TE671) xenografts in Tumor (T) and Muscle (M),Intermediate,10090.0,,A,,BAO_0000218,14439,,,1,CHEMBL628656,,,Mus musculus,N,1,,
11912,Ratio of biodistributions in Athymic mice bearing human Tumor (TE671) xenografts in Tumor (T) and blood (B),Intermediate,10090.0,,A,,BAO_0000218,14439,,,1,CHEMBL628657,,,Mus musculus,N,1,,
11913,"Biodistribution in abdominal Dawley rat after 30min, expressed as percent injected dose/g",Intermediate,10116.0,,A,,BAO_0000218,13751,,,1,CHEMBL628658,,,Rattus norvegicus,N,1,,
11914,"Biodistribution in abdominal of mature female Dawley rat after 10min, expressed as percent injected dose/g",Intermediate,10116.0,,A,,BAO_0000218,13751,,,1,CHEMBL628659,,,Rattus norvegicus,N,1,,
11915,"Biodistribution in abdominal of mature female Dawley rat after 15min, expressed as percent injected dose/g",Intermediate,10116.0,,A,,BAO_0000218,13751,,,1,CHEMBL877500,,,Rattus norvegicus,N,1,,
11916,"Biodistribution in abdominal of mature female Dawley rat after 1h, expressed as percent injected dose/g",Intermediate,10116.0,,A,,BAO_0000218,13751,,,1,CHEMBL628660,,,Rattus norvegicus,N,1,,
11917,"Biodistribution in abdominal of mature female Dawley rat after 3 h, expressed as percent injected dose/g",Intermediate,10116.0,,A,,BAO_0000218,13751,,,1,CHEMBL628661,,,Rattus norvegicus,N,1,,
11918,"Biodistribution in abdominal of mature female Dawley rat after 30min, expressed as percent injected dose/g",Intermediate,10116.0,,A,,BAO_0000218,13751,,,1,CHEMBL628662,,,Rattus norvegicus,N,1,,
11919,"Biodistribution in abdominal of mature female Dawley rat after 45min, expressed as percent injected dose/g",Intermediate,10116.0,,A,,BAO_0000218,13751,,,1,CHEMBL628663,,,Rattus norvegicus,N,1,,
11920,"Biodistribution in abdominal of mature female Dawley rat after 5min, expressed as percent injected dose/g",Intermediate,10116.0,,A,,BAO_0000218,13751,,,1,CHEMBL628664,,,Rattus norvegicus,N,1,,
11921,"Biodistribution in blood of mature female Dawley rat after 10min, expressed as percent injected dose/g",Intermediate,10116.0,,A,,BAO_0000218,13751,,,1,CHEMBL628665,,,Rattus norvegicus,N,1,178.0,
11922,"Biodistribution in blood of mature female Dawley rat after 15min, expressed as percent injected dose/g",Intermediate,10116.0,,A,,BAO_0000218,13751,,,1,CHEMBL628666,,,Rattus norvegicus,N,1,178.0,
11923,"Biodistribution in blood of mature female Dawley rat after 1h, expressed as percent injected dose/g",Intermediate,10116.0,,A,,BAO_0000218,13751,,,1,CHEMBL628667,,,Rattus norvegicus,N,1,178.0,
11924,"Biodistribution in blood of mature female Dawley rat after 3 h, expressed as percent injected dose/g",Intermediate,10116.0,,A,,BAO_0000218,13751,,,1,CHEMBL628668,,,Rattus norvegicus,N,1,178.0,
11925,"Biodistribution in blood of mature female Dawley rat after 30min, expressed as percent injected dose/g",Intermediate,10116.0,,A,,BAO_0000218,13751,,,1,CHEMBL628669,,,Rattus norvegicus,N,1,178.0,
11926,"Biodistribution in blood of mature female Dawley rat after 45min, expressed as percent injected dose/g",Intermediate,10116.0,,A,,BAO_0000218,13751,,,1,CHEMBL628670,,,Rattus norvegicus,N,1,178.0,
11927,"Biodistribution in blood of mature female Dawley rat after 5min, expressed as percent injected dose/g",Intermediate,10116.0,,A,,BAO_0000218,13751,,,1,CHEMBL628671,,,Rattus norvegicus,N,1,178.0,
11928,"Biodistribution in bone of mature female Dawley rat after 10min, expressed as percent injected dose/g",Intermediate,10116.0,,A,,BAO_0000218,13751,,,1,CHEMBL628672,,,Rattus norvegicus,N,1,10000001.0,
11929,"Biodistribution in bone of mature female Dawley rat after 1h, expressed as percent injected dose/g",Intermediate,10116.0,,A,,BAO_0000218,13751,,,1,CHEMBL630300,,,Rattus norvegicus,N,1,10000001.0,
11930,"Biodistribution in bone of mature female Dawley rat after 3 h, expressed as percent injected dose/g",Intermediate,10116.0,,A,,BAO_0000218,13751,,,1,CHEMBL629787,,,Rattus norvegicus,N,1,10000001.0,
11931,"Biodistribution in bone of mature female Dawley rat after 30min, expressed as percent injected dose/g",Intermediate,10116.0,,A,,BAO_0000218,13751,,,1,CHEMBL629788,,,Rattus norvegicus,N,1,10000001.0,
11932,"Biodistribution in brain of mature female Dawley rat after 10min, expressed as percent injected dose/g",Intermediate,10116.0,,A,,BAO_0000218,13751,,,1,CHEMBL629789,,,Rattus norvegicus,N,1,955.0,
11933,"Biodistribution in brain of mature female Dawley rat after 15min, expressed as percent injected dose/g",Intermediate,10116.0,,A,,BAO_0000218,13751,,,1,CHEMBL629790,,,Rattus norvegicus,N,1,955.0,
11934,"Biodistribution in brain of mature female Dawley rat after 1h, expressed as percent injected dose/g",Intermediate,10116.0,,A,,BAO_0000218,13751,,,1,CHEMBL629791,,,Rattus norvegicus,N,1,955.0,
11935,"Biodistribution in brain of mature female Dawley rat after 3 h, expressed as percent injected dose/g",Intermediate,10116.0,,A,,BAO_0000218,13751,,,1,CHEMBL629792,,,Rattus norvegicus,N,1,955.0,
11936,"Biodistribution in brain of mature female Dawley rat after 30min, expressed as percent injected dose/g",Intermediate,10116.0,,A,,BAO_0000218,13751,,,1,CHEMBL629793,,,Rattus norvegicus,N,1,955.0,
11937,"Biodistribution in brain of mature female Dawley rat after 45min, expressed as percent injected dose/g",Intermediate,10116.0,,A,,BAO_0000218,13751,,,1,CHEMBL629794,,,Rattus norvegicus,N,1,955.0,
11938,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 2-3 hr time,Intermediate,10116.0,,A,,BAO_0000218,10677,,,1,CHEMBL874459,,,Rattus norvegicus,N,1,,
11939,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 3-4 hr time,Intermediate,10116.0,,A,,BAO_0000218,10677,,,1,CHEMBL629795,,,Rattus norvegicus,N,1,,
11940,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 4-5 hr time,Intermediate,10116.0,,A,,BAO_0000218,10677,,,1,CHEMBL629796,,,Rattus norvegicus,N,1,,
11941,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 5-6 hr time,Intermediate,10116.0,,A,,BAO_0000218,10677,,,1,CHEMBL629797,,,Rattus norvegicus,N,1,,
11942,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 6-24 h time,Intermediate,10116.0,,A,,BAO_0000218,10677,,,1,CHEMBL629798,,,Rattus norvegicus,N,1,,
11943,Biodistribution studied in the adrenals of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,Intermediate,10116.0,,A,,BAO_0000218,10911,,,1,CHEMBL629799,,,Rattus norvegicus,N,1,2369.0,
11944,Biodistribution studied in the adrenals of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,Intermediate,10116.0,,A,,BAO_0000218,10911,,,1,CHEMBL629800,,,Rattus norvegicus,N,1,2369.0,
11945,Biodistribution studied in the adrenals of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,Intermediate,10116.0,,A,,BAO_0000218,10911,,,1,CHEMBL629801,,,Rattus norvegicus,N,1,2369.0,
11946,Biodistribution studied in the adrenals of immature Fischer female rats at 5 hour,Intermediate,10116.0,,A,,BAO_0000218,10911,,,1,CHEMBL629802,,,Rattus norvegicus,N,1,2369.0,
11947,Biodistribution studied in the adrenals of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,Intermediate,10116.0,,A,,BAO_0000218,10911,,,1,CHEMBL629803,,,Rattus norvegicus,N,1,2369.0,
11948,Biodistribution studied in the blood of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,Intermediate,10116.0,,A,,BAO_0000218,10911,,,1,CHEMBL629804,,,Rattus norvegicus,N,1,178.0,
11949,Biodistribution studied in the blood of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,Intermediate,10116.0,,A,,BAO_0000218,10911,,,1,CHEMBL629805,,,Rattus norvegicus,N,1,178.0,
11950,Biodistribution studied in the blood of immature Fischer female rats at 2 hou; activity is expressed as inductive dose / gram,Intermediate,10116.0,,A,,BAO_0000218,10911,,,1,CHEMBL629806,,,Rattus norvegicus,N,1,178.0,
11951,Biodistribution studied in the blood of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,Intermediate,10116.0,,A,,BAO_0000218,10911,,,1,CHEMBL629807,,,Rattus norvegicus,N,1,178.0,
11952,Biodistribution studied in the blood of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,Intermediate,10116.0,,A,,BAO_0000218,10911,,,1,CHEMBL629808,,,Rattus norvegicus,N,1,178.0,
11953,Biodistribution studied in the brain of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,Intermediate,10116.0,,A,,BAO_0000218,10911,,,1,CHEMBL629809,,,Rattus norvegicus,N,1,955.0,
11954,Biodistribution studied in the brain of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,Intermediate,10116.0,,A,,BAO_0000218,10911,,,1,CHEMBL629810,,,Rattus norvegicus,N,1,955.0,
11955,Biodistribution studied in the brain of immature Fischer female rats at 2 hou; activity is expressed as inductive dose / gram,Intermediate,10116.0,,A,,BAO_0000218,10911,,,1,CHEMBL629811,,,Rattus norvegicus,N,1,955.0,
11956,Biodistribution studied in the brain of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,Intermediate,10116.0,,A,,BAO_0000218,10911,,,1,CHEMBL629812,,,Rattus norvegicus,N,1,955.0,
11957,Biodistribution studied in the brain of immature Fischer female rats at 5 hou; activity is expressed as inductive dose / gram,Intermediate,10116.0,,A,,BAO_0000218,10911,,,1,CHEMBL629813,,,Rattus norvegicus,N,1,955.0,
11958,Biodistribution studied in the brain of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,Intermediate,10116.0,,A,,BAO_0000218,10911,,,1,CHEMBL874460,,,Rattus norvegicus,N,1,955.0,
11959,Biodistribution studied in the fat of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,Intermediate,10116.0,,A,,BAO_0000218,10911,,,1,CHEMBL629814,,,Rattus norvegicus,N,1,,
11960,Biodistribution studied in the fat of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,Intermediate,10116.0,,A,,BAO_0000218,10911,,,1,CHEMBL629815,,,Rattus norvegicus,N,1,,
11961,Biodistribution studied in the fat of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,Intermediate,10116.0,,A,,BAO_0000218,10911,,,1,CHEMBL629816,,,Rattus norvegicus,N,1,,
11962,Biodistribution studied in the fat of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,Intermediate,10116.0,,A,,BAO_0000218,10911,,,1,CHEMBL629817,,,Rattus norvegicus,N,1,,
11963,Biodistribution studied in the kidneys of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,Intermediate,10116.0,,A,,BAO_0000218,10911,,,1,CHEMBL626643,,,Rattus norvegicus,N,1,2113.0,
11964,Biodistribution studied in the kidneys of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,Intermediate,10116.0,,A,,BAO_0000218,10911,,,1,CHEMBL626644,,,Rattus norvegicus,N,1,2113.0,
11965,Biodistribution studied in the kidneys of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,Intermediate,10116.0,,A,,BAO_0000218,10911,,,1,CHEMBL626806,,,Rattus norvegicus,N,1,2113.0,
11966,Biodistribution studied in the kidneys of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,Intermediate,10116.0,,A,,BAO_0000218,10911,,,1,CHEMBL626807,,,Rattus norvegicus,N,1,2113.0,
11967,Biodistribution studied in the liver of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,Intermediate,10116.0,,A,,BAO_0000218,10911,,,1,CHEMBL627261,,,Rattus norvegicus,N,1,2107.0,
11968,Biodistribution studied in the liver of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,Intermediate,10116.0,,A,,BAO_0000218,10911,,,1,CHEMBL627262,,,Rattus norvegicus,N,1,2107.0,
11969,Biodistribution studied in the liver of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,Intermediate,10116.0,,A,,BAO_0000218,10911,,,1,CHEMBL627263,,,Rattus norvegicus,N,1,2107.0,
11970,Biodistribution studied in the liver of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,Intermediate,10116.0,,A,,BAO_0000218,10911,,,1,CHEMBL627264,,,Rattus norvegicus,N,1,2107.0,
11971,Biodistribution studied in the lungs of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,Intermediate,10116.0,,A,,BAO_0000218,10911,,,1,CHEMBL627265,,,Rattus norvegicus,N,1,2048.0,
11972,Biodistribution studied in the lungs of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,Intermediate,10116.0,,A,,BAO_0000218,10911,,,1,CHEMBL627266,,,Rattus norvegicus,N,1,2048.0,
11973,Biodistribution studied in the lungs of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,Intermediate,10116.0,,A,,BAO_0000218,10911,,,1,CHEMBL627267,,,Rattus norvegicus,N,1,2048.0,
11974,Biodistribution studied in the lungs of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,Intermediate,10116.0,,A,,BAO_0000218,10911,,,1,CHEMBL627268,,,Rattus norvegicus,N,1,2048.0,
11975,Biodistribution studied in the muscle of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,Intermediate,10116.0,,A,,BAO_0000218,10911,,,1,CHEMBL627269,,,Rattus norvegicus,N,1,2385.0,
11976,Biodistribution studied in the muscle of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,Intermediate,10116.0,,A,,BAO_0000218,10911,,,1,CHEMBL627270,,,Rattus norvegicus,N,1,2385.0,
11977,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 0.95-1.44",Intermediate,10116.0,,A,,BAO_0000218,8608,,,1,CHEMBL627271,,,Rattus norvegicus,N,1,,
11978,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 1.39-2.43",Intermediate,10116.0,,A,,BAO_0000218,8608,,,1,CHEMBL627946,,,Rattus norvegicus,N,1,,
11979,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 2.47-2.96",Intermediate,10116.0,,A,,BAO_0000218,8608,,,1,CHEMBL875472,,,Rattus norvegicus,N,1,,
11980,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 2.67-3.69",Intermediate,10116.0,,A,,BAO_0000218,8608,,,1,CHEMBL627947,,,Rattus norvegicus,N,1,,
11981,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 2.67-4.31",Intermediate,10116.0,,A,,BAO_0000218,8608,,,1,CHEMBL627948,,,Rattus norvegicus,N,1,,
11982,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 3.17-4.70",Intermediate,10116.0,,A,,BAO_0000218,8608,,,1,CHEMBL628113,,,Rattus norvegicus,N,1,,
11983,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration.; dose/g, range 2.20-2.97",Intermediate,10116.0,,A,,BAO_0000218,8608,,,1,CHEMBL628114,,,Rattus norvegicus,N,1,,
11984,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 0.90-1.46",Intermediate,10116.0,,A,,BAO_0000218,8608,,,1,CHEMBL628115,,,Rattus norvegicus,N,1,,
11985,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 2.72-3.52",Intermediate,10116.0,,A,,BAO_0000218,8608,,,1,CHEMBL628116,,,Rattus norvegicus,N,1,,
11986,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 2.78-3.62",Intermediate,10116.0,,A,,BAO_0000218,8608,,,1,CHEMBL628117,,,Rattus norvegicus,N,1,,
11987,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 2.82-3.86",Intermediate,10116.0,,A,,BAO_0000218,8608,,,1,CHEMBL628118,,,Rattus norvegicus,N,1,,
11988,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 3.80-5.74",Intermediate,10116.0,,A,,BAO_0000218,8608,,,1,CHEMBL628119,,,Rattus norvegicus,N,1,,
11989,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 1.05-1.57",Intermediate,10116.0,,A,,BAO_0000218,8608,,,1,CHEMBL628120,,,Rattus norvegicus,N,1,,
11990,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 1.93-3.58",Intermediate,10116.0,,A,,BAO_0000218,8608,,,1,CHEMBL628121,,,Rattus norvegicus,N,1,,
11991,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 2.88-4.32",Intermediate,10116.0,,A,,BAO_0000218,8608,,,1,CHEMBL628122,,,Rattus norvegicus,N,1,,
11992,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 3-3.70",Intermediate,10116.0,,A,,BAO_0000218,8608,,,1,CHEMBL627297,,,Rattus norvegicus,N,1,,
11993,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 3.21-3.92",Intermediate,10116.0,,A,,BAO_0000218,8608,,,1,CHEMBL627298,,,Rattus norvegicus,N,1,,
11994,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 3.51-5.44",Intermediate,10116.0,,A,,BAO_0000218,8608,,,1,CHEMBL627299,,,Rattus norvegicus,N,1,,
11995,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 0.24-0.31",Intermediate,10116.0,,A,,BAO_0000218,8608,,,1,CHEMBL627300,,,Rattus norvegicus,N,1,,
11996,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 10.5-14.4",Intermediate,10116.0,,A,,BAO_0000218,8608,,,1,CHEMBL627301,,,Rattus norvegicus,N,1,,
11997,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 6.28-7.41",Intermediate,10116.0,,A,,BAO_0000218,8608,,,1,CHEMBL627302,,,Rattus norvegicus,N,1,,
11998,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 6.47-10.2",Intermediate,10116.0,,A,,BAO_0000218,8608,,,1,CHEMBL627303,,,Rattus norvegicus,N,1,,
11999,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 7.21-7.95",Intermediate,10116.0,,A,,BAO_0000218,8608,,,1,CHEMBL627304,,,Rattus norvegicus,N,1,,
12000,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 8.28-10.72",Intermediate,10116.0,,A,,BAO_0000218,8608,,,1,CHEMBL627305,,,Rattus norvegicus,N,1,,
12001,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 1.04-2.56",Intermediate,10116.0,,A,,BAO_0000218,8608,,,1,CHEMBL627306,,,Rattus norvegicus,N,1,,
12002,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 10.7-16.9",Intermediate,10116.0,,A,,BAO_0000218,8608,,,1,CHEMBL623982,,,Rattus norvegicus,N,1,,
12003,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 11.7-14.6",Intermediate,10116.0,,A,,BAO_0000218,8608,,,1,CHEMBL623983,,,Rattus norvegicus,N,1,,
12004,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 14.4-20.1",Intermediate,10116.0,,A,,BAO_0000218,8608,,,1,CHEMBL623984,,,Rattus norvegicus,N,1,,
12005,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 4.78-9.72",Intermediate,10116.0,,A,,BAO_0000218,8608,,,1,CHEMBL623985,,,Rattus norvegicus,N,1,,
12006,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 9.87-11.9",Intermediate,10116.0,,A,,BAO_0000218,8608,,,1,CHEMBL623986,,,Rattus norvegicus,N,1,,
12007,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 0.17-0.25",Intermediate,10116.0,,A,,BAO_0000218,8608,,,1,CHEMBL623987,,,Rattus norvegicus,N,1,,
12008,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 3.33-4.68",Intermediate,10116.0,,A,,BAO_0000218,8608,,,1,CHEMBL623988,,,Rattus norvegicus,N,1,,
12009,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 4.59-8.81",Intermediate,10116.0,,A,,BAO_0000218,8608,,,1,CHEMBL623989,,,Rattus norvegicus,N,1,,
12010,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 4.62-5.60",Intermediate,10116.0,,A,,BAO_0000218,8608,,,1,CHEMBL622215,,,Rattus norvegicus,N,1,,
12011,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 5.02-6.57",Intermediate,10116.0,,A,,BAO_0000218,8608,,,1,CHEMBL622216,,,Rattus norvegicus,N,1,,
12012,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 5.67-8.41",Intermediate,10116.0,,A,,BAO_0000218,8608,,,1,CHEMBL877481,,,Rattus norvegicus,N,1,,
12013,Pharmacokinetic parameter was evaluated which is represented as AUC when administered orally a dose of 5 mg/kg; range (4.2-8.8),Autocuration,,,A,,BAO_0000218,16359,,,1,CHEMBL622217,,,,U,0,,
12014,Pharmacokinetic parameters was measured at 55 mg/kg dose by oral administration in mice serum.; AUC 0-r (mM.h),Intermediate,10090.0,,A,,BAO_0000218,13701,,,1,CHEMBL622218,,,Mus musculus,N,1,,
12015,Pharmacokinetic profile AUC was evaluated in rats,Intermediate,10116.0,,A,,BAO_0000218,14554,,,1,CHEMBL622219,,,Rattus norvegicus,N,1,,
12016,Pharmacokinetic property (Area under curve),Autocuration,,,A,,BAO_0000019,6241,,,1,CHEMBL622220,,,,U,0,,
12017,"Pharmacokinetic property(AUC- area under curve, (micro g/mL/h)) after oral administration in dog (25 mg/kg).",Intermediate,9615.0,,A,,BAO_0000218,11537,,,1,CHEMBL622221,,,Canis lupus familiaris,N,1,,
12018,"Pharmacokinetic property(AUC- area under curve, (micro g/mL/h)) after oral administration in mice (50 mg/kg).",Intermediate,10090.0,,A,,BAO_0000218,11537,,,1,CHEMBL622222,,,Mus musculus,N,1,,
12019,"Pharmacokinetic property(AUC- area under curve, (micro g/mL/h)) after oral administration to dog (25 mg/kg).",Intermediate,9615.0,,A,,BAO_0000218,11537,,,1,CHEMBL622223,,,Canis lupus familiaris,N,1,,
12020,"Pharmacokinetic property(AUC- area under curve, (micro g/mL/h)) after oral administration to mice (50 mg/kg).",Intermediate,10090.0,,A,,BAO_0000218,11537,,,1,CHEMBL622224,,,Mus musculus,N,1,,
12021,Plasma concentration (AUC) was determined,Autocuration,,,A,,BAO_0000019,13118,,,1,CHEMBL622225,,,,U,0,,
12022,Plasma concentration (AUC) was determined; Not detectable,Autocuration,,,A,,BAO_0000019,13118,,,1,CHEMBL622226,,,,U,0,,
12023,Prolongation of time to collapse in guinea pig treated with aerosolized histamine was measured in vivo as area under curve (AUC),Intermediate,10141.0,,A,,BAO_0000218,9562,,,1,CHEMBL624154,,,Cavia porcellus,N,1,,
12024,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 30 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,10363,,,1,CHEMBL624155,,,Rattus norvegicus,N,1,,
12025,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 30 mg/kg; Not significant,Intermediate,10116.0,,A,,BAO_0000218,10363,,,1,CHEMBL624156,,,Rattus norvegicus,N,1,,
12026,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 60 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,10363,,,1,CHEMBL624157,,,Rattus norvegicus,N,1,,
12027,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 7.5 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,10363,,,1,CHEMBL624158,,,Rattus norvegicus,N,1,,
12028,Tested for area under the curve (AUC) after intravenous bolus administration of 100 mg/kg in rat 1,Intermediate,10116.0,,A,,BAO_0000218,12504,,,1,CHEMBL624159,,,Rattus norvegicus,N,1,,
12029,Tested for area under the curve (AUC) after intravenous bolus administration of 100 mg/kg in rat 2,Intermediate,10116.0,,A,,BAO_0000218,12504,,,1,CHEMBL624160,,,Rattus norvegicus,N,1,,
12030,Tested for area under the curve (AUC) after intravenous bolus administration of 100 mg/kg in rat 3,Intermediate,10116.0,,A,,BAO_0000218,12504,,,1,CHEMBL624161,,,Rattus norvegicus,N,1,,
12031,Tested for area under the curve (AUC) after intravenous bolus administration of 100 mg/kg in rat 4,Intermediate,10116.0,,A,,BAO_0000218,12504,,,1,CHEMBL624162,,,Rattus norvegicus,N,1,,
12032,Tested for pharmacokinetic parameter in fasted Beagle dogs (Area Under Curve value) iv administration.,Intermediate,9615.0,,A,,BAO_0000218,13317,,,1,CHEMBL624163,,,Canis lupus familiaris,N,1,,
12033,"The AUC(0-infinitive) value in female wistar rat at 100 mg/kg, p.o. dose",Intermediate,10116.0,,A,,BAO_0000218,15078,,,1,CHEMBL624164,,,Rattus norvegicus,N,1,,
12034,The AUC(0-infinity) values in female wistar rats.,Intermediate,10116.0,,A,,BAO_0000218,14941,,,1,CHEMBL624165,,,Rattus norvegicus,N,1,,
12035,"The AUC(0-t)value in female wistar rat at 100 mg/kg, p.o. dose",Intermediate,10116.0,,A,,BAO_0000218,15078,,,1,CHEMBL624166,,,Rattus norvegicus,N,1,,
12036,"The AUC(0-t)value in female wistar rat at 100 mg/kg, p.o. dose in mice",Intermediate,10116.0,,A,,BAO_0000218,15078,,,1,CHEMBL624167,,,Rattus norvegicus,N,1,,
12037,The AUC(0-t)values in female wistar rats.,Intermediate,10116.0,,A,,BAO_0000218,14941,,,1,CHEMBL624168,,,Rattus norvegicus,N,1,,
12038,The Area under the concentration time curve of compound was measured on rats,Intermediate,10116.0,,A,,BAO_0000218,14067,,,1,CHEMBL624169,,,Rattus norvegicus,N,1,,
12039,The area under curve (100 mg/kg) administered orally in humans,Intermediate,9606.0,,A,,BAO_0000218,14215,,,1,CHEMBL624170,,,Homo sapiens,N,1,,
12040,The area under curve (12.5 mg/kg) administered intravenously in marmoset,Autocuration,9481.0,,A,,BAO_0000218,14215,,,1,CHEMBL624171,,,Callithrix,U,0,,
12041,The area under curve (12.5 mg/kg) administered intravenously in monkey,Autocuration,314293.0,,A,,BAO_0000218,14215,,,1,CHEMBL624172,,,Simiiformes,U,0,,
12042,The area under curve (15 mg/kg) administered intravenously in dog,Intermediate,9615.0,,A,,BAO_0000218,14215,,,1,CHEMBL624173,,,Canis lupus familiaris,N,1,,
12043,The area under curve (200 mg/kg) administered orally in humans,Intermediate,9606.0,,A,,BAO_0000218,14215,,,1,CHEMBL877488,,,Homo sapiens,N,1,,
12044,The area under curve (25 mg/kg) administered intravenously in rat,Intermediate,10116.0,,A,,BAO_0000218,14215,,,1,CHEMBL624174,,,Rattus norvegicus,N,1,,
12045,The area under curve (25 mg/kg) administered orally in marmoset,Autocuration,9481.0,,A,,BAO_0000218,14215,,,1,CHEMBL624175,,,Callithrix,U,0,,
12046,The area under curve (25 mg/kg) administered orally in monkey,Autocuration,314293.0,,A,,BAO_0000218,14215,,,1,CHEMBL624176,,,Simiiformes,U,0,,
12047,The area under curve (30 mg/kg) administered orally in dog,Intermediate,9615.0,,A,,BAO_0000218,14215,,,1,CHEMBL624177,,,Canis lupus familiaris,N,1,,
12048,The area under curve (400 mg/kg) administered orally in humans,Intermediate,9606.0,,A,,BAO_0000218,14215,,,1,CHEMBL624178,,,Homo sapiens,N,1,,
12049,The area under curve (50 mg/kg) administered orally in fasted rat,Intermediate,10116.0,,A,,BAO_0000218,14215,,,1,CHEMBL624179,,,Rattus norvegicus,N,1,,
12050,The area under curve (50 mg/kg) administered orally in rat,Intermediate,10116.0,,A,,BAO_0000218,14215,,,1,CHEMBL627689,,,Rattus norvegicus,N,1,,
12051,The area under curve (800 mg/kg) administered orally in humans,Intermediate,9606.0,,A,,BAO_0000218,14215,,,1,CHEMBL627690,,,Homo sapiens,N,1,,
12052,The compound was evaluated for area under the curve,Autocuration,,,A,,BAO_0000019,11324,,,1,CHEMBL627691,,,,U,0,,
12053,The compound was evaluated for area under the curve in marmosets,Autocuration,9481.0,,A,,BAO_0000019,11324,,,1,CHEMBL627692,,,Callithrix,U,0,,
12054,The compound was evaluated for area under the curve in marmosets,Autocuration,9481.0,,A,,BAO_0000019,11324,,,1,CHEMBL627693,,,Callithrix,U,0,,
12055,The compound was tested for the area of the change in MABP versus time curve at dose 30 mg/kg (po) in conscious spontaneously hypertensive rat,Intermediate,10116.0,,A,,BAO_0000218,13875,,,1,CHEMBL627694,,,Rattus norvegicus,N,1,,
12056,The compound was tested for the area of the change in MABP versus time curve at dose 10 mg/kg (po) in conscious spontaneously hypertensive rat,Intermediate,10116.0,,A,,BAO_0000218,13875,,,1,CHEMBL627695,,,Rattus norvegicus,N,1,,
12057,The compound was tested for the area of the change in MABP versus time curve at dose 10 mg/kg (po),Autocuration,,,A,,BAO_0000218,13875,,,1,CHEMBL627696,,,,U,0,,
12058,The compound was tested for the area of the change in MABP versus time curve at dose 30 mg/kg (po) in conscious spontaneously hypertensive rat,Intermediate,10116.0,,A,,BAO_0000218,13875,,,1,CHEMBL627697,,,Rattus norvegicus,N,1,,
12059,The compound was tested for the area of the change in MABP versus time curve at dose 30 mg/kg (po) in conscious spontaneously hypertensive rat,Intermediate,10116.0,,A,,BAO_0000218,13875,,,1,CHEMBL627698,,,Rattus norvegicus,N,1,,
12060,The compound was tested for the area of the change in MABP versus time curve at dose 5 mg/kg (po) in conscious spontaneously hypertensive rat,Intermediate,10116.0,,A,,BAO_0000218,13875,,,1,CHEMBL627699,,,Rattus norvegicus,N,1,,
12061,Total absorption was estimated by area under curve (AUC) after intravenous administration in rat,Intermediate,10116.0,,A,,BAO_0000218,13807,,,1,CHEMBL627700,,,Rattus norvegicus,N,1,,
12062,Total drug exposure is determined after oral dosing in rats.,Intermediate,10116.0,,A,,BAO_0000218,14127,,,1,CHEMBL627701,,,Rattus norvegicus,N,1,,
12063,Total drug exposure (5 mg/kg) when administered intravenously,Autocuration,,,A,,BAO_0000218,15116,,,1,CHEMBL627702,,,,U,0,,
12064,Total drug exposure (5 mg/kg) when administered orally,Autocuration,,,A,,BAO_0000218,15116,,,1,CHEMBL627703,,,,U,0,,
12065,area under curve in preclinical species was measured after Intravenous administration at the given dose (0.01 mg/kg) in monkey,Autocuration,314293.0,,A,,BAO_0000218,15604,,,1,CHEMBL626873,,,Simiiformes,U,0,,
12066,area under curve in preclinical species was measured after Intravenous administration at the given dose (0.05 mg/kg) in rat,Intermediate,10116.0,,A,,BAO_0000218,15604,,,1,CHEMBL629583,,,Rattus norvegicus,N,1,,
12067,area under curve in preclinical species was measured after Intravenous administration at the given dose (0.1 mg/kg) in dog,Intermediate,9615.0,,A,,BAO_0000218,15604,,,1,CHEMBL629584,,,Canis lupus familiaris,N,1,,
12068,area under curve in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in dog,Intermediate,9615.0,,A,,BAO_0000218,15604,,,1,CHEMBL629585,,,Canis lupus familiaris,N,1,,
12069,"Biodistribution in brain of mature female Dawley rat after 5min, expressed as percent injected dose/g",Intermediate,10116.0,,A,,BAO_0000218,13751,,,1,CHEMBL629586,,,Rattus norvegicus,N,1,955.0,
12070,"Biodistribution in brain of mature female Dawley rat after 30min, expressed as percent injected dose/g",Intermediate,10116.0,,A,,BAO_0000218,13751,,,1,CHEMBL629587,,,Rattus norvegicus,N,1,955.0,
12071,"Biodistribution in fat of mature female Dawley rat after 10min, expressed as percent injected dose/g",Intermediate,10116.0,,A,,BAO_0000218,13751,,,1,CHEMBL629588,,,Rattus norvegicus,N,1,,
12072,"Biodistribution in fat of mature female Dawley rat after 15min, expressed as percent injected dose/g",Intermediate,10116.0,,A,,BAO_0000218,13751,,,1,CHEMBL629589,,,Rattus norvegicus,N,1,,
12073,"Biodistribution in fat of mature female Dawley rat after 1h, expressed as percent injected dose/g",Intermediate,10116.0,,A,,BAO_0000218,13751,,,1,CHEMBL629590,,,Rattus norvegicus,N,1,,
12074,"Biodistribution in fat of mature female Dawley rat after 3 h, expressed as percent injected dose/g",Intermediate,10116.0,,A,,BAO_0000218,13751,,,1,CHEMBL629591,,,Rattus norvegicus,N,1,,
12075,"Biodistribution in fat of mature female Dawley rat after 30min, expressed as percent injected dose/g",Intermediate,10116.0,,A,,BAO_0000218,13751,,,1,CHEMBL629592,,,Rattus norvegicus,N,1,,
12076,"Biodistribution in fat of mature female Dawley rat after 45min, expressed as percent injected dose/g",Intermediate,10116.0,,A,,BAO_0000218,13751,,,1,CHEMBL629593,,,Rattus norvegicus,N,1,,
12077,"Biodistribution in fat of mature female Dawley rat after 5min, expressed as percent injected dose/g",Intermediate,10116.0,,A,,BAO_0000218,13751,,,1,CHEMBL629594,,,Rattus norvegicus,N,1,,
12078,"Biodistribution in heart of mature female Dawley rat after 10min, expressed as percent injected dose/g",Intermediate,10116.0,,A,,BAO_0000218,13751,,,1,CHEMBL629595,,,Rattus norvegicus,N,1,948.0,
12079,"Biodistribution in heart of mature female Dawley rat after 15min, expressed as percent injected dose/g",Intermediate,10116.0,,A,,BAO_0000218,13751,,,1,CHEMBL630290,,,Rattus norvegicus,N,1,948.0,
12080,"Biodistribution in heart of mature female Dawley rat after 1h, expressed as percent injected dose/g",Intermediate,10116.0,,A,,BAO_0000218,13751,,,1,CHEMBL627137,,,Rattus norvegicus,N,1,948.0,
12081,"Biodistribution in heart of mature female Dawley rat after 3 h, expressed as percent injected dose/g",Intermediate,10116.0,,A,,BAO_0000218,13751,,,1,CHEMBL627138,,,Rattus norvegicus,N,1,948.0,
12082,"Biodistribution in heart of mature female Dawley rat after 30min, expressed as percent injected dose/g",Intermediate,10116.0,,A,,BAO_0000218,13751,,,1,CHEMBL627139,,,Rattus norvegicus,N,1,948.0,
12083,"Biodistribution in heart of mature female Dawley rat after 45min, expressed as percent injected dose/g",Intermediate,10116.0,,A,,BAO_0000218,13751,,,1,CHEMBL627140,,,Rattus norvegicus,N,1,948.0,
12084,"Biodistribution in heart of mature female Dawley rat after 5min, expressed as percent injected dose/g",Intermediate,10116.0,,A,,BAO_0000218,13751,,,1,CHEMBL627141,,,Rattus norvegicus,N,1,948.0,
12085,"Biodistribution in kidney of mature female Dawley rat after 10min, expressed as percent injected dose/g",Intermediate,10116.0,,A,,BAO_0000218,13751,,,1,CHEMBL627142,,,Rattus norvegicus,N,1,2113.0,
12086,"Biodistribution in kidney of mature female Dawley rat after 15min, expressed as percent injected dose/g",Intermediate,10116.0,,A,,BAO_0000218,13751,,,1,CHEMBL627143,,,Rattus norvegicus,N,1,2113.0,
12087,"Biodistribution in kidney of mature female Dawley rat after 1h, expressed as percent injected dose/g",Intermediate,10116.0,,A,,BAO_0000218,13751,,,1,CHEMBL874449,,,Rattus norvegicus,N,1,2113.0,
12088,"Biodistribution in kidney of mature female Dawley rat after 3 h, expressed as percent injected dose/g",Intermediate,10116.0,,A,,BAO_0000218,13751,,,1,CHEMBL627144,,,Rattus norvegicus,N,1,2113.0,
12089,"Biodistribution in kidney of mature female Dawley rat after 30min, expressed as percent injected dose/g",Intermediate,10116.0,,A,,BAO_0000218,13751,,,1,CHEMBL627145,,,Rattus norvegicus,N,1,2113.0,
12090,"Biodistribution in kidney of mature female Dawley rat after 45min, expressed as percent injected dose/g",Intermediate,10116.0,,A,,BAO_0000218,13751,,,1,CHEMBL627146,,,Rattus norvegicus,N,1,2113.0,
12091,"Biodistribution in kidney of mature female Dawley rat after 5min, expressed as percent injected dose/g",Intermediate,10116.0,,A,,BAO_0000218,13751,,,1,CHEMBL627147,,,Rattus norvegicus,N,1,2113.0,
12092,"Biodistribution in liver of mature female Dawley rat after 10min, expressed as percent injected dose/g",Intermediate,10116.0,,A,,BAO_0000218,13751,,,1,CHEMBL627148,,,Rattus norvegicus,N,1,2107.0,
12093,"Biodistribution in lung of mature female Dawley rat after 10min, expressed as percent injected dose/g",Intermediate,10116.0,,A,,BAO_0000218,13751,,,1,CHEMBL627149,,,Rattus norvegicus,N,1,2048.0,
12094,"Biodistribution in lung of mature female Dawley rat after 15min, expressed as percent injected dose/g",Intermediate,10116.0,,A,,BAO_0000218,13751,,,1,CHEMBL632160,,,Rattus norvegicus,N,1,2048.0,
12095,"Biodistribution in lung of mature female Dawley rat after 1h, expressed as percent injected dose/g",Intermediate,10116.0,,A,,BAO_0000218,13751,,,1,CHEMBL632161,,,Rattus norvegicus,N,1,2048.0,
12096,"Biodistribution in lung of mature female Dawley rat after 3 h, expressed as percent injected dose/g",Intermediate,10116.0,,A,,BAO_0000218,13751,,,1,CHEMBL632162,,,Rattus norvegicus,N,1,2048.0,
12097,"Biodistribution in lung of mature female Dawley rat after 30min, expressed as percent injected dose/g",Intermediate,10116.0,,A,,BAO_0000218,13751,,,1,CHEMBL632163,,,Rattus norvegicus,N,1,2048.0,
12098,"Biodistribution in lung of mature female Dawley rat after 45min, expressed as percent injected dose/g",Intermediate,10116.0,,A,,BAO_0000218,13751,,,1,CHEMBL874469,,,Rattus norvegicus,N,1,2048.0,
12099,"Biodistribution in lung of mature female Dawley rat after 5min, expressed as percent injected dose/g",Intermediate,10116.0,,A,,BAO_0000218,13751,,,1,CHEMBL627182,,,Rattus norvegicus,N,1,2048.0,
12100,"Biodistribution in muscle of mature female Dawley rat after 10min, expressed as percent injected dose/g",Intermediate,10116.0,,A,,BAO_0000218,13751,,,1,CHEMBL627183,,,Rattus norvegicus,N,1,2385.0,
12101,"Biodistribution in muscle of mature female Dawley rat after 15min, expressed as percent injected dose/g",Intermediate,10116.0,,A,,BAO_0000218,13751,,,1,CHEMBL627184,,,Rattus norvegicus,N,1,2385.0,
12102,"Biodistribution in muscle of mature female Dawley rat after 1h, expressed as percent injected dose/g",Intermediate,10116.0,,A,,BAO_0000218,13751,,,1,CHEMBL627185,,,Rattus norvegicus,N,1,2385.0,
12103,"Biodistribution in muscle of mature female Dawley rat after 3 h, expressed as percent injected dose/g",Intermediate,10116.0,,A,,BAO_0000218,13751,,,1,CHEMBL627186,,,Rattus norvegicus,N,1,2385.0,
12104,"Biodistribution in muscle of mature female Dawley rat after 30min, expressed as percent injected dose/g",Intermediate,10116.0,,A,,BAO_0000218,13751,,,1,CHEMBL627187,,,Rattus norvegicus,N,1,2385.0,
12105,"Biodistribution in muscle of mature female Dawley rat after 45min, expressed as percent injected dose/g",Intermediate,10116.0,,A,,BAO_0000218,13751,,,1,CHEMBL627188,,,Rattus norvegicus,N,1,2385.0,
12106,"Biodistribution in muscle of mature female Dawley rat after 5min, expressed as percent injected dose/g",Intermediate,10116.0,,A,,BAO_0000218,13751,,,1,CHEMBL627189,,,Rattus norvegicus,N,1,2385.0,
12107,"Biodistribution inl ilver of mature female Dawley rat after 30min, expressed as percent injected dose/g",Intermediate,10116.0,,A,,BAO_0000218,13751,,,1,CHEMBL627190,,,Rattus norvegicus,N,1,,
12108,"Biodistribution inl iver of mature female Dawley rat after 15min, expressed as percent injected dose/g",Intermediate,10116.0,,A,,BAO_0000218,13751,,,1,CHEMBL627191,,,Rattus norvegicus,N,1,2107.0,
12109,"Biodistribution inl iver of mature female Dawley rat after 3 h, expressed as percent injected dose/g",Intermediate,10116.0,,A,,BAO_0000218,13751,,,1,CHEMBL627192,,,Rattus norvegicus,N,1,2107.0,
12110,"Biodistribution inl iver of mature female Dawley rat after 5min, expressed as percent injected dose/g",Intermediate,10116.0,,A,,BAO_0000218,13751,,,1,CHEMBL627193,,,Rattus norvegicus,N,1,2107.0,
12111,Biodistribution studied in the muscle of immature Fischer female rats at 2 hou; activity is expressed as inductive dose / gram,Intermediate,10116.0,,A,,BAO_0000218,10911,,,1,CHEMBL874590,,,Rattus norvegicus,N,1,2385.0,
12112,Biodistribution studied in the muscle of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,Intermediate,10116.0,,A,,BAO_0000218,10911,,,1,CHEMBL627194,,,Rattus norvegicus,N,1,2385.0,
12113,Biodistribution studied in the muscle of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,Intermediate,10116.0,,A,,BAO_0000218,10911,,,1,CHEMBL627195,,,Rattus norvegicus,N,1,2385.0,
12114,Biodistribution studied in the ovaries of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,Intermediate,10116.0,,A,,BAO_0000218,10911,,,1,CHEMBL627196,,,Rattus norvegicus,N,1,992.0,
12115,Biodistribution studied in the ovaries of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,Intermediate,10116.0,,A,,BAO_0000218,10911,,,1,CHEMBL627197,,,Rattus norvegicus,N,1,992.0,
12116,Biodistribution studied in the ovaries of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,Intermediate,10116.0,,A,,BAO_0000218,10911,,,1,CHEMBL627198,,,Rattus norvegicus,N,1,992.0,
12117,Biodistribution studied in the ovaries of immature Fischer female rats at 5 hour,Intermediate,10116.0,,A,,BAO_0000218,10911,,,1,CHEMBL627199,,,Rattus norvegicus,N,1,992.0,
12118,Biodistribution studied in the ovaries of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,Intermediate,10116.0,,A,,BAO_0000218,10911,,,1,CHEMBL627200,,,Rattus norvegicus,N,1,992.0,
12119,Biodistribution studied in the plasma of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,Intermediate,10116.0,,A,,BAO_0000218,10911,,,1,CHEMBL627201,,,Rattus norvegicus,N,1,1969.0,
12120,Biodistribution studied in the plasma of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,Intermediate,10116.0,,A,,BAO_0000218,10911,,,1,CHEMBL627202,,,Rattus norvegicus,N,1,1969.0,
12121,Biodistribution studied in the plasma of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,Intermediate,10116.0,,A,,BAO_0000218,10911,,,1,CHEMBL627203,,,Rattus norvegicus,N,1,1969.0,
12122,Biodistribution studied in the plasma of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,Intermediate,10116.0,,A,,BAO_0000218,10911,,,1,CHEMBL627204,,,Rattus norvegicus,N,1,1969.0,
12123,Biodistribution studied in the spleen of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,Intermediate,10116.0,,A,,BAO_0000218,10911,,,1,CHEMBL627205,,,Rattus norvegicus,N,1,2106.0,
12124,Biodistribution studied in the spleen of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,Intermediate,10116.0,,A,,BAO_0000218,10911,,,1,CHEMBL627206,,,Rattus norvegicus,N,1,2106.0,
12125,Biodistribution studied in the spleen of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,Intermediate,10116.0,,A,,BAO_0000218,10911,,,1,CHEMBL627207,,,Rattus norvegicus,N,1,2106.0,
12126,Biodistribution studied in the spleen of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,Intermediate,10116.0,,A,,BAO_0000218,10911,,,1,CHEMBL627208,,,Rattus norvegicus,N,1,2106.0,
12127,Biodistribution studied in the thyroid of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,Intermediate,10116.0,,A,,BAO_0000218,10911,,,1,CHEMBL627209,,,Rattus norvegicus,N,1,2046.0,
12128,Biodistribution studied in the thyroid of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,Intermediate,10116.0,,A,,BAO_0000218,10911,,,1,CHEMBL627210,,,Rattus norvegicus,N,1,2046.0,
12129,Biodistribution studied in the thyroid of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,Intermediate,10116.0,,A,,BAO_0000218,10911,,,1,CHEMBL627211,,,Rattus norvegicus,N,1,2046.0,
12130,Biodistribution studied in the thyroid of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,Intermediate,10116.0,,A,,BAO_0000218,10911,,,1,CHEMBL627212,,,Rattus norvegicus,N,1,2046.0,
12131,Biodistribution studied in the uterus of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,Intermediate,10116.0,,A,,BAO_0000218,10911,,,1,CHEMBL627213,,,Rattus norvegicus,N,1,995.0,
12132,Biodistribution studied in the uterus of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,Intermediate,10116.0,,A,,BAO_0000218,10911,,,1,CHEMBL626599,,,Rattus norvegicus,N,1,995.0,
12133,Biodistribution studied in the uterus of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,Intermediate,10116.0,,A,,BAO_0000218,10911,,,1,CHEMBL626600,,,Rattus norvegicus,N,1,995.0,
12134,Biodistribution studied in the uterus of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,Intermediate,10116.0,,A,,BAO_0000218,10911,,,1,CHEMBL626601,,,Rattus norvegicus,N,1,995.0,
12135,C(f=2) is the concentration at which the half life (t1/2) in the time course of inhibition of BChE by DFP increased by twofold in the presence of compound,Autocuration,,,A,,BAO_0000019,8081,,,1,CHEMBL627484,,,,U,0,,
12136,Compound was tested for plasma concentration in CM-monkeys 7 hours after oral administration (50 mg/kg),Intermediate,9541.0,,A,,BAO_0000218,17248,,,1,CHEMBL627485,,,Macaca fascicularis,N,1,1969.0,
12137,Compound was tested for plasma concentration in CM-monkeys 7 hours after oral administration (50 mg/kg); Not applicable,Intermediate,9541.0,,A,,BAO_0000218,17248,,,1,CHEMBL628147,,,Macaca fascicularis,N,1,1969.0,
12138,Compound was tested for plasma concentration in CM-monkeys 7 hours after oral administration (50 mg/kg); Not determined,Intermediate,9541.0,,A,,BAO_0000218,17248,,,1,CHEMBL628148,,,Macaca fascicularis,N,1,1969.0,
12139,Compound was tested for plasma concentration in dogs 7 hours after oral administration (30 mg/kg),Intermediate,9615.0,,A,,BAO_0000218,17248,,,1,CHEMBL628149,,,Canis lupus familiaris,N,1,1969.0,
12140,Compound was tested for plasma concentration in dogs 7 hours after oral administration (30 mg/kg) in experiment 1,Intermediate,9615.0,,A,,BAO_0000218,17248,,,1,CHEMBL628150,,,Canis lupus familiaris,N,1,1969.0,
12141,Compound was tested for plasma concentration in dogs 7 hours after oral administration (30 mg/kg) in experiment 2,Intermediate,9615.0,,A,,BAO_0000218,17248,,,1,CHEMBL628318,,,Canis lupus familiaris,N,1,1969.0,
12142,Compound was tested for plasma concentration in dogs 7 hours after oral administration (30 mg/kg); Not applicable,Intermediate,9615.0,,A,,BAO_0000218,17248,,,1,CHEMBL628319,,,Canis lupus familiaris,N,1,1969.0,
12143,"Concentration after 8 hour (bioavailability in dog, compound was delivered orally in 0.05 M citric acid at 10 mg/Kg. n=2 )",Intermediate,9615.0,,A,,BAO_0000218,15592,,,1,CHEMBL875609,,,Canis lupus familiaris,N,1,,
12144,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 10,Autocuration,,,A,,BAO_0000019,7040,,,1,CHEMBL628320,,,,U,0,,
12145,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 10.5,Autocuration,,,A,,BAO_0000019,7040,,,1,CHEMBL628321,,,,U,0,,
12146,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 6.8,Autocuration,,,A,,BAO_0000019,7040,,,1,CHEMBL628322,,,,U,0,,
12147,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 7.2,Autocuration,,,A,,BAO_0000019,7040,,,1,CHEMBL628323,,,,U,0,,
12148,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 7.6,Autocuration,,,A,,BAO_0000019,7040,,,1,CHEMBL628324,,,,U,0,,
12149,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 8.2,Autocuration,,,A,,BAO_0000019,7040,,,1,CHEMBL628325,,,,U,0,,
12150,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 9.6,Autocuration,,,A,,BAO_0000019,7040,,,1,CHEMBL628326,,,,U,0,,
12151,"Concentration of compound in adrenal medulla of dog 2, after administering intravenously",Intermediate,9615.0,,A,,BAO_0000218,9614,,,1,CHEMBL628327,,,Canis lupus familiaris,N,1,1236.0,
12152,"Concentration of compound in adrenal medulla of dog1, after administering intravenously",Intermediate,9615.0,,A,,BAO_0000218,9614,,,1,CHEMBL628328,,,Canis lupus familiaris,N,1,1236.0,
12153,"Concentration of compound in blood of dog 1, after administering intravenously",Intermediate,9615.0,,A,,BAO_0000218,9614,,,1,CHEMBL628329,,,Canis lupus familiaris,N,1,178.0,
12154,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration.; dose/g, range 0.23-0.29",Intermediate,10116.0,,A,,BAO_0000218,8608,,,1,CHEMBL628330,,,Rattus norvegicus,N,1,2107.0,
12155,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 0.22-0.30",Intermediate,10116.0,,A,,BAO_0000218,8608,,,1,CHEMBL628331,,,Rattus norvegicus,N,1,2107.0,
12156,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 0.55-0.71",Intermediate,10116.0,,A,,BAO_0000218,8608,,,1,CHEMBL628332,,,Rattus norvegicus,N,1,2107.0,
12157,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 0.57-0.72",Intermediate,10116.0,,A,,BAO_0000218,8608,,,1,CHEMBL628333,,,Rattus norvegicus,N,1,2107.0,
12158,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 1.51-2.23",Intermediate,10116.0,,A,,BAO_0000218,8608,,,1,CHEMBL628334,,,Rattus norvegicus,N,1,2107.0,
12159,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 2.30-3.12",Intermediate,10116.0,,A,,BAO_0000218,8608,,,1,CHEMBL628335,,,Rattus norvegicus,N,1,2107.0,
12160,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 0.93-1.20",Intermediate,10116.0,,A,,BAO_0000218,8608,,,1,CHEMBL628336,,,Rattus norvegicus,N,1,2107.0,
12161,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 1.04-2.56",Intermediate,10116.0,,A,,BAO_0000218,8608,,,1,CHEMBL628337,,,Rattus norvegicus,N,1,2107.0,
12162,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 1.06-1.70",Intermediate,10116.0,,A,,BAO_0000218,8608,,,1,CHEMBL628338,,,Rattus norvegicus,N,1,2107.0,
12163,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 1.26-2.45",Intermediate,10116.0,,A,,BAO_0000218,8608,,,1,CHEMBL875610,,,Rattus norvegicus,N,1,2107.0,
12164,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 3.12-4.56",Intermediate,10116.0,,A,,BAO_0000218,8608,,,1,CHEMBL628339,,,Rattus norvegicus,N,1,2107.0,
12165,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 4.12-6.30",Intermediate,10116.0,,A,,BAO_0000218,8608,,,1,CHEMBL628340,,,Rattus norvegicus,N,1,2107.0,
12166,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.14-0.19",Intermediate,10116.0,,A,,BAO_0000218,8608,,,1,CHEMBL628341,,,Rattus norvegicus,N,1,2107.0,
12167,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.15-0.19",Intermediate,10116.0,,A,,BAO_0000218,8608,,,1,CHEMBL622214,,,Rattus norvegicus,N,1,2107.0,
12168,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.24-0.30",Intermediate,10116.0,,A,,BAO_0000218,8608,,,1,CHEMBL623167,,,Rattus norvegicus,N,1,2107.0,
12169,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.44-0.54",Intermediate,10116.0,,A,,BAO_0000218,8608,,,1,CHEMBL623168,,,Rattus norvegicus,N,1,2107.0,
12170,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.73-1.19",Intermediate,10116.0,,A,,BAO_0000218,8608,,,1,CHEMBL623169,,,Rattus norvegicus,N,1,2107.0,
12171,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 1.08-2.31",Intermediate,10116.0,,A,,BAO_0000218,8608,,,1,CHEMBL623170,,,Rattus norvegicus,N,1,2107.0,
12172,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration.; dose/g, range 0.34-0.47",Intermediate,10116.0,,A,,BAO_0000218,8608,,,1,CHEMBL627224,,,Rattus norvegicus,N,1,2048.0,
12173,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 0.83-1.21",Intermediate,10116.0,,A,,BAO_0000218,8608,,,1,CHEMBL875634,,,Rattus norvegicus,N,1,2048.0,
12174,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 0.91-1.74",Intermediate,10116.0,,A,,BAO_0000218,8608,,,1,CHEMBL627225,,,Rattus norvegicus,N,1,2048.0,
12175,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 0.99-1.23",Intermediate,10116.0,,A,,BAO_0000218,8608,,,1,CHEMBL627226,,,Rattus norvegicus,N,1,2048.0,
12176,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 1.07-1.30",Intermediate,10116.0,,A,,BAO_0000218,8608,,,1,CHEMBL626083,,,Rattus norvegicus,N,1,2048.0,
12177,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 1.12-1.39",Intermediate,10116.0,,A,,BAO_0000218,8608,,,1,CHEMBL626084,,,Rattus norvegicus,N,1,2048.0,
12178,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 0.51-0.66",Intermediate,10116.0,,A,,BAO_0000218,8608,,,1,CHEMBL626085,,,Rattus norvegicus,N,1,2048.0,
12179,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 0.95-1.49",Intermediate,10116.0,,A,,BAO_0000218,8608,,,1,CHEMBL626086,,,Rattus norvegicus,N,1,2048.0,
12180,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 0.96-1.35",Intermediate,10116.0,,A,,BAO_0000218,8608,,,1,CHEMBL626087,,,Rattus norvegicus,N,1,2048.0,
12181,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 1.18-1.44",Intermediate,10116.0,,A,,BAO_0000218,8608,,,1,CHEMBL626088,,,Rattus norvegicus,N,1,2048.0,
12182,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 1.20-1.52",Intermediate,10116.0,,A,,BAO_0000218,8608,,,1,CHEMBL626089,,,Rattus norvegicus,N,1,2048.0,
12183,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 1.41-2.17",Intermediate,10116.0,,A,,BAO_0000218,8608,,,1,CHEMBL626090,,,Rattus norvegicus,N,1,2048.0,
12184,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.28-0.33",Intermediate,10116.0,,A,,BAO_0000218,8608,,,1,CHEMBL626091,,,Rattus norvegicus,N,1,2048.0,
12185,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.81-1.13",Intermediate,10116.0,,A,,BAO_0000218,8608,,,1,CHEMBL626092,,,Rattus norvegicus,N,1,2048.0,
12186,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.83-2.11",Intermediate,10116.0,,A,,BAO_0000218,8608,,,1,CHEMBL626093,,,Rattus norvegicus,N,1,2048.0,
12187,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.94-1.36",Intermediate,10116.0,,A,,BAO_0000218,8608,,,1,CHEMBL626094,,,Rattus norvegicus,N,1,2048.0,
12188,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.97-1.54",Intermediate,10116.0,,A,,BAO_0000218,8608,,,1,CHEMBL626095,,,Rattus norvegicus,N,1,2048.0,
12189,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 1.07-1.26",Intermediate,10116.0,,A,,BAO_0000218,8608,,,1,CHEMBL626096,,,Rattus norvegicus,N,1,2048.0,
12190,area under curve in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in monkey,Autocuration,314293.0,,A,,BAO_0000218,15604,,,1,CHEMBL626097,,,Simiiformes,U,0,,
12191,area under curve in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in rat,Intermediate,10116.0,,A,,BAO_0000218,15604,,,1,CHEMBL626098,,,Rattus norvegicus,N,1,,
12192,compound was evaluated for area under the plasma concentration vs. time curve at different dose 27.5 mg/kg DMP323 equiv,Autocuration,,,A,,BAO_0000218,1806,,,1,CHEMBL626099,,,,U,0,1969.0,
12193,compound was evaluated for area under the plasma concentration vs. time curve at different dose 7.7 mg/kg DMP323 equiv,Autocuration,,,A,,BAO_0000218,1806,,,1,CHEMBL626100,,,,U,0,1969.0,
12194,AUC 0-inf in dog,Intermediate,9615.0,,A,,BAO_0000218,17237,,,1,CHEMBL626101,,,Canis lupus familiaris,N,1,1969.0,
12195,AUC 0-inf in guinea pig,Intermediate,10141.0,,A,,BAO_0000218,17237,,,1,CHEMBL626102,,,Cavia porcellus,N,1,1969.0,
12196,AUC 0-t in dog,Intermediate,9615.0,,A,,BAO_0000218,17237,,,1,CHEMBL626103,,,Canis lupus familiaris,N,1,1969.0,
12197,AUC 0-t in guinea pig,Intermediate,10141.0,,A,,BAO_0000218,17237,,,1,CHEMBL628391,,,Cavia porcellus,N,1,1969.0,
12198,The compound was tested for brain to plasma partition in rat,Intermediate,10116.0,,A,,BAO_0000218,15194,,,1,CHEMBL628392,,,Rattus norvegicus,N,1,,
12199,The compound was tested for brain to plasma partition in rat.,Intermediate,10116.0,,A,,BAO_0000218,15194,,,1,CHEMBL628393,,,Rattus norvegicus,N,1,,
12200,Area under curve was determined for 0-6 hr duration using dihydralazine as reference drug for the peak blood pressure,Autocuration,,,A,,BAO_0000019,8787,,,1,CHEMBL628394,,,,U,0,178.0,
12201,Area under concentration-time curve of compound was determined in dog at 5 mg/kg intravenously admn.,Intermediate,9615.0,,A,,BAO_0000218,17025,,,1,CHEMBL628395,,,Canis lupus familiaris,N,1,,
12202,Area under concentration-time curve of compound was determined in monkey at 5 mg/kg intravenously admn.,Autocuration,314293.0,,A,,BAO_0000218,17025,,,1,CHEMBL628396,,,Simiiformes,U,0,,
12203,Area under concentration-time curve of compound was determined in rabbit at 5 mg/kg intravenously admn.,Intermediate,9986.0,,A,,BAO_0000218,17025,,,1,CHEMBL628397,,,Oryctolagus cuniculus,N,1,,
12204,Area under concentration-time curve of compound was determined in rat at 5 mg/kg intravenously admn.,Intermediate,10116.0,,A,,BAO_0000218,17025,,,1,CHEMBL628398,,,Rattus norvegicus,N,1,,
12205,Area under curve obtained at a dose of 10 mg/kg when administered orally to rhesus monkey,Intermediate,9544.0,,A,,BAO_0000218,4236,,,1,CHEMBL628399,,,Macaca mulatta,N,1,,
12206,The Plasma area under the compound concentration -time curve was measured in dogs after oral administration of 1 mg/kg dose,Intermediate,9615.0,,A,,BAO_0000218,15343,,,1,CHEMBL628400,,,Canis lupus familiaris,N,1,,
12207,The Plasma area under the compound concentration -time curve was measured in rats after oral administration of 1 mg/kg dose,Intermediate,10116.0,,A,,BAO_0000218,15343,,,1,CHEMBL874907,,,Rattus norvegicus,N,1,,
12208,Area under curve of the compound was determined,Autocuration,,,A,,BAO_0000019,17720,,,1,CHEMBL628401,,,,U,0,,
12209,AUC in monkeys at a dose of 1 mg/kg,Autocuration,314293.0,,A,,BAO_0000218,17788,,,1,CHEMBL628402,,,Simiiformes,U,0,1969.0,
12210,AUC in rats at a dose of 1 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,17788,,,1,CHEMBL628403,,,Rattus norvegicus,N,1,1969.0,
12211,Compound was evaluated for the overall absorbance loss at pH of 2,Autocuration,,,A,,BAO_0000019,8778,,,1,CHEMBL628404,,,,U,0,,
12212,Compound was evaluated for the overall absorbance loss at pH of 4,Autocuration,,,A,,BAO_0000019,8778,,,1,CHEMBL628405,,,,U,0,,
12213,Compound was evaluated for the overall absorbance loss at pH of 7,Autocuration,,,A,,BAO_0000019,8778,,,1,CHEMBL628406,,,,U,0,,
12214,Compound was evaluated for its absorption in the rats,Intermediate,10116.0,,A,,BAO_0000218,2249,,,1,CHEMBL628407,,,Rattus norvegicus,N,1,,
12215,Compound was evaluated for percent tranexamic acid recovered in rat urine within 24 hr after oral administration of 0.1 mmol/kg of body weight per mole of pro drug,Intermediate,10116.0,,A,,BAO_0000218,8881,,,1,CHEMBL628408,,,Rattus norvegicus,N,1,1088.0,
12216,Compound was evaluated for percent tranexamic acid recovered in rat urine within 24 hr after oral administration of 0.1 mmol/kg of body weight.,Intermediate,10116.0,,A,,BAO_0000218,8881,,,1,CHEMBL629171,,,Rattus norvegicus,N,1,1088.0,
12217,Compound was evaluated for percent tranexamic acid recovered in rat urine within 24 hr after oral administration of 0.1 mmol/kg of body weight per mole of pro drug,Intermediate,10116.0,,A,,BAO_0000218,8881,,,1,CHEMBL629172,,,Rattus norvegicus,N,1,1088.0,
12218,Compound was evaluated for percent tranexamic acid recovered in rat urine within 24 hr after oral administration of per moiety tranexamic acid,Intermediate,10116.0,,A,,BAO_0000218,8881,,,1,CHEMBL629173,,,Rattus norvegicus,N,1,1088.0,
12219,In vitro percent permeability into rat ileum,Intermediate,10116.0,,A,,BAO_0000218,15286,,,1,CHEMBL629174,,,Rattus norvegicus,N,1,,
12220,In vitro percent permeability into rat ileum; Range is 10-17,Intermediate,10116.0,,A,,BAO_0000218,15286,,,1,CHEMBL629175,,,Rattus norvegicus,N,1,,
12221,In vitro percent permeability into rat ileum; Range is 10-18,Intermediate,10116.0,,A,,BAO_0000218,15286,,,1,CHEMBL629176,,,Rattus norvegicus,N,1,,
12222,In vitro percent permeability into rat ileum; Range is 10-19,Intermediate,10116.0,,A,,BAO_0000218,15286,,,1,CHEMBL629177,,,Rattus norvegicus,N,1,,
12223,In vitro percent permeability into rat ileum; Range is 12-15,Intermediate,10116.0,,A,,BAO_0000218,15286,,,1,CHEMBL629178,,,Rattus norvegicus,N,1,,
12224,In vitro percent permeability into rat ileum; Range is 13-19,Intermediate,10116.0,,A,,BAO_0000218,15286,,,1,CHEMBL631869,,,Rattus norvegicus,N,1,,
12225,In vitro percent permeability into rat ileum; Range is 14-17,Intermediate,10116.0,,A,,BAO_0000218,15286,,,1,CHEMBL631870,,,Rattus norvegicus,N,1,,
12226,In vitro percent permeability into rat ileum; Range is 15-18,Intermediate,10116.0,,A,,BAO_0000218,15286,,,1,CHEMBL631871,,,Rattus norvegicus,N,1,,
12227,In vitro percent permeability into rat ileum; Range is 2-5,Intermediate,10116.0,,A,,BAO_0000218,15286,,,1,CHEMBL631872,,,Rattus norvegicus,N,1,,
12228,In vitro percent permeability into rat ileum; Range is 23-42,Autocuration,,,A,,BAO_0000221,15286,,,1,CHEMBL875775,,,,U,0,2116.0,
12229,In vitro percent permeability into rat ileum; Range is 28-36,Intermediate,10116.0,,A,,BAO_0000218,15286,,,1,CHEMBL631873,,,Rattus norvegicus,N,1,,
12230,In vitro percent permeability into rat ileum; Range is 29-35,Intermediate,10116.0,,A,,BAO_0000218,15286,,,1,CHEMBL631874,,,Rattus norvegicus,N,1,,
12231,In vitro percent permeability into rat ileum; Range is 46-66,Intermediate,10116.0,,A,,BAO_0000218,15286,,,1,CHEMBL631875,,,Rattus norvegicus,N,1,,
12232,In vitro percent permeability into rat ileum; Range is 50-68,Intermediate,10116.0,,A,,BAO_0000218,15286,,,1,CHEMBL631876,,,Rattus norvegicus,N,1,,
12233,In vitro percent permeability into rat ileum; Range is 78-81,Intermediate,10116.0,,A,,BAO_0000218,15286,,,1,CHEMBL631877,,,Rattus norvegicus,N,1,,
12234,In vitro percent permeability into rat ileum; insol indicates not soluble in aqueous buffer,Intermediate,10116.0,,A,,BAO_0000218,15286,,,1,CHEMBL631878,,,Rattus norvegicus,N,1,,
12235,In vitro percent permeability into rat ileum; nd indicates not detected,Intermediate,10116.0,,A,,BAO_0000218,15286,,,1,CHEMBL631879,,,Rattus norvegicus,N,1,,
12236,In vitro percent permeability into rat ileum; nt indicates not detected,Intermediate,10116.0,,A,,BAO_0000218,15286,,,1,CHEMBL631880,,,Rattus norvegicus,N,1,,
12237,In vitro percent permeability into rat ileum; nt indicates not tested,Intermediate,10116.0,,A,,BAO_0000218,15286,,,1,CHEMBL631881,,,Rattus norvegicus,N,1,,
12238,Compound was tested for oral absorption in bile-duct cannulated rats,Intermediate,10116.0,,A,,BAO_0000218,13770,,,1,CHEMBL631882,,,Rattus norvegicus,N,1,,
12239,Compound was tested for oral absorption in bile-duct cannulated rats.,Intermediate,10116.0,,A,,BAO_0000218,13770,,,1,CHEMBL630749,,,Rattus norvegicus,N,1,,
12240,Oral absorption using Caco-2 cell monolayers.,Intermediate,9606.0,,A,,BAO_0000218,5202,,,1,CHEMBL630750,,,Homo sapiens,N,1,,
12241,Percent of the drug absorbed after administration to humans was determined,Intermediate,9606.0,,A,,BAO_0000218,14920,,,1,CHEMBL630253,,,Homo sapiens,N,1,,
12242,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 120 minutes.,Intermediate,10116.0,,A,,BAO_0000218,14103,,,1,CHEMBL630254,,,Rattus norvegicus,N,1,1969.0,
12243,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 15 minutes.,Intermediate,10116.0,,A,,BAO_0000218,14103,,,1,CHEMBL630255,,,Rattus norvegicus,N,1,1969.0,
12244,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 180 minutes.,Intermediate,10116.0,,A,,BAO_0000218,14103,,,1,CHEMBL630256,,,Rattus norvegicus,N,1,1969.0,
12245,"Biodistribution inl liver of mature female Dawley rat after 1h, expressed as percent injected dose/g",Intermediate,10116.0,,A,,BAO_0000218,13751,,,1,CHEMBL875781,,,Rattus norvegicus,N,1,2107.0,
12246,"Biodistribution inl liver of mature female Dawley rat after 30min, expressed as percent injected dose/g",Intermediate,10116.0,,A,,BAO_0000218,13751,,,1,CHEMBL630257,,,Rattus norvegicus,N,1,2107.0,
12247,"Biodistribution inl liver of mature female Dawley rat after 45min, expressed as percent injected dose/g",Intermediate,10116.0,,A,,BAO_0000218,13751,,,1,CHEMBL630258,,,Rattus norvegicus,N,1,2107.0,
12248,"Distribution of radioactivity in rat blood after 2 minutes of iv administration at the dose of 10.05-0.07 gram of tissue, expressed as percent injected dose per gram of tissue",Intermediate,10116.0,,A,,BAO_0000218,15807,,,1,CHEMBL630259,,,Rattus norvegicus,N,1,,
12249,"Distribution of radioactivity in rat striatum after 5 minutes of iv administration at the dose of 1.89-3.73 g of tissue, expressed as percent injected dose per gram of tissue",Intermediate,10116.0,,A,,BAO_0000218,15807,,,1,CHEMBL630260,,,Rattus norvegicus,N,1,2435.0,
12250,"Distribution of radioactivity in rat striatum after 5 minutes of iv administration at the dose of 3.44-4.80 g of tissue, expressed as percent injected dose per gram of tissue",Intermediate,10116.0,,A,,BAO_0000218,15807,,,1,CHEMBL630261,,,Rattus norvegicus,N,1,2435.0,
12251,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat and 5-alpha-DHT was reported,Intermediate,10116.0,,A,,BAO_0000218,14950,,,1,CHEMBL630262,,,Rattus norvegicus,N,1,,
12252,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat blood at 1 hour time,Intermediate,10116.0,,A,,BAO_0000218,14950,,,1,CHEMBL630263,,,Rattus norvegicus,N,1,,
12253,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat blood at 2 hours time,Intermediate,10116.0,,A,,BAO_0000218,14950,,,1,CHEMBL630264,,,Rattus norvegicus,N,1,,
12254,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat fat at 0.5 hours time,Intermediate,10116.0,,A,,BAO_0000218,14950,,,1,CHEMBL630265,,,Rattus norvegicus,N,1,,
12255,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat fat at 4 hours time,Intermediate,10116.0,,A,,BAO_0000218,14950,,,1,CHEMBL630266,,,Rattus norvegicus,N,1,,
12256,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat kidney at 0.5 hours time,Intermediate,10116.0,,A,,BAO_0000218,14950,,,1,CHEMBL630267,,,Rattus norvegicus,N,1,2113.0,
12257,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat kidney at 4 hours time,Intermediate,10116.0,,A,,BAO_0000218,14950,,,1,CHEMBL630268,,,Rattus norvegicus,N,1,2113.0,
12258,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat liver at 1 hour time,Intermediate,10116.0,,A,,BAO_0000218,14950,,,1,CHEMBL630269,,,Rattus norvegicus,N,1,,
12259,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat liver at 2 hours time,Intermediate,10116.0,,A,,BAO_0000218,14950,,,1,CHEMBL630270,,,Rattus norvegicus,N,1,,
12260,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat lung at 1 hour time,Intermediate,10116.0,,A,,BAO_0000218,14950,,,1,CHEMBL630141,,,Rattus norvegicus,N,1,2048.0,
12261,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat lung at 2 hours time,Intermediate,10116.0,,A,,BAO_0000218,14950,,,1,CHEMBL630142,,,Rattus norvegicus,N,1,2048.0,
12262,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat muscle at 0.5 hours time,Intermediate,10116.0,,A,,BAO_0000218,14950,,,1,CHEMBL630143,,,Rattus norvegicus,N,1,2385.0,
12263,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat muscle at 4 hours time,Intermediate,10116.0,,A,,BAO_0000218,14950,,,1,CHEMBL630144,,,Rattus norvegicus,N,1,2385.0,
12264,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate at 0.5 hours time,Intermediate,10116.0,,A,,BAO_0000218,14950,,,1,CHEMBL630145,,,Rattus norvegicus,N,1,2367.0,
12265,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate at 4 hours time,Intermediate,10116.0,,A,,BAO_0000218,14950,,,1,CHEMBL630146,,,Rattus norvegicus,N,1,2367.0,
12266,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate/blood,Intermediate,10116.0,,A,,BAO_0000218,14950,,,1,CHEMBL630147,,,Rattus norvegicus,N,1,,
12267,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate/blood at 1 hours time,Intermediate,10116.0,,A,,BAO_0000218,14950,,,1,CHEMBL630148,,,Rattus norvegicus,N,1,,
12268,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate/blood at 2 hours time,Intermediate,10116.0,,A,,BAO_0000218,14950,,,1,CHEMBL630149,,,Rattus norvegicus,N,1,,
12269,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat spleen at 1 hour time,Intermediate,10116.0,,A,,BAO_0000218,14950,,,1,CHEMBL630150,,,Rattus norvegicus,N,1,2106.0,
12270,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat spleen at 2 hours time,Intermediate,10116.0,,A,,BAO_0000218,14950,,,1,CHEMBL630151,,,Rattus norvegicus,N,1,2106.0,
12271,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat thyroid at 0.5 hours time,Intermediate,10116.0,,A,,BAO_0000218,14950,,,1,CHEMBL632031,,,Rattus norvegicus,N,1,2046.0,
12272,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat thyroid at 4 hours time,Intermediate,10116.0,,A,,BAO_0000218,14950,,,1,CHEMBL632032,,,Rattus norvegicus,N,1,2046.0,
12273,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat fat at 1 hour time,Intermediate,10116.0,,A,,BAO_0000218,14950,,,1,CHEMBL632033,,,Rattus norvegicus,N,1,,
12274,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat kidney at 1 hour time,Intermediate,10116.0,,A,,BAO_0000218,14950,,,1,CHEMBL632034,,,Rattus norvegicus,N,1,,
12275,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat muscle at 1 hour time,Intermediate,10116.0,,A,,BAO_0000218,14950,,,1,CHEMBL632035,,,Rattus norvegicus,N,1,2385.0,
12276,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat prostrateat 1 hour time,Intermediate,10116.0,,A,,BAO_0000218,14950,,,1,CHEMBL632036,,,Rattus norvegicus,N,1,,
12277,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat thyroid at 1 hour time,Intermediate,10116.0,,A,,BAO_0000218,14950,,,1,CHEMBL632037,,,Rattus norvegicus,N,1,2046.0,
12278,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 10 minutes,Intermediate,10116.0,,A,,BAO_0000218,8631,,,1,CHEMBL632038,,,Rattus norvegicus,N,1,178.0,
12279,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 15 minutes,Intermediate,10116.0,,A,,BAO_0000218,8631,,,1,CHEMBL632039,,,Rattus norvegicus,N,1,178.0,
12280,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 20 minutes,Intermediate,10116.0,,A,,BAO_0000218,8631,,,1,CHEMBL632040,,,Rattus norvegicus,N,1,178.0,
12281,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 30 minutes,Intermediate,10116.0,,A,,BAO_0000218,8631,,,1,CHEMBL632041,,,Rattus norvegicus,N,1,178.0,
12282,"Concentration of compound in blood of dog 2, after administering intravenously",Intermediate,9615.0,,A,,BAO_0000218,9614,,,1,CHEMBL632042,,,Canis lupus familiaris,N,1,178.0,
12283,"Concentration of compound in left ventricle of dog 1, after administering intravenously",Intermediate,9615.0,,A,,BAO_0000218,9614,,,1,CHEMBL632043,,,Canis lupus familiaris,N,1,,
12284,"Concentration of compound in left ventricle of dog 2, after administering intravenously",Intermediate,9615.0,,A,,BAO_0000218,9614,,,1,CHEMBL632044,,,Canis lupus familiaris,N,1,,
12285,"Concentration of compound in liver of dog 1, after administering intravenously",Intermediate,9615.0,,A,,BAO_0000218,9614,,,1,CHEMBL632045,,,Canis lupus familiaris,N,1,2107.0,
12286,"Concentration of compound in liver of dog 2, after administering intravenously",Intermediate,9615.0,,A,,BAO_0000218,9614,,,1,CHEMBL632046,,,Canis lupus familiaris,N,1,2107.0,
12287,"Concentration of compound in lung of dog 1, after administering intravenously",Intermediate,9615.0,,A,,BAO_0000218,9614,,,1,CHEMBL632047,,,Canis lupus familiaris,N,1,2048.0,
12288,"Concentration of compound in lung of dog 2, after administering intravenously",Intermediate,9615.0,,A,,BAO_0000218,9614,,,1,CHEMBL632048,,,Canis lupus familiaris,N,1,2048.0,
12289,"Concentration of compound in muscle of dog 1, after administering intravenously",Intermediate,9615.0,,A,,BAO_0000218,9614,,,1,CHEMBL632049,,,Canis lupus familiaris,N,1,2385.0,
12290,"Concentration of compound in muscle of dog 2, after administering intravenously",Intermediate,9615.0,,A,,BAO_0000218,9614,,,1,CHEMBL876418,,,Canis lupus familiaris,N,1,2385.0,
12291,"Concentration of compound in spleen of dog 1,after administering intravenously",Intermediate,9615.0,,A,,BAO_0000218,9614,,,1,CHEMBL632050,,,Canis lupus familiaris,N,1,2106.0,
12292,"Concentration of compound in spleen of dog 2, after administering intravenously",Intermediate,9615.0,,A,,BAO_0000218,9614,,,1,CHEMBL632051,,,Canis lupus familiaris,N,1,2106.0,
12293,Concentration of liberated compound in serum after 120 min at the dose of 50 mg/kg (po).,Autocuration,,,F,,BAO_0000218,10353,,,1,CHEMBL632052,,,,U,0,,
12294,Concentration of liberated compound in serum after 240 min at the dose of 50 mg/kg (po).,Autocuration,,,F,,BAO_0000218,10353,,,1,CHEMBL632053,,,,U,0,,
12295,Concentration of liberated compound in serum after 30 min at the dose of 50 mg/kg (po).,Autocuration,,,A,,BAO_0000218,10353,,,1,CHEMBL632054,,,,U,0,,
12296,Concentration of liberated compound in serum after 30 min at the dose of 50 mg/kg (po).,Autocuration,,,F,,BAO_0000218,10353,,,1,CHEMBL632055,,,,U,0,,
12297,Concentration of liberated compound in serum after 60 min at the dose of 50 mg/kg (po).,Autocuration,,,F,,BAO_0000218,10353,,,1,CHEMBL631181,,,,U,0,,
12298,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous after 1.5 hr,Autocuration,,,A,,BAO_0000218,9196,,,1,CHEMBL631182,,,,U,0,,
12299,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.5 hr,Autocuration,,,A,,BAO_0000218,9196,,,1,CHEMBL631183,,,,U,0,,
12300,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 4.0 hr,Autocuration,,,A,,BAO_0000218,9196,,,1,CHEMBL631184,,,,U,0,,
12301,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 0.5 hr,Autocuration,,,A,,BAO_0000218,9196,,,1,CHEMBL629774,,,,U,0,,
12302,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr,Autocuration,,,A,,BAO_0000218,9196,,,1,CHEMBL629775,,,,U,0,,
12303,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.0 hr,Autocuration,,,A,,BAO_0000218,9196,,,1,CHEMBL876549,,,,U,0,,
12304,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.0 hr,Autocuration,,,A,,BAO_0000218,9196,,,1,CHEMBL628172,,,,U,0,,
12305,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.5 hr,Autocuration,,,A,,BAO_0000218,9196,,,1,CHEMBL628173,,,,U,0,,
12306,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous after 1.5 hr,Autocuration,,,A,,BAO_0000218,9196,,,1,CHEMBL628174,,,,U,0,,
12307,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage a after 4.0 hr,Autocuration,,,A,,BAO_0000218,9196,,,1,CHEMBL628175,,,,U,0,,
12308,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 0.5 hr,Autocuration,,,A,,BAO_0000218,9196,,,1,CHEMBL628176,,,,U,0,,
12309,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.0 hr,Autocuration,,,A,,BAO_0000218,9196,,,1,CHEMBL628177,,,,U,0,,
12310,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.0 hr,Autocuration,,,A,,BAO_0000218,9196,,,1,CHEMBL628178,,,,U,0,,
12311,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.5 hr,Autocuration,,,A,,BAO_0000218,9196,,,1,CHEMBL628179,,,,U,0,,
12312,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg i intravenous dosage after 1.0 hr; insufficient gastric juice produced,Autocuration,,,A,,BAO_0000218,9196,,,1,CHEMBL628180,,,,U,0,,
12313,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage a after 2.5 hr,Autocuration,,,A,,BAO_0000218,9196,,,1,CHEMBL628181,,,,U,0,,
12314,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 0.5 hr,Autocuration,,,A,,BAO_0000218,9196,,,1,CHEMBL628182,,,,U,0,,
12315,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr,Autocuration,,,A,,BAO_0000218,9196,,,1,CHEMBL628183,,,,U,0,,
12316,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr; ND means not determined,Autocuration,,,A,,BAO_0000218,9196,,,1,CHEMBL628184,,,,U,0,,
12317,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.0 hr,Autocuration,,,A,,BAO_0000218,9196,,,1,CHEMBL628185,,,,U,0,,
12318,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.0 hr,Autocuration,,,A,,BAO_0000218,9196,,,1,CHEMBL875617,,,,U,0,,
12319,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.5 hr; ND means not determined,Autocuration,,,A,,BAO_0000218,9196,,,1,CHEMBL628186,,,,U,0,,
12320,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 4.0 hr,Autocuration,,,A,,BAO_0000218,9196,,,1,CHEMBL628187,,,,U,0,,
12321,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 0.5 hr,Autocuration,,,A,,BAO_0000218,9196,,,1,CHEMBL628188,,,,U,0,,
12322,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.0 hr,Autocuration,,,A,,BAO_0000218,9196,,,1,CHEMBL628189,,,,U,0,,
12323,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.5 hr; ND means not determined,Autocuration,,,A,,BAO_0000218,9196,,,1,CHEMBL628190,,,,U,0,,
12324,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.0 hr,Autocuration,,,A,,BAO_0000218,9196,,,1,CHEMBL628191,,,,U,0,,
12325,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.5 hr; ND means not determined,Autocuration,,,A,,BAO_0000218,9196,,,1,CHEMBL626513,,,,U,0,,
12326,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 19-24",Intermediate,10116.0,,A,,BAO_0000218,8608,,,1,CHEMBL626514,,,Rattus norvegicus,N,1,2046.0,
12327,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 26-40",Intermediate,10116.0,,A,,BAO_0000218,8608,,,1,CHEMBL626515,,,Rattus norvegicus,N,1,2046.0,
12328,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 29-44",Intermediate,10116.0,,A,,BAO_0000218,8608,,,1,CHEMBL626516,,,Rattus norvegicus,N,1,2046.0,
12329,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 32-42",Intermediate,10116.0,,A,,BAO_0000218,8608,,,1,CHEMBL626517,,,Rattus norvegicus,N,1,2046.0,
12330,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 33-60",Intermediate,10116.0,,A,,BAO_0000218,8608,,,1,CHEMBL626518,,,Rattus norvegicus,N,1,2046.0,
12331,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 4-7",Intermediate,10116.0,,A,,BAO_0000218,8608,,,1,CHEMBL626519,,,Rattus norvegicus,N,1,2046.0,
12332,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 13-18",Intermediate,10116.0,,A,,BAO_0000218,8608,,,1,CHEMBL626520,,,Rattus norvegicus,N,1,2046.0,
12333,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 16-32",Intermediate,10116.0,,A,,BAO_0000218,8608,,,1,CHEMBL626521,,,Rattus norvegicus,N,1,2046.0,
12334,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 22-25",Intermediate,10116.0,,A,,BAO_0000218,8608,,,1,CHEMBL626522,,,Rattus norvegicus,N,1,2046.0,
12335,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 26-49",Intermediate,10116.0,,A,,BAO_0000218,8608,,,1,CHEMBL626523,,,Rattus norvegicus,N,1,2046.0,
12336,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 29-36",Intermediate,10116.0,,A,,BAO_0000218,8608,,,1,CHEMBL626524,,,Rattus norvegicus,N,1,2046.0,
12337,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 5-8",Intermediate,10116.0,,A,,BAO_0000218,8608,,,1,CHEMBL626688,,,Rattus norvegicus,N,1,2046.0,
12338,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 26-42",Intermediate,10116.0,,A,,BAO_0000218,8608,,,1,CHEMBL626689,,,Rattus norvegicus,N,1,2046.0,
12339,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 30-53",Intermediate,10116.0,,A,,BAO_0000218,8608,,,1,CHEMBL626690,,,Rattus norvegicus,N,1,2046.0,
12340,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 32-43",Intermediate,10116.0,,A,,BAO_0000218,8608,,,1,CHEMBL626691,,,Rattus norvegicus,N,1,2046.0,
12341,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 35-53",Intermediate,10116.0,,A,,BAO_0000218,8608,,,1,CHEMBL627319,,,Rattus norvegicus,N,1,2046.0,
12342,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 5-12",Intermediate,10116.0,,A,,BAO_0000218,8608,,,1,CHEMBL624052,,,Rattus norvegicus,N,1,2046.0,
12343,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 55-102",Intermediate,10116.0,,A,,BAO_0000218,8608,,,1,CHEMBL624053,,,Rattus norvegicus,N,1,2046.0,
12344,In vivo distribution of the drug in plasma was determined at 1 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,Intermediate,10116.0,,A,,BAO_0000218,8085,,,1,CHEMBL624054,,,Rattus norvegicus,N,1,,
12345,In vivo distribution of the drug in plasma was determined at 2 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,Intermediate,10116.0,,A,,BAO_0000218,8085,,,1,CHEMBL624055,,,Rattus norvegicus,N,1,,
12346,In vivo distribution of the drug in plasma was determined at 3h following injection of five microcurics of the radiolabeled [125 I] compound in rats,Intermediate,10116.0,,A,,BAO_0000218,8085,,,1,CHEMBL624056,,,Rattus norvegicus,N,1,,
12347,In vivo distribution of the drug in uterus was determined at 1 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,Intermediate,10116.0,,A,,BAO_0000218,8085,,,1,CHEMBL624057,,,Rattus norvegicus,N,1,995.0,
12348,In vivo distribution of the drug in uterus was determined at 2 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,Intermediate,10116.0,,A,,BAO_0000218,8085,,,1,CHEMBL622281,,,Rattus norvegicus,N,1,995.0,
12349,In vivo distribution of the drug in uterus was determined at 3h following injection of five microcurics of the radiolabeled [125 I] compound in rats,Intermediate,10116.0,,A,,BAO_0000218,8085,,,1,CHEMBL622282,,,Rattus norvegicus,N,1,995.0,
12350,In vivo distribution of the drug in uterus/plasma was determined at 1 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,Intermediate,10116.0,,A,,BAO_0000218,8085,,,1,CHEMBL622283,,,Rattus norvegicus,N,1,995.0,
12351,In vivo distribution of the drug in uterus/plasma was determined at 2 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,Intermediate,10116.0,,A,,BAO_0000218,8085,,,1,CHEMBL622284,,,Rattus norvegicus,N,1,995.0,
12352,In vivo distribution of the drug in uterus/plasma was determined at 3h following injection of five microcurics of the radiolabeled [125 I] compound in rats,Intermediate,10116.0,,A,,BAO_0000218,8085,,,1,CHEMBL622285,,,Rattus norvegicus,N,1,995.0,
12353,In vivo distribution of the drug in uterus/plasma was determined at 3h following injection of five microcurics of the radiolabeled [125 I] compound in rats,Intermediate,10116.0,,A,,BAO_0000218,8085,,,1,CHEMBL622286,,,Rattus norvegicus,N,1,995.0,
12354,Distribution coefficient (D %) between octanol and buffer of pH 7.4,Autocuration,,,P,,BAO_0000100,7657,,,1,CHEMBL622287,,,,U,0,,
12355,Partition coefficient (logD7.4),Intermediate,10090.0,,A,,BAO_0000218,8935,,,1,CHEMBL622288,,,Mus musculus,N,1,,
12356,"Percentage of radioactivity in P1 subregion in mouse brain that contains nuclei and cell debris, after Jugular Vein Injection",Intermediate,10090.0,,A,,BAO_0000218,13792,,,1,CHEMBL622289,,,Mus musculus,N,1,,
12357,"Percentage of radioactivity in P2 subregion in mouse brain that contains myelin fragments, synaptosomes (pinched-nerve endings), and mitochondria after Jugular Vein Injection",Intermediate,10090.0,,A,,BAO_0000218,13792,,,1,CHEMBL622290,,,Mus musculus,N,1,955.0,
12358,Percentage of radioactivity in P3 subregion in mouse brain that contains microsomal fraction after Jugular Vein Injection,Intermediate,10090.0,,A,,BAO_0000218,13792,,,1,CHEMBL622291,,,Mus musculus,N,1,,
12359,Percentage of radioactivity in S3 which is the soluble fraction in mouse brain after Jugular Vein Injection,Intermediate,10090.0,,A,,BAO_0000218,13792,,,1,CHEMBL622292,,,Mus musculus,N,1,955.0,
12360,"Percentage of total protein recovered in P1 subregion in mouse brain that contains nuclei and cell debris, after Jugular Vein Injection",Intermediate,10090.0,,A,,BAO_0000218,13792,,,1,CHEMBL622293,,,Mus musculus,N,1,,
12361,"Percentage of total protein recovered in P2 subregion in mouse brain that contains myelin fragments, synaptosomes (pinched-nerve endings), and mitochondria after Jugular Vein Injection",Intermediate,10090.0,,A,,BAO_0000218,13792,,,1,CHEMBL622294,,,Mus musculus,N,1,955.0,
12362,Percentage of total protein recovered in P3 subregion in mouse brain that contains microsomal fraction after Jugular Vein Injection,Intermediate,10090.0,,A,,BAO_0000218,13792,,,1,CHEMBL622295,,,Mus musculus,N,1,,
12363,Percentage of total protein recovered in S3 which is the soluble fraction in mouse brain after Jugular Vein Injection,Intermediate,10116.0,,A,,BAO_0000218,13792,,,1,CHEMBL622296,,,Rattus norvegicus,N,1,955.0,
12364,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 2 minutes.,Intermediate,10116.0,,A,,BAO_0000218,14103,,,1,CHEMBL874409,,,Rattus norvegicus,N,1,1969.0,
12365,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 240 minutes.,Intermediate,10116.0,,A,,BAO_0000218,14103,,,1,CHEMBL622297,,,Rattus norvegicus,N,1,1969.0,
12366,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 30 minutes.,Intermediate,10116.0,,A,,BAO_0000218,14103,,,1,CHEMBL622298,,,Rattus norvegicus,N,1,1969.0,
12367,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 45 minutes.,Intermediate,10116.0,,A,,BAO_0000218,14103,,,1,CHEMBL622299,,,Rattus norvegicus,N,1,1969.0,
12368,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 5 minutes.,Intermediate,10116.0,,A,,BAO_0000218,14103,,,1,CHEMBL622300,,,Rattus norvegicus,N,1,1969.0,
12369,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 60 minutes.,Intermediate,10116.0,,A,,BAO_0000218,14103,,,1,CHEMBL622301,,,Rattus norvegicus,N,1,1969.0,
12370,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 90 minutes.,Intermediate,10116.0,,A,,BAO_0000218,14103,,,1,CHEMBL622302,,,Rattus norvegicus,N,1,1969.0,
12371,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 120 minutes.,Intermediate,10116.0,,A,,BAO_0000218,14103,,,1,CHEMBL622303,,,Rattus norvegicus,N,1,1969.0,
12372,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 15 minutes.,Intermediate,10116.0,,A,,BAO_0000218,14103,,,1,CHEMBL622304,,,Rattus norvegicus,N,1,1969.0,
12373,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 15 minutes;nd=not determined,Intermediate,10116.0,,A,,BAO_0000218,14103,,,1,CHEMBL622305,,,Rattus norvegicus,N,1,1969.0,
12374,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 180 minutes.,Intermediate,10116.0,,A,,BAO_0000218,14103,,,1,CHEMBL622306,,,Rattus norvegicus,N,1,1969.0,
12375,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 2 minutes;nd=not determined,Intermediate,10116.0,,A,,BAO_0000218,14103,,,1,CHEMBL626864,,,Rattus norvegicus,N,1,1969.0,
12376,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 240 minutes.,Intermediate,10116.0,,A,,BAO_0000218,14103,,,1,CHEMBL626865,,,Rattus norvegicus,N,1,1969.0,
12377,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 240 minutes;nd=not determined,Intermediate,10116.0,,A,,BAO_0000218,14103,,,1,CHEMBL626866,,,Rattus norvegicus,N,1,1969.0,
12378,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 30 minutes.,Intermediate,10116.0,,A,,BAO_0000218,14103,,,1,CHEMBL626867,,,Rattus norvegicus,N,1,1969.0,
12379,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 45 minutes.,Intermediate,10116.0,,A,,BAO_0000218,14103,,,1,CHEMBL626868,,,Rattus norvegicus,N,1,1969.0,
12380,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 45 minutes;nd=not determined,Intermediate,10116.0,,A,,BAO_0000218,14103,,,1,CHEMBL626869,,,Rattus norvegicus,N,1,1969.0,
12381,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 5 minutes.,Intermediate,10116.0,,A,,BAO_0000218,14103,,,1,CHEMBL626870,,,Rattus norvegicus,N,1,1969.0,
12382,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 5 minutes;nd=not determined,Intermediate,10116.0,,A,,BAO_0000218,14103,,,1,CHEMBL626871,,,Rattus norvegicus,N,1,1969.0,
12383,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 60 minutes.,Intermediate,10116.0,,A,,BAO_0000218,14103,,,1,CHEMBL626872,,,Rattus norvegicus,N,1,1969.0,
12384,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 90 minutes.,Intermediate,10116.0,,A,,BAO_0000218,14103,,,1,CHEMBL632185,,,Rattus norvegicus,N,1,1969.0,
12385,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 90 minutes;nd=not determined,Intermediate,10116.0,,A,,BAO_0000218,14103,,,1,CHEMBL632186,,,Rattus norvegicus,N,1,1969.0,
12386,Amount of acetic acid produced by the compound,Autocuration,,,A,,BAO_0000019,12904,,,1,CHEMBL629310,,,,U,0,,
12387,Apparent first-order rate of solvolysis for the bipinnatin-A(A4) was determined,Autocuration,,,A,,BAO_0000019,12904,,,1,CHEMBL629311,,,,U,0,,
12388,Log of (Cbrain/Cblood) in rats,Intermediate,10116.0,,A,,BAO_0000218,9663,,,1,CHEMBL629312,,,Rattus norvegicus,N,1,,
12389,Compound in absence of MPM cell homogenate at pH 3 to isolate compound 4 (ng),Autocuration,,,A,,BAO_0000221,7652,,,1,CHEMBL629313,,,,U,0,,
12390,Compound in absence of MPM cell homogenate at pH 4.5 to isolate compound 4 (ng),Autocuration,,,A,,BAO_0000221,7652,,,1,CHEMBL629314,,,,U,0,,
12391,Compound in absence of MPM cell homogenate at pH 7 to isolate compound 4 (ng),Autocuration,,,A,,BAO_0000221,7652,,,1,CHEMBL629315,,,,U,0,,
12392,Compound in presence of MPM cells and in absence of inactivator at pH 8 to isolate compound 4 (ng),Autocuration,,,B,,BAO_0000219,7652,,,1,CHEMBL629316,,,,U,0,,
12393,Compound treated in absence of MPM cell homogenate at pH 4.5 to isolate compound 4 (ng),Autocuration,,,A,,BAO_0000221,7652,,,1,CHEMBL629317,,,,U,0,,
12394,Compound treated with MPM cell homogenate at pH 3 to isolate compound 4 (ng),Autocuration,,,A,,BAO_0000019,7652,,,1,CHEMBL629318,,,,U,0,,
12395,Compound treated with MPM cell homogenate at pH 3.5 to isolate compound 4 (ng),Autocuration,,,A,,BAO_0000019,7652,,,1,CHEMBL877497,,,,U,0,,
12396,Compound treated with MPM cell homogenate at pH 4 to isolate compound 4 (ng),Autocuration,,,A,,BAO_0000019,7652,,,1,CHEMBL629319,,,,U,0,,
12397,Compound treated with MPM cell homogenate at pH 4.5 to isolate compound 4 (ng),Autocuration,,,A,,BAO_0000019,7652,,,1,CHEMBL629320,,,,U,0,,
12398,Compound treated with MPM cell homogenate at pH 5 to isolate compound 4 (ng),Autocuration,,,A,,BAO_0000019,7652,,,1,CHEMBL629496,,,,U,0,,
12399,Compound treated with MPM cell homogenate at pH 5.5 to isolate compound 4 (ng),Autocuration,,,A,,BAO_0000019,7652,,,1,CHEMBL629497,,,,U,0,,
12400,Compound treated with MPM cell homogenate at pH 6 to isolate compound 4 (ng),Autocuration,,,A,,BAO_0000019,7652,,,1,CHEMBL629498,,,,U,0,,
12401,Compound treated with MPM cell homogenate at pH 6.5 to isolate compound 4 (ng),Autocuration,,,A,,BAO_0000019,7652,,,1,CHEMBL629499,,,,U,0,,
12402,Compound treated with MPM cell homogenate at pH 7 to isolate compound 4 (ng),Autocuration,,,A,,BAO_0000019,7652,,,1,CHEMBL629500,,,,U,0,,
12403,Compound treated with MPM cell homogenate at pH 7.5 to isolate compound 4 (ng),Autocuration,,,A,,BAO_0000019,7652,,,1,CHEMBL629501,,,,U,0,,
12404,Compound treated with MPM cell homogenate at pH 8 to isolate compound 4 (ng),Autocuration,,,A,,BAO_0000019,7652,,,1,CHEMBL629502,,,,U,0,,
12405,Compound was evaluated for its urinary recovery after oral administration (100 mg) to Beagle dogs,Autocuration,,,F,,BAO_0000218,8267,,,1,CHEMBL629503,,,,U,0,,
12406,Compound was evaluated for its urinary recovery after oral administration (200 mg) to Beagle dogs,Intermediate,9615.0,,A,,BAO_0000218,8267,,,1,CHEMBL629504,,,Canis lupus familiaris,N,1,,
12407,Compound was evaluated for the rate of degradation by Carboxypeptidase A.,Autocuration,,,A,,BAO_0000019,14479,,,1,CHEMBL629505,,,,U,0,,
12408,Compound was evaluated for total body clearance,Autocuration,,,A,,BAO_0000019,17515,,,1,CHEMBL629506,,,,U,0,,
12409,Compound was evaluated for volume of distribution at steady state,Autocuration,,,A,,BAO_0000019,17515,,,1,CHEMBL629507,,,,U,0,,
12410,Compound was tested for hydrolysis by acetylcholinesterase and the kinetic constant KOH- was reported.,Autocuration,,,A,,BAO_0000019,8142,,,1,CHEMBL877498,,,,U,0,,
12411,Percentage of the diamine which is monoprotonated at pH 7.4,Autocuration,,,A,,BAO_0000019,14849,,,1,CHEMBL629508,,,,U,0,,
12412,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells,Autocuration,,,A,,BAO_0000019,7653,,,1,CHEMBL629509,,,,U,0,,
12413,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 5 minutes,Intermediate,10116.0,,A,,BAO_0000218,8631,,,1,CHEMBL629510,,,Rattus norvegicus,N,1,178.0,
12414,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 10 minutes,Intermediate,10116.0,,A,,BAO_0000218,8631,,,1,CHEMBL629511,,,Rattus norvegicus,N,1,178.0,
12415,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 15 minutes,Intermediate,10116.0,,A,,BAO_0000218,8631,,,1,CHEMBL629512,,,Rattus norvegicus,N,1,178.0,
12416,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 20 minutes,Intermediate,10116.0,,A,,BAO_0000218,8631,,,1,CHEMBL629513,,,Rattus norvegicus,N,1,178.0,
12417,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 30 minutes,Intermediate,10116.0,,A,,BAO_0000218,8631,,,1,CHEMBL629514,,,Rattus norvegicus,N,1,178.0,
12418,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 5 minutes,Intermediate,10116.0,,A,,BAO_0000218,8631,,,1,CHEMBL628447,,,Rattus norvegicus,N,1,178.0,
12419,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 10 minutes,Intermediate,10116.0,,A,,BAO_0000218,8631,,,1,CHEMBL628448,,,Rattus norvegicus,N,1,178.0,
12420,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 15 minutes,Intermediate,10116.0,,A,,BAO_0000218,8631,,,1,CHEMBL628449,,,Rattus norvegicus,N,1,178.0,
12421,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 20 minutes,Intermediate,10116.0,,A,,BAO_0000218,8631,,,1,CHEMBL631119,,,Rattus norvegicus,N,1,178.0,
12422,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 30 minutes,Intermediate,10116.0,,A,,BAO_0000218,8631,,,1,CHEMBL631120,,,Rattus norvegicus,N,1,178.0,
12423,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 5 minutes,Intermediate,10116.0,,A,,BAO_0000218,8631,,,1,CHEMBL631121,,,Rattus norvegicus,N,1,178.0,
12424,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 10 min,Intermediate,10116.0,,A,,BAO_0000218,8631,,,1,CHEMBL874458,,,Rattus norvegicus,N,1,178.0,
12425,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 15 minutes,Intermediate,10116.0,,A,,BAO_0000218,8631,,,1,CHEMBL631122,,,Rattus norvegicus,N,1,178.0,
12426,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 20 minutes,Intermediate,10116.0,,A,,BAO_0000218,8631,,,1,CHEMBL631123,,,Rattus norvegicus,N,1,178.0,
12427,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 5 minutes,Intermediate,10116.0,,A,,BAO_0000218,8631,,,1,CHEMBL631124,,,Rattus norvegicus,N,1,178.0,
12428,Amount of compound present in blood of rat 3 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 10 minutes,Intermediate,10116.0,,A,,BAO_0000218,8631,,,1,CHEMBL631125,,,Rattus norvegicus,N,1,178.0,
12429,Amount of compound present in blood of rat 3 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 15 minutes,Intermediate,10116.0,,A,,BAO_0000218,8631,,,1,CHEMBL631290,,,Rattus norvegicus,N,1,178.0,
12430,Amount of compound present in blood of rat 3 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 20 minutes,Intermediate,10116.0,,A,,BAO_0000218,8631,,,1,CHEMBL631291,,,Rattus norvegicus,N,1,178.0,
12431,Amount of compound present in blood of rat 3 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 5 minutes,Intermediate,10116.0,,A,,BAO_0000218,8631,,,1,CHEMBL631292,,,Rattus norvegicus,N,1,178.0,
12432,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 10 minutes,Intermediate,10116.0,,A,,BAO_0000218,8631,,,1,CHEMBL631293,,,Rattus norvegicus,N,1,178.0,
12433,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 15 minutes,Intermediate,10116.0,,A,,BAO_0000218,8631,,,1,CHEMBL631294,,,Rattus norvegicus,N,1,178.0,
12434,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 20 minutes,Intermediate,10116.0,,A,,BAO_0000218,8631,,,1,CHEMBL631295,,,Rattus norvegicus,N,1,178.0,
12435,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 30 minutes,Intermediate,10116.0,,A,,BAO_0000218,8631,,,1,CHEMBL631296,,,Rattus norvegicus,N,1,178.0,
12436,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 5 minutes,Intermediate,10116.0,,A,,BAO_0000218,8631,,,1,CHEMBL631297,,,Rattus norvegicus,N,1,178.0,
12437,Maximum biodistribution (Bmax) was determined.,Autocuration,,,A,,BAO_0000218,10263,,,1,CHEMBL631298,,,,U,0,,
12438,Mean difference between rectal temperature measured at time zero and rectal temperature measured at 10 min at 1.5625 (mg/kg) intravenous dose in 6 mice,Intermediate,10090.0,,A,,BAO_0000218,12364,,,1,CHEMBL631299,,,Mus musculus,N,1,,
12439,Mean difference between rectal temperature measured at time zero and rectal temperature measured at 10 min at 10 (mg/kg) intravenous dose in 6 mice,Intermediate,10090.0,,A,,BAO_0000218,12364,,,1,CHEMBL631300,,,Mus musculus,N,1,,
12440,Mean difference between rectal temperature measured at time zero and rectal temperature measured at 10 min at 3.125 (mg/kg) intravenous dose in 6 mice,Intermediate,10090.0,,A,,BAO_0000218,12364,,,1,CHEMBL631301,,,Mus musculus,N,1,,
12441,Mean difference between rectal temperature measured at time zero and rectal temperature measured at 10 min at 6.25 (mg/kg) intravenous dose in 6 mice,Intermediate,10090.0,,A,,BAO_0000218,12364,,,1,CHEMBL630291,,,Mus musculus,N,1,,
12442,Brain concentration after 0.25 hr at a dose of 10 mg/kg when administered intraperitoneally,Autocuration,,,A,,BAO_0000218,14793,,,1,CHEMBL630292,,,,U,0,,
12443,Brain concentration after 0.25 h at a dose of 10 mg/kg when administered intravenously,Autocuration,,,A,,BAO_0000218,14793,,,1,CHEMBL630293,,,,U,0,,
12444,Brain concentration after 0.5 h at a dose of 100 mg/kg when administered perorally,Autocuration,,,A,,BAO_0000218,14793,,,1,CHEMBL630294,,,,U,0,,
12445,Brain concentration after 0.5 h at a dose of 10 mg/kg when administered intraperitoneally,Autocuration,,,A,,BAO_0000218,14793,,,1,CHEMBL630295,,,,U,0,,
12446,Brain concentration after 0.5 hr at a dose of 10 mg/kg when administered intravenously,Autocuration,,,A,,BAO_0000218,14793,,,1,CHEMBL630296,,,,U,0,,
12447,Brain concentration after 0.5 hr at a dose of 10 mg/kg when administered perorally,Autocuration,,,A,,BAO_0000218,14793,,,1,CHEMBL626782,,,,U,0,,
12448,Brain concentration after 1 hr at a dose of 100 mg/kg when administered perorally,Autocuration,,,A,,BAO_0000218,14793,,,1,CHEMBL626783,,,,U,0,,
12449,Brain concentration after 1 hr at a dose of 10 mg/kg when administered intraperitoneally,Autocuration,,,A,,BAO_0000218,14793,,,1,CHEMBL626784,,,,U,0,,
12450,Brain concentration after 1 hr at a dose of 10 mg/kg when administered intravenously,Autocuration,,,A,,BAO_0000218,14793,,,1,CHEMBL626785,,,,U,0,,
12451,Brain concentration after 1 hr at a dose of 10 mg/kg when administered perorally,Autocuration,,,A,,BAO_0000218,14793,,,1,CHEMBL626786,,,,U,0,,
12452,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.0 hr,Autocuration,,,A,,BAO_0000218,9196,,,1,CHEMBL626787,,,,U,0,,
12453,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.5 hr; ND means not determined,Autocuration,,,A,,BAO_0000218,9196,,,1,CHEMBL626788,,,,U,0,,
12454,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 4.0 hr,Autocuration,,,A,,BAO_0000218,9196,,,1,CHEMBL625927,,,,U,0,,
12455,Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,Intermediate,10116.0,,A,,BAO_0000218,8374,,,1,CHEMBL625928,,,Rattus norvegicus,N,1,178.0,
12456,Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg; ND is Not Detected,Intermediate,10116.0,,A,,BAO_0000218,8374,,,1,CHEMBL625929,,,Rattus norvegicus,N,1,178.0,
12457,Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg; ND is Not Detected.,Intermediate,10116.0,,A,,BAO_0000218,8374,,,1,CHEMBL625930,,,Rattus norvegicus,N,1,178.0,
12458,"Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound, Compound was found to be in trace amount.",Intermediate,10116.0,,A,,BAO_0000218,8374,,,1,CHEMBL625931,,,Rattus norvegicus,N,1,178.0,
12459,Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound; ND is Not Detected.,Intermediate,10116.0,,A,,BAO_0000218,8374,,,1,CHEMBL627230,,,Rattus norvegicus,N,1,178.0,
12460,Concentration 1 detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,Intermediate,10116.0,,A,,BAO_0000218,8374,,,1,CHEMBL627231,,,Rattus norvegicus,N,1,178.0,
12461,Concentration 1 detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected,Intermediate,10116.0,,A,,BAO_0000218,8374,,,1,CHEMBL627232,,,Rattus norvegicus,N,1,178.0,
12462,Concentration 1 detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected.,Intermediate,10116.0,,A,,BAO_0000218,8374,,,1,CHEMBL627233,,,Rattus norvegicus,N,1,178.0,
12463,Concentration 5a detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,Intermediate,10116.0,,A,,BAO_0000218,8374,,,1,CHEMBL875470,,,Rattus norvegicus,N,1,178.0,
12464,Concentration 5a detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,Intermediate,10116.0,,A,,BAO_0000218,8374,,,1,CHEMBL627234,,,Rattus norvegicus,N,1,178.0,
12465,Concentration 5b detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,Intermediate,10116.0,,A,,BAO_0000218,8374,,,1,CHEMBL627235,,,Rattus norvegicus,N,1,178.0,
12466,Concentration 5b detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,Intermediate,10116.0,,A,,BAO_0000218,8374,,,1,CHEMBL627236,,,Rattus norvegicus,N,1,178.0,
12467,Concentration 5c detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,Intermediate,10116.0,,A,,BAO_0000218,8374,,,1,CHEMBL627237,,,Rattus norvegicus,N,1,178.0,
12468,Concentration 5c detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,Intermediate,10116.0,,A,,BAO_0000218,8374,,,1,CHEMBL627238,,,Rattus norvegicus,N,1,178.0,
12469,Concentration 5d detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,Intermediate,10116.0,,A,,BAO_0000218,8374,,,1,CHEMBL627239,,,Rattus norvegicus,N,1,178.0,
12470,Concentration 5d detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,Intermediate,10116.0,,A,,BAO_0000218,8374,,,1,CHEMBL627240,,,Rattus norvegicus,N,1,178.0,
12471,Concentration 5e detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,Intermediate,10116.0,,A,,BAO_0000218,8374,,,1,CHEMBL627241,,,Rattus norvegicus,N,1,178.0,
12472,Concentration 5e detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,Intermediate,10116.0,,A,,BAO_0000218,8374,,,1,CHEMBL627242,,,Rattus norvegicus,N,1,178.0,
12473,Concentration 5f detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound; ND is Not Detected,Intermediate,10116.0,,A,,BAO_0000218,8374,,,1,CHEMBL627243,,,Rattus norvegicus,N,1,178.0,
12474,Concentration 5f detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected,Intermediate,10116.0,,A,,BAO_0000218,8374,,,1,CHEMBL627244,,,Rattus norvegicus,N,1,178.0,
12475,Concentration 6a detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,Intermediate,10116.0,,A,,BAO_0000218,8374,,,1,CHEMBL627245,,,Rattus norvegicus,N,1,178.0,
12476,Concentration 6a detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,Intermediate,10116.0,,A,,BAO_0000218,8374,,,1,CHEMBL627246,,,Rattus norvegicus,N,1,178.0,
12477,Concentration 6c detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,Intermediate,10116.0,,A,,BAO_0000218,8374,,,1,CHEMBL627247,,,Rattus norvegicus,N,1,178.0,
12478,Concentration 6c detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,Intermediate,10116.0,,A,,BAO_0000218,8374,,,1,CHEMBL627248,,,Rattus norvegicus,N,1,178.0,
12479,Concentration 6d detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,Intermediate,10116.0,,A,,BAO_0000218,8374,,,1,CHEMBL627249,,,Rattus norvegicus,N,1,178.0,
12480,Concentration 6d detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,Intermediate,10116.0,,A,,BAO_0000218,8374,,,1,CHEMBL625569,,,Rattus norvegicus,N,1,178.0,
12481,Concentration 6e detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,Intermediate,10116.0,,A,,BAO_0000218,8374,,,1,CHEMBL625570,,,Rattus norvegicus,N,1,178.0,
12482,Concentration 6e detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,Intermediate,10116.0,,A,,BAO_0000218,8374,,,1,CHEMBL625571,,,Rattus norvegicus,N,1,178.0,
12483,Concentration 6f detected in blood of rat 1 hr after an oral dose of 200 mg/kg; ND is Not Detected,Intermediate,10116.0,,A,,BAO_0000218,8374,,,1,CHEMBL625572,,,Rattus norvegicus,N,1,178.0,
12484,Concentration 6f detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected,Intermediate,10116.0,,A,,BAO_0000218,8374,,,1,CHEMBL625573,,,Rattus norvegicus,N,1,178.0,
12485,Concentration detected in blood of rat 1 hr after an oral dose of 200 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,8374,,,1,CHEMBL625574,,,Rattus norvegicus,N,1,178.0,
12486,Concentration detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected,Intermediate,10116.0,,A,,BAO_0000218,8374,,,1,CHEMBL626245,,,Rattus norvegicus,N,1,178.0,
12487,Concentration detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,Intermediate,10116.0,,A,,BAO_0000218,8374,,,1,CHEMBL626246,,,Rattus norvegicus,N,1,178.0,
12488,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 0.5 hr,Autocuration,,,A,,BAO_0000218,9196,,,1,CHEMBL626247,,,,U,0,,
12489,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr,Autocuration,,,A,,BAO_0000218,9196,,,1,CHEMBL626248,,,,U,0,,
12490,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.5 hr,Autocuration,,,A,,BAO_0000218,9196,,,1,CHEMBL626249,,,,U,0,,
12491,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.0 hr,Autocuration,,,A,,BAO_0000218,9196,,,1,CHEMBL626420,,,,U,0,,
12492,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.5 hr,Autocuration,,,A,,BAO_0000218,9196,,,1,CHEMBL626421,,,,U,0,,
12493,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.5 hr,Autocuration,,,A,,BAO_0000218,9196,,,1,CHEMBL626422,,,,U,0,,
12494,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 4.0 hr,Autocuration,,,A,,BAO_0000218,9196,,,1,CHEMBL626423,,,,U,0,,
12495,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.0 hr,Autocuration,,,A,,BAO_0000218,9196,,,1,CHEMBL626424,,,,U,0,,
12496,Volume of distribution in Beagles dog at a dose of 1 mg/kg given intravenously,Intermediate,9615.0,,A,,BAO_0000218,12023,,,1,CHEMBL626425,,,Canis lupus familiaris,N,1,,
12497,Volume of distribution in CD rat at a dose of 5 mg/kg given intravenously,Intermediate,10116.0,,A,,BAO_0000218,12023,,,1,CHEMBL875476,,,Rattus norvegicus,N,1,,
12498,Volume of distribution in Cynomolgus monkey at a dose of 5 mg/kg given intravenously,Intermediate,9541.0,,A,,BAO_0000218,12023,,,1,CHEMBL626426,,,Macaca fascicularis,N,1,,
12499,Distribution coefficient and iron(III) complex was measured at an aqueous phase buffered at pH 7.4 and octanol,Autocuration,,,P,,BAO_0000100,10580,,,1,CHEMBL626427,,,,U,0,,
12500,Distribution coefficient was measured at an aqueous phase buffered at pH 7.4 and octanol,Autocuration,,,P,,BAO_0000100,10580,,,1,CHEMBL626428,,,,U,0,,
12501,Iron clearance was stimulated by the compound was expressed as % distribution of excreted Fe in bile by subcutaneous dose of 150 umol/kg,Autocuration,,,A,,BAO_0000019,16032,,,1,CHEMBL626429,,,,U,0,,
12502,Iron clearance was stimulated by the compound was expressed as % distribution of excreted Fe in urine by subcutaneous dose of 150 umol/kg,Autocuration,,,A,,BAO_0000019,16032,,,1,CHEMBL625025,,,,U,0,1088.0,
12503,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,Intermediate,10116.0,,A,,BAO_0000218,8594,,,1,CHEMBL625026,,,Rattus norvegicus,N,1,178.0,
12504,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,Intermediate,10116.0,,A,,BAO_0000218,8594,,,1,CHEMBL625027,,,Rattus norvegicus,N,1,178.0,
12505,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,Intermediate,10116.0,,A,,BAO_0000218,8594,,,1,CHEMBL874410,,,Rattus norvegicus,N,1,178.0,
12506,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,Intermediate,10116.0,,A,,BAO_0000218,8594,,,1,CHEMBL625028,,,Rattus norvegicus,N,1,178.0,
12507,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,Intermediate,10116.0,,A,,BAO_0000218,8594,,,1,CHEMBL625029,,,Rattus norvegicus,N,1,178.0,
12508,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,Intermediate,10116.0,,A,,BAO_0000218,8594,,,1,CHEMBL625030,,,Rattus norvegicus,N,1,178.0,
12509,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,Intermediate,10116.0,,A,,BAO_0000218,8594,,,1,CHEMBL625031,,,Rattus norvegicus,N,1,178.0,
12510,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,Intermediate,10116.0,,A,,BAO_0000218,8594,,,1,CHEMBL625032,,,Rattus norvegicus,N,1,178.0,
12511,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,Intermediate,10116.0,,A,,BAO_0000218,8594,,,1,CHEMBL625033,,,Rattus norvegicus,N,1,178.0,
12512,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,Intermediate,10116.0,,A,,BAO_0000218,8594,,,1,CHEMBL625034,,,Rattus norvegicus,N,1,178.0,
12513,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,Intermediate,10116.0,,A,,BAO_0000218,8594,,,1,CHEMBL624872,,,Rattus norvegicus,N,1,948.0,
12514,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,Intermediate,10116.0,,A,,BAO_0000218,8594,,,1,CHEMBL624873,,,Rattus norvegicus,N,1,948.0,
12515,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,Intermediate,10116.0,,A,,BAO_0000218,8594,,,1,CHEMBL624874,,,Rattus norvegicus,N,1,948.0,
12516,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,Intermediate,10116.0,,A,,BAO_0000218,8594,,,1,CHEMBL624875,,,Rattus norvegicus,N,1,948.0,
12517,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,Intermediate,10116.0,,A,,BAO_0000218,8594,,,1,CHEMBL624876,,,Rattus norvegicus,N,1,948.0,
12518,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,Intermediate,10116.0,,A,,BAO_0000218,8594,,,1,CHEMBL624877,,,Rattus norvegicus,N,1,948.0,
12519,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,Intermediate,10116.0,,A,,BAO_0000218,8594,,,1,CHEMBL624878,,,Rattus norvegicus,N,1,948.0,
12520,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,Intermediate,10116.0,,A,,BAO_0000218,8594,,,1,CHEMBL624879,,,Rattus norvegicus,N,1,948.0,
12521,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,Intermediate,10116.0,,A,,BAO_0000218,8594,,,1,CHEMBL624880,,,Rattus norvegicus,N,1,948.0,
12522,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 10 min (radiolabeled with [125I]-,Intermediate,10116.0,,A,,BAO_0000218,8594,,,1,CHEMBL624881,,,Rattus norvegicus,N,1,948.0,
12523,"Concentration was measured in heart tissue of unfasted Fischer 344 rats, administered intravenous, after 5 minute (radiolabeled with [125I]-",Intermediate,10116.0,,A,,BAO_0000218,8594,,,1,CHEMBL624882,,,Rattus norvegicus,N,1,948.0,
12524,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,Intermediate,10116.0,,A,,BAO_0000218,8594,,,1,CHEMBL624883,,,Rattus norvegicus,N,1,2113.0,
12525,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,Intermediate,10116.0,,A,,BAO_0000218,8594,,,1,CHEMBL624884,,,Rattus norvegicus,N,1,2113.0,
12526,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,Intermediate,10116.0,,A,,BAO_0000218,8594,,,1,CHEMBL624885,,,Rattus norvegicus,N,1,2113.0,
12527,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,Intermediate,10116.0,,A,,BAO_0000218,8594,,,1,CHEMBL624886,,,Rattus norvegicus,N,1,2113.0,
12528,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,Intermediate,10116.0,,A,,BAO_0000218,8594,,,1,CHEMBL624887,,,Rattus norvegicus,N,1,2113.0,
12529,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,Intermediate,10116.0,,A,,BAO_0000218,8594,,,1,CHEMBL624888,,,Rattus norvegicus,N,1,2113.0,
12530,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,Intermediate,10116.0,,A,,BAO_0000218,8594,,,1,CHEMBL624889,,,Rattus norvegicus,N,1,2113.0,
12531,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,Intermediate,10116.0,,A,,BAO_0000218,8594,,,1,CHEMBL624890,,,Rattus norvegicus,N,1,2113.0,
12532,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,Intermediate,10116.0,,A,,BAO_0000218,8594,,,1,CHEMBL621964,,,Rattus norvegicus,N,1,2113.0,
12533,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,Intermediate,10116.0,,A,,BAO_0000218,8594,,,1,CHEMBL621965,,,Rattus norvegicus,N,1,2113.0,
12534,Concentration was measured in liver tissue f unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,Intermediate,10116.0,,A,,BAO_0000218,8594,,,1,CHEMBL621966,,,Rattus norvegicus,N,1,2107.0,
12535,Concentration was measured in liver tissue f unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,Intermediate,10116.0,,A,,BAO_0000218,8594,,,1,CHEMBL621967,,,Rattus norvegicus,N,1,2107.0,
12536,Concentration was measured in liver tissue f unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,Intermediate,10116.0,,A,,BAO_0000218,8594,,,1,CHEMBL622164,,,Rattus norvegicus,N,1,2107.0,
12537,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells; acid insoluble (nucleic acids),Autocuration,,,A,,BAO_0000019,7653,,,1,CHEMBL623097,,,,U,0,,
12538,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells; acid insoluble (protein),Autocuration,,,A,,BAO_0000019,7653,,,1,CHEMBL623098,,,,U,0,,
12539,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells; acid soluble,Autocuration,,,A,,BAO_0000019,7653,,,1,CHEMBL623099,,,,U,0,,
12540,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells; total uptake,Autocuration,,,A,,BAO_0000019,7653,,,1,CHEMBL623100,,,,U,0,,
12541,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated Number of new tumors observed",Intermediate,10116.0,,A,,BAO_0000218,9104,,,1,CHEMBL628673,,,Rattus norvegicus,N,1,,
12542,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated complete percent remission indicates tumor not palpable.",Intermediate,10116.0,,A,,BAO_0000218,9104,,,1,CHEMBL628674,,,Rattus norvegicus,N,1,,
12543,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated number of tumors at the beginning of the test.",Intermediate,10116.0,,A,,BAO_0000218,9104,,,1,CHEMBL628675,,,Rattus norvegicus,N,1,,
12544,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated of percent static tumors indicates size of tumor 51-150% of the initial size",Intermediate,10116.0,,A,,BAO_0000218,9104,,,1,CHEMBL627644,,,Rattus norvegicus,N,1,,
12545,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated partial percent remission indicates reduction of initial tumor size <=50%.",Intermediate,10116.0,,A,,BAO_0000218,9104,,,1,CHEMBL627645,,,Rattus norvegicus,N,1,,
12546,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated percent progress in tumor size indicates >150% of the initial size",Intermediate,10116.0,,A,,BAO_0000218,9104,,,1,CHEMBL627646,,,Rattus norvegicus,N,1,,
12547,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated percent static tumors indicates size of tumor 51-150% of the initial size",Intermediate,10116.0,,A,,BAO_0000218,9104,,,1,CHEMBL627647,,,Rattus norvegicus,N,1,,
12548,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated percent tumor area measured as the average on the 28th day of therapy.",Intermediate,10116.0,,A,,BAO_0000218,9104,,,1,CHEMBL627648,,,Rattus norvegicus,N,1,,
12549,Free level in rat plasma,Intermediate,10116.0,,A,,BAO_0000218,12902,,,1,CHEMBL627649,,,Rattus norvegicus,N,1,,
12550,Level reaching in blood plasma of rat or human was determined,Autocuration,,,A,,BAO_0000019,6614,,,1,CHEMBL628313,,,,U,0,,
12551,Log (Cbrain/Cblood) in rats,Intermediate,10116.0,,A,,BAO_0000218,9663,,,1,CHEMBL628314,,,Rattus norvegicus,N,1,,
12552,Mean percentage of compound transport through P-glycoprotein; expressed as p-glycoprotein affinity,Autocuration,,,A,,BAO_0000019,17658,,,1,CHEMBL628315,,,,U,0,,
12553,Mean percentage of compound transport through membrane; expressed as membrane transport,Autocuration,,,A,,BAO_0000019,17658,,,1,CHEMBL628316,,,,U,0,,
12554,Metabolic breakdown to the o-sulfate of p-chloroaniline (2-amino-5-chlorophenyl sulfate) by giving 100 mg/kg oral doses of the compound,Autocuration,,,A,,BAO_0000218,14314,,,1,CHEMBL628317,,,,U,0,,
12555,Michaelis-Menten constant was measured in the inactivation of HPK; Km x 10 e5,Autocuration,,,A,,BAO_0000019,7385,,,1,CHEMBL628473,,,,U,0,,
12556,"Michaelis-Menten constant was measured in the inactivation of HPK; Km x 10 e5, ND=Not determined",Autocuration,,,A,,BAO_0000019,7385,,,1,CHEMBL628474,,,,U,0,,
12557,Michaelis-Menten constant was measured in the inactivation of trypsin; Km x 10 e5,Autocuration,,,A,,BAO_0000019,7385,,,1,CHEMBL628475,,,,U,0,,
12558,Net water uptake by a carrier mediated transport (%cm) mechanism,Autocuration,,,A,,BAO_0000019,1329,,,1,CHEMBL628476,,,,U,0,,
12559,Peak concentration was determined in portal circulation after intraduodenal dose of 10 mg/kg in monkey,Autocuration,314293.0,,A,,BAO_0000218,12187,,,1,CHEMBL628477,,,Simiiformes,U,0,,
12560,Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in ferret,Intermediate,9669.0,,A,,BAO_0000218,12187,,,1,CHEMBL628478,,,Mustela putorius furo,N,1,,
12561,"Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in ferret, determined by renin inhibition assay",Intermediate,9669.0,,A,,BAO_0000218,12187,,,1,CHEMBL628479,,,Mustela putorius furo,N,1,,
12562,Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in monkey,Autocuration,314293.0,,A,,BAO_0000218,12187,,,1,CHEMBL628480,,,Simiiformes,U,0,,
12563,"Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in monkey, determined by renin inhibition assay",Autocuration,314293.0,,A,,BAO_0000218,12187,,,1,CHEMBL628481,,,Simiiformes,U,0,,
12564,Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in rat,Intermediate,10116.0,,A,,BAO_0000218,12187,,,1,CHEMBL628482,,,Rattus norvegicus,N,1,,
12565,"Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in rat, determined by renin inhibition assay",Intermediate,10116.0,,A,,BAO_0000218,12187,,,1,CHEMBL628483,,,Rattus norvegicus,N,1,,
12566,"Peak plasma concentration at a dose of 10 mg/kg, ip route in rat suspended in carboxymethyl cellulose (CMC);ND is defined as no-data.",Intermediate,10116.0,,A,,BAO_0000218,9278,,,1,CHEMBL628484,,,Rattus norvegicus,N,1,1969.0,
12567,"Peak plasma concentration at a dose of 100 mg/kg, os route in rat suspended in carboxymethyl cellulose (CMC)",Intermediate,10116.0,,A,,BAO_0000218,9278,,,1,CHEMBL628485,,,Rattus norvegicus,N,1,1969.0,
12568,"Peak plasma concentration at a dose of 20 mg/kg, oral route in monkey (Macaca fascicularis) suspended in carboxymethyl cellulose (CMC);Range is between (5.5-6)",Intermediate,9541.0,,A,,BAO_0000218,9278,,,1,CHEMBL628486,,,Macaca fascicularis,N,1,1969.0,
12569,"Peak plasma concentration at a dose of 200 mg/kg, oral route in human",Intermediate,9606.0,,A,,BAO_0000218,9278,,,1,CHEMBL628487,,,Homo sapiens,N,1,1969.0,
12570,"Peak plasma concentration at a dose of 25 mg/kg, ip route in rat suspended in carboxymethyl cellulose (CMC);ND is defined as no-data.",Intermediate,10116.0,,A,,BAO_0000218,9278,,,1,CHEMBL628488,,,Rattus norvegicus,N,1,1969.0,
12571,"Peak plasma concentration at a dose of 25 mg/kg, os route in rat suspended in carboxymethyl cellulose (CMC)",Intermediate,10116.0,,A,,BAO_0000218,9278,,,1,CHEMBL628489,,,Rattus norvegicus,N,1,1969.0,
12572,"Peak plasma concentration at a dose of 50 mg/kg, os route in rat suspended in carboxymethyl cellulose (CMC)",Intermediate,10116.0,,A,,BAO_0000218,9278,,,1,CHEMBL628490,,,Rattus norvegicus,N,1,1969.0,
12573,Peak plasma drug level after intraduodenal administration at a dose 10 mg/kg from portal circulation in salt-depleted cynomolgus monkeys using HPLC assay,Intermediate,9541.0,,A,,BAO_0000218,12186,,,1,CHEMBL628491,,,Macaca fascicularis,N,1,,
12574,Peak plasma drug level after intraduodenal administration at a dose 10 mg/kg from systemic circulation in salt-depleted cynomolgus monkeys using HPLC assay,Intermediate,9541.0,,A,,BAO_0000218,12186,,,1,CHEMBL877507,,,Macaca fascicularis,N,1,,
12575,Peak plasma drug level after intraduodenal administration at a dose 10 mg/kg from systemic circulation in salt-depleted cynomolgus monkeys using renin inhibition assay,Autocuration,,,A,,BAO_0000218,12186,,,1,CHEMBL628492,,,,U,0,,
12576,% metabolized in monkey S-9 after 2 hours (10 ug/mL),Autocuration,314293.0,,A,,BAO_0000019,12041,,,1,CHEMBL628493,,,Simiiformes,U,0,,
12577,% metabolized in monkey S-9 after 2 hours (1 ug/ml),Autocuration,314293.0,,A,,BAO_0000019,12041,,,1,CHEMBL628494,,,Simiiformes,U,0,,
12578,% metabolized in monkey S-9 after 2 hours (10 ug/ml),Autocuration,314293.0,,A,,BAO_0000019,12041,,,1,CHEMBL628495,,,Simiiformes,U,0,,
12579,Permeability in Caco-2 assay at 10E-6,Intermediate,9606.0,,A,,BAO_0000218,6737,,,1,CHEMBL628496,,,Homo sapiens,N,1,,
12580,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered intravenously in brain,Autocuration,,,A,,BAO_0000218,13758,,,1,CHEMBL628497,,,,U,0,955.0,
12581,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered orally in brain,Autocuration,,,A,,BAO_0000218,13758,,,1,CHEMBL628498,,,,U,0,955.0,
12582,Plasma protein binding was determined,Autocuration,,,A,,BAO_0000019,5676,,,1,CHEMBL628499,,,,U,0,,
12583,Brain concentration after 2 hr at a dose of 100 mg/kg when administered perorally,Autocuration,,,A,,BAO_0000218,14793,,,1,CHEMBL627656,,,,U,0,,
12584,Brain concentration after 2 hr at a dose of 10 mg/kg when administered intraperitoneally,Autocuration,,,A,,BAO_0000218,14793,,,1,CHEMBL627657,,,,U,0,,
12585,Brain concentration after 2 hr at a dose of 10 mg/kg when administered intravenously,Autocuration,,,A,,BAO_0000218,14793,,,1,CHEMBL626808,,,,U,0,,
12586,Brain concentration after 2 hr at a dose of 10 mg/kg when administered perorally,Autocuration,,,A,,BAO_0000218,14793,,,1,CHEMBL626809,,,,U,0,,
12587,Brain concentration after 4 hr at a dose of 100 mg/kg when administered perorally,Autocuration,,,A,,BAO_0000218,14793,,,1,CHEMBL626810,,,,U,0,,
12588,Brain concentration after 4 hr at a dose of 10 mg/kg when administered intraperitoneally,Autocuration,,,A,,BAO_0000218,14793,,,1,CHEMBL626811,,,,U,0,,
12589,Brain concentration after 4 hr at a dose of 10 mg/kg when administered intravenously,Autocuration,,,A,,BAO_0000218,14793,,,1,CHEMBL874465,,,,U,0,,
12590,Brain concentration after 4 hr at a dose of 10 mg/kg when administered perorally,Autocuration,,,A,,BAO_0000218,14793,,,1,CHEMBL626812,,,,U,0,,
12591,Brain concentration after 6 hr at a dose of 100 mg/kg when administered perorally,Autocuration,,,A,,BAO_0000218,14793,,,1,CHEMBL626813,,,,U,0,,
12592,Brain concentration after 6 hr at a dose of 10 mg/kg when administered perorally,Autocuration,,,A,,BAO_0000218,14793,,,1,CHEMBL626814,,,,U,0,,
12593,Bullaticin index relates the IC50 values by normalizing to the value of bullatacin for easy comparison.,Autocuration,,,A,,BAO_0000019,14000,,,1,CHEMBL626815,,,,U,0,,
12594,Partition coefficient (logP),Autocuration,,,A,,BAO_0000019,5948,,,1,CHEMBL628566,,,,U,0,,
12595,Calculated partition coefficient (clogP) (CLOGP3 V3.4),Autocuration,,,P,,BAO_0000100,13824,,,1,CHEMBL628567,,,,U,0,,
12596,Calculated partition coefficient (clogP),Autocuration,,,P,,BAO_0000100,10778,,,1,CHEMBL628568,,,,U,0,,
12597,C max in dog,Intermediate,9615.0,,A,,BAO_0000218,17237,,,1,CHEMBL628569,,,Canis lupus familiaris,N,1,,
12598,C max in guinea pig,Intermediate,10141.0,,A,,BAO_0000218,17237,,,1,CHEMBL628570,,,Cavia porcellus,N,1,,
12599,C max value was evaluated,Autocuration,,,A,,BAO_0000218,2809,,,1,CHEMBL628571,,,,U,0,,
12600,Cmax value after oral dose of 0.1 mg//kg,Autocuration,,,A,,BAO_0000218,11954,,,1,CHEMBL628572,,,,U,0,,
12601,Cmax value after oral dose of 0.3 mg/kg,Autocuration,,,A,,BAO_0000218,11954,,,1,CHEMBL628573,,,,U,0,,
12602,Cmax value after oral dose of 1 mg/kg,Autocuration,,,A,,BAO_0000218,11954,,,1,CHEMBL628574,,,,U,0,,
12603,Cmax value after oral dose of 10 mg/kg,Autocuration,,,A,,BAO_0000218,11954,,,1,CHEMBL628575,,,,U,0,,
12604,Cmax value after oral dose of 23.4 mg/kg,Autocuration,,,A,,BAO_0000218,11954,,,1,CHEMBL628576,,,,U,0,,
12605,Cmax value after oral dose of 3 mg/kg,Autocuration,,,A,,BAO_0000218,11954,,,1,CHEMBL628577,,,,U,0,,
12606,Cmax value after oral dose of 3.87 mg/kg,Autocuration,,,A,,BAO_0000218,11954,,,1,CHEMBL628578,,,,U,0,,
12607,Cmax value in female Beagle dogs,Intermediate,9615.0,,A,,BAO_0000218,12768,,,1,CHEMBL874466,,,Canis lupus familiaris,N,1,,
12608,Cmax value in male rats,Intermediate,10116.0,,A,,BAO_0000218,12768,,,1,CHEMBL628579,,,Rattus norvegicus,N,1,,
12609,Cmax value in rat plasma when administered 20 mg/kg perorally,Intermediate,10116.0,,A,,BAO_0000218,12780,,,1,CHEMBL628580,,,Rattus norvegicus,N,1,1969.0,
12610,Maximal plasma concentration in dogs at 10mg/kg oral dose 0.05M citric acid,Intermediate,9615.0,,A,,BAO_0000218,15592,,,1,CHEMBL628581,,,Canis lupus familiaris,N,1,1969.0,
12611,Maximal plasma concentration in dogs at 10mg/kg oral dose 0.05M citric acid,Intermediate,9615.0,,A,,BAO_0000218,15592,,,1,CHEMBL628582,,,Canis lupus familiaris,N,1,1969.0,
12612,Peak concentration of compound at Time = 0 was determined in dog at 5 mg/kg intravenously admn.,Intermediate,9615.0,,A,,BAO_0000218,17025,,,1,CHEMBL628583,,,Canis lupus familiaris,N,1,,
12613,Peak concentration of compound at Time = 0 was determined in monkey at 5 mg/kg intravenously admn.,Autocuration,314293.0,,A,,BAO_0000218,17025,,,1,CHEMBL625782,,,Simiiformes,U,0,,
12614,Peak concentration of compound at Time = 0 was determined in rabbit at 5 mg/kg intravenously admn.,Intermediate,9986.0,,A,,BAO_0000218,17025,,,1,CHEMBL625783,,,Oryctolagus cuniculus,N,1,,
12615,Peak concentration of compound at Time = 0 was determined in rat at 5 mg/kg intravenously admn.,Intermediate,10116.0,,A,,BAO_0000218,17025,,,1,CHEMBL625784,,,Rattus norvegicus,N,1,,
12616,Total plasma concentration at 24 hr at a dose of 10 mg/kg when administered orally to rhesus monkey,Intermediate,9544.0,,A,,BAO_0000218,4236,,,1,CHEMBL625785,,,Macaca mulatta,N,1,1969.0,
12617,C5min (nM) value was determined in rats after intravenous dose of 5 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,15791,,,1,CHEMBL625786,,,Rattus norvegicus,N,1,,
12618,C6h was measured as concentration obtained after 6 hr of oral administration in air pouch exudate,Autocuration,,,A,,BAO_0000019,11149,,,1,CHEMBL874467,,,,U,0,,
12619,"Concentration after 8 hour (bioavailability in dog, compound was delivered orally in 0.05 M citric acid at 10 mg/Kg. n=2 )",Intermediate,9615.0,,A,,BAO_0000218,15592,,,1,CHEMBL625787,,,Canis lupus familiaris,N,1,,
12620,cytotoxicity against HIV protease enzyme.,Intermediate,12721.0,,A,,BAO_0000218,15778,,,1,CHEMBL625964,,,Human immunodeficiency virus,N,1,,
12621,Apparent clearance in mice after intravenous administration of 105.1 mg/kg of dose,Intermediate,10090.0,,A,,BAO_0000218,12745,,,1,CHEMBL625965,,,Mus musculus,N,1,,
12622,Apparent clearance in mice after oral administration of 100 mg/kg of dose,Intermediate,10090.0,,A,,BAO_0000218,12745,,,1,CHEMBL625966,,,Mus musculus,N,1,,
12623,The plasma clearance in dog.,Intermediate,9615.0,,A,,BAO_0000218,13941,,,1,CHEMBL625967,,,Canis lupus familiaris,N,1,1969.0,
12624,The plasma clearance in rat.,Intermediate,10116.0,,A,,BAO_0000218,13941,,,1,CHEMBL625968,,,Rattus norvegicus,N,1,1969.0,
12625,Clearance from plasma in male Sprague-Dawley rats,Intermediate,10116.0,,A,,BAO_0000218,16449,,,1,CHEMBL625969,,,Rattus norvegicus,N,1,1969.0,
12626,Clearance from plasma in male cynomolgus monkeys,Intermediate,9541.0,,A,,BAO_0000218,16449,,,1,CHEMBL625970,,,Macaca fascicularis,N,1,1969.0,
12627,"Clearance of compound (5 mg/kg, intravenously), in dog plasma",Intermediate,9615.0,,A,,BAO_0000218,14224,,,1,CHEMBL625971,,,Canis lupus familiaris,N,1,1969.0,
12628,Clearance of compound in dog plasma,Intermediate,9615.0,,A,,BAO_0000218,14224,,,1,CHEMBL625972,,,Canis lupus familiaris,N,1,1969.0,
12629,Clearance of compound in human plasma,Intermediate,9606.0,,A,,BAO_0000218,14224,,,1,CHEMBL625973,,,Homo sapiens,N,1,1969.0,
12630,Clearance of compound when administered intravenously as a mixture (five-in-one dose) to a single dog.,Intermediate,9615.0,,A,,BAO_0000218,14317,,,1,CHEMBL625974,,,Canis lupus familiaris,N,1,,
12631,Clearance of compound when administered intravenously as an individual dose to a single dog.,Intermediate,9615.0,,A,,BAO_0000218,14317,,,1,CHEMBL625975,,,Canis lupus familiaris,N,1,,
12632,"Clearance (10 mg/kg, intravenously) in dog plasma",Intermediate,9615.0,,A,,BAO_0000218,14224,,,1,CHEMBL625976,,,Canis lupus familiaris,N,1,1969.0,
12633,Clearance value in dog,Intermediate,9615.0,,A,,BAO_0000218,17237,,,1,CHEMBL625977,,,Canis lupus familiaris,N,1,,
12634,Clearance value in guinea pig,Intermediate,10141.0,,A,,BAO_0000218,17237,,,1,CHEMBL625978,,,Cavia porcellus,N,1,,
12635,Clearance values in rats after iv administration.,Intermediate,10116.0,,A,,BAO_0000218,14187,,,1,CHEMBL874468,,,Rattus norvegicus,N,1,,
12636,Compound was tested for plasma clearance on administered orally as aqueous solutions at 1 mpk and by iv at 0.2 mpk,Autocuration,,,A,,BAO_0000218,4806,,,1,CHEMBL625421,,,,U,0,1969.0,
12637,In vivo clearance (5 mg/kg) was determined in rabbits,Intermediate,9986.0,,A,,BAO_0000218,15025,,,1,CHEMBL625422,,,Oryctolagus cuniculus,N,1,,
12638,Plasma Clearance rate was determined for the compound in rats,Intermediate,10116.0,,A,,BAO_0000218,13197,,,1,CHEMBL625423,,,Rattus norvegicus,N,1,,
12639,Plasma Clearance rate was determined for the compound in squirrel monkeys,Autocuration,9520.0,,A,,BAO_0000218,13197,,,1,CHEMBL625424,,,Saimiri,U,0,,
12640,Plasma clearance in rat,Intermediate,10116.0,,A,,BAO_0000218,13960,,,1,CHEMBL625425,,,Rattus norvegicus,N,1,,
12641,Plasma clearance of the compound,Autocuration,,,A,,BAO_0000218,17820,,,1,CHEMBL625426,,,,U,0,,
12642,Plasma clearance in guinea pigs at 2 mg/kg after iv administration,Intermediate,10141.0,,A,,BAO_0000218,14706,,,1,CHEMBL625427,,,Cavia porcellus,N,1,,
12643,Plasma clearance in guinea pigs at 3 mg/kg after iv administration,Intermediate,10141.0,,A,,BAO_0000218,14706,,,1,CHEMBL625428,,,Cavia porcellus,N,1,,
12644,Plasma clearance was determined,Autocuration,,,A,,BAO_0000218,6504,,,1,CHEMBL625429,,,,U,0,,
12645,Plasma clearance rate (CL) was determined in dogs after intravenous administration of 25 mg/kg of the compound.,Intermediate,9615.0,,A,,BAO_0000218,14925,,,1,CHEMBL625430,,,Canis lupus familiaris,N,1,,
12646,Plasma clearance rate was determined for the compound in rats,Intermediate,10116.0,,A,,BAO_0000218,13197,,,1,CHEMBL625431,,,Rattus norvegicus,N,1,,
12647,Plasma clearance rate was determined for the compound in squirrel monkeys,Autocuration,9520.0,,A,,BAO_0000218,13197,,,1,CHEMBL627307,,,Saimiri,U,0,,
12648,Slow clearance (CL) was determined,Autocuration,,,A,,BAO_0000218,3437,,,1,CHEMBL627308,,,,U,0,,
12649,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 0.5 hr,Autocuration,,,A,,BAO_0000218,9196,,,1,CHEMBL627309,,,,U,0,,
12650,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.0 hr; insufficient gastric juice produced,Autocuration,,,A,,BAO_0000218,9196,,,1,CHEMBL627310,,,,U,0,,
12651,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.5 hr,Autocuration,,,A,,BAO_0000218,9196,,,1,CHEMBL627311,,,,U,0,,
12652,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.0 hr,Autocuration,,,A,,BAO_0000218,9196,,,1,CHEMBL627312,,,,U,0,,
12653,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.5 hr,Autocuration,,,A,,BAO_0000218,9196,,,1,CHEMBL627313,,,,U,0,,
12654,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.5 hr,Autocuration,,,A,,BAO_0000218,9196,,,1,CHEMBL627314,,,,U,0,,
12655,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 4.0 hr,Autocuration,,,A,,BAO_0000218,9196,,,1,CHEMBL627315,,,,U,0,,
12656,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.0 hr,Autocuration,,,A,,BAO_0000218,9196,,,1,CHEMBL627316,,,,U,0,,
12657,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 0.5 hr,Autocuration,,,A,,BAO_0000218,9196,,,1,CHEMBL627317,,,,U,0,,
12658,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr,Autocuration,,,A,,BAO_0000218,9196,,,1,CHEMBL627318,,,,U,0,,
12659,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.5 hr,Autocuration,,,A,,BAO_0000218,9196,,,1,CHEMBL627999,,,,U,0,,
12660,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.0 hr,Autocuration,,,A,,BAO_0000218,9196,,,1,CHEMBL628000,,,,U,0,,
12661,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.5 hr,Autocuration,,,A,,BAO_0000218,9196,,,1,CHEMBL628001,,,,U,0,,
12662,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.0 hr,Autocuration,,,A,,BAO_0000218,9196,,,1,CHEMBL628002,,,,U,0,,
12663,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.5 hr,Autocuration,,,A,,BAO_0000218,9196,,,1,CHEMBL625610,,,,U,0,,
12664,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 4.0 hr,Autocuration,,,A,,BAO_0000218,9196,,,1,CHEMBL625611,,,,U,0,,
12665,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.0 hr,Autocuration,,,A,,BAO_0000218,9196,,,1,CHEMBL625612,,,,U,0,,
12666,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.5 hr,Autocuration,,,A,,BAO_0000218,9196,,,1,CHEMBL625613,,,,U,0,,
12667,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.0 hr,Autocuration,,,A,,BAO_0000218,9196,,,1,CHEMBL875479,,,,U,0,,
12668,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.5 hr,Autocuration,,,A,,BAO_0000218,9196,,,1,CHEMBL625614,,,,U,0,,
12669,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 4.0 hr,Autocuration,,,A,,BAO_0000218,9196,,,1,CHEMBL625615,,,,U,0,,
12670,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.5 hr,Autocuration,,,A,,BAO_0000218,9196,,,1,CHEMBL626302,,,,U,0,,
12671,Cumulative concentration 6b and compound 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,Intermediate,10116.0,,A,,BAO_0000218,8374,,,1,CHEMBL626303,,,Rattus norvegicus,N,1,178.0,
12672,Cumulative concentration 6b and compound 1 detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,Intermediate,10116.0,,A,,BAO_0000218,8374,,,1,CHEMBL627420,,,Rattus norvegicus,N,1,178.0,
12673,Degradation of compound in incubations at 25 uM with normal rat liver microsomes after 1 hour relative to initial concentration of 1 uM,Intermediate,10116.0,,A,,BAO_0000218,13477,,,1,CHEMBL627421,,,Rattus norvegicus,N,1,,
12674,Degradation of compound in incubations at 25 uM with normal rat liver microsomes after 24 hour relative to initial concentration of 1 uM,Intermediate,10116.0,,A,,BAO_0000218,13477,,,1,CHEMBL625695,,,Rattus norvegicus,N,1,,
12675,Degradation of compound in incubations at 25 uM with normal rat liver microsomes after 4 hour relative to initial concentration of 1 uM,Intermediate,10116.0,,A,,BAO_0000218,13477,,,1,CHEMBL625696,,,Rattus norvegicus,N,1,,
12676,Distribution of compound in mice brain was measured after 1 hr,Intermediate,10090.0,,A,,BAO_0000218,10009,,,1,CHEMBL875606,,,Mus musculus,N,1,955.0,
12677,Distribution of compound in mice brain was measured after 24 hr r,Intermediate,10090.0,,A,,BAO_0000218,10009,,,1,CHEMBL625697,,,Mus musculus,N,1,955.0,
12678,Distribution of compound in mice brain was measured after 2 hr,Intermediate,10090.0,,A,,BAO_0000218,10009,,,1,CHEMBL625698,,,Mus musculus,N,1,955.0,
12679,Distribution of compound in mice brain was measured after 3 hr,Intermediate,10090.0,,A,,BAO_0000218,10009,,,1,CHEMBL625699,,,Mus musculus,N,1,955.0,
12680,Distribution of compound in mice brain was measured after 6 hr,Intermediate,10090.0,,A,,BAO_0000218,10009,,,1,CHEMBL625700,,,Mus musculus,N,1,955.0,
12681,Distribution of compound in mice liver was measured after 1 hr,Intermediate,10090.0,,A,,BAO_0000218,10009,,,1,CHEMBL625701,,,Mus musculus,N,1,,
12682,Distribution of compound in mice liver was measured after 24 hr; b=Undetected,Intermediate,10090.0,,A,,BAO_0000218,10009,,,1,CHEMBL625702,,,Mus musculus,N,1,,
12683,Distribution of compound in mice liver was measured after 2 hr,Intermediate,10090.0,,A,,BAO_0000218,10009,,,1,CHEMBL625703,,,Mus musculus,N,1,,
12684,Distribution of compound in mice liver was measured after 3 hr,Intermediate,10090.0,,A,,BAO_0000218,10009,,,1,CHEMBL625704,,,Mus musculus,N,1,,
12685,Distribution of compound in mice liver was measured after 6 hr,Intermediate,10090.0,,A,,BAO_0000218,10009,,,1,CHEMBL625705,,,Mus musculus,N,1,,
12686,Distribution in dog adrenal medulla 30 min after administration.,Intermediate,9615.0,,A,,BAO_0000218,8170,,,1,CHEMBL625706,,,Canis lupus familiaris,N,1,1236.0,
12687,Distribution in dog adrenal medulla 72 hours after administration.,Intermediate,9615.0,,A,,BAO_0000218,8170,,,1,CHEMBL625707,,,Canis lupus familiaris,N,1,1236.0,
12688,Distribution in female dog Ovary 24 hours after administration.,Intermediate,9615.0,,A,,BAO_0000218,8170,,,1,CHEMBL625708,,,Canis lupus familiaris,N,1,,
12689,Distribution in female dog Ovary 72 hours after administration.,Intermediate,9615.0,,A,,BAO_0000218,8170,,,1,CHEMBL625709,,,Canis lupus familiaris,N,1,,
12690,Distribution in female dog adipose 24 hours after administration.,Intermediate,9615.0,,A,,BAO_0000218,8170,,,1,CHEMBL624180,,,Canis lupus familiaris,N,1,,
12691,Distribution in female dog adipose 72 hours after administration.,Intermediate,9615.0,,A,,BAO_0000218,8170,,,1,CHEMBL624181,,,Canis lupus familiaris,N,1,,
12692,Distribution in female dog adrenal cortex 72 hours after administration.,Intermediate,9615.0,,A,,BAO_0000218,8170,,,1,CHEMBL624182,,,Canis lupus familiaris,N,1,1235.0,
12693,Distribution in female dog adrenal cortex 72 hours after administration.,Intermediate,9615.0,,A,,BAO_0000218,8170,,,1,CHEMBL624183,,,Canis lupus familiaris,N,1,1235.0,
12694,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,Intermediate,10116.0,,A,,BAO_0000218,8594,,,1,CHEMBL624184,,,Rattus norvegicus,N,1,2107.0,
12695,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,Intermediate,10116.0,,A,,BAO_0000218,8594,,,1,CHEMBL877489,,,Rattus norvegicus,N,1,2107.0,
12696,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,Intermediate,10116.0,,A,,BAO_0000218,8594,,,1,CHEMBL624185,,,Rattus norvegicus,N,1,2107.0,
12697,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,Intermediate,10116.0,,A,,BAO_0000218,8594,,,1,CHEMBL624186,,,Rattus norvegicus,N,1,2107.0,
12698,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,Intermediate,10116.0,,A,,BAO_0000218,8594,,,1,CHEMBL624187,,,Rattus norvegicus,N,1,2107.0,
12699,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,Intermediate,10116.0,,A,,BAO_0000218,8594,,,1,CHEMBL624188,,,Rattus norvegicus,N,1,2107.0,
12700,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,Intermediate,10116.0,,A,,BAO_0000218,8594,,,1,CHEMBL624189,,,Rattus norvegicus,N,1,2048.0,
12701,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,Intermediate,10116.0,,A,,BAO_0000218,8594,,,1,CHEMBL624190,,,Rattus norvegicus,N,1,2048.0,
12702,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,Intermediate,10116.0,,A,,BAO_0000218,8594,,,1,CHEMBL624191,,,Rattus norvegicus,N,1,2048.0,
12703,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,Intermediate,10116.0,,A,,BAO_0000218,8594,,,1,CHEMBL624192,,,Rattus norvegicus,N,1,2048.0,
12704,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,Intermediate,10116.0,,A,,BAO_0000218,8594,,,1,CHEMBL624193,,,Rattus norvegicus,N,1,2048.0,
12705,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,Intermediate,10116.0,,A,,BAO_0000218,8594,,,1,CHEMBL624194,,,Rattus norvegicus,N,1,2048.0,
12706,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,Intermediate,10116.0,,A,,BAO_0000218,8594,,,1,CHEMBL624891,,,Rattus norvegicus,N,1,2048.0,
12707,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,Intermediate,10116.0,,A,,BAO_0000218,8594,,,1,CHEMBL624892,,,Rattus norvegicus,N,1,2048.0,
12708,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,Intermediate,10116.0,,A,,BAO_0000218,8594,,,1,CHEMBL624893,,,Rattus norvegicus,N,1,2048.0,
12709,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,Intermediate,10116.0,,A,,BAO_0000218,8594,,,1,CHEMBL627632,,,Rattus norvegicus,N,1,2048.0,
12710,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,Intermediate,10116.0,,A,,BAO_0000218,8594,,,1,CHEMBL627633,,,Rattus norvegicus,N,1,,
12711,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,Intermediate,10116.0,,A,,BAO_0000218,8594,,,1,CHEMBL627634,,,Rattus norvegicus,N,1,,
12712,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,Intermediate,10116.0,,A,,BAO_0000218,8594,,,1,CHEMBL627635,,,Rattus norvegicus,N,1,,
12713,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,Intermediate,10116.0,,A,,BAO_0000218,8594,,,1,CHEMBL627636,,,Rattus norvegicus,N,1,,
12714,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,Intermediate,10116.0,,A,,BAO_0000218,8594,,,1,CHEMBL626816,,,Rattus norvegicus,N,1,,
12715,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,Intermediate,10116.0,,A,,BAO_0000218,8594,,,1,CHEMBL626817,,,Rattus norvegicus,N,1,,
12716,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,Intermediate,10116.0,,A,,BAO_0000218,8594,,,1,CHEMBL626818,,,Rattus norvegicus,N,1,,
12717,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,Intermediate,10116.0,,A,,BAO_0000218,8594,,,1,CHEMBL626819,,,Rattus norvegicus,N,1,,
12718,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,Intermediate,10116.0,,A,,BAO_0000218,8594,,,1,CHEMBL626820,,,Rattus norvegicus,N,1,,
12719,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,Intermediate,10116.0,,A,,BAO_0000218,8594,,,1,CHEMBL626821,,,Rattus norvegicus,N,1,,
12720,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,Intermediate,10116.0,,A,,BAO_0000218,8594,,,1,CHEMBL626822,,,Rattus norvegicus,N,1,2046.0,
12721,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,Intermediate,10116.0,,A,,BAO_0000218,8594,,,1,CHEMBL626823,,,Rattus norvegicus,N,1,2046.0,
12722,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,Intermediate,10116.0,,A,,BAO_0000218,8594,,,1,CHEMBL626824,,,Rattus norvegicus,N,1,2046.0,
12723,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,Intermediate,10116.0,,A,,BAO_0000218,8594,,,1,CHEMBL626825,,,Rattus norvegicus,N,1,2046.0,
12724,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,Intermediate,10116.0,,A,,BAO_0000218,8594,,,1,CHEMBL626826,,,Rattus norvegicus,N,1,2046.0,
12725,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,Intermediate,10116.0,,A,,BAO_0000218,8594,,,1,CHEMBL626827,,,Rattus norvegicus,N,1,2046.0,
12726,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,Intermediate,10116.0,,A,,BAO_0000218,8594,,,1,CHEMBL626828,,,Rattus norvegicus,N,1,2046.0,
12727,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,Intermediate,10116.0,,A,,BAO_0000218,8594,,,1,CHEMBL626829,,,Rattus norvegicus,N,1,2046.0,
12728,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,Intermediate,10116.0,,A,,BAO_0000218,8594,,,1,CHEMBL626830,,,Rattus norvegicus,N,1,2046.0,
12729,Concentration was measured in tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,Intermediate,10116.0,,A,,BAO_0000218,8594,,,1,CHEMBL627150,,,Rattus norvegicus,N,1,,
12730,Concentration was measured in tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,Intermediate,10116.0,,A,,BAO_0000218,8594,,,1,CHEMBL627151,,,Rattus norvegicus,N,1,,
12731,Concentration was measured in tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,Intermediate,10116.0,,A,,BAO_0000218,8594,,,1,CHEMBL627152,,,Rattus norvegicus,N,1,,
12732,Concentration was measured in tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,Intermediate,10116.0,,A,,BAO_0000218,8594,,,1,CHEMBL627153,,,Rattus norvegicus,N,1,,
12733,Rate of acetate production by the compound was determined,Autocuration,,,A,,BAO_0000019,12904,,,1,CHEMBL627154,,,,U,0,,
12734,Rate of acetate production by the compound was determined; Not determined,Autocuration,,,A,,BAO_0000019,12904,,,1,CHEMBL627155,,,,U,0,,
12735,Rate of hydrolysis of nitrocefin by compound was evaluated in water,Autocuration,,,A,,BAO_0000019,3730,,,1,CHEMBL627156,,,,U,0,,
12736,Reductive elimination of leaving group was determined at pH 7.4; expressed as loss of parent,Autocuration,,,A,,BAO_0000019,3627,,,1,CHEMBL627157,,,,U,0,,
12737,Relative concentration of compound (70 mg/Kg) in brain compared to concentration in plasma (160 ug/mL) at the time of tissue collection from rabbit; relative concentration,Intermediate,9986.0,,A,,BAO_0000218,13799,,,1,CHEMBL627158,,,Oryctolagus cuniculus,N,1,,
12738,Relative concentration of compound (70 mg/Kg) in lung compared to concentration in plasma (160 ug/mL) at the time of tissue collection from rabbit; relative concentration,Intermediate,9986.0,,A,,BAO_0000218,13799,,,1,CHEMBL627159,,,Oryctolagus cuniculus,N,1,1969.0,
12739,Relative concentration of compound in brain compared to concentration in plasma (0.4 ug/mL) at the time of tissue collection from mice; relative concentration,Intermediate,10090.0,,A,,BAO_0000218,13799,,,1,CHEMBL627160,,,Mus musculus,N,1,,
12740,Relative concentration of compound in brain compared to concentration in plasma (3.5 ug/mL) at the time of tissue collection from mice; relative concentration,Intermediate,10116.0,,A,,BAO_0000218,13799,,,1,CHEMBL628540,,,Rattus norvegicus,N,1,,
12741,Relative concentration of compound in lung compared to concentration in plasma (0.4 ug/mL) at the time of tissue collection from mice; relative concentration,Intermediate,10116.0,,A,,BAO_0000218,13799,,,1,CHEMBL628541,,,Rattus norvegicus,N,1,1969.0,
12742,Relative concentration of compound in lung compared to concentration in plasma (3.5 ug/mL) at the time of tissue collection from mice; relative concentration,Intermediate,10116.0,,A,,BAO_0000218,13799,,,1,CHEMBL628542,,,Rattus norvegicus,N,1,1969.0,
12743,Solubility after at a pH 1.2,Autocuration,,,P,,BAO_0000100,6629,,,1,CHEMBL628543,,,,U,0,,
12744,Solubility after at pH 1.2,Autocuration,,,P,,BAO_0000100,6629,,,1,CHEMBL628544,,,,U,0,,
12745,Solubility after injection of water,Autocuration,,,P,,BAO_0000100,6629,,,1,CHEMBL628545,,,,U,0,,
12746,Statistical significance of IC 50 values; Expressed as R value,Autocuration,,,A,,BAO_0000019,14000,,,1,CHEMBL628546,,,,U,0,,
12747,Systemic availability with respect to methyldopa was determined,Autocuration,,,A,,BAO_0000019,8267,,,1,CHEMBL874455,,,,U,0,,
12748,Tissue distribution of the in rat brain relative to plasma concentration of 1 ug/kg; relative concentration,Intermediate,10116.0,,A,,BAO_0000218,13799,,,1,CHEMBL628547,,,Rattus norvegicus,N,1,,
12749,Tissue distribution of the in rat lung relative to plasma concentration of 1 ug/kg; relative concentration,Intermediate,10116.0,,A,,BAO_0000218,13799,,,1,CHEMBL628548,,,Rattus norvegicus,N,1,1969.0,
12750,"100 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit 1 lung, and radioactivity content in feces was estimated",Intermediate,9986.0,,A,,BAO_0000218,7132,,,1,CHEMBL628549,,,Oryctolagus cuniculus,N,1,1988.0,
12751,"100 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit 1 liver, and radioactivity content in feces was estimated",Intermediate,9986.0,,A,,BAO_0000218,7132,,,1,CHEMBL628550,,,Oryctolagus cuniculus,N,1,1988.0,
12752,"100 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit3, and radioactivity content in feces was estimated at total hours",Intermediate,9986.0,,A,,BAO_0000218,7132,,,1,CHEMBL628551,,,Oryctolagus cuniculus,N,1,1988.0,
12753,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit1, and radioactivity content in urine was estimated at 0-2 hr",Intermediate,9986.0,,A,,BAO_0000218,7132,,,1,CHEMBL628552,,,Oryctolagus cuniculus,N,1,1088.0,
12754,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at 0-24 hr",Intermediate,9986.0,,A,,BAO_0000218,7132,,,1,CHEMBL628553,,,Oryctolagus cuniculus,N,1,1088.0,
12755,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at 0-48 hr",Intermediate,9986.0,,A,,BAO_0000218,7132,,,1,CHEMBL628554,,,Oryctolagus cuniculus,N,1,1088.0,
12756,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at 24-48 h",Intermediate,9986.0,,A,,BAO_0000218,7132,,,1,CHEMBL628555,,,Oryctolagus cuniculus,N,1,1088.0,
12757,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at 48-72 h",Intermediate,9986.0,,A,,BAO_0000218,7132,,,1,CHEMBL628556,,,Oryctolagus cuniculus,N,1,1088.0,
12758,"100 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit kidney, and radioactivity content in feces was estimated",Intermediate,9986.0,,A,,BAO_0000218,7132,,,1,CHEMBL628557,,,Oryctolagus cuniculus,N,1,2113.0,
12759,"100 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated",Intermediate,9986.0,,A,,BAO_0000218,7132,,,1,CHEMBL628558,,,Oryctolagus cuniculus,N,1,1988.0,
12760,"100 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 1 lung, and radioactivity content in feces was estimated at",Intermediate,9986.0,,A,,BAO_0000218,7132,,,1,CHEMBL628559,,,Oryctolagus cuniculus,N,1,1988.0,
12761,"100 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit1plasma, and radioactivity content in feces was estimated",Intermediate,9986.0,,A,,BAO_0000218,7132,,,1,CHEMBL628560,,,Oryctolagus cuniculus,N,1,1988.0,
12762,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at total hours",Intermediate,9986.0,,A,,BAO_0000218,7132,,,1,CHEMBL874456,,,Oryctolagus cuniculus,N,1,1088.0,
12763,"200 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit4, and radioactivity content in feces was estimated at 0-48 hr",Intermediate,9986.0,,A,,BAO_0000218,7132,,,1,CHEMBL628561,,,Oryctolagus cuniculus,N,1,1988.0,
12764,"200 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit4, and radioactivity content in feces was estimated at total hours",Intermediate,9986.0,,A,,BAO_0000218,7132,,,1,CHEMBL628562,,,Oryctolagus cuniculus,N,1,1988.0,
12765,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit2, and radioactivity content in urine was estimated at 0-4 hr",Intermediate,9986.0,,A,,BAO_0000218,7132,,,1,CHEMBL628563,,,Oryctolagus cuniculus,N,1,1088.0,
12766,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit4, and radioactivity content in urine was estimated at",Intermediate,9986.0,,A,,BAO_0000218,7132,,,1,CHEMBL628564,,,Oryctolagus cuniculus,N,1,1088.0,
12767,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit4, and radioactivity content in urine was estimated at 24-48 h",Intermediate,9986.0,,A,,BAO_0000218,7132,,,1,CHEMBL628565,,,Oryctolagus cuniculus,N,1,1088.0,
12768,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit4, and radioactivity content in urine was estimated at 48-72 h",Intermediate,9986.0,,A,,BAO_0000218,7132,,,1,CHEMBL631248,,,Oryctolagus cuniculus,N,1,1088.0,
12769,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit4, and radioactivity content in urine was estimated at total hours",Intermediate,9986.0,,A,,BAO_0000218,7132,,,1,CHEMBL631249,,,Oryctolagus cuniculus,N,1,1088.0,
12770,"200 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 2 kidney, and radioactivity content in feces was estimated",Intermediate,9986.0,,A,,BAO_0000218,7132,,,1,CHEMBL627214,,,Oryctolagus cuniculus,N,1,2113.0,
12771,"200 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 2 liver, and radioactivity content in feces was estimated",Intermediate,9986.0,,A,,BAO_0000218,7132,,,1,CHEMBL874591,,,Oryctolagus cuniculus,N,1,1988.0,
12772,"200 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 2 lung, and radioactivity content in feces was estimated",Intermediate,9986.0,,A,,BAO_0000218,7132,,,1,CHEMBL627215,,,Oryctolagus cuniculus,N,1,1988.0,
12773,200 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 2 plasma and radioactivity content in feces was estimated,Intermediate,9986.0,,A,,BAO_0000218,7132,,,1,CHEMBL625471,,,Oryctolagus cuniculus,N,1,1988.0,
12774,Percent of 3-Methyl-thiazolidin-2-ylideneamine as administered dose was reported in rabbit 1,Intermediate,9986.0,,A,,BAO_0000218,7132,,,1,CHEMBL625472,,,Oryctolagus cuniculus,N,1,,
12775,Percent of 3-Methyl-thiazolidin-2-ylideneamine as administered dose was reported in rabbit 3 by Gas-liquid chromatographic analysis,Intermediate,9986.0,,A,,BAO_0000218,7132,,,1,CHEMBL625473,,,Oryctolagus cuniculus,N,1,,
12776,Tested for pharmacokinetic parameter in fasted Beagle dogs (Clearance value of the compound) iv administration.,Intermediate,9615.0,,A,,BAO_0000218,13317,,,1,CHEMBL625474,,,Canis lupus familiaris,N,1,,
12777,The clearance was measured in dog at dose 5 mg/kg after intravenous administration.,Intermediate,9615.0,,A,,BAO_0000218,15341,,,1,CHEMBL625475,,,Canis lupus familiaris,N,1,,
12778,The clearance was measured in rat at dose 12 mg/kg after intravenous administration.,Intermediate,10116.0,,A,,BAO_0000218,15341,,,1,CHEMBL625476,,,Rattus norvegicus,N,1,,
12779,The clearance was measured in rat at dose 1 mg/kg after intravenous administration.,Intermediate,10116.0,,A,,BAO_0000218,15341,,,1,CHEMBL625477,,,Rattus norvegicus,N,1,,
12780,The clearance was measured in rat at dose 30 mg/kg after intravenous administration.,Intermediate,10116.0,,A,,BAO_0000218,15341,,,1,CHEMBL625478,,,Rattus norvegicus,N,1,,
12781,The compound was evaluated for clearance value in rat isolated esophageal tunica muscularis mucose,Intermediate,10116.0,,A,,BAO_0000218,12801,,,1,CHEMBL625479,,,Rattus norvegicus,N,1,,
12782,The compound was evaluated for the value in rat isolated esophageal tunica muscularis mucose,Intermediate,10116.0,,A,,BAO_0000218,12801,,,1,CHEMBL625480,,,Rattus norvegicus,N,1,,
12783,The compound was tested for systemic plasma clearance(CL) in rats and is expressed in mL/min/kg.,Intermediate,10116.0,,A,,BAO_0000218,14856,,,1,CHEMBL625481,,,Rattus norvegicus,N,1,1969.0,
12784,Total body clearance at an intravenous dose of 5.2 mg/kg in rat,Intermediate,10116.0,,A,,BAO_0000218,14062,,,1,CHEMBL625482,,,Rattus norvegicus,N,1,,
12785,Total body clearance at an intravenous dose of 5.5 mg/kg in rat,Intermediate,10116.0,,A,,BAO_0000218,14062,,,1,CHEMBL625483,,,Rattus norvegicus,N,1,,
12786,Total body clearance at an intravenous dose of 6.3 mg/kg in rat,Intermediate,10116.0,,A,,BAO_0000218,14062,,,1,CHEMBL625484,,,Rattus norvegicus,N,1,,
12787,Total body clearance at an intravenous dose of 6.5 mg/kg in rat,Intermediate,10116.0,,A,,BAO_0000218,14062,,,1,CHEMBL625485,,,Rattus norvegicus,N,1,,
12788,Total plasma clearance value was obtained after intravenous administration of 1.8 mg/kg of drug in male Beagle dogs,Intermediate,9615.0,,A,,BAO_0000218,14346,,,1,CHEMBL625486,,,Canis lupus familiaris,N,1,1969.0,
12789,Total plasma clearance value was obtained after intravenous administration of 2.5 mg/kg of drug in male Dawley rats,Intermediate,10116.0,,A,,BAO_0000218,14346,,,1,CHEMBL625487,,,Rattus norvegicus,N,1,1969.0,
12790,Total plasma clearance value was obtained after intravenous administration of 2.6 mg/kg of drug in male Dawley rats,Intermediate,10116.0,,A,,BAO_0000218,14346,,,1,CHEMBL625488,,,Rattus norvegicus,N,1,1969.0,
12791,Total plasma clearance value was obtained after intravenous administration of 2.7 mg/kg of drug in male Dawley rats,Intermediate,10116.0,,A,,BAO_0000218,14346,,,1,CHEMBL625489,,,Rattus norvegicus,N,1,1969.0,
12792,Total plasma clearance value was obtained after intravenous administration of 2.8 mg/kg of drug in male Dawley rats,Intermediate,10116.0,,A,,BAO_0000218,14346,,,1,CHEMBL625490,,,Rattus norvegicus,N,1,1969.0,
12793,Total plasma clearance value was obtained after intravenous administration of 4.9 mg/kg of drug in male Beagle dogs,Intermediate,9615.0,,A,,BAO_0000218,14346,,,1,CHEMBL625491,,,Canis lupus familiaris,N,1,1969.0,
12794,Total plasma clearance value was obtained after intravenous administration of 5.1 mg/kg of drug in male Dawley rats,Intermediate,10116.0,,A,,BAO_0000218,14346,,,1,CHEMBL625492,,,Rattus norvegicus,N,1,1969.0,
12795,plasma clearance in human,Intermediate,9606.0,,A,,BAO_0000218,15711,,,1,CHEMBL625493,,,Homo sapiens,N,1,1969.0,
12796,Pharmacokinetic parameter (CL/F ) was evaluated in Spargue-Dawley rat when given intravenously at dose 15 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,14886,,,1,CHEMBL625494,,,Rattus norvegicus,N,1,,
12797,Pharmacokinetic parameter (CL/F ) was evaluated in Spargue-Dawley rat when given peroral at dose 30 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,14886,,,1,CHEMBL625495,,,Rattus norvegicus,N,1,,
12798,Pharmacokinetic parameter (CL/F) was evaluated in Spargue-Dawley rat when given peroral at dose 80 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,14886,,,1,CHEMBL625496,,,Rattus norvegicus,N,1,,
12799,1-Octanol/water partition coefficient measured at 7.4,Autocuration,,,P,,BAO_0000100,4115,,,1,CHEMBL625497,,,,U,0,,
12800,Calculated partition coefficient (clogP),Autocuration,,,P,,BAO_0000100,13733,,,1,CHEMBL625498,,,,U,0,,
12801,Partition coefficient (logP),Autocuration,,,A,,BAO_0000019,12102,,,1,CHEMBL625499,,,,U,0,,
12802,Calculated partition coefficient (clogP),Autocuration,,,P,,BAO_0000100,12676,,,1,CHEMBL625500,,,,U,0,,
12803,Calculated partition coefficient (clogP),Autocuration,,,P,,BAO_0000100,13733,,,1,CHEMBL625501,,,,U,0,,
12804,Calculated partition coefficient (clogP),Autocuration,,,P,,BAO_0000100,13740,,,1,CHEMBL625502,,,,U,0,,
12805,Calculated partition coefficient (clogP) (relative to BAY K 8644),Autocuration,,,P,,BAO_0000100,12766,,,1,CHEMBL625503,,,,U,0,,
12806,Calculated partition coefficient (clogP),Autocuration,,,P,,BAO_0000100,2764,,,1,CHEMBL625504,,,,U,0,,
12807,Calculated partition coefficient (clogP),Autocuration,,,P,,BAO_0000100,12355,,,1,CHEMBL625505,,,,U,0,,
12808,Calculated partition coefficient of the compound,Autocuration,,,P,,BAO_0000100,11314,,,1,CHEMBL625506,,,,U,0,,
12809,Partition coefficient (logP),Autocuration,,,A,,BAO_0000019,12706,,,1,CHEMBL625507,,,,U,0,,
12810,Calculated partition coefficient (clogP),Autocuration,,,P,,BAO_0000100,12645,,,1,CHEMBL625508,,,,U,0,,
12811,Calculated partition coefficient (clogP),Autocuration,,,P,,BAO_0000100,13668,,,1,CHEMBL625509,,,,U,0,,
12812,Calculated partition coefficient (clogP),Autocuration,,,P,,BAO_0000100,12819,,,1,CHEMBL625510,,,,U,0,,
12813,Calculated partition coefficient (clogP),Autocuration,,,P,,BAO_0000100,13668,,,1,CHEMBL883125,,,,U,0,,
12814,Calculated partition coefficient (clogP),Autocuration,,,P,,BAO_0000100,13017,,,1,CHEMBL625511,,,,U,0,,
12815,Partition coefficient of the compound,Autocuration,,,A,,BAO_0000019,2448,,,1,CHEMBL874650,,,,U,0,,
12816,Partition coefficient of the compound,Autocuration,,,A,,BAO_0000019,11526,,,1,CHEMBL625512,,,,U,0,,
12817,Partition coefficient of compound was determined,Autocuration,,,A,,BAO_0000019,12426,,,1,CHEMBL625513,,,,U,0,,
12818,Partition coefficient was determined,Autocuration,,,A,,BAO_0000019,2448,,,1,CHEMBL625514,,,,U,0,,
12819,Calculated partition coefficient (clogP),Autocuration,,,P,,BAO_0000100,12001,,,1,CHEMBL625515,,,,U,0,,
12820,partition coefficient of compound was determined,Autocuration,,,P,,BAO_0000100,12426,,,1,CHEMBL625516,,,,U,0,,
12821,The total body administered intravenously in dog,Intermediate,9615.0,,A,,BAO_0000218,13204,,,1,CHEMBL625517,,,Canis lupus familiaris,N,1,,
12822,The total body administered intravenously in rats,Intermediate,10116.0,,A,,BAO_0000218,13204,,,1,CHEMBL625518,,,Rattus norvegicus,N,1,,
12823,Time taken for the administration to female NIH mice weighing 25-30 g.,Intermediate,10090.0,,A,,BAO_0000218,13889,,,1,CHEMBL625519,,,Mus musculus,N,1,,
12824,Time taken for the administration,Autocuration,,,A,,BAO_0000019,13889,,,1,CHEMBL625520,,,,U,0,,
12825,Total clearance of compound was determined in dog at 5 mg/kg intravenously admn.,Intermediate,9615.0,,A,,BAO_0000218,17025,,,1,CHEMBL874651,,,Canis lupus familiaris,N,1,,
12826,Total clearance of compound was determined in monkey at 5 mg/kg intravenously admn.,Autocuration,314293.0,,A,,BAO_0000218,17025,,,1,CHEMBL625521,,,Simiiformes,U,0,,
12827,Total clearance of compound was determined in rabbit at 5 mg/kg intravenously admn.,Intermediate,9986.0,,A,,BAO_0000218,17025,,,1,CHEMBL623171,,,Oryctolagus cuniculus,N,1,,
12828,Total clearance of compound was determined in rat at 5 mg/kg intravenously admn.,Intermediate,10116.0,,A,,BAO_0000218,17025,,,1,CHEMBL623853,,,Rattus norvegicus,N,1,,
12829,Plasma clearance for the compound was determined.,Autocuration,,,A,,BAO_0000019,15067,,,1,CHEMBL623854,,,,U,0,,
12830,CLog P value of the compound,Autocuration,,,P,,BAO_0000100,3091,,,1,CHEMBL874405,,,,U,0,,
12831,Calculated partition coefficient (clogP),Autocuration,,,P,,BAO_0000100,15592,,,1,CHEMBL623855,,,,U,0,,
12832,Calculated partition coefficient (clogP),Autocuration,,,P,,BAO_0000100,14738,,,1,CHEMBL623856,,,,U,0,,
12833,ClogP value of the compound; nd ='no data',Autocuration,,,P,,BAO_0000100,14738,,,1,CHEMBL623857,,,,U,0,,
12834,ClogP value of the compound; nd ='not determined',Autocuration,,,P,,BAO_0000100,14738,,,1,CHEMBL623858,,,,U,0,,
12835,CLog P was determined,Autocuration,,,P,,BAO_0000100,6076,,,1,CHEMBL623859,,,,U,0,,
12836,Calculated partition coefficient (clogP),Autocuration,,,P,,BAO_0000100,17840,,,1,CHEMBL839829,,,,U,0,,
12837,CLogP was calculated,Autocuration,,,A,,BAO_0000019,13589,,,1,CHEMBL623860,,,,U,0,,
12838,CLogP value was determined,Autocuration,,,A,,BAO_0000019,17655,,,1,CHEMBL623861,,,,U,0,,
12839,CLogP value was evaluated using http://esc.syrres.com/interkow/kowdemo.htm.,Autocuration,,,A,,BAO_0000019,5867,,,1,CHEMBL623862,,,,U,0,,
12840,Calculated partition coefficient (clogP),Autocuration,,,P,,BAO_0000100,5867,,,1,CHEMBL874406,,,,U,0,,
12841,Calculated partition coefficient (clogP),Autocuration,,,P,,BAO_0000100,10783,,,1,CHEMBL623863,,,,U,0,,
12842,Calculated partition coefficient (clogP),Autocuration,,,P,,BAO_0000100,14849,,,1,CHEMBL624021,,,,U,0,,
12843,Distribution in female dog adrenal medulla 24 hours after administration.,Intermediate,9615.0,,A,,BAO_0000218,8170,,,1,CHEMBL624022,,,Canis lupus familiaris,N,1,1236.0,
12844,Distribution in female dog adrenal medulla 72 hours after administration.,Intermediate,9615.0,,A,,BAO_0000218,8170,,,1,CHEMBL624023,,,Canis lupus familiaris,N,1,1236.0,
12845,Distribution in female dog bile 24 hours after administration.,Intermediate,9615.0,,A,,BAO_0000218,8170,,,1,CHEMBL624024,,,Canis lupus familiaris,N,1,,
12846,Distribution in female dog bile 72 hr after administration.,Intermediate,9615.0,,A,,BAO_0000218,8170,,,1,CHEMBL624025,,,Canis lupus familiaris,N,1,,
12847,Distribution in female dog blood 24 hours after administration.,Intermediate,9615.0,,A,,BAO_0000218,8170,,,1,CHEMBL624026,,,Canis lupus familiaris,N,1,,
12848,Distribution in female dog blood 72 hours after administration.,Intermediate,9615.0,,A,,BAO_0000218,8170,,,1,CHEMBL624027,,,Canis lupus familiaris,N,1,,
12849,Distribution in female dog heart 24 hours after administration.,Intermediate,9615.0,,A,,BAO_0000218,8170,,,1,CHEMBL624028,,,Canis lupus familiaris,N,1,,
12850,Distribution in female dog heart 72 hours after administration.,Intermediate,9615.0,,A,,BAO_0000218,8170,,,1,CHEMBL624029,,,Canis lupus familiaris,N,1,,
12851,Distribution in female dog kidney 24 hours after administration.,Intermediate,9615.0,,A,,BAO_0000218,8170,,,1,CHEMBL624030,,,Canis lupus familiaris,N,1,,
12852,Distribution in female dog kidney 72 hours after administration.,Intermediate,9615.0,,A,,BAO_0000218,8170,,,1,CHEMBL624031,,,Canis lupus familiaris,N,1,,
12853,Distribution in female dog large intestine 24 hours after administration.,Intermediate,9615.0,,A,,BAO_0000218,8170,,,1,CHEMBL624032,,,Canis lupus familiaris,N,1,160.0,
12854,Distribution in female dog large intestine 72 hours after administration.,Intermediate,9615.0,,A,,BAO_0000218,8170,,,1,CHEMBL874407,,,Canis lupus familiaris,N,1,160.0,
12855,Distribution in female dog liver 24 hours after administration.,Intermediate,9615.0,,A,,BAO_0000218,8170,,,1,CHEMBL624033,,,Canis lupus familiaris,N,1,,
12856,Distribution in female dog liver 72 hours after administration.,Intermediate,9615.0,,A,,BAO_0000218,8170,,,1,CHEMBL624034,,,Canis lupus familiaris,N,1,,
12857,Distribution in female dog lung 24 hours after administration.,Intermediate,9615.0,,A,,BAO_0000218,8170,,,1,CHEMBL624035,,,Canis lupus familiaris,N,1,,
12858,Distribution in female dog lung 72 hours after administration.,Intermediate,9615.0,,A,,BAO_0000218,8170,,,1,CHEMBL624036,,,Canis lupus familiaris,N,1,,
12859,Distribution in female dog muscle 24 hours after administration.,Intermediate,9615.0,,A,,BAO_0000218,8170,,,1,CHEMBL624037,,,Canis lupus familiaris,N,1,2385.0,
12860,Distribution in female dog muscle 72 hours after administration.,Intermediate,9615.0,,A,,BAO_0000218,8170,,,1,CHEMBL624038,,,Canis lupus familiaris,N,1,2385.0,
12861,Distribution in female dog pancreas 24 hours after administration.,Intermediate,9615.0,,A,,BAO_0000218,8170,,,1,CHEMBL624039,,,Canis lupus familiaris,N,1,,
12862,Distribution in female dog pancreas 72 hours after administration.,Intermediate,9615.0,,A,,BAO_0000218,8170,,,1,CHEMBL624040,,,Canis lupus familiaris,N,1,,
12863,Distribution in female dog small intestine 24 hours after administration.,Intermediate,9615.0,,A,,BAO_0000218,8170,,,1,CHEMBL624041,,,Canis lupus familiaris,N,1,160.0,
12864,Distribution in female dog small intestine 72 hours after administration.,Intermediate,9615.0,,A,,BAO_0000218,8170,,,1,CHEMBL624042,,,Canis lupus familiaris,N,1,160.0,
12865,Distribution in female dog spleen 24 hours after administration.,Intermediate,9615.0,,A,,BAO_0000218,8170,,,1,CHEMBL624043,,,Canis lupus familiaris,N,1,2106.0,
12866,Distribution in female dog spleen 72 hours after administration.,Intermediate,9615.0,,A,,BAO_0000218,8170,,,1,CHEMBL624044,,,Canis lupus familiaris,N,1,2106.0,
12867,Distribution in female dog stomach 24 hours after administration.,Intermediate,9615.0,,A,,BAO_0000218,8170,,,1,CHEMBL624045,,,Canis lupus familiaris,N,1,945.0,
12868,Distribution in female dog stomach 72 hours after administration.,Intermediate,9615.0,,A,,BAO_0000218,8170,,,1,CHEMBL624046,,,Canis lupus familiaris,N,1,945.0,
12869,Distribution in female dog thyroid 24 hours after administration.,Intermediate,9615.0,,A,,BAO_0000218,8170,,,1,CHEMBL624047,,,Canis lupus familiaris,N,1,2046.0,
12870,Distribution in female dog thyroid 72 hours after administration.,Intermediate,9615.0,,A,,BAO_0000218,8170,,,1,CHEMBL624048,,,Canis lupus familiaris,N,1,2046.0,
12871,Distribution in female dog urine 24 hours after administration.,Intermediate,9615.0,,A,,BAO_0000218,8170,,,1,CHEMBL874408,,,Canis lupus familiaris,N,1,1088.0,
12872,Distribution in female dog urine 72 hr after administration.,Intermediate,9615.0,,A,,BAO_0000218,8170,,,1,CHEMBL624049,,,Canis lupus familiaris,N,1,1088.0,
12873,Mean plasma concentration measured 1 h following an oral dose of 30 mg/kg,Autocuration,,,A,,BAO_0000218,14283,,,1,CHEMBL624050,,,,U,0,1969.0,
12874,Plasma concentration at 7 hr after intravenous dosing,Autocuration,,,A,,BAO_0000019,5623,,,1,CHEMBL624051,,,,U,0,,
12875,Plasma concentration of 3 mg/kg iv after 0.25 hr in rats,Intermediate,10116.0,,A,,BAO_0000218,13477,,,1,CHEMBL623278,,,Rattus norvegicus,N,1,,
12876,Plasma concentration of 3 mg/kg iv after 0.5 hr in rats,Intermediate,10116.0,,A,,BAO_0000218,13477,,,1,CHEMBL623279,,,Rattus norvegicus,N,1,,
12877,Plasma concentration of 3 mg/kg iv after 1 hr in rats,Intermediate,10116.0,,A,,BAO_0000218,13477,,,1,CHEMBL623280,,,Rattus norvegicus,N,1,,
12878,Plasma concentration of 3 mg/kg iv after 2 hr in rats,Intermediate,10116.0,,A,,BAO_0000218,13477,,,1,CHEMBL623963,,,Rattus norvegicus,N,1,,
12879,Plasma concentration of 3 mg/kg iv after 4 hr in rats,Intermediate,10116.0,,A,,BAO_0000218,13477,,,1,CHEMBL623964,,,Rattus norvegicus,N,1,,
12880,Plasma concentration of 3 mg/kg iv after 6 hr in rats,Intermediate,10116.0,,A,,BAO_0000218,13477,,,1,CHEMBL623965,,,Rattus norvegicus,N,1,,
12881,Plasma concentration of 3 mg/kg po after 0.083 hr in rats,Intermediate,10116.0,,A,,BAO_0000218,13477,,,1,CHEMBL623966,,,Rattus norvegicus,N,1,,
12882,Plasma concentration after 3 mg/kg peroral dosing in rat at 0.083 h,Intermediate,10116.0,,A,,BAO_0000218,13477,,,1,CHEMBL874415,,,Rattus norvegicus,N,1,,
12883,Plasma concentration after 3 mg/kg peroral dosing in rat at 0.25 hr,Intermediate,10116.0,,A,,BAO_0000218,13477,,,1,CHEMBL623967,,,Rattus norvegicus,N,1,,
12884,Plasma concentration after 3 mg/kg peroral dosing in rat at 0.5 hr,Intermediate,10116.0,,A,,BAO_0000218,13477,,,1,CHEMBL623968,,,Rattus norvegicus,N,1,,
12885,Plasma concentration after 3 mg/kg peroral dosing in rat at 1 hr,Intermediate,10116.0,,A,,BAO_0000218,13477,,,1,CHEMBL623969,,,Rattus norvegicus,N,1,,
12886,Plasma concentration after 3 mg/kg peroral dosing in rat at 2 hr,Intermediate,10116.0,,A,,BAO_0000218,13477,,,1,CHEMBL628409,,,Rattus norvegicus,N,1,,
12887,Plasma concentration after 3 mg/kg peroral dosing in rat at 4 hr,Intermediate,10116.0,,A,,BAO_0000218,13477,,,1,CHEMBL628410,,,Rattus norvegicus,N,1,,
12888,Plasma concentration after 3 mg/kg peroral dosing in rat at 6 hr,Intermediate,10116.0,,A,,BAO_0000218,13477,,,1,CHEMBL628411,,,Rattus norvegicus,N,1,,
12889,Plasma concentration after 3 mg/kg peroral dosing in rat at 8 hr,Intermediate,10116.0,,A,,BAO_0000218,13477,,,1,CHEMBL628412,,,Rattus norvegicus,N,1,,
12890,Tested for the highest concentration at which toxicity was not observed or the concentration which provided the highest number of net grain counts,Autocuration,,,A,,BAO_0000019,12553,,,1,CHEMBL628413,,,,U,0,,
12891,The concentration in plasmat; Not determined,Autocuration,,,A,,BAO_0000019,14548,,,1,CHEMBL628414,,,,U,0,1969.0,
12892,Tissue level at 10 mg/kg/po in wistar rats in blood,Intermediate,10116.0,,A,,BAO_0000218,14393,,,1,CHEMBL628415,,,Rattus norvegicus,N,1,,
12893,Tissue level at 10 mg/kg/po in wistar rats in brown fat,Intermediate,10116.0,,A,,BAO_0000218,14393,,,1,CHEMBL628416,,,Rattus norvegicus,N,1,,
12894,Tissue level at 10 mg/kg/po in wistar rats in heart,Intermediate,10116.0,,A,,BAO_0000218,14393,,,1,CHEMBL628417,,,Rattus norvegicus,N,1,,
12895,Tissue level at 10 mg/kg/po in wistar rats in liver,Intermediate,10116.0,,A,,BAO_0000218,14393,,,1,CHEMBL874908,,,Rattus norvegicus,N,1,2107.0,
12896,Tissue level at 10 mg/kg/po in wistar rats in plasma,Intermediate,10116.0,,A,,BAO_0000218,14393,,,1,CHEMBL628418,,,Rattus norvegicus,N,1,,
12897,Tissue level at 10 mg/kg/po in wistar rats in skeletal muscle,Intermediate,10116.0,,A,,BAO_0000218,14393,,,1,CHEMBL628419,,,Rattus norvegicus,N,1,2385.0,
12898,Tissue level at 10 mg/kg/po in wistar rats in subcutaneous fat,Intermediate,10116.0,,A,,BAO_0000218,14393,,,1,CHEMBL628420,,,Rattus norvegicus,N,1,,
12899,Water solubility at 37 degree C.,Autocuration,,,A,,BAO_0000019,1629,,,1,CHEMBL628421,,,,U,0,,
12900,Solubility of 10 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 13.5 hr,Autocuration,,,P,,BAO_0000100,8194,,,1,CHEMBL626726,,,,U,0,,
12901,Solubility of 10 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 4.0 hr,Autocuration,,,P,,BAO_0000100,8194,,,1,CHEMBL626727,,,,U,0,,
12902,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,Intermediate,10116.0,,A,,BAO_0000218,8594,,,1,CHEMBL626728,,,Rattus norvegicus,N,1,178.0,
12903,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,Intermediate,10116.0,,A,,BAO_0000218,8594,,,1,CHEMBL626729,,,Rattus norvegicus,N,1,178.0,
12904,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,Intermediate,10116.0,,A,,BAO_0000218,8594,,,1,CHEMBL626730,,,Rattus norvegicus,N,1,178.0,
12905,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,Intermediate,10116.0,,A,,BAO_0000218,8594,,,1,CHEMBL626731,,,Rattus norvegicus,N,1,178.0,
12906,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,Intermediate,10116.0,,A,,BAO_0000218,8594,,,1,CHEMBL626732,,,Rattus norvegicus,N,1,178.0,
12907,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,Intermediate,10116.0,,A,,BAO_0000218,8594,,,1,CHEMBL626733,,,Rattus norvegicus,N,1,948.0,
12908,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,Intermediate,10116.0,,A,,BAO_0000218,8594,,,1,CHEMBL626734,,,Rattus norvegicus,N,1,948.0,
12909,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,Intermediate,10116.0,,A,,BAO_0000218,8594,,,1,CHEMBL626735,,,Rattus norvegicus,N,1,948.0,
12910,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,Intermediate,10116.0,,A,,BAO_0000218,8594,,,1,CHEMBL874909,,,Rattus norvegicus,N,1,948.0,
12911,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,Intermediate,10116.0,,A,,BAO_0000218,8594,,,1,CHEMBL626736,,,Rattus norvegicus,N,1,948.0,
12912,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,Intermediate,10116.0,,A,,BAO_0000218,8594,,,1,CHEMBL626737,,,Rattus norvegicus,N,1,2113.0,
12913,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,Intermediate,10116.0,,A,,BAO_0000218,8594,,,1,CHEMBL630999,,,Rattus norvegicus,N,1,2113.0,
12914,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,Intermediate,10116.0,,A,,BAO_0000218,8594,,,1,CHEMBL631000,,,Rattus norvegicus,N,1,2113.0,
12915,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,Intermediate,10116.0,,A,,BAO_0000218,8594,,,1,CHEMBL631001,,,Rattus norvegicus,N,1,2113.0,
12916,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,Intermediate,10116.0,,A,,BAO_0000218,8594,,,1,CHEMBL631002,,,Rattus norvegicus,N,1,2113.0,
12917,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,Intermediate,10116.0,,A,,BAO_0000218,8594,,,1,CHEMBL631003,,,Rattus norvegicus,N,1,2107.0,
12918,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,Intermediate,10116.0,,A,,BAO_0000218,8594,,,1,CHEMBL631004,,,Rattus norvegicus,N,1,2107.0,
12919,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,Intermediate,10116.0,,A,,BAO_0000218,8594,,,1,CHEMBL631005,,,Rattus norvegicus,N,1,2107.0,
12920,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,Intermediate,10116.0,,A,,BAO_0000218,8594,,,1,CHEMBL631006,,,Rattus norvegicus,N,1,2107.0,
12921,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,Intermediate,10116.0,,A,,BAO_0000218,8594,,,1,CHEMBL631007,,,Rattus norvegicus,N,1,2107.0,
12922,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,Intermediate,10116.0,,A,,BAO_0000218,8594,,,1,CHEMBL631008,,,Rattus norvegicus,N,1,2048.0,
12923,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,Intermediate,10116.0,,A,,BAO_0000218,8594,,,1,CHEMBL631009,,,Rattus norvegicus,N,1,2048.0,
12924,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,Intermediate,10116.0,,A,,BAO_0000218,8594,,,1,CHEMBL631010,,,Rattus norvegicus,N,1,2048.0,
12925,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,Intermediate,10116.0,,A,,BAO_0000218,8594,,,1,CHEMBL631011,,,Rattus norvegicus,N,1,2048.0,
12926,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,Intermediate,10116.0,,A,,BAO_0000218,8594,,,1,CHEMBL631012,,,Rattus norvegicus,N,1,2048.0,
12927,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,Intermediate,10116.0,,A,,BAO_0000218,8594,,,1,CHEMBL630271,,,Rattus norvegicus,N,1,2046.0,
12928,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,Intermediate,10116.0,,A,,BAO_0000218,8594,,,1,CHEMBL630272,,,Rattus norvegicus,N,1,2046.0,
12929,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,Intermediate,10116.0,,A,,BAO_0000218,8594,,,1,CHEMBL630273,,,Rattus norvegicus,N,1,2046.0,
12930,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,Intermediate,10116.0,,A,,BAO_0000218,8594,,,1,CHEMBL630274,,,Rattus norvegicus,N,1,2046.0,
12931,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,Intermediate,10116.0,,A,,BAO_0000218,8594,,,1,CHEMBL630275,,,Rattus norvegicus,N,1,2046.0,
12932,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 15 minutes (radiolabeled with [125I]-,Intermediate,10116.0,,A,,BAO_0000218,8594,,,1,CHEMBL875782,,,Rattus norvegicus,N,1,,
12933,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 2 minutes (radiolabeled with [125I]-,Intermediate,10116.0,,A,,BAO_0000218,8594,,,1,CHEMBL630276,,,Rattus norvegicus,N,1,,
12934,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 30 minutes (radiolabeled with [125I]-,Intermediate,10116.0,,A,,BAO_0000218,8594,,,1,CHEMBL630277,,,Rattus norvegicus,N,1,,
12935,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 5 minutes (radiolabeled with [125I]-,Intermediate,10116.0,,A,,BAO_0000218,8594,,,1,CHEMBL630278,,,Rattus norvegicus,N,1,,
12936,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 60 minutes (radiolabeled with [125I]-,Intermediate,10116.0,,A,,BAO_0000218,8594,,,1,CHEMBL630279,,,Rattus norvegicus,N,1,,
12937,Antidiuretic activity was determined expressed as Na+(sodium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 10 mg/Kg,Autocuration,,,A,,BAO_0000019,8151,,,1,CHEMBL630280,,,,U,0,,
12938,Antidiuretic activity was determined expressed as Na+(sodium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg,Autocuration,,,A,,BAO_0000019,8151,,,1,CHEMBL630281,,,,U,0,,
12939,Percent of 3-Methyl-thiazolidin-2-ylideneamine as administered dose was reported in rabbit 4 by Gas-liquid chromatographic analysis,Intermediate,9986.0,,A,,BAO_0000218,7132,,,1,CHEMBL630282,,,Oryctolagus cuniculus,N,1,,
12940,Percent of 3-Methyl-thiazolidin-2-ylideneamine as administered dose was reported in rabbit 2,Intermediate,9986.0,,A,,BAO_0000218,7132,,,1,CHEMBL630283,,,Oryctolagus cuniculus,N,1,,
12941,Alkylating activity (0.1 mM) was determined at pH 7.4; expressed as OD (540n m)/mM of drug),Autocuration,,,A,,BAO_0000019,5797,,,1,CHEMBL630284,,,,U,0,,
12942,Alkylating activity was determined,Autocuration,,,A,,BAO_0000019,7849,,,1,CHEMBL630285,,,,U,0,,
12943,Amount of metabolites in the microsomal medium after 90 min incubation of BTCP (500 uM),Autocuration,,,A,,BAO_0000251,14220,Microsomes,,1,CHEMBL630286,,,,U,0,,
12944,"Formation of metabolite by rabbit liver microsomal preparation in absence of NADPH, at 2 hours",Intermediate,9986.0,,A,,BAO_0000218,8650,,,1,CHEMBL630069,,,Oryctolagus cuniculus,N,1,,
12945,"Formation of metabolite by rabbit liver microsomal preparation in presence of Co-O2 (90:10),at 2 hour",Intermediate,9986.0,,A,,BAO_0000218,8650,,,1,CHEMBL630070,,,Oryctolagus cuniculus,N,1,,
12946,"Formation of metabolite by rabbit liver microsomal preparation in presence of N2,at 2 hour",Intermediate,9986.0,,A,,BAO_0000218,8650,,,1,CHEMBL630071,,,Oryctolagus cuniculus,N,1,,
12947,"Formation of metabolite by rabbit liver microsomal preparation in presence of NADPH, at 2 hours",Intermediate,9986.0,,A,,BAO_0000218,8650,,,1,CHEMBL630072,,,Oryctolagus cuniculus,N,1,,
12948,"Formation of metabolite by rabbit liver microsomal preparation in presence of SKF525A,at 2 hour",Intermediate,9986.0,,A,,BAO_0000218,8650,,,1,CHEMBL875110,,,Oryctolagus cuniculus,N,1,,
12949,Compound was tested for antidiuretic activity in rats,Intermediate,10116.0,,A,,BAO_0000218,7116,,,1,CHEMBL630073,,,Rattus norvegicus,N,1,,
12950,Compound was tested for inactivation kinetic values,Autocuration,,,A,,BAO_0000019,14131,,,1,CHEMBL630074,,,,U,0,,
12951,Compound was evaluated for the average apparent volume of distribution when administered through intravenous route,Autocuration,,,A,,BAO_0000218,7415,,,1,CHEMBL630075,,,,U,0,,
12952,Dissociation rate calculated from the first-order equation using the t1/2 value,Autocuration,,,A,,BAO_0000019,13178,,,1,CHEMBL630076,,,,U,0,,
12953,Compound was evaluated for pKa by titration of the compounds in 1:2 methyl alcohol and water,Autocuration,,,P,,BAO_0000100,8815,,,1,CHEMBL630077,,,,U,0,,
12954,Aqueous solubility was measured,Autocuration,,,P,,BAO_0000100,1450,,,1,CHEMBL630078,,,,U,0,,
12955,Aqueous solubility was measured at a pH 4,Autocuration,,,P,,BAO_0000100,1450,,,1,CHEMBL630079,,,,U,0,,
12956,Aqueous solubility (pH 7),Autocuration,,,P,,BAO_0000100,1450,,,1,CHEMBL630080,,,,U,0,,
12957,Aqueous solubility was measured at a pH 9,Autocuration,,,P,,BAO_0000100,1450,,,1,CHEMBL630081,,,,U,0,,
12958,"Aqueous solubilities were determined by dissolving an crystalline hemisulfate and dichloride salts, respectively in water and adding acetate to pH 5.0, concentrations are expressed in free base equivalents",Autocuration,,,A,,BAO_0000019,12711,,,1,CHEMBL630082,,,,U,0,,
12959,"Aqueous solubilities were determined by dissolving an crystalline hemisulfate and dichloride salts, respectively in water and adding acetate to pH 5.0, concentrations are expressed in free base equivalents.",Autocuration,,,A,,BAO_0000019,12711,,,1,CHEMBL630083,,,,U,0,,
12960,"Aqueous solubilities were determined by dissolving an crystalline hemisulfate and dichloride salts, respectively in water and adding acetate to pH 5.0, concentrations are expressed in free base equivalents.",Autocuration,,,A,,BAO_0000019,12711,,,1,CHEMBL630084,,,,U,0,,
12961,Aqueous solubility of the compound,Autocuration,,,P,,BAO_0000100,15032,,,1,CHEMBL629198,,,,U,0,,
12962,Aqueous solubility at 37 degree Celsius at pH 7.38,Autocuration,,,P,,BAO_0000100,9964,,,1,CHEMBL629199,,,,U,0,,
12963,Aqueous solubility in pH 7.4 phosphate buffer,Autocuration,,,P,,BAO_0000100,14962,,,1,CHEMBL629200,,,,U,0,,
12964,Mean arterial pressure response following 10 mg/kg intraduodenal administration to salt depleted dog,Intermediate,9615.0,,A,,BAO_0000218,12487,,,1,CHEMBL629201,,,Canis lupus familiaris,N,1,,
12965,Mean arterial pressure response following 1 mg/kg intravenous administration to salt depleted dog,Intermediate,9615.0,,A,,BAO_0000218,12487,,,1,CHEMBL629202,,,Canis lupus familiaris,N,1,,
12966,Percentage of aspirin formed during hydrolysis in 10% human plasma at pH 7.4 at 37 degrees celsius,Intermediate,9606.0,,A,,BAO_0000218,10026,,,1,CHEMBL875111,,,Homo sapiens,N,1,,
12967,Percentage of aspirin formed during hydrolysis in undiluted human plasma at pH 7.4 at 37 degrees celsius,Intermediate,9606.0,,A,,BAO_0000218,10026,,,1,CHEMBL629203,,,Homo sapiens,N,1,,
12968,The percentage of aspirin formed during hydrolysis in 100% human plasma at pH 7.4 at 37 degrees celsius,Intermediate,9606.0,,A,,BAO_0000218,10026,,,1,CHEMBL629204,,,Homo sapiens,N,1,,
12969,The percentage of aspirin formed during hydrolysis in 20% human plasma at pH 7.4 at 37 degrees celsius,Intermediate,9606.0,,A,,BAO_0000218,10026,,,1,CHEMBL629205,,,Homo sapiens,N,1,,
12970,The percentage of aspirin formed during hydrolysis in 60% human plasma at pH 7.4 at 37 degrees celsius,Intermediate,9606.0,,A,,BAO_0000218,10026,,,1,CHEMBL629206,,,Homo sapiens,N,1,,
12971,The percentage of aspirin formed during hydrolysis in 80% human plasma at pH 7.4 at 37 degrees celsius,Autocuration,,,A,,BAO_0000019,10026,,,1,CHEMBL631185,,,,U,0,,
12972,Compound was evaluated for the average bile flow rat in rats,Intermediate,10116.0,,A,,BAO_0000218,7415,,,1,CHEMBL631186,,,Rattus norvegicus,N,1,,
12973,"Effect of compound on cartilage in surgically induced osteoarthritis (OA) model in rabbit at 15 mg/kg, value are relative to activity of RS-130830 (7.9+/-1.5) at 25 mg/kg",Intermediate,9986.0,,A,,BAO_0000218,17025,,,1,CHEMBL631187,,,Oryctolagus cuniculus,N,1,,
12974,"Effect of compound on cartilage in surgically induced osteoarthritis (OA) model in rabbit at 25 mg/kg, value are relative to activity of RS-130830 (7.9+/-1.5) at 25 mg/kg",Intermediate,9986.0,,A,,BAO_0000218,17025,,,1,CHEMBL631188,,,Oryctolagus cuniculus,N,1,,
12975,Average half life period was determined,Autocuration,,,A,,BAO_0000019,10184,,,1,CHEMBL876419,,,,U,0,,
12976,Average half life period was determined,Autocuration,,,A,,BAO_0000019,10184,,,1,CHEMBL631189,,,,U,0,,
12977,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 0.8 mg/kg per day.,Intermediate,10298.0,,A,,BAO_0000218,8613,,,1,CHEMBL631190,,,Human herpesvirus 1,N,1,,
12978,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 0.8 mg/kg per day.,Intermediate,10298.0,,A,,BAO_0000218,8613,,,1,CHEMBL631191,,,Human herpesvirus 1,N,1,,
12979,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 12.5 mg/kg per day.,Intermediate,10298.0,,A,,BAO_0000218,8613,,,1,CHEMBL631192,,,Human herpesvirus 1,N,1,,
12980,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 3.1 mg/kg per day.,Intermediate,10298.0,,A,,BAO_0000218,8613,,,1,CHEMBL632400,,,Human herpesvirus 1,N,1,,
12981,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 50 mg/kg per day.,Intermediate,10298.0,,A,,BAO_0000218,8613,,,1,CHEMBL630564,,,Human herpesvirus 1,N,1,,
12982,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 50 mg/kg per day.,Intermediate,10298.0,,A,,BAO_0000218,8613,,,1,CHEMBL630565,,,Human herpesvirus 1,N,1,,
12983,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.02 mg/kg per day.,Intermediate,10298.0,,A,,BAO_0000218,8613,,,1,CHEMBL630566,,,Human herpesvirus 1,N,1,,
12984,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.06 mg/kg per day.,Intermediate,10298.0,,A,,BAO_0000218,8613,,,1,CHEMBL631229,,,Human herpesvirus 1,N,1,,
12985,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.25 mg/kg per day.,Intermediate,10298.0,,A,,BAO_0000218,8613,,,1,CHEMBL631230,,,Human herpesvirus 1,N,1,,
12986,Calculated partition coefficient (clogP),Autocuration,,,P,,BAO_0000100,6030,,,1,CHEMBL876428,,,,U,0,,
12987,Calculated partition coefficient (clogP),Autocuration,,,P,,BAO_0000100,6147,,,1,CHEMBL631231,,,,U,0,,
12988,Calculated partition coefficient (clogP) (MacLogP),Autocuration,,,P,,BAO_0000100,14556,,,1,CHEMBL631232,,,,U,0,,
12989,Hydrophilicity was determined,Autocuration,,,A,,BAO_0000019,768,,,1,CHEMBL631233,,,,U,0,,
12990,Calculated partition coefficient (clogP),Autocuration,,,P,,BAO_0000100,14452,,,1,CHEMBL631234,,,,U,0,,
12991,Increased absorption was determined,Autocuration,,,A,,BAO_0000019,5237,,,1,CHEMBL883126,,,,U,0,,
12992,Lipophilicity value was evaluated,Autocuration,,,P,,BAO_0000100,14378,,,1,CHEMBL631235,,,,U,0,,
12993,Log P value of the compound.,Autocuration,,,P,,BAO_0000100,14418,,,1,CHEMBL631236,,,,U,0,,
12994,Partition coefficient of compound was determined,Autocuration,,,A,,BAO_0000019,5249,,,1,CHEMBL631237,,,,U,0,,
12995,Calculated partition coefficient (clogP),Autocuration,,,P,,BAO_0000100,14621,,,1,CHEMBL631238,,,,U,0,,
12996,Calculated partition coefficient (clogP),Autocuration,,,P,,BAO_0000100,12542,,,1,CHEMBL876429,,,,U,0,,
12997,Partition coefficient was measured by medchem software; Not calculated,Autocuration,,,A,,BAO_0000019,12542,,,1,CHEMBL631414,,,,U,0,,
12998,Partition coefficient was measured by octanol-water using standard shake-flask method,Autocuration,,,P,,BAO_0000100,12542,,,1,CHEMBL631415,,,,U,0,,
12999,Calculated partition coefficient (clogP),Autocuration,,,P,,BAO_0000100,15462,,,1,CHEMBL631416,,,,U,0,,
13000,Partition coefficient (logP),Autocuration,,,A,,BAO_0000019,14884,,,1,CHEMBL631417,,,,U,0,,
13001,Calculated partition coefficient (clogP),Autocuration,,,P,,BAO_0000100,16526,,,1,CHEMBL631418,,,,U,0,,
13002,The Octanol/Water partition coefficient CLogP,Autocuration,,,P,,BAO_0000100,13693,,,1,CHEMBL631419,,,,U,0,,
13003,The pharmacokinetic parameter C Log p was reported,Autocuration,,,A,,BAO_0000019,13693,,,1,CHEMBL631420,,,,U,0,,
13004,Calculated partition coefficient (clogP),Autocuration,,,P,,BAO_0000100,13779,,,1,CHEMBL631421,,,,U,0,,
13005,Calculated partition coefficient (clogP),Autocuration,,,P,,BAO_0000100,14772,,,1,CHEMBL631422,,,,U,0,,
13006,Calculated partition coefficient (clogP),Autocuration,,,P,,BAO_0000100,14393,,,1,CHEMBL631423,,,,U,0,,
13007,Clearance rate in rat plasma when administered intraperitoneally at a dose of 10 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,14793,,,1,CHEMBL876430,,,Rattus norvegicus,N,1,1969.0,
13008,Clearance rate in rat plasma when administered intravenously at a dose of 10 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,14793,,,1,CHEMBL631424,,,Rattus norvegicus,N,1,1969.0,
13009,Compound was administered intravenously in dog to evaluate plasma clearance values,Intermediate,9615.0,,A,,BAO_0000218,13744,,,1,CHEMBL631425,,,Canis lupus familiaris,N,1,1969.0,
13010,Compound was administered intravenously in monkey to evaluate plasma clearance values,Autocuration,314293.0,,A,,BAO_0000218,13744,,,1,CHEMBL631426,,,Simiiformes,U,0,1969.0,
13011,Compound was administered intravenously in mouse to evaluate plasma clearance values,Intermediate,10090.0,,A,,BAO_0000218,13744,,,1,CHEMBL631427,,,Mus musculus,N,1,1969.0,
13012,Compound was evaluated in vivo for plasma clearance in dog after intravenous dose at 2 mg/Kg,Intermediate,9615.0,,A,,BAO_0000218,13207,,,1,CHEMBL631428,,,Canis lupus familiaris,N,1,1969.0,
13013,Intrinsic clearance in Rhesus liver microsome,Intermediate,9544.0,,A,,BAO_0000218,5669,Microsomes,,1,CHEMBL631429,,,Macaca mulatta,N,1,2107.0,
13014,Intrinsic clearance in dog liver microsome,Intermediate,9615.0,,A,,BAO_0000218,5669,Microsomes,,1,CHEMBL631430,,,Canis lupus familiaris,N,1,2107.0,
13015,Intrinsic clearance in rat liver microsome,Intermediate,10116.0,,A,,BAO_0000218,5669,Microsomes,,1,CHEMBL631431,,,Rattus norvegicus,N,1,2107.0,
13016,Low plasma clearance was calculated in rhesus monkey,Intermediate,9544.0,,A,,BAO_0000218,4853,,,1,CHEMBL631432,,,Macaca mulatta,N,1,1969.0,
13017,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,Intermediate,9615.0,,A,,BAO_0000218,16452,,,1,CHEMBL631433,,,Canis lupus familiaris,N,1,,
13018,Plasma clearance after intravenous dose of 0.3 mg/kg,Autocuration,,,A,,BAO_0000218,11954,,,1,CHEMBL631434,,,,U,0,,
13019,Plasma clearance after intravenous dose of 1 mg/kg,Autocuration,,,A,,BAO_0000218,11954,,,1,CHEMBL631435,,,,U,0,,
13020,Plasma clearance after intravenous dose of 3 mg/kg,Autocuration,,,A,,BAO_0000218,11954,,,1,CHEMBL631436,,,,U,0,,
13021,Plasma clearance after intravenous dose of 3.87 mg/kg,Autocuration,,,A,,BAO_0000218,11954,,,1,CHEMBL631437,,,,U,0,,
13022,Plasma clearance after peroral administration at 10 mpk in Rat,Intermediate,10116.0,,A,,BAO_0000218,5669,,,1,CHEMBL631438,,,Rattus norvegicus,N,1,,
13023,Plasma clearance after peroral administration at 10 mpk in Rhesus,Intermediate,9544.0,,A,,BAO_0000218,5669,,,1,CHEMBL876431,,,Macaca mulatta,N,1,,
13024,Plasma clearance after peroral administration at 10 mpk in dog,Intermediate,9615.0,,A,,BAO_0000218,5669,,,1,CHEMBL631439,,,Canis lupus familiaris,N,1,,
13025,Totla clearance of compound reported after 5 mg/kg i.v. dose in rat,Intermediate,10116.0,,A,,BAO_0000218,13662,,,1,CHEMBL631440,,,Rattus norvegicus,N,1,,
13026,Compound was evaluated for physico-chemical property of Critical micellar concentration (CMC),Autocuration,,,A,,BAO_0000019,8272,,,1,CHEMBL631441,,,,U,0,,
13027,Critical Micellar concentration was determined,Autocuration,,,A,,BAO_0000019,13410,,,1,CHEMBL631442,,,,U,0,,
13028,Critical Micellar concentration of the compound. was determined,Autocuration,,,A,,BAO_0000019,13410,,,1,CHEMBL626525,,,,U,0,,
13029,Critical micelle concentration determined from the plots of the fluorescence intensity as a function of compound concentration,Autocuration,,,A,,BAO_0000019,12628,,,1,CHEMBL627168,,,,U,0,,
13030,Critical micellar concentration was measured in water by the dye solubilization method,Autocuration,,,A,,BAO_0000019,9675,,,1,CHEMBL875618,,,,U,0,,
13031,Hydrolysis turn over determined from the plots of the fluorescence assay quantified by HPLC,Autocuration,,,B,,BAO_0000019,12628,,,1,CHEMBL626612,,,,U,0,,
13032,CMR value (relative to BAY K 8644),Autocuration,,,A,,BAO_0000019,12766,,,1,CHEMBL626613,,,,U,0,,
13033,Carbamoylating activity was determined,Autocuration,,,A,,BAO_0000019,7849,,,1,CHEMBL626614,,,,U,0,,
13034,Hypotension peak is percentage change from predose baseline pressure observed after intraduodenal dose of 10 mg/kg in monkey,Autocuration,314293.0,,A,,BAO_0000218,12187,,,1,CHEMBL626615,,,Simiiformes,U,0,,
13035,Compound was evaluated for induced thermal stabilization for compound: DNA ratio of 1:10 at 0.1 to 0.2 degrees Centigrade.,Autocuration,,,A,,BAO_0000019,2040,,,1,CHEMBL626616,,,,U,0,,
13036,Compound was evaluated for induced thermal stabilization for compound: DNA ratio of 1:5 at 0.1 to 0.2 degrees Centigrade.,Autocuration,,,A,,BAO_0000019,2040,,,1,CHEMBL626617,,,,U,0,,
13037,Clearance from dog plasma after intravenous injection of 1 mg/kg of compound,Intermediate,9615.0,,A,,BAO_0000218,14180,,,1,CHEMBL626618,,,Canis lupus familiaris,N,1,1969.0,
13038,Clearance from rat plasma after intravenous injection of 1 mg/kg of compound,Intermediate,10116.0,,A,,BAO_0000218,14180,,,1,CHEMBL626619,,,Rattus norvegicus,N,1,1969.0,
13039,"Clearance rate at 0.46 mg/kg, iv, in dogs",Intermediate,9615.0,,A,,BAO_0000218,14474,,,1,CHEMBL626620,,,Canis lupus familiaris,N,1,,
13040,"Clearance rate at 5.5 mg/kg, iv, in rat",Intermediate,10116.0,,A,,BAO_0000218,14474,,,1,CHEMBL626621,,,Rattus norvegicus,N,1,,
13041,Pharmacokinetic parameter Cl calculated in cynomolgus monkey when the compound was administered intravenously at 1 mg/kg concentration,Intermediate,9541.0,,A,,BAO_0000218,14548,,,1,CHEMBL626622,,,Macaca fascicularis,N,1,,
13042,Pharmacokinetic parameter Cl calculated in cynomolgus monkey when the compound was administered intravenously at 0.5 mg/kg concentration,Intermediate,9541.0,,A,,BAO_0000218,14548,,,1,CHEMBL626623,,,Macaca fascicularis,N,1,,
13043,Pharmacokinetic parameter Cl calculated in dog when the compound was administered intravenously at 2 mg/kg concentration,Intermediate,9615.0,,A,,BAO_0000218,14548,,,1,CHEMBL626624,,,Canis lupus familiaris,N,1,,
13044,Pharmacokinetic parameter Cl calculated in rat when the compound was administered intravenously at 5 mg/kg concentration,Intermediate,10116.0,,A,,BAO_0000218,14548,,,1,CHEMBL626625,,,Rattus norvegicus,N,1,,
13045,Clearance rate constant using isolated perfused rat liver (IPRL) assay,Intermediate,10116.0,,A,,BAO_0000218,6125,,,1,CHEMBL626626,,,Rattus norvegicus,N,1,2107.0,
13046,Tested for the total clearance of the compound,Autocuration,,,A,,BAO_0000218,6874,,,1,CHEMBL626627,,,,U,0,,
13047,The clearance was measured in dogs after intravenous administration of 1 mg/kg dose,Intermediate,9615.0,,A,,BAO_0000218,15343,,,1,CHEMBL626628,,,Canis lupus familiaris,N,1,,
13048,Total body clearance was determined,Autocuration,,,A,,BAO_0000218,6236,,,1,CHEMBL626629,,,,U,0,,
13049,Mean Chlorine excretion in rats when compound administered at 0 mg/kg po and vehicle dosed at 0 umol/kg,Intermediate,10116.0,,A,,BAO_0000218,11510,,,1,CHEMBL626630,,,Rattus norvegicus,N,1,,
13050,Mean Chlorine excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 30.23 umol/kg,Intermediate,10116.0,,A,,BAO_0000218,11510,,,1,CHEMBL626631,,,Rattus norvegicus,N,1,,
13051,Solubility of 10 mg compound in aqueous buffer at pH 7.3 and 37 degree Centigrade after 8.0 hr,Autocuration,,,P,,BAO_0000100,8194,,,1,CHEMBL626632,,,,U,0,,
13052,Solubility of 150 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 4.0 hr,Autocuration,,,P,,BAO_0000100,8194,,,1,CHEMBL626633,,,,U,0,,
13053,Solubility of 150 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 8.0 hr,Autocuration,,,P,,BAO_0000100,8194,,,1,CHEMBL626634,,,,U,0,,
13054,Solubility of 20 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 13.5 hr,Autocuration,,,P,,BAO_0000100,8194,,,1,CHEMBL626635,,,,U,0,,
13055,Solubility of 20 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 4.0 hr,Autocuration,,,P,,BAO_0000100,8194,,,1,CHEMBL626636,,,,U,0,,
13056,Solubility of 20 mg compound in aqueous buffer at pH 7.3 and 37 degree Centigrade after 8.0 hr,Autocuration,,,P,,BAO_0000100,8194,,,1,CHEMBL626637,,,,U,0,,
13057,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 10.9 uM/Kg/day),Intermediate,4754.0,,A,,BAO_0000218,13273,,,1,CHEMBL626638,,,Pneumocystis carinii,N,1,,
13058,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 2.3 uM/Kg/day,Intermediate,4754.0,,A,,BAO_0000218,13273,,,1,CHEMBL626639,,,Pneumocystis carinii,N,1,,
13059,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 23.3 uM/Kg/day,Intermediate,4754.0,,A,,BAO_0000218,13273,,,1,CHEMBL626640,,,Pneumocystis carinii,N,1,,
13060,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 4.8 uM/Kg/day,Intermediate,4754.0,,A,,BAO_0000218,13273,,,1,CHEMBL626641,,,Pneumocystis carinii,N,1,,
13061,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 9.2 uM/Kg/day,Intermediate,4754.0,,A,,BAO_0000218,13273,,,1,CHEMBL627272,,,Pneumocystis carinii,N,1,,
13062,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted uM/Kg/day,Intermediate,4754.0,,A,,BAO_0000218,13273,,,1,CHEMBL627273,,,Pneumocystis carinii,N,1,,
13063,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 0.027 (uM/kg/day),Intermediate,4754.0,,A,,BAO_0000218,13273,,,1,CHEMBL627441,,,Pneumocystis carinii,N,1,,
13064,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 0.27 (uM/kg/day),Intermediate,4754.0,,A,,BAO_0000218,13273,,,1,CHEMBL628355,,,Pneumocystis carinii,N,1,,
13065,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 13.3 (uM/kg/day),Intermediate,4754.0,,A,,BAO_0000218,13273,,,1,CHEMBL628356,,,Pneumocystis carinii,N,1,,
13066,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 2.7 (uM/kg/day),Intermediate,4754.0,,A,,BAO_0000218,13273,,,1,CHEMBL628357,,,Pneumocystis carinii,N,1,,
13067,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 22.1 (uM/kg/day),Intermediate,4754.0,,A,,BAO_0000218,13273,,,1,CHEMBL628358,,,Pneumocystis carinii,N,1,,
13068,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 66.3 (uM/kg/day),Intermediate,4754.0,,A,,BAO_0000218,13273,,,1,CHEMBL622307,,,Pneumocystis carinii,N,1,,
13069,Conversion rate by hydrolysis of compound in plasma after 2 hr at a pH of 1.0,Autocuration,,,A,,BAO_0000019,13118,,,1,CHEMBL622527,,,,U,0,,
13070,Conversion rate by hydrolysis of compound in plasma after 2 hr at a pH of 1.0; Not detectable,Autocuration,,,A,,BAO_0000019,13118,,,1,CHEMBL622528,,,,U,0,,
13071,Conversion rate by hydrolysis of compound in plasma after 4 hr at a pH of 7.4,Autocuration,,,A,,BAO_0000019,13118,,,1,CHEMBL622529,,,,U,0,,
13072,Conversion rate by hydrolysis of compound in plasma after 4 hr at a pH of 7.4; Not detectable,Autocuration,,,A,,BAO_0000019,13118,,,1,CHEMBL622992,,,,U,0,,
13073,Conversion rate by hydrolysis of compound in plasma after 6 hr. ,Autocuration,,,A,,BAO_0000019,13118,,,1,CHEMBL622993,,,,U,0,,
13074,Conversion rate by hydrolysis of compound in plasma after 6 h; Not detectable,Autocuration,,,A,,BAO_0000019,13118,,,1,CHEMBL622994,,,,U,0,,
13075,"In vitro rate constant, correlation coefficient for the conversion to progesterone in rat liver homogenate",Intermediate,10116.0,,A,,BAO_0000218,10633,,,1,CHEMBL622995,,,Rattus norvegicus,N,1,,
13076,"In vitro rate constant, correlation coefficient for the conversion to progesterone in whole rat blood.",Intermediate,10116.0,,A,,BAO_0000218,10633,,,1,CHEMBL622996,,,Rattus norvegicus,N,1,,
13077,"In vitro rate constant, correlation coefficient for the disappearance in rat liver homogenate",Intermediate,10116.0,,A,,BAO_0000218,10633,,,1,CHEMBL622997,,,Rattus norvegicus,N,1,,
13078,"In vitro rate constant, correlation coefficient for the disappearance in rat brain homogenate",Intermediate,10116.0,,A,,BAO_0000218,10633,,,1,CHEMBL622998,,,Rattus norvegicus,N,1,,
13079,Cp max following ip administration at 1 mg/kg,Autocuration,,,A,,BAO_0000218,5767,,,1,CHEMBL622999,,,,U,0,,
13080,Maximum concentration in plasma was reported at 0.5 hour,Autocuration,,,A,,BAO_0000218,3302,,,1,CHEMBL623000,,,,U,0,1969.0,
13081,Maximum concentration in plasma was reported at 2 hour,Autocuration,,,A,,BAO_0000218,3302,,,1,CHEMBL623001,,,,U,0,1969.0,
13082,Cellular uptake kinetics of Porphycenes saturation cell level (cs) in SSK3 murine fibrosarcoma cells,Intermediate,10090.0,,A,,BAO_0000218,12467,,,1,CHEMBL623002,,,Mus musculus,N,1,,
13083,Aqueous solubility in 25 mM N-glycyl-glycine and 10 mM MgSO4 (pH 7.8),Autocuration,,,P,,BAO_0000100,11778,,,1,CHEMBL623003,,,,U,0,,
13084,Steady state concentration was evaluated,Autocuration,,,A,,BAO_0000019,4321,,,1,CHEMBL623004,,,,U,0,,
13085,Partition coefficient (logP),Autocuration,,,A,,BAO_0000019,14884,,,1,CHEMBL623005,,,,U,0,,
13086,Partition coefficient (logD7.4),Autocuration,,,A,,BAO_0000019,15234,,,1,CHEMBL623006,,,,U,0,,
13087,Biodistribution of {18]Fluoro-CGP 12388 (60 minutes post injection) in liver of male wistar rats,Intermediate,10116.0,,A,,BAO_0000218,14198,,,1,CHEMBL623007,,,Rattus norvegicus,N,1,2107.0,
13088,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in bone of male wistar rats,Intermediate,10116.0,,A,,BAO_0000218,14198,,,1,CHEMBL623008,,,Rattus norvegicus,N,1,10000001.0,
13089,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in cerebellum of male wistar rats,Intermediate,10116.0,,A,,BAO_0000218,14198,,,1,CHEMBL876654,,,Rattus norvegicus,N,1,2037.0,
13090,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in cortex of male wistar rats,Intermediate,10116.0,,A,,BAO_0000218,14198,,,1,CHEMBL623009,,,Rattus norvegicus,N,1,,
13091,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in fat of male wistar rats,Intermediate,10116.0,,A,,BAO_0000218,14198,,,1,CHEMBL623010,,,Rattus norvegicus,N,1,,
13092,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in heart of male wistar rats,Intermediate,10116.0,,A,,BAO_0000218,14198,,,1,CHEMBL623011,,,Rattus norvegicus,N,1,948.0,
13093,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in intestine of male wistar rats,Intermediate,10116.0,,A,,BAO_0000218,14198,,,1,CHEMBL623012,,,Rattus norvegicus,N,1,160.0,
13094,Antidiuretic activity was determined expressed as Na+(sodium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 25 mg/Kg,Autocuration,,,A,,BAO_0000019,8151,,,1,CHEMBL623013,,,,U,0,,
13095,Antidiuretic activity was determined expressed as Na+(sodium) excreted in milli euivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg,Autocuration,,,A,,BAO_0000019,8151,,,1,CHEMBL623014,,,,U,0,,
13096,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 10 mg/Kg,Autocuration,,,A,,BAO_0000019,8151,,,1,CHEMBL623015,,,,U,0,1088.0,
13097,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 100 mg/Kg,Autocuration,,,A,,BAO_0000019,8151,,,1,CHEMBL623016,,,,U,0,1088.0,
13098,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 25 mg/Kg,Autocuration,,,A,,BAO_0000019,8151,,,1,CHEMBL624858,,,,U,0,1088.0,
13099,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 10 mg/Kg.,Intermediate,10116.0,,A,,BAO_0000218,8151,,,1,CHEMBL624859,,,Rattus norvegicus,N,1,,
13100,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg,Intermediate,10116.0,,A,,BAO_0000218,8151,,,1,CHEMBL624860,,,Rattus norvegicus,N,1,,
13101,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg.,Intermediate,10116.0,,A,,BAO_0000218,8151,,,1,CHEMBL624861,,,Rattus norvegicus,N,1,,
13102,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 25 mg/Kg,Intermediate,10116.0,,A,,BAO_0000218,8151,,,1,CHEMBL624862,,,Rattus norvegicus,N,1,,
13103,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 25 mg/Kg.,Intermediate,10116.0,,A,,BAO_0000218,8151,,,1,CHEMBL624863,,,Rattus norvegicus,N,1,,
13104,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli euivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg.,Intermediate,10116.0,,A,,BAO_0000218,8151,,,1,CHEMBL876655,,,Rattus norvegicus,N,1,,
13105,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog,Intermediate,9615.0,,A,,BAO_0000218,6996,,,1,CHEMBL624864,,,Canis lupus familiaris,N,1,,
13106,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 0-99,Intermediate,9615.0,,A,,BAO_0000218,6996,,,1,CHEMBL624865,,,Canis lupus familiaris,N,1,,
13107,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 100-249,Intermediate,9615.0,,A,,BAO_0000218,6996,,,1,CHEMBL624866,,,Canis lupus familiaris,N,1,,
13108,Salidiuretic activity in dog following i.v. dosing at 5 mg/kg,Expert,9615.0,,F,,BAO_0000218,6996,,,1,CHEMBL624867,,,Canis lupus familiaris,N,1,,
13109,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 400-599,Intermediate,9615.0,,A,,BAO_0000218,6996,,,1,CHEMBL624868,,,Canis lupus familiaris,N,1,,
13110,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 600- 799,Intermediate,9615.0,,A,,BAO_0000218,6996,,,1,CHEMBL628450,,,Canis lupus familiaris,N,1,,
13111,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 600-799,Intermediate,9615.0,,A,,BAO_0000218,6996,,,1,CHEMBL628451,,,Canis lupus familiaris,N,1,,
13112,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 800-899,Intermediate,9615.0,,A,,BAO_0000218,6996,,,1,CHEMBL628452,,,Canis lupus familiaris,N,1,,
13113,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 100-249,Intermediate,9615.0,,A,,BAO_0000218,6996,,,1,CHEMBL628453,,,Canis lupus familiaris,N,1,,
13114,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; act above 5 mg/kg,Intermediate,9615.0,,A,,BAO_0000218,6996,,,1,CHEMBL628454,,,Canis lupus familiaris,N,1,,
13115,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog,Intermediate,9615.0,,A,,BAO_0000218,6996,,,1,CHEMBL628455,,,Canis lupus familiaris,N,1,,
13116,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 0-99,Intermediate,9615.0,,A,,BAO_0000218,6996,,,1,CHEMBL628456,,,Canis lupus familiaris,N,1,,
13117,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 100-249,Intermediate,9615.0,,A,,BAO_0000218,6996,,,1,CHEMBL628457,,,Canis lupus familiaris,N,1,,
13118,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 100-299,Intermediate,9615.0,,A,,BAO_0000218,6996,,,1,CHEMBL877505,,,Canis lupus familiaris,N,1,,
13119,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 250-399,Intermediate,9615.0,,A,,BAO_0000218,6996,,,1,CHEMBL628458,,,Canis lupus familiaris,N,1,,
13120,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 400-599,Intermediate,9615.0,,A,,BAO_0000218,6996,,,1,CHEMBL628459,,,Canis lupus familiaris,N,1,,
13121,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 600-799,Intermediate,9615.0,,A,,BAO_0000218,6996,,,1,CHEMBL628460,,,Canis lupus familiaris,N,1,,
13122,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 800-899,Intermediate,9615.0,,A,,BAO_0000218,6996,,,1,CHEMBL628461,,,Canis lupus familiaris,N,1,,
13123,"Evaluated for salidiuretic activity measured as sodium ion excretion in Rat, administered orally at a dose of 16.5 mg/kg",Autocuration,,,B,,BAO_0000218,6996,,,1,CHEMBL628462,,,,U,0,,
13124,Compound administered orally at a dose of 1 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Rat,Intermediate,9615.0,,A,,BAO_0000218,6996,,,1,CHEMBL628463,,,Canis lupus familiaris,N,1,,
13125,"Evaluated for salidiuretic activity measured as sodium ion excretion in Rat, administered orally at a dose of 50 mg/kg",Expert,10116.0,,F,,BAO_0000218,6996,,,1,CHEMBL625666,,,Rattus norvegicus,N,1,,
13126,Compound administered orally at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Rat,Autocuration,,,B,,BAO_0000218,6996,,,1,CHEMBL625667,,,,U,0,,
13127,Compound administered orally at a dose of 81 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Rat,Expert,10116.0,,A,,BAO_0000218,6996,,,1,CHEMBL625668,,,Rattus norvegicus,N,1,,
13128,Compound administered orally was evaluated for salidiuretic activity measured as sodium ion excretion in Rat,Intermediate,10116.0,,A,,BAO_0000218,6996,,,1,CHEMBL625669,,,Rattus norvegicus,N,1,,
13129,Compound was tested for diuretic activity in potassium content of the 3-h sample was measured by flame photometry,Autocuration,,,A,,BAO_0000019,7114,,,1,CHEMBL625670,,,,U,0,,
13130,Compound was tested for diuretic activity in potassium content of the 3-h sample was measured by flame photometry in rat,Intermediate,10116.0,,A,,BAO_0000218,7114,,,1,CHEMBL625671,,,Rattus norvegicus,N,1,,
13131,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 1 mg/kg per day.,Intermediate,10298.0,,A,,BAO_0000218,8613,,,1,CHEMBL625672,,,Human herpesvirus 1,N,1,,
13132,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 0.8 mg/kg administered subcutaneously,Intermediate,10298.0,,A,,BAO_0000218,8613,,,1,CHEMBL625673,,,Human herpesvirus 1,N,1,,
13133,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 0.8 mg/kg administered subcutaneously.,Intermediate,10298.0,,A,,BAO_0000218,8613,,,1,CHEMBL625674,,,Human herpesvirus 1,N,1,,
13134,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 12.5 mg/kg administered subcutaneously,Intermediate,10298.0,,A,,BAO_0000218,8613,,,1,CHEMBL625675,,,Human herpesvirus 1,N,1,,
13135,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 12.5 mg/kg administered subcutaneously.,Intermediate,10298.0,,A,,BAO_0000218,8613,,,1,CHEMBL627637,,,Human herpesvirus 1,N,1,,
13136,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 12.5 mg/kg administered orally.,Intermediate,10298.0,,A,,BAO_0000218,8613,,,1,CHEMBL627638,,,Human herpesvirus 1,N,1,,
13137,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 3.1 mg/kg administered subcutaneously,Intermediate,10298.0,,A,,BAO_0000218,8613,,,1,CHEMBL627639,,,Human herpesvirus 1,N,1,,
13138,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 3.1 mg/kg administered subcutaneously.,Intermediate,10298.0,,A,,BAO_0000218,8613,,,1,CHEMBL627640,,,Human herpesvirus 1,N,1,,
13139,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 3.1 mg/kg administered orally.,Intermediate,10298.0,,A,,BAO_0000218,8613,,,1,CHEMBL627641,,,Human herpesvirus 1,N,1,,
13140,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 50 mg/kg administered orally.,Intermediate,10298.0,,A,,BAO_0000218,8613,,,1,CHEMBL627642,,,Human herpesvirus 1,N,1,,
13141,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 50 mg/kg administered orally.,Intermediate,10298.0,,A,,BAO_0000218,8613,,,1,CHEMBL877506,,,Human herpesvirus 1,N,1,,
13142,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 12.5 mg/kg administered subcutaneously.,Intermediate,10090.0,,A,,BAO_0000218,8613,,,1,CHEMBL627275,,,Mus musculus,N,1,,
13143,"Average area under curve value dosed at 0.3 mg/kg, iv in ferrets.",Intermediate,9669.0,,A,,BAO_0000218,11219,,,1,CHEMBL627643,,,Mustela putorius furo,N,1,,
13144,"Average area under curve value dosed at 10 mg/kg, id in ferrets.",Intermediate,9669.0,,A,,BAO_0000218,11219,,,1,CHEMBL631246,,,Mustela putorius furo,N,1,,
13145,"Average area under curve value dosed at 10 mg/kg, id in ferrets.",Intermediate,9669.0,,A,,BAO_0000218,11219,,,1,CHEMBL631247,,,Mustela putorius furo,N,1,,
13146,Average peak plasma drug concentration after id dose of 10 mg/kg in ferrets(Plasma samples collected from portal blood).,Intermediate,9669.0,,A,,BAO_0000218,11219,,,1,CHEMBL629532,,,Mustela putorius furo,N,1,,
13147,Average peak plasma drug concentration after id dose of 10 mg/kg in ferrets(Plasma samples collected from arterial blood).,Intermediate,9669.0,,A,,BAO_0000218,11219,,,1,CHEMBL629533,,,Mustela putorius furo,N,1,,
13148,Average peak plasma drug concentration after id dose of 10 mg/kg in ferrets(Plasma samples collected from portal blood).,Intermediate,9669.0,,A,,BAO_0000218,11219,,,1,CHEMBL629534,,,Mustela putorius furo,N,1,,
13149,Average peak plasma drug concentration after iv dose of 0.3 mg/kg in ferrets.,Intermediate,9669.0,,A,,BAO_0000218,11219,,,1,CHEMBL629535,,,Mustela putorius furo,N,1,,
13150,Pharmacokinetic parameter :drug bound to plasma was reported,Autocuration,,,A,,BAO_0000019,14837,,,1,CHEMBL625932,,,,U,0,,
13151,compound was evaluated for drug bound in plasma,Autocuration,,,A,,BAO_0000019,14837,,,1,CHEMBL625933,,,,U,0,,
13152,The Brain concentration compared to plasma concentration in rats after oral administration of 1 mg/kg dose,Intermediate,10116.0,,A,,BAO_0000218,15343,,,1,CHEMBL625934,,,Rattus norvegicus,N,1,,
13153,Bioavailability,Autocuration,9347.0,,A,,BAO_0000218,13761,,,1,CHEMBL625935,,,Eutheria,U,0,,
13154,Compound at a dose of 10 mg/kg was orally administered to rats and Bioavailability was reported,Intermediate,10116.0,,A,,BAO_0000218,14810,,,1,CHEMBL625936,,,Rattus norvegicus,N,1,,
13155,Compound at a dose of 10 mg/kg was orally administered to rats and Bioavailability was reported; Not tested,Intermediate,10116.0,,A,,BAO_0000218,14810,,,1,CHEMBL625937,,,Rattus norvegicus,N,1,,
13156,Oral bioavailability in Beagle dogs at oral dose of 20 mg/kg and an intravenous dose of 5 mg/kg was administered,Intermediate,9615.0,,A,,BAO_0000218,13249,,,1,CHEMBL625938,,,Canis lupus familiaris,N,1,,
13157,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-1 hr after the treatment.,Intermediate,10116.0,,A,,BAO_0000218,9267,,,1,CHEMBL625939,,,Rattus norvegicus,N,1,1970.0,
13158,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-2 hr after the treatment.,Intermediate,10116.0,,A,,BAO_0000218,9267,,,1,CHEMBL625940,,,Rattus norvegicus,N,1,1970.0,
13159,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-3 hr after the treatment.,Intermediate,10116.0,,A,,BAO_0000218,9267,,,1,CHEMBL874464,,,Rattus norvegicus,N,1,1970.0,
13160,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-4 hr after the treatment.,Intermediate,10116.0,,A,,BAO_0000218,9267,,,1,CHEMBL625941,,,Rattus norvegicus,N,1,1970.0,
13161,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-5 hr after the treatment.,Intermediate,10116.0,,A,,BAO_0000218,9267,,,1,CHEMBL625942,,,Rattus norvegicus,N,1,1970.0,
13162,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-6 hr after the treatment.,Intermediate,10116.0,,A,,BAO_0000218,9267,,,1,CHEMBL625943,,,Rattus norvegicus,N,1,1970.0,
13163,In vitro protein binding in human serum at 5 ug/ml,Intermediate,9606.0,,A,,BAO_0000218,15549,,,1,CHEMBL625944,,,Homo sapiens,N,1,1977.0,
13164,Serum protein binding ability was measured,Autocuration,,,A,,BAO_0000019,10929,,,1,CHEMBL625945,,,,U,0,,
13165,The ability binding to plasma (Binding classified based on injection of compound at 80 concentration.),Autocuration,,,A,,BAO_0000019,15444,,,1,CHEMBL625946,,,,U,0,,
13166,Oral bioavailability in dog,Autocuration,9615.0,,A,,BAO_0000218,12860,,,1,CHEMBL625947,,,Canis lupus familiaris,U,0,,
13167,% bioavailability in rat after oral dose (10 mg/kg) 0 - 6 h.,Intermediate,10116.0,,A,,BAO_0000218,12170,,,1,CHEMBL625948,,,Rattus norvegicus,N,1,,
13168,Absolute oral bioavailability at an iv dose of 14 mg/kg,Autocuration,,,A,,BAO_0000218,15173,,,1,CHEMBL625949,,,,U,0,,
13169,Absolute oral bioavailability at an iv dose of 15.2 mg/kg,Autocuration,,,A,,BAO_0000218,15173,,,1,CHEMBL625950,,,,U,0,,
13170,Oral bioavailability (dose 15 mg/kg i.v.),Autocuration,9347.0,,A,,BAO_0000218,15173,,,1,CHEMBL625951,,,Eutheria,U,0,,
13171,Absolute oral bioavailability at an peroral dose of 15 mg/kg orally.,Autocuration,,,A,,BAO_0000218,15173,,,1,CHEMBL625952,,,,U,0,,
13172,Absolute oral bioavailability at an peroral dose of 30 mg/kg orally,Autocuration,,,A,,BAO_0000218,15173,,,1,CHEMBL625953,,,,U,0,,
13173,Absolute oral bioavailability at an peroral dose of 30.2 mg/kg orally.,Autocuration,,,A,,BAO_0000218,15173,,,1,CHEMBL625954,,,,U,0,,
13174,Absolute oral bioavailability at an peroral dose of 30.3 mg/kg orally.,Autocuration,,,A,,BAO_0000218,15173,,,1,CHEMBL882959,,,,U,0,,
13175,Apparent bioavailability in dogs at 15 mg/kg in an iv vs po dosing regimen,Intermediate,9615.0,,A,,BAO_0000218,11767,,,1,CHEMBL625955,,,Canis lupus familiaris,N,1,,
13176,Bioavailability in ferret,Autocuration,9669.0,,A,,BAO_0000218,11219,,,1,CHEMBL625956,,,Mustela putorius furo,U,0,,
13177,Bioavailability after intraduodenal administration at a dose 10 mg/kg in cynomolgus monkeys using renin inhibition assay,Intermediate,9541.0,,A,,BAO_0000218,12186,,,1,CHEMBL625957,,,Macaca fascicularis,N,1,,
13178,Mean Chlorine excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 33.59 umol/kg,Intermediate,10116.0,,A,,BAO_0000218,11510,,,1,CHEMBL625958,,,Rattus norvegicus,N,1,,
13179,Mean Chlorine excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 37.13 umol/kg,Intermediate,10116.0,,A,,BAO_0000218,11510,,,1,CHEMBL625959,,,Rattus norvegicus,N,1,,
13180,Mean Chlorine excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 39.48 umol/kg,Intermediate,10116.0,,A,,BAO_0000218,11510,,,1,CHEMBL626642,,,Rattus norvegicus,N,1,,
13181,Mean Chlorine excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 483.72 umol/kg,Intermediate,10116.0,,A,,BAO_0000218,11510,,,1,CHEMBL631330,,,Rattus norvegicus,N,1,,
13182,Mean Chlorine excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg,Intermediate,10116.0,,A,,BAO_0000218,11510,,,1,CHEMBL631331,,,Rattus norvegicus,N,1,,
13183,Mean Chlorine excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg; Not determined,Intermediate,10116.0,,A,,BAO_0000218,11510,,,1,CHEMBL631332,,,Rattus norvegicus,N,1,,
13184,Mean Chlorine excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 631.76 umol/kg,Intermediate,10116.0,,A,,BAO_0000218,11510,,,1,CHEMBL631333,,,Rattus norvegicus,N,1,,
13185,Mean Chlorine excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 7.56 umol/kg,Intermediate,10116.0,,A,,BAO_0000218,11510,,,1,CHEMBL632018,,,Rattus norvegicus,N,1,,
13186,Mean Chlorine excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 8.4 umol/kg,Intermediate,10116.0,,A,,BAO_0000218,11510,,,1,CHEMBL632019,,,Rattus norvegicus,N,1,,
13187,Mean Chlorine excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.28 umol/kg,Intermediate,10116.0,,A,,BAO_0000218,11510,,,1,CHEMBL632020,,,Rattus norvegicus,N,1,,
13188,Mean Chlorine excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.87 umol/kg,Intermediate,10116.0,,A,,BAO_0000218,11510,,,1,CHEMBL632021,,,Rattus norvegicus,N,1,,
13189,Mean Chlorine excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 60.46 umol/kg,Intermediate,10116.0,,A,,BAO_0000218,11510,,,1,CHEMBL632022,,,Rattus norvegicus,N,1,,
13190,Mean Chlorine excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 67.18 umol/kg,Intermediate,10116.0,,A,,BAO_0000218,11510,,,1,CHEMBL632023,,,Rattus norvegicus,N,1,,
13191,Mean Chlorine excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 74.26 umol/kg,Intermediate,10116.0,,A,,BAO_0000218,11510,,,1,CHEMBL632024,,,Rattus norvegicus,N,1,,
13192,Mean Chlorine excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 78.97 umol/kg,Intermediate,10116.0,,A,,BAO_0000218,11510,,,1,CHEMBL874472,,,Rattus norvegicus,N,1,,
13193,Mean Chlorine excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 120.93 umol/kg,Intermediate,10116.0,,A,,BAO_0000218,11510,,,1,CHEMBL632025,,,Rattus norvegicus,N,1,,
13194,Mean Chlorine excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 134.35 umol/kg,Intermediate,10116.0,,A,,BAO_0000218,11510,,,1,CHEMBL632026,,,Rattus norvegicus,N,1,,
13195,Mean Chlorine excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 148.52 umol/kg,Intermediate,10116.0,,A,,BAO_0000218,11510,,,1,CHEMBL632027,,,Rattus norvegicus,N,1,,
13196,Mean Chlorine excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 157.94 umol/kg,Intermediate,10116.0,,A,,BAO_0000218,11510,,,1,CHEMBL632028,,,Rattus norvegicus,N,1,,
13197,Mean Chlorine excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 15.12 umol/kg,Intermediate,10116.0,,A,,BAO_0000218,11510,,,1,CHEMBL626430,,,Rattus norvegicus,N,1,,
13198,Mean Chlorine excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 16.79 umol/kg,Intermediate,10116.0,,A,,BAO_0000218,11510,,,1,CHEMBL626431,,,Rattus norvegicus,N,1,,
13199,Mean Chlorine excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 18.56 umol/kg,Intermediate,10116.0,,A,,BAO_0000218,11510,,,1,CHEMBL626432,,,Rattus norvegicus,N,1,,
13200,Mean Chlorine excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 19.74 umol/kg,Intermediate,10116.0,,A,,BAO_0000218,11510,,,1,CHEMBL626433,,,Rattus norvegicus,N,1,,
13201,Mean Chlorine excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 241.86 umol/kg,Intermediate,10116.0,,A,,BAO_0000218,11510,,,1,CHEMBL626434,,,Rattus norvegicus,N,1,,
13202,Mean Chlorine excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 268.71 umol/kg,Intermediate,10116.0,,A,,BAO_0000218,11510,,,1,CHEMBL627280,,,Rattus norvegicus,N,1,,
13203,Mean Chlorine excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 297.03 umol/kg,Intermediate,10116.0,,A,,BAO_0000218,11510,,,1,CHEMBL627281,,,Rattus norvegicus,N,1,,
13204,Mean Chlorine excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 315.88 umol/kg,Intermediate,10116.0,,A,,BAO_0000218,11510,,,1,CHEMBL627282,,,Rattus norvegicus,N,1,,
13205,Total body clearance was measured at given dose,Autocuration,,,A,,BAO_0000019,7199,,,1,CHEMBL627283,,,,U,0,,
13206,Total body clearance was measured at given dose.,Autocuration,,,A,,BAO_0000218,7199,,,1,CHEMBL627284,,,,U,0,,
13207,Metabolic clearance from the body in rat,Intermediate,10116.0,,A,,BAO_0000218,7095,,,1,CHEMBL627285,,,Rattus norvegicus,N,1,,
13208,Renal clearance from the body,Autocuration,,,A,,BAO_0000218,7095,,,1,CHEMBL627286,,,,U,0,,
13209,Renal clearance from the body in rat,Intermediate,10116.0,,A,,BAO_0000218,7095,,,1,CHEMBL875477,,,Rattus norvegicus,N,1,,
13210,Tested for pharmacokinetic parameter to calculate the total body clearance at a dosage of 12 mg/kg in rat,Intermediate,10116.0,,A,,BAO_0000218,12528,,,1,CHEMBL627287,,,Rattus norvegicus,N,1,,
13211,Tested for pharmacokinetic parameter to calculate the total body clearance at a dosage of 2.5 mg/kg in dog,Intermediate,9615.0,,A,,BAO_0000218,12528,,,1,CHEMBL627288,,,Canis lupus familiaris,N,1,,
13212,Total clearance from the body in rat,Intermediate,10116.0,,A,,BAO_0000218,7095,,,1,CHEMBL627289,,,Rattus norvegicus,N,1,,
13213,Clearance into cortex from rat plasma or PBS,Intermediate,10116.0,,A,,BAO_0000218,14223,,,1,CHEMBL627290,,,Rattus norvegicus,N,1,1969.0,
13214,Clearance at an iv dose of 15 mg/Kg and po dose of 120 mg/Kg,Autocuration,,,A,,BAO_0000218,13569,,,1,CHEMBL627291,,,,U,0,,
13215,Clearance at an iv dose of 15 mg/Kg and po dose of 240 mg/Kg,Autocuration,,,A,,BAO_0000218,13569,,,1,CHEMBL627292,,,,U,0,,
13216,Clearance at an iv dose of 15 mg/Kg and po dose of 29.1 mg/Kg,Autocuration,,,A,,BAO_0000218,13569,,,1,CHEMBL627293,,,,U,0,,
13217,Clearance at an iv dose of 15 mg/Kg and po dose of 30 mg/Kg,Autocuration,,,A,,BAO_0000218,13569,,,1,CHEMBL627294,,,,U,0,,
13218,Clearance at an iv dose of 15 mg/Kg and po dose of 60 mg/Kg,Autocuration,,,A,,BAO_0000218,13569,,,1,CHEMBL875478,,,,U,0,,
13219,Clearance was determined,Autocuration,,,A,,BAO_0000218,13979,,,1,CHEMBL627295,,,,U,0,,
13220,Clearance was measured in mouse after administration of compound 20 mg/kg intravenously,Intermediate,10090.0,,A,,BAO_0000218,14315,,,1,CHEMBL627296,,,Mus musculus,N,1,,
13221,Clearance was measured in rabbit after administration of compound 20 mg/kg intravenously,Intermediate,9986.0,,A,,BAO_0000218,14315,,,1,CHEMBL626119,,,Oryctolagus cuniculus,N,1,,
13222,Clearance was measured in rat after administration of compound 20 mg/kg intravenously,Intermediate,10116.0,,A,,BAO_0000218,14315,,,1,CHEMBL626120,,,Rattus norvegicus,N,1,,
13223,Clearance in rat after iv dose (100 ug/kg),Intermediate,10116.0,,A,,BAO_0000218,12174,,,1,CHEMBL626121,,,Rattus norvegicus,N,1,,
13224,Clearance in guinea pig,Autocuration,10141.0,,A,,BAO_0000218,12797,,,1,CHEMBL626122,,,Cavia porcellus,U,0,,
13225,Compound was evaluated for clearance in rat,Intermediate,10116.0,,A,,BAO_0000218,12797,,,1,CHEMBL626123,,,Rattus norvegicus,N,1,,
13226,Compound was evaluated for the clearance in dog,Intermediate,9615.0,,A,,BAO_0000218,12797,,,1,CHEMBL623456,,,Canis lupus familiaris,N,1,,
13227,Compound was evaluated for the clearance in rat,Intermediate,10116.0,,A,,BAO_0000218,12797,,,1,CHEMBL623457,,,Rattus norvegicus,N,1,,
13228,Compound was tested in vivo for clearance after iv administration in the rat,Intermediate,10116.0,,A,,BAO_0000218,11500,,,1,CHEMBL623458,,,Rattus norvegicus,N,1,,
13229,IV clearance determined at an iv dose of 14 mg/kg,Autocuration,,,A,,BAO_0000218,15173,,,1,CHEMBL623459,,,,U,0,,
13230,IV clearance determined at an iv dose of 15.2 mg/kg,Autocuration,,,A,,BAO_0000218,15173,,,1,CHEMBL875484,,,,U,0,,
13231,IV clearance determined at an iv dose of 15 mg/kg,Autocuration,,,A,,BAO_0000218,15173,,,1,CHEMBL623460,,,,U,0,,
13232,IV clearance determined at an peroral dose of 30 mg/kg.,Autocuration,,,A,,BAO_0000218,15173,,,1,CHEMBL623461,,,,U,0,,
13233,IV clearance determined at an peroral dose of 30.2 mg/kg.,Autocuration,,,A,,BAO_0000218,15173,,,1,CHEMBL623462,,,,U,0,,
13234,IV clearance determined at an peroral dose of 30.3 mg/kg.,Autocuration,,,A,,BAO_0000218,15173,,,1,CHEMBL627386,,,,U,0,,
13235,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in kidney of male wistar rats,Intermediate,10116.0,,A,,BAO_0000218,14198,,,1,CHEMBL627387,,,Rattus norvegicus,N,1,2113.0,
13236,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in liver of male wistar rats,Intermediate,10116.0,,A,,BAO_0000218,14198,,,1,CHEMBL627388,,,Rattus norvegicus,N,1,2107.0,
13237,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in lung of male wistar rats,Intermediate,10116.0,,A,,BAO_0000218,14198,,,1,CHEMBL627389,,,Rattus norvegicus,N,1,2048.0,
13238,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in muscle of male wistar rats,Intermediate,10116.0,,A,,BAO_0000218,14198,,,1,CHEMBL627390,,,Rattus norvegicus,N,1,2385.0,
13239,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in plasma of male wistar rats,Intermediate,10116.0,,A,,BAO_0000218,14198,,,1,CHEMBL627391,,,Rattus norvegicus,N,1,1969.0,
13240,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in red blood cells of male wistar rats,Intermediate,10116.0,,A,,BAO_0000218,14198,,,1,CHEMBL627392,,,Rattus norvegicus,N,1,,
13241,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in spleen of male wistar rats,Intermediate,10116.0,,A,,BAO_0000218,14198,,,1,CHEMBL627393,,,Rattus norvegicus,N,1,2106.0,
13242,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in trachea of male wistar rats,Intermediate,10116.0,,A,,BAO_0000218,14198,,,1,CHEMBL627394,,,Rattus norvegicus,N,1,3126.0,
13243,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in bone of male wistar rats,Intermediate,10116.0,,A,,BAO_0000218,14198,,,1,CHEMBL627395,,,Rattus norvegicus,N,1,10000001.0,
13244,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in cerebellum of male wistar rats,Intermediate,10116.0,,A,,BAO_0000218,14198,,,1,CHEMBL875485,,,Rattus norvegicus,N,1,2037.0,
13245,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in cortex of male wistar rats,Intermediate,10116.0,,A,,BAO_0000218,14198,,,1,CHEMBL627396,,,Rattus norvegicus,N,1,,
13246,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in fat of male wistar rats,Intermediate,10116.0,,A,,BAO_0000218,14198,,,1,CHEMBL627397,,,Rattus norvegicus,N,1,,
13247,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in heart of male wistar rats,Intermediate,10116.0,,A,,BAO_0000218,14198,,,1,CHEMBL627398,,,Rattus norvegicus,N,1,948.0,
13248,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in intestine bone of male wistar rats,Intermediate,10116.0,,A,,BAO_0000218,14198,,,1,CHEMBL627399,,,Rattus norvegicus,N,1,10000001.0,
13249,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in kidney of male wistar rats,Intermediate,10116.0,,A,,BAO_0000218,14198,,,1,CHEMBL627400,,,Rattus norvegicus,N,1,2113.0,
13250,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in liver of male wistar rats,Intermediate,10116.0,,A,,BAO_0000218,14198,,,1,CHEMBL627401,,,Rattus norvegicus,N,1,2107.0,
13251,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in lung of male wistar rats,Intermediate,10116.0,,A,,BAO_0000218,14198,,,1,CHEMBL627402,,,Rattus norvegicus,N,1,2048.0,
13252,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in muscle of male wistar rats,Intermediate,10116.0,,A,,BAO_0000218,14198,,,1,CHEMBL627403,,,Rattus norvegicus,N,1,2385.0,
13253,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in plasma of male wistar rats,Intermediate,10116.0,,A,,BAO_0000218,14198,,,1,CHEMBL627404,,,Rattus norvegicus,N,1,1969.0,
13254,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in red blood cells of male wistar rats,Intermediate,10116.0,,A,,BAO_0000218,14198,,,1,CHEMBL623101,,,Rattus norvegicus,N,1,,
13255,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in spleen of male wistar rats,Intermediate,10116.0,,A,,BAO_0000218,14198,,,1,CHEMBL877480,,,Rattus norvegicus,N,1,2106.0,
13256,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in trachea of male wistar rats,Intermediate,10116.0,,A,,BAO_0000218,14198,,,1,CHEMBL623102,,,Rattus norvegicus,N,1,3126.0,
13257,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in bone of male wistar rats,Intermediate,10116.0,,A,,BAO_0000218,14198,,,1,CHEMBL623103,,,Rattus norvegicus,N,1,10000001.0,
13258,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in cerebellum of male wistar rats,Intermediate,10116.0,,A,,BAO_0000218,14198,,,1,CHEMBL623104,,,Rattus norvegicus,N,1,2037.0,
13259,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in cortex of male wistar rats,Intermediate,10116.0,,A,,BAO_0000218,14198,,,1,CHEMBL623105,,,Rattus norvegicus,N,1,,
13260,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in fat of male wistar rats,Intermediate,10116.0,,A,,BAO_0000218,14198,,,1,CHEMBL623106,,,Rattus norvegicus,N,1,,
13261,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in heart of male wistar rats,Intermediate,10116.0,,A,,BAO_0000218,14198,,,1,CHEMBL623107,,,Rattus norvegicus,N,1,948.0,
13262,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in intestine of male wistar rats,Intermediate,10116.0,,A,,BAO_0000218,14198,,,1,CHEMBL623108,,,Rattus norvegicus,N,1,160.0,
13263,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in kidney of male wistar rats,Intermediate,10116.0,,A,,BAO_0000218,14198,,,1,CHEMBL623109,,,Rattus norvegicus,N,1,2113.0,
13264,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in liver of male wistar rats,Intermediate,10116.0,,A,,BAO_0000218,14198,,,1,CHEMBL623110,,,Rattus norvegicus,N,1,2107.0,
13265,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in lung of male wistar rats,Intermediate,10116.0,,A,,BAO_0000218,14198,,,1,CHEMBL623111,,,Rattus norvegicus,N,1,2048.0,
13266,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in muscle of male wistar rats,Intermediate,10116.0,,A,,BAO_0000218,14198,,,1,CHEMBL625060,,,Rattus norvegicus,N,1,2385.0,
13267,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in plasma of male wistar rats,Intermediate,10116.0,,A,,BAO_0000218,14198,,,1,CHEMBL625061,,,Rattus norvegicus,N,1,1969.0,
13268,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in red blood cells of male wistar rats,Intermediate,10116.0,,A,,BAO_0000218,14198,,,1,CHEMBL625062,,,Rattus norvegicus,N,1,,
13269,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in spleen of male wistar rats,Intermediate,10116.0,,A,,BAO_0000218,14198,,,1,CHEMBL625063,,,Rattus norvegicus,N,1,2106.0,
13270,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in trachea of male wistar rats,Intermediate,10116.0,,A,,BAO_0000218,14198,,,1,CHEMBL625064,,,Rattus norvegicus,N,1,3126.0,
13271,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in bone of male wistar rats,Intermediate,10116.0,,A,,BAO_0000218,14198,,,1,CHEMBL625065,,,Rattus norvegicus,N,1,10000001.0,
13272,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in cerebellum of male wistar rats,Intermediate,10116.0,,A,,BAO_0000218,14198,,,1,CHEMBL625066,,,Rattus norvegicus,N,1,2037.0,
13273,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in cortex of male wistar rats,Intermediate,10116.0,,A,,BAO_0000218,14198,,,1,CHEMBL625067,,,Rattus norvegicus,N,1,,
13274,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in fat of male wistar rats,Intermediate,10116.0,,A,,BAO_0000218,14198,,,1,CHEMBL625068,,,Rattus norvegicus,N,1,,
13275,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in heart of male wistar rats,Intermediate,10116.0,,A,,BAO_0000218,14198,,,1,CHEMBL622159,,,Rattus norvegicus,N,1,948.0,
13276,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in intestine of male wistar rats,Intermediate,10116.0,,A,,BAO_0000218,14198,,,1,CHEMBL622160,,,Rattus norvegicus,N,1,160.0,
13277,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in kidney of male wistar rats,Intermediate,10116.0,,A,,BAO_0000218,14198,,,1,CHEMBL622161,,,Rattus norvegicus,N,1,2113.0,
13278,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in lung of male wistar rats,Intermediate,10116.0,,A,,BAO_0000218,14198,,,1,CHEMBL622162,,,Rattus norvegicus,N,1,2048.0,
13279,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in muscle of male wistar rats,Intermediate,10116.0,,A,,BAO_0000218,14198,,,1,CHEMBL622163,,,Rattus norvegicus,N,1,2385.0,
13280,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in plasma of male wistar rats,Intermediate,10116.0,,A,,BAO_0000218,14198,,,1,CHEMBL622313,,,Rattus norvegicus,N,1,1969.0,
13281,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in red blood cells of male wistar rats,Intermediate,10116.0,,A,,BAO_0000218,14198,,,1,CHEMBL622314,,,Rattus norvegicus,N,1,,
13282,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in spleen of male wistar rats,Intermediate,10116.0,,A,,BAO_0000218,14198,,,1,CHEMBL622315,,,Rattus norvegicus,N,1,2106.0,
13283,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in trachea of male wistar rats,Intermediate,10116.0,,A,,BAO_0000218,14198,,,1,CHEMBL622316,,,Rattus norvegicus,N,1,3126.0,
13284,Normal diffusion coefficient in water for Escherichia coli,Intermediate,562.0,,A,,BAO_0000218,15599,,,1,CHEMBL877486,,,Escherichia coli,N,1,,
13285,Average max percent decrease in RVR (renal vascular resistance) was determined,Autocuration,,,A,,BAO_0000019,8204,,,1,CHEMBL622317,,,,U,0,,
13286,Average max percent decrease in RVR (renal vascular resistance) was determined.,Autocuration,,,A,,BAO_0000019,8204,,,1,CHEMBL622318,,,,U,0,,
13287,In vitro stability to pepsin promoting hydrolysis after 1 hr incubation time,Autocuration,,,A,,BAO_0000019,6154,,,1,CHEMBL622319,,,,U,0,,
13288,In vitro stability to pepsin promoting hydrolysis after 2 hr incubation time,Autocuration,,,A,,BAO_0000019,6154,,,1,CHEMBL622320,,,,U,0,,
13289,In vitro stability to pepsin promoting hydrolysis after 64h incubation time,Autocuration,,,A,,BAO_0000019,6154,,,1,CHEMBL622321,,,,U,0,,
13290,In vitro stability to pepsin promoting hydrolysis after 84 hr incubation time,Autocuration,,,A,,BAO_0000019,6154,,,1,CHEMBL622322,,,,U,0,,
13291,Compound was tested for diuretic activity in sodium content of the 3-h sample was measured by flame photometry,Autocuration,,,A,,BAO_0000019,7114,,,1,CHEMBL622323,,,,U,0,,
13292,Compound was tested for diuretic activity in sodium content of the 3-h sample was measured by flame photometry in rat,Intermediate,10116.0,,A,,BAO_0000218,7114,,,1,CHEMBL622324,,,Rattus norvegicus,N,1,,
13293,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded dogs at 0.03mg/kg, po",Intermediate,9615.0,,A,,BAO_0000218,8133,,,1,CHEMBL622325,,,Canis lupus familiaris,N,1,1088.0,
13294,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 1.0 mg/kg, po",Intermediate,9615.0,,A,,BAO_0000218,8133,,,1,CHEMBL622326,,,Canis lupus familiaris,N,1,1088.0,
13295,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 10.0 mg/kg, po",Intermediate,9615.0,,A,,BAO_0000218,8133,,,1,CHEMBL877487,,,Canis lupus familiaris,N,1,1088.0,
13296,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded dogs at 1 mg/kg, po",Intermediate,9615.0,,A,,BAO_0000218,8133,,,1,CHEMBL622327,,,Canis lupus familiaris,N,1,1088.0,
13297,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 3.0 mg/kg, po",Intermediate,9615.0,,A,,BAO_0000218,8133,,,1,CHEMBL622328,,,Canis lupus familiaris,N,1,1088.0,
13298,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 30 mg/kg, po",Intermediate,9615.0,,A,,BAO_0000218,8133,,,1,CHEMBL622329,,,Canis lupus familiaris,N,1,1088.0,
13299,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded dogs at 0.1 mg/kg, po",Intermediate,9615.0,,A,,BAO_0000218,8133,,,1,CHEMBL622330,,,Canis lupus familiaris,N,1,1088.0,
13300,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 0.3mg/kg, po",Intermediate,9615.0,,A,,BAO_0000218,8133,,,1,CHEMBL622331,,,Canis lupus familiaris,N,1,1088.0,
13301,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded dogs at 10mg/kg, po",Intermediate,9615.0,,A,,BAO_0000218,8133,,,1,CHEMBL622332,,,Canis lupus familiaris,N,1,1088.0,
13302,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 3 mg/kg, po",Intermediate,9615.0,,A,,BAO_0000218,8133,,,1,CHEMBL622333,,,Canis lupus familiaris,N,1,1088.0,
13303,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded monkey at 100 mg/kg, po",Autocuration,314293.0,,A,,BAO_0000218,8133,,,1,CHEMBL627658,,,Simiiformes,U,0,1088.0,
13304,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded monkey at 10mg/kg, po",Autocuration,314293.0,,A,,BAO_0000218,8133,,,1,CHEMBL630428,,,Simiiformes,U,0,1088.0,
13305,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded monkey at 1 mg/kg, po",Autocuration,314293.0,,A,,BAO_0000218,8133,,,1,CHEMBL630429,,,Simiiformes,U,0,1088.0,
13306,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded monkey at 30 mg/kg, po",Autocuration,314293.0,,A,,BAO_0000218,8133,,,1,CHEMBL630430,,,Simiiformes,U,0,1088.0,
13307,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded monkey at 3 mg/kg, po",Autocuration,314293.0,,A,,BAO_0000218,8133,,,1,CHEMBL630431,,,Simiiformes,U,0,1088.0,
13308,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 0.1 mg/kg, po",Intermediate,10116.0,,A,,BAO_0000218,8133,,,1,CHEMBL630432,,,Rattus norvegicus,N,1,1088.0,
13309,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 0.3mg/kg, po",Intermediate,10116.0,,A,,BAO_0000218,8133,,,1,CHEMBL630433,,,Rattus norvegicus,N,1,1088.0,
13310,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 1.0mg/kg, po",Intermediate,10116.0,,A,,BAO_0000218,8133,,,1,CHEMBL630434,,,Rattus norvegicus,N,1,1088.0,
13311,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 10.0mg/kg, po",Intermediate,10116.0,,A,,BAO_0000218,8133,,,1,CHEMBL629372,,,Rattus norvegicus,N,1,1088.0,
13312,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 100.0mg/kg, po",Intermediate,10116.0,,A,,BAO_0000218,8133,,,1,CHEMBL629553,,,Rattus norvegicus,N,1,1088.0,
13313,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 2.1 mg/kg, po",Intermediate,10116.0,,A,,BAO_0000218,8133,,,1,CHEMBL629554,,,Rattus norvegicus,N,1,1088.0,
13314,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 20.8mg/kg, po",Intermediate,10116.0,,A,,BAO_0000218,8133,,,1,CHEMBL874447,,,Rattus norvegicus,N,1,1088.0,
13315,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 207.6mg/kg, po",Intermediate,10116.0,,A,,BAO_0000218,8133,,,1,CHEMBL629555,,,Rattus norvegicus,N,1,1088.0,
13316,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 3.0mg/kg, po",Intermediate,10116.0,,A,,BAO_0000218,8133,,,1,CHEMBL629556,,,Rattus norvegicus,N,1,1088.0,
13317,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded rats at 30.0 mg/kg, po",Intermediate,10116.0,,A,,BAO_0000218,8133,,,1,CHEMBL629557,,,Rattus norvegicus,N,1,1088.0,
13318,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 6.9mg/kg, po",Intermediate,10116.0,,A,,BAO_0000218,8133,,,1,CHEMBL629558,,,Rattus norvegicus,N,1,1088.0,
13319,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 69.2mg/kg, po",Intermediate,10116.0,,A,,BAO_0000218,8133,,,1,CHEMBL629559,,,Rattus norvegicus,N,1,1088.0,
13320,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 691.9mg/kg, po",Intermediate,10116.0,,A,,BAO_0000218,8133,,,1,CHEMBL629560,,,Rattus norvegicus,N,1,1088.0,
13321,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 0.03mg/kg, po",Intermediate,9615.0,,A,,BAO_0000218,8133,,,1,CHEMBL629561,,,Canis lupus familiaris,N,1,1088.0,
13322,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 0.1 mg/kg, po",Intermediate,9615.0,,A,,BAO_0000218,8133,,,1,CHEMBL629562,,,Canis lupus familiaris,N,1,1088.0,
13323,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 0.3mg/kg, po",Intermediate,9615.0,,A,,BAO_0000218,8133,,,1,CHEMBL629563,,,Canis lupus familiaris,N,1,1088.0,
13324,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded dogs at 1.0 mg/kg, po",Intermediate,9615.0,,A,,BAO_0000218,8133,,,1,CHEMBL629564,,,Canis lupus familiaris,N,1,1088.0,
13325,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 10.0mg/kg, po",Intermediate,9615.0,,A,,BAO_0000218,8133,,,1,CHEMBL629565,,,Canis lupus familiaris,N,1,1088.0,
13326,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 10mg/kg, po",Intermediate,9615.0,,A,,BAO_0000218,8133,,,1,CHEMBL629566,,,Canis lupus familiaris,N,1,1088.0,
13327,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded dogs at 1 mg/kg, po",Intermediate,9615.0,,A,,BAO_0000218,8133,,,1,CHEMBL629567,,,Canis lupus familiaris,N,1,1088.0,
13328,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 3.0mg/kg, po",Intermediate,9615.0,,A,,BAO_0000218,8133,,,1,CHEMBL629568,,,Canis lupus familiaris,N,1,1088.0,
13329,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 30mg/kg, po",Intermediate,9615.0,,A,,BAO_0000218,8133,,,1,CHEMBL629569,,,Canis lupus familiaris,N,1,1088.0,
13330,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 3mg/kg, po",Intermediate,9615.0,,A,,BAO_0000218,8133,,,1,CHEMBL629570,,,Canis lupus familiaris,N,1,1088.0,
13331,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded monkey at 100 mg/kg, po",Autocuration,314293.0,,A,,BAO_0000218,8133,,,1,CHEMBL629571,,,Simiiformes,U,0,1088.0,
13332,% bioavailability in rat after oral dose (10 mg/kg) 0 - 6 h.,Autocuration,10116.0,,A,,BAO_0000218,12170,,,1,CHEMBL629572,,,Rattus norvegicus,U,0,,
13333,% bioavailability in rat after oral dose (10 mg/kg) 0 - 6 h.,Autocuration,10116.0,,A,,BAO_0000218,12170,,,1,CHEMBL629573,,,Rattus norvegicus,U,0,,
13334,Bioavailability (dose 20 mg/kg),Autocuration,9347.0,,A,,BAO_0000218,4985,,,1,CHEMBL629574,,,Eutheria,U,0,,
13335,Bioavailability in dog,Autocuration,9615.0,,A,,BAO_0000218,15145,,,1,CHEMBL629575,,,Canis lupus familiaris,U,0,,
13336,Bioavailability in rat (Sprague-Dawley) (male),Autocuration,10116.0,,A,,BAO_0000218,14080,,,1,CHEMBL874448,,,Rattus norvegicus,U,0,,
13337,Bioavailability in monkey (dose 10 mg/kg i.d.),Autocuration,9443.0,,A,,BAO_0000218,11219,,,1,CHEMBL629576,,,Primates,U,0,,
13338,Bioavailability in rat,Autocuration,10116.0,,A,,BAO_0000218,15145,,,1,CHEMBL629577,,,Rattus norvegicus,U,0,,
13339,Bioavailability in rat,Autocuration,10116.0,,A,,BAO_0000218,15145,,,1,CHEMBL629578,,,Rattus norvegicus,U,0,,
13340,Bioavailability in dog (dose 3.0 mg/kg p.o.),Autocuration,9615.0,,A,,BAO_0000218,1202,,,1,CHEMBL629579,,,Canis lupus familiaris,U,0,,
13341,Bioavailability in dog (dose of 1.0 mg/kg i.v.) 0.5 hr,Autocuration,9615.0,,A,,BAO_0000218,1202,,,1,CHEMBL882958,,,Canis lupus familiaris,U,0,,
13342,Bioavailability was calculated after peroral dose of 10 mg/Kg in chimp,Intermediate,9598.0,,A,,BAO_0000218,1202,,,1,CHEMBL629580,,,Pan troglodytes,N,1,,
13343,Bioavailability,Autocuration,9347.0,,A,,BAO_0000218,4026,,,1,CHEMBL629581,,,Eutheria,U,0,,
13344,Bioavailability in squirrel monkey,Autocuration,9520.0,,A,,BAO_0000218,1492,,,1,CHEMBL629582,,,Saimiri,U,0,,
13345,Bioavailability was evaluated in dog,Intermediate,9615.0,,A,,BAO_0000218,12793,,,1,CHEMBL628522,,,Canis lupus familiaris,N,1,,
13346,Bioavailability was evaluated in hamster,Intermediate,10026.0,,A,,BAO_0000218,12793,,,1,CHEMBL625432,,,Cricetinae,N,1,,
13347,Bioavailability in rat,Autocuration,10116.0,,A,,BAO_0000218,12793,,,1,CHEMBL625433,,,Rattus norvegicus,U,0,,
13348,Bioavailability was evaluated in rat plasma when administered intraperitoneally at a dose of 10 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,14793,,,1,CHEMBL625434,,,Rattus norvegicus,N,1,1969.0,
13349,Bioavailability was evaluated in rat plasma when administered intravenously at a dose of 10 mg/kg; <Tr>,Intermediate,10116.0,,A,,BAO_0000218,14793,,,1,CHEMBL625435,,,Rattus norvegicus,N,1,1969.0,
13350,Bioavailability in rat (dose 10 mg/kg p.o.),Autocuration,10116.0,,A,,BAO_0000218,14793,,,1,CHEMBL625436,,,Rattus norvegicus,U,0,,
13351,Bioavailability was measured in cynomolgus monkeys.,Intermediate,9541.0,,A,,BAO_0000218,14731,,,1,CHEMBL874588,,,Macaca fascicularis,N,1,,
13352,Bioavailability was measured in nude mice.,Intermediate,10090.0,,A,,BAO_0000218,14731,,,1,CHEMBL625437,,,Mus musculus,N,1,,
13353,Bioavailability in ferret (dose 10 mg/kg i.d.),Autocuration,9669.0,,A,,BAO_0000218,12187,,,1,CHEMBL625438,,,Mustela putorius furo,U,0,,
13354,Bioavailability was determined after intraduodenal dose of 10 mg/kg in monkey (compared to 0.3 mg/kg intravenous dose),Autocuration,314293.0,,A,,BAO_0000218,12187,,,1,CHEMBL625439,,,Simiiformes,U,0,,
13355,"Bioavailability was determined after intraduodenal dose of 10 mg/kg in monkey (compared to 0.3 mg/kg intravenous dose), determined by renin inhibition assay",Autocuration,314293.0,,A,,BAO_0000218,12187,,,1,CHEMBL625440,,,Simiiformes,U,0,,
13356,Bioavailability was determined after intraduodenal dose of 10 mg/kg in monkey (compared to 1 mg/kg intravenous dose),Autocuration,314293.0,,A,,BAO_0000218,12187,,,1,CHEMBL625441,,,Simiiformes,U,0,,
13357,Bioavailability in rat (dose 10 mg/kg i.d.),Autocuration,10116.0,,A,,BAO_0000218,12187,,,1,CHEMBL625442,,,Rattus norvegicus,U,0,,
13358,"Bioavailability was determined after intraduodenal dose of 10 mg/kg in rat, determined by renin inhibition assay",Intermediate,10116.0,,A,,BAO_0000218,12187,,,1,CHEMBL625443,,,Rattus norvegicus,N,1,,
13359,Bioavailability was determined; extremely poor,Autocuration,,,A,,BAO_0000218,17431,,,1,CHEMBL625444,,,,U,0,,
13360,% bioavailability in mice after oral administration of prodrug,Intermediate,10090.0,,A,,BAO_0000218,13318,,,1,CHEMBL625445,,,Mus musculus,N,1,,
13361,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose 10/30 range (low/high); -21/-5,Intermediate,9615.0,,A,,BAO_0000218,9025,,,1,CHEMBL625446,,,Canis lupus familiaris,N,1,,
13362,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 1/3 range (low/high); -2/6,Intermediate,9615.0,,A,,BAO_0000218,9025,,,1,CHEMBL882960,,,Canis lupus familiaris,N,1,,
13363,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 1/3 range (low/high); -4/-14,Intermediate,9615.0,,A,,BAO_0000218,9025,,,1,CHEMBL625447,,,Canis lupus familiaris,N,1,,
13364,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 1/3 range (low/high); -5/-12,Intermediate,9615.0,,A,,BAO_0000218,9025,,,1,CHEMBL625448,,,Canis lupus familiaris,N,1,,
13365,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 1/3/10 range (low/high); -1/-7/-11,Intermediate,9615.0,,A,,BAO_0000218,9025,,,1,CHEMBL625449,,,Canis lupus familiaris,N,1,,
13366,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high),Intermediate,9615.0,,A,,BAO_0000218,9025,,,1,CHEMBL874589,,,Canis lupus familiaris,N,1,,
13367,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -1/-9,Intermediate,9615.0,,A,,BAO_0000218,9025,,,1,CHEMBL625450,,,Canis lupus familiaris,N,1,,
13368,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -11/-28,Intermediate,9615.0,,A,,BAO_0000218,9025,,,1,CHEMBL625451,,,Canis lupus familiaris,N,1,,
13369,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -13/-29,Intermediate,9615.0,,A,,BAO_0000218,9025,,,1,CHEMBL626584,,,Canis lupus familiaris,N,1,,
13370,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -13/30,Intermediate,9615.0,,A,,BAO_0000218,9025,,,1,CHEMBL626585,,,Canis lupus familiaris,N,1,,
13371,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -16/-18,Intermediate,9615.0,,A,,BAO_0000218,9025,,,1,CHEMBL626586,,,Canis lupus familiaris,N,1,,
13372,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -16/-35,Intermediate,9615.0,,A,,BAO_0000218,9025,,,1,CHEMBL626587,,,Canis lupus familiaris,N,1,,
13373,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -19/-50,Intermediate,9615.0,,A,,BAO_0000218,9025,,,1,CHEMBL626588,,,Canis lupus familiaris,N,1,,
13374,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -21/-29,Intermediate,9615.0,,A,,BAO_0000218,9025,,,1,CHEMBL626589,,,Canis lupus familiaris,N,1,,
13375,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -24/-56,Intermediate,9615.0,,A,,BAO_0000218,9025,,,1,CHEMBL626590,,,Canis lupus familiaris,N,1,,
13376,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -25/-33,Intermediate,9615.0,,A,,BAO_0000218,9025,,,1,CHEMBL626591,,,Canis lupus familiaris,N,1,,
13377,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -3/-13,Intermediate,9615.0,,A,,BAO_0000218,9025,,,1,CHEMBL627181,,,Canis lupus familiaris,N,1,,
13378,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -5/-47,Intermediate,9615.0,,A,,BAO_0000218,9025,,,1,CHEMBL628083,,,Canis lupus familiaris,N,1,,
13379,IV clearance determined at an peroral dose of 15 mg/kg.,Autocuration,,,A,,BAO_0000218,15173,,,1,CHEMBL628084,,,,U,0,,
13380,Mouse oral clearance was measured against Hymenolepiasis nana.,Expert,102285.0,,F,,BAO_0000218,7732,,,1,CHEMBL628085,,,Hymenolepis nana,N,1,,
13381,Mouse oral clearance was measured against Nematospiroides dubius,Expert,6339.0,,F,,BAO_0000218,7732,,,1,CHEMBL628086,,,Heligmosomoides polygyrus,N,1,,
13382,Mouse oral clearance was measured against N. dubius; NT is Not Tested,Autocuration,,,F,,BAO_0000218,7732,,,1,CHEMBL628087,,,,U,0,,
13383,Mouse oral clearance was measured against N. nana; NT is Not Tested,Intermediate,10090.0,,A,,BAO_0000218,7732,,,1,CHEMBL628088,,,Mus musculus,N,1,,
13384,Mouse oral clearance was measured against N. nana; NT is Not Tested,Autocuration,,,B,,BAO_0000218,7732,,,1,CHEMBL628089,,,,U,0,,
13385,Percentage of clearance of psoriatic lesions by 8-methoxypsoralen (8-MOP) for comparison at dose of 10 J/cm e2 ultraviolet-A radiation,Autocuration,,,A,,BAO_0000218,8328,,,1,CHEMBL628090,,,,U,0,,
13386,Percentage of clearance of psoriatic lesions by 8-methoxypsoralen (8-MOP) for comparison at dose of 6 J/cm e2 ultraviolet-A radiation,Autocuration,,,A,,BAO_0000218,8328,,,1,CHEMBL628091,,,,U,0,,
13387,Percentage of clearance of psoriatic lesions by 8-methoxypsoralen (8-MOP) for comparison at dose of 8 J/cm e2 ultraviolet-A radiation,Autocuration,,,A,,BAO_0000218,8328,,,1,CHEMBL628092,,,,U,0,,
13388,Percentage of clearance of psoriatic lesions by 8-methoxypsoralen (8-MOP) for comparison at dose of 9 J/cm e2 ultraviolet-A radiation,Autocuration,,,A,,BAO_0000218,8328,,,1,CHEMBL628093,,,,U,0,,
13389,Percentage of clearance of psoriatic lesions by the compound at dose of 10 J/cm e2 ultraviolet-A radiation,Autocuration,,,A,,BAO_0000218,8328,,,1,CHEMBL875607,,,,U,0,,
13390,Percentage of clearance of psoriatic lesions by the compound at dose of 4 J/cm e2 ultraviolet-A radiation,Autocuration,,,A,,BAO_0000218,8328,,,1,CHEMBL625710,,,,U,0,,
13391,Percentage of clearance of psoriatic lesions by the compound at dose of 6 J/cm e2 ultraviolet-A radiation,Autocuration,,,A,,BAO_0000218,8328,,,1,CHEMBL625711,,,,U,0,,
13392,Percentage of clearance of psoriatic lesions by the compound at dose of 8 J/cm e2 ultraviolet-A radiation,Autocuration,,,A,,BAO_0000218,8328,,,1,CHEMBL625712,,,,U,0,,
13393,Percentage of clearance of psoriatic lesions by the compound at dose of 9 J/cm e2 ultraviolet-A radiation,Autocuration,,,A,,BAO_0000218,8328,,,1,CHEMBL625713,,,,U,0,,
13394,Pharmacokinetic parameter clearance was determined in fed Beagle dogs after iv administration of 1.5 mg/kg,Intermediate,9615.0,,A,,BAO_0000218,13376,,,1,CHEMBL625714,,,Canis lupus familiaris,N,1,,
13395,Plasma clearance after intravenous administration dosing (30 mg/kg) in Rhesus monkey,Intermediate,9544.0,,A,,BAO_0000218,13477,,,1,CHEMBL625715,,,Macaca mulatta,N,1,,
13396,Plasma clearance after intravenous administration dosing (30 mg/kg) in rat,Intermediate,10116.0,,A,,BAO_0000218,13477,,,1,CHEMBL625716,,,Rattus norvegicus,N,1,,
13397,Plasma clearance after intravenous administration iv dosing of 3 mg/kg in rat,Intermediate,10116.0,,A,,BAO_0000218,13477,,,1,CHEMBL625717,,,Rattus norvegicus,N,1,,
13398,Plasma clearance was determined for the compound in rats,Intermediate,10116.0,,A,,BAO_0000218,13313,,,1,CHEMBL625718,,,Rattus norvegicus,N,1,,
13399,Tested for total body clearance (CL) after intravenous bolus administration of 100 mg/kg in rat 1,Intermediate,10116.0,,A,,BAO_0000218,12504,,,1,CHEMBL625719,,,Rattus norvegicus,N,1,,
13400,Tested for total body clearance (CL) after intravenous bolus administration of 100 mg/kg in rat 2,Intermediate,10116.0,,A,,BAO_0000218,12504,,,1,CHEMBL625720,,,Rattus norvegicus,N,1,,
13401,Tested for total body clearance (CL) after intravenous bolus administration of 100 mg/kg in rat 3,Intermediate,10116.0,,A,,BAO_0000218,12504,,,1,CHEMBL625721,,,Rattus norvegicus,N,1,,
13402,Tested for total body clearance (CL) after intravenous bolus administration of 100 mg/kg in rat 4,Intermediate,10116.0,,A,,BAO_0000218,12504,,,1,CHEMBL625722,,,Rattus norvegicus,N,1,,
13403,The compound was tested for systemic clearance pharmacokinetic parameter in the male Sprague-Dawley rat.,Intermediate,10116.0,,A,,BAO_0000218,13129,,,1,CHEMBL625723,,,Rattus norvegicus,N,1,,
13404,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.0125 concentration of diet.,Intermediate,6339.0,,A,,BAO_0000218,7732,,,1,CHEMBL625724,,,Heligmosomoides polygyrus,N,1,,
13405,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.025 concentration of diet.,Intermediate,6339.0,,A,,BAO_0000218,7732,,,1,CHEMBL625725,,,Heligmosomoides polygyrus,N,1,,
13406,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.05 concentration of diet.,Intermediate,6339.0,,A,,BAO_0000218,7732,,,1,CHEMBL625726,,,Heligmosomoides polygyrus,N,1,,
13407,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.1 concentration of diet.,Intermediate,6339.0,,A,,BAO_0000218,7732,,,1,CHEMBL875608,,,Heligmosomoides polygyrus,N,1,,
13408,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.2 concentration of diet.,Intermediate,6339.0,,A,,BAO_0000218,7732,,,1,CHEMBL625727,,,Heligmosomoides polygyrus,N,1,,
13409,Urinary clearance was determined in rat at 100 mg/kg os dosage;ND is defined as no-data.,Autocuration,10116.0,,A,,BAO_0000218,9278,,,1,CHEMBL625728,,,Rattus norvegicus,U,0,1088.0,
13410,Total clearance was determined in rat at 10 mg/kg intraperitoneal dosage,Autocuration,10116.0,,A,,BAO_0000218,9278,,,1,CHEMBL625729,,,Rattus norvegicus,U,0,,
13411,Total clearance was determined in rat at 25 mg/kg os dosage;ND is defined as no-data.,Autocuration,10116.0,,A,,BAO_0000218,9278,,,1,CHEMBL625730,,,Rattus norvegicus,U,0,,
13412,Urinary clearance was determined in rat at 10 mg/kg intraperitoneal dosage,Autocuration,10116.0,,A,,BAO_0000218,9278,,,1,CHEMBL625731,,,Rattus norvegicus,U,0,1088.0,
13413,Urinary clearance was determined in rat at 25 mg/kg os dosage,Autocuration,10116.0,,A,,BAO_0000218,9278,,,1,CHEMBL626417,,,Rattus norvegicus,U,0,1088.0,
13414,Urinary clearance was determined at 100 mg/kg oral dosage in human,Intermediate,9606.0,,A,,BAO_0000218,9278,,,1,CHEMBL626418,,,Homo sapiens,N,1,1088.0,
13415,Urinary clearance was determined at 20 mg/kg oral dosage in dog(beagle);ND is defined as no-data.,Intermediate,9615.0,,A,,BAO_0000218,9278,,,1,CHEMBL626419,,,Canis lupus familiaris,N,1,1088.0,
13416,Plasma concentration in dogs after 2 hr at 30mg/kg oral dose,Intermediate,9615.0,,A,,BAO_0000218,5932,,,1,CHEMBL626592,,,Canis lupus familiaris,N,1,1969.0,
13417,Plasma concentration in rats after 7 hr at 30mg/kg oral dose,Intermediate,10116.0,,A,,BAO_0000218,5932,,,1,CHEMBL626593,,,Rattus norvegicus,N,1,1969.0,
13418,Clearance was determined by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat,Intermediate,10116.0,,A,,BAO_0000218,5182,,,1,CHEMBL626594,,,Rattus norvegicus,N,1,,
13419,Clearance rate in dogs,Intermediate,9615.0,,A,,BAO_0000218,10499,,,1,CHEMBL625035,,,Canis lupus familiaris,N,1,,
13420,Compound was measured for intrinsic clearance,Autocuration,,,A,,BAO_0000019,6051,,,1,CHEMBL625036,,,,U,0,,
13421,Calculated partition coefficient (clogP),Autocuration,,,P,,BAO_0000100,17508,,,1,CHEMBL625037,,,,U,0,,
13422,Calculated partition coefficient (clogP),Autocuration,,,P,,BAO_0000100,6228,,,1,CHEMBL625038,,,,U,0,,
13423,Calculated partition coefficient (clogP),Autocuration,,,P,,BAO_0000100,6231,,,1,CHEMBL625039,,,,U,0,,
13424,Calculated partition coefficient (clogP),Autocuration,,,P,,BAO_0000100,17740,,,1,CHEMBL625040,,,,U,0,,
13425,Calculated partition coefficient (clogP),Autocuration,,,P,,BAO_0000100,6495,,,1,CHEMBL625041,,,,U,0,,
13426,Calculated partition coefficient (clogP),Autocuration,,,P,,BAO_0000100,2171,,,1,CHEMBL625042,,,,U,0,,
13427,Partition coefficient of the compound,Autocuration,,,A,,BAO_0000019,3255,,,1,CHEMBL874411,,,,U,0,,
13428,Permeability,Autocuration,,,A,,BAO_0000019,6821,,,1,CHEMBL625043,,,,U,0,,
13429,Calculated partition coefficient (clogP),Autocuration,,,P,,BAO_0000100,2685,,,1,CHEMBL625044,,,,U,0,,
13430,Partition coefficient (logD),Autocuration,,,A,,BAO_0000019,17584,,,1,CHEMBL625045,,,,U,0,,
13431,Calculated partition coefficient (clogP) (CLOGP3 V3.4),Autocuration,,,P,,BAO_0000100,13824,,,1,CHEMBL625046,,,,U,0,,
13432,Calculated partition coefficient (clogP) (CLOGP3 V3.4),Autocuration,,,P,,BAO_0000100,13824,,,1,CHEMBL625047,,,,U,0,,
13433,Calculated partition coefficient (clogP),Autocuration,,,P,,BAO_0000100,16479,,,1,CHEMBL625048,,,,U,0,,
13434,Calculated partition coefficient (clogP),Autocuration,,,P,,BAO_0000100,11997,,,1,CHEMBL625049,,,,U,0,,
13435,Calculated logarithm of partition coefficient (P) was determined,Autocuration,,,P,,BAO_0000100,2988,,,1,CHEMBL625050,,,,U,0,,
13436,Calculated partition coefficient (clogP),Autocuration,,,P,,BAO_0000100,931,,,1,CHEMBL625051,,,,U,0,,
13437,Calculated partition coefficient (clogP),Autocuration,,,P,,BAO_0000100,4381,,,1,CHEMBL874412,,,,U,0,,
13438,Calculated partition coefficient (clogP),Autocuration,,,P,,BAO_0000100,4397,,,1,CHEMBL625052,,,,U,0,,
13439,Calculated partition coefficient (clogP),Autocuration,,,P,,BAO_0000100,5889,,,1,CHEMBL625053,,,,U,0,,
13440,In vitro stability to pepsin promoting hydrolysis after 8 hr incubation time,Autocuration,,,A,,BAO_0000019,6154,,,1,CHEMBL623250,,,,U,0,,
13441,In vitro stability to trypsin promoting hydrolysis after 1 hr incubation time,Autocuration,,,A,,BAO_0000019,6154,,,1,CHEMBL623251,,,,U,0,,
13442,In vitro stability to trypsin promoting hydrolysis after 2 hr incubation time,Autocuration,,,A,,BAO_0000019,6154,,,1,CHEMBL623252,,,,U,0,,
13443,In vitro stability to trypsin promoting hydrolysis after 64h incubation time,Autocuration,,,A,,BAO_0000019,6154,,,1,CHEMBL623253,,,,U,0,,
13444,In vitro stability to trypsin promoting hydrolysis after 84 hr incubation time,Autocuration,,,A,,BAO_0000019,6154,,,1,CHEMBL623254,,,,U,0,,
13445,In vitro stability to trypsin promoting hydrolysis after 8 hr incubation time,Autocuration,,,A,,BAO_0000019,6154,,,1,CHEMBL623255,,,,U,0,,
13446,Percent degradation of compound at a pH of 1 over a 18 hr period,Autocuration,,,A,,BAO_0000019,6887,,,1,CHEMBL626831,,,,U,0,,
13447,Percent degradation of compound at pH of 1 over an 18 hr period,Autocuration,,,A,,BAO_0000019,6887,,,1,CHEMBL877494,,,,U,0,,
13448,Delta Logarithm of Partition Coefficient value was determined.,Autocuration,,,A,,BAO_0000019,14116,,,1,CHEMBL626832,,,,U,0,,
13449,Delta logPoct-cyc,Autocuration,,,A,,BAO_0000019,11137,,,1,CHEMBL626833,,,,U,0,,
13450,Lipophilicity estimated on reversed phase TLC,Autocuration,,,P,,BAO_0000100,7230,,,1,CHEMBL626834,,,,U,0,,
13451,Delta Tm value ( Tmdrug-DNA )-TmDNA ) was obtained for the covalently cross-linked compound in the absence of formaldehyde using calf thymus DNA.,Autocuration,,,A,,BAO_0000019,15741,,,1,CHEMBL626835,,,,U,0,,
13452,Delta logPoct-cyc,Autocuration,,,A,,BAO_0000019,9663,,,1,CHEMBL626836,,,,U,0,,
13453,Change in logarithm of partition coefficient of the compound,Autocuration,,,P,,BAO_0000100,9663,,,1,CHEMBL626837,,,,U,0,,
13454,Delta logD (pH 6.5),Autocuration,,,A,,BAO_0000019,13807,,,1,CHEMBL626838,,,,U,0,,
13455,"Partition coefficient by standard shake-flask techniquesat 37 C, using octanol and cyclohexane",Autocuration,,,P,,BAO_0000100,13807,,,1,CHEMBL626839,,,,U,0,,
13456,Oxygen pressure at which hemoglobin is 50% oxygenated; negative sign indicates that P50 of modified Hb is lower than that of unmodified Hb,Autocuration,,,A,,BAO_0000019,17425,,,1,CHEMBL626840,,,,U,0,,
13457,Deoxyribose-damaging property as a measure of hydroxyl-radical formation (uM of malondialdehyde/mmol of deoxyribose released by 75 uM test compound),Autocuration,,,A,,BAO_0000019,12143,,,1,CHEMBL626841,,,,U,0,,
13458,Peak depolarizations produced by injections of 100 micro M Ins p3 isomers in nine cells,Autocuration,,,A,,BAO_0000219,12608,,,1,CHEMBL626842,,,,U,0,,
13459,Peak depolarizations produced by injections of 100 micro M Ins p3 isomers in six cells,Autocuration,,,A,,BAO_0000219,12608,,,1,CHEMBL626843,,,,U,0,,
13460,Amount of deuterium retained was reported after normal workup in beta-naphthoflavone-treated male rats with the substrate rac 7-D,Intermediate,10116.0,,A,,BAO_0000218,8649,,,1,CHEMBL626844,,,Rattus norvegicus,N,1,,
13461,Amount of deuterium retained was reported after normal workup in rats,Intermediate,10116.0,,A,,BAO_0000218,8649,,,1,CHEMBL877495,,,Rattus norvegicus,N,1,,
13462,Amount of deuterium retained was reported after reincubation followed by normal workup in phenobarbital treated male rats,Intermediate,10116.0,,A,,BAO_0000218,8649,,,1,CHEMBL626845,,,Rattus norvegicus,N,1,,
13463,Amount of deuterium retained was reported after reincubation followed by normal workup in phenobarbital treated male rats with rac 8-D,Intermediate,10116.0,,A,,BAO_0000218,8649,,,1,CHEMBL626846,,,Rattus norvegicus,N,1,,
13464,Compound incubated with microsomal preparations from beta-naphthoflavone-treated male rats with the substrate rac 7-D and the amount of deuterium retained was reported after reincubation followed by normal workup,Intermediate,10116.0,,A,,BAO_0000218,8649,,,1,CHEMBL626847,,,Rattus norvegicus,N,1,,
13465,Compound incubated with microsomal preparations from beta-naphthoflavone-treated male rats with the substrate rac 7-D and the amount of deuterium retained was reported after reincubation followed by normal workup,Intermediate,10116.0,,A,,BAO_0000218,8649,,,1,CHEMBL628677,,,Rattus norvegicus,N,1,,
13466,Compound incubated with microsomal preparations from phenobarbital treated male rats with the substrate rac 8-D and the amount of deuterium retained was reported after normal workup,Intermediate,10116.0,,A,,BAO_0000218,8649,,,1,CHEMBL628678,,,Rattus norvegicus,N,1,,
13467,Compound was subjected to electrochemical oxidation,Autocuration,,,A,,BAO_0000019,9659,,,1,CHEMBL628679,,,,U,0,,
13468,Compound was subjected to photochemical oxidation,Autocuration,,,A,,BAO_0000019,9659,,,1,CHEMBL628680,,,,U,0,,
13469,Oxidation of compound by Chloroperoxidase in presence of ethylperoxide,Autocuration,,,A,,BAO_0000019,9659,,,1,CHEMBL628681,,,,U,0,,
13470,Oxidation of compound by horseradish peroxidase in presence of hydroperoxide,Autocuration,,,A,,BAO_0000019,9659,,,1,CHEMBL628682,,,,U,0,,
13471,Oxidation of compound by methemoglobin in presence of hydroperoxide,Autocuration,,,A,,BAO_0000019,9659,,,1,CHEMBL628683,,,,U,0,,
13472,Percent diffusion through fuzzy rat skin after 48 h of incubation,Intermediate,10116.0,,A,,BAO_0000218,9607,,,1,CHEMBL628684,,,Rattus norvegicus,N,1,,
13473,Dissociation constant (pKa),Autocuration,,,P,,BAO_0000100,7057,,,1,CHEMBL877501,,,,U,0,,
13474,Dissociation constant value of the compound; ND means not determined.,Autocuration,,,P,,BAO_0000100,7057,,,1,CHEMBL628685,,,,U,0,,
13475,% distribution of the radioiron in blood of rat followed by intravenous injection of chelating agent,Intermediate,10116.0,,A,,BAO_0000218,7911,,,1,CHEMBL628686,,,Rattus norvegicus,N,1,178.0,
13476,% distribution of the radioiron in blood of rats followed by intravenous injection of transferrin pre-incubated with 10 mg of chelating agent,Intermediate,10116.0,,A,,BAO_0000218,7911,,,1,CHEMBL628687,,,Rattus norvegicus,N,1,178.0,
13477,% distribution of the radioiron in rat kidney followed by intravenous injection of chelating agent,Intermediate,10116.0,,A,,BAO_0000218,7911,,,1,CHEMBL628688,,,Rattus norvegicus,N,1,,
13478,% distribution of the radioiron in rat kidney followed by intravenous injection of transferrin pre-incubated with 10 mg of chelating agent,Intermediate,10116.0,,A,,BAO_0000218,7911,,,1,CHEMBL628689,,,Rattus norvegicus,N,1,,
13479,% distribution of the radioiron in rat liver followed by intravenous injection of chelating agent,Intermediate,10116.0,,A,,BAO_0000218,7911,,,1,CHEMBL628690,,,Rattus norvegicus,N,1,2107.0,
13480,% distribution of the radioiron in rat liver followed by intravenous injection of transferrin preincubated with 10 mg of chelating agent,Intermediate,10116.0,,A,,BAO_0000218,7911,,,1,CHEMBL629363,,,Rattus norvegicus,N,1,2107.0,
13481,% distribution of the radioiron in rat spleen followed by intravenous injection of chelating agent,Intermediate,10116.0,,A,,BAO_0000218,7911,,,1,CHEMBL629364,,,Rattus norvegicus,N,1,2106.0,
13482,% distribution of the radioiron in rat spleen followed by intravenous injection of transferrin pre-incubated with 10 mg of chelating agent,Intermediate,10116.0,,A,,BAO_0000218,7911,,,1,CHEMBL629365,,,Rattus norvegicus,N,1,2106.0,
13483,% excretion of ferritin determined in faces of rat followed by intravenous injection of chelating agent,Intermediate,10116.0,,A,,BAO_0000218,7911,,,1,CHEMBL629366,,,Rattus norvegicus,N,1,,
13484,% excretion of ferritin determined in urine of rat followed by intravenous injection of chelating agent,Intermediate,10116.0,,A,,BAO_0000218,7911,,,1,CHEMBL629367,,,Rattus norvegicus,N,1,1088.0,
13485,% excretion of radioiron determined in feces of rat followed by intravenous injection of transferrin pre-incubated with 10 mg of chelating agent,Intermediate,10116.0,,A,,BAO_0000218,7911,,,1,CHEMBL629368,,,Rattus norvegicus,N,1,1988.0,
13486,% excretion of radioiron determined in urine of rat followed by intravenous injection of transferrin preincubated with 10 mg of chelating agent,Intermediate,10116.0,,A,,BAO_0000218,7911,,,1,CHEMBL877502,,,Rattus norvegicus,N,1,1088.0,
13487,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into cerebellum,Intermediate,10090.0,,A,,BAO_0000218,13792,,,1,CHEMBL629369,,,Mus musculus,N,1,2037.0,
13488,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into cortex,Intermediate,10090.0,,A,,BAO_0000218,13792,,,1,CHEMBL629370,,,Mus musculus,N,1,955.0,
13489,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded monkey at 10 mg/kg, po",Autocuration,314293.0,,A,,BAO_0000218,8133,,,1,CHEMBL629371,,,Simiiformes,U,0,1088.0,
13490,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded monkey at 1 mg/kg, po",Autocuration,314293.0,,A,,BAO_0000218,8133,,,1,CHEMBL626276,,,Simiiformes,U,0,1088.0,
13491,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded monkey at 30mg/kg, po",Autocuration,314293.0,,A,,BAO_0000218,8133,,,1,CHEMBL626277,,,Simiiformes,U,0,1088.0,
13492,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded monkey at 3mg/kg, po",Autocuration,314293.0,,A,,BAO_0000218,8133,,,1,CHEMBL631250,,,Simiiformes,U,0,1088.0,
13493,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 0.1 mg/kg, po",Intermediate,10116.0,,A,,BAO_0000218,8133,,,1,CHEMBL631251,,,Rattus norvegicus,N,1,1088.0,
13494,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 0.3mg/kg, po",Intermediate,10116.0,,A,,BAO_0000218,8133,,,1,CHEMBL631252,,,Rattus norvegicus,N,1,1088.0,
13495,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded rats at 1.0 mg/kg, po",Intermediate,10116.0,,A,,BAO_0000218,8133,,,1,CHEMBL631253,,,Rattus norvegicus,N,1,1088.0,
13496,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 10.0mg/kg, po",Intermediate,10116.0,,A,,BAO_0000218,8133,,,1,CHEMBL631254,,,Rattus norvegicus,N,1,1088.0,
13497,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded rats at 100.0 mg/kg, po",Intermediate,10116.0,,A,,BAO_0000218,8133,,,1,CHEMBL631255,,,Rattus norvegicus,N,1,1088.0,
13498,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 2.1 mg/kg, po",Intermediate,10116.0,,A,,BAO_0000218,8133,,,1,CHEMBL631256,,,Rattus norvegicus,N,1,1088.0,
13499,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 20.8mg/kg, po",Intermediate,10116.0,,A,,BAO_0000218,8133,,,1,CHEMBL631257,,,Rattus norvegicus,N,1,1088.0,
13500,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded rats at 207.6 mg/kg, po",Intermediate,10116.0,,A,,BAO_0000218,8133,,,1,CHEMBL628009,,,Rattus norvegicus,N,1,1088.0,
13501,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 3.0mg/kg, po",Intermediate,10116.0,,A,,BAO_0000218,8133,,,1,CHEMBL628010,,,Rattus norvegicus,N,1,1088.0,
13502,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 30.0mg/kg, po",Intermediate,10116.0,,A,,BAO_0000218,8133,,,1,CHEMBL628011,,,Rattus norvegicus,N,1,1088.0,
13503,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded rats at 6.9 mg/kg, po",Intermediate,10116.0,,A,,BAO_0000218,8133,,,1,CHEMBL628012,,,Rattus norvegicus,N,1,1088.0,
13504,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 69.2mg/kg, po",Intermediate,10116.0,,A,,BAO_0000218,8133,,,1,CHEMBL628013,,,Rattus norvegicus,N,1,1088.0,
13505,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 691.9mg/kg, po",Intermediate,10116.0,,A,,BAO_0000218,8133,,,1,CHEMBL628014,,,Rattus norvegicus,N,1,1088.0,
13506,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 0.03 mg/kg, po",Intermediate,9615.0,,A,,BAO_0000218,8133,,,1,CHEMBL628015,,,Canis lupus familiaris,N,1,1088.0,
13507,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 0.1 mg/kg, po",Intermediate,9615.0,,A,,BAO_0000218,8133,,,1,CHEMBL628016,,,Canis lupus familiaris,N,1,1088.0,
13508,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 0.3 mg/kg, po",Intermediate,9615.0,,A,,BAO_0000218,8133,,,1,CHEMBL874461,,,Canis lupus familiaris,N,1,1088.0,
13509,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 1.0 mg/kg, po",Intermediate,9615.0,,A,,BAO_0000218,8133,,,1,CHEMBL628017,,,Canis lupus familiaris,N,1,1088.0,
13510,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 10.0mg/kg, po",Intermediate,9615.0,,A,,BAO_0000218,8133,,,1,CHEMBL628018,,,Canis lupus familiaris,N,1,1088.0,
13511,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 10mg/kg, po",Intermediate,9615.0,,A,,BAO_0000218,8133,,,1,CHEMBL628019,,,Canis lupus familiaris,N,1,1088.0,
13512,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 1 mg/kg, po",Intermediate,9615.0,,A,,BAO_0000218,8133,,,1,CHEMBL628020,,,Canis lupus familiaris,N,1,1088.0,
13513,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 30 mg/kg, po",Intermediate,9615.0,,A,,BAO_0000218,8133,,,1,CHEMBL628021,,,Canis lupus familiaris,N,1,1088.0,
13514,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 3mg/kg, po",Intermediate,9615.0,,A,,BAO_0000218,8133,,,1,CHEMBL628022,,,Canis lupus familiaris,N,1,1088.0,
13515,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 3.0mg/kg, po",Intermediate,9615.0,,A,,BAO_0000218,8133,,,1,CHEMBL628023,,,Canis lupus familiaris,N,1,1088.0,
13516,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 100 mg/kg, po",Autocuration,314293.0,,A,,BAO_0000218,8133,,,1,CHEMBL628024,,,Simiiformes,U,0,1088.0,
13517,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 10mg/kg, po",Autocuration,314293.0,,A,,BAO_0000218,8133,,,1,CHEMBL628025,,,Simiiformes,U,0,1088.0,
13518,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 1 mg/kg, po",Autocuration,314293.0,,A,,BAO_0000218,8133,,,1,CHEMBL628026,,,Simiiformes,U,0,1088.0,
13519,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 30mg/kg, po",Autocuration,314293.0,,A,,BAO_0000218,8133,,,1,CHEMBL628027,,,Simiiformes,U,0,1088.0,
13520,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 3mg/kg, po",Autocuration,314293.0,,A,,BAO_0000218,8133,,,1,CHEMBL628028,,,Simiiformes,U,0,1088.0,
13521,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 0.1 mg/kg, po",Intermediate,10116.0,,A,,BAO_0000218,8133,,,1,CHEMBL628029,,,Rattus norvegicus,N,1,1088.0,
13522,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 0.3 mg/kg, po",Intermediate,10116.0,,A,,BAO_0000218,8133,,,1,CHEMBL628030,,,Rattus norvegicus,N,1,1088.0,
13523,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 1.0mg/kg, po",Intermediate,10116.0,,A,,BAO_0000218,8133,,,1,CHEMBL628031,,,Rattus norvegicus,N,1,1088.0,
13524,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 10.0 mg/kg, po",Intermediate,10116.0,,A,,BAO_0000218,8133,,,1,CHEMBL628032,,,Rattus norvegicus,N,1,1088.0,
13525,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 100.0 mg/kg, po",Intermediate,10116.0,,A,,BAO_0000218,8133,,,1,CHEMBL628033,,,Rattus norvegicus,N,1,1088.0,
13526,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 2.08 mg/kg, po",Intermediate,10116.0,,A,,BAO_0000218,8133,,,1,CHEMBL628034,,,Rattus norvegicus,N,1,1088.0,
13527,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 207.6mg/kg, po",Intermediate,10116.0,,A,,BAO_0000218,8133,,,1,CHEMBL628035,,,Rattus norvegicus,N,1,1088.0,
13528,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 3.0 mg/kg, po",Intermediate,10116.0,,A,,BAO_0000218,8133,,,1,CHEMBL628036,,,Rattus norvegicus,N,1,1088.0,
13529,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 30.0mg/kg, po",Intermediate,10116.0,,A,,BAO_0000218,8133,,,1,CHEMBL874462,,,Rattus norvegicus,N,1,1088.0,
13530,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -8/-38,Intermediate,9615.0,,A,,BAO_0000218,9025,,,1,CHEMBL628037,,,Canis lupus familiaris,N,1,,
13531,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); 13/-25,Intermediate,9615.0,,A,,BAO_0000218,9025,,,1,CHEMBL628123,,,Canis lupus familiaris,N,1,,
13532,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); 27/-15,Intermediate,9615.0,,A,,BAO_0000218,9025,,,1,CHEMBL628124,,,Canis lupus familiaris,N,1,,
13533,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -2/-19,Intermediate,9615.0,,A,,BAO_0000218,9025,,,1,CHEMBL628125,,,Canis lupus familiaris,N,1,,
13534,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/60 range (low/high); -3/-4,Intermediate,9615.0,,A,,BAO_0000218,9025,,,1,CHEMBL628126,,,Canis lupus familiaris,N,1,,
13535,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 3 range (low/high),Intermediate,9615.0,,A,,BAO_0000218,9025,,,1,CHEMBL628127,,,Canis lupus familiaris,N,1,,
13536,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 3/10 range (low/high); -9/24,Intermediate,9615.0,,A,,BAO_0000218,9025,,,1,CHEMBL628128,,,Canis lupus familiaris,N,1,,
13537,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 3/10 range (low/high); 3/-1,Intermediate,9615.0,,A,,BAO_0000218,9025,,,1,CHEMBL628129,,,Canis lupus familiaris,N,1,,
13538,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/030 range (low/high); 12/23,Intermediate,9615.0,,A,,BAO_0000218,9025,,,1,CHEMBL628130,,,Canis lupus familiaris,N,1,,
13539,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/3 range (low/high); 1/3,Intermediate,9615.0,,A,,BAO_0000218,9025,,,1,CHEMBL628131,,,Canis lupus familiaris,N,1,,
13540,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/3 range (low/high); 6/16,Intermediate,9615.0,,A,,BAO_0000218,9025,,,1,CHEMBL628132,,,Canis lupus familiaris,N,1,,
13541,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/3 range (low/high); 7/14,Intermediate,9615.0,,A,,BAO_0000218,9025,,,1,CHEMBL628133,,,Canis lupus familiaris,N,1,,
13542,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/3/10 range (low/high); 4/4/23,Intermediate,9615.0,,A,,BAO_0000218,9025,,,1,CHEMBL628134,,,Canis lupus familiaris,N,1,,
13543,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 10/14,Intermediate,9615.0,,A,,BAO_0000218,9025,,,1,CHEMBL628135,,,Canis lupus familiaris,N,1,,
13544,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 11/15,Intermediate,9615.0,,A,,BAO_0000218,9025,,,1,CHEMBL628136,,,Canis lupus familiaris,N,1,,
13545,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 11/44,Intermediate,9615.0,,A,,BAO_0000218,9025,,,1,CHEMBL628137,,,Canis lupus familiaris,N,1,,
13546,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 14/28,Intermediate,9615.0,,A,,BAO_0000218,9025,,,1,CHEMBL628138,,,Canis lupus familiaris,N,1,,
13547,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 15-28,Intermediate,9615.0,,A,,BAO_0000218,9025,,,1,CHEMBL628139,,,Canis lupus familiaris,N,1,,
13548,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 2/3,Intermediate,9615.0,,A,,BAO_0000218,9025,,,1,CHEMBL628140,,,Canis lupus familiaris,N,1,,
13549,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 26/32,Intermediate,9615.0,,A,,BAO_0000218,9025,,,1,CHEMBL628141,,,Canis lupus familiaris,N,1,,
13550,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 5/1,Intermediate,9615.0,,A,,BAO_0000218,9025,,,1,CHEMBL628142,,,Canis lupus familiaris,N,1,,
13551,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 5/12,Intermediate,9615.0,,A,,BAO_0000218,9025,,,1,CHEMBL628143,,,Canis lupus familiaris,N,1,,
13552,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 6/7,Intermediate,9615.0,,A,,BAO_0000218,9025,,,1,CHEMBL628144,,,Canis lupus familiaris,N,1,,
13553,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 7/6,Intermediate,9615.0,,A,,BAO_0000218,9025,,,1,CHEMBL628145,,,Canis lupus familiaris,N,1,,
13554,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 8/12,Intermediate,9615.0,,A,,BAO_0000218,9025,,,1,CHEMBL628146,,,Canis lupus familiaris,N,1,,
13555,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 8/27,Intermediate,9615.0,,A,,BAO_0000218,9025,,,1,CHEMBL625355,,,Canis lupus familiaris,N,1,,
13556,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 9/14,Intermediate,9615.0,,A,,BAO_0000218,9025,,,1,CHEMBL625356,,,Canis lupus familiaris,N,1,,
13557,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 9/16,Intermediate,9615.0,,A,,BAO_0000218,9025,,,1,CHEMBL625357,,,Canis lupus familiaris,N,1,,
13558,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/60 range (low/high); 12/23,Intermediate,9615.0,,A,,BAO_0000218,9025,,,1,CHEMBL625527,,,Canis lupus familiaris,N,1,,
13559,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 3 range (low/high),Intermediate,9615.0,,A,,BAO_0000218,9025,,,1,CHEMBL875473,,,Canis lupus familiaris,N,1,,
13560,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 3/10 range (low/high); 10/22,Intermediate,9615.0,,A,,BAO_0000218,9025,,,1,CHEMBL625528,,,Canis lupus familiaris,N,1,,
13561,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 3/10 range (low/high); 4/12,Intermediate,10116.0,,A,,BAO_0000218,9025,,,1,CHEMBL626304,,,Rattus norvegicus,N,1,,
13562,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a 10/30 dose range; 11/-11,Intermediate,9615.0,,A,,BAO_0000218,9025,,,1,CHEMBL624138,,,Canis lupus familiaris,N,1,1637.0,
13563,Calculated partition coefficient (clogP),Autocuration,,,P,,BAO_0000100,6448,,,1,CHEMBL624139,,,,U,0,,
13564,Calculated partition coefficient (clogP),Autocuration,,,P,,BAO_0000100,17221,,,1,CHEMBL624140,,,,U,0,,
13565,Calculated partition coefficient (clogP),Autocuration,,,P,,BAO_0000100,6545,,,1,CHEMBL624141,,,,U,0,,
13566,Calculated partition coefficient (clogP),Autocuration,,,P,,BAO_0000100,577,,,1,CHEMBL624142,,,,U,0,,
13567,Calculated partition coefficient (clogP),Autocuration,,,P,,BAO_0000100,6285,,,1,CHEMBL624143,,,,U,0,,
13568,Calculated partition coefficient (clogP),Autocuration,,,P,,BAO_0000100,6500,,,1,CHEMBL624144,,,,U,0,,
13569,Calculated partition coefficient (clogP),Autocuration,,,P,,BAO_0000100,6716,,,1,CHEMBL624145,,,,U,0,,
13570,Calculated partition coefficient (clogP),Autocuration,,,P,,BAO_0000100,13658,,,1,CHEMBL624146,,,,U,0,,
13571,Calculated partition coefficient (clogP),Autocuration,,,P,,BAO_0000100,6549,,,1,CHEMBL624147,,,,U,0,,
13572,Calculated partition coefficient (clogP) (MacLogP),Autocuration,,,P,,BAO_0000100,14685,,,1,CHEMBL883123,,,,U,0,,
13573,Partition coefficient (logP),Autocuration,,,A,,BAO_0000019,6893,,,1,CHEMBL624148,,,,U,0,,
13574,Kinetic parameter was determined,Autocuration,,,A,,BAO_0000019,3687,,,1,CHEMBL874416,,,,U,0,,
13575,Calculated partition coefficient (clogP),Autocuration,,,P,,BAO_0000100,4207,,,1,CHEMBL624149,,,,U,0,,
13576,Calculated partition coefficient (clogP),Autocuration,,,P,,BAO_0000100,4626,,,1,CHEMBL624150,,,,U,0,,
13577,Lipophilicity was determined,Autocuration,,,P,,BAO_0000100,1021,,,1,CHEMBL624151,,,,U,0,,
13578,Lipophilicity was determined,Autocuration,,,P,,BAO_0000100,3777,,,1,CHEMBL624152,,,,U,0,,
13579,Lipophilicity was determined,Autocuration,,,P,,BAO_0000100,17533,,,1,CHEMBL622139,,,,U,0,,
13580,Calculated partition coefficient (clogP),Autocuration,,,P,,BAO_0000100,6524,,,1,CHEMBL622140,,,,U,0,,
13581,Lipophilicity was determined,Autocuration,,,P,,BAO_0000100,17533,,,1,CHEMBL622141,,,,U,0,,
13582,Lipophilicity in octanol-water,Autocuration,,,P,,BAO_0000100,6480,,,1,CHEMBL622142,,,,U,0,,
13583,Calculated partition coefficient (clogP),Autocuration,,,P,,BAO_0000100,17606,,,1,CHEMBL622143,,,,U,0,,
13584,Octanol-water partition coefficient was determined,Autocuration,,,P,,BAO_0000100,6863,,,1,CHEMBL622144,,,,U,0,,
13585,Partition coefficient (logP),Autocuration,,,A,,BAO_0000019,1356,,,1,CHEMBL877473,,,,U,0,,
13586,Calculated partition coefficient (clogP),Autocuration,,,P,,BAO_0000100,3326,,,1,CHEMBL622145,,,,U,0,,
13587,Partition coefficient was determined; ND means not determined,Autocuration,,,A,,BAO_0000019,1356,,,1,CHEMBL622146,,,,U,0,,
13588,Calculated partition coefficient (clogP),Autocuration,,,P,,BAO_0000100,12984,,,1,CHEMBL622147,,,,U,0,,
13589,Partition coefficient of the compound,Autocuration,,,A,,BAO_0000019,17363,,,1,CHEMBL622148,,,,U,0,,
13590,Permeability was determined,Autocuration,,,A,,BAO_0000019,6827,,,1,CHEMBL883124,,,,U,0,,
13591,The compound was evaluated for the partition coefficient,Autocuration,,,P,,BAO_0000100,261,,,1,CHEMBL622149,,,,U,0,,
13592,Partition coefficient (logP),Autocuration,,,A,,BAO_0000019,2685,,,1,CHEMBL622150,,,,U,0,,
13593,The lipophilicity was reported,Autocuration,,,P,,BAO_0000100,414,,,1,CHEMBL622151,,,,U,0,,
13594,logarithm of the octanol-water partition coefficient for the compound,Autocuration,,,P,,BAO_0000100,15769,,,1,CHEMBL622152,,,,U,0,,
13595,Clogp value was determined,Autocuration,,,A,,BAO_0000019,17248,,,1,CHEMBL622153,,,,U,0,,
13596,Clp at a dose of 1.5 mg/kg,Autocuration,,,A,,BAO_0000218,16935,,,1,CHEMBL877474,,,,U,0,,
13597,Clp at a dose of 2.0 mg/kg,Autocuration,,,A,,BAO_0000218,16935,,,1,CHEMBL622154,,,,U,0,,
13598,"Clp, plasma clearance at a dose of 10 mg/kg",Autocuration,,,A,,BAO_0000218,14832,,,1,CHEMBL622155,,,,U,0,1969.0,
13599,"Clp, plasma clearance at a dose of 50 mg/kg",Autocuration,,,A,,BAO_0000218,14832,,,1,CHEMBL622156,,,,U,0,1969.0,
13600,Compound was tested for plasma clearance in rat,Intermediate,10116.0,,A,,BAO_0000218,2399,,,1,CHEMBL622157,,,Rattus norvegicus,N,1,1969.0,
13601,Compound was tested for plasma clearance in rat; Not determined,Intermediate,10116.0,,A,,BAO_0000218,2399,,,1,CHEMBL622158,,,Rattus norvegicus,N,1,1969.0,
13602,Plasma clearance (pharmacokinetic parameter) in rat (in vivo) at a dose of 10 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,6227,,,1,CHEMBL622807,,,Rattus norvegicus,N,1,,
13603,Plasma clearance (pharmacokinetic parameter) in rhesus (in vivo) at a dose of 5 mg/kg,Intermediate,9544.0,,A,,BAO_0000218,6227,,,1,CHEMBL622808,,,Macaca mulatta,N,1,,
13604,Plasma clearance by iv administration at a dose 0.003 ug/mL,Autocuration,,,A,,BAO_0000218,5623,,,1,CHEMBL622809,,,,U,0,,
13605,Plasma clearance determined,Autocuration,,,A,,BAO_0000218,4854,,,1,CHEMBL622810,,,,U,0,,
13606,Plasma clearance after iv administration at 3 mg/kg in hamster,Intermediate,10026.0,,A,,BAO_0000218,4493,,,1,CHEMBL876653,,,Cricetinae,N,1,,
13607,Plasma clearance after iv administration at 4 mg/kg in hamster,Intermediate,10026.0,,A,,BAO_0000218,4493,,,1,CHEMBL622811,,,Cricetinae,N,1,,
13608,Rate of clearance in rat was determined,Intermediate,10116.0,,A,,BAO_0000218,14956,,,1,CHEMBL622986,,,Rattus norvegicus,N,1,,
13609,Total plasma clearance Clp was determined for the compound after iv dose of 5.06 mg/kg in rats,Intermediate,10116.0,,A,,BAO_0000218,15372,,,1,CHEMBL622987,,,Rattus norvegicus,N,1,1969.0,
13610,Total plasma clearance after iv dose of 5.10 mg/kg in rats,Intermediate,10116.0,,A,,BAO_0000218,15372,,,1,CHEMBL622988,,,Rattus norvegicus,N,1,1969.0,
13611,Total plasma clearance was determined for the compound after iv dose of 4.74 mg/kg in rats,Intermediate,10116.0,,A,,BAO_0000218,15372,,,1,CHEMBL622989,,,Rattus norvegicus,N,1,1969.0,
13612,Total plasma clearance was determined for the compound after iv dose of 4.97 mg/kg in rats,Intermediate,10116.0,,A,,BAO_0000218,15372,,,1,CHEMBL622990,,,Rattus norvegicus,N,1,1969.0,
13613,plasma clearance in preclinical species was measured after Intravenous administration at the given dose (0.01 mg/kg) in monkey,Autocuration,314293.0,,A,,BAO_0000218,15604,,,1,CHEMBL622991,,,Simiiformes,U,0,1969.0,
13614,plasma clearance in preclinical species was measured after Intravenous administration at the given dose (0.05 mg/kg) in rat,Intermediate,10116.0,,A,,BAO_0000218,15604,,,1,CHEMBL622227,,,Rattus norvegicus,N,1,1969.0,
13615,plasma clearance in preclinical species was measured after Intravenous administration at the given dose (0.1 mg/kg) in dog,Intermediate,9615.0,,A,,BAO_0000218,15604,,,1,CHEMBL622228,,,Canis lupus familiaris,N,1,1969.0,
13616,Clpl value in rat,Intermediate,10116.0,,A,,BAO_0000218,14964,,,1,CHEMBL622229,,,Rattus norvegicus,N,1,,
13617,Cmax (ng /mL) value after oral administration of 10 mg/kg in guinea pig.,Intermediate,10141.0,,A,,BAO_0000218,15240,,,1,CHEMBL622230,,,Cavia porcellus,N,1,,
13618,Cmax after an oral dose of 10 uM/Kg in male Sprague-Dawley rats,Intermediate,10116.0,,A,,BAO_0000218,16449,,,1,CHEMBL622231,,,Rattus norvegicus,N,1,,
13619,Cmax after an oral dose of 10 uM/Kg in male cynomolgus monkeys,Intermediate,9541.0,,A,,BAO_0000218,16449,,,1,CHEMBL622232,,,Macaca fascicularis,N,1,,
13620,Cmax in minutes at a iv dose of 1.0(pmol/g/h).,Autocuration,,,A,,BAO_0000218,12902,,,1,CHEMBL622233,,,,U,0,,
13621,Cmax in minutes at a iv dose of 2.0(pmol/g/h).,Autocuration,,,A,,BAO_0000218,12902,,,1,CHEMBL622234,,,,U,0,,
13622,Cmax in minutes at a iv dose of 4.0(pmol/g/h).,Autocuration,,,A,,BAO_0000218,12902,,,1,CHEMBL622235,,,,U,0,,
13623,Cmax in minutes at a iv dose of 5.0(pmol/g/h).,Autocuration,,,A,,BAO_0000218,12902,,,1,CHEMBL622236,,,,U,0,,
13624,Cmax in minutes at a iv dose of 54.0(pmol/g/h).,Autocuration,,,A,,BAO_0000218,12902,,,1,CHEMBL622237,,,,U,0,,
13625,Cmax in minutes at a po dose of 10.0(pmol/g/h).,Autocuration,,,A,,BAO_0000218,12902,,,1,CHEMBL877482,,,,U,0,,
13626,Cmax in minutes at a po dose of 20.0(pmol/g/h).,Autocuration,,,A,,BAO_0000218,12902,,,1,CHEMBL622238,,,,U,0,,
13627,Cmax in minutes at a po dose of 40.0(pmol/g/h).,Autocuration,,,A,,BAO_0000218,12902,,,1,CHEMBL622239,,,,U,0,,
13628,Cmax was calculated as maximum concentration reached in the blood,Autocuration,,,A,,BAO_0000218,11149,,,1,CHEMBL622240,,,,U,0,178.0,
13629,Cmax was calculated as maximum concentration reached in the blood in air pouch exudate,Autocuration,,,A,,BAO_0000218,11149,,,1,CHEMBL622241,,,,U,0,178.0,
13630,Cmax was determine after peroral administration at 10 mpk in Rat,Intermediate,10116.0,,A,,BAO_0000218,5669,,,1,CHEMBL631013,,,Rattus norvegicus,N,1,,
13631,Cmax was determine after peroral administration at 10 mpk in Rhesus,Intermediate,9544.0,,A,,BAO_0000218,5669,,,1,CHEMBL631014,,,Macaca mulatta,N,1,,
13632,Cmax was determine after peroral administration at 10 mpk in dog,Intermediate,9615.0,,A,,BAO_0000218,5669,,,1,CHEMBL631015,,,Canis lupus familiaris,N,1,,
13633,Cmax was determine after peroral administration at 160 mpk in Rat,Intermediate,10116.0,,A,,BAO_0000218,5669,,,1,CHEMBL631016,,,Rattus norvegicus,N,1,,
13634,Cmax was determine after peroral administration at 20 mpk in Rat,Intermediate,10116.0,,A,,BAO_0000218,5669,,,1,CHEMBL631017,,,Rattus norvegicus,N,1,,
13635,Cmax was determine after peroral administration at 50 mpk in Rat,Intermediate,10116.0,,A,,BAO_0000218,5669,,,1,CHEMBL631018,,,Rattus norvegicus,N,1,,
13636,Cmax was determined,Autocuration,,,A,,BAO_0000218,4236,,,1,CHEMBL631019,,,,U,0,,
13637,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into hippocampus,Intermediate,10090.0,,A,,BAO_0000218,13792,,,1,CHEMBL875761,,,Mus musculus,N,1,955.0,
13638,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into hypothalamus,Intermediate,10090.0,,A,,BAO_0000218,13792,,,1,CHEMBL631020,,,Mus musculus,N,1,955.0,
13639,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into pons and medulla,Intermediate,10090.0,,A,,BAO_0000218,13792,,,1,CHEMBL631669,,,Mus musculus,N,1,955.0,
13640,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into rest of the brain,Intermediate,10090.0,,A,,BAO_0000218,13792,,,1,CHEMBL631670,,,Mus musculus,N,1,955.0,
13641,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into striatum,Intermediate,10090.0,,A,,BAO_0000218,13792,,,1,CHEMBL631671,,,Mus musculus,N,1,2435.0,
13642,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 0.31-0.4,Intermediate,10116.0,,A,,BAO_0000218,8418,,,1,CHEMBL631672,,,Rattus norvegicus,N,1,178.0,
13643,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 0.97-1.12,Intermediate,10116.0,,A,,BAO_0000218,8418,,,1,CHEMBL631673,,,Rattus norvegicus,N,1,178.0,
13644,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.35-0.37,Intermediate,10116.0,,A,,BAO_0000218,8418,,,1,CHEMBL631856,,,Rattus norvegicus,N,1,178.0,
13645,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.72-1.03,Intermediate,10116.0,,A,,BAO_0000218,8418,,,1,CHEMBL631857,,,Rattus norvegicus,N,1,178.0,
13646,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.95-1.06,Intermediate,10116.0,,A,,BAO_0000218,8418,,,1,CHEMBL631858,,,Rattus norvegicus,N,1,178.0,
13647,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.35-0.4,Intermediate,10116.0,,A,,BAO_0000218,8418,,,1,CHEMBL631859,,,Rattus norvegicus,N,1,178.0,
13648,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.73-0.85,Intermediate,10116.0,,A,,BAO_0000218,8418,,,1,CHEMBL631860,,,Rattus norvegicus,N,1,178.0,
13649,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.65-0.83,Intermediate,10116.0,,A,,BAO_0000218,8418,,,1,CHEMBL631861,,,Rattus norvegicus,N,1,178.0,
13650,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.69-0.84,Intermediate,10116.0,,A,,BAO_0000218,8418,,,1,CHEMBL631862,,,Rattus norvegicus,N,1,178.0,
13651,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 0.28-0.46,Intermediate,10116.0,,A,,BAO_0000218,8418,,,1,CHEMBL631863,,,Rattus norvegicus,N,1,178.0,
13652,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.38-1.5,Intermediate,10116.0,,A,,BAO_0000218,8418,,,1,CHEMBL631864,,,Rattus norvegicus,N,1,178.0,
13653,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.34-0.48,Intermediate,10116.0,,A,,BAO_0000218,8418,,,1,CHEMBL631865,,,Rattus norvegicus,N,1,178.0,
13654,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.58-1.17,Intermediate,10116.0,,A,,BAO_0000218,8418,,,1,CHEMBL631866,,,Rattus norvegicus,N,1,178.0,
13655,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 1.0-1.24,Intermediate,10116.0,,A,,BAO_0000218,8418,,,1,CHEMBL629360,,,Rattus norvegicus,N,1,178.0,
13656,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.28-0.37,Intermediate,10116.0,,A,,BAO_0000218,8418,,,1,CHEMBL629361,,,Rattus norvegicus,N,1,178.0,
13657,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.54-0.63,Intermediate,10116.0,,A,,BAO_0000218,8418,,,1,CHEMBL629362,,,Rattus norvegicus,N,1,178.0,
13658,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.25-0.32,Intermediate,10116.0,,A,,BAO_0000218,8418,,,1,CHEMBL630740,,,Rattus norvegicus,N,1,178.0,
13659,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.49-0.58,Intermediate,10116.0,,A,,BAO_0000218,8418,,,1,CHEMBL630741,,,Rattus norvegicus,N,1,178.0,
13660,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.58-0.77,Intermediate,10116.0,,A,,BAO_0000218,8418,,,1,CHEMBL630742,,,Rattus norvegicus,N,1,178.0,
13661,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 0.20-0.25,Intermediate,10116.0,,A,,BAO_0000218,8418,,,1,CHEMBL630743,,,Rattus norvegicus,N,1,,
13662,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 1.05-1.25,Intermediate,10116.0,,A,,BAO_0000218,8418,,,1,CHEMBL630744,,,Rattus norvegicus,N,1,,
13663,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.03-0.03,Intermediate,10116.0,,A,,BAO_0000218,8418,,,1,CHEMBL630745,,,Rattus norvegicus,N,1,,
13664,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.03-0.06,Intermediate,10116.0,,A,,BAO_0000218,8418,,,1,CHEMBL630746,,,Rattus norvegicus,N,1,,
13665,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.34-0.5,Intermediate,10116.0,,A,,BAO_0000218,8418,,,1,CHEMBL630747,,,Rattus norvegicus,N,1,,
13666,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.17-0.20,Intermediate,10116.0,,A,,BAO_0000218,8418,,,1,CHEMBL630748,,,Rattus norvegicus,N,1,,
13667,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.81-1.26,Intermediate,10116.0,,A,,BAO_0000218,8418,,,1,CHEMBL632056,,,Rattus norvegicus,N,1,,
13668,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.03-0.06,Intermediate,10116.0,,A,,BAO_0000218,8418,,,1,CHEMBL632057,,,Rattus norvegicus,N,1,,
13669,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.18-0.36,Intermediate,10116.0,,A,,BAO_0000218,8418,,,1,CHEMBL632058,,,Rattus norvegicus,N,1,,
13670,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 0.28-0.37,Intermediate,10116.0,,A,,BAO_0000218,8418,,,1,CHEMBL632059,,,Rattus norvegicus,N,1,,
13671,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 0.97-2.17,Intermediate,10116.0,,A,,BAO_0000218,8418,,,1,CHEMBL632060,,,Rattus norvegicus,N,1,,
13672,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.02-0.03,Intermediate,10116.0,,A,,BAO_0000218,8418,,,1,CHEMBL632061,,,Rattus norvegicus,N,1,,
13673,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.05-0.07,Intermediate,10116.0,,A,,BAO_0000218,8418,,,1,CHEMBL629207,,,Rattus norvegicus,N,1,,
13674,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.35-0.72,Intermediate,10116.0,,A,,BAO_0000218,8418,,,1,CHEMBL629208,,,Rattus norvegicus,N,1,,
13675,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.15-0.19,Intermediate,10116.0,,A,,BAO_0000218,8418,,,1,CHEMBL629209,,,Rattus norvegicus,N,1,,
13676,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.76-1.42,Intermediate,10116.0,,A,,BAO_0000218,8418,,,1,CHEMBL629210,,,Rattus norvegicus,N,1,,
13677,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.02-0.03,Intermediate,10116.0,,A,,BAO_0000218,8418,,,1,CHEMBL629211,,,Rattus norvegicus,N,1,,
13678,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.03-0.06,Intermediate,10116.0,,A,,BAO_0000218,8418,,,1,CHEMBL629212,,,Rattus norvegicus,N,1,,
13679,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.05-0.06,Intermediate,10116.0,,A,,BAO_0000218,8418,,,1,CHEMBL629213,,,Rattus norvegicus,N,1,,
13680,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 6.9mg/kg, po",Intermediate,10116.0,,A,,BAO_0000218,8133,,,1,CHEMBL629214,,,Rattus norvegicus,N,1,1088.0,
13681,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 69.2 mg/kg, po",Intermediate,10116.0,,A,,BAO_0000218,8133,,,1,CHEMBL629215,,,Rattus norvegicus,N,1,1088.0,
13682,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 691.9 mg/kg, po",Intermediate,10116.0,,A,,BAO_0000218,8133,,,1,CHEMBL635154,,,Rattus norvegicus,N,1,1088.0,
13683,Oral diuretic activity measured by Na+ excretion in Rat at 9 mg/kg after ip administration (0-5 hr),Intermediate,10116.0,,A,,BAO_0000218,6996,,,1,CHEMBL629216,,,Rattus norvegicus,N,1,,
13684,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration,Intermediate,10116.0,,A,,BAO_0000218,6996,,,1,CHEMBL629217,,,Rattus norvegicus,N,1,,
13685,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),Intermediate,10116.0,,A,,BAO_0000218,6996,,,1,CHEMBL629218,,,Rattus norvegicus,N,1,,
13686,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration (0-5 hr),Intermediate,10116.0,,A,,BAO_0000218,6996,,,1,CHEMBL629219,,,Rattus norvegicus,N,1,,
13687,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration ( 0 - 5 hr),Intermediate,10116.0,,A,,BAO_0000218,6996,,,1,CHEMBL629220,,,Rattus norvegicus,N,1,,
13688,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr ),Intermediate,10116.0,,A,,BAO_0000218,6996,,,1,CHEMBL629221,,,Rattus norvegicus,N,1,,
13689,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),Intermediate,10116.0,,A,,BAO_0000218,6996,,,1,CHEMBL631127,,,Rattus norvegicus,N,1,,
13690,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration,Intermediate,10116.0,,A,,BAO_0000218,6996,,,1,CHEMBL631128,,,Rattus norvegicus,N,1,,
13691,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),Intermediate,10116.0,,A,,BAO_0000218,6996,,,1,CHEMBL631129,,,Rattus norvegicus,N,1,,
13692,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration (0-5 hr),Intermediate,10116.0,,A,,BAO_0000218,6996,,,1,CHEMBL631130,,,Rattus norvegicus,N,1,,
13693,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration ( 0 - 5 hr),Intermediate,10116.0,,A,,BAO_0000218,6996,,,1,CHEMBL631131,,,Rattus norvegicus,N,1,,
13694,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr ),Intermediate,10116.0,,A,,BAO_0000218,6996,,,1,CHEMBL631132,,,Rattus norvegicus,N,1,,
13695,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),Intermediate,10116.0,,A,,BAO_0000218,6996,,,1,CHEMBL631133,,,Rattus norvegicus,N,1,,
13696,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration,Intermediate,10116.0,,A,,BAO_0000218,6996,,,1,CHEMBL631134,,,Rattus norvegicus,N,1,,
13697,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),Intermediate,10116.0,,A,,BAO_0000218,6996,,,1,CHEMBL875120,,,Rattus norvegicus,N,1,,
13698,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration (0-5 hr),Intermediate,10116.0,,A,,BAO_0000218,6996,,,1,CHEMBL631135,,,Rattus norvegicus,N,1,,
13699,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration ( 0 - 5 hr),Intermediate,10116.0,,A,,BAO_0000218,6996,,,1,CHEMBL631136,,,Rattus norvegicus,N,1,,
13700,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr ),Intermediate,10116.0,,A,,BAO_0000218,6996,,,1,CHEMBL631137,,,Rattus norvegicus,N,1,,
13701,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),Intermediate,10116.0,,A,,BAO_0000218,6996,,,1,CHEMBL631138,,,Rattus norvegicus,N,1,,
13702,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration,Intermediate,10116.0,,A,,BAO_0000218,6996,,,1,CHEMBL631139,,,Rattus norvegicus,N,1,,
13703,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),Intermediate,10116.0,,A,,BAO_0000218,6996,,,1,CHEMBL631140,,,Rattus norvegicus,N,1,,
13704,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration (0-5 hr),Intermediate,10116.0,,A,,BAO_0000218,6996,,,1,CHEMBL631141,,,Rattus norvegicus,N,1,,
13705,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration ( 0 - 5 hr),Intermediate,10116.0,,A,,BAO_0000218,6996,,,1,CHEMBL631142,,,Rattus norvegicus,N,1,,
13706,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr ),Intermediate,10116.0,,A,,BAO_0000218,6996,,,1,CHEMBL631143,,,Rattus norvegicus,N,1,,
13707,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),Intermediate,10116.0,,A,,BAO_0000218,6996,,,1,CHEMBL631144,,,Rattus norvegicus,N,1,,
13708,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 0.312 mg/kg after ip administration,Intermediate,9615.0,,A,,BAO_0000218,6996,,,1,CHEMBL631145,,,Canis lupus familiaris,N,1,,
13709,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 0.3 mg/kg after ip administration (0-6 hr),Intermediate,9615.0,,A,,BAO_0000218,6996,,,1,CHEMBL631146,,,Canis lupus familiaris,N,1,,
13710,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 0.625 mg/kg after ip administration,Intermediate,9615.0,,A,,BAO_0000218,6996,,,1,CHEMBL631147,,,Canis lupus familiaris,N,1,,
13711,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 0.6 mg/kg after ip administration ( 0-6 hr),Intermediate,9615.0,,A,,BAO_0000218,6996,,,1,CHEMBL631148,,,Canis lupus familiaris,N,1,,
13712,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1.8 mg/kg after ip administration ( 0-6 hr),Intermediate,9615.0,,A,,BAO_0000218,6996,,,1,CHEMBL631149,,,Canis lupus familiaris,N,1,,
13713,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 10 mg/kg after ip administration (0-6 hr),Intermediate,9615.0,,A,,BAO_0000218,6996,,,1,CHEMBL631150,,,Canis lupus familiaris,N,1,,
13714,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 10 mg/kg after ip administration ( 0-6 hr),Intermediate,9615.0,,A,,BAO_0000218,6996,,,1,CHEMBL631151,,,Canis lupus familiaris,N,1,,
13715,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 16.2 mg/kg after ip administration ( 0-6 hr),Intermediate,9615.0,,A,,BAO_0000218,6996,,,1,CHEMBL631152,,,Canis lupus familiaris,N,1,,
13716,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg after ip administration ( 0-6 hr),Intermediate,9615.0,,A,,BAO_0000218,6996,,,1,CHEMBL631443,,,Canis lupus familiaris,N,1,,
13717,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg after ip administration (0-6 hr),Intermediate,9615.0,,A,,BAO_0000218,6996,,,1,CHEMBL631444,,,Canis lupus familiaris,N,1,,
13718,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg after ip administration ( 0 - 6 hr),Intermediate,9615.0,,A,,BAO_0000218,6996,,,1,CHEMBL631445,,,Canis lupus familiaris,N,1,,
13719,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg after ip administration ( 0-6 hr ),Intermediate,9615.0,,A,,BAO_0000218,6996,,,1,CHEMBL631446,,,Canis lupus familiaris,N,1,,
13720,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg g after ip administration (0-6 hr),Intermediate,9615.0,,A,,BAO_0000218,6996,,,1,CHEMBL631447,,,Canis lupus familiaris,N,1,,
13721,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 20 mg/kg after ip administration ( 0-6 hr),Intermediate,9615.0,,A,,BAO_0000218,6996,,,1,CHEMBL631448,,,Canis lupus familiaris,N,1,,
13722,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 2 mg/kg after ip administration,Intermediate,9615.0,,A,,BAO_0000218,6996,,,1,CHEMBL631449,,,Canis lupus familiaris,N,1,,
13723,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 2 mg/kg after ip administration (0-6 hr),Intermediate,9615.0,,A,,BAO_0000218,6996,,,1,CHEMBL631450,,,Canis lupus familiaris,N,1,,
13724,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 2 mg/kg after ip administration ( 0 - 6 hr),Intermediate,9615.0,,A,,BAO_0000218,6996,,,1,CHEMBL629724,,,Canis lupus familiaris,N,1,,
13725,"Biodistribution in mice skin, after 24 hr of intravenous aadministration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",Intermediate,10090.0,,A,,BAO_0000218,9716,,,1,CHEMBL629725,,,Mus musculus,N,1,14.0,
13726,"Biodistribution in mice skin, after 48 hr of intravenous administration of 1-2 ug ofcompound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",Intermediate,10090.0,,A,,BAO_0000218,9716,,,1,CHEMBL629726,,,Mus musculus,N,1,14.0,
13727,"Biodistribution in mice spleen, after 12 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",Intermediate,10090.0,,A,,BAO_0000218,9716,,,1,CHEMBL629727,,,Mus musculus,N,1,2106.0,
13728,"Biodistribution in mice spleen, after 1 hr of intravenous aadministration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",Intermediate,10090.0,,A,,BAO_0000218,9716,,,1,CHEMBL630404,,,Mus musculus,N,1,2106.0,
13729,"Biodistribution in mice spleen, after 24 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",Intermediate,10090.0,,A,,BAO_0000218,9716,,,1,CHEMBL630405,,,Mus musculus,N,1,2106.0,
13730,"Biodistribution in mice spleen, after 48 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",Intermediate,10090.0,,A,,BAO_0000218,9716,,,1,CHEMBL630406,,,Mus musculus,N,1,2106.0,
13731,"Biodistribution in mice stomach, after 12 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",Intermediate,10090.0,,A,,BAO_0000218,9716,,,1,CHEMBL630407,,,Mus musculus,N,1,945.0,
13732,"Biodistribution in mice stomach, after 1 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",Intermediate,10090.0,,A,,BAO_0000218,9716,,,1,CHEMBL630573,,,Mus musculus,N,1,945.0,
13733,"Biodistribution in mice stomach, after 24 hr of intravenous administration of 1-2 ug of ofcompound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",Intermediate,10090.0,,A,,BAO_0000218,9716,,,1,CHEMBL630574,,,Mus musculus,N,1,945.0,
13734,"Biodistribution in mice stomach, after 48 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",Intermediate,10090.0,,A,,BAO_0000218,9716,,,1,CHEMBL630575,,,Mus musculus,N,1,945.0,
13735,"Biodistribution in mice tail, after 12 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",Intermediate,10090.0,,A,,BAO_0000218,9716,,,1,CHEMBL630576,,,Mus musculus,N,1,,
13736,"Biodistribution in mice tail, after 1 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",Intermediate,10090.0,,A,,BAO_0000218,9716,,,1,CHEMBL630577,,,Mus musculus,N,1,,
13737,"Biodistribution in mice tail, after 24 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",Intermediate,10090.0,,A,,BAO_0000218,9716,,,1,CHEMBL630578,,,Mus musculus,N,1,,
13738,"Biodistribution in mice tail, after 48 hr of intravenous administration of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",Intermediate,10090.0,,A,,BAO_0000218,9716,,,1,CHEMBL630579,,,Mus musculus,N,1,,
13739,Percent of injected 238-Plutonium(IV) in mice kidney at 24 hr (orally administered),Intermediate,10090.0,,A,,BAO_0000218,12192,,,1,CHEMBL630580,,,Mus musculus,N,1,2113.0,
13740,Percent of injected 238-Plutonium(IV) in mice kidneys at 24 h,Intermediate,10090.0,,A,,BAO_0000218,12192,,,1,CHEMBL630581,,,Mus musculus,N,1,2113.0,
13741,Percent of injected 238-Plutonium(IV) in mice kidneys at 24 hr (orally administered),Intermediate,10090.0,,A,,BAO_0000218,12192,,,1,CHEMBL630582,,,Mus musculus,N,1,2113.0,
13742,Percent of injected 238-Plutonium(IV) in mice liver at 24 h,Intermediate,10090.0,,A,,BAO_0000218,12192,,,1,CHEMBL630583,,,Mus musculus,N,1,,
13743,Percent of injected 238-Plutonium(IV) in mice liver at 24 hr (orally administered),Intermediate,10090.0,,A,,BAO_0000218,12192,,,1,CHEMBL630584,,,Mus musculus,N,1,,
13744,Percent of injected 238-Plutonium(IV) in mice skeleton at 24 h,Intermediate,10090.0,,A,,BAO_0000218,12192,,,1,CHEMBL630585,,,Mus musculus,N,1,,
13745,Percent of injected 238-Plutonium(IV) in mice skeleton at 24 hr (orally administered),Intermediate,10090.0,,A,,BAO_0000218,12192,,,1,CHEMBL630586,,,Mus musculus,N,1,,
13746,Percent of injected 238-Plutonium(IV) in mice soft tissue at 24 h,Intermediate,10090.0,,A,,BAO_0000218,12192,,,1,CHEMBL630587,,,Mus musculus,N,1,,
13747,Percent of injected 238-Plutonium(IV) in mice soft tissue at 24 hr (orally administered),Intermediate,10090.0,,A,,BAO_0000218,12192,,,1,CHEMBL630588,,,Mus musculus,N,1,,
13748,Percent of injected 238-Plutonium(IV) in mice whole body at 24 h,Intermediate,10090.0,,A,,BAO_0000218,12192,,,1,CHEMBL630589,,,Mus musculus,N,1,,
13749,Percent of injected 238-Plutonium(IV) in mice whole body at 24 hr (orally administered),Intermediate,10090.0,,A,,BAO_0000218,12192,,,1,CHEMBL630590,,,Mus musculus,N,1,,
13750,Removal of 238-Plutonium(IV) in feces at 24 h,Autocuration,,,A,,BAO_0000019,12192,,,1,CHEMBL630591,,,,U,0,1988.0,
13751,Removal of 238-Plutonium(IV) in feces at 24 hr (orally administered),Autocuration,,,A,,BAO_0000019,12192,,,1,CHEMBL630592,,,,U,0,1988.0,
13752,Removal of 238-Plutonium(IV) in gastrointestinal (GI) contents at 24 h,Autocuration,,,A,,BAO_0000019,12192,,,1,CHEMBL630593,,,,U,0,,
13753,Removal of 238-Plutonium(IV) in gastrointestinal (GI) contents at 24 hr (orally administered),Autocuration,,,A,,BAO_0000019,12192,,,1,CHEMBL630594,,,,U,0,,
13754,Removal of 238-Plutonium(IV) in urine 0-4 h (orally administered),Autocuration,,,A,,BAO_0000019,12192,,,1,CHEMBL630595,,,,U,0,1088.0,
13755,Removal of 238-Plutonium(IV) in urine 4-24 hr (orally administered),Autocuration,,,A,,BAO_0000019,12192,,,1,CHEMBL630596,,,,U,0,1088.0,
13756,Removal of 238-Plutonium(IV) in urine after 0-24 h,Autocuration,,,A,,BAO_0000019,12192,,,1,CHEMBL630597,,,,U,0,1088.0,
13757,Removal of 238-Plutonium(IV) in urine after 0-24 hr (orally administered),Autocuration,,,A,,BAO_0000019,12192,,,1,CHEMBL630598,,,,U,0,1088.0,
13758,Removal of 238-Plutonium(IV) in urine after 0-4 h,Autocuration,,,A,,BAO_0000019,12192,,,1,CHEMBL630599,,,,U,0,1088.0,
13759,Removal of 238-Plutonium(IV) in urine after 0-4 hr (orally administered),Autocuration,,,A,,BAO_0000019,12192,,,1,CHEMBL630600,,,,U,0,1088.0,
13760,Removal of 238-Plutonium(IV) in urine after 4-24 h,Autocuration,,,A,,BAO_0000019,12192,,,1,CHEMBL630601,,,,U,0,1088.0,
13761,Removal of 238-Plutonium(IV) in urine after 4-24 hr (orally administered),Autocuration,,,A,,BAO_0000019,12192,,,1,CHEMBL630602,,,,U,0,1088.0,
13762,Removal of 238-Plutonium(IV) in urine at 0-4 hr (orally administered),Autocuration,,,A,,BAO_0000019,12192,,,1,CHEMBL630603,,,,U,0,1088.0,
13763,Removal of 238-Plutonium(IV) in urine at 4-24 hr (orally administered),Autocuration,,,A,,BAO_0000019,12192,,,1,CHEMBL630604,,,,U,0,1088.0,
13764,Biodistribution in blood of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,10116.0,,A,,BAO_0000218,12017,,,1,CHEMBL624869,,,Rattus norvegicus,N,1,178.0,
13765,Biodistribution in blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,10116.0,,A,,BAO_0000218,12017,,,1,CHEMBL624870,,,Rattus norvegicus,N,1,178.0,
13766,Biodistribution in blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),Intermediate,10116.0,,A,,BAO_0000218,12017,,,1,CHEMBL623189,,,Rattus norvegicus,N,1,178.0,
13767,Biodistribution in blood of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,10116.0,,A,,BAO_0000218,12017,,,1,CHEMBL623190,,,Rattus norvegicus,N,1,178.0,
13768,Biodistribution in blood of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,10116.0,,A,,BAO_0000218,12017,,,1,CHEMBL623191,,,Rattus norvegicus,N,1,178.0,
13769,Biodistribution in fat of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,10116.0,,A,,BAO_0000218,12017,,,1,CHEMBL623192,,,Rattus norvegicus,N,1,,
13770,Biodistribution in fat of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,10116.0,,A,,BAO_0000218,12017,,,1,CHEMBL623193,,,Rattus norvegicus,N,1,,
13771,Biodistribution in fat of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),Intermediate,10116.0,,A,,BAO_0000218,12017,,,1,CHEMBL623194,,,Rattus norvegicus,N,1,,
13772,Biodistribution in fat of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,10116.0,,A,,BAO_0000218,12017,,,1,CHEMBL623195,,,Rattus norvegicus,N,1,,
13773,Biodistribution in fat of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,10116.0,,A,,BAO_0000218,12017,,,1,CHEMBL623196,,,Rattus norvegicus,N,1,,
13774,Tested in vivo for the biodistribution in rat uterus/blood at 1 hour after intravenous dose of 15 microCi of the drug and 15 micro g of estradiol,Intermediate,10116.0,,A,,BAO_0000218,11836,,,1,CHEMBL623197,,,Rattus norvegicus,N,1,,
13775,Tested in vivo for the biodistribution in rat uterus/blood at 1 hour after intravenous dose of 50 microCi of drug in 10%ethanol saline,Intermediate,10116.0,,A,,BAO_0000218,11836,,,1,CHEMBL623198,,,Rattus norvegicus,N,1,,
13776,Tested in vivo for the biodistribution in rat uterus/blood at 1 hour after intravenous dose of 50 microCi of the drug and 15 ug of estradiol,Intermediate,10116.0,,A,,BAO_0000218,11836,,,1,CHEMBL623199,,,Rattus norvegicus,N,1,,
13777,Tested in vivo for the biodistribution in rat uterus/muscle after 3 hours following an intravenous dose of 100 microCi of drug in 10%ethanol saline,Intermediate,10116.0,,A,,BAO_0000218,11836,,,1,CHEMBL623200,,,Rattus norvegicus,N,1,2385.0,
13778,Tested in vivo for the biodistribution in rat uterus/muscle after 3 hours following an intravenous dose of 120 microCi of drug in 10%ethanol saline,Intermediate,10116.0,,A,,BAO_0000218,11836,,,1,CHEMBL623201,,,Rattus norvegicus,N,1,2385.0,
13779,Tested in vivo for the biodistribution in rat uterus/muscle after 3 hours following an intravenous dose of 15 microCi of drug in 10%ethanol saline,Intermediate,10116.0,,A,,BAO_0000218,11836,,,1,CHEMBL623202,,,Rattus norvegicus,N,1,2385.0,
13780,Tested in vivo for the biodistribution in rat uterus/muscle after 3 hours following an intravenous dose of 50 microCi of drug in 10%ethanol saline,Intermediate,10116.0,,A,,BAO_0000218,11836,,,1,CHEMBL623203,,,Rattus norvegicus,N,1,2385.0,
13781,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 100 microCi of drug in 10%ethanol saline,Intermediate,10116.0,,A,,BAO_0000218,11836,,,1,CHEMBL623204,,,Rattus norvegicus,N,1,2385.0,
13782,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 100 microCi of the drug and 15 ug of estradiol,Intermediate,10116.0,,A,,BAO_0000218,11836,,,1,CHEMBL623205,,,Rattus norvegicus,N,1,2385.0,
13783,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 120 microCi of drug in 10%ethanol saline,Intermediate,10116.0,,A,,BAO_0000218,11836,,,1,CHEMBL623206,,,Rattus norvegicus,N,1,2385.0,
13784,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 120 microCi of the drug and 15 micro g of estradiol,Intermediate,10116.0,,A,,BAO_0000218,11836,,,1,CHEMBL623207,,,Rattus norvegicus,N,1,2385.0,
13785,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 15 microCi of the drug and 15 ug of estradiol,Intermediate,10116.0,,A,,BAO_0000218,11836,,,1,CHEMBL623208,,,Rattus norvegicus,N,1,2385.0,
13786,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 50 microCi of drug in 10%ethanol saline,Intermediate,10116.0,,A,,BAO_0000218,11836,,,1,CHEMBL623209,,,Rattus norvegicus,N,1,2385.0,
13787,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 50 microCi of the drug and 15 ug of estradiol,Intermediate,10116.0,,A,,BAO_0000218,11836,,,1,CHEMBL623210,,,Rattus norvegicus,N,1,2385.0,
13788,Tested in vivo for the biodistribution in rat fat at 1 hour after intravenous dose of 50 microCi of drug in 10%ethanol saline,Intermediate,10116.0,,A,,BAO_0000218,11836,,,1,CHEMBL623211,,,Rattus norvegicus,N,1,,
13789,Tested in vivo for the biodistribution in rat uterus at 1 hour after intravenous dose of 120 microCi of drug in 10%ethanol saline,Intermediate,10116.0,,A,,BAO_0000218,11836,,,1,CHEMBL623212,,,Rattus norvegicus,N,1,995.0,
13790,Tested in vitro for intrinsic activity relative to quinpirole,Autocuration,,,A,,BAO_0000019,12640,,,1,CHEMBL623213,,,,U,0,,
13791,"Relative ion enhancement, determined in pulsed ultrafiltration",Autocuration,,,A,,BAO_0000019,14218,,,1,CHEMBL623214,,,,U,0,,
13792,% ionization at the pH 7.4 at 37 degree Centigrade,Autocuration,,,A,,BAO_0000019,11296,,,1,CHEMBL623215,,,,U,0,,
13793,Percentage ionization was measured,Autocuration,,,A,,BAO_0000019,10929,,,1,CHEMBL623216,,,,U,0,,
13794,Association constant of binding of compound with calf thymus DNA was determined by using equilibrium dialysis.,Intermediate,9913.0,,A,,BAO_0000218,13841,,,1,CHEMBL623217,,,Bos taurus,N,1,,
13795,Compound was autooxidized for 2 hour at 37 degree Celsius in pH 7.4 Pseudo-first-order rate constant,Autocuration,,,A,,BAO_0000019,10431,,,1,CHEMBL623218,,,,U,0,,
13796,Compound was autooxidized for 2 hour at 37 degree Celsius in pH 7.4 phosphate buffer Pseudo-first-order rate constant,Autocuration,,,A,,BAO_0000019,10431,,,1,CHEMBL623913,,,,U,0,,
13797,Compound was autooxidized for 2 hour at 37 degree Celsius in pH 7.4 phosphate buffer pseudo-first-order rate constant 0.1 mM EDTA,Autocuration,,,A,,BAO_0000019,10431,,,1,CHEMBL623914,,,,U,0,,
13798,Compound was evaluated for the partition coefficient in octanol/water,Autocuration,,,P,,BAO_0000100,8826,,,1,CHEMBL623915,,,,U,0,,
13799,Compound was evaluated for the partition coefficient in octanol/water (1-octanol / 10 mM phosphate buffer at pH 7.4),Autocuration,,,P,,BAO_0000100,8826,,,1,CHEMBL624080,,,,U,0,,
13800,Equilibrium constant measured by the pulse radiolysis at pH 7,Autocuration,,,A,,BAO_0000019,9884,,,1,CHEMBL624081,,,,U,0,,
13801,In vitro hydrolytic rate constant determined in human blood,Intermediate,9606.0,,A,,BAO_0000218,9827,,,1,CHEMBL624082,,,Homo sapiens,N,1,,
13802,In vitro oxidation of compound to its pyridinium salt (3) in presence of human plasma,Intermediate,9606.0,,A,,BAO_0000218,10009,,,1,CHEMBL625054,,,Homo sapiens,N,1,,
13803,In vitro oxidation of compound to its pyridinium salt (3) in presence of hydrogen peroxide,Autocuration,,,A,,BAO_0000019,10009,,,1,CHEMBL877485,,,,U,0,,
13804,In vitro oxidation of compound to its pyridinium salt (3) in presence of mouse brain homogenate,Intermediate,10090.0,,A,,BAO_0000218,10009,,,1,CHEMBL625055,,,Mus musculus,N,1,,
13805,In vitro oxidation of compound to its pyridinium salt (3) in presence of mouse liver homogenate,Intermediate,10090.0,,A,,BAO_0000218,10009,,,1,CHEMBL625056,,,Mus musculus,N,1,,
13806,In vitro oxidation of compound in presence of human plasma,Intermediate,9606.0,,A,,BAO_0000218,10009,,,1,CHEMBL625057,,,Homo sapiens,N,1,,
13807,In vitro oxidation of compound in presence of hydrogen peroxide,Autocuration,,,A,,BAO_0000019,10009,,,1,CHEMBL625058,,,,U,0,,
13808,In vitro oxidation of compound in presence of mouse brain homogenate,Intermediate,10090.0,,A,,BAO_0000218,10009,,,1,CHEMBL625059,,,Mus musculus,N,1,,
13809,In vitro oxidation of compound in presence of mouse liver homogenate,Intermediate,10090.0,,A,,BAO_0000218,10009,,,1,CHEMBL629536,,,Mus musculus,N,1,,
13810,Mean potassium excretion in rats when compound administered at 0 mg/kg po and vehicle dosed at 0 umol/kg,Intermediate,10116.0,,A,,BAO_0000218,11510,,,1,CHEMBL629537,,,Rattus norvegicus,N,1,,
13811,Mean potassium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 30.23 umol/kg,Intermediate,10116.0,,A,,BAO_0000218,11510,,,1,CHEMBL629538,,,Rattus norvegicus,N,1,,
13812,Mean potassium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 33.59 umol/kg,Intermediate,10116.0,,A,,BAO_0000218,11510,,,1,CHEMBL629539,,,Rattus norvegicus,N,1,,
13813,Mean potassium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 37.13 umol/kg,Intermediate,10116.0,,A,,BAO_0000218,11510,,,1,CHEMBL874445,,,Rattus norvegicus,N,1,,
13814,Mean potassium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 39.48 umol/kg,Intermediate,10116.0,,A,,BAO_0000218,11510,,,1,CHEMBL629540,,,Rattus norvegicus,N,1,,
13815,Mean potassium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 483.72 umol/kg,Intermediate,10116.0,,A,,BAO_0000218,11510,,,1,CHEMBL629541,,,Rattus norvegicus,N,1,,
13816,Mean potassium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg,Intermediate,10116.0,,A,,BAO_0000218,11510,,,1,CHEMBL629542,,,Rattus norvegicus,N,1,,
13817,Mean potassium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg; Not determined,Intermediate,10116.0,,A,,BAO_0000218,11510,,,1,CHEMBL630243,,,Rattus norvegicus,N,1,,
13818,Mean potassium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 631.76 umol/kg,Intermediate,10116.0,,A,,BAO_0000218,11510,,,1,CHEMBL630244,,,Rattus norvegicus,N,1,,
13819,Mean potassium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 7.56 umol/kg,Intermediate,10116.0,,A,,BAO_0000218,11510,,,1,CHEMBL630245,,,Rattus norvegicus,N,1,,
13820,Mean potassium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 8.4 umol/kg,Intermediate,10116.0,,A,,BAO_0000218,11510,,,1,CHEMBL630246,,,Rattus norvegicus,N,1,,
13821,Mean potassium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.28 umol/kg,Intermediate,10116.0,,A,,BAO_0000218,11510,,,1,CHEMBL630247,,,Rattus norvegicus,N,1,,
13822,Mean potassium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.87 umol/kg,Intermediate,10116.0,,A,,BAO_0000218,11510,,,1,CHEMBL630248,,,Rattus norvegicus,N,1,,
13823,Biodistribution in rat blood at 240 minutes after dose administration.,Intermediate,10116.0,,A,,BAO_0000218,13100,,,1,CHEMBL630249,,,Rattus norvegicus,N,1,178.0,
13824,Biodistribution in rat blood at 30 minutes after dose administration.,Intermediate,10116.0,,A,,BAO_0000218,13100,,,1,CHEMBL630250,,,Rattus norvegicus,N,1,178.0,
13825,Biodistribution in rat blood at 360 minutes after dose administration.,Intermediate,10116.0,,A,,BAO_0000218,13100,,,1,CHEMBL630251,,,Rattus norvegicus,N,1,178.0,
13826,Biodistribution in rat blood at 3 hr after dose administration.,Intermediate,10116.0,,A,,BAO_0000218,13100,,,1,CHEMBL630252,,,Rattus norvegicus,N,1,178.0,
13827,Biodistribution in rat blood at 60 minutes after dose administration.,Intermediate,10116.0,,A,,BAO_0000218,13100,,,1,CHEMBL630408,,,Rattus norvegicus,N,1,178.0,
13828,Biodistribution in rat cerebellum at 120 minutes after dose administration.,Intermediate,10116.0,,A,,BAO_0000218,13100,,,1,CHEMBL630409,,,Rattus norvegicus,N,1,2037.0,
13829,Biodistribution in rat cerebellum at 1440 minutes after dose administration.,Intermediate,10116.0,,A,,BAO_0000218,13100,,,1,CHEMBL874446,,,Rattus norvegicus,N,1,2037.0,
13830,Biodistribution in rat cerebellum at 15 minutes after dose administration.,Intermediate,10116.0,,A,,BAO_0000218,13100,,,1,CHEMBL630410,,,Rattus norvegicus,N,1,2037.0,
13831,Biodistribution in rat cerebellum at 240 minutes after dose administration.,Intermediate,10116.0,,A,,BAO_0000218,13100,,,1,CHEMBL630411,,,Rattus norvegicus,N,1,2037.0,
13832,Biodistribution in rat cerebellum at 30 minutes after dose administration.,Intermediate,10116.0,,A,,BAO_0000218,13100,,,1,CHEMBL630412,,,Rattus norvegicus,N,1,2037.0,
13833,Biodistribution in rat cerebellum at 360 minutes after dose administration.,Intermediate,10116.0,,A,,BAO_0000218,13100,,,1,CHEMBL630413,,,Rattus norvegicus,N,1,2037.0,
13834,Biodistribution in rat cerebellum at 3 hr after dose administration.,Intermediate,10116.0,,A,,BAO_0000218,13100,,,1,CHEMBL630414,,,Rattus norvegicus,N,1,2037.0,
13835,Biodistribution in rat cerebellum at 60 minutes after dose administration.,Intermediate,10116.0,,A,,BAO_0000218,13100,,,1,CHEMBL630415,,,Rattus norvegicus,N,1,2037.0,
13836,Biodistribution in rat cortex at 120 minutes after dose administration.,Intermediate,10116.0,,A,,BAO_0000218,13100,,,1,CHEMBL630416,,,Rattus norvegicus,N,1,,
13837,Biodistribution in rat cortex at 1440 minutes after dose administration.,Intermediate,10116.0,,A,,BAO_0000218,13100,,,1,CHEMBL630417,,,Rattus norvegicus,N,1,,
13838,Biodistribution in rat cortex at 15 minutes after dose administration.,Intermediate,10116.0,,A,,BAO_0000218,13100,,,1,CHEMBL630418,,,Rattus norvegicus,N,1,,
13839,Biodistribution in rat cortex at 240 minutes after dose administration.,Intermediate,10116.0,,A,,BAO_0000218,13100,,,1,CHEMBL630419,,,Rattus norvegicus,N,1,,
13840,Biodistribution in rat cortex at 30 minutes after dose administration.,Intermediate,10116.0,,A,,BAO_0000218,13100,,,1,CHEMBL630420,,,Rattus norvegicus,N,1,,
13841,Biodistribution in rat cortex at 360 minutes after dose administration.,Intermediate,10116.0,,A,,BAO_0000218,13100,,,1,CHEMBL630421,,,Rattus norvegicus,N,1,,
13842,Biodistribution in rat cortex at 3 hr after dose administration.,Intermediate,10116.0,,A,,BAO_0000218,13100,,,1,CHEMBL630422,,,Rattus norvegicus,N,1,,
13843,Biodistribution in rat cortex at 60 minutes after dose administration.,Intermediate,10116.0,,A,,BAO_0000218,13100,,,1,CHEMBL630423,,,Rattus norvegicus,N,1,,
13844,Biodistribution in rat heart at 120 minutes after dose administration.,Intermediate,10116.0,,A,,BAO_0000218,13100,,,1,CHEMBL630424,,,Rattus norvegicus,N,1,948.0,
13845,Biodistribution in rat heart at 15 minutes after dose administration.,Intermediate,10116.0,,A,,BAO_0000218,13100,,,1,CHEMBL630425,,,Rattus norvegicus,N,1,948.0,
13846,Biodistribution in rat heart at 240 minutes after dose administration.,Intermediate,10116.0,,A,,BAO_0000218,13100,,,1,CHEMBL629462,,,Rattus norvegicus,N,1,948.0,
13847,Biodistribution in rat heart at 30 minutes after dose administration.,Intermediate,10116.0,,A,,BAO_0000218,13100,,,1,CHEMBL630426,,,Rattus norvegicus,N,1,948.0,
13848,Biodistribution in rat heart at 360 minutes after dose administration.,Intermediate,10116.0,,A,,BAO_0000218,13100,,,1,CHEMBL630427,,,Rattus norvegicus,N,1,948.0,
13849,Biodistribution in rat heart at 3 hr after dose administration.,Intermediate,10116.0,,A,,BAO_0000218,13100,,,1,CHEMBL625877,,,Rattus norvegicus,N,1,948.0,
13850,Biodistribution in rat heart at 60 minutes after dose administration.,Intermediate,10116.0,,A,,BAO_0000218,13100,,,1,CHEMBL625878,,,Rattus norvegicus,N,1,948.0,
13851,Biodistribution in rat hippocampus at 1440 minutes after dose administration.,Intermediate,10116.0,,A,,BAO_0000218,13100,,,1,CHEMBL625879,,,Rattus norvegicus,N,1,10000000.0,
13852,Biodistribution in rat hippocampus at 240 minutes after dose administration.,Intermediate,10116.0,,A,,BAO_0000218,13100,,,1,CHEMBL625880,,,Rattus norvegicus,N,1,10000000.0,
13853,Biodistribution in rat hippocampus at 30 minutes after dose administration.,Intermediate,10116.0,,A,,BAO_0000218,13100,,,1,CHEMBL625881,,,Rattus norvegicus,N,1,10000000.0,
13854,Biodistribution in rat hippocampus at 360 minutes after dose administration.,Intermediate,10116.0,,A,,BAO_0000218,13100,,,1,CHEMBL625882,,,Rattus norvegicus,N,1,10000000.0,
13855,Biodistribution in rat hippocampus at 15 minutes after dose administration.,Intermediate,10116.0,,A,,BAO_0000218,13100,,,1,CHEMBL625883,,,Rattus norvegicus,N,1,10000000.0,
13856,Biodistribution in rat kidney at 120 minutes after dose administration.,Intermediate,10116.0,,A,,BAO_0000218,13100,,,1,CHEMBL625884,,,Rattus norvegicus,N,1,2113.0,
13857,Biodistribution in rat kidney at 1440 minutes after dose administration.,Intermediate,10116.0,,A,,BAO_0000218,13100,,,1,CHEMBL625885,,,Rattus norvegicus,N,1,2113.0,
13858,Biodistribution in rat kidney at 15 minutes after dose administration.,Intermediate,10116.0,,A,,BAO_0000218,13100,,,1,CHEMBL628649,,,Rattus norvegicus,N,1,2113.0,
13859,Biodistribution in rat kidney at 240 minutes after dose administration.,Intermediate,10116.0,,A,,BAO_0000218,13100,,,1,CHEMBL628650,,,Rattus norvegicus,N,1,2113.0,
13860,Biodistribution in rat kidney at 30 minutes after dose administration.,Intermediate,10116.0,,A,,BAO_0000218,13100,,,1,CHEMBL628651,,,Rattus norvegicus,N,1,2113.0,
13861,Biodistribution in rat kidney at 360 minutes after dose administration.,Intermediate,10116.0,,A,,BAO_0000218,13100,,,1,CHEMBL628652,,,Rattus norvegicus,N,1,2113.0,
13862,Biodistribution in rat kidney at 60 minutes after dose administration.,Intermediate,10116.0,,A,,BAO_0000218,13100,,,1,CHEMBL628653,,,Rattus norvegicus,N,1,2113.0,
13863,Biodistribution in rat liver at 120 minutes after dose administration.,Intermediate,10116.0,,A,,BAO_0000218,13100,,,1,CHEMBL628654,,,Rattus norvegicus,N,1,2107.0,
13864,Biodistribution in rat liver at 1440 minutes after dose administration.,Intermediate,10116.0,,A,,BAO_0000218,13100,,,1,CHEMBL628655,,,Rattus norvegicus,N,1,2107.0,
13865,Biodistribution in rat liver at 15 minutes after dose administration.,Intermediate,10116.0,,A,,BAO_0000218,13100,,,1,CHEMBL625238,,,Rattus norvegicus,N,1,2107.0,
13866,Biodistribution in rat liver at 240 minutes after dose administration.,Intermediate,10116.0,,A,,BAO_0000218,13100,,,1,CHEMBL625239,,,Rattus norvegicus,N,1,2107.0,
13867,Biodistribution in rat liver at 30 minutes after dose administration.,Intermediate,10116.0,,A,,BAO_0000218,13100,,,1,CHEMBL625240,,,Rattus norvegicus,N,1,2107.0,
13868,Biodistribution in rat liver at 360 minutes after dose administration.,Intermediate,10116.0,,A,,BAO_0000218,13100,,,1,CHEMBL625241,,,Rattus norvegicus,N,1,2107.0,
13869,Biodistribution in rat liver at 60 minutes after dose administration.,Intermediate,10116.0,,A,,BAO_0000218,13100,,,1,CHEMBL625242,,,Rattus norvegicus,N,1,2107.0,
13870,Biodistribution in rat lung at 120 minutes after dose administration.,Intermediate,10116.0,,A,,BAO_0000218,13100,,,1,CHEMBL874587,,,Rattus norvegicus,N,1,2048.0,
13871,Biodistribution in rat lung at 1440 minutes after dose administration.,Intermediate,10116.0,,A,,BAO_0000218,13100,,,1,CHEMBL625405,,,Rattus norvegicus,N,1,2048.0,
13872,Biodistribution in rat lung at 15 minutes after dose administration.,Intermediate,10116.0,,A,,BAO_0000218,13100,,,1,CHEMBL625406,,,Rattus norvegicus,N,1,2048.0,
13873,Biodistribution in rat lung at 240 minutes after dose administration.,Intermediate,10116.0,,A,,BAO_0000218,13100,,,1,CHEMBL625407,,,Rattus norvegicus,N,1,2048.0,
13874,Biodistribution in rat lung at 30 minutes after dose administration.,Intermediate,10116.0,,A,,BAO_0000218,13100,,,1,CHEMBL625408,,,Rattus norvegicus,N,1,2048.0,
13875,Biodistribution in rat lung at 360 minutes after dose administration.,Intermediate,10116.0,,A,,BAO_0000218,13100,,,1,CHEMBL625409,,,Rattus norvegicus,N,1,2048.0,
13876,Percent of maximal contractile response to compound in rat thoracic aorta strips in the presence of calcium deficient buffer,Intermediate,10116.0,,A,,BAO_0000218,12361,,,1,CHEMBL625410,,,Rattus norvegicus,N,1,1515.0,
13877,Percent of maximal contractile response to compound in rat thoracic aorta strips in the presence of nifedipine,Intermediate,10116.0,,A,,BAO_0000218,12361,,,1,CHEMBL625411,,,Rattus norvegicus,N,1,1515.0,
13878,Percent of maximal contractile response to compound in rat thoracic aorta strips in the presence of verapamil,Intermediate,10116.0,,A,,BAO_0000218,12361,,,1,CHEMBL625412,,,Rattus norvegicus,N,1,1515.0,
13879,Percent of maximal contractile response to compound in rat thoracic aorta strips presence of PBZ and CIR,Intermediate,10116.0,,A,,BAO_0000218,12361,,,1,CHEMBL625413,,,Rattus norvegicus,N,1,1515.0,
13880,Percent of maximal contractile response to compound in rat thoracic aorta strips v,Intermediate,10116.0,,A,,BAO_0000218,12361,,,1,CHEMBL625414,,,Rattus norvegicus,N,1,1515.0,
13881,Percent of maximal contractile response to compound with phenoxybenzamine pretreatment on rat thoracic aorta strips,Intermediate,10116.0,,A,,BAO_0000218,12361,,,1,CHEMBL625415,,,Rattus norvegicus,N,1,1515.0,
13882,Percent of maximal contractile response to compound without phenoxybenzamine pretreatment on rat thoracic aorta strips,Intermediate,10116.0,,A,,BAO_0000218,12361,,,1,CHEMBL625416,,,Rattus norvegicus,N,1,1515.0,
13883,% of the total radioactive dose of compound present in the 0-24 hour urine after a single 5 mg/kg dose administered intravenously in rats,Intermediate,10116.0,,A,,BAO_0000218,12712,,,1,CHEMBL625417,,,Rattus norvegicus,N,1,1088.0,
13884,Compound at the dose 10 mg/kg administered intraperitoneally was evaluated for the excretion rate in rats in 7 days through feces,Intermediate,10116.0,,A,,BAO_0000218,7415,,,1,CHEMBL625418,,,Rattus norvegicus,N,1,1988.0,
13885,Compound at the dose 10 mg/kg administered intraperitoneally was evaluated for the excretion rate in rats in 7 days through urine,Intermediate,10116.0,,A,,BAO_0000218,7415,,,1,CHEMBL625419,,,Rattus norvegicus,N,1,1088.0,
13886,Compound was evaluated for the biliary excretion in the anesthetized rats in 6 hours after intravenous doses 1 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,7415,,,1,CHEMBL625420,,,Rattus norvegicus,N,1,,
13887,Compound was evaluated for the biliary excretion in the anesthetized rats in 6 hours after intravenous doses 10 mg/kg,Intermediate,10116.0,,A,,BAO_0000218,7415,,,1,CHEMBL626996,,,Rattus norvegicus,N,1,,
13888,"Compound was evaluated for the cumulative excretion rate in rats at the dose 10 mg/kg, intraperitoneally for 18 days through feces",Intermediate,10116.0,,A,,BAO_0000218,7415,,,1,CHEMBL626997,,,Rattus norvegicus,N,1,1988.0,
13889,"Compound was evaluated for the cumulative excretion rate in rats at the dose 10 mg/kg, intraperitoneally for 18 days through urine",Intermediate,10116.0,,A,,BAO_0000218,7415,,,1,CHEMBL626998,,,Rattus norvegicus,N,1,1088.0,
13890,"Compound was evaluated for the in rats after the dose of 5 mg/kg intravenously, at the dose 4 hour biliary excretion",Intermediate,10116.0,,A,,BAO_0000218,7415,,,1,CHEMBL626999,,,Rattus norvegicus,N,1,,
13891,faecal levels excreted after administration of cysteamine (175 mg/kg) to mice measured at 0-30h,Intermediate,10090.0,,A,,BAO_0000218,8050,,,1,CHEMBL627000,,,Mus musculus,N,1,,
13892,fecal levels excreted after administration of 2-(3-bromophenyl)thiazolidine(500 mg/kg) to mice measured at 0-30h,Intermediate,10090.0,,A,,BAO_0000218,8050,,,1,CHEMBL627001,,,Mus musculus,N,1,,
13893,fecal levels excreted after administration of 2-phenylthiazolidine (500 mg/kg) to mice measured at 0-30h,Intermediate,10090.0,,A,,BAO_0000218,8050,,,1,CHEMBL627002,,,Mus musculus,N,1,,
13894,fecal levels excreted after administration of benzaldehyde (250 mg/kg) to mice measured at 0-30h,Intermediate,10090.0,,A,,BAO_0000218,8050,,,1,CHEMBL627003,,,Mus musculus,N,1,,
13895,urine levels excreted after administration of 2-(3-bromophenyl)thiazolidine(500 mg/kg) to mice measured at 0-24 hr,Intermediate,10090.0,,A,,BAO_0000218,8050,,,1,CHEMBL627004,,,Mus musculus,N,1,1088.0,
13896,urine levels excreted after administration of 2-(3-bromophenyl)thiazolidine(500 mg/kg) to mice measured at 0-6 hr,Intermediate,10090.0,,A,,BAO_0000218,8050,,,1,CHEMBL627005,,,Mus musculus,N,1,1088.0,
13897,urine levels excreted after administration of 2-(3-bromophenyl)thiazolidine(500 mg/kg) to mice measured at 24-30 hr,Intermediate,10090.0,,A,,BAO_0000218,8050,,,1,CHEMBL874594,,,Mus musculus,N,1,1088.0,
13898,urine levels excreted after administration of 2-phenylthiazolidine (500 mg/kg) to mice measured at 0-24 hr,Intermediate,10090.0,,A,,BAO_0000218,8050,,,1,CHEMBL627006,,,Mus musculus,N,1,1088.0,
13899,urine levels excreted after administration of 2-phenylthiazolidine (500 mg/kg) to mice measured at 0-6 hr,Intermediate,10090.0,,A,,BAO_0000218,8050,,,1,CHEMBL627007,,,Mus musculus,N,1,1088.0,
13900,urine levels excreted after administration of 2-phenylthiazolidine (500 mg/kg) to mice measured at 24-30 hr,Intermediate,10090.0,,A,,BAO_0000218,8050,,,1,CHEMBL627884,,,Mus musculus,N,1,1088.0,
13901,urine levels excreted after administration of benzaldehyde (250 mg/kg) to mice measured at 0-24 hr,Intermediate,10090.0,,A,,BAO_0000218,8050,,,1,CHEMBL627885,,,Mus musculus,N,1,1088.0,
13902,urine levels excreted after administration of benzaldehyde (250 mg/kg) to mice measured at 0-6 hr,Intermediate,10090.0,,A,,BAO_0000218,8050,,,1,CHEMBL627886,,,Mus musculus,N,1,1088.0,
13903,urine levels excreted after administration of benzaldehyde (250 mg/kg) to mice measured at 24-30 hr,Intermediate,10090.0,,A,,BAO_0000218,8050,,,1,CHEMBL627887,,,Mus musculus,N,1,1088.0,
13904,urine levels excreted after administration of cysteamine (175 mg/kg) to mice measured at 0-24 hr,Intermediate,10090.0,,A,,BAO_0000218,8050,,,1,CHEMBL627888,,,Mus musculus,N,1,1088.0,
13905,urine levels excreted after administration of cysteamine (175 mg/kg) to mice measured at 0-6 hr,Intermediate,10090.0,,A,,BAO_0000218,8050,,,1,CHEMBL628057,,,Mus musculus,N,1,1088.0,
13906,urine levels excreted after administration of cysteamine (175 mg/kg) to mice measured at 24-30 hr,Intermediate,10090.0,,A,,BAO_0000218,8050,,,1,CHEMBL627405,,,Mus musculus,N,1,1088.0,
13907,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 11.9 uM/Kg of drug,Intermediate,9615.0,,A,,BAO_0000218,12582,,,1,CHEMBL627406,,,Canis lupus familiaris,N,1,1088.0,
13908,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 2.49 uM/Kg of drug,Intermediate,9615.0,,A,,BAO_0000218,12582,,,1,CHEMBL627407,,,Canis lupus familiaris,N,1,1088.0,
13909,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 26.2 uM/Kg of drug,Intermediate,9615.0,,A,,BAO_0000218,12582,,,1,CHEMBL627408,,,Canis lupus familiaris,N,1,1088.0,
13910,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 3.03 uM/Kg of drug,Intermediate,9615.0,,A,,BAO_0000218,12582,,,1,CHEMBL627409,,,Canis lupus familiaris,N,1,1088.0,
13911,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 30.3 uM/Kg of drug,Intermediate,9615.0,,A,,BAO_0000218,12582,,,1,CHEMBL875486,,,Canis lupus familiaris,N,1,1088.0,
13912,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 34.1 uM/Kg of drug,Intermediate,9615.0,,A,,BAO_0000218,12582,,,1,CHEMBL627410,,,Canis lupus familiaris,N,1,1088.0,
13913,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 52.4 uM/Kg of drug,Intermediate,9615.0,,A,,BAO_0000218,12582,,,1,CHEMBL627411,,,Canis lupus familiaris,N,1,1088.0,
13914,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 7.85 uM/Kg of drug,Intermediate,9615.0,,A,,BAO_0000218,12582,,,1,CHEMBL627412,,,Canis lupus familiaris,N,1,1088.0,
13915,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 8.47 uM/Kg of drug,Intermediate,9615.0,,A,,BAO_0000218,12582,,,1,CHEMBL627413,,,Canis lupus familiaris,N,1,1088.0,
13916,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 9.09 uM/Kg of drug,Intermediate,9615.0,,A,,BAO_0000218,12582,,,1,CHEMBL627414,,,Canis lupus familiaris,N,1,1088.0,
13917,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 10.1 uM/Kg of drug,Intermediate,9615.0,,A,,BAO_0000218,12582,,,1,CHEMBL627415,,,Canis lupus familiaris,N,1,1088.0,
13918,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 102 uM/Kg of drug,Intermediate,9615.0,,A,,BAO_0000218,12582,,,1,CHEMBL627416,,,Canis lupus familiaris,N,1,1088.0,
13919,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 3.40 uM/Kg of drug,Intermediate,9615.0,,A,,BAO_0000218,12582,,,1,CHEMBL627417,,,Canis lupus familiaris,N,1,1088.0,
13920,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 3.76 uM/Kg of drug,Intermediate,9615.0,,A,,BAO_0000218,12582,,,1,CHEMBL627418,,,Canis lupus familiaris,N,1,1088.0,
13921,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 34.1 uM/Kg of drug,Intermediate,9615.0,,A,,BAO_0000218,12582,,,1,CHEMBL627419,,,Canis lupus familiaris,N,1,1088.0,
13922,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 50.8 uM/Kg of drug,Intermediate,9615.0,,A,,BAO_0000218,12582,,,1,CHEMBL627320,,,Canis lupus familiaris,N,1,1088.0,
13923,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 68.1 uM/Kg of drug,Intermediate,9615.0,,A,,BAO_0000218,12582,,,1,CHEMBL627321,,,Canis lupus familiaris,N,1,1088.0,
13924,Biodistribution in kidney of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,10116.0,,A,,BAO_0000218,12017,,,1,CHEMBL627322,,,Rattus norvegicus,N,1,2113.0,
13925,Biodistribution in kidney of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,10116.0,,A,,BAO_0000218,12017,,,1,CHEMBL627323,,,Rattus norvegicus,N,1,2113.0,
13926,Biodistribution in kidney of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),Intermediate,10116.0,,A,,BAO_0000218,12017,,,1,CHEMBL627491,,,Rattus norvegicus,N,1,2113.0,
13927,Biodistribution in kidney of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,10116.0,,A,,BAO_0000218,12017,,,1,CHEMBL627492,,,Rattus norvegicus,N,1,2113.0,
13928,Biodistribution in kidney of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,10116.0,,A,,BAO_0000218,12017,,,1,CHEMBL627493,,,Rattus norvegicus,N,1,2113.0,
13929,Biodistribution in liver of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,10116.0,,A,,BAO_0000218,12017,,,1,CHEMBL627494,,,Rattus norvegicus,N,1,2107.0,
13930,Biodistribution in liver of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,10116.0,,A,,BAO_0000218,12017,,,1,CHEMBL627495,,,Rattus norvegicus,N,1,2107.0,
13931,Biodistribution in liver of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),Intermediate,10116.0,,A,,BAO_0000218,12017,,,1,CHEMBL627496,,,Rattus norvegicus,N,1,2107.0,
13932,Biodistribution in liver of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,10116.0,,A,,BAO_0000218,12017,,,1,CHEMBL627497,,,Rattus norvegicus,N,1,2107.0,
13933,Biodistribution in liver of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,10116.0,,A,,BAO_0000218,12017,,,1,CHEMBL627498,,,Rattus norvegicus,N,1,2107.0,
13934,Biodistribution in lungs of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,10116.0,,A,,BAO_0000218,12017,,,1,CHEMBL627499,,,Rattus norvegicus,N,1,2048.0,
13935,Biodistribution in lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,10116.0,,A,,BAO_0000218,12017,,,1,CHEMBL627500,,,Rattus norvegicus,N,1,2048.0,
13936,Biodistribution in lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),Intermediate,10116.0,,A,,BAO_0000218,12017,,,1,CHEMBL627501,,,Rattus norvegicus,N,1,2048.0,
13937,Biodistribution in lungs of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,10116.0,,A,,BAO_0000218,12017,,,1,CHEMBL625616,,,Rattus norvegicus,N,1,2048.0,
13938,Biodistribution in lungs of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,10116.0,,A,,BAO_0000218,12017,,,1,CHEMBL625617,,,Rattus norvegicus,N,1,2048.0,
13939,Biodistribution in muscle of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,10116.0,,A,,BAO_0000218,12017,,,1,CHEMBL625618,,,Rattus norvegicus,N,1,2385.0,
13940,Biodistribution in muscle of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,10116.0,,A,,BAO_0000218,12017,,,1,CHEMBL625619,,,Rattus norvegicus,N,1,2385.0,
13941,Biodistribution in muscle of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),Intermediate,10116.0,,A,,BAO_0000218,12017,,,1,CHEMBL625620,,,Rattus norvegicus,N,1,2385.0,
13942,Biodistribution in muscle of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,10116.0,,A,,BAO_0000218,12017,,,1,CHEMBL625621,,,Rattus norvegicus,N,1,2385.0,
13943,Biodistribution in muscle of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,10116.0,,A,,BAO_0000218,12017,,,1,CHEMBL625622,,,Rattus norvegicus,N,1,2385.0,
13944,Biodistribution in spleen of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,10116.0,,A,,BAO_0000218,12017,,,1,CHEMBL625788,,,Rattus norvegicus,N,1,2106.0,
13945,Biodistribution in spleen of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,10116.0,,A,,BAO_0000218,12017,,,1,CHEMBL625789,,,Rattus norvegicus,N,1,2106.0,
13946,Biodistribution in spleen of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),Intermediate,10116.0,,A,,BAO_0000218,12017,,,1,CHEMBL625790,,,Rattus norvegicus,N,1,2106.0,
13947,Biodistribution in spleen of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,10116.0,,A,,BAO_0000218,12017,,,1,CHEMBL625791,,,Rattus norvegicus,N,1,2106.0,
13948,Biodistribution in spleen of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,10116.0,,A,,BAO_0000218,12017,,,1,CHEMBL622334,,,Rattus norvegicus,N,1,2106.0,
13949,Biodistribution in thyroid of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,10116.0,,A,,BAO_0000218,12017,,,1,CHEMBL622335,,,Rattus norvegicus,N,1,2046.0,
13950,Biodistribution in thyroid of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,10116.0,,A,,BAO_0000218,12017,,,1,CHEMBL622336,,,Rattus norvegicus,N,1,2046.0,
13951,Biodistribution in thyroid of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),Intermediate,10116.0,,A,,BAO_0000218,12017,,,1,CHEMBL622337,,,Rattus norvegicus,N,1,2046.0,
13952,Biodistribution in thyroid of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,10116.0,,A,,BAO_0000218,12017,,,1,CHEMBL622338,,,Rattus norvegicus,N,1,2046.0,
13953,Biodistribution in thyroid of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,10116.0,,A,,BAO_0000218,12017,,,1,CHEMBL622339,,,Rattus norvegicus,N,1,2046.0,
13954,Biodistribution in uterus / blood of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,10116.0,,A,,BAO_0000218,12017,,,1,CHEMBL624153,,,Rattus norvegicus,N,1,,
13955,Biodistribution in uterus / blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,10116.0,,A,,BAO_0000218,12017,,,1,CHEMBL628430,,,Rattus norvegicus,N,1,,
13956,Biodistribution in uterus / blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),Intermediate,10116.0,,A,,BAO_0000218,12017,,,1,CHEMBL628431,,,Rattus norvegicus,N,1,,
13957,Biodistribution in uterus / blood of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,10116.0,,A,,BAO_0000218,12017,,,1,CHEMBL628432,,,Rattus norvegicus,N,1,,
13958,Biodistribution in uterus / blood of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,10116.0,,A,,BAO_0000218,12017,,,1,CHEMBL628433,,,Rattus norvegicus,N,1,,
13959,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",Intermediate,10116.0,,A,,BAO_0000218,12017,,,1,CHEMBL628434,,,Rattus norvegicus,N,1,2106.0,
13960,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",Intermediate,10116.0,,A,,BAO_0000218,12017,,,1,CHEMBL626789,,,Rattus norvegicus,N,1,2106.0,
13961,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2)",Intermediate,10116.0,,A,,BAO_0000218,12017,,,1,CHEMBL626790,,,Rattus norvegicus,N,1,2106.0,
13962,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",Intermediate,10116.0,,A,,BAO_0000218,12017,,,1,CHEMBL626791,,,Rattus norvegicus,N,1,2106.0,
13963,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",Intermediate,10116.0,,A,,BAO_0000218,12017,,,1,CHEMBL626792,,,Rattus norvegicus,N,1,2106.0,
13964,"Biodistribution in uterus / spleen, muscle, lungs of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",Intermediate,10116.0,,A,,BAO_0000218,12017,,,1,CHEMBL626793,,,Rattus norvegicus,N,1,2106.0,
13965,Mean potassium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 60.46 umol/kg,Intermediate,10116.0,,A,,BAO_0000218,11510,,,1,CHEMBL627436,,,Rattus norvegicus,N,1,,
13966,Mean potassium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 67.18 umol/kg,Intermediate,10116.0,,A,,BAO_0000218,11510,,,1,CHEMBL627437,,,Rattus norvegicus,N,1,,
13967,Mean potassium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 74.26 umol/kg,Intermediate,10116.0,,A,,BAO_0000218,11510,,,1,CHEMBL627438,,,Rattus norvegicus,N,1,,
13968,Mean potassium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 78.97 umol/kg,Intermediate,10116.0,,A,,BAO_0000218,11510,,,1,CHEMBL627439,,,Rattus norvegicus,N,1,,
13969,Mean potassium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 120.93 umol/kg,Intermediate,10116.0,,A,,BAO_0000218,11510,,,1,CHEMBL627440,,,Rattus norvegicus,N,1,,
13970,Mean potassium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 134.35 umol/kg,Intermediate,10116.0,,A,,BAO_0000218,11510,,,1,CHEMBL627602,,,Rattus norvegicus,N,1,,
13971,Mean potassium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 148.52 umol/kg,Intermediate,10116.0,,A,,BAO_0000218,11510,,,1,CHEMBL627603,,,Rattus norvegicus,N,1,,
13972,Mean potassium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 157.94 umol/kg,Intermediate,10116.0,,A,,BAO_0000218,11510,,,1,CHEMBL627604,,,Rattus norvegicus,N,1,,
13973,Mean potassium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 15.12 umol/kg,Intermediate,10116.0,,A,,BAO_0000218,11510,,,1,CHEMBL627605,,,Rattus norvegicus,N,1,,
13974,Mean potassium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 16.79 umol/kg,Intermediate,10116.0,,A,,BAO_0000218,11510,,,1,CHEMBL627606,,,Rattus norvegicus,N,1,,
13975,Mean potassium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 18.56 umol/kg,Intermediate,10116.0,,A,,BAO_0000218,11510,,,1,CHEMBL627607,,,Rattus norvegicus,N,1,,
13976,Mean potassium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 19.74 umol/kg,Intermediate,10116.0,,A,,BAO_0000218,11510,,,1,CHEMBL627608,,,Rattus norvegicus,N,1,,
13977,Mean potassium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 241.86 umol/kg,Intermediate,10116.0,,A,,BAO_0000218,11510,,,1,CHEMBL627609,,,Rattus norvegicus,N,1,,
13978,Mean potassium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 268.71 umol/kg,Intermediate,10116.0,,A,,BAO_0000218,11510,,,1,CHEMBL627610,,,Rattus norvegicus,N,1,,
13979,Mean potassium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 297.03 umol/kg,Intermediate,10116.0,,A,,BAO_0000218,11510,,,1,CHEMBL627611,,,Rattus norvegicus,N,1,,
13980,Mean potassium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 315.88 umol/kg,Intermediate,10116.0,,A,,BAO_0000218,11510,,,1,CHEMBL627612,,,Rattus norvegicus,N,1,,
13981,Octanol:water partition coefficient is evaluated,Autocuration,,,P,,BAO_0000100,8362,,,1,CHEMBL627613,,,,U,0,,
13982,Partition coefficient in 1-octanol/water system,Autocuration,,,P,,BAO_0000100,8257,,,1,CHEMBL627614,,,,U,0,,
13983,Partition coefficient in 1-octanol/water system measured using radio active compounds,Autocuration,,,P,,BAO_0000100,8257,,,1,CHEMBL627615,,,,U,0,,
13984,Partition coefficient in octanol/water system was determined,Autocuration,,,P,,BAO_0000100,9468,,,1,CHEMBL627616,,,,U,0,,
13985,Partition coefficient in octanol/water system was determined using [14C]-labeled compounds.,Autocuration,,,P,,BAO_0000100,9468,,,1,CHEMBL627617,,,,U,0,,
13986,Pseudo-first-order rate constant at pH 10 and 35 degrees Centigrade,Autocuration,,,A,,BAO_0000019,10568,,,1,CHEMBL627618,,,,U,0,,
13987,"Pseudo-first-order rate constant at pH 10, micro=0.5, 35 degrees Centigrade",Autocuration,,,A,,BAO_0000019,10568,,,1,CHEMBL627619,,,,U,0,,
13988,Pseudo-first-order rate constant of the compound,Autocuration,,,A,,BAO_0000019,15359,,,1,CHEMBL627620,,,,U,0,,
13989,Pseudo-first-order rate constant with 1-min time point,Autocuration,,,A,,BAO_0000019,15359,,,1,CHEMBL627621,,,,U,0,,
13990,Pseudo-first-order rate constant without 1-min time point,Autocuration,,,A,,BAO_0000019,15359,,,1,CHEMBL627622,,,,U,0,,
13991,Pseudo-first-order rate constant was determined in pH 7.4 phosphate buffer in presence 0.5 mM EDTA,Autocuration,,,A,,BAO_0000019,10431,,,1,CHEMBL627623,,,,U,0,,
13992,Pseudo-first-order rate constant was determined in pH 7.4 phosphate buffer in presence 50 mM EDTA,Autocuration,,,A,,BAO_0000019,10431,,,1,CHEMBL627624,,,,U,0,,
13993,Pseudo-first-order rate constant was determined in pH 7.4 phosphate buffer in presence 70 mM EDTA,Autocuration,,,A,,BAO_0000019,10431,,,1,CHEMBL627625,,,,U,0,,
13994,Rate constants determined using 31P NMR Kinetics experiments at 37 degrees Centigrade,Autocuration,,,A,,BAO_0000019,15704,,,1,CHEMBL628523,,,,U,0,,
13995,The alkaline hydrolysis second order rate constant(K OH) of the compound,Autocuration,,,A,,BAO_0000019,15287,,,1,CHEMBL628524,,,,U,0,,
13996,The efflux rate constant of the compound,Autocuration,,,A,,BAO_0000019,7516,,,1,CHEMBL628525,,,,U,0,,
13997,The reaction rate constant (K) by measuring competition with nitroblue tetrazolium of the superoxide radicals formed by xanthine oxidase/xanthine,Autocuration,,,A,,BAO_0000019,12973,,,1,CHEMBL625732,,,,U,0,,
13998,The reaction rate constant(K) by measuring competition with nitroblue tetrazolium of the superoxide radicals formed by xanthine oxidase/xanthine,Autocuration,,,A,,BAO_0000019,12973,,,1,CHEMBL625733,,,,U,0,,
13999,The reaction rate constant(K) by measuring competition with nitroblue tetrazolium of the superoxide radicals formed by xanthine oxidase/xanthine,Autocuration,,,F,,BAO_0000019,12973,,,1,CHEMBL625734,,,,U,0,,
14000,The reaction rate constant(K) by measuring competition with nitroblue tetrazolium of the superoxide radicals formed by xanthine oxidase/xanthine; ND= not determined,Autocuration,,,A,,BAO_0000019,12973,,,1,CHEMBL625913,,,,U,0,,
14001,Association constant was evaluated towards synthetic peptidoglycan analogue Ac2-Lys-D-Ala-D-Ala,Autocuration,,,A,,BAO_0000019,8696,,,1,CHEMBL625914,,,,U,0,,
14002,Equilibrium association (binding) constant interacting with Unilamellar Vesicles of electroneutral DMPC in PBSbuffer at pH 7.4 and 37 C,Autocuration,,,A,,BAO_0000019,15052,,,1,CHEMBL625915,,,,U,0,,
14003,Equilibrium association (binding) constant interacting with Unilamellar Vesicles of negatively charged DMPG in PBS buffer at pH 7.4 and 37 C,Autocuration,,,A,,BAO_0000019,15052,,,1,CHEMBL625916,,,,U,0,,
14004,Evaluated for the mustard reactivity by determining rate constant for hydrolysis of mustard in aqueous acetone (K H),Autocuration,,,A,,BAO_0000019,10503,,,1,CHEMBL625917,,,,U,0,,
14005,"Effective biomolecular rate constant at the concentration 0.500 mM [HOX] in the conditions of 25degreeC,pH 7.6",Autocuration,,,A,,BAO_0000019,8354,,,1,CHEMBL625918,,,,U,0,,
14006,"Effective biomolecular rate constant at the concentration 0.767 mM [HOX] in the conditions of 25degreeC,pH 7.6",Autocuration,,,A,,BAO_0000019,8354,,,1,CHEMBL625919,,,,U,0,,
14007,"Effective biomolecular rate constant at the concentration 0.790 mM [HOX] in the conditions of 25degreeC,pH 7.6",Autocuration,,,A,,BAO_0000019,8354,,,1,CHEMBL625920,,,,U,0,,
14008,"Effective biomolecular rate constant at the concentration 1.00 mM [HOX] in the conditions of 25degreeC,pH 7.6",Autocuration,,,A,,BAO_0000019,8354,,,1,CHEMBL874453,,,,U,0,,
14009,"Effective biomolecular rate constant in the conditions of 25degreeC,pH 7.6",Autocuration,,,A,,BAO_0000019,8354,,,1,CHEMBL625921,,,,U,0,,
14010,Evaluated for the mustard reactivity by determining rate constant for alkylation of 4-(4-nitrobenzyl)pyridine using NBP alkylation assay,Autocuration,,,A,,BAO_0000019,10503,,,1,CHEMBL625922,,,,U,0,,
14011,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator at the concentration 0.500 mM [HOX] in the conditions of 25degreeC,pH 7.6",Autocuration,,,A,,BAO_0000019,8354,,,1,CHEMBL625923,,,,U,0,,
14012,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator at the concentration 0.767 mM [HOX] in the conditions of 25degreeC,pH 7.6",Autocuration,,,A,,BAO_0000019,8354,,,1,CHEMBL625924,,,,U,0,,
14013,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator at the concentration 0.790 mM [HOX] in the conditions of 25degreeC,pH 7.6",Autocuration,,,A,,BAO_0000019,8354,,,1,CHEMBL625925,,,,U,0,,
14014,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator at the concentration 1.00 mM [HOX] in the conditions of 25degreeC,pH 7.6",Autocuration,,,A,,BAO_0000019,8354,,,1,CHEMBL625926,,,,U,0,,
14015,Biodistribution in rat lung at 60 minutes after dose administration.,Intermediate,10116.0,,A,,BAO_0000218,13100,,,1,CHEMBL627704,,,Rattus norvegicus,N,1,2048.0,
14016,Biodistribution in rat pons/medulla at 120 minutes after dose administration.,Intermediate,10116.0,,A,,BAO_0000218,13100,,,1,CHEMBL627705,,,Rattus norvegicus,N,1,,
14017,Biodistribution in rat pons/medulla at 15 minutes after dose administration.,Intermediate,10116.0,,A,,BAO_0000218,13100,,,1,CHEMBL627706,,,Rattus norvegicus,N,1,,
14018,Biodistribution in rat pons/medulla at 240 minutes after dose administration.,Intermediate,10116.0,,A,,BAO_0000218,13100,,,1,CHEMBL627707,,,Rattus norvegicus,N,1,,
14019,Biodistribution in rat pons/medulla at 30 minutes after dose administration.,Intermediate,10116.0,,A,,BAO_0000218,13100,,,1,CHEMBL627708,,,Rattus norvegicus,N,1,,
14020,Biodistribution in rat pons/medulla at 360 minutes after dose administration.,Intermediate,10116.0,,A,,BAO_0000218,13100,,,1,CHEMBL628361,,,Rattus norvegicus,N,1,,
14021,Biodistribution in rat pons/medulla at 60 minutes after dose administration.,Intermediate,10116.0,,A,,BAO_0000218,13100,,,1,CHEMBL628362,,,Rattus norvegicus,N,1,,
14022,Biodistribution in rat striatum at 120 minutes after dose administration.,Intermediate,10116.0,,A,,BAO_0000218,13100,,,1,CHEMBL628363,,,Rattus norvegicus,N,1,2435.0,
14023,Biodistribution in rat striatum at 1440 minutes after dose administration.,Intermediate,10116.0,,A,,BAO_0000218,13100,,,1,CHEMBL628364,,,Rattus norvegicus,N,1,2435.0,
14024,Biodistribution in rat striatum at 15 minutes after dose administration.,Intermediate,10116.0,,A,,BAO_0000218,13100,,,1,CHEMBL628365,,,Rattus norvegicus,N,1,2435.0,
14025,Biodistribution in rat striatum at 240 minutes after dose administration.,Intermediate,10116.0,,A,,BAO_0000218,13100,,,1,CHEMBL874454,,,Rattus norvegicus,N,1,2435.0,
14026,Biodistribution in rat striatum at 30 minutes after dose administration.,Intermediate,10116.0,,A,,BAO_0000218,13100,,,1,CHEMBL628531,,,Rattus norvegicus,N,1,2435.0,
14027,Biodistribution in rat striatum at 360 minutes after dose administration.,Intermediate,10116.0,,A,,BAO_0000218,13100,,,1,CHEMBL628532,,,Rattus norvegicus,N,1,2435.0,
14028,Biodistribution in rat striatum at 3 hr after dose administration.,Intermediate,10116.0,,A,,BAO_0000218,13100,,,1,CHEMBL628533,,,Rattus norvegicus,N,1,2435.0,
14029,Biodistribution in rat striatum at 60 minutes after dose administration.,Intermediate,10116.0,,A,,BAO_0000218,13100,,,1,CHEMBL628534,,,Rattus norvegicus,N,1,2435.0,
14030,Biodistribution in rat thyroid at 120 minutes after dose administration.,Intermediate,10116.0,,A,,BAO_0000218,13100,,,1,CHEMBL628535,,,Rattus norvegicus,N,1,2046.0,
14031,Biodistribution in rat thyroid at 1440 minutes after dose administration.,Intermediate,10116.0,,A,,BAO_0000218,13100,,,1,CHEMBL628536,,,Rattus norvegicus,N,1,2046.0,
14032,Biodistribution in rat thyroid at 15 minutes after dose administration.,Intermediate,10116.0,,A,,BAO_0000218,13100,,,1,CHEMBL628537,,,Rattus norvegicus,N,1,2046.0,
14033,Biodistribution in rat thyroid at 240 minutes after dose administration.,Intermediate,10116.0,,A,,BAO_0000218,13100,,,1,CHEMBL628538,,,Rattus norvegicus,N,1,2046.0,
14034,Biodistribution in rat thyroid at 30 minutes after dose administration.,Intermediate,10116.0,,A,,BAO_0000218,13100,,,1,CHEMBL628539,,,Rattus norvegicus,N,1,2046.0,
14035,Biodistribution in rat thyroid at 360 minutes after dose administration.,Intermediate,10116.0,,A,,BAO_0000218,13100,,,1,CHEMBL630297,,,Rattus norvegicus,N,1,2046.0,
14036,Biodistribution in rat thyroid at 60 minutes after dose administration.,Intermediate,10116.0,,A,,BAO_0000218,13100,,,1,CHEMBL630298,,,Rattus norvegicus,N,1,2046.0,
14037,Biodistribution in rest of brain of rat 120 minutes after dose administration.,Intermediate,10116.0,,A,,BAO_0000218,13100,,,1,CHEMBL630299,,,Rattus norvegicus,N,1,955.0,
14038,Biodistribution in rest of brain of rat at 1440 minutes after dose administration.,Intermediate,10116.0,,A,,BAO_0000218,13100,,,1,CHEMBL628094,,,Rattus norvegicus,N,1,955.0,
14039,Biodistribution in rest of brain of rat at 15 minutes after dose administration.,Intermediate,10116.0,,A,,BAO_0000218,13100,,,1,CHEMBL628095,,,Rattus norvegicus,N,1,955.0,
14040,Biodistribution in rest of brain of rat at 240 minutes after dose administration.,Intermediate,10116.0,,A,,BAO_0000218,13100,,,1,CHEMBL874648,,,Rattus norvegicus,N,1,955.0,
14041,Biodistribution in rest of brain of rat at 30 minutes after dose administration.,Intermediate,10116.0,,A,,BAO_0000218,13100,,,1,CHEMBL628096,,,Rattus norvegicus,N,1,955.0,
14042,Biodistribution in rest of brain of rat at 360 minutes after dose administration.,Intermediate,10116.0,,A,,BAO_0000218,13100,,,1,CHEMBL628097,,,Rattus norvegicus,N,1,955.0,
14043,Biodistribution in rest of brain of rat at 60 minutes after dose administration.,Intermediate,10116.0,,A,,BAO_0000218,13100,,,1,CHEMBL628098,,,Rattus norvegicus,N,1,955.0,
14044,"Mean rate constant for the hydrolysis of compound in buffers at pH 6.5, at 37 degrees Celsius in incubation mixture - d(A)-d(T) (10:1)",Autocuration,,,A,,BAO_0000019,13331,,,1,CHEMBL628099,,,,U,0,,
14045,"Mean rate constant for the hydrolysis of compound in buffers at pH 6.5, at 37 degrees Celsius in incubation mixture - d(G)-d(C) (10:1)",Autocuration,,,A,,BAO_0000019,13331,,,1,CHEMBL628100,,,,U,0,,
14046,Mean rate constant for the hydrolysis of compound in buffers at pH 7.4 at 37 degrees Centigrade in incubation mixture - d(A)-d(T) (10:!),Autocuration,,,A,,BAO_0000019,13331,,,1,CHEMBL628101,,,,U,0,,
14047,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - 5'-GMP/5'-CMP (1:1)",Autocuration,,,A,,BAO_0000019,13331,,,1,CHEMBL628102,,,,U,0,,
14048,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - d(A)-d(T) (1:1)",Autocuration,,,A,,BAO_0000019,13331,,,1,CHEMBL628103,,,,U,0,,
14049,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - d(G)-d(C) (10:1)",Autocuration,,,A,,BAO_0000019,13331,,,1,CHEMBL628104,,,,U,0,,
14050,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - d(G)-d(C) (1:1)",Autocuration,,,A,,BAO_0000019,13331,,,1,CHEMBL628105,,,,U,0,,
14051,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - d(G)-d(T) (10:1)",Autocuration,,,A,,BAO_0000019,13331,,,1,CHEMBL628106,,,,U,0,,
14052,Mean urine volume excretion in conscious rats at a dose of 0.3 mg/kg given orally,Intermediate,10116.0,,A,,BAO_0000218,10086,,,1,CHEMBL628107,,,Rattus norvegicus,N,1,1088.0,
14053,Mean urine volume excretion in conscious rats at a dose of 0.3 mg/kg given orally,Autocuration,,,F,,BAO_0000218,10086,,,1,CHEMBL628108,,,,U,0,1088.0,
14054,Mean urine volume excretion in conscious rats at a dose of 1.0 mg/kg given orally,Intermediate,10116.0,,A,,BAO_0000218,10086,,,1,CHEMBL628109,,,Rattus norvegicus,N,1,1088.0,
14055,Mean urine volume excretion in conscious rats at a dose of 1.0 mg/kg given orally,Autocuration,,,F,,BAO_0000218,10086,,,1,CHEMBL625299,,,,U,0,1088.0,
14056,Mean urine volume excretion in conscious rats at a dose of 10 mg/kg given orally,Intermediate,10116.0,,A,,BAO_0000218,10086,,,1,CHEMBL625300,,,Rattus norvegicus,N,1,1088.0,
14057,Mean urine volume excretion in conscious rats at a dose of 100 mg/kg given orally,Intermediate,10116.0,,A,,BAO_0000218,10086,,,1,CHEMBL625301,,,Rattus norvegicus,N,1,1088.0,
14058,Mean urine volume excretion in conscious rats at a dose of 3.0 mg/kg given orally,Intermediate,10116.0,,A,,BAO_0000218,10086,,,1,CHEMBL625302,,,Rattus norvegicus,N,1,1088.0,
14059,Mean urine volume excretion in conscious rats at a dose of 30 mg/kg given orally,Intermediate,10116.0,,A,,BAO_0000218,10086,,,1,CHEMBL874649,,,Rattus norvegicus,N,1,1088.0,
14060,In vitro metabolic stability of the test compound was evaluated after incubation in the presence of freshly isolated rat hepatocytes,Intermediate,10116.0,,A,,BAO_0000218,13248,,,1,CHEMBL625303,,,Rattus norvegicus,N,1,,
14061,In vitro metabolic stability of the test compound was evaluated after incubation in the presence of freshly isolated rat hepatocytes; NA= Not tested,Intermediate,10116.0,,A,,BAO_0000218,13248,,,1,CHEMBL625463,,,Rattus norvegicus,N,1,,
14062,In vitro metabolism in human liver microsomes,Intermediate,9606.0,,A,,BAO_0000218,14527,,,1,CHEMBL625464,,,Homo sapiens,N,1,2107.0,
14063,Metabolism (NADH oxidation) by recombinant human NAD(P)H: quinone oxidoreductase (NQO1) is evaluated.,Intermediate,9606.0,,A,,BAO_0000218,3008,,,1,CHEMBL625465,,,Homo sapiens,N,1,,
14064,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 9.06 uM/Kg of drug,Intermediate,9615.0,,A,,BAO_0000218,12582,,,1,CHEMBL625466,,,Canis lupus familiaris,N,1,1088.0,
14065,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 9.6 uM/Kg of drug,Intermediate,9615.0,,A,,BAO_0000218,12582,,,1,CHEMBL625467,,,Canis lupus familiaris,N,1,1088.0,
14066,Total electrolytic excretion of chlorine in urine of rats after intravenous administration of 7.94 uM/Kg of drug,Intermediate,10116.0,,A,,BAO_0000218,12582,,,1,CHEMBL625468,,,Rattus norvegicus,N,1,1088.0,
14067,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 0 uM/Kg of drug,Intermediate,10116.0,,A,,BAO_0000218,12582,,,1,CHEMBL625469,,,Rattus norvegicus,N,1,1088.0,
14068,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 1.01 uM/Kg of drug,Intermediate,10116.0,,A,,BAO_0000218,12582,,,1,CHEMBL625470,,,Rattus norvegicus,N,1,1088.0,
14069,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 1.13 uM/Kg of drug,Intermediate,10116.0,,A,,BAO_0000218,12582,,,1,CHEMBL632418,,,Rattus norvegicus,N,1,1088.0,
14070,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 10.1 uM/Kg of drug,Intermediate,10116.0,,A,,BAO_0000218,12582,,,1,CHEMBL627250,,,Rattus norvegicus,N,1,1088.0,
14071,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 102 uM/Kg of drug,Intermediate,10116.0,,A,,BAO_0000218,12582,,,1,CHEMBL627251,,,Rattus norvegicus,N,1,1088.0,
14072,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 105 uM/Kg of drug,Intermediate,10116.0,,A,,BAO_0000218,12582,,,1,CHEMBL627252,,,Rattus norvegicus,N,1,1088.0,
14073,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 11.3 uM/Kg of drug,Intermediate,10116.0,,A,,BAO_0000218,12582,,,1,CHEMBL627253,,,Rattus norvegicus,N,1,1088.0,
14074,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 113 uM/Kg of drug,Intermediate,10116.0,,A,,BAO_0000218,12582,,,1,CHEMBL627254,,,Rattus norvegicus,N,1,1088.0,
14075,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 19.5 uM/Kg of drug,Intermediate,10116.0,,A,,BAO_0000218,12582,,,1,CHEMBL875471,,,Rattus norvegicus,N,1,1088.0,
14076,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 195 uM/Kg of drug,Intermediate,10116.0,,A,,BAO_0000218,12582,,,1,CHEMBL627255,,,Rattus norvegicus,N,1,1088.0,
14077,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 21.7 uM/Kg of drug,Intermediate,10116.0,,A,,BAO_0000218,12582,,,1,CHEMBL627256,,,Rattus norvegicus,N,1,1088.0,
14078,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 217 uM/Kg of drug,Intermediate,10116.0,,A,,BAO_0000218,12582,,,1,CHEMBL627257,,,Rattus norvegicus,N,1,1088.0,
14079,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 23.9 uM/Kg of drug,Intermediate,10116.0,,A,,BAO_0000218,12582,,,1,CHEMBL627258,,,Rattus norvegicus,N,1,1088.0,
14080,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 239 uM/Kg of drug,Intermediate,10116.0,,A,,BAO_0000218,12582,,,1,CHEMBL627259,,,Rattus norvegicus,N,1,1088.0,
14081,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 24.9 uM/Kg of drug,Intermediate,10116.0,,A,,BAO_0000218,12582,,,1,CHEMBL627260,,,Rattus norvegicus,N,1,1088.0,
14082,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 249 uM/Kg of drug,Intermediate,10116.0,,A,,BAO_0000218,12582,,,1,CHEMBL623256,,,Rattus norvegicus,N,1,1088.0,
14083,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 25.9 uM/Kg of drug,Intermediate,10116.0,,A,,BAO_0000218,12582,,,1,CHEMBL874413,,,Rattus norvegicus,N,1,1088.0,
14084,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 259 uM/Kg of drug,Intermediate,10116.0,,A,,BAO_0000218,12582,,,1,CHEMBL623257,,,Rattus norvegicus,N,1,1088.0,
14085,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 26.5 uM/Kg of drug,Intermediate,10116.0,,A,,BAO_0000218,12582,,,1,CHEMBL623258,,,Rattus norvegicus,N,1,1088.0,
14086,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 265 uM/Kg of drug,Intermediate,10116.0,,A,,BAO_0000218,12582,,,1,CHEMBL623259,,,Rattus norvegicus,N,1,1088.0,
14087,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 27 uM/Kg of drug,Intermediate,10116.0,,A,,BAO_0000218,12582,,,1,CHEMBL623260,,,Rattus norvegicus,N,1,1088.0,
14088,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 27.9 uM/Kg of drug,Intermediate,10116.0,,A,,BAO_0000218,12582,,,1,CHEMBL623261,,,Rattus norvegicus,N,1,1088.0,
14089,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 270 uM/Kg of drug,Intermediate,10116.0,,A,,BAO_0000218,12582,,,1,CHEMBL623262,,,Rattus norvegicus,N,1,1088.0,
14090,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 279 uM/Kg of drug,Intermediate,10116.0,,A,,BAO_0000218,12582,,,1,CHEMBL623263,,,Rattus norvegicus,N,1,1088.0,
14091,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 28.2 uM/Kg of drug,Intermediate,10116.0,,A,,BAO_0000218,12582,,,1,CHEMBL623264,,,Rattus norvegicus,N,1,1088.0,
14092,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 28.22 uM/Kg of drug,Intermediate,10116.0,,A,,BAO_0000218,12582,,,1,CHEMBL623265,,,Rattus norvegicus,N,1,1088.0,
14093,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 28.9 uM/Kg of drug,Intermediate,10116.0,,A,,BAO_0000218,12582,,,1,CHEMBL623266,,,Rattus norvegicus,N,1,1088.0,
14094,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 282 uM/Kg of drug,Intermediate,10116.0,,A,,BAO_0000218,12582,,,1,CHEMBL623267,,,Rattus norvegicus,N,1,1088.0,
14095,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 289 uM/Kg of drug,Intermediate,10116.0,,A,,BAO_0000218,12582,,,1,CHEMBL623268,,,Rattus norvegicus,N,1,1088.0,
14096,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 3.40 uM/Kg of drug,Intermediate,10116.0,,A,,BAO_0000218,12582,,,1,CHEMBL623269,,,Rattus norvegicus,N,1,1088.0,
14097,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 3.76 uM/Kg of drug,Intermediate,10116.0,,A,,BAO_0000218,12582,,,1,CHEMBL623270,,,Rattus norvegicus,N,1,1088.0,
14098,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 30.2 uM/Kg of drug,Intermediate,10116.0,,A,,BAO_0000218,12582,,,1,CHEMBL623271,,,Rattus norvegicus,N,1,1088.0,
14099,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 302 uM/Kg of drug,Intermediate,10116.0,,A,,BAO_0000218,12582,,,1,CHEMBL623272,,,Rattus norvegicus,N,1,1088.0,
14100,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 31.6 uM/Kg of drug,Intermediate,10116.0,,A,,BAO_0000218,12582,,,1,CHEMBL623273,,,Rattus norvegicus,N,1,1088.0,
14101,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 316 uM/Kg of drug,Intermediate,10116.0,,A,,BAO_0000218,12582,,,1,CHEMBL623274,,,Rattus norvegicus,N,1,1088.0,
14102,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 32.4 uM/Kg of drug,Intermediate,10116.0,,A,,BAO_0000218,12582,,,1,CHEMBL874414,,,Rattus norvegicus,N,1,1088.0,
14103,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 324 uM/Kg of drug,Intermediate,10116.0,,A,,BAO_0000218,12582,,,1,CHEMBL623275,,,Rattus norvegicus,N,1,1088.0,
14104,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 34.0 uM/Kg of drug,Intermediate,10116.0,,A,,BAO_0000218,12582,,,1,CHEMBL629150,,,Rattus norvegicus,N,1,1088.0,
14105,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 34.1 uM/Kg of drug,Intermediate,10116.0,,A,,BAO_0000218,12582,,,1,CHEMBL623276,,,Rattus norvegicus,N,1,1088.0,
14106,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 34.8 uM/Kg of drug,Intermediate,10116.0,,A,,BAO_0000218,12582,,,1,CHEMBL623277,,,Rattus norvegicus,N,1,1088.0,
14107,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 341 uM/Kg of drug,Intermediate,10116.0,,A,,BAO_0000218,12582,,,1,CHEMBL623112,,,Rattus norvegicus,N,1,1088.0,
14108,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 348 uM/Kg of drug,Intermediate,10116.0,,A,,BAO_0000218,12582,,,1,CHEMBL623113,,,Rattus norvegicus,N,1,1088.0,
14109,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 37.6 uM/Kg of drug,Intermediate,10116.0,,A,,BAO_0000218,12582,,,1,CHEMBL623800,,,Rattus norvegicus,N,1,1088.0,
14110,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 58.4 uM/Kg of drug,Intermediate,10116.0,,A,,BAO_0000218,12582,,,1,CHEMBL623801,,,Rattus norvegicus,N,1,1088.0,
14111,"Biodistribution in uterus / spleen, muscle, lungs of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",Intermediate,10116.0,,A,,BAO_0000218,12017,,,1,CHEMBL623802,,,Rattus norvegicus,N,1,2106.0,
14112,Biodistribution in uterus of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,10116.0,,A,,BAO_0000218,12017,,,1,CHEMBL623803,,,Rattus norvegicus,N,1,995.0,
14113,Biodistribution in uterus of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,10116.0,,A,,BAO_0000218,12017,,,1,CHEMBL623970,,,Rattus norvegicus,N,1,995.0,
14114,Biodistribution in uterus of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,10116.0,,A,,BAO_0000218,12017,,,1,CHEMBL623971,,,Rattus norvegicus,N,1,995.0,
14115,Biodistribution of 99m Tc complexes in rat and radio activity in blood at 10 min post injection (Average of three to five animals),Intermediate,10116.0,,A,,BAO_0000218,14045,,,1,CHEMBL623972,,,Rattus norvegicus,N,1,178.0,
14116,Biodistribution of 99m Tc complexes in rat and radio activity in blood at 30 min post injection (Average of three to five animals),Intermediate,10116.0,,A,,BAO_0000218,14045,,,1,CHEMBL623973,,,Rattus norvegicus,N,1,178.0,
14117,Biodistribution of 99m Tc complexes in rat and radio activity in blood at 5 min post injection (Average of three to five animals),Intermediate,10116.0,,A,,BAO_0000218,14045,,,1,CHEMBL623974,,,Rattus norvegicus,N,1,178.0,
14118,Biodistribution of 99m Tc complexes in rat and radio activity in blood at 60 min post injection (Average of three to five animals),Intermediate,10116.0,,A,,BAO_0000218,14045,,,1,CHEMBL623975,,,Rattus norvegicus,N,1,178.0,
14119,Biodistribution of 99m Tc complexes in rat and radio activity in brain at 10 min post injection (Average of three to five animals),Intermediate,10116.0,,A,,BAO_0000218,14045,,,1,CHEMBL623976,,,Rattus norvegicus,N,1,955.0,
14120,Biodistribution of 99m Tc complexes in rat and radio activity in brain at 30 min post injection (Average of three to five animals),Intermediate,10116.0,,A,,BAO_0000218,14045,,,1,CHEMBL623977,,,Rattus norvegicus,N,1,955.0,
14121,Biodistribution of 99m Tc complexes in rat and radio activity in brain at 5 min post injection (Average of three to five animals),Intermediate,10116.0,,A,,BAO_0000218,14045,,,1,CHEMBL623978,,,Rattus norvegicus,N,1,955.0,
14122,Biodistribution of 99m Tc complexes in rat and radio activity in brain at 60 min post injection (Average of three to five animals),Intermediate,10116.0,,A,,BAO_0000218,14045,,,1,CHEMBL623979,,,Rattus norvegicus,N,1,955.0,
14123,Biodistribution of 99m Tc complexes in rat and radio activity in brain/blood at 10 min post injection (Average of three to five animals),Intermediate,10116.0,,A,,BAO_0000218,14045,,,1,CHEMBL623980,,,Rattus norvegicus,N,1,,
14124,Biodistribution of 99m Tc complexes in rat and radio activity in brain/blood at 30 min post injection (Average of three to five animals),Intermediate,10116.0,,A,,BAO_0000218,14045,,,1,CHEMBL623981,,,Rattus norvegicus,N,1,,
14125,Biodistribution of 99m Tc complexes in rat and radio activity in brain/blood at 5 min post injection (Average of three to five animals),Intermediate,10116.0,,A,,BAO_0000218,14045,,,1,CHEMBL626278,,,Rattus norvegicus,N,1,,
14126,Biodistribution of 99m Tc complexes in rat and radio activity in brain/blood at 60 min post injection (Average of three to five animals),Intermediate,10116.0,,A,,BAO_0000218,14045,,,1,CHEMBL626279,,,Rattus norvegicus,N,1,,
14127,Biodistribution in mice bladder plus excreted urine was determined,Intermediate,10090.0,,A,,BAO_0000218,14045,,,1,CHEMBL626280,,,Mus musculus,N,1,,
14128,"Percentage biodistribution in mouse blood, 10 minutes post injection",Intermediate,10090.0,,A,,BAO_0000218,14045,,,1,CHEMBL626281,,,Mus musculus,N,1,,
14129,"Percentage biodistribution in mouse blood, 30 minutes post injection",Intermediate,10090.0,,A,,BAO_0000218,14045,,,1,CHEMBL626282,,,Mus musculus,N,1,,
14130,"Percentage biodistribution in mouse blood, 5 minutes post injection",Intermediate,10090.0,,A,,BAO_0000218,14045,,,1,CHEMBL626283,,,Mus musculus,N,1,,
14131,"Percentage biodistribution in mouse blood, 60 minutes post injection",Intermediate,10090.0,,A,,BAO_0000218,14045,,,1,CHEMBL626284,,,Mus musculus,N,1,,
14132,"Percentage biodistribution in mouse brain, 10 minutes post injection",Intermediate,10090.0,,A,,BAO_0000218,14045,,,1,CHEMBL626285,,,Mus musculus,N,1,955.0,
14133,"Percentage biodistribution in mouse brain, 30 minutes post injection",Intermediate,10090.0,,A,,BAO_0000218,14045,,,1,CHEMBL626286,,,Mus musculus,N,1,955.0,
14134,"Percentage biodistribution in mouse brain, 5 minutes post injection",Intermediate,10090.0,,A,,BAO_0000218,14045,,,1,CHEMBL626287,,,Mus musculus,N,1,955.0,
14135,"Percentage biodistribution in mouse brain, 60 minutes post injection",Intermediate,10090.0,,A,,BAO_0000218,14045,,,1,CHEMBL626288,,,Mus musculus,N,1,955.0,
14136,"Percentage biodistribution in mouse heart, 10 minutes post injection",Intermediate,10090.0,,A,,BAO_0000218,14045,,,1,CHEMBL626289,,,Mus musculus,N,1,,
14137,"Percentage biodistribution in mouse heart, 30 minutes post injection",Intermediate,10090.0,,A,,BAO_0000218,14045,,,1,CHEMBL626290,,,Mus musculus,N,1,,
14138,"Percentage biodistribution in mouse heart, 5 minutes post injection",Intermediate,10090.0,,A,,BAO_0000218,14045,,,1,CHEMBL626291,,,Mus musculus,N,1,,
14139,"Percentage biodistribution in mouse heart, 60 minutes post injection",Intermediate,10090.0,,A,,BAO_0000218,14045,,,1,CHEMBL839888,,,Mus musculus,N,1,,
14140,"Percentage biodistribution in mouse intestine, 10 minutes post injection",Intermediate,10090.0,,A,,BAO_0000218,14045,,,1,CHEMBL626292,,,Mus musculus,N,1,160.0,
14141,"Percentage biodistribution in mouse intestine, 30 minutes post injection",Intermediate,10090.0,,A,,BAO_0000218,14045,,,1,CHEMBL626293,,,Mus musculus,N,1,160.0,
14142,"Percentage biodistribution in mouse intestine, 5 minutes post injection",Intermediate,10090.0,,A,,BAO_0000218,14045,,,1,CHEMBL626294,,,Mus musculus,N,1,160.0,
14143,"Percentage biodistribution in mouse intestine, 60 minutes post injection",Intermediate,10090.0,,A,,BAO_0000218,14045,,,1,CHEMBL626295,,,Mus musculus,N,1,160.0,
14144,"Percentage biodistribution in mouse liver, 10 minutes post injection",Intermediate,10090.0,,A,,BAO_0000218,14045,,,1,CHEMBL627659,,,Mus musculus,N,1,2107.0,
14145,"Percentage biodistribution in mouse liver, 30 minutes of post injection",Intermediate,10090.0,,A,,BAO_0000218,14045,,,1,CHEMBL627660,,,Mus musculus,N,1,2107.0,
14146,"Percentage biodistribution in mouse liver, 5 minutes post injection",Intermediate,10090.0,,A,,BAO_0000218,14045,,,1,CHEMBL627661,,,Mus musculus,N,1,2107.0,
14147,Biodistribution in mice liver at 60 minutes of post injection,Intermediate,10090.0,,A,,BAO_0000218,14045,,,1,CHEMBL627662,,,Mus musculus,N,1,2107.0,
14148,Biodistribution in mice lungs at 10 min of post injection,Intermediate,10090.0,,A,,BAO_0000218,14045,,,1,CHEMBL627663,,,Mus musculus,N,1,2048.0,
14149,"Percentage biodistribution in mouse lung, 30 minutes post injection",Intermediate,10090.0,,A,,BAO_0000218,14045,,,1,CHEMBL627664,,,Mus musculus,N,1,,
14150,"Percentage biodistribution in mousee lung, 5 minutes post injection",Intermediate,10090.0,,A,,BAO_0000218,14045,,,1,CHEMBL627665,,,Mus musculus,N,1,,
14151,Biodistribution in mice lungs at 60 min of post injection,Intermediate,10090.0,,A,,BAO_0000218,14045,,,1,CHEMBL627666,,,Mus musculus,N,1,2048.0,
14152,Percentage biodistribution in mouse spleen,Intermediate,10090.0,,A,,BAO_0000218,14045,,,1,CHEMBL627667,,,Mus musculus,N,1,2106.0,
14153,Percentage biodistribution in mouse stomach,Intermediate,10090.0,,A,,BAO_0000218,14045,,,1,CHEMBL627668,,,Mus musculus,N,1,945.0,
14154,Mean biodistribution and elimination data in urine was reported 24 h after administering compound intravenously in tumor-bearing female BALB-C mice.,Intermediate,10090.0,,A,,BAO_0000218,11745,,,1,CHEMBL627669,,,Mus musculus,N,1,1088.0,
14155,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in bladder,Autocuration,,,A,,BAO_0000218,13257,,,1,CHEMBL627670,,,,U,0,1255.0,
14156,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in blood,Autocuration,,,A,,BAO_0000218,13257,,,1,CHEMBL627671,,,,U,0,178.0,
14157,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in bone,Autocuration,,,A,,BAO_0000218,13257,,,1,CHEMBL627672,,,,U,0,1474.0,
14158,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in fat,Autocuration,,,A,,BAO_0000218,13257,,,1,CHEMBL627673,,,,U,0,,
14159,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in kidney,Autocuration,,,A,,BAO_0000218,13257,,,1,CHEMBL627674,,,,U,0,2113.0,
14160,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in liver,Autocuration,,,A,,BAO_0000218,13257,,,1,CHEMBL627675,,,,U,0,2107.0,
14161,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in lung,Autocuration,,,A,,BAO_0000218,13257,,,1,CHEMBL627676,,,,U,0,2048.0,
14162,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in muscle,Autocuration,,,A,,BAO_0000218,13257,,,1,CHEMBL627677,,,,U,0,2385.0,
14163,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator in the conditions of 25degreeC,pH 7.6",Autocuration,,,A,,BAO_0000019,8354,,,1,CHEMBL627678,,,,U,0,,
14164,Affinity for protein binding expressed as association constant in fresh rat serum,Intermediate,10116.0,,A,,BAO_0000218,7095,,,1,CHEMBL627679,,,Rattus norvegicus,N,1,1977.0,
14165,Kinetic constant (Kcat) was calculated by inhibition of monoamino oxidase B (MAO B) at saturation,Autocuration,,,A,,BAO_0000019,12185,,,1,CHEMBL627680,,,,U,0,,
14166,Kinetic constant (Kcat) was calculated by inhibition of monoamino oxidase B (MAO B) at saturation; Inactive,Autocuration,,,A,,BAO_0000019,12185,,,1,CHEMBL627681,,,,U,0,,
14167,Inactivation constant (Kinact) was calculated by inhibition of monoamino oxidase B (MAO B) at saturation,Autocuration,,,A,,BAO_0000019,12185,,,1,CHEMBL627682,,,,U,0,,
14168,Inactivation constant (Kinact) was calculated by inhibition of monoamino oxidase B (MAO B) at saturation; Inactive,Autocuration,,,A,,BAO_0000019,12185,,,1,CHEMBL627683,,,,U,0,,
14169,The observed pseudo-first-order rate constants of compound for cyclization reaction at pH 2.4,Autocuration,,,A,,BAO_0000019,12686,,,1,CHEMBL627684,,,,U,0,,
14170,"The observed pseudo-first-order rate constants of compound for cyclization reaction at pH 2.4; Significant cyclization occurred during nitro reduction, precluding isolation of the pure amine and determination of rate constants",Autocuration,,,A,,BAO_0000019,12686,,,1,CHEMBL874441,,,,U,0,,
14171,The observed pseudo-first-order rate constants of compound for cyclization reaction at pH 6.8; No cyclization detected over 4 h,Autocuration,,,A,,BAO_0000019,12686,,,1,CHEMBL627685,,,,U,0,,
14172,"The observed pseudo-first-order rate constants of compound for cyclization reaction at pH 6.8; Significant cyclization occurred during nitro reduction, precluding isolation of the pure amine and determination of rate constants",Autocuration,,,A,,BAO_0000019,12686,,,1,CHEMBL627686,,,,U,0,,
14173,Apparent rate constant Koff for inactivation of dTMP synthase.,Autocuration,,,A,,BAO_0000019,8057,,,1,CHEMBL627687,,,,U,0,,
14174,The irreversible inhibitor activity by second order rate equation.,Autocuration,,,A,,BAO_0000019,15778,,,1,CHEMBL627688,,,,U,0,,
14175,Compound was tested for oral diuretic effect on spontaneously hypertensive rats by measuring the potassium excretion at 1 mg/kg concentration,Intermediate,10116.0,,A,,BAO_0000218,12375,,,1,CHEMBL628038,,,Rattus norvegicus,N,1,,
14176,Compound was tested for oral diuretic effect on spontaneously hypertensive rats by measuring the potassium excretion at 5 mg/kg concentration,Intermediate,10116.0,,A,,BAO_0000218,12375,,,1,CHEMBL628039,,,Rattus norvegicus,N,1,,
14177,Compound was tested for oral diuretic effect on spontaneously hypertensive rats by measuring the potassium excretion at vehicle concentration,Intermediate,10116.0,,A,,BAO_0000218,12375,,,1,CHEMBL628040,,,Rattus norvegicus,N,1,,
14178,Dissociation rate calculated from the first-order equation using t1/2 value,Autocuration,,,A,,BAO_0000019,13588,,,1,CHEMBL628041,,,,U,0,,
14179,The compound was tested for Binding constant against DNA,Autocuration,,,A,,BAO_0000019,15039,,,1,CHEMBL630226,,,,U,0,,
14180,First order rate constant for cyclization of the compound,Autocuration,,,A,,BAO_0000019,9500,,,1,CHEMBL628042,,,,U,0,,
14181,First order rate constant of compound was determined in 50 mM phosphate buffer (pH 7.4) at 24 degree celsius,Autocuration,,,A,,BAO_0000019,10014,,,1,CHEMBL625232,,,,U,0,,
14182,First order rate constant of compound was determined in 50 mM phosphate buffer (pH 7.4) at 37 degree celsius,Autocuration,,,A,,BAO_0000019,10014,,,1,CHEMBL625233,,,,U,0,,
14183,Hydrolysis rate constant was determined,Autocuration,,,A,,BAO_0000019,568,,,1,CHEMBL625979,,,,U,0,,
14184,Observed first order rate constant,Autocuration,,,A,,BAO_0000019,10026,,,1,CHEMBL625980,,,,U,0,,
14185,Rate constant (cyclization rate) in CD3CN-deuterated phosphate buffer at pH 7.4,Autocuration,,,A,,BAO_0000019,10281,,,1,CHEMBL625981,,,,U,0,,
14186,Rate constant (cyclization rate) in CD3CN-deuterated phosphate buffer at pH 7.4,Autocuration,,,A,,BAO_0000019,10281,,,1,CHEMBL625982,,,,U,0,,
14187,Second-order rate constant for attack on PNPA at 25 degree Centigrade,Autocuration,,,A,,BAO_0000019,9680,,,1,CHEMBL625983,,,,U,0,,
14188,Kinetic parameter of epimerization at a salt concentration (0.01 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,Autocuration,,,A,,BAO_0000019,13028,,,1,CHEMBL625984,,,,U,0,,
14189,Kinetic parameter of epimerization at a salt concentration (0.1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,Autocuration,,,A,,BAO_0000019,13028,,,1,CHEMBL625985,,,,U,0,,
14190,Kinetic parameter of epimerization at a salt concentration (1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,Autocuration,,,A,,BAO_0000019,13028,,,1,CHEMBL625986,,,,U,0,,
14191,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,Autocuration,,,A,,BAO_0000019,13028,,,1,CHEMBL625987,,,,U,0,,
14192,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,Autocuration,,,A,,BAO_0000019,13028,,,1,CHEMBL625988,,,,U,0,,
14193,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 11.3 (or )in RMPI 1640 cell culture medium containing 10%FCS,Autocuration,,,A,,BAO_0000019,13028,,,1,CHEMBL625989,,,,U,0,,
14194,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 7.5 (or )in RMPI 1640 cell culture medium containing 10%FCS,Autocuration,,,A,,BAO_0000019,13028,,,1,CHEMBL625990,,,,U,0,,
14195,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 8.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,Autocuration,,,A,,BAO_0000019,13028,,,1,CHEMBL625991,,,,U,0,,
14196,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,Autocuration,,,A,,BAO_0000019,13028,,,1,CHEMBL625992,,,,U,0,,
14197,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,Autocuration,,,A,,BAO_0000019,13028,,,1,CHEMBL625993,,,,U,0,,
14198,Kinetic parameter of epimerization at a salt concentration (0.01 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,Autocuration,,,A,,BAO_0000019,13028,,,1,CHEMBL631973,,,,U,0,,
14199,Kinetic parameter of epimerization at a salt concentration (0.1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,Autocuration,,,A,,BAO_0000019,13028,,,1,CHEMBL632143,,,,U,0,,
14200,Kinetic parameter of epimerization at a salt concentration (1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,Autocuration,,,A,,BAO_0000019,13028,,,1,CHEMBL632144,,,,U,0,,
14201,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,Autocuration,,,A,,BAO_0000019,13028,,,1,CHEMBL632145,,,,U,0,,
14202,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,Autocuration,,,A,,BAO_0000019,13028,,,1,CHEMBL632146,,,,U,0,,
14203,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 11.3 (or )in RMPI 1640 cell culture medium containing 10%FCS,Autocuration,,,A,,BAO_0000019,13028,,,1,CHEMBL632147,,,,U,0,,
14204,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 7.5 (or )in RMPI 1640 cell culture medium containing 10%FCS,Autocuration,,,A,,BAO_0000019,13028,,,1,CHEMBL632148,,,,U,0,,
14205,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 8.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,Autocuration,,,A,,BAO_0000019,13028,,,1,CHEMBL632149,,,,U,0,,
14206,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,Autocuration,,,A,,BAO_0000019,13028,,,1,CHEMBL632150,,,,U,0,,
14207,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,Autocuration,,,A,,BAO_0000019,13028,,,1,CHEMBL632151,,,,U,0,,
14208,Metabolism (NADH oxidation) by recombinant human NAD(P)H: quinone oxidoreductase (NQO1) is evaluated; not detected,Intermediate,9606.0,,A,,BAO_0000218,3008,,,1,CHEMBL632152,,,Homo sapiens,N,1,,
14209,Metabolism after 30 min of incubation with human liver microsomes in the absence of cofactor NADH (2.0 mM) at a concentration of 25 uM,Intermediate,9606.0,,A,,BAO_0000218,4509,,,1,CHEMBL632153,,,Homo sapiens,N,1,,
14210,Metabolism after 30 min of incubation with human liver microsomes in the presence of cofactor NADH (2.0 mM) at a concentration of 25 uM,Intermediate,9606.0,,A,,BAO_0000218,4509,,,1,CHEMBL632154,,,Homo sapiens,N,1,,
14211,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 12.5 mg/kg per day; Tested mice 10,Intermediate,10298.0,,A,,BAO_0000218,8613,,,1,CHEMBL632155,,,Human herpesvirus 1,N,1,,
14212,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 12.5 mg/kg per day; Total mice tested 10,Intermediate,10298.0,,A,,BAO_0000218,8613,,,1,CHEMBL632156,,,Human herpesvirus 1,N,1,,
14213,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 3.1 mg/kg per day; Tested mice 10,Intermediate,10298.0,,A,,BAO_0000218,8613,,,1,CHEMBL632157,,,Human herpesvirus 1,N,1,,
14214,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 50 mg/kg per day; Tested mice 10,Intermediate,10298.0,,A,,BAO_0000218,8613,,,1,CHEMBL632158,,,Human herpesvirus 1,N,1,,
14215,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 50 mg/kg per day; Total mice tested 10,Intermediate,10298.0,,A,,BAO_0000218,8613,,,1,CHEMBL632159,,,Human herpesvirus 1,N,1,,
14216,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at dose 0.8 mg/kg per day; Tested mice 10,Intermediate,10298.0,,A,,BAO_0000218,8613,,,1,CHEMBL626305,,,Human herpesvirus 1,N,1,,
14217,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at dose 3.1 mg/kg per day; Total mice tested 10,Intermediate,10298.0,,A,,BAO_0000218,8613,,,1,CHEMBL626306,,,Human herpesvirus 1,N,1,,
14218,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.02 mg/kg per day; Tested mice 10,Intermediate,10298.0,,A,,BAO_0000218,8613,,,1,CHEMBL626307,,,Human herpesvirus 1,N,1,,
14219,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.06 mg/kg per day; Tested mice 10,Intermediate,10298.0,,A,,BAO_0000218,8613,,,1,CHEMBL626308,,,Human herpesvirus 1,N,1,,
14220,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.25 mg/kg per day; Tested mice 10,Intermediate,10298.0,,A,,BAO_0000218,8613,,,1,CHEMBL626479,,,Human herpesvirus 1,N,1,,
14221,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 1 mg/kg per day; Tested mice 10,Intermediate,10298.0,,A,,BAO_0000218,8613,,,1,CHEMBL626480,,,Human herpesvirus 1,N,1,,
14222,Calculated partition coefficient (clogP) (MlogP),Autocuration,,,P,,BAO_0000100,6021,,,1,CHEMBL626481,,,,U,0,,
14223,Equipotent potent ratio relative to carbachol (nicotinic activity),Autocuration,,,A,,BAO_0000019,9348,,,1,CHEMBL626482,,,,U,0,,
14224,"Concentration after 8 hour (bioavailability in dog, compound was delivered orally in 0.05 M citric acid at 10 mg/Kg. n=2 ); NA denotes not available",Intermediate,9615.0,,A,,BAO_0000218,15592,,,1,CHEMBL626483,,,Canis lupus familiaris,N,1,,
14225,"Concentration after 8 hour (bioavailability in dog, compound was delivered orally in 0.05 M citric acid at 10 mg/Kg. n=2 );NA denotes not available",Intermediate,9615.0,,A,,BAO_0000218,15592,,,1,CHEMBL626484,,,Canis lupus familiaris,N,1,,
14226,Solubility at pH 7.4 in micro g/mL;NA denotes available,Autocuration,,,P,,BAO_0000100,15592,,,1,CHEMBL626485,,,,U,0,,
14227,Solubility at pH 7.4 in micro g/mL;NA denotes not available,Autocuration,,,P,,BAO_0000100,15592,,,1,CHEMBL626486,,,,U,0,,
14228,Solubility at pH 7.4 in ug/mL;NA denotes not available,Autocuration,,,P,,BAO_0000100,15592,,,1,CHEMBL626487,,,,U,0,,
14229,Maximal plasma concentration in dogs at 10mg/kg oral dose 0.05M citric acid,Intermediate,9615.0,,A,,BAO_0000218,15592,,,1,CHEMBL626488,,,Canis lupus familiaris,N,1,1969.0,
14230,Affinity for protein binding expressed as association constant in fresh rat serum; ND is Not Determined.,Intermediate,10116.0,,A,,BAO_0000218,7095,,,1,CHEMBL626489,,,Rattus norvegicus,N,1,1977.0,
14231,Area under the MAP curve measured over 5 min; ND means Not determined,Autocuration,,,A,,BAO_0000019,16618,,,1,CHEMBL626490,,,,U,0,,
14232,Lipophilicity expressed as the negative logarithm of the equilibrium constant; ND denotes no data.,Autocuration,,,P,,BAO_0000100,16835,,,1,CHEMBL626491,,,,U,0,,
14233,The apparent partition coefficient(D) in cyclohexane-0.05 M phosphate buffer (pH 7.4) at 21 degree celsius; not determined,Autocuration,,,P,,BAO_0000100,15284,,,1,CHEMBL626492,,,,U,0,,
14234,Half-life was measured in the presence of NADPH at 20 uM; No inhibition,Autocuration,,,A,,BAO_0000019,15750,,,1,CHEMBL626493,,,,U,0,,
14235,Half life after oral administration to Sprague-Dawley rats; NT is Not tested,Intermediate,10116.0,,A,,BAO_0000218,16618,,,1,CHEMBL626494,,,Rattus norvegicus,N,1,,
14236,Half life after oral tested,Autocuration,,,A,,BAO_0000218,16618,,,1,CHEMBL626495,,,,U,0,,
14237,Half life was determined in plasma of rat; NT indicates not tested,Intermediate,10116.0,,A,,BAO_0000218,15812,,,1,CHEMBL626496,,,Rattus norvegicus,N,1,1969.0,
14238,Oral bioavailability after oral administration to Sprague-Dawley rats; NT is Not tested,Intermediate,10116.0,,A,,BAO_0000218,16618,,,1,CHEMBL626497,,,Rattus norvegicus,N,1,,
14239,Oral bioavailability after oral tested,Autocuration,,,A,,BAO_0000218,16618,,,1,CHEMBL626498,,,,U,0,,
14240,The bioavailability in rats at 15.9 uM/Kg after intravenous administration; NT=Not tested (F),Intermediate,10116.0,,A,,BAO_0000218,13098,,,1,CHEMBL626499,,,Rattus norvegicus,N,1,,
14241,The compound was tested for volume of distribution in rat at 15.9 uM/Kg after peroral administration; NT=Not tested (Vd L/Kg),Intermediate,10116.0,,A,,BAO_0000218,13098,,,1,CHEMBL626500,,,Rattus norvegicus,N,1,,
14242,half life was determined in plasma of rat; NT indicates not tested,Intermediate,10116.0,,A,,BAO_0000218,15812,,,1,CHEMBL626501,,,Rattus norvegicus,N,1,1969.0,
14243,half life was determined in plasma of rat; NT means not tested,Intermediate,10116.0,,A,,BAO_0000218,15812,,,1,CHEMBL626502,,,Rattus norvegicus,N,1,1969.0,
14244,Mean sodium excretion in rats (Control/Drug treatment value); Value 0.41/2.32,Intermediate,10116.0,,A,,BAO_0000218,11510,,,1,CHEMBL626503,,,Rattus norvegicus,N,1,,
14245,Mean sodium excretion in rats (Control/Drug treatment value); inactive,Intermediate,10116.0,,A,,BAO_0000218,11510,,,1,CHEMBL626504,,,Rattus norvegicus,N,1,,
14246,Mean sodium excretion in rats (Control/Drug treatment value); value 0.17/0.43,Intermediate,10116.0,,A,,BAO_0000218,11510,,,1,CHEMBL626505,,,Rattus norvegicus,N,1,,
14247,Mean sodium excretion in rats (Control/Drug treatment value); value 0.2/0.38,Intermediate,10116.0,,A,,BAO_0000218,11510,,,1,CHEMBL626506,,,Rattus norvegicus,N,1,,
14248,Mean sodium excretion in rats (Control/Drug treatment value); value 0.26/0.23,Intermediate,10116.0,,A,,BAO_0000218,11510,,,1,CHEMBL626507,,,Rattus norvegicus,N,1,,
14249,Mean sodium excretion in rats (Control/Drug treatment value); value 0.28/0.26,Intermediate,10116.0,,A,,BAO_0000218,11510,,,1,CHEMBL626508,,,Rattus norvegicus,N,1,,
14250,Mean sodium excretion in rats (Control/Drug treatment value); value 0.31/0.35,Intermediate,10116.0,,A,,BAO_0000218,11510,,,1,CHEMBL626509,,,Rattus norvegicus,N,1,,
14251,Mean sodium excretion in rats (Control/Drug treatment value); value 0.35/2.88,Intermediate,10116.0,,A,,BAO_0000218,11510,,,1,CHEMBL875480,,,Rattus norvegicus,N,1,,
14252,Mean sodium excretion in rats (Control/Drug treatment value); value 0.36/0.29,Intermediate,10116.0,,A,,BAO_0000218,11510,,,1,CHEMBL626510,,,Rattus norvegicus,N,1,,
14253,Mean sodium excretion in rats (Control/Drug treatment value); value 0.36/0.47,Intermediate,10116.0,,A,,BAO_0000218,11510,,,1,CHEMBL626511,,,Rattus norvegicus,N,1,,
14254,Mean sodium excretion in rats (Control/Drug treatment value); value 0.36/0.49,Intermediate,10116.0,,A,,BAO_0000218,11510,,,1,CHEMBL626512,,,Rattus norvegicus,N,1,,
14255,Mean sodium excretion in rats (Control/Drug treatment value); value 0.38/0.23,Intermediate,10116.0,,A,,BAO_0000218,11510,,,1,CHEMBL628208,,,Rattus norvegicus,N,1,,
14256,Mean sodium excretion in rats (Control/Drug treatment value); value 0.39/0.22,Intermediate,10116.0,,A,,BAO_0000218,11510,,,1,CHEMBL628209,,,Rattus norvegicus,N,1,,
14257,Mean sodium excretion in rats (Control/Drug treatment value); value 0.41/0.48,Intermediate,10116.0,,A,,BAO_0000218,11510,,,1,CHEMBL628210,,,Rattus norvegicus,N,1,,
14258,Mean sodium excretion in rats (Control/Drug treatment value); value 0.41/1.49,Intermediate,10116.0,,A,,BAO_0000218,11510,,,1,CHEMBL628211,,,Rattus norvegicus,N,1,,
14259,Mean sodium excretion in rats (Control/Drug treatment value); value 0.41/2.06,Intermediate,10116.0,,A,,BAO_0000218,11510,,,1,CHEMBL628212,,,Rattus norvegicus,N,1,,
14260,Mean sodium excretion in rats (Control/Drug treatment value); value 0.42/0.65,Intermediate,10116.0,,A,,BAO_0000218,11510,,,1,CHEMBL628213,,,Rattus norvegicus,N,1,,
14261,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 65.2 uM/Kg of drug,Intermediate,10116.0,,A,,BAO_0000218,12582,,,1,CHEMBL628214,,,Rattus norvegicus,N,1,1088.0,
14262,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 71.6 uM/Kg of drug,Intermediate,10116.0,,A,,BAO_0000218,12582,,,1,CHEMBL628215,,,Rattus norvegicus,N,1,1088.0,
14263,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 71.8 uM/Kg of drug,Intermediate,10116.0,,A,,BAO_0000218,12582,,,1,CHEMBL628216,,,Rattus norvegicus,N,1,1088.0,
14264,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 74.8 uM/Kg of drug,Intermediate,10116.0,,A,,BAO_0000218,12582,,,1,CHEMBL626595,,,Rattus norvegicus,N,1,1088.0,
14265,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 77.5 uM/Kg of drug,Intermediate,10116.0,,A,,BAO_0000218,12582,,,1,CHEMBL626596,,,Rattus norvegicus,N,1,1088.0,
14266,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 79.4 uM/Kg of drug,Intermediate,10116.0,,A,,BAO_0000218,12582,,,1,CHEMBL626597,,,Rattus norvegicus,N,1,1088.0,
14267,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 80.9 uM/Kg of drug,Intermediate,10116.0,,A,,BAO_0000218,12582,,,1,CHEMBL626598,,,Rattus norvegicus,N,1,1088.0,
14268,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 83.8 uM/Kg of drug,Intermediate,10116.0,,A,,BAO_0000218,12582,,,1,CHEMBL622242,,,Rattus norvegicus,N,1,1088.0,
14269,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 84.5 uM/Kg of drug,Intermediate,10116.0,,A,,BAO_0000218,12582,,,1,CHEMBL622243,,,Rattus norvegicus,N,1,1088.0,
14270,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 84.7 uM/Kg of drug,Intermediate,10116.0,,A,,BAO_0000218,12582,,,1,CHEMBL622244,,,Rattus norvegicus,N,1,1088.0,
14271,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 86.7 uM/Kg of drug,Intermediate,10116.0,,A,,BAO_0000218,12582,,,1,CHEMBL622245,,,Rattus norvegicus,N,1,1088.0,
14272,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 86.9 uM/Kg of drug,Intermediate,10116.0,,A,,BAO_0000218,12582,,,1,CHEMBL622246,,,Rattus norvegicus,N,1,1088.0,
14273,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 9.06 uM/Kg of drug,Intermediate,10116.0,,A,,BAO_0000218,12582,,,1,CHEMBL622247,,,Rattus norvegicus,N,1,1088.0,
14274,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 90.6 uM/Kg of drug,Intermediate,10116.0,,A,,BAO_0000218,12582,,,1,CHEMBL622248,,,Rattus norvegicus,N,1,1088.0,
14275,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 94.9 uM/Kg of drug,Intermediate,10116.0,,A,,BAO_0000218,12582,,,1,CHEMBL877483,,,Rattus norvegicus,N,1,1088.0,
14276,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 97.1 uM/Kg of drug,Intermediate,10116.0,,A,,BAO_0000218,12582,,,1,CHEMBL622249,,,Rattus norvegicus,N,1,1088.0,
14277,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 11.9 uM/Kg of drug,Intermediate,9615.0,,A,,BAO_0000218,12582,,,1,CHEMBL622250,,,Canis lupus familiaris,N,1,1088.0,
14278,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 2.49 uM/Kg of drug,Intermediate,9615.0,,A,,BAO_0000218,12582,,,1,CHEMBL622251,,,Canis lupus familiaris,N,1,1088.0,
14279,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 26.2 uM/Kg of drug,Intermediate,9615.0,,A,,BAO_0000218,12582,,,1,CHEMBL622252,,,Canis lupus familiaris,N,1,1088.0,
14280,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 3.03 uM/Kg of drug,Intermediate,9615.0,,A,,BAO_0000218,12582,,,1,CHEMBL622253,,,Canis lupus familiaris,N,1,1088.0,
14281,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 30.3 uM/Kg of drug,Intermediate,9615.0,,A,,BAO_0000218,12582,,,1,CHEMBL622254,,,Canis lupus familiaris,N,1,1088.0,
14282,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 34.1 uM/Kg of drug,Intermediate,9615.0,,A,,BAO_0000218,12582,,,1,CHEMBL622255,,,Canis lupus familiaris,N,1,1088.0,
14283,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 52.4 uM/Kg of drug,Intermediate,9615.0,,A,,BAO_0000218,12582,,,1,CHEMBL622256,,,Canis lupus familiaris,N,1,1088.0,
14284,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 7.85 uM/Kg of drug,Intermediate,9615.0,,A,,BAO_0000218,12582,,,1,CHEMBL622257,,,Canis lupus familiaris,N,1,1088.0,
14285,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 8.47 uM/Kg of drug,Intermediate,9615.0,,A,,BAO_0000218,12582,,,1,CHEMBL622258,,,Canis lupus familiaris,N,1,1088.0,
14286,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 9.09 uM/Kg of drug,Intermediate,9615.0,,A,,BAO_0000218,12582,,,1,CHEMBL622259,,,Canis lupus familiaris,N,1,1088.0,
14287,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 10.1 uM/Kg of drug,Intermediate,9615.0,,A,,BAO_0000218,12582,,,1,CHEMBL622927,,,Canis lupus familiaris,N,1,1088.0,
14288,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 3.40 uM/Kg of drug,Intermediate,9615.0,,A,,BAO_0000218,12582,,,1,CHEMBL622928,,,Canis lupus familiaris,N,1,1088.0,
14289,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 3.76 uM/Kg of drug,Intermediate,9615.0,,A,,BAO_0000218,12582,,,1,CHEMBL622929,,,Canis lupus familiaris,N,1,1088.0,
14290,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 9.06 uM/Kg of drug,Intermediate,9615.0,,A,,BAO_0000218,12582,,,1,CHEMBL623182,,,Canis lupus familiaris,N,1,1088.0,
14291,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 9.6 uM/Kg of drug,Intermediate,9615.0,,A,,BAO_0000218,12582,,,1,CHEMBL623183,,,Canis lupus familiaris,N,1,1088.0,
14292,Total electrolytic excretion of potassium in urine of rats after peroral administration of 0 uM/Kg of drug,Intermediate,10116.0,,A,,BAO_0000218,12582,,,1,CHEMBL623184,,,Rattus norvegicus,N,1,1088.0,
14293,Total electrolytic excretion of potassium in urine of rats after peroral administration of 1.01 uM/Kg of drug,Intermediate,10116.0,,A,,BAO_0000218,12582,,,1,CHEMBL623185,,,Rattus norvegicus,N,1,1088.0,
14294,Total electrolytic excretion of potassium in urine of rats after peroral administration of 1.13 uM/Kg of drug,Intermediate,10116.0,,A,,BAO_0000218,12582,,,1,CHEMBL877484,,,Rattus norvegicus,N,1,1088.0,
14295,Total electrolytic excretion of potassium in urine of rats after peroral administration of 10.1 uM/Kg of drug,Intermediate,10116.0,,A,,BAO_0000218,12582,,,1,CHEMBL627274,,,Rattus norvegicus,N,1,1088.0,
14296,Total electrolytic excretion of potassium in urine of rats after peroral administration of 102 uM/Kg of drug,Intermediate,10116.0,,A,,BAO_0000218,12582,,,1,CHEMBL623186,,,Rattus norvegicus,N,1,1088.0,
14297,Total electrolytic excretion of potassium in urine of rats after peroral administration of 105 uM/Kg of drug,Intermediate,10116.0,,A,,BAO_0000218,12582,,,1,CHEMBL623187,,,Rattus norvegicus,N,1,1088.0,
14298,Total electrolytic excretion of potassium in urine of rats after peroral administration of 11.3 uM/Kg of drug,Intermediate,10116.0,,A,,BAO_0000218,12582,,,1,CHEMBL623188,,,Rattus norvegicus,N,1,1088.0,
14299,Total electrolytic excretion of potassium in urine of rats after peroral administration of 113 uM/Kg of drug,Intermediate,10116.0,,A,,BAO_0000218,12582,,,1,CHEMBL628055,,,Rattus norvegicus,N,1,1088.0,
14300,Total electrolytic excretion of potassium in urine of rats after peroral administration of 19.5 uM/Kg of drug,Intermediate,10116.0,,A,,BAO_0000218,12582,,,1,CHEMBL628056,,,Rattus norvegicus,N,1,1088.0,
14301,Total electrolytic excretion of potassium in urine of rats after peroral administration of 195 uM/Kg of drug,Intermediate,10116.0,,A,,BAO_0000218,12582,,,1,CHEMBL628200,,,Rattus norvegicus,N,1,1088.0,
14302,Total electrolytic excretion of potassium in urine of rats after peroral administration of 21.7 uM/Kg of drug,Intermediate,10116.0,,A,,BAO_0000218,12582,,,1,CHEMBL628201,,,Rattus norvegicus,N,1,1088.0,
14303,Total electrolytic excretion of potassium in urine of rats after peroral administration of 217 uM/Kg of drug,Intermediate,10116.0,,A,,BAO_0000218,12582,,,1,CHEMBL628202,,,Rattus norvegicus,N,1,1088.0,
14304,Total electrolytic excretion of potassium in urine of rats after peroral administration of 23.9 uM/Kg of drug,Intermediate,10116.0,,A,,BAO_0000218,12582,,,1,CHEMBL628203,,,Rattus norvegicus,N,1,1088.0,
14305,Total electrolytic excretion of potassium in urine of rats after peroral administration of 239 uM/Kg of drug,Intermediate,10116.0,,A,,BAO_0000218,12582,,,1,CHEMBL628204,,,Rattus norvegicus,N,1,1088.0,
14306,Total electrolytic excretion of potassium in urine of rats after peroral administration of 24.9 uM/Kg of drug,Intermediate,10116.0,,A,,BAO_0000218,12582,,,1,CHEMBL628205,,,Rattus norvegicus,N,1,1088.0,
14307,Total electrolytic excretion of potassium in urine of rats after peroral administration of 249 uM/Kg of drug,Intermediate,10116.0,,A,,BAO_0000218,12582,,,1,CHEMBL628206,,,Rattus norvegicus,N,1,1088.0,
14308,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (d),Autocuration,,,A,,BAO_0000218,13257,,,1,CHEMBL628207,,,,U,0,2367.0,
14309,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (d)/biood,Autocuration,,,A,,BAO_0000218,13257,,,1,CHEMBL627220,,,,U,0,2367.0,
14310,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (d)/muscle,Autocuration,,,A,,BAO_0000218,13257,,,1,CHEMBL627221,,,,U,0,2385.0,
14311,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (v),Autocuration,,,A,,BAO_0000218,13257,,,1,CHEMBL627222,,,,U,0,2367.0,
14312,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (v)/blood,Autocuration,,,A,,BAO_0000218,13257,,,1,CHEMBL627223,,,,U,0,,
14313,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (v)/muscle,Autocuration,,,A,,BAO_0000218,13257,,,1,CHEMBL632062,,,,U,0,2385.0,
14314,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in spleen,Autocuration,,,A,,BAO_0000218,13257,,,1,CHEMBL632063,,,,U,0,2106.0,
14315,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in bladder,Autocuration,,,A,,BAO_0000218,13257,,,1,CHEMBL632064,,,,U,0,1255.0,
14316,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in blood,Autocuration,,,A,,BAO_0000218,13257,,,1,CHEMBL632065,,,,U,0,178.0,
14317,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in bone,Autocuration,,,A,,BAO_0000218,13257,,,1,CHEMBL632066,,,,U,0,1474.0,
14318,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in fat,Autocuration,,,A,,BAO_0000218,13257,,,1,CHEMBL632067,,,,U,0,,
14319,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in kidney,Autocuration,,,A,,BAO_0000218,13257,,,1,CHEMBL629188,,,,U,0,2113.0,
14320,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in liver,Autocuration,,,A,,BAO_0000218,13257,,,1,CHEMBL629189,,,,U,0,2107.0,
14321,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in lung,Autocuration,,,A,,BAO_0000218,13257,,,1,CHEMBL629190,,,,U,0,2048.0,
14322,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in muscle,Autocuration,,,A,,BAO_0000218,13257,,,1,CHEMBL629191,,,,U,0,2385.0,
14323,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (d),Autocuration,,,A,,BAO_0000218,13257,,,1,CHEMBL629192,,,,U,0,2367.0,
14324,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (d)/muscle,Autocuration,,,A,,BAO_0000218,13257,,,1,CHEMBL629193,,,,U,0,2385.0,
14325,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (v),Autocuration,,,A,,BAO_0000218,13257,,,1,CHEMBL629194,,,,U,0,2367.0,
14326,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (v)/blood,Autocuration,,,A,,BAO_0000218,13257,,,1,CHEMBL629195,,,,U,0,,
14327,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (v)/muscle,Autocuration,,,A,,BAO_0000218,13257,,,1,CHEMBL629373,,,,U,0,2385.0,
14328,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in spleen,Autocuration,,,A,,BAO_0000218,13257,,,1,CHEMBL629374,,,,U,0,2106.0,
14329,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked)i n prostate (d)/biood,Autocuration,,,A,,BAO_0000218,13257,,,1,CHEMBL629375,,,,U,0,2367.0,
14330,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in bladder,Autocuration,,,A,,BAO_0000218,13257,,,1,CHEMBL629376,,,,U,0,1255.0,
14331,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in blood,Autocuration,,,A,,BAO_0000218,13257,,,1,CHEMBL629377,,,,U,0,178.0,
14332,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in bone,Autocuration,,,A,,BAO_0000218,13257,,,1,CHEMBL629378,,,,U,0,1474.0,
14333,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in fat,Autocuration,,,A,,BAO_0000218,13257,,,1,CHEMBL629379,,,,U,0,,
14334,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in kidney,Autocuration,,,A,,BAO_0000218,13257,,,1,CHEMBL629151,,,,U,0,2113.0,
14335,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in liver,Autocuration,,,A,,BAO_0000218,13257,,,1,CHEMBL629152,,,,U,0,2107.0,
14336,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in lung,Autocuration,,,A,,BAO_0000218,13257,,,1,CHEMBL629153,,,,U,0,2048.0,
14337,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in muscle,Autocuration,,,A,,BAO_0000218,13257,,,1,CHEMBL629154,,,,U,0,2385.0,
14338,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (d),Autocuration,,,A,,BAO_0000218,13257,,,1,CHEMBL629155,,,,U,0,2367.0,
14339,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (d)/biood,Autocuration,,,A,,BAO_0000218,13257,,,1,CHEMBL629156,,,,U,0,2367.0,
14340,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (d)/muscle,Autocuration,,,A,,BAO_0000218,13257,,,1,CHEMBL629157,,,,U,0,2385.0,
14341,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (v),Autocuration,,,A,,BAO_0000218,13257,,,1,CHEMBL629158,,,,U,0,2367.0,
14342,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (v)/blood,Autocuration,,,A,,BAO_0000218,13257,,,1,CHEMBL629159,,,,U,0,,
14343,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (v)/muscle,Autocuration,,,A,,BAO_0000218,13257,,,1,CHEMBL629160,,,,U,0,2385.0,
14344,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in spleen,Autocuration,,,A,,BAO_0000218,13257,,,1,CHEMBL629161,,,,U,0,2106.0,
14345,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in bladder,Autocuration,,,A,,BAO_0000218,13257,,,1,CHEMBL629162,,,,U,0,1255.0,
14346,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in blood,Autocuration,,,A,,BAO_0000218,13257,,,1,CHEMBL629163,,,,U,0,178.0,
14347,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in bone,Autocuration,,,A,,BAO_0000218,13257,,,1,CHEMBL629164,,,,U,0,1474.0,
14348,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in fat,Autocuration,,,A,,BAO_0000218,13257,,,1,CHEMBL629165,,,,U,0,,
14349,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in liver,Autocuration,,,A,,BAO_0000218,13257,,,1,CHEMBL629166,,,,U,0,2107.0,
14350,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in lung,Autocuration,,,A,,BAO_0000218,13257,,,1,CHEMBL629167,,,,U,0,2048.0,
14351,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in muscle,Autocuration,,,A,,BAO_0000218,13257,,,1,CHEMBL629168,,,,U,0,2385.0,
14352,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 100 uM,Autocuration,,,A,,BAO_0000019,2193,,,1,CHEMBL629169,,,,U,0,,
14353,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 100 uM; no inhibition is observed at this concentration,Autocuration,,,A,,BAO_0000019,2193,,,1,CHEMBL629170,,,,U,0,,
14354,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 10 uM,Autocuration,,,A,,BAO_0000019,2193,,,1,CHEMBL631153,,,,U,0,,
14355,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 10 uM; too active and complete inhibition is observed,Autocuration,,,A,,BAO_0000019,2193,,,1,CHEMBL875121,,,,U,0,,
14356,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 1 uM,Autocuration,,,A,,BAO_0000019,2193,,,1,CHEMBL631154,,,,U,0,,
14357,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 1 uM; too active and complete inhibition is observed,Autocuration,,,A,,BAO_0000019,2193,,,1,CHEMBL631155,,,,U,0,,
14358,Hydrolysis rate constant was determined,Autocuration,,,A,,BAO_0000019,568,,,1,CHEMBL631156,,,,U,0,,
14359,"K2, The intrinsic biomolecular reactivation rate constant on VX at 25 degree Centigrade",Autocuration,,,A,,BAO_0000019,9680,,,1,CHEMBL631157,,,,U,0,,
14360,"K2, The intrinsic biomolecular reactivation rate constant on paraxon at 25 degree Centigrade",Autocuration,,,A,,BAO_0000019,9680,,,1,CHEMBL631158,,,,U,0,,
14361,"K2, The intrinsic biomolecular reactivation rate constant on sarin at 25 degree Centigrade",Autocuration,,,A,,BAO_0000019,9680,,,1,CHEMBL631159,,,,U,0,,
14362,Observed second order rate constant,Autocuration,,,A,,BAO_0000019,10026,,,1,CHEMBL631160,,,,U,0,,
14363,Rate constant (cyclization rate) in CD3CN-deuterated phosphate buffer at pH 7.4,Autocuration,,,A,,BAO_0000019,10281,,,1,CHEMBL631161,,,,U,0,,
14364,Rate constant for decay of compound was determined in 50 mM phosphate buffer (pH 7.4) at 24 degree celsius,Autocuration,,,A,,BAO_0000019,10014,,,1,CHEMBL631162,,,,U,0,,
14365,Rate constant for decay of compound was determined in 50 mM phosphate buffer (pH 7.4) at 37 degree celsius,Autocuration,,,A,,BAO_0000019,10014,,,1,CHEMBL630313,,,,U,0,,
14366,"k2, The intrinsic biomolecular reactivation rate constant on paraxon at 25 degree Centigrade",Autocuration,,,A,,BAO_0000019,9680,,,1,CHEMBL630314,,,,U,0,,
14367,"k2, The intrinsic biomolecular reactivation rate constant on sarin at 25 degree Centigrade",Autocuration,,,A,,BAO_0000019,9680,,,1,CHEMBL630315,,,,U,0,,
14368,Kinetic parameter of epimerization at a salt concentration (0.01 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,Autocuration,,,A,,BAO_0000019,13028,,,1,CHEMBL630316,,,,U,0,,
14369,Kinetic parameter of epimerization at a salt concentration (0.1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,Autocuration,,,A,,BAO_0000019,13028,,,1,CHEMBL630986,,,,U,0,,
14370,Kinetic parameter of epimerization at a salt concentration (1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,Autocuration,,,A,,BAO_0000019,13028,,,1,CHEMBL630987,,,,U,0,,
14371,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.0(or )in RMPI 1640 cell culture medium containing 10%FCS,Autocuration,,,A,,BAO_0000019,13028,,,1,CHEMBL630988,,,,U,0,,
14372,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,Autocuration,,,A,,BAO_0000019,13028,,,1,CHEMBL630989,,,,U,0,,
14373,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 11.3 (or )in RMPI 1640 cell culture medium containing 10%FCS,Autocuration,,,A,,BAO_0000019,13028,,,1,CHEMBL630990,,,,U,0,,
14374,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 7.5 (or )in RMPI 1640 cell culture medium containing 10%FCS,Autocuration,,,A,,BAO_0000019,13028,,,1,CHEMBL630991,,,,U,0,,
14375,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 8.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,Autocuration,,,A,,BAO_0000019,13028,,,1,CHEMBL630992,,,,U,0,,
14376,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,Autocuration,,,A,,BAO_0000019,13028,,,1,CHEMBL630993,,,,U,0,,
14377,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,Autocuration,,,A,,BAO_0000019,13028,,,1,CHEMBL630994,,,,U,0,,
14378,Rate constants of compound was determined at muscarinic receptor in the rat cerebral cortex,Intermediate,10116.0,,A,,BAO_0000218,10014,,,1,CHEMBL630995,,,Rattus norvegicus,N,1,,
14379,Association constant for compound at 31 degree C was determined,Autocuration,,,A,,BAO_0000019,9962,,,1,CHEMBL629252,,,,U,0,,
14380,Calculated antagonist equilibrium dissociation constant of the compound,Autocuration,,,A,,BAO_0000019,12029,,,1,CHEMBL629253,,,,U,0,,
14381,Calculated antagonist equilibrium dissociation constant of the compound; No statistically significant antagonism observed,Autocuration,,,A,,BAO_0000019,12029,,,1,CHEMBL629944,,,,U,0,,
14382,Dissociation constants vs LTE4 on guinea pig trachea,Intermediate,10141.0,,A,,BAO_0000218,10583,,,1,CHEMBL629945,,,Cavia porcellus,N,1,3126.0,
14383,"Tested for hydrolysis in presence of boric acid by UV spectrophotometry, dissociation constant was evaluated at the pH < 8",Autocuration,,,A,,BAO_0000019,568,,,1,CHEMBL629946,,,,U,0,,
14384,"Tested for hydrolysis in presence of boric acid, rate constant was evaluated at the pH 8.5",Autocuration,,,A,,BAO_0000019,568,,,1,CHEMBL629947,,,,U,0,,
14385,"Tested for hydrolysis in presence of boric acid, rate constant was evaluated at the pH 9.5",Autocuration,,,A,,BAO_0000019,568,,,1,CHEMBL629948,,,,U,0,,
14386,"Tested for hydrolysis in presence of phenylboronic acid, rate constant was evaluated at the pH 9.5",Autocuration,,,A,,BAO_0000019,568,,,1,CHEMBL856024,,,,U,0,,
14387,Affinity constant KD value was derived from TMP,Autocuration,,,A,,BAO_0000019,7493,,,1,CHEMBL629949,,,,U,0,,
14388,Apparent dissociation (binding) rate constant was evaluated,Autocuration,,,A,,BAO_0000019,8371,,,1,CHEMBL629950,,,,U,0,,
14389,Dissociation constant (KD) of the compound,Autocuration,,,P,,BAO_0000100,13114,,,1,CHEMBL630127,,,,U,0,,
14390,Dissociation constant determined by heteronuclear 1H/15N correlation NMR spectroscopy,Autocuration,,,P,,BAO_0000100,15515,,,1,CHEMBL630128,,,,U,0,,
14391,Dissociation constant from ESR titration experiments,Autocuration,,,P,,BAO_0000100,522,,,1,CHEMBL630129,,,,U,0,,
14392,Dissociation constant was evaluated which is similar to Ki (inhibitory constant),Autocuration,,,,,BAO_0000019,13888,,,1,CHEMBL630130,,,,U,0,,
14393,Dissociation constant was evaluated.,Autocuration,,,P,,BAO_0000100,2616,,,1,CHEMBL875234,,,,U,0,,
14394,Dissociation constant was reported,Autocuration,,,P,,BAO_0000100,3798,,,1,CHEMBL630131,,,,U,0,,
14395,Dissociation constant was determined in rat pituitary cells.,Intermediate,10116.0,,A,,BAO_0000218,8731,,,1,CHEMBL630132,,,Rattus norvegicus,N,1,,
14396,Equilibrium dissociation constant of CA complex for enantiomer 1 of compound,Autocuration,,,A,,BAO_0000019,11892,,,1,CHEMBL630133,,,,U,0,,
14397,Equilibrium dissociation constant of CA complex for enantiomer 2 of compound,Autocuration,,,A,,BAO_0000019,11892,,,1,CHEMBL630134,,,,U,0,,
14398,Equilibrium dissociation constant of the compound,Autocuration,,,A,,BAO_0000019,2582,,,1,CHEMBL630135,,,,U,0,,
14399,Equilibrium dissociation constant was determined,Autocuration,,,A,,BAO_0000019,11892,,,1,CHEMBL630136,,,,U,0,,
14400,Kinetic constant KD was evaluated,Autocuration,,,A,,BAO_0000019,13396,,,1,CHEMBL630137,,,,U,0,,
14401,Tested for dissociation constant of the compound; Value ranges from 0.1-0.3,Autocuration,,,A,,BAO_0000019,603,,,1,CHEMBL630138,,,,U,0,,
14402,Equilibrium association constant interacting with unilamellar vesicles of electroneutral in PBS buffer at pH 7.4,Autocuration,,,A,,BAO_0000019,15673,,,1,CHEMBL630139,,,,U,0,,
14403,Rate constant for hydrolysis in aqueous acetone.,Autocuration,,,A,,BAO_0000019,10368,,,1,CHEMBL630140,,,,U,0,,
14404,Disassociation constant (KI) was obtained from Cheng and Prusoff equation for quercetin trypsin complex,Autocuration,,,A,,BAO_0000019,14228,,,1,CHEMBL875235,,,,U,0,,
14405,Mean sodium excretion in rats (Control/Drug treatment value); value 0.43/2.86,Intermediate,10116.0,,A,,BAO_0000218,11510,,,1,CHEMBL876439,,,Rattus norvegicus,N,1,,
14406,Mean sodium excretion in rats (Control/Drug treatment value); value 0.44/2.68,Intermediate,10116.0,,A,,BAO_0000218,11510,,,1,CHEMBL630605,,,Rattus norvegicus,N,1,,
14407,Mean sodium excretion in rats (Control/Drug treatment value); value 0.45/1.55,Intermediate,10116.0,,A,,BAO_0000218,11510,,,1,CHEMBL630606,,,Rattus norvegicus,N,1,,
14408,Mean sodium excretion in rats (Control/Drug treatment value); value 0.48/0.95,Intermediate,10116.0,,A,,BAO_0000218,11510,,,1,CHEMBL630607,,,Rattus norvegicus,N,1,,
14409,Mean sodium excretion in rats (Control/Drug treatment value); value 0.5/1.79,Intermediate,10116.0,,A,,BAO_0000218,11510,,,1,CHEMBL630608,,,Rattus norvegicus,N,1,,
14410,Mean sodium excretion in rats (Control/Drug treatment value); value 0.51/0.66,Intermediate,10116.0,,A,,BAO_0000218,11510,,,1,CHEMBL630609,,,Rattus norvegicus,N,1,,
14411,Mean sodium excretion in rats (Control/Drug treatment value); value 0.52/2.02,Intermediate,10116.0,,A,,BAO_0000218,11510,,,1,CHEMBL630610,,,Rattus norvegicus,N,1,,
14412,Mean sodium excretion in rats (Control/Drug treatment value); value 0.61//0.37,Intermediate,10116.0,,A,,BAO_0000218,11510,,,1,CHEMBL630611,,,Rattus norvegicus,N,1,,
14413,Mean sodium excretion in rats (Control/Drug treatment value); value 0.71/0.36,Intermediate,10116.0,,A,,BAO_0000218,11510,,,1,CHEMBL629552,,,Rattus norvegicus,N,1,,
14414,Mean sodium excretion in rats when compound administered at 0 mg/kg po and vehicle dosed at 0 umol/kg,Intermediate,10116.0,,A,,BAO_0000218,11510,,,1,CHEMBL629733,,,Rattus norvegicus,N,1,,
14415,Mean sodium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 30.23 umol/kg,Intermediate,10116.0,,A,,BAO_0000218,11510,,,1,CHEMBL629734,,,Rattus norvegicus,N,1,,
14416,Mean sodium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 33.59 umol/kg,Intermediate,10116.0,,A,,BAO_0000218,11510,,,1,CHEMBL629735,,,Rattus norvegicus,N,1,,
14417,Mean sodium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 37.13 umol/kg,Intermediate,10116.0,,A,,BAO_0000218,11510,,,1,CHEMBL629736,,,Rattus norvegicus,N,1,,
14418,Mean sodium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 39.48 umol/kg,Intermediate,10116.0,,A,,BAO_0000218,11510,,,1,CHEMBL629737,,,Rattus norvegicus,N,1,,
14419,Mean sodium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 483.72 umol/kg,Intermediate,10116.0,,A,,BAO_0000218,11510,,,1,CHEMBL629738,,,Rattus norvegicus,N,1,,
14420,Mean sodium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg,Intermediate,10116.0,,A,,BAO_0000218,11510,,,1,CHEMBL629739,,,Rattus norvegicus,N,1,,
14421,Mean sodium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg; Not determined,Intermediate,10116.0,,A,,BAO_0000218,11510,,,1,CHEMBL629740,,,Rattus norvegicus,N,1,,
14422,Mean sodium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 631.76 umol/kg,Intermediate,10116.0,,A,,BAO_0000218,11510,,,1,CHEMBL629741,,,Rattus norvegicus,N,1,,
14423,Mean sodium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 7.56 umol/kg,Intermediate,10116.0,,A,,BAO_0000218,11510,,,1,CHEMBL629742,,,Rattus norvegicus,N,1,,
14424,Mean sodium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 8.4 umol/kg,Intermediate,10116.0,,A,,BAO_0000218,11510,,,1,CHEMBL629743,,,Rattus norvegicus,N,1,,
14425,Mean sodium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.28 umol/kg,Intermediate,10116.0,,A,,BAO_0000218,11510,,,1,CHEMBL629744,,,Rattus norvegicus,N,1,,
14426,Mean sodium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.87 umol/kg,Intermediate,10116.0,,A,,BAO_0000218,11510,,,1,CHEMBL629745,,,Rattus norvegicus,N,1,,
14427,Mean sodium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 60.46 umol/kg,Intermediate,10116.0,,A,,BAO_0000218,11510,,,1,CHEMBL629746,,,Rattus norvegicus,N,1,,
14428,Mean sodium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 67.18 umol/kg,Intermediate,10116.0,,A,,BAO_0000218,11510,,,1,CHEMBL629747,,,Rattus norvegicus,N,1,,
14429,Mean sodium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 74.26 umol/kg,Intermediate,10116.0,,A,,BAO_0000218,11510,,,1,CHEMBL629748,,,Rattus norvegicus,N,1,,
14430,Mean sodium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 78.97 umol/kg,Intermediate,10116.0,,A,,BAO_0000218,11510,,,1,CHEMBL629749,,,Rattus norvegicus,N,1,,
14431,Mean sodium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 120.93 umol/kg,Intermediate,10116.0,,A,,BAO_0000218,11510,,,1,CHEMBL629750,,,Rattus norvegicus,N,1,,
14432,Mean sodium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 134.35 umol/kg,Intermediate,10116.0,,A,,BAO_0000218,11510,,,1,CHEMBL629751,,,Rattus norvegicus,N,1,,
14433,Mean sodium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 148.52 umol/kg,Intermediate,10116.0,,A,,BAO_0000218,11510,,,1,CHEMBL629752,,,Rattus norvegicus,N,1,,
14434,Mean sodium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 157.94 umol/kg,Intermediate,10116.0,,A,,BAO_0000218,11510,,,1,CHEMBL629753,,,Rattus norvegicus,N,1,,
14435,Mean sodium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 15.12 umol/kg,Intermediate,10116.0,,A,,BAO_0000218,11510,,,1,CHEMBL629754,,,Rattus norvegicus,N,1,,
14436,Mean sodium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 16.79 umol/kg,Intermediate,10116.0,,A,,BAO_0000218,11510,,,1,CHEMBL629755,,,Rattus norvegicus,N,1,,
14437,Mean sodium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 18.56 umol/kg,Intermediate,10116.0,,A,,BAO_0000218,11510,,,1,CHEMBL629756,,,Rattus norvegicus,N,1,,
14438,Mean sodium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 19.74 umol/kg,Intermediate,10116.0,,A,,BAO_0000218,11510,,,1,CHEMBL629757,,,Rattus norvegicus,N,1,,
14439,Mean sodium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 241.86 umol/kg,Intermediate,10116.0,,A,,BAO_0000218,11510,,,1,CHEMBL629758,,,Rattus norvegicus,N,1,,
14440,Mean sodium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 268.71 umol/kg,Intermediate,10116.0,,A,,BAO_0000218,11510,,,1,CHEMBL629759,,,Rattus norvegicus,N,1,,
14441,Mean sodium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 297.03 umol/kg,Intermediate,10116.0,,A,,BAO_0000218,11510,,,1,CHEMBL629760,,,Rattus norvegicus,N,1,,
14442,Mean sodium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 315.88 umol/kg,Intermediate,10116.0,,A,,BAO_0000218,11510,,,1,CHEMBL876443,,,Rattus norvegicus,N,1,,
14443,Na+ excretion mequiv /kg in 6 conscious female dogs administered perorally during 0-6 hr,Intermediate,9615.0,,A,,BAO_0000218,8310,,,1,CHEMBL629761,,,Canis lupus familiaris,N,1,,
14444,Na+ excretion mequiv /kg in conscious female dogs administered perorally during 0-6 hr,Intermediate,9615.0,,A,,BAO_0000218,8310,,,1,CHEMBL629762,,,Canis lupus familiaris,N,1,,
14445,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 10 ml/kg perorally,Intermediate,10090.0,,A,,BAO_0000218,8310,,,1,CHEMBL629763,,,Mus musculus,N,1,,
14446,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 2 ml/kg perorally,Intermediate,10090.0,,A,,BAO_0000218,8310,,,1,CHEMBL629764,,,Mus musculus,N,1,,
14447,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 2 ml/kg perorally,Intermediate,10090.0,,A,,BAO_0000218,8310,,,1,CHEMBL629765,,,Mus musculus,N,1,,
14448,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 50 ml/kg perorally,Intermediate,10090.0,,A,,BAO_0000218,8310,,,1,CHEMBL629766,,,Mus musculus,N,1,,
14449,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 10 ml/kg perorally,Intermediate,10090.0,,A,,BAO_0000218,8310,,,1,CHEMBL629767,,,Mus musculus,N,1,,
14450,Na+ excretion mequiv/kg in 4 conscious female dogs administered perorally during 0-6 hr,Intermediate,9615.0,,A,,BAO_0000218,8310,,,1,CHEMBL629768,,,Canis lupus familiaris,N,1,,
14451,Na+ excretion mequiv/kg in 4 saline-loaded mice administered at a dose 50 ml/kg perorally,Intermediate,10090.0,,A,,BAO_0000218,8310,,,1,CHEMBL629769,,,Mus musculus,N,1,,
14452,Na+ excretion mequiv/kg in 6 conscious female dogs administered perorally during 0-6 hr,Intermediate,9615.0,,A,,BAO_0000218,8310,,,1,CHEMBL629770,,,Canis lupus familiaris,N,1,,
14453,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 0.3 ml/kg perorally,Intermediate,9615.0,,A,,BAO_0000218,8310,,,1,CHEMBL629771,,,Canis lupus familiaris,N,1,,
14454,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 10 ml/kg perorally,Intermediate,10090.0,,A,,BAO_0000218,8310,,,1,CHEMBL629772,,,Mus musculus,N,1,,
14455,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 10 ml/kg perorally,Intermediate,10090.0,,A,,BAO_0000218,8310,,,1,CHEMBL629773,,,Mus musculus,N,1,,
14456,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 2 ml/kg perorally,Intermediate,10090.0,,A,,BAO_0000218,8310,,,1,CHEMBL625455,,,Mus musculus,N,1,,
14457,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 250 ml/kg perorally,Intermediate,10090.0,,A,,BAO_0000218,8310,,,1,CHEMBL625456,,,Mus musculus,N,1,,
14458,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 3 ml/kg perorally,Intermediate,10090.0,,A,,BAO_0000218,8310,,,1,CHEMBL625457,,,Mus musculus,N,1,,
14459,Total electrolytic excretion of potassium in urine of rats after peroral administration of 25.9 uM/Kg of drug,Intermediate,10116.0,,A,,BAO_0000218,12582,,,1,CHEMBL625458,,,Rattus norvegicus,N,1,1088.0,
14460,Total electrolytic excretion of potassium in urine of rats after peroral administration of 259 uM/Kg of drug,Intermediate,10116.0,,A,,BAO_0000218,12582,,,1,CHEMBL625459,,,Rattus norvegicus,N,1,1088.0,
14461,Total electrolytic excretion of potassium in urine of rats after peroral administration of 26.5 uM/Kg of drug,Intermediate,10116.0,,A,,BAO_0000218,12582,,,1,CHEMBL875483,,,Rattus norvegicus,N,1,1088.0,
14462,Total electrolytic excretion of potassium in urine of rats after peroral administration of 265 uM/Kg of drug,Intermediate,10116.0,,A,,BAO_0000218,12582,,,1,CHEMBL634779,,,Rattus norvegicus,N,1,1088.0,
14463,Total electrolytic excretion of potassium in urine of rats after peroral administration of 27 uM/Kg of drug,Intermediate,10116.0,,A,,BAO_0000218,12582,,,1,CHEMBL625460,,,Rattus norvegicus,N,1,1088.0,
14464,Total electrolytic excretion of potassium in urine of rats after peroral administration of 27.9 uM/Kg of drug,Intermediate,10116.0,,A,,BAO_0000218,12582,,,1,CHEMBL626117,,,Rattus norvegicus,N,1,1088.0,
14465,Total electrolytic excretion of potassium in urine of rats after peroral administration of 270 uM/Kg of drug,Intermediate,10116.0,,A,,BAO_0000218,12582,,,1,CHEMBL626118,,,Rattus norvegicus,N,1,1088.0,
14466,Total electrolytic excretion of potassium in urine of rats after peroral administration of 279 uM/Kg of drug,Intermediate,10116.0,,A,,BAO_0000218,12582,,,1,CHEMBL628342,,,Rattus norvegicus,N,1,1088.0,
14467,Total electrolytic excretion of potassium in urine of rats after peroral administration of 28.2 uM/Kg of drug,Intermediate,10116.0,,A,,BAO_0000218,12582,,,1,CHEMBL628343,,,Rattus norvegicus,N,1,1088.0,
14468,Total electrolytic excretion of potassium in urine of rats after peroral administration of 28.22 uM/Kg of drug,Intermediate,10116.0,,A,,BAO_0000218,12582,,,1,CHEMBL628344,,,Rattus norvegicus,N,1,1088.0,
14469,Total electrolytic excretion of potassium in urine of rats after peroral administration of 28.9 uM/Kg of drug,Intermediate,10116.0,,A,,BAO_0000218,12582,,,1,CHEMBL628345,,,Rattus norvegicus,N,1,1088.0,
14470,Total electrolytic excretion of potassium in urine of rats after peroral administration of 282 uM/Kg of drug,Intermediate,10116.0,,A,,BAO_0000218,12582,,,1,CHEMBL628346,,,Rattus norvegicus,N,1,1088.0,
14471,Total electrolytic excretion of potassium in urine of rats after peroral administration of 289 uM/Kg of drug,Intermediate,10116.0,,A,,BAO_0000218,12582,,,1,CHEMBL628347,,,Rattus norvegicus,N,1,1088.0,
14472,Total electrolytic excretion of potassium in urine of rats after peroral administration of 3.40 uM/Kg of drug,Intermediate,10116.0,,A,,BAO_0000218,12582,,,1,CHEMBL628348,,,Rattus norvegicus,N,1,1088.0,
14473,Total electrolytic excretion of potassium in urine of rats after peroral administration of 3.76 uM/Kg of drug,Intermediate,10116.0,,A,,BAO_0000218,12582,,,1,CHEMBL628349,,,Rattus norvegicus,N,1,1088.0,
14474,Total electrolytic excretion of potassium in urine of rats after peroral administration of 30.2 uM/Kg of drug,Intermediate,10116.0,,A,,BAO_0000218,12582,,,1,CHEMBL875611,,,Rattus norvegicus,N,1,1088.0,
14475,Total electrolytic excretion of potassium in urine of rats after peroral administration of 302 uM/Kg of drug,Intermediate,10116.0,,A,,BAO_0000218,12582,,,1,CHEMBL628350,,,Rattus norvegicus,N,1,1088.0,
14476,Total electrolytic excretion of potassium in urine of rats after peroral administration of 31.6 uM/Kg of drug,Intermediate,10116.0,,A,,BAO_0000218,12582,,,1,CHEMBL628351,,,Rattus norvegicus,N,1,1088.0,
14477,Total electrolytic excretion of potassium in urine of rats after peroral administration of 316 uM/Kg of drug,Intermediate,10116.0,,A,,BAO_0000218,12582,,,1,CHEMBL628352,,,Rattus norvegicus,N,1,1088.0,
14478,Total electrolytic excretion of potassium in urine of rats after peroral administration of 32.4 uM/Kg of drug,Intermediate,10116.0,,A,,BAO_0000218,12582,,,1,CHEMBL628353,,,Rattus norvegicus,N,1,1088.0,
14479,Total electrolytic excretion of potassium in urine of rats after peroral administration of 324 uM/Kg of drug,Intermediate,10116.0,,A,,BAO_0000218,12582,,,1,CHEMBL628354,,,Rattus norvegicus,N,1,1088.0,
14480,Total electrolytic excretion of potassium in urine of rats after peroral administration of 34.0 uM/Kg of drug,Intermediate,10116.0,,A,,BAO_0000218,12582,,,1,CHEMBL626667,,,Rattus norvegicus,N,1,1088.0,
14481,Total electrolytic excretion of potassium in urine of rats after peroral administration of 34.1 uM/Kg of drug,Intermediate,10116.0,,A,,BAO_0000218,12582,,,1,CHEMBL626668,,,Rattus norvegicus,N,1,1088.0,
14482,Total electrolytic excretion of potassium in urine of rats after peroral administration of 34.8 uM/Kg of drug,Intermediate,10116.0,,A,,BAO_0000218,12582,,,1,CHEMBL626669,,,Rattus norvegicus,N,1,1088.0,
14483,Total electrolytic excretion of potassium in urine of rats after peroral administration of 341 uM/Kg of drug,Intermediate,10116.0,,A,,BAO_0000218,12582,,,1,CHEMBL626670,,,Rattus norvegicus,N,1,1088.0,
14484,Total electrolytic excretion of potassium in urine of rats after peroral administration of 348 uM/Kg of drug,Intermediate,10116.0,,A,,BAO_0000218,12582,,,1,CHEMBL626671,,,Rattus norvegicus,N,1,1088.0,
14485,Total electrolytic excretion of potassium in urine of rats after peroral administration of 37.6 uM/Kg of drug,Intermediate,10116.0,,A,,BAO_0000218,12582,,,1,CHEMBL626672,,,Rattus norvegicus,N,1,1088.0,
14486,Total electrolytic excretion of potassium in urine of rats after peroral administration of 50.8 uM/Kg of drug,Intermediate,10116.0,,A,,BAO_0000218,12582,,,1,CHEMBL626673,,,Rattus norvegicus,N,1,1088.0,
14487,Total electrolytic excretion of potassium in urine of rats after peroral administration of 58.4 uM/Kg of drug,Intermediate,10116.0,,A,,BAO_0000218,12582,,,1,CHEMBL626674,,,Rattus norvegicus,N,1,1088.0,
14488,Total electrolytic excretion of potassium in urine of rats after peroral administration of 65.2 uM/Kg of drug,Intermediate,10116.0,,A,,BAO_0000218,12582,,,1,CHEMBL626675,,,Rattus norvegicus,N,1,1088.0,
14489,Total electrolytic excretion of potassium in urine of rats after peroral administration of 68.1 uM/Kg of drug,Intermediate,10116.0,,A,,BAO_0000218,12582,,,1,CHEMBL626676,,,Rattus norvegicus,N,1,1088.0,
14490,Total electrolytic excretion of potassium in urine of rats after peroral administration of 7.94 uM/Kg of drug,Intermediate,10116.0,,A,,BAO_0000218,12582,,,1,CHEMBL626677,,,Rattus norvegicus,N,1,1088.0,
14491,Total electrolytic excretion of potassium in urine of rats after peroral administration of 71.6 uM/Kg of drug,Intermediate,10116.0,,A,,BAO_0000218,12582,,,1,CHEMBL626678,,,Rattus norvegicus,N,1,1088.0,
14492,Total electrolytic excretion of potassium in urine of rats after peroral administration of 71.8 uM/Kg of drug,Intermediate,10116.0,,A,,BAO_0000218,12582,,,1,CHEMBL626679,,,Rattus norvegicus,N,1,1088.0,
14493,Total electrolytic excretion of potassium in urine of rats after peroral administration of 74.8 uM/Kg of drug,Intermediate,10116.0,,A,,BAO_0000218,12582,,,1,CHEMBL875612,,,Rattus norvegicus,N,1,1088.0,
14494,Total electrolytic excretion of potassium in urine of rats after peroral administration of 77.5 uM/Kg of drug,Intermediate,10116.0,,A,,BAO_0000218,12582,,,1,CHEMBL626680,,,Rattus norvegicus,N,1,1088.0,
14495,Total electrolytic excretion of potassium in urine of rats after peroral administration of 79.4 uM/Kg of drug,Intermediate,10116.0,,A,,BAO_0000218,12582,,,1,CHEMBL626681,,,Rattus norvegicus,N,1,1088.0,
14496,Total electrolytic excretion of potassium in urine of rats after peroral administration of 80.9 uM/Kg of drug,Intermediate,10116.0,,A,,BAO_0000218,12582,,,1,CHEMBL626682,,,Rattus norvegicus,N,1,1088.0,
14497,Total electrolytic excretion of potassium in urine of rats after peroral administration of 83.8 uM/Kg of drug,Intermediate,10116.0,,A,,BAO_0000218,12582,,,1,CHEMBL626683,,,Rattus norvegicus,N,1,1088.0,
14498,Total electrolytic excretion of potassium in urine of rats after peroral administration of 84.5 uM/Kg of drug,Intermediate,10116.0,,A,,BAO_0000218,12582,,,1,CHEMBL626684,,,Rattus norvegicus,N,1,1088.0,
14499,Total electrolytic excretion of potassium in urine of rats after peroral administration of 84.7 uM/Kg of drug,Intermediate,10116.0,,A,,BAO_0000218,12582,,,1,CHEMBL626685,,,Rattus norvegicus,N,1,1088.0,
14500,Total electrolytic excretion of potassium in urine of rats after peroral administration of 86.7 uM/Kg of drug,Intermediate,10116.0,,A,,BAO_0000218,12582,,,1,CHEMBL626686,,,Rattus norvegicus,N,1,1088.0,
14501,Total electrolytic excretion of potassium in urine of rats after peroral administration of 86.9 uM/Kg of drug,Intermediate,10116.0,,A,,BAO_0000218,12582,,,1,CHEMBL626687,,,Rattus norvegicus,N,1,1088.0,
14502,Total electrolytic excretion of potassium in urine of rats after peroral administration of 9.06 uM/Kg of drug,Intermediate,10116.0,,A,,BAO_0000218,12582,,,1,CHEMBL624978,,,Rattus norvegicus,N,1,1088.0,
14503,Total electrolytic excretion of potassium in urine of rats after peroral administration of 90.6 uM/Kg of drug,Intermediate,10116.0,,A,,BAO_0000218,12582,,,1,CHEMBL624979,,,Rattus norvegicus,N,1,1088.0,
14504,Total electrolytic excretion of potassium in urine of rats after peroral administration of 94.9 uM/Kg of drug,Intermediate,10116.0,,A,,BAO_0000218,12582,,,1,CHEMBL624980,,,Rattus norvegicus,N,1,1088.0,
14505,Total electrolytic excretion of potassium in urine of rats after peroral administration of 97.1 uM/Kg of drug,Intermediate,10116.0,,A,,BAO_0000218,12582,,,1,CHEMBL624981,,,Rattus norvegicus,N,1,1088.0,
14506,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 52.4 uM/Kg of drug,Intermediate,9615.0,,A,,BAO_0000218,12582,,,1,CHEMBL624982,,,Canis lupus familiaris,N,1,1088.0,
14507,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (d),Autocuration,,,A,,BAO_0000218,13257,,,1,CHEMBL627564,,,,U,0,2367.0,
14508,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (v),Autocuration,,,A,,BAO_0000218,13257,,,1,CHEMBL627565,,,,U,0,2367.0,
14509,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (v)/blood,Autocuration,,,A,,BAO_0000218,13257,,,1,CHEMBL627566,,,,U,0,,
14510,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (v)/muscle,Autocuration,,,A,,BAO_0000218,13257,,,1,CHEMBL627567,,,,U,0,2385.0,
14511,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in spleen,Autocuration,,,A,,BAO_0000218,13257,,,1,CHEMBL627568,,,,U,0,2106.0,
14512,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hr in kidney,Autocuration,,,A,,BAO_0000218,13257,,,1,CHEMBL627569,,,,U,0,2113.0,
14513,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in bladder,Autocuration,,,A,,BAO_0000218,13257,,,1,CHEMBL627570,,,,U,0,1255.0,
14514,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in blood,Autocuration,,,A,,BAO_0000218,13257,,,1,CHEMBL627571,,,,U,0,178.0,
14515,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in bone,Autocuration,,,A,,BAO_0000218,13257,,,1,CHEMBL627572,,,,U,0,1474.0,
14516,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in fat,Autocuration,,,A,,BAO_0000218,13257,,,1,CHEMBL627573,,,,U,0,,
14517,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in kidney,Autocuration,,,A,,BAO_0000218,13257,,,1,CHEMBL627574,,,,U,0,2113.0,
14518,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in liver,Autocuration,,,A,,BAO_0000218,13257,,,1,CHEMBL627575,,,,U,0,2107.0,
14519,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in lung,Autocuration,,,A,,BAO_0000218,13257,,,1,CHEMBL627576,,,,U,0,2048.0,
14520,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in muscle,Autocuration,,,A,,BAO_0000218,13257,,,1,CHEMBL627577,,,,U,0,2385.0,
14521,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (d),Autocuration,,,A,,BAO_0000218,13257,,,1,CHEMBL627578,,,,U,0,2367.0,
14522,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (d)/biood,Autocuration,,,A,,BAO_0000218,13257,,,1,CHEMBL627579,,,,U,0,2367.0,
14523,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (d)/muscle,Autocuration,,,A,,BAO_0000218,13257,,,1,CHEMBL627580,,,,U,0,2385.0,
14524,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (v),Autocuration,,,A,,BAO_0000218,13257,,,1,CHEMBL627581,,,,U,0,2367.0,
14525,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (v)/blood,Autocuration,,,A,,BAO_0000218,13257,,,1,CHEMBL627582,,,,U,0,,
14526,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (v)/muscle,Autocuration,,,A,,BAO_0000218,13257,,,1,CHEMBL627583,,,,U,0,2385.0,
14527,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in spleen,Autocuration,,,A,,BAO_0000218,13257,,,1,CHEMBL627584,,,,U,0,2106.0,
14528,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (d)/biood,Autocuration,,,A,,BAO_0000218,13257,,,1,CHEMBL627585,,,,U,0,2367.0,
14529,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (d)/muscle,Autocuration,,,A,,BAO_0000218,13257,,,1,CHEMBL627586,,,,U,0,2385.0,
14530,Biodistribution of the Radiolabeled FBWAY compound in rat Cerebellum at 30 min co-injected with 200 nmol of WAY 100635,Intermediate,10116.0,,A,,BAO_0000218,15413,,,1,CHEMBL627587,,,Rattus norvegicus,N,1,,
14531,Biodistribution of the Radiolabeled FBWAY compound in rat Cerebellum at 30 min co-injected with 50 nmol of WAY 100635,Intermediate,10116.0,,A,,BAO_0000218,15413,,,1,CHEMBL627588,,,Rattus norvegicus,N,1,,
14532,Biodistribution of the Radiolabeled FBWAY compound in rat cortex at 30 min co-injected with 200 nmol of WAY 100635,Intermediate,10116.0,,A,,BAO_0000218,15413,,,1,CHEMBL628250,,,Rattus norvegicus,N,1,,
14533,Biodistribution of the Radiolabeled FBWAY compound in rat cortex at 30 min co-injected with 50 nmol of WAY 100635,Intermediate,10116.0,,A,,BAO_0000218,15413,,,1,CHEMBL628251,,,Rattus norvegicus,N,1,,
14534,Biodistribution of the Radiolabeled FBWAY compound in rat hippocampus at 30 min co-injected with 200 nmol of WAY 100635,Intermediate,10116.0,,A,,BAO_0000218,15413,,,1,CHEMBL628252,,,Rattus norvegicus,N,1,10000000.0,
14535,Biodistribution of the Radiolabeled FBWAY compound in rat hippocampus at 30 min co-injected with 50 nmol of WAY 100635,Intermediate,10116.0,,A,,BAO_0000218,15413,,,1,CHEMBL628253,,,Rattus norvegicus,N,1,10000000.0,
14536,Biodistribution of the Radiolabeled FBWAY compound in rat hypothalamus at 30 min co-injected with 200 nmol of WAY 100635,Intermediate,10116.0,,A,,BAO_0000218,15413,,,1,CHEMBL628254,,,Rattus norvegicus,N,1,1898.0,
14537,Biodistribution of the Radiolabeled FBWAY compound in rat hypothalamus at 30 min co-injected with 50 nmol of WAY 100635,Intermediate,10116.0,,A,,BAO_0000218,15413,,,1,CHEMBL877493,,,Rattus norvegicus,N,1,1898.0,
14538,Biodistribution of the Radiolabeled FCWAY compound in rat Cerebellum at 30 min co-injected with 50 nmol of WAY 100635,Intermediate,10116.0,,A,,BAO_0000218,15413,,,1,CHEMBL628255,,,Rattus norvegicus,N,1,,
14539,Biodistribution of the Radiolabeled FCWAY compound in rat cortex at 30 min co-injected with 50 nmol of WAY 100635,Intermediate,10116.0,,A,,BAO_0000218,15413,,,1,CHEMBL628256,,,Rattus norvegicus,N,1,,
14540,Biodistribution of the Radiolabeled FCWAY compound in rat hippocampus at 30 min co-injected with 50 nmol of WAY 100635,Intermediate,10116.0,,A,,BAO_0000218,15413,,,1,CHEMBL628257,,,Rattus norvegicus,N,1,10000000.0,
14541,Biodistribution of the Radiolabeled FCWAY compound in rat hypothalamus at 30 min co-injected with 50 nmol of WAY 100635,Intermediate,10116.0,,A,,BAO_0000218,15413,,,1,CHEMBL628258,,,Rattus norvegicus,N,1,1898.0,
14542,Biodistribution of the Radiolabeled MeFBWAY compound in rat Cerebellum at 30 min co-injected with 50 nmol of WAY 100635,Intermediate,10116.0,,A,,BAO_0000218,15413,,,1,CHEMBL628259,,,Rattus norvegicus,N,1,,
14543,Biodistribution of the Radiolabeled MeFBWAY compound in rat cortex at 30 min co-injected with 50 nmol of WAY 100635,Intermediate,10116.0,,A,,BAO_0000218,15413,,,1,CHEMBL628429,,,Rattus norvegicus,N,1,,
14544,Biodistribution of the Radiolabeled MeFBWAY compound in rat hippocampus at 30 min co-injected with 50 nmol of WAY 100635,Intermediate,10116.0,,A,,BAO_0000218,15413,,,1,CHEMBL626862,,,Rattus norvegicus,N,1,10000000.0,
14545,Biodistribution of the Radiolabeled MeFBWAY compound in rat hypothalamus at 30 min co-injected with 50 nmol of WAY 100635; Not determined,Intermediate,10116.0,,A,,BAO_0000218,15413,,,1,CHEMBL626863,,,Rattus norvegicus,N,1,1898.0,
14546,Biodistribution of the [11C]-radiolabeled compound in rat cerebellum,Intermediate,10116.0,,A,,BAO_0000218,15413,,,1,CHEMBL625886,,,Rattus norvegicus,N,1,2037.0,
14547,Biodistribution of the [11C]-radiolabeled compound in rat cerebellum co-injected with 50 nM of WAY 100635.,Intermediate,10116.0,,A,,BAO_0000218,15413,,,1,CHEMBL625887,,,Rattus norvegicus,N,1,2037.0,
14548,Biodistribution of the [11C]-radiolabeled compound in rat cortex,Intermediate,10116.0,,A,,BAO_0000218,15413,,,1,CHEMBL625888,,,Rattus norvegicus,N,1,,
14549,Biodistribution of the [11C]-radiolabeled compound in rat cortex co-injected with 50 nM of WAY 100635.,Intermediate,10116.0,,A,,BAO_0000218,15413,,,1,CHEMBL625889,,,Rattus norvegicus,N,1,,
14550,Biodistribution of the [11C]-radiolabeled compound in rat hippocampus,Intermediate,10116.0,,A,,BAO_0000218,15413,,,1,CHEMBL625890,,,Rattus norvegicus,N,1,10000000.0,
14551,Biodistribution of the [11C]-radiolabeled compound in rat hippocampus co-injected with 50 nM of WAY 100635.,Intermediate,10116.0,,A,,BAO_0000218,15413,,,1,CHEMBL625891,,,Rattus norvegicus,N,1,10000000.0,
14552,Biodistribution of the [11C]-radiolabeled compound in rat hypothalamus,Intermediate,10116.0,,A,,BAO_0000218,15413,,,1,CHEMBL625892,,,Rattus norvegicus,N,1,1898.0,
14553,Biodistribution of the [11C]-radiolabeled compound in rat hypothalamus co-injected with 50 nM of WAY 100635.,Intermediate,10116.0,,A,,BAO_0000218,15413,,,1,CHEMBL625893,,,Rattus norvegicus,N,1,1898.0,
14554,Biodistribution of the [18F]-radiolabeled compound in rat cerebellum,Intermediate,10116.0,,A,,BAO_0000218,15413,,,1,CHEMBL625894,,,Rattus norvegicus,N,1,2037.0,
14555,Biodistribution of the [18F]-radiolabeled compound in rat cortex,Intermediate,10116.0,,A,,BAO_0000218,15413,,,1,CHEMBL625895,,,Rattus norvegicus,N,1,,
14556,Reaction rate parameter value for phosphate with transfer with respect to ATP,Autocuration,,,A,,BAO_0000019,12404,,,1,CHEMBL625896,,,,U,0,,
14557,"Tested for hydrolysis in presence of boric acid, dissociation constant was evaluated at the pH 8.5(Apparent inhibition constant)",Autocuration,,,A,,BAO_0000019,568,,,1,CHEMBL625897,,,,U,0,,
14558,"Tested for hydrolysis in presence of boric acid, dissociation constant was evaluated at the pH 9.5(Apparent inhibition constant)",Autocuration,,,A,,BAO_0000019,568,,,1,CHEMBL625898,,,,U,0,,
14559,"Tested for hydrolysis in presence of phenylboronic acid, dissociation constant was evaluated at the pH 9.5(Apparent inhibition constant)",Autocuration,,,A,,BAO_0000019,568,,,1,CHEMBL625899,,,,U,0,,
14560,Reaction rate parameter value for phosphate with transfer with respect to ATP,Autocuration,,,A,,BAO_0000019,12404,,,1,CHEMBL626124,,,,U,0,,
14561,Ability to inhibit Escherichia coli adenylate kinase II activity expressed as half maximal velocity,Intermediate,562.0,,A,,BAO_0000218,7624,,,1,CHEMBL628500,,,Escherichia coli,N,1,,
14562,"Ability to inhibit rat adenylate kinase II, activity expressed as half-maximal velocity",Intermediate,10116.0,,A,,BAO_0000218,7624,,,1,CHEMBL857856,,,Rattus norvegicus,N,1,,
14563,"Ability to inhibit rat adenylate kinase III, activity expressed as half-maximal velocity",Intermediate,10116.0,,A,,BAO_0000218,7624,,,1,CHEMBL628501,,,Rattus norvegicus,N,1,,
14564,"Compound was evaluated for the Michaelis-Menten constant, Km in a generic protein phosphatase stopped assay system",Autocuration,,,A,,BAO_0000019,4643,,,1,CHEMBL628502,,,,U,0,,
14565,Kinetic parameter KM (nM) for the MAO-B catalyzed oxidation of the compound.,Autocuration,,,A,,BAO_0000019,11532,,,1,CHEMBL628503,,,,U,0,,
14566,Kinetic parameter KM at pH 7.4 and 37 degree Centigrade,Autocuration,,,A,,BAO_0000019,11018,,,1,CHEMBL628504,,,,U,0,,
14567,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 0.25% acetonitrile and 4B2 as catalyst was expressed as KM; Not determined",Autocuration,,,A,,BAO_0000019,2276,,,1,CHEMBL628505,,,,U,0,,
14568,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 4B2 as catalyst was expressed as KM",Autocuration,,,A,,BAO_0000019,2276,,,1,CHEMBL874452,,,,U,0,,
14569,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 6C2 as catalyst was expressed as KM; Not determined",Autocuration,,,A,,BAO_0000019,2276,,,1,CHEMBL628506,,,,U,0,,
14570,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 10% acetonitrile and 4B2 as catalyst was expressed as KM; Not determined",Autocuration,,,A,,BAO_0000019,2276,,,1,CHEMBL628507,,,,U,0,,
14571,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 5% acetonitrile and 4B2 as catalyst was expressed as KM",Autocuration,,,A,,BAO_0000019,2276,,,1,CHEMBL628508,,,,U,0,,
14572,Michaelis constant (KM) was evaluated,Autocuration,,,A,,BAO_0000019,8949,,,1,CHEMBL628509,,,,U,0,,
14573,Reaction rate parameter value for phosphate with transfer with respect to ATP,Autocuration,,,A,,BAO_0000019,12404,,,1,CHEMBL628510,,,,U,0,,
14574,Substrate concentration for half maximal velocity was reported for rat hexokinase I,Autocuration,,,B,,BAO_0000019,7625,,,1,CHEMBL628511,,,,U,0,,
14575,Substrate concentration for half maximal velocity was reported for rat hexokinase II,Autocuration,,,B,,BAO_0000019,7625,,,1,CHEMBL628512,,,,U,0,,
14576,Substrate concentration for half maximal velocity was reported for rat hexokinase III,Autocuration,,,B,,BAO_0000019,7625,,,1,CHEMBL628513,,,,U,0,,
14577,Substrate concentration for half maximal velocity was reported for yeast hexokinase,Autocuration,,,B,,BAO_0000019,7625,,,1,CHEMBL628514,,,,U,0,,
14578,Pseudo-first-order rate constant for alkylation of NBP in 50% aqueous acetone at 66 degrees celsius with 50 uM and 25 uM of NBP.,Autocuration,,,A,,BAO_0000019,12908,,,1,CHEMBL628515,,,,U,0,,
14579,Rate constant for alkylation of 4-(4-nitrobenzyl)pyridine,Autocuration,,,A,,BAO_0000019,10368,,,1,CHEMBL628516,,,,U,0,,
14580,Bimolecular rate constant (KOH) at 25 degree C (m = 0.5),Autocuration,,,A,,BAO_0000019,13108,,,1,CHEMBL628517,,,,U,0,,
14581,its bimolecular rate constant (KOH) at 25 degree C (m = 0.5),Autocuration,,,A,,BAO_0000019,13108,,,1,CHEMBL628518,,,,U,0,,
14582,Acid dissociation constant evaluated towards Hematin mu-oxo dimer,Autocuration,,,A,,BAO_0000019,15217,,,1,CHEMBL628519,,,,U,0,,
14583,Acid dissociation constant evaluated towards Hematin mu-oxo dimer; Not available,Autocuration,,,A,,BAO_0000019,15217,,,1,CHEMBL628520,,,,U,0,,
14584,Binding constant was determined,Autocuration,,,A,,BAO_0000019,10933,,,1,CHEMBL628521,,,,U,0,,
14585,Alkylation of 4-(4-nitrobenzyl)pyridine (NBP) by the compound at a temperature of 66 degree Centigrade,Autocuration,,,A,,BAO_0000019,2363,,,1,CHEMBL630443,,,,U,0,,
14586,Alkylation of 4-(4-nitrobenzyl)pyridine (NBP) by the compound at a temperature of 66 degree centigrade; Not determined,Autocuration,,,A,,BAO_0000019,2363,,,1,CHEMBL630444,,,,U,0,,
14587,Rate constant with triethylamine at 30 degree C in 0.1 M potassium chloride was expressed as Kamine,Autocuration,,,A,,BAO_0000019,2276,,,1,CHEMBL857732,,,,U,0,,
14588,Octanol-water apparent distribution coefficient measured in TRIS buffer at a pH 7.4.,Autocuration,,,P,,BAO_0000100,14915,,,1,CHEMBL630445,,,,U,0,,
14589,Catalytic rate constant of the compound,Autocuration,,,A,,BAO_0000019,8847,,,1,CHEMBL630446,,,,U,0,,
14590,inactivation rate constant calculated from experimental IC50 value for dipeptidyl peptidase IV inhibition,Autocuration,,,B,,BAO_0000019,15357,,,1,CHEMBL630447,,,,U,0,,
14591,Catalytic constant expressed as Kinetic behavior of enzyme (PicK/6-His),Autocuration,,,A,,BAO_0000019,2869,,,1,CHEMBL630448,,,,U,0,,
14592,Catalytic rate constant against phospholipase A2 was determined,Autocuration,,,A,,BAO_0000019,3484,,,1,CHEMBL630449,,,,U,0,,
14593,"Compound was evaluated for catalytic constant, Kcat",Autocuration,,,A,,BAO_0000019,1373,,,1,CHEMBL630450,,,,U,0,,
14594,Compound was tested for hydrolysis by acetylcholinesterase and the kinetic constant (kcat) which is a first-order rate constant was determined,Autocuration,,,A,,BAO_0000019,8142,,,1,CHEMBL630451,,,,U,0,,
14595,Kcat calculated from 0.693/T1/2,Autocuration,,,A,,BAO_0000019,14131,,,1,CHEMBL630452,,,,U,0,,
14596,Kcat was determined,Autocuration,,,A,,BAO_0000019,17269,,,1,CHEMBL630453,,,,U,0,,
14597,Kcat against class A PCI beta-lactamase catalyzed lactone hydrolysis,Autocuration,,,A,,BAO_0000019,3485,,,1,CHEMBL630454,,,,U,0,,
14598,Kcat against class A TEM beta-lactamase catalyzed lactone hydrolysis,Autocuration,,,A,,BAO_0000019,3485,,,1,CHEMBL630455,,,,U,0,,
14599,Kcat against class C P99 beta-lactamase catalyzed lactone hydrolysis,Autocuration,,,A,,BAO_0000019,3485,,,1,CHEMBL631487,,,,U,0,,
14600,Kcat value was determined,Autocuration,,,A,,BAO_0000019,5962,,,1,CHEMBL631488,,,,U,0,,
14601,Kinetic constant for the hydrolysis by the catalyst CPA was evaluated,Autocuration,,,A,,BAO_0000019,3133,,,1,CHEMBL876440,,,,U,0,,
14602,Kinetic constant for the hydrolysis by the catalyst McAbIIF9D8 was evaluated,Autocuration,,,A,,BAO_0000019,3133,,,1,CHEMBL631489,,,,U,0,,
14603,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 0.25% acetonitrile and 4B2 as catalyst was expressed as Kcat; Not determined",Autocuration,,,A,,BAO_0000019,2276,,,1,CHEMBL857742,,,,U,0,,
14604,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 4B2 as catalyst was expressed as Kcat",Autocuration,,,A,,BAO_0000019,2276,,,1,CHEMBL631490,,,,U,0,,
14605,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 6C2 as catalyst was expressed as Kcat; Not determined",Autocuration,,,A,,BAO_0000019,2276,,,1,CHEMBL631491,,,,U,0,,
14606,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 10% acetonitrile and 4B2 as catalyst was expressed as Kcat; Not determined",Autocuration,,,A,,BAO_0000019,2276,,,1,CHEMBL631492,,,,U,0,,
14607,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 5% acetonitrile and 4B2 as catalyst was expressed as Kcat",Autocuration,,,A,,BAO_0000019,2276,,,1,CHEMBL631493,,,,U,0,,
14608,Kinetic parameter for rate of conversion to PABA was determined,Autocuration,,,A,,BAO_0000019,4892,,,1,CHEMBL631494,,,,U,0,,
14609,Rate acceleration expressed as ratio of Kcat to Kuncat was evaluated,Autocuration,,,A,,BAO_0000019,3133,,,1,CHEMBL631495,,,,U,0,,
14610,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 48-72 hr",Intermediate,10116.0,,A,,BAO_0000218,11488,,,1,CHEMBL631496,,,Rattus norvegicus,N,1,1988.0,
14611,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after intravenous administration of compound dose (1 mg/kg) at 0-24 hr",Intermediate,10116.0,,A,,BAO_0000218,11488,,,1,CHEMBL631497,,,Rattus norvegicus,N,1,1088.0,
14612,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after intravenous administration of compound dose (1 mg/kg) at 24-48 hr",Intermediate,10116.0,,A,,BAO_0000218,11488,,,1,CHEMBL631498,,,Rattus norvegicus,N,1,1088.0,
14613,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 0-24 hr",Intermediate,10116.0,,A,,BAO_0000218,11488,,,1,CHEMBL629776,,,Rattus norvegicus,N,1,1088.0,
14614,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 24-48 hr",Intermediate,10116.0,,A,,BAO_0000218,11488,,,1,CHEMBL629777,,,Rattus norvegicus,N,1,1088.0,
14615,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 48-72 hr",Intermediate,10116.0,,A,,BAO_0000218,11488,,,1,CHEMBL629778,,,Rattus norvegicus,N,1,1088.0,
14616,Cumulative dose excreted after intraduodenal administration at 0-0.5 hours in rats,Intermediate,10116.0,,A,,BAO_0000218,11488,,,1,CHEMBL630456,,,Rattus norvegicus,N,1,,
14617,Cumulative dose excreted after intraduodenal administration at 0.5-1.0 hours in rats,Intermediate,10116.0,,A,,BAO_0000218,11488,,,1,CHEMBL630457,,,Rattus norvegicus,N,1,,
14618,Cumulative dose excreted after intraduodenal administration at 1.0-1.5 hours in rats,Intermediate,10116.0,,A,,BAO_0000218,11488,,,1,CHEMBL630458,,,Rattus norvegicus,N,1,,
14619,Cumulative dose excreted after intraduodenal administration at 1.5-2.0 hours in rats,Intermediate,10116.0,,A,,BAO_0000218,11488,,,1,CHEMBL630459,,,Rattus norvegicus,N,1,,
14620,Cumulative dose excreted after intraduodenal administration at 2-3 hours in rats,Intermediate,10116.0,,A,,BAO_0000218,11488,,,1,CHEMBL630460,,,Rattus norvegicus,N,1,,
14621,Cumulative dose excreted after intraduodenal administration at 3-4 hours in rats,Intermediate,10116.0,,A,,BAO_0000218,11488,,,1,CHEMBL876550,,,Rattus norvegicus,N,1,,
14622,Cumulative dose excreted after intraduodenal administration at 4-6 hours in rats,Intermediate,10116.0,,A,,BAO_0000218,11488,,,1,CHEMBL630461,,,Rattus norvegicus,N,1,,
14623,Cumulative dose excreted after intraduodenal administration at 6-8 hours in rats,Intermediate,10116.0,,A,,BAO_0000218,11488,,,1,CHEMBL630462,,,Rattus norvegicus,N,1,,
14624,Cumulative dose excreted after intraduodenal administration at 8-24 hours in rats,Intermediate,10116.0,,A,,BAO_0000218,11488,,,1,CHEMBL630463,,,Rattus norvegicus,N,1,,
14625,Cumulative dose excreted after intravenous administration at 0-0.5 hours in rats,Intermediate,10116.0,,A,,BAO_0000218,11488,,,1,CHEMBL630464,,,Rattus norvegicus,N,1,,
14626,Cumulative dose excreted after intravenous administration at 0.5-1 hours in rats,Intermediate,10116.0,,A,,BAO_0000218,11488,,,1,CHEMBL630465,,,Rattus norvegicus,N,1,,
14627,Cumulative dose excreted after intravenous administration at 1.0-1.5 hours in rats,Intermediate,10116.0,,A,,BAO_0000218,11488,,,1,CHEMBL630466,,,Rattus norvegicus,N,1,,
14628,Cumulative dose excreted after intravenous administration at 1.5-2 hours in rats,Intermediate,10116.0,,A,,BAO_0000218,11488,,,1,CHEMBL630467,,,Rattus norvegicus,N,1,,
14629,Cumulative dose excreted after intravenous administration at 2-3 hours in rats,Intermediate,10116.0,,A,,BAO_0000218,11488,,,1,CHEMBL630633,,,Rattus norvegicus,N,1,,
14630,Cumulative dose excreted after intravenous administration at 3-4 hours in rats,Intermediate,10116.0,,A,,BAO_0000218,11488,,,1,CHEMBL630634,,,Rattus norvegicus,N,1,,
14631,Cumulative dose excreted after intravenous administration at 4-6 hours in rats,Intermediate,10116.0,,A,,BAO_0000218,11488,,,1,CHEMBL630635,,,Rattus norvegicus,N,1,,
14632,Cumulative dose excreted after intravenous administration at 6-8 hours in rats,Intermediate,10116.0,,A,,BAO_0000218,11488,,,1,CHEMBL630636,,,Rattus norvegicus,N,1,,
14633,Cumulative dose excreted after intravenous administration at 8-24 hours in rats,Intermediate,10116.0,,A,,BAO_0000218,11488,,,1,CHEMBL630637,,,Rattus norvegicus,N,1,,
14634,"10 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit, and radioactivity content in feces was estimated (total)",Intermediate,9986.0,,A,,BAO_0000218,7132,,,1,CHEMBL630638,,,Oryctolagus cuniculus,N,1,1988.0,
14635,"10 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit, and radioactivity content in feces was estimated at 0-24 h",Intermediate,9986.0,,A,,BAO_0000218,7132,,,1,CHEMBL630639,,,Oryctolagus cuniculus,N,1,1988.0,
14636,"10 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit, and radioactivity content in feces was estimated at 24-48 h",Intermediate,9986.0,,A,,BAO_0000218,7132,,,1,CHEMBL630640,,,Oryctolagus cuniculus,N,1,1988.0,
14637,"10 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit, and radioactivity content in feces was estimated at 48-72 h",Intermediate,9986.0,,A,,BAO_0000218,7132,,,1,CHEMBL876551,,,Oryctolagus cuniculus,N,1,1988.0,
14638,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated (total)",Intermediate,9986.0,,A,,BAO_0000218,7132,,,1,CHEMBL630641,,,Oryctolagus cuniculus,N,1,1088.0,
14639,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated at 0-6 h",Intermediate,9986.0,,A,,BAO_0000218,7132,,,1,CHEMBL630642,,,Oryctolagus cuniculus,N,1,1088.0,
14640,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated at 24-48 h",Intermediate,9986.0,,A,,BAO_0000218,7132,,,1,CHEMBL630643,,,Oryctolagus cuniculus,N,1,1088.0,
14641,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated at 48-72 h",Intermediate,9986.0,,A,,BAO_0000218,7132,,,1,CHEMBL630644,,,Oryctolagus cuniculus,N,1,1088.0,
14642,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated at 6-24 h",Intermediate,9986.0,,A,,BAO_0000218,7132,,,1,CHEMBL630645,,,Oryctolagus cuniculus,N,1,1088.0,
14643,"25 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated (total)",Intermediate,9986.0,,A,,BAO_0000218,7132,,,1,CHEMBL625599,,,Oryctolagus cuniculus,N,1,1988.0,
14644,"25 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated at 0-24 h",Intermediate,9986.0,,A,,BAO_0000218,7132,,,1,CHEMBL625600,,,Oryctolagus cuniculus,N,1,1988.0,
14645,"25 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated at 24-48 h",Intermediate,9986.0,,A,,BAO_0000218,7132,,,1,CHEMBL625601,,,Oryctolagus cuniculus,N,1,1988.0,
14646,"25 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated at 48-72 h",Intermediate,9986.0,,A,,BAO_0000218,7132,,,1,CHEMBL625602,,,Oryctolagus cuniculus,N,1,1988.0,
14647,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated (total)",Intermediate,9986.0,,A,,BAO_0000218,7132,,,1,CHEMBL627470,,,Oryctolagus cuniculus,N,1,1088.0,
14648,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated at 0-6 h",Intermediate,9986.0,,A,,BAO_0000218,7132,,,1,CHEMBL627471,,,Oryctolagus cuniculus,N,1,1088.0,
14649,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated at 24-48 h",Intermediate,9986.0,,A,,BAO_0000218,7132,,,1,CHEMBL627472,,,Oryctolagus cuniculus,N,1,1088.0,
14650,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated at 48-72 h",Intermediate,9986.0,,A,,BAO_0000218,7132,,,1,CHEMBL627473,,,Oryctolagus cuniculus,N,1,1088.0,
14651,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated at 6-24 h",Intermediate,9986.0,,A,,BAO_0000218,7132,,,1,CHEMBL627474,,,Oryctolagus cuniculus,N,1,1088.0,
14652,Biodistribution in rat blood post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,Intermediate,10116.0,,A,,BAO_0000218,13925,,,1,CHEMBL627475,,,Rattus norvegicus,N,1,178.0,
14653,Biodistribution in rat blood post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,Intermediate,10116.0,,A,,BAO_0000218,13925,,,1,CHEMBL627476,,,Rattus norvegicus,N,1,178.0,
14654,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 11.9 uM/Kg of drug,Intermediate,9615.0,,A,,BAO_0000218,12582,,,1,CHEMBL627477,,,Canis lupus familiaris,N,1,1088.0,
14655,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 2.49 uM/Kg of drug,Intermediate,9615.0,,A,,BAO_0000218,12582,,,1,CHEMBL627478,,,Canis lupus familiaris,N,1,1088.0,
14656,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 26.2 uM/Kg of drug,Intermediate,9615.0,,A,,BAO_0000218,12582,,,1,CHEMBL627479,,,Canis lupus familiaris,N,1,1088.0,
14657,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 3.03 uM/Kg of drug,Intermediate,9615.0,,A,,BAO_0000218,12582,,,1,CHEMBL627480,,,Canis lupus familiaris,N,1,1088.0,
14658,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 30.3 uM/Kg of drug,Intermediate,9615.0,,A,,BAO_0000218,12582,,,1,CHEMBL627481,,,Canis lupus familiaris,N,1,1088.0,
14659,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 34.1 uM/Kg of drug,Intermediate,9615.0,,A,,BAO_0000218,12582,,,1,CHEMBL627482,,,Canis lupus familiaris,N,1,1088.0,
14660,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 7.85 uM/Kg of drug,Intermediate,9615.0,,A,,BAO_0000218,12582,,,1,CHEMBL627483,,,Canis lupus familiaris,N,1,1088.0,
14661,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 8.47 uM/Kg of drug,Intermediate,9615.0,,A,,BAO_0000218,12582,,,1,CHEMBL875636,,,Canis lupus familiaris,N,1,1088.0,
14662,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 9.09 uM/Kg of drug,Intermediate,9615.0,,A,,BAO_0000218,12582,,,1,CHEMBL625764,,,Canis lupus familiaris,N,1,1088.0,
14663,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 10.1 uM/Kg of drug,Intermediate,9615.0,,A,,BAO_0000218,12582,,,1,CHEMBL625765,,,Canis lupus familiaris,N,1,1088.0,
14664,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 102 uM/Kg of drug,Intermediate,9615.0,,A,,BAO_0000218,12582,,,1,CHEMBL625766,,,Canis lupus familiaris,N,1,1088.0,
14665,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 3.40 uM/Kg of drug,Intermediate,9615.0,,A,,BAO_0000218,12582,,,1,CHEMBL625767,,,Canis lupus familiaris,N,1,1088.0,
14666,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 3.76 uM/Kg of drug,Intermediate,9615.0,,A,,BAO_0000218,12582,,,1,CHEMBL625768,,,Canis lupus familiaris,N,1,1088.0,
14667,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 34.1 uM/Kg of drug,Intermediate,9615.0,,A,,BAO_0000218,12582,,,1,CHEMBL625769,,,Canis lupus familiaris,N,1,1088.0,
14668,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 50.8 uM/Kg of drug,Intermediate,9615.0,,A,,BAO_0000218,12582,,,1,CHEMBL625770,,,Canis lupus familiaris,N,1,1088.0,
14669,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 68.1 uM/Kg of drug,Intermediate,9615.0,,A,,BAO_0000218,12582,,,1,CHEMBL625771,,,Canis lupus familiaris,N,1,1088.0,
14670,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 9.060 uM/Kg of drug,Intermediate,9615.0,,A,,BAO_0000218,12582,,,1,CHEMBL625772,,,Canis lupus familiaris,N,1,1088.0,
14671,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 9.6 uM/Kg of drug,Intermediate,9615.0,,A,,BAO_0000218,12582,,,1,CHEMBL625773,,,Canis lupus familiaris,N,1,1088.0,
14672,Total electrolytic excretion of sodium in urine of rats after intravenous administration of 7.94 uM/Kg of drug,Intermediate,10116.0,,A,,BAO_0000218,12582,,,1,CHEMBL625774,,,Rattus norvegicus,N,1,1088.0,
14673,Total electrolytic excretion of sodium in urine of rats after peroral administration of 0 uM/Kg of drug,Intermediate,10116.0,,A,,BAO_0000218,12582,,,1,CHEMBL625775,,,Rattus norvegicus,N,1,1088.0,
14674,Total electrolytic excretion of sodium in urine of rats after peroral administration of 1.01 uM/Kg of drug,Intermediate,10116.0,,A,,BAO_0000218,12582,,,1,CHEMBL625776,,,Rattus norvegicus,N,1,1088.0,
14675,Total electrolytic excretion of sodium in urine of rats after peroral administration of 1.13 uM/Kg of drug,Intermediate,10116.0,,A,,BAO_0000218,12582,,,1,CHEMBL625777,,,Rattus norvegicus,N,1,1088.0,
14676,Total electrolytic excretion of sodium in urine of rats after peroral administration of 10.1 uM/Kg of drug,Intermediate,10116.0,,A,,BAO_0000218,12582,,,1,CHEMBL625778,,,Rattus norvegicus,N,1,1088.0,
14677,Total electrolytic excretion of sodium in urine of rats after peroral administration of 102 uM/Kg of drug,Intermediate,10116.0,,A,,BAO_0000218,12582,,,1,CHEMBL625779,,,Rattus norvegicus,N,1,1088.0,
14678,Total electrolytic excretion of sodium in urine of rats after peroral administration of 105 uM/Kg of drug,Intermediate,10116.0,,A,,BAO_0000218,12582,,,1,CHEMBL625780,,,Rattus norvegicus,N,1,1088.0,
14679,Total electrolytic excretion of sodium in urine of rats after peroral administration of 11.3 uM/Kg of drug,Intermediate,10116.0,,A,,BAO_0000218,12582,,,1,CHEMBL625781,,,Rattus norvegicus,N,1,1088.0,
14680,Total electrolytic excretion of sodium in urine of rats after peroral administration of 113 uM/Kg of drug,Intermediate,10116.0,,A,,BAO_0000218,12582,,,1,CHEMBL875637,,,Rattus norvegicus,N,1,1088.0,
14681,Total electrolytic excretion of sodium in urine of rats after peroral administration of 19.5 uM/Kg of drug,Intermediate,10116.0,,A,,BAO_0000218,12582,,,1,CHEMBL626473,,,Rattus norvegicus,N,1,1088.0,
14682,Total electrolytic excretion of sodium in urine of rats after peroral administration of 195 uM/Kg of drug,Intermediate,10116.0,,A,,BAO_0000218,12582,,,1,CHEMBL626474,,,Rattus norvegicus,N,1,1088.0,
14683,Total electrolytic excretion of sodium in urine of rats after peroral administration of 21.7 uM/Kg of drug,Intermediate,10116.0,,A,,BAO_0000218,12582,,,1,CHEMBL626475,,,Rattus norvegicus,N,1,1088.0,
14684,Total electrolytic excretion of sodium in urine of rats after peroral administration of 217 uM/Kg of drug,Intermediate,10116.0,,A,,BAO_0000218,12582,,,1,CHEMBL626476,,,Rattus norvegicus,N,1,1088.0,
14685,Total electrolytic excretion of sodium in urine of rats after peroral administration of 23.9 uM/Kg of drug,Intermediate,10116.0,,A,,BAO_0000218,12582,,,1,CHEMBL634397,,,Rattus norvegicus,N,1,1088.0,
14686,Total electrolytic excretion of sodium in urine of rats after peroral administration of 239 uM/Kg of drug,Intermediate,10116.0,,A,,BAO_0000218,12582,,,1,CHEMBL626477,,,Rattus norvegicus,N,1,1088.0,
14687,Total electrolytic excretion of sodium in urine of rats after peroral administration of 24.9 uM/Kg of drug,Intermediate,10116.0,,A,,BAO_0000218,12582,,,1,CHEMBL631069,,,Rattus norvegicus,N,1,1088.0,
14688,Total electrolytic excretion of sodium in urine of rats after peroral administration of 249 uM/Kg of drug,Intermediate,10116.0,,A,,BAO_0000218,12582,,,1,CHEMBL631070,,,Rattus norvegicus,N,1,1088.0,
14689,Total electrolytic excretion of sodium in urine of rats after peroral administration of 25.9 uM/Kg of drug,Intermediate,10116.0,,A,,BAO_0000218,12582,,,1,CHEMBL631071,,,Rattus norvegicus,N,1,1088.0,
14690,Total electrolytic excretion of sodium in urine of rats after peroral administration of 259 uM/Kg of drug,Intermediate,10116.0,,A,,BAO_0000218,12582,,,1,CHEMBL631072,,,Rattus norvegicus,N,1,1088.0,
14691,Total electrolytic excretion of sodium in urine of rats after peroral administration of 26.5 uM/Kg of drug,Intermediate,10116.0,,A,,BAO_0000218,12582,,,1,CHEMBL631073,,,Rattus norvegicus,N,1,1088.0,
14692,Total electrolytic excretion of sodium in urine of rats after peroral administration of 265 uM/Kg of drug,Intermediate,10116.0,,A,,BAO_0000218,12582,,,1,CHEMBL631074,,,Rattus norvegicus,N,1,1088.0,
14693,Total electrolytic excretion of sodium in urine of rats after peroral administration of 27 uM/Kg of drug,Intermediate,10116.0,,A,,BAO_0000218,12582,,,1,CHEMBL631075,,,Rattus norvegicus,N,1,1088.0,
14694,Total electrolytic excretion of sodium in urine of rats after peroral administration of 27.9 uM/Kg of drug,Intermediate,10116.0,,A,,BAO_0000218,12582,,,1,CHEMBL631725,,,Rattus norvegicus,N,1,1088.0,
14695,Total electrolytic excretion of sodium in urine of rats after peroral administration of 270 uM/Kg of drug,Intermediate,10116.0,,A,,BAO_0000218,12582,,,1,CHEMBL631726,,,Rattus norvegicus,N,1,1088.0,
14696,Total electrolytic excretion of sodium in urine of rats after peroral administration of 279 uM/Kg of drug,Intermediate,10116.0,,A,,BAO_0000218,12582,,,1,CHEMBL631727,,,Rattus norvegicus,N,1,1088.0,
14697,Total electrolytic excretion of sodium in urine of rats after peroral administration of 28.2 uM/Kg of drug,Intermediate,10116.0,,A,,BAO_0000218,12582,,,1,CHEMBL631728,,,Rattus norvegicus,N,1,1088.0,
14698,Total electrolytic excretion of sodium in urine of rats after peroral administration of 28.9 uM/Kg of drug,Intermediate,10116.0,,A,,BAO_0000218,12582,,,1,CHEMBL631729,,,Rattus norvegicus,N,1,1088.0,
14699,Total electrolytic excretion of sodium in urine of rats after peroral administration of 282 uM/Kg of drug,Intermediate,10116.0,,A,,BAO_0000218,12582,,,1,CHEMBL631730,,,Rattus norvegicus,N,1,1088.0,
14700,Total electrolytic excretion of sodium in urine of rats after peroral administration of 289 uM/Kg of drug,Intermediate,10116.0,,A,,BAO_0000218,12582,,,1,CHEMBL631731,,,Rattus norvegicus,N,1,1088.0,
14701,Total electrolytic excretion of sodium in urine of rats after peroral administration of 3.40 uM/Kg of drug,Intermediate,10116.0,,A,,BAO_0000218,12582,,,1,CHEMBL631910,,,Rattus norvegicus,N,1,1088.0,
14702,Biodistribution of the [18F]-radiolabeled compound in rat hippocampus,Intermediate,10116.0,,A,,BAO_0000218,15413,,,1,CHEMBL631911,,,Rattus norvegicus,N,1,10000000.0,
14703,Biodistribution of the [18F]-radiolabeled compound in rat hypothalamus,Intermediate,10116.0,,A,,BAO_0000218,15413,,,1,CHEMBL631912,,,Rattus norvegicus,N,1,1898.0,
14704,Biodistribution of the [18F]-radiolabeled compound in rat hypothalamus; Not determined,Intermediate,10116.0,,A,,BAO_0000218,15413,,,1,CHEMBL631913,,,Rattus norvegicus,N,1,1898.0,
14705,Biodistribution in blood of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,10116.0,,A,,BAO_0000218,12017,,,1,CHEMBL631914,,,Rattus norvegicus,N,1,178.0,
14706,Biodistribution in blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,10116.0,,A,,BAO_0000218,12017,,,1,CHEMBL631915,,,Rattus norvegicus,N,1,178.0,
14707,Biodistribution in blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),Intermediate,10116.0,,A,,BAO_0000218,12017,,,1,CHEMBL875778,,,Rattus norvegicus,N,1,178.0,
14708,Biodistribution in blood of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,10116.0,,A,,BAO_0000218,12017,,,1,CHEMBL631916,,,Rattus norvegicus,N,1,178.0,
14709,Biodistribution in blood of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,10116.0,,A,,BAO_0000218,12017,,,1,CHEMBL631917,,,Rattus norvegicus,N,1,178.0,
14710,Biodistribution in blood of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,10116.0,,A,,BAO_0000218,12017,,,1,CHEMBL631918,,,Rattus norvegicus,N,1,178.0,
14711,Biodistribution in blood of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,10116.0,,A,,BAO_0000218,12017,,,1,CHEMBL631919,,,Rattus norvegicus,N,1,178.0,
14712,Biodistribution in blood of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),Intermediate,10116.0,,A,,BAO_0000218,12017,,,1,CHEMBL631920,,,Rattus norvegicus,N,1,178.0,
14713,Biodistribution in blood of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,10116.0,,A,,BAO_0000218,12017,,,1,CHEMBL631921,,,Rattus norvegicus,N,1,178.0,
14714,Biodistribution in blood of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,10116.0,,A,,BAO_0000218,12017,,,1,CHEMBL631922,,,Rattus norvegicus,N,1,178.0,
14715,Biodistribution in blood of immature femalee rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),Intermediate,10116.0,,A,,BAO_0000218,12017,,,1,CHEMBL631923,,,Rattus norvegicus,N,1,178.0,
14716,Biodistribution in fat of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,10116.0,,A,,BAO_0000218,12017,,,1,CHEMBL631924,,,Rattus norvegicus,N,1,,
14717,Biodistribution in fat of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,10116.0,,A,,BAO_0000218,12017,,,1,CHEMBL630234,,,Rattus norvegicus,N,1,,
14718,Biodistribution in fat of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),Intermediate,10116.0,,A,,BAO_0000218,12017,,,1,CHEMBL630235,,,Rattus norvegicus,N,1,,
14719,Biodistribution in fat of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,10116.0,,A,,BAO_0000218,12017,,,1,CHEMBL630236,,,Rattus norvegicus,N,1,,
14720,Biodistribution in fat of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,10116.0,,A,,BAO_0000218,12017,,,1,CHEMBL630237,,,Rattus norvegicus,N,1,,
14721,Biodistribution in fat of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,10116.0,,A,,BAO_0000218,12017,,,1,CHEMBL630238,,,Rattus norvegicus,N,1,,
14722,Biodistribution in fat of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,10116.0,,A,,BAO_0000218,12017,,,1,CHEMBL630239,,,Rattus norvegicus,N,1,,
14723,Biodistribution in fat of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),Intermediate,10116.0,,A,,BAO_0000218,12017,,,1,CHEMBL630303,,,Rattus norvegicus,N,1,,
14724,Biodistribution in fat of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,10116.0,,A,,BAO_0000218,12017,,,1,CHEMBL630304,,,Rattus norvegicus,N,1,,
14725,Biodistribution in fat of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,10116.0,,A,,BAO_0000218,12017,,,1,CHEMBL630305,,,Rattus norvegicus,N,1,,
14726,Biodistribution in kidney of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,10116.0,,A,,BAO_0000218,12017,,,1,CHEMBL630306,,,Rattus norvegicus,N,1,2113.0,
14727,Biodistribution in kidney of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,10116.0,,A,,BAO_0000218,12017,,,1,CHEMBL630307,,,Rattus norvegicus,N,1,2113.0,
14728,Biodistribution in kidney of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),Intermediate,10116.0,,A,,BAO_0000218,12017,,,1,CHEMBL630308,,,Rattus norvegicus,N,1,2113.0,
14729,Biodistribution in kidney of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,10116.0,,A,,BAO_0000218,12017,,,1,CHEMBL630309,,,Rattus norvegicus,N,1,2113.0,
14730,Biodistribution in kidney of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,10116.0,,A,,BAO_0000218,12017,,,1,CHEMBL629309,,,Rattus norvegicus,N,1,2113.0,
14731,Biodistribution in kidney of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,10116.0,,A,,BAO_0000218,12017,,,1,CHEMBL629993,,,Rattus norvegicus,N,1,2113.0,
14732,Biodistribution in kidney of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,10116.0,,A,,BAO_0000218,12017,,,1,CHEMBL629994,,,Rattus norvegicus,N,1,2113.0,
14733,Biodistribution in kidney of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),Intermediate,10116.0,,A,,BAO_0000218,12017,,,1,CHEMBL629995,,,Rattus norvegicus,N,1,2113.0,
14734,Biodistribution in kidney of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,10116.0,,A,,BAO_0000218,12017,,,1,CHEMBL631993,,,Rattus norvegicus,N,1,2113.0,
14735,Biodistribution in kidney of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,10116.0,,A,,BAO_0000218,12017,,,1,CHEMBL631994,,,Rattus norvegicus,N,1,2113.0,
14736,Biodistribution in kidney of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,10116.0,,A,,BAO_0000218,12017,,,1,CHEMBL631995,,,Rattus norvegicus,N,1,2113.0,
14737,Biodistribution in liver of Iimmature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),Intermediate,10116.0,,A,,BAO_0000218,12017,,,1,CHEMBL631996,,,Rattus norvegicus,N,1,2107.0,
14738,Biodistribution in liver of Iimmature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,10116.0,,A,,BAO_0000218,12017,,,1,CHEMBL631997,,,Rattus norvegicus,N,1,2107.0,
14739,Biodistribution in liver of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,10116.0,,A,,BAO_0000218,12017,,,1,CHEMBL631998,,,Rattus norvegicus,N,1,2107.0,
14740,Biodistribution in liver of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,10116.0,,A,,BAO_0000218,12017,,,1,CHEMBL631999,,,Rattus norvegicus,N,1,2107.0,
14741,Biodistribution in liver of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),Intermediate,10116.0,,A,,BAO_0000218,12017,,,1,CHEMBL632000,,,Rattus norvegicus,N,1,2107.0,
14742,Biodistribution in liver of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,10116.0,,A,,BAO_0000218,12017,,,1,CHEMBL632001,,,Rattus norvegicus,N,1,2107.0,
14743,Biodistribution in liver of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,10116.0,,A,,BAO_0000218,12017,,,1,CHEMBL874424,,,Rattus norvegicus,N,1,2107.0,
14744,Biodistribution in liver of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,10116.0,,A,,BAO_0000218,12017,,,1,CHEMBL632002,,,Rattus norvegicus,N,1,2107.0,
14745,Biodistribution in liver of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,10116.0,,A,,BAO_0000218,12017,,,1,CHEMBL632003,,,Rattus norvegicus,N,1,2107.0,
14746,Rate acceleration expressed as ratio of Kcat to Kuncat was evaluated,Autocuration,,,A,,BAO_0000019,3133,,,1,CHEMBL632004,,,,U,0,,
14747,Compound was tested for amidase rate in the presence of N62C fully characterised enzyme,Autocuration,,,A,,BAO_0000019,2742,,,1,CHEMBL632005,,,,U,0,,
14748,Compound was tested for amidase rate in the presence of N62C screen enzyme,Autocuration,,,A,,BAO_0000019,2742,,,1,CHEMBL632006,,,,U,0,,
14749,Compound was tested for amidase rate in the presence of S166C fully characterised enzyme,Autocuration,,,A,,BAO_0000019,2742,,,1,CHEMBL632007,,,,U,0,,
14750,Compound was tested for amidase rate in the presence of S166C screen enzyme,Autocuration,,,A,,BAO_0000019,2742,,,1,CHEMBL632008,,,,U,0,,
14751,Compound was tested for esterase rate in the presence of N62C fully characterised enzyme,Autocuration,,,A,,BAO_0000019,2742,,,1,CHEMBL632009,,,,U,0,,
14752,Compound was tested for esterase rate in the presence of N62C screen enzyme,Autocuration,,,A,,BAO_0000019,2742,,,1,CHEMBL632010,,,,U,0,,
14753,Compound was tested for esterase rate in the presence of S166C fully characterised enzyme,Autocuration,,,A,,BAO_0000019,2742,,,1,CHEMBL857750,,,,U,0,,
14754,Compound was tested for esterase rate in the presence of S166C screen enzyme,Autocuration,,,A,,BAO_0000019,2742,,,1,CHEMBL632011,,,,U,0,,
14755,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 0.25% acetonitrile and 4B2 as catalyst was expressed as Kcat/KM",Autocuration,,,A,,BAO_0000019,2276,,,1,CHEMBL632012,,,,U,0,,
14756,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 4B2 as catalyst was expressed as Kcat/KM",Autocuration,,,A,,BAO_0000019,2276,,,1,CHEMBL632013,,,,U,0,,
14757,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 6C2 as catalyst was expressed as Kcat/KM",Autocuration,,,A,,BAO_0000019,2276,,,1,CHEMBL632014,,,,U,0,,
14758,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 10% acetonitrile and 4B2 as catalyst was expressed as Kcat/KM",Autocuration,,,A,,BAO_0000019,2276,,,1,CHEMBL629622,,,,U,0,,
14759,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 5% acetonitrile and 4B2 as catalyst was expressed as Kcat/KM",Autocuration,,,A,,BAO_0000019,2276,,,1,CHEMBL629623,,,,U,0,,
14760,"Rate constant at 30 degree C in phosphate buffer pH 7.1, 0.5 % acetonitrile was expressed as Kcat/KM",Autocuration,,,A,,BAO_0000019,2276,,,1,CHEMBL629624,,,,U,0,,
14761,Ratio of Kcat to that of Km was determined,Autocuration,,,A,,BAO_0000019,17269,,,1,CHEMBL629625,,,,U,0,,
14762,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 4B2 as catalyst was expressed as Kcat/Kuncat",Autocuration,,,A,,BAO_0000019,2276,,,1,CHEMBL629626,,,,U,0,,
14763,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 5% acetonitrile and 4B2 as catalyst was expressed as Kcat/Kuncat",Autocuration,,,A,,BAO_0000019,2276,,,1,CHEMBL629627,,,,U,0,,
14764,"Compound was evaluated for constant, Kd",Autocuration,,,A,,BAO_0000019,15917,,,1,CHEMBL629628,,,,U,0,,
14765,Deacylation rate constant(Kd fast) was determined by proflavin displacement assay,Autocuration,,,A,,BAO_0000019,10933,,,1,CHEMBL629629,,,,U,0,,
14766,Deacylation rate constant(Kd slow) was determined by proflavin displacement assay,Autocuration,,,A,,BAO_0000019,10933,,,1,CHEMBL629630,,,,U,0,,
14767,Dissociation Constant of compound determined,Autocuration,,,A,,BAO_0000019,14293,,,1,CHEMBL856030,,,,U,0,,
14768,Dissociation constant for the binding of compound to PDZ3 from PSD-95 was determined,Autocuration,,,B,,BAO_0000019,6698,,,1,CHEMBL629631,,,,U,0,,
14769,Dissociation constant for the binding of compound to PDZ3 from PSD-95 was determined; No data,Autocuration,,,B,,BAO_0000019,6698,,,1,CHEMBL629632,,,,U,0,,
14770,Dissociation constant of compound with Fructose was determined,Autocuration,,,P,,BAO_0000100,4318,,,1,CHEMBL629633,,,,U,0,,
14771,Dissociation constant of compound with Fructose was determined; Not determined,Autocuration,,,P,,BAO_0000100,4318,,,1,CHEMBL629634,,,,U,0,,
14772,Dissociation constant of compound with Lactulose was determined,Autocuration,,,P,,BAO_0000100,4318,,,1,CHEMBL629635,,,,U,0,,
14773,Dissociation constant of compound with Lactulose was determined; Not determined,Autocuration,,,P,,BAO_0000100,4318,,,1,CHEMBL629636,,,,U,0,,
14774,Dissociation constant of the Compound,Autocuration,,,P,,BAO_0000100,14959,,,1,CHEMBL629637,,,,U,0,,
14775,Dissociation constant by non-linear regression analysis,Autocuration,,,P,,BAO_0000100,5913,,,1,CHEMBL629638,,,,U,0,,
14776,Dissociation constant was determined,Autocuration,,,P,,BAO_0000100,14218,,,1,CHEMBL629639,,,,U,0,,
14777,Dissociation constant of the compound; value ranges from 0.81-1.2 nM,Autocuration,,,P,,BAO_0000100,10689,,,1,CHEMBL629640,,,,U,0,,
14778,Dissociation constant was determined,Autocuration,,,P,,BAO_0000100,13925,,,1,CHEMBL629641,,,,U,0,,
14779,Dissociation constant was determined,Autocuration,,,P,,BAO_0000100,16359,,,1,CHEMBL631344,,,,U,0,,
14780,Equilibrium dissociation constant based on membrane concentration in rat smooth muscle,Intermediate,10116.0,,A,,BAO_0000218,10944,,,1,CHEMBL631345,,,Rattus norvegicus,N,1,2385.0,
14781,The dissociation constant determined by fluorescence displacement assay,Autocuration,,,A,,BAO_0000019,11080,,,1,CHEMBL631346,,,,U,0,,
14782,kd value surface plasmon resonance (SPR) method,Autocuration,,,A,,BAO_0000019,17805,,,1,CHEMBL631524,,,,U,0,,
14783,Equilibrium dissociation constant based on aqueous concentration in rat smooth muscle,Intermediate,10116.0,,A,,BAO_0000218,10944,,,1,CHEMBL631525,,,Rattus norvegicus,N,1,2385.0,
14784,First dissociation constant of the binding of compound to V30M TTR,Autocuration,,,F,,BAO_0000019,16645,,,1,CHEMBL631526,,,,U,0,,
14785,Second dissociation constant of the binding of compound to V30M TTR,Autocuration,,,F,,BAO_0000019,16645,,,1,CHEMBL631527,,,,U,0,,
14786,"Compound was evaluated for equilibrium constant, Ke",Autocuration,,,A,,BAO_0000019,7793,,,1,CHEMBL631528,,,,U,0,,
14787,Equilibrium constant from the dorsal raphe and the ventromedial hypothalamus,Autocuration,,,A,,BAO_0000019,12199,,,1,CHEMBL631529,,,,U,0,1898.0,
14788,Equilibrium constant from the dorsal raphe and the ventromedial hypothalamus; inactive,Autocuration,,,A,,BAO_0000019,12199,,,1,CHEMBL631530,,,,U,0,1898.0,
14789,Keff is the effective biomolecular rate constant on VX for reactivation at pH 7.8 at 25 degree Centigrade,Autocuration,,,A,,BAO_0000019,9680,,,1,CHEMBL631531,,,,U,0,,
14790,Keff is the effective biomolecular rate constant on paraxon for reactivation at pH 7.8 at 25 degree Centigrade,Autocuration,,,A,,BAO_0000019,9680,,,1,CHEMBL631532,,,,U,0,,
14791,Keff is the effective biomolecular rate constant on sarin for reactivation at pH 7.8 at 25 degree Centigrade,Autocuration,,,A,,BAO_0000019,9680,,,1,CHEMBL631533,,,,U,0,,
14792,In vitro biotransformation of compound along with coformycin in mice liver homogenate 9-(beta-D-arabinifuranosyl)-6-azidopurine(6-AAP) analyte,Intermediate,10090.0,,A,,BAO_0000218,13758,,,1,CHEMBL876552,,,Mus musculus,N,1,,
14793,In vitro biotransformation of compound along with coformycin in mice liver homogenate 9-(beta-D-arabinifuranosyl)adenine(ara-A) analyte,Intermediate,10090.0,,A,,BAO_0000218,13758,,,1,CHEMBL631534,,,Mus musculus,N,1,,
14794,In vitro biotransformation of compound in mice brain homogenate 9-(beta-D-arabinifuranosyl)-6-azidopurine(6-AAP) analyte,Intermediate,10090.0,,A,,BAO_0000218,13758,,,1,CHEMBL631535,,,Mus musculus,N,1,,
14795,In vitro biotransformation of compound in mice liver homogenate 9-(beta-D-arabinifuranosyl)-6-azidopurine(6-AAP) analyte,Intermediate,10090.0,,A,,BAO_0000218,13758,,,1,CHEMBL631536,,,Mus musculus,N,1,,
14796,In vitro biotransformation of compound in mice liver homogenate 9-(beta-D-arabinifuranosyl)-6-hypoxanthine(ara-H) analyte,Intermediate,10090.0,,A,,BAO_0000218,13758,,,1,CHEMBL631537,,,Mus musculus,N,1,,
14797,In vitro biotransformation of compound in mice liver homogenate 9-(beta-D-arabinifuranosyl)adenine(ara-A) analyte,Intermediate,10090.0,,A,,BAO_0000218,13758,,,1,CHEMBL631538,,,Mus musculus,N,1,,
14798,In vitro biotransformation of compound in mice liver homogenate 9-(beta-D-arabinifuranosyl)adenine(ara-H) analyte,Intermediate,10090.0,,A,,BAO_0000218,13758,,,1,CHEMBL631539,,,Mus musculus,N,1,,
14799,In vitro biotransformation of compound in mice serum 9-(beta-D-arabinifuranosyl)-6-azidopurine(6-AAP) analyte,Intermediate,10090.0,,A,,BAO_0000218,13758,,,1,CHEMBL631540,,,Mus musculus,N,1,,
14800,Pharmacokinetic Parameter [Kel(1/h)] was evaluated at 10 mg/kg (p.o.) in Wistar rats,Intermediate,10116.0,,A,,BAO_0000218,14393,,,1,CHEMBL625637,,,Rattus norvegicus,N,1,,
14801,Pharmacokinetic parameter [Kel(1/h)] was evaluated at 10 mg/kg (p.o.) in Wistar rats,Intermediate,10116.0,,A,,BAO_0000218,14393,,,1,CHEMBL625638,,,Rattus norvegicus,N,1,,
14802,"The Kel value in female wistar rat at 100 mg/kg, p.o. dose",Intermediate,10116.0,,A,,BAO_0000218,15078,,,1,CHEMBL625639,,,Rattus norvegicus,N,1,,
14803,Biodistribution in rat brain post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,Intermediate,10116.0,,A,,BAO_0000218,13925,,,1,CHEMBL625640,,,Rattus norvegicus,N,1,955.0,
14804,Biodistribution in rat brain post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,Intermediate,10116.0,,A,,BAO_0000218,13925,,,1,CHEMBL625641,,,Rattus norvegicus,N,1,955.0,
14805,Biodistribution in rat heart post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,Intermediate,10116.0,,A,,BAO_0000218,13925,,,1,CHEMBL625642,,,Rattus norvegicus,N,1,948.0,
14806,Biodistribution in rat heart post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,Intermediate,10116.0,,A,,BAO_0000218,13925,,,1,CHEMBL625643,,,Rattus norvegicus,N,1,948.0,
14807,Biodistribution in rat kidney post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,Intermediate,10116.0,,A,,BAO_0000218,13925,,,1,CHEMBL625644,,,Rattus norvegicus,N,1,2113.0,
14808,Biodistribution in rat kidney post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,Intermediate,10116.0,,A,,BAO_0000218,13925,,,1,CHEMBL625645,,,Rattus norvegicus,N,1,2113.0,
14809,Biodistribution in rat liver post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,Intermediate,10116.0,,A,,BAO_0000218,13925,,,1,CHEMBL625646,,,Rattus norvegicus,N,1,2107.0,
14810,Biodistribution in rat liver post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,Intermediate,10116.0,,A,,BAO_0000218,13925,,,1,CHEMBL625647,,,Rattus norvegicus,N,1,2107.0,
14811,Biodistribution in rat lung post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,Intermediate,10116.0,,A,,BAO_0000218,13925,,,1,CHEMBL625648,,,Rattus norvegicus,N,1,2048.0,
14812,Biodistribution in rat lung post intravenous injection for 60 min of [99mTc]-TRODAT ligand expressed as percent dose per organ,Intermediate,10116.0,,A,,BAO_0000218,13925,,,1,CHEMBL625649,,,Rattus norvegicus,N,1,2048.0,
14813,Biodistribution in rat muscle post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,Intermediate,10116.0,,A,,BAO_0000218,13925,,,1,CHEMBL625650,,,Rattus norvegicus,N,1,2385.0,
14814,Biodistribution in rat muscle post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,Intermediate,10116.0,,A,,BAO_0000218,13925,,,1,CHEMBL625651,,,Rattus norvegicus,N,1,2385.0,
14815,Biodistribution in rat skin post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,Intermediate,10116.0,,A,,BAO_0000218,13925,,,1,CHEMBL625652,,,Rattus norvegicus,N,1,14.0,
14816,Biodistribution in rat skin post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,Intermediate,10116.0,,A,,BAO_0000218,13925,,,1,CHEMBL625653,,,Rattus norvegicus,N,1,14.0,
14817,Biodistribution in rat spleen post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,Intermediate,10116.0,,A,,BAO_0000218,13925,,,1,CHEMBL625654,,,Rattus norvegicus,N,1,2106.0,
14818,Biodistribution in rat spleen post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,Intermediate,10116.0,,A,,BAO_0000218,13925,,,1,CHEMBL625655,,,Rattus norvegicus,N,1,2106.0,
14819,Biodistribution of Compound in rat blood after 15 minutes of administration,Intermediate,10116.0,,A,,BAO_0000218,9712,,,1,CHEMBL625656,,,Rattus norvegicus,N,1,178.0,
14820,Biodistribution of Compound in rat blood after 2 minutes of administration,Intermediate,10116.0,,A,,BAO_0000218,9712,,,1,CHEMBL625657,,,Rattus norvegicus,N,1,178.0,
14821,Biodistribution of Compound in rat brain after 15 minutes of administration,Intermediate,10116.0,,A,,BAO_0000218,9712,,,1,CHEMBL625658,,,Rattus norvegicus,N,1,955.0,
14822,Biodistribution of Compound in rat brain after 2 minutes of administration,Intermediate,10116.0,,A,,BAO_0000218,9712,,,1,CHEMBL625659,,,Rattus norvegicus,N,1,955.0,
14823,Biodistribution of Compound in rat heart after 15 minutes of administration,Intermediate,10116.0,,A,,BAO_0000218,9712,,,1,CHEMBL625660,,,Rattus norvegicus,N,1,948.0,
14824,Biodistribution of Compound in rat heart after 2 minutes of administration,Intermediate,10116.0,,A,,BAO_0000218,9712,,,1,CHEMBL625661,,,Rattus norvegicus,N,1,948.0,
14825,Biodistribution of Compound in rat liver after 15 minutes of administration,Intermediate,10116.0,,A,,BAO_0000218,9712,,,1,CHEMBL625662,,,Rattus norvegicus,N,1,2107.0,
14826,Biodistribution of Compound in rat liver after 2 minutes of administration,Intermediate,10116.0,,A,,BAO_0000218,9712,,,1,CHEMBL625663,,,Rattus norvegicus,N,1,2107.0,
14827,Biodistribution of Compound in rat lung after 15 minutes of administration,Intermediate,10116.0,,A,,BAO_0000218,9712,,,1,CHEMBL875621,,,Rattus norvegicus,N,1,2048.0,
14828,Biodistribution of Compound in rat lung after 2 minutes of administration,Intermediate,10116.0,,A,,BAO_0000218,9712,,,1,CHEMBL628382,,,Rattus norvegicus,N,1,2048.0,
14829,Biodistribution of Compound in rat muscle after 15 minutes of administration,Intermediate,10116.0,,A,,BAO_0000218,9712,,,1,CHEMBL628383,,,Rattus norvegicus,N,1,2385.0,
14830,Biodistribution of Compound in rat muscle after 2 minutes of administration,Intermediate,10116.0,,A,,BAO_0000218,9712,,,1,CHEMBL628384,,,Rattus norvegicus,N,1,2385.0,
14831,Brain uptake of [99mTc]TRODAT in rat expressed as percent dose per organ at time of 2 mins,Intermediate,10116.0,,A,,BAO_0000218,13925,,,1,CHEMBL628385,,,Rattus norvegicus,N,1,,
14832,Brain uptake of [99mTc]TRODAT in rat expressed as percent dose per organ at time of 30 mins,Intermediate,10116.0,,A,,BAO_0000218,13925,,,1,CHEMBL875753,,,Rattus norvegicus,N,1,,
14833,Brain uptake of [99mTc]TRODAT in rat expressed as percent dose per organ at time of 60 mins,Intermediate,10116.0,,A,,BAO_0000218,13925,,,1,CHEMBL628386,,,Rattus norvegicus,N,1,,
14834,Organ distribution in rat blood 2 minutes after intravenous injection,Intermediate,10116.0,,A,,BAO_0000218,6941,,,1,CHEMBL628387,,,Rattus norvegicus,N,1,,
14835,Organ distribution in rat blood 2 hr after intravenous injection,Intermediate,10116.0,,A,,BAO_0000218,6941,,,1,CHEMBL628388,,,Rattus norvegicus,N,1,,
14836,Organ distribution in rat blood 30 minutes after intravenous injection,Intermediate,10116.0,,A,,BAO_0000218,6941,,,1,CHEMBL628389,,,Rattus norvegicus,N,1,,
14837,Organ distribution in rat blood 30 min after intravenous injection,Intermediate,10116.0,,A,,BAO_0000218,6941,,,1,CHEMBL632756,,,Rattus norvegicus,N,1,,
14838,Organ distribution in rat brain 2 minutes after intravenous injection,Intermediate,10116.0,,A,,BAO_0000218,6941,,,1,CHEMBL628390,,,Rattus norvegicus,N,1,,
14839,Organ distribution in rat brain 2 hr after intravenous injection,Intermediate,10116.0,,A,,BAO_0000218,6941,,,1,CHEMBL631811,,,Rattus norvegicus,N,1,,
14840,Organ distribution in rat brain 30 minutes after intravenous injection,Intermediate,10116.0,,A,,BAO_0000218,6941,,,1,CHEMBL631812,,,Rattus norvegicus,N,1,,
14841,Organ distribution in rat heart 2 minutes after intravenous injection,Intermediate,10116.0,,A,,BAO_0000218,6941,,,1,CHEMBL631813,,,Rattus norvegicus,N,1,,
14842,Organ distribution in rat heart 2 hr after intravenous injection,Intermediate,10116.0,,A,,BAO_0000218,6941,,,1,CHEMBL631814,,,Rattus norvegicus,N,1,,
14843,Organ distribution in rat heart 30 minutes after intravenous injection,Intermediate,10116.0,,A,,BAO_0000218,6941,,,1,CHEMBL631815,,,Rattus norvegicus,N,1,,
14844,Organ distribution in rat kidney 2 minutes after intravenous injection,Intermediate,10116.0,,A,,BAO_0000218,6941,,,1,CHEMBL631816,,,Rattus norvegicus,N,1,,
14845,Organ distribution in rat kidney 2 hr after intravenous injection,Intermediate,10116.0,,A,,BAO_0000218,6941,,,1,CHEMBL875758,,,Rattus norvegicus,N,1,,
14846,Organ distribution in rat kidney 30 minutes after intravenous injection,Intermediate,10116.0,,A,,BAO_0000218,6941,,,1,CHEMBL631817,,,Rattus norvegicus,N,1,,
14847,Organ distribution in rat liver 2 minutes after intravenous injection,Intermediate,10116.0,,A,,BAO_0000218,6941,,,1,CHEMBL631818,,,Rattus norvegicus,N,1,2107.0,
14848,Organ distribution in rat liver 2 hr after intravenous injection,Intermediate,10116.0,,A,,BAO_0000218,6941,,,1,CHEMBL631819,,,Rattus norvegicus,N,1,2107.0,
14849,Organ distribution in rat liver 30 minutes after intravenous injection,Intermediate,10116.0,,A,,BAO_0000218,6941,,,1,CHEMBL631820,,,Rattus norvegicus,N,1,2107.0,
14850,Organ distribution in rat lung 2 minutes after intravenous injection,Intermediate,10116.0,,A,,BAO_0000218,6941,,,1,CHEMBL631821,,,Rattus norvegicus,N,1,,
14851,Organ distribution in rat lung 2 hr after intravenous injection,Intermediate,10116.0,,A,,BAO_0000218,6941,,,1,CHEMBL631822,,,Rattus norvegicus,N,1,,
14852,Organ distribution in rat lung 30 minutes after intravenous injection,Intermediate,10116.0,,A,,BAO_0000218,6941,,,1,CHEMBL631823,,,Rattus norvegicus,N,1,,
14853,Organ distribution in rat muscle 2 minutes after intravenous injection,Intermediate,10116.0,,A,,BAO_0000218,6941,,,1,CHEMBL631824,,,Rattus norvegicus,N,1,2385.0,
14854,Organ distribution in rat muscle 2 hr after intravenous injection,Intermediate,10116.0,,A,,BAO_0000218,6941,,,1,CHEMBL631825,,,Rattus norvegicus,N,1,2385.0,
14855,Organ distribution in rat muscle 30 minutes after intravenous injection,Intermediate,10116.0,,A,,BAO_0000218,6941,,,1,CHEMBL631826,,,Rattus norvegicus,N,1,2385.0,
14856,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Blood (B),Intermediate,10090.0,,A,,BAO_0000218,14439,,,1,CHEMBL631827,,,Mus musculus,N,1,,
14857,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Heart (H),Intermediate,10090.0,,A,,BAO_0000218,14439,,,1,CHEMBL631828,,,Mus musculus,N,1,,
14858,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Lung (L),Intermediate,10090.0,,A,,BAO_0000218,14439,,,1,CHEMBL631829,,,Mus musculus,N,1,,
14859,Total electrolytic excretion of sodium in urine of rats after peroral administration of 3.76 uM/Kg of drug,Intermediate,10116.0,,A,,BAO_0000218,12582,,,1,CHEMBL875759,,,Rattus norvegicus,N,1,1088.0,
14860,Total electrolytic excretion of sodium in urine of rats after peroral administration of 30.20 uM/Kg of drug,Intermediate,10116.0,,A,,BAO_0000218,12582,,,1,CHEMBL631830,,,Rattus norvegicus,N,1,1088.0,
14861,Total electrolytic excretion of sodium in urine of rats after peroral administration of 302 uM/Kg of drug,Intermediate,10116.0,,A,,BAO_0000218,12582,,,1,CHEMBL631831,,,Rattus norvegicus,N,1,1088.0,
14862,Total electrolytic excretion of sodium in urine of rats after peroral administration of 31.6 uM/Kg of drug,Intermediate,10116.0,,A,,BAO_0000218,12582,,,1,CHEMBL631832,,,Rattus norvegicus,N,1,1088.0,
14863,Total electrolytic excretion of sodium in urine of rats after peroral administration of 316 uM/Kg of drug,Intermediate,10116.0,,A,,BAO_0000218,12582,,,1,CHEMBL631833,,,Rattus norvegicus,N,1,1088.0,
14864,Total electrolytic excretion of sodium in urine of rats after peroral administration of 32.4 uM/Kg of drug,Intermediate,10116.0,,A,,BAO_0000218,12582,,,1,CHEMBL631834,,,Rattus norvegicus,N,1,1088.0,
14865,Total electrolytic excretion of sodium in urine of rats after peroral administration of 324 uM/Kg of drug,Intermediate,10116.0,,A,,BAO_0000218,12582,,,1,CHEMBL631835,,,Rattus norvegicus,N,1,1088.0,
14866,Total electrolytic excretion of sodium in urine of rats after peroral administration of 34.0 uM/Kg of drug,Intermediate,10116.0,,A,,BAO_0000218,12582,,,1,CHEMBL631836,,,Rattus norvegicus,N,1,1088.0,
14867,Total electrolytic excretion of sodium in urine of rats after peroral administration of 34.1 uM/Kg of drug,Intermediate,10116.0,,A,,BAO_0000218,12582,,,1,CHEMBL631837,,,Rattus norvegicus,N,1,1088.0,
14868,Total electrolytic excretion of sodium in urine of rats after peroral administration of 34.8 uM/Kg of drug,Intermediate,10116.0,,A,,BAO_0000218,12582,,,1,CHEMBL631838,,,Rattus norvegicus,N,1,1088.0,
14869,Total electrolytic excretion of sodium in urine of rats after peroral administration of 341 uM/Kg of drug,Intermediate,10116.0,,A,,BAO_0000218,12582,,,1,CHEMBL631839,,,Rattus norvegicus,N,1,1088.0,
14870,Total electrolytic excretion of sodium in urine of rats after peroral administration of 348 uM/Kg of drug,Intermediate,10116.0,,A,,BAO_0000218,12582,,,1,CHEMBL631840,,,Rattus norvegicus,N,1,1088.0,
14871,Total electrolytic excretion of sodium in urine of rats after peroral administration of 37.6 uM/Kg of drug,Intermediate,10116.0,,A,,BAO_0000218,12582,,,1,CHEMBL631841,,,Rattus norvegicus,N,1,1088.0,
14872,Total electrolytic excretion of sodium in urine of rats after peroral administration of 58.4 uM/Kg of drug,Intermediate,10116.0,,A,,BAO_0000218,12582,,,1,CHEMBL631842,,,Rattus norvegicus,N,1,1088.0,
14873,Total electrolytic excretion of sodium in urine of rats after peroral administration of 65.2 uM/Kg of drug,Intermediate,10116.0,,A,,BAO_0000218,12582,,,1,CHEMBL631843,,,Rattus norvegicus,N,1,1088.0,
14874,Total electrolytic excretion of sodium in urine of rats after peroral administration of 71.6 uM/Kg of drug,Intermediate,10116.0,,A,,BAO_0000218,12582,,,1,CHEMBL631844,,,Rattus norvegicus,N,1,1088.0,
14875,Total electrolytic excretion of sodium in urine of rats after peroral administration of 71.8 uM/Kg of drug,Intermediate,10116.0,,A,,BAO_0000218,12582,,,1,CHEMBL631845,,,Rattus norvegicus,N,1,1088.0,
14876,Total electrolytic excretion of sodium in urine of rats after peroral administration of 74.8 uM/Kg of drug,Intermediate,10116.0,,A,,BAO_0000218,12582,,,1,CHEMBL631846,,,Rattus norvegicus,N,1,1088.0,
14877,Total electrolytic excretion of sodium in urine of rats after peroral administration of 77.5 uM/Kg of drug,Intermediate,10116.0,,A,,BAO_0000218,12582,,,1,CHEMBL875760,,,Rattus norvegicus,N,1,1088.0,
14878,Total electrolytic excretion of sodium in urine of rats after peroral administration of 79.4 uM/Kg of drug,Intermediate,10116.0,,A,,BAO_0000218,12582,,,1,CHEMBL632199,,,Rattus norvegicus,N,1,1088.0,
14879,Total electrolytic excretion of sodium in urine of rats after peroral administration of 80.9 uM/Kg of drug,Intermediate,10116.0,,A,,BAO_0000218,12582,,,1,CHEMBL631847,,,Rattus norvegicus,N,1,1088.0,
14880,Total electrolytic excretion of sodium in urine of rats after peroral administration of 83.8 uM/Kg of drug,Intermediate,10116.0,,A,,BAO_0000218,12582,,,1,CHEMBL631848,,,Rattus norvegicus,N,1,1088.0,
14881,Total electrolytic excretion of sodium in urine of rats after peroral administration of 84.5 uM/Kg of drug,Intermediate,10116.0,,A,,BAO_0000218,12582,,,1,CHEMBL628707,,,Rattus norvegicus,N,1,1088.0,
14882,Total electrolytic excretion of sodium in urine of rats after peroral administration of 84.7 uM/Kg of drug,Intermediate,10116.0,,A,,BAO_0000218,12582,,,1,CHEMBL628708,,,Rattus norvegicus,N,1,1088.0,
14883,Total electrolytic excretion of sodium in urine of rats after peroral administration of 86.7 uM/Kg of drug,Intermediate,10116.0,,A,,BAO_0000218,12582,,,1,CHEMBL628709,,,Rattus norvegicus,N,1,1088.0,
14884,Total electrolytic excretion of sodium in urine of rats after peroral administration of 86.9 uM/Kg of drug,Intermediate,10116.0,,A,,BAO_0000218,12582,,,1,CHEMBL628710,,,Rattus norvegicus,N,1,1088.0,
14885,Total electrolytic excretion of sodium in urine of rats after peroral administration of 9.06 uM/Kg of drug,Intermediate,10116.0,,A,,BAO_0000218,12582,,,1,CHEMBL628711,,,Rattus norvegicus,N,1,1088.0,
14886,Total electrolytic excretion of sodium in urine of rats after peroral administration of 90.6 uM/Kg of drug,Intermediate,10116.0,,A,,BAO_0000218,12582,,,1,CHEMBL628712,,,Rattus norvegicus,N,1,1088.0,
14887,Total electrolytic excretion of sodium in urine of rats after peroral administration of 94.9 uM/Kg of drug,Intermediate,10116.0,,A,,BAO_0000218,12582,,,1,CHEMBL628713,,,Rattus norvegicus,N,1,1088.0,
14888,Total electrolytic excretion of sodium in urine of rats after peroral administration of 97.1 uM/Kg of drug,Intermediate,10116.0,,A,,BAO_0000218,12582,,,1,CHEMBL628714,,,Rattus norvegicus,N,1,1088.0,
14889,"excretion rate in rats after the dose of 5 mg/kg intravenously, at the dose 4 hour Rate of biliary excretion; 0.06-0.15%/h",Intermediate,10116.0,,A,,BAO_0000218,7415,,,1,CHEMBL628715,,,Rattus norvegicus,N,1,,
14890,Extent rates of formation of metabolic intermediate Cytochrome P-450 at compound concentration of 3.75-120 uM,Autocuration,,,A,,BAO_0000019,7313,,,1,CHEMBL629179,,,,U,0,,
14891,Extent rates of formation of metabolic intermediate Cytochrome P-450 at compound concentration of 30 uM,Autocuration,,,A,,BAO_0000019,7313,,,1,CHEMBL629180,,,,U,0,,
14892,Extent rates of formation of metabolic intermediate Cytochrome P-450 at compound concentration of 7.5-120 uM,Autocuration,,,A,,BAO_0000019,7313,,,1,CHEMBL875108,,,,U,0,,
14893,Percent lipid extracted at 0.5 hr from adrenal cortex liver using CHCl3/CH3OH.,Autocuration,,,A,,BAO_0000019,7570,,,1,CHEMBL629181,,,,U,0,1235.0,
14894,Percent lipid extracted at 0.5 hr from adrenal cortex liver using CHCl3/CH3OH.,Autocuration,,,A,,BAO_0000019,7570,,,1,CHEMBL629182,,,,U,0,1235.0,
14895,Percent lipid extracted at 0.5 hr from liver plasma using CHCl3/CH3OH.,Autocuration,,,A,,BAO_0000019,7570,,,1,CHEMBL629183,,,,U,0,,
14896,Percent lipid extracted at 0.5 hr from liver using CHCl3/CH3OH.,Autocuration,,,A,,BAO_0000019,7570,,,1,CHEMBL629184,,,,U,0,,
14897,Percent lipid extracted at 24 hours from adrenal cortex using CHCl3/CH3OH.,Autocuration,,,A,,BAO_0000019,7570,,,1,CHEMBL629185,,,,U,0,1235.0,
14898,Percent lipid extracted at 24 hours from adrenal cortex liver using CHCl3/CH3OH.,Autocuration,,,A,,BAO_0000019,7570,,,1,CHEMBL629186,,,,U,0,1235.0,
14899,Percent lipid extracted at 24 hours from liverliver using CHCl3/CH3OH.,Autocuration,,,A,,BAO_0000019,7570,,,1,CHEMBL629187,,,,U,0,,
14900,Percent lipid extracted at 24 hours from plasma using CHCl3/CH3OH.,Autocuration,,,A,,BAO_0000019,7570,,,1,CHEMBL629887,,,,U,0,,
14901,Percent lipid extracted at 24 hours from plasmaliver using CHCl3/CH3OH.,Autocuration,,,A,,BAO_0000019,7570,,,1,CHEMBL629888,,,,U,0,,
14902,Percent lipid extracted at 24 hr from liver using CHCl3/CH3OH.,Autocuration,,,A,,BAO_0000019,7570,,,1,CHEMBL629889,,,,U,0,,
14903,Percent parent compound extracted at 0.5 hr from adrenal cortex using CHCl3/CH3OH.,Autocuration,,,A,,BAO_0000019,7570,,,1,CHEMBL629890,,,,U,0,1235.0,
14904,Percent parent compound extracted at 0.5 hr from liver using CHCl3/CH3OH.,Autocuration,,,A,,BAO_0000019,7570,,,1,CHEMBL629891,,,,U,0,,
14905,Percent parent compound extracted at 0.5 hr from plasma using CHCl3/CH3OH.,Autocuration,,,A,,BAO_0000019,7570,,,1,CHEMBL629892,,,,U,0,,
14906,Percent parent compound extracted at 24 hours from adrenal cortex using CHCl3/CH3OH.,Autocuration,,,A,,BAO_0000019,7570,,,1,CHEMBL629893,,,,U,0,1235.0,
14907,Percent parent compound extracted at 24 hours from liver using CHCl3/CH3OH.,Autocuration,,,A,,BAO_0000019,7570,,,1,CHEMBL629894,,,,U,0,,
14908,Percent parent compound extracted at 24 hours from plasma using CHCl3/CH3OH.,Autocuration,,,A,,BAO_0000019,7570,,,1,CHEMBL629895,,,,U,0,,
14909,"+Ratio of intravenous to oral integrated area under the concentration vs time curve, for compound in dog plasma",Autocuration,9615.0,,A,,BAO_0000218,14122,,,1,CHEMBL875109,,,Canis lupus familiaris,U,0,,
14910,Absolute bioavailability in male cynomolgus monkeys,Autocuration,9541.0,,A,,BAO_0000218,16449,,,1,CHEMBL629896,,,Macaca fascicularis,U,0,,
14911,Absolute bioavailability in maleSprague-Dawley rats,Autocuration,10116.0,,A,,BAO_0000218,16449,,,1,CHEMBL629897,,,Rattus norvegicus,U,0,,
14912,Biodistribution in liver of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),Intermediate,10116.0,,A,,BAO_0000218,12017,,,1,CHEMBL629898,,,Rattus norvegicus,N,1,2107.0,
14913,Biodistribution in liver of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,10116.0,,A,,BAO_0000218,12017,,,1,CHEMBL630057,,,Rattus norvegicus,N,1,2107.0,
14914,Biodistribution in liver of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,10116.0,,A,,BAO_0000218,12017,,,1,CHEMBL630058,,,Rattus norvegicus,N,1,2107.0,
14915,Biodistribution in lungs of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,10116.0,,A,,BAO_0000218,12017,,,1,CHEMBL630059,,,Rattus norvegicus,N,1,2048.0,
14916,Biodistribution in lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,10116.0,,A,,BAO_0000218,12017,,,1,CHEMBL630060,,,Rattus norvegicus,N,1,2048.0,
14917,Biodistribution in lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),Intermediate,10116.0,,A,,BAO_0000218,12017,,,1,CHEMBL630061,,,Rattus norvegicus,N,1,2048.0,
14918,Biodistribution in lungs of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,10116.0,,A,,BAO_0000218,12017,,,1,CHEMBL630062,,,Rattus norvegicus,N,1,2048.0,
14919,Biodistribution in lungs of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,10116.0,,A,,BAO_0000218,12017,,,1,CHEMBL630063,,,Rattus norvegicus,N,1,2048.0,
14920,Biodistribution in lungs of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,10116.0,,A,,BAO_0000218,12017,,,1,CHEMBL630064,,,Rattus norvegicus,N,1,2048.0,
14921,Biodistribution in lungs of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,10116.0,,A,,BAO_0000218,12017,,,1,CHEMBL630065,,,Rattus norvegicus,N,1,2048.0,
14922,Biodistribution in lungs of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),Intermediate,10116.0,,A,,BAO_0000218,12017,,,1,CHEMBL630066,,,Rattus norvegicus,N,1,2048.0,
14923,Biodistribution in lungs of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,10116.0,,A,,BAO_0000218,12017,,,1,CHEMBL630067,,,Rattus norvegicus,N,1,2048.0,
14924,Biodistribution in lungs of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,10116.0,,A,,BAO_0000218,12017,,,1,CHEMBL630068,,,Rattus norvegicus,N,1,2048.0,
14925,Biodistribution in muscle of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,10116.0,,A,,BAO_0000218,12017,,,1,CHEMBL631113,,,Rattus norvegicus,N,1,2385.0,
14926,Biodistribution in muscle of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,10116.0,,A,,BAO_0000218,12017,,,1,CHEMBL631114,,,Rattus norvegicus,N,1,2385.0,
14927,Biodistribution in muscle of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),Intermediate,10116.0,,A,,BAO_0000218,12017,,,1,CHEMBL631115,,,Rattus norvegicus,N,1,2385.0,
14928,Biodistribution in muscle of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,10116.0,,A,,BAO_0000218,12017,,,1,CHEMBL631116,,,Rattus norvegicus,N,1,2385.0,
14929,Biodistribution in muscle of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,10116.0,,A,,BAO_0000218,12017,,,1,CHEMBL630528,,,Rattus norvegicus,N,1,2385.0,
14930,Biodistribution in muscle of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,10116.0,,A,,BAO_0000218,12017,,,1,CHEMBL630529,,,Rattus norvegicus,N,1,2385.0,
14931,Biodistribution in muscle of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,10116.0,,A,,BAO_0000218,12017,,,1,CHEMBL630530,,,Rattus norvegicus,N,1,2385.0,
14932,Biodistribution in muscle of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),Intermediate,10116.0,,A,,BAO_0000218,12017,,,1,CHEMBL630531,,,Rattus norvegicus,N,1,2385.0,
14933,Biodistribution in muscle of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,10116.0,,A,,BAO_0000218,12017,,,1,CHEMBL630532,,,Rattus norvegicus,N,1,2385.0,
14934,Biodistribution in muscle of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,10116.0,,A,,BAO_0000218,12017,,,1,CHEMBL630533,,,Rattus norvegicus,N,1,2385.0,
14935,Biodistribution in normal mice blood after 120 hr,Intermediate,10090.0,,A,,BAO_0000218,15045,,,1,CHEMBL630534,,,Mus musculus,N,1,178.0,
14936,Biodistribution in normal mice blood after 24 hr,Intermediate,10090.0,,A,,BAO_0000218,15045,,,1,CHEMBL630535,,,Mus musculus,N,1,178.0,
14937,Biodistribution in normal mice blood after 4 hr,Intermediate,10090.0,,A,,BAO_0000218,15045,,,1,CHEMBL630536,,,Mus musculus,N,1,178.0,
14938,Biodistribution in normal mice bone after 120 hr,Intermediate,10090.0,,A,,BAO_0000218,15045,,,1,CHEMBL630537,,,Mus musculus,N,1,10000001.0,
14939,Biodistribution in normal mice bone after 24 hr,Intermediate,10090.0,,A,,BAO_0000218,15045,,,1,CHEMBL630538,,,Mus musculus,N,1,10000001.0,
14940,Biodistribution in normal mice bone after 4 hr,Intermediate,10090.0,,A,,BAO_0000218,15045,,,1,CHEMBL630539,,,Mus musculus,N,1,10000001.0,
14941,Biodistribution in normal mice heart after 120 hr,Intermediate,10090.0,,A,,BAO_0000218,15045,,,1,CHEMBL630540,,,Mus musculus,N,1,948.0,
14942,Biodistribution in normal mice heart after 24 hr,Intermediate,10090.0,,A,,BAO_0000218,15045,,,1,CHEMBL630541,,,Mus musculus,N,1,948.0,
14943,Biodistribution in normal mice heart after 4 hr,Intermediate,10090.0,,A,,BAO_0000218,15045,,,1,CHEMBL630542,,,Mus musculus,N,1,948.0,
14944,Biodistribution in normal mice kidney after 120 hr,Intermediate,10090.0,,A,,BAO_0000218,15045,,,1,CHEMBL630543,,,Mus musculus,N,1,2113.0,
14945,Biodistribution in normal mice kidney after 24 hr,Intermediate,10090.0,,A,,BAO_0000218,15045,,,1,CHEMBL630544,,,Mus musculus,N,1,2113.0,
14946,Biodistribution in normal mice kidney after 4 hr,Intermediate,10090.0,,A,,BAO_0000218,15045,,,1,CHEMBL630545,,,Mus musculus,N,1,2113.0,
14947,Biodistribution in normal mice liver after 120 hr,Intermediate,10090.0,,A,,BAO_0000218,15045,,,1,CHEMBL630546,,,Mus musculus,N,1,2107.0,
14948,Biodistribution in normal mice liver after 24 hr,Intermediate,10090.0,,A,,BAO_0000218,15045,,,1,CHEMBL630547,,,Mus musculus,N,1,2107.0,
14949,Biodistribution in normal mice liver after 4 hr,Intermediate,10090.0,,A,,BAO_0000218,15045,,,1,CHEMBL630548,,,Mus musculus,N,1,2107.0,
14950,Biodistribution in normal mice spleen after 120 hr,Intermediate,10090.0,,A,,BAO_0000218,15045,,,1,CHEMBL630549,,,Mus musculus,N,1,2106.0,
14951,Biodistribution in normal mice spleen after 24 hr,Intermediate,10090.0,,A,,BAO_0000218,15045,,,1,CHEMBL630550,,,Mus musculus,N,1,2106.0,
14952,Biodistribution in normal mice spleen after 4 hr,Intermediate,10090.0,,A,,BAO_0000218,15045,,,1,CHEMBL876426,,,Mus musculus,N,1,2106.0,
14953,Biodistribution in spleen of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,10116.0,,A,,BAO_0000218,12017,,,1,CHEMBL630551,,,Rattus norvegicus,N,1,2106.0,
14954,Biodistribution in spleen of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,10116.0,,A,,BAO_0000218,12017,,,1,CHEMBL630552,,,Rattus norvegicus,N,1,2106.0,
14955,Biodistribution in spleen of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),Intermediate,10116.0,,A,,BAO_0000218,12017,,,1,CHEMBL630553,,,Rattus norvegicus,N,1,2106.0,
14956,Biodistribution in spleen of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,10116.0,,A,,BAO_0000218,12017,,,1,CHEMBL630554,,,Rattus norvegicus,N,1,2106.0,
14957,Biodistribution in spleen of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,10116.0,,A,,BAO_0000218,12017,,,1,CHEMBL630555,,,Rattus norvegicus,N,1,2106.0,
14958,Biodistribution in spleen of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,10116.0,,A,,BAO_0000218,12017,,,1,CHEMBL630556,,,Rattus norvegicus,N,1,2106.0,
14959,Biodistribution in spleen of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,10116.0,,A,,BAO_0000218,12017,,,1,CHEMBL630557,,,Rattus norvegicus,N,1,2106.0,
14960,Biodistribution in spleen of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),Intermediate,10116.0,,A,,BAO_0000218,12017,,,1,CHEMBL630558,,,Rattus norvegicus,N,1,2106.0,
14961,Biodistribution in spleen of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,10116.0,,A,,BAO_0000218,12017,,,1,CHEMBL630559,,,Rattus norvegicus,N,1,2106.0,
14962,Biodistribution in spleen of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,10116.0,,A,,BAO_0000218,12017,,,1,CHEMBL630560,,,Rattus norvegicus,N,1,2106.0,
14963,Biodistribution in thyroid of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Intermediate,10116.0,,A,,BAO_0000218,12017,,,1,CHEMBL876427,,,Rattus norvegicus,N,1,2046.0,
14964,The Kel values in female wistar rats.,Intermediate,10116.0,,A,,BAO_0000218,14941,,,1,CHEMBL630561,,,Rattus norvegicus,N,1,,
14965,The equilibrium constant pair at a pH of 7.0 and temperature of 25 degree Centigrade,Autocuration,,,A,,BAO_0000019,4646,,,1,CHEMBL630562,,,,U,0,,
14966,Hydrolysis rate constant of the compound,Autocuration,,,A,,BAO_0000019,8847,,,1,CHEMBL630563,,,,U,0,,
14967,Headecane/water partition coefficient expressed as the equilibrium ratio of the molar concentration in n-hexadecane to that in the buffer,Autocuration,,,P,,BAO_0000100,11778,,,1,CHEMBL629673,,,,U,0,,
14968,"Hydrolysis in acetone/water (50:50) at a pH of 8.0, T=66 degree Centigrade",Autocuration,,,A,,BAO_0000019,2363,,,1,CHEMBL629674,,,,U,0,,
14969,"Hydrolysis in acetone/water (50:50) at a pH of 8.0,T =66 degree Centigrade",Autocuration,,,A,,BAO_0000019,2363,,,1,CHEMBL629675,,,,U,0,,
14970,"Hydrolysis in acetone/water (50:50) at a pH of 8.0,T =66 degree centigrade; No data",Autocuration,,,A,,BAO_0000019,2363,,,1,CHEMBL629676,,,,U,0,,
14971,"Hydrolysis in acetone/water (50:50) at a pH of 8.0,T =66 degree centigrade; Not determined",Autocuration,,,A,,BAO_0000019,2363,,,1,CHEMBL629677,,,,U,0,,
14972,Apparent inactivation rate constant was evaluated,Autocuration,,,A,,BAO_0000019,8371,,,1,CHEMBL629678,,,,U,0,,
14973,Compound was evaluated for equilibrium constant K obtained from the ratio of reverse rate constants at 25 degree Centigrade.,Autocuration,,,A,,BAO_0000019,14883,,,1,CHEMBL629679,,,,U,0,,
14974,Compound was evaluated for equilibrium constant K obtained from the ratio of reverse rate constants at 37 degree Centigrade,Autocuration,,,A,,BAO_0000019,14883,,,1,CHEMBL629680,,,,U,0,,
14975,Compound was evaluated for the Ki value for peptide alcohol for competitive inhibition in the presence of Mn2+ ions at pH 7.5,Autocuration,,,A,,BAO_0000019,4643,,,1,CHEMBL629681,,,,U,0,,
14976,Compound was tested for the inhibition of antibody-catalyzed hydrolysis.,Autocuration,,,A,,BAO_0000019,3519,,,1,CHEMBL629682,,,,U,0,,
14977,DBH (dopamine beta-hydroxylase) activity expressed as Ki value determined by degree to which compound inhibited conversion of tyramine to octopamine,Autocuration,,,A,,BAO_0000019,10600,,,1,CHEMBL629683,,,,U,0,,
14978,Dissociation constant against constrictor response to the compound blocked competitively by phentolamine for alpha-mediated events,Autocuration,,,F,,BAO_0000019,8501,,,1,CHEMBL629684,,,,U,0,,
14979,Dissociation constant was determined,Autocuration,,,P,,BAO_0000100,8505,,,1,CHEMBL629685,,,,U,0,,
14980,Dissociation constant was determined,Autocuration,,,P,,BAO_0000100,9778,,,1,CHEMBL629686,,,,U,0,,
14981,Dissociation constant at pH 7.4,Autocuration,,,P,,BAO_0000100,9778,,,1,CHEMBL872932,,,,U,0,,
14982,Dissociation constant in presence of 1 mM dithiothreitol,Autocuration,,,P,,BAO_0000100,9778,,,1,CHEMBL629687,,,,U,0,,
14983,Kinetic Parameter Ki for Inhibition of Type 1 5-alpha-reductase,Autocuration,,,A,,BAO_0000019,13007,,,1,CHEMBL872931,,,,U,0,,
14984,Kinetic Parameter Ki for Inhibition of Type 1 5-alpha-reductase,Autocuration,,,A,,BAO_0000019,13007,,,1,CHEMBL628151,,,,U,0,,
14985,Kinetic Parameter Ki for Inhibition of Type-2 5-alpha-reductase,Autocuration,,,A,,BAO_0000019,13007,,,1,CHEMBL628152,,,,U,0,,
14986,Kinetic Parameter Ki for Inhibition of Type-2 5-alpha-reductase,Autocuration,,,A,,BAO_0000019,13007,,,1,CHEMBL628153,,,,U,0,,
14987,Kinetic constant for aromatization of androstenedione,Autocuration,,,A,,BAO_0000019,11482,,,1,CHEMBL628154,,,,U,0,,
14988,Kinetic constant for aromatization of testosterone,Autocuration,,,A,,BAO_0000019,11482,,,1,CHEMBL628155,,,,U,0,,
14989,Kinetic parameter for hydrolysis of 1 by Antibody 2D10 after addition of compound 12,Autocuration,,,A,,BAO_0000019,2303,,,1,CHEMBL628156,,,,U,0,,
14990,Local inhibition constant was determined,Autocuration,,,A,,BAO_0000019,11964,,,1,CHEMBL628157,,,,U,0,,
14991,Rate of inactivation of sterol methyl transferase from Saccharomyces cerevisiae using mechanism based inhibitor,Intermediate,4932.0,,A,,BAO_0000218,3140,,,1,CHEMBL857533,,,Saccharomyces cerevisiae,N,1,,
14992,Dissociation constant value of the compound,Autocuration,,,P,,BAO_0000100,10650,,,1,CHEMBL628158,,,,U,0,,
14993,In vitro permeability through cornea without epithelium,Autocuration,,,A,,BAO_0000019,4667,,,1,CHEMBL628159,,,,U,0,964.0,
14994,In vitro permeability through intact cornea,Autocuration,,,A,,BAO_0000019,4667,,,1,CHEMBL875616,,,,U,0,964.0,
14995,Evaluated for first order rate constant (Kin) for transcorneal penetration in anesthetized rabbits,Intermediate,9986.0,,A,,BAO_0000218,9199,,,1,CHEMBL628160,,,Oryctolagus cuniculus,N,1,964.0,
14996,Rate of enzyme inactivation for the compound was determined,Autocuration,,,A,,BAO_0000019,11966,,,1,CHEMBL628161,,,,U,0,,
14997,In vitro permeability through cornea without epithelium,Autocuration,,,A,,BAO_0000019,4667,,,1,CHEMBL628162,,,,U,0,964.0,
14998,In vitro permeability through intact cornea,Autocuration,,,A,,BAO_0000019,4667,,,1,CHEMBL628163,,,,U,0,964.0,
14999,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0300 mM [HOX] in the conditions of 25degreeC,pH 7.6",Autocuration,,,A,,BAO_0000019,8354,,,1,CHEMBL628164,,,,U,0,,
15000,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0384 mM [HOX] in the conditions of 25degreeC,pH 7.6",Autocuration,,,A,,BAO_0000019,8354,,,1,CHEMBL628165,,,,U,0,,
15001,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0395 mM [HOX] in the conditions of 25degreeC,pH 7.6",Autocuration,,,A,,BAO_0000019,8354,,,1,CHEMBL628166,,,,U,0,,
15002,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0500 mM [HOX] in the conditions of 25degreeC,pH 7.6",Autocuration,,,A,,BAO_0000019,8354,,,1,CHEMBL628167,,,,U,0,,
15003,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.050 mM [HOX] in the conditions of 25degreeC,pH 7.6",Autocuration,,,A,,BAO_0000019,8354,,,1,CHEMBL628168,,,,U,0,,
15004,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0767 mM [HOX] in the conditions of 25degreeC,pH 7.6",Autocuration,,,A,,BAO_0000019,8354,,,1,CHEMBL628169,,,,U,0,,
15005,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0790 mM [HOX] in the conditions of 25degreeC,pH 7.6",Autocuration,,,A,,BAO_0000019,8354,,,1,CHEMBL628170,,,,U,0,,
15006,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0800 mM [HOX] in the conditions of 25degreeC,pH 7.6",Autocuration,,,A,,BAO_0000019,8354,,,1,CHEMBL628171,,,,U,0,,
15007,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.100 mM [HOX] in the conditions of 25degreeC,pH 7.6",Autocuration,,,A,,BAO_0000019,8354,,,1,CHEMBL627434,,,,U,0,,
15008,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.200 mM [HOX] in the conditions of 25degreeC,pH 7.6",Autocuration,,,A,,BAO_0000019,8354,,,1,CHEMBL627435,,,,U,0,,
15009,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.300 mM [HOX] in the conditions of 25degreeC,pH 7.6",Autocuration,,,A,,BAO_0000019,8354,,,1,CHEMBL628110,,,,U,0,,
15010,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.384 mM [HOX] in the conditions of 25degreeC,pH 7.6",Autocuration,,,A,,BAO_0000019,8354,,,1,CHEMBL628111,,,,U,0,,
15011,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.395 mM [HOX] in the conditions of 25degreeC,pH 7.6",Autocuration,,,A,,BAO_0000019,8354,,,1,CHEMBL628112,,,,U,0,,
15012,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.500 mM [HOX] in the conditions of 25degreeC,pH 7.6",Autocuration,,,A,,BAO_0000019,8354,,,1,CHEMBL628260,,,,U,0,,
15013,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.767 mM [HOX] in the conditions of 25degreeC,pH 7.6",Autocuration,,,A,,BAO_0000019,8354,,,1,CHEMBL628261,,,,U,0,,
15014,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Muscle (M),Intermediate,10090.0,,A,,BAO_0000218,14439,,,1,CHEMBL628262,,,Mus musculus,N,1,,
15015,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Tumor (T) cells,Intermediate,9606.0,,A,,BAO_0000218,14439,,,1,CHEMBL628263,,,Homo sapiens,N,1,,
15016,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Blood (B),Intermediate,10090.0,,A,,BAO_0000218,14439,,,1,CHEMBL628264,,,Mus musculus,N,1,,
15017,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Heart (H),Intermediate,10090.0,,A,,BAO_0000218,14439,,,1,CHEMBL628265,,,Mus musculus,N,1,,
15018,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Lung (L),Intermediate,10090.0,,A,,BAO_0000218,14439,,,1,CHEMBL628266,,,Mus musculus,N,1,,
15019,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Muscle (M),Intermediate,10090.0,,A,,BAO_0000218,14439,,,1,CHEMBL628267,,,Mus musculus,N,1,,
15020,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Tumor (T) cells,Intermediate,10090.0,,A,,BAO_0000218,14439,,,1,CHEMBL628268,,,Mus musculus,N,1,,
15021,Biodistribution in athymic mice bearing Human Tumor (TE671) Xenografts 1 hour after injection in Blood (B),Intermediate,10090.0,,A,,BAO_0000218,14439,,,1,CHEMBL628269,,,Mus musculus,N,1,,
15022,Biodistribution in athymic mice bearing Human Tumor (TE671) Xenografts 1 hour after injection in Heart (H),Intermediate,10090.0,,A,,BAO_0000218,14439,,,1,CHEMBL628270,,,Mus musculus,N,1,,
15023,Biodistribution in athymic mice bearing Human Tumor (TE671) Xenografts 1 hour after injection in Lung (L),Intermediate,10090.0,,A,,BAO_0000218,14439,,,1,CHEMBL628271,,,Mus musculus,N,1,,
15024,Biodistribution in athymic mice bearing Human Tumor (TE671) Xenografts 1 hour after injection in Muscle (M),Intermediate,10090.0,,A,,BAO_0000218,14439,,,1,CHEMBL628272,,,Mus musculus,N,1,,
